0000200406-25-000038.txt : 20250213 0000200406-25-000038.hdr.sgml : 20250213 20250213160739 ACCESSION NUMBER: 0000200406-25-000038 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 168 CONFORMED PERIOD OF REPORT: 20241229 FILED AS OF DATE: 20250213 DATE AS OF CHANGE: 20250213 FILER: COMPANY DATA: COMPANY CONFORMED NAME: JOHNSON & JOHNSON CENTRAL INDEX KEY: 0000200406 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 221024240 STATE OF INCORPORATION: NJ FISCAL YEAR END: 1229 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-03215 FILM NUMBER: 25620252 BUSINESS ADDRESS: STREET 1: ONE JOHNSON & JOHNSON PLZ CITY: NEW BRUNSWICK STATE: NJ ZIP: 08933 BUSINESS PHONE: 732-524-2455 MAIL ADDRESS: STREET 1: ONE JOHNSON & JOHNSON PLZ CITY: NEW BRUNSWICK STATE: NJ ZIP: 08933 10-K 1 jnj-20241229.htm 10-K jnj-20241229
00002004062024FYfalseJohnson & Johnsonhttp://fasb.org/us-gaap/2024#OtherAssetsNoncurrenthttp://fasb.org/us-gaap/2024#OtherAssetsNoncurrenthttp://fasb.org/us-gaap/2024#AccruedLiabilitiesCurrenthttp://fasb.org/us-gaap/2024#AccruedLiabilitiesCurrenthttp://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrenthttp://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrenthttp://fasb.org/us-gaap/2024#AccountsPayableCurrenthttp://fasb.org/us-gaap/2024#AccountsPayableCurrentP25Yhttp://fasb.org/us-gaap/2024#OtherNonoperatingIncomeExpensehttp://fasb.org/us-gaap/2024#OtherNonoperatingIncomeExpensehttp://fasb.org/us-gaap/2024#OtherNonoperatingIncomeExpenseiso4217:USDxbrli:sharesiso4217:USDxbrli:sharesjnj:Employeexbrli:purejnj:Segmentiso4217:EURiso4217:GBPjnj:StockBasedCompensationPlansjnj:segmentjnj:claimantjnj:cases00002004062024-01-012024-12-290000200406us-gaap:CommonStockMember2024-01-012024-12-290000200406jnj:A1.150NotesDueNovember2028Member2024-01-012024-12-290000200406jnj:A3.20NotesDueNovember2032Member2024-01-012024-12-290000200406jnj:A1.650NotesDue2035Member2024-01-012024-12-290000200406jnj:A3.350NotesDueNovember2036Member2024-01-012024-12-290000200406jnj:A3.550NotesDueNovember2044Member2024-01-012024-12-2900002004062024-06-3000002004062025-02-0600002004062024-12-2900002004062023-12-3100002004062023-01-022023-12-3100002004062022-01-032023-01-0100002004062022-01-020000200406us-gaap:RetainedEarningsMember2022-01-020000200406us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-020000200406us-gaap:CommonStockMember2022-01-020000200406us-gaap:TreasuryStockCommonMember2022-01-020000200406us-gaap:RetainedEarningsMember2022-01-032023-01-010000200406us-gaap:TreasuryStockCommonMember2022-01-032023-01-010000200406us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-032023-01-0100002004062023-01-010000200406us-gaap:RetainedEarningsMember2023-01-010000200406us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-010000200406us-gaap:CommonStockMember2023-01-010000200406us-gaap:TreasuryStockCommonMember2023-01-010000200406us-gaap:RetainedEarningsMember2023-01-022023-12-310000200406us-gaap:TreasuryStockCommonMember2023-01-022023-12-310000200406us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-022023-12-310000200406us-gaap:RetainedEarningsMember2023-12-310000200406us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310000200406us-gaap:CommonStockMember2023-12-310000200406us-gaap:TreasuryStockCommonMember2023-12-310000200406us-gaap:RetainedEarningsMember2024-01-012024-12-290000200406us-gaap:TreasuryStockCommonMember2024-01-012024-12-290000200406us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-12-290000200406us-gaap:RetainedEarningsMember2024-12-290000200406us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-12-290000200406us-gaap:CommonStockMember2024-12-290000200406us-gaap:TreasuryStockCommonMember2024-12-290000200406us-gaap:IPOMemberjnj:KenvueIncMember2023-05-082023-05-080000200406jnj:KenvueIncMember2023-05-0800002004062023-05-082023-05-080000200406jnj:KenvueIncMemberjnj:JohnsonJohnsonMember2023-05-082023-05-080000200406jnj:KenvueIncMemberjnj:JohnsonJohnsonMember2023-07-020000200406jnj:KenvueIncMember2023-08-232023-08-230000200406jnj:KenvueIncMemberjnj:JohnsonJohnsonMember2023-08-232023-08-230000200406srt:MaximumMemberus-gaap:BuildingAndBuildingImprovementsMember2024-12-290000200406srt:MinimumMemberjnj:LandAndLeaseholdImprovementsMember2024-12-290000200406srt:MaximumMemberjnj:LandAndLeaseholdImprovementsMember2024-12-290000200406srt:MinimumMemberus-gaap:MachineryAndEquipmentMember2024-12-290000200406srt:MaximumMemberus-gaap:MachineryAndEquipmentMember2024-12-290000200406srt:MinimumMemberus-gaap:SoftwareDevelopmentMember2024-12-290000200406srt:MaximumMemberus-gaap:SoftwareDevelopmentMember2024-12-290000200406srt:MinimumMember2024-01-012024-12-290000200406srt:MaximumMember2024-01-012024-12-290000200406jnj:PharmaceuticalMember2024-12-290000200406jnj:PharmaceuticalMember2023-12-310000200406us-gaap:ShippingAndHandlingMember2024-01-012024-12-290000200406us-gaap:ShippingAndHandlingMember2023-01-022023-12-310000200406us-gaap:ShippingAndHandlingMember2021-01-042022-01-020000200406us-gaap:ProductConcentrationRiskMemberus-gaap:ResearchAndDevelopmentExpenseMember2024-01-012024-12-290000200406us-gaap:ProductConcentrationRiskMemberus-gaap:ResearchAndDevelopmentExpenseMember2023-01-022023-12-310000200406us-gaap:ProductConcentrationRiskMemberus-gaap:ResearchAndDevelopmentExpenseMember2022-01-032023-01-010000200406jnj:YellowJerseyTherapeuticsMember2024-01-012024-12-2900002004062018-12-312019-12-2900002004062019-12-302021-01-030000200406us-gaap:HeldtomaturitySecuritiesMemberus-gaap:CashMember2024-12-290000200406us-gaap:HeldtomaturitySecuritiesMemberus-gaap:SovereignDebtSecuritiesMember2024-12-290000200406us-gaap:HeldtomaturitySecuritiesMemberus-gaap:RepurchaseAgreementsMember2024-12-290000200406us-gaap:HeldtomaturitySecuritiesMemberus-gaap:MoneyMarketFundsMember2024-12-290000200406us-gaap:HeldtomaturitySecuritiesMemberus-gaap:CorporateDebtSecuritiesMember2024-12-290000200406us-gaap:HeldtomaturitySecuritiesMemberus-gaap:BankTimeDepositsMember2024-12-290000200406us-gaap:HeldtomaturitySecuritiesMember2024-12-290000200406us-gaap:AvailableforsaleSecuritiesMemberus-gaap:USTreasuryAndGovernmentMember2024-12-290000200406us-gaap:AvailableforsaleSecuritiesMemberjnj:OtherSovereignSecuritiesMember2024-12-290000200406us-gaap:AvailableforsaleSecuritiesMemberus-gaap:CorporateDebtSecuritiesMember2024-12-290000200406us-gaap:AvailableforsaleSecuritiesMember2024-12-290000200406us-gaap:HeldtomaturitySecuritiesMemberus-gaap:CashMember2023-12-310000200406us-gaap:HeldtomaturitySecuritiesMemberus-gaap:SovereignDebtSecuritiesMember2023-12-310000200406us-gaap:HeldtomaturitySecuritiesMemberus-gaap:RepurchaseAgreementsMember2023-12-310000200406us-gaap:HeldtomaturitySecuritiesMemberus-gaap:CorporateDebtSecuritiesMember2023-12-310000200406us-gaap:HeldtomaturitySecuritiesMemberus-gaap:MoneyMarketFundsMember2023-12-310000200406us-gaap:HeldtomaturitySecuritiesMemberus-gaap:BankTimeDepositsMember2023-12-310000200406us-gaap:HeldtomaturitySecuritiesMember2023-12-310000200406us-gaap:AvailableforsaleSecuritiesMemberus-gaap:USTreasuryAndGovernmentMember2023-12-310000200406us-gaap:AvailableforsaleSecuritiesMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2023-12-310000200406us-gaap:AvailableforsaleSecuritiesMemberjnj:OtherSovereignSecuritiesMember2023-12-310000200406us-gaap:AvailableforsaleSecuritiesMemberus-gaap:CorporateDebtSecuritiesMember2023-12-310000200406us-gaap:AvailableforsaleSecuritiesMember2023-12-310000200406jnj:LandAndLeaseholdImprovementsMember2024-12-290000200406jnj:LandAndLeaseholdImprovementsMember2023-12-310000200406us-gaap:BuildingAndBuildingImprovementsMember2024-12-290000200406us-gaap:BuildingAndBuildingImprovementsMember2023-12-310000200406us-gaap:MachineryAndEquipmentMember2024-12-290000200406us-gaap:MachineryAndEquipmentMember2023-12-310000200406us-gaap:ConstructionInProgressMember2024-12-290000200406us-gaap:ConstructionInProgressMember2023-12-310000200406jnj:PatentsAndTrademarksMember2024-12-290000200406jnj:PatentsAndTrademarksMember2023-12-310000200406us-gaap:OtherIntangibleAssetsMember2024-12-290000200406us-gaap:OtherIntangibleAssetsMember2023-12-310000200406us-gaap:TrademarksMember2024-12-290000200406us-gaap:TrademarksMember2023-12-310000200406jnj:PurchasedInProcessResearchAndDevelopmentMember2024-12-290000200406jnj:PurchasedInProcessResearchAndDevelopmentMember2023-12-310000200406us-gaap:TrademarksMember2024-09-300000200406jnj:InnovativeMedicineMember2023-01-010000200406jnj:MedTechMember2023-01-010000200406jnj:InnovativeMedicineMember2023-01-022023-12-310000200406jnj:MedTechMember2023-01-022023-12-310000200406jnj:InnovativeMedicineMember2023-12-310000200406jnj:MedTechMember2023-12-310000200406jnj:InnovativeMedicineMember2024-01-012024-12-290000200406jnj:MedTechMember2024-01-012024-12-290000200406jnj:InnovativeMedicineMember2024-12-290000200406jnj:MedTechMember2024-12-290000200406us-gaap:ForeignExchangeContractMember2024-12-290000200406us-gaap:ForeignExchangeContractMember2023-12-310000200406us-gaap:CrossCurrencyInterestRateContractMember2024-12-290000200406us-gaap:InterestRateSwapMember2024-12-290000200406us-gaap:CrossCurrencyInterestRateContractMember2023-12-310000200406us-gaap:InterestRateSwapMember2023-12-310000200406us-gaap:InterestRateSwapMemberus-gaap:FairValueHedgingMemberus-gaap:SalesMember2024-01-012024-12-290000200406us-gaap:InterestRateSwapMemberus-gaap:FairValueHedgingMemberus-gaap:CostOfSalesMember2024-01-012024-12-290000200406us-gaap:InterestRateSwapMemberus-gaap:FairValueHedgingMemberus-gaap:ResearchAndDevelopmentExpenseMember2024-01-012024-12-290000200406us-gaap:InterestRateSwapMemberus-gaap:FairValueHedgingMemberjnj:InterestIncomeExpenseNetMember2024-01-012024-12-290000200406us-gaap:InterestRateSwapMemberus-gaap:FairValueHedgingMemberjnj:OtherIncomeExpenseNetMember2024-01-012024-12-290000200406us-gaap:InterestRateSwapMemberus-gaap:FairValueHedgingMemberus-gaap:SalesMember2023-01-022023-12-310000200406us-gaap:InterestRateSwapMemberus-gaap:FairValueHedgingMemberus-gaap:CostOfSalesMember2023-01-022023-12-310000200406us-gaap:InterestRateSwapMemberus-gaap:FairValueHedgingMemberus-gaap:ResearchAndDevelopmentExpenseMember2023-01-022023-12-310000200406us-gaap:InterestRateSwapMemberus-gaap:FairValueHedgingMemberjnj:InterestIncomeExpenseNetMember2023-01-022023-12-310000200406us-gaap:InterestRateSwapMemberus-gaap:FairValueHedgingMemberjnj:OtherIncomeExpenseNetMember2023-01-022023-12-310000200406us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:FairValueHedgingMemberus-gaap:SalesMember2024-01-012024-12-290000200406us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:FairValueHedgingMemberus-gaap:CostOfSalesMember2024-01-012024-12-290000200406us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:FairValueHedgingMemberus-gaap:ResearchAndDevelopmentExpenseMember2024-01-012024-12-290000200406us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:FairValueHedgingMemberjnj:InterestIncomeExpenseNetMember2024-01-012024-12-290000200406us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:FairValueHedgingMemberjnj:OtherIncomeExpenseNetMember2024-01-012024-12-290000200406us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:FairValueHedgingMemberus-gaap:SalesMember2023-01-022023-12-310000200406us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:FairValueHedgingMemberus-gaap:CostOfSalesMember2023-01-022023-12-310000200406us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:FairValueHedgingMemberus-gaap:ResearchAndDevelopmentExpenseMember2023-01-022023-12-310000200406us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:FairValueHedgingMemberjnj:InterestIncomeExpenseNetMember2023-01-022023-12-310000200406us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:FairValueHedgingMemberjnj:OtherIncomeExpenseNetMember2023-01-022023-12-310000200406us-gaap:ForeignExchangeContractMemberus-gaap:CashFlowHedgingMemberus-gaap:SalesMember2024-01-012024-12-290000200406us-gaap:ForeignExchangeContractMemberus-gaap:CashFlowHedgingMemberus-gaap:CostOfSalesMember2024-01-012024-12-290000200406us-gaap:ForeignExchangeContractMemberus-gaap:CashFlowHedgingMemberus-gaap:ResearchAndDevelopmentExpenseMember2024-01-012024-12-290000200406us-gaap:ForeignExchangeContractMemberus-gaap:CashFlowHedgingMemberjnj:InterestIncomeExpenseNetMember2024-01-012024-12-290000200406us-gaap:ForeignExchangeContractMemberus-gaap:CashFlowHedgingMemberjnj:OtherIncomeExpenseNetMember2024-01-012024-12-290000200406us-gaap:ForeignExchangeContractMemberus-gaap:CashFlowHedgingMemberus-gaap:SalesMember2023-01-022023-12-310000200406us-gaap:ForeignExchangeContractMemberus-gaap:CashFlowHedgingMemberus-gaap:CostOfSalesMember2023-01-022023-12-310000200406us-gaap:ForeignExchangeContractMemberus-gaap:CashFlowHedgingMemberus-gaap:ResearchAndDevelopmentExpenseMember2023-01-022023-12-310000200406us-gaap:ForeignExchangeContractMemberus-gaap:CashFlowHedgingMemberjnj:InterestIncomeExpenseNetMember2023-01-022023-12-310000200406us-gaap:ForeignExchangeContractMemberus-gaap:CashFlowHedgingMemberjnj:OtherIncomeExpenseNetMember2023-01-022023-12-310000200406us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:CashFlowHedgingMemberus-gaap:SalesMember2024-01-012024-12-290000200406us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:CashFlowHedgingMemberus-gaap:CostOfSalesMember2024-01-012024-12-290000200406us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:CashFlowHedgingMemberus-gaap:ResearchAndDevelopmentExpenseMember2024-01-012024-12-290000200406us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:CashFlowHedgingMemberjnj:InterestIncomeExpenseNetMember2024-01-012024-12-290000200406us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:CashFlowHedgingMemberjnj:OtherIncomeExpenseNetMember2024-01-012024-12-290000200406us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:CashFlowHedgingMemberus-gaap:SalesMember2023-01-022023-12-310000200406us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:CashFlowHedgingMemberus-gaap:CostOfSalesMember2023-01-022023-12-310000200406us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:CashFlowHedgingMemberus-gaap:ResearchAndDevelopmentExpenseMember2023-01-022023-12-310000200406us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:CashFlowHedgingMemberjnj:InterestIncomeExpenseNetMember2023-01-022023-12-310000200406us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:CashFlowHedgingMemberjnj:OtherIncomeExpenseNetMember2023-01-022023-12-310000200406us-gaap:LongTermDebtMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-12-290000200406us-gaap:LongTermDebtMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-12-310000200406us-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMember2024-01-012024-12-290000200406us-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMember2023-01-022023-12-310000200406jnj:OtherIncomeExpenseNetMember2024-09-302024-12-290000200406jnj:OtherIncomeExpenseNetMember2023-10-022023-12-310000200406us-gaap:CrossCurrencyInterestRateContractMember2024-01-012024-12-290000200406us-gaap:CrossCurrencyInterestRateContractMember2023-01-022023-12-310000200406jnj:OtherIncomeExpenseNetMemberus-gaap:CrossCurrencyInterestRateContractMember2024-09-302024-12-290000200406jnj:OtherIncomeExpenseNetMemberus-gaap:CrossCurrencyInterestRateContractMember2023-10-022023-12-310000200406us-gaap:EquitySecuritiesMemberjnj:EquityInvestmentswithReadilyDeterminableValueMember2023-12-310000200406us-gaap:EquitySecuritiesMemberjnj:EquityInvestmentswithReadilyDeterminableValueMember2024-01-012024-12-290000200406us-gaap:EquitySecuritiesMemberjnj:EquityInvestmentswithReadilyDeterminableValueMember2024-12-290000200406us-gaap:EquitySecuritiesMemberjnj:EquityInvestmentswithoutReadilyDeterminableValueMember2023-12-310000200406us-gaap:EquitySecuritiesMemberjnj:EquityInvestmentswithoutReadilyDeterminableValueMember2024-01-012024-12-290000200406us-gaap:EquitySecuritiesMemberjnj:EquityInvestmentswithoutReadilyDeterminableValueMember2024-12-290000200406us-gaap:EquitySecuritiesMemberjnj:EquityInvestmentswithReadilyDeterminableValueMember2023-01-010000200406us-gaap:EquitySecuritiesMemberjnj:EquityInvestmentswithReadilyDeterminableValueMember2023-01-022023-12-310000200406us-gaap:EquitySecuritiesMemberjnj:EquityInvestmentswithoutReadilyDeterminableValueMember2023-01-010000200406us-gaap:EquitySecuritiesMemberjnj:EquityInvestmentswithoutReadilyDeterminableValueMember2023-01-022023-12-3100002004062024-05-1500002004062024-05-152024-05-1500002004062024-05-1700002004062024-05-172024-05-170000200406us-gaap:FairValueInputsLevel1Memberus-gaap:ForeignExchangeContractMember2024-12-290000200406us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignExchangeContractMember2024-12-290000200406us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignExchangeContractMember2024-12-290000200406us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignExchangeContractMember2023-12-310000200406us-gaap:FairValueInputsLevel1Memberus-gaap:InterestRateContractMember2024-12-290000200406us-gaap:FairValueInputsLevel2Memberus-gaap:InterestRateContractMember2024-12-290000200406us-gaap:FairValueInputsLevel3Memberus-gaap:InterestRateContractMember2024-12-290000200406us-gaap:InterestRateContractMember2024-12-290000200406us-gaap:FairValueInputsLevel2Memberus-gaap:InterestRateContractMember2023-12-310000200406us-gaap:FairValueInputsLevel1Member2024-12-290000200406us-gaap:FairValueInputsLevel2Member2024-12-290000200406us-gaap:FairValueInputsLevel3Member2024-12-290000200406us-gaap:FairValueInputsLevel2Member2023-12-310000200406us-gaap:FairValueInputsLevel1Member2023-12-310000200406us-gaap:FairValueInputsLevel3Member2023-12-310000200406us-gaap:OtherNoncurrentLiabilitiesMember2024-12-290000200406us-gaap:OtherNoncurrentLiabilitiesMember2023-12-310000200406us-gaap:OtherNoncurrentLiabilitiesMember2023-01-010000200406us-gaap:OtherCurrentLiabilitiesMember2023-01-010000200406jnj:ProteologixMember2024-12-290000200406jnj:AbiomedMember2023-01-010000200406jnj:A0.650NotesDue2024Member2024-12-290000200406jnj:A0.650NotesDue2024Member2023-12-310000200406jnj:A5.50NotesDue2024Member2024-12-290000200406jnj:A5.50NotesDue2024Member2023-12-310000200406jnj:A2.625Notesdue2025Member2024-12-290000200406jnj:A2.625Notesdue2025Member2023-12-310000200406jnj:A055NotesDue2025Member2024-12-290000200406jnj:A055NotesDue2025Member2023-12-310000200406jnj:A2.45Notesdue2026Member2024-12-290000200406jnj:A2.45Notesdue2026Member2023-12-310000200406jnj:A2.95Notesdue2027Member2024-12-290000200406jnj:A2.95Notesdue2027Member2023-12-310000200406jnj:A095NotesDue2027Member2024-12-290000200406jnj:A095NotesDue2027Member2023-12-310000200406jnj:A1.150NotesDue2028Member2024-12-290000200406jnj:A1.150NotesDue2028Member2023-12-310000200406jnj:A2.900Notesdue2028Member2024-12-290000200406jnj:A2.900Notesdue2028Member2023-12-310000200406jnj:A6.95Notesdue2029Member2024-12-290000200406jnj:A6.95Notesdue2029Member2023-12-310000200406jnj:A4.80DebenturesDue2029Member2024-12-290000200406jnj:A4.80DebenturesDue2029Member2023-12-310000200406jnj:A130NotesDue2030Member2024-12-290000200406jnj:A130NotesDue2030Member2023-12-310000200406jnj:A4.90DebenturesDue2031Member2024-12-290000200406jnj:A4.90DebenturesDue2031Member2023-12-310000200406jnj:A3.20DebenturesDue2032Member2024-12-290000200406jnj:A3.20DebenturesDue2032Member2023-12-310000200406jnj:A4.95Debenturesdue2033Member2024-12-290000200406jnj:A4.95Debenturesdue2033Member2023-12-310000200406jnj:A4.375Notesdue2033Member2024-12-290000200406jnj:A4.375Notesdue2033Member2023-12-310000200406jnj:A4.95DebenturesDue2034Member2024-12-290000200406jnj:A4.95DebenturesDue2034Member2023-12-310000200406jnj:A1.650NotesDue2035Member2024-12-290000200406jnj:A1.650NotesDue2035Member2023-12-310000200406jnj:A3.35DebenturesDue2036Member2024-12-290000200406jnj:A3.35DebenturesDue2036Member2023-12-310000200406jnj:A3.55Notesdue2036Member2024-12-290000200406jnj:A3.55Notesdue2036Member2023-12-310000200406jnj:A5.95Notesdue2037Member2024-12-290000200406jnj:A5.95Notesdue2037Member2023-12-310000200406jnj:A3.625Notesdue2037Member2024-12-290000200406jnj:A3.625Notesdue2037Member2023-12-310000200406jnj:A5.85Debenturesdue2038Member2024-12-290000200406jnj:A5.85Debenturesdue2038Member2023-12-310000200406jnj:A3.400Notesdue2038Member2024-12-290000200406jnj:A3.400Notesdue2038Member2023-12-310000200406jnj:A4.50Debenturesdue2040Member2024-12-290000200406jnj:A4.50Debenturesdue2040Member2023-12-310000200406jnj:A210NotesDue2040Member2024-12-290000200406jnj:A210NotesDue2040Member2023-12-310000200406jnj:A4.85Notesdue2041Member2024-12-290000200406jnj:A4.85Notesdue2041Member2023-12-310000200406jnj:A4.50Notesdue2043Member2024-12-290000200406jnj:A4.50Notesdue2043Member2023-12-310000200406jnj:A3.55DebenturesDue2044Member2024-12-290000200406jnj:A3.55DebenturesDue2044Member2023-12-310000200406jnj:A3.70Notesdue2046Member2024-12-290000200406jnj:A3.70Notesdue2046Member2023-12-310000200406jnj:A3.75Notesdue2047Member2024-12-290000200406jnj:A3.75Notesdue2047Member2023-12-310000200406jnj:A3.500Notesdue2048Member2024-12-290000200406jnj:A3.500Notesdue2048Member2023-12-310000200406jnj:A2250NotesDue2050Member2024-12-290000200406jnj:A2250NotesDue2050Member2023-12-310000200406jnj:A5.25DebenturesDue2054Member2024-12-290000200406jnj:A5.25DebenturesDue2054Member2023-12-310000200406jnj:A2450NotesDue2060Member2024-12-290000200406jnj:A2450NotesDue2060Member2023-12-310000200406us-gaap:OtherDebtSecuritiesMember2024-12-290000200406us-gaap:OtherDebtSecuritiesMember2023-12-310000200406us-gaap:CommercialPaperMember2024-12-290000200406us-gaap:CommercialPaperMember2024-01-012024-12-290000200406us-gaap:CommercialPaperMember2023-12-310000200406us-gaap:CommercialPaperMember2023-01-022023-12-310000200406jnj:TalcMemberjnj:ConsumerMember2024-01-012024-12-290000200406jnj:TalcMemberjnj:ConsumerMember2023-01-022023-12-3100002004062023-10-022023-12-310000200406us-gaap:StateAndLocalJurisdictionMember2024-01-012024-12-290000200406jnj:TalcMemberjnj:ConsumerMember2022-01-032023-01-010000200406us-gaap:PensionPlansDefinedBenefitMembersrt:MaximumMember2024-01-012024-12-290000200406us-gaap:PensionPlansDefinedBenefitMember2024-01-012024-12-290000200406us-gaap:PensionPlansDefinedBenefitMember2023-01-022023-12-310000200406us-gaap:PensionPlansDefinedBenefitMember2022-01-032023-01-010000200406us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2024-01-012024-12-290000200406us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2023-01-022023-12-310000200406us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2022-01-032023-01-010000200406us-gaap:PensionPlansDefinedBenefitMember2024-12-290000200406us-gaap:PensionPlansDefinedBenefitMember2023-12-310000200406us-gaap:PensionPlansDefinedBenefitMember2023-01-010000200406us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2024-12-290000200406us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2023-12-310000200406us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2023-01-010000200406country:US2024-01-012024-12-290000200406us-gaap:ForeignPlanMember2024-01-012024-12-290000200406country:USjnj:QualifiedPlansMember2024-12-290000200406country:USjnj:QualifiedPlansMember2023-12-310000200406country:USjnj:NonQualifiedPlansMember2024-12-290000200406country:USjnj:NonQualifiedPlansMember2023-12-310000200406us-gaap:ForeignPlanMemberjnj:FundedPlansMember2024-12-290000200406us-gaap:ForeignPlanMemberjnj:FundedPlansMember2023-12-310000200406us-gaap:ForeignPlanMemberjnj:UnfundedPlansMember2024-12-290000200406us-gaap:ForeignPlanMemberjnj:UnfundedPlansMember2023-12-310000200406us-gaap:EquitySecuritiesMember2024-12-290000200406us-gaap:EquitySecuritiesMember2023-12-310000200406us-gaap:DebtSecuritiesMember2024-12-290000200406us-gaap:DebtSecuritiesMember2023-12-310000200406us-gaap:FairValueInputsLevel1Memberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasurementsRecurringMemberjnj:ShortTermInvestmentFundsMember2024-12-290000200406us-gaap:FairValueInputsLevel1Memberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasurementsRecurringMemberjnj:ShortTermInvestmentFundsMember2023-12-310000200406us-gaap:FairValueInputsLevel2Memberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasurementsRecurringMemberjnj:ShortTermInvestmentFundsMember2024-12-290000200406us-gaap:FairValueInputsLevel2Memberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasurementsRecurringMemberjnj:ShortTermInvestmentFundsMember2023-12-310000200406us-gaap:FairValueInputsLevel3Memberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasurementsRecurringMemberjnj:ShortTermInvestmentFundsMember2024-12-290000200406us-gaap:FairValueInputsLevel3Memberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasurementsRecurringMemberjnj:ShortTermInvestmentFundsMember2023-12-310000200406us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasurementsRecurringMemberjnj:ShortTermInvestmentFundsMember2024-12-290000200406us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasurementsRecurringMemberjnj:ShortTermInvestmentFundsMember2023-12-310000200406us-gaap:FairValueInputsLevel1Memberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember2024-12-290000200406us-gaap:FairValueInputsLevel1Memberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember2023-12-310000200406us-gaap:FairValueInputsLevel2Memberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember2024-12-290000200406us-gaap:FairValueInputsLevel2Memberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember2023-12-310000200406us-gaap:FairValueInputsLevel3Memberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember2024-12-290000200406us-gaap:FairValueInputsLevel3Memberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember2023-12-310000200406us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember2024-12-290000200406us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember2023-12-310000200406us-gaap:FairValueInputsLevel1Memberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:DebtSecuritiesMember2024-12-290000200406us-gaap:FairValueInputsLevel1Memberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:DebtSecuritiesMember2023-12-310000200406us-gaap:FairValueInputsLevel2Memberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:DebtSecuritiesMember2024-12-290000200406us-gaap:FairValueInputsLevel2Memberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:DebtSecuritiesMember2023-12-310000200406us-gaap:FairValueInputsLevel3Memberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:DebtSecuritiesMember2024-12-290000200406us-gaap:FairValueInputsLevel3Memberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:DebtSecuritiesMember2023-12-310000200406us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:DebtSecuritiesMember2024-12-290000200406us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:DebtSecuritiesMember2023-12-310000200406us-gaap:FairValueInputsLevel1Memberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:EquitySecuritiesMember2024-12-290000200406us-gaap:FairValueInputsLevel1Memberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:EquitySecuritiesMember2023-12-310000200406us-gaap:FairValueInputsLevel2Memberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:EquitySecuritiesMember2024-12-290000200406us-gaap:FairValueInputsLevel2Memberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:EquitySecuritiesMember2023-12-310000200406us-gaap:FairValueInputsLevel3Memberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:EquitySecuritiesMember2024-12-290000200406us-gaap:FairValueInputsLevel3Memberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:EquitySecuritiesMember2023-12-310000200406us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:EquitySecuritiesMember2024-12-290000200406us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:EquitySecuritiesMember2023-12-310000200406us-gaap:FairValueInputsLevel1Memberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasurementsRecurringMemberjnj:CommingledFundsMember2024-12-290000200406us-gaap:FairValueInputsLevel1Memberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasurementsRecurringMemberjnj:CommingledFundsMember2023-12-310000200406us-gaap:FairValueInputsLevel2Memberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasurementsRecurringMemberjnj:CommingledFundsMember2024-12-290000200406us-gaap:FairValueInputsLevel2Memberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasurementsRecurringMemberjnj:CommingledFundsMember2023-12-310000200406us-gaap:FairValueInputsLevel3Memberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasurementsRecurringMemberjnj:CommingledFundsMember2024-12-290000200406us-gaap:FairValueInputsLevel3Memberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasurementsRecurringMemberjnj:CommingledFundsMember2023-12-310000200406us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasurementsRecurringMemberjnj:CommingledFundsMember2024-12-290000200406us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasurementsRecurringMemberjnj:CommingledFundsMember2023-12-310000200406us-gaap:FairValueInputsLevel1Memberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherAssetsMember2024-12-290000200406us-gaap:FairValueInputsLevel1Memberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherAssetsMember2023-12-310000200406us-gaap:FairValueInputsLevel2Memberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherAssetsMember2024-12-290000200406us-gaap:FairValueInputsLevel2Memberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherAssetsMember2023-12-310000200406us-gaap:FairValueInputsLevel3Memberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherAssetsMember2024-12-290000200406us-gaap:FairValueInputsLevel3Memberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherAssetsMember2023-12-310000200406us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherAssetsMember2024-12-290000200406us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherAssetsMember2023-12-310000200406us-gaap:FairValueInputsLevel1Memberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasurementsRecurringMember2024-12-290000200406us-gaap:FairValueInputsLevel1Memberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000200406us-gaap:FairValueInputsLevel2Memberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasurementsRecurringMember2024-12-290000200406us-gaap:FairValueInputsLevel2Memberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000200406us-gaap:FairValueInputsLevel3Memberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasurementsRecurringMember2024-12-290000200406us-gaap:FairValueInputsLevel3Memberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000200406us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasurementsRecurringMember2024-12-290000200406us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000200406us-gaap:FairValueInputsLevel2Memberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberjnj:CommingledFundsMember2024-12-290000200406us-gaap:FairValueInputsLevel2Memberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberjnj:CommingledFundsMember2023-12-310000200406us-gaap:SubsequentEventMember2025-01-022025-01-020000200406jnj:December172018ShareRepurchaseProgramMember2022-09-140000200406us-gaap:AccumulatedTranslationAdjustmentMember2022-01-020000200406us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2022-01-020000200406us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2022-01-020000200406us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2022-01-020000200406us-gaap:AccumulatedTranslationAdjustmentMember2022-01-032023-01-010000200406us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2022-01-032023-01-010000200406us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2022-01-032023-01-010000200406us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2022-01-032023-01-010000200406us-gaap:AccumulatedTranslationAdjustmentMember2023-01-010000200406us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2023-01-010000200406us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-01-010000200406us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2023-01-010000200406us-gaap:AccumulatedTranslationAdjustmentMember2023-01-022023-12-310000200406us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2023-01-022023-12-310000200406us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-01-022023-12-310000200406us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2023-01-022023-12-310000200406us-gaap:AccumulatedTranslationAdjustmentMember2023-12-310000200406us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2023-12-310000200406us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-12-310000200406us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2023-12-310000200406us-gaap:AccumulatedTranslationAdjustmentMember2024-01-012024-12-290000200406us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2024-01-012024-12-290000200406us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2024-01-012024-12-290000200406us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2024-01-012024-12-290000200406us-gaap:AccumulatedTranslationAdjustmentMember2024-12-290000200406us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2024-12-290000200406us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2024-12-290000200406us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2024-12-2900002004062021-01-042022-01-020000200406jnj:A2022LongTermIncentivePlanMember2024-12-290000200406us-gaap:EmployeeStockOptionMember2024-01-012024-12-290000200406us-gaap:EmployeeStockOptionMembersrt:MinimumMember2024-01-012024-12-290000200406us-gaap:EmployeeStockOptionMembersrt:MaximumMember2024-01-012024-12-290000200406jnj:ExercisePriceRangeOneMember2024-01-012024-12-290000200406jnj:ExercisePriceRangeOneMember2024-12-290000200406jnj:ExercisePriceRangeTwoMember2024-01-012024-12-290000200406jnj:ExercisePriceRangeTwoMember2024-12-290000200406jnj:ExercisePriceRangeThreeMember2024-01-012024-12-290000200406jnj:ExercisePriceRangeThreeMember2024-12-290000200406jnj:ExercisePriceRangeFourMember2024-01-012024-12-290000200406jnj:ExercisePriceRangeFourMember2024-12-290000200406jnj:ExercisePriceRangeFiveMember2024-01-012024-12-290000200406jnj:ExercisePriceRangeFiveMember2024-12-290000200406us-gaap:RestrictedStockUnitsRSUMembersrt:MinimumMember2024-01-012024-12-290000200406us-gaap:RestrictedStockUnitsRSUMembersrt:MaximumMember2024-01-012024-12-290000200406us-gaap:PerformanceSharesMember2024-01-012024-12-290000200406us-gaap:PerformanceSharesMembersrt:MinimumMember2024-01-012024-12-290000200406us-gaap:PerformanceSharesMembersrt:MaximumMember2024-01-012024-12-290000200406us-gaap:RestrictedStockUnitsRSUMember2023-12-310000200406us-gaap:PerformanceSharesMember2023-12-310000200406us-gaap:RestrictedStockUnitsRSUMember2024-01-012024-12-290000200406us-gaap:RestrictedStockUnitsRSUMember2024-12-290000200406us-gaap:PerformanceSharesMember2024-12-290000200406us-gaap:RestrictedStockUnitsRSUMember2023-01-022023-12-310000200406us-gaap:RestrictedStockUnitsRSUMember2022-01-032023-01-010000200406us-gaap:PerformanceSharesMember2023-01-022023-12-310000200406us-gaap:PerformanceSharesMember2022-01-032023-01-010000200406country:USjnj:InnovativeMedicineMemberjnj:ImmunologyMember2024-01-012024-12-290000200406country:USjnj:InnovativeMedicineMemberjnj:ImmunologyMember2023-01-022023-12-310000200406country:USjnj:InnovativeMedicineMemberjnj:ImmunologyMember2022-01-032023-01-010000200406us-gaap:NonUsMemberjnj:InnovativeMedicineMemberjnj:ImmunologyMember2024-01-012024-12-290000200406us-gaap:NonUsMemberjnj:InnovativeMedicineMemberjnj:ImmunologyMember2023-01-022023-12-310000200406us-gaap:NonUsMemberjnj:InnovativeMedicineMemberjnj:ImmunologyMember2022-01-032023-01-010000200406jnj:InnovativeMedicineMemberjnj:ImmunologyMember2024-01-012024-12-290000200406jnj:InnovativeMedicineMemberjnj:ImmunologyMember2023-01-022023-12-310000200406jnj:InnovativeMedicineMemberjnj:ImmunologyMember2022-01-032023-01-010000200406country:USjnj:RemicadeMemberjnj:InnovativeMedicineMemberjnj:ImmunologyMember2024-01-012024-12-290000200406country:USjnj:RemicadeMemberjnj:InnovativeMedicineMemberjnj:ImmunologyMember2023-01-022023-12-310000200406country:USjnj:RemicadeMemberjnj:InnovativeMedicineMemberjnj:ImmunologyMember2022-01-032023-01-010000200406jnj:UNITEDSTATESExportsMemberjnj:RemicadeMemberjnj:InnovativeMedicineMemberjnj:ImmunologyMember2024-01-012024-12-290000200406jnj:UNITEDSTATESExportsMemberjnj:RemicadeMemberjnj:InnovativeMedicineMemberjnj:ImmunologyMember2023-01-022023-12-310000200406jnj:UNITEDSTATESExportsMemberjnj:RemicadeMemberjnj:InnovativeMedicineMemberjnj:ImmunologyMember2022-01-032023-01-010000200406us-gaap:NonUsMemberjnj:RemicadeMemberjnj:InnovativeMedicineMemberjnj:ImmunologyMember2024-01-012024-12-290000200406us-gaap:NonUsMemberjnj:RemicadeMemberjnj:InnovativeMedicineMemberjnj:ImmunologyMember2023-01-022023-12-310000200406us-gaap:NonUsMemberjnj:RemicadeMemberjnj:InnovativeMedicineMemberjnj:ImmunologyMember2022-01-032023-01-010000200406jnj:RemicadeMemberjnj:InnovativeMedicineMemberjnj:ImmunologyMember2024-01-012024-12-290000200406jnj:RemicadeMemberjnj:InnovativeMedicineMemberjnj:ImmunologyMember2023-01-022023-12-310000200406jnj:RemicadeMemberjnj:InnovativeMedicineMemberjnj:ImmunologyMember2022-01-032023-01-010000200406country:USjnj:SimponiSimponiAriaMemberjnj:InnovativeMedicineMemberjnj:ImmunologyMember2024-01-012024-12-290000200406country:USjnj:SimponiSimponiAriaMemberjnj:InnovativeMedicineMemberjnj:ImmunologyMember2023-01-022023-12-310000200406country:USjnj:SimponiSimponiAriaMemberjnj:InnovativeMedicineMemberjnj:ImmunologyMember2022-01-032023-01-010000200406us-gaap:NonUsMemberjnj:SimponiSimponiAriaMemberjnj:InnovativeMedicineMemberjnj:ImmunologyMember2024-01-012024-12-290000200406us-gaap:NonUsMemberjnj:SimponiSimponiAriaMemberjnj:InnovativeMedicineMemberjnj:ImmunologyMember2023-01-022023-12-310000200406us-gaap:NonUsMemberjnj:SimponiSimponiAriaMemberjnj:InnovativeMedicineMemberjnj:ImmunologyMember2022-01-032023-01-010000200406jnj:SimponiSimponiAriaMemberjnj:InnovativeMedicineMemberjnj:ImmunologyMember2024-01-012024-12-290000200406jnj:SimponiSimponiAriaMemberjnj:InnovativeMedicineMemberjnj:ImmunologyMember2023-01-022023-12-310000200406jnj:SimponiSimponiAriaMemberjnj:InnovativeMedicineMemberjnj:ImmunologyMember2022-01-032023-01-010000200406country:USjnj:StelaraMemberjnj:InnovativeMedicineMemberjnj:ImmunologyMember2024-01-012024-12-290000200406country:USjnj:StelaraMemberjnj:InnovativeMedicineMemberjnj:ImmunologyMember2023-01-022023-12-310000200406country:USjnj:StelaraMemberjnj:InnovativeMedicineMemberjnj:ImmunologyMember2022-01-032023-01-010000200406us-gaap:NonUsMemberjnj:StelaraMemberjnj:InnovativeMedicineMemberjnj:ImmunologyMember2024-01-012024-12-290000200406us-gaap:NonUsMemberjnj:StelaraMemberjnj:InnovativeMedicineMemberjnj:ImmunologyMember2023-01-022023-12-310000200406us-gaap:NonUsMemberjnj:StelaraMemberjnj:InnovativeMedicineMemberjnj:ImmunologyMember2022-01-032023-01-010000200406jnj:StelaraMemberjnj:InnovativeMedicineMemberjnj:ImmunologyMember2024-01-012024-12-290000200406jnj:StelaraMemberjnj:InnovativeMedicineMemberjnj:ImmunologyMember2023-01-022023-12-310000200406jnj:StelaraMemberjnj:InnovativeMedicineMemberjnj:ImmunologyMember2022-01-032023-01-010000200406country:USjnj:TremfyaMemberjnj:InnovativeMedicineMemberjnj:ImmunologyMember2024-01-012024-12-290000200406country:USjnj:TremfyaMemberjnj:InnovativeMedicineMemberjnj:ImmunologyMember2023-01-022023-12-310000200406country:USjnj:TremfyaMemberjnj:InnovativeMedicineMemberjnj:ImmunologyMember2022-01-032023-01-010000200406us-gaap:NonUsMemberjnj:TremfyaMemberjnj:InnovativeMedicineMemberjnj:ImmunologyMember2024-01-012024-12-290000200406us-gaap:NonUsMemberjnj:TremfyaMemberjnj:InnovativeMedicineMemberjnj:ImmunologyMember2023-01-022023-12-310000200406us-gaap:NonUsMemberjnj:TremfyaMemberjnj:InnovativeMedicineMemberjnj:ImmunologyMember2022-01-032023-01-010000200406jnj:TremfyaMemberjnj:InnovativeMedicineMemberjnj:ImmunologyMember2024-01-012024-12-290000200406jnj:TremfyaMemberjnj:InnovativeMedicineMemberjnj:ImmunologyMember2023-01-022023-12-310000200406jnj:TremfyaMemberjnj:InnovativeMedicineMemberjnj:ImmunologyMember2022-01-032023-01-010000200406country:USjnj:OtherImmunologyMemberjnj:InnovativeMedicineMemberjnj:ImmunologyMember2024-01-012024-12-290000200406country:USjnj:OtherImmunologyMemberjnj:InnovativeMedicineMemberjnj:ImmunologyMember2023-01-022023-12-310000200406country:USjnj:OtherImmunologyMemberjnj:InnovativeMedicineMemberjnj:ImmunologyMember2022-01-032023-01-010000200406us-gaap:NonUsMemberjnj:OtherImmunologyMemberjnj:InnovativeMedicineMemberjnj:ImmunologyMember2024-01-012024-12-290000200406us-gaap:NonUsMemberjnj:OtherImmunologyMemberjnj:InnovativeMedicineMemberjnj:ImmunologyMember2023-01-022023-12-310000200406us-gaap:NonUsMemberjnj:OtherImmunologyMemberjnj:InnovativeMedicineMemberjnj:ImmunologyMember2022-01-032023-01-010000200406jnj:OtherImmunologyMemberjnj:InnovativeMedicineMemberjnj:ImmunologyMember2024-01-012024-12-290000200406jnj:OtherImmunologyMemberjnj:InnovativeMedicineMemberjnj:ImmunologyMember2023-01-022023-12-310000200406jnj:OtherImmunologyMemberjnj:InnovativeMedicineMemberjnj:ImmunologyMember2022-01-032023-01-010000200406country:USjnj:InnovativeMedicineMemberjnj:InfectiousDiseasesMember2024-01-012024-12-290000200406country:USjnj:InnovativeMedicineMemberjnj:InfectiousDiseasesMember2023-01-022023-12-310000200406country:USjnj:InnovativeMedicineMemberjnj:InfectiousDiseasesMember2022-01-032023-01-010000200406us-gaap:NonUsMemberjnj:InnovativeMedicineMemberjnj:InfectiousDiseasesMember2024-01-012024-12-290000200406us-gaap:NonUsMemberjnj:InnovativeMedicineMemberjnj:InfectiousDiseasesMember2023-01-022023-12-310000200406us-gaap:NonUsMemberjnj:InnovativeMedicineMemberjnj:InfectiousDiseasesMember2022-01-032023-01-010000200406jnj:InnovativeMedicineMemberjnj:InfectiousDiseasesMember2024-01-012024-12-290000200406jnj:InnovativeMedicineMemberjnj:InfectiousDiseasesMember2023-01-022023-12-310000200406jnj:InnovativeMedicineMemberjnj:InfectiousDiseasesMember2022-01-032023-01-010000200406country:USjnj:COVID19Memberjnj:InnovativeMedicineMemberjnj:InfectiousDiseasesMember2024-01-012024-12-290000200406country:USjnj:COVID19Memberjnj:InnovativeMedicineMemberjnj:InfectiousDiseasesMember2023-01-022023-12-310000200406country:USjnj:COVID19Memberjnj:InnovativeMedicineMemberjnj:InfectiousDiseasesMember2022-01-032023-01-010000200406us-gaap:NonUsMemberjnj:COVID19Memberjnj:InnovativeMedicineMemberjnj:InfectiousDiseasesMember2024-01-012024-12-290000200406us-gaap:NonUsMemberjnj:COVID19Memberjnj:InnovativeMedicineMemberjnj:InfectiousDiseasesMember2023-01-022023-12-310000200406us-gaap:NonUsMemberjnj:COVID19Memberjnj:InnovativeMedicineMemberjnj:InfectiousDiseasesMember2022-01-032023-01-010000200406jnj:COVID19Memberjnj:InnovativeMedicineMemberjnj:InfectiousDiseasesMember2024-01-012024-12-290000200406jnj:COVID19Memberjnj:InnovativeMedicineMemberjnj:InfectiousDiseasesMember2023-01-022023-12-310000200406jnj:COVID19Memberjnj:InnovativeMedicineMemberjnj:InfectiousDiseasesMember2022-01-032023-01-010000200406country:USjnj:EDURANTrilpivirineMemberjnj:InnovativeMedicineMemberjnj:InfectiousDiseasesMember2024-01-012024-12-290000200406country:USjnj:EDURANTrilpivirineMemberjnj:InnovativeMedicineMemberjnj:InfectiousDiseasesMember2023-01-022023-12-310000200406country:USjnj:EDURANTrilpivirineMemberjnj:InnovativeMedicineMemberjnj:InfectiousDiseasesMember2022-01-032023-01-010000200406us-gaap:NonUsMemberjnj:EDURANTrilpivirineMemberjnj:InnovativeMedicineMemberjnj:InfectiousDiseasesMember2024-01-012024-12-290000200406us-gaap:NonUsMemberjnj:EDURANTrilpivirineMemberjnj:InnovativeMedicineMemberjnj:InfectiousDiseasesMember2023-01-022023-12-310000200406us-gaap:NonUsMemberjnj:EDURANTrilpivirineMemberjnj:InnovativeMedicineMemberjnj:InfectiousDiseasesMember2022-01-032023-01-010000200406jnj:EDURANTrilpivirineMemberjnj:InnovativeMedicineMemberjnj:InfectiousDiseasesMember2024-01-012024-12-290000200406jnj:EDURANTrilpivirineMemberjnj:InnovativeMedicineMemberjnj:InfectiousDiseasesMember2023-01-022023-12-310000200406jnj:EDURANTrilpivirineMemberjnj:InnovativeMedicineMemberjnj:InfectiousDiseasesMember2022-01-032023-01-010000200406country:USjnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMemberjnj:InnovativeMedicineMemberjnj:InfectiousDiseasesMember2024-01-012024-12-290000200406country:USjnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMemberjnj:InnovativeMedicineMemberjnj:InfectiousDiseasesMember2023-01-022023-12-310000200406country:USjnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMemberjnj:InnovativeMedicineMemberjnj:InfectiousDiseasesMember2022-01-032023-01-010000200406us-gaap:NonUsMemberjnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMemberjnj:InnovativeMedicineMemberjnj:InfectiousDiseasesMember2024-01-012024-12-290000200406us-gaap:NonUsMemberjnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMemberjnj:InnovativeMedicineMemberjnj:InfectiousDiseasesMember2023-01-022023-12-310000200406us-gaap:NonUsMemberjnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMemberjnj:InnovativeMedicineMemberjnj:InfectiousDiseasesMember2022-01-032023-01-010000200406jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMemberjnj:InnovativeMedicineMemberjnj:InfectiousDiseasesMember2024-01-012024-12-290000200406jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMemberjnj:InnovativeMedicineMemberjnj:InfectiousDiseasesMember2023-01-022023-12-310000200406jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMemberjnj:InnovativeMedicineMemberjnj:InfectiousDiseasesMember2022-01-032023-01-010000200406country:USjnj:OtherInfectiousDiseasesMemberjnj:InnovativeMedicineMemberjnj:InfectiousDiseasesMember2024-01-012024-12-290000200406country:USjnj:OtherInfectiousDiseasesMemberjnj:InnovativeMedicineMemberjnj:InfectiousDiseasesMember2023-01-022023-12-310000200406country:USjnj:OtherInfectiousDiseasesMemberjnj:InnovativeMedicineMemberjnj:InfectiousDiseasesMember2022-01-032023-01-010000200406us-gaap:NonUsMemberjnj:OtherInfectiousDiseasesMemberjnj:InnovativeMedicineMemberjnj:InfectiousDiseasesMember2024-01-012024-12-290000200406us-gaap:NonUsMemberjnj:OtherInfectiousDiseasesMemberjnj:InnovativeMedicineMemberjnj:InfectiousDiseasesMember2023-01-022023-12-310000200406us-gaap:NonUsMemberjnj:OtherInfectiousDiseasesMemberjnj:InnovativeMedicineMemberjnj:InfectiousDiseasesMember2022-01-032023-01-010000200406jnj:OtherInfectiousDiseasesMemberjnj:InnovativeMedicineMemberjnj:InfectiousDiseasesMember2024-01-012024-12-290000200406jnj:OtherInfectiousDiseasesMemberjnj:InnovativeMedicineMemberjnj:InfectiousDiseasesMember2023-01-022023-12-310000200406jnj:OtherInfectiousDiseasesMemberjnj:InnovativeMedicineMemberjnj:InfectiousDiseasesMember2022-01-032023-01-010000200406country:USjnj:InnovativeMedicineMemberjnj:NeuroscienceMember2024-01-012024-12-290000200406country:USjnj:InnovativeMedicineMemberjnj:NeuroscienceMember2023-01-022023-12-310000200406country:USjnj:InnovativeMedicineMemberjnj:NeuroscienceMember2022-01-032023-01-010000200406us-gaap:NonUsMemberjnj:InnovativeMedicineMemberjnj:NeuroscienceMember2024-01-012024-12-290000200406us-gaap:NonUsMemberjnj:InnovativeMedicineMemberjnj:NeuroscienceMember2023-01-022023-12-310000200406us-gaap:NonUsMemberjnj:InnovativeMedicineMemberjnj:NeuroscienceMember2022-01-032023-01-010000200406jnj:InnovativeMedicineMemberjnj:NeuroscienceMember2024-01-012024-12-290000200406jnj:InnovativeMedicineMemberjnj:NeuroscienceMember2023-01-022023-12-310000200406jnj:InnovativeMedicineMemberjnj:NeuroscienceMember2022-01-032023-01-010000200406country:USjnj:CONCERTAMethylphenidateMemberjnj:InnovativeMedicineMemberjnj:NeuroscienceMember2024-01-012024-12-290000200406country:USjnj:CONCERTAMethylphenidateMemberjnj:InnovativeMedicineMemberjnj:NeuroscienceMember2023-01-022023-12-310000200406country:USjnj:CONCERTAMethylphenidateMemberjnj:InnovativeMedicineMemberjnj:NeuroscienceMember2022-01-032023-01-010000200406us-gaap:NonUsMemberjnj:CONCERTAMethylphenidateMemberjnj:InnovativeMedicineMemberjnj:NeuroscienceMember2024-01-012024-12-290000200406us-gaap:NonUsMemberjnj:CONCERTAMethylphenidateMemberjnj:InnovativeMedicineMemberjnj:NeuroscienceMember2023-01-022023-12-310000200406us-gaap:NonUsMemberjnj:CONCERTAMethylphenidateMemberjnj:InnovativeMedicineMemberjnj:NeuroscienceMember2022-01-032023-01-010000200406jnj:CONCERTAMethylphenidateMemberjnj:InnovativeMedicineMemberjnj:NeuroscienceMember2024-01-012024-12-290000200406jnj:CONCERTAMethylphenidateMemberjnj:InnovativeMedicineMemberjnj:NeuroscienceMember2023-01-022023-12-310000200406jnj:CONCERTAMethylphenidateMemberjnj:InnovativeMedicineMemberjnj:NeuroscienceMember2022-01-032023-01-010000200406country:USjnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMemberjnj:InnovativeMedicineMemberjnj:NeuroscienceMember2024-01-012024-12-290000200406country:USjnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMemberjnj:InnovativeMedicineMemberjnj:NeuroscienceMember2023-01-022023-12-310000200406country:USjnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMemberjnj:InnovativeMedicineMemberjnj:NeuroscienceMember2022-01-032023-01-010000200406us-gaap:NonUsMemberjnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMemberjnj:InnovativeMedicineMemberjnj:NeuroscienceMember2024-01-012024-12-290000200406us-gaap:NonUsMemberjnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMemberjnj:InnovativeMedicineMemberjnj:NeuroscienceMember2023-01-022023-12-310000200406us-gaap:NonUsMemberjnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMemberjnj:InnovativeMedicineMemberjnj:NeuroscienceMember2022-01-032023-01-010000200406jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMemberjnj:InnovativeMedicineMemberjnj:NeuroscienceMember2024-01-012024-12-290000200406jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMemberjnj:InnovativeMedicineMemberjnj:NeuroscienceMember2023-01-022023-12-310000200406jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMemberjnj:InnovativeMedicineMemberjnj:NeuroscienceMember2022-01-032023-01-010000200406country:USjnj:SPRAVATOMemberjnj:InnovativeMedicineMemberjnj:NeuroscienceMember2024-01-012024-12-290000200406country:USjnj:SPRAVATOMemberjnj:InnovativeMedicineMemberjnj:NeuroscienceMember2023-01-022023-12-310000200406country:USjnj:SPRAVATOMemberjnj:InnovativeMedicineMemberjnj:NeuroscienceMember2022-01-032023-01-010000200406us-gaap:NonUsMemberjnj:SPRAVATOMemberjnj:InnovativeMedicineMemberjnj:NeuroscienceMember2024-01-012024-12-290000200406us-gaap:NonUsMemberjnj:SPRAVATOMemberjnj:InnovativeMedicineMemberjnj:NeuroscienceMember2023-01-022023-12-310000200406us-gaap:NonUsMemberjnj:SPRAVATOMemberjnj:InnovativeMedicineMemberjnj:NeuroscienceMember2022-01-032023-01-010000200406jnj:SPRAVATOMemberjnj:InnovativeMedicineMemberjnj:NeuroscienceMember2024-01-012024-12-290000200406jnj:SPRAVATOMemberjnj:InnovativeMedicineMemberjnj:NeuroscienceMember2023-01-022023-12-310000200406jnj:SPRAVATOMemberjnj:InnovativeMedicineMemberjnj:NeuroscienceMember2022-01-032023-01-010000200406country:USjnj:OTHERNEUROSCIENCEMemberjnj:InnovativeMedicineMemberjnj:NeuroscienceMember2024-01-012024-12-290000200406country:USjnj:OTHERNEUROSCIENCEMemberjnj:InnovativeMedicineMemberjnj:NeuroscienceMember2023-01-022023-12-310000200406country:USjnj:OTHERNEUROSCIENCEMemberjnj:InnovativeMedicineMemberjnj:NeuroscienceMember2022-01-032023-01-010000200406us-gaap:NonUsMemberjnj:OTHERNEUROSCIENCEMemberjnj:InnovativeMedicineMemberjnj:NeuroscienceMember2024-01-012024-12-290000200406us-gaap:NonUsMemberjnj:OTHERNEUROSCIENCEMemberjnj:InnovativeMedicineMemberjnj:NeuroscienceMember2023-01-022023-12-310000200406us-gaap:NonUsMemberjnj:OTHERNEUROSCIENCEMemberjnj:InnovativeMedicineMemberjnj:NeuroscienceMember2022-01-032023-01-010000200406jnj:OTHERNEUROSCIENCEMemberjnj:InnovativeMedicineMemberjnj:NeuroscienceMember2024-01-012024-12-290000200406jnj:OTHERNEUROSCIENCEMemberjnj:InnovativeMedicineMemberjnj:NeuroscienceMember2023-01-022023-12-310000200406jnj:OTHERNEUROSCIENCEMemberjnj:InnovativeMedicineMemberjnj:NeuroscienceMember2022-01-032023-01-010000200406country:USjnj:InnovativeMedicineMemberjnj:OncologyMember2024-01-012024-12-290000200406country:USjnj:InnovativeMedicineMemberjnj:OncologyMember2023-01-022023-12-310000200406country:USjnj:InnovativeMedicineMemberjnj:OncologyMember2022-01-032023-01-010000200406us-gaap:NonUsMemberjnj:InnovativeMedicineMemberjnj:OncologyMember2024-01-012024-12-290000200406us-gaap:NonUsMemberjnj:InnovativeMedicineMemberjnj:OncologyMember2023-01-022023-12-310000200406us-gaap:NonUsMemberjnj:InnovativeMedicineMemberjnj:OncologyMember2022-01-032023-01-010000200406jnj:InnovativeMedicineMemberjnj:OncologyMember2024-01-012024-12-290000200406jnj:InnovativeMedicineMemberjnj:OncologyMember2023-01-022023-12-310000200406jnj:InnovativeMedicineMemberjnj:OncologyMember2022-01-032023-01-010000200406country:USjnj:CARVYKTIMemberjnj:InnovativeMedicineMemberjnj:OncologyMember2024-01-012024-12-290000200406country:USjnj:CARVYKTIMemberjnj:InnovativeMedicineMemberjnj:OncologyMember2023-01-022023-12-310000200406country:USjnj:CARVYKTIMemberjnj:InnovativeMedicineMemberjnj:OncologyMember2022-01-032023-01-010000200406us-gaap:NonUsMemberjnj:CARVYKTIMemberjnj:InnovativeMedicineMemberjnj:OncologyMember2024-01-012024-12-290000200406us-gaap:NonUsMemberjnj:CARVYKTIMemberjnj:InnovativeMedicineMemberjnj:OncologyMember2023-01-022023-12-310000200406us-gaap:NonUsMemberjnj:CARVYKTIMemberjnj:InnovativeMedicineMemberjnj:OncologyMember2022-01-032023-01-010000200406jnj:CARVYKTIMemberjnj:InnovativeMedicineMemberjnj:OncologyMember2024-01-012024-12-290000200406jnj:CARVYKTIMemberjnj:InnovativeMedicineMemberjnj:OncologyMember2023-01-022023-12-310000200406jnj:CARVYKTIMemberjnj:InnovativeMedicineMemberjnj:OncologyMember2022-01-032023-01-010000200406country:USjnj:DARZALEXMemberjnj:InnovativeMedicineMemberjnj:OncologyMember2024-01-012024-12-290000200406country:USjnj:DARZALEXMemberjnj:InnovativeMedicineMemberjnj:OncologyMember2023-01-022023-12-310000200406country:USjnj:DARZALEXMemberjnj:InnovativeMedicineMemberjnj:OncologyMember2022-01-032023-01-010000200406us-gaap:NonUsMemberjnj:DARZALEXMemberjnj:InnovativeMedicineMemberjnj:OncologyMember2024-01-012024-12-290000200406us-gaap:NonUsMemberjnj:DARZALEXMemberjnj:InnovativeMedicineMemberjnj:OncologyMember2023-01-022023-12-310000200406us-gaap:NonUsMemberjnj:DARZALEXMemberjnj:InnovativeMedicineMemberjnj:OncologyMember2022-01-032023-01-010000200406jnj:DARZALEXMemberjnj:InnovativeMedicineMemberjnj:OncologyMember2024-01-012024-12-290000200406jnj:DARZALEXMemberjnj:InnovativeMedicineMemberjnj:OncologyMember2023-01-022023-12-310000200406jnj:DARZALEXMemberjnj:InnovativeMedicineMemberjnj:OncologyMember2022-01-032023-01-010000200406country:USjnj:ErleadaMemberjnj:InnovativeMedicineMemberjnj:OncologyMember2024-01-012024-12-290000200406country:USjnj:ErleadaMemberjnj:InnovativeMedicineMemberjnj:OncologyMember2023-01-022023-12-310000200406country:USjnj:ErleadaMemberjnj:InnovativeMedicineMemberjnj:OncologyMember2022-01-032023-01-010000200406us-gaap:NonUsMemberjnj:ErleadaMemberjnj:InnovativeMedicineMemberjnj:OncologyMember2024-01-012024-12-290000200406us-gaap:NonUsMemberjnj:ErleadaMemberjnj:InnovativeMedicineMemberjnj:OncologyMember2023-01-022023-12-310000200406us-gaap:NonUsMemberjnj:ErleadaMemberjnj:InnovativeMedicineMemberjnj:OncologyMember2022-01-032023-01-010000200406jnj:ErleadaMemberjnj:InnovativeMedicineMemberjnj:OncologyMember2024-01-012024-12-290000200406jnj:ErleadaMemberjnj:InnovativeMedicineMemberjnj:OncologyMember2023-01-022023-12-310000200406jnj:ErleadaMemberjnj:InnovativeMedicineMemberjnj:OncologyMember2022-01-032023-01-010000200406country:USjnj:IMBRUVICAMemberjnj:InnovativeMedicineMemberjnj:OncologyMember2024-01-012024-12-290000200406country:USjnj:IMBRUVICAMemberjnj:InnovativeMedicineMemberjnj:OncologyMember2023-01-022023-12-310000200406country:USjnj:IMBRUVICAMemberjnj:InnovativeMedicineMemberjnj:OncologyMember2022-01-032023-01-010000200406us-gaap:NonUsMemberjnj:IMBRUVICAMemberjnj:InnovativeMedicineMemberjnj:OncologyMember2024-01-012024-12-290000200406us-gaap:NonUsMemberjnj:IMBRUVICAMemberjnj:InnovativeMedicineMemberjnj:OncologyMember2023-01-022023-12-310000200406us-gaap:NonUsMemberjnj:IMBRUVICAMemberjnj:InnovativeMedicineMemberjnj:OncologyMember2022-01-032023-01-010000200406jnj:IMBRUVICAMemberjnj:InnovativeMedicineMemberjnj:OncologyMember2024-01-012024-12-290000200406jnj:IMBRUVICAMemberjnj:InnovativeMedicineMemberjnj:OncologyMember2023-01-022023-12-310000200406jnj:IMBRUVICAMemberjnj:InnovativeMedicineMemberjnj:OncologyMember2022-01-032023-01-010000200406country:USjnj:TECVAYLIMemberjnj:PharmaceuticalMemberjnj:OncologyMember2024-01-012024-12-290000200406country:USjnj:TECVAYLIMemberjnj:PharmaceuticalMemberjnj:OncologyMember2023-01-022023-12-310000200406country:USjnj:TECVAYLIMemberjnj:PharmaceuticalMemberjnj:OncologyMember2022-01-032023-01-010000200406us-gaap:NonUsMemberjnj:TECVAYLIMemberjnj:PharmaceuticalMemberjnj:OncologyMember2024-01-012024-12-290000200406us-gaap:NonUsMemberjnj:TECVAYLIMemberjnj:PharmaceuticalMemberjnj:OncologyMember2023-01-022023-12-310000200406us-gaap:NonUsMemberjnj:TECVAYLIMemberjnj:PharmaceuticalMemberjnj:OncologyMember2022-01-032023-01-010000200406jnj:TECVAYLIMemberjnj:PharmaceuticalMemberjnj:OncologyMember2024-01-012024-12-290000200406jnj:TECVAYLIMemberjnj:PharmaceuticalMemberjnj:OncologyMember2023-01-022023-12-310000200406jnj:TECVAYLIMemberjnj:PharmaceuticalMemberjnj:OncologyMember2022-01-032023-01-010000200406country:USjnj:ZYTIGAMemberjnj:InnovativeMedicineMemberjnj:OncologyMember2024-01-012024-12-290000200406country:USjnj:ZYTIGAMemberjnj:InnovativeMedicineMemberjnj:OncologyMember2023-01-022023-12-310000200406country:USjnj:ZYTIGAMemberjnj:InnovativeMedicineMemberjnj:OncologyMember2022-01-032023-01-010000200406us-gaap:NonUsMemberjnj:ZYTIGAMemberjnj:InnovativeMedicineMemberjnj:OncologyMember2024-01-012024-12-290000200406us-gaap:NonUsMemberjnj:ZYTIGAMemberjnj:InnovativeMedicineMemberjnj:OncologyMember2023-01-022023-12-310000200406us-gaap:NonUsMemberjnj:ZYTIGAMemberjnj:InnovativeMedicineMemberjnj:OncologyMember2022-01-032023-01-010000200406jnj:ZYTIGAMemberjnj:InnovativeMedicineMemberjnj:OncologyMember2024-01-012024-12-290000200406jnj:ZYTIGAMemberjnj:InnovativeMedicineMemberjnj:OncologyMember2023-01-022023-12-310000200406jnj:ZYTIGAMemberjnj:InnovativeMedicineMemberjnj:OncologyMember2022-01-032023-01-010000200406country:USjnj:OtherOncologyMemberjnj:InnovativeMedicineMemberjnj:OncologyMember2024-01-012024-12-290000200406country:USjnj:OtherOncologyMemberjnj:InnovativeMedicineMemberjnj:OncologyMember2023-01-022023-12-310000200406country:USjnj:OtherOncologyMemberjnj:InnovativeMedicineMemberjnj:OncologyMember2022-01-032023-01-010000200406us-gaap:NonUsMemberjnj:OtherOncologyMemberjnj:InnovativeMedicineMemberjnj:OncologyMember2024-01-012024-12-290000200406us-gaap:NonUsMemberjnj:OtherOncologyMemberjnj:InnovativeMedicineMemberjnj:OncologyMember2023-01-022023-12-310000200406us-gaap:NonUsMemberjnj:OtherOncologyMemberjnj:InnovativeMedicineMemberjnj:OncologyMember2022-01-032023-01-010000200406jnj:OtherOncologyMemberjnj:InnovativeMedicineMemberjnj:OncologyMember2024-01-012024-12-290000200406jnj:OtherOncologyMemberjnj:InnovativeMedicineMemberjnj:OncologyMember2023-01-022023-12-310000200406jnj:OtherOncologyMemberjnj:InnovativeMedicineMemberjnj:OncologyMember2022-01-032023-01-010000200406country:USjnj:InnovativeMedicineMemberjnj:PulmonaryHypertensionMember2024-01-012024-12-290000200406country:USjnj:InnovativeMedicineMemberjnj:PulmonaryHypertensionMember2023-01-022023-12-310000200406country:USjnj:InnovativeMedicineMemberjnj:PulmonaryHypertensionMember2022-01-032023-01-010000200406us-gaap:NonUsMemberjnj:InnovativeMedicineMemberjnj:PulmonaryHypertensionMember2024-01-012024-12-290000200406us-gaap:NonUsMemberjnj:InnovativeMedicineMemberjnj:PulmonaryHypertensionMember2023-01-022023-12-310000200406us-gaap:NonUsMemberjnj:InnovativeMedicineMemberjnj:PulmonaryHypertensionMember2022-01-032023-01-010000200406jnj:InnovativeMedicineMemberjnj:PulmonaryHypertensionMember2024-01-012024-12-290000200406jnj:InnovativeMedicineMemberjnj:PulmonaryHypertensionMember2023-01-022023-12-310000200406jnj:InnovativeMedicineMemberjnj:PulmonaryHypertensionMember2022-01-032023-01-010000200406country:USjnj:OPSUMITMemberjnj:InnovativeMedicineMemberjnj:PulmonaryHypertensionMember2024-01-012024-12-290000200406country:USjnj:OPSUMITMemberjnj:InnovativeMedicineMemberjnj:PulmonaryHypertensionMember2023-01-022023-12-310000200406country:USjnj:OPSUMITMemberjnj:InnovativeMedicineMemberjnj:PulmonaryHypertensionMember2022-01-032023-01-010000200406us-gaap:NonUsMemberjnj:OPSUMITMemberjnj:InnovativeMedicineMemberjnj:PulmonaryHypertensionMember2024-01-012024-12-290000200406us-gaap:NonUsMemberjnj:OPSUMITMemberjnj:InnovativeMedicineMemberjnj:PulmonaryHypertensionMember2023-01-022023-12-310000200406us-gaap:NonUsMemberjnj:OPSUMITMemberjnj:InnovativeMedicineMemberjnj:PulmonaryHypertensionMember2022-01-032023-01-010000200406jnj:OPSUMITMemberjnj:InnovativeMedicineMemberjnj:PulmonaryHypertensionMember2024-01-012024-12-290000200406jnj:OPSUMITMemberjnj:InnovativeMedicineMemberjnj:PulmonaryHypertensionMember2023-01-022023-12-310000200406jnj:OPSUMITMemberjnj:InnovativeMedicineMemberjnj:PulmonaryHypertensionMember2022-01-032023-01-010000200406country:USjnj:UPTRAVIMemberjnj:InnovativeMedicineMemberjnj:PulmonaryHypertensionMember2024-01-012024-12-290000200406country:USjnj:UPTRAVIMemberjnj:InnovativeMedicineMemberjnj:PulmonaryHypertensionMember2023-01-022023-12-310000200406country:USjnj:UPTRAVIMemberjnj:InnovativeMedicineMemberjnj:PulmonaryHypertensionMember2022-01-032023-01-010000200406us-gaap:NonUsMemberjnj:UPTRAVIMemberjnj:InnovativeMedicineMemberjnj:PulmonaryHypertensionMember2024-01-012024-12-290000200406us-gaap:NonUsMemberjnj:UPTRAVIMemberjnj:InnovativeMedicineMemberjnj:PulmonaryHypertensionMember2023-01-022023-12-310000200406us-gaap:NonUsMemberjnj:UPTRAVIMemberjnj:InnovativeMedicineMemberjnj:PulmonaryHypertensionMember2022-01-032023-01-010000200406jnj:UPTRAVIMemberjnj:InnovativeMedicineMemberjnj:PulmonaryHypertensionMember2024-01-012024-12-290000200406jnj:UPTRAVIMemberjnj:InnovativeMedicineMemberjnj:PulmonaryHypertensionMember2023-01-022023-12-310000200406jnj:UPTRAVIMemberjnj:InnovativeMedicineMemberjnj:PulmonaryHypertensionMember2022-01-032023-01-010000200406country:USjnj:OtherPulmonaryHypertensionMemberjnj:InnovativeMedicineMemberjnj:PulmonaryHypertensionMember2024-01-012024-12-290000200406country:USjnj:OtherPulmonaryHypertensionMemberjnj:InnovativeMedicineMemberjnj:PulmonaryHypertensionMember2023-01-022023-12-310000200406country:USjnj:OtherPulmonaryHypertensionMemberjnj:InnovativeMedicineMemberjnj:PulmonaryHypertensionMember2022-01-032023-01-010000200406us-gaap:NonUsMemberjnj:OtherPulmonaryHypertensionMemberjnj:InnovativeMedicineMemberjnj:PulmonaryHypertensionMember2024-01-012024-12-290000200406us-gaap:NonUsMemberjnj:OtherPulmonaryHypertensionMemberjnj:InnovativeMedicineMemberjnj:PulmonaryHypertensionMember2023-01-022023-12-310000200406us-gaap:NonUsMemberjnj:OtherPulmonaryHypertensionMemberjnj:InnovativeMedicineMemberjnj:PulmonaryHypertensionMember2022-01-032023-01-010000200406jnj:OtherPulmonaryHypertensionMemberjnj:InnovativeMedicineMemberjnj:PulmonaryHypertensionMember2024-01-012024-12-290000200406jnj:OtherPulmonaryHypertensionMemberjnj:InnovativeMedicineMemberjnj:PulmonaryHypertensionMember2023-01-022023-12-310000200406jnj:OtherPulmonaryHypertensionMemberjnj:InnovativeMedicineMemberjnj:PulmonaryHypertensionMember2022-01-032023-01-010000200406country:USjnj:InnovativeMedicineMemberjnj:CardiovascularMetabolismOtherMember2024-01-012024-12-290000200406country:USjnj:InnovativeMedicineMemberjnj:CardiovascularMetabolismOtherMember2023-01-022023-12-310000200406country:USjnj:InnovativeMedicineMemberjnj:CardiovascularMetabolismOtherMember2022-01-032023-01-010000200406us-gaap:NonUsMemberjnj:InnovativeMedicineMemberjnj:CardiovascularMetabolismOtherMember2024-01-012024-12-290000200406us-gaap:NonUsMemberjnj:InnovativeMedicineMemberjnj:CardiovascularMetabolismOtherMember2023-01-022023-12-310000200406us-gaap:NonUsMemberjnj:InnovativeMedicineMemberjnj:CardiovascularMetabolismOtherMember2022-01-032023-01-010000200406jnj:InnovativeMedicineMemberjnj:CardiovascularMetabolismOtherMember2024-01-012024-12-290000200406jnj:InnovativeMedicineMemberjnj:CardiovascularMetabolismOtherMember2023-01-022023-12-310000200406jnj:InnovativeMedicineMemberjnj:CardiovascularMetabolismOtherMember2022-01-032023-01-010000200406country:USjnj:XareltoMemberjnj:InnovativeMedicineMemberjnj:CardiovascularMetabolismOtherMember2024-01-012024-12-290000200406country:USjnj:XareltoMemberjnj:InnovativeMedicineMemberjnj:CardiovascularMetabolismOtherMember2023-01-022023-12-310000200406country:USjnj:XareltoMemberjnj:InnovativeMedicineMemberjnj:CardiovascularMetabolismOtherMember2022-01-032023-01-010000200406us-gaap:NonUsMemberjnj:XareltoMemberjnj:InnovativeMedicineMemberjnj:CardiovascularMetabolismOtherMember2024-01-012024-12-290000200406us-gaap:NonUsMemberjnj:XareltoMemberjnj:InnovativeMedicineMemberjnj:CardiovascularMetabolismOtherMember2023-01-022023-12-310000200406us-gaap:NonUsMemberjnj:XareltoMemberjnj:InnovativeMedicineMemberjnj:CardiovascularMetabolismOtherMember2022-01-032023-01-010000200406jnj:XareltoMemberjnj:InnovativeMedicineMemberjnj:CardiovascularMetabolismOtherMember2024-01-012024-12-290000200406jnj:XareltoMemberjnj:InnovativeMedicineMemberjnj:CardiovascularMetabolismOtherMember2023-01-022023-12-310000200406jnj:XareltoMemberjnj:InnovativeMedicineMemberjnj:CardiovascularMetabolismOtherMember2022-01-032023-01-010000200406country:USjnj:OtherMemberjnj:InnovativeMedicineMemberjnj:CardiovascularMetabolismOtherMember2024-01-012024-12-290000200406country:USjnj:OtherMemberjnj:InnovativeMedicineMemberjnj:CardiovascularMetabolismOtherMember2023-01-022023-12-310000200406country:USjnj:OtherMemberjnj:InnovativeMedicineMemberjnj:CardiovascularMetabolismOtherMember2022-01-032023-01-010000200406us-gaap:NonUsMemberjnj:OtherMemberjnj:InnovativeMedicineMemberjnj:CardiovascularMetabolismOtherMember2024-01-012024-12-290000200406us-gaap:NonUsMemberjnj:OtherMemberjnj:InnovativeMedicineMemberjnj:CardiovascularMetabolismOtherMember2023-01-022023-12-310000200406us-gaap:NonUsMemberjnj:OtherMemberjnj:InnovativeMedicineMemberjnj:CardiovascularMetabolismOtherMember2022-01-032023-01-010000200406jnj:OtherMemberjnj:InnovativeMedicineMemberjnj:CardiovascularMetabolismOtherMember2024-01-012024-12-290000200406jnj:OtherMemberjnj:InnovativeMedicineMemberjnj:CardiovascularMetabolismOtherMember2023-01-022023-12-310000200406jnj:OtherMemberjnj:InnovativeMedicineMemberjnj:CardiovascularMetabolismOtherMember2022-01-032023-01-010000200406country:USjnj:InnovativeMedicineMember2024-01-012024-12-290000200406country:USjnj:InnovativeMedicineMember2023-01-022023-12-310000200406country:USjnj:InnovativeMedicineMember2022-01-032023-01-010000200406us-gaap:NonUsMemberjnj:InnovativeMedicineMember2024-01-012024-12-290000200406us-gaap:NonUsMemberjnj:InnovativeMedicineMember2023-01-022023-12-310000200406us-gaap:NonUsMemberjnj:InnovativeMedicineMember2022-01-032023-01-010000200406jnj:InnovativeMedicineMember2022-01-032023-01-010000200406country:USjnj:MedTechMemberjnj:CardiovascularMember2024-01-012024-12-290000200406country:USjnj:MedTechMemberjnj:CardiovascularMember2023-01-022023-12-310000200406country:USjnj:MedTechMemberjnj:CardiovascularMember2022-01-032023-01-010000200406us-gaap:NonUsMemberjnj:MedTechMemberjnj:CardiovascularMember2024-01-012024-12-290000200406us-gaap:NonUsMemberjnj:MedTechMemberjnj:CardiovascularMember2023-01-022023-12-310000200406us-gaap:NonUsMemberjnj:MedTechMemberjnj:CardiovascularMember2022-01-032023-01-010000200406jnj:MedTechMemberjnj:CardiovascularMember2024-01-012024-12-290000200406jnj:MedTechMemberjnj:CardiovascularMember2023-01-022023-12-310000200406jnj:MedTechMemberjnj:CardiovascularMember2022-01-032023-01-010000200406country:USjnj:ELECTROPHYSIOLOGYMemberjnj:MedTechMemberjnj:CardiovascularMember2024-01-012024-12-290000200406country:USjnj:ELECTROPHYSIOLOGYMemberjnj:MedTechMemberjnj:CardiovascularMember2023-01-022023-12-310000200406country:USjnj:ELECTROPHYSIOLOGYMemberjnj:MedTechMemberjnj:CardiovascularMember2022-01-032023-01-010000200406us-gaap:NonUsMemberjnj:ELECTROPHYSIOLOGYMemberjnj:MedTechMemberjnj:CardiovascularMember2024-01-012024-12-290000200406us-gaap:NonUsMemberjnj:ELECTROPHYSIOLOGYMemberjnj:MedTechMemberjnj:CardiovascularMember2023-01-022023-12-310000200406us-gaap:NonUsMemberjnj:ELECTROPHYSIOLOGYMemberjnj:MedTechMemberjnj:CardiovascularMember2022-01-032023-01-010000200406jnj:ELECTROPHYSIOLOGYMemberjnj:MedTechMemberjnj:CardiovascularMember2024-01-012024-12-290000200406jnj:ELECTROPHYSIOLOGYMemberjnj:MedTechMemberjnj:CardiovascularMember2023-01-022023-12-310000200406jnj:ELECTROPHYSIOLOGYMemberjnj:MedTechMemberjnj:CardiovascularMember2022-01-032023-01-010000200406country:USjnj:AbiomedMemberjnj:MedTechMemberjnj:CardiovascularMember2024-01-012024-12-290000200406country:USjnj:AbiomedMemberjnj:MedTechMemberjnj:CardiovascularMember2023-01-022023-12-310000200406country:USjnj:AbiomedMemberjnj:MedTechMemberjnj:CardiovascularMember2022-01-032023-01-010000200406us-gaap:NonUsMemberjnj:AbiomedMemberjnj:MedTechMemberjnj:CardiovascularMember2024-01-012024-12-290000200406us-gaap:NonUsMemberjnj:AbiomedMemberjnj:MedTechMemberjnj:CardiovascularMember2023-01-022023-12-310000200406us-gaap:NonUsMemberjnj:AbiomedMemberjnj:MedTechMemberjnj:CardiovascularMember2022-01-032023-01-010000200406jnj:AbiomedMemberjnj:MedTechMemberjnj:CardiovascularMember2024-01-012024-12-290000200406jnj:AbiomedMemberjnj:MedTechMemberjnj:CardiovascularMember2023-01-022023-12-310000200406jnj:AbiomedMemberjnj:MedTechMemberjnj:CardiovascularMember2022-01-032023-01-010000200406country:USjnj:ShockwaveMedicalInc.Memberjnj:MedTechMemberjnj:CardiovascularMember2024-01-012024-12-290000200406country:USjnj:ShockwaveMedicalInc.Memberjnj:MedTechMemberjnj:CardiovascularMember2023-01-022023-12-310000200406country:USjnj:ShockwaveMedicalInc.Memberjnj:MedTechMemberjnj:CardiovascularMember2022-01-032023-01-010000200406us-gaap:NonUsMemberjnj:ShockwaveMedicalInc.Memberjnj:MedTechMemberjnj:CardiovascularMember2024-01-012024-12-290000200406us-gaap:NonUsMemberjnj:ShockwaveMedicalInc.Memberjnj:MedTechMemberjnj:CardiovascularMember2023-01-022023-12-310000200406us-gaap:NonUsMemberjnj:ShockwaveMedicalInc.Memberjnj:MedTechMemberjnj:CardiovascularMember2022-01-032023-01-010000200406jnj:ShockwaveMedicalInc.Memberjnj:MedTechMemberjnj:CardiovascularMember2024-01-012024-12-290000200406jnj:ShockwaveMedicalInc.Memberjnj:MedTechMemberjnj:CardiovascularMember2023-01-022023-12-310000200406jnj:ShockwaveMedicalInc.Memberjnj:MedTechMemberjnj:CardiovascularMember2022-01-032023-01-010000200406country:USjnj:OtherCardiovascularMemberjnj:MedTechMemberjnj:CardiovascularMember2024-01-012024-12-290000200406country:USjnj:OtherCardiovascularMemberjnj:MedTechMemberjnj:CardiovascularMember2023-01-022023-12-310000200406country:USjnj:OtherCardiovascularMemberjnj:MedTechMemberjnj:CardiovascularMember2022-01-032023-01-010000200406us-gaap:NonUsMemberjnj:OtherCardiovascularMemberjnj:MedTechMemberjnj:CardiovascularMember2024-01-012024-12-290000200406us-gaap:NonUsMemberjnj:OtherCardiovascularMemberjnj:MedTechMemberjnj:CardiovascularMember2023-01-022023-12-310000200406us-gaap:NonUsMemberjnj:OtherCardiovascularMemberjnj:MedTechMemberjnj:CardiovascularMember2022-01-032023-01-010000200406jnj:OtherCardiovascularMemberjnj:MedTechMemberjnj:CardiovascularMember2024-01-012024-12-290000200406jnj:OtherCardiovascularMemberjnj:MedTechMemberjnj:CardiovascularMember2023-01-022023-12-310000200406jnj:OtherCardiovascularMemberjnj:MedTechMemberjnj:CardiovascularMember2022-01-032023-01-010000200406country:USjnj:MedTechMemberjnj:OrthopaedicsMember2024-01-012024-12-290000200406country:USjnj:MedTechMemberjnj:OrthopaedicsMember2023-01-022023-12-310000200406country:USjnj:MedTechMemberjnj:OrthopaedicsMember2022-01-032023-01-010000200406us-gaap:NonUsMemberjnj:MedTechMemberjnj:OrthopaedicsMember2024-01-012024-12-290000200406us-gaap:NonUsMemberjnj:MedTechMemberjnj:OrthopaedicsMember2023-01-022023-12-310000200406us-gaap:NonUsMemberjnj:MedTechMemberjnj:OrthopaedicsMember2022-01-032023-01-010000200406jnj:MedTechMemberjnj:OrthopaedicsMember2024-01-012024-12-290000200406jnj:MedTechMemberjnj:OrthopaedicsMember2023-01-022023-12-310000200406jnj:MedTechMemberjnj:OrthopaedicsMember2022-01-032023-01-010000200406country:USjnj:HIPSMemberjnj:MedTechMemberjnj:OrthopaedicsMember2024-01-012024-12-290000200406country:USjnj:HIPSMemberjnj:MedTechMemberjnj:OrthopaedicsMember2023-01-022023-12-310000200406country:USjnj:HIPSMemberjnj:MedTechMemberjnj:OrthopaedicsMember2022-01-032023-01-010000200406us-gaap:NonUsMemberjnj:HIPSMemberjnj:MedTechMemberjnj:OrthopaedicsMember2024-01-012024-12-290000200406us-gaap:NonUsMemberjnj:HIPSMemberjnj:MedTechMemberjnj:OrthopaedicsMember2023-01-022023-12-310000200406us-gaap:NonUsMemberjnj:HIPSMemberjnj:MedTechMemberjnj:OrthopaedicsMember2022-01-032023-01-010000200406jnj:HIPSMemberjnj:MedTechMemberjnj:OrthopaedicsMember2024-01-012024-12-290000200406jnj:HIPSMemberjnj:MedTechMemberjnj:OrthopaedicsMember2023-01-022023-12-310000200406jnj:HIPSMemberjnj:MedTechMemberjnj:OrthopaedicsMember2022-01-032023-01-010000200406country:USjnj:KNEESMemberjnj:MedTechMemberjnj:OrthopaedicsMember2024-01-012024-12-290000200406country:USjnj:KNEESMemberjnj:MedTechMemberjnj:OrthopaedicsMember2023-01-022023-12-310000200406country:USjnj:KNEESMemberjnj:MedTechMemberjnj:OrthopaedicsMember2022-01-032023-01-010000200406us-gaap:NonUsMemberjnj:KNEESMemberjnj:MedTechMemberjnj:OrthopaedicsMember2024-01-012024-12-290000200406us-gaap:NonUsMemberjnj:KNEESMemberjnj:MedTechMemberjnj:OrthopaedicsMember2023-01-022023-12-310000200406us-gaap:NonUsMemberjnj:KNEESMemberjnj:MedTechMemberjnj:OrthopaedicsMember2022-01-032023-01-010000200406jnj:KNEESMemberjnj:MedTechMemberjnj:OrthopaedicsMember2024-01-012024-12-290000200406jnj:KNEESMemberjnj:MedTechMemberjnj:OrthopaedicsMember2023-01-022023-12-310000200406jnj:KNEESMemberjnj:MedTechMemberjnj:OrthopaedicsMember2022-01-032023-01-010000200406country:USjnj:TRAUMAMemberjnj:MedTechMemberjnj:OrthopaedicsMember2024-01-012024-12-290000200406country:USjnj:TRAUMAMemberjnj:MedTechMemberjnj:OrthopaedicsMember2023-01-022023-12-310000200406country:USjnj:TRAUMAMemberjnj:MedTechMemberjnj:OrthopaedicsMember2022-01-032023-01-010000200406us-gaap:NonUsMemberjnj:TRAUMAMemberjnj:MedTechMemberjnj:OrthopaedicsMember2024-01-012024-12-290000200406us-gaap:NonUsMemberjnj:TRAUMAMemberjnj:MedTechMemberjnj:OrthopaedicsMember2023-01-022023-12-310000200406us-gaap:NonUsMemberjnj:TRAUMAMemberjnj:MedTechMemberjnj:OrthopaedicsMember2022-01-032023-01-010000200406jnj:TRAUMAMemberjnj:MedTechMemberjnj:OrthopaedicsMember2024-01-012024-12-290000200406jnj:TRAUMAMemberjnj:MedTechMemberjnj:OrthopaedicsMember2023-01-022023-12-310000200406jnj:TRAUMAMemberjnj:MedTechMemberjnj:OrthopaedicsMember2022-01-032023-01-010000200406country:USjnj:SPINESPORTSOTHERMemberjnj:MedTechMemberjnj:OrthopaedicsMember2024-01-012024-12-290000200406country:USjnj:SPINESPORTSOTHERMemberjnj:MedTechMemberjnj:OrthopaedicsMember2023-01-022023-12-310000200406country:USjnj:SPINESPORTSOTHERMemberjnj:MedTechMemberjnj:OrthopaedicsMember2022-01-032023-01-010000200406us-gaap:NonUsMemberjnj:SPINESPORTSOTHERMemberjnj:MedTechMemberjnj:OrthopaedicsMember2024-01-012024-12-290000200406us-gaap:NonUsMemberjnj:SPINESPORTSOTHERMemberjnj:MedTechMemberjnj:OrthopaedicsMember2023-01-022023-12-310000200406us-gaap:NonUsMemberjnj:SPINESPORTSOTHERMemberjnj:MedTechMemberjnj:OrthopaedicsMember2022-01-032023-01-010000200406jnj:SPINESPORTSOTHERMemberjnj:MedTechMemberjnj:OrthopaedicsMember2024-01-012024-12-290000200406jnj:SPINESPORTSOTHERMemberjnj:MedTechMemberjnj:OrthopaedicsMember2023-01-022023-12-310000200406jnj:SPINESPORTSOTHERMemberjnj:MedTechMemberjnj:OrthopaedicsMember2022-01-032023-01-010000200406country:USjnj:MedTechMemberjnj:SurgeryMember2024-01-012024-12-290000200406country:USjnj:MedTechMemberjnj:SurgeryMember2023-01-022023-12-310000200406country:USjnj:MedTechMemberjnj:SurgeryMember2022-01-032023-01-010000200406us-gaap:NonUsMemberjnj:MedTechMemberjnj:SurgeryMember2024-01-012024-12-290000200406us-gaap:NonUsMemberjnj:MedTechMemberjnj:SurgeryMember2023-01-022023-12-310000200406us-gaap:NonUsMemberjnj:MedTechMemberjnj:SurgeryMember2022-01-032023-01-010000200406jnj:MedTechMemberjnj:SurgeryMember2024-01-012024-12-290000200406jnj:MedTechMemberjnj:SurgeryMember2023-01-022023-12-310000200406jnj:MedTechMemberjnj:SurgeryMember2022-01-032023-01-010000200406country:USjnj:ADVANCEDMemberjnj:MedTechMemberjnj:SurgeryMember2024-01-012024-12-290000200406country:USjnj:ADVANCEDMemberjnj:MedTechMemberjnj:SurgeryMember2023-01-022023-12-310000200406country:USjnj:ADVANCEDMemberjnj:MedTechMemberjnj:SurgeryMember2022-01-032023-01-010000200406us-gaap:NonUsMemberjnj:ADVANCEDMemberjnj:MedTechMemberjnj:SurgeryMember2024-01-012024-12-290000200406us-gaap:NonUsMemberjnj:ADVANCEDMemberjnj:MedTechMemberjnj:SurgeryMember2023-01-022023-12-310000200406us-gaap:NonUsMemberjnj:ADVANCEDMemberjnj:MedTechMemberjnj:SurgeryMember2022-01-032023-01-010000200406jnj:ADVANCEDMemberjnj:MedTechMemberjnj:SurgeryMember2024-01-012024-12-290000200406jnj:ADVANCEDMemberjnj:MedTechMemberjnj:SurgeryMember2023-01-022023-12-310000200406jnj:ADVANCEDMemberjnj:MedTechMemberjnj:SurgeryMember2022-01-032023-01-010000200406country:USjnj:GENERALMemberjnj:MedTechMemberjnj:SurgeryMember2024-01-012024-12-290000200406country:USjnj:GENERALMemberjnj:MedTechMemberjnj:SurgeryMember2023-01-022023-12-310000200406country:USjnj:GENERALMemberjnj:MedTechMemberjnj:SurgeryMember2022-01-032023-01-010000200406us-gaap:NonUsMemberjnj:GENERALMemberjnj:MedTechMemberjnj:SurgeryMember2024-01-012024-12-290000200406us-gaap:NonUsMemberjnj:GENERALMemberjnj:MedTechMemberjnj:SurgeryMember2023-01-022023-12-310000200406us-gaap:NonUsMemberjnj:GENERALMemberjnj:MedTechMemberjnj:SurgeryMember2022-01-032023-01-010000200406jnj:GENERALMemberjnj:MedTechMemberjnj:SurgeryMember2024-01-012024-12-290000200406jnj:GENERALMemberjnj:MedTechMemberjnj:SurgeryMember2023-01-022023-12-310000200406jnj:GENERALMemberjnj:MedTechMemberjnj:SurgeryMember2022-01-032023-01-010000200406country:USjnj:MedTechMemberjnj:VisionMember2024-01-012024-12-290000200406country:USjnj:MedTechMemberjnj:VisionMember2023-01-022023-12-310000200406country:USjnj:MedTechMemberjnj:VisionMember2022-01-032023-01-010000200406us-gaap:NonUsMemberjnj:MedTechMemberjnj:VisionMember2024-01-012024-12-290000200406us-gaap:NonUsMemberjnj:MedTechMemberjnj:VisionMember2023-01-022023-12-310000200406us-gaap:NonUsMemberjnj:MedTechMemberjnj:VisionMember2022-01-032023-01-010000200406jnj:MedTechMemberjnj:VisionMember2024-01-012024-12-290000200406jnj:MedTechMemberjnj:VisionMember2023-01-022023-12-310000200406jnj:MedTechMemberjnj:VisionMember2022-01-032023-01-010000200406country:USjnj:CONTACTLENSESOTHERMemberjnj:MedTechMemberjnj:VisionMember2024-01-012024-12-290000200406country:USjnj:CONTACTLENSESOTHERMemberjnj:MedTechMemberjnj:VisionMember2023-01-022023-12-310000200406country:USjnj:CONTACTLENSESOTHERMemberjnj:MedTechMemberjnj:VisionMember2022-01-032023-01-010000200406us-gaap:NonUsMemberjnj:CONTACTLENSESOTHERMemberjnj:MedTechMemberjnj:VisionMember2024-01-012024-12-290000200406us-gaap:NonUsMemberjnj:CONTACTLENSESOTHERMemberjnj:MedTechMemberjnj:VisionMember2023-01-022023-12-310000200406us-gaap:NonUsMemberjnj:CONTACTLENSESOTHERMemberjnj:MedTechMemberjnj:VisionMember2022-01-032023-01-010000200406jnj:CONTACTLENSESOTHERMemberjnj:MedTechMemberjnj:VisionMember2024-01-012024-12-290000200406jnj:CONTACTLENSESOTHERMemberjnj:MedTechMemberjnj:VisionMember2023-01-022023-12-310000200406jnj:CONTACTLENSESOTHERMemberjnj:MedTechMemberjnj:VisionMember2022-01-032023-01-010000200406country:USjnj:SURGICALMemberjnj:MedTechMemberjnj:VisionMember2024-01-012024-12-290000200406country:USjnj:SURGICALMemberjnj:MedTechMemberjnj:VisionMember2023-01-022023-12-310000200406country:USjnj:SURGICALMemberjnj:MedTechMemberjnj:VisionMember2022-01-032023-01-010000200406us-gaap:NonUsMemberjnj:SURGICALMemberjnj:MedTechMemberjnj:VisionMember2024-01-012024-12-290000200406us-gaap:NonUsMemberjnj:SURGICALMemberjnj:MedTechMemberjnj:VisionMember2023-01-022023-12-310000200406us-gaap:NonUsMemberjnj:SURGICALMemberjnj:MedTechMemberjnj:VisionMember2022-01-032023-01-010000200406jnj:SURGICALMemberjnj:MedTechMemberjnj:VisionMember2024-01-012024-12-290000200406jnj:SURGICALMemberjnj:MedTechMemberjnj:VisionMember2023-01-022023-12-310000200406jnj:SURGICALMemberjnj:MedTechMemberjnj:VisionMember2022-01-032023-01-010000200406country:USjnj:MedTechMember2024-01-012024-12-290000200406country:USjnj:MedTechMember2023-01-022023-12-310000200406country:USjnj:MedTechMember2022-01-032023-01-010000200406us-gaap:NonUsMemberjnj:MedTechMember2024-01-012024-12-290000200406us-gaap:NonUsMemberjnj:MedTechMember2023-01-022023-12-310000200406us-gaap:NonUsMemberjnj:MedTechMember2022-01-032023-01-010000200406jnj:MedTechMember2022-01-032023-01-010000200406country:US2024-01-012024-12-290000200406country:US2023-01-022023-12-310000200406country:US2022-01-032023-01-010000200406us-gaap:NonUsMember2024-01-012024-12-290000200406us-gaap:NonUsMember2023-01-022023-12-310000200406us-gaap:NonUsMember2022-01-032023-01-010000200406us-gaap:OperatingSegmentsMemberjnj:InnovativeMedicineMember2024-01-012024-12-290000200406us-gaap:OperatingSegmentsMemberjnj:MedTechMember2024-01-012024-12-290000200406us-gaap:OperatingSegmentsMemberjnj:InnovativeMedicineMember2023-01-022023-12-310000200406us-gaap:OperatingSegmentsMemberjnj:MedTechMember2023-01-022023-12-310000200406us-gaap:OperatingSegmentsMemberjnj:InnovativeMedicineMember2022-01-032023-01-010000200406us-gaap:OperatingSegmentsMemberjnj:MedTechMember2022-01-032023-01-010000200406us-gaap:OperatingSegmentsMember2024-01-012024-12-290000200406us-gaap:OperatingSegmentsMember2023-01-022023-12-310000200406us-gaap:OperatingSegmentsMember2022-01-032023-01-010000200406us-gaap:OperatingSegmentsMemberjnj:InnovativeMedicineMember2024-12-290000200406us-gaap:OperatingSegmentsMemberjnj:InnovativeMedicineMember2023-12-310000200406us-gaap:OperatingSegmentsMemberjnj:MedTechMember2024-12-290000200406us-gaap:OperatingSegmentsMemberjnj:MedTechMember2023-12-310000200406jnj:SegmentsTotalMember2024-12-290000200406jnj:SegmentsTotalMember2023-12-310000200406us-gaap:CorporateNonSegmentMemberjnj:GeneralCorporateMember2024-12-290000200406us-gaap:CorporateNonSegmentMemberjnj:GeneralCorporateMember2023-12-310000200406jnj:SegmentsTotalMember2024-01-012024-12-290000200406jnj:SegmentsTotalMember2023-01-022023-12-310000200406jnj:SegmentsTotalMember2022-01-032023-01-010000200406jnj:ConsumerMember2024-01-012024-12-290000200406jnj:ConsumerMember2023-01-022023-12-310000200406jnj:ConsumerMember2022-01-032023-01-010000200406us-gaap:CorporateNonSegmentMemberjnj:GeneralCorporateMember2024-01-012024-12-290000200406us-gaap:CorporateNonSegmentMemberjnj:GeneralCorporateMember2023-01-022023-12-310000200406us-gaap:CorporateNonSegmentMemberjnj:GeneralCorporateMember2022-01-032023-01-010000200406country:USus-gaap:OperatingSegmentsMember2024-01-012024-12-290000200406country:USus-gaap:OperatingSegmentsMember2023-01-022023-12-310000200406country:USus-gaap:OperatingSegmentsMember2022-01-032023-01-010000200406country:USus-gaap:OperatingSegmentsMember2024-12-290000200406country:USus-gaap:OperatingSegmentsMember2023-12-310000200406srt:EuropeMemberus-gaap:OperatingSegmentsMember2024-01-012024-12-290000200406srt:EuropeMemberus-gaap:OperatingSegmentsMember2023-01-022023-12-310000200406srt:EuropeMemberus-gaap:OperatingSegmentsMember2022-01-032023-01-010000200406srt:EuropeMemberus-gaap:OperatingSegmentsMember2024-12-290000200406srt:EuropeMemberus-gaap:OperatingSegmentsMember2023-12-310000200406jnj:WesternHemisphereExcludingUSMemberus-gaap:OperatingSegmentsMember2024-01-012024-12-290000200406jnj:WesternHemisphereExcludingUSMemberus-gaap:OperatingSegmentsMember2023-01-022023-12-310000200406jnj:WesternHemisphereExcludingUSMemberus-gaap:OperatingSegmentsMember2022-01-032023-01-010000200406jnj:WesternHemisphereExcludingUSMemberus-gaap:OperatingSegmentsMember2024-12-290000200406jnj:WesternHemisphereExcludingUSMemberus-gaap:OperatingSegmentsMember2023-12-310000200406jnj:AsiaPacificAfricaMemberus-gaap:OperatingSegmentsMember2024-01-012024-12-290000200406jnj:AsiaPacificAfricaMemberus-gaap:OperatingSegmentsMember2023-01-022023-12-310000200406jnj:AsiaPacificAfricaMemberus-gaap:OperatingSegmentsMember2022-01-032023-01-010000200406jnj:AsiaPacificAfricaMemberus-gaap:OperatingSegmentsMember2024-12-290000200406jnj:AsiaPacificAfricaMemberus-gaap:OperatingSegmentsMember2023-12-310000200406us-gaap:OperatingSegmentsMember2024-12-290000200406us-gaap:OperatingSegmentsMember2023-12-310000200406us-gaap:CorporateNonSegmentMember2024-12-290000200406us-gaap:CorporateNonSegmentMember2023-12-310000200406jnj:Wholesaler1Memberjnj:WholesalerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2024-01-012024-12-290000200406jnj:Wholesaler2Memberjnj:WholesalerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2024-01-012024-12-290000200406jnj:Wholesaler3Memberjnj:WholesalerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2024-01-012024-12-290000200406jnj:Wholesaler1Memberjnj:WholesalerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2023-01-022023-12-310000200406jnj:Wholesaler2Memberjnj:WholesalerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2023-01-022023-12-310000200406jnj:Wholesaler3Memberjnj:WholesalerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2023-01-022023-12-310000200406jnj:Wholesaler1Memberjnj:WholesalerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2022-01-032023-01-010000200406jnj:Wholesaler2Memberjnj:WholesalerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2022-01-032023-01-010000200406jnj:Wholesaler3Memberjnj:WholesalerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2022-01-032023-01-010000200406jnj:BabyPowderMemberjnj:TalcMember2024-01-012024-12-290000200406jnj:BabyPowderMemberjnj:TalcMember2023-01-022023-12-310000200406jnj:MomentaMemberjnj:InnovativeMedicineMember2024-01-012024-12-290000200406jnj:VWaveLtd.Memberjnj:MedTechMember2024-01-012024-12-290000200406jnj:MomentaMemberjnj:InnovativeMedicineMember2023-01-022023-12-310000200406jnj:LaminarMemberjnj:MedTechMember2023-01-022023-12-310000200406jnj:BermekimabMemberus-gaap:InProcessResearchAndDevelopmentMember2022-01-032023-01-010000200406us-gaap:PropertyPlantAndEquipmentMember2024-12-290000200406us-gaap:PropertyPlantAndEquipmentMember2023-12-310000200406us-gaap:OtherIntangibleAssetsMember2024-12-290000200406us-gaap:OtherIntangibleAssetsMember2023-12-310000200406jnj:IntraCellularTherapiesInc.Membersrt:ScenarioForecastMember2025-02-130000200406jnj:IntraCellularTherapiesInc.Membersrt:ScenarioForecastMember2025-01-012025-02-130000200406jnj:ProteologixMember2024-06-202024-06-200000200406jnj:ProteologixMember2024-06-200000200406jnj:ProteologixMembersrt:MinimumMember2024-06-200000200406jnj:ProteologixMembersrt:MaximumMember2024-06-200000200406jnj:ProteologixMember2024-01-012024-12-290000200406jnj:ShockwaveMedicalInc.Member2024-05-310000200406jnj:ShockwaveMedicalInc.Member2024-12-290000200406jnj:ShockwaveMedicalInc.Member2024-06-012024-06-290000200406jnj:ShockwaveMedicalInc.Member2024-06-200000200406jnj:ShockwaveMedicalInc.Member2024-05-312024-05-310000200406jnj:ShockwaveMedicalInc.Member2024-01-012024-12-290000200406jnj:ShockwaveMedicalInc.Membersrt:MinimumMember2024-05-310000200406jnj:AmbrxMember2024-01-012024-12-290000200406jnj:AmbrxMember2024-12-290000200406jnj:AmbrxMembersrt:MinimumMember2024-12-290000200406jnj:AmbrxMembersrt:MaximumMember2024-12-290000200406jnj:AbiomedMember2022-12-220000200406jnj:AbiomedMember2022-12-222022-12-220000200406jnj:NonTradeableContingentValueRightMemberjnj:AbiomedMember2022-12-222022-12-2200002004062022-12-220000200406jnj:AbiomedMemberjnj:ImpellaMember2022-12-220000200406jnj:ClassIRecommendationForImpellaMember2022-12-220000200406jnj:AbiomedMember2024-12-290000200406jnj:AbiomedMember2024-01-012024-12-290000200406jnj:AbiomedMembersrt:MinimumMember2022-12-220000200406jnj:AbiomedMembersrt:MaximumMember2022-12-220000200406jnj:VWaveLtd.Member2024-10-082024-10-080000200406srt:MaximumMemberjnj:VWaveLtd.Member2024-10-082024-10-080000200406jnj:VWaveLtd.Member2024-10-080000200406jnj:YellowJerseyTherapeuticsMember2024-07-112024-07-110000200406jnj:YellowJerseyTherapeuticsMember2024-07-110000200406jnj:LaminarMember2023-01-022023-12-310000200406jnj:LaminarMember2023-12-310000200406jnj:AcclarentMember2024-01-012024-12-290000200406jnj:PonvoryMember2024-01-012024-12-290000200406jnj:InghamVsJohnsonJohnsonMember2018-07-012018-07-310000200406jnj:InghamVsJohnsonJohnsonMember2020-06-012020-06-300000200406jnj:InghamVsJohnsonJohnsonMember2021-06-012021-06-300000200406jnj:TalcMember2024-05-012024-05-010000200406jnj:TalcMember2024-05-010000200406jnj:TalcMember2024-09-202024-09-200000200406jnj:MesotheliomaAndStateClaimsMember2024-05-012024-05-010000200406jnj:TalcMember2024-09-302024-12-290000200406jnj:TalcMember2024-12-290000200406jnj:OpioidMember2024-12-290000200406jnj:OpioidMember2021-07-040000200406jnj:TalcMember2024-12-290000200406jnj:AsrMember2024-12-290000200406jnj:PinnacleAcetabularCupSystemMember2024-12-290000200406jnj:PelvicMeshesMember2024-12-290000200406jnj:PhysiomeshMember2024-12-290000200406jnj:RisperdalMember2024-12-290000200406jnj:ElmironMember2024-12-290000200406jnj:DePuyASRU.S.Memberus-gaap:SettledLitigationMember2024-12-290000200406jnj:PhysiomeshMemberus-gaap:PendingLitigationMember2021-05-310000200406jnj:PhysiomeshMemberus-gaap:PendingLitigationMember2021-09-300000200406us-gaap:JudicialRulingMember2019-10-012019-10-310000200406us-gaap:JudicialRulingMember2020-01-012020-01-310000200406jnj:RDRestructuringPlanMember2024-01-012024-12-290000200406jnj:RDRestructuringPlanMember2023-01-022023-12-310000200406jnj:RDRestructuringPlanMember2024-12-290000200406jnj:OrthopaedicsRestructuringPlanMember2024-01-012024-12-290000200406jnj:OrthopaedicsRestructuringPlanMember2023-01-022023-12-310000200406jnj:OrthopaedicsRestructuringPlanMember2024-12-290000200406jnj:OrthopaedicsRestructuringPlanMembersrt:MinimumMember2024-12-290000200406jnj:OrthopaedicsRestructuringPlanMembersrt:MaximumMember2024-12-290000200406us-gaap:RestructuringChargesMemberjnj:InnovativeMedicineMember2023-01-022023-12-310000200406jnj:CostsOfGoodsAndServicesSoldMemberjnj:InnovativeMedicineMember2023-01-022023-12-310000200406us-gaap:RestructuringChargesMemberjnj:MedTechMember2024-01-012024-12-290000200406jnj:CostsOfGoodsAndServicesSoldMemberjnj:MedTechMember2024-01-012024-12-290000200406us-gaap:RestructuringChargesMemberjnj:MedTechMember2023-01-022023-12-310000200406jnj:CostsOfGoodsAndServicesSoldMemberjnj:MedTechMember2023-01-022023-12-310000200406jnj:KenvueIncMember2023-08-232023-08-230000200406jnj:KenvueIncMember2023-08-232023-08-2300002004062023-08-230000200406jnj:KenvueIncMemberjnj:JohnsonJohnsonMember2023-08-230000200406jnj:KenvueIncMemberjnj:JohnsonJohnsonMember2024-12-290000200406jnj:ConsumerHealthMember2023-08-230000200406jnj:ConsumerHealthMember2023-08-232023-08-230000200406jnj:KenvueIncMemberjnj:ConsumerHealthMemberjnj:JohnsonJohnsonMember2023-08-2300002004062023-08-232023-08-230000200406srt:MinimumMember2023-08-232023-08-230000200406srt:MaximumMember2023-08-232023-08-2300002004062024-09-302024-12-29

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-K
ANNUAL REPORT PURSUANT TO SECTION 13 OF THE SECURITIES EXCHANGE ACT OF 1934
For the fiscal year ended December 29, 2024
or
Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
for the transition period from            to
Commission file number 1-3215
Johnson & Johnson
(Exact name of registrant as specified in its charter)
New Jersey 22-1024240
(State of incorporation) (I.R.S. Employer Identification No.)
One Johnson & Johnson Plaza
New Brunswick, New Jersey
 08933
(Address of principal executive offices) (Zip Code)
One Johnson & Johnson Plaza
New Brunswick, New Jersey 08933
(Address of principal executive offices)
Registrant’s telephone number, including area code: (732524-0400
SECURITIES REGISTERED PURSUANT TO SECTION 12(b) OF THE ACT
Title of each class
Trading Symbol
Name of each exchange on which registered
Common Stock, Par Value $1.00JNJNew York Stock Exchange
1.150% Notes Due November 2028JNJ28New York Stock Exchange
3.20% Notes Due November 2032JNJ32New York Stock Exchange
1.650% Notes Due May 2035JNJ35New York Stock Exchange
3.350% Notes Due November 2036JNJ36ANew York Stock Exchange
3.550% Notes Due November 2044JNJ44New York Stock Exchange
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.  Yes þ     No o
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Exchange Act.  Yes o     No þ
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes þ     No o
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).  Yes þ     No o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange  Act.
Large accelerated filer Accelerated filer
Non-accelerated filer Smaller reporting company
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Indicate by check mark whether the registrant has filed a report on and attestation to its management's assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. Yes      No o
If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. o
Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b). o
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  Yes      No þ
The aggregate market value of the Common Stock held by non-affiliates computed by reference to the price at which the Common Stock was last sold as of the last business day of the registrant’s most recently completed second fiscal quarter was approximately $352 billion.
On February 6, 2025, there were 2,407,616,693 shares of Common Stock outstanding.
DOCUMENTS INCORPORATED BY REFERENCE
Part III:
Portions of the registrant’s proxy statement for its 2025 annual meeting of shareholders to be filed within 120 days after the close of the registrant’s fiscal year (the “Proxy Statement”), are incorporated by reference to this report on Form 10-K (this “Report”).



ItemPage
 
 
 
 
 
 
 
 
 
 
 
 
 



Cautionary note regarding forward-looking statements
This Annual Report on Form 10-K and Johnson & Johnson’s other publicly available documents contain “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Management and representatives of Johnson & Johnson and its subsidiaries (the Company) also may from time to time make forward-looking statements. Forward-looking statements do not relate strictly to historical or current facts and reflect management’s assumptions, views, plans, objectives and projections about the future. Forward-looking statements may be identified by the use of words such as “plans,” “expects,” “will,” “anticipates,” “estimates” and other words of similar meaning in conjunction with, among other things: discussions of future operations; expected operating results and financial performance; impact of planned acquisitions and dispositions; impact and timing of restructuring initiatives, including associated cost savings and other benefits; the Company’s strategy for growth; product development activities; regulatory approvals; market position and expenditures.
Because forward-looking statements are based on current beliefs, expectations and assumptions regarding future events, they are subject to uncertainties, risks and changes that are difficult to predict and many of which are outside of the Company’s control. Investors should realize that if underlying assumptions prove inaccurate, or known or unknown risks or uncertainties materialize, the Company’s actual results and financial condition could vary materially from expectations and projections expressed or implied in its forward-looking statements. Investors are therefore cautioned not to rely on these forward-looking statements. Risks and uncertainties include, but are not limited to:
Risks related to product development, market success and competition
Challenges and uncertainties inherent in innovation and development of new and improved products and technologies on which the Company’s continued growth and success depend, including uncertainty of clinical outcomes, additional analysis of existing clinical data, obtaining regulatory approvals, health plan coverage and customer access, and initial and continued commercial success;
Challenges to the Company’s ability to secure and maintain adequate patent and other intellectual property rights for new and existing products and technologies in the United States and other important markets;
The impact of patent expirations, typically followed by the introduction of competing generic, biosimilar or other products and resulting revenue and market share losses;
Increasingly aggressive and frequent challenges to the Company’s patents by competitors and others seeking to launch competing generic, biosimilar or other products and increased receptivity of courts, the United States Patent and Trademark Office and other decision makers to such challenges, potentially resulting in loss of market exclusivity and rapid decline in sales for the relevant product sooner than expected;
Competition in research and development of new and improved products, processes and technologies, which can result in product and process obsolescence;
Competition to reach agreement with third parties for collaboration, licensing, development and marketing agreements for products and technologies;
Competition based on cost-effectiveness, product performance, technological advances and patents attained by competitors; and
Allegations that the Company’s products infringe the patents and other intellectual property rights of third parties, which could adversely affect the Company’s ability to sell the products in question and require the payment of money damages and future royalties.
Risks related to product liability, litigation and regulatory activity
Product efficacy or safety concerns, whether or not based on scientific evidence, potentially resulting in product withdrawals, recalls, regulatory action on the part of the United States Food and Drug Administration (U.S. FDA) (or international counterparts), declining sales, reputational damage, increased litigation expense and share price impact;
The impact, including declining sales and reputational damage, of significant litigation or government action adverse to the Company, including product liability claims and allegations related to pharmaceutical marketing practices and contracting strategies;
The impact of an adverse judgment or settlement and the adequacy of reserves related to legal proceedings, including patent litigation, product liability, personal injury claims, securities class actions, government investigations, employment and other legal proceedings;



Increased scrutiny of the healthcare industry by government agencies and state attorneys general resulting in investigations and prosecutions, which carry the risk of significant civil and criminal penalties, including, but not limited to, debarment from government business;
Failure to meet compliance obligations in compliance agreements with governments or government agencies, which could result in significant sanctions;
Potential changes to applicable laws and regulations affecting United States and international operations, including relating to: approval of new products; licensing and patent rights; sales and promotion of healthcare products; access to, and reimbursement and pricing for, healthcare products and services; environmental protection; and sourcing of raw materials;
Compliance with local regulations and laws that may restrict the Company’s ability to manufacture or sell its products in relevant markets, including requirements to comply with medical device reporting regulations and other requirements such as the European Union’s Medical Devices Regulation;
Changes in domestic and international tax laws and regulations, increasing audit scrutiny by tax authorities around the world may cause exposures to additional tax liabilities potentially in excess of existing reserves; and
The issuance of new or revised accounting standards by the Financial Accounting Standards Board and regulations by the Securities and Exchange Commission.
Risks related to the Company’s strategic initiatives and healthcare market trends
Pricing pressures resulting from trends toward healthcare cost containment, including the continued consolidation among healthcare providers and other market participants, trends toward managed care, the shift toward governments increasingly becoming the primary payors of healthcare expenses, significant new entrants to the healthcare markets seeking to reduce costs and government pressure on companies to voluntarily reduce costs and price increases;
Restricted spending patterns of individual, institutional and governmental purchasers of healthcare products and services due to economic hardship and budgetary constraints;
Challenges to the Company’s ability to realize its strategy for growth including through externally sourced innovations, such as development collaborations, strategic acquisitions, licensing and marketing agreements, and the potential heightened costs of any such external arrangements due to competitive pressures;
The potential that the expected strategic benefits and opportunities from any planned or completed acquisition or divestiture by the Company, including the divestment of Kenvue Inc., may not be realized or may take longer to realize than expected; and
The potential that the expected benefits and opportunities related to past and ongoing restructuring actions may not be realized or may take longer to realize than expected.
Risks related to economic conditions, financial markets and operating internationally
The risks associated with global operations on the Company and its customers and suppliers, including foreign governments in countries in which the Company operates;
The impact of inflation and fluctuations in interest rates and currency exchange rates and the potential effect of such fluctuations on revenues, expenses and resulting margins;
Potential changes in export/import and trade laws, regulations and policies of the United States and other countries, including any increased trade restrictions or tariffs and potential drug reimportation legislation, and the impact of such changes on raw material prices, supply chains market volatility and the pace of product development;
The impact on international operations from financial instability in international economies, sovereign risk, possible imposition of governmental controls and restrictive economic policies, and unstable international governments and legal systems;
The impact of global public health crises and pandemics;
Changes to global climate, extreme weather and natural disasters that could affect demand for the Company’s products and services, cause disruptions in manufacturing and distribution networks, alter the availability of goods and services within the supply chain, and affect the overall design and integrity of the Company’s products and operations;
The impact of global or economic changes or events, including global tensions and war; and
The impact of armed conflicts and terrorist attacks in the United States and other parts of the world, including social and economic disruptions and instability of financial and other markets.



Risks related to supply chain and operations
Difficulties and delays in manufacturing, internally, through third-party providers or otherwise within the supply chain, that may lead to voluntary or involuntary business interruptions or shutdowns, product shortages, withdrawals or suspensions of products from the market, and potential regulatory action;
Interruptions and breaches of the Company’s information technology systems or those of the Company’s vendors, which could result in reputational, competitive, operational or other business harm as well as financial costs and regulatory action;
Reliance on global supply chains and production and distribution processes that are complex and subject to increasing regulatory requirements that may adversely affect supply, sourcing and pricing of materials used in the Company’s products; and
The potential that the expected benefits and opportunities related to restructuring actions may not be realized or may take longer to realize than expected, including due to any required approvals from applicable regulatory authorities.
Investors also should carefully read the risk factors described in Item 1A of this Annual Report on Form 10-K for a description of certain risks that could, among other things, cause the Company’s actual results to differ materially from those expressed in its forward-looking statements. Investors should understand that it is not possible to predict or identify all such factors and should not consider the risks described above and in Item 1A to be a complete statement of all potential risks and uncertainties. The Company does not undertake to publicly update any forward-looking statement that may be made from time to time, whether as a result of new information or future events or developments.



Part I
Item 1. Business
General
Johnson & Johnson and its subsidiaries (the Company) have approximately 138,100 employees worldwide engaged in the research and development, manufacture and sale of a broad range of products in the healthcare field. Johnson & Johnson is a holding company, with operating companies conducting business in virtually all countries of the world. The Company’s primary focus is products related to human health and well-being. Johnson & Johnson was incorporated in the State of New Jersey in 1887.
The Chief Operating Decision Maker (CODM) is the Company's Chief Executive Officer (Principal Executive Officer). The Executive Committee is Johnson & Johnson’s senior leadership team responsible for setting the strategy and priorities of the Company and driving accountability at all levels. Within the strategic parameters provided by the Executive Committee, senior management groups at U.S. and international operating companies are each responsible for their own strategic plans and the day-to-day operations of those companies.
Segments of business
The Company is organized into two business segments: Innovative Medicine and MedTech. Additional information required by this item is incorporated herein by reference to the narrative and tabular descriptions of segments and operating results under: Item 7. Management’s discussion and analysis of results of operations and financial condition of this Report; and Note 17 Segments of business and geographic areas of the notes to consolidated financial statements included in Item 8 of this Report.
Innovative Medicine
The Innovative Medicine segment is focused on the following therapeutic areas: Immunology (e.g., rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease and psoriasis), Infectious Diseases (e.g., HIV/AIDS), Neuroscience (e.g., mood disorders, neurodegenerative disorders and schizophrenia), Oncology (e.g., prostate cancer, hematologic malignancies, lung cancer and bladder cancer), Cardiovascular and Metabolism (e.g., thrombosis, diabetes and macular degeneration) and Pulmonary Hypertension (e.g., Pulmonary Arterial Hypertension). Medicines in this segment are distributed directly to retailers, wholesalers, distributors, hospitals and healthcare professionals for prescription use. Key products in the Innovative Medicine segment include: REMICADE (infliximab), a treatment for a number of immune-mediated inflammatory diseases; SIMPONI (golimumab), a subcutaneous treatment for adults with moderate to severe rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis and moderately active to severely active ulcerative colitis; SIMPONI ARIA (golimumab), an intravenous treatment for adults with moderate to severe rheumatoid arthritis, active psoriatic arthritis and active ankylosing spondylitis and active polyarticular juvenile idiopathic arthritis (pJIA) in people 2 years of age and older; STELARA (ustekinumab), a treatment for adults and children with moderate to severe plaque psoriasis, for adults with active psoriatic arthritis, for adults with moderately to severely active Crohn's disease and treatment of moderately to severely active ulcerative colitis; TREMFYA (guselkumab), a treatment for adults with moderate to severe plaque psoriasis and active psoriatic arthritis and ulcerative colitis; EDURANT (rilpivirine), PREZISTA (darunavir) and PREZCOBIX/REZOLSTA (darunavir/cobicistat), antiretroviral medicines for the treatment of human immunodeficiency virus (HIV) in combination with other antiretroviral products and SYMTUZA (darunavir/cobicistat/emtricitabine/tenofovir alafenamide), a once-daily single tablet regimen for the treatment of HIV; CONCERTA (methylphenidate HCl) extended-release tablets CII, a treatment for attention deficit hyperactivity disorder; INVEGA SUSTENNA/XEPLION (paliperidone palmitate), for the treatment of schizophrenia and schizoaffective disorder in adults; INVEGA TRINZA/TREVICTA (paliperidone palmitate), for the treatment of schizophrenia in patients after they have been adequately treated with INVEGA SUSTENNA for at least four months; SPRAVATO (Esketamine), a nasal spray, used along with an oral antidepressant, to treat adults with treatment-resistant depression (TRD) and depressive symptoms in adults with major depressive disorder (MDD) with suicidal thoughts or actions; CARVYKTI (ciltacabtagene autoleucel), a chimeric antigen receptor (CAR)-T-cell therapy for the treatment of patients with relapsed/refractory multiple
2024 Annual Report
1


myeloma; ZYTIGA (abiraterone acetate), a treatment for patients with prostate cancer; ERLEADA (apalutamide), a next-generation androgen receptor inhibitor for the treatment of patients with prostate cancer; IMBRUVICA (ibrutinib), a treatment for certain B-cell malignancies, or blood cancers and chronic graft versus host disease; DARZALEX (daratumumab), a treatment for multiple myeloma; DARZALEX FASPRO (daratumumab and hyaluronidase-fihj), a treatment for multiple myeloma and light chain (AL) Amyloidosis; TECVAYLI (teclistamab-cqyv), a ready-to-use bispecific antibody for adults with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy; XARELTO (rivaroxaban), an oral anticoagulant for the prevention of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE) in patients undergoing hip or knee replacement surgery, to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation, and for the treatment and reduction of risk of recurrence of DVT and PE to reduce the risk of major cardiovascular events in patients with coronary artery disease (CAD) and peripheral artery disease (PAD), for the treatment and secondary prevention of thromboembolism in pediatric patients, and for thromboprophylaxis in pediatric patients following the Fontan procedure; OPSUMIT (macitentan) as monotherapy or in combination, indicated for the long-term treatment of pulmonary arterial hypertension (PAH); UPTRAVI (selexipag), the only approved oral and intravenous, selective IP receptor agonist targeting a prostacyclin pathway in PAH. Many of these medicines were developed in collaboration with strategic partners or are licensed from other companies and maintain active lifecycle development programs.
MedTech
The MedTech segment includes a broad portfolio of products used in the cardiovascular, orthopaedics, surgery, and vision categories. The Cardiovascular (previously referred to as Interventional solutions) portfolio includes electrophysiology products to treat heart rhythm disorders, the heart recovery portfolio (Abiomed) which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock, circulatory restoration products (Shockwave) for the treatment of calcified coronary artery disease (CAD) and peripheral artery disease (PAD), and neurovascular care that treats hemorrhagic and ischemic stroke. The Orthopaedics portfolio includes products and enabling technologies that support hips, knees, trauma, spine, sports, and others. The Surgery portfolios include advanced and general surgery technologies, as well as solutions that focus on breast aesthetics and reconstruction (Mentor). Vision products include ACUVUE brand contact lenses and TECNIS intraocular lenses for cataract surgery. These products are distributed to wholesalers, hospitals, and retailers and are used predominantly in the professional fields by physicians, nurses, hospitals, eye care professionals, and clinics.
Geographic areas
The Company conducts business in virtually all countries of the world with the primary focus on products related to human health and well-being. The products made and sold in the international business include many of those described above under Segments of Business – Innovative Medicine and MedTech. However, the principal markets, products and methods of distribution in the international business vary with the country and the culture. The products sold in the international business include those developed in the U.S. and by subsidiaries abroad.
Investments and activities in some countries outside the U.S. are subject to higher risks than comparable U.S. activities because the investment and commercial climate may be influenced by financial instability in international economies, restrictive economic policies and political and legal system uncertainties.
Raw materials
Raw materials essential to the Company's business are generally readily available from multiple sources. Where there are exceptions, the temporary unavailability of those raw materials would not likely have a material adverse effect on the financial results of the Company.
Patents
The Company's subsidiaries have made a practice of obtaining patent protection on their products and processes where possible. They own, or are licensed under, a significant number of patents in the U.S. and other countries relating to their products, product uses, formulations and manufacturing processes, which in the aggregate are believed to be of material importance to the Company in the operation of its businesses. The Company’s subsidiaries face patent challenges from third parties, including challenges seeking to manufacture and market generic and biosimilar versions of the Company's key pharmaceutical products prior to expiration of the applicable patents covering those products. Significant legal proceedings
2
 Jhonson&Jhonson.jpg 


and claims involving the Company's patent and other intellectual property are described in Note 19 Legal proceedings—Intellectual property of the Notes to Consolidated Financial Statements included in Item 8 of this Report.
Sales of the Company’s largest product, collectively DARZALEX (daratumumab) and DARZALEX FASPRO (daratumumab and hyaluronidase-fihj), accounted for approximately 13.1% of the Company's total revenues for fiscal 2024. Accordingly, the patents related to these products are believed to be material to the Company. Genmab A/S owns two patent families related to DARZALEX, and Janssen Biotech, Inc. has an exclusive license to those patent families. The two patent families both expire in the United States in 2029, and in Europe, compound/use patent protection in select countries extends to 2031/2032. Janssen Biotech, Inc. owns a separate patent portfolio related to DARZALEX FASPRO.
Sales of the Company’s second largest product, STELARA (ustekinumab) accounted for approximately 11.7% of the Company's total revenues for fiscal 2024. According to patent settlement and license agreements, the Company expects continued launches of biosimilar versions of STELARA in Europe and the United States in 2025 which will impact the Company’s sales of STELARA.
Trademarks
The Company’s subsidiaries have made a practice of selling their products under trademarks and of obtaining protection for these trademarks by all available means. These trademarks are protected by registration in the U.S. and other countries where such products are marketed. The Company considers these trademarks in the aggregate to be of material importance in the operation of its businesses.
Seasonality
Worldwide sales do not reflect any significant degree of seasonality; however, spending has typically been heavier in the fourth quarter of each year than in other quarters. This reflects increased spending decisions, principally for advertising and research and development activity.
Competition
In all of their product lines, the Company's subsidiaries compete with companies both locally and globally. Competition exists in all product lines without regard to the number and size of the competing companies involved. Competition in research, both internally and externally sourced, involving the development and the improvement of new and existing products and processes, is particularly significant. The development of new and innovative products, as well as protecting the underlying intellectual property of the Company’s product portfolio, is important to the Company's success in all areas of its business. The competitive environment requires substantial investments in continuing research.
Environment
The Company is subject to a variety of environmental laws and regulations in the United States and other jurisdictions. The Company believes that its operations comply in all material respects with applicable environmental laws and regulations. The Company’s compliance with these requirements is not expected to have a material effect upon its capital expenditures, cash flows, earnings or competitive position.
Regulation
The Company’s businesses are subject to varying degrees of governmental regulation in the countries in which operations are conducted, and the general trend is toward increasingly stringent regulation and enforcement. The Company is subject to costly and complex U.S. and foreign laws and governmental regulations, and any adverse regulatory action may materially adversely affect the Company's financial condition and business operations. In the U.S., the pharmaceutical product and medical technology industries have long been subject to regulation by various federal and state agencies, primarily as to product safety, efficacy, manufacturing, advertising, labeling and safety reporting. The exercise of broad regulatory powers by the U.S. Food and Drug Administration (the U.S. FDA) continues to result in increases in the amounts of testing and documentation required for U.S. FDA approval of new drugs and devices and a corresponding increase in the expense of product introduction. Similar trends are also evident in major markets outside of the U.S.
2024 Annual Report
3


The medical device regulatory framework and the evolving privacy, data localization, and emerging cyber security laws and regulations around the world are examples of such increased regulation. Within the U.S., an increasing number of U.S. States have enacted comprehensive privacy laws, and federal regulators (e.g., the U.S. FDA, FTC and HHS) continue to stress the intersection of health and privacy as a compliance and enforcement priority. In the EU, multiple directives and laws (including NIS2, EHDS, the Data Act, the Cyber Resilience Act, and the AI Act) are rapidly changing privacy and cybersecurity compliance requirements while introducing new enforcement risks. In addition, China has introduced broad personal information protection and data security regulations, with more anticipated, thereby increasing China’s scrutiny of company compliance and data transfer practices. With other jurisdictions enacting similar privacy laws, local data protection authorities will force greater accountability on the collection, access and use of personal data in the healthcare industry. These laws can also restrict transfers of data across borders, potentially impacting how data-driven health care solutions are developed and deployed globally in a compliant manner. Moreover, as a result of the broad scale release and availability of Artificial Intelligence (AI) technologies such as generative AI, a global trend towards more comprehensive and nuanced regulation to ensure the ethical use, privacy, and security of AI is underway that includes standards for transparency, accountability, and fairness, which will require compliance developments or enhancements.
The regulatory agencies under whose purview the Company operates have administrative powers that may subject it to actions such as product withdrawals, recalls, seizure of products and other civil and criminal sanctions. In some cases, the Company’s subsidiaries may deem it advisable to initiate product recalls regardless of whether it has been required or directed to.
The U.S. FDA and regulatory agencies around the globe are also increasing their enforcement activities. If the U.S. FDA were to conclude that we are not in compliance with applicable laws or regulations, or that any of our pharmaceutical products or medical technologies are ineffective or pose an unreasonable safety risk, the U.S. FDA could ban such products, detain or seize adulterated or misbranded products, order a recall, repair, replacement, or refund of such products, withdraw approval for such products, refuse to grant pending applications for marketing authorization or require certificates of foreign governments for exports, and/or require us to notify health professionals and others that the products present unreasonable risks of substantial harm to the public health. The U.S. FDA may also assess civil or criminal penalties against us, our officers or employees and impose operating restrictions on a company-wide basis, or enjoin and/or restrain certain conduct resulting in violations of applicable law. The U.S. FDA may also recommend prosecution to the U.S. Department of Justice. Any adverse regulatory action, depending on its magnitude, may restrict us from effectively marketing and selling our products and limit our ability to obtain future clearances, classifications or approvals, and could result in a substantial modification to our business practices and operations. Equivalent enforcement mechanisms exist in different countries in which we conduct business.
The costs of human healthcare have been and continue to be a subject of study, investigation and regulation by governmental agencies and legislative bodies around the world. In the U.S., attention has been focused by states, regulatory agencies and Congress on prices, profits, overutilization and the quality and costs of healthcare generally. Laws and regulations have been enacted to require adherence to strict compliance standards and prevent fraud and abuse in the healthcare industry. There is increased focus on interactions and financial relationships between healthcare companies and healthcare providers. Various state and federal transparency laws and regulations require disclosures of payments and other transfers of value made to certain healthcare practitioners, including physicians, teaching hospitals, and certain non-physician practitioners. Federal and foreign laws governing international business practices require strict compliance with anti-bribery standards and certain prohibitions with respect to payments to any foreign government official. Payors and Pharmacy Benefit Managers (PBMs) are a potent force in the marketplace, and increased attention is being paid to the impact of PBM practices on healthcare cost and access in the U.S.
Our business has been and continues to be affected by federal and state legislation that alters the pricing, coverage, and reimbursement landscape. At the federal level, in August 2022, President Biden signed into law the Inflation Reduction Act (IRA), which includes provisions that effectively authorize the government to establish prices for certain high-spend single-source drugs and biologics reimbursed by the Medicare program, starting in 2026 for Medicare Part D drugs and 2028 for Medicare Part B drugs. On August 29, 2023, the Centers for Medicare & Medicaid Services (“CMS”) published the first “Selected Drug” list, which includes XARELTO and STELARA as well as IMBRUVICA, which is developed in collaboration and co-commercialized in the U.S. with Pharmacyclics LLC, an AbbVie company. The Selected Drug list also included other medicines targeting disease states that are prevalent in the Medicare population. Although CMS published an explanation for how it determined prices for selected drugs in December 2024, uncertainty remains as to the methodology used to determine these prices. The IRA specifies a ceiling price but not a minimum price for selected drugs and does not require CMS to use a specific framework for determining selected drug prices. In any event, we anticipate that the selected products will be subjected to a government-established price for the Medicare population beginning in 2026.
4
 Jhonson&Jhonson.jpg 


The IRA also contains provisions that impose rebates if certain prices increase at a rate that outpaces the rate of inflation, beginning October 1, 2022, for Medicare Part D drugs and January 1, 2023, for Medicare Part B drugs. Separate IRA provisions redesign the Medicare Part D benefit in various ways, including by shifting a greater portion of costs to manufacturers within certain coverage phases and replacing the Part D coverage gap discount program with a new manufacturer discounting program. Failure to comply with IRA provisions may subject manufacturers to various penalties, including civil monetary penalties.
In July 2023, Janssen Pharmaceuticals, Inc. (Janssen) filed litigation against the U.S. Department of Health and Human Services as well as the Centers for Medicare and Medicaid Services challenging the constitutionality of the IRA's Medicare Drug Price Negotiation Program. The litigation requests a declaration that the IRA violates Janssen’s rights under the First Amendment and the Fifth Amendment to the Constitution and therefore that Janssen is not subject to the IRA’s mandatory pricing scheme. The impact of the IRA on our business and the broader pharmaceutical industry remains uncertain, as litigation filed by Janssen and other pharmaceutical companies remains ongoing and while CMS has publicly announced the maximum fair price for each of the selected drugs, implementation of the program is still in progress. In April 2024, Janssen appealed the district court’s denial of its summary judgment motion to the Third Circuit.
Additionally, we expect continued scrutiny on drug pricing and government price reporting from Congress, agencies, and other bodies at the federal and state levels, which may result in additional regulations or other mechanisms to increase pricing transparency and controls.
There are a number of additional bills pending in Congress and healthcare reform proposals at the state level that would affect drug pricing, including in the Medicare and Medicaid programs. This changing legal landscape has both positive and negative impacts on the U.S. healthcare industry with much remaining uncertain as to how various provisions of federal and state law, and potential modification or repeal of these laws, will ultimately affect the industry. The IRA and any other federal or state legislative change could affect the pricing and market conditions for our products.
In addition, business practices in the healthcare industry have come under increased scrutiny, particularly in the U.S., by government agencies and state attorneys general, and resulting investigations and prosecutions carry the risk of significant civil and criminal penalties. Of note is the increased enforcement activity by data protection authorities in various jurisdictions, particularly in the European Union, where significant fines have been levied on companies for data breaches, violations of privacy requirements, and unlawful cross-border data transfers. In the U.S., the Federal Trade Commission has stepped up enforcement of data privacy with several significant settlements (including settlements concerning the downstream sharing of personal information and use and disclosure of personal health data) and there have been a material increase in class-action lawsuits linked to the collection and use of biometric data and use of tracking technologies.
Further, the Company relies on global supply chains, and production and distribution processes, that are complex, and subject to increasing regulatory requirements that may affect sourcing, supply and pricing of materials used in the Company's products. These processes also are subject to complex and lengthy regulatory approvals.
2024 Annual Report
5


Employees and human capital management
As of December 29, 2024 and December 31, 2023 the number of employees was approximately:
20242023
Employees(1)
139,800 134,400 
Full-time equivalent (FTE) positions(2)
138,100 131,900 
(1)“Employee” is defined as an individual working full-time or part-time, excluding fixed term employees, interns and co-op employees. Employee data may not include full population from more recently acquired companies and individuals on long-term disability are excluded. Contingent workers, contractors and subcontractors are also excluded. Shockwave has been included in the fiscal 2024 headcount in the above table.
(2)FTE represents the total number of full-time equivalent positions and does not reflect the total number of individual employees as some work part-time.
Employees by region (in percentages)
632
Strategy
The Company believes that its employees are critical to its continued success and are an essential element of its long-term strategy. Management is responsible for ensuring that its policies and processes reflect and reinforce the Company's desired corporate culture, including policies and processes related to strategy, risk management, and ethics and compliance. The Company’s human capital management strategy is built on three fundamental focus areas:
Attracting and recruiting top talent
Developing and retaining top talent
Empowering and inspiring talent
Underpinning these focus areas are ongoing efforts to cultivate and foster a culture built on innovation, health, well-being and safety, inclusion and belonging where the Company's employees are encouraged to succeed both professionally and personally while helping the Company achieve its business goals.
Culture and employee engagement
At Johnson & Johnson, employees are guided by Our Credo, which sets forth the Company's responsibilities to patients, consumers, customers, healthcare professionals, employees, communities and shareholders. Employees worldwide must adhere to the Company’s Code of Business Conduct, which sets fundamental requirements and serves as a foundation for the Company policies, procedures and guidelines, all of which provide additional guidance on expected employee behaviors in every market where it operates. The Company conducts global surveys that offer its employees the ability to provide feedback and valuable insight to help address potential human resources risks and identify opportunities to improve. In 2024, 94% of global employees across 73 countries participated in Our Credo Survey which was offered in 36 languages.
6
 Jhonson&Jhonson.jpg 


Growth and development
To lead in the changing healthcare landscape, it is crucial that the Company continue to attract and retain top talent. In 2024, the Company's voluntary turnover rate was 6.3%. The Company believes that its employees must be equipped with the right knowledge and skills and be provided with opportunities to grow and develop in their careers. Accordingly, professional development programs and educational resources are available to all employees. The Company's objective is to foster a learning culture that helps shape each person’s unique career path while creating a robust pipeline of talent to deliver on the Company’s long-term strategies. In furtherance of this objective, the Company deploys a global approach to ensure development is for everyone, regardless of where they are on their career journey. To prioritize learning, the Company recently held Johnson & Johnson's second Global Learning Day. Employees were encouraged to set aside a full day to explore skill-building courses on J&J Learn, the new state-of-the-art learning platform.
Our workforce
As stated in Our Credo, we are responsible to our employees who work with us throughout the world. The Company is committed to cultivating, fostering and advancing an inclusive, credo-based work environment for employees that recognizes and rewards based on merit. The Company is dedicated to the values in Our Credo and strives to meet the needs of its employees and stakeholders through compliance with law and the following evidence based strategies:
Sustain a global workforce of individuals with many different backgrounds, abilities, cultures and perspectives
Maintain a work environment where each person’s dignity is respected and they have an opportunity to advance based on their merit
Drive innovation and growth with our business to serve markets around the world
Our approach with respect to our workforce is guided by applicable laws, internal and external insights, global best practices and employee feedback.
Compensation and benefits
As part of the Company's total rewards philosophy, the Company offers competitive compensation and benefits to attract and retain top talent. The Company is committed to fair treatment in its compensation and benefits for employees at all levels. The Company observes legal minimum wage provisions and exceeds them where possible. The Company's total rewards offerings include an array of programs to support its employees' well-being, including annual performance incentive opportunities, pension and retirement savings programs, health and welfare benefits, paid time off, leave programs, flexible work schedules and employee assistance programs.
Health, wellness and safety
The Company’s investment in employee health, well-being and safety is built on its conviction that advancing health for humanity starts with advancing the health of its employees. With the right awareness, focus, practices and tools, the Company works to ensure that all its employees around the world, as well as contingent workers, contractors and visitors to the Company's sites, can work safely. The Company has continuously expanded health and well-being programs throughout the Company and across the globe, incorporating new thinking and technologies to keep its offerings best-in-class and to help employees achieve their personal health goals. The programs and practices the Company provides—physical, mental, emotional and financial—help promote holistic employee health. The Company continues to address our employees needs through J&J Flex, a hybrid model that empowers the Company’s office-based employees to find a balance of in-person and remote work, while preserving the Company's culture and need for face-to-face engagement and leadership.
2024 Annual Report
7


Available information
The Company’s main corporate website address is www.jnj.com. The Company makes its SEC filings available on the Company’s website at www.investor.jnj.com/financials/sec-filings, as soon as reasonably practicable after having been electronically filed or furnished to the SEC. The Company's SEC filings are also available at the SEC’s website at www.sec.gov.
Investors and the public should note that the Company also announces information through its press releases and media statements at www.jnj.com/mediacenter, investor.jnj.com and www.factsabouttalc.com. We use these websites to communicate with investors and the public about our products, litigation and other matters. It is possible that the information we post to these websites could be deemed to be material information. Therefore, we encourage investors and others interested in the Company to review the information posted to these websites in conjunction with www.jnj.com, the Company's SEC filings, press releases, public conference calls and webcasts.
In addition, the Restated Certificate of Incorporation, as amended, Amended and Restated By-Laws, the written charters of the Audit Committee, the Compensation & Benefits Committee, the Nominating & Corporate Governance Committee, the Regulatory Compliance & Sustainability Committee, and the Science & Technology Committee of the Board of Directors, and the Company’s Principles of Corporate Governance, Code of Business Conduct (for employees), Code of Business Conduct & Ethics for Members of the Board of Directors and Executive Officers, and other corporate governance materials are available on the Company's website at www.investor.jnj.com/governance/corporate-governance-overview and will be provided without charge to any shareholder submitting a written request, as provided above. The information on www.jnj.com, investor.jnj.com and www.factsabouttalc.com is not, and will not be deemed, a part of this Report or incorporated into any other filings the Company makes with the SEC.
8
 Jhonson&Jhonson.jpg 


Item 1A. Risk factors
An investment in the Company’s common stock or debt securities involves risks and uncertainties. The Company seeks to identify, manage and mitigate risks to our business, but uncertainties and risks are difficult to predict and many are outside of the Company’s control and cannot therefore be eliminated. In addition to the other information in this report and the Company’s other filings with the SEC, investors should consider carefully the factors set forth below. Investors should be aware that it is not possible to predict or identify all such factors and that the following is not meant to be a complete discussion of all potential risks or uncertainties. If known or unknown risks or uncertainties materialize, the Company’s business, results of operations or financial condition could be adversely affected, potentially in a material way.
Risks related to our business, industry and operations
The Company’s businesses operate in highly competitive product markets and competitive pressures could adversely affect the Company’s earnings.
The Company faces substantial competition in its two operating segments and in all geographic markets. The Company’s businesses compete with companies of all sizes on the basis of cost-effectiveness, technological innovations, intellectual property rights, product performance, real or perceived product advantages, pricing and availability and rate of reimbursement. The Company also competes with other market participants in securing rights to acquisitions, collaborations and licensing agreements with third parties. Competition for rights to product candidates and technologies may result in significant investment and acquisition costs and onerous agreement terms for the Company. Competitors’ development of more effective or less costly products, and/or their ability to secure patent and other intellectual property rights and successfully market products ahead of the Company, could negatively impact sales of the Company’s existing products as well as its ability to bring new products to market despite significant prior investment in the related product development. The Company may also experience operational and financial risk in connection with acquisitions if we are unable to fully identify potential risks and liabilities associated with acquired businesses or products, successfully integrate operations and employees, and successfully identify and realize synergies with existing businesses while containing acquisition-related strain on our management, operations and financial resources.
For the Company’s Innovative Medicine businesses, loss of patent exclusivity for a product often is followed by a substantial reduction in sales as competitors gain regulatory approval for generic, biosimilar and other competing products and enter the market. For the Company’s MedTech businesses, technological innovation, product quality, reputation and customer service are especially important to competitiveness. Development by other companies of new or improved products, processes and technologies could threaten to make the Company’s products or technologies less desirable, less economical or obsolete. The Company’s business and operations will be negatively impacted if we are unable to introduce new products or technological advances that are safe, more effective, more effectively marketed or otherwise outperform those of our competitors.
Interruptions and delays in manufacturing operations could adversely affect the Company’s business, sales and reputation.
The Company’s manufacturing of products requires the timely delivery of sufficient amounts of complex, high-quality components and materials. The Company’s subsidiaries operate 64 manufacturing facilities as well as sourcing from thousands of suppliers around the world. The Company has in the past, and may in the future, face unanticipated interruptions and delays in manufacturing through its internal or external supply chain. Manufacturing disruptions can occur for many reasons including regulatory action, production quality deviations or safety issues, labor disputes, labor shortages, site-specific incidents (such as fires), natural disasters such as hurricanes and other severe weather events, raw material shortages, lack of available inspectors, political unrest, terrorist attacks and epidemics or pandemics. Such delays and difficulties in manufacturing can result in product shortages, declines in sales and reputational impact as well as significant remediation and related costs associated with addressing the shortage.
The Company relies on third parties to manufacture and supply certain of our products. Any failure by or loss of a third-party manufacturer or supplier could result in delays and increased costs, which may adversely affect our business.
The Company relies on third parties to manufacture and supply certain of our raw materials, component parts and products. We depend on these third-party manufacturers to allocate to us a portion of their manufacturing capacity sufficient to meet our needs, to produce products of acceptable quality and at acceptable manufacturing yields and to deliver those products to us on a timely basis and at acceptable prices. However, we cannot guarantee that these third-party manufacturers will be able to meet our near-term or long-term manufacturing requirements, which could result in lost sales and have an adverse effect on our business.
2024 Annual Report
9


Other risks associated with our reliance on third parties to manufacture these products include reliance on the third party for regulatory compliance and quality assurance, misappropriation of the Company’s intellectual property, limited ability to manage our inventory, possible breach of the manufacturing agreement by the third party and the possible termination or nonrenewal of the manufacturing agreement by the third party at a time that is costly or inconvenient for us. Moreover, if any of our third-party manufacturers suffers any damage to facilities, loses benefits under material agreements, experiences power outages, encounters financial difficulties, is unable to secure necessary raw materials from its suppliers or suffers any other reduction in efficiency, the Company may experience significant business disruption. In the event of any such disruption, the Company would need to seek and source other qualified third-party manufacturers, likely resulting in further delays and increased costs which could affect our business adversely.
Counterfeit versions of our products could harm our patients and have a negative impact on our revenues, earnings, reputation and business.
Our industry continues to be challenged by the vulnerability of distribution channels to illegal counterfeiting and the presence of counterfeit products in a growing number of markets and over the Internet. Third parties may illegally distribute and sell counterfeit versions of our products, which do not meet our rigorous manufacturing and testing standards. To distributors and patients, counterfeit products may be visually indistinguishable from the authentic version. Counterfeit medicines pose a risk to patient health and safety because of the conditions under which they are manufactured – often in unregulated, unlicensed, uninspected and unsanitary sites – as well as the lack of regulation of their contents.
The industry’s failure to mitigate the threat of counterfeit medicines could adversely impact our business and reputation by impacting patient confidence in our authentic products, potentially resulting in lost sales, product recalls, and an increased threat of litigation. In addition, diversion of our products from their authorized market into other channels may result in reduced revenues and negatively affect our profitability.
Global health crises, pandemics, epidemics, or other outbreaks could adversely disrupt or impact certain aspects of the Company’s business, results of operations and financial condition.
We are subject to risks associated with global health crises, epidemics, pandemics and other outbreaks (such incident(s), a health crisis or health crises). The spread of health crises have caused and may cause the Company to modify its business practices, and take further actions as may be required by government authorities or as the Company determines are in the best interests of our patients, customers, employees and business partners under such circumstances. Impacts to the Company have included and may include adverse impacts to results of operations and financial condition, including lower sales and reduced customer demand and usage of certain of our products. While the Company has robust business continuity plans in place across our global supply chain network designed to help mitigate the impact of health crises, these efforts may not completely prevent our business from being adversely affected in the event of a health crisis. Health crises could adversely impact the Company’s operations, including, among other things, our manufacturing operations, supply chain, third-party suppliers, sales and marketing, and clinical trial operations. Any of these factors could adversely affect the Company’s business, financial results, and global economic conditions generally.
Risks related to government regulation and legal proceedings
Global sales in the Company’s Innovative Medicine and MedTech segments may be negatively impacted by healthcare reforms and increasing pricing pressures.
Sales of the Company’s Innovative Medicine and MedTech products are significantly affected by reimbursements by third-party payors such as government healthcare programs, private insurance plans and managed care organizations. As part of various efforts to contain healthcare costs, these payors are putting downward pressure on prices at which products will be reimbursed. In the U.S., increased purchasing power of entities that negotiate on behalf of Medicare, Medicaid, and private sector beneficiaries, in part due to continued consolidation among healthcare providers, could result in further pricing pressures. In addition, recent legislation and ongoing political scrutiny on pricing, coverage and reimbursement could result in additional pricing pressures. Specifically, the Inflation Reduction Act of 2022 (IRA) has changed Medicare Part D benefit design and has subjected certain of the Company's products to government-established pricing beginning in 2026 and may subject additional products in the future. Failure to adhere to the government's interpretations of the law pending ongoing litigation may expose the Company to penalties. In addition, change to Medicare Part D could have a negative impact on U.S. Innovative Medicine sales. Further, increased third-party utilization of the 340B Federal Drug Discount Program from expanded interpretations of the statute and program abuse may have a negative impact on the Company's financial performance. Outside the U.S., numerous major markets, including the EU, United Kingdom, Japan and China, have pervasive government involvement in funding healthcare and, in that regard, directly or indirectly impose price controls, limit access to, or reimbursement for, the Company’s products, or reduce the value of its intellectual property protection.
10
 Jhonson&Jhonson.jpg 


We are subject to an increasing number of costly and complex governmental regulations in the countries in which operations are conducted which may materially adversely affect the Company’s financial condition and business operations.
As described in Item 1. Business, the Company is subject to an increasing number of extensive government laws and regulations, investigations and legal action by national, state and local government agencies in the U.S. and other countries in which it operates. For example, changes to the U.S. FDA’s timing or requirements for approval or clearance of our products may have a negative impact on our ability to bring new products to market. New and changing laws, regulations, executive orders and other directives may also impose deadlines on the Company, or its third-party suppliers, manufacturers or other partners and providers, for which there may be insufficient time to implement changes to comply with such new regulations and may result in manufacturing delays or other supply chain constraints. If the Company is unable to identify ways to mitigate these delays or constraints, there may be an adverse effect on sales and access to our products.
The Company is subject to significant legal proceedings that can result in significant expenses, fines and reputational damage.
In the ordinary course of business, Johnson & Johnson and its subsidiaries are subject to numerous claims and lawsuits involving various issues such as product liability, patent disputes and claims that their product sales, marketing and pricing practices violate various antitrust, unfair trade practices and/or consumer protection laws. The Company’s more significant legal proceedings are described in Note 19 Legal proceedings under Notes to the Consolidated Financial Statements included in Item 8 of this Report. Litigation, in general, and securities, derivative action, class action and multi-district litigation, in particular, can be expensive and disruptive. Some of these matters may include thousands of plaintiffs, may involve parties seeking large and/or indeterminate amounts, including punitive or exemplary damages, and may remain unresolved for several years. For example, the Company is a defendant in numerous lawsuits arising out of the use of body powders containing talc, primarily JOHNSON’S Baby Powder. While the Company believes it has substantial defenses in these matters, it is not feasible to predict the ultimate outcome of litigation. The Company has been and could in the future be required to pay significant amounts as a result of settlements or judgments in these matters, potentially in excess of accruals, including matters where the Company could be held jointly and severally liable among other defendants. The resolution of, or increase in accruals for, one or more of these matters in any reporting period could have a material adverse effect on the Company’s results of operations and cash flows for that period. The Company does not purchase third-party product liability insurance; however, the Company utilizes a wholly owned captive insurance company subject to certain limits.
Product reliability, safety and effectiveness concerns can have significant negative impacts on sales and results of operations, lead to litigation and cause reputational damage.
Product concerns, whether raised internally or by litigants, regulators or consumer advocates, and whether or not based on scientific evidence, can result in safety alerts, product recalls, governmental investigations, regulatory action on the part of the U.S. FDA (or its counterpart in other countries), private claims and lawsuits, payment of fines and settlements, declining sales and reputational damage. These circumstances can also result in damage to brand image, brand equity and consumer trust in the Company’s products. Product recalls have in the past, and could in the future, prompt government investigations and inspections, the shutdown of manufacturing facilities, continued product shortages and related sales declines, significant remediation costs, reputational damage, possible civil penalties and criminal prosecution.
The Company faces significant regulatory scrutiny, which imposes significant compliance costs and exposes the Company to government investigations, legal actions and penalties.
The rapid increase in new government laws and regulations imposes significant compliance costs to the Company and a failure of the Company to timely implement changes to comply with these new laws may expose the Company to investigations, legal actions or penalties. Regulatory issues regarding compliance with current Good Manufacturing Practices (cGMP) (and comparable quality regulations in foreign countries) by manufacturers of drugs and devices can lead to fines and penalties, product recalls, product shortages, interruptions in production, delays in new product approvals and litigation. In addition, the marketing, pricing and sale of the Company’s products are subject to regulation, investigations and legal actions including under the Federal Food, Drug, and Cosmetic Act, the Medicaid Rebate Program, federal and state false claims acts, state unfair trade practices acts and consumer protection laws. Scrutiny of healthcare industry business practices by government agencies and state attorneys general in the U.S., and any resulting investigations and prosecutions, carry risk of significant civil and criminal penalties including, but not limited to, debarment from participation in government healthcare programs. Any such debarment could have a material adverse effect on the Company’s business and results of operations. The most significant current investigations and litigation brought by government agencies are described in Note 19 Legal proceedings—Government proceedings under Notes to the Consolidated Financial Statements included in Item 8 of this Report.
2024 Annual Report
11


Changes in tax laws or exposures to additional tax liabilities could negatively impact the Company’s operating results.
Changes in tax laws or regulations around the world, including in the U.S. and as led by the Organization for Economic Cooperation and Development, such as the enactment by certain EU and non-EU countries, and the anticipated enactment by additional countries, of a global minimum tax, could negatively impact the Company’s effective tax rate and results of operations. A change in statutory tax rate or certain international tax provisions in any country would result in the revaluation of the Company’s deferred tax assets and liabilities related to that particular jurisdiction in the period in which the new tax law is enacted. This change would result in an expense or benefit recorded to the Company’s Consolidated Statement of Earnings. The Company closely monitors these proposals as they arise in the countries where it operates. Changes to tax laws or regulations may occur at any time, and any related expense or benefit recorded may be material to the fiscal quarter and year in which the law change is enacted.
See Note 8 Income taxes under Notes to the Consolidated Financial Statements included in Item 8 of this Report for additional information.
The Company conducts business and files tax returns in numerous countries and is addressing tax audits and disputes with many tax authorities. In connection with various government initiatives, companies are required to disclose more information to tax authorities on operations around the world, which may lead to greater audit scrutiny of profits earned in other countries. The Company regularly assesses the likely outcomes of its tax audits and disputes to determine the appropriateness of its tax reserves. However, any tax authority could take a position on tax treatment that is contrary to the Company’s expectations, which could result in tax liabilities in excess of reserves.
Risks related to our intellectual property
The Company faces increased challenges to intellectual property rights central to its business.
The Company owns or licenses a significant number of patents and other proprietary rights relating to its products and manufacturing processes. These rights are essential to the Company’s businesses and the inability of the Company to secure and maintain these rights may have a detrimental impact on the Company’s financial results. Public policy, both within and outside the U.S., has become increasingly unfavorable toward intellectual property rights. The Company cannot be certain that it will secure and maintain adequate patent protection for new products and technologies in the United States and other important markets.
Competitors routinely challenge the validity or extent of the Company’s owned or licensed patents and proprietary rights through litigation, interferences, oppositions and other proceedings, such as inter partes review (IPR) proceedings before the United States Patent & Trademark Office (USPTO). These proceedings absorb resources and can be protracted as well as unpredictable. In addition, others may claim the Company has infringed their intellectual property rights, including copyrights, patents, or trademarks, and/or has misappropriated their trade secrets, any of which could result in an injunction and/or the need to pay past damages and future royalties and adversely affect the competitive position and sales of our products.
The Company has faced increasing patent challenges from third parties seeking to manufacture and market generic and biosimilar versions of the Company’s key pharmaceutical products prior to expiration of the applicable patents covering those products. In the event the Company is not successful in defending its patents against such challenges, or upon the “at-risk” launch by the generic or biosimilar firm of its product, the Company can lose a major portion of revenues for the referenced product in a very short period of time. Current legal proceedings involving the Company’s patents and other intellectual property rights are described in Note 19 Legal proceedings—Intellectual property under Notes to the Consolidated Financial Statements included in Item 8 of this Report.
12
 Jhonson&Jhonson.jpg 


Risks related to product development, regulatory approval and commercialization
Significant challenges or delays in the Company’s innovation, development and implementation of new products, technologies and indications could have an adverse impact on the Company’s long-term success.
The Company’s continued growth and success depends on its ability to innovate and develop new and differentiated products and services that address the evolving healthcare needs of patients, providers and consumers. Development of successful products and technologies is also necessary to offset revenue losses when the Company’s existing products lose market share due to various factors such as competition and loss of patent exclusivity. New products introduced within the past five years accounted for approximately 25% of 2024 sales. The Company cannot be certain when or whether it will be able to develop, license or otherwise acquire companies, products and technologies, whether particular product candidates will be granted regulatory approval, and, if approved, whether the products will be commercially successful.
The Company pursues product development through internal research and development as well as through collaborations, acquisitions, joint ventures and licensing or other arrangements with third parties. In all of these contexts, developing new products, particularly pharmaceutical and biotechnology products and medical devices, requires significant investment of resources over many years. Only a very few biopharmaceutical research and development programs result in commercially viable products. The process depends on many factors including the ability to: discern patients’ and healthcare providers’ future needs; develop promising new compounds, strategies and technologies; achieve successful clinical trial results; secure effective intellectual property protection; obtain regulatory approvals on a timely basis; and, if and when they reach the market, successfully differentiate the Company’s products from competing products and approaches to treatment. Moreover, the development and regulatory approval of new products may be delayed due to limits on federal agency budgets or personnel, including reductions to the U.S. FDA’s budget, employees, and operations, which may lead to slower response times and longer review periods. After approval, new products or enhancements to existing products may not be accepted quickly or significantly in the marketplace due to product and price competition, changes in customer preferences or healthcare purchasing patterns, resistance by healthcare providers or uncertainty over third-party reimbursement. Even following initial regulatory approval, the success of a product can be adversely impacted by safety and efficacy findings in larger real-world patient populations, as well as market entry of competitive products.
The Company leverages the use of data science, machine learning and other forms of AI and emerging technologies across varying parts of its business and operations, and the introduction and incorporation of AI may result in unintended consequences or other new or expanded risks and liabilities. AI technology is continuously evolving, and the AI technologies we develop and adopt may become obsolete earlier than planned. Our investments in these technologies may not result in the benefits we anticipate or enable us to obtain or maintain a competitive advantage. The application of AI in our business is emerging and evolving alongside new laws and regulations that may entail significant costs or ultimately limit our ability to continue the use of these technologies. These technologies also carry inherent risks related to data privacy and security further described below.
Risks related to financial and economic market conditions
The Company faces a variety of financial, economic, legal, social and political risks associated with conducting business internationally.
The Company’s extensive operations and business activity throughout the world are accompanied by certain financial, economic, legal, social and political risks, including those listed below.
Foreign currency exchange: In fiscal 2024, approximately 43% of the Company’s sales occurred outside of the U.S., with approximately 23% in Europe, 5% in the Western Hemisphere, excluding the U.S., and 15% in the Asia-Pacific and Africa region. Changes in non-U.S. currencies relative to the U.S. dollar impact the Company’s revenues and expenses. While the Company uses financial instruments to mitigate the impact of fluctuations in currency exchange rates on its cash flows, unhedged exposures continue to be subject to currency fluctuations. In addition, the weakening or strengthening of the U.S. dollar may result in significant favorable or unfavorable translation effects when the operating results of the Company’s non-U.S. business activity are translated into U.S. dollars.
Inflation and currency devaluation risks: The Company faces challenges in maintaining profitability of operations in economies experiencing high inflation rates. Specifically, the Company has accounted for operations in Argentina, Turkey, Venezuela and Egypt (beginning in the fiscal fourth quarter of 2024) as highly inflationary, as the prior three-year cumulative inflation rate surpassed 100%. While the Company strives to maintain profit margins in these areas through cost reduction programs, productivity improvements and periodic price increases, it might experience operating losses as a result of continued inflation.
2024 Annual Report
13


In addition, the impact of currency devaluations in countries experiencing high inflation rates or significant currency exchange fluctuations could negatively impact the Company’s operating results.
Illegal importation of pharmaceutical products: The illegal importation of pharmaceutical products from countries where government price controls or other market dynamics result in lower prices may adversely affect the Company’s sales and profitability in the U.S. and other countries in which the Company operates. With the exception of limited quantities of prescription drugs for personal use, foreign imports of pharmaceutical products are illegal under current U.S. law. However, the volume of illegal imports continues to rise as the ability of patients and other customers to obtain the lower-priced imports has grown significantly.
Anti-bribery and other regulations: The Company is subject to various federal and foreign laws that govern its international business practices with respect to payments to government officials. Those laws include the U.S. Foreign Corrupt Practices Act (FCPA), which prohibits U.S. publicly traded companies from promising, offering, or giving anything of value to foreign officials with the corrupt intent of influencing the foreign official for the purpose of helping the Company obtain or retain business or gain any improper advantage. The Company’s business is heavily regulated and therefore involves significant interaction with foreign officials. Also, in many countries outside the U.S., the healthcare providers who prescribe human pharmaceuticals are employed by the government and the purchasers of human pharmaceuticals are government entities; therefore, the Company’s interactions with these prescribers and purchasers are subject to regulation under the FCPA. In addition to the U.S. application and enforcement of the FCPA, various jurisdictions in which the Company operates have laws and regulations, including the U.K. Bribery Act 2010, aimed at preventing and penalizing corrupt and anticompetitive behavior. Enforcement activities under these laws could subject the Company to additional administrative and legal proceedings and actions, which could include claims for civil penalties, criminal sanctions, and administrative remedies, including exclusion from healthcare programs.
Other financial, economic, legal, social and political risks. Other risks inherent in conducting business globally include:
local and regional economic environments and policies in the markets that we serve, including interest rates, monetary policy, inflation, economic growth, recession, commodity prices, and currency controls or other limitations on the ability to expatriate cash;
protective economic policies taken by governments, such as trade protection measures, increased antitrust reporting requirements and enforcement activity, and import/export licensing requirements;
compliance with local regulations and laws including, in some countries, regulatory requirements restricting the Company’s ability to manufacture or sell its products in the relevant market;
diminished protection of intellectual property and contractual rights in certain jurisdictions;
potential nationalization or expropriation of the Company’s foreign assets;
political or social upheavals, economic instability, repression, or human rights issues; and
geopolitical events, including natural disasters, disruptions to markets due to war, armed conflict, terrorism, epidemics or pandemics.
Due to the international nature of the Company's business, geopolitical or economic changes or events, including global tensions and war, could adversely affect our business, results of operations or financial condition.
As described above, the Company has extensive operations and business activity throughout the world. Global tensions, conflict and/or war among any of the countries in which we conduct business or distribute our products may result in foreign currency volatility, decreased demand for our products in affected countries, and challenges to our global supply chain related to increased costs of materials and other inputs for our products and suppliers. Most recently, we have experienced, and expect to continue to experience, impacts to the Company's business resulting from the Russia-Ukraine war, rising conflict in the Middle East as well as increasing tensions between the U.S. and China. In response to heightened conflict, such as the Russia-Ukraine war, governments may impose export controls and broad financial and economic sanctions. Our business and operations may be further impacted by the imposition of tariffs, trade protection measures or other policies adopted by any country that favor domestic companies and technologies over foreign competitors. Additional sanctions or other measures may be imposed by the global community, including but not limited to limitations on our ability to file, prosecute and maintain patents, trademarks and other intellectual property rights. Furthermore, in some countries, such as in Russia, action may be taken that allows companies and individuals to exploit inventions owned by patent holders from the United States and many other countries without consent or compensation and we may not be able to prevent third parties from practicing the Company's inventions in Russia or from selling or importing products in and into Russia. In addition, the U.S. government recently announced tariffs on products manufactured in several jurisdictions, including China, Mexico and Canada, and has
14
 Jhonson&Jhonson.jpg 


made announcements regarding the potential imposition of tariffs on other jurisdictions. While certain of the announced tariffs have been delayed, the U.S. government may in the future pause, reimpose or increase tariffs, and countries subject to such tariffs have and in the future may impose reciprocal tariffs or other restrictive trade measures in response. Any of these actions could increase uncertainties and associated risks relating to the Company’s global operations.
Weak financial performance, failure to maintain a satisfactory credit rating or disruptions in the financial markets could adversely affect our liquidity, capital position, borrowing costs and access to capital markets.
We currently maintain investment grade credit ratings with Moody’s Investors Service and Standard & Poor’s Ratings Services. Rating agencies routinely evaluate us, and their ratings of our long-term and short-term debt are based on a number of factors. Any downgrade of our credit ratings by a credit rating agency, whether as a result of our actions or factors which are beyond our control, can increase the cost of borrowing under any indebtedness we may incur, reduce market capacity for our commercial paper or require the posting of additional collateral under our derivative contracts. There can be no assurance that we will be able to maintain our credit ratings, and any additional actual or anticipated changes or downgrades in our credit ratings, including any announcement that our ratings are under review for a downgrade, may have a negative impact on our liquidity, capital position and access to capital markets.
Other risks
Our business depends on our ability to recruit and retain talented and highly skilled employees.
Our continued growth requires us to recruit and retain talented employees representing many different backgrounds, experiences, and skill sets. The market for highly skilled workers and leaders in our industry is extremely competitive and our ability to compete depends on our ability to hire, develop and motivate highly skilled personnel in all areas of our organization. Maintaining our brand and reputation, as well as a credo-based work environment enables us to attract top talent. If we are less successful in our recruiting efforts, or if we cannot retain highly skilled workers and key leaders, our ability to develop and deliver successful products and services may be adversely affected. In addition, effective succession planning is important to our long-term success. Any unsuccessful implementation of our succession plans or failure to ensure effective transfer of knowledge and smooth transitions involving key employees could adversely affect our business, financial condition, or results of operations.
Climate change or legal, regulatory or market measures to address climate change may negatively affect our business and results of operations.
Climate change resulting from increased concentrations of carbon dioxide and other greenhouse gases in the atmosphere could present risks to our operations, including an adverse impact on global temperatures, weather patterns and the frequency and severity of extreme weather and natural disasters. Natural disasters and extreme weather conditions, such as a hurricane, tornado, earthquake, wildfire or flooding, may pose physical risks to our facilities and disrupt the operation of our supply chain. The impacts of the changing climate on water resources may result in water scarcity, limiting our ability to access sufficient high-quality water in certain locations, which may increase operational costs.
Concern over climate change may also result in new or additional legal or regulatory requirements designed to reduce greenhouse gas emissions and/or mitigate the effects of climate change on the environment. If such laws or regulations are more stringent than current legal or regulatory obligations, we may experience disruption in, or an increase in the costs associated with sourcing, manufacturing and distribution of our products, which may adversely affect our business, results of operations or financial condition. Further, the impacts of climate change have an influence on customer preferences, and failure to provide climate-friendly products could potentially result in loss of market share.
An information security incident, including a cybersecurity breach, could have a negative impact on the Company’s business or reputation.
To meet business objectives, the Company relies on both internal information technology (IT) systems and networks, and those of third parties and their vendors, to process and store sensitive data (including confidential research, business plans, financial information, intellectual property, and personal data that may be subject to legal protection) to ensure the continuity of the Company’s supply chain and operations, and as part of many of the products we deliver to customers. The extensive range of information security and cybersecurity threats, which affect companies globally, pose a persistent risk to the security and availability of these systems and networks, including to customer products that are connected to or rely on such systems and networks, and the confidentiality, integrity, and availability of the Company’s sensitive data. The Company assesses these threats, responds to attacks and breaches that it has experienced, and makes investments to increase internal protection, detection, and response capabilities, as well as ensure the Company’s third-party providers have required capabilities and
2024 Annual Report
15


controls, to address this risk. Because of the frequently changing attack techniques, along with the increased volume and sophistication of the attacks, there is the potential for the Company to be adversely impacted. This impact could result in reputational, competitive, operational or other business harm as well as financial costs and regulatory action. Also, increasing use of AI could increase these risks. The Company maintains cybersecurity insurance in the event of an information security or cyber incident; however, the coverage may not be sufficient to cover all financial, legal, business or reputational losses.
As a result of increased global tensions, the Company expects there will continue to be, an increased risk of information security or cybersecurity incidents, including cyberattacks perpetrated by adversaries of countries where the Company maintains operations. Given the potential sophistication of these attacks, the Company may not be able to address the threat of information security or cybersecurity incidents proactively or implement adequate preventative measures and we may not be able to detect and address any such disruption or security breach promptly, or at all, which could adversely affect customers that use our products, our business, results of operations or financial condition. Moreover, these threats could also impact our third-party partners resulting in compromise of the Company's IT systems, networks and data which could negatively affect the Company.
A breach of privacy laws or unauthorized access, loss or misuse of personal data could have a negative impact on the Company’s business or reputation.
The Company is subject to privacy and data protection laws and regulations across the globe that impose broad compliance obligations on the collection, possession, use, storage, access, disclosure, transfer, deletion and protection of personal data. Breach of the requirements of these laws and regulations could result in substantial fines, penalties, governmental actions, private right of actions, including class actions, and damage to our reputation and business. New privacy laws are expected globally, together with greater privacy enforcement by governmental authorities globally, particularly on data localization requirements and data transfers including international data flows. The Company has established privacy compliance programs and controls with which our businesses worldwide are required to comply. However, with many technology and data-driven initiatives evolving across the Company, involving multiple vendors and third parties, there are threats that could impact our business operations and research activities, including potential risks of unauthorized access and loss of personal data as well as legislative actions imposing limitations and controls on the use and sharing of personal data as well as on cross border data flows.
16
 Jhonson&Jhonson.jpg 


Item 1B. Unresolved staff comments
Not applicable.
Item 1C. Cybersecurity
Risk management and strategy
The Company has documented cybersecurity policies and standards, assesses risks from cybersecurity threats, and monitors information systems for potential cybersecurity issues. To protect the Company’s information systems from cybersecurity threats, the Company uses various security tools supporting protection, detection, and response capabilities. The Company maintains a cybersecurity incident response plan to help ensure a timely, consistent response to actual or attempted cybersecurity incidents impacting the Company.
The Company also identifies and assesses third-party risks within the enterprise, and through the Company's use of third-party service providers, across a range of areas including data security and supply chain through a structured third-party risk management program.
The Company maintains a formal information security training program for all employees that includes training on matters such as phishing and email security best practices. Employees are also required to complete mandatory training on data privacy.
To evaluate and enhance its cybersecurity program, the Company periodically utilizes third-party experts to undertake maturity assessments of the Company’s information security program.
To date, the Company is not aware of any cybersecurity incident that has had or is reasonably likely to have a material impact on the Company’s business or operations; however, because of the frequently changing attack techniques, along with the increased volume and sophistication of the attacks, there is the potential for the Company to be adversely impacted. This impact could result in reputational, competitive, operational or other business harm as well as financial costs and regulatory action. Refer to the risk factor captioned An information security incident, including a cybersecurity breach, could have a negative impact to the Company’s business or reputation in Part I, Item 1A. Risk factors for additional description of cybersecurity risks and potential related impacts on the Company.
Governance - management’s responsibility
The Company takes a risk-based approach to cybersecurity and has implemented cybersecurity controls designed to address cybersecurity threats and risks. The Chief Information Officer (CIO), who is a member of the Company’s Executive Committee, and the Chief Information Security Officer (CISO) are responsible for assessing and managing cybersecurity risks, including security incident detection, response, and recovery.
The Company’s CISO, in coordination with the CIO, is responsible for leading the Company’s cybersecurity program and management of cybersecurity risk. The current CISO has over twenty-five years of experience in information security, and his background includes technical experience, strategy and architecture focused roles, cyber and threat experience, and various leadership roles.
Governance - board oversight
The Company’s Board of Directors oversees the overall risk management process, including cybersecurity risks, directly and through its committees. The Regulatory Compliance & Sustainability Committee (RCSC) of the board is primarily responsible for oversight of risk from cybersecurity threats and oversees compliance with applicable laws, regulations and Company policies related to, among others, privacy and cybersecurity.
RCSC meetings include discussions of specific risk areas throughout the year including, among others, those relating to cybersecurity. The CISO provides quarterly updates each year to RCSC on cybersecurity matters. These reports include an overview of the cybersecurity threat landscape, key cybersecurity initiatives to improve the Company’s risk posture, changes in the legal and regulatory landscape relative to cybersecurity, and overviews of certain cybersecurity incidents that have occurred within the Company and within the industry.
2024 Annual Report
17


Item 2. Properties
The Company's subsidiaries operate 64 manufacturing facilities occupying approximately 9.6 million square feet of floor space. The manufacturing facilities are used by the industry segments of the Company’s business approximately as follows:
SegmentSquare Feet
(in thousands)
Innovative Medicine4,696
MedTech4,911
Worldwide Total9,607
Within the U.S., four facilities are used by the Innovative Medicine segment and 19 by the MedTech segment. Outside of the U.S., 14 facilities are used by the Innovative Medicine segment and 27 by the MedTech segment.
The locations of the manufacturing facilities by major geographic areas of the world are as follows:
Geographic AreaNumber of
Facilities
Square Feet
(in thousands)
United States232,892
Europe214,521
Western Hemisphere, excluding U.S. 7898
Africa, Asia and Pacific131,296
Worldwide Total649,607
In addition to the manufacturing facilities discussed above, the Company maintains numerous office and warehouse facilities throughout the world.
The Company's subsidiaries generally seek to own, rather than lease, their manufacturing facilities, although some, principally in non-U.S. locations, are leased. Office and warehouse facilities are often leased. The Company also engages contract manufacturers.
The Company is committed to maintaining all of its properties in good operating condition.
Segment information on additions to property, plant and equipment is contained in Note 17 Segments of business and geographic areas of the Notes to Consolidated Financial Statements included in Item 8 of this Report.
Item 3. Legal proceedings
The information called for by this item is incorporated herein by reference to the information set forth in Note 19 Legal proceedings of the Notes to Consolidated Financial Statements included in Item 8 of this Report.
Item 4. Mine safety disclosures
Not applicable.
18
 Jhonson&Jhonson.jpg 


Executive officers of the registrant
Listed below are the executive officers of the Company. There are no family relationships between any of the executive officers, and there is no arrangement or understanding between any executive officer and any other person pursuant to which the executive officer was selected. At the annual meeting of the Board of Directors, the executive officers are elected by the Board to hold office for one year and until their respective successors are elected and qualified, or until earlier resignation or removal.
05_PRO013333_pic_J&J_directors_BroadhurstV.jpg
Vanessa Broadhurst, 56
Member, Executive Committee; Executive Vice President, Global Corporate Affairs
Ms. V. Broadhurst was named Executive Vice President, Global Corporate Affairs and appointed to the Executive Committee in 2022. Ms. Broadhurst rejoined the Company in 2017 and was appointed Company Group Chairman, Global Commercial Strategy Organization in 2018. From 2013 to 2017, she held General Manager roles at Amgen in Inflammation & Cardiovascular, and Cardiovascular & Bone. Prior to her roles at Amgen, she served in various leadership roles at the Company from 2005-2013.
05_PRO013333_pic_J&J_directors_DuatoJ.jpg
Joaquin Duato, 62
Chairman of the Board; Chief Executive Officer
Mr. J. Duato became Chairman of the Board of Directors in 2023 subsequent to his appointments as Chief Executive Officer and Director in 2022. Mr. Duato was appointed to the Executive Committee in 2016 when he was named Executive Vice President, Worldwide Chairman, Pharmaceuticals and subsequently served as Vice Chairman of the Executive Committee. Mr. Duato first joined the Company in 1989 with Janssen-Farmaceutica S.A. (Spain), a subsidiary of the Company, and held executive positions of increasing responsibility in all business sectors and across multiple geographies and functions.
05_PRO013333_pic_J&J_directors_ForminardE.jpg
Elizabeth Forminard, 54
Member, Executive Committee; Executive Vice President, Chief Legal Officer
Ms. E. Forminard was appointed Executive Vice President, Chief Legal Officer and a member of the Executive Committee in 2022. Ms. Forminard joined the Company in 2006, serving in roles of increasing responsibility including General Counsel Medical Devices & Diagnostics, General Counsel Consumer Group & Supply Chain, Worldwide Vice President Corporate Governance, and in her immediate past role as General Counsel Pharmaceuticals.
05_PRO013333_pic_J&J_directors_MulhollandK.jpg
Kristen Mulholland, 58
Member, Executive Committee; Executive Vice President, Chief Human Resources Officer
Ms. K. Mulholland was appointed Executive Vice President, Chief Human Resources Officer and appointed to the Executive Committee in 2024. She joined the company in 2005 and has held HR leadership positions across the full breadth of the company including MedTech, Innovative Medicines, our Corporate Functions and Corporate HR Services including Performance and Development and most recently, Global Total Rewards.
05_PRO013333_pic_J&J_directors_ReedJ.jpg
John C. Reed, M.D., Ph.D., 66
Member, Executive Committee; Executive Vice President, Innovative Medicine, R&D
Dr. J. C. Reed joined the Company in 2023 as Executive Vice President, Innovative Medicine, R&D and a member of the Executive Committee. Prior to joining the Company, Dr. Reed held executive leadership positions at Sanofi (2018-2022) and Roche (2013-2018), serving on their respective executive committees. He also served as CEO of Sanford-Burnham Medical Research Institute (now Sanford Burnham Prebys) where he established multiple therapeutic area-aligned research centers and platform technology centers.
2024 Annual Report
19


05_PRO013333_pic_J&J_directors_SchmidT.jpg
Tim Schmid, 55
Member, Executive Committee; Executive Vice President, Worldwide Chairman, MedTech
Mr. T. Schmid was appointed Executive Vice President, Worldwide Chairman, MedTech and a member of the Executive Committee in 2023. He joined the Company in 1993 and has served in leadership positions throughout Johnson & Johnson MedTech, including Chief Strategic Customer Officer and President of Ethicon, and most recently served as Company Group Chairman MedTech Asia Pacific from 2018-2023.
05_PRO013333_pic_J&J_directors_SwansonJ.jpg
James Swanson, 59
Member, Executive Committee; Executive Vice President, Chief Information Officer
Mr. J. Swanson was appointed Executive Vice President, Chief Information Officer and a member of the Executive Committee in 2022. He rejoined the Company in 2019 as Chief Information Officer of Johnson & Johnson from Bayer Crop Science, where he served as a member of the Executive Leadership Team and as Chief Information Officer and Head of Digital Transformation. From 1996 to 2005, Mr. Swanson held positions of increasing responsibility at the Company, including Project Manager, Director IT, Sr. Director IT and Vice President, Chief Information Officer.
05_PRO013333_pic_J&J_directors_TaubertJ.jpg
Jennifer L. Taubert, 61
Member, Executive Committee; Executive Vice President, Worldwide Chairman, Innovative Medicine
Ms. J. L. Taubert was appointed Executive Vice President, Worldwide Chairman, Innovative Medicine (formerly Pharmaceuticals) and a member of the Executive Committee in 2018. She joined the Company in 2005 as Worldwide Vice President and held several executive positions of increasing responsibility in the Pharmaceuticals sector, including Company Group Chairman, North America, and Company Group Chairman, The Americas from 2012-2018.
05_PRO013333_pic_J&J_directors_WengelK.jpg
Kathryn E. Wengel, 59
Member, Executive Committee; Executive Vice President, Chief Technical Operations & Risk Officer
Ms. K. E. Wengel was appointed Executive Vice President, Chief Technical Operations & Risk Officer in 2023, subsequent to her appointment to the Executive Committee in 2018 when she was named as Executive Vice President, Chief Global Supply Chain Officer. Ms. Wengel first joined the Company in 1988 as Project Engineer and Engineering Supervisor at Janssen, a subsidiary of the Company. During her tenure with the Company, she has held a variety of strategic leadership and executive positions, including in roles within operations, quality, engineering, new products, information technology, and other technical and business functions.
05_PRO013333_pic_J&J_directors_WolkJ.jpg
Joseph J. Wolk, 58
Member, Executive Committee; Executive Vice President, Chief Financial Officer
Mr. J. J. Wolk was appointed Executive Vice President, Chief Financial Officer and a member of the Executive Committee in 2018. He first joined the Company in 1998 as Finance Manager, Business Development for Ortho-McNeil, a subsidiary of the Company. During his tenure at the Company, he has held a variety of senior leadership roles in several segments and functions across the Company's subsidiaries, including Vice President, Finance and Chief Financial Officer of the Janssen Pharmaceutical Companies, and Vice President, Investor Relations.
20
 Jhonson&Jhonson.jpg 


Part II
Item 5. Market for registrant’s common equity, related stockholder matters and issuer purchases of equity securities
As of February 6, 2025, there were 114,147 record holders of common stock of the Company. Additional information called for by this item is incorporated herein by reference to the following sections of this Report: Note 16 “Common Stock, Stock Option Plans and Stock Compensation Agreements” of the Notes to Consolidated Financial Statements included in Item 8; and Item 12 “Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters – Equity Compensation Plan Information.”
Issuer purchases of equity securities
The following table provides information with respect to common stock purchases by the Company during the fiscal fourth quarter of 2024. Common stock purchases on the open market are made as part of a systematic plan to meet the needs of the Company’s compensation programs. The repurchases below also include the stock-for-stock option exercises that settled in the fiscal fourth quarter.
Fiscal Period
Total Number
of Shares
Purchased(1)
Avg. Price
Paid Per
Share
Total Number of Shares (or
Units) Purchased as Part
of Publicly Announced
Plans or Programs
Maximum Number (or Approximate
Dollar Value) of Shares (or Units)
that May Yet Be Purchased Under
the Plans or Programs
September 30, 2024 through October 27, 2024621,412$163.13
October 28, 2024 through November 24, 2024831,866$158.98
November 25, 2024 through December 29, 2024150,000$152.96
Total1,603,278
(1)During the fiscal fourth quarter of 2024, the Company repurchased an aggregate of 1,603,278 shares of Johnson & Johnson Common Stock in open-market transactions, all of which were purchased as part of a systematic plan to meet the needs of the Company’s compensation programs.
Item 6. Reserved
2024 Annual Report
21


Item 7. Management’s discussion and analysis of results of operations and financial condition
Organization and business segments
Description of the company and business segments
Johnson & Johnson and its subsidiaries (the Company) have approximately 138,100 employees worldwide engaged in the research and development, manufacture and sale of a broad range of products in the healthcare field. The Company conducts business in virtually all countries of the world with the primary focus on products related to human health and well-being.
The Company is organized into two business segments: Innovative Medicine and MedTech. The Innovative Medicine segment is focused on the following therapeutic areas: Immunology, Infectious Diseases, Neuroscience, Oncology, Pulmonary Hypertension, and Cardiovascular and Metabolism. Products in this segment are distributed directly to retailers, wholesalers, distributors, hospitals and healthcare professionals for prescription use. The MedTech segment includes a broad portfolio of products used in the Orthopaedic, Surgery, Cardiovascular (previously referred to as Interventional Solutions) and Vision fields. These products are distributed to wholesalers, hospitals and retailers, and used principally in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics.
The Chief Operating Decision Maker (CODM) is the Company's Chief Executive Officer (Principal Executive Officer).The Executive Committee is Johnson & Johnson’s senior leadership team responsible for setting the strategy and priorities of the Company and driving accountability at all levels. Within the strategic parameters provided by the Executive Committee, senior management groups at U.S. and international operating companies are each responsible for their own strategic plans and the day-to-day operations of those companies.
In all of its product lines, the Company competes with other companies both locally and globally, throughout the world. Competition exists in all product lines without regard to the number and size of the competing companies involved. Competition in research, involving the development and the improvement of new and existing products and processes, is particularly significant. The development of new and innovative products, as well as protecting the underlying intellectual property of the Company's product portfolio, is important to the Company’s success in all areas of its business. The competitive environment requires substantial investments in continuing research.
Management’s objectives
With Our Credo as the foundation, the Company  believes health is everything. The Company's strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through the Company's expertise in Innovative Medicine and MedTech, the Company is uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity.
New products introduced within the past five years accounted for approximately 25% of 2024 sales. In 2024, $17.2 billion was invested in research and development reflecting management’s commitment to create life-enhancing innovations and to create value through partnerships that will profoundly impact of health for humanity.
Our approximately 138,100 employees are critical drivers of the Company’s success. Employees are empowered and inspired to lead with Our Credo and purpose as guides. This allows every employee to use the Company’s reach and size to advance the Company’s purpose, and to also lead with agility and urgency. Leveraging the extensive resources across the enterprise enables the Company to innovate and execute with excellence. This ensures the Company can remain focused on addressing the unmet needs of society every day and invest for an enduring impact, ultimately delivering value to its patients, consumers and healthcare professionals, employees, communities and shareholders.
22
 Jhonson&Jhonson.jpg 


Research &
development
3895
Acquisitions*
(net of cash acquired)
3938
Dividends paid
per share
4102
*    Includes business combinations and asset acquisitions
Results of operations
Analysis of consolidated sales
For discussion on results of operations and financial condition pertaining to the fiscal years 2023 and 2022 see the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, Item 7. Management's discussion and analysis of results of operations and financial condition. Prior periods disclosed herein were recast to reflect the continuing operations of the Company.
In 2024, worldwide sales increased 4.3% to $88.8 billion as compared to an increase of 6.5% in 2023. These sales changes consisted of the following:
Sales increase/(decrease) due to:20242023
Volume5.9 %6.8 %
Price0.0 0.6 
Currency(1.6)(0.9)
Total4.3 %6.5 %
The net impact of acquisitions and divestitures on the worldwide sales growth was a positive impact of 0.5% in 2024 and a positive impact of 1.5% in 2023.
Sales by U.S. companies were $50.3 billion in 2024 and $46.4 billion in 2023. This represents increases of 8.3% in 2024 and 10.6% in 2023. In the fiscal 2024, acquisitions and divestitures had a net positive impact of 0.7% on the U.S. operational sales growth. Sales by international companies were $38.5 billion in 2024 and $38.7 billion in 2023. This represents a decrease of 0.5% in 2024 and an increase of 1.9% in 2023. In fiscal 2024, acquisitions and divestitures had a net positive impact of 0.2% on the international operational sales growth. In fiscal 2024, the impact of the Covid-19 Vaccine sales decline on the international operational sales was a negative 2.6%.
The five-year compound annual growth rates for worldwide, U.S. and international sales were 5.4%, 6.8% and 3.8%, respectively. The ten-year compound annual growth rates for worldwide, U.S. and international sales were 4.0%, 5.4% and 2.5%, respectively.
2024 Annual Report
23


In 2024, sales by companies in Europe experienced a decline of 1.0% as compared to the prior year, which included an operational decline of 0.6% and a negative currency impact of 0.4%. In fiscal 2024, the net impact of the Covid-19 Vaccine on the European regions change in operational sales was a negative 4.7%. Sales by companies in the Western Hemisphere, excluding the U.S., achieved growth of 3.6% as compared to the prior year, which included operational growth of 20.4%, and a negative currency impact of 16.8%. Sales by companies in the Asia-Pacific, Africa region experienced a decline of 1.2% as compared to the prior year, including operational growth of 2.3% offset by a negative currency impact of 3.5%.
In 2024, the Company utilized three wholesalers distributing products for both segments that represented approximately 20.5%, 15.6% and 12.3% of the total gross revenues. In 2023, the Company had three wholesalers distributing products for both segments that represented approximately 18.2%, 15.1% and 14.2% of the total gross revenues.
2024 Sales by geographic region (in billions)
2384
2024 Sales by segment (in billions)
2422
Note: values may have been rounded
Analysis of sales by business segments
Innovative Medicine segment
Innovative Medicine segment sales in 2024 were $57.0 billion, an increase of 4.0% from 2023, which included operational growth of 5.7% and a negative currency impact of 1.7%. U.S. sales were $34.0 billion, an increase of 9.0%. International sales were $23.0 billion, a decrease of 2.5%, which included operational growth of 1.3% offset by a negative currency impact of 3.8%. In 2024, acquisitions and divestitures had a net negative impact of 0.1% on the operational sales growth of the worldwide Innovative Medicine segment. In fiscal 2024, the net impact of the Covid-19 Vaccine on the total Innovative Medicine and International change in operational sales was a negative 1.8% and 4.2%, respectively.
24
 Jhonson&Jhonson.jpg 


Major Innovative Medicine therapeutic area sales:
(Dollars in Millions)20242023Total
Change
Operations
Change
Currency
Change
Total Immunology$17,828$18,052(1.2 %)0.4 %(1.6)%
REMICADE1,6051,839(12.8)(11.4)(1.4)
SIMPONI/SIMPONI ARIA2,1902,197(0.3)4.5 (4.8)
STELARA10,36110,858(4.6)(3.4)(1.2)
TREMFYA3,6703,14716.6 18.1 (1.5)
Other Immunology311(74.1)(74.1)— 
Total Infectious Diseases3,3964,418(23.1)(22.7)(0.4)
COVID-19 VACCINE1981,117(82.4)(82.4)0.0 
EDURANT/rilpivirine1,2721,15010.6 10.6 0.0 
PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA1,7121,854(7.7)(7.1)(0.6)
Other Infectious Diseases214297(27.6)(25.0)(2.6)
Total Neuroscience7,1157,140(0.4)1.3 (1.7)
CONCERTA/methylphenidate641783(18.1)(15.1)(3.0)
INVEGA SUSTENNA/XEPLION/INVEGA TRINZA/TREVICTA4,2224,1152.6 3.4 (0.8)
SPRAVATO1,07768956.4 56.8 (0.4)
Other Neuroscience1,1751,553(24.3)(20.7)(3.6)
Total Oncology20,78117,66117.7 19.8 (2.1)
CARVYKTI96350092.792.70.0
DARZALEX11,6709,74419.8 22.2 (2.4)
ERLEADA2,9992,38725.6 27.3 (1.7)
IMBRUVICA3,0383,264(6.9)(5.2)(1.7)
TECVAYLI54939538.8 39.8 (1.0)
ZYTIGA /abiraterone acetate631887(28.8)(25.0)(3.8)
Other Oncology93148492.594.3(1.8)
Total Pulmonary Hypertension 4,2823,81512.3 14.1 (1.8)
OPSUMIT2,1841,97310.7 11.9 (1.2)
UPTRAVI1,8171,58214.9 16.1 (1.2)
Other Pulmonary Hypertension2812607.9 18.3 (10.4)
Total Cardiovascular / Metabolism / Other3,5623,671(3.0)(2.6)(0.4)
XARELTO2,3732,3650.3 0.3 — 
Other1,1891,306(8.9)(7.8)(1.1)
Total Innovative Medicine Sales$56,96454,7594.0 %5.7 %(1.7)%
2024 Annual Report
25


Immunology products sales were $17.8 billion in 2024, representing a decrease of 1.2% as compared to the prior year. The decline of STELARA (ustekinumab) sales was driven by share loss primarily due to European biosimilar entrants. Lower sales of REMICADE (infliximab) was due to continued biosimilar competition. The growth of TREMFYA (guselkumab) was due to market growth and share gains.
Sales of STELARA in the United States were approximately $6.7 billion in fiscal 2024. Third parties have filed abbreviated Biologics License Applications with the FDA seeking approval to market biosimilar versions of STELARA. The Company has settled certain litigation under the Biosimilar Price Competition and Innovation Act of 2009. According to patent settlement and license agreements, the Company expects continued launches of biosimilar versions of STELARA in Europe and the United States in 2025 which will impact the Company’s sales of STELARA.
Biosimilar versions of REMICADE have been introduced in the United States and certain markets outside the United States and additional competitors continue to enter the market. Continued infliximab biosimilar competition will result in a further reduction in sales of REMICADE.
Infectious disease products sales were $3.4 billion in 2024, a decline of 23.1% as compared to the prior year primarily driven by a decline in COVID-19 vaccine revenue.
Neuroscience products sales were $7.1 billion in 2024, representing a decrease of 0.4% as compared to the prior year primarily driven by a decline in Other Neuroscience. The decline was partially offset by the growth of SPRAVATO (esketamine) driven by the ongoing launch and increased physician and patient demand.
Oncology products achieved sales of $20.8 billion in 2024, representing an increase of 17.7% as compared to the prior year. Strong sales of DARZALEX (daratumumab) were driven by continued share gains and market growth. Growth of ERLEADA (apalutamide) was primarily due to continued share gains and market growth. Sales of CARVYKTI (ciltacabtagene autoleucel) were driven by continued share gains, capacity expansion and manufacturing efficiencies. Additionally, sales from the ongoing launches of TECVAYLI (teclistamab-cqyv), TALVEY (talquetamab-tgvs) and RYBREVANT (amivantamab), included in Other Oncology, contributed to the growth. Growth was partially offset by ZYTIGA (abiraterone acetate) due to loss of exclusivity and IMBRUVICA (ibrutinib) due to global competitive pressures.
Pulmonary Hypertension products sales were $4.3 billion, representing an increase of 12.3% as compared to the prior year. Sales growth of both OPSUMIT (macitentan) and UPTRAVI (selexipag) was driven by market growth and share gains. Growth in Other Pulmonary Hypertension was driven by OPSYNVI (macitentan/tadalafil).
Cardiovascular/Metabolism/Other products sales were $3.6 billion, a decline of 3.0% as compared to the prior year driven by declines in Other.
The Company maintains a policy that no end customer will be permitted direct delivery of product to a location other than the billing location. This policy impacts contract pharmacy transactions involving non-grantee 340B covered entities for most of the Company’s drugs, subject to multiple exceptions. Both grantee and non-grantee covered entities can maintain certain contract pharmacy arrangements under policy exceptions. The Company has been and will continue to offer 340B discounts to covered entities on all of its covered outpatient drugs, and it believes its policy will improve its ability to identify inappropriate duplicate discounts and diversion prohibited by the 340B statute. The 340B Drug Pricing Program is a U.S. federal government program requiring drug manufacturers to provide significant discounts on covered outpatient drugs to covered entities.
26
 Jhonson&Jhonson.jpg 


During 2024, the Company advanced its pipeline with several regulatory submissions and approvals for new drugs and additional indications for existing drugs as follows:
Product Name
(Chemical Name)
IndicationUS
Approval
EU
Approval
US
Filing
EU
Filing
BALVERSA (erdafitinib)Treatment of Patients with Locally Advanced or Metastatic Urothelial Carcinoma and Selected Fibroblast Growth Factor Receptor Gene Alterations (THOR)
CARVYKTI (ciltacabtagene autoleucel)Treatment for Relapsed and Refactor multiple myeloma with 1-3 PL (CARTITUDE-4)
DARZALEX (daratumumab)Treatment for frontline multiple myeloma transplant eligible (PERSEUS)
DARZALEX (daratumumab)Treatment for frontline multiple myeloma transplant ineligible (CEPHEUS)
DARZALEX (daratumumab)Treatment as subcutaneous monotherapy for high-risk smoldering multiple myeloma (AQUILA)
EDURANT (rilpivirine)Treatment for pediatric patients (2-12 years old) with HIV
IMBRUVICA (ibrutinib)Treatment for frontline MCL (Triangle)
nipocalimabTreatment for Generalized Myasthenia Gravis
OPSUMIT (macitentan)Treatment for pediatric pulmonary arterial hypertension (TOMORROW)
OPSYNVI (macitentan/tadalafil STCT)Treatment for pulmonary arterial hypertension
REKAMBYSTreatment for Adolescents HIV
RYBREVANT (amivantamab)In Combination with Chemotherapy for the First-Line Treatment of Adult Patients with Advanced Non-Small Cell Lung Cancer with Activating EGFR Exon 20 Insertion Mutations (PAPILLON)
RYBREVANT (amivantamab)Treatment for subcutaneous (PALOMA-3)
RYBREVANT / LAZCLUZETreatment for Non-Small Cell Lung Cancer (MARIPOSA)
RYBREVANTTreatment for Non-Small Cell Lung Cancer 2L (MARIPOSA-2)
SIMPONI (golimumab)Treatment of Patients with Pediatric Ulcerative Colitis
SPRAVATO (esketamine) monotherapyTreatment of Patients with Treatment Resistant Depression (TRD4005)
STELARA (ustekinumab)Treatment of Patients with Pediatric Crohn's Disease
TREMFYA (guselkumab)Treatment of Patients with Ulcerative Colitis (QUASAR)
TREMFYA (guselkumab)Subcutaneous Induction for treatment of patients with Ulcerative Colitis (ASTRO)
TREMFYA (guselkumab)Subcutaneous Induction for treatment of patients with Crohn's Disease (GRAVITI)
TREMFYA (guselkumab)Treatment of Patients with Crohn's Disease (GALAXI)
TREMFYA (guselkumab)Treatment of Patients with Pediatric Psoriasis
UPTRAVI (selexipag)Treatment of Patients with Pediatric Pulmonary Arterial Hypertension (SALTO)
2024 Annual Report
27


MedTech segment
The MedTech segment sales in 2024 were $31.9 billion, an increase of 4.8% from 2023, which included operational growth of 6.2% and a negative currency impact of 1.4%. U.S. sales were $16.3 billion, an increase of 6.9% as compared to the prior year. International sales were $15.5 billion, an increase of 2.6% as compared to the prior year, which included operational growth of 5.4% and a negative currency impact of 2.8%. In 2024, the net impact of acquisitions and divestitures on the MedTech segment worldwide operational sales growth was a positive 1.5% primarily related to the Shockwave acquisition.
Major MedTech franchise sales:
(Dollars in Millions)20242023Total
Change
Operations
Change
Currency
Change
Surgery$9,845 10,037 (1.9)%0.1 %(2.0)%
Advanced4,488 4,671 (3.9)(2.0)(1.9)
General5,358 5,366 (0.2)2.0 (2.2)
Orthopaedics9,158 8,942 2.4 3.0 (0.6)
Hips1,638 1,560 5.0 5.6 (0.6)
Knees1,545 1,456 6.1 6.5 (0.4)
Trauma3,049 2,979 2.3 2.9 (0.6)
Spine, Sports & Other2,926 2,947 (0.7)(0.1)(0.6)
Cardiovascular (1)
7,707 6,350 21.4 22.8 (1.4)
Electrophysiology5,267 4,688 12.3 14.0 (1.7)
Abiomed1,496 1,306 14.514.9(0.4)
Shockwave (2)
564 — **— 
Other Cardiovascular380 356 6.9 8.4 (1.5)
Vision5,146 5,072 1.5 3.0 (1.5)
Contact Lenses/Other3,733 3,702 0.8 2.6 (1.8)
Surgical1,413 1,370 3.2 4.3 (1.1)
Total MedTech Sales$31,857 30,400 4.8 %6.2 %(1.4)%
(1)Previously referred to as Interventional Solutions
(2)Acquired on May 31, 2024
*    Percentage greater than 100% or not meaningful
The Surgery franchise sales were $9.8 billion in 2024, representing a decrease of 1.9% from 2023. The decline in Advanced Surgery was primarily due to China volume-based procurement across all platforms and competitive pressures in Energy and Endocutters. This was partially offset by the strength of the portfolio and commercial execution in Biosurgery as well as the strength of new products in Endocutters. Growth in General Surgery was primarily driven by technology penetration and benefits from the differentiated Wound Closure portfolio as well as increased procedure volume. This growth was offset by the negative impact of currency and the Acclarent divestiture.
The Orthopaedics franchise sales were $9.2 billion in 2024, representing an increase of 2.4% from 2023. The fiscal 2024 includes a one-time revenue recognition timing change related to certain products across all Orthopaedic platforms in the U.S. which positively impacted the worldwide Orthopaedics franchise growth as well as the negative impact from the near-term revenue disruption related to the previously announced Orthopaedics restructuring. The growth in Hips reflects continued strength of the portfolio primarily in the Anterior approach, and global procedure growth. The growth in Knees was primarily driven by the ATTUNE portfolio, pull through related to the VELYS Robotic assisted solution and global procedure growth. Growth in Trauma was driven by the adoption of recently launched products. The decline in Spine, Sports & Other was primarily driven by competitive pressures and impacts from China volume-based procurement. This was partially offset by growth in the U.S. market.
28
 Jhonson&Jhonson.jpg 


The Cardiovascular franchise, which includes sales from Shockwave Medical (Shockwave) acquired on May 31, 2024, achieved sales of $7.7 billion in 2024, representing an increase of 21.4% from 2023. Electrophysiology growth was driven by global procedure growth, new product performance and commercial execution. This was partially offset by the impacts of volume-based procurement in China and competitive pressures in Pulsed Field Ablation catheters in the U.S. Abiomed sales reflect the strength of all major commercialized regions driven by the continued adoption of Impella 5.5 and Impella RP.
The Vision franchise achieved sales of $5.1 billion in 2024, representing an increase of 1.5% from 2023. Contact Lenses/Other growth was primarily driven by price actions, continued strong performance in the ACUVUE OASYS 1-Day family of products (including recent launches), impacts from a one-time change in contract shipping terms in the U.S. and lapping of prior year impacts of Russian sanctions partially offset by U.S. distributor stocking dynamics. Surgical growth was primarily driven by the continued strength of recent innovations and commercial execution partially offset by China volume-based procurement and competitive pressures in the U.S.
Analysis of consolidated earnings before provision for taxes on income
Consolidated earnings before provision for taxes on income was $16.7 billion and $15.1 billion for the years 2024 and 2023, respectively. As a percent to sales, consolidated earnings before provision for taxes on income was 18.8% and 17.7%, in 2024 and 2023, respectively.
Earnings before provision for taxes
364
(Dollars in billions. Percentages in chart are as a percent to total sales)
Cost of products sold and selling, marketing and administrative expenses:
Cost of products sold
538
Selling, marketing & administrative
576
(Dollars in billions. Percentages in chart are as a percent to total sales)
2024 Annual Report
29


Cost of products sold:
Cost of products sold decreased as a percent to sales driven by:
Lower one-time COVID-19 vaccine supply network related exit costs in 2024 ($0 in 2024 versus $0.2 billion 2023) in the Innovative Medicine business
Prior year restructuring related excess inventory costs in the MedTech business
partially offset by
The fair value Inventory step-up of $0.4 billion related to the business combination accounting associated with Shockwave
The intangible asset amortization expense included in cost of products sold was $4.5 billion for both fiscal years 2024 and 2023.
Selling, Marketing and Administrative expense:
Selling, Marketing and Administrative Expenses increased as a percent to sales driven by:
Increased commercial investment in the Innovative Medicine business
partially offset by
Optimization efforts related to the residual costs associated with the Kenvue separation
Research and Development expense:
Research and development expense by segment of business was as follows:
 20242023
(Dollars in Millions)Amount% of Sales*Amount% of Sales*
Innovative Medicine$13,529 23.8 %$11,963 21.8 %
MedTech3,703 11.6 3,122 10.3 
Total research and development expense$17,232 19.4 %$15,085 17.7 %
Percent increase/(decrease) over the prior year14.2 % 6.7 % 
*As a percent to segment sales
Research and development activities represent a significant part of the Company's business. These expenditures relate to the processes of discovering, testing and developing new products, upfront payments and developmental milestones, improving existing products, as well as ensuring product efficacy and regulatory compliance prior to launch. The Company remains committed to investing in research and development with the aim of delivering high quality and innovative products.
Research and Development increased as a percent to sales primarily driven by:
Acquired in-process research & development expense of $1.25 billion to secure the global rights to the NM26 bispecific antibody (Yellow Jersey acquisition) and pipeline advancement in the Innovative Medicine business
Acquired in-process research & development expense of $0.5 billion from the V-Wave acquisition in the MedTech business
In-Process Research and Development Impairments (IPR&D): In the fiscal year 2024, the Company recorded a charge of approximately $0.2 billion associated with the M710 (biosimilar) asset acquired as part of the acquisition of Momenta Pharmaceuticals in 2020. There was also a partial impairment of this asset for $0.2 billion in the fiscal 2023. This asset is now fully impaired.
Other (Income) Expense, Net: Other (income) expense, net is the account where the Company records gains and losses related to the sale and write-down of certain investments in equity securities held by Johnson & Johnson Innovation - JJDC, Inc. (JJDC), changes in the fair value of securities, investment (income)/loss related to employee benefit programs, gains and losses on divestitures, certain transactional currency gains and losses, acquisition and divestiture related costs, litigation accruals and settlements, as well as royalty income.
30
 Jhonson&Jhonson.jpg 


Other (income) expense, net for the fiscal year 2024 reflected less expense of $1.9 billion as compared to the prior year primarily due to the following:
(Dollars in Billions)(Income)/Expense20242023Change
Litigation related(1)
$5.56.9(1.4)
Acquisition, Integration and Divestiture related(2)
0.80.30.5
Changes in the fair value of securities(3)
0.30.6(0.3)
COVID-19 vaccine manufacturing exit related costs0.10.4(0.3)
Monetization of royalty rights(0.3)0.0(0.3)
Employee benefit plan related(0.9)(1.4)0.5
Other(0.8)(0.2)(0.6)
Total Other (Income) Expense, Net$4.76.6(1.9)
(1)The fiscal years 2024 and 2023 include charges primarily for talc matters (See Note 19 to the Consolidated Financial Statements for more details). The fiscal year 2023 includes favorable intellectual property related litigation settlements of approximately $0.3 billion.
(2)The fiscal year 2024 is primarily related to the acquisition of Shockwave. The fiscal year 2023 is primarily related to the impairment of Ponvory and one-time integration costs related to the acquisition of Abiomed.
(3)The fiscal year 2024 includes the loss of $0.4 billion on the completion of the debt for equity exchange of the retained stake in Kenvue. The fiscal year 2023 includes $0.4 billion related to the unfavorable change in the fair value of the remaining stake in Kenvue and $0.4 billion related to the partial impairment of Idorsia convertible debt and the change in the fair value of the Idorsia equity securities held.
Interest (Income) Expense: Interest income in the fiscal years 2024 and 2023 was $1.3 billion. Interest expense in the fiscal years 2024 and 2023 was $0.8 billion. Cash, cash equivalents and marketable securities totaled $24.5 billion at the end of 2024, and averaged $23.7 billion as compared to the cash, cash equivalents and marketable securities total of $22.9 billion and $22.6 billion average balance in 2023. The total debt balance at the end of 2024 was $36.6 billion with an average debt balance of $33.0 billion as compared to $29.3 billion at the end of 2023 and an average debt balance of $34.5 billion. The higher debt balance was due to the senior unsecured notes issued by the Company in the fiscal second quarter of 2024. The net proceeds from this offering were used to fund the Shockwave acquisition which closed on May 31, 2024 and for general corporate purposes.
Income before tax by segment
Income (loss) before tax by segment of business were as follows:
 Income Before TaxSegment SalesPercent of Segment
Sales
(Dollars in Millions)202420232024202320242023
Innovative Medicine$18,91918,24656,96454,75933.2 %33.3 
MedTech3,7404,66931,85730,40011.7 15.4 
Segment earnings before tax(1)
22,65922,91588,82185,15925.5 26.9 
Less: Expenses not allocated to segments(2)
5,9727,853
Worldwide income before tax$16,68715,06288,82185,15918.8 %17.7 
(1)See Note 17 to the Consolidated Financial Statements for more details.
(2)Amounts not allocated to segments include interest (income) expense and general corporate (income) expense. The fiscal years 2024 and 2023 include charges for talc matters of approximately $5.1 billion and $7.0 billion, respectively. The fiscal 2024 includes a loss of approximately $0.4 billion related to the debt to equity exchange of the Company's remaining shares of Kenvue Common Stock. The fiscal year 2023 includes an approximately $0.4 billion unfavorable change in the fair value of the retained stake in Kenvue.
2024 Annual Report
31


Innovative Medicine segment:
In 2024, the Innovative Medicine segment income before tax as a percent to sales was 33.2% versus 33.3% in 2023. The decrease in the income before tax as a percent of sales was primarily driven by the following:
Acquired in-process research and development expense of $1.25 billion to secure the global rights to the NM26 bispecific antibody
Litigation expense of $0.4 billion in 2024, primarily related to Risperdal Gynecomastia, versus favorable litigation related items of $0.1 billion in 2023
Increased research and development to advance the pipeline
Increased commercial investment in selling and marketing expenses
partially offset by
Monetization of royalty rights of $0.3 billion in 2024
Lower one-time COVID-19 Vaccine related exit costs of $0.1 billion in 2024 versus $0.7 billion in 2023
Lower amortization expense of $0.2 billion in 2024 versus 2023
Restructuring charges of $0.1 billion in 2024 versus $0.5 billion in 2023
A gain of $0.1 billion in 2024 as compared to a loss of $0.4 billion in 2023 related to changes in the fair value of securities
MedTech segment:
In 2024, the MedTech segment income before tax as a percent to sales was 11.7% versus 15.4% in 2023. The decrease in the income before tax as a percent to sales was primarily driven by the following:
Acquisition and integration related costs of $1.0 billion in 2024 (primarily related to the Shockwave acquisition) versus $0.2 billion in 2023 related to Abiomed
Acquired in-process research and development expense of $0.5 billion from the V-Wave acquisition in 2024
Higher amortization expense of $0.2 billion in 2024 related to Shockwave
partially offset by
A gain of $0.2 billion related to the Acclarent divestiture in 2024
Restructuring related charge of $0.2 billion in 2024 versus $0.3 billion in 2023
Restructuring: In the fiscal year 2023, the Company completed a prioritization of its research and development (R&D) investment within the Innovative Medicine segment to focus on the most promising medicines with the greatest benefit to patients. This resulted in the exit of certain programs within therapeutic areas. The R&D program exits are primarily in infectious diseases and vaccines including the discontinuation of its respiratory syncytial virus (RSV) adult vaccine program, hepatitis and HIV development. The pre-tax restructuring charge of approximately $0.1 billion in the fiscal year 2024 was recorded in Restructuring on the Consolidated Statement of Earnings, and included the termination of partnered and non-partnered development program costs, asset impairments and asset divestments. The pre-tax restructuring charge of approximately $0.5 billion in the fiscal year 2023, of which $449 million was recorded in Restructuring and $30 million was recorded in Cost of products sold on the Consolidated Statement of Earnings, and included the termination of partnered and non-partnered program costs and asset impairments. Total project costs of approximately $0.6 billion have been recorded since the restructuring was announced. The program was completed in the fiscal fourth quarter of 2024.
32
 Jhonson&Jhonson.jpg 


In the fiscal year 2023, the Company initiated a restructuring program of its Orthopaedics franchise within the MedTech segment to streamline operations by exiting certain markets, product lines and distribution network arrangements. The pre-tax restructuring expense of $0.2 billion in the fiscal year 2024, of which $132 million was recorded in Restructuring and $35 million was recorded in Cost of products sold on the Consolidated Statement of Earnings, primarily included costs related to market and product exits. The pre-tax restructuring expense of $0.3 billion in the fiscal year 2023, of which $40 million was recorded in Restructuring and $279 million was recorded in Cost of products sold on the Consolidated Statement of Earnings, primarily included inventory and instrument charges related to market and product exits. Total project costs of approximately $0.5 billion have been recorded since the restructuring was announced.
See Note 20 to the Consolidated Financial Statements for additional details related to the restructuring programs.
Provision for Taxes on Income: The worldwide effective income tax rate from continuing operations was 15.7% in 2024 and 11.5% in 2023. For discussion related to the fiscal year 2024 provision for taxes refer to Note 8 to the Consolidated Financial Statements.
On December 15, 2022, the European Union (EU) Member States formally adopted the EU’s Pillar Two Directive, which generally provides for a minimum effective tax rate of 15%, as established by the Organization for Economic Co-operation and Development (OECD) Pillar Two Framework that was supported by over 130 countries worldwide. Several EU and non-EU countries have enacted Pillar Two legislation with an initial effective date of January 1, 2024, with other aspects of the law effective in 2025 or later. In the fiscal year 2024, the net impact of Pillar Two legislation was less than 1.0% to the Company’s effective tax rate. While countries continue to enact new provisions or issue new regulations, based on current guidance, the Company expects the net impact of Pillar Two in fiscal year 2025 to be up to 1.0% to the Company’s effective tax rate.
Liquidity and capital resources
Liquidity & cash flows
Cash and cash equivalents were $24.1 billion at the end of 2024 as compared to $21.9 billion at the end of 2023.
The primary sources and uses of cash that contributed to the $2.2 billion increase were:
(Dollars in billions)
$21.9Q4 2023 Cash and cash equivalents balance
24.3cash generated from operating activities
(18.6)net cash used by investing activities
(3.1)net cash used by financing activities
(0.4)effect of exchange rate and rounding
$24.1Q4 2024 Cash and cash equivalents balance
In addition, the Company had $0.4 billion in marketable securities at the end of fiscal year 2024 and $1.1 billion at the end of fiscal year 2023. See Note 1 to the Consolidated Financial Statements for additional details on cash, cash equivalents and marketable securities.
Cash flow from operations of $24.3 billion was the result of:
(Dollars In billions)
$14.1Net Earnings
8.4non-cash expenses and other adjustments primarily for depreciation and amortization, stock-based compensation, asset write-downs and charges for acquired in-process research and development assets partially offset by net gain on sale of assets/businesses and the deferred tax provision
1.7a decrease in other current and non-current assets
1.6an increase in accounts payable and accrued liabilities
(1.5)an increase in accounts receivable and inventories
$24.3Cash flow from operations
2024 Annual Report
33


Cash flow used for investing activities of $18.6 billion was primarily due to:
(Dollars in billions)
$(4.4)additions to property, plant and equipment
(15.1)acquisitions, net of cash acquired
0.7proceeds from the disposal of assets/businesses, net
(1.8)acquired in-process research and development assets
0.7net sales of investments
1.5credit support agreements activity, net
(0.2)other (including capitalized licenses and milestones)
$(18.6)Net cash used for investing activities
Cash flow used for financing activities of $3.1 billion was primarily due to:
(Dollars in billions)
$(11.8)dividends to shareholders
(2.4)repurchase of common stock
11.0net proceeds from short and long-term debt
0.8proceeds from stock options exercised/employee withholding tax on stock awards, net
0.3credit support agreements activity, net
(1.0)settlement of convertible debt acquired from Shockwave
$(3.1)Net cash used for financing activities
The following table summarizes cash taxes paid net of refunds:
(Dollars in Millions)202420232022
U.S. Federal (1)
$3,8154,7222,158
U.S. State and Local taxes341236216
Total U.S.$4,1564,9582,374
Total Foreign2,5583,6162,849
Total cash taxes paid net of refunds$6,714$8,574$5,223
(1)Includes TCJA foreign undistributed earnings payments of $2.0 billion in fiscal year 2024, $1.5 billion in fiscal year 2023 and $0.8 billion in fiscal year 2022
As of December 29, 2024, the Company's notes payable and long-term debt was in excess of cash, cash equivalents and marketable securities. As of December 29, 2024, the net debt position was $12.1 billion as compared to the prior year of $6.4 billion. The debt balance at the end of 2024 was $36.6 billion as compared to $29.3 billion in 2023. In the fiscal second quarter of 2024, the Company issued senior unsecured notes for a total of $6.7 billion. For additional details on borrowings, see Note 7 to the Consolidated Financial Statements. The net proceeds from this offering were used to fund the Shockwave acquisition which closed on May 31, 2024, and for general corporate purposes. Considering recent market conditions, the Company has re-evaluated its operating cash flows and liquidity profile and does not foresee any significant incremental risk. The Company anticipates that operating cash flows, the ability to raise funds from external sources, borrowing capacity from existing committed credit facilities and access to the commercial paper markets will continue to provide sufficient resources to fund operating needs, including the Company's remaining balance to be paid on the agreement to settle opioid litigation for approximately $1.5 billion and the approximately $11.6 billion ($13.5 billion nominal) reserve for talc matters (See Note 19 to the Consolidated Financial Statements for additional details). In addition, the Company monitors the global capital markets on an ongoing basis and from time to time may raise capital when market conditions are favorable.
On May 8, 2023, Kenvue, completed an initial public offering (the IPO) resulting in the issuance of 198,734,444 shares of its common stock, par value $0.01 per share (the Kenvue Common Stock), at an initial public offering of $22.00 per share for net proceeds of $4.2 billion. The excess of the net proceeds from the IPO over the net book value of the Johnson & Johnson
34
 Jhonson&Jhonson.jpg 


divested interest was $2.5 billion and was recorded to additional paid-in capital. As of the closing of the IPO, Johnson & Johnson owned approximately 89.6% of the total outstanding shares of Kenvue Common Stock and at July 2, 2023, the non-controlling interest of $1.3 billion associated with Kenvue was reflected in equity attributable to non-controlling interests in the consolidated balance sheet.
On August 23, 2023, Johnson & Johnson completed the disposition of an additional 80.1% ownership of Kenvue Common Stock through an exchange offer, which resulted in Johnson & Johnson acquiring 190,955,436 shares of the Company’s common stock in exchange for 1,533,830,450 shares of Kenvue Common Stock. The $31.4 billion of Johnson & Johnson common stock received in the exchange offer is recorded in Treasury stock. Following the exchange offer, the Company owned 9.5% of the total outstanding shares of Kenvue Common Stock that was recorded in other assets within continuing operations at the fair market value of $4.3 billion as of August 23, 2023 and $3.9 billion as of December 31, 2023.
Johnson & Johnson divested net assets of $11.6 billion as of August 23, 2023, and the accumulated other comprehensive loss attributable to the Consumer Health business at that date was $4.3 billion. Additionally, at the date of the exchange offer, Johnson & Johnson decreased the non-controlling interest by $1.2 billion to record the deconsolidation of Kenvue. This resulted in a gain on the exchange offer of $21.0 billion that was recorded in Net earnings from discontinued operations, net of taxes in the consolidated statements of earnings for the fiscal third quarter of 2023. This one-time gain includes a gain of $2.8 billion on the Kenvue Common Stock retained by Johnson & Johnson. The gain on the exchange offer qualifies as a tax-free transaction for U.S. federal income tax purposes.
On May 15, 2024, the Company issued $3.6 billion aggregate principal amount of commercial paper and received $3.6 billion of net cash proceeds to be used for general corporate purposes. On May 17, 2024, the Company completed a Debt-for-Equity Exchange of its remaining 182,329,550 shares of Kenvue Common Stock for the outstanding Commercial Paper. Upon completion of the Debt-for-Equity Exchange, the Commercial Paper was satisfied and discharged and the Company no longer owns any shares of Kenvue Common Stock. This exchange resulted in a loss of approximately $0.4 billion recorded in Other (income) expense.
The following table summarizes the Company’s material contractual obligations and their aggregate maturities as of December 29, 2024: To satisfy these obligations, the Company intends to use cash from operations.
(Dollars in Millions)Tax Legislation
(TCJA)
Debt ObligationsInterest on
Debt Obligations
Total
2025$2,5361,7491,0755,360
20261,9991,0303,029
20272,3851,0213,406
20282,2759773,252
20291,4449222,366
After 202922,5488,92131,469
Total$2,53632,40013,94648,882
For tax matters, see Note 8 to the Consolidated Financial Statements. For the proposed talc settlement payments, see Note 19 to the Consolidated Financial Statements.
2024 Annual Report
35


Financing and market risk
The Company uses financial instruments to manage the impact of foreign exchange rate changes on cash flows. Accordingly, the Company enters into forward foreign exchange contracts to protect the value of certain foreign currency assets and liabilities and to hedge future foreign currency transactions primarily related to product costs. Gains or losses on these contracts are offset by the gains or losses on the underlying transactions. A 10% appreciation of the U.S. Dollar from the December 29, 2024 market rates would increase the unrealized value of the Company’s forward contracts by $0.2 billion. Conversely, a 10% depreciation of the U.S. Dollar from the December 29, 2024 market rates would decrease the unrealized value of the Company’s forward contracts by $0.2 billion. In either scenario, the gain or loss on the forward contract would be offset by the gain or loss on the underlying transaction, and therefore, would have no impact on future anticipated earnings and cash flows.
The Company hedges the exposure to fluctuations in currency exchange rates, and the effect on certain assets and liabilities in foreign currency, by entering into currency swap contracts. A 1% change in the spread between U.S. and foreign interest rates on the Company’s interest rate sensitive financial instruments would either increase or decrease the unrealized value of the Company’s swap contracts by approximately $1.5 billion. In either scenario, at maturity, the gain or loss on the swap contract would be offset by the gain or loss on the underlying transaction, and therefore, would have no impact on future anticipated cash flows.
The Company does not enter into financial instruments for trading or speculative purposes. Further, the Company has a policy of only entering into contracts with parties that have at least an investment grade credit rating. The counterparties to these contracts are major financial institutions and there is no significant concentration of exposure with any one counterparty. Management believes the risk of loss is remote. The Company entered into credit support agreements (CSA) with certain derivative counterparties establishing collateral thresholds based on respective credit ratings and netting agreements. See Note 6 to the Consolidated Financial Statements for additional details on credit support agreements.
The Company invests in both fixed rate and floating rate interest earning securities which carry a degree of interest rate risk. The fair market value of fixed rate securities may be adversely impacted due to a rise in interest rates, while floating rate securities may produce less income than predicted if interest rates fall. A 1% (100 basis points) change in spread on the Company’s interest rate sensitive investments would either increase or decrease the unrealized value of cash equivalents and current marketable securities by less than $8.0 million.
The Company has access to substantial sources of funds at numerous banks worldwide. In June 2024, the Company secured a new 364-day Credit Facility of $10 billion, which expires on June 25, 2025. Interest charged on borrowings under the credit line agreement is based on either Secured Overnight Financing Rate (SOFR) Reference Rate or other applicable market rate as allowed plus applicable margins. Commitment fees under the agreement are not material.
Total borrowings at the end of 2024 and 2023 were $36.6 billion and $29.3 billion, respectively. The increase in the borrowings was due to the issuance of new debt in 2024. In 2024, net debt (cash and current marketable securities, net of debt) was $12.1 billion compared to net debt of $6.4 billion in 2023. Total debt represented 34.0% of total capital (shareholders’ equity and total debt) in 2024 and 30.0% of total capital in 2023. Shareholders’ equity per share at the end of 2024 was $29.70 compared to $28.57 at year-end 2023.
A summary of borrowings can be found in Note 7 to the Consolidated Financial Statements.
Dividends
The Company increased its dividend in 2024 for the 62nd consecutive year. Cash dividends paid were $4.91 per share in 2024 and $4.70 per share in 2023.
On January 2, 2025, the Board of Directors declared a regular cash dividend of $1.24 per share, payable on March 4, 2025 to shareholders of record as of February 18, 2025.
36
 Jhonson&Jhonson.jpg 


Other information
Critical accounting policies and estimates
Management’s discussion and analysis of results of operations and financial condition are based on the Company’s consolidated financial statements that have been prepared in accordance with accounting principles generally accepted in the U.S. (GAAP). The preparation of these financial statements requires that management make estimates and assumptions that affect the amounts reported for revenues, expenses, assets, liabilities and other related disclosures. Actual results may or may not differ from these estimates. The Company believes that the understanding of certain key accounting policies and estimates are essential in achieving more insight into the Company’s operating results and financial condition. These key accounting policies include revenue recognition, income taxes, legal and self-insurance contingencies, valuation of long-lived assets, assumptions used to determine the amounts recorded for pensions and other employee benefit plans and accounting for stock based awards.
Revenue Recognition: The Company recognizes revenue from product sales when obligations under the terms of a contract with the customer are satisfied; generally, this occurs with the transfer of control of the goods to customers. The Company's global payment terms are typically between 30 to 90 days. Provisions for certain rebates, sales incentives, trade promotions, coupons, product returns, discounts to customers and governmental clawback provisions are accounted for as variable consideration and recorded as a reduction in sales.
Product discounts granted are based on the terms of arrangements with direct, indirect and other market participants, as well as market conditions, including consideration of competitor pricing. Rebates and discounts are estimated based on contractual terms, historical experience, patient outcomes, trend analysis and projected market conditions in the various markets served. The Company evaluates market conditions for products or groups of products primarily through the analysis of wholesaler and other third-party sell-through and market research data, as well as internally generated information.
Sales returns are estimated and recorded based on historical sales and returns information. Products that have lost patent exclusivity, or that otherwise exhibit unusual sales or return patterns due to dating, competition or other marketing matters are specifically investigated and analyzed as part of the accounting for sales return accruals.
Sales returns allowances represent a reserve for products that may be returned due to expiration, destruction in the field, or in specific areas, product recall. In accordance with the Company’s accounting policies, the Company generally issues credit to customers for returned goods. The Company’s sales returns reserves are accounted for in accordance with the U.S. GAAP guidance for revenue recognition when right of return exists. Sales returns reserves are recorded at full sales value. Sales returns in the Innovative Medicine segment are almost exclusively not resalable. Sales returns for certain franchises in the MedTech segment are typically resalable but are not material. The Company infrequently exchanges products from inventory for returned products. The sales returns reserve for the total Company has been approximately 1.0% of annual net trade sales during the fiscal years 2024, 2023 and 2022.
Promotional programs, such as product listing allowances are recorded in the same period as related sales and include volume-based sales incentive programs. Volume-based incentive programs are based on the estimated sales volumes for the incentive period and are recorded as products are sold. These arrangements are evaluated to determine the appropriate amounts to be deferred or recorded as a reduction of revenue. The Company also earns profit-share payments through collaborative arrangements of certain products, which are included in sales to customers. Profit-share payments were less than 2.0% of the total revenues in fiscal year 2024 and 2023, respectively, and less than 3.0% of the total revenues in the fiscal year 2022 and are included in sales to customers.
In addition, the Company enters into collaboration arrangements that contain multiple revenue generating activities. Amounts due from collaborative partners for these arrangements are recognized as each activity is performed or delivered, based on the relative selling price. Upfront fees received as part of these arrangements are deferred and recognized over the performance period. See Note 1 to the Consolidated Financial Statements for additional disclosures on collaborations.
Reasonably likely changes to assumptions used to calculate the accruals for rebates, returns and promotions are not anticipated to have a material effect on the financial statements. The Company currently discloses the impact of changes to assumptions in the quarterly or annual filing in which there is a material financial statement impact.
2024 Annual Report
37


Below are tables that show the progression of accrued rebates, returns, promotions, reserve for doubtful accounts and reserve for cash discounts by segment of business for the fiscal years ended December 29, 2024 and December 31, 2023.
Innovative Medicine segment
(Dollars in Millions)
Balance at
Beginning
of Period
Accruals
Payments/
Credits(2)
Balance at
End of
Period
2024    
Accrued rebates (1)
$14,66152,786(51,667)15,780
Accrued returns634845(355)1,124
Accrued promotions63(6)3
Subtotal$15,30153,634(52,028)16,907
Reserve for doubtful accounts3314(6)41
Reserve for cash discounts1111,493(1,495)109
Total$15,44555,141(53,529)17,057
2023    
Accrued rebates (1)
$12,28947,523(45,151)14,661
Accrued returns649332(347)634
Accrued promotions112(7)6
Subtotal$12,93947,867(45,505)15,301
Reserve for doubtful accounts440(11)33
Reserve for cash discounts1101,386(1,385)111
Total$13,09349,253(46,901)15,445
(1)Includes reserve for customer rebates of $187 million at December 29, 2024 and $165 million at December 31, 2023, recorded as a contra asset.
(2)Includes prior period adjustments
38
 Jhonson&Jhonson.jpg 


MedTech segment
(Dollars in Millions)Balance at
Beginning of
Period
AccrualsPayments/
Credits
Balance at
End of
Period
2024    
Accrued rebates(1)
$1,4555,955(5,986)1,424
Accrued returns125543(550)118
Accrued promotions2562(65)22
Subtotal$1,6056,560(6,601)1,564
Reserve for doubtful accounts13331(38)126
Reserve for cash discounts592(91)6
Total$1,7436,683(6,730)1,696
2023    
Accrued rebates(1)
$1,4706,241(6,256)1,455
Accrued returns134555(564)125
Accrued promotions4374(92)25
Subtotal$1,6476,870(6,912)1,605
Reserve for doubtful accounts12533(25)133
Reserve for cash discounts996(100)5
Total$1,7816,999(7,037)1,743
(1)Includes reserve for customer rebates of $704 million at December 29, 2024 and $740 million at December 31, 2023, recorded as a contra asset.
Income Taxes: Income taxes are recorded based on amounts refundable or payable for the current year and include the results of any difference between U.S. GAAP accounting and tax reporting, recorded as deferred tax assets or liabilities. The Company estimates deferred tax assets and liabilities based on enacted tax regulations and rates. Future changes in tax laws and rates may affect recorded deferred tax assets and liabilities.
The Company has unrecognized tax benefits for uncertain tax positions. The Company follows U.S. GAAP, which prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. Management believes that changes in these estimates would not have a material effect on the Company's results of operations, cash flows or financial position.
The Company has recorded deferred tax liabilities on all undistributed earnings prior to December 31, 2017 from its international subsidiaries. The Company has not provided deferred taxes on the undistributed earnings subsequent to January 1, 2018 from certain international subsidiaries where the earnings are considered to be indefinitely reinvested. The Company intends to continue to reinvest these earnings in those international operations. If the Company decides at a later date to repatriate these earnings to the U.S., the Company would be required to provide for the net tax effects on these amounts. The Company estimates that the tax effect of this repatriation would be approximately $0.5 billion under currently enacted tax laws and regulations and at current currency exchange rates. This amount does not include the possible benefit of U.S. foreign tax credits, which may substantially offset this cost.
See Note 1 and Note 8 to the Consolidated Financial Statements for further information regarding income taxes.
Legal and Self Insurance Contingencies: The Company records accruals for various contingencies, including legal proceedings and product liability claims as these arise in the normal course of business. The accruals are based on management’s judgment as to the probability of losses and, where applicable, actuarially determined estimates. The Company has self insurance through a wholly-owned captive insurance company. In addition to accruals in the self insurance program, claims that exceed the insurance coverage are accrued when losses are probable and amounts can be reasonably estimated.
The Company follows the provisions of U.S. GAAP when recording litigation related contingencies. A liability is recorded when a loss is probable and can be reasonably estimated.
2024 Annual Report
39


See Notes 1 and 19 to the Consolidated Financial Statements for further information regarding product liability and legal proceedings.
Long-Lived and Intangible Assets: The Company assesses changes, both qualitatively and quantitatively, in economic conditions and makes assumptions regarding estimated future cash flows in evaluating the value of the Company’s property, plant and equipment, goodwill and intangible assets. As these assumptions and estimates may change over time, it may or may not be necessary for the Company to record impairment charges.
Employee Benefit Plans: The Company sponsors various retirement and pension plans, including defined benefit, defined contribution and termination indemnity plans, which cover most employees worldwide. These plans are based on assumptions for the discount rate, expected return on plan assets, mortality rates, expected salary increases, healthcare cost trend rates and attrition rates. See Note 10 to the Consolidated Financial Statements for further details on these rates.
Stock Based Compensation: The Company recognizes compensation expense associated with the issuance of equity instruments to employees for their services. Based on the type of equity instrument, the fair value is estimated on the date of grant using either the Black-Scholes option valuation model or a combination of both the Black-Scholes option valuation model and Monte Carlo valuation model, and is expensed in the financial statements over the service period. The input assumptions used in determining fair value are the expected life, expected volatility, risk-free rate and expected dividend yield. For performance share units, the fair market value is calculated for the two component goals at the date of grant: adjusted operational earnings per share and relative total shareholder return. The fair values for the earnings per share goal of each performance share unit was estimated on the date of grant using the fair market value of the shares at the time of the award, discounted for dividends, which are not paid on the performance share units during the vesting period. The fair value for the relative total shareholder return goal of each performance share unit was estimated on the date of grant using the Monte Carlo valuation model. See Note 16 to the Consolidated Financial Statements for additional information.
New accounting pronouncements
Refer to Note 1 to the Consolidated Financial Statements for recently adopted accounting pronouncements and recently issued accounting pronouncements not yet adopted as of December 29, 2024.
40
 Jhonson&Jhonson.jpg 


Economic and market factors
The Company is aware that its products are used in an environment where, for more than a decade, policymakers, consumers and businesses have expressed concerns about the rising cost of healthcare. In response to these concerns, the Company has a long-standing policy of pricing products responsibly. For the period 2014 - 2024, in the U.S., the weighted average compound annual growth rate of the Company’s net price increases for healthcare products (prescription and over-the-counter drugs, hospital and professional products) was below the U.S. Consumer Price Index (CPI).
The Company operates in certain countries where the economic conditions continue to present significant challenges. The Company continues to monitor these situations and take appropriate actions. Inflation rates continue to have an effect on worldwide economies and, consequently, on the way companies operate. The Company has accounted for operations in Argentina, Venezuela, Turkey and Egypt (beginning in the fiscal fourth quarter of 2024) as highly inflationary, as the prior three-year cumulative inflation rate surpassed 100%. This did not have a material impact to the Company's results in the period. In the face of increasing costs, the Company strives to maintain its profit margins through cost reduction programs, productivity improvements and periodic price increases.
In July 2023, Janssen Pharmaceuticals, Inc. (Janssen) filed litigation against the U.S. Department of Health and Human Services as well as the Centers for Medicare and Medicaid Services challenging the constitutionality of the IRA's Medicare Drug Price Negotiation Program. The litigation requests a declaration that the IRA violates Janssen’s rights under the First Amendment and the Fifth Amendment to the Constitution and therefore that Janssen is not subject to the IRA’s mandatory pricing scheme. The impact of the IRA on our business and the broader pharmaceutical industry remains uncertain, as litigation filed by Janssen and other pharmaceutical companies remains ongoing and while CMS has publicly announced the maximum fair price for each of the selected drugs, implementation of the program is still in progress. In April 2024, Janssen appealed the district court’s denial of its summary judgment motion to the Third Circuit.
Russia-Ukraine War
Although the long-term implications of Russia’s invasion of Ukraine are difficult to predict at this time, the financial impact of the conflict in the fiscal year 2024, including accounts receivable or inventory reserves, was not material. As of and for each of the fiscal years ending December 29, 2024 and December 31, 2023, the business of the Company’s Russian subsidiaries represented less than 1% of the Company’s consolidated assets and revenues. The Company does not maintain Ukraine subsidiaries subsequent to the Kenvue separation.
In March of 2022, the Company took steps to suspend all advertising, enrollment in clinical trials, and any additional investment in Russia. The Company continues to supply products relied upon by patients for healthcare purposes.
Conflict in the Middle East
Although the long-term implications of the conflict in the Middle East are difficult to predict at this time, the financial impact of the conflict in the fiscal year 2024, including accounts receivable or inventory reserves, was not material. As of and for each of the fiscal years ending December 29, 2024 and December 31, 2023, the business of the Company’s Israel subsidiaries represented 1% of the Company’s consolidated assets and represented less than 1% of revenues.
The Company is exposed to fluctuations in currency exchange rates. A 1% change in the value of the U.S. Dollar as compared to all foreign currencies in which the Company had sales, income or expense in 2024 would have increased or decreased the translation of foreign sales by approximately $0.4 billion and net income by approximately $0.1 billion.
Governments around the world consider various proposals to make changes to tax laws, which may include increasing or decreasing existing statutory tax rates. In connection with various government initiatives, companies are required to disclose more information to tax authorities on operations around the world, which may lead to greater audit scrutiny of profits earned in other countries. A change in statutory tax rate in any country would result in the revaluation of the Company’s deferred tax assets and liabilities related to that particular jurisdiction in the period in which the new tax law is enacted. This change would result in an expense or benefit recorded to the Company’s Consolidated Statement of Earnings. The Company closely monitors these proposals as they arise in the countries where it operates. Changes to the statutory tax rate may occur at any time, and any related expense or benefit recorded may be material to the fiscal quarter and year in which the law change is enacted.
The Company faces various worldwide healthcare changes that may continue to result in pricing pressures that include healthcare cost containment and government legislation relating to sales, promotions, pricing and reimbursement of healthcare products.
2024 Annual Report
41


Changes in the behavior and spending patterns of purchasers of healthcare products and services, including delaying medical procedures, rationing prescription medications, reducing the frequency of physician visits and foregoing healthcare insurance coverage may continue to impact the Company’s businesses.
The Company also operates in an environment increasingly hostile to intellectual property rights. Firms have filed Abbreviated New Drug Applications or Biosimilar Biological Product Applications with the U.S. FDA or otherwise challenged the coverage and/or validity of the Company's patents, seeking to market generic or biosimilar forms of many of the Company’s key pharmaceutical products prior to expiration of the applicable patents covering those products. In the event the Company is not successful in defending the patent claims challenged in the resulting lawsuits, generic or biosimilar versions of the products at issue will be introduced to the market, resulting in the potential for substantial market share and revenue losses for those products, and which may result in a non-cash impairment charge in any associated intangible asset. There is also a risk that one or more competitors could launch a generic or biosimilar version of the product at issue following regulatory approval even though one or more valid patents are in place.
Legal proceedings
Johnson & Johnson and certain of its subsidiaries are involved in various lawsuits and claims regarding product liability, intellectual property, commercial, employment, indemnification and other matters; governmental investigations; and other legal proceedings that arise from time to time in the ordinary course of business.
The Company records accruals for loss contingencies associated with these legal matters when it is probable that a liability will be incurred and the amount of the loss can be reasonably estimated. As of December 29, 2024, the Company has determined that the liabilities associated with certain litigation matters are probable and can be reasonably estimated. The Company has accrued for these matters and will continue to monitor each related legal issue and adjust accruals as might be warranted based on new information and further developments in accordance with ASC 450-20-25, Contingencies. For these and other litigation and regulatory matters discussed below for which a loss is probable or reasonably possible, the Company is unable to estimate the possible loss or range of loss beyond the amounts accrued. Amounts accrued for legal contingencies often result from a complex series of judgments about future events and uncertainties that rely heavily on estimates and assumptions including timing of related payments. The ability to make such estimates and judgments can be affected by various factors including, among other things, whether damages sought in the proceedings are unsubstantiated or indeterminate; scientific and legal discovery has not commenced or is not complete; proceedings are in early stages; matters present legal uncertainties; there are significant facts in dispute; procedural or jurisdictional issues; the uncertainty and unpredictability of the number of potential claims; ability to achieve comprehensive multi-party settlements; complexity of related cross-claims and counterclaims; and/or there are numerous parties involved. To the extent adverse awards, judgments or verdicts have been rendered against the Company, the Company does not record an accrual until a loss is determined to be probable and can be reasonably estimated.
In the Company's opinion, based on its examination of these matters, its experience to date and discussions with counsel, the ultimate outcome of legal proceedings, net of liabilities accrued in the Company's balance sheet, is not expected to have a material adverse effect on the Company's financial position. However, the resolution of, or increase in accruals for, one or more of these matters in any reporting period may have a material adverse effect on the Company's results of operations and cash flows for that period.
See Note 19 to the Consolidated Financial Statements included in Item 8 of this report for further information regarding legal proceedings.
Common stock
The Company’s Common Stock is listed on the New York Stock Exchange under the symbol JNJ. As of February 6, 2025, there were 114,147 record holders of Common Stock of the Company.
Item 7A. Quantitative and qualitative disclosures about market risk
The information called for by this item is incorporated herein by reference to Item 7. Management’s discussion and analysis of results of operations and financial condition - Liquidity and capital resources - Financing and market risk of this Report; and Note 1 Summary of significant accounting policies - Financial instruments of the Notes to Consolidated Financial Statements included in Item 8 of this Report.
42
 Jhonson&Jhonson.jpg 


Item 8. Financial statements and supplementary data
Index to audited Consolidated Financial Statements
2024 Annual Report
43


Johnson & Johnson and subsidiaries consolidated balance sheets
At December 29, 2024 and December 31, 2023
(Dollars in Millions Except Share and Per Share Amounts) (Note 1)
20242023
Assets
Current assets  
Cash and cash equivalents (Notes 1 and 2)$24,10521,859
Marketable securities (Notes 1 and 2)4171,068
Accounts receivable trade, less allowances $167 (2023, $166)
14,84214,873
Inventories (Notes 1 and 3)12,44411,181
Prepaid expenses and other receivables4,0854,514
Total current assets55,89353,495
Property, plant and equipment, net (Notes 1 and 4)20,51819,898
Intangible assets, net (Notes 1 and 5)37,61834,175
Goodwill (Notes 1 and 5)44,20036,558
Deferred taxes on income (Note 8)10,4619,279
Other assets11,41414,153
Total assets$180,104167,558
Liabilities and Shareholders’ Equity  
Current liabilities  
Loans and notes payable (Note 7)$5,9833,451
Accounts payable10,3119,632
Accrued liabilities8,54910,212
Accrued rebates, returns and promotions17,58016,001
Accrued compensation and employee related obligations4,1263,993
Accrued taxes on income (Note 8)3,7722,993
Total current liabilities50,32146,282
Long-term debt (Note 7)30,65125,881
Deferred taxes on income (Note 8)2,4483,193
Employee related obligations (Notes 9 and 10)7,2557,149
Long-term taxes payable (Note 1)3902,881
Other liabilities17,54913,398
Total liabilities108,61498,784
Commitments and Contingencies (Note 19)
Shareholders’ equity  
Preferred stock — without par value (authorized and unissued 2,000,000 shares)
Common stock — par value $1.00 per share (Note 12) (authorized 4,320,000,000 shares; issued 3,119,843,000 shares)
3,1203,120
Accumulated other comprehensive income (loss) (Note 13)(11,741)(12,527)
Retained earnings and Additional-paid-in-capital155,791153,843
Less: common stock held in treasury, at cost (Note 12) (712,921,000 shares and 712,765,000 shares)
75,68075,662
Total shareholders’ equity71,49068,774
Total liabilities and shareholders’ equity$180,104167,558
See Notes to Consolidated Financial Statements
44
 Jhonson&Jhonson.jpg 


Johnson & Johnson and subsidiaries consolidated statements of earnings
(Dollars and Shares in Millions Except Per Share Amounts) (Note 1)
202420232022
Sales to customers$88,82185,15979,990
Cost of products sold27,47126,55324,596
Gross profit61,35058,60655,394
Selling, marketing and administrative expenses22,86921,51220,246
Research and development expense17,23215,08514,135
In-process research and development impairments211313783
Interest income(1,332)(1,261)(490)
Interest expense, net of portion capitalized (Note 4)755772276
Other (income) expense, net4,6946,634810
Restructuring (Note 20)234489275
Earnings before provision for taxes on income16,68715,06219,359
Provision for taxes on income (Note 8)2,6211,7362,989
Net earnings from continuing operations14,06613,32616,370
Net earnings from discontinued operations, net of tax (Note 21)21,8271,571
Net earnings
$14,06635,15317,941
Net earnings per share (Notes 1 and 15)
Continuing operations - basic$5.845.266.23
Discontinued operations - basic8.620.60
Total net earnings per share - basic$5.8413.886.83
Continuing operations - diluted$5.795.206.14
Discontinued operations - diluted8.520.59
Total net earnings per share - diluted$5.7913.726.73
Average shares outstanding (Notes 1 and 15)
Basic2,407.32,533.52,625.2
Diluted2,429.42,560.42,663.9
See Notes to Consolidated Financial Statements
2024 Annual Report
45


Johnson & Johnson and subsidiaries consolidated statements of comprehensive income
(Dollars in Millions) (Note 1)
202420232022
Net earnings $14,06635,15317,941
Other comprehensive income (loss), net of tax
Foreign currency translation1,708(3,221)(1,796)
Securities:
Unrealized holding gain (loss) arising during period226(24)
Reclassifications to earnings
Net change226(24)
Employee benefit plans:
Prior service credit (cost), net of amortization(154)(149)(160)
Gain (loss), net of amortization541(1,183)1,854
Consumer settlement/ curtailment23
Effect of exchange rates62(90)111
Net change449(1,399)1,805
Derivatives & hedges:
Unrealized gain (loss) arising during period(511)422454
Reclassifications to earnings(862)(569)(348)
Net change(1,373)(147)106
Other comprehensive income (loss)786(4,741)91
Comprehensive income $14,85230,41218,032
The tax cost/(benefit) effects in other comprehensive income for the fiscal years 2024, 2023 and 2022 respectively: Foreign Currency Translation; $(1.1) billion, $797 million and $(460) million; Employee Benefit Plans: $86 million, $(289) million and $461 million, Derivatives & Hedges: $(365) million, $(39) million and $30 million.
See Notes to Consolidated Financial Statements
Amounts presented for 2023 and 2022 have not been recast to exclude discontinued operations
46
 Jhonson&Jhonson.jpg 


Johnson & Johnson and subsidiaries consolidated statements of equity
(Dollars in Millions) (Note 1)
TotalRetained
Earnings and
Additional
paid-in
capital
Accumulated
Other
Comprehensive
Income (Loss)
Common
Stock
Issued
Amount
Treasury
Stock
Amount
Balance, January 2, 2022$74,023123,060(13,058)3,120(39,099)
Net earnings 17,94117,941   
Cash dividends paid ($4.45 per share)
(11,682)(11,682)   
Employee compensation and stock option plans2,466(974)  3,440
Repurchase of common stock(6,035)  (6,035)
Other comprehensive income (loss), net of tax9191  
Balance, January 1, 202376,804128,345(12,967)3,120(41,694)
Net earnings35,15335,153   
Cash dividends paid ($4.70 per share)
(11,770)(11,770)   
Employee compensation and stock option plans2,193(336)  2,529
Repurchase of common stock(5,054)  (5,054)
Other(25)(25)
Kenvue Separation /IPO (Note 21)(23,786)2,451 5,181 (31,418)
Other comprehensive income (loss), net of tax(4,741) (4,741)  
Balance, December 31, 202368,774153,843(12,527)3,120(75,662)
Net earnings 14,06614,066   
Cash dividends paid ($4.91 per share)
(11,823)(11,823)   
Employee compensation and stock option plans2,094(295)  2,389
Repurchase of common stock(2,407)  (2,407)
Other comprehensive income (loss), net of tax786 786  
Balance, December 29, 2024$71,490155,791(11,741)3,120(75,680)
See Notes to Consolidated Financial Statements
2024 Annual Report
47


Johnson & Johnson and subsidiaries consolidated statements of cash flows
(Dollars in Millions) (Note 1)
202420232022
Cash flows from operating activities  
Net earnings$14,06635,15317,941
Adjustments to reconcile net earnings to cash flows from operating activities:  
Depreciation and amortization of property and intangibles7,3397,4866,970
Stock based compensation1,1761,1621,138
Asset write-downs4051,2951,216
Charges for acquired in-process research and development assets1,841483
Gain on Kenvue separation(20,984)
Net gain on sale of assets/businesses(226)(117)(380)
Deferred tax provision(2,183)(4,194)(1,663)
Credit losses and accounts receivable allowances11(17)
Changes in assets and liabilities, net of effects from acquisitions and divestitures:  
Increase in accounts receivable(406)(624)(1,290)
Increase in inventories(1,128)(1,323)(2,527)
Increase in accounts payable and accrued liabilities1,6212,3461,098
Decrease/(Increase) in other current and non-current assets1,717(3,480)687
Increase/(Decrease) in other current and non-current liabilities335,588(1,979)
Net cash flows from operating activities24,26622,79121,194
Cash flows from investing activities  
Additions to property, plant and equipment(4,424)(4,543)(4,009)
Proceeds from the disposal of assets/businesses, net675358543
Acquisitions, net of cash acquired (Note 18)(15,146)(17,652)
Acquired in-process research and development assets (Note 18)(1,783)(470)
Purchases of investments(1,726)(10,906)(32,384)
Sales of investments2,46219,39041,609
Credit support agreements activity, net1,517(2,963)(249)
Other (including capitalized licenses and milestones)(174)12(229)
Net cash (used by)/from investing activities(18,599)878(12,371)
Cash flows from financing activities 
Dividends to shareholders(11,823)(11,770)(11,682)
Repurchase of common stock(2,432)(5,054)(6,035)
Proceeds from short-term debt15,27713,74316,134
Repayment of short-term debt(9,463)(22,973)(6,550)
Proceeds from long-term debt, net of issuance costs6,6602
Repayment of long-term debt(1,453)(1,551)(2,134)
Proceeds from the exercise of stock options/employee withholding tax on stock awards, net8381,0941,329
Credit support agreements activity, net272(219)(28)
48
 Jhonson&Jhonson.jpg 


202420232022
Settlement of convertible debt acquired from Shockwave(970)
Proceeds of short and long-term debt, net of issuance cost, related to the debt that transferred to Kenvue at separation8,047
Proceeds from Kenvue initial public offering4,241
Cash transferred to Kenvue at separation(1,114)
Other(38)(269)93
Net cash used by financing activities(3,132)(15,825)(8,871)
Effect of exchange rate changes on cash and cash equivalents(289)(112)(312)
Increase/(Decrease) in cash and cash equivalents2,2467,732(360)
Cash and cash equivalents from continuing operations, beginning of period21,85912,88913,309
Cash and cash equivalents from discontinued operations, beginning of period1,2381,178
Cash and cash equivalents, beginning of year (Note 1)21,85914,12714,487
Cash and cash equivalents from continuing operations, end of period24,10521,85912,889
Cash and cash equivalents from discontinued operations, end of period1,238
Cash and cash equivalents, end of year (Note 1)$24,10521,85914,127
Supplemental cash flow data   
Cash paid during the year for:   
Interest$1,9901,836982
Interest, net of amount capitalized1,9111,766933
Income taxes, inclusive of discontinued operations6,7148,5745,223
Supplemental schedule of non-cash investing and financing activities   
Treasury stock issued for employee compensation and stock option plans, net of cash proceeds/ employee withholding tax on stock awards$1,5511,4352,114
Acquisitions   
Fair value of assets acquired$16,09118,710
Fair value of liabilities assumed(1,632)(1,058)
Net cash paid for acquisitions (Note 18)$14,45917,652
See Notes to Consolidated Financial Statements
Amounts presented for 2023 and 2022 have not been recast to exclude discontinued operations.
2024 Annual Report
49


Notes to consolidated financial statements
1. Summary of significant accounting policies
Principles of consolidation
The consolidated financial statements include the accounts of Johnson & Johnson and its subsidiaries (the Company). Intercompany accounts and transactions are eliminated. Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures.
Description of the company
The Company has approximately 138,100 employees worldwide engaged in the research and development, manufacture and sale of a broad range of products in the healthcare field. The Company conducts business in virtually all countries of the world and its primary focus is on products related to human health and well-being.
Kenvue IPO/separation and discontinued operations
On May 8, 2023, Kenvue, completed an initial public offering (the IPO) resulting in the issuance of 198,734,444 shares of its common stock, par value $0.01 per share (the “Kenvue Common Stock”), at an initial public offering of $22.00 per share for net proceeds of $4.2 billion. The excess of the net proceeds from the IPO over the net book value of the Johnson & Johnson divested interest was $2.5 billion and was recorded to additional paid-in capital. As of the closing of the IPO, Johnson & Johnson owned approximately 89.6% of the total outstanding shares of Kenvue Common Stock and at July 2, 2023, the
non-controlling interest of $1.3 billion associated with Kenvue was reflected in equity attributable to non-controlling interests in the consolidated balance sheet in the fiscal second quarter of 2023.
On August 23, 2023, Johnson & Johnson completed the disposition of an additional 80.1% ownership of the shares of Kenvue through an exchange offer. Following the exchange offer, the Company owned 9.5% of the shares of Kenvue which were accounted for as an equity investment carried at fair value within continuing operations. The historical results of the Consumer Health business (which previously represented the Consumer Health business segment) are reflected as discontinued operations in the Company’s Consolidated Financial Statements through the date of the exchange offer (see Note 21 for additional details). Unless otherwise indicated, the information in the notes to the Consolidated Financial Statements refer only to Johnson & Johnson’s continuing operations.
In the fiscal second quarter of 2024 the Company completed a debt for equity exchange of the retained stake in Kenvue. Upon completion of the debt for equity exchange, the Company no longer owns any shares of Kenvue Common Stock.
Business segments
The Company is organized into two business segments: Innovative Medicine and MedTech. The Innovative Medicine segment is focused on the following therapeutic areas: Immunology, Infectious Diseases, Neuroscience, Oncology, Pulmonary Hypertension, and Cardiovascular and Metabolic. Products in this segment are distributed directly to retailers, wholesalers, distributors, hospitals and healthcare professionals for prescription use. The MedTech segment includes a broad portfolio of products used in the Orthopaedic, Surgery, Cardiovascular (previously referred to as Interventional Solutions) and Vision fields. These products are distributed to wholesalers, hospitals and retailers, and used principally in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics.
New accounting standards
Recently adopted accounting standards
ASU 2023-07: Segment Reporting (Topic 280) – Improvements to Reportable Segment Disclosures
The Company adopted the standard in the fiscal year 2024, which requires expanded annual and interim disclosures for significant segment expenses that are regularly provided to the chief operating decision maker and included within each reported measure of segment profit or loss. The standard was applied retrospectively to all periods presented in the financial statements. As this accounting standard only impacts disclosures, it did not have a material impact on the Company’s Consolidated Financial Statements. See Note 17 for the required disclosures.
50
 Jhonson&Jhonson.jpg 


Recently issued accounting standards
Not adopted as of December 29, 2024
ASU 2024-03: Income Statement – Reporting Comprehensive Income – Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses
This update requires disclosure of disaggregated information about certain income statement expense line items on an annual and interim basis. This update will be effective for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. As this accounting standard only impacts disclosures, it will not have a material impact on the Company’s Consolidated Financial Statements.
ASU 2023-09: Income Taxes (Topic 740) - Improvements to Income Tax Disclosures
This update standardizes categories for the effective tax rate reconciliation, requires disaggregation of income taxes and additional income tax-related disclosures. This update is required to be effective for the Company for fiscal periods beginning after December 15, 2024. As this accounting standard only impacts disclosures, it will not have a material impact on the Company’s Consolidated Financial Statements.
Cash equivalents
The Company classifies all highly liquid investments with stated maturities of three months or less from date of purchase as cash equivalents and all highly liquid investments with stated maturities of greater than three months from the date of purchase as current marketable securities. The Company has a policy of making investments only with commercial institutions that have at least an investment grade credit rating. The Company invests its cash primarily in government securities and obligations, corporate debt securities, money market funds and reverse repurchase agreements (RRAs).
RRAs are collateralized by deposits in the form of Government Securities and Obligations for an amount not less than 102% of their value. The Company does not record an asset or liability as the Company is not permitted to sell or repledge the associated collateral. The Company has a policy that the collateral has at least an A (or equivalent) credit rating. The Company utilizes a third party custodian to manage the exchange of funds and ensure that collateral received is maintained at 102% of the value of the RRAs on a daily basis. RRAs with stated maturities of greater than three months from the date of purchase are classified as marketable securities.
Investments
Investments classified as held to maturity investments are reported at amortized cost and realized gains or losses are reported in earnings. Investments classified as available-for-sale debt securities are carried at estimated fair value with unrealized gains and losses recorded as a component of accumulated other comprehensive income. Available-for-sale securities available for current operations are classified as current assets; otherwise, they are classified as long term. Management determines the appropriate classification of its investment in debt and equity securities at the time of purchase and re-evaluates such determination at each balance sheet date. The Company reviews its investments for impairment and adjusts these investments to fair value through earnings, as required. 
Property, plant and equipment and depreciation
Property, plant and equipment are stated at cost. The Company utilizes the straight-line method of depreciation over the estimated useful lives of the assets:
Building and building equipment
30 years
Land and leasehold improvements
10 - 20 years
Machinery and equipment
2 - 13 years
The Company capitalizes certain computer software and development costs, included in machinery and equipment, when incurred in connection with developing or obtaining computer software for internal use. Capitalized software costs are amortized over the estimated useful lives of the software, which generally range from 3 to 8 years.
2024 Annual Report
51


The Company reviews long-lived assets to assess recoverability using undiscounted cash flows. When certain events or changes in operating or economic conditions occur, an impairment assessment may be performed on the recoverability of the carrying value of these assets. If the asset is determined to be impaired, the loss is measured based on the difference between the asset’s fair value and its carrying value. If quoted market prices are not available, the Company will estimate fair value using a discounted value of estimated future cash flows.
Revenue recognition
The Company recognizes revenue from product sales when obligations under the terms of a contract with the customer are satisfied; generally, this occurs with the transfer of control of the goods to customers. The Company's global payment terms are typically between 30 to 90 days. Provisions for certain rebates, sales incentives, trade promotions, coupons, product returns, discounts to customers and governmental clawback provisions are accounted for as variable consideration and recorded as a reduction in sales. The liability is recognized within Accrued rebates, returns, and promotions on the consolidated balance sheet.
Product discounts granted are based on the terms of arrangements with direct, indirect and other market participants, as well as market conditions, including consideration of competitor pricing. Rebates and discounts are estimated based on contractual terms, historical experience, patient outcomes, trend analysis and projected market conditions in the various markets served. A significant portion of the liability related to rebates is from the sale of the Company's pharmaceutical products within the U.S., primarily the Managed Care, Medicare and Medicaid programs, which amounted to $12.3 billion and $11.5 billion as of December 29, 2024 and December 31, 2023, respectively. The Company evaluates market conditions for products or groups of products primarily through the analysis of wholesaler and other third-party sell-through and market research data, as well as internally generated information.
Sales returns are estimated and recorded based on historical sales and returns information. Products that have lost patent exclusivity, or that otherwise exhibit unusual sales or return patterns due to dating, competition or other marketing matters are specifically investigated and analyzed as part of the accounting for sales return accruals.
Sales returns allowances represent a reserve for products that may be returned due to expiration, destruction in the field, or in specific areas, product recall. In accordance with the Company’s accounting policies, the Company generally issues credit to customers for returned goods. The Company’s sales returns reserves are accounted for in accordance with the U.S. GAAP guidance for revenue recognition when right of return exists. Sales returns reserves are recorded at full sales value. Sales returns in the Innovative Medicine segment are almost exclusively not resalable. Sales returns for certain franchises in the MedTech segment are typically resalable but are not material. The Company infrequently exchanges products from inventory for returned products. The sales returns reserve for the total Company has been approximately 1.0% of annual net trade sales during each of the fiscal years 2024, 2023 and 2022.
Promotional programs, such as product listing allowances are recorded in the same period as related sales and include
volume-based sales incentive programs. Volume-based incentive programs are based on the estimated sales volumes for the incentive period and are recorded as products are sold. These arrangements are evaluated to determine the appropriate amounts to be deferred or recorded as a reduction of revenue. The Company also earns profit-share payments through collaborative arrangements of certain products, which are included in sales to customers. Profit-share payments were less than 2.0% of the total revenues in the fiscal year 2024 and 2023, respectively, and less than 3.0% of total revenues in the fiscal year 2022 and are included in sales to customers.
See Note 17 to the Consolidated Financial Statements for further disaggregation of revenue.
Shipping and handling
Shipping and handling costs incurred were $0.9 billion, $0.9 billion and $0.8 billion in fiscal years 2024, 2023 and 2022, respectively, and are included in selling, marketing and administrative expense. The amount of revenue received for shipping and handling is less than 1.0% of sales to customers for all periods presented.
Inventories
Inventories are stated at the lower of cost or net realizable value determined by the first-in, first-out method.
52
 Jhonson&Jhonson.jpg 


Intangible assets and goodwill
The authoritative literature on U.S. GAAP requires that goodwill and intangible assets with indefinite lives be assessed annually for impairment. The Company completed its annual impairment test for 2024 in the fiscal fourth quarter. Future impairment tests will be performed annually in the fiscal fourth quarter, or sooner if warranted. In-process research and development purchased as part of a business combination is accounted for as an indefinite lived intangible asset until the underlying project is completed, at which point the intangible asset will be accounted for as a definite lived intangible asset. If warranted the purchased in-process research and development could be written off or partially impaired depending on the underlying program.
Intangible assets that have finite useful lives continue to be amortized over their useful lives and are reviewed for impairment when warranted by economic conditions. See Note 5 for further details on Intangible Assets and Goodwill.
Financial instruments
As required by U.S. GAAP, all derivative instruments are recorded on the balance sheet at fair value. Fair value is the exit price that would be received to sell an asset or paid to transfer a liability. Fair value is a market-based measurement determined using assumptions that market participants would use in pricing an asset or liability. The authoritative literature establishes a three-level hierarchy to prioritize the inputs used in measuring fair value, with Level 1 having the highest priority and Level 3 having the lowest. Changes in the fair value of derivatives are recorded each period in current earnings or other comprehensive income, depending on whether the derivative is designated as part of a hedge transaction, and if so, the type of hedge transaction.
The Company documents all relationships between hedged items and derivatives. The overall risk management strategy includes reasons for undertaking hedge transactions and entering into derivatives. The objectives of this strategy are: (1) minimize foreign currency exposure’s impact on the Company’s financial performance; (2) protect the Company’s cash flow from adverse movements in foreign exchange rates; (3) ensure the appropriateness of financial instruments; and (4) manage the enterprise risk associated with financial institutions. See Note 6 for additional information on Financial Instruments.
Leases
The Company determines whether an arrangement is a lease at contract inception by establishing if the contract conveys the right to control the use of identified property, plant, or equipment for a period of time in exchange for consideration. Right of Use (ROU) Assets and Lease Liabilities for operating leases are included in Other assets, Accrued liabilities, and Other liabilities on the consolidated balance sheet. The ROU Assets represent the right to use an underlying asset for the lease term and lease liabilities represent an obligation to make lease payments arising from the lease. Commitments under finance leases are not significant, and are included in Property, plant and equipment, Loans and notes payable, and Long-term debt on the consolidated balance sheet.
ROU Assets and Lease Liabilities are recognized at the lease commencement date based on the present value of all minimum lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments, when the implicit rate is not readily determinable. Lease terms may include options to extend or terminate the lease. These options are included in the lease term when it is reasonably certain that the Company will exercise that option. Operating lease expense is recognized on a straight-line basis over the lease term. The Company has elected the following policy elections on adoption: use of portfolio approach on leases of assets under master service agreements, exclusion of short term leases on the balance sheet, and not separating lease and non-lease components.
The Company primarily has operating lease for space, vehicles, manufacturing equipment and data processing equipment. The ROU asset pertaining to leases from continuing operations was $1.1 billion and $1.0 billion in fiscal years 2024 and 2023, respectively. The lease liability from continuing operations was $1.2 billion and $1.1 billion in fiscal years 2024 and 2023, respectively. The operating lease costs from continuing operations were $0.2 billion in fiscal years 2024, 2023 and 2022. Cash paid for amounts included in the measurement of lease liabilities from continuing operations were $0.2 billion in fiscal years 2024, 2023 and 2022.
2024 Annual Report
53


Product liability
Accruals for product liability claims are recorded, on an undiscounted basis, when it is probable that a liability has been incurred and the amount of the liability can be reasonably estimated based on existing information and actuarially determined estimates where applicable. The accruals are adjusted periodically as additional information becomes available. The Company accrues an estimate of the legal defense costs needed to defend each matter when those costs are probable and can be reasonably estimated. To the extent adverse verdicts have been rendered against the Company, the Company does not record an accrual until a loss is determined to be probable and can be reasonably estimated.
The Company has self insurance through a wholly-owned captive insurance company. In addition to accruals in the self insurance program, claims that exceed the insurance coverage are accrued when losses are probable and amounts can be reasonably estimated.
Research and development
Research and development expenses are expensed as incurred in accordance with ASC 730, Research and Development. Upfront and milestone payments made to third parties in connection with research and development collaborations are expensed as incurred up to the point of regulatory approval. Payments made to third parties subsequent to regulatory approval are capitalized and amortized over the remaining useful life of the related product. Amounts capitalized for such payments are included in other intangibles, net of accumulated amortization.
The Company enters into collaborative arrangements, typically with other pharmaceutical or biotechnology companies, to develop and commercialize drug candidates or intellectual property. These arrangements typically involve two (or more) parties who are active participants in the collaboration and are exposed to significant risks and rewards dependent on the commercial success of the activities. These collaborations usually involve various activities by one or more parties, including research and development, marketing and selling and distribution. Often, these collaborations require upfront, milestone and royalty or profit share payments, contingent upon the occurrence of certain future events linked to the success of the asset in development. Amounts due from collaborative partners related to development activities are generally reflected as a reduction of research and development expense because the performance of contract development services is not central to the Company’s operations. In general, the income statement presentation for these collaborations is as follows:
Nature/Type of CollaborationStatement of Earnings Presentation
Third-party sale of product & profit share payments receivedSales to customers
Royalties/milestones paid to collaborative partner (post-regulatory approval)*Cost of products sold
Royalties received from collaborative partnerOther income (expense), net
Upfront payments & milestones paid to collaborative partner (pre-regulatory approval)Research and development expense
Research and development payments to collaborative partnerResearch and development expense
Research and development payments received from collaborative partner or government entityReduction of Research and development expense
*    Milestones are capitalized as intangible assets and amortized to cost of products sold over the useful life.
For all years presented, there was no individual project that represented greater than 5% of the total annual consolidated research and development expense other than the acquired in-process research & development expense of $1.25 billion to secure the global rights to the NM26 bispecific antibody (Yellow Jersey acquisition) in fiscal year 2024.
The Company has a number of products and compounds developed in collaboration with strategic partners including XARELTO, co-developed with Bayer HealthCare AG, IMBRUVICA, developed in collaboration and co-marketed with Pharmacyclics LLC, an AbbVie company and CARVYKTI, licensed and developed in collaboration with Legend Biotech USA Inc. and Legend Biotech Ireland Limited.
Separately, the Company has a number of licensing arrangements for products and compounds including DARZALEX, licensed from Genmab A/S.
54
 Jhonson&Jhonson.jpg 


Advertising
Costs associated with advertising are expensed in the year incurred and are included in selling, marketing and administrative expenses. Advertising expenses worldwide, which comprised television, radio, print media and Internet advertising, were $0.6 billion, $0.5 billion and $0.7 billion in fiscal years 2024, 2023 and 2022, respectively.
Income taxes
Income taxes are recorded based on amounts refundable or payable for the current year and include the results of any difference between U.S. GAAP accounting and tax reporting, recorded as deferred tax assets or liabilities. The Company estimates deferred tax assets and liabilities based on enacted tax regulations and rates. Future changes in tax laws and rates may affect recorded deferred tax assets and liabilities in the future.
The Company has unrecognized tax benefits for uncertain tax positions. The Company follows U.S. GAAP which prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. Management believes that changes in these estimates would not have a material effect on the Company's results of operations, cash flows or financial position.
In 2017, the United States enacted into law new U.S. tax legislation, the U.S. Tax Cuts and Jobs Act (TCJA). This law included provisions for a comprehensive overhaul of the corporate income tax code, including a reduction of the statutory corporate tax rate from 35% to 21%, effective on January 1, 2018. The TCJA included a provision for a tax on all previously undistributed earnings of U.S. companies located in foreign jurisdictions. Undistributed earnings in the form of cash and cash equivalents were taxed at a rate of 15.5% and all other earnings were taxed at a rate of 8.0%. This tax is payable over 8 years and will not accrue interest. These payments began in fiscal year 2018 and will continue through 2025. The final payment of $2.5 billion will be made in fiscal year 2025.
The TCJA also includes provisions for a tax on global intangible low-taxed income (GILTI). GILTI is described as the excess of a U.S. shareholder’s total net foreign income over a deemed return on tangible assets, as provided by the TCJA. In January 2018, the FASB issued guidance that allows companies to elect as an accounting policy whether to record the tax effects of GILTI in the period the tax liability is generated (i.e., “period cost”) or provide for deferred tax assets and liabilities related to basis differences that exist and are expected to affect the amount of GILTI inclusion in future years upon reversal (i.e., “deferred method”). The Company has elected to account for GILTI under the deferred method. The deferred tax amounts recorded are based on the evaluation of temporary differences that are expected to reverse as GILTI is incurred in future periods.
The Company has recorded deferred tax liabilities on all undistributed earnings prior to December 31, 2017 from its international subsidiaries. The Company has not provided deferred taxes on the undistributed earnings subsequent to January 1, 2018 from certain international subsidiaries where the earnings are considered to be indefinitely reinvested. The Company intends to continue to reinvest these earnings in those international operations. If the Company decides at a later date to repatriate these earnings to the U.S., the Company would be required to provide for the net tax effects on these amounts. The Company estimates that the tax effect of this repatriation would be approximately $0.5 billion under currently enacted tax laws and regulations and at current currency exchange rates. This amount does not include the possible benefit of U.S. foreign tax credits, which may substantially offset this cost.
See Note 8 to the Consolidated Financial Statements for further information regarding income taxes.
Net earnings per share
Basic earnings per share is computed by dividing net earnings available to common shareholders by the weighted average number of common shares outstanding for the period. Diluted earnings per share reflects the potential dilution that could occur if securities were exercised or converted into common stock using the treasury stock method.
Use of estimates
The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the U.S. requires management to make estimates and assumptions that affect the amounts reported. Estimates are used when accounting for sales discounts, rebates, allowances and incentives, product liabilities, income taxes, withholding taxes, depreciation, amortization, employee benefits, contingencies and intangible asset and liability valuations. Actual results may or may not differ from those estimates.
2024 Annual Report
55


The Company follows the provisions of U.S. GAAP when recording litigation related contingencies. A liability is recorded when a loss is probable and can be reasonably estimated. The best estimate of a loss within a range is accrued; however, if no estimate in the range is better than any other, the minimum amount is accrued.
Supplier finance program obligations
The Company has agreements for supplier finance programs with third-party financial institutions. These programs provide participating suppliers the ability to finance payment obligations from the Company with the third-party financial institutions. The Company is not a party to the arrangements between the suppliers and the third-party financial institutions. The Company’s obligations to its suppliers, including amounts due, and scheduled payment dates (which have general payment terms of 90 days), are not affected by a participating supplier’s decision to participate in the program.
Confirmed obligations under the program as of December 29, 2024, and December 31, 2023, were $0.8 billion and $0.7 billion, respectively. The obligations are presented as Accounts payable on the Consolidated Balance Sheets.
The rollforward of the Company's valid obligations under the program were as follows:
2024
(Dollars in Millions)
Confirmed obligations - beginning of the year$704
Invoices confirmed during the year3,048
Confirmed invoices paid during the year2,964
Confirmed obligations - end of the year$788
Annual closing date
The Company follows the concept of a fiscal year, which ends on the Sunday nearest to the end of the month of December. Normally each fiscal year consists of 52 weeks, but every five or six years the fiscal year consists of 53 weeks, and therefore includes additional shipping days, as was the case in fiscal year 2020, and will be the case again in fiscal year 2026.

















56
 Jhonson&Jhonson.jpg 


2. Cash, cash equivalents and current marketable securities
At the end of the fiscal year 2024 and 2023, cash, cash equivalents and current marketable securities comprised:
(Dollars in Millions)2024
Carrying
 Amount
Unrecognized
Gain
Estimated
 Fair Value
Cash & Cash
Equivalents
Current
Marketable
Securities
Cash$2,9182,9182,918
Non-U.S. Sovereign Securities(1)
120120120
U.S. Reverse repurchase agreements7,1007,1007,100
Money market funds6,1236,1236,123
Time deposits(1)
1,0451,0451,045
Subtotal $17,30617,30617,186120
U.S. Gov't Securities$6,81516,8166,79620
Other Sovereign Securities1761768393
Corporate and other debt securities22422440184
Subtotal available for sale(2)
$7,21517,2166,919297
Total cash, cash equivalents and current marketable securities
$24,105417
(Dollars in Millions)2023
Carrying AmountUnrecognized
Loss
Estimated Fair ValueCash & Cash EquivalentsCurrent Marketable Securities
Cash$3,3403,3403,340
Non-U.S. Sovereign Securities(1)
522522174348
U.S. Reverse repurchase agreements4,3774,3774,377
Corporate debt securities(1)
338338189149
Money market funds4,8144,8144,814
Time deposits(1)
662662662
Subtotal 14,05314,05313,556497
U.S. Gov't Securities$8,5628,5628,259303
U.S. Gov't Agencies71(1)7070
Other Sovereign Securities5514
Corporate and other debt securities23723743194
Subtotal available for sale(2)
$8,875(1)8,8748,303571
Total cash, cash equivalents and current marketable securities
$21,8591,068
(1)Held to maturity investments are reported at amortized cost and realized gains or losses are reported in earnings.
(2)Available for sale debt securities are reported at fair value with unrealized gains and losses reported net of taxes in other comprehensive income.
Fair value of government securities and obligations and corporate debt securities were estimated using quoted broker prices and significant other observable inputs.
2024 Annual Report
57


The contractual maturities of the available for sale debt securities at December 29, 2024 are as follows:
(Dollars in Millions)Cost BasisFair Value
Due within one year$7,2047,205
Due after one year through five years1111
Due after five years through ten years
Total debt securities$7,2157,216
The Company invests its excess cash in both deposits with major banks throughout the world and other high-quality money market instruments. The Company has a policy of making investments only with commercial institutions that have at least an investment grade credit rating.
3. Inventories
At the end of fiscal years 2024 and 2023, inventories comprised:
(Dollars in Millions)20242023
Raw materials and supplies$2,3372,355
Goods in process2,8151,952
Finished goods7,2926,874
Total inventories$12,44411,181
4. Property, plant and equipment
At the end of fiscal years 2024 and 2023, property, plant and equipment at cost and accumulated depreciation were:
(Dollars in Millions)20242023
Land and land improvements$718795
Buildings and building equipment12,31712,375
Machinery and equipment29,44428,979
Construction in progress6,2895,627
Total property, plant and equipment, gross$48,76847,776
Less accumulated depreciation28,25027,878
Total property, plant and equipment, net$20,51819,898
The Company capitalizes interest expense as part of the cost of construction of facilities and equipment. Interest expense capitalized in fiscal years 2024, 2023 and 2022 was $79 million, $70 million and $49 million, respectively.
Depreciation expense, including the amortization of capitalized interest in fiscal years 2024, 2023 and 2022 was $2.8 billion, $2.6 billion and $2.4 billion, respectively.
Upon retirement or other disposal of property, plant and equipment, the costs and related amounts of accumulated depreciation or amortization are eliminated from the asset and accumulated depreciation accounts, respectively. The difference, if any, between the net asset value and the proceeds are recorded in earnings.
58
 Jhonson&Jhonson.jpg 


5. Intangible assets and goodwill
At the end of fiscal years 2024 and 2023, the gross and net amounts of intangible assets were:
(Dollars in Millions)20242023
Intangible assets with definite lives:  
Patents and trademarks — gross(1)
$44,69540,417
Less accumulated amortization(26,124)(24,808)
Patents and trademarks — net$18,57115,609
Customer relationships and other intangibles — gross$20,31020,322
Less accumulated amortization(13,544)(12,685)
Customer relationships and other intangibles — net(2)
$6,7667,637
Intangible assets with indefinite lives:  
Trademarks(1)
 1,714
Purchased in-process research and development12,2819,215
Total intangible assets with indefinite lives$12,28110,929
Total intangible assets — net$37,61834,175
(1)In September 2024, the Company announced changes to its MedTech brand identity and the $1.7 billion of trademarks associated with the DePuy Synthes business were reclassified from indefinite lived to definite lived and will be amortized over a 25 year period.
(2)The majority is comprised of customer relationships
Goodwill as of December 29, 2024 and December 31, 2023, as allocated by segment of business, was as follows:
(Dollars in Millions)Innovative
Medicine
MedTechTotal
Goodwill at January 1, 2023$10,18425,86336,047
Goodwill, related to acquisitions
Goodwill, related to divestitures
Currency translation/other223288*511
Goodwill at December 31, 202310,40726,15136,558
Goodwill, related to acquisitions6407,5698,209
Goodwill, related to divestitures(56)(56)
Currency translation/other(355)(156)(511)
Goodwill at December 29, 2024$10,69233,50844,200
*    Includes purchase price allocation adjustments for Abiomed
The weighted average amortization period for patents and trademarks is approximately 12 years. The weighted average amortization period for customer relationships and other intangible assets is approximately 18 years. The amortization expense of amortizable assets included in Cost of products sold was $4.5 billion, $4.5 billion and $3.9 billion before tax, for the fiscal years ended December 29, 2024, December 31, 2023 and January 1, 2023, respectively. Intangible asset write-downs are included in Other (income) expense, net.
The estimated amortization expense related to intangible assets for approved products, before tax, for the five succeeding years is approximately:
(Dollars in Millions)
20252026202720282029
$4,0003,4002,8002,2002,200
See Note 18 to the Consolidated Financial Statements for additional details related to acquisitions and divestitures.
2024 Annual Report
59


6. Fair value measurements
The Company uses forward foreign exchange contracts to manage its exposure to the variability of cash flows, primarily related to the foreign exchange rate changes of future intercompany products and third-party purchases of materials denominated in a foreign currency. The Company uses cross currency interest rate swaps to manage currency risk primarily related to borrowings. Both types of derivatives are designated as cash flow hedges.
Additionally, the Company uses interest rate swaps as an instrument to manage interest rate risk related to fixed rate borrowings. These derivatives are designated as fair value hedges. The Company uses cross currency interest rate swaps and forward foreign exchange contracts designated as net investment hedges. Additionally, the Company uses forward foreign exchange contracts to offset its exposure to certain foreign currency assets and liabilities. These forward foreign exchange contracts are not designated as hedges and therefore, changes in the fair values of these derivatives are recognized in earnings, thereby offsetting the current earnings effect of the related foreign currency assets and liabilities.
The Company does not enter into derivative financial instruments for trading or speculative purposes, or that contain credit risk related contingent features. The Company maintains credit support agreements (CSA) with certain derivative counterparties establishing collateral thresholds based on respective credit ratings and netting agreements. As of December 29, 2024 and December 31, 2023, the total amount of cash collateral paid by the Company under the CSA amounted to $2.2 billion and $4.0 billion net respectively, related to net investment and cash flow hedges. On an ongoing basis, the Company monitors counter-party credit ratings. The Company considers credit non-performance risk to be low, because the Company primarily enters into agreements with commercial institutions that have at least an investment grade credit rating. Refer to the table on significant financial assets and liabilities measured at fair value contained in this footnote for receivables and payables with these commercial institutions. As of December 29, 2024, the Company had notional amounts outstanding for forward foreign exchange contracts, cross currency interest rate swaps and interest rate swaps of $45.1 billion, $40.5 billion and $9.0 billion, respectively. As of December 31, 2023, the Company had notional amounts outstanding for forward foreign exchange contracts, cross currency interest rate swaps and interest rate swaps of $42.9 billion, $39.7 billion and $10.0 billion, respectively.
All derivative instruments are recorded on the balance sheet at fair value. Changes in the fair value of derivatives are recorded each period in current earnings or other comprehensive income, depending on whether the derivative is designated as part of a hedge transaction, and if so, the type of hedge transaction. Cash exchanged for derivatives is primarily in cash flows from operating activities.
The designation as a cash flow hedge is made at the entrance date of the derivative contract. At inception, all derivatives are expected to be highly effective. Foreign exchange contracts designated as cash flow hedges are accounted for under the forward method and all gains/losses associated with these contracts will be recognized in the income statement when the hedged item impacts earnings. Changes in the fair value of these derivatives are recorded in accumulated other comprehensive income until the underlying transaction affects earnings, and are then reclassified to earnings in the same account as the hedged transaction.
Gains and losses associated with interest rate swaps and changes in fair value of hedged debt attributable to changes in interest rates are recorded to interest expense in the period in which they occur. Gains and losses on net investment hedges are accounted through the currency translation account within accumulated other comprehensive income. The portion excluded from effectiveness testing is recorded through interest (income) expense using the spot method. On an ongoing basis, the Company assesses whether each derivative continues to be highly effective in offsetting changes of hedged items. If and when a derivative is no longer expected to be highly effective, hedge accounting is discontinued.
The Company designated its Euro denominated notes with due dates ranging from 2024 to 2044 as a net investment hedge of the Company's investments in certain of its international subsidiaries that use the Euro as their functional currency in order to reduce the volatility caused by changes in exchange rates.
As of December 29, 2024, the balance of deferred net loss on derivatives included in accumulated other comprehensive income was $1.7 billion after-tax. For additional information, see the Consolidated Statements of Comprehensive Income and Note 13. The Company expects that substantially all of the amounts related to forward foreign exchange contracts will be reclassified into earnings over the next 12 months as a result of transactions that are expected to occur over that period. The maximum length of time over which the Company is hedging transaction exposure is 18 months, excluding interest rate contracts and net investment hedges. The amount ultimately realized in earnings may differ as foreign exchange rates change. Realized gains and losses are ultimately determined by actual exchange rates at maturity of the derivative.
60
 Jhonson&Jhonson.jpg 


The following table is a summary of the activity related to derivatives and hedges for the fiscal years ended December 29, 2024 and December 31, 2023, net of tax:
December 29, 2024December 31, 2023
(Dollars in Millions)SalesCost of
Products
 Sold
R&D
 Expense
Interest
(Income)
 Expense
Other
(Income)
Expense
SalesCost of
Products
Sold
R&D
Expense
Interest
(Income)
Expense
Other
(Income)
Expense
The effects of fair value, net investment and cash flow hedging:
Gain (Loss) on fair value hedging relationship:
Interest rate swaps contracts:
Hedged items$64168
Derivatives designated as hedging instruments(64)(168)
Gain (Loss) on net investment hedging relationship:
Cross currency interest rate swaps contracts:
Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing$148130
Amount of gain or (loss) recognized in AOCI148130
Gain (Loss) on cash flow hedging relationship:
Forward foreign exchange contracts:
Amount of gain or (loss) reclassified from AOCI into income24263367186(37)8
Amount of gain or (loss) recognized in AOCI(7)(156)802110447(18)9
Cross currency interest rate swaps contracts:
Amount of gain or (loss) reclassified from AOCI into income247275
Amount of gain or (loss) recognized in AOCI$(597)(156)



2024 Annual Report
61


As of December 29, 2024 and December 31, 2023, the following amounts were recorded on the consolidated balance sheet related to cumulative basis adjustment for fair value hedges:
Line item in the Consolidated Balance Sheet
in which the hedged item is included
Carrying Amount of the Hedged LiabilityCumulative Amount of Fair Value Hedging
Adjustment Included in the Carrying
Amount of the Hedged Liability
(Dollars in Millions)December 29, 2024December 31, 2023December 29, 2024December 31, 2023
Long-term Debt$7,935$8,862$(1,132)$(1,216)
The following table is the effect of derivatives not designated as hedging instrument for the fiscal years ended
December 29, 2024 and December 31, 2023:
(Dollars in Millions)Location of Gain /(Loss)
Recognized in Income on
Derivative
Gain/(Loss)
Recognized In
Income on Derivative
Derivatives Not Designated as Hedging InstrumentsDecember 29, 2024December 31, 2023
Foreign Exchange ContractsOther (income) expense$8(60)
The following table is the effect of net investment hedges for the fiscal years ended December 29, 2024 and
December 31, 2023:
Gain/(Loss)
Recognized In
Accumulated OCI
Location of Gain or
(Loss) Reclassified
from Accumulated Other Comprehensive Income Into Income
Gain/(Loss)
Reclassified from
Accumulated OCI
Into Income
(Dollars in Millions)December 29, 2024December 31, 2023December 29, 2024December 31, 2023
Debt$282(131)Interest (income) expense
Cross Currency interest rate swaps$955642Interest (income) expense
The Company holds equity investments with readily determinable fair values and equity investments without readily determinable fair values. The Company measures equity investments that do not have readily determinable fair values at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer.
The following table is a summary of the activity related to equity investments for the fiscal years ended December 29, 2024 and December 31, 2023:
December 31, 2023December 29, 2024
(Dollars in Millions)Carrying Value
Changes in Fair
Value Reflected in
Net Income(1)
Sales/
Purchases/
Other(2)
Carrying ValueNon-Current
Other Assets
Equity Investments with readily determinable value *$4,473(17)(4,005)451451
Equity Investments without readily determinable value$696(197)274773773
62
 Jhonson&Jhonson.jpg 


January 1, 2023December 31, 2023
(Dollars in Millions)Carrying Value
Changes in Fair
Value Reflected in
Net Income(1)
Sales/
Purchases/
Other(2)
Carrying ValueNon-Current
Other Assets
Equity Investments with readily determinable value *$576(368)4,2654,4734,473
Equity Investments without readily determinable value$613182696696
(1)Recorded in Other Income/Expense
(2)Other includes impact of currency
*    The December 31, 2023 balance includes the 9.5% remaining stake in Kenvue. A debt-for-equity exchange was completed in the fiscal second quarter of 2024.
On May 15, 2024, the Company issued $3.6 billion aggregate principal amount of commercial paper and received $3.6 billion of net cash proceeds to be used for general corporate purposes. On May 17, 2024, the Company completed a Debt-for-Equity Exchange of its remaining 182,329,550 shares of Kenvue Common Stock for the outstanding Commercial Paper. Upon completion of the Debt-for-Equity Exchange, the Commercial Paper was satisfied and discharged, and the Company no longer owns any shares of Kenvue Common Stock. This exchange resulted in a loss of approximately $0.4 billion recorded in Other (income) expense.
For the fiscal years ended December 29, 2024 and December 31, 2023 for equity investments without readily determinable market values, $171 million and $1 million, respectively, of the changes in fair value reflected in net income were the result of impairments. There were impacts of $26 million and $27 million, respectively, of changes in the fair value reflected in net income due to changes in observable prices and gains on the disposal of investments.
Fair value is the exit price that would be received to sell an asset or paid to transfer a liability. Fair value is a market-based measurement determined using assumptions that market participants would use in pricing an asset or liability. In accordance with ASC 820, a three-level hierarchy to prioritize the inputs used in measuring fair value. The levels within the hierarchy are described below with Level 1 having the highest priority and Level 3 having the lowest.
The fair value of a derivative financial instrument (i.e., forward foreign exchange contracts, interest rate contracts) is the aggregation by currency of all future cash flows discounted to its present value at the prevailing market interest rates and subsequently converted to the U.S. Dollar at the current spot foreign exchange rate. The Company does not believe that fair values of these derivative instruments materially differ from the amounts that could be realized upon settlement or maturity, or that the changes in fair value will have a material effect on the Company’s results of operations, cash flows or financial position. The Company also holds equity investments which are classified as Level 1 and debt securities which are classified as Level 2. The Company holds acquisition related contingent liabilities based upon certain regulatory and commercial events, which are classified as Level 3, whose values are determined using discounted cash flow methodologies or similar techniques for which the determination of fair value requires significant judgment or estimations.
The following three levels of inputs are used to measure fair value:
Level 1 — Quoted prices in active markets for identical assets and liabilities.
Level 2 — Significant other observable inputs.
Level 3 — Significant unobservable inputs.
2024 Annual Report
63


The Company’s significant financial assets and liabilities measured at fair value as of the fiscal year ended December 29, 2024 and December 31, 2023 were as follows:
20242023
(Dollars in Millions)Level 1Level 2Level 3Total
Total(1)
Derivatives designated as hedging instruments:     
Assets:     
Forward foreign exchange contracts $660660539
Interest rate contracts(2)
1,4841,484988
Total$2,1442,1441,527
Liabilities:     
Forward foreign exchange contracts794794624
Interest rate contracts(2)
3,7533,7535,338
Total$4,5474,5475,962
Derivatives not designated as hedging instruments:     
Assets:     
Forward foreign exchange contracts $505064
Liabilities:     
Forward foreign exchange contracts171775
Available For Sale Other Investments:
Equity investments(3)
4514514,473
Debt securities(4)
7,2167,2168,874
Other Liabilities
Contingent Consideration(5)
$1,2171,2171,092

Gross to Net Derivative Reconciliation20242023
(Dollars in Millions)
Total Gross Assets$2,1941,591
Credit Support Agreements (CSA)(2,172)(1,575)
Total Net Asset2216
Total Gross Liabilities4,5646,037
Credit Support Agreements (CSA)(4,412)(5,604)
Total Net Liabilities$152433
64
 Jhonson&Jhonson.jpg 


Summarized information about changes in liabilities for contingent consideration is as follows:
202420232022
(Dollars in Millions)
Beginning Balance$1,0921,120533
Changes in estimated fair value 8829(194)
Additions(6)
112792
Payments/Other(75)(57)(11)
Ending Balance(5)
$1,2171,0921,120
(1)2023 assets and liabilities are all classified as Level 2 with the exception of equity investments of $4,473 million, which are classified as Level 1 and contingent consideration of $1,092 million, classified as Level 3.
(2)Includes cross currency interest rate swaps and interest rate swaps.
(3)Classified as non-current other assets.
(4)Classified as cash equivalents and current marketable securities.
(5)Includes $1,217 million, $1,092 million and $1,116 million, classified as non-current other liabilities as of December 29, 2024,
December 31, 2023 and January 1, 2023, respectively. Includes $4 million classified as current liabilities as of January 1, 2023.
(6)In fiscal year 2024, the Company recorded $105 million of contingent consideration related to Proteologix. In fiscal year 2022, the Company recorded $704 million of contingent consideration related to Abiomed.
See Notes 2 and 7 for financial assets and liabilities held at carrying amount on the Consolidated Balance Sheet.
2024 Annual Report
65


7. Borrowings
The components of long-term debt are as follows:
(Dollars in Millions)2024 Effective
Rate
%
 2023 Effective
Rate
%
0.650% Notes due 2024
(750MM Euro 1.1090)(3)
$ %$831
(3)
0.68 %
5.50% Notes due 2024
(500MM GBP 1.2756)(3)
  637
(3)
6.75 
2.625% Notes due 2025
7502.63 7502.63 
0.55% Notes due 2025
9990.57 9500.57 
2.46% Notes due 2026
1,9992.47 1,9972.47 
2.95% Notes due 2027
9272.96 9002.96 
0.95% Notes due 2027
1,4580.96 1,4190.96 
1.150% Notes due 2028
(750MM Euro 1.0401)
(2)/(750MM Euro 1.1090)(3)
777
(2)
1.21 828
(3)
1.21 
2.90% Notes due 2028
1,4982.91 1,4972.91 
6.95% Notes due 2029
298 7.14  298 7.14 
4.80% Debentures due 2029
1,1464.83  
1.30% Notes due 2030
1,6461.30 1,6301.30 
4.90% Debentures due 2031
1,1454.92  
3.20% Debenture due 2032
(700M EUR 1.0401)(2)
725
(2)
3.21  
4.95% Debentures due 2033
499 4.95  499 4.95 
4.375% Notes due 2033
8544.24 8544.24 
4.95% Debentures due 2034
8464.96  
1.650% Notes due 2035
(1.5B Euro 1.0401)
(2)/(1.5B Euro 1.1090)(3)
1,550
(2)
1.68 1,652
(3)
1.68 
3.35% Debentures due 2036
(800MM EUR 1.0401)(2)
827
(2)
3.37  
3.587% Notes due 2036
8693.59 8643.59 
5.95% Notes due 2037
994 5.99  994 5.99 
3.625% Notes due 2037
1,3583.64 1,3573.64 
5.85% Debentures due 2038
697 5.85  697 5.85 
3.40% Notes due 2038
9933.42 9933.42 
4.50% Debentures due 2040
541 4.63  541 4.63 
2.10% Notes due 2040
8452.14 8492.14 
4.85% Notes due 2041
2974.89 2974.89 
4.50% Notes due 2043
4964.52 4964.52 
3.55% Debentures due 2044
(1B EUR 1.0401)(2)
1,030
(2)
3.58  
3.73% Notes due 2046
1,9783.74 1,9773.74 
3.75% Notes due 2047
8223.76 8323.76 
3.500% Notes due 2048
7443.52 7433.52 
2.250% Notes due 2050
8082.29 8262.29 
66
 Jhonson&Jhonson.jpg 


5.25% Debentures due 2054
8435.26  
2.450% Notes due 2060
1,0582.49 1,0732.49 
Other83   69  
Subtotal32,400
(4)
3.36 %
(1)
27,350
(4)
2.98 %
(1)
Less current portion1,749   1,469  
Total long-term debt$30,651   $25,881  
(1)Weighted average effective rate.
(2)Translation rate at December 29, 2024.
(3)Translation rate at December 31, 2023.
(4)The excess of the carrying value over the fair value of debt was $2.0 billion and $1.0 billion at the end of fiscal year 2024 and fiscal year 2023, respectively.
Fair value of the long-term debt was estimated using market prices, which were corroborated by quoted broker prices and significant other observable inputs.
The Company has access to substantial sources of funds at numerous banks worldwide. In June 2024, the Company secured a new 364-day Credit Facility of $10 billion, which expires on June 25, 2025. Interest charged on borrowings under the credit line agreement is based on either the Term SOFR Reference Rate or other applicable market rates as allowed under the terms of the agreement, plus applicable margins. Commitment fees under the agreements are not material.
Throughout fiscal years 2024 and 2023, the Company continued to have access to liquidity through the commercial paper market. Short-term borrowings and the current portion of long-term debt amounted to approximately $6.0 billion and $3.5 billion at the end of fiscal years 2024 and 2023, respectively. The current portion of the long-term debt was $1.7 billion and $1.5 billion in 2024 and 2023, respectively, and the remainder is commercial paper and local borrowing by international subsidiaries.
The current debt balance as of December 29, 2024 includes $4.1 billion of commercial paper which has a weighted average interest rate of 4.46% and a weighted average maturity of approximately two months. The current debt balance as of December 31, 2023 includes $2.0 billion of commercial paper which has a weighted average interest rate of 5.37% and a weighted average maturity of approximately two months.
Aggregate maturities of long-term debt obligations commencing in 2025 are:
(Dollars in Millions)
20252026202720282029After 2029
$1,7491,9992,3852,2751,44422,548
8. Income taxes
The provision for taxes on income on continuing operations consists of:
(Dollars in Millions)202420232022
Currently payable:
U.S. taxes$2,2002,7052,274
International taxes2,6043,0902,295
Total currently payable4,8045,7954,569
Deferred:
U.S. taxes(2,539)(3,440)(1,990)
International taxes356(619)410
Total deferred(2,183)(4,059)(1,580)
Provision for taxes on income$2,6211,7362,989
2024 Annual Report
67


A comparison of income tax expense at the U.S. statutory rate of 21% in fiscal years 2024, 2023 and 2022, to the Company’s effective tax rate is as follows:
(Dollars in Millions)202420232022
U.S. $(458)(2,033)4,606
International17,14517,09514,753
Earnings before taxes on income:$16,68715,06219,359
Tax rates:
U.S. statutory rate21.0 %21.0 21.0 
International operations(1)
(5.2)(8.1)(5.0)
U.S. tax settlements1.0 (3.0) 
U.S. taxes on international income(2)
(2.6)(0.3)(1.1)
U.S. state taxes1.5 1.0 0.3 
Tax benefits on share-based compensation(0.6)(0.8)(1.4)
All other0.6 1.7 1.6 
Effective Rate15.7 %11.5 15.4 
(1)International operations reflect the impacts of operations in jurisdictions with statutory tax rates different than the U.S., particularly Ireland, Switzerland, and Belgium, which is a favorable impact on the effective tax rate as compared with the U.S. statutory rate.
(2)Includes the net impact of the GILTI tax, the Foreign-Derived Intangible Income deduction and other foreign income that is taxable under the U.S. tax code as well as related foreign tax credits.
The fiscal year 2024 effective tax rate increased 4.2% as compared to the fiscal year 2023 effective tax rate. The primary drivers of this change are discussed below.
In fiscal year 2024, The Company had more income in higher tax jurisdictions compared to fiscal year 2023, primarily in the U.S. where the Company recorded a charge of approximately $5.1 billion in the fiscal year of 2024 versus approximately $7.0 billion in the fiscal year of 2023, both for the talc matters in the United States. Both charges were recorded at an effective U.S. tax rate of approximately 21% (for further information see Note 19 to the Consolidated Financial Statements).
Additionally in the fiscal year 2024, the effective tax rate was unfavorably impacted by legislative changes that went into effect for Pillar Two in some of the Company's foreign jurisdictions which are reflected in International operations on the Company’s effective tax rate reconciliation. Also in fiscal year 2024, the Company generated incremental U.S. foreign tax credits related to income sourced and taxed outside the United States and is reflected in U.S. taxes on international income on the Company’s effective tax rate reconciliation. In 2024, the Company finalized multi-year transfer pricing agreements with the U.S. Internal Revenue Service (IRS) and certain other foreign jurisdictions. The U.S portion of the agreements were partially offset by the related tax adjustments in the foreign jurisdictions which are reflected in U.S tax settlements and International operations, respectively, on the Company’s effective rate reconciliation.
The fiscal year 2023 effective tax rate decreased 3.9% as compared to the fiscal year 2022 effective tax rate as the Company recorded certain non-recurring favorable tax items in fiscal year 2023 when compared to the prior fiscal year.
In the fiscal fourth quarter of 2023, the Company settled the U.S. Internal Revenue Service audit for tax years 2013 through 2016 which resulted in a favorable impact to the rate of 3.0%. This settlement was partially offset by the Company recording a $0.4 billion decrease in expected U.S. foreign tax credits, an unfavorable effective rate impact of 2.6%, which has been reflected as a current tax expense in U.S. taxes on international income on the Company’s effective tax rate reconciliation.
In the fiscal year 2023, the Company had certain non-recurring impacts as a result of legislative tax elections made in certain international subsidiaries which resulted in a change in the Company’s tax basis in certain assets resulting in deferred tax re-measurements. The net impact of these non-recurring items is a net benefit of 3.4% to the Company’s annual effective tax rate, comprised of the following items:
approximately $0.3 billion of tax benefit on local deferred tax assets to record the remeasurement of the increased tax basis, this benefit has been reflected as International operations on the Company’s effective tax rate reconciliation. This benefit was offset by approximately $0.1 billion of U.S. deferred tax expense on the GILTI deferred tax liability resulting from the remeasurement of these deferred tax assets. This has been reflected in the “U.S. tax on international income” on the Company’s effective tax rate reconciliation.
68
 Jhonson&Jhonson.jpg 


approximately $0.3 billion of U.S. deferred tax benefit on the GILTI deferred tax related to an election made by an international subsidiary resulting in a decrease in local deferred tax assets. This has been reflected in the U.S. taxes on international income on the Company’s effective tax rate reconciliation.
The Company also had lower income in higher tax jurisdictions vs. fiscal year 2022, primarily in the U.S. where the Company recorded an approximately $7.0 billion charge related to talc matters in the United States at an effective tax rate of 21.1% (for further information see Note 19 to the Consolidated Financial Statements).
Temporary differences and carryforwards at the end of fiscal years 2024 and 2023 were as follows:
2024 Deferred Tax2023 Deferred Tax
(Dollars in Millions)AssetLiabilityAssetLiability
Employee related obligations$372586
Stock based compensation717686
Depreciation of property, plant and equipment(833)(902)
Goodwill and intangibles(3,261)(1,252)
R&D capitalized for tax4,3983,595
Reserves & liabilities4,4443,816
Inventory related371359
Operating loss carryforwards2,2982,145
Undistributed foreign earnings1,931(1,492)1,801(1,695)
Global intangible low-taxed income(1,589)(2,731)
Miscellaneous international1,212831
Miscellaneous U.S. 1,083(4)
Total deferred income taxes16,826(7,175)13,819(6,584)
Valuation allowances(1,638)(1,149)
Total deferred income taxes net of valuation allowances15,188(7,175)12,670(6,584)
The Company has wholly-owned international subsidiaries that have cumulative net losses. The Company believes that it is more likely than not that these subsidiaries will generate future taxable income sufficient to partially utilize these deferred tax assets. In certain jurisdictions, valuation allowances have been recorded against deferred tax assets for loss carryforwards that are not more likely than not to be realized. The net operating loss carryforwards for these international subsidiaries that do not have an indefinite carryforward period will begin to expire in 2025 for various amounts.
The following table summarizes the activity related to valuation allowances for continuing operations:
(Dollars in Millions)20242023
Beginning of year$1,149775
Provision451355
Utilization(116)
Foreign currency translation(46)25
Net acquisitions / (dispositions/liquidations)84110
End of year$1,638$1,149
2024 Annual Report
69


The following table summarizes the activity related to unrecognized tax benefits for continuing operations:
(Dollars in Millions)202420232022
Beginning of year$2,4853,7163,210
Increases related to current year tax positions176239523
Increases related to prior period tax positions129244143
Decreases related to prior period tax positions(147)(781)(148)
Settlements(583)(880)(1)
Lapse of statute of limitations(40)(53)(11)
End of year$2,0202,4853,716
As of December 29, 2024 the Company had approximately $2.0 billion of unrecognized tax benefits. The Company conducts business and files tax returns in numerous countries and currently has tax audits in progress with a number of tax authorities. With respect to the United States, the Internal Revenue Service (IRS) has completed its audit for the tax years through 2016 and has commenced the audit for tax years 2017 through 2020. The Company recently finalized multi-year transfer pricing agreements with the IRS and certain other foreign jurisdictions in the fiscal fourth quarter of 2024.
In other major jurisdictions where the Company conducts business, the years that remain open to tax audits go back to the year 2013. The Company believes it is possible that some tax audits may be completed over the next twelve months by taxing authorities in some jurisdictions. The Company anticipates a change in uncertain tax positions of approximately $200 million in certain jurisdictions in the next twelve months due to the expected expiration of the statute of limitations. However, generally the Company is not able to provide a reasonably reliable estimate of the timing of any other future tax payments, audit settlements, or changes in uncertain tax positions.
The Company classifies liabilities for unrecognized tax benefits and related interest and penalties as long-term liabilities. Interest expense and penalties related to unrecognized tax benefits are classified as income tax expense. The Company recognized after tax interest expense of $217 million, $99 million and $136 million in fiscal years 2024, 2023 and 2022, respectively. The total amount of accrued interest was $274 million and $264 million in fiscal years 2024 and 2023, respectively.
9. Employee related obligations
At the end of fiscal 2024 and fiscal 2023, employee related obligations recorded on the Consolidated Balance Sheets were:
(Dollars in Millions)20242023
Pension benefits$2,9683,129
Postretirement benefits1,9201,963
Postemployment benefits2,9102,527
Deferred compensation4968
Total employee obligations7,8477,687
Less current benefits payable592538
Employee related obligations — non-current$7,2557,149
Prepaid employee related obligations of $6,046 million and $4,992 million for 2024 and 2023, respectively, are included in Other assets on the Consolidated Balance Sheets.
70
 Jhonson&Jhonson.jpg 


10. Pensions and other benefit plans
The Company sponsors various retirement and pension plans, including defined benefit, defined contribution and termination indemnity plans, which cover most employees worldwide. The Company also provides post-retirement benefits, primarily healthcare, to all eligible U.S. retired employees and their dependents.
Many international employees are covered by government-sponsored programs and the cost to the Company is not significant.
In the U.S., non-union pension benefits for employees hired before January 1, 2015 are primarily based on the employee’s compensation during the last five years before retirement and the number of years of service (the Final Average Pay formula). U.S. pension benefits for employees hired after 2014, are calculated using a different formula based on employee compensation over total years of service (the Retirement Value formula).
In January 2021, the Company announced that, effective on January 1, 2026, all eligible U.S. non-union employees, regardless of hire date, will earn benefits under the Retirement Value formula. This amendment does not affect the benefits accrued under the Final Average Pay formula for service before January 1, 2026.
International subsidiaries have plans under which funds are deposited with trustees, annuities are purchased under group contracts, or reserves are provided.
The Company does not fund retiree healthcare benefits in advance and has the right to modify these plans in the future.
In 2024 and 2023 the Company used December 31, 2024 and December 31, 2023, respectively, as the measurement date for all U.S. and international retirement and other benefit plans.
Net periodic benefit costs for the Company’s defined benefit retirement plans and other benefit plans for 2024, 2023 and 2022 include the following components:
Retirement PlansOther Benefit Plans
(Dollars in Millions)202420232022202420232022
Service cost$9488931,319277264320
Interest cost1,4021,437908209214104
Expected return on plan assets(2,560)(2,716)(2,756)(7)(7)(8)
Amortization of prior service cost (184)(184)(184)(2)(2)(5)
Recognized actuarial losses (gains)174(199)6505323122
Curtailments and settlements(2)931(5)
Net periodic benefit cost (credit)$(222)(676)(62)530487533
The service cost component of net periodic benefit cost is presented in the same line items on the Consolidated Statement of Earnings where other employee compensation costs are reported, including Cost of products sold, Research and development expense, Selling, marketing and administrative expenses, and Net earnings from discontinued operations, net of taxes if related to the separation of Kenvue. All other components of net periodic benefit cost are presented as part of Other (income) expense, net on the Consolidated Statement of Earnings, with the exception of certain amounts for curtailments and settlements, which are reported in Net earnings from discontinued operations, net of taxes if related to the separation of Kenvue (as noted above).
Unrecognized gains and losses for the U.S. pension plans are amortized over the average remaining future service for each plan. For plans with no active employees, they are amortized over the average life expectancy. The amortization of gains and losses for the other U.S. benefit plans is determined by using a 10% corridor of the greater of the market value of assets or the accumulated postretirement benefit obligation. Total unamortized gains and losses in excess of the corridor are amortized over the average remaining future service.
Prior service costs/benefits for the U.S. pension plans are amortized over the average remaining future service of plan participants at the time of the plan amendment. Prior service cost/benefit for the other U.S. benefit plans is amortized over the average remaining service to full eligibility age of plan participants at the time of the plan amendment.
2024 Annual Report
71


The following table represents the weighted-average actuarial assumptions:
Retirement PlansOther Benefit Plans
Worldwide Benefit Plans202420232022202420232022
Net Periodic Benefit Cost
Service cost discount rate4.39 %4.85 2.46 5.09 5.40 2.59 
Interest cost discount rate4.95 %5.25 2.80 5.12 5.43 2.64 
Rate of increase in compensation levels3.70 %3.71 4.02 4.22 4.22 4.21 
Expected long-term rate of return on plan assets7.25 %7.21 7.25 
Benefit Obligation
Discount rate4.95 %4.58 5.01 5.54 5.11 5.42 
Rate of increase in compensation levels3.70 %3.69 4.00 4.22 4.22 4.21 
The Company’s discount rates are determined by considering current yield curves representing high quality, long-term fixed income instruments. The resulting discount rates are consistent with the duration of plan liabilities. The Company's methodology in determining service and interest cost uses duration specific spot rates along that yield curve to the plans' liability cash flows.
The expected rates of return on plan asset assumptions represent the Company's assessment of long-term returns on diversified investment portfolios globally. The assessment is determined using projections from external financial sources, long-term historical averages, actual returns by asset class and the various asset class allocations by market.
The following table displays the assumed healthcare cost trend rates, for all individuals:
Healthcare Plans20242023
Healthcare cost trend rate assumed for next year9.33 %13.90 %
Rate to which the cost trend rate is assumed to decline (ultimate trend)4.02 %4.00 %
Year the rate reaches the ultimate trend rate2048 2048 
The following table sets forth information related to the benefit obligation and the fair value of plan assets at fiscal year-end 2024 and 2023 for the Company’s defined benefit retirement plans and other post-retirement plans:
Retirement PlansOther Benefit Plans
(Dollars in Millions)2024202320242023
Change in Benefit Obligation
Projected benefit obligation — beginning of year$31,74429,3904,1084,192
Service cost948893277264
Interest cost1,4021,437209214
Plan participant contributions7573
Amendments(6)
Actuarial (gains) losses(1)
(1,245)2,068398469
Divestitures & acquisitions(2)
(352)1
Curtailments, settlements & restructuring(121)(238)(332)
Benefits paid from plan(3)
(1,801)(2,122)(556)(702)
Effect of exchange rates(685)601(11)2
Projected benefit obligation — end of year$30,31731,7444,4254,108
72
 Jhonson&Jhonson.jpg 


Change in Plan Assets
Plan assets at fair value — beginning of year$33,60731,4968678
Actual return (loss) on plan assets2,1133,9511516
Company contributions229268548694
Plan participant contributions7573
Settlements(114)(176)
Divestitures & acquisitions(2)
(509)
Benefits paid from plan assets(3)
(1,801)(2,122)(556)(702)
Effect of exchange rates(714)626
Plan assets at fair value — end of year$33,39533,6079386
Funded status — end of year$3,0781,863(4,332)(4,022)
Amounts Recognized in the Company’s Balance Sheet consist of the following:
Non-current assets$6,0464,992
Current liabilities(136)(119)(453)(416)
Non-current liabilities(2,832)(3,010)(3,879)(3,606)
Total recognized in the consolidated balance sheet — end of year$3,0781,863(4,332)(4,022)
Amounts Recognized in Accumulated Other Comprehensive Income consist of the following:
Net actuarial loss$3,9034,962691354
Prior service cost (credit)(1,051)(1,236)(4)(6)
Unrecognized net transition obligation
Total before tax effects$2,8523,726687348
Accumulated Benefit Obligations — end of year$28,88330,139
(1)The actuarial (gains)/losses for retirement plans in 2024 and 2023 were primarily driven by changes in the discount rates.
(2)Driven by the Kenvue separation.
(3)The fiscal years 2024 and 2023 includes approximately $400 million and $800 million, respectively, transferred to a group annuity contract issued by a third-party insurer for the U.S. Salaried Pension Plan.
Retirement PlansOther Benefit Plans
(Dollars in Millions)2024202320242023
Amounts Recognized in Net Periodic Benefit Cost and Other Comprehensive Income
Net periodic benefit cost (credit)$(222)(676)530487
Net actuarial (gain) loss(807)711389136
Amortization of net actuarial loss(172)199(53)(22)
Prior service cost (credit)(2)
Amortization of prior service (cost) credit18418522
Effect of exchange rates(79)1031
Total loss/(income) recognized in other comprehensive income, before tax$(874)1,195339116
Total recognized in net periodic benefit cost and other comprehensive income$(1,096)519869603
2024 Annual Report
73


The Company plans to continue to fund its U.S. Qualified Plans to comply with the Pension Protection Act of 2006. International Plans are funded in accordance with local regulations. Additional discretionary contributions are made when deemed appropriate to meet the long-term obligations of the plans. For certain plans, funding is not a common practice, as funding provides no economic benefit. Consequently, the Company has several pension plans that are not funded.
In 2024, the Company contributed $122 million and $107 million to its U.S. and international pension plans, respectively.
The following table displays the funded status of the Company's U.S. Qualified & Non-Qualified pension plans and international funded and unfunded pension plans at December 31, 2024 and December 31, 2023, respectively:
U.S. PlansInternational Plans
Qualified PlansNon-Qualified PlansFunded PlansUnfunded Plans
(Dollars in Millions)20242023202420232024202320242023
Plan Assets$22,25022,29811,14511,309
Projected Benefit Obligation18,14619,1521,9902,03710,06910,431112124
Accumulated Benefit Obligation17,72618,5571,9491,9829,1159,49893102
Over (Under) Funded Status
Projected Benefit Obligation$4,1043,146(1,990)(2,037)1,076878(112)(124)
Accumulated Benefit Obligation4,5243,741(1,949)(1,982)2,0301,811(93)(102)
Plans with accumulated benefit obligations in excess of plan assets have an accumulated benefit obligation, projected benefit obligation and plan assets of $5.8 billion, $6.1 billion and $3.2 billion, respectively, at the end of 2024, and $5.8 billion, $6.1 billion and $3.1 billion, respectively, at the end of 2023.
The following table displays the projected future benefit payments from the Company’s retirement and other benefit plans:
(Dollars in Millions)202520262027202820292030-2034
Projected future benefit payments
Retirement plans$1,4801,5031,6041,7021,79710,401
Other benefit plans $4644784324454622,537
The following table displays the projected future minimum contributions to the unfunded retirement plans. These amounts do not include any discretionary contributions that the Company may elect to make in the future.
(Dollars in Millions)202520262027202820292030-2034
Projected future contributions$133135140145150815
Each pension plan is overseen by a local committee or board that is responsible for the overall administration and investment of the pension plans. In determining investment policies, strategies and goals, each committee or board considers factors including, local pension rules and regulations; local tax regulations; availability of investment vehicles (separate accounts, commingled accounts, insurance funds, etc.); funded status of the plans; ratio of actives to retirees; duration of liabilities; and other relevant factors including: diversification, liquidity of local markets and liquidity of base currency. A majority of the Company’s pension funds are open to new entrants and are expected to be on-going plans. Permitted investments are primarily liquid and/or listed, with little reliance on illiquid and non-traditional investments such as hedge funds.
74
 Jhonson&Jhonson.jpg 


The Company’s retirement plan asset allocation at the end of 2024 and 2023 and target allocations for 2025 are as follows:
Percent of
Plan Assets
Target
Allocation
Worldwide Retirement Plans202420232025
Equity securities55 %58 %54 %
Debt securities45 42 46 
Total plan assets100 %100 %100 %
Determination of fair value of plan assets
The Plan has an established and well-documented process for determining fair values. Fair value is based upon quoted market prices, where available. If listed prices or quotes are not available, fair value is based upon models that primarily use, as inputs, market-based or independently sourced market parameters, including yield curves, interest rates, volatilities, equity or debt prices, foreign exchange rates and credit curves.
While the Plan believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different estimate of fair value at the reporting date.
Valuation hierarchy
The authoritative literature establishes a three-level hierarchy to prioritize the inputs used in measuring fair value. The levels within the hierarchy are described in the table below with Level 1 having the highest priority and Level 3 having the lowest.
The Net Asset Value (NAV) is based on the value of the underlying assets owned by the fund, minus its liabilities, and then divided by the number of shares outstanding.
A financial instrument’s categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.
Following is a description of the valuation methodologies used for the investments measured at fair value.
Short-term investment funds — Cash and quoted short-term instruments are valued at the closing price or the amount held on deposit by the custodian bank. Other investments are through investment vehicles valued using the NAV provided by the administrator of the fund. The NAV is a quoted price in a market that is not active and classified as Level 2.
Government and agency securities — A limited number of these investments are valued at the closing price reported on the major market on which the individual securities are traded. Where quoted prices are available in an active market, the investments are classified within Level 1 of the valuation hierarchy. If quoted market prices are not available for the specific security, then fair values are estimated by using pricing models, quoted prices of securities with similar characteristics or discounted cash flows. When quoted market prices for a security are not available in an active market, they are classified as Level 2.
Debt instruments — A limited number of these investments are valued at the closing price reported on the major market on which the individual securities are traded. Where quoted prices are available in an active market, the investments are classified as Level 1. If quoted market prices are not available for the specific security, then fair values are estimated by using pricing models, quoted prices of securities with similar characteristics or discounted cash flows and are classified as Level 2. Level 3 debt instruments are priced based on unobservable inputs.
Equity securities — Equity securities are valued at the closing price reported on the major market on which the individual securities are traded. Substantially all equity securities are classified within Level 1 of the valuation hierarchy.
Commingled funds — These investment vehicles are valued using the NAV provided by the fund administrator. Assets in the Level 2 category have a quoted market price.
Other assets — Other assets are represented primarily by limited partnerships. These investment vehicles are valued using the NAV provided by the fund administrator. Other assets that are exchange listed and actively traded are classified as Level 1, while inactively traded assets are classified as Level 2.
2024 Annual Report
75


The following table sets forth the Retirement Plans' investments measured at fair value as of December 31, 2024 and December 31, 2023:
Quoted Prices
in Active
Markets for
Identical Assets
Significant
Other
Observable
Inputs
Significant
Unobservable
Inputs(1)
Investments
Measured at Net
Asset Value
(Level 1)(Level 2)(Level 3)Total Assets
(Dollars in Millions)2024202320242023202420232024202320242023
Short-term investment funds$ 12511829511841
Government and agency securities7,8855,9857,8855,985
Debt instruments2,3213,8992,3213,899
Equity securities7,1447,7647,1447,764
Commingled funds5,0044,96737436,1906,67211,23111,682
Other assets8849128924,0873,2954,3033,436
Investments at fair value$7,144 7,77615,80915,72916513510,2779,96733,39533,607
(1)The activity for the Level 3 assets is not significant for all years presented.
The Company's Other Benefit Plans are unfunded except for U.S. commingled funds (Level 2) of $93 million and $86 million at December 31, 2024 and December 31, 2023, respectively.
The fair value of Johnson & Johnson Common Stock directly held in plan assets was $13 million at December 31, 2024 and $14 million at December 31, 2023.
11. Savings plan
The Company has voluntary 401(k) savings plans designed to enhance the existing retirement programs covering eligible employees. The Company matches a percentage of each employee’s contributions consistent with the provisions of the plan for which the employee is eligible. Total Company matching contributions to the plans were $282 million, $263 million and $257 million in fiscal years 2024, 2023 and 2022, respectively.
76
 Jhonson&Jhonson.jpg 


12. Capital and treasury stock
Changes in treasury stock were:
Treasury Stock
(Amounts in Millions Except Treasury Stock Shares in Thousands)SharesAmount
Balance at January 2, 2022490,878$39,099
Employee compensation and stock option plans(20,007)(3,440)
Repurchase of common stock35,3756,035
Balance at January 1, 2023506,24641,694
Employee compensation and stock option plans(15,521)(2,529)
Repurchase of common stock31,0855,079
Kenvue share exchange (Note 21)190,955 31,418
Balance at December 31, 2023712,76575,662
Employee compensation and stock option plans(15,027)(2,389)
Repurchase of common stock15,1832,407
Balance at December 29, 2024712,921$75,680
Aggregate shares of common stock issued were approximately 3,119,843,000 shares at the end of fiscal years 2024, 2023 and 2022.
Cash dividends paid were $4.91 per share in fiscal year 2024, compared with dividends of $4.70 per share in fiscal year 2023, and $4.45 per share in fiscal year 2022.
On January 2, 2025, the Board of Directors declared a regular cash dividend of $1.24 per share, payable on March 4, 2025 to shareholders of record as of February 18, 2025.
On September 14, 2022, the Company announced that its Board of Directors approved a share repurchase program, authorizing the Company to purchase up to $5.0 billion of the Company's shares of common stock. The repurchase program was completed during the fiscal first quarter of 2023.
13. Accumulated other comprehensive income (loss)
Components of other comprehensive income (loss) consist of the following:
(Dollars in Millions)Foreign
Currency
Translation
Gain/
(Loss) On
Securities
Employee
Benefit Plans
Gain/
(Loss) On
Derivatives
& Hedges
Total
Accumulated
Other
Comprehensive
Income (Loss)
January 2, 2022$(10,017)(3)(2,702)(336)(13,058)
Net 2022 changes(1,796)(24)1,80510691
January 1, 2023(11,813)(27)(897)(230)(12,967)
Net 2023 changes(3,221)26(1,399)(147)(4,741)
Kenvue Separation/IPO4,885296*5,181
December 31, 2023(10,149)(1)(2,000)(377)(12,527)
Net 2024 changes1,7082449(1,373)786
December 29, 2024$(8,441)1(1,551)(1,750)(11,741)
2024 Annual Report
77


Amounts in accumulated other comprehensive income are presented net of the related tax impact. Foreign currency translation is not adjusted for income taxes where it relates to permanent investments in international subsidiaries. For additional details on comprehensive income see the Consolidated Statements of Comprehensive Income.
Details on reclassifications out of Accumulated Other Comprehensive Income:
Gain/(Loss) On Securities - reclassifications released to Other (income) expense, net.
Employee Benefit Plans - reclassifications are included in net periodic benefit cost. See Note 10 for additional details.
Gain/(Loss) On Derivatives & Hedges - reclassifications to earnings are recorded in the same account as the hedged transaction. See Note 6 for additional details.
*    Includes impact of curtailments and settlements in connection with separation from Kenvue.
14. International currency translation
For translation of its subsidiaries operating in non-U.S. Dollar currencies, the Company has determined that the local currencies of its international subsidiaries are the functional currencies except those in highly inflationary economies, which are defined as those which have had compound cumulative rates of inflation of 100% or more during the past three years, or where a substantial portion of its cash flows are not in the local currency. For the majority of the Company's subsidiaries the local currency is the functional currency.
In consolidating international subsidiaries, balance sheet currency effects are recorded as a component of accumulated other comprehensive income. The other current and non-current assets line within the Statement of Cash flows includes the impact of foreign currency translation. This equity account includes the results of translating certain balance sheet assets and liabilities at current exchange rates and some accounts at historical rates, except for those located in highly inflationary economies (Argentina, Turkey and Venezuela). Beginning in the fiscal fourth quarter of 2024, the Company also accounted for operations in Egypt as highly inflationary. The translation of balance sheet accounts for highly inflationary economies are reflected in the operating results.
A rollforward of the changes during fiscal years 2024, 2023 and 2022 for foreign currency translation adjustments is included in Note 13.
Net currency transaction gains and losses included in Other (income) expense were losses of $214 million, $366 million and $286 million in fiscal years 2024, 2023 and 2022, respectively.
78
 Jhonson&Jhonson.jpg 


15. Earnings per share
The following is a reconciliation of basic net earnings per share to diluted net earnings per share for the fiscal years ended December 29, 2024, December 31, 2023 and January 1, 2023:
(In Millions Except Per Share Amounts)202420232022
Basic net earnings per share from continuing operations$5.84 5.266.23
Basic net earnings per share from discontinued operations 8.620.60
Total net earnings per share - basic5.8413.886.83
Average shares outstanding — basic2,407.32,533.52,625.2
Potential shares exercisable under stock option plans77.794.1140.1
Less: shares repurchased under treasury stock method(55.6)(67.2)(101.4)
Adjusted average shares outstanding — diluted2,429.42,560.42,663.9
Diluted net earnings per share from continuing operations5.79 5.206.14
Diluted net earnings per share from discontinuing operations 8.520.59
Total net earnings per share - diluted$5.79 13.726.73
(Shares in Millions)
The diluted net earnings per share calculation excluded the following number of shares related to stock options, as the exercise price of these options was greater than the average market value of the Company’s stock. 54.1 43.0 0.0
16. Common stock, stock option plans and stock compensation agreements
At December 29, 2024, the Company had one active stock-based compensation plan, the 2022 Long-Term Incentive Plan. The shares outstanding are for contracts under the Company's 2012 Long-Term Incentive Plan and 2022 Long-Term Incentive Plan. The 2012 Long-Term Incentive Plan expired on April 26, 2022. All awards (stock options, restricted shares units and performance share units) granted subsequent to that date were under the 2022 Long-Term Incentive Plan. Under the 2022 Long-Term Incentive Plan, the Company may issue up to 150 million shares of common stock, of which up to 110 million shares of common stock may be issued subject to stock options or stock appreciation rights and up to 40 million shares of common stock may be issued subject to full value awards. Awards will generally be counted on a 1-for-1 basis against the share reserve, provided that if more than 40 million full value awards are granted, each full value award in excess of 40 million will be counted on a 5-for-1 basis against the share reserve. Shares available for future grants under the 2022 Long-Term Incentive Plan were 111 million at the end of fiscal year 2024.
The compensation cost that has been charged against income for these plans was $1,176 million, $1,087 million and $1,028 million for fiscal years 2024, 2023 and 2022, respectively. The total income tax benefit recognized in the income statement for share-based compensation costs was $251 million, $221 million and $177 million for fiscal years 2024, 2023 and 2022, respectively. The Company also recognized additional income tax benefits of $94 million, $126 million and $267 million for fiscal years 2024, 2023 and 2022, respectively, for which options were exercised or restricted shares were vested. The total unrecognized compensation cost was $1,002 million, $907 million and $866 million for fiscal years 2024, 2023 and 2022, respectively. The weighted average period for this cost to be recognized was 1.81 years, 1.80 years and 1.80 years for fiscal years 2024, 2023, and 2022, respectively. Share-based compensation costs capitalized as part of inventory were insignificant in all periods.
The Company settles employee benefit equity issuances with treasury shares. Treasury shares are replenished through market purchases throughout the year for the number of shares used to settle employee benefit equity issuances.
2024 Annual Report
79


Stock options
Stock options expire 10 years from the date of grant and vest over service periods that range from 6 months to 4 years. Options granted under the 2012 Long-Term Incentive Plan were granted at the average of the high and low prices of the Company’s Common Stock on the New York Stock Exchange on the date of grant. Options granted under the 2022 Long-Term incentive Plan were granted at the closing price of the Company’s Common Stock on the New York Stock Exchange on the date of grant.
The fair value of each option award was estimated on the date of grant using the Black-Scholes option valuation model that uses the assumptions noted in the following table. For 2024, 2023, and 2022 grants, expected volatility represents a blended rate of 10-year weekly historical overall volatility rate, and a 5-week average implied volatility rate based on at-the-money traded Johnson & Johnson options with a life of 2 years. For all grants, historical data is used to determine the expected life of the option. The risk-free rate was based on the U.S. Treasury yield curve in effect at the time of grant.
The average fair value of options granted was $27.67, $27.85 and $23.23, in fiscal years 2024, 2023 and 2022, respectively. The fair value was estimated based on the weighted average assumptions of:
202420232022
Risk-free rate4.15 %3.74 %1.98 %
Expected volatility17.85 %17.69 %18.00 %
Expected life (in years)7.07.07.0
Expected dividend yield3.10 %2.90 %2.70 %
A summary of option activity under the Plan as of December 29, 2024, is presented below:
(Shares in Thousands)Outstanding
Shares
Weighted
Average Exercise
Price
Aggregate
Intrinsic
Value
(Dollars in Millions)
Shares at December 31, 2023112,238$139.88$2,239
Options granted13,917157.92
Options exercised(10,771)107.06
Options canceled/forfeited(2,755)162.45
Shares at December 29, 2024112,629$144.69$1,129
The total intrinsic value of options exercised was $560 million, $729 million and $1,228 million in fiscal years 2024, 2023 and 2022, respectively.
80
 Jhonson&Jhonson.jpg 


The following table summarizes stock options outstanding and exercisable at December 29, 2024:
(Shares in Thousands)OutstandingExercisable
Exercise Price RangeOptions
Average Life(1)
Weighted
Average
Exercise Price
OptionsWeighted
Average
Exercise Price
$100.06 - $101.87
13,0160.8$101.2913,016$101.29
$115.67 - $129.51
18,2522.6122.4918,252122.49
$131.94 - $151.41
25,6244.6142.8725,624142.87
$157.92 - $162.75
26,3918.6160.334,269162.75
$164.62 - $165.89
29,3466.6165.2913,522164.64
 112,6295.3$144.6974,683$135.72
(1)Average contractual life remaining in years.
Stock options outstanding at December 31, 2023 and January 1, 2023 were 112,238 and an average life of 5.5 years and 118,672 and an average life of 5.8 years, respectively. Stock options exercisable at December 31, 2023 and January 1, 2023 were 66,998 at an average price of $123.39 and 63,661 at an average price of $113.06, respectively.
Restricted share units and performance share units
The Company grants restricted share units which vest over service periods that range from 6 months to 3 years. The Company also grants performance share units, which are paid in shares of Johnson & Johnson Common Stock after the end of a three-year performance period. Performance shares were granted with two equally-weighted goals that directly align with or help drive long-term total shareholder return: adjusted operational earnings per share and relative total shareholder return. The number of shares actually earned at the end of the three-year period will vary, based only on actual performance, from 0% to 200% of the target number of performance share units granted.
A summary of the restricted share units and performance share units activity under the Plans as of December 29, 2024 is presented below:
(Shares in Thousands)Outstanding
Restricted Share Units
Outstanding
Performance Share Units
Shares at December 31, 202312,9382,037
Granted6,331906
Issued(5,454)(808)
Canceled/forfeited/adjusted(774)(122)
Shares at December 29, 202413,0412,013
The average fair value of the restricted share units granted was $147.51, $152.63 and $153.67 in fiscal years 2024, 2023 and 2022, respectively, using the fair market value at the date of grant. The fair value of restricted share units was discounted for dividends, which are not paid on the restricted share units during the vesting period. The fair value of restricted share units issued was $833 million, $605 million and $591 million in 2024, 2023 and 2022, respectively.
The weighted average fair value of the performance share units granted was $133.76, $145.17 and $170.46 in fiscal years 2024, 2023 and 2022, calculated using the weighted average fair market value for each of the component goals at the date of grant.
The fair values for the earnings per share goals of each performance share unit were estimated on the date of grant using the fair market value of the shares at the time of the award discounted for dividends, which are not paid on the performance share units during the vesting period. The fair value for the relative total shareholder return goal of each performance share unit was estimated on the date of grant using the Monte Carlo valuation model. The fair value of performance share units issued was $146 million, $140 million and $94 million in fiscal years 2024, 2023 and 2022, respectively.

2024 Annual Report
81


17. Segments of business and geographic areas
Following the separation of the Consumer Health business in the fiscal third quarter of 2023, the Company is now organized into two reportable segments: Innovative Medicine and MedTech. The segment results have been recast for all periods to reflect the continuing operations of the Company.
The Company’s chief operating decision maker (CODM) is the Chief Executive Officer (Principal Executive Officer). For the Innovative Medicine and MedTech segments, the CODM uses segment income before tax to allocate resources (including employees, financial, and capital resources) for each segment predominantly in the annual forecasting process. The CODM considers planning-to-actual variances on a quarterly basis to assess performance and make decisions about allocating resources to the segments.
 Sales to Customers % Change
(Dollars in Millions)202420232022’24 vs. ’23’23 vs. ’22
INNOVATIVE MEDICINE
Immunology
U.S.$11,35511,53911,036(1.6)%4.6 
International6,4736,5135,899(0.6)10.4 
Worldwide17,82818,05216,935(1.2)6.6 
REMICADE
U.S.1,0091,1431,417(11.7)(19.3)
U.S. Exports98147204(33.0)(28.0)
International497549722(9.5)(23.9)
Worldwide1,6051,8392,343(12.8)(21.5)
SIMPONI / SIMPONI ARIA
U.S.1,0821,1241,166(3.8)(3.6)
International1,1081,0731,0173.3 5.4 
Worldwide2,1902,1972,184(0.3)0.6 
STELARA
U.S.6,7206,9666,388(3.5)9.0 
International3,6413,8923,335(6.4)16.7 
Worldwide10,36110,8589,723(4.6)11.7 
TREMFYA
U.S.2,4432,1471,84413.7 16.5 
International1,22799982422.8 21.2 
Worldwide3,6703,1472,66816.6 17.9 
OTHER IMMUNOLOGY
U.S.31117(74.1)(33.8)
International000 
Worldwide31117(74.1)(33.8)
Infectious Diseases
U.S.1,3541,5001,680(9.8)(10.7)
International2,0422,9183,769(30.0)(22.6)
Worldwide3,3964,4185,449(23.1)(18.9)
COVID-19 VACCINE
U.S.00120*
International1981,1172,059(82.4)(45.8)
82
 Jhonson&Jhonson.jpg 


 Sales to Customers % Change
(Dollars in Millions)202420232022’24 vs. ’23’23 vs. ’22
Worldwide1981,1172,179(82.4)(48.8)
EDURANT / rilpivirine
U.S.313536(10.0)(3.7)
International1,2411,11597211.2 14.8 
Worldwide1,2721,1501,00810.6 14.1 
PREZISTA / PREZCOBIX /
REZOLSTA / SYMTUZA
U.S.1,3111,4461,494(9.4)(3.2)
International401408449(1.7)(9.2)
Worldwide1,7121,8541,943(7.7)(4.6)
OTHER INFECTIOUS DISEASES
U.S.111930(41.0)(34.5)
International203278289(26.7)(3.8)
Worldwide214297318(27.6)(6.7)
Neuroscience
U.S.4,3984,0653,5708.2 13.9 
International2,7183,0763,323(11.6)(7.5)
Worldwide7,1157,1406,893(0.4)3.6 
CONCERTA / methylphenidate
U.S.134230151(41.7)52.5 
International507554493(8.4)12.2 
Worldwide641783644(18.1)21.6 
INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA
U.S.3,1252,8972,7147.9 6.7 
International1,0971,2181,426(9.9)(14.6)
Worldwide4,2224,1154,1402.6 (0.6)
SPRAVATO
U.S.92958932857.8 79.7 
International1481004648.2 *
Worldwide1,07768937456.4 84.1 
OTHER NEUROSCIENCE
U.S.210349376(39.8)(7.3)
International9651,2041,358(19.8)(11.3)
Worldwide1,1751,5531,734(24.3)(10.4)
Oncology
U.S.10,8548,4626,93028.3 22.1 
International9,9269,1999,0527.9 1.6 
Worldwide20,78117,66115,98317.7 10.5 
CARVYKTI
U.S.86946913385.2*
International9430**
2024 Annual Report
83


 Sales to Customers % Change
(Dollars in Millions)202420232022’24 vs. ’23’23 vs. ’22
Worldwide96350013392.7*
DARZALEX
U.S.6,5885,2774,21024.8 25.4 
International5,0824,4673,76713.8 18.6 
Worldwide11,6709,7447,97719.8 22.2 
ERLEADA
U.S.1,2821,06596820.3 10.0 
International1,7171,32291329.8 44.8 
Worldwide2,9992,3871,88125.6 26.9 
IMBRUVICA
U.S.1,0201,0511,390(3.0)(24.4)
International2,0182,2142,394(8.8)(7.5)
Worldwide3,0383,2643,784(6.9)(13.7)
TECVAYLI
U.S.4183341225.3 *
International131613**
Worldwide5493951538.8 *
ZYTIGA /abiraterone acetate
U.S.345074(32.2)(32.1)
International5978371,696(28.6)(50.7)
Worldwide6318871,770(28.8)(49.9)
OTHER ONCOLOGY
U.S.643215144*49.3 
International2882692807.1 (3.9)
Worldwide93148442392.5 14.4 
Pulmonary Hypertension
U.S.3,1432,6972,34616.5 15.0 
International1,1401,1171,0712.0 4.3 
Worldwide4,2823,8153,41712.3 11.6 
OPSUMIT
U.S.1,5201,2921,13217.7 14.1 
International664681651(2.4)4.6 
Worldwide2,1841,9731,78310.7 10.6 
UPTRAVI
U.S.1,5111,3261,10413.9 20.1 
International30725521820.1 17.3 
Worldwide1,8171,5821,32214.9 19.7 
OTHER PULMONARY HYPERTENSION
U.S.1127911041.8 (28.6)
International169182202(6.9)(10.3)
Worldwide2812603137.9 (16.7)
84
 Jhonson&Jhonson.jpg 


 Sales to Customers % Change
(Dollars in Millions)202420232022’24 vs. ’23’23 vs. ’22
Cardiovascular / Metabolism / Other
U.S.2,8662,9063,042(1.4)(4.5)
International696765845(9.1)(9.4)
Worldwide3,5623,6713,887(3.0)(5.5)
XARELTO
U.S.2,3732,3652,4730.3 (4.4)
International  
Worldwide2,3732,3652,4730.3 (4.4)
OTHER
U.S.494541569(8.8)(5.0)
International696765845(9.1)(9.4)
Worldwide1,1891,3061,414(8.9)(7.6)
TOTAL INNOVATIVE MEDICINE
U.S.33,97031,16928,6049.0 9.0 
International22,99423,59023,959(2.5)(1.5)
Worldwide56,96454,75952,5634.0 4.2 
MEDTECH
Cardiovascular (1)
U.S.4,5133,6332,16924.2 67.5 
International3,1942,7172,13117.6 27.5 
Worldwide7,7076,3504,30021.4 47.7 
ELECTROPHYSIOLOGY
U.S.2,7382,4582,03611.4 20.7 
International2,5292,2301,90113.4 17.3 
Worldwide5,2674,6883,93712.3 19.1 
ABIOMED(2)
U.S.1,2131,0663113.7 *
International28424018.2 *
Worldwide1,4961,3063114.5 *
SHOCKWAVE(3)
U.S.442**
International122**
Worldwide564**
OTHER CARDIOVASCULAR(1)
U.S.12010910210.7 6.7 
International2602472305.3 7.3 
Worldwide3803563326.9 7.1 
Orthopaedics
U.S.5,6895,5255,3213.0 3.8 
International3,4703,4173,2671.5 4.6 
Worldwide9,1588,9428,5872.4 4.1 
2024 Annual Report
85


 Sales to Customers % Change
(Dollars in Millions)202420232022’24 vs. ’23’23 vs. ’22
HIPS
U.S.1,0579969436.2 5.6 
International5815645713.0 (1.2)
Worldwide1,6381,5601,5145.0 3.0 
KNEES
U.S.9228968512.9 5.3 
International62355950811.3 10.2 
Worldwide1,5451,4561,3596.1 7.1 
TRAUMA
U.S.2,0131,9491,8823.3 3.6 
International1,0361,0309890.6 4.1 
Worldwide3,0492,9792,8712.3 3.8 
SPINE, SPORTS & OTHER
U.S.1,6961,6841,6450.7 2.4 
International1,2301,2631,198(2.6)5.4 
Worldwide2,9262,9472,843(0.7)3.7 
Surgery
U.S.4,0034,0313,897(0.7)3.4 
International5,8426,0065,793(2.7)3.7 
Worldwide9,84510,0379,690(1.9)3.6 
ADVANCED
U.S.1,8381,8331,7840.2 2.8 
International2,6502,8372,785(6.6)1.9 
Worldwide4,4884,6714,569(3.9)2.2 
GENERAL
U.S.2,1652,1982,113(1.5)4.0 
International3,1923,1683,0080.8 5.3 
Worldwide5,3585,3665,121(0.2)4.8 
Vision
U.S.2,1282,0861,9902.0 4.8 
International3,0182,9862,8591.1 4.5 
Worldwide5,1465,0724,8491.5 4.6 
CONTACT LENSES / OTHER
U.S.1,6841,6261,5223.6 6.8 
International2,0492,0762,022(1.3)2.7 
Worldwide3,7333,7023,5430.8 4.5 
SURGICAL
U.S.444460468(3.4)(1.8)
International9699108376.5 8.6 
Worldwide1,4131,3701,3063.2 4.9 
86
 Jhonson&Jhonson.jpg 


 Sales to Customers % Change
(Dollars in Millions)202420232022’24 vs. ’23’23 vs. ’22
TOTAL MEDTECH   
U.S.16,33215,27513,3776.9 14.2 
International15,52515,12514,0502.6 7.7 
Worldwide31,85730,40027,4274.8 10.8 
WORLDWIDE   
U.S.50,30246,44441,9818.3 10.6 
International38,51938,71538,009(0.5)1.9 
Worldwide$88,82185,15979,9904.3 %6.5 
*    percentage greater than 100% or not meaningful
(1)Previously referred to as Interventional Solutions
(2)Acquired on December 22, 2022
(3)Acquired on May 31, 2024
Income Before Tax by Segment
(Dollars in Millions)
2024 (3)
2023 (4)
2022 (5)
Innovative
Medicine
MedTechTotalInnovative
Medicine
MedTechTotalInnovative
Medicine
MedTechTotal
Sales to customers$56,96431,85754,75930,40052,56327,427
Cost of products sold14,03613,34513,71512,72214,06610,397
Selling, marketing and administrative 10,90610,8129,84210,4769,7149,537
Research and development expense13,5293,70311,9633,12211,6422,493
Other segment items (1)
(426)257993(589)1,494553
Segment income before tax$18,9193,74022,65918,2464,66922,91515,6474,44720,094
Less: Expense not allocated to segments (2)
5,9727,853735
Worldwide total$16,68715,06219,359
 Identifiable Assets
(Dollars in Millions)20242023
Innovative Medicine$57,07058,324
MedTech84,32274,710
Total141,392133,034
General corporate (6)
38,71234,524
Worldwide total$180,104167,558
2024 Annual Report
87


Additions to Property,
Plant & Equipment
Depreciation and
Amortization
(Dollars in Millions)202420232022202420232022
Innovative Medicine$1,7101,6531,374$3,7603,8473,687
MedTech2,4432,3722,1203,2372,9432,302
Segments total4,1534,0253,4946,9976,7905,989
Discontinued operations162303383641
General corporate271356212342313340
Worldwide total$4,4244,5434,009$7,3397,4866,970
 Sales to Customers
Long-Lived Assets (7)
(Dollars in Millions)20242023202220242023
United States$50,30246,44441,981$70,67054,832
Europe20,21220,41020,66427,26731,616
Western Hemisphere excluding U.S. 4,7144,5494,1081,7281,491
Asia-Pacific, Africa13,59313,75613,2371,4541,500
Segments total88,82185,15979,990101,11989,439
General corporate1,2171,192
Other non long-lived assets77,76876,927
Worldwide total$88,82185,15979,990$180,104167,558
See Note 1 for a description of the segments in which the Company operates.
Export sales are not significant. In fiscal year 2024, the Company utilized three wholesalers distributing products for both segments that represented approximately 20.5%, 15.6% and 12.3% of the total gross revenues. In fiscal year 2023, the Company had three wholesalers distributing products for both segments that represented approximately 18.2%, 15.1% and 14.2% of the total gross revenues. In fiscal year 2022, the Company had three wholesalers distributing products for all three segments that represented approximately 18.9%, 15.0%, and 13.8% of the total gross revenues.
(1)Other segment expenses for each reportable segment include charges related to other income and expenses, restructuring activities and impairment charges related to in-process research and development.
(2)Amounts not allocated to segments include interest (income)/expense and general corporate (income)/expense. The fiscal years 2024 and 2023 include charges for talc matters of approximately $5.1 billion and $7 billion, respectively (See Note 19, Legal proceedings, for additional details). The fiscal year 2024 includes a loss of approximately $0.4 billion related to the debt to equity exchange of the Company's remaining shares of Kenvue Common Stock. The fiscal year 2023 includes the unfavorable change in the fair value of the retained stake in Kenvue of approximately $0.4 billion.
(3)Innovative Medicine segment income before tax includes:
Acquired in-process research & development expense of $1.25 billion to secure the global rights to the NM26 bispecific antibody (Yellow Jersey acquisition)
Monetization of royalty rights of $0.3 billion
Litigation expense of $0.3 billion primarily related to Risperdal Gynecomastia
An intangible asset impairment charge of approximately $0.2 billion associated with the M710 (biosimilar) asset acquired as part of the acquisition of Momenta Pharmaceuticals in 2020.
A restructuring related charge of $0.1 billion
One-time COVID-19 Vaccine manufacturing exit related costs of $0.1 billion
Favorable changes in the fair value of securities of $0.1 billion
MedTech segment income before tax includes:
Acquisition and integration related costs of $1.0 billion primarily related to the acquisition of Shockwave
88
 Jhonson&Jhonson.jpg 


Acquired in-process research and development expense of $0.5 billion from the V-Wave acquisition
A gain of $0.2 billion related to the Acclarent divestiture
A Medical Device Regulation charge of $0.2 billion
A restructuring related charge of $0.2 billion
(4)Innovative Medicine segment income before tax includes:
One-time COVID-19 Vaccine manufacturing exit related costs of $0.7 billion
A restructuring related charge of $0.5 billion
Unfavorable changes in the fair value of securities of $0.4 billion
Favorable litigation related items of $0.1 billion
Loss on divestiture of $0.2 billion.
An intangible asset impairment charge of approximately $0.2 billion related to market dynamics associated with a non-strategic asset (M710) acquired as part of the acquisition of Momenta Pharmaceuticals in 2020.
MedTech segment income before tax includes:
Acquired in-process research and development expense of $0.4 billion related to the Laminar acquisition in 2023
A restructuring related charge of $0.3 billion
Acquisition and integration related costs of $0.2 billion primarily related to the acquisition of Abiomed
A Medical Device Regulation charge of $0.3 billion
Income from litigation settlements of $0.1 billion
(5)Innovative Medicine segment income before tax includes:
One-time COVID-19 Vaccine manufacturing exit related costs of $1.5 billion
An intangible asset impairment charge of approximately $0.8 billion related to an in-process research and development asset, bermekimab (JnJ-77474462), an investigational drug for the treatment of Atopic Dermatitis (AD) and Hidradenitis Suppurativa (HS) acquired with the acquisition of XBiotech, Inc. in the fiscal year 2020. Additional information regarding efficacy of the AD and HS indications became available which led the Company to the decision to terminate the development of bermekimab for AD and HS
Litigation expense of $0.1 billion
Unfavorable changes in the fair value of securities of $0.7 billion
A restructuring related charge of $0.1 billion
MedTech segment income before tax includes:
Litigation expense of $0.6 billion primarily for pelvic mesh related costs
A restructuring related charge of $0.3 billion
Acquisition and integration related costs of $0.3 billion primarily related to the acquisition of Abiomed
A Medical Device Regulation charge of $0.3 billion
(6) General corporate includes cash, cash equivalents, marketable securities and other corporate assets.
(7)Long-lived assets include property, plant and equipment, net for fiscal years 2024, and 2023 of $20,518 and $19,898, respectively, and intangible assets and goodwill, net for fiscal years 2024 and 2023 of $81,818 and $70,733, respectively.
2024 Annual Report
89


18. Acquisitions and divestitures
Subsequent to the fiscal year end 2024, the Company announced it has entered into a definitive agreement to acquire Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, for $132.00 per share in cash for a total equity value of approximately $14.6 billion. The Company expects to fund the transaction through a combination of cash on hand and debt. The closing of the transaction is expected to occur later this year subject to applicable regulatory approvals, approval by Intra-Cellular Therapies’ stockholders and other customary closing conditions for a transaction of this type. The results of operations will be included in the Innovative Medicine segment beginning on the acquisition date.
Business combinations
Acquisitions of a business are accounted for as business combinations applying the acquisition method of accounting. Under this method, the assets acquired and liabilities assumed are recorded at their respective fair values as of the acquisition date in the Company’s consolidated financial statements. The excess of the purchase price over the fair value of the acquired net assets, where applicable, is recorded as goodwill. The results of operations of these acquisitions have been included in the Company’s financial statements from their respective dates of acquisition.
During the fiscal year 2024, certain businesses were acquired for $15.1 billion, net of cash acquired. The fiscal year 2024 acquisitions primarily included; Ambrx Biopharma, Inc., Shockwave Medical Inc., and Proteologix, Inc. The remaining acquisitions were not material.
On June 20, 2024, the Company completed the acquisition of Proteologix, Inc., a privately held biotechnology company focused on bispecific antibodies for immune-mediated diseases, for approximately $0.8 billion net of cash acquired, with potential for an additional milestone payment. The results of operations are included in the Innovative Medicine segment as of the acquisition date. The fair value of the acquisition was allocated to assets acquired of $1.2 billion, primarily non-amortizable intangible assets, inclusive of purchased IPR&D, for $0.9 billion, goodwill for $0.3 billion, and $0.3 billion of liabilities assumed which included $0.1 billion related to a contingent consideration. The preliminary purchase price allocation is subject to any subsequent valuation adjustments within the measurement period. A probability of success factor ranging from 30% to 45% was used in the fair value calculation to reflect inherent regulatory and commercial risk of the IPR&D. The discount rate applied was approximately 16%. The goodwill is primarily attributable to synergies expected to arise from the business acquisition and is not expected to be deductible for tax purposes. Acquisition related costs before tax for the fiscal 2024 were not material.
On May 31, 2024, the Company completed the acquisition of Shockwave Medical Inc. (SWAV)(Shockwave), a leading, first-to-market provider of innovative intravascular lithotripsy (IVL) technology for the treatment of calcified coronary artery disease (CAD) and peripheral artery disease (PAD) in an all-cash merger transaction. The Company acquired all the outstanding shares of Shockwave’s common stock for $335.00 per share through a merger of Shockwave with a subsidiary of the Company. The results of operations were included in the MedTech segment as of the acquisition date.
90
 Jhonson&Jhonson.jpg 


Details of the fair value amounts recognized for assets acquired and liabilities assumed as of the purchase date and at the end of fiscal year 2024, which includes measurement period adjustments, are included in the table below. As the acquisition occurred in May 2024, the Company is still finalizing the allocation of the purchase price to the individual assets acquired and liabilities assumed. The allocation of the purchase price included in the current period balance sheet is based on the best estimate of management and is preliminary and subject to change.
(Dollars in Billions)May 31, 2024December 29, 2024
Assets acquired:
Cash $1.1$1.1
Goodwill7.57.6
Amortizable intangibles5.35.3
IPR&D0.60.6
Inventory0.50.5
Other assets0.50.4
Total assets acquired$15.5$15.5
Liabilities assumed:
Deferred taxes$1.5$1.5
Notes payable*1.01.0
Accrued liabilities**0.40.4
Total liabilities assumed$2.9$2.9
Net assets acquired$12.6$12.6
Net assets acquired as of May 31, 2024$12.6
Less: Cash acquired1.1
Equity awards settled0.6
Settlement of Note payable*1.0
Total enterprise value as of June 30, 2024$13.1
*    Represents the convertible debt which was subsequently paid in the fiscal second quarter of 2024.
**    Includes $0.2 billion of equity awards
The goodwill is primarily attributable to synergies expected to arise from the business acquisition and is not expected to be deductible for tax purposes. Acquisition related costs before tax for the fiscal 2024 were $0.9 billion of which $0.4 billion was related to the fair value of the inventory step-up and was recorded in Cost of products sold and $0.5 billion primarily related to equity awards and was recorded in Other (income) expense. The amortizable intangible assets were primarily comprised of already in-market CAD and PAD IVL products with the average weighted lives of 14 years. The IPR&D assets were valued for technology programs for unapproved products. The value of the IPR&D was calculated using a probability-adjusted cash flow projection discounted for the risk inherent in such projects with the weighted average probability of success factors of approximately 50%. The discount rate applied was 9.0%.
On March 7, 2024, the Company completed the acquisition of Ambrx Biopharma, Inc., (Ambrx), a clinical-stage biopharmaceutical company with a proprietary synthetic biology technology platform to design and develop next-generation antibody drug conjugates (ADCs), in an all-cash merger transaction for a total equity value of approximately $2.0 billion, or $1.8 billion net of cash acquired. The Company acquired all of the outstanding shares of Ambrx’s common stock for $28.00 per share through a merger of Ambrx with a subsidiary of the Company. The results of operations were included in the Innovative Medicine segment as of the acquisition date. The fair value of the acquisition was allocated to assets acquired of $2.3 billion, primarily non-amortizable intangible assets, inclusive of purchased IPR&D, for $1.9 billion, goodwill for $0.3 billion and liabilities assumed of $0.5 billion, which includes deferred taxes of $0.4 billion. The preliminary purchase price allocation is subject to any subsequent valuation adjustments within the measurement period. A probability of success factor ranging from 40% to
2024 Annual Report
91


70% was used in the fair value calculation to reflect inherent regulatory and commercial risk of the IPR&D. The discount rate applied was approximately 17%. The goodwill is primarily attributable to synergies expected to arise from the business acquisition and is not expected to be deductible for tax purposes. Acquisition related costs before tax for the fiscal year 2024 were not material.
During the fiscal year 2023, the Company did not make any acquisitions that qualified as a business combination.
During the fiscal year 2022, certain businesses were acquired for $17.7 billion, net of cash acquired. The fiscal year 2022 acquisitions primarily included Abiomed, Inc. (Abiomed). The remaining acquisitions were not material.
On December 22, 2022, the Company completed the acquisition of Abiomed, a leading, first-to-market provider of cardiovascular medical technology with a first-in-kind portfolio for the treatment of coronary artery disease and heart failure which also has an extensive innovation pipeline of life-saving technologies. The transaction broadens the Company’s position as a growing cardiovascular innovator, advancing the standard of care in heart failure and recovery, one of healthcare’s largest areas of unmet need. The results of operations were included in the MedTech segment as of the date of the acquisition. The acquisition was completed through a tender offer for all outstanding shares. The consideration paid in the acquisition consisted of an upfront payment of $380.00 per share in cash, amounting to $17.1 billion, net of cash acquired, as well as a non-tradeable contingent value right (“CVR”) entitling the holder to receive up to $35.00 per share in cash (which with respect to the CVRs total approximately $1.6 billion in the aggregate) if certain commercial and clinical milestones are achieved. The corresponding enterprise value (without taking into account the CVRs) of approximately $16.5 billion includes cash, cash equivalents and marketable securities acquired.
The milestones of the CVR consist of:
a.$17.50 per share, payable if net sales for Abiomed products exceeds $3.7 billion during Johnson & Johnson’s fiscal second quarter of 2027 through fiscal first quarter of 2028, or if this threshold is not met during this period and is subsequently met during any rolling four quarter period up to the end of Johnson & Johnson’s fiscal first quarter of 2029, $8.75 per share;
b.$7.50 per share payable upon FDA premarket application approval of the use of Impella® products in ST-elevated myocardial infarction (STEMI) patients without cardiogenic shock by January 1, 2028; and
c.$10.00 per share payable upon the first publication of a Class I recommendation for the use of Impella® products in high risk PCI or STEMI with or without cardiogenic shock within four years from their respective clinical endpoint publication dates, but in all cases no later than December 31, 2029.
During the fiscal fourth quarter of 2023, the Company finalized the purchase price allocation. In fiscal 2023, there were purchase price allocation adjustments netting to approximately $0.2 billion with an offsetting increase to goodwill. The fair value of the acquisition was allocated to assets acquired of $20.1 billion (net of $0.3 billion cash acquired), primarily to goodwill for $11.1 billion, amortizable intangible assets for $6.6 billion, IPR&D for $1.1 billion, marketable securities of $0.6 billion and liabilities assumed of $3.0 billion, which includes the fair value of the contingent consideration mentioned above for $0.7 billion and deferred taxes of $2.0 billion. The goodwill is primarily attributable to the commercial acceleration and expansion of the portfolio and is not expected to be deductible for tax purposes. The contingent consideration was recorded in Other Liabilities and adjusted to fair value through the fiscal year end 2024 on the Consolidated Balance Sheet.
The amortizable intangible assets were primarily comprised of already in-market products of the Impella® platform with an average weighted life of 14 years. The IPR&D assets were valued for technology programs for unapproved products. The value of the IPR&D was calculated using probability-adjusted cash flow projections discounted for the risk inherent in such projects. The probability of success factor ranged from 52% to 70%. The discount rate applied was 9.5%.
In the fiscal years 2024, 2023 and 2022, the Company recorded acquisition related costs before tax of approximately $0.3 billion, $0.2 billion and $0.3 billion, which was primarily recorded in Other (income)/expense.
In accordance with U.S. GAAP standards related to business combinations, and goodwill and other intangible assets, supplemental pro forma information for fiscal years 2024, 2023 and 2022 is not provided, as the impact of the aforementioned acquisitions did not have a material effect on the Company’s results of operations.
92
 Jhonson&Jhonson.jpg 


Asset acquisitions
Acquired In-process research and development (IPR&D) in an asset acquisition is immediately expensed as research and development expense in the Company's consolidated financial statements. Milestone payments incurred prior to regulatory approval are expensed as research and development expense when the milestone event occurs.
The fiscal year 2024 asset acquisitions expensed as research and development included V-Wave Ltd. and the global rights to the NM26 bispecific antibody (Yellow Jersey acquisition). The remaining activity was not material.
On October 8, 2024, the Company completed the acquisition of V-Wave Ltd, a privately-held company focused on developing innovative treatment options for patients with heart failure, for an upfront payment of $0.6 billion, with the potential for additional regulatory and commercial milestone payments up to approximately $1.1 billion. The Company recorded an IPR&D charge of approximately $0.5 billion, net of a gain recorded on the Company's existing investment in V-Wave and the results of operations are included in the MedTech segment as of the acquisition date.
On July 11, 2024, the Company completed the acquisition of Yellow Jersey, a demerged subsidiary of Numab Therapeutics AG, to secure the global rights to NM26, a novel, investigational first-in-class bispecific antibody targeting two clinically proven pathways in atopic dermatitis (AD), in an all-cash transaction for approximately $1.25 billion. The Company recorded an IPR&D charge of approximately $1.25 billion, and the results of operations are included in the Innovative Medicine segment as of the acquisition date.
The fiscal year 2023 asset acquisitions expensed as research and development included Laminar Inc. The remaining activity was not material.
During the fiscal year 2023, the Company completed the acquisition of Laminar Inc., a privately-held medical device company focused on eliminating the left atrial appendage (LAA) in patients with non-valvular atrial fibrillation (AFib), for an upfront payment of $0.4 billion. The Company recorded an IPR&D charge of approximately $0.4 billion and the results of operations are included in the MedTech segment as of the acquisition date.
There were no significant asset acquisitions in 2022.
Divestitures
During the fiscal year 2024, the Company completed the divestiture of Acclarent resulting in approximately $0.3 billion in proceeds and the divestiture of Ponvory outside of the U.S. resulting in approximately $0.2 billion in proceeds. All other divestitures were not material.
During the fiscal year 2023, the Company executed divestitures resulting in approximately $0.2 billion in proceeds resulting in gains or losses that were not material. At fiscal year end 2023, the Company held assets, primarily intangibles, on its Consolidated Balance Sheet of approximately $0.3 billion, primarily related to Acclarent and Ponvory, that were subsequently divested in fiscal 2024.
During fiscal year 2022, the Company did not make any material divestitures.
19. Legal proceedings
Johnson & Johnson and certain of its subsidiaries are involved in various lawsuits and claims regarding product liability; intellectual property; commercial; indemnification and other matters; governmental investigations; and other legal proceedings that arise from time to time in the ordinary course of their business.
The Company records accruals for loss contingencies associated with these legal matters when it is probable that a liability will be incurred, and the amount of the loss can be reasonably estimated. As of December 29, 2024, the Company has determined that the liabilities associated with certain litigation matters are probable and can be reasonably estimated. The Company has accrued for these matters and will continue to monitor each related legal issue and adjust accruals as might be warranted based on new information and further developments in accordance with ASC 450-20-25. For these and other litigation and regulatory matters discussed below for which a loss is probable or reasonably possible, the Company is unable to estimate the possible loss or range of loss beyond the amounts accrued. Amounts accrued for legal contingencies often result from a complex series of judgments about future events and uncertainties that rely heavily on estimates and assumptions including timing of related payments. The ability to make such estimates and judgments can be affected by various factors including, among other things, whether damages sought in the proceedings are unsubstantiated or indeterminate; scientific and legal discovery has not commenced or is not complete; proceedings are in early stages; matters present legal uncertainties; there are significant facts in dispute; procedural or jurisdictional issues; the uncertainty and unpredictability of the number of
2024 Annual Report
93


potential claims; ability to achieve comprehensive multi-party settlements; complexity of related cross-claims and counterclaims; and/or there are numerous parties involved. To the extent adverse awards, judgments or verdicts have been rendered against the Company, the Company does not record an accrual until a loss is determined to be probable and can be reasonably estimated.
In the Company’s opinion, based on its examination of these matters, its experience to date and discussions with counsel, the ultimate outcome of legal proceedings, net of liabilities accrued in the Company’s balance sheet, is not expected to have a material adverse effect on the Company’s financial position. However, the resolution of, or increase in accruals for, one or more of these matters in any reporting period may have a material adverse effect on the Company’s results of operations and cash flows for that period.
Matters concerning talc
A significant number of personal injury claims alleging that talc causes cancer have been asserted against the Company and its affiliates arising out of the use of body powders containing talc, primarily JOHNSON’S Baby Powder.
In talc cases that have gone to trial, the Company has obtained a number of defense verdicts, but there also have been verdicts against the Company, many of which have been reversed on appeal. In June 2020, the Missouri Court of Appeals reversed in part and affirmed in part a July 2018 verdict of $4.7 billion in Ingham v. Johnson & Johnson, et al., No. ED 207476 (Mo. App.), reducing the overall award to $2.1 billion. An application for transfer of the case to the Missouri Supreme Court was subsequently denied, and in June 2021, a petition for certiorari, seeking a review of the Ingham decision by the United States Supreme Court, was denied. In June 2021, the Company paid the award, which, including interest, totaled approximately $2.5 billion. The facts and circumstances, including the terms of the award, were unique to the Ingham decision and not representative of other claims brought against the Company. The Company continues to believe that it has strong legal grounds to contest the other talc verdicts that it has appealed. Notwithstanding the Company’s confidence in the safety of its talc products, in certain circumstances the Company has settled cases.
In June 2014, the Mississippi Attorney General filed a complaint against the Company alleging violation of the Mississippi Consumer Protection Act by failing to disclose alleged health risks associated with female consumers’ use of talc contained in JOHNSON’S Baby Powder and JOHNSON’S Shower to Shower (a product divested in 2012). The Company has reached an agreement to resolve this matter.
In January 2020, the State of New Mexico filed a consumer protection case alleging that the Company deceptively marketed and sold its talcum powder products by making misrepresentations about the safety of the products and the presence of carcinogens, including asbestos. The Company has reached an agreement to resolve this matter.
Forty-two states and the District of Columbia commenced a joint investigation into the Company’s marketing of its talcum powder products. In January 2024, the Company reached an agreement in principle with the multi-state group of state Attorneys General, subject to ongoing negotiation of non-monetary terms. In June 2024, the settlements were finalized.
In October 2021, Johnson & Johnson Consumer Inc. (Old JJCI) implemented a corporate restructuring (the 2021 Corporate Restructuring). As a result of that restructuring, Old JJCI ceased to exist and three new entities were created: (a) LTL Management LLC, a North Carolina limited liability company (LTL or Debtor); (b) Royalty A&M LLC, a North Carolina limited liability company and a direct subsidiary of LTL (RAM); and (c) the Debtor’s direct parent, Johnson & Johnson Consumer Inc., a New Jersey company (New JJCI). The Debtor received certain of Old JJCI’s assets and became solely responsible for the talc-related liabilities of Old JJCI, including all liabilities related in any way to injury or damage, or alleged injury or damage, sustained or incurred in the purchase or use of, or exposure to, talc, including talc contained in any product, or to the risk of, or responsibility for, any such damage or injury, except for any liabilities for which the exclusive remedy is provided under a workers’ compensation statute or act (the Talc-Related Liabilities).
In October 2021, notwithstanding the Company’s confidence in the safety of its talc products, the Debtor filed a voluntary petition with the United States Bankruptcy Court for the Western District of North Carolina, Charlotte Division, seeking relief under Chapter 11 of the Bankruptcy Code (the LTL Bankruptcy Case). All litigation against LTL, Old JJCI, New JJCI, the Company, other of their corporate affiliates, identified retailers, insurance companies, and certain other parties (the Protected Parties) was stayed. The LTL Bankruptcy Case was transferred to the United States Bankruptcy Court for the District of New Jersey. Claimants filed motions to dismiss the LTL Bankruptcy Case and, following a multiple day hearing, the New Jersey Bankruptcy Court denied those motions in March 2022.
The claimants subsequently filed notices of appeal as to the denial of the motions to dismiss the LTL Bankruptcy Case and the extension of the stay to the Protected Parties. On January 30, 2023, the Third Circuit reversed the Bankruptcy Court’s ruling and remanded to the Bankruptcy Court to dismiss the LTL bankruptcy.
94
 Jhonson&Jhonson.jpg 


In April 2023, the New Jersey Bankruptcy Court dismissed the LTL Bankruptcy Case, effectively lifting the stay as to all parties and returning the talc litigation to the tort system. LTL re-filed in the United States Bankruptcy Court for the District of New Jersey seeking relief under Chapter 11 of the Bankruptcy Code (the LTL 2 Bankruptcy Case). As a result of the new filing, all talc claims against LTL were again automatically stayed pursuant to section 362 of the Bankruptcy Code. Additionally, the New Jersey Bankruptcy Court issued a temporary restraining order staying all litigation as to LTL, Old JJCI, New JJCI, the Company, identified retailers, and certain other parties (the New Protected Parties).
Also in April 2023, the New Jersey Bankruptcy Court issued a decision that granted limited injunctive relief to the Company and the New Protected Parties (the LTL 2 Preliminary Injunction). The LTL 2 Preliminary Injunction remained in force until late August 2023, following the Bankruptcy Court’s extension of the initial LTL 2 Preliminary Injunction in June 2023. Under the LTL 2 Preliminary Injunction, except for those cases filed in the federal court ovarian cancer multi-district litigation, discovery in all personal injury and wrongful death matters was permitted to proceed.
Furthermore, in April 2023, the Talc Claimants' Committee filed a motion to dismiss the LTL 2 Bankruptcy followed by similar motions from other claimants. Hearings on the motions to dismiss occurred in June 2023. In July 2023, the court dismissed the LTL 2 Bankruptcy case and, the same day, the Company stated its intent to appeal the decision and to continue its efforts to obtain a resolution of the talc claims. In September 2023, the Bankruptcy Court entered an order granting LTL leave to seek a direct appeal to the Third Circuit Court of Appeals. In October 2023, the Third Circuit granted LTL’s petition for a direct appeal. In July 2024, the Third Circuit issued a non-precedential opinion affirming the Bankruptcy Court's decision to dismiss the LTL Bankruptcy case.
In October 2023, the Company stated that it was pursuing the following four parallel and alternative pathways to achieve a comprehensive and final resolution of the talc claims: (i) the appeal of the LTL 2 dismissal decision; (ii) pursuing a consensual “prepackaged” bankruptcy case, as “strongly encouraged” by the Bankruptcy Court in its dismissal decision; (iii) aggressively litigating the talc claims in the tort system; and (iv) pursuing affirmative claims against experts for false and defamatory narratives regarding the Company’s talc powder products. In December 2023, LTL changed its state of formation to Texas and its name to LLT Management LLC ("LLT").
Following the dismissal of LTL 2, new lawsuits were filed, cases across the country that had been stayed were reactivated, and trials have commenced. The majority of the cases are pending in federal court, organized in a multi-district litigation (MDL) in the United States District Court for the District of New Jersey. In the MDL, case-specific discovery proceeded. The MDL proceedings have been stayed by order of the bankruptcy court in the Red River Bankruptcy case discussed below. In March 2024, the court granted the Company's motion for a renewed Daubert hearing prior to the trial. The briefing on the renewed Daubert issues was completed in August 2024.
In May 2024, the Company commenced a three-month solicitation period of its proposed consensual “prepackaged” Chapter 11 bankruptcy plan (the “Proposed Plan”) for the comprehensive and final resolution of all current and future claims related to cosmetic talc in the United States, excluding claims related to mesothelioma or State consumer protection claims, in exchange for the payment by the Company of present value of approximately $6.475 billion payable over 25 years (nominal value of approximately $8.0 billion, discounted at a rate of 4.4%). The claims encompassed by the Proposed Plan constitute 99.75% of pending lawsuits against the Company relating to its talc powder products.
In August 2024, LLT engaged in a restructuring that resulted in the creation of three new Texas limited liability companies: (a) Red River Talc, LLC ("Red River"); (b) Pecos River Talc LLC ("Pecos River"); and (3) New Holdco (Texas) LLC. As a result of this restructuring, all claims related to ovarian and other gynecological cancers were separated and allocated to Red River, and mesothelioma, governmental unit and certain other claims were allocated to Pecos River.
In September 2024, while reiterating the Company's continued confidence in the safety of its talc products, Red River filed a voluntary petition with the United States Bankruptcy Court for the Southern District of Texas, seeking relief under Chapter 11 of the Bankruptcy Code (the Red River Bankruptcy Case), in furtherance of the Company's consensual "prepackaged" Proposed Plan. Red River also filed a motion for a temporary restraining order, seeking to extend the automatic stay to additional non-debtor entities. Prior to filing, the initial proposed plan was amended to, among other things, increase the proposed resolution by $1.75 billion.
2024 Annual Report
95


Shortly after Red River filed its Chapter 11 petition, the U.S. Trustee's office filed a motion to transfer venue in the New Jersey Bankruptcy Court, and thereafter, a motion to transfer venue and a motion to dismiss in the Texas Bankruptcy Court. A coalition of six plaintiff law firms also filed a motion to transfer venue and a motion to dismiss in the Texas Bankruptcy Court. In September 2024, the Texas Bankruptcy Court entered a temporary order enjoining the commencement or prosecution of all claims against Red River and certain non-debtor entities, including the Company, until October 11, 2024. The temporary order was extended in October 2024 and again in December 2024. The commencement and prosecution of all claims against Red River and certain non-debtor entities are currently enjoined until March 15, 2025. Also in September 2024, the New Jersey Bankruptcy Court denied the U.S. Trustee's motion to transfer venue without prejudice. In October 2024, the Texas Bankruptcy Court denied the motion to transfer venue from Texas to New Jersey Bankruptcy Court. A consolidated hearing to address, among other things, the motions to dismiss and plan confirmation is currently scheduled to begin on February 18, 2025.
Mesothelioma and State consumer protection claims are being addressed outside the Proposed Plan. The Company separately has resolved 95% of the mesothelioma lawsuits filed to date and has resolved the State claims.
To account for these settlements and the contemplated comprehensive resolution through the Proposed Plan, the Company recorded a cumulative incremental charge of approximately $5.0 billion, through the fourth fiscal quarter 2024. As of December 29, 2024, the total present value of the reserve is approximately $11.6 billion (or nominal value of approximately $13.5 billion), net of payments made in fiscal 2024. Approximately ten percent of the reserve is recorded as a current liability. The recorded amount remains the Company's best estimate of probable loss.
In February 2019, the Company’s talc supplier, Imerys Talc America, Inc. and two of its affiliates, Imerys Talc Vermont, Inc. and Imerys Talc Canada, Inc. (collectively, Imerys) filed a voluntary petition for relief under Chapter 11 of the United States Code (the Bankruptcy Code) in the United States Bankruptcy Court for the District of Delaware (Imerys Bankruptcy). The Imerys Bankruptcy relates to Imerys’s potential liability for personal injury from exposure to talcum powder sold by Imerys. In its bankruptcy, Imerys alleges it has claims against the Company for indemnification and rights to joint insurance proceeds. In its bankruptcy, Imerys proposed a Chapter 11 plan (the Imerys Plan) that contemplated all talc-related claims against it being channeled to a trust along with its alleged indemnification rights against the Company. Following confirmation and consummation of the plan, the trust would pay talc claims pursuant to proposed trust distribution procedures (the TDP) and then seek indemnification from the Company.
In February 2021, Cyprus Mines Corporation (Cyprus), which had owned certain Imerys talc mines, filed a voluntary petition for relief under Chapter 11 of the Bankruptcy Code and filed its Disclosure Statement and Plan (the Cyprus Plan). The Cyprus Plan contemplates a settlement with Imerys and talc claimants where Cyprus would make a monetary contribution to a trust established under the Imerys Plan in exchange for an injunction against talc claims asserted against it and certain affiliated parties. Cyprus also asserts it has claims for indemnity against the Company arising out of talc personal injury claims. Under the Cyprus Plan, Cyprus would also contribute its alleged indemnification rights to the trust.
In September 2023, Imerys and Cyprus filed amended plans of reorganization. The amended plans contemplate a similar construct as the prior Imerys and Cyprus Plans, including all talc claims against Imerys and Cyprus (and certain other protected parties) being channeled to a trust along with Imerys’s and Cyprus’s alleged indemnification rights against the Company. The Company opposed both plans on the basis that the plans inflated Imerys’s and Cyprus’s liability for talc claims and had the potential effect of imposing those inflated liabilities on the Company through the Company’s alleged indemnification obligations.
In July 2024, the Company, Imerys, and Cyprus and certain of their affiliates (including their parent entities), and the tort claimants' committees and future claimants' representatives appointed in their respective Chapter 11 cases entered into a global settlement agreement (the Imerys Settlement Agreement) to resolve their ongoing disputes, including disputes raised in the Imerys and Cyprus bankruptcies. In August 2024, Imerys and Cyprus filed amended Chapter 11 plans and disclosure statements incorporating the terms of the settlement with the Company. In October 2024, the Imerys Bankruptcy Court entered an order approving the Imerys Settlement Agreement (the Settlement Order). The effectiveness of certain provisions of the settlement, including mutual releases, are subject to certain conditions, including the Imerys and Cyprus Plans being accepted by a sufficient number and amount of voting creditors to be confirmed under the Bankruptcy Code. Certain insurers have appealed the Settlement Order and sought a stay of the order pending appeal, which the Court denied on January 13, 2025. The briefing of the appeal in the District Court is scheduled to be completed in April 2025. On January 5, 2025, Imerys and Cyprus each filed a certification of voting results, indicating that their respective plan had been accepted by each voting class of creditors. A joint confirmation hearing for the plans is scheduled for April 2025.
96
 Jhonson&Jhonson.jpg 


In February 2018, a securities class action lawsuit was filed against the Company and certain named officers in the United States District Court for the District of New Jersey, alleging that the Company violated the federal securities laws by failing to disclose alleged asbestos contamination in body powders containing talc, primarily JOHNSON’S Baby Powder, and that purchasers of the Company’s shares suffered losses as a result. In April 2019, the Company moved to dismiss the complaint. In December 2019, the Court denied, in part, the motion to dismiss. The case was stayed in May 2022 pursuant to the LTL Bankruptcy Case and was reopened in May 2023. In December 2023, the Court granted Plaintiff’s motion for class certification. In January 2024, Defendants filed a petition with the Third Circuit under Federal Rule of Civil Procedure 23(f) for permission to appeal the Court’s order granting class certification, and in February 2024, the Third Circuit granted Defendants' petition. In February 2024, fact discovery closed, the Court ordered the parties to mediate, and stayed the case pending mediation. In May 2024, the parties participated in an unsuccessful mediation. In June 2024, at the parties' request, the Court lifted the stay for certain limited discovery, but otherwise kept the stay in place pending a decision from the Third Circuit on the 23(f) petition. Briefing on the 23(f) petition was completed in September 2024. In January 2025, the Third Circuit listed the appeal for oral argument in March 2025.
Matters concerning opioids
Beginning in 2014 and continuing to the present, the Company and Janssen Pharmaceuticals, Inc. (JPI), along with other pharmaceutical companies, have been named in close to 3,500 lawsuits related to the marketing of opioids, including DURAGESIC, NUCYNTA and NUCYNTA ER. Similar lawsuits have also been filed by private plaintiffs and organizations, including but not limited to the following: individual plaintiffs on behalf of children born with Neonatal Abstinence Syndrome (NAS); hospitals; and health insurers/payors.
To date, the Company and JPI have litigated two of the cases to judgment and have prevailed in both, either at trial or on appeal.
In July 2021, the Company announced finalization of an agreement to settle the state and subdivision claims for up to $5.0 billion. Approximately 70% of the all-in settlement was paid by the end of fiscal fourth quarter 2024. A few government entities opted out of the settlement. In September 2024, the Company reached an agreement to resolve the hospital cases.
The Company and JPI continue to defend the cases brought by the remaining government entity litigants as well as the cases brought by private litigants. In total, there are approximately 35 remaining opioid cases against the Company and JPI in various state courts, 390 remaining cases in the Ohio multi-district litigation (MDL), and 4 additional cases in other federal courts.
In addition, the Province of British Columbia filed suit against the Company and its Canadian affiliate Janssen Inc., and many other industry members, in Canada. That action was certified as an opt in class action on behalf of other provincial/territorial and the federal governments in Canada in January 2025. Additional proposed class actions have been filed in Canada against the Company and Janssen Inc., and many other industry members, by and on behalf of people who used opioids (for personal injuries), municipalities and First Nations bands. The proposed class action in Quebec on behalf of residents diagnosed with opioid use disorder was authorized to proceed against Janssen Inc. and other industry members in April 2024; and leave to appeal was denied in October 2024.
Starting in November 2019, a series of shareholder derivative complaints were filed against the Company as the nominal defendant and certain current and former directors and officers as defendants in the Superior Court of New Jersey. The complaint alleges breaches of fiduciary duties related to the marketing of opioids, and that the Company has suffered damages as a result of those alleged breaches. As of September 2024, all the complaints had been dismissed, and all appeals exhausted.
Product liability
The Company and certain of its subsidiaries are involved in numerous product liability claims and lawsuits involving multiple products. Claimants in these cases seek substantial compensatory and, where available, punitive damages. While the Company believes it has substantial defenses, it is not feasible to predict the ultimate outcome of litigation. From time to time, even if it has substantial defenses, the Company considers isolated settlements based on a variety of circumstances. The Company has accrued for these matters and will continue to monitor each related legal issue and adjust accruals as might be warranted based on new information and further developments in accordance with ASC 450-20-25, Contingencies. The Company accrues an estimate of the legal defense costs needed to defend each matter when those costs are probable and can be reasonably estimated. For certain of these matters, the Company has accrued additional amounts such as estimated costs associated with settlements, damages and other losses. Product liability accruals can represent projected product liability for thousands of claims around the world, each in different litigation environments and with different fact patterns. Changes to the accruals may be required in the future as additional information becomes available.
2024 Annual Report
97


The table below contains the most significant of these cases and provides the approximate number of plaintiffs in the United States with direct claims in pending lawsuits regarding injuries allegedly due to the relevant product or product category as of December 29, 2024:
Product or product categoryNumber of plaintiffs
Body powders containing talc, primarily JOHNSON’S Baby Powder62,830 
DePuy ASR XL Acetabular System and DePuy ASR Hip Resurfacing System60 
PINNACLE Acetabular Cup System910 
Pelvic meshes5,990 
ETHICON PHYSIOMESH Flexible Composite Mesh130 
RISPERDAL7 
ELMIRON2,170 
The number of pending lawsuits is expected to fluctuate as certain lawsuits are settled or dismissed and additional lawsuits are filed. There may be additional claims that have not yet been filed.
MedTech
DePuy ASR XL Acetabular System and ASR Hip Resurfacing System
In August 2010, DePuy Orthopaedics, Inc. (DePuy) announced a worldwide voluntary recall of its ASR XL Acetabular System and DePuy ASR Hip Resurfacing System (ASR Hip) used in hip replacement surgery. Claims for personal injury have been made against DePuy and the Company. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Northern District of Ohio. Litigation has also been filed in countries outside of the United States, primarily in the United Kingdom, Ireland, India and Italy. In November 2013, DePuy reached an agreement with a Court-appointed committee of lawyers representing ASR Hip plaintiffs to establish a program to settle claims with eligible ASR Hip patients in the United States. This settlement program has resolved more than 10,000 claims, thereby bringing to resolution significant ASR Hip litigation activity in the United States. However, lawsuits in the United States remain, and the settlement program does not address litigation outside of the United States. The Company continues to receive information with respect to potential additional costs associated with this recall on a worldwide basis. The Company has established accruals for the costs associated with the United States settlement program and ASR Hip-related product liability litigation.
DePuy PINNACLE Acetabular Cup System
Claims for personal injury have also been made against DePuy Orthopaedics, Inc. and the Company (collectively, DePuy) relating to the PINNACLE Acetabular Cup System used in hip replacement surgery. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. Most cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Northern District of Texas (Texas MDL). Beginning on June 1, 2022, the Judicial Panel on Multidistrict Litigation ceased transfer of new cases into the Texas MDL, and there are now cases pending in federal court outside the Texas MDL. Litigation also has been filed in state courts and in countries outside of the United States. During the first quarter of 2019, DePuy established a United States settlement program to resolve these cases. As part of the settlement program, adverse verdicts have been settled. The Company has established an accrual for product liability litigation associated with the PINNACLE Acetabular Cup System and the related settlement program.
Ethicon Pelvic Mesh
Claims for personal injury have been made against Ethicon, Inc. (Ethicon) and the Company arising out of Ethicon’s pelvic mesh devices used to treat stress urinary incontinence and pelvic organ prolapse. The Company continues to receive information with respect to potential costs and additional cases. Cases filed in federal courts in the United States had been organized as a multi-district litigation (MDL) in the United States District Court for the Southern District of West Virginia. In March 2021, the MDL Court entered an order closing the MDL. The MDL Court has remanded cases for trial to the jurisdictions where the case was originally filed and additional pelvic mesh lawsuits have been filed, and remain, outside of the MDL. The Company has settled or otherwise resolved the majority of the United States cases and the estimated costs associated with these settlements and the remaining cases are reflected in the Company’s accruals. In addition, class actions and individual personal injury cases or claims seeking damages for alleged injury resulting from Ethicon’s pelvic mesh devices have been commenced in
98
 Jhonson&Jhonson.jpg 


various countries outside of the United States, including claims and cases in the United Kingdom, the Netherlands, and Ireland, and class actions in Israel, Australia, Canada and South Africa. The vast majority of these actions are now resolved. The Company has established accruals with respect to product liability litigation associated with Ethicon’s pelvic mesh products.
Ethicon Physiomesh
Following a June 2016 worldwide market withdrawal of Ethicon Physiomesh Flexible Composite Mesh (Physiomesh), claims for personal injury have been made against Ethicon, Inc. (Ethicon) and the Company alleging personal injury arising out of the use of this hernia mesh device. Cases filed in federal courts in the United States have been organized as a multi-district litigation (MDL) in the United States District Court for the Northern District of Georgia. A multi-county litigation (MCL) also has been formed in New Jersey state court and assigned to Atlantic County for cases pending in New Jersey. In addition to the matters in the MDL and MCL, there are additional lawsuits pending in the United States District Court for the Southern District of Ohio, which are part of the MDL for polypropylene mesh devices manufactured by C.R. Bard, Inc., and lawsuits pending in two New Jersey MCLs formed for Proceed/Proceed Ventral Patch and Prolene Hernia systems, and lawsuits pending outside the United States. In May 2021, Ethicon and lead counsel for the plaintiffs entered into a term sheet to resolve approximately 3,600 Physiomesh cases (covering approximately 4,300 plaintiffs) pending in the MDL and MCL at that time. A master settlement agreement (MSA) was entered into in September 2021 and includes 3,729 cases in the MDL and MCL. Other than a small number of cases still pending in the MDL, all Physiomesh matters in the United States have been resolved or are undergoing formal review for purposes of settlement.
Claims have also been filed against Ethicon and the Company alleging personal injuries arising from the PROCEED Mesh and PROCEED Ventral Patch hernia mesh products. In March 2019, the New Jersey Supreme Court entered an order consolidating these cases pending in New Jersey as an MCL in Atlantic County Superior Court. Additional cases have been filed in various federal and state courts in the United States, and in jurisdictions outside the United States.
Ethicon and the Company also have been subject to claims for personal injuries arising from the PROLENE Polypropylene Hernia System. In January 2020, the New Jersey Supreme Court created an MCL in Atlantic County Superior Court to handle such cases. Cases involving this product have also been filed in other federal and state courts in the United States.
In October 2022, an agreement in principle, subject to various conditions, was reached to settle the majority of the pending cases involving Proceed, Proceed Ventral Patch, Prolene Hernia System and related multi-layered mesh products, as well as a number of unfiled claims. All litigation activities in the two New Jersey MCLs are stayed pending effectuation of the proposed settlement. Future cases that are filed in the New Jersey MCLs will be subject to docket control orders requiring early expert reports and discovery requirements.
The Company has established accruals with respect to product liability litigation associated with Ethicon Physiomesh Flexible Composite Mesh, PROCEED Mesh and PROCEED Ventral Patch, and PROLENE Polypropylene Hernia System products.
Innovative Medicine
RISPERDAL
Claims for personal injury have been made against Janssen Pharmaceuticals, Inc. and the Company arising out of the use of RISPERDAL, and related compounds, indicated for the treatment of schizophrenia, acute manic or mixed episodes associated with bipolar I disorder and irritability associated with autism. Lawsuits primarily have been filed in state courts in Pennsylvania, California, and Missouri. Other actions are pending in various courts in the United States and Canada. The Company continues to defend RISPERDAL product liability lawsuits, and continues to evaluate potential costs related to those claims. The Company has successfully defended a number of these cases but there have been verdicts against the Company, including a verdict in October 2019 of $8.0 billion of punitive damages related to one plaintiff, which the trial judge reduced to $6.8 million in January 2020. In September 2021, the Company entered into a settlement in principle with the counsel representing plaintiffs in this matter and in substantially all of the outstanding cases in the United States. The costs associated with this and other settlements are reflected in the Company's accruals.
ELMIRON
Claims for personal injury have been made against a number of Johnson & Johnson companies, including Janssen Pharmaceuticals, Inc. and the Company, arising out of the use of ELMIRON, a prescription medication indicated for the relief of bladder pain or discomfort associated with interstitial cystitis. These lawsuits, which allege that ELMIRON contributes to the development of permanent retinal injury and vision loss, have been filed in both state and federal courts across the United States. In December 2020, lawsuits filed in federal courts in the United States, including putative class action cases seeking medical monitoring, were organized as a multi-district litigation in the United States District Court for the District of New
2024 Annual Report
99


Jersey (MDL). In addition, cases have been filed in various state courts of New Jersey, which have been coordinated in a multi-county litigation in Bergen County, as well as the Court of Common Pleas in Philadelphia, which have been coordinated and granted mass tort designation. In addition, three class action lawsuits have been filed in Canada. The Company continues to defend ELMIRON product liability lawsuits and continues to evaluate potential costs related to those claims. All U.S. based ELMIRON matters have been resolved or are undergoing formal review for purposes of settlement. The Company has established accruals for defense and indemnity costs associated with ELMIRON related product liability litigation.
Intellectual property
Certain subsidiaries of the Company are subject, from time to time, to legal proceedings and claims related to patent, trademark and other intellectual property matters arising out of their businesses. Many of these matters involve challenges to the scope and/or validity of patents that relate to various products and allegations that certain of the Company’s products infringe the intellectual property rights of third parties. Although these subsidiaries believe that they have substantial defenses to these challenges and allegations with respect to all significant patents, there can be no assurance as to the outcome of these matters. A loss in any of these cases could adversely affect the ability of these subsidiaries to sell their products, result in loss of sales due to loss of market exclusivity, require the payment of past damages and future royalties, and may result in a non-cash impairment charge for any associated intangible asset.
Innovative Medicine - litigation against filers of abbreviated new drug applications (ANDAs)
The Company’s subsidiaries have brought lawsuits against generic companies that have filed ANDAs with the U.S. FDA (or similar lawsuits outside of the United States) seeking to market generic versions of products sold by various subsidiaries of the Company prior to expiration of the applicable patents covering those products. These lawsuits typically include allegations of non-infringement and/or invalidity of patents listed in FDA’s publication “Approved Drug Products with Therapeutic Equivalence Evaluations” (commonly known as the Orange Book). In each of these lawsuits, the Company’s subsidiaries are seeking an order enjoining the defendant from marketing a generic version of a product before the expiration of the relevant patents (Orange Book Listed Patents). In the event the Company’s subsidiaries are not successful in an action, or any automatic statutory stay expires before the court rulings are obtained, the generic companies involved would have the ability, upon regulatory approval, to introduce generic versions of their products to the market, resulting in the potential for substantial market share and revenue losses for the applicable products, and which may result in a non-cash impairment charge in any associated intangible asset. In addition, from time to time, the Company’s subsidiaries may settle these types of actions and such settlements can involve the introduction of generic versions of the products at issue to the market prior to the expiration of the relevant patents.
The Inter Partes Review (IPR) process with the United States Patent and Trademark Office (USPTO), created under the 2011 America Invents Act, is also being used at times by generic companies in conjunction with ANDAs and lawsuits to challenge the applicable patents.
XARELTO
Beginning in March 2021, Janssen Pharmaceuticals, Inc.; Bayer Pharma AG; Bayer AG; and Bayer Intellectual Property GmbH filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of XARELTO before expiration of certain Orange Book Listed Patents. The following entities are named defendants: Dr. Reddy’s Laboratories, Inc.; Dr. Reddy’s Laboratories, Ltd.; Lupin Limited; Lupin Pharmaceuticals, Inc.; Taro Pharmaceutical Industries Ltd.; Taro Pharmaceuticals U.S.A., Inc.; Teva Pharmaceuticals USA, Inc.; Mylan Pharmaceuticals Inc.; Mylan Inc.; Mankind Pharma Limited; Apotex Inc.; Apotex Corp.; Auson Pharmaceuticals Inc.; Shanghai Auson Pharmaceuticals Co. Ltd.; Cipla Ltd.; Cipla USA Inc.; InvaGen Pharmaceuticals, Inc.; Prinston Pharmaceuticals, Inc.; Ascent Pharmaceuticals, Inc.; and Hetero Labs Limited. In October 2024, the Company entered into a confidential settlement agreement with Auson Pharmaceuticals Inc. and Shanghai Auson Pharmaceuticals Co., Ltd. and the case was dismissed. In November 2024, the Company entered into confidential settlement agreements with Ascent Pharmaceuticals Inc. that resulted in dismissal of litigation against Ascent Pharmaceuticals, Inc. and Hetero Labs Limited. In January 2025, the Company entered into a confidential settlement agreement with Prinston Pharmaceutical, Inc. (as to U.S. Patent No. 9,539,218). The following U.S. patents are included in one or more cases: 9,539,218 and 10,828,310.
U.S. Patent No. 10,828,310 was also under consideration by the USPTO in an IPR proceeding. In July 2023, the USPTO issued a final written decision finding the claims of the patent invalid. In September 2023, Bayer Pharma AG filed an appeal to the U.S. Court of Appeals for the Federal Circuit.
INVEGA SUSTENNA
100
 Jhonson&Jhonson.jpg 


Beginning in January 2018, Janssen Pharmaceutica NV and Janssen Pharmaceuticals, Inc. filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of INVEGA SUSTENNA before expiration of the Orange Book Listed Patent. The following entities are named defendants: Teva Pharmaceuticals USA, Inc.; Mylan Laboratories Limited; Pharmascience Inc.; Mallinckrodt PLC; Specgx LLC; Tolmar, Inc.; Accord Healthcare, Inc.; Qilu Pharmaceutical Co. Ltd.; and Qilu Pharma Inc. The following U.S. patent is included in one or more cases: 9,439,906. In October 2020, the district court issued a decision in the case against Teva Pharmaceuticals USA, Inc., finding that United States Patent No. 9,439,906 is not invalid. Teva previously stipulated to infringement. Teva appealed the decision, and, in April 2024, the United States Court of Appeals for the Federal Circuit vacated and remanded the case to the district court for further proceedings. In November 2024, the district court issued its decision on remand, finding that United States Patent No. 9,439,906 is not invalid. Teva appealed to the Court of Appeals for the Federal Circuit, and oral argument is scheduled for April 2025. In February 2024, the district court issued a decision in the case against Tolmar Inc. finding that United States Patent No. 9,439,906 is not invalid. Tolmar previously stipulated to infringement. Tolmar has appealed the decision.
Beginning in February 2018, Janssen Inc. and Janssen Pharmaceutica NV initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against generic manufacturers who have filed ANDSs seeking approval to market generic versions of INVEGA SUSTENNA before expiration of the listed patent. The following entities are named defendants: Pharmascience Inc. and Apotex Inc. The following Canadian patent is included in one or more cases: 2,655,335. In June 2024, the Supreme Court dismissed the Apotex case. In September 2024, the Supreme Court granted Pharmascience's motion to appeal the Federal Court's decision that the 2,655,335 Patent is not invalid.
INVEGA TRINZA
Beginning in September 2020, Janssen Pharmaceuticals, Inc., Janssen Pharmaceutica NV, and Janssen Research & Development, LLC filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of INVEGA TRINZA before expiration of the Orange Book Listed Patent. The following entities are named defendants: Mylan Laboratories Limited; Mylan Pharmaceuticals Inc.; and Mylan Institutional LLC. The following U.S. patent is included in one or more cases: 10,143,693. In May 2023, the District Court issued a decision finding that Mylan’s proposed generic product infringes the asserted patent and that the patent is not invalid. Mylan has appealed the decision. Oral argument before the Court of Appeals for the Federal Circuit was held in February 2025.
SYMTUZA
Beginning in November 2021, Janssen Products, L.P., Janssen Sciences Ireland Unlimited Company, Gilead Sciences, Inc. and Gilead Sciences Ireland UC filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of SYMTUZA before expiration of certain Orange Book Listed Patents. The following entities are named defendants: Lupin Limited; Lupin Pharmaceuticals, Inc.; MSN Laboratories Private Ltd.; MSN Life Sciences Private Ltd.; MSN Pharmaceuticals Inc.; Apotex Inc.; and Apotex Corp. The following U.S. patents are included in one or more cases: 10,039,718 and 10,786,518. A trial is scheduled to begin in February 2025.
ERLEADA
Beginning in May 2022, Aragon Pharmaceuticals, Inc., Janssen Biotech, Inc. (collectively, Janssen), Sloan Kettering Institute for Cancer Research (SKI) and The Regents of the University of California filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of ERLEADA before expiration of certain Orange Book Listed Patents. The following entities are named defendants: Zydus Worldwide DMCC; Zydus Pharmaceuticals (USA), Inc.; Zydus Lifesciences Limited; Hetero Labs Limited Unit V; and Hetero USA, Inc. The following U.S. patents are included in one or more cases: 9,481,663; 9,884,054; 10,052,314 (which reissued as RE49,353); 10,702,508; 10,849,888; 8,445,507; 8,802,689; 9,388,159; 9,987,261; RE49,353; and 11,963,952. In October 2024, Janssen, The Regents of the University of California, SKI, Hetero Labs Limited Unit V, and Hetero USA, Inc. entered into a confidential settlement, and the case was dismissed. In November 2024, Janssen, The Regents of the University of California, Zydus Worldwide DMCC, Zydus Pharmaceuticals (USA), Inc., and Zydus Lifesciences Limited entered into confidential settlements, and the cases were dismissed.
SPRAVATO
Beginning in May 2023, Janssen Pharmaceuticals, Inc. and Janssen Pharmaceutica NV filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of SPRAVATO before expiration of certain Orange Book Listed Patents. The following entities are named defendants: Sandoz
2024 Annual Report
101


Inc.; Hikma Pharmaceuticals Inc. USA; Hikma Pharmaceuticals PLC; and Alkem Laboratories Ltd. The following U.S. patents are included in one or more cases: 10,869,844; 11,173,134; 11,311,500; and 11,446,260.
INVOKANA
Beginning in January 2024, Janssen Inc. and Mitsubishi Tanabe Pharma Corporation initiated Statements of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against generic manufacturers who filed ANDSs seeking approval to market generic versions of INVOKANA before expiration of the listed patents. The following entities are named defendants: Jamp Pharma Corporation and Apotex Inc. The following Canadian patents are included in one or more cases: 2,534,024 and 2,671,357. Trial in the Jamp action is scheduled for September 2025, and trial in the Apotex action is scheduled for December 2025.
MedTech
In March 2016, Abiomed, Inc. (Abiomed) filed a declaratory judgment action against Maquet Cardiovascular LLC (Maquet) in U.S. District Court for the District of Massachusetts seeking a declaration that the Impella does not infringe certain Maquet patents, currently U.S. Patent Nos. 7,022,100 (’100); 8,888,728; 9,327,068; 9,545,468; 9,561,314; and 9,597,437. Maquet counterclaimed for infringement of each of those patents. After claim construction, Maquet alleged infringement of only the ’100 patent. In September 2021, the court granted Abiomed’s motion for summary judgment of non-infringement of the ’100 patent, and in September 2023, the district court entered final judgment in favor of Abiomed on all patents-in-suit. Maquet appealed.
Government proceedings
Like other companies in the pharmaceutical and medical technologies industries, the Company and certain of its subsidiaries are subject to extensive regulation by national, state and local government agencies in the United States and other countries in which they operate. Such regulation has been the basis of government investigations and litigations. The most significant litigation brought by, and investigations conducted by, government agencies are listed below. It is possible that criminal charges and substantial fines and/or civil penalties or damages could result from government investigations or litigation.
MedTech
In July 2018, the Public Prosecution Service in Rio de Janeiro and representatives from the Brazilian antitrust authority CADE inspected the offices of more than 30 companies including Johnson & Johnson do Brasil Indústria e Comércio de Produtos para Saúde Ltda. The authorities appear to be investigating allegations of possible anti-competitive behavior and possible improper payments in the medical device industry. The Company continues to respond to inquiries regarding the Foreign Corrupt Practices Act from the United States Department of Justice (DOJ) and the United States Securities and Exchange Commission. The Company has been informed DOJ has closed its investigation.
In July 2023, the DOJ issued Civil Investigative Demands to the Company, Johnson & Johnson Surgical Vision, Inc., and Johnson & Johnson Vision Care, Inc. (collectively, J&J Vision) in connection with a civil investigation under the False Claims Act relating to free or discounted intraocular lenses and equipment used in eye surgery, such as phacoemulsification and laser systems. J&J Vision has begun producing documents and information responsive to the Civil Investigative Demands. J&J Vision is in ongoing discussions with the DOJ regarding its inquiry.
Innovative Medicine
In July 2016, the Company and Janssen Products, LP were served with a qui tam complaint pursuant to the False Claims Act filed in the United States District Court for the District of New Jersey alleging the off-label promotion of two HIV products, PREZISTA and INTELENCE, and anti-kickback violations in connection with the promotion of these products. The complaint was filed under seal in December 2012. The federal and state governments have declined to intervene, and the lawsuit is being prosecuted by the relators. The Court denied summary judgment on all claims in December 2021. Daubert motions were granted in part and denied in part in January 2022, and trial commenced in May 2024. On June 13, 2024, a jury found no liability regarding the anti-kickback violations but found liability for a portion of the off-label promotion claims. The Company is pursuing post-trial briefing challenging the verdict on the off-label claims.
In March 2017, Janssen Biotech, Inc. (JBI) received a Civil Investigative Demand from the United States Department of Justice regarding a False Claims Act investigation concerning management and advisory services provided to rheumatology and gastroenterology practices that purchased REMICADE or SIMPONI ARIA. In August 2019, the United States Department of Justice notified JBI that it was closing the investigation. Subsequently, the United States District Court for the District of Massachusetts unsealed a qui tam False Claims Act complaint, which was served on the Company. The Department of Justice
102
 Jhonson&Jhonson.jpg 


had declined to intervene in the qui tam lawsuit in August 2019. The Company filed a motion to dismiss, which was granted in part and denied in part. Discovery is underway.
General litigation
The Company or its subsidiaries are also parties to various proceedings brought under the Comprehensive Environmental Response, Compensation, and Liability Act, commonly known as Superfund, and comparable state, local or foreign laws in which the primary relief sought is the Company’s agreement to implement remediation activities at designated hazardous waste sites or to reimburse the government or third parties for the costs they have incurred in performing remediation as such sites.
In October 2017, certain United States service members and their families brought a complaint against a number of pharmaceutical and medical devices companies, including Johnson & Johnson and certain of its subsidiaries in United States District Court for the District of Columbia, alleging that the defendants violated the United States Anti-Terrorism Act. The complaint alleges that the defendants provided funding for terrorist organizations through their sales practices pursuant to pharmaceutical and medical device contracts with the Iraqi Ministry of Health. In July 2020, the District Court dismissed the complaint. In January 2022, the United States Court of Appeals for the District of Columbia Circuit reversed the District Court’s decision. In June 2023, defendants filed a petition for a writ of certiorari to the United States Supreme Court. In June 2024, the Supreme Court vacated the D.C. Circuit's decision and remanded the case to the D.C. Circuit. Oral argument was held in November 2024.
In February 2024, a putative class action was filed against the Company, the Pension & Benefits Committee of Johnson & Johnson (Committee), and certain named officers and employees, in United States District Court for the District of New Jersey. In May 2024, the plaintiff filed an amended complaint against the Company and the Committee. The complaint alleges that defendants breached fiduciary duties under the Employee Retirement Income Security Act (ERISA) by allegedly mismanaging the Company’s prescription-drug benefits program. The complaint seeks damages and other relief. In January 2025, the Court granted in part and denied in part defendants’ motion to dismiss.
MedTech
In October 2020, Fortis Advisors LLC (Fortis), in its capacity as representative of the former stockholders of Auris Health Inc. (Auris), filed a complaint against the Company, Ethicon Inc., and certain named officers and employees (collectively, Ethicon) in the Court of Chancery of the State of Delaware. The complaint alleges breach of contract, fraud, and other causes of action against Ethicon in connection with Ethicon’s acquisition of Auris in 2019. The complaint seeks damages and other relief. In December 2021, the Court granted in part and denied in part defendants’ motion to dismiss certain causes of action. All claims against the individual defendants were dismissed. The trial occurred in January 2024. In September 2024, the court found liability with respect to certain claims and no liability with respect to other claims. The Company has appealed the decision.
In October 2019, Innovative Health, LLC filed a complaint against Biosense Webster, Inc (BWI) in the United States District Court for the Central District of California. The complaint alleges that certain of BWI's business practices and contractual terms violate the antitrust laws of the United States and the State of California by restricting competition in the sale of High Density Mapping Catheters and Ultrasound Catheters. Trial is scheduled for April 2025.
Innovative Medicine
In June 2019, the United States Federal Trade Commission (FTC) issued a Civil Investigative Demand to the Company and Janssen Biotech, Inc. (collectively, Janssen) in connection with its investigation of whether Janssen’s REMICADE contracting practices violate federal antitrust laws. The Company has produced documents and information responsive to the Civil Investigative Demand. Janssen is in ongoing discussions with the FTC staff regarding its inquiry.
In February 2022, the United States Federal Trade Commission (FTC) issued Civil Investigative Demands to Johnson & Johnson and Janssen Biotech, Inc. (collectively, Janssen) in connection with its investigation of whether advertising practices for REMICADE violate federal law. Janssen has produced documents and information responsive to the Civil Investigative Demands. In January 2025, the FTC Bureau of Consumer Protection informed Janssen that it was closing its investigation.
2024 Annual Report
103


In October 2018, two separate putative class actions were filed against Actelion Pharmaceutical Ltd., Actelion Pharmaceuticals U.S., Inc., and Actelion Clinical Research, Inc. (collectively Actelion) in United States District Court for the District of Maryland and United States District Court for the District of Columbia. The complaints allege that Actelion violated state and federal antitrust and unfair competition laws by allegedly refusing to supply generic pharmaceutical manufacturers with samples of TRACLEER. TRACLEER is subject to a Risk Evaluation and Mitigation Strategy required by the U.S. Food and Drug Administration, which imposes restrictions on distribution of the product. In January 2019, the plaintiffs dismissed the District of Columbia case and filed a consolidated complaint in the United States District Court for the District of Maryland. In September 2024, the district court granted plaintiff's motion for class certification. Trial is scheduled for March 2026.
In December 2023, a putative class action lawsuit was filed against the Company and Janssen Biotech Inc. (collectively Janssen) in the United States District Court for the Eastern District of Virginia. The complaint alleges that Janssen violated federal and state antitrust laws and other state laws by delaying biosimilar competition with STELARA through Janssen's enforcement of patent rights covering STELARA. The complaint seeks damages and other relief. In February 2024, plaintiffs filed an amended complaint, which Janssen moved to dismiss in March 2024. In August 2024, the court granted in part and denied in part Janssen's motion to dismiss.
In December 2018, Janssen Biotech, Inc., Janssen Oncology, Inc., Janssen Research & Development, LLC, and Johnson & Johnson (collectively, Janssen) were served with a qui tam complaint on behalf of the United States, certain states, and the District of Columbia. The complaint alleges that Janssen violated the federal False Claims Act and state law when providing pricing information for ZYTIGA to the government in connection with direct sales and reimbursement programs. At this time, the federal and state governments have declined to intervene. In December 2021, the United States District Court for the District of New Jersey denied Janssen's motion to dismiss.
20. Restructuring
In fiscal 2023, the Company commenced restructuring actions within its Innovative Medicine and MedTech segments. The amounts and details of the current year programs are included below.
In fiscal 2023, the Company completed a prioritization of its research and development (R&D) investment within its Innovative Medicine segment to focus on the most promising medicines with the greatest benefit to patients. This resulted in the exit of certain programs within certain therapeutic areas. The R&D program exits are primarily in infectious diseases and vaccines including the discontinuation of its respiratory syncytial virus (RSV) adult vaccine program, hepatitis and HIV development. Pre-tax Restructuring expenses of $0.1 billion in the fiscal year 2024, included the termination of partnered and non-partnered development program costs, asset impairments and asset divestments. Pre-tax Restructuring expenses of $0.5 billion in the fiscal year 2023, included the termination of partnered and non-partnered development program costs and asset impairments. Total project costs of approximately $0.6 billion have been recorded since the restructuring was announced. The program was completed in the fiscal fourth quarter of 2024.
In fiscal 2023, the Company initiated a restructuring program of its Orthopaedics franchise within the MedTech segment to streamline operations by exiting certain markets, product lines and distribution network arrangements. The pre-tax restructuring expense of $0.2 billion in the fiscal year 2024 primarily included costs related to market and product exits. The pre-tax restructuring expense of $0.3 billion in the fiscal year 2023 primarily included inventory and instrument charges related to market and product exits. Total project costs of approximately $0.5 billion have been recorded since the restructuring was announced. The estimated costs of the total program are between $0.7 billion - $0.8 billion and is expected to be completed by the end of fiscal year 2025.
The following table summarizes the restructuring expenses for the fiscal years 2024 and 2023:
(Pre-tax Dollars in Millions)20242023
Innovative Medicine Segment(1)
$102479
MedTech Segment(2)
167319
Total Programs$269$798
(1)The fiscal year of 2024 included $102 million in Restructuring on the Consolidated Statement of Earnings. The fiscal year of 2023 included $449 million in Restructuring and $30 million in Cost of products sold on the Consolidated Statement of Earnings.
(2)The fiscal year of 2024 included $132 million in Restructuring and $35 million in Cost of products sold on the Consolidated Statement of Earnings. The fiscal year of 2023 Included $40 million in Restructuring and $279 million in Cost of products sold on the Consolidated Statement of Earnings.
Restructuring reserves as of December 29, 2024 and December 31, 2023 were insignificant.

104
 Jhonson&Jhonson.jpg 


21. Kenvue separation and discontinued operations
The results of the Consumer Health business (previously reported as a separate business segment) have been reflected as discontinued operations in the Company’s consolidated statements of earnings as Net earnings from discontinued operations, net of taxes through August 23, 2023, the date of the exchange offer. Prior periods have been recast to reflect this presentation.
On May 15, 2024, the Company issued $3.6 billion aggregate principal amount of commercial paper and received $3.6 billion of net cash proceeds to be used for general corporate purposes. On May 17, 2024, the Company completed a Debt-for-Equity Exchange of its remaining 182,329,550 shares of Kenvue Common Stock for the outstanding Commercial Paper. Upon completion of the Debt-for-Equity Exchange, the Commercial Paper was satisfied and discharged and the Company no longer owns any shares of Kenvue Common Stock. This exchange resulted in a loss of approximately $0.4 billion recorded in Other (income) expense.
On May 8, 2023, Kenvue, completed an initial public offering (the IPO) resulting in the issuance of 198,734,444 shares of its common stock, par value $0.01 per share (the “Kenvue Common Stock”), at an initial public offering of $22.00 per share for net proceeds of $4.2 billion. The excess of the net proceeds from the IPO over the net book value of the Johnson & Johnson divested interest was $2.5 billion and was recorded to additional paid-in capital. As of the closing of the IPO, Johnson & Johnson owned approximately 89.6% of the total outstanding shares of Kenvue Common Stock and at July 2, 2023, the non-controlling interest of $1.3 billion associated with Kenvue was reflected in equity attributable to non-controlling interests in the consolidated balance sheet in the fiscal second quarter of 2023.
On August 23, 2023, Johnson & Johnson completed the disposition of an additional 80.1% ownership of Kenvue Common Stock through an exchange offer, which resulted in Johnson & Johnson acquiring 190,955,436 shares of the Company’s common stock in exchange for 1,533,830,450 shares of Kenvue Common Stock. The $31.4 billion of Johnson & Johnson common stock received in the exchange offer is recorded in Treasury stock. Following the exchange offer, the Company owned 9.5% of the total outstanding shares of Kenvue Common Stock that was recorded in other assets within continuing operations at the fair market value of $4.3 billion as of August 23, 2023. Subsequent changes are reflected in other income/expense and amounted to $0.4 billion expense through December 31, 2023.
Johnson & Johnson divested net assets of $11.6 billion as of August 23, 2023, and the accumulated other comprehensive loss attributable to the Consumer Health business at that date was $4.3 billion. Additionally, at the date of the exchange offer, Johnson & Johnson decreased the non-controlling interest by $1.2 billion to record the deconsolidation of Kenvue. This resulted in a non-cash gain on the exchange offer of $21.0 billion that was recorded in Net earnings from discontinued operations, net of taxes in the consolidated statements of earnings for the fiscal third quarter of 2023. This one-time gain includes a gain of $2.8 billion on the Kenvue Common Stock retained by Johnson & Johnson. The gain on the exchange offer qualifies as a tax-free transaction for U.S. federal income tax purposes.
Also in connection with the separation, Johnson & Johnson and Kenvue entered into a separation agreement and also entered into various other agreements that provide for certain transactions to effect the transfer of the assets and liabilities of the Consumer Health business to Kenvue and to govern various interim and ongoing relationships between Kenvue and Johnson & Johnson following the completion of the Kenvue IPO, including transition services agreements (TSAs), transition manufacturing agreements (TMAs), trademark agreements, intellectual property agreements, an employee matters agreement, and a tax matters agreement. Under the TSAs, Johnson & Johnson will provide Kenvue various services and, similarly, Kenvue will provide Johnson & Johnson various services. The provision of services under the TSAs generally will terminate within 24 months following the Kenvue IPO. Additionally, Johnson & Johnson and Kenvue entered into TMAs pursuant to which Johnson & Johnson will manufacture and supply to Kenvue certain products and, similarly, Kenvue will manufacture and supply to Johnson & Johnson certain products. The terms of the TMAs range in initial duration from 3 months to 5 years.
Amounts related to the TSAs and TMAs included in the consolidated statements of earnings were immaterial for both fiscal years 2024 and 2023. Additionally, the amounts due to and from Kenvue for the above agreements was not material as of December 31, 2023.
The results of the Consumer Health business (previously reported as a separate business segment), as well as the associated gain, have been reflected as discontinued operations in the Company’s consolidated statements of earnings as Net earnings from discontinued operations, net of taxes. As a result of the separation of Kenvue, Johnson & Johnson incurred separation costs of $145 million in the fiscal year 2024, which was included in Net Earnings and incurred separation costs of $986 million and $1,089 million in the fiscal years 2023 and 2022, respectively, which were included in Net earnings from discontinued operations, net of taxes. These costs were primarily related to external advisory, legal, accounting, contractor and other
2024 Annual Report
105


incremental costs directly related to separation activities. In the fiscal 2022, as part of the planned separation of the Company’s Consumer Health business, the Company recognized approximately $0.5 billion in net incremental tax costs.
Details of Net Earnings from Discontinued Operations, net of taxes are as follows:
(Dollars in Millions)
 2023(1)
2022
Sales to customers$10,03614,953
Cost of products sold4,3696,494
Gross profit5,6678,459
Selling, marketing and administrative expenses3,0854,519
Research and development expense258468
Interest Income(117)
Interest expense, net of portion capitalized199
Other (income) expense, net1,0921,060
(Gain) on separation of Kenvue(20,984)
Restructuring46
Earnings from Discontinued Operations Before Provision for Taxes on Income22,1342,366
Provision for taxes on income307795
Net earnings from Discontinued Operations$21,8271,571
(1)The Company ceased consolidating the results of the Consumer Health business on August 23, 2023, the date of the exchange offer, but continued to reflect any separation costs incurred as part of discontinued operations through the end of the fiscal fourth quarter.
The following table presents depreciation, amortization and capital expenditures of the discontinued operations related to Kenvue:
(Dollars in Millions)
 2023(1)
2022
Depreciation and Amortization$383641
Capital expenditures$162303

106
 Jhonson&Jhonson.jpg 


Report of Independent Registered Public Accounting Firm
To the Board of Directors and Shareholders of Johnson & Johnson
Opinions on the Financial Statements and Internal Control over Financial Reporting
We have audited the accompanying consolidated balance sheets of Johnson & Johnson and its subsidiaries (the “Company”) as of December 29, 2024 and December 31, 2023, and the related consolidated statements of earnings, of comprehensive income, of equity and of cash flows for each of the three fiscal years in the period ended December 29, 2024, including the related notes (collectively referred to as the “consolidated financial statements”). We also have audited the Company's internal control over financial reporting as of December 29, 2024, based on criteria established in Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).
In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of the Company as of December 29, 2024 and December 31, 2023, and the results of its operations and its cash flows for each of the three fiscal years in the period ended December 29, 2024 in conformity with accounting principles generally accepted in the United States of America. Also in our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 29, 2024, based on criteria established in Internal Control - Integrated Framework (2013) issued by the COSO.
Basis for Opinions
The Company's management is responsible for these consolidated financial statements, for maintaining effective internal control over financial reporting, and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Management’s report on internal control over financial reporting. Our responsibility is to express opinions on the Company’s consolidated financial statements and on the Company's internal control over financial reporting based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud, and whether effective internal control over financial reporting was maintained in all material respects.
Our audits of the consolidated financial statements included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audits also included performing such other procedures as we considered necessary in the circumstances. We believe that our audits provide a reasonable basis for our opinions.
As described in Management’s report on internal control over financial reporting, management has excluded Shockwave Medical, Inc., (“Shockwave”) from its assessment of internal control over financial reporting as of December 29, 2024 because it was acquired by the Company in a purchase business combination during 2024. We have also excluded Shockwave from our audit of internal control over financial reporting. Shockwave is a wholly-owned subsidiary whose total assets and total sales excluded from management’s assessment and our audit of internal control over financial reporting represent less than 1% of each of the related consolidated financial statement amounts as of and for the fiscal year ended December 29, 2024.
2024 Annual Report
107


Definition and Limitations of Internal Control over Financial Reporting
A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
Critical Audit Matters
The critical audit matters communicated below are matters arising from the current period audit of the consolidated financial statements that were communicated or required to be communicated to the audit committee and that (i) relate to accounts or disclosures that are material to the consolidated financial statements and (ii) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.
U.S. Innovative Medicine Rebate Reserves – Managed Care, Medicare and Medicaid
As described in Note 1 to the consolidated financial statements, the Company recognizes revenue from product sales when obligations under the terms of a contract with the customer are satisfied. Rebates and discounts provided to customers are accounted for as variable consideration and recorded as a reduction in sales. The liability for such rebates and discounts is recognized within Accrued rebates, returns, and promotions on the consolidated balance sheet. A significant portion of the liability related to rebates is from the sale of pharmaceutical products within the U.S., primarily the Managed Care, Medicare and Medicaid programs, which amounted to $12.3 billion as of December 29, 2024. For significant rebate programs, which include the U.S. Managed Care, Medicare and Medicaid rebate programs, rebates and discounts estimated by management are based on contractual terms, historical experience, patient outcomes, trend analysis, and projected market conditions in the various markets served.
The principal considerations for our determination that performing procedures relating to U.S. Innovative Medicine rebate reserves - Managed Care, Medicare and Medicaid is a critical audit matter are (i) the significant judgment by management due to the significant measurement uncertainty when developing the estimate of these reserves and (ii) a high degree of auditor judgment, subjectivity, and effort in performing procedures and evaluating the assumptions related to contractual terms, historical experience, patient outcomes, trend analysis, and projected market conditions in the U.S. pharmaceutical market.
Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the consolidated financial statements. These procedures included testing the effectiveness of controls relating to management’s estimate of the U.S. Innovative Medicine rebate reserves - Managed Care, Medicare and Medicaid, including controls over the assumptions used to estimate these rebates. These procedures also included, among others (i) developing an independent estimate of the rebates by utilizing third party information on price and market conditions in the U.S. pharmaceutical market, the terms of the specific rebate programs, and the historical experience and trend analysis of actual rebate claims paid; (ii) testing, on a sample basis, rebate claims processed by the Company, including evaluating those claims for consistency with the contractual and mandated terms of the Company’s rebate arrangements; and (iii) comparing the independent estimates to management’s estimates to evaluate the reasonableness of management’s estimates.
108
 Jhonson&Jhonson.jpg 


Litigation Contingencies – Talc
As described in Notes 1 and 19 to the consolidated financial statements, the Company records accruals for loss contingencies associated with legal matters, including talc, when it is probable that a liability will be incurred and the amount of the loss can be reasonably estimated. To the extent adverse awards, judgments, or verdicts have been rendered against the Company, management does not record an accrual until a loss is determined to be probable and can be reasonably estimated. For these matters, management is unable to estimate the possible loss or range of loss beyond the amounts accrued. Amounts accrued for legal contingencies often result from a complex series of judgments about future events and uncertainties that rely heavily on estimates and assumptions including timing of related payments. The ability to make such estimates and judgments can be affected by various factors, including, among other things, whether damages sought in the proceedings are unsubstantiated or indeterminate; scientific and legal discovery has not commenced or is not complete; proceedings are in early stages; matters present legal uncertainties; there are significant facts in dispute; procedural or jurisdictional issues; the uncertainty and unpredictability of the number of potential claims; ability to achieve comprehensive multi-party settlements; complexity of related cross-claims and counterclaims; and/or there are numerous parties involved. Management continues to believe that the Company has strong legal grounds to contest the talc verdicts it has appealed. Notwithstanding management’s confidence in the safety of the Company’s talc products, in certain circumstances the Company has settled cases. In May 2024, the Company proposed a consensual “prepackaged” Chapter 11 bankruptcy plan (the “Proposed Plan”) for the final resolution of all current and future claims related to cosmetic talc in the United States, excluding claims related to mesothelioma or State consumer protection claims. In September 2024, the Company’s subsidiary Red River Talc, LLC filed a voluntary petition, seeking relief under Chapter 11 of the Bankruptcy Code, in furtherance of the Company’s consensual “prepackaged” Proposed Plan. As of December 29, 2024, the total present value of the reserve to resolve the talc claims is approximately $11.6 billion, of which approximately ten percent is recorded as a current liability. The recorded amount remains the Company's best estimate of probable loss. The Company is unable to estimate the possible loss or range of loss beyond the amounts accrued.
The principal considerations for our determination that performing procedures relating to the litigation contingencies - talc is a critical audit matter are (i) the significant judgment by management when assessing the likelihood of a loss being incurred for the remaining unresolved talc claims, when determining whether a reasonable estimate of the loss or range of loss for the remaining unresolved talc claims can be made, and when determining the timing of settlement payments for the remaining unresolved talc claims, and (ii) a high degree of auditor judgment, subjectivity, and effort in performing procedures and evaluating audit evidence related to management’s assessment of the loss contingencies associated with the talc litigation.
Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the consolidated financial statements. These procedures included testing the effectiveness of controls relating to management’s assessment of the litigation contingencies – talc, including controls over determining whether a loss is probable and whether the amount of loss can be reasonably estimated, as well as financial statement disclosures. These procedures also included, among others (i) gaining an understanding of the Company’s process around the accounting and reporting for the talc litigation; (ii) obtaining and evaluating certain executed settlement agreements related to the talc litigation; (iii) discussing the status of significant known actual and potential litigation and settlements activity with the Company’s in-house legal counsel, as well as external counsel when deemed necessary; (iv) obtaining and evaluating the letters of audit inquiry with internal and external legal counsel related to the talc litigation; (v) evaluating the reasonableness of management’s assessment regarding whether an unfavorable outcome is reasonably possible or probable and reasonably estimable; and (vi) evaluating the sufficiency of the Company’s litigation contingencies disclosures.


/s/ PricewaterhouseCoopers LLP
Florham Park, New Jersey
February 13, 2025
We have served as the Company’s auditor since at least 1920. We have not been able to determine the specific year we began serving as auditor of the Company.
2024 Annual Report
109


Management’s report on internal control over financial reporting
Under Section 404 of the Sarbanes-Oxley Act of 2002, management is required to assess the effectiveness of the Company’s internal control over financial reporting as of the end of each fiscal year and report, based on that assessment, whether the Company’s internal control over financial reporting is effective.
Management of the Company is responsible for establishing and maintaining adequate internal control over financial reporting. The Company’s internal control over financial reporting is designed to provide reasonable assurance as to the reliability of the Company’s financial reporting and the preparation of external financial statements in accordance with generally accepted accounting principles.
Internal controls over financial reporting, no matter how well designed, have inherent limitations. Therefore, internal control over financial reporting determined to be effective can provide only reasonable assurance with respect to financial statement preparation and may not prevent or detect all misstatements. Moreover, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
The Company’s management has assessed the effectiveness of the Company’s internal control over financial reporting as of December 29, 2024. In making this assessment, the Company used the criteria established by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in “Internal Control-Integrated Framework (2013).” These criteria are in the areas of control environment, risk assessment, control activities, information and communication, and monitoring. The Company’s assessment included extensive documenting, evaluating and testing the design and operating effectiveness of its internal controls over financial reporting.
The Company acquired Shockwave Medical, Inc. (Shockwave), in a business combination in May 2024. Shockwave’s total assets, excluding intangible assets and goodwill, and total sales represented less than 1% of each of the related consolidated financial statement amounts as of and for the fiscal year ended December 29, 2024. As the acquisition occurred in the fiscal year 2024, the scope of the Company's assessment of the design and effectiveness of internal control over financial reporting for the fiscal year 2024 excluded the above mentioned acquisition. This exclusion is in accordance with the SEC's general guidance that an assessment of a recently acquired business may be omitted from the scope in the year of acquisition.
Based on the Company’s processes and assessment, as described above, management has concluded that, as of December 29, 2024, the Company’s internal control over financial reporting was effective.
The effectiveness of the Company’s internal control over financial reporting as of December 29, 2024 has been audited by PricewaterhouseCoopers LLP, an independent registered public accounting firm, as stated in their report, which appears herein.


/s/ J. Duato
/s/ J. J. Wolk
Joaquin DuatoJoseph J. Wolk
Chairman, Board of DirectorsExecutive Vice President, Chief Financial Officer
Chief Executive Officer
110
 Jhonson&Jhonson.jpg 


Shareholder return performance graphs
Set forth below are line graphs comparing the cumulative total shareholder return on the Company’s Common Stock for periods of five years and ten years ending December 31, 2024, against the cumulative total return of the Standard & Poor’s 500 Stock Index, the Standard & Poor’s Pharmaceutical Index and the Standard & Poor’s Healthcare Equipment Index. The graphs and tables assume that $100 was invested on December 31, 2019 and December 31, 2014 in each of the Company’s Common Stock, the Standard & Poor’s 500 Stock Index, the Standard & Poor’s Pharmaceutical Index and the Standard & Poor’s Healthcare Equipment Index and that all dividends were reinvested.
5 Year Shareholder Return Performance J&J vs. Indices
icon-legend_red.jpg 
Johnson & Johnson
icon-legend_black.jpg 
S&P 500 Index
icon-legend_darkgray.jpg 
S&P Pharmaceutical Index
icon-legend_gray.jpg 
S&P Healthcare Equipment Index
5-year CAGR
J&J2.6 %
S&P 50014.5 %
S&P Pharm9.8 %
S&P H/C Equip6.6 %
763
201920202021202220232024
Johnson & Johnson$100.00$110.85$123.54$130.91$119.65$113.91
S&P 500 Index$100.00$118.39$152.36$124.75$157.52$196.90
S&P Pharmaceutical Index$100.00$107.53$135.34$146.78$147.27$159.35
S&P Healthcare Equipment Index$100.00$117.63$140.40$113.92$124.22$137.81
2024 Annual Report
111


10 Year Shareholder Return Performance J&J vs. Indices
icon-legend_red.jpg 
Johnson & Johnson
icon-legend_black.jpg 
S&P 500 Index
icon-legend_darkgray.jpg 
S&P Pharmaceutical Index
icon-legend_gray.jpg 
S&P Healthcare Equipment Index
10-year CAGR
J&J6.2 %
S&P 50013.1 %
S&P Pharm8.8 %
S&P H/C Equip11.8 %
837
20142015201620172018201920202021202220232024
Johnson & Johnson$100.00$101.16$116.66$145.13$137.67$159.99$177.35$197.66$209.45$191.43$182.25
S&P 500 Index$100.00$101.37$113.48$138.25$132.18$173.81$205.78$264.82$216.83$273.79$342.24
S&P Pharmaceutical Index$100.00$105.79$104.13$117.22$126.71$145.83$156.80$197.36$214.04$214.75$232.38
S&P Healthcare Equipment Index$100.00$105.97$112.85$147.71$171.70$222.04$261.19$311.74$252.95$275.82$306.00
112
 Jhonson&Jhonson.jpg 


Item 9. Changes in and disagreements with accountants on accounting and financial disclosure
Not applicable.
Item 9A. Controls and procedures
Disclosure controls and procedures. At the end of the period covered by this Report, the Company evaluated the effectiveness of the design and operation of its disclosure controls and procedures. The Company’s disclosure controls and procedures are designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the Company’s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. Joaquin Duato, Chairman and Chief Executive Officer, and Joseph J. Wolk, Executive Vice President, Chief Financial Officer, reviewed and participated in this evaluation. Based on this evaluation, Messrs. Duato and Wolk concluded that, as of the end of the period covered by this Report, the Company’s disclosure controls and procedures were effective.
Reports on internal control over financial reporting. The information called for by this item is incorporated herein by reference to Management’s report on internal control over financial reporting, and the attestation regarding internal controls over financial reporting included in the report of independent registered public accounting firm included in Item 8 of this Report.
Changes in internal control over financial reporting. During the fiscal quarter ended December 29, 2024, there were no changes in the Company’s internal control over financial reporting identified in connection with the evaluation required under Rules 13a-15 and 15d-15 under the Exchange Act that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting. The Company continues to monitor and assess the effectiveness of the design and operation of its disclosure controls and procedures.
The Company is implementing a multi-year, enterprise-wide initiative to integrate, simplify and standardize processes and systems for the human resources, information technology, procurement, supply chain and finance functions. These are enhancements to support the growth of the Company’s financial shared service capabilities and standardize financial systems. This initiative is not in response to any identified deficiency or weakness in the Company’s internal control over financial reporting. In response to this initiative, the Company has and will continue to align and streamline the design and operation of its financial control environment.
Item 9B. Other information
Securities trading plans of Directors and Executive Officers. During the fiscal fourth quarter of 2024, none of our directors or officers (as defined in Rule 16a-1(f) of the Exchange Act) informed us of the adoption or termination of a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” each as defined in Item 408 of Regulation S-K.
Item 9C. Disclosure regarding foreign jurisdictions that prevent inspections
Not applicable.
2024 Annual Report
113


Part III
Item 10. Directors, executive officers and corporate governance
The information called for by this item is incorporated herein by reference to the discussion of the Audit Committee under the caption Item 1. Election of Directors - Board committees; and the material under the captions Item 1. Election of Directors and, if applicable, Delinquent Section 16(a) reporting in the Proxy Statement; and the material under the caption “Executive Officers of the Registrant” in Part I of this Report.
The Company’s Code of Business Conduct, which covers all employees (including the Chief Executive Officer, Chief Financial Officer and Controller), meets the requirements of the SEC rules promulgated under Section 406 of the Sarbanes-Oxley Act of 2002. The Code of Business Conduct is available on the Company’s website at www.jnj.com/code-of-business-conduct, and copies are available to shareholders without charge upon written request to the Secretary at the Company’s principal executive offices. Any substantive amendment to the Code of Business Conduct or any waiver of the Code granted to the Chief Executive Officer, the Chief Financial Officer or the Controller will be posted on the Company’s website at www.jnj.com/code-of-business-conduct within five business days (and retained on the website for at least one year).
In addition, the Company has adopted a Code of Business Conduct & Ethics for Members of the Board of Directors and Executive Officers. The Code of Business Conduct & Ethics for Members of the Board of Directors and Executive Officers is available on the Company’s website at www.investor.jnj.com/governance/corporate-governance-overview/code-of-business-conduct--ethics, and copies are available to shareholders without charge upon written request to the Secretary at the Company’s principal executive offices. Any substantive amendment to the Code or any waiver of the Code granted to any member of the Board of Directors or any executive officer will be posted on the Company’s website at www.investor.jnj.com/governance/corporate-governance-overview/code-of-business-conduct--ethics within five business days (and retained on the website for at least one year).
In addition to the prohibition on insider trading for all employees covered in our Code of Business Conduct, the Company has adopted an insider trading policy governing the purchase, sale and other dispositions of its securities by directors, officers and certain other insiders that is reasonably designed to promote compliance with insider trading laws, rules and regulations and any applicable listing standards. A copy of this policy is filed with this Annual Report on Form 10-K as Exhibit 19.
Item 11. Executive compensation
The information called for by this item is incorporated herein by reference to the material under the captions Item 1. Election of Directors – Director compensation, and Item 2. Compensation Committee report, Compensation discussion and analysis and Executive compensation tables in the Proxy Statement.
The material incorporated herein by reference to the material under the caption Compensation Committee report in the Proxy Statement shall be deemed furnished, and not filed, in this Report and shall not be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, as a result of this furnishing, except to the extent that the Company specifically incorporates it by reference.
Item 12. Security ownership of certain beneficial owners and management and related stockholder matters
The information called for by this item is incorporated herein by reference to the material under the caption Stock ownership in the Proxy Statement; and Note 16 Common stock, stock option plans and stock compensation agreements of the Notes to Consolidated Financial Statements in Item 8 of this Report.
114
 Jhonson&Jhonson.jpg 


Equity compensation plan information
The following table provides certain information as of December 29, 2024 concerning the shares of the Company’s Common Stock that may be issued under existing equity compensation plans.
Plan CategoryNumber of
Securities to
be Issued Upon
Exercise of
Outstanding
Options and Rights
Weighted Average
Exercise Price of
Outstanding
Options
and Rights
Number of Securities
Remaining Available for
Future Issuance Under
Equity Compensation
Plans(2)(3)
Equity Compensation Plans Approved by Security Holders(1)
127,682,644$127.63111,042,139
Equity Compensation Plans Not Approved by Security Holders
Total127,682,644$127.63111,042,139
(1)Included in this category are the following equity compensation plans which have been approved by the Company’s shareholders: 2012 Long-Term Incentive Plan and 2022 Long-Term Incentive Plan.
(2)This column excludes shares reflected under the column “Number of Securities to be Issued Upon Exercise of Outstanding Options and Rights.”
(3)The 2012 Long-Term Incentive Plan expired April 26, 2022. All options and restricted shares granted subsequent to that date were under the 2022 Long-Term Incentive Plan.
Item 13. Certain relationships and related transactions, and director independence
The information called for by this item is incorporated herein by reference to the material under the captions Item 1. Election of Directors - Related person transactions & Director independence in the Proxy Statement.
Item 14. Principal accountant fees and services
The information called for by this item is incorporated herein by reference to the material under the caption Item 3. Ratification of appointment of independent registered public accounting firm in the Proxy Statement.
2024 Annual Report
115


Part IV
Item 15. Exhibits and financial statement schedules
The following documents are filed as part of this report:
1.Financial Statements
Consolidated balance sheets at end of fiscal years 2024 and 2023
Consolidated statements of earnings for fiscal years 2024, 2023 and 2022
Consolidated statements of comprehensive income for Fiscal Years 2024, 2023 and 2022
Consolidated statements of equity for fiscal years 2024, 2023 and 2022
Consolidated statements of cash flows for fiscal years 2024, 2023 and 2022
Notes to Consolidated Financial Statements
Report of independent registered public accounting firm
All schedules are omitted because they are not applicable or the required information is included in the financial statements or notes.
2.Exhibits required to be filed by item 60l of regulation S-K
The information called for by this item is incorporated herein by reference to the Exhibit Index in this Report.
Item 16. Form 10-K summary
Registrants may voluntarily include a summary of information required by Form 10-K under this Item 16. The Company has elected not to include such summary information.
116
 Jhonson&Jhonson.jpg 


Signatures
Pursuant to the requirements of Section 13 of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.
Date: February 13, 2025
JOHNSON & JOHNSON
(Registrant)
By 
/s/  J. Duato
J. Duato, Chairman of the Board
and Chief Executive Officer
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
SignatureTitleDate
/s/ J. Duato
Chairman of the BoardFebruary 13, 2025
J. DuatoChief Executive Officer
(Principal Executive Officer)
/s/ J. J. Wolk
Chief Financial Officer February 13, 2025
J. J. Wolk(Principal Financial Officer)
/s/ R. J. Decker Jr.
Controller and Chief Accounting OfficerFebruary 13, 2025
R. J. Decker Jr.(Principal Accounting Officer)
/s/ D. Adamczyk
DirectorFebruary 13, 2025
D. Adamczyk
/s/ M. C. Beckerle
DirectorFebruary 13, 2025
M. C. Beckerle
/s/ J. A. Doudna
DirectorFebruary 13, 2025
J. A. Doudna  
2024 Annual Report
117


SignatureTitleDate
/s/ M. A. Hewson
DirectorFebruary 13, 2025
M. A. Hewson
/s/ P. A. Johnson
DirectorFebruary 13, 2025
P. A. Johnson
/s/ H. Joly
DirectorFebruary 13, 2025
H. Joly
/s/ M. B. McClellan
DirectorFebruary 13, 2025
M. B. McClellan
/s/ A. M. Mulcahy
DirectorFebruary 13, 2025
A. M. Mulcahy
/s/ M. A. Weinberger
DirectorFebruary 13, 2025
M. A. Weinberger
/s/ N. Y. West
DirectorFebruary 13, 2025
N. Y. West
/s/ E. A. Woods
DirectorFebruary 13, 2025
E. A. Woods
118
 Jhonson&Jhonson.jpg 


Exhibit index
Reg. S-K
Exhibit Table
Item No.
Description
of Exhibit
Agreement and Plan of Merger, dated as of October 31, 2022, by and among Johnson & Johnson, Athos Merger Sub, Inc. and ABIOMED, Inc. – Incorporated herein by reference to Exhibit 2.1 of the Registrant’s Form 8-K Current Report filed November 1, 2022.†
Restated Certificate of Incorporation effective February 19, 2016 — Incorporated herein by reference to Exhibit 3(i) of the Registrant’s Form 10-K Annual Report for the fiscal year ended January 3, 2016.
Certificate of Amendment to the Certificate of Incorporation of Johnson & Johnson effective April 30, 2020 — Incorporated herein by reference to Exhibit 3.1 of the Registrant's Form 8-K Current Report filed April 29, 2020.
Amended and Restated By-Laws of the Company, as amended effective April 25, 2024 — Incorporated herein by reference to Exhibit 3.1 of the Registrant’s Form 8-K Current Report filed April 29, 2024.
4(a)Upon the request of the Securities and Exchange Commission, the Registrant will furnish a copy of all instruments defining the rights of holders of long-term debt of the Registrant.
Description of Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 — Filed with this document.
4(c)**Indenture, dated as of September 15, 1987 – Incorporated herein by reference to Exhibit 4(a) to the Registrant’s Form S-3 Registration Statement filed on October 11, 1994
4(d)**First Supplemental Indenture, dated as of September 1, 1990 – Incorporated herein by reference to Exhibit 4(b) to the Registrant’s Form S-3 Registration Statement filed on October 11, 1994
Second Supplemental Indenture, dated as of November 9, 2017 – Incorporated herein by reference to Exhibit 4.1 to the Registrant’s Form 8-K Current Report filed on November 13, 2017
2012 Long-Term Incentive Plan — Incorporated herein by reference to Appendix A of the Registrant’s Proxy Statement filed on March 15, 2012.*
Form of Stock Option Certificate under the 2012 Long-Term Incentive Plan — Incorporated herein by reference to Exhibit 10.2 of the Registrant’s Form 10-Q Quarterly Report for the quarter ended April 1, 2012.*
Global NonQualified Stock Option Award Agreement under the 2012 Long-Term Incentive Plan — Incorporated herein by reference to Exhibit 10.1 of the Registrant’s Form 10-Q Quarterly Report for the quarter ended April 1, 2018.*
Global Restricted Share Unit Award Agreement under the 2012 Long-Term Incentive Plan — Incorporated herein by reference to Exhibit 10.2 of the Registrant’s Form 10-Q Quarterly Report for the quarter ended April 1, 2018.*
Global Performance Share Unit Award Agreement under the 2012 Long-Term Incentive Plan — Incorporated herein by reference to Exhibit 10.3 of the Registrant’s Form 10-Q Quarterly Report for the quarter ended April 1, 2018.*
Global Restricted Share Unit Award Agreement granted to John Reed on May 1, 2023 under the 2022 Long-Term Incentive Plan — Incorporated herein by reference to Exhibit 10(h) of the Registrant’s Form 10-K Annual Report for the fiscal year ended December 31, 2023*
Domestic Deferred Compensation (Certificate of Extra Compensation) Plan — Incorporated herein by reference to Exhibit 10(g) of the Registrant’s Form 10-K Annual Report for the year ended December 28, 2003.*
Amendments to the Certificate of Extra Compensation Plan effective as of January 1, 2009 — Incorporated herein by reference to Exhibit 10(j) of the Registrant’s Form 10-K Annual Report for the year ended December 28, 2008.*
Amended and Restated Deferred Fee Plan for Directors (Amended as of January 17, 2012) — Incorporated herein by reference to Exhibit 10(k) of the Registrant's Form 10-K Annual Report for the fiscal year ended January 1, 2012.*
2024 Annual Report
119


Reg. S-K
Exhibit Table
Item No.
Description
of Exhibit
The Johnson & Johnson Executive Income Deferral Plan Amended and Restated Effective January 1, 2010 — Incorporated herein by reference to Exhibit 10.1 of the Registrant’s Form 10-Q Quarterly Report for the quarter ended September 30, 2012.*
The Johnson & Johnson Excess Savings Plan (amended and restated as of January 1, 2022) — Incorporated herein by reference to Exhibit 10(l) of the Registrant’s Form 10-K Annual Report for the fiscal year ended January 1, 2023.*
Excess Benefit Plan of Johnson & Johnson and Affiliated Companies (amended and restated as of January 1, 2020) — incorporated by reference to Exhibit 10(m) of the Registrant’s Form 10-K Annual Report for the fiscal year ended January 3, 2021.
10(m)**Executive Life Plan Agreement — Incorporated herein by reference to Exhibit 10(i) of the Registrant’s Form 10-K Annual Report for the fiscal year ended January 3, 1993.*
Executive Life Plan Agreement Closure Letter — Incorporated herein by reference to Exhibit 10.1 of the Registrant’s Form 10-Q Quarterly Report for the quarter ended March 29, 2015.*
2022 Long-Term Incentive Plan — Incorporated by reference to Appendix A of the Registrant’s Proxy Statement filed on March 16, 2022.*
Severance Pay Plan of Johnson & Johnson and U.S. Affiliated Companies, Amended and Restated as of October 1, 2014 — Incorporated herein by reference to Exhibit 10.1 of the Registrant's Form 10-Q Quarterly Report for the quarter ended September 28, 2014.*
First Amendment to the Severance Pay Plan of Johnson & Johnson and U.S. Affiliated Companies (as amended and restated effective October 1, 2014) — Incorporated herein by reference to Exhibit 10.1 of the Registrant's Form 10-Q Quarterly Report for the quarter ended June 28, 2015.*
Second Amendment to the Severance Pay Plan of Johnson & Johnson and U.S. Affiliated Companies (as amended and restated effective October 1, 2014) — Incorporated herein by reference to Exhibit 10(x) of the Registrant's Form 10-K Annual Report for the fiscal year ended January 3, 2016.*
Contingent Value Rights Agreement, dated as of December 22, 2022, by and between Johnson & Johnson and American Stock Transfer & Trust Company, LLC – Incorporated herein by reference to Exhibit 10.1 of the Registrant’s Form 8-K Current Report filed December 22, 2022.†
Intellectual Property Agreement, dated as of May 3, 2023, by and between Johnson & Johnson and Kenvue Inc. — Incorporated herein by reference to Exhibit 10.4 of the Registrant's Form 8-K Current Report filed May 8, 2023.
Trademark Phase-Out License Agreement, dated as of April 3, 2023, by and between Johnson & Johnson and Johnson & Johnson Consumer Inc. — Incorporated herein by reference to Exhibit 10.5 of the Registrant's Form 8-K Current Report filed May 8, 2023.
10(v)
Johnson & Johnson Deferred Compensation Plan — Incorporated herein by reference to Exhibit 10.1 of the Registrant's Form 8-K Current Report filed November 27, 2023.*
Global Performance Share Unit Award Agreement under the Johnson & Johnson 2022 Long-Term Incentive Plan — Incorporated herein by reference to Exhibit 10.1 of the Registrant’s Form 10-Q Quarterly Report for the quarter year ended April 2, 2023.*
Global Restricted Share Unit Award Agreement under the Johnson & Johnson 2022 Long-Term Incentive Plan — Incorporated herein by reference to Exhibit 10.2 of the Registrant’s Form 10-Q Quarterly Report for the quarter year ended April 2, 2023.*
Global Nonqualified Stock Option Award Agreement under the Johnson & Johnson 2022 Long-Term Incentive Plan — Incorporated herein by reference to Exhibit 10.3 of the Registrant’s Form 10-Q Quarterly Report for the quarter year ended April 2, 2023.*
Amendment One to the Johnson & Johnson Excess Savings Plan (amended and restated effective as of January 1, 2022) — Incorporated herein by reference to Exhibit 10.1 of the Registrant’s Form 10-Q Quarterly Report for the quarter ended October 1, 2023.*
120
 Jhonson&Jhonson.jpg 


Reg. S-K
Exhibit Table
Item No.
Description
of Exhibit
Johnson & Johnson Executive Incentive Plan (Amended as of September 7, 2023) — Incorporated herein by reference to Exhibit 10.2 of the Registrant’s Form 10-Q Quarterly Report for the quarter ended October 1, 2023.*
Johnson & Johnson Executive Officer Cash Severance Policy — Filed with this document.*
Johnson & Johnson Stock Trading Policy for Directors, Executive Officers and Insiders (Amended as of April 27, 2023) — Incorporated herein by reference to Exhibit 19 of the Registrant’s Form 10-K Annual Report for the fiscal year ended December 31, 2023.
Subsidiaries — Filed with this document.
Consent of Independent Registered Public Accounting Firm — Filed with this document.
Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act — Filed with this document.
Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act — Filed with this document.
Certification of Chief Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act — Furnished with this document.
Certification of Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act — Furnished with this document.
Johnson & Johnson Clawback Policy (effective as of August 8, 2023) — Incorporated herein by reference to
Exhibit 97 of the Registrant’s Form 10-K Annual Report for the fiscal year ended December 31, 2023.
Exhibit 101:
EX-101.INSInstance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document
EX-101.SCHInline XBRL Taxonomy Extension Schema
EX-101.CALInline XBRL Taxonomy Extension Calculation Linkbase
EX-101.LABInline XBRL Taxonomy Extension Label Linkbase
EX-101.PREInline XBRL Taxonomy Extension Presentation Linkbase
EX-101.DEFInline XBRL Taxonomy Extension Definition Document
Exhibit 104:Cover Page Interactive Data File––the cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
*Management contract or compensatory plan.
**Paper filing.
Certain exhibits and schedules have been omitted pursuant to Item 601(b)(2)(ii) or 601(b)(10)(iv) of Regulation S-K, as applicable.
A copy of any of the Exhibits listed above will be provided without charge to any shareholder submitting a written request specifying the desired exhibit(s) to the Secretary at the principal executive offices of the Company. Pursuant to Item 601(b)(4)(iii)(A) of Regulation S-K, the Company has not filed as exhibits to this Form 10-K certain long-term debt instruments, under which the total amount of securities authorized does not exceed 10% of the total assets of the Company and its subsidiaries on a consolidated basis. The Company hereby agrees to furnish a copy of any such instrument to the SEC upon request.
2024 Annual Report
121
EX-4.B 2 ex4b-descriptionofcapitals.htm EX-4.B Document

Exhibit 4(b)
DESCRIPTION OF SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934
Description of Capital Stock
The following summary of the capital stock of Johnson & Johnson (“we,” “us” or “our”) does not purport to be complete and is subject in all respects to applicable New Jersey law, the Johnson & Johnson restated certificate of incorporation, as amended, and the Johnson & Johnson by-laws.
General
The total authorized shares of capital stock of Johnson & Johnson consist of (1) 4,320,000,000 shares of common stock, par value $1.00 per share, and (2) 2,000,000 shares of preferred stock, without par value. As of the date of this filing, no shares of Johnson & Johnson preferred stock were issued and outstanding.
The Johnson & Johnson board of directors is authorized to provide for the issuance from time to time of Johnson & Johnson preferred stock in series and, as to each series, to fix the designation; the dividend rate and the preferences, if any, which dividends on that series will have compared to any other class or series of capital stock of Johnson & Johnson; the voting rights, if any; the liquidation preferences, if any; the conversion privileges, if any, and the redemption price or prices and the other terms of redemption, if any, applicable to that series. Cumulative dividends, dividend preferences and conversion, exchange and redemption provisions, to the extent that some or all of these features may be present when shares of Johnson & Johnson preferred stock are issued, could have an adverse effect on the availability of earnings for distribution to the holders of Johnson & Johnson common stock or for other corporate purposes.
Board of Directors
The Johnson & Johnson restated certificate of incorporation and the Johnson & Johnson by-laws provide that the total number of Johnson & Johnson directors will be not less than nine nor more than 18, as determined by the Johnson & Johnson board from time to time.
All directors are elected at each annual meeting of shareholders to serve until the next annual meeting. The Johnson & Johnson by-laws do not provide for cumulative voting in the election of directors.
Dividends
The Johnson & Johnson restated certificate of incorporation, as amended, provides that the Johnson & Johnson board of directors may from time to time declare dividends on its outstanding shares in accordance with New Jersey law.
Voting Rights
Each holder of Johnson & Johnson common stock is entitled to one vote for each share held of record and may not cumulate votes for the election of directors.
Liquidation Rights
In the event of a liquidation, dissolution or winding-up of Johnson & Johnson, each share of Johnson & Johnson common stock will be entitled to receive an equal share in our net assets that remain after paying all liabilities and the liquidation preferences of any preferred stock.

WEIL:\100244599\4\54966.0187


Preemptive Rights
Holders of Johnson & Johnson common stock have no preemptive rights to purchase, subscribe for or otherwise acquire any common stock or preferred stock or other securities.
Merger or Consolidation
Under New Jersey law, the completion of a merger or consolidation of a New Jersey corporation organized prior to January 1, 1969, such as Johnson & Johnson, requires the approval of such corporation’s board of directors and the affirmative vote of two-thirds of the votes cast by the holders of shares of the corporation entitled to vote thereon; provided that no such approval and vote are required if such corporation is the surviving corporation and:
such corporation’s certificate of incorporation is not amended;
the shareholders of the surviving corporation whose shares were outstanding immediately before the effective date of the merger will hold the same number of shares, with identical designations, preferences, limitations, and rights, immediately after; and
the number of voting shares and participation shares outstanding after the merger will not exceed by more than 40% the total number of voting or participating shares of the surviving corporation before the merger.
Similarly, a sale of all or substantially all of such corporation’s assets other than in the ordinary course of business, or a voluntary dissolution of such corporation, requires the approval of such corporation’s board of directors and the affirmative vote of two-thirds of the votes cast by the holders of shares of such corporation entitled to vote thereon.
Business Combinations
Under New Jersey law, no New Jersey corporation may engage in any “business combination” with any interested shareholder (generally, a 10% or greater shareholder) for a period of five years following such interested shareholder’s stock acquisition, unless such business combination is approved by the board of directors of such corporation prior to the stock acquisition.
Under New Jersey law, “business combination” includes:
any merger or consolidation of a resident domestic corporation or one of its subsidiaries:
owith an interested shareholder; or
owith any corporation which is, or would be after such merger or consolidation, an affiliate or associate of an interested shareholder.
any transfer or other disposition to or with an interested shareholder or any affiliate or associate of an interested shareholder of at least 10% of (1) the assets, (2) the outstanding shares or (3) the earning power or income on a consolidated basis, of such resident domestic corporation; and
other specified self-dealing transactions between such resident domestic corporation and an interested shareholder or any affiliate or associate thereof.
In addition, no resident domestic corporation may engage, at any time, in any business combination with any interested shareholder of such corporation other than:
a business combination approved by the board of directors of such corporation prior to the stock acquisition;
a business combination approved by the affirmative vote of the holders of two-thirds of the voting stock not beneficially owned by such interested shareholder at a meeting called for such purpose; or
2
WEIL:\100244599\4\54966.0187


a business combination in which the interested shareholder meets certain fair price criteria.
Description of Debt Securities:
1.150% Notes due 2028
3.200% Notes due 2032
1.650% Notes due 2035
3.350% Notes due 2036
3.550% Notes due 2044
General
The notes (as defined below) are our unsecured obligations and were issued under an Indenture dated as of September 15, 1987, between us and The Bank of New York Mellon Trust Company, N.A. (as successor to BNY Midwest Trust Company, which succeeded Harris Trust and Savings Bank), as trustee (the “Trustee”), as amended by a First Supplemental Indenture dated as of September 1, 1990 and, solely with respect to the 2032 notes, the 2036 notes and the 2044 notes (each, as hereinafter defined), a Second Supplemental Indenture dated as of November 9, 2017 (collectively, the “Indenture”). The 1.150% notes due 2028, the 3.200% notes due 2032, 1.650% notes due 2035, the 3.350% notes due 2036 and the 3.550% notes due 2044 are sometimes respectively referred to herein as the “2028 notes,” the “2032 notes,” the “2035 notes,” the “2036 notes” and the “2044 notes.” The 2028 notes, the 2032 notes, the 2035 notes, the 2036 notes and the 2044 notes are sometimes collectively referred to herein as the “notes.” This summary is subject to and qualified in its entirety by reference to all of the provisions of the Indenture and the notes, including definitions of certain terms used in the Indenture and the notes. The Indenture has been incorporated by reference as an exhibit to the Annual Report on Form 10-K to which this exhibit is a part.
We issued €750,000,000 aggregate principal amount of the 2028 notes on May 20, 2016. The 2028 notes will mature on November 20, 2028.
We issued €700,000,000 aggregate principal amount of the 2032 notes on May 20, 2024. The 2032 notes will mature on June 1, 2032.
We issued €1,500,000,000 aggregate principal amount of the 2035 notes on May 20, 2016. The 2035 notes will mature on May 20, 2035.
We issued €800,000,000 aggregate principal amount of the 2036 notes on May 20, 2024. The 2036 notes will mature on June 1, 2036.
We issued €1,000,000,000 aggregate principal amount of the 2044 notes on May 20, 2024. The 2044 notes will mature on June 1, 2044.
The notes of each series were issued only in book-entry form, in minimum denominations of €100,000 and integral multiples of €1,000 above that amount, through the facilities of Euroclear Bank S.A./N.V., as operator of the Euroclear System (“Euroclear”), and Clearstream Banking, société anonyme (“Clearstream”), and sales in book-entry form are effected only through participants in Euroclear or Clearstream. The notes do not have the benefit of a sinking fund.
Interest on the Notes
Interest on the 2028 notes is payable annually on November 20 of each year to the holders of the 2028 notes at the close of business the November 5 preceding such interest payment date. Interest on the 2035 notes is payable annually on May 20 of each year to the holders of the 2035 notes at the close of business the May 5 preceding such interest payment date. Interest on the 2032 notes, the 2036 notes and the 2044 notes is payable annually on June 1 of each year to the holders of each of the 2032 notes, the 2036 notes and the 2044 notes at the close of business the May 15 preceding such interest payment date.
3
WEIL:\100244599\4\54966.0187


The 2028 notes bear interest at the rate of 1.150% per annum, the 2032 notes bear interest at the rate of 3.200% per annum, the 2035 notes bear interest at the rate of 1.650% per annum, the 2036 notes bear interest at the rate of 3.350% per annum and the 2044 notes bear interest at the rate of 3.550% per annum. Interest on the notes is computed on the basis of the actual number of days in the period for which interest is being calculated and the actual number of days from and including the last date on which interest was paid on the notes, to but excluding the next scheduled interest payment date. This payment convention is referred to as ACTUAL/ACTUAL (ICMA) as defined in the rulebook of the International Capital Market Association.
Issuance in Euro
All payments of interest and principal, including payments made upon any redemption of the notes, are payable in euro. If the euro becomes unavailable to us due to the imposition of exchange controls or other circumstances beyond our control or if the euro is no longer being used by the then member states of the European Monetary Union that have adopted the euro as their currency or for the settlement of transactions by public institutions of or within the international banking community, then all payments in respect of the notes will be made in U.S. dollars until the euro is again available to us or so used. The amount payable on any date in euro is converted into U.S. dollars at the rate mandated by the U.S. Federal Reserve Board as of the close of business on the second business day prior to the relevant payment date or, in the event the U.S. Federal Reserve Board has not mandated a rate of conversion, on the basis of the most recent euro/U.S. dollar exchange rate available on or prior to the second business day prior to the relevant payment date, as reported by Bloomberg. Any payment in respect of the notes so made in U.S. dollars does not constitute an event of default under the notes or the indenture governing the notes. Neither the trustee nor any paying agent has any responsibility for any calculation or conversion in connection with the forgoing.
Business Day
The term “business day” means any day, other than a Saturday or Sunday, (1) that is not a day on which banking institutions in The City of New York or London are authorized or required by law, regulation or executive order to close and (2) on which the Trans-European Automated Real-time Gross Settlement Express Transfer system (the TARGET2 system), or any successor thereto, is open.
Paying Agent and Registrar
The Bank of New York Mellon (London Branch) is paying agent for the notes, and The Bank of New York Mellon Trust Company, N.A. acts as security registrar for the notes. We may at any time designate additional paying agents or rescind the designations or approve a change in the offices where they act.
In the case of the 2028 notes and the 2035 notes, to the extent permitted by law, we maintain a paying agent that is not required to withhold or deduct tax pursuant to European Council Directive 2003/48/EC on the taxation of savings income or any law implementing or complying with, or introduced in order to conform to, such European Council Directive.
Optional Redemption
We may, at our option, redeem the notes at any time prior to the applicable Par Call Date, either in whole or in part, at a redemption price equal to the greater of the following amounts, plus, in each case, accrued and unpaid interest thereon to, but not including, the redemption date:
100% of the principal amount of the notes to be redeemed; or
the sum of the present values of the remaining scheduled payments of principal and interest thereon (not including any portion of such payments of interest accrued as of the date of redemption), discounted to the date of redemption on an annual basis (ACTUAL/ACTUAL (ICMA)) at the applicable Comparable Government Bond Rate (as defined below), plus 20 basis points in the case of each of the 2028 notes and the 2035 notes and 15 basis points in the case of each of the 2032 notes, the 2036 notes and the 2044 notes.
4
WEIL:\100244599\4\54966.0187


At any time on or after the applicable Par Call Date, the notes may be redeemed in whole or in part, at our option, at a redemption price equal to 100% of the principal amount of notes to be redeemed, plus accrued and unpaid interest to, but excluding, the date of redemption.
Installments of interest on notes being redeemed that are due and payable on interest payment dates falling on or prior to a redemption date are payable on the interest payment date to the holders as of the close of business on the relevant regular record date according to the notes and the indenture.
“Comparable Government Bond” means, in relation to any Comparable Government Bond Rate calculation, at the discretion of an independent investment bank selected by us, a German government bond whose maturity is closest to the maturity of the notes being redeemed, or if such independent investment bank in its discretion determines that such similar bond is not in issue, such other German government bond as such independent investment bank may, with the advice of three brokers of, and/or market makers in, German government bonds selected by us, determine to be appropriate for determining the Comparable Government Bond Rate.
“Comparable Government Bond Rate” means, (i) with respect to the 2028 notes and the 2035 notes, the price, expressed as a percentage (rounded to three decimal places, with 0.0005 being rounded upwards), at which the gross redemption yield on the notes, if they were to be purchased at such price on the third business day prior to the date fixed for redemption, would be equal to the gross redemption yield on such business day of the Comparable Government Bond on the basis of the middle market price of the Comparable Government Bond prevailing at 11:00 a.m. (London time) on such business day as determined by an independent investment bank selected by us and (ii) with respect to the 2032 notes, the 2036 notes and the 2044 notes, the yield to maturity, expressed as a percentage (rounded to three decimal places, 0.0005 being rounded upwards), on the third business day prior to the date fixed for redemption, of the applicable Comparable Government Bond on the basis of the middle market price of such Comparable Government Bond prevailing at 11:00 a.m. (London time) on such business day as determined by an independent investment bank selected by us.
“Par Call Date” means (i) August 20, 2028 (three months prior to the maturity date of such notes), in the case of the 2028 notes; (ii) March 1, 2032 (three months prior to the maturity date of such notes), in the case of the 2032 notes; (iii) February 20, 2035 (three months prior to the maturity date of such notes), in the case of the 2035 notes; (iv) March 1, 2036 (three months prior to the maturity date of such notes), in the case of the 2036 notes; and (v) March 1, 2044 (three months prior to the maturity date of such notes), in the case of the 2044 notes.
Notice of any redemption will be delivered (or otherwise transmitted in accordance with the depositary’s procedures) in the case of the 2028 notes and the 2035 notes, at least 30 days, and in the case of the 2032 notes, the 2036 notes and the 2044 notes, at least 15 days, but in any case not more than 60 days before the redemption date to each holder of notes to be redeemed. In the case of the 2032 notes, the 2036 notes and the 2035 notes, any redemption or notice may, at our discretion, be subject to one or more conditions precedent and, at our discretion, the redemption date may be delayed until such time as any or all such conditions shall be satisfied (or waived by us in our sole discretion) or the redemption date may not occur and such notice may be rescinded if all such conditions precedent included at our discretion shall not have been satisfied (or waived by us in our sole discretion). Once notice of redemption is delivered, the notes called for redemption will become due and payable on the redemption date and at the applicable redemption price, plus accrued and unpaid interest to the redemption date, subject to, in the case of the 2032 notes, the 2036 notes and the 2035 notes conditions precedent, if any, that we specify in the notice of redemption.
If less than all of the notes of a series are to be redeemed, the notes of such series to be redeemed will be selected in accordance with applicable depositary procedures or such method as the Trustee may deem fair and appropriate; provided, however, that no notes of a principal amount of €100,000 or less shall be redeemed in part. Unless we default in payment of the redemption price, on and after the redemption date interest will cease to accrue on the notes or portions thereof called for redemption. On or before the redemption date, we will deposit with the paying agent (or the Trustee) money sufficient to pay the redemption price of and accrued interest on the notes to be redeemed on that date.
5
WEIL:\100244599\4\54966.0187


The notes of each series are also subject to redemption prior to maturity if certain changes in U.S. tax law occur. If such changes occur, the notes may be redeemed at a redemption price of 100% of their principal amount plus accrued and unpaid interest to the date of redemption. See “—Redemption for Tax Reasons.”
Payment of Additional Amounts
Subject to the exceptions and limitations set forth below, we will pay as additional interest on the notes such additional amounts as are necessary in order that the net payment by us or a paying agent of the principal of and interest on the notes to a holder who is not a United States person (as defined below), after deduction for any present or future tax, assessment or other governmental charge of the United States or a political subdivision or taxing authority of or in the United States, imposed by withholding with respect to the payment, will not be less than the amount provided in the Notes to be then due and payable; provided, however, that the foregoing obligation to pay additional amounts shall not apply:
(1)to any tax, assessment or other governmental charge that is imposed or withheld solely by reason of the holder, or a fiduciary, settlor, beneficiary, member or shareholder of the holder if the holder is an estate, trust, partnership or corporation, or a person holding a power over an estate or trust administered by a fiduciary holder, being considered as:
(a)being or having been present or engaged in a trade or business in the United States or having had a permanent establishment in the United States;
(b)having a current or former relationship with the United States, including a relationship as a citizen or resident of the United States;
(c)being or having been a foreign or domestic personal holding company, a passive foreign investment company or a controlled foreign corporation with respect to the United States or a corporation that has accumulated earnings to avoid United States federal income tax;
(d)being or having been a “10-percent shareholder” of us as defined in section 871(h)(3) of the United States Internal Revenue Code or any successor provision; or
(e)being a bank receiving payments on an extension of credit made pursuant to a loan agreement entered into the ordinary course of its trade or business;
(2)to any holder that is not the sole beneficial owner of the notes, or a portion of the notes, or that is a fiduciary or partnership, but only to the extent that a beneficiary or settlor with respect to the fiduciary, a beneficial owner or member of the partnership would not have been entitled to the payment of an additional amount had the beneficiary, settlor, beneficial owner or member received directly its beneficial or distributive share of the payment;
(3)to any tax, assessment or other governmental charge that is imposed or otherwise withheld solely by reason of a failure of the holder or any other person to comply with certification, identification or information reporting requirements concerning the nationality, residence, identity or connection with the United States of the holder or beneficial owner of the Notes, if compliance is required by statute, by regulation of the United States Treasury Department or by an applicable income tax treaty to which the United States is a party as a precondition to exemption from such tax, assessment or other governmental charge;
(4)to any tax, assessment or other governmental charge that is imposed otherwise than by withholding by us or a paying agent from the payment;
(5)to any tax, assessment or other governmental charge that is imposed or withheld solely by reason of a change in law, regulation, or administrative or judicial interpretation that becomes effective after the payment becomes due or is duly provided for, whichever occurs later;
(6)to any estate, inheritance, gift, sales, excise, transfer, wealth or personal property tax or similar tax, assessment or other governmental charge;
6
WEIL:\100244599\4\54966.0187


(7)to any tax, assessment or other governmental charge any paying agent (which term may include us) must withhold from any payment of principal of or interest on any note, if such payment can be made without such withholding by any other paying agent;
(8)to any tax, assessment or governmental charge that would not have been so imposed or withheld but for the presentation by the holder of a note for payment on a date more than 30 days after the date on which such payment became due and payable or the date on which payment thereof is duly provided for, whichever occurs later;
(9)any withholding or deduction pursuant to an agreement described in Section 1471(b) of the Code or otherwise imposed pursuant to Sections 1471 through 1474 of the Code (or any regulations or agreements thereunder or official interpretations thereof) or any intergovernmental agreement between the United States and another jurisdiction facilitating the implementation thereof (or any law implementing such an intergovernmental agreement); or
(10)in the case of any combination of the above items.
The notes are subject in all cases to any tax, fiscal or other law or regulation or administrative or judicial interpretation applicable to the notes. Except as specifically provided under this heading “—Payment of Additional Amounts” and under the heading “—Redemption for Tax Reasons,” we are not required to make any payment for any tax, assessment or other governmental charge imposed by any government or a political subdivision or taxing authority of or in any government or political subdivision.
We do not pay additional amounts on any note:
in the case of the 2028 notes and the 2035 notes, where withholding or deduction is imposed on a payment and is required to be made pursuant to European Union Directive 2003/48/EC or any law implementing or complying with, or introduced in order to conform to, that Directive, or
presented for payment by or on behalf of a beneficial owner who would have been able to avoid the withholding or deduction by presenting the relevant global note to another paying agent in a Member State of the EU.
As used under this heading “—Payment of Additional Amounts” and under the heading “—Redemption for Tax Reasons”, the term “United States” means the United States of America (including the states and the District of Columbia) and its territories, possessions and other areas subject to its jurisdiction, “United States person” means any individual who is a citizen or resident of the United States, a corporation, partnership or other entity created or organized in or under the laws of the United States, any state of the United States or the District of Columbia (other than a partnership that is not treated as a United States person under any applicable Treasury regulations), or any estate or trust the income of which is subject to United States federal income taxation regardless of its source.
Redemption for Tax Reasons
If, as a result of any change in, or amendment to, the laws (or any regulations or rulings promulgated under the laws) of the United States (or any political subdivision or taxing authority of or in the United States), or any change in, or amendments to, an official position regarding the application or interpretation of such laws, regulations or rulings, which change or amendment is announced or becomes effective on or after the date of the prospectus supplement covering the offer and sale of the applicable series of notes, we become or, based upon a written opinion of independent counsel selected by us, will become obligated to pay additional amounts as described herein under the heading “—Payment of Additional Amounts” with respect to the notes, then we may at our option redeem, in whole, but not in part, the notes on not less than 30 nor more than 60 days prior notice, at a redemption price equal to 100% of their principal amount, together with interest accrued but unpaid on those notes to the date fixed for redemption.
Further Issues
7
WEIL:\100244599\4\54966.0187


We may from time to time, without notice to, or the consent of, the registered holders of any series of notes, create and issue further notes equal in rank to the notes in all respects (or in all respects except for the payment of interest accruing prior to the issue date of the further notes or except for the first payment of interest following the issue date of the further notes). These further notes may be consolidated and form a single series with the applicable existing series of notes and will have the same terms as to status, redemption or otherwise as that existing series of notes.
Book-Entry; Delivery and Form; Global Notes
We have obtained the information in this section concerning Clearstream and Euroclear and their book-entry systems and procedures from sources that we believe to be reliable. We take no responsibility for an accurate portrayal of this information. In addition, the description of the clearing systems in this section reflects our understanding of the rules and procedures of Clearstream and Euroclear as they are currently in effect. Those clearing systems could change their rules and procedures at any time.
The notes were initially represented by one or more fully registered global notes. Each such global note was deposited with, or on behalf of, a common depositary and registered in the name of the nominee of the common depositary for the accounts of Clearstream and Euroclear. Except as set forth below, the global notes may be transferred, in whole and not in part, only to Euroclear or Clearstream or their respective nominees. Interests in the global notes may be held in Europe through Clearstream or Euroclear, either as a participant in such systems or indirectly through organizations that are participants in such systems. Clearstream and Euroclear hold interests in the global notes on behalf of their respective participating organizations or customers through customers’ securities accounts in Clearstream’s or Euroclear’s names on the books of their respective depositaries. Book-entry interests in the notes and all transfers relating to the notes are reflected in the book-entry records of Clearstream and Euroclear.
The distribution of the notes is cleared through Clearstream and Euroclear. The secondary market trading of book-entry interests in the notes takes place through Clearstream and Euroclear participants and settle in same-day funds. Owners of book-entry interests in the notes receive payments relating to their notes in euro, with certain exceptions.
Clearstream and Euroclear have established electronic securities and payment transfer, processing, depositary and custodial links among themselves and others, either directly or through custodians and depositaries. These links allow the notes to be issued, held and transferred among the clearing systems without the physical transfer of certificates. Special procedures to facilitate clearance and settlement have been established among these clearing systems to trade securities across borders in the secondary market.
The policies of Clearstream and Euroclear govern payments, transfers, exchanges and other matters relating to an investor’s interest in the notes held by them. We have no responsibility for any aspect of the records kept by Clearstream or Euroclear or any of their direct or indirect participants. We also do not supervise these systems in any way.
Clearstream and Euroclear and their participants perform these clearance and settlement functions under agreements they have made with one another or with their customers. They are not obligated to perform or continue to perform these procedures and may modify them or discontinue them at any time.
With certain exceptions, owners of beneficial interests in the notes are not entitled to have the notes registered in their names, do not receive and are not entitled to receive physical delivery of the notes in definitive form and are not considered the owners or holders of the notes under the indenture, including for purposes of receiving any reports delivered by us or the trustee pursuant to the indenture. Accordingly, each person owning a beneficial interest in a note must rely on the procedures of the depositary and, if such person is not a participant, on the procedures of the participant through which such person owns its interest, in order to exercise any rights of a holder of notes.
Notices
8
WEIL:\100244599\4\54966.0187


Notices to holders of the notes are sent to such holders. Any notice shall be deemed to have been given on the date of mailing. So long as the notes are represented by a global security deposited with The Bank of New York Mellon (London Branch), or any successor thereto, as the common depositary for Clearstream and Euroclear, notices to holders may be given by delivery to Clearstream and Euroclear, and such notices shall be deemed to be given on the date of delivery to Clearstream and Euroclear. The trustee will transmit notices to each registered holder’s last known address as it appears in the security register that the trustee maintains. The trustee will only transmit these notices to the registered holder of the notes. Holders of notes will not receive notices regarding the notes directly from us unless we reissue the notes to the holders in fully certificated form.
Amendment and Waiver
Other than amendments not adverse to holders of the debt securities, amendments of the Indenture or the debt securities may be made with the consent of the holders of a majority in principal amount of the debt securities affected (acting as one class). Waivers of compliance with any provision of the Indenture or the debt securities with respect to any series of debt securities may be made only with the consent of the holders of a majority in principal amount of the debt securities of that series. The consent of all holders of affected debt securities will be required to:
(1)make any debt security payable in a currency not specified or described in the debt security;
(2)change the stated maturity of any debt security;
(3)reduce the principal amount of any debt security;
(4)reduce the rate or change the time of payment of interest on any debt security;
(5)reduce the amount of debt securities whose holders must consent to an amendment or waiver; or
(6)impair the right to institute suit for the payment of principal of any debt security or interest on any debt security.
The holders of a majority in aggregate principal amount of debt securities affected may waive any past default under the Indenture and its consequences, except a default (1) in the payment of the principal of or interest on any debt securities, or (2) in respect of a provision that cannot be waived or amended without the consent of all holders of debt securities affected.
Events of Default
Events of Default with respect to any series of debt securities under the Indenture will include:
(7)default in payment of any principal of that series;
(8)default in the payment of any installment of interest on such series and continuance of that default for a period of 30 days;
(9)default in the performance of any other covenant in the Indenture or in the debt securities and continuance of the default for a period of 90 days after we receive notice of the default from the Trustee or the holders of at least 25% in principal amount of debt securities of the series; or
(10)certain events of bankruptcy, insolvency or reorganization in respect of Johnson & Johnson.
The Trustee may withhold notice to the holders of a series of debt securities of any default (except in the payment of principal of or interest on the series of debt securities) if it considers withholding of notice to be in the interest of holders of the debt securities. Not all Events of Default with respect to a particular series of debt securities issued under the Indenture necessarily constitute Events of Default with respect to any other series of debt securities.
9
WEIL:\100244599\4\54966.0187


On the occurrence of an Event of Default with respect to a series of debt securities, the Trustee or the holders of at least 25% in principal amount of debt securities of that series then outstanding may declare the principal (or, in the case of debt securities sold at an original issue discount, the amount specified in the terms thereof) and accrued interest thereon to be due and payable immediately.
Within 120 days after the end of each fiscal year, an officer of Johnson & Johnson must inform the Trustee whether he or she knows of any default, describing any default and the status thereof. Subject to provisions relating to its duties in case of default, the Trustee is under no obligation to exercise any of its rights or powers under the Indenture at the direction of any holders of debt securities unless the Trustee shall have received a satisfactory indemnity.
Governing Law
The Indenture and the notes are governed by, and construed in accordance with, the laws of the State of New York.
10
WEIL:\100244599\4\54966.0187
EX-10.AB 3 ex10ab-executivecashsevera.htm EX-10.AB Document
Exhibit 10(ab)
JOHNSON & JOHNSON
EXECUTIVE OFFICER CASH SEVERANCE POLICY
Johnson & Johnson (the “Company”) will not enter into any new employment agreement, severance agreement or separation agreement with any Executive Officer of the Company, or establish any new severance plan or policy covering any Executive Officer of the Company, in each case that provides for Cash Severance Benefits exceeding 2.99 times the sum of the Executive Officer’s Base Salary and Target Bonus, without seeking stockholder ratification of such agreement, plan or policy.
Pre-existing agreements and arrangements assumed by the Company in the context of a corporate transaction are not subject to this policy.
The Compensation & Benefits Committee of the Company’s Board of Directors shall administer and make all determinations regarding the interpretation of the provisions of this Executive Officer Cash Severance Policy (this “Policy”).
For purposes of this Policy:
“Base Salary” means the Executive Officer’s annualized base salary in effect immediately prior to the Executive Officer’s termination date, excluding any overtime, bonus or incentive compensation.
“Cash Severance Benefits” means cash payments: (i) in respect of the termination of the Executive Officer’s employment; (ii) to secure an agreement not to compete with the Company; or (iii) to offset any tax liability in respect of any of the foregoing. For the avoidance of doubt, “Cash Severance Benefits” do not include
(a) the grant, payment, vesting, acceleration or other handling of long-term incentive awards granted under the Company’s equity-based compensation plans, including without limitation the Johnson & Johnson 2022 Long-Term Incentive Plan or any predecessor or successor plans,
(b) payment of deferred compensation, earned retirement benefits or other vested employee benefits, in each case consistent with normal practices, provided under the Company’s qualified or nonqualified retirement plans or employee benefit plans,
(c) the provision of perquisites, insurance, disability, health and welfare plan coverage, outplacement or retraining and other non-cash benefits generally available to similarly-situated employees,
(d) any notice pay or interest required to be paid pursuant to the terms of any Company plan or policy between the termination date and the payment date,


Exhibit 10(ab)
(e) any unpaid bonus for any previously completed performance period required to be paid pursuant to the terms of any Company plan or policy,
(f) accrued but unpaid base salary or vacation pay through the termination date and reimbursement for any expenses validly incurred prior to the termination date, or
(g) any payment in respect of the Executive Officer’s bonus for the year of termination (prorated based on the Executive Officer’s completed service during the annual performance period).

Executive Officer” means any “officer” of the Company within the meaning of Rule 16a-1(f) of the Securities Exchange Act of 1934, as amended.
“Target Bonus” means the Executive Officer’s target annual incentive bonus in effect immediately prior to the Executive Officer’s termination date for the year of termination, provided that if no target annual incentive bonus has been established for such year, “Target Bonus” means the Executive Officer’s target annual incentive bonus in effect for the year immediately preceding the year of termination.

EX-21 4 ex21-subsidiariesxform10xk.htm EX-21 Document

EXHIBIT 21
SUBSIDIARIES
Johnson & Johnson, a New Jersey corporation, had the U.S. and international subsidiaries shown below as of December 29, 2024. Johnson & Johnson is not a subsidiary of any other entity.

Name of SubsidiaryJurisdiction
U.S. Subsidiaries:
ABD Holding Company, Inc.Delaware
ABIOMED COMMERCIAL, LLCDelaware
ABIOMED R&D, Inc.Delaware
ABIOMED, Inc.Delaware
Actelion Pharmaceuticals US, Inc.Delaware
Albany Street LLCNew Jersey
ALZA CorporationDelaware
Ambrx Biopharma, Inc.Delaware
Ambrx, Inc.Delaware
AMO Development, LLCDelaware
AMO Manufacturing USA, LLCDelaware
AMO Sales and Service, Inc.Delaware
AMO Spain Holdings, LLCDelaware
Anakuria Therapeutics, Inc.Delaware
AorTx, Inc.Delaware
Aragon Pharmaceuticals, Inc.Delaware
Asia Pacific Holdings, LLCNew Jersey
Atrionix, Inc.California
AUB Holdings LLCDelaware
Auris Health, Inc.Delaware
BeneVir BioPharm, Inc.Delaware
Biosense Webster, Inc.California
Breethe, Inc.Delaware
Cerenovus, Inc.New Jersey
Coherex Medical, Inc.Delaware
CoTherix Inc.Delaware
CRES Holdings, Inc.Delaware
CrossRoads Extremity Systems, LLCTennessee
CSATS, Inc.Washington
DePuy Mitek, LLCMassachusetts
DePuy Orthopaedics, Inc.Indiana
DePuy Products, Inc.Indiana
DePuy Spine, LLCOhio
DePuy Synthes Institute, LLCDelaware
DePuy Synthes Products, Inc.Delaware
DePuy Synthes Sales, Inc.Massachusetts
DePuy Synthes, Inc.Delaware
Dutch Holding LLCDelaware
ECL7, LLCDelaware
Ethicon Endo-Surgery, Inc.Ohio
Ethicon Endo-Surgery, LLCDelaware
Ethicon LLCDelaware
Ethicon US, LLCDelaware
Ethicon, Inc.New Jersey
Hansen Medical International, Inc.Delaware
Hansen Medical, Inc.Delaware
I.D. Acquisition Corp.New Jersey



Name of SubsidiaryJurisdiction
Janssen Biotech, Inc.Pennsylvania
Janssen Global Services, LLCNew Jersey
Janssen Oncology, Inc.Delaware
Janssen Ortho LLCDelaware
Janssen Pharmaceuticals, Inc.Pennsylvania
Janssen Products, LPNew Jersey
Janssen Research & Development, LLCNew Jersey
Janssen Scientific Affairs, LLCNew Jersey
Janssen Supply Group, LLCPennsylvania
Janssen-Cilag Manufacturing, LLCDelaware
Jevco Holding, Inc.New Jersey
JJHC, LLCDelaware
JNJ International Investment LLCDelaware
JNTL (Russia) HoldCo LLCDelaware
Johnson & JohnsonNew Jersey
Johnson & Johnson (Middle East) Inc.New Jersey
Johnson & Johnson (Singapore) HoldCo LLCDelaware
Johnson & Johnson Enterprise Innovation Inc.Delaware
Johnson & Johnson Finance CorporationNew Jersey
Johnson & Johnson Gateway, LLCNew Jersey
Johnson & Johnson Health Care Systems Inc.New Jersey
Johnson & Johnson Holdco (NA) Inc.New Jersey
Johnson & Johnson Innovation - JJDC, Inc.Delaware
Johnson & Johnson Innovation LLCDelaware
Johnson & Johnson InternationalNew Jersey
Johnson & Johnson Medical Devices & Diagnostics Group - Latin America, L.L.C.Florida
Johnson & Johnson S.E., Inc.New Jersey
Johnson & Johnson Services, Inc.New Jersey
Johnson & Johnson Surgical Vision, Inc.Delaware
Johnson & Johnson Urban Renewal AssociatesNew Jersey
Johnson & Johnson Vision Care, Inc.Florida
JOM Pharmaceutical Services, LLCDelaware
Laminar, Inc.Delaware
Medical Device Business Services, Inc.Indiana
Medical Devices & Diagnostics Global Services, LLCDelaware
MegaDyne Medical Products, Inc.Utah
Mentor Partnership Holding Company I, LLCDelaware
Mentor Texas GP LLCDelaware
Mentor Texas L.P.Delaware
Mentor Worldwide LLCDelaware
Middlesex Assurance Company LimitedVermont
Momenta Pharmaceuticals, Inc.Delaware
Netherlands Holding CompanyDelaware
NeuWave Medical, Inc.Delaware
NuVera Medical, Inc.Delaware
OMJ Pharmaceuticals, Inc.Delaware
Omrix Biopharmaceuticals, Inc.Delaware
Ortho Biologics LLCDelaware
Ortho Biotech Holding LLCDelaware
Patient Service Center LLCPennsylvania
Patriot Pharmaceuticals, LLCPennsylvania
Pecos River Talc LLCTexas
Princeton Laboratories, Inc.Delaware
Propel Merger Sub, Inc.Delaware



Name of SubsidiaryJurisdiction
Prosidyan, Inc.Delaware
Proteologix US Inc.Delaware
Proteologix, Inc.Delaware
PSC Holding Co LLCPennsylvania
PSC Pass Co LLCPennsylvania
Pulsar Vascular, Inc.Delaware
Red River Talc LLCTexas
Regency Urban Renewal AssociatesNew Jersey
Royalty A&M LLCNorth Carolina
Rutan Realty LLCNew Jersey
Scios LLCDelaware
Serotiny, Inc.Delaware
Shockwave Medical, Inc.Delaware
SterilMed, Inc.Minnesota
Synthes USA Products, LLCDelaware
Synthes USA, LLCDelaware
Synthes, Inc.Delaware
TalCo LLCTexas
TARIS Biomedical LLCDelaware
TearScience, Inc.Delaware
The Anspach Effort, LLCFlorida
Tibotec, LLCDelaware
Torax Medical, Inc.Delaware
Verb Surgical Inc.Delaware
V-Wave Inc.Delaware
WH4110 Development Company, L.L.C.Georgia
Wolverine Merger Subsidiary, Inc.Delaware
Name of SubsidiaryJurisdiction
International Subsidiaries:
ABIOMED AUSTRALIA PTY LTDAustralia
Abiomed Europe GmbHGermany
Abiomed Japan K.K.Japan
ABIOMED SARLFrance
ABIOMED SINGAPORE PTE. LTD.Singapore
ABIOMED, LTD.United Kingdom
Actelion Pharmaceuticals LtdSwitzerland
Actelion Pharmaceuticals Trading (Shanghai) Co., Ltd.China
Actelion Treasury Unlimited CompanyIreland
AIS GmbH Aachen Innovative SolutionsGermany
Ambrx Australia Pty LimitedAustralia
Ambrx Biopharma Cayman, Inc.Cayman Islands
AMO (Hangzhou) Co., Ltd.China
AMO (Shanghai) Medical Devices Trading Co., Ltd.China
AMO ASIA LIMITEDHong Kong
AMO Australia Pty LimitedAustralia
AMO Canada CompanyCanada
AMO Denmark ApSDenmark
AMO FranceFrance
AMO Germany GmbHGermany
AMO Groningen B.V.Netherlands
AMO International Holdings Unlimited CompanyIreland
AMO IrelandCayman Islands
AMO Italy SRLItaly



Name of SubsidiaryJurisdiction
AMO Japan K.K.Japan
AMO Netherlands BVNetherlands
AMO Norway ASNorway
AMO Puerto Rico Manufacturing, Inc.Cayman Islands
AMO Singapore Pte. Ltd.Singapore
AMO Switzerland GmbHSwitzerland
AMO United Kingdom, Ltd.United Kingdom
AMO Uppsala ABSweden
ApsisFrance
Arterica Inc.United States
B-Balloon LtdIsrael
Berna Rhein B.V.Netherlands
Biosense Webster (Israel) Ltd.Israel
CathWorks Ltd.Israel
ChromaGenics B.V.Netherlands
Cilag AGSwitzerland
Cilag GmbH InternationalSwitzerland
Cilag Holding AGSwitzerland
Cilag Holding Treasury Unlimited CompanyIreland
Cilag-Biotech, S.L.Spain
Cordis de Mexico, S.A. de C.V.Mexico
Corimmun GmbHGermany
DePuy Hellas SAGreece
DePuy International LimitedUnited Kingdom
DePuy Ireland Unlimited CompanyIreland
DePuy Mexico, S.A. de C.V.Mexico
ECP Entwicklungsgesellschaft mbHGermany
EES Holdings de Mexico, S. de R.L. de C.V.Mexico
EES, S.A. de C.V.Mexico
EIT Emerging Implant Technologies GmbHGermany
Ethicon Endo-Surgery (Europe) GmbHGermany
Ethicon SarlSwitzerland
Ethicon Women's Health & Urology SarlSwitzerland
Ethnor (Proprietary) LimitedSouth Africa
Ethnor del Istmo S.A.Panama
Finsbury (Development) LimitedUnited Kingdom
Finsbury (Instruments) LimitedUnited Kingdom
Finsbury Medical LimitedUnited Kingdom
Finsbury Orthopaedics International LimitedUnited Kingdom
Finsbury Orthopaedics LimitedUnited Kingdom
FMS Future Medical System SASwitzerland
GATT Technologies B.V.Netherlands
Genesis Shockwave Private LimitedSingapore
GH Biotech Holdings LimitedIreland



Name of SubsidiaryJurisdiction
GMED Healthcare BVBelgium
Guangzhou Bioseal Biotech Co., Ltd.China
Hansen Medical Deutschland GmbHGermany
Hansen Medical UK LimitedUnited Kingdom
Healthcare Services (Shanghai) Ltd.China
Innomedic Gesellschaft für innovative Medizintechnik und Informatik mbHGermany
Intratech Medical Ltd.Israel
J & J Company West Africa LimitedNigeria
J&J Argentina S.A.Argentina
J&J Pension Trustees LimitedUnited Kingdom
J&J Productos Medicos & Farmaceuticos del Peru S.A.Peru
J.C. General Services BVBelgium
Janssen Biologics B.V.Netherlands
Janssen Cilag Farmaceutica S.A.Argentina
Janssen Cilag S.p.A.Italy
Janssen Cilag SPAAlgeria
Janssen Cilag, C.A.Venezuela, Bolivarian  Republic of
Janssen Egypt LLCEgypt
Janssen Farmaceutica Portugal LdaPortugal
Janssen France Treasury Unlimited CompanyIreland
Janssen Inc.Canada
Janssen Irish Finance Unlimited CompanyIreland
Janssen Japan Treasury Unlimited CompanyIreland
Janssen Korea Ltd.Korea, Republic of
Janssen Mexico Treasury Unlimited CompanyIreland
Janssen Pharmaceutica (Proprietary) LimitedSouth Africa
Janssen Pharmaceutica NVBelgium
Janssen Pharmaceutical K.K.Japan
Janssen Pharmaceutical Sciences Unlimited CompanyIreland
Janssen Pharmaceutical Unlimited CompanyIreland
Janssen Sciences Ireland Unlimited CompanyIreland
Janssen Vaccines & Prevention B.V.Netherlands
Janssen Vaccines Corp.Korea, Republic of
Janssen-CilagFrance
Janssen-Cilag (New Zealand) LimitedNew Zealand
Janssen-Cilag A/SDenmark
Janssen-Cilag AGSwitzerland
Janssen-Cilag AktiebolagSweden
Janssen-Cilag ASNorway
Janssen-Cilag B.V.Netherlands
Janssen-Cilag d.o.o. BeogradSerbia
Janssen-Cilag de Mexico S. de R.L. de C.V.Mexico
Janssen-Cilag Farmaceutica Lda.Portugal



Name of SubsidiaryJurisdiction
Janssen-Cilag Farmaceutica Ltda.Brazil
Janssen-Cilag GmbHGermany
Janssen-Cilag International NVBelgium
Janssen-Cilag Kft.Hungary
Janssen-Cilag LimitedThailand
Janssen-Cilag LimitedUnited Kingdom
Janssen-Cilag NVBelgium
Janssen-Cilag OYFinland
Janssen-Cilag Pharma GmbHAustria
Janssen-Cilag Pharmaceutical Single Member S.A.C.I.Greece
Janssen-Cilag Polska, Sp. z o.o.Poland
Janssen-Cilag Pty LtdAustralia
Janssen-Cilag S.A.Colombia
Janssen-Cilag s.r.o.Czech Republic
Janssen-Cilag, S.A.Spain
Janssen-Cilag, S.A. de C.V.Mexico
Janssen-Pharma, S.L.Spain
J-C Health Care Ltd.Israel
JJ Surgical Vision Spain, S.L.Spain
JJC Acquisition Company B.V.Netherlands
JJSV Belgium BVBelgium
JJSV Manufacturing Malaysia SDN. BHD.Malaysia
JJSV Norden ABSweden
JJSV Produtos Oticos Ltda.Brazil
JNJ Global Business Services s.r.o.Czech Republic
JNJ Holding EMEA B.V.Netherlands
JNTL Russia HoldCo 1 Pte. LtdSingapore
JNTL Russia HoldCo 2 Pte. LtdSingapore
Johnson & Johnson (Angola), LimitadaAngola
Johnson & Johnson (Australia) Pty LtdAustralia
Johnson & Johnson (Canada) Inc.Canada
Johnson & Johnson (China) Investment Ltd.China
Johnson & Johnson (Ecuador) S.A.Ecuador
Johnson & Johnson (Hong Kong) LimitedHong Kong
Johnson & Johnson (Ireland) LimitedIreland
Johnson & Johnson (Kenya) LimitedKenya
Johnson & Johnson (Mozambique), LimitadaMozambique
Johnson & Johnson (Namibia) (Proprietary) LimitedNamibia
Johnson & Johnson (New Zealand) LimitedNew Zealand
Johnson & Johnson (Philippines), Inc.Philippines
Johnson & Johnson (Private) LimitedZimbabwe
Johnson & Johnson (Trinidad) LimitedTrinidad and Tobago
Johnson & Johnson (Vietnam) Co., LtdVietnam



Name of SubsidiaryJurisdiction
Johnson & Johnson ABSweden
Johnson & Johnson AGSwitzerland
Johnson & Johnson Bulgaria EOODBulgaria
Johnson & Johnson d.o.o.Slovenia
Johnson & Johnson de Chile S.A.Chile
Johnson & Johnson de Mexico, S.A. de C.V.Mexico
Johnson & Johnson de Uruguay S.A.Uruguay
Johnson & Johnson do Brasil Industria E Comercio de Produtos Para Saude Ltda.Brazil
Johnson & Johnson Dominicana, S.A.S.Dominican Republic
Johnson & Johnson European Treasury Unlimited CompanyIreland
Johnson & Johnson Finance LimitedUnited Kingdom
Johnson & Johnson Financial Services GmbHGermany
Johnson & Johnson for Export and Import LLCEgypt
Johnson & Johnson GT, Sociedad AnónimaGuatemala
Johnson & Johnson Healthcare SPCKuwait
Johnson & Johnson Hemisferica S.A.Puerto Rico
Johnson & Johnson Holding GmbHGermany
Johnson & Johnson Holdings (Austria) GmbHAustria
Johnson & Johnson Innovation LimitedUnited Kingdom
Johnson & Johnson International (Singapore) Pte. Ltd.Singapore
Johnson & Johnson International Financial Services Unlimited CompanyIreland
Johnson & Johnson Irish Finance Company LimitedIreland
Johnson & Johnson K.K.Japan
Johnson & Johnson Kazakhstan Limited Liability PartnershipKazakhstan
Johnson & Johnson Kft.Hungary
Johnson & Johnson LLCRussian Federation
Johnson & Johnson Management LimitedUnited Kingdom
Johnson & Johnson Medical (China) Ltd.China
Johnson & Johnson Medical (Proprietary) LtdSouth Africa
Johnson & Johnson Medical (Shanghai) Ltd.China
Johnson & Johnson Medical (Suzhou) Ltd.China
Johnson & Johnson Medical B.V.Netherlands
Johnson & Johnson Medical GmbHGermany
Johnson & Johnson Medical Greece Single Member S.A.Greece
Johnson & Johnson Medical Korea Ltd.Korea, Republic of
Johnson & Johnson Medical LimitedUnited Kingdom
Johnson & Johnson Medical Mexico, S.A. de C.V.Mexico
Johnson & Johnson Medical NVBelgium
Johnson & Johnson Medical Products GmbHAustria
Johnson & Johnson Medical Pty LtdAustralia
Johnson & Johnson Medical S.A.Argentina
Johnson & Johnson Medical S.p.A.Italy
Johnson & Johnson Medical SASFrance



Name of SubsidiaryJurisdiction
Johnson & Johnson Medical Saudi Arabia LimitedSaudi Arabia
Johnson & Johnson Medical Taiwan Ltd.Taiwan (Province of  China)
Johnson & Johnson Medical, S.A.Venezuela, Bolivarian  Republic of
Johnson & Johnson Medikal Sanayi ve Ticaret Limited SirketiTurkey
Johnson & Johnson MedTech (Thailand) Ltd.Thailand
Johnson & Johnson Medtech Colombia S.A.S.Colombia
Johnson & Johnson Medtech CR LimitadaCosta Rica
Johnson & Johnson MENA RHQ LimitedSaudi Arabia
Johnson & Johnson Middle East FZ-LLCUnited Arab Emirates
Johnson & Johnson Morocco Societe AnonymeMorocco
Johnson & Johnson Nordic ABSweden
Johnson & Johnson Pakistan (Private) LimitedPakistan
Johnson & Johnson Pharmaceutical Ltd.China
Johnson & Johnson Poland Sp. z o.o.Poland
Johnson & Johnson Private LimitedIndia
Johnson & Johnson Romania S.R.L.Romania
Johnson & Johnson S.E. d.o.o.Croatia
Johnson & Johnson SDN. BHD.Malaysia
Johnson & Johnson Surgical Vision India Private LimitedIndia
Johnson & Johnson Taiwan Ltd.Taiwan (Province of  China)
Johnson & Johnson Trading LimitedSaudi Arabia
Johnson & Johnson UK Treasury Company LimitedUnited Kingdom
Johnson & Johnson Ukraine II LLCUkraine
Johnson & Johnson Vision Care (Australia) Pty LtdAustralia
Johnson & Johnson Vision Care (Shanghai) Ltd.China
Johnson & Johnson Vision Care Ireland Unlimited CompanyIreland
Johnson & Johnson Vision Korea, Ltd.Korea, Republic of
Johnson & Johnson, LdaPortugal
Johnson & Johnson, S.A.Spain
Johnson & Johnson, s.r.o.Czech Republic
Johnson & Johnson, s.r.o.Slovakia
Johnson & Johnson, s.r.o.Turkey
JTNL LLCRussian Federation
La Concha Land Investment CorporationPhilippines
McNeil Panama, LLCPanama
Medos International SarlSwitzerland
Medos SarlSwitzerland
Menlo Care De Mexico, S.A. de C.V.Mexico
Mentor B.V.Netherlands
Mentor Medical Systems B.V.Netherlands
Neovasc (UK) LimitedUnited Kingdom
Neovasc Inc.Canada



Neovasc Medical LtdIsrael
Name of SubsidiaryJurisdiction
Neovasc Tiara Inc.Canada
Neuravi LimitedIreland
Obtech Medical Mexico, S.A. de C.V.Mexico
OBTECH Medical SarlSwitzerland
OMJ Holding GmbHSwitzerland
Omrix Biopharmaceuticals Ltd.Israel
Omrix Biopharmaceuticals NVBelgium
Orthospin Ltd.Israel
OrthotaxyFrance
preCARDIAFrance
Proleader S.A.Uruguay
Protembis GmbHGermany
Proteologix Australia Pty LtdAustralia
PT Johnson and Johnson Indonesia TwoIndonesia
RespiVert Ltd.United Kingdom
Serhum S.A. de C.V.Mexico
Shockwave Medical France SaRLFrance
ShockWave Medical GmbHGermany
Shockwave Medical India Private LimitedIndia
Shockwave Medical Ireland LimitedIreland
Shockwave Medical Italy S.R.L.Italy
Shockwave Medical Japan KKJapan
Shockwave Medical Portugal, Unipessoal Lda.Portugal
Shockwave Medical UK LimitedUnited Kingdom
Spectrum Vision Limited Liability CompanyUkraine
Spectrum Vision Limited Liability PartnershipKazakhstan
Surgical Process Institute Deutschland GmbHGermany
Swav CR, Sociedad de Responsabilidad LimitadaCosta Rica
SWAV Medical Spain, S.L.Spain
Synthes Costa Rica S.C.R., LimitadaCosta Rica
SYNTHES GmbHGermany
Synthes GmbHSwitzerland
Synthes Holding AGSwitzerland
Synthes Holding LimitedUnited Arab Emirates
SYNTHES Medical Immobilien GmbHGermany
Synthes Medical Surgical Equipment & Instruments Trading LLCUnited Arab Emirates
Synthes Produktions GmbHSwitzerland
Synthes S.M.P., S. de R.L. de C.V.Mexico
Synthes Tuttlingen GmbHGermany
UAB "Johnson & Johnson"Lithuania
Vision Care Finance Unlimited CompanyIreland
V-Wave (Australia) Pty Ltd.Australia



V-Wave Ltd.Israel
Name of SubsidiaryJurisdiction
Xian Janssen Pharmaceutical Ltd.China
XO1 LimitedUnited Kingdom
Yellow Jersey Therapeutics AGSwitzerland


EX-23 5 ex23-pwcconsentxform10xkx2.htm EX-23 Document

EXHIBIT 23
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (Nos. 333-264596, 333-211250, 333-181092, and 333-129542) and Form S-3 (No. 333-269836) of Johnson & Johnson of our report dated February 13, 2025 relating to the financial statements and the effectiveness of internal control over financial reporting, which appears in this Form 10-K.


/s/PricewaterhouseCoopers LLP
Florham Park, New Jersey
February 13, 2025




EX-31.1 6 ex311-302certofceoxform10x.htm EX-31.1 CEO Document

Exhibit 31.1
CERTIFICATION OF CHIEF EXECUTIVE OFFICER
PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT
I, Joaquin Duato, certify that:
1. I have reviewed this Annual Report on Form 10-K for the fiscal year ended December 29, 2024 (the “report”) of Johnson & Johnson (the “Company”);
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Company as of, and for, the periods presented in this report;
4. The Company’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Company and have:
    (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
    (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
    (c) Evaluated the effectiveness of the Company’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
    (d) Disclosed in this report any change in the Company’s internal control over financial reporting that occurred during the Company’s most recent fiscal quarter (the Company’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting; and
5. The Company’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Company’s auditors and the audit committee of the Company’s board of directors (or persons performing the equivalent functions):
    (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Company’s ability to record, process, summarize and report financial information; and
    (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the Company’s internal control over financial reporting.
  
  
 
/s/ Joaquin Duato
 Joaquin Duato
 Chief Executive Officer 
 
Date: February 13, 2025


EX-31.2 7 ex312-302certofcfoxform10x.htm EX-31.2 CFO Document

Exhibit 31.2
CERTIFICATION OF CHIEF FINANCIAL OFFICER
PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT
I, Joseph J. Wolk certify that:
1. I have reviewed this Annual Report on Form 10-K for the fiscal year ended December 29, 2024 (the “report”) of Johnson & Johnson (the “Company”);
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Company as of, and for, the periods presented in this report;
4. The Company’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Company and have:
    (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
    (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
    (c) Evaluated the effectiveness of the Company’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
    (d) Disclosed in this report any change in the Company’s internal control over financial reporting that occurred during the Company’s most recent fiscal quarter (the Company’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting; and
5. The Company’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Company’s auditors and the audit committee of the Company’s board of directors (or persons performing the equivalent functions):
    (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Company’s ability to record, process, summarize and report financial information; and
    (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the Company’s internal control over financial reporting.
  
  
 
/s/ Joseph J. Wolk
 Joseph J. Wolk
 Chief Financial Officer 
 
Date: February 13, 2025


EX-32.1 8 ex321-906certofceoxform10x.htm EX-32.1 CEO Document

Exhibit 32.1
CERTIFICATION OF CHIEF EXECUTIVE OFFICER
PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT
The undersigned, Joaquin Duato, the Chief Executive Officer of Johnson & Johnson, a New Jersey corporation (the “Company”), pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, hereby certifies that, to the best of my knowledge:

(1)the Company's Annual Report on Form 10-K for the fiscal year ended December 29, 2024 (the “Report”) fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934; and

(2)the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
  
  
 
/s/ Joaquin Duato
 Joaquin Duato
 Chief Executive Officer 
 
Dated: February 13, 2025
This certification is being furnished to the SEC with this Report on Form 10-K pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by such Act, be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section.











EX-32.2 9 ex322-906certofcfoxform10x.htm EX-32.2 CFO Document

Exhibit 32.2
CERTIFICATION OF CHIEF FINANCIAL OFFICER
PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT
The undersigned, Joseph J. Wolk, the Chief Financial Officer of Johnson & Johnson, a New Jersey corporation (the “Company”), pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, hereby certifies that, to the best of my knowledge:

(1)the Company's Annual Report on Form 10-K for the fiscal year ended December 29, 2024 (the “Report") fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934; and

(2)the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
  
 
/s/ Joseph J. Wolk
 Joseph J. Wolk 
 Chief Financial Officer 
 
Dated: February 13, 2025
This certification is being furnished to the SEC with this Report on Form 10-K pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by such Act, be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section.


EX-101.SCH 10 jnj-20241229.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink 0000002 - Document - Audit Information link:presentationLink link:calculationLink link:definitionLink 9952151 - Statement - Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 9952152 - Statement - Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 9952153 - Statement - Consolidated Statements of Earnings link:presentationLink link:calculationLink link:definitionLink 9952154 - Statement - Consolidated Statements of Comprehensive Income link:presentationLink link:calculationLink link:definitionLink 9952155 - Statement - Consolidated Statements of Comprehensive Income (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 9952156 - Statement - Consolidated Statements of Equity link:presentationLink link:calculationLink link:definitionLink 9952157 - Statement - Consolidated Statements of Equity (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 9952158 - Statement - Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 9952159 - Disclosure - Summary of significant accounting policies link:presentationLink link:calculationLink link:definitionLink 9952160 - Disclosure - Cash, cash equivalents and current marketable securities link:presentationLink link:calculationLink link:definitionLink 9952161 - Disclosure - Inventories link:presentationLink link:calculationLink link:definitionLink 9952162 - Disclosure - Property, plant and equipment link:presentationLink link:calculationLink link:definitionLink 9952163 - Disclosure - Intangible assets and goodwill link:presentationLink link:calculationLink link:definitionLink 9952164 - Disclosure - Fair value measurements link:presentationLink link:calculationLink link:definitionLink 9952165 - Disclosure - Borrowings link:presentationLink link:calculationLink link:definitionLink 9952166 - Disclosure - Income taxes link:presentationLink link:calculationLink link:definitionLink 9952167 - Disclosure - Employee related obligations link:presentationLink link:calculationLink link:definitionLink 9952168 - Disclosure - Pensions and other benefit plans link:presentationLink link:calculationLink link:definitionLink 9952169 - Disclosure - Savings plan link:presentationLink link:calculationLink link:definitionLink 9952170 - Disclosure - Capital and treasury stock link:presentationLink link:calculationLink link:definitionLink 9952171 - Disclosure - Accumulated other comprehensive income (loss) link:presentationLink link:calculationLink link:definitionLink 9952172 - Disclosure - International currency translation link:presentationLink link:calculationLink link:definitionLink 9952173 - Disclosure - Earnings per share link:presentationLink link:calculationLink link:definitionLink 9952174 - Disclosure - Common stock, stock option plans and stock compensation agreements link:presentationLink link:calculationLink link:definitionLink 9952175 - Disclosure - Segments of business and geographic areas link:presentationLink link:calculationLink link:definitionLink 9952176 - Disclosure - Acquisitions and divestitures link:presentationLink link:calculationLink link:definitionLink 9952177 - Disclosure - Legal proceedings link:presentationLink link:calculationLink link:definitionLink 9952178 - Disclosure - Restructuring link:presentationLink link:calculationLink link:definitionLink 9952179 - Disclosure - Kenvue separation and discontinued operations link:presentationLink link:calculationLink link:definitionLink 9955511 - Disclosure - Summary of significant accounting policies (Policies) link:presentationLink link:calculationLink link:definitionLink 9955512 - Disclosure - Summary of significant accounting policies (Tables) link:presentationLink link:calculationLink link:definitionLink 9955513 - Disclosure - Cash, cash equivalents and current marketable securities (Tables) link:presentationLink link:calculationLink link:definitionLink 9955514 - Disclosure - Inventories (Tables) link:presentationLink link:calculationLink link:definitionLink 9955515 - Disclosure - Property, plant and equipment (Tables) link:presentationLink link:calculationLink link:definitionLink 9955516 - Disclosure - Intangible assets and goodwill (Tables) link:presentationLink link:calculationLink link:definitionLink 9955517 - Disclosure - Fair value measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 9955518 - Disclosure - Borrowings (Tables) link:presentationLink link:calculationLink link:definitionLink 9955519 - Disclosure - Income taxes (Tables) link:presentationLink link:calculationLink link:definitionLink 9955520 - Disclosure - Employee related obligations (Tables) link:presentationLink link:calculationLink link:definitionLink 9955521 - Disclosure - Pensions and other benefit plans (Tables) link:presentationLink link:calculationLink link:definitionLink 9955522 - Disclosure - Capital and treasury stock (Tables) link:presentationLink link:calculationLink link:definitionLink 9955523 - Disclosure - Accumulated other comprehensive income (loss) (Tables) link:presentationLink link:calculationLink link:definitionLink 9955524 - Disclosure - Earnings per share (Tables) link:presentationLink link:calculationLink link:definitionLink 9955525 - Disclosure - Common stock, stock option plans and stock compensation agreements (Tables) link:presentationLink link:calculationLink link:definitionLink 9955526 - Disclosure - Segments of business and geographic areas (Tables) link:presentationLink link:calculationLink link:definitionLink 9955527 - Disclosure - Acquisitions and divestitures (Tables) link:presentationLink link:calculationLink link:definitionLink 9955528 - Disclosure - Legal proceedings (Tables) link:presentationLink link:calculationLink link:definitionLink 9955529 - Disclosure - Restructuring (Tables) link:presentationLink link:calculationLink link:definitionLink 9955530 - Disclosure - Kenvue separation and discontinued operations (Tables) link:presentationLink link:calculationLink link:definitionLink 9955531 - Disclosure - Summary of significant accounting policies - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9955532 - Disclosure - Summary of significant accounting policies - Estimated Useful Lives of Assets (Details) link:presentationLink link:calculationLink link:definitionLink 9955533 - Disclosure - Summary of significant accounting policies - Supplier Finance Program (Details) link:presentationLink link:calculationLink link:definitionLink 9955534 - Disclosure - Cash, cash equivalents and current marketable securities - Cash and Cash Equivalent Composition (Details) link:presentationLink link:calculationLink link:definitionLink 9955535 - Disclosure - Cash, cash equivalents and current marketable securities - Contractual Maturities of Available for Sale Securities (Details) link:presentationLink link:calculationLink link:definitionLink 9955536 - Disclosure - Inventories (Details) link:presentationLink link:calculationLink link:definitionLink 9955537 - Disclosure - Property, plant and equipment - Property, Plant and Equipment at Cost and Accumulated Depreciation (Details) link:presentationLink link:calculationLink link:definitionLink 9955538 - Disclosure - Property, plant and equipment - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9955539 - Disclosure - Intangible assets and goodwil - Schedule of Intangible Assets and Goodwill (Details) link:presentationLink link:calculationLink link:definitionLink 9955540 - Disclosure - Intangible assets and goodwill - Goodwill (Details) link:presentationLink link:calculationLink link:definitionLink 9955541 - Disclosure - Intangible assets and goodwill - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9955542 - Disclosure - Intangible assets and goodwill - Estimated Amortization of Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 9955543 - Disclosure - Fair value measurements - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9955544 - Disclosure - Fair value measurements - Summary of Derivative Activity (Details) link:presentationLink link:calculationLink link:definitionLink 9955545 - Disclosure - Fair value measurements - Schedule of Derivatives Recorded in Consolidated Balance Sheets (Details) link:presentationLink link:calculationLink link:definitionLink 9955546 - Disclosure - Fair value measurements - Schedule of Effect of Derivatives not Designated as Hedging Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 9955547 - Disclosure - Fair value measurements - Schedule of Effect of Net Investment Hedges (Details) link:presentationLink link:calculationLink link:definitionLink 9955548 - Disclosure - Fair value measurements - Summary of Activity Related to Equity Investments (Details) link:presentationLink link:calculationLink link:definitionLink 9955549 - Disclosure - Fair value measurements - Financial Assets and Liabilities at Fair Value (Details) link:presentationLink link:calculationLink link:definitionLink 9955550 - Disclosure - Borrowings - Schedule of Long-term Debt Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 9955551 - Disclosure - Borrowings - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9955552 - Disclosure - Borrowings - Aggregate Maturities of Long Term Obligations (Details) link:presentationLink link:calculationLink link:definitionLink 9955553 - Disclosure - Income taxes - Provision for Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 9955554 - Disclosure - Income taxes - Comparison of Income Taxes at Statutory Rate and Company's Effective Tax Rate (Details) link:presentationLink link:calculationLink link:definitionLink 9955555 - Disclosure - Income taxes - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9955556 - Disclosure - Income taxes - Temporary Differences and Carryforwards (Details) link:presentationLink link:calculationLink link:definitionLink 9955557 - Disclosure - Income taxes - Valuation Allowance Activity (Details) link:presentationLink link:calculationLink link:definitionLink 9955558 - Disclosure - Income taxes - Summary of Activity Related to Unrecognized Tax Benefits (Details) link:presentationLink link:calculationLink link:definitionLink 9955559 - Disclosure - Employee related obligations - Employee Related Obligations (Details) link:presentationLink link:calculationLink link:definitionLink 9955559 - Disclosure - Employee related obligations - Employee Related Obligations (Details) link:presentationLink link:calculationLink link:definitionLink 9955560 - Disclosure - Employee related obligations - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9955561 - Disclosure - Pensions and other benefit plans - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9955562 - Disclosure - Pensions and other benefit plans - Components of Net Periodic Benefit Cost (Details) link:presentationLink link:calculationLink link:definitionLink 9955563 - Disclosure - Pensions and other benefit plans - Rates Used to Develop Actuarial Present Value of Projected Benefit Obligation (Details) link:presentationLink link:calculationLink link:definitionLink 9955564 - Disclosure - Pensions and other benefit plans - Assumed Health Care Cost Trend Rates (Details) link:presentationLink link:calculationLink link:definitionLink 9955565 - Disclosure - Pensions and other benefit plans - Schedule of Net Funded Status (Details) link:presentationLink link:calculationLink link:definitionLink 9955566 - Disclosure - Pensions and other benefit plans - Information Related to the Benefit Obligation and the Fair Value of Plan Assets (Details) link:presentationLink link:calculationLink link:definitionLink 9955567 - Disclosure - Pensions and other benefit plans - Projected Future Benefit Payments from Company's Retirement and Other Benefit Plans (Details) link:presentationLink link:calculationLink link:definitionLink 9955568 - Disclosure - Pensions and other benefit plans - Projected Future Minimum Contributions to the Company's U.S. and International Unfunded Retirement Plans (Details) link:presentationLink link:calculationLink link:definitionLink 9955569 - Disclosure - Pensions and other benefit plans - Company' Retirement Plan Asset Allocation and Target Allocations (Details) link:presentationLink link:calculationLink link:definitionLink 9955570 - Disclosure - Pensions and other benefit plans - Schedule of Defined Benefit Plans Disclosures (Details) link:presentationLink link:calculationLink link:definitionLink 9955571 - Disclosure - Savings plan (Details) link:presentationLink link:calculationLink link:definitionLink 9955572 - Disclosure - Capital and treasury stock - Changes in Treasury Stock (Details) link:presentationLink link:calculationLink link:definitionLink 9955573 - Disclosure - Capital and treasury stock - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9955574 - Disclosure - Accumulated other comprehensive income (loss) (Details) link:presentationLink link:calculationLink link:definitionLink 9955575 - Disclosure - International currency translation (Details) link:presentationLink link:calculationLink link:definitionLink 9955576 - Disclosure - Earnings per share - Reconciliation of Basic Net Earnings per Share to Diluted Net Earnings per Share (Details) link:presentationLink link:calculationLink link:definitionLink 9955577 - Disclosure - Earnings per share - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9955578 - Disclosure - Common stock, stock option plans and stock compensation agreements - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9955579 - Disclosure - Common stock, stock option plans and stock compensation agreements - Schedule Valuation Assumptions (Details) link:presentationLink link:calculationLink link:definitionLink 9955580 - Disclosure - Common stock, stock option plans and stock compensation agreements - Summary of Stock Option Activity (Details) link:presentationLink link:calculationLink link:definitionLink 9955581 - Disclosure - Common stock, stock option plans and stock compensation agreements - Summary of Options Outstanding (Details) link:presentationLink link:calculationLink link:definitionLink 9955582 - Disclosure - Common stock, stock option plans and stock compensation agreements - Summary of Restricted Share Units (Details) link:presentationLink link:calculationLink link:definitionLink 9955583 - Disclosure - Segments of Business and Geographic Areas - Sales by Segment of Business (Details) link:presentationLink link:calculationLink link:definitionLink 9955584 - Disclosure - Segments of Business and Geographic Areas - Income Before Tax by Segment (Details) link:presentationLink link:calculationLink link:definitionLink 9955585 - Disclosure - Segments of Business and Geographic Areas - Schedule of Segment Reporting Information (Details) link:presentationLink link:calculationLink link:definitionLink 9955586 - Disclosure - Segments of Business and Geographic Areas - Schedule of Segment Reporting By Geographic Area (Details) link:presentationLink link:calculationLink link:definitionLink 9955587 - Disclosure - Acquisitions and divestitures - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9955588 - Disclosure - Acquisitions and divestitures (Details) link:presentationLink link:calculationLink link:definitionLink 9955589 - Disclosure - Legal proceedings - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9955590 - Disclosure - Legal proceedings - Product Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9955591 - Disclosure - Restructuring - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9955592 - Disclosure - Restructuring - Schedule of Restructuring Reserve (Details) link:presentationLink link:calculationLink link:definitionLink 9955593 - Disclosure - Kenvue separation and discontinued operations - Details (Details) link:presentationLink link:calculationLink link:definitionLink 9955594 - Disclosure - Kenvue separation and discontinued operations - Net Earnings from Discontinued Operation (Details) link:presentationLink link:calculationLink link:definitionLink 9955595 - Disclosure - Kenvue separation and discontinued operations - Depreciation and Amortization of Discontinued Operation (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 11 jnj-20241229_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 12 jnj-20241229_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 13 jnj-20241229_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT International currency translation Foreign Currency Disclosure [Text Block] Government and agency securities US Government Corporations and Agencies Securities [Member] 2025 Defined Benefit Plan, Expected Future Benefit Payment, Year Two Adjustments to reconcile net earnings to cash flows from operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Baby Powder Baby Powder [Member] Baby Powder [Member] Repayment of long-term debt Repayments of Long-Term Debt Debt for equity exchange, shares exchanged (in shares) Debt For Equity Exchange, Shares Exchanged Debt For Equity Exchange, Shares Exchanged Supplier finance program, obligation, current Confirmed obligations - beginning of the year Confirmed obligations - end of the year Supplier Finance Program, Obligation, Current Damages sought, nominal value Loss Contingency, Damages Sought, Nominal Value Loss Contingency, Damages Sought, Nominal Value Cover page. Cover [Abstract] Undistributed foreign earnings Deferred Tax Assets, Undistributed Foreign Earnings Deferred Tax Assets, Undistributed Foreign Earnings Increase/(Decrease) in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 3.550% Notes Due November 2044 3.550% Notes Due November 2044 [Member] 3.550% Notes Due November 2044 In Process Research and Development In Process Research and Development [Member] Consumer Health Consumer [Member] Consumer. $164.62 - $165.89 Exercise Price Range Five [Member] Exercise Price Range. International Plans Foreign Plan [Member] Inventory related Deferred Tax Assets, Inventory Income Tax Jurisdiction [Domain] Income Tax Jurisdiction [Domain] Trading Symbol Trading Symbol Fair Value Hedging Fair Value Hedging [Member] Comprehensive income Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest ADVANCED ADVANCED [Member] ADVANCED [Member] Cash and Cash Equivalent [Table] Cash and Cash Equivalent [Table] Total Gross Assets Derivative Asset, Subject to Master Netting Arrangement, before Offset Non-NEOs Non-NEOs [Member] Fair value of company's common stock directly held in plan assets Fair Value Of Company's Common Stock Directly Held In Plan Assets Fair value of company's common stock directly held in plan assets. Total income tax benefit recognized Share-Based Payment Arrangement, Expense, Tax Benefit Other Investment Not Readily Marketable [Table] Other Investment Not Readily Marketable [Table] Borrowed under the commercial paper program Long-Term Commercial Paper, Current Cash dividend (in dollars per share) Common Stock, Dividends, Per Share, Declared 2026 Defined Benefit Plan, Expected Future Benefit Payment, Year Three Allowances for doubtful accounts Accounts Receivable, Allowance for Credit Loss, Current Judicial Ruling Judicial Ruling [Member] Disposal Group Name [Domain] Disposal Group Name [Domain] Derivatives & hedges Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax Increase in accounts receivable Increase (Decrease) in Accounts Receivable 3.20% Notes Due November 2032 3.20% Notes Due November 2032 [Member] 3.20% Notes Due November 2032 Equity securities, FV-NI, gain (loss) Equity securities, FV-NI, gain (loss) Equity Securities, FV-NI, Gain (Loss) Deferred net losses (gains) on derivatives included in accumulated other comprehensive income AOCI, Cash Flow Hedge, Cumulative Gain (Loss), after Tax Net earnings per share Earnings Per Share, Policy [Policy Text Block] Inventories Inventory, Policy [Policy Text Block] Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] CONTACT LENSES/OTHER CONTACT LENSES/OTHER [Member] CONTACT LENSES/OTHER [Member] Hedging Relationship [Domain] Hedging Relationship [Domain] Fair value measurements Fair Value Disclosures [Text Block] Unrealized holding gain (loss) arising during period OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax Award Timing Disclosures [Line Items] R&D capitalized for tax Deferred Tax Assets International Research And Development Capitalized Deferred tax assets international research and development capitalized. Divestitures & acquisitions Defined Benefit Plan, Benefit Obligation, Business Combination and Divestiture, Increase (Decrease) Defined Benefit Plan, Benefit Obligation, Business Combination and Divestiture, Increase (Decrease) Gain/(Loss) Recognized In Income on Derivative Derivative, Gain (Loss) on Derivative, Net Investment, Name [Domain] Investment, Name [Domain] HIPS HIPS [Member] HIPS [Member] Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table] Share-Based Payment Arrangement, Option, Exercise Price Range [Table] Unfunded Plans Unfunded Plans [Member] Unfunded plans. Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration] Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration] Number of pending claims Loss Contingency, Pending Claims, Number Concentration of Credit Risk [Table] Concentration of Credit Risk [Table] Concentration of Credit Risk [Table] Business segments Segment Reporting, Policy [Policy Text Block] 1.650% Notes Due May 2035 1.650% Notes due 2035
(1.5B Euro 1.0401)(2)/(1.5B Euro 1.1090)(3) 1.650% Notes Due 2035 [Member] 1.650% Notes Due 2035 [Member] Plan Name [Domain] Plan Name [Domain] Sale of stock (in USD per share) Sale of Stock, Price Per Share Non-Tradeable Contingent Value Right Non-Tradeable Contingent Value Right [Member] Non-Tradeable Contingent Value Right V-Wave Ltd. V-Wave Ltd. [Member] V-Wave Ltd. U.S. Plans United States UNITED STATES Summary of Inventories Inventory, Net [Abstract] Other assets Other assets, noncurrent Other Assets, Noncurrent Wholesaler Concentration Risk Wholesaler Concentration Risk [Member] Wholesaler Concentration Risk Non-tradeable contingent value right (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Shares, Non-Tradeable Contingent Value Right Share-Based Compensation Arrangement by Share-Based Payment Award, Shares, Non-Tradeable Contingent Value Right Finite lived intangible assets gross Finite-Lived Intangible Assets, Gross Credit support agreements activity, net Proceeds (Payments) from (to) Credit Support Agreements, Investing Activities Proceeds (Payments) from (to) Credit Support Agreements, Investing Activities Number of claims within settlement agreement Loss Contingency, Number of Claims within Settlement Agreement Loss Contingency, Number of Claims within Settlement Agreement Equity Investment [Roll Forward] Equity Investment [Roll Forward] Equity Investment [Roll Forward] Tax rates: Effective Income Tax Rate Reconciliation, Percent [Abstract] OTHER NEUROSCIENCE OTHER NEUROSCIENCE [Member] OTHER NEUROSCIENCE [Member] Operating Segments Operating Segments [Member] Net cash flows from operating activities Net Cash Provided by (Used in) Operating Activities Cash flows from operating activities Net Cash Provided by (Used in) Operating Activities [Abstract] Components of Accumulated Other Comprehensive Income Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Physiomesh Physiomesh [Member] Physiomesh [Member] Other Stockholders' Equity, Other 0.55% Notes due 2025 0.55% Notes due 2025 [Member] 0.55% Notes due 2025 U.S. Reverse repurchase agreements Repurchase Agreements [Member] Award Timing Method Award Timing Method [Text Block] Net periodic benefit cost (credit) Net periodic benefit cost (credit) Defined Benefit Plan, Net Periodic Benefit Cost (Credit) 6.95% Notes due 2029 6.95% Notes due 2029 [Member] 6.95% Notes due 2029 [Member] Total debt securities Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Amortized Cost Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Fair value of liabilities assumed Noncash or Part Noncash Acquisition, Value of Liabilities Assumed Measurement Frequency [Axis] Measurement Frequency [Axis] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Excess of carrying value over fair value of debt Excess Of Carrying Value Over Fair Value Of Debt Excess Of Carrying Value Over Fair Value Of Debt Insider Trading Policies and Procedures [Line Items] Proceeds from divestiture of brands Proceeds from Divestiture of Businesses Plan with accumulated benefit obligation in excess of plan assets, plan assets Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Plan Assets Equity Investments with readily determinable value Equity Investments with Readily Determinable Value [Member] Equity Investments with Readily Determinable Value [Member] Use of estimates Use of Estimates, Policy [Policy Text Block] Western Hemisphere excluding U.S.  Western Hemisphere, excluding U.S. [Member] Western Hemisphere, excluding U.S. [Member] Adjustment to Compensation, Amount Adjustment to Compensation Amount Compensation Amount Outstanding Recovery Compensation Amount Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member] Entity Small Business Entity Small Business Company Selected Measure Amount Company Selected Measure Amount ERLEADA Erleada [Member] Erleada Tabular List, Table Tabular List [Table Text Block] Level 3 Fair Value, Inputs, Level 3 [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Foreign currency exchange rate, translation Foreign Currency Exchange Rate, Translation Finite-lived intangible assets acquired Finite-Lived Intangible Assets Acquired Expected long-term rate of return on plan assets Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-Term Rate of Return on Plan Assets 3.55% Debentures due 2044 3.55% Debentures due 2044 [Member] 3.55% Debentures due 2044 Accrued liabilities Accrued Liabilities, Current Antidilutive securities excluded from computation of earnings per share (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Transition service agreement, term Discontinued Operations, Transition Service Agreement, Term Discontinued Operations, Transition Service Agreement, Term Yellow Jersey Therapeutics Yellow Jersey Therapeutics [Member] Yellow Jersey Therapeutics Schedule of Effect of Net Investment Hedges Schedule of Derivative Instruments, Effect on Other Comprehensive Income (Loss) [Table Text Block] Asset Acquisition [Axis] Asset Acquisition [Axis] Foreign currency translation Valuation Allowance, Deferred Tax Asset, Foreign Currency Translation Valuation Allowance, Deferred Tax Asset, Foreign Currency Translation Goodwill Goodwill beginning of period Goodwill end of period Goodwill Other comprehensive income (loss), net of tax Other Comprehensive Income (Loss), Net of Tax [Abstract] Stock repurchase program, authorized amount Share Repurchase Program, Authorized, Amount Inventories Inventory Disclosure [Text Block] $100.06 - $101.87 Exercise Price Range One Member Exercise price range. DePuy ASR U.S. DePuy ASR U.S. [Member] DePuy ASR U.S. [Member] 0.95% Notes due 2027 0.95% Notes due 2027 [Member] 0.95% Notes due 2027 Employee Stock Option Share-Based Payment Arrangement, Option [Member] Other Proceeds from (Payments for) Other Financing Activities Equity, fair value adjustment Equity, Fair Value Adjustment Retirement Plans Retirement plans Pension Plan [Member] Accrued taxes on income Accrued Income Taxes, Current All other Effective Income Tax Rate Reconciliation, Other Adjustments, Percent Mesothelioma and State Claims Mesothelioma and State Claims [Member] Mesothelioma and State Claims 4.375% Notes due 2033 4.375% Notes due 2033 [Member] 4.375% Notes due 2033 [Member] Award Type [Axis] Award Type [Axis] Total deferred income taxes net of valuation allowances Deferred Tax Liabilities, Net Corporate debt securities Corporate Debt Securities [Member] 4.80% Debentures due 2029 4.80% Debentures due 2029 [Member] 4.80% Debentures due 2029 Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block] Summary of Options Outstanding Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block] Goods in process Inventory, Work in Process, Net of Reserves Projected Future Minimum Contributions to the Company's U.S. and International Unfunded Retirement Plans Schedule Of Estimated Future Employer Contributions [Table Text Block] Schedule of estimated future employer contributions. Property, plant and equipment, net Total property, plant and equipment, net Property, Plant and Equipment, Net ICFR Auditor Attestation Flag ICFR Auditor Attestation Flag Total liabilities Liabilities Sales return reserve (as a percent) Sales Return Reserve Sales return reserve Cash dividends paid (in dollars per share) Common Stock, Dividends, Per Share, Cash Paid Long-Lived Assets Long-Lived Assets Stock options average price (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Common stock, par value per share (in usd per share) Common Stock, Par or Stated Value Per Share Common Stock, Par or Stated Value Per Share Supplier finance program obligations Supplier Finance Program [Policy Text Block] Supplier Finance Program Weighted average useful life Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Expiration Date Trading Arrangement Expiration Date Cash flows from investing activities Net Cash Provided by (Used in) Investing Activities [Abstract] Total Shareholder Return Amount Total Shareholder Return Amount IPR&D charge Asset Acquisition, Recognized Identifiable Assets Acquired, Intangible Assets, Other than Goodwill Asset Acquisition, Recognized Identifiable Assets Acquired, Intangible Assets, Other than Goodwill Currency translation/other Goodwill, Other Increase (Decrease) Equity Awards Adjustments, Footnote Equity Awards Adjustments, Footnote [Text Block] Operating loss carryforwards Deferred Tax Assets, Operating Loss Carryforwards Shares issued subject to stock options or stock appreciation rights (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number, May Be Issued Subject To Stock Options Or Stock Appreciation Rights Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number, May Be Issued Subject To Stock Options Or Stock Appreciation Rights Noncash gain on exchange offer Noncash Or Part Noncash Transaction, Gain On Exchange Of Stock Noncash Or Part Noncash Transaction, Gain On Exchange Of Stock Total property, plant and equipment, gross Property, Plant and Equipment, Gross Notes payable Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-Term Debt Options exercised (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Land and leasehold improvements Land And Leasehold Improvements [Member] Land and leasehold improvements. 2025 Defined Benefit Plan Expected Future Benefit Contribution In Year Two Defined benefit plan expected future benefit contribution in year two. Prior service cost (credit) Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), before Tax Plan participant contributions Defined Benefit Plan, Plan Assets, Contributions by Plan Participant Debt Instrument [Line Items] Debt Instrument [Line Items] Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] R&D Expense Research and Development Expense [Member] Intangible assets and goodwill Goodwill and Intangible Assets, Policy [Policy Text Block] Lapse of statute of limitations Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations Cash Cash [Member] Net change OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax Diluted (in shares) Average shares outstanding - diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Prior service credit (cost), net of amortization Other Comprehensive (Income) Loss, Pension and Other Postretirement Benefit Plans, Net Prior Service Cost (Credit), Net of Amortization, Arising During Period, Net of Tax Other Comprehensive (Income) Loss, Pension and Other Postretirement Benefit Plans, Net Prior Service Cost (Credit), Net of Amortization, Arising During Period, Net of Tax Pre-tax restructuring charges Restructuring and Related Cost, Expected Cost INVEGA SUSTENNA/XEPLION/TRINZA/TREVICTA INVEGA SUSTENNA/XEPLION/TRINZA/TREVICTA [Member] INVEGA SUSTENNA/XEPLION/TRINZA/TREVICTA [Member] Restructuring Disposal Group, Including Discontinued Operation, Restructuring Expense Disposal Group, Including Discontinued Operation, Restructuring Expense MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Loss contingency, payment period Loss Contingency, Payment Period Loss Contingency, Payment Period Pinnacle Acetabular Cup System Pinnacle Acetabular Cup System [Member] Pinnacle Acetabular cup system. Income reported for tax purposes Deferred Tax Assets, Gross Effective income tax rate reconciliation, GILTI, amount Effective Income Tax Rate Reconciliation, GILTI, Amount Less: common stock held in treasury, at cost (Note 12) (712,921,000 shares and 712,765,000 shares) Treasury Stock, Balance Treasury Stock, Ending Balance Treasury Stock, Value Due within one year Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One Separation costs incurred Discontinued Operations, Separation Costs Incurred Discontinued Operations, Separation Costs Incurred Sales to customers Disposal Group, Including Discontinued Operation, Revenue Litigation Case [Axis] Litigation Case [Axis] Goodwill Schedule of Goodwill [Table Text Block] Concentration Risk Type [Domain] Concentration Risk Type [Domain] 4.50% Debentures due 2040 4.50% Debentures due 2040 [Member] 4.50% Debentures due 2040 [Member] Selling, marketing and administrative expenses Selling, General and Administrative Expense Matching contributions Defined Contribution Plan, Cost Cost of Products Sold Cost of Sales [Member] Wholesaler 3 Wholesaler 3 [Member] Wholesaler 3 [Member] Deferred tax assets, tax basis increase of certain assets due to reorganization Deferred Tax Assets, Tax Basis Increase of Certain Assets due to Reorganization Deferred Tax Assets, Tax Basis Increase of Certain Assets due to Reorganization Number of shares authorized for issuance under long-term incentive plan (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized Sale of Stock [Domain] Sale of Stock [Domain] Accrual, nominal value Loss Contingency Accrual, Nominal Value Loss Contingency Accrual, Nominal Value Document Fiscal Period Focus Document Fiscal Period Focus Invoices confirmed during the year Supplier Finance Program, Obligation, Addition Acquisition related costs Business Combination, Acquisition Related Costs Employee compensation and stock option plans Stock Issued During Period, Value, Other 2028 Long-Term Debt, Maturity, Year Four All Executive Categories All Executive Categories [Member] Potential shares exercisable under stock option plans (in shares) Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements Shipping and handling costs as a percent of sales Shipping and Handling Costs as a Percent of Sales Shipping and Handling Costs as a Percent of Sales Simponi/Simponi Aria Simponi/Simponi Aria [Member] Simponi/Simponi Aria [Member] Statement of Financial Position Location, Balance [Domain] Statement of Financial Position Location, Balance [Domain] Acquisition price (in dollars per share) Business Acquisition, Share Price Equity securities Equity Securities [Member] Summary of Severance Charges and Associated Spending Schedule of Restructuring Reserve by Type of Cost [Table Text Block] Gain/ (Loss) On Securities AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Parent [Member] 2026 Finite-Lived Intangible Asset, Expected Amortization, Year Two Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Assets Assets [Abstract] Retirement Plan Type [Domain] Retirement Plan Type [Domain] Other comprehensive income (loss) Other comprehensive income (loss), net of tax Net change Other Comprehensive Income (Loss), Net of Tax Expected dividend yield Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items] Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items] Held-to-maturity Securities Held-to-Maturity Securities [Member] Document Type Document Type Effective interest rate Debt Instrument, Interest Rate, Effective Percentage Derivative Contract [Domain] Derivative Contract [Domain] XARELTO Xarelto [Member] Xarelto [Member] Actuarial (gains) losses Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss) Schedule of Segment Reporting Information Schedule of Segment Reporting Information, by Segment [Table Text Block] 2026 Defined Benefit Plan Expected Future Benefit Contribution In Year Three Defined benefit plan expected future benefit contribution in year three. Cash and cash equivalents from discontinued operations, beginning of period Cash and cash equivalents from discontinued operations, end of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations Defined Benefit Plan [Table] Defined Benefit Plan [Table] Carrying Amount, available-for-sale Debt Securities, Available-for-Sale, Amortized Cost Sales Sales [Member] Dividends payable, amount per share (in dollars per share) Dividends Payable, Amount Per Share Maximum Maximum [Member] Stock options outstanding (in shares) Outstanding number of Options (in shares) Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Supplier finance program, payment timing, period Supplier Finance Program, Payment Timing, Period Finite lived intangible assets net Finite-Lived Intangible Assets, Net Accounts payable Accounts Payable, Current Gain (loss) related to litigation settlement Gain (Loss) from Litigation Settlement Acquisitions Noncash or Part Noncash Acquisition, Net Nonmonetary Assets Acquired (Liabilities Assumed) [Abstract] Schedule Valuation Assumptions Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Range [Axis] Statistical Measurement [Axis] ZYTIGA/abiraterone acetate ZYTIGA [Member] ZYTIGA [Member] Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Earnings before provision for taxes on income Earnings before provision for taxes on income Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Schedule of Intangible Assets and Goodwill Schedule of Finite and Indefinite-Lived Intangible Assets Excluding Goodwill by Major Class [Table Text Block] Schedule of Finite and Indefinite-Lived Intangible Assets Excluding Goodwill by Major Class [Table Text Block] Depreciation of property, plant and equipment Deferred Tax Liabilities, Property, Plant and Equipment Name Outstanding Recovery, Individual Name Summary of Valuation Allowance Summary of Valuation Allowance [Table Text Block] Disposal Groups, Including Discontinued Operations Disposal Groups, Including Discontinued Operations [Table Text Block] Other non long-lived assets Other Non Long Lived Assets Other non long lived assets. Kenvue Separation /IPO Stockholders' Equity Note, Spinoff Transaction Defined Benefit Plan, Assumed Health Care Cost Trend Rates [Abstract] Defined Benefit Plan, Assumed Health Care Cost Trend Rates [Abstract] Equity Investments without readily determinable value Equity Investments without Readily Determinable Value [Member] Equity Investments without Readily Determinable Value [Member] Non-tradeable contingent value right Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Tradeable Contingent Value Right Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Tradeable Contingent Value Right Award Timing Predetermined Award Timing Predetermined [Flag] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Foreign currency translation Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss), before Reclassification and Tax Investment, Name [Axis] Investment, Name [Axis] Forecast Forecast [Member] Amortization of prior service cost Defined Benefit Plan, Amortization of Prior Service Cost (Credit) Diluted (in dollars per share) Diluted net earnings per share (in dollars per share) Earnings Per Share, Diluted Intangible Asset Amortization Expense Finite-Lived Intangible Assets Amortization Expense [Table Text Block] State and Local Jurisdiction State and Local Jurisdiction [Member] U.S.  Income (Loss) from Continuing Operations before Income Taxes, Domestic Total currently payable Current Income Tax Expense (Benefit) Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Ownership [Axis] Ownership [Axis] Vesting percentage Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage Surgery Surgery [Member] Surgery [Member] Retirement Benefits [Abstract] Retirement Benefits [Abstract] Foreign currency transaction gain (loss), before tax Gain (Loss), Foreign Currency Transaction, before Tax Customer [Axis] Customer [Axis] Derivative Asset, Statement Of Financial Position, Extensible Enumeration, Not Disclosed Flag Derivative Asset, Statement Of Financial Position, Extensible Enumeration, Not Disclosed Flag Derivative Asset, Statement Of Financial Position, Extensible Enumeration, Not Disclosed Flag Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Retirement plan benefits employee compensation period Employee Compensation Period Employee Compensation Period. Total deferred Deferred Income Tax Expense (Benefit), Net Of Discontinued Operations Deferred Income Tax Expense (Benefit), Net Of Discontinued Operations Elmiron Elmiron [Member] Elmiron Unrecognized tax benefits, period increase (decrease) Unrecognized Tax Benefits, Period Increase (Decrease) Fair Value of RSU or PSU units settled Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value Inventory Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory Provision for taxes on income Provision for taxes on income Income Tax Expense (Benefit) Interest cost Interest cost Defined Benefit Plan, Interest Cost Derivative, notional amount Derivative, Notional Amount Total Net Asset Derivative Asset Amount of gain or (loss) recognized in AOCI Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, after Tax Weighted average period for total compensation cost not yet recognized Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Sales to customers Sales to Customers Revenue from Contract with Customer, Excluding Assessed Tax Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] R&D Restructuring Plan R&D Restructuring Plan [Member] R&D Restructuring Plan Defined Benefit Plan, Amounts Recognized in Other Comprehensive Income (Loss) [Abstract] Defined Benefit Plan, Amounts Recognized in Other Comprehensive Income (Loss) [Abstract] Net cash (used by)/from investing activities Net Cash Provided by (Used in) Investing Activities Purchases of in-process research and development assets Payments To Acquired In-Process Research And Development Assets Payments To Acquired In-Process Research And Development Assets Business Acquisition [Line Items] Business Acquisition [Line Items] Income Tax Jurisdiction [Axis] Income Tax Jurisdiction [Axis] Restructuring and Related Cost, Cost Incurred to Date Restructuring and Related Cost, Cost Incurred to Date Tax benefits on share-based compensation Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent Vision Vision [Member] Vision[Member] All Adjustments to Compensation All Adjustments to Compensation [Member] Accrued compensation and employee related obligations Employee-related Liabilities, Current Laminar Laminar [Member] Laminar 2022 Long-Term Incentive Plan 2022 Long-Term Incentive Plan [Member] 2022 Long-Term Incentive Plan Short-term Debt, Type [Domain] Short-Term Debt, Type [Domain] 2027 Defined Benefit Plan Expected Future Benefit Contribution In Year Four Defined benefit plan expected future benefit contribution in year four. Marketable securities, noncurrent Marketable Securities, Noncurrent Derivative Instruments, Gain (Loss) [Table] Derivative Instruments, Gain (Loss) [Table] Restructuring Restructuring charges Restructuring Charges Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Legal Entity [Axis] Legal Entity [Axis] Increase (decrease) in deferred tax liabilities, global intangible low-taxed income (GILTI) Increase (Decrease) in Deferred Tax Liabilities, Global Intangible Low-Taxed Income (GILTI) Increase (Decrease) in Deferred Tax Liabilities, Global Intangible Low-Taxed Income (GILTI) GENERAL GENERAL [Member] GENERAL [Member] Scenario [Domain] Scenario [Domain] Common stock, value Common Stock, Value, Outstanding Interest expense, net of portion capitalized Disposal Group, Including Discontinued Operation, Interest Expense Gain/ (Loss) On Derivatives & Hedges Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member] U.S. Gov't Agencies US Government Agencies Debt Securities [Member] Basic net earnings per share from discontinued operations (in dollars per share) Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Basic Share Weighted average assumptions of fair value of options Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract] Entity Address, State or Province Entity Address, State or Province Short-term investment funds Short Term Investment Funds [Member] Short term investment funds. Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Defined Benefit Plan, Plan Assets, Category [Domain] Defined Benefit Plan, Plan Assets, Category [Domain] Defined Benefit Plan Disclosure [Line Items] Defined Benefit Plan Disclosure [Line Items] Assumed Health Care Cost Trend Rates Schedule of Health Care Cost Trend Rates [Table Text Block] Equity, Class of Treasury Stock [Line Items] Equity, Class of Treasury Stock [Line Items] Amortization of prior service (cost) credit Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), Reclassification Adjustment from AOCI, before Tax Financial Instruments [Domain] Financial Instruments [Domain] Liabilities and Shareholders’ Equity Liabilities and Equity [Abstract] Components of Net Periodic Benefit Cost Schedule of Net Benefit Costs [Table Text Block] Total employee obligations Employee Obligations Total employee obligations current and non current. In-process research and development impairments Research and development in process Research and Development In Process1 Research and Development In Process1 Restatement Determination Date Restatement Determination Date Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Interest rate swaps contracts: Interest Rate Contract [Member] Increase in damages sought Loss Contingency, Damages Sought, Value, Increase Loss Contingency, Damages Sought, Value, Increase Summary of Activity Related to Equity Investments Schedule of Available-for-Sale Securities Reconciliation [Table Text Block] Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Options exercise price beginning of period (in dollars per share) Options exercise price end of period (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Operating lease, right-of-use asset Operating Lease, Right-of-Use Asset Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Derivative Instruments, Gain (Loss) [Line Items] Derivative Instruments, Gain (Loss) [Line Items] Immunology Immunology [Member] Immunology [Member] Options outstanding beginning of period (in shares) Options outstanding end of period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Domain] Exercise Price Range [Domain] Short-term Debt, Type [Axis] Short-Term Debt, Type [Axis] Property, Plant and Equipment [Abstract] Property, Plant and Equipment [Abstract] Amendments Defined Benefit Plan, Benefit Obligation, Increase (Decrease) for Plan Amendment Claims settled, percent Loss Contingency, Claims Settled, Percent Loss Contingency, Claims Settled, Percent Earnings per share Earnings Per Share [Text Block] Subsequent Event Subsequent Event [Member] Innovative Medicine Innovative Medicine [Member] Innovative Medicine Finite-Lived And Indefinite-Lived Intangible Assets [Line Items] Finite-Lived And Indefinite-Lived Intangible Assets [Line Items] Finite-Lived And Indefinite-Lived Intangible Assets [Line Items] Unrealized gain (loss) arising during period Amount of gain or (loss) recognized in AOCI Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax Average fair value of RSU's and PSU's granted (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Subsegments [Domain] Subsegments [Domain] Accrued liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Accrued Liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Accrued Liabilities Income taxes Income Tax, Policy [Policy Text Block] Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Restructuring Plan [Axis] Restructuring Plan [Axis] Other Other Debt Obligations [Member] Percentage of profit share payments (less than) Profit Loss Percent To Sales Profit loss percent to sales. Segments [Domain] Segments [Domain] $157.92 - $162.75 Exercise Price Range Four [Member] Exercise Price Range. Exercisable, Average Exercise Price (in dollars per share) Share-Based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price Summary of unrecognized tax benefits Unrecognized Tax Benefits [Roll Forward] 0.650% Notes due 2024 (750MM Euro 1.1090)(3) 0.650% Notes Due 2024 [Member] 0.650% Notes Due 2024 [Member] PEO PEO [Member] Confirmed invoices paid during the year Supplier Finance Program, Obligation, Settlement Name Trading Arrangement, Individual Name Funded status - end of year Projected Benefit Obligation Defined Benefit Plan, Funded (Unfunded) Status of Plan Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table] Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table] Probability of success factor Business Combination, Probability Of Success Factor Business Combination, Probability Of Success Factor Property, Plant and Equipment, Type [Axis] Long-Lived Tangible Asset [Axis] Total before tax effects Defined Benefit Plan, Accumulated Other Comprehensive (Income) Loss, before Tax Entity Public Float Entity Public Float Disposal Group Name [Axis] Disposal Group Name [Axis] Stock options outstanding and exercisable Share Based Compensation Shares Authorized Under Stock Option Plans By Exercise Price Range [Abstract] Share based compensation shares authorized under stock option plans by exercise price range. Projected benefit obligation - beginning of year Projected benefit obligation - end of year Projected Benefit Obligation Defined Benefit Plan, Benefit Obligation Cumulative Amount of Fair Value Hedging Adjustment Included in the Carrying Amount of the Hedged Liability Hedged Liability, Fair Value Hedge, Cumulative Increase (Decrease) Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Capital expenditures Capital Expenditure, Discontinued Operations Dividends to shareholders Payments of Ordinary Dividends Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member] OPSUMIT OPSUMIT [Member] OPSUMIT [Member] Retirement Plan Sponsor Location [Domain] Retirement Plan Sponsor Location [Domain] Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Cash, cash equivalents and current marketable securities Cash, Cash Equivalents, and Marketable Securities [Text Block] Gross profit Disposal Group, Including Discontinued Operation, Gross Profit (Loss) Diluted net earnings per share from discontinuing operations (in dollars per share) Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Diluted Share Local Phone Number Local Phone Number Liabilities assumed: Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities [Abstract] Valuation allowances Beginning of year End of year Deferred Tax Assets, Valuation Allowance Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] 2.90% Notes due 2028 2.900% Notes due 2028 [Member] 2.900% Notes due 2028 [Member] UNITED STATES Exports UNITED STATES Exports [Member] UNITED STATES Exports [Member] Defined Benefit Plan, Amount Recognized in Net Periodic Benefit Cost (Credit) and Other Comprehensive (Income) Loss, before Tax [Abstract] Defined Benefit Plan, Amount Recognized in Net Periodic Benefit Cost (Credit) and Other Comprehensive (Income) Loss, before Tax [Abstract] Summary of option activity under the Plan Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract] Changes in assets and liabilities, net of effects from acquisitions and divestitures: Increase (Decrease) in Operating Capital [Abstract] U.S. taxes on international income Effective Income Tax Rate Reconciliation Related To Domestic Tax On International Income Effective income tax rate reconciliation related to domestic tax on international income. Maximum length of time for hedging transaction exposure Maximum Length of Time, Foreign Currency Cash Flow Hedge PEO Total Compensation Amount PEO Total Compensation Amount Carrying Amount of the Hedged Liability Total Gross Liabilities Derivative Liability, Subject to Master Netting Arrangement, before Offset Property, Plant and Equipment, Type [Domain] Long-Lived Tangible Asset [Domain] Excess of fair value over carrying value of debt Excess Of Fair Value Over Carrying Value Of Debt Excess of fair value over carrying value of debt. Statement of Income Location, Balance [Axis] Statement of Income Location, Balance [Axis] Defined Benefit Plan, Plan Assets, Category [Axis] Defined Benefit Plan, Plan Assets, Category [Axis] Defined Benefit Plan, Plan Assets, Category [Axis] Debt Disclosure [Abstract] Debt Disclosure [Abstract] Common Stock, Par Value $1.00 Common Stock Issued Amount Common Stock [Member] 4.95% Debentures due 2033 4.95% Debentures due 2033 [Member] 4.95% Debentures due 2033 [Member] KNEES KNEES [Member] KNEES [Member] Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Marketable securities assumed Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Marketable Securities Accumulated Benefit Obligation Defined Benefit Plan Over (Under) Funded Status ABO Defined benefit plan over (under) funded status ABO Segment Reporting [Abstract] Segment Reporting [Abstract] Derivatives designated as hedging instruments : Assets Derivative Instruments in Hedges, Assets, at Fair Value Entity Central Index Key Entity Central Index Key Litigation contingency Loss Contingency, Damages Sought, Value Scenario [Axis] Scenario [Axis] Less: Expense not allocated to segments Segment Reporting, Other Segment Item, Amount Summary of Inventories Schedule of Inventory, Current [Table Text Block] Other Sovereign Securities Other Sovereign Securities [Member] Other Sovereign Securities Foreign Currency Translation Accumulated Foreign Currency Adjustment Attributable to Parent [Member] Discontinued Operations and Disposal Groups [Abstract] Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount TCJA, transition tax for accumulated foreign earnings, payment period Tax Cuts and Jobs Act, Transition Tax for Accumulated Foreign Earnings, Payment Period Tax Cuts and Jobs Act, Transition Tax for Accumulated Foreign Earnings, Payment Period Increase in accounts payable and accrued liabilities Increase (Decrease) in Accounts Payable and Accrued Liabilities Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Product liability contingency, number of claimants Product Liability Contingency Number Of Claimant Product liability contingency number of claimant. Financial Instrument [Axis] Financial Instrument [Axis] Less current portion Long-Term Debt, Current Maturities Segments of business and geographic areas Segment Reporting Disclosure [Text Block] SPRAVATO SPRAVATO [Member] SPRAVATO Employee compensation and stock option plans APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Liability Deferred Tax Liabilities, Net [Abstract] Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration] Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration] 3.40% Notes due 2038 3.400% Notes due 2038 [Member] 3.400% Notes due 2038 [Member] Intangible assets and Goodwill Intangible Assets, Net (Excluding Goodwill) [Abstract] Loss contingency, loss in period Loss Contingency, Loss in Period Title Trading Arrangement, Individual Title Unrecognized tax benefits Beginning of year End of year Unrecognized Tax Benefits City Area Code City Area Code Provision for taxes on income Discontinued Operation, Tax Effect of Discontinued Operation Solicitation period Loss Contingency, Solicitation Period Loss Contingency, Solicitation Period Current liabilities Liabilities, Current [Abstract] Auditor Location Auditor Location Contingent Consideration Business Combination, Contingent Consideration, Liability Revenue recognition Revenue [Policy Text Block] Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Derivatives not designated as hedging instruments : Assets Foreign Currency Derivative Instruments Not Designated as Hedging Instruments, Asset at Fair Value Repurchase of common stock Payments for Repurchase of Common Stock Document Information [Line Items] Document Information [Line Items] Undistributed foreign earnings Deferred Tax Liabilities, Undistributed Foreign Earnings Long-term debt Total long-term debt Long-Term Debt, Excluding Current Maturities Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] 5.50% Notes due 2024 (500MM GBP 1.2756)(3) 5.50% Notes Due 2024 [Member] 5.50% Notes Due 2024 [Member] Restructuring Reserve [Roll Forward] Restructuring Reserve [Roll Forward] Subsequent Event Type [Axis] Subsequent Event Type [Axis] Net earnings per share Earnings Per Share [Abstract] Earnings Per Share [Abstract] Risperdal Risperdal [Member] Risperdal. Equity [Abstract] Equity [Abstract] Fair Value Debt Securities, Available-for-Sale, Fair Value, Fiscal Year Maturity [Abstract] Retained earnings and Additional-paid-in-capital Retained Earnings (Accumulated Deficit) Interest Income Disposal Group, Including Discontinued Operation, Interest Income Class of Stock [Domain] Class of Stock [Domain] Increase in inventories Increase (Decrease) in Inventories Foreign Currency Translation [Abstract] Foreign Currency Translation [Abstract] 2026 Long-Term Debt, Maturity, Year Two Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Equity Awards Adjustments Equity Awards Adjustments [Member] Other Oncology Other Oncology [Member] Other Oncology [Member] Operating lease liabilities Operating Lease, Liability Underlying Securities Award Underlying Securities Amount Performance Shares Performance Shares [Member] Deferred compensation Deferred Compensation Liability, Current and Noncurrent Depreciation expense, including the amortization of capitalized interest Depreciation Expense Including Amortization Of Capitalized Interest Depreciation expense including the amortization of capitalized interest. Net Periodic Benefit Cost Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Net Periodic Benefit Cost [Abstract] Cash dividends paid Dividends, Common Stock, Cash Amendment Flag Amendment Flag Commercial paper Commercial Paper Plan participant contributions Defined Benefit Plan, Benefit Obligation, Contributions by Plan Participant 3.20% Debentures due 2032 3.20% Debentures due 2032 [Member] 3.20% Debentures due 2032 Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Global intangible low-taxed income Deferred Tax Liability, Global Intangible Low-Taxed Income Deferred Tax Liability, Global Intangible Low-Taxed Income Machinery and equipment Machinery and Equipment [Member] Actual return on plan assets Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss) bermekimab bermekimab [Member] bermekimab Due within one year Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One Sale of stock, number of shares issued in transaction (in shares) Sale of Stock, Number of Shares Issued in Transaction Borrowings Debt Disclosure [Text Block] Fair Value, Measurements, Fair Value Hierarchy [Domain] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Debt instrument, face amount Debt Instrument, Face Amount Proceeds from short-term debt Proceeds from Short-Term Debt Payments/Other Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements Entity Address, Postal Zip Code Entity Address, Postal Zip Code Advertising expense Advertising Expense Interest Rate Swap Interest Rate Swap [Member] Changes in treasury stock Changes In Treasury Stock [Roll Forward] Changes in treasury stock. 4.95% Debentures due 2034 4.95% Debentures due 2034 [Member] 4.95% Debentures due 2034 Cash and cash equivalents Cash & Cash Equivalents Cash and Cash Equivalents, at Carrying Value Litigation Status [Axis] Litigation Status [Axis] Other (including capitalized licenses and milestones) Payments for (Proceeds from) Other Investing Activities Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member] $115.67 - $129.51 Exercise Price Range Two [Member] Exercise Price Range. Estimated Useful Lives of Assets Estimated Useful Lives Of Assets [Table Text Block] Estimated useful lives of the assets. Auditor Name Auditor Name Currently payable: Current Income Tax Expense (Benefit), Continuing Operations [Abstract] Other Current Liabilities Other Current Liabilities [Member] Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member] Sales of investments Proceeds from Sale, Maturity and Collection of Investments Non-Qualified Plans Non Qualified Plans [Member] Non qualified plans. Estimated useful lives of the assets Property, Plant and Equipment, Useful Life Outstanding Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] 2028 Defined Benefit Plan Expected Future Benefit Contribution In Year Five Defined benefit plan expected future benefit contribution in year five. Schedule of Short-term Debt [Table] Short-Term Debt [Table] Fair value of assets acquired Noncash or Part Noncash Acquisition, Value of Assets Acquired Cash acquired from acquisition Cash Acquired from Acquisition Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] General Corporate General Corporate [Member] General corporate member. Common stock received in exchange offer Exchange Of Stock, Common Stock, Value, Received Exchange Of Stock, Common Stock, Value, Received Designated as Hedging Instrument Designated as Hedging Instrument [Member] 4.85% Notes due 2041 4.85% Notes due 2041 [Member] 4.85% Notes due 2041 [Member] Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Effect of exchange rates Defined Benefit Plan, Benefit Obligation, Foreign Currency Translation Gain (Loss) Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member] Effective tax rate reconciliation, net increase (decrease) in tax rate, percent Effective Tax Rate Reconciliation, Net Increase (Decrease) In Tax Rate, Percent Effective Tax Rate Reconciliation, Net Increase (Decrease) In Tax Rate, Percent Average shares outstanding Weighted Average Number of Shares Outstanding, Diluted [Abstract] Projected benefit obligation, unfunded plans Defined Benefit Plan, Pension Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Projected Benefit Obligation Total assets Identifiable Assets Assets Assets Pension benefits Liability, Defined Benefit Pension Plan Cost of products sold Cost of Goods and Services Sold Advertising Advertising Cost [Policy Text Block] Total recognized in net periodic benefit cost and other comprehensive income Defined Benefit Plan, Amount Recognized in Net Periodic Benefit Cost (Credit) and Other Comprehensive (Income) Loss, before Tax Cash and Cash Equivalents [Abstract] Cash and Cash Equivalents [Abstract] Additions to property, plant and equipment Payments to Acquire Property, Plant, and Equipment Equity interest in acquiree, remeasurement loss Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Loss Other liabilities Other Liabilities, Noncurrent Capital and treasury stock Treasury Stock [Text Block] Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Commitments and Contingencies Commitments and Contingencies Reclassifications to earnings Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax Comparison of Income Taxes at Statutory Rate and Company's Effective Tax Rate Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] Loss contingency, damages paid, value Loss Contingency, Damages Paid, Value Termination Date Trading Arrangement Termination Date Net cash paid for acquisitions (Note 18) Noncash or Part Noncash Acquisition, Net Nonmonetary Assets Acquired (Liabilities Assumed) TRAUMA TRAUMA [Member] TRAUMA [Member] Incremental tax cost Discontinued Operation, Incremental Tax Cost Discontinued Operation, Incremental Tax Cost Other (Income) Expense Other Income Expense Net [Member] Other Income Expense Net [Member] 2025 Long-Term Debt, Maturity, Year One 3.35% Debentures due 2036 3.35% Debentures due 2036 [Member] 3.35% Debentures due 2036 Assets acquired: Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets [Abstract] Funded Plans Funded Plans [Member] Funded plans. Not Designated as Hedging Instrument Not Designated as Hedging Instrument [Member] Due after one year through five years Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five Debt Instrument [Axis] Debt Instrument [Axis] Net earnings Net earnings Net earnings Net Income (Loss) Attributable to Parent Trading Arrangement: Trading Arrangement [Axis] Impella Impella [Member] Impella Consumer Health Business Consumer Health [Member] Consumer Health 2029-2033 Defined Benefit Plan, Expected Future Benefit Payment, after Year Five for Next Five Years Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Percentage of corridor of greater of market value of assets Percentage Of Corridor Of Greater Of Market Value Of Assets Percentage of corridor of greater of market value of assets. Held-to-maturity, unrecognized gain Debt Securities, Held-to-Maturity, Accumulated Unrecognized Gain Company' Retirement Plan Asset Allocation and Target Allocations Schedule of Allocation of Plan Assets [Table Text Block] Equity Awards Adjustments, Excluding Value Reported in Compensation Table Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member] Available-for-sale Securities Available-for-Sale Securities [Member] Entity File Number Entity File Number Rates Used to Develop Actuarial Present Value of Projected Benefit Obligation Defined Benefit Plan, Assumptions [Table Text Block] Income Statement [Abstract] Income Statement [Abstract] Entity Address, Address Line One Entity Address, Address Line One Debt Security Category [Axis] Debt Security Category [Axis] U.S. taxes Current Federal Tax Expense (Benefit) Intangible assets with indefinite lives: Indefinite-Lived Intangible Assets (Excluding Goodwill) [Abstract] Effect of exchange rate changes on cash and cash equivalents Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations Restructuring Plan [Domain] Restructuring Plan [Domain] Name Forgone Recovery, Individual Name Litigation Settlement By Companies Litigation Settlement By Companies [Domain] Litigation settlement by companies. CONCERTA/Methylphenidate CONCERTA/Methylphenidate [Member] CONCERTA/Methylphenidate [Member] Stelara Stelara [Member] Stelara [Member] Investments Investment, Policy [Policy Text Block] Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Projected Future Benefit Payments from Company's Retirement and Other Benefit Plans Schedule of Expected Benefit Payments [Table Text Block] Orthopaedics Orthopaedics [Member] Orthopaedics [Member] ELECTROPHYSIOLOGY ELECTROPHYSIOLOGY [Member] ELECTROPHYSIOLOGY Decreases related to prior period tax positions Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions Inventory Disclosure [Abstract] Inventory Disclosure [Abstract] Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount Percentage ownership after transaction Exchange of Stock, Percentage Ownership After Transaction Exchange of Stock, Percentage Ownership After Transaction Decrease in foreign tax credits Effective Income Tax Rate Reconciliation, Tax Credit, Foreign, Amount PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Curtailments, settlements & restructuring Curtailments And Settlements And Restructuring The amount of increase or decrease related to curtailments, settlements and restructuring. Diluted net earnings per share from continuing operations (in dollars per share) Income (Loss) from Continuing Operations, Per Diluted Share Adjustment to Compensation: Adjustment to Compensation [Axis] Other than Temporary Impairment, Credit Losses Recognized in Earnings, Categories of Investments [Domain] Other than Temporary Impairment, Credit Losses Recognized in Earnings, Categories of Investments [Domain] Goodwill, related to divestitures Goodwill, Written off Related to Sale of Business Unit Reclassifications to earnings Amount of gain or (loss) reclassified from AOCI into income Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax Due after one year through five years Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five Litigation Case Type [Domain] Litigation Case [Domain] Accumulated other comprehensive income (loss) Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Pension Adjustments Service Cost Pension Adjustments Service Cost [Member] Basic (in shares) Average shares outstanding — basic (in shares) Weighted Average Number of Shares Outstanding, Basic Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Asia-Pacific, Africa Asia-Pacific, Africa [Member] Asia-Pacific, Africa [Member] Proceeds from the disposal of assets/businesses, net Proceeds from Sale of Productive Assets Document Information [Table] Document Information [Table] Total shareholders’ equity Beginning Balance Ending Balance Equity, Including Portion Attributable to Noncontrolling Interest Realized gain (loss) Debt Securities, Available-for-Sale, Realized Gain (Loss) Target Allocation Defined Benefit Plan, Plan Assets, Target Allocation, Percentage Components of Deferred Tax Assets and Liabilities [Abstract] Components of Deferred Tax Assets and Liabilities [Abstract] Name Awards Close in Time to MNPI Disclosures, Individual Name Depreciation and Amortization Disposal Group, Including Discontinued Operation, Depreciation and Amortization Year the rate reaches the ultimate trend rate Defined Benefit Plan, Year Health Care Cost Trend Rate Reaches Ultimate Trend Rate Construction in progress Construction in Progress [Member] Sales Revenue, Net Revenue Benchmark [Member] Options canceled/forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Segments Total Segments Total [Member] Segments Total Entity Filer Category Entity Filer Category Collateral paid Collateral Already Posted, Aggregate Fair Value Loss Contingencies [Line Items] Loss Contingencies [Line Items] Exercisable number of Options (in shares) Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable Utilization Valuation Allowance, Deferred Tax Assets, Utilization Valuation Allowance, Deferred Tax Assets, Utilization Goodwill, related to acquisitions Goodwill, Acquired During Period Range [Domain] Statistical Measurement [Domain] Additions to Property, Plant & Equipment Segment, Expenditure, Addition to Long-Lived Assets Available-for-sale, unrecognized loss Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Derivatives, Fair Value [Line Items] Derivatives, Fair Value [Line Items] Cash and Cash Equivalent Composition Cash, Cash Equivalents and Investments [Table Text Block] Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract] Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract] Debt securities Debt instruments Debt Securities [Member] Changes in estimated fair value Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Change In Estimated Fair Value Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Change In Estimated Fair Value DARZALEX DARZALEX [Member] DARZALEX [Member] Settlement of notes payable Business Combination, Settlement Of Notes Payable Business Combination, Settlement Of Notes Payable Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] 1.150% Notes Due November 2028 1.150% Notes Due November 2028 [Member] 1.150% Notes Due November 2028 All Trading Arrangements All Trading Arrangements [Member] Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Reconciliation of Basic Net Earnings per Share to Diluted Net Earnings per Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Award vesting period Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Long-term Debt Long-Term Debt [Member] Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Ambrx Ambrx [Member] Ambrx Derivative [Line Items] Derivative [Line Items] Goodwill, measurement period adjustment Goodwill, Measurement Period Adjustment Pay vs Performance Disclosure [Line Items] Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount 3.75% Notes due 2047 3.75% Notes due 2047 [Member] 3.75% Notes due 2047 [Member] Derivative [Table] Derivative [Table] Proteologix Proteologix [Member] Proteologix Deferred: Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract] Financial Assets and Liabilities at Fair Value Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block] Information Related to the Benefit Obligation and the Fair Value of Plan Assets Information Related To Benefit Obligation And Fair Value Of Plan Assets [Table Text Block] Information related to the benefit obligation and the fair value of plan assets. Restructuring and Related Activities [Abstract] Restructuring and Related Activities [Abstract] Less: shares repurchased under treasury stock method (in shares) Shares Which Could Be Repurchased Under Treasury Stock Method Common stock assumed to be purchased using the proceeds that could be obtained upon exercise of potential shares exercisable under stock option plans, at the average market price during the period. Other Performance Measure, Amount Other Performance Measure, Amount Rate of increase in compensation levels Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Rate of Compensation Increase 2027 Finite-Lived Intangible Asset, Expected Amortization, Year Three Legal proceedings Legal Matters and Contingencies [Text Block] Goodwill [Line Items] Goodwill [Line Items] Documents Incorporated by Reference Documents Incorporated by Reference [Text Block] Operating lease costs Operating Lease, Cost Shares available for future grants under long-term incentive plan Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant Benefits paid from plan Defined Benefit Plan, Benefit Obligation, Benefits Paid Cash Flow Hedging Cash Flow Hedging [Member] other cardiovascular other cardiovascular [Member] other cardiovascular Service cost Service cost Defined Benefit Plan, Service Cost Entity Tax Identification Number Entity Tax Identification Number Schedule of Finite-Lived Intangible Assets by Major Class [Table] Intangible Asset, Finite-Lived [Table] Schedule of Long-term Debt Instruments Schedule of Long-Term Debt Instruments [Table Text Block] Repurchase of common stock (shares) Treasury Stock, Shares, Acquired Increases related to prior period tax positions Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions Retirement Plan Type [Axis] Retirement Plan Type [Axis] International taxes Deferred Foreign Income Tax Expense (Benefit) Postemployment benefits Postemployment Benefits Liability Rate to which the cost trend rate is assumed to decline (ultimate trend) Defined Benefit Plan, Ultimate Health Care Cost Trend Rate Money market funds Money Market Funds [Member] Rate of increase in compensation levels Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Rate of Compensation Increase 1.30% Notes due 2030 1.30% Notes due 2030 [Member] 1.30% Notes due 2030 Treasury Stock Amount Treasury Stock, Common [Member] Reconciliation of basic net earnings per share to diluted net earnings per share Earnings Per Share Reconciliation [Abstract] Asset Deferred Tax Assets, Net [Abstract] December 17, 2018 Share Repurchase Program December 17, 2018 Share Repurchase Program [Member] December 17, 2018 Share Repurchase Program [Member] Plan Name [Axis] Plan Name [Axis] Damages awarded Loss Contingency, Damages Awarded, Value Number of patients in settlement Number of patients in settlement Number of patients in settlement Equity Components [Axis] Equity Components [Axis] Equity Components [Axis] Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing Derivative, Excluded Component, Gain (Loss), Recognized in Earnings Changes in Treasury Stock Changes In Treasury Stock [Table Text Block] Changes in treasury stock. Research and development Research and Development Expense, Policy [Policy Text Block] Fair value, available-for-sale Debt securities Debt Securities, Available-for-Sale Carrying Amount, held-to-maturity Debt Securities, Held-to-Maturity, Amortized Cost, before Allowance for Credit Loss Outstanding Average Exercise Price (in dollars per share) Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price Gain/(Loss) Recognized In Accumulated OCI Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments and Tax Abiomed Abiomed [Member] Abiomed Employee compensation and stock option plans (shares) Stock Issued During Period, Shares, Other Net acquisitions / (dispositions/liquidations) Valuation Allowance, Deferred Tax Assets, Acquisitions (Dispositions) Valuation Allowance, Deferred Tax Assets, Acquisitions (Dispositions) Net actuarial loss Defined Benefit Plan, Accumulated Other Comprehensive Income (Loss), Gain (Loss), before Tax Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Contribution to pension plans Payment for Pension Benefits Equity interests issued and issuable Business Combination, Consideration Transferred, Equity Interests Issued and Issuable Aggregate intrinsic value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Effect of exchange rates Effect Of Exchange Rates Effect Of Exchange Rates. Supplemental schedule of non-cash investing and financing activities Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] (Gain) on separation of Kenvue Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of Tax Repatriation of foreign earnings amount Effective Income Tax Rate Reconciliation, Repatriation of Foreign Earnings, Amount Geographical [Axis] Geographical [Axis] Gain (loss) on divestiture Gain (Loss) on Disposition of Business Supplier Finance Program, Obligation, Current, Statement of Financial Position [Extensible Enumeration] Supplier Finance Program, Obligation, Current, Statement of Financial Position [Extensible Enumeration] Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member] Amount reserved for settlement Loss Contingency Accrual Other assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets Long-term taxes payable Accrued Income Taxes, Noncurrent Net earnings from Discontinued Operations Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Noncontrolling Interest Proceeds from Royalties Received Proceeds from Royalties Received Cash and cash equivalents from continuing operations, beginning of period Cash and cash equivalents from continuing operations, end of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations Prior service cost (credit) Defined Benefit Plan, Accumulated Other Comprehensive (Income) Loss, Prior Service Cost (Credit), before Tax Cash and cash equivalents, beginning of year Cash and cash equivalents, end of year Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Debt, weighted average interest rate Debt, Weighted Average Interest Rate Equity investments Equity Securities, FV-NI, Current COVID-19 COVID-19 [Member] COVID-19 Total compensation cost not yet recognized for option Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Net actuarial (gain) loss Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, before Tax International taxes Current Foreign Tax Expense (Benefit) Current assets: Assets, Current [Abstract] Treasury stock issued for employee compensation and stock option plans, net of cash proceeds/ employee withholding tax on stock awards Treasury Stock Issued For Employee Compensation And Stock Option Plans Net Of Cash Proceeds Treasury stock issued for employee compensation and stock option plans, net of cash proceeds. Consolidation Items [Axis] Consolidation Items [Axis] Postretirement benefits Liability, Other Postretirement Defined Benefit Plan Indefinite-lived Intangible Assets, Major Class Name [Domain] Indefinite-Lived Intangible Assets, Major Class Name [Domain] Stock issued in exchange offer (in shares) Stock Issued During Period, Shares, Exchange Offer Stock Issued During Period, Shares, Exchange Offer Net earnings from continuing operations Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent Treasury stock (in shares) Treasury Stock, beginning balance (shares) Treasury Stock, ending balance (shares) Treasury Stock, Common, Shares Unrecognized tax benefits, interest on income taxes accrued Unrecognized Tax Benefits, Interest on Income Taxes Accrued Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Interest Interest Paid, Including Capitalized Interest, Operating and Investing Activities Product and Service [Domain] Product and Service [Domain] PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA [Member] PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA [Member] Goodwill [Roll Forward] Goodwill [Roll Forward] Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Marketable securities Current Marketable Securities Marketable Securities, Current Raw materials and supplies Inventory, Raw Materials and Supplies, Net of Reserves Security Exchange Name Security Exchange Name Options exercised, average exercise price (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price TCJA, undistributed foreign earnings percent related to cash and cash equivalents Tax Cuts And Jobs Act Of 2017, Undistributed Foreign Earnings, Cash And Cash Equivalents, Tax Rate, Percent Tax Cuts And Jobs Act Of 2017, Undistributed Foreign Earnings, Cash And Cash Equivalents, Tax Rate, Percent Settled Litigation Settled Litigation [Member] Wholesaler 1 Wholesaler 1 [Member] Wholesaler 1 [Member] Number of stock-based compensation plans Number Of Stock Based Compensation Plans Number of stock-based compensation plans. Loans and notes payable Loans and notes payable Short-Term Debt Cost Basis Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Amortized Cost [Abstract] Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Contractual Maturities of Available for Sale Securities Debt Securities, Available-for-Sale [Table Text Block] Charges for acquired in-process research and development assets Research and Development Expense Employee related obligations Compensation Related Costs, General [Text Block] Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward] Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward] Subsegments [Axis] Subsegments [Axis] Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Common stock, shares issued (in shares) Common Stock, Shares, Issued Other assets Other Assets [Member] Amortization of net actuarial loss Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), Reclassification Adjustment from AOCI, before Tax Entity [Domain] Entity [Domain] Concentration risk (as a percent) Concentration Risk, Percentage Borrowing capacity under credit facility Line of Credit Facility, Maximum Borrowing Capacity Discount rate Business Acquisition, Discount Rate Business Acquisition, Discount Rate Other Investment Not Readily Marketable [Axis] Other Investment Not Readily Marketable [Axis] Net assets divested Disposal Group, Including Discontinued Operation, Assets Total Net Liabilities Derivative Liability Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Less accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Cardiovascular/Metabolism/Other Cardiovascular/Metabolism/Other [Member] Cardiovascular/Metabolism/Other [Member] Europe Europe [Member] Common stock, shares authorized (in shares) Common Stock, Shares Authorized Acquisitions, net of cash acquired Acquisitions, net of cash acquired (Note 18) Payments to Acquire Businesses, Net of Cash Acquired Legal Proceeding (Textuals) Legal Proceeding (Textuals) [Abstract] Legal Proceeding Textuals Abstract. Accrued rebates, returns and promotions Accrued Rebates Returns And Promotions Reflects the estimated obligations due within one year for rebates, returns and promotions. Reserves include such items related to Medicaid rebates, product returns due to expiration, product recalls, current portion of coupons and volume-based sales incentives programs. Purchased in-process research and development Purchased in-process research and development(1) Purchased In-Process Research And Development [Member] Purchased In-Process Research And Development [Member] Settlements Defined Benefit Plan, Plan Assets, Payment for Settlement Entity Voluntary Filers Entity Voluntary Filers Recognized actuarial losses (gains) Defined Benefit Plan, Amortization of Gain (Loss) Cash and Cash Equivalents [Line Items] Cash and Cash Equivalents [Line Items] Hedging Designation [Domain] Hedging Designation [Domain] Statement of Financial Position Location, Balance [Axis] Statement of Financial Position Location, Balance [Axis] Interest expense, net of portion capitalized Interest Expense, Nonoperating Deferred tax provision Deferred Income Tax Expense (Benefit) Property, plant and equipment Property, Plant and Equipment Disclosure [Text Block] Discount rate Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate 3.587% Notes due 2036 3.55% Notes due 2036 [Member] 3.55% Notes due 2036 [Member] 2024 Defined Benefit Plan Expected Future Benefit Contribution In Year One Defined benefit plan expected future benefit contribution in year one. Exercise of options, tax benefit Share-Based Payment Arrangement, Exercise of Option, Tax Benefit Talc Talc [Member] Talc [Member] Orthopaedics Restructuring Plan Orthopaedics Restructuring Plan [Member] Orthopaedics Restructuring Plan Short-term borrowings and the current portion of long-term debt Debt, Current Fair Value, Measurements, Recurring Fair Value, Recurring [Member] Accounts receivable trade, less allowances $167 (2023, $166) Accounts Receivable, after Allowance for Credit Loss, Current Interest cost discount rate Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Interest Cost, Discount Rate Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Interest Cost, Discount Rate Revenues from External Customers and Long-Lived Assets [Line Items] Revenues from External Customers and Long-Lived Assets [Line Items] Increase/(Decrease) in other current and non-current liabilities Increase (Decrease) in Other Operating Liabilities Asset write-downs Asset Impairment Charges Long-term debt Long-Term Debt Pension Adjustments Prior Service Cost Pension Adjustments Prior Service Cost [Member] 5.85% Debentures due 2038 5.85% Debentures due 2038 [Member] 5.85% Debentures due 2038 [Member] Plan Assets Plan assets at fair value — beginning of year Plan assets at fair value - End of year Defined Benefit Plan, Plan Assets, Amount After 2029 Long-Term Debt, Maturity, after Year Five Pelvic Meshes Pelvic Meshes [Member] Pelvic meshes. Commercial Paper Commercial Paper [Member] Pension Benefits Adjustments, Footnote Pension Benefits Adjustments, Footnote [Text Block] Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Payments to Acquire in Process Research and Development Payments to Acquire in Process Research and Development Employee benefits Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, Tax Document Annual Report Document Annual Report Restructuring Charges Restructuring Charges [Member] Employee Related Obligations Employee Related Obligations [Table Text Block] Employee related obligations. Price Range, Minimum (in dollars per share) Share-Based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit 2.46% Notes due 2026 2.45% Notes due 2026 [Member] 2.45% Notes due 2026 [Member] Realized gain (loss) on investment Equity Method Investment, Realized Gain (Loss) on Disposal Issued (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Shockwave Medical, Inc. Shockwave Medical, Inc. [Member] Shockwave Medical, Inc. Risk-free rate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Financial assets and liabilities at fair value Derivative Instrument Detail [Abstract] Indefinite lived intangible assets Indefinite-Lived Intangible Assets (Excluding Goodwill) 4.50% Notes due 2043 4.50% Notes due 2043 [Member] 4.50% Notes due 2043 [Member] Amortization expense of amortizable intangible assets Amortization of Intangible Assets Non-US Non-US [Member] Other Investment Not Readily Marketable [Line Items] Other Investment Not Readily Marketable [Line Items] Accounting Policies [Abstract] Accounting Policies [Abstract] Equity investments, increase (decrease) from acquisition (sale) during period Equity Investments, Increase (Decrease) from Acquisition (Sale) During Period Equity Investments, Increase (Decrease) from Acquisition (Sale) During Period Acquisitions and divestitures Business Combination Disclosure [Text Block] Current Fiscal Year End Date Current Fiscal Year End Date Regulation charge Regulation charge Regulation charge PEO Name PEO Name Intra-Cellular Therapies, Inc. Intra-Cellular Therapies, Inc. [Member] Intra-Cellular Therapies, Inc. Award Type [Domain] Award Type [Domain] Cash and equivalents Less: Cash acquired Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents Stock based compensation Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Employee related obligations Employee related obligations — non-current Non-current liabilities Liability, Defined Benefit Plan, Noncurrent Deferred taxes on income Deferred Income Tax Assets, Net Non-PEO NEO Non-PEO NEO [Member] Intangible assets useful life Finite-Lived Intangible Asset, Useful Life Other assets assumed Other assets assumed Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets Acquisition costs, period cost Oil and Gas, Full Cost Method, Capitalized Cost Excluded from Amortization, Acquisition Cost, Period Cost Hedging Relationship [Axis] Hedging Relationship [Axis] Litigation Settlement By Companies Litigation Settlement By Companies [Axis] Litigation settlement by companies. Pensions and other benefit plans Retirement Benefits [Text Block] Pharmaceutical Pharmaceutical Pharmaceutical [Member] Pharmaceutical. Deferred taxes Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities Short-term Debt [Line Items] Short-Term Debt [Line Items] New accounting standards and Recently issued accounting standards New Accounting Pronouncements, Policy [Policy Text Block] Class of Stock [Axis] Class of Stock [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Less accumulated amortization Finite-Lived Intangible Assets, Accumulated Amortization Schedule of Defined Benefit Plans Disclosures Schedule of Defined Benefit Plans Disclosures [Table Text Block] Name Measure Name Entity Interactive Data Current Entity Interactive Data Current Net earnings from discontinued operations Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent Savings plan Savings Plan [Text Block] Savings Plan. Number of segments Number of Operating Segments SPINE,SPORTS & OTHER SPINE, SPORTS & OTHER [Member] SPINE & OTHER [Member] Pending Litigation Pending Litigation [Member] Income taxes, inclusive of discontinued operations Income Taxes Paid Employee benefit plans: Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent [Abstract] Remicade Remicade [Member] Remicade [Member] Restructuring Restructuring and Related Activities Disclosure [Text Block] Securities: Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent [Abstract] Tremfya Tremfya [Member] Tremfaya Stock based compensation Share-Based Payment Arrangement, Noncash Expense Summary of Restricted Share Units Share-Based Payment Arrangement, Activity [Table Text Block] Total deferred income taxes net of valuation allowances Deferred Tax Assets, Net of Valuation Allowance Other Pulmonary Hypertension Other Pulmonary Hypertension [Member] Other Pulmonary Hypertension Employee Benefit Plans Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member] Neuroscience Neuroscience [Member] Neuroscience [Member] TECVAYLI TECVAYLI [Member] TECVAYLI Decrease in foreign tax credits, percent Effective Income Tax Rate Reconciliation, Tax Credit, Foreign, Percent Stated interest rate (as a percent) Debt Instrument, Interest Rate, Stated Percentage Segment Reporting, Reconciling Item, Corporate Nonsegment Segment Reporting, Reconciling Item, Corporate Nonsegment [Member] $131.94 - $151.41 Exercise Price Range Three [Member] Exercise Price Range. Supplemental cash flow data Supplemental Cash Flow Information [Abstract] Equity securities, fair market value Equity Securities, FV-NI Settlements Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities Summary of Derivative Activity Derivative Instruments, Gain (Loss) [Table Text Block] Compensation Related Costs [Abstract] Compensation Related Costs [Abstract] U.S. tax settlements Effective Income Tax Rate Reconciliation, Consumer Health Separation Effective Income Tax Rate Reconciliation, Consumer Health Separation Interest expense capitalized Interest Costs Capitalized Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Minimum reverse repurchase agreement collateral (as a percent) Minimum Collateral Value as a Percent, Reverse Repurchase Agreement Minimum Collateral Value as a Percent, Reverse Repurchase Agreement Auditor Firm ID Auditor Firm ID Effective Rate Effective Income Tax Rate Reconciliation, Percent AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward] AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward] Research and development expense Research and Development Expense (Excluding Acquired in Process Cost) Number of business segments Number of Reportable Segments Total liabilities and shareholders’ equity Liabilities and Equity 4.90% Debentures due 2031 4.90% Debentures due 2031 [Member] 4.90% Debentures due 2031 Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Percentage ownership after transaction Sale of Stock, Percentage of Ownership after Transaction Costs of Goods and Services Sold Costs of Goods and Services Sold [Member] Costs of Goods and Services Sold Hedging Designation [Axis] Hedging Designation [Axis] Auditor Information [Abstract] Auditor Information Interest income Investment Income, Interest Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Ingham vs. Johnson & Johnson Ingham vs. Johnson & Johnson [Member] Ingham vs. Johnson & Johnson Shipping and Handling Shipping and Handling [Member] Aggregate Maturities of Long Term Obligations Schedule of Maturities of Long-Term Debt [Table Text Block] Underlying Security Market Price Change Underlying Security Market Price Change, Percent Expected return on plan assets Defined Benefit Plan, Expected Return (Loss) on Plan Assets Individual: Individual [Axis] Building and building equipment Building and Building Improvements [Member] Accumulated Other Comprehensive Income (Loss) AOCI Attributable to Parent [Member] Bankruptcy loss contingency, discount rate Loss Contingency, Discount Rate Loss Contingency, Discount Rate Options canceled/forfeited, average exercise price (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 3.500% Notes due 2048 3.500% Notes due 2048 [Member] 3.500% Notes due 2048 [Member] Additions Business Combination, Consideration Transferred, Liabilities Incurred Cardiovascular Cardiovascular [Member] Cardiovascular [Member] Expected life (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Inventories Total inventories Inventory, Net Product and Service [Axis] Product and Service [Axis] Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Statement [Line Items] Statement [Line Items] Equity, fair value adjustment, impairment loss Equity, Fair Value Adjustment, Impairment Loss Equity, Fair Value Adjustment, Impairment Loss Reconciliation of Operating Profit (Loss) from Segments to Consolidated Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block] Net assets acquired Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net Benefits paid from plan assets Defined Benefit Plan, Plan Assets, Benefits Paid Property, Plant and Equipment at Cost and Accumulated Depreciation Property, Plant and Equipment [Table Text Block] Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] IPO IPO [Member] 2029-2033 Defined Benefit Plan Expected Future Benefit Contribution In Five Fiscal Years Thereafter Defined benefit plan expected future benefit contribution in five fiscal years thereafter. Beginning Balance Ending Balance Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value Financial instruments Derivatives, Policy [Policy Text Block] Software Development Software Development [Member] Minimum Minimum [Member] Gain (loss), net of amortization Other Comprehensive (Income) Loss, Reclassification Adjustment from AOCI Pension and Other Postretirement Benefit Plans for Net Gain Loss, Net of Amortization, Net of Tax Other Comprehensive (Income) Loss, Reclassification Adjustment from AOCI Pension and Other Postretirement Benefit Plans for Net Gain Loss, Net of Amortization, Net of Tax Adoption Date Trading Arrangement Adoption Date Other Investment Not Readily Marketable, Name [Domain] Other Investment Not Readily Marketable, Name [Domain] Due after five years through ten years Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10 Foreign currency translation Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax Credit losses and accounts receivable allowances Accounts Receivable, Credit Loss Expense (Reversal) Segments [Axis] Segments [Axis] Segments [Axis] Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member] Derivative Instrument [Axis] Derivative Instrument [Axis] U.S. statutory rate Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent Exercise Price Award Exercise Price Selling, marketing and administrative expenses Disposal Group, Including Discontinued Operation, General and Administrative Expense Equity awards Business Combination, Acquisition Related Costs, Equity Awards Business Combination, Acquisition Related Costs, Equity Awards Temporary Differences and Carryforwards Schedule of Deferred Tax Assets and Liabilities [Table Text Block] Healthcare cost trend rate assumed for next year Defined Benefit Plan, Health Care Cost Trend Rate Assumed, Next Fiscal Year Arrangement Duration Trading Arrangement Duration Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table] Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table] Credit support agreements activity, net Proceeds (Payments) from (to) Credit Support Agreements, Financing Activities Proceeds (Payments) from (to) Credit Support Agreements, Financing Activities Total loss/(income) recognized in other comprehensive income, before tax Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, before Tax Intangible assets and goodwill Goodwill and Intangible Assets Disclosure [Text Block] Basic net earnings per share from continuing operations (in dollars per share) Income (Loss) from Continuing Operations, Per Basic Share 1.150% Notes Due November 2028 1.150% Notes due 2028
(750MM Euro 1.0401)(2)/(750MM Euro 1.1090)(3) 1.150% Notes Due 2028 [Member] 1.150% Notes Due 2028 [Member] Shareholders’ equity Equity, Attributable to Parent [Abstract] Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Debt instrument, term Debt Instrument, Term EDURANT/rilpivirine EDURANT/rilpivirine [Member] EDURANT/rilpivirine [Member] 2028 Finite-Lived Intangible Asset, Expected Amortization, Year Four All Individuals All Individuals [Member] Other (income) expense, net Disposal Group, Including Discontinued Operation, Other Income (Expense), Net Disposal Group, Including Discontinued Operation, Other Income (Expense), Net Held-to-maturity, unrecognized loss Debt Securities, Held-to-Maturity, Accumulated Unrecognized Loss Revenue, performance obligation, payment terms Revenue, Performance Obligation, Payment Terms Revenue, Performance Obligation, Payment Terms Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Effective income tax rate reconciliation, increase (decrease), percent Effective Income Tax Rate Reconciliation, Increase (Decrease), Percent Effective Income Tax Rate Reconciliation, Increase (Decrease), Percent Effect of exchange rates Defined Benefit Plan, Plan Assets, Foreign Currency Translation Gain (Loss) Other (income) expense, net Other (income) expense, net Other Nonoperating Income (Expense) Other Benefit Plans Other benefit plans  Other Postretirement Benefits Plan [Member] TCJA, undistributed foreign earnings percent related to earnings other than cash and cash equivalents Tax Cuts And Jobs Act Of 2017, Undistributed Foreign Earnings, Other Than Cash And Cash Equivalents, Tax Rate, Percent Tax Cuts And Jobs Act Of 2017, Undistributed Foreign Earnings, Other Than Cash And Cash Equivalents, Tax Rate, Percent Net gain on sale of assets/businesses Gain (Loss) on Sale of Assets and Asset Impairment Charges Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Intangible assets, net Total intangible assets - net Intangible Assets, Net (Excluding Goodwill) IMBRUVICA IMBRUVICA [Member] IMBRUVICA [Member] 2.250% Notes due 2050 2.250% Notes due 2050 [Member] 2.250% Notes due 2050 Available-for-sale, unrealized gain Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward] Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward] Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract] Less current benefits payable Current liabilities Liability, Defined Benefit Plan, Current Cash transferred to Kenvue at separation Payments Made In Business Separation Payments Made In Business Separation Disposal Groups, Including Discontinued Operations [Table] Disposal Groups, Including Discontinued Operations [Table] Schedule of Finite-Lived And Indefinite-Lived Intangible Assets By Major Class [Table] Schedule of Finite-Lived And Indefinite-Lived Intangible Assets By Major Class [Table] Schedule of Finite-Lived And Indefinite-Lived Intangible Assets By Major Class [Table] Restructuring Cost and Reserve [Line Items] Restructuring Cost and Reserve [Line Items] Schedule of Loss Contingencies by Contingency Schedule of Loss Contingencies by Contingency [Table Text Block] Total claims against company, percent Total Claims Against Company, Percent Total Claims Against Company, Percent Total liabilities assumed Total liabilities assumed Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities Tax Credit Carryforward [Line Items] Tax Credit Carryforward [Line Items] Deferred taxes on income Deferred Income Tax Liabilities, Net Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items] Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items] Expected volatility Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate Shares subject to full value award, excess (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number, May Be Issued Subject To Full Value Awards, Excess Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number, May Be Issued Subject To Full Value Awards, Excess Retirement Plan Sponsor Location [Axis] Retirement Plan Sponsor Location [Axis] International operations Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent Decrease/(Increase) in other current and non-current assets Increase (Decrease) in Other Operating Assets Wholesaler 2 Wholesaler 2 [Member] Wholesaler 2 [Member] Amortizable intangibles Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles Net change Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax ASR ASR [Member] ASR. U.S. taxes Deferred Federal Income Tax Expense (Benefit) Share Repurchase Program [Domain] Share Repurchase Program [Domain] Cash equivalents Cash and Cash Equivalents, Policy [Policy Text Block] Provision Valuation Allowance, Deferred Tax Assets, Provision Valuation Allowance, Deferred Tax Assets, Provision Acclarent Acclarent [Member] Acclarent Change in Benefit Obligation Defined Benefit Plan, Change in Benefit Obligation [Roll Forward] Effect of exchange rates Other comprehensive income (loss), pension and other, effects of exchange rate net of tax other comprehensive income loss, pension and other , effects of exchange rate net of tax Measure: Measure [Axis] Derivatives designated as hedging instruments : Liabilities Derivative Instruments in Hedges, Liabilities, at Fair Value Increases related to current year tax positions Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions Asset Class [Domain] Asset Class [Domain] Divestitures & acquisitions Defined Benefit Plan, Plan Assets, Business Combination and Divestiture, Increase (Decrease) Defined Benefit Plan, Plan Assets, Business Combination and Divestiture, Increase (Decrease) Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized 2024 Defined Benefit Plan, Expected Future Benefit Payment, Year One Options granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures Entity Emerging Growth Company Entity Emerging Growth Company Indefinite-lived Intangible Assets by Major Class [Axis] Indefinite-Lived Intangible Assets [Axis] Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration] Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration] 2029 Long-Term Debt, Maturity, Year Five CARVYKTI CARVYKTI [Member] CARVYKTI Cost of products sold Disposal Group, Including Discontinued Operation, Costs of Goods Sold Repurchase of common stock Treasury Stock, Value, Acquired, Cost Method, Net Of Tax Treasury Stock, Value, Acquired, Cost Method, Net Of Tax Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Accumulated benefit obligation unfunded plans Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Accumulated Benefit Obligation Research and development expense Disposal Group, Including Discontinued Operation, Research and Development Expense Disposal Group, Including Discontinued Operation, Research and Development Expense Non-U.S. Sovereign Securities Sovereign Debt Securities [Member] Equity Component [Domain] Equity Component [Domain] Total recognized in the consolidated balance sheet — end of year Defined Benefit Plan, Amounts for Asset (Liability) Recognized in Statement of Financial Position Class of Treasury Stock [Table] Class of Treasury Stock [Table] 3.350% Notes Due November 2036 3.350% Notes Due November 2036 [Member] 3.350% Notes Due November 2036 Class I Recommendation For Impella Class I Recommendation For Impella [Member] Class I Recommendation For Impella Stock option average life Outstanding, Average Life Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Remaining Contractual Term Derivatives & hedges: Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent [Abstract] Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Entity Shell Company Entity Shell Company Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code 2027 Defined Benefit Plan, Expected Future Benefit Payment, Year Four Shipping and handling Shipping and Handling Cost, Policy [Policy Text Block] Statement [Table] Statement [Table] Concentration of Credit Risk [Line Items] Concentration of Credit Risk [Line Items] Concentration of credit risk. Fair Value, Measurement Frequency [Domain] Measurement Frequency [Domain] Summary of significant accounting policies Significant Accounting Policies [Text Block] Consolidation Items [Domain] Consolidation Items [Domain] Earnings from Discontinued Operations Before Provision for Taxes on Income Discontinued Operation, Income (Loss) from Discontinued Operation, before Income Tax Schedule of Effect of Derivatives not Designated as Hedging Instruments Derivatives Not Designated as Hedging Instruments [Table Text Block] Interest, net of amount capitalized Interest Paid, Excluding Capitalized Interest, Operating Activities Level 1 Fair Value, Inputs, Level 1 [Member] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Loss on shares exchanged Debt For Equity Exchange, Loss On Shares Exchanged Debt For Equity Exchange, Loss On Shares Exchanged Total current assets Assets, Current Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Effective income tax rate reconciliation, tax settlement, percent Effective Income Tax Rate Reconciliation, Tax Settlement, Percent Schedule of Sales by Segment of Business Sales By Segment Of Business [Table Text Block] Sales by segment of business. Stock options exercisable (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Unrecognized tax benefits, interest on income tax expense Unrecognized Tax Benefits, Interest on Income Taxes Expense 2027 Long-Term Debt, Maturity, Year Three Schedule of Long-term Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] Company contributions Defined Benefit Plan, Plan Assets, Contributions by Employer Intangible assets assumed Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill Average fair value of option granted (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Loss contingency accrual, payment percentage Loss contingency accrual, payment percentage Loss contingency accrual, payment percentage Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] Equity securities without readily determinable fair value, amount Equity Securities without Readily Determinable Fair Value, Amount Due after five years through ten years Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10 Entity Well-known Seasoned Issuer Entity Well-known Seasoned Issuer Customer relationships and other intangible assets Other Intangible Assets Other Intangible Assets [Member] Transferred to group annuity contract Defined Benefit Plan, Benefit Obligation, Transferred To Group Annuity Contract Defined Benefit Plan, Benefit Obligation, Transferred To Group Annuity Contract Time deposits Bank Time Deposits [Member] Income taxes Income Tax Disclosure [Text Block] Product liability Product Liability [Policy Text Block] Product liability. 3.73% Notes due 2046 3.70% Notes due 2046 [Member] 3.70% Notes due 2046 [Member] Equity, fair value adjustment, change in observable prices Equity, Fair Value Adjustment, Change in Observable Prices Equity, Fair Value Adjustment, Change in Observable Prices Miscellaneous U.S.  Deferred Tax Assets Other Domestic Deferred tax assets other domestic. Concentration risk, threshold percentage (as a percent) Concentration Risk, Threshold Percentage Concentration Risk, Threshold Percentage Domestic Plan Domestic Plan [Member] Supplier Finance Program Supplier Finance Program [Table Text Block] Other Noncurrent Liabilities Other Noncurrent Liabilities [Member] Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Axis] Exercise Price Range [Axis] Net cash used by financing activities Net Cash Provided by (Used in) Financing Activities Reserves & liabilities Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals Equity awards settled Business Combination, Settlement Of Equity Awards Business Combination, Settlement Of Equity Awards Description of reclassification of cash flow hedge gain (loss) Description of Reclassification of Cash Flow Hedge Gain (Loss) Patents And Trademarks Patents And Trademarks [Member] Patents And Trademarks [Member] Entity Registrant Name Entity Registrant Name Payments to acquire businesses, gross Payments to Acquire Businesses, Gross MedTech MedTech MedTech [Member] MedTech [Member] Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] 3.625% Notes due 2037 3.625% Notes due 2037 [Member] 3.625% Notes due 2037 [Member] Depreciation and amortization of property and intangibles Depreciation and Amortization Depreciation, Depletion and Amortization Gross profit Gross Profit Fair Value as of Grant Date Award Grant Date Fair Value Other Immunology Other Immunology [Member] Other Immunology [Member] Prepaid employee related obligations Non-current assets Assets for Plan Benefits, Defined Benefit Plan Annual closing date Fiscal Period [Policy Text Block] Fiscal period policy. Level 2 Fair Value, Inputs, Level 2 [Member] Geographical [Domain] Geographical [Domain] Commingled funds Commingled Funds [Member] Commingled funds. Property, Plant and Equipment Property, Plant and Equipment [Member] Principles of consolidation Consolidation, Policy [Policy Text Block] Restructuring Cost [Table] Restructuring Cost [Table] Restatement Determination Date: Restatement Determination Date [Axis] Title of 12(b) Security Title of 12(b) Security Impairment, Intangible Asset, Statement of Income or Comprehensive Income [Extensible Enumeration] Impairment, Intangible Asset, Statement of Income or Comprehensive Income [Extensible Enumeration] Concentration Risk Type [Axis] Concentration Risk Type [Axis] Common stock — par value $1.00 per share (Note 12) (authorized 4,320,000,000 shares; issued 3,119,843,000 shares) Common Stock, Value, Issued Ponvory Ponvory [Member] Ponvory Document Financial Statement Error Correction Document Financial Statement Error Correction [Flag] Employee-related Liabilities [Abstract] Employee-related Liabilities [Abstract] Gain/(Loss) Reclassified from Accumulated OCI Into Income Derivative Instruments, Gain (Loss) Reclassification from Accumulated OCI to Income, Estimated Net Amount to be Transferred Amounts Recognized in the Company’s Balance Sheet consist of the following: Defined Benefit Plan, Amounts for Asset (Liability) Recognized in Statement of Financial Position [Abstract] Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Share-Based Payment Arrangement [Abstract] Contingent consideration Revenues, Contingent Consideration Revenues, Contingent Consideration U.S. state taxes Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent Miscellaneous international Deferred Tax Assets, Other Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] Proceeds of short and long-term debt, net of issuance cost, related to the debt that transferred to Kenvue at separation Proceeds From Issuance Of Long-Term Debt, Transferred In Business Separation Proceeds From Issuance Of Long-Term Debt, Transferred In Business Separation Proceeds from the exercise of stock options/employee withholding tax on stock awards, net Proceeds From The Exercise Of Stock Options And Excess Tax Benefits Proceeds From The Exercise Of Stock Options And Excess Tax Benefits Impairment of intangible assets, excluding goodwill Impairment of Intangible Assets (Excluding Goodwill) TJCA , provisional liability, non-current Tax Cuts And Jobs Act Of 2017, Incomplete Accounting, Provisional Liability, Noncurrent Tax Cuts And Jobs Act Of 2017, Incomplete Accounting, Provisional Liability, Current Cash flows from financing activities Net Cash Provided by (Used in) Financing Activities [Abstract] 2028 Defined Benefit Plan, Expected Future Benefit Payment, Year Five Preferred stock — without par value (authorized and unissued 2,000,000 shares) Preferred Stock, Value, Issued Cash, Cash Equivalents, and Short-term Investments [Abstract] Cash, Cash Equivalents, and Short-Term Investments [Abstract] Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Aggregate maturities of long-term obligations Long-Term Debt, Fiscal Year Maturity [Abstract] 2.95% Notes due 2027 2.95% Notes due 2027 [Member] 2.95% Notes due 2027 [Member] Basic (in dollars per share) Basic net earnings per share (in dollars per share) Earnings Per Share, Basic Cash paid for operating leases Operating Lease, Payments Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Stock options expiration period Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period Johnson & Johnson Johnson & Johnson [Member] Johnson & Johnson Number of employees Number Of Employees Engaged In Company Activities Worldwide Number of employees engaged in company activities worldwide. Opioid opioid [Member] Opioid Ownership [Domain] Ownership [Domain] Trademarks Trademarks [Member] Tax Credit Carryforward [Table] Tax Credit Carryforward [Table] 2.450% Notes due 2060 2.450% Notes due 2060 [Member] 2.450% Notes due 2060 Aggregate Pension Adjustments Service Cost Aggregate Pension Adjustments Service Cost [Member] Percent of Plan Assets Defined Benefit Plan, Plan Assets, Actual Allocation, Percentage Goodwill [Table] Goodwill [Table] Property, plant and equipment and depreciation Property, Plant and Equipment, Policy [Policy Text Block] Goodwill and intangibles Deferred Tax Liabilities, Intangible Assets Intangible assets with definite lives: Finite-Lived Intangible Assets, Net [Abstract] Total current liabilities Liabilities, Current Share Repurchase Program [Axis] Share Repurchase Program [Axis] Proceeds from issuance of commercial paper Proceeds from Issuance of Commercial Paper 2025 Finite-Lived Intangible Asset, Expected Amortization, Year One Other Other [Member] Other [Member] Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period U.S. Gov't Securities US Treasury and Government [Member] Unrecognized net transition obligation Defined Benefit Plan, Accumulated Other Comprehensive Income (Loss), Transition Asset (Obligation), before Tax Fair value, held-to-maturity Debt Securities, Held-to-Maturity, Fair Value Credit Support Agreements (CSA) Derivative Liability, Subject to Master Netting Arrangement, Asset Offset Interest (Income) Expense Interest Income Expense Net Member Interest Income Expense Net Member. Cash paid during the year for: Cash Paid During The Year [Abstract] Cash Paid During The Year [Abstract] Investments Measured at Net Asset Value Defined Benefit Plan, Alternative Investments, Fair Value of Plan Assets Defined Benefit Plan, Alternative Investments, Fair Value of Plan Assets Consumer settlement/ curtailment Other Comprehensive Income (Loss), Defined Benefit Plan, Adjustment for Settlement or Curtailment Gain (Loss), Tax Canceled/forfeited/adjusted (in shares) Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Canceled, Forfeited and Adjusted During the Period Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Canceled, Forfeited and Adjusted During the Period Service cost discount rate Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate Repayment of short-term debt Repayments of Short-Term Debt Kenvue Separation/IPO Decrease in noncontrolling interest Noncontrolling Interest, Decrease from Deconsolidation Common stock, stock option plans and stock compensation agreements Share-Based Payment Arrangement [Text Block] Consideration transferred Asset Acquisition, Consideration Transferred Oncology Oncology [Member] Oncology [Member] Entity Address, City or Town Entity Address, City or Town Proceeds from long-term debt, net of issuance costs Proceeds from Issuance of Long-Term Debt Leases Lessee, Leases [Policy Text Block] Summary of Stock Option Activity Share-Based Payment Arrangement, Option, Activity [Table Text Block] Qualified Plans Qualified Plans [Member] Qualified plans. Total intrinsic value of options exercised Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value Curtailments and settlements Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement and Curtailment Credit Support Agreements (CSA) Derivative Asset, Subject to Master Netting Arrangement, Liability Offset Compensation cost charged for Long term incentive plan Share-Based Payment Arrangement, Expense Kenvue separation and discontinued operations Disposal Groups, Including Discontinued Operations, Disclosure [Text Block] Savings Plan [Abstract] Savings Plan [Abstract] Savings Plan. Options granted, average exercise price (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Accumulated other comprehensive income (loss) Comprehensive Income (Loss) Note [Text Block] Product Liability Contingencies [Table] Loss Contingencies [Table] Loss Contingencies [Table] Benefit Obligation Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Benefit Obligation [Abstract] 5.95% Notes due 2037 5.95% Notes due 2037 [Member] 5.95% Notes due 2037 [Member] Business Acquisition [Axis] Business Acquisition [Axis] Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member] Net change Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax Document Fiscal Year Focus Document Fiscal Year Focus Employee related obligations Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Employee Benefits Total debt securities Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Fair Value Project Concentration Risk Product Concentration Risk [Member] Repurchase of common stock Repurchase of common stock Treasury Stock, Value, Acquired, Cost Method Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] International Income (Loss) from Continuing Operations before Income Taxes, Foreign 2.10% Notes due 2040 2.10% Notes due 2040 [Member] 2.10% Notes due 2040 2029 Finite-Lived Intangible Asset, Expected Amortization, Year Five Document Period End Date Document Period End Date Sale of Stock [Axis] Sale of Stock [Axis] Incremental charges Loss Contingency Accrual, Provision Kenvue Inc. Kenvue Inc. [Member] Kenvue Inc. SURGICAL SURGICAL [Member] SURGICAL [Member] Finished goods Inventory, Finished Goods, Net of Reserves Schedule of Net Funded Status Schedule of Net Funded Status [Table Text Block] Cross currency interest rate swaps Cross currency interest rate swaps contracts: Cross Currency Interest Rate Contract [Member] Beginning balance (in shares) Ending balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Asset Class [Axis] Asset Class [Axis] Insider Trading Arrangements [Line Items] Infectious Diseases Infectious Diseases [Member] Infectious Diseases [Member] Shares subject to full value awards (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number, May Be Issued Subject To Full Value Awards Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number, May Be Issued Subject To Full Value Awards Pulmonary Hypertension Pulmonary Hypertension [Member] Pulmonary Hypertension [Member] Accumulated Benefit Obligation Defined Benefit Plan, Accumulated Benefit Obligation Schedule of Business Acquisitions, by Acquisition Schedule of Business Acquisitions, by Acquisition [Table Text Block] Prepaid expenses and other receivables Prepaid Expense and Other Assets, Current Split-off percentage Ownership Percentage, Split-Off Percent Ownership Percentage, Split-Off Percent Foreign exchange contracts Forward foreign exchange contracts: Foreign Exchange Contract [Member] Document Transition Report Document Transition Report Asset, held-for-sale, not part of disposal group Asset, Held-for-Sale, Not Part of Disposal Group Momenta Momenta [Member] Momenta Changes in Treasury Stock Shares Outstanding [Roll Forward] Changes in Treasury Stock Shares Outstanding [Roll Forward] Changes in Treasury Stock Shares Outstanding [Roll Forward] Miscellaneous U.S.  Deferred Tax Liabilities, Other Domestic Deferred Tax Liabilities, Other Domestic Schedule of Unrecognized Tax Benefits Roll Forward Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block] Supplies expense Supplies Expense Derivatives not designated as hedging instruments : Liabilities Foreign Currency Derivative Instruments Not Designated as Hedging Instruments, Liability at Fair Value Customer [Domain] Customer [Domain] Entity Current Reporting Status Entity Current Reporting Status Retained Earnings and Additional paid-in capital Retained Earnings [Member] % Change Percentage Change In Sales By Segment Of Business Percentage change in sales by segment of business. 2.625% Notes due 2025 2.625 Notes due 2025 [Member] 2.625 Notes due 2025 [Member] Proceeds from Kenvue initial public offering Proceeds from Issuance Initial Public Offering Litigation Status [Domain] Litigation Status [Domain] Asset Acquisition [Domain] Asset Acquisition [Domain] Valuation Allowance [Roll Forward] Valuation Allowance [Roll Forward] Valuation Allowance Comparison Of Income Tax Expense At Statutory Rate And Company's Tax Rate Abstract Comparison Of Income Tax Expense At Statutory Rate And Company's Tax Rate Abstract Comparison of income tax expense at the Statutory rate and Company's tax rate. Derivative Liability, Statement Of Financial Position, Extensible Enumeration, Not Disclosed Flag Derivative Liability, Statement Of Financial Position, Extensible Enumeration, Not Disclosed Flag Derivative Liability, Statement Of Financial Position, Extensible Enumeration, Not Disclosed Flag Price Range, Maximum (in dollars per share) Share-Based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit Litigation expense Litigation Settlement, Fee Expense 5.25% Debentures due 2054 5.25% Debentures due 2054 [Member] 5.25% Debentures due 2054 UPTRAVI UPTRAVI [Member] UPTRAVI [Member] Schedule of Revenues from External Customers and Long-Lived Assets [Table] Schedule of Revenues from External Customers and Long-Lived Assets [Table] Restricted Stock Units (RSUs) Restricted Stock Units (RSUs) [Member] Transition manufacturing agreement, term Discontinued Operation, Transition Manufacturing Agreement, Term Discontinued Operation, Transition Manufacturing Agreement, Term Supplier Finance Program, Obligation [Roll Forward] Supplier Finance Program, Obligation [Roll Forward] Executive Category: Executive Category [Axis] Purchases of investments Payments to Acquire Investments Other Infectious Diseases Other Infectious Diseases [Member] Other Infectious Diseases [Member] Provision for Income Taxes Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] Statement of Income Location, Balance [Domain] Statement of Income Location, Balance [Domain] Settlement of convertible debt acquired from Shockwave Settlement of convertible debt acquired from Shockwave Settlement of convertible debt acquired from Shockwave Company Selected Measure Name Company Selected Measure Name EX-101.PRE 14 jnj-20241229_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 15 jnj-20241229_g1.jpg begin 644 jnj-20241229_g1.jpg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end GRAPHIC 16 jnj-20241229_g10.jpg begin 644 jnj-20241229_g10.jpg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end GRAPHIC 17 jnj-20241229_g11.jpg begin 644 jnj-20241229_g11.jpg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end GRAPHIC 28 jnj-20241229_g21.jpg begin 644 jnj-20241229_g21.jpg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end GRAPHIC 29 jnj-20241229_g22.jpg begin 644 jnj-20241229_g22.jpg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jnj-20241229_g23.jpg begin 644 jnj-20241229_g23.jpg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end GRAPHIC 31 jnj-20241229_g24.jpg begin 644 jnj-20241229_g24.jpg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jnj-20241229_g25.jpg begin 644 jnj-20241229_g25.jpg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end GRAPHIC 33 jnj-20241229_g26.jpg begin 644 jnj-20241229_g26.jpg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end GRAPHIC 34 jnj-20241229_g3.jpg begin 644 jnj-20241229_g3.jpg M_]C_X 02D9)1@ ! @$!] 'T #_[0 L4&AO=&]S:&]P(#,N, X0DE- ^T M ! !] $ 0'T 0 !_^(,6$E#0U]04D]&24Q% $! ,2$QI M;F\"$ ;6YT ", * M #( -P [ $ 10!* $\ M5 !9 %X 8P!H &T <@!W 'P @0"& (L D "5 )H GP"D *D K@"R +< O #! M ,8 RP#0 -4 VP#@ .4 ZP#P /8 ^P$! 0&!YD'K >_!](' MY0?X" L('P@R"$8(6@AN"(((E@BJ"+X(T@CG"/L)$ DE"3H)3PED"7D)CPFD M";H)SPGE"?L*$0HG"CT*5 IJ"H$*F JN"L4*W KS"PL+(@LY"U$+:0N "Y@+ ML O("^$+^0P2#"H,0PQ<#'4,C@RG#, ,V0SS#0T-)@U #5H-= V.#:D-PPW> M#?@.$PXN#DD.9 Y_#IL.M@[2#NX/"0\E#T$/7@]Z#Y8/LP_/#^P0"1 F$$,0 M81!^$)L0N1#7$/41$Q$Q$4\1;1&,$:H1R1'H$@<2)A)%$F02A!*C$L,2XQ,# M$R,30Q-C$X,3I!/%$^44!A0G%$D4:A2+%*T4SA3P%1(5-!56%7@5FQ6]%> 6 M Q8F%DD6;!:/%K(6UA;Z%QT701=E%XD7KA?2%_<8&QA &&48BABO&-48^AD@ M&449:QF1&;<9W1H$&BH:41IW&IX:Q1KL&Q0;.QMC&XH;LAO:' (<*AQ2''L< MHQS,'/4='AU''7 =F1W#'>P>%AY 'FH>E!Z^'ND?$Q\^'VD?E!^_'^H@%2!! M(&P@F"#$(/ A'"%((74AH2'.(?LB)R)5(H(BKR+=(PHC."-F(Y0CPB/P)!\D M321\)*LDVB4))3@E:"67)< ^(#Y@/J ^X#\A/V$_HC_B0"- 9$"F0.=!*4%J0:Q! M[D(P0G)"M4+W0SI#?4/ 1 -$1T2*1,Y%$D5519I%WD8B1F=&JT;P1S5'>T? M2 5(2TB12-=)'4EC2:E)\$HW2GU*Q$L,2U-+FDOB3"I,%W)7AI>;%Z]7P]?85^S8 5@5V"J8/QA3V&B8?5B26*< M8O!C0V.78^MD0&249.EE/6629>=F/6:29NAG/6>39^EH/VB6:.QI0VF::?%J M2&J?:O=K3VNG:_]L5VRO;0AM8&VY;A)N:V[$;QYO>&_1<"MPAG#@<3IQE7'P M,QY*GF)>>=Z M1GJE>P1[8WO"?"%\@7SA?4%]H7X!?F)^PG\C?X1_Y8!'@*B!"H%K@%JX8.AG*&UX<[AY^(!(AIB,Z),XF9B?Z*9(K*BS"+ MEHO\C&.,RHTQC9B-_XYFCLZ/-H^>D :0;I#6D3^1J)(1DGJ2XY--D[:4()2* ME/257Y7)EC26GY<*EW67X)A,F+B9))F0F?R::)K5FT*;KYP M0)ZNGQV?BY_ZH&F@V*%'H;:B)J*6HP:C=J/FI%:DQZ4XI:FF&J:+IOVG;J?@ MJ%*HQ*DWJ:FJ'*J/JP*K=:OIK%RLT*U$K;BN+:ZAKQ:OB[ L'6PZK%@L=:R M2[+"LSBSKK0EM)RU$[6*M@&V>;;PMVBWX+A9N-&Y2KG"NCNZM;LNNZ>\(;R; MO16]C[X*OH2^_[]ZO_7 <,#LP6?!X\)?PMO#6,/4Q%'$SL5+Q MHM\IWZ_@-N"]X43AS.)3XMOC8^/KY'/D_.6$Y@WFENV<[BCNM.] [\SP6/#E\7+Q__*,\QGSI_0T],+U4/7>]FWV M^_>*^!GXJ/DX^'EZA8:'B(F*E)66EYB9 MFJ2EIJ>HJ:JTM;:WN+FZQ,7&Q\C)RM35UM?8V=KDY>;GZ.GJ]/7V]_CY^A$ M @$# @0$ P4$! 0&!@5M 0(#$00A$@4Q!@ B$T%1!S)A%'$(0H$CD152H6(6 M,PFQ),'10W+P%^&"-"624QAC1/&BLB8U&50V160G"G.#DT9TPM+B\E5E=58W MA(6CL\/3X_,I&I2DM,34Y/25I;7%U>7U*$=79CAVAI:FML;6YO9G=X>7I[?' MU^?W2%AH>(B8J+C(V.CX.4E9:7F)F:FYR=GI^2HZ2EIJ>HJ:JKK*VNKZ_]H M# ,! (1 Q$ /P#?X]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW4&KR>/H M?O*VFIR!?1)*HD(_VF($R-]?P#[V 3P'6B0./28J]]X>"XITJ:QOP4C\,7^Q M:8F-Y,I7M^;" MJF5;\\Z$=5OS_3WO2OIUK4?7J"U14/\ KGF?BWJE=N/Z.??J#TZU6O'K# M[WU[KWOW7NN:RR)^B1TYOZ79>?Z\$<^_4'IU[J9'E,G#_FLC71_\$JYU^O)X M60?7WJ@].MU/KTY0[JS\%M.2FX_H3-&[<_P"!O[UH7TZWJ;UZ>*?? MV7CL)X*.I7\G1)#(?^0DD\8_Y(]Z*#R/6]9Z?J7L&A>PK*&HIR?JT+I4H#_4 MZO X'^L#[J4/EU8./,=*:CW'A:ZP@R$ =OI',33R$_ZE5G$9=O\ @M_=2".( MZMJ7UZ>_>NM]>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O? MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N MO=>]^Z]U&JJVDH8C-65$5/&+^J5PNHC\(#ZG;_ GW[C@=:) XGI$9'?U'#J M3&T[U;?0337@@!_JJ6,T@_P(3W<(?/JA?T'2)KMU9NON'K&IXS_NFCO3I8_4 M%E)F8'^C.?=PBCJA8GSZ3Q)))))))))-R2>223R23[MUKKKW[KW7O?NO=>]^ MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW3 ME19?)XXC[.MJ(5!OX@^N$G^I@DUPD_ZZ^]$ \1UL$C@>EIC^P)TTIDZ19EX! MGI#XY+?DM#(3&['_ 9!_A[H4]#U8.?,=+O'9W%90 4E7&TI%S3R?M5 L+G] MI[,UOR5N/\?=""./3@8'@>G?WKK?7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[ MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=> M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U"KLC M18V+SUM1'3Q\VUDEW(_LQQJ#)(W^"@^]@$\.M$@9/0]^Z]U[W[KW7O?NO=>]^Z]U[W[KW M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO==@D M$$$@@@@@V((Y!!'((/OW7NE;BMY97'E8YV_B%,+#QU#'S*!Q^W4V9P?^#AQ_ M0#W0H#PZL&(Z$O$[DQ>7LD$WBJ2.:6HM'-_CXS]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N MO=>]^Z]U[W[KW7%W2-6>1E1$4L[NP554"Y9F) 50/J3[]U[H/9Z;+^G09U574ULS5%7/)43-]7E8L M0+DA5'T1!?A18#\#VX !PZ;XY/4?W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z] MU[W[KW7O?NO=<6945G=E1$4LS,0JJJB[,S&P55 N2?I[]U[HK?;/SB^&W1&1 M_@OEBS*H)9E4!2Q+$ !5_4Q)^BK?D_CWOJO7?OW7NO>_=>Z][ M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KL$@@@D$&X(X((^A!_!'OW7 MNEMA=ZUM#H@R.NOI18>0F]9$O^$C$"<#^CF_^U?CW0I7AU=7(X\.A4H,C1Y. M 5%%.D\9X;3P\;?ZB6,V>-O\".?J./;9!''IP$'AU-]ZZWU[W[KW7O?NO=>] M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW35E#S5DEF:_A@2S3SL/J( MT)' ORQLH_)Y'O8!/#K1(''H'[=:Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z"7N;OOI M'XZ[0DW]WWVYUQTULM*E:)=S=F;RP&R\/4Y!XY)H<705F?KZ&/(Y:ICB8Q4E M/Y*F:UD1CQ[T2!Q/5E1G-%4D_+K6[^7_ /PJ9^,'6T57MSX:]8;R^4NZR4BA MWQN"ERO4O3M+*T,QVB4,,EJ'C9+)>0I2AJ3Z M=&<&U3R9D&E?3%:^GRZH3[$_X4>?S8>U(\XF#[!ZFZ5Q=::O10]2=4X.MRV+ MHGF>-8*'-]F5>_*R-Z>)@#4!A.S -&0Q"^T,FY-3M 'V]'%OLD(HTRU/I4_S M.!_+JNON#Y?_ "^^0U!)COD)\JOD-VKB9ED>;:&5["W5/LTGPZ9(SLO%Y'&[ M8,LRDP.YHD:Q/!!]IVN9G_T4_EC_ =&,=E:PD^' H/KT5>/'Q8D5-+AS4;? MI:Q()Y:?%4:8TU"4Y6K@CK8Z6ECEE6.IT.A$CPJZ^33=+AHDM\9K]N>KF,)0 MH-/V"G^#J/7) E7&)6S>8BEIYFK8YZNN23S3"(-"$^X9Y8TN/(YYF":K*#8; M501D #A0=:U#!J>.>GW:^[_.M\O3T\ZP9C9.X,YM3<5+]U%( MA$69P%?CVC_ #-_ MG=L-$@VS\S._X5I<*^W\9)G.S-S;FH*+&/2S4E-'3T&Z*_)QTKX^%V\-@-#$ M$EB%'M]+VX4#(8T_$!4_GTCDVRT9M6G23G'#]G76P?YI?\Q/JJH^]V?\H^X: M=:R/< KJB/>&6K8,O)NK)29;.Y[<%-D9Z^BW/NBKS,LD_P#&LE#6Y:#R>"*I MBI5AAB\NY,Q; 6GEZ])9-K0%:(7%: G@!_J_U4ZL3Z"_X4Z?S(.J9L9B^RJ_ MJSN_;-!3QT9@WSM*7&;FEAI9E96EW9M&IQ%9/724W[1GK(*LO99'N^MI'QN( M^%DX>8Z3':HGK44;Y5_XKK:9^&?_ H.^#GR>V NX.QNP=J_&/L/&54U#N;J MWMCBR;;IXVTA"WS'5V^QNPMB]F[7P>]NN]X;9WQL__=> MZ][]U[KWOW7NO>_=>Z][]U[J90Y"KQLZU-%.\,J_72?2ZWOHD0W61#_0@^]$ M \1U[AD="[@-VTN6T4U5HI*\\!+V@J#_ ,V&8DAS_J"2?Z$^VF4C[.G0X/V] M*_W7J_7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O? MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]TE=Q;HI\,I@A"U&19; MK#>\< (!62H(((N#<(.6_P !S[LJU^SJC-3'GT#=96U-?4/55]^Z]U[W[KW7O?NO=>]^Z]T#/? MWR$Z<^+W5VX^YN]M]8KK[KK:XI$R>=R:U52\M;D9TI<9B,3B\=3UF6S>;R=3 M($IZ.D@FJ).2%TJS#1( ))P.G(H9)W$<2%G]!UIX?/+_ (4P]L;W_BFU/@KA MH.D.NUKI\.O?G8V PF[.T-UU5'5J:J;8&RZE\_L'9N$:BAE1O[MS?_ M &'W)NBH#4]7O/MG=F=W5E3CI/-55N/.6RV3KLEB<;&'M#C<=5P4*+V@=W8=[DUX5/V_LZ,8HU!'A0A4X4Q3/&OF?\ !^?0;UV+S.1K:VF>"CT4 M-''#5S?<1T6&Q.)A :"EGGADBH<;CZ>9UM&1)425+>)+R60,T)!Z,@A()(H M ,"@'RZ7.+PU/1FG2*&3)Q2BG:#+2+/C*2LKZZH>F6+#8V!8LQF'>J8QPM4- M"H-Y)05 0M^&6(S3U''_ (KIS6JJ!2JGSX9X]1*F6KJGJO0)YC-M M)4)#!F*2(5PE M_P"4>;;M/+)#'5S)%/44\< M\61I:-FUB)#!!3*I,=.T*0Q+--*\L<05U!7639QI%TF@S_J_P]-F AN%#QU# M_/\ 9U'RN"J, *B.?QY>AJ8FGIJJ%IH(DJ*9*<22.:@-4ZXED*."-#2L"A*< M^]!@6!.#UXQ/&*L*@Y!^S_5^WHW/PN_F)_-#X+;CE;X]=TUVU,5EZG^*Y;KS M=-!0[TZQW%5!8C?*;/S@DI<3EZZ)5BGR6)DQ^4>)0AG*\>S&"Z=0="]M?/\ MR=()[*&Y6DR4;^(#K?K_ )2O\Z'J[^8CAGZV[ I\%U+\KL!CWR>4ZTBKY6P? M8.WZ>G6:KWEU755[&IRN.HG67[[&L\U?C(D664R0MYO9O;W23 @X<>7^7H+W M^VR69##,1X'J\!65@&4AE/T*D$'_ %B.#[5]%G7?OW7NO>_=>Z][]U[KWOW7 MNO>_=>Z][]U[KL$@@@D$&X(X((^A!_K[]U[H1]N;S*>.AS$A9.$AKVY9/P%J MC]67_FY]1_:OR0VR>8ZNKTP>'0G@A@&4@@@$$&X(/(((X((]M].]=^_=>Z][ M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N MO>_=>Z][]U[KWOW7ND-N?=:8X/0XYUDKSZ990 R48MR.05>H-^!R%_//'NZK M7)X=49J8''H(G=Y':21F=W8N[N2S.S&[,S&Y9F)Y/MWIKKC[]U[KWOW7NO>_ M=>Z][]U[KWOW7NO>_=>Z(Y_,$^?/3/\ +L^/V9[Q[:EDR^1J)VV]UCUGBJVF MI-U=J[]GI9JG';6P33QU HJ.**!JG)Y%X98L;01R3&.:7PT\U))%B4NYQTHM MK:2ZE$ Z^;Y\X_Y@WR5_F#]DUW9'?F\FIJ'9^!BD2GS&>FHZHKD]T5WDR-;^X#)%214U-2$TTSSL<_IC(7_/ZGH5 MV]M#8PD1G5(W$CS]!_J^WHCRXV7+/14U9JKXXY_%>@/V]&\CRF*EP>W8)'"+ M05-5K!J"1+6U!DF9DB 7W1B/(?ZO\_6@OBL"P)IZ8^0 ^7S\_LZ7@CHZ*A2A MH X/\_\ 9Z6Q MKHX\,''3"M="#2559CXS3XV0UE+C*MJ7^ /7%&2GKJN.=HHIYXQ(3(VMVIX4 M(0@%A[LJ#)KD^?G_ ,5THK05(QY>E?GTGFW7J:HB&09S2GR&0(QQ"4[M)+-X MBH@:NAR9LD-'I$=0H8N=#/>V!7[>DI-2 -3!;AF6YB@!,C8\SZ?/I7;;=/=LB M1K5JT"@5J?3R_/'^#I:X?I/>63ECC&*\$MZOF, DG_5PZ'W M:'Q+S,U:E-7Y1#4325%.^*P==%6Y2 T^F-X:NA$5%50AWTOXIXXA-&P(+:U] MA^XYV@5&:$4CH#J<44@YP<@C[/\ )T,;'VVN"P2X.IJGLC.13Y$ _D1^>>C) M[._E^YC.4-3+'E:NE"M)-D,;5T#T:BE=6@D=35TD!QU7 0 L-I"87].D@ AF M]]RUC<1B$%3P=3Q/I@FH_P O0DL_:995):21#Q96'EPQ4"A'IG'0H[>_EF9S M,02I5;TIX6C\446/^VJJV>GAJ$E:D66IA!(<>-F>(6J@L>L(Z$>RF3W-T$:; M4D>I-*T_U?9T9Q^TG: UV:4QBM,8J?\ 4>D?O;X#[SZ]SDM13U%'N*EFA;(U MM1AZ!Z9XOLHC+$BX]2TU%,DT&A6G5H9XV#!F8%0;;?S[:WD7ZB>&U=(U'&?. MOG_A'1-N'MG=6GZR@J,;]UALC_D81:I)! M4TZR0*GVIFI5D9(XE$H\2R,#%&H"(3H#>Q7:;Q#D'3[4QRT'<>BV:! M:D)4K6G^K/2MZP[L[ Z;WG@]\]>[KW!L_=NT,[!E]L;LP.8;$;PVOEJ6.IID MRNWLO"#/BGJ**HDIZI05@K8I&AGCDB=D9?"64^(K4:M?]C_5CI&0C!XI4#)P M(:G[?]G'6]G_ "DO^%!FVOD+D-L?'?YO9#:W6W=N8.-PG7?<,<,&U.N^Y,K+ M'0TM+@=T45152X_87;67FG5HUBDCP>:J9#'2)13M3T,IM:WGBG1( '^7 _[/ M07W#:C$&FMQ6.N5XD?YQ_/K:3]F/1'U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=> M]^Z]U[W[KW2UVSNJ3%E:*N9Y<<>$:Q:2D8F]T'ZGA)/*_CZK^0:,M]^Z]U[W[K MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW2&W7N<8Y M'QU"]Z^10)95M:C1@#P>;U#J>!_9!O\ 6WNZK7)X=49J8''H(22Q+,222223 MFNNO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW1<_EC\INHOA? MT#V'\CN[\Q58O8?7N+BJ):/%4R5^Y-U[@R=5!BMJ['V?BI)Z9,KN[>6X:RGQ M]!#)+!3B><25$T%-'-/'IF"J68T R>KQQM*ZQH.XFG7R]/G7\Y>Y/YA7?>Y_ MD)WGD/M:&-JC =8=>8S(&KVCU)LEZ^HGQ'6^WV*4WW-=5^+[S/9DPK69RIB\ M[+#2BAI*8DGG:=C_ X'0LM+:&TB5:CQ6XL?\ _U9XUI0 E>0GJJF=I:J\4 M]12Z8HR!3K28YO5/%&L048^BJ X#-I669&"*(T4EJ%JA0>K-IJ5\_*OEZY], M_GT\XV29:2*K02CQJ26/^3562B6-EC,D#V*8YH6.BY0", !=&MO=:C((Z?0J M*9-33Y5]/V]1JG/5D]''B*1X)),C52U61FBB_M^A\WO MW(TD-3%24]$GDKG \YDHH=1,\C1R5$4E>)],'JS;IWXO8O'3 M)!4T\4=+6RR.M+1P0PUI@EIDGD:)G 2$!97+?U)CZ\WJ5T\ M+4S1ZM9!XELBI.#C[?EU(=OLEI!(\PA42TTAE P!Z"E/G@<>C5[/Z.QE+D4> M6"2O0(R-5S1T1J44MK\:5E%24DL-$ OJBB 1SR1?V5FX:8XP/05IZ5H:Y^?2 M]H8XU+4S3%:5Z'9>HL9# GVJ^*,QI(&H:=?)((W:0!YZEIOMI5E8NDZ$2+?T MD<^U49 K4UQY]%$LWD*JP^?2IQ75N*:@>&L@A9D9JF$QFU-3RL8[S)XK2B9Y M(AKE6P9E(M8CVX-%:D=-BZ?@K^?ITSY38U)"3)F:"FRE/6@Z344*U+*CR0HC M31.C?CTRU4J,>1\_V\.B3][_%+ ;]H*.# M&K%218\O_!EI@M*,1/3AC'"_^3S3M1.K.#2.0T/Q5J M:C_/T7;GR[9;I&D;*%TY6E!0^7EP_P YZI_[G^'>9HJ^MI8\)-0"&JQ$5%DJ ME%DBG=H:>B.0BGH6-3+,30+).)"ODG<%FL')D39>=(HPAG.H$,6"^5,TSC-: M#T'V]17O?(#.T@B2BJRA6.:DBA.,UQ4UXGSX]5=]B=?[JV;F:JFK,;-%''7% M3DA&T5%DU>>115P-(J23.$C,G)(8DZB; "4++=;6[B#I,"66M :D&G#'#J&M MWV2\VZXE22'L#4#\ PJ>X5SY5Z"W(2[9K*^L^WJXX9)%53,:"A@A5 5#Q&DA M=-,J@EI)(HU:_P!&MOE_FZ#MNTMWUU; M,N2P.2$D-+MW.5!26CJ!_#JYO$U',AQ:7E2(9F[O(_Y.@QNNT_%]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]TLMK;F;$R MBCK'9L;*W!Y8TDC'_.(.286/ZU'_ 8]^Z]U[W[KW7O?NO=>]^Z]U[W[KW M7O?NO=>]^Z]U[W[KW7O?NO=)7=&XEPU.(8"K9&H4^%38B",W!J)%((-B+(#^ MH_X ^[*M?LZHS4X<>@3=WD=I)&9W=B[NY+,[,;LS,;EF8GD^WNFNN/OW7NO> M_=>Z][]U[KWOW7NO>_=>Z][]U[J)D,A08F@K.GI*2DIXVDDDD94C12S$ $^_=>Z^8O_.7_FA;E_F1?)+( MOM/<=71?$SIO(Y;"= ;:C6MH\?GHTE.(S/?.XL?40T]=6;R[(CDDCQ,51%%- MA-LF*FB@@JJO*35I5<3--)X:G],'/S_U>70BLK9($61UU.PK\A\OS_U<3U3] M*32T]*M,8JAP:A:+7^NCKWTS5D,5G\<;0P0Q25$@#1A_VE)"!@P4I3NZ5')I M3-<=-]&$JZI9:Z5C2Q2/45-1I6>6NF>0\PB5M,ZZT_:#W1V#N045[MR$<*>? M^JO[.G$BJU:@*#^W[/\ )_L=.]77O+5QUHD#R3I^S*4:/[1(# &G:+R,:N9) MI52G#\RS@&PTL/>@,$TZ?SJ8D\?Y#U^WT]?V]2(5>1H,6N-2M>OE,E&5J%BK M))YP/MD6LTL4@=U5V=U>24QD_0IH;DD2)2[M10*G[.C""WEE9(8DU2L0%]:^ MG1I>G_C[5.T,V>K(I\O4R13-,(W>*A9I%](H8!9HY67]J% TM5(!<,%]$9MRV?L^Q?0^F2QXUIBSWJCI3% M8,03Q1.DXJ))6+V:J4TVN2>JEE5IHUDAEF:.-P?VM9$1_5[AC=M^N;Z1C(_; M2E!PSY 8P:5^?GU/>RC%;9\4)IE2E+11L MGB,4#*S7M]20%*@ *P]9N0/=[:0L0:&GD>DUS'4&C9I3H8HH:G[#Q/"BM(_ M[7ED6*4QLH/[H$4BG2YYL;M?_;FJL2 .@].$,C,C'A0TZS8VABE6\Y"NBB/Q M+(3 UV))D&M@_P!."0#EL4Q"D:N)Z*SV3M"(4IAK:2D: M"KC>*1EAFT3T8"2RTD[,EB8U()35Z.=-KD&T99&#*:,,BGKT9JRS(U5JM*&O M57?R8^*>WMX15N:D##&(RC'_ &,*+18H5DOHHWI1*:B8U$SG[5$LH;4K7)6X MHV/F.\VV98T&I'/=4Y-/.O ?/S].'0&YFY4LMQBDD=* <*#"U/"GS/#]AZH1 M[CZ-AWR M/GK2F*=+G"Y)X<;78NKURT%? (IHY:IO*;31?=KBY#$K04>0@.B MP5&4'2UR"/:TTH*,1]G3.:>?7T+OY$_\U*?Y7];8+XP]\9.JE^2/6VRVKMM[ MFJZ.L"]N=4;7;"X"EW#F\BQFHHNS<+/71096'R7R<.C(Q:B]4D![97(E01N? MU ./J/7[>@9O&W?3.9XA^BQR/0G/[#UL1^U_1'U[W[KW7O?NO=>]^Z]U[W[K MW7O?NO=>]^Z]U[W[KW0@;/W+]HZ8JOD_R61K4LSGBGD8_P":8G@02,>#]%;_ M /#;KYCCU=6I@\.A8]M].]>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^ MZ]U[W[KW7O?NO=-68RL&'H9*R;U,/1!#>S3SL"4C!YL.+L?PH)Y^GO8%33K1 M-!7H!JVLJ*^IFJZIS)-,Y9C^!^%1!SI1%X _ 'MX"F!TQQR>HOO?7NO>_=>Z M][]U[KWOW7NO>_=>Z][]U[KWOW7NM6C_ (4]?S EZ/\ CM@_A1U]N*?'=F_) MS'3Y7LYL9,R5N$^.^/JJW'Y'$51C>*2.+N+<] V%9"6AJ\)0YFGF4K(H9'=S M%$T(>\_X.C+;K<2.9G%8UP/M\ORZT&:FL6%X("]*TE.]7)42L?),TP69A3I- M#Y5G<&J,NTE.U)!$MY07C!I M3(Y$D:-HTRZ?TA=#?J9AMY""<8\B?\/2F.$:58\?E\CP/I7SZDF*HBD$U1$) M*EX/)CZ4?;F&69E$9GEB'F08JABBLK'2'2/2OIUZ6P.../5R'!4A1J_U5_V. MN4:PK'7US%J@8V* 10S:VIZRH+201HRA@PCGJ)W8@$ K)(Q(_2S;, M:]H\^ ME$*%]7;D?[/1P/CQUA'79!\_F4:?(U:B6&LJ6IZI:=33PRUU1'#&P\1"V6F2 MR*Z'2#H1KQ?SAOKLGT\,G8#W 5%3P _S^GVGJ:>0^7XP_P!9/&#*5PQH:<*G MCC'#U^P=6+[!V[18Z2*:*C)+"2..LG99)TD=P%DDD9%9ZR0&QMP;V4 #B)MQ MN'E0AG\ZT'#[/LZF[:[:&-PZ1YH0&.3_ ,7_ *AT>KJ[:$=:T<;"-HY&B*QF M2632#&(FEE-AYM,2V13?2Q-A<^P7>N013)/^K\NA[9JJJ"36O#H[FR-D2QJJ MF'2P14GJ#&"Y2.1"$+:0 "0MF!!T?4G1A-E.C%[=V M@)8(D;3.L-VBT11H'DM&FJH97$@=PIO>_ O<"P]N&V!HI%3\^D/UM":=O^;H M?=G[5B\2J8UC",DD9"N!)8^G4B^EA&HMI-N>3?\ "V"U# !>'E3HHO\ <:95 MB?(_*O\ GZ7,>U#4ETD#R1.&58@H/ACB_=DO6X>2GCEG=)(YM,B2* LLA5 MN%7E-&EOSSR0.1P/:)E&6LR4;AG@1T3C.D_A^0 MADB$E0@:,J]U$DE76_!!;V^K,I#*:$&H^WI]M!!!6HI2GRZK, M^5W2E ^.3(E(74>\T[3#-"[&.JFM/,UI_/JACMOK#^ZPR..6)T-+7I7 M4M5$C-J@KXU98*FWD6 LA -]%["YU CWD!LVZ&XT2L0V*,I]1Z>O\_LX=8S\ MR;(ED)X<@*X9&'HWD>-,?9CH#,/7U%/%% [:)6F\-+)(\JK$T[QZ MZ[;Z^K*[';BV-N"+(93%41QT\&Z]L2PU.,W#MV**MC-"3F]OY6KI%4@QB:6. M>,Q5$$3)>-_!<.N2/+K_=>Z][]U[KWOW7NO> M_=>Z][]U[H7=F[A^^A&,K'O64Z7@D<^JI@3^R2?U30CZ_EEY_#'VTZTR.'3J M-7!X]+OW3J_7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=<7=8T:1V5 M$16=W8@*JJ"69B> J@7)]^Z]T!6Y,V^:KVD4L*.GU14D9N/1?U3,/Q),1<_T M _'MY10?/IAC4])[W;K77O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW20[!W M[L_JK8>]NS^P\_0[5V#UQM+<>^][[HR9E&.VYM#:.'K,_N3.UY@CFG^SQ&&Q M\U1+H1WT1G2I-A[]PR>M@$D <>ODN_/KY<[N^;_RO[B^3NXZ:HQ[]D;CDGV1 MMZID0U&T>L\'$=N=:[2G2FEJ8%R&&VSCZ=\B(6$,F4>MJ -50?9%+)XLC.:E M:X'R_P!GH60P>#!%$$R,MQXG_5]G10!#*TDD5*\9 CAJ6FTHOV]&GV]+1LT@ M14BDJ*IPL2\:Y/W#PJ-[I7\7Y?ZOLZL$(:A-/,GT\@?M/EZ].0J+*[TL7VR0 MS2X^CB5XWG6."[9)DD:,:BC *SK93*;\CZ^D^&I/H?V_Y^G4)J #VU*@?9Q_ M9P^WILI*8SS#63]O$I$TQ9R9Y70".FB"?N+]LJ_6Q'( N2/>D /$BO\ J_+I MU:DZ"F/VC_5CH;^O-IQ;FW11XDF.N3$B+*/!!&DN/-1&8*9I*B2]I:&D=)52 M-%N[1K?4)"00&*CQZH)(Q4R5AE"!IJBI993*844JH@O\ HL @"K:WI,'W MUW+N]OI42QQDEA!#$ MH"E?/)K:Y8EKK&K.UM0-SJX^E_87O22K-6E?V=#7;T ((X "GSZL-ZOP"0RP M),'>0>-5N-#R%-+E 59$&@ : #PS<)K..'^K^?0DBFH ",]'MVKB:> M;'M65$RF>0,[2"W%E^M[*/9A HU4 H2 M1]G15=R&@!J:#/\ D\NES!CWE<%G\"1NVM8X4",@9+ $DECE'2T6OQ@H1%&'TV@5GBTW4$R.78M-P6)#?6R_4' MV;P1ZE4$4 ^7[,]%D)F\.D23, M\,+:5ECU>-6"-$ZNJ)*@5Y(9$%A=B "0!];$5Q:Z:D@'R-!Z'U].CRUN"V@ MD YR?4>GET7C>%"\=+-XUBEE_;7I_Q?12]Z[1!!%;3_N()YJ2HTEG2*1/5&7(6TZNHU&R MZCSH%O;0R/GT:P39H>'^K^71*.QMK2U>*R5'F*/[NE,%6GAD"K.JRTTCP2(Z MA@C"=5;6HX*V8:2?:Z#5$%DC-&7(^W_+TQJ1/D/TW/ MB:&MEK)8Y*2&IFBE/VLK&;&U4*&[FC1J1DZ@K9()_R?\ %=,U)N*JQLHTQ54#TU5ZT=ZJ M,L 5),"L[1R)<7O8G5];_7V8K =2O7S_P!@_GT@%P48G0=0/G_A'KUMI_\ M">7^;2_5O8$7Q4[RW#A:'J3>51/)LG/9G(0XJ/KK=F9R:3549JZVJ*S[5W;F M\@IEIU"QX[(3R58 CJ*R55EE/H?PS71P^S_8Z+=VM1>1FXBI]0.('XA_G_U> MG6^DK!E#*0RL RL""""+@@BX((]G/00Z[]^Z]U[W[KW7O?NO=>]^Z]U[W[KW M7O?NO=>]^Z]UFIZB:EGBJ8',\)EHL MSCXJM++)_FZF(&_BG4#6O]=#7U+_ %4C\W]L$4-.GP:BO3O[UUOKWOW7NO>_ M=>Z][]U[KWOW7NO>_=>Z][]U[H.]\YLPQ+AZ=[23J)*QE/*07O'!<<@S$7;Z M>D ]^Z]U[W[KW7O?NO=>]^Z]U[W[ MKW6J9_PJ,^;$_6W2'67PHV+FV@WAWW6_Z2.V**B,,LT?2^P\HB;>V_F$9#+0 MXSL/LR&&?RAA'54&URZ(](.3Q^SHZV6W,EQXQ6JIP^WR\^M" M"NG$-.=-04I:IA(L032)UA26F$\9<-*T"Z9(N."3):YY)/4X '0A&65Y-49!7[9I(AX))EL%=XX'H:/U#]!'NQ%#DX_U? MX>JJN!7%G#'QF+P(@CC8O]L1,OK#RQ3"JKY%9B76AI M2=*D >:0Z>1[V6" MY?ZATZB:W"U-/\ 5_+'1MOCOMM<;--DI(YJ62O8U$%/ M)*?+]E%.@@0U+'B2!8D8J18R$FW"^XPYNNO&/@H:QJ:?F>/^:O4R\CV)MXC< M2*0[@$8S0'_BCU8=L?"S5KT]486C$K$K/(59II?*ZR+J?QZE!8 #Z,$^I%Q[ MC6YQ5:\/\'4O6,9?2YK^?K7Y]'&ZQP4334\@2:2FA62H\:PJ[ %23H_1<*R^ M1AJ4A%:Y!(]AV]DP0:5Z%=F*QK_@ZL V+CXQ40J6A-4LH"03.+OK2:2)2Z!2 M)(W"J='U8 7M?V124&?*O1CJTYH>C@[&FAIV: P*CR4BRSZ=,KT^DTR&73'J M1_*9VU>,VO\ T"BS(8(37JLM67#-./IQH. MA8IJ%Y$5X4":CY/0PCB9HU9XPEU;2 &;5_:4L;_7V>)%4 BF<^@QG]GKZ=$3 MRJ"0QJ>'J['Y= UGJ.3Q/2S1Z;)(2X,0#Q.EVG MBNQ5O&6#*O+W_P!>WLFN%:NEAD9_XKH^MY%)UAJU_P!5#T7SV&H\QM_&3UF#:M3*RK1.4DBI_LJDTTJ''M)(@6*DR<)81\(89B/PP/L M3[!*8KJ0)( RC73CJH1FGF5_P= [F.!9K5-<>I2:>E#Z9\F&/MZUUN]-EY+8 MF\ZCQ2K6&AE6:!75"STQGFE@DIO0L@IH85"LXNNH$J2OTR(V&]BO(=3]I)X\ M!/"%%05IY9X?GT#;C4%9B:U_A&?MX^O M[>'4';N;K=NYK'YC#5S4F3Q=51UV/R.,J:F@KZ#(T[*])D*>8>.IH:V"8:PR M'0&'#$6N[HT&HX?/_ /LZW P:HH*8_XNGE7KZ8W\B/\ F/T/S4^-=!U5OVKA MI/D-T!MO;N*W+322U1/8'6\JR8C9G:&*ER-1/69*HG..;'Y^S-]MEXA*1'!7 M488ULIQ+&%_$/\'KT%MWLFMIO&4?HR$D4\CYC_-_L=7L>UO11U[W[KW7O?NO M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW2EVOFCA\BIE8BCJM,-4/P@O^W4?Z\+, M;_[23[JRU'SZLK4/RZ'($$ @@@BX(Y!!^A!_(/MGI[KOW[KW7O?NO=>]^Z]U M[W[KW7O?NO=0LC718VBJ*V?_ #=/&7M>Q=R0L<:_[5)(0H_U_>P*FG6B:"IZ M+Y5U4U;4SU=0VJ:HD:5SS8%CPJ@DV1!PH_ 'M\"@ITQQR>H_OW7NO>_=>Z] M[]U[KWOW7NO>_=>Z][]U[KWOW7NN$DB1(\LKI''&C2222,$2-$!9W=V(5451 M_=>Z^4%_-8^5%=\M?FUWIW:NX:7,X/=.ZJS&;!^RGF\&#ZCVU31[6ZZ MV\],TDM-19>#;^-:OS$4#R0G-U]:0[>R"ZK$ZN[%#@#T\A^7^7I0PO%+6SH5GEAG=9)ON77SPT=/'',TU5/ %IXYZV MM0*]KZ/T:C=B?,:>9/3H5M1%,GU\A^7J>N2PV=9'C\NJ!X50 $7E1)('XTLQ MJ68-(PL$5P#>Q \!_J^75R. ^5.E)M#%G+[GH**-))M4D<$AF+IJ@8--D)F) MY0NK70'ZWO\ 6WLMW2X6VM)9*^6#\_+^?1SLEFUUN%O%IQ7/R7SZL7Z^PD-' MD:.@AC%X?$J1'E(+ H8EN"KB.",D-<%R#^1[B+<)]<;2,<9SZ_/[:_ZL]3MM MT*Q2I$B444%/2GE^P='TV9CFIH1I71]HL6M9)5\8X.I]8*./6038DH2+>P3< MR5)U')ZD*S32 1BG1GMH,T16*DIY9(XHK.8U82135"^9Y()#)H+30+J(_22P M(/U #\N0"3G_ %?X#T>VZUH!\/GT=;K^I%1' U12M*9):9V?QB"21W;RF@1H MU?RV,QDTHS-?_ 7]E,A!) X#I:ZD4(/EGSZ.=LNB2EA2NFC*L9:R\CA/+*LC M12*55&4:*8P&(N. 6(4GDLU4 U(Q_/IB0E_TU\Z?ZOY]"_25LLVN"*(*LPFA MB)#ZX[?0^UMNS%V<$ >G[?MS_FZ+[I M0B(N@U/XO0U'0SX"0I$IFFFE*PI&&8J\*QAU.B-$E8B29P+A5)N>3:WL0VTO MZ=6-])CC5985@990 MC2AHVU/I96%]) X'T]J6G58V-26(\@*BF<\.D"V[M*!H4*"*Y.:CB./#!Z0M M16D2S.@= M6;))+*(R3:-"+)/"L91EU*6( Y-R?9-+==[-FE>!X>GS%/V]'D M5M54!_AI4 5]?4&O4"<-.@,I+C2PC!EY*6:0Q@"%AKA)M&P/K! O2E36]TL M[@NJ>NX^OLOU&O'HUCQ0$#[>BH]KX6-<9EW:/QR0TBRK#.O[3 /]M&2B>F:6 M(*-)8$@V()! ]J$;N4>1Z7>(65@U2".B ]D4D.3VW7[5JJ>4SS^:B9E"*',M M+42*E#,@"K)1O&K&4GTR:21=0/9O9R-#/%CF$M+70*T)F MH,A"NK(4,]-J$B0LMYX'*!'&JWJB[.7PY*DY'^ ]6O[<75N\1]*C[?(_Z MO+'7U <-F,9N'#XK/X6LAR&'SF-H@ 05)4C(P>G+WOK77O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K MW7O?NO=#)LK,&OQYHIGU5./"H"Q]4E*>(6Y-R8K:#_0!?R?;3K0U\NG4-13S MZ6GNG5^O>_=>Z][]U[KWOW7NO>_=>Z"S?N6\DT.(A;T0::BKL?K,Z_LQ'_EG M$VH_@ZQ^1[=0>?33FIIT'7N_5.O>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N MO>_=>Z(A_,L^2&"^+'PL[\[6R[&:JQ_7^%PRS,DK4 M=-E\WFJ6BFJD222E2J\J*SJJEF=]$;'Y=*K.)IKB-5XU!SU\EC+IYG2"&P04 MZ2$@OX_LZ:%%CF5')EB:NG!DT-:QE YY]A]"3J/[*=#B0=H0>8_D.H4,<\ZF MICB2**+[*E1$5D1%57$ E8%@9YC#)(.3?Q%K7/-B?4_;3_)TQ&FHD@C2:4'^ M?_)]G3M1O)XZBF6!$^ZEBCA217)CCAE$\[SH#:0)#I72P+ N=-BI'OU //IX M*:-5<>G^'^72KJ(THZJ"B2FC!HZ.)\HU00[2+XQ-5,?W"8I9JFJ-H@-5Y4'] M +$T%0M?/K>D:J ?G7^?[?V="GTUCY7R]7FZL+,\LSK$\YU*U9,QED=3I>/R M1'QAP38/P?Q["',4^L+ "1YG[/\ 57H>\HVZB5[DJ*BBKC]OYC'1_.LDC^_D MR-0Z"(D10QEE7R001.TTK(+O'(J C2>0+FX]QQN@.@1J<^OVT_;U+&TE6E:8 MG'E^7'H[VW*L5-+24L;0Q">.,L))'4IXRRAO.GD(!>0(%;29/[(X!(&NA1F) M'#'0^M#J55! !]?]7^:OE\S<]98.L:ACJ!3L[&,*L,L"-Y7=8G^]FF8ZP&$^ M@O0@MXNQ:*<^O\ AZ-IL#;V:B:!IO5:M/VRFDDJ M4BK$4+H@(D1#(JD,02MBQ_J/95,P/PCSZ7L%"$&E:?ZJ]'VVML]HJ0"HDL5@ MW!;R.NKACHL-TB]JD$UQ_EKZ^O0G MOMQ!4QQ1-%-400J9AI#>1XZ83/-$)&BD]<3QG4 #KL%-R?;K6A5M"D:@,U_; MP_/I*MX"FIE81DX/I4TI_A_+CTN:"A58XT1;131W).J'0ICG20.NJ3TO)3:@ M!I\=BIMQC;[ 3Z5C1$U)$ MQ)*?<-:*2)F5KRR2QE2#90Q_UB#9(CX.O@*5"GY\*?,GU]>BEIE$P05)K0D? M+C7ABAX_[/2;K#//-(L$1),RJ4UZ =:P\J7=+1QCZ*P_# 7X]ELA:21P :UI M_(>OD.E\6B-%U&@"DUX\/\IZPST_V[*@C4M/(//,%:01M]':1G4^C])Y) M:^E3_2Y!LIL+>UL6VM(*B0@_[.>DD^XK$[*RBM37_BND?N/9$[0R3Q2LRJ': MK(,2&,MI99B^@*)%$H&H?3CCBY0WNT2I^JN0!5O+]O[>EMIND3.J'!_"/7HN M6:PE5C*\F,0R(92 K1RJT1NKJZ$G2I"C26 !O?\ 'L..C([(10]":.5)$&? M+_5]O16>W%CFILBA@=! SE?)='E4+*2[-I5!&GJ!%E6W]1R- D%#T9PFJ'.: M=5U]DB"CBKZ:.6"F6:"HJ5=RT7E:6%Y9V2?4?M&8%')TV?D^S2T9WDC-*BH_ MS &%R,*03_ *O3JC#Y.T%!7;[K,O3";'YJ3%B#=%/34DE/'#E:CB?5:5&/,9ZKZIX,G2FNCJJJDI80)IDC>GDI!15$8CE5L;2+ M(^E?'+'Y73R@J]V"DDB4(C&4&E<'\_\ 57_BNHA97%=3*.)QBA^RI\NDON'& M24\TDT3!#71 S13R?>*\\?AD8P54<2H%8N&A&&FQ]?4QH*W 9*.1H%9Z2:>D.B)29D)E5&IV<2%"'#Q!@#>QN M?TG6C5C/"O\ /]G^#K4;,\0U"CCRX?8?/_B^OJQ_RM?D!1?(CX7=2;F%=DJ[ M/[8PU/L?=51EJN&NJZ[+8&EIQ!FX:Z".%*S&;AQ4]/64S%$DBCF\$H$T,H]B M2!M24K4CSZ ^X1>%_=>Z][]U[KWOW7 MNO>_=>Z][]U[IWP63;$9.GK 3X@WBJ5']NFD($HL/U%.&4?ZI1[T144ZV#0@ M]#^K*ZJZ,&1U#*RFZLK"ZL".""#[8Z?ZY>_=>Z][]U[KWOW7NHU;514-)45D MQM'3Q/*W-BVD7"#_ &IVL!_B??N.!UHF@)Z+O55,M94SU4QO+42O,Y_&IV+$ M#^BK>P'X'M0!04Z8XY/6#W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7 MO?NO=:27_"H[YAQ1;UVS\2L%E9);;1VYNK>-%2U=*4_P O7'[R;QP1Q:"JRS$"X(;7&(99]/Z(T@I(EC#<6 )'U/NPKD, M#\NK"BY 'Y=/6W9X(ZY*XSZ**C\H,=5Y%$T5,9ZR3QV8WBIHU,\J@D/,PCY+ M^[U)[1U3Q%R:4 XU_;\N'G\\==Y&:2DH*BNJI&&5S$XD:.4^2H:"4/4R232$ MNIDJ7D]6G3HT"U@+>W"H"8&>'28R"-@S"CFM1T9?JN(T^W*6>G*JP@IJEM#6 M)DD"ZHHD!8 B(!F^ER;_ -3[ >\FMV].%2/EU*'+Q5;%*<::C]IZ-WM7+"DQ ME/5(5:J)T0 MXVC\J:8U9"R-?QO+>Z$L 3^D^P9?0$R,*'32I\Z_ZL=#NPN/ M#AJ/CSCA3T_;G_4>K N@,%%DEIJW-3D4ZZIB[R2>.2>70M.FB1E4SK)(=&IM M"*-5N![C[>I@LLD42TJ:8\J-'E;CG[:TIU<+UY2["V[@'R.=R& M.QD96*E:LJI(CJ+-+*K4X<*TLI5-8T*Y54=B "& 7$,\\K$1L1P%!PZ$5U<- M$U-8'F1TMU[TZ.VC4F/([QVICGHXHJ]EJ,[AHIHZ6&)7JII4-;Y:>M:DJ%U* MZAV1AI4DA2OCV6_D"NEF[ F@('^#'\QT5S[A -<;72!Z9!8"GVU. .A'P'R\ MZ#R58V*A[1VQ45,[I'2S_?PI#-&[1Z,C"46W\.,E0@T:M1L0MPA(5/M5_'%6 M2UE5?72<@JXECC1H2&8U4+.SZ&LP<);_4CV5R%XF1W%57\O+SZ,X$$R/&HI(PX M>5:GA\Z#H0J7?^/#4KQUE*TIDMJCD\K-Y!&^J9I'-/-&SW\=FMH/=QN,: M:.6-:4@RP"9W>'68F M@FB6)Y:R:MCG2^A9'4I;U77V(XI/%MPA(*Z?+TX4/K4'H+3PF*Y,BJ0VKS]> M-1F@ IYT'0929*DBJZ[[:IL:6>8J)IK,(5;R1,/*3#-(!HC:VK5I)4!02"9' MA$L@C:FDD9_:./$\.CO1*8HS(N"!D>OG\QZ] 'V]\O\ IOHJFCJ>P-Z8ZAJL MA&QI<4)YZ_-NRE28X<'2RRU=?-+"[NBHG[B E@$0O[.+1)KIB+:/7_$2<#[3 M_JKTFEA6!$DN7$4?X2U 6_TN"?\ -QZ(;NS^>)T=MC)_P[;^V=P[L1:N&.)Y M4I-O5,Q;4E8135"3UQCHR?VB(Y#*OI(4 D"2WV?RR"(&1P4"J[$>U$NT749_4:.OH:C_ #@]4M[BVF;]"5]-:$TK M2HI]O0H;5^;_ %9VWF8:"DQ.:V]Y,=-6UU1FL+6XO'4:44*UE=''5GS%GI(7 M9"C\AHY#(8]#,0)O.QWH+2QI&4K0*G'S\Z^?0WV^XB,00ROXG$:@=>JE^PS)D*"&"J*_EG7,O86=IJB*?'TVXJ6$Q9A?T MU%()ZN&ODI=!=#-45%"PC(*%AJ9D)O(9QY&426$9$E?#<@IZ&@I^5#\_M\NL M>^?CIW&9&72)%%']14ZJ?,D?+S/SZ(309$I5UQAG"4)DF I*L3S0!)RE+)%5 M5E1K*3X^)RZRQ,%])XTD>Y1B!5:')(R:X/4.NY+L1A*D '_*?,@=8JY9!@3=' .JVKV^.VITT\ATG)ZR2"%2U,<7DX SPM^[I]84 ^,J*N=F\-4FS1-&BR-47.;- MPR1LOPE:8]1T%=V4DL'_ +1#_P 9/G_('[&'6T/[7]$?7O?NO=>]^Z]U[W[K MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T,VRJK?S3 ?400$:% M/^$DQ!'_ 3W=!FO3;G@.@G]N]-]>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N MO=>]^Z]TS[ASV*VM@)'8VZ*F?; M^V*RJ-?4;5V;C5H\%L[;35(DE4)C=N8>D:816@:MDD:-0)"?86>4W5P7(Q4T M'V=#^"%+2VCA5@:"E?GBO[?\PZ*#7?[C*)<6JQOD*QHZK(R*0TE/$BMX*)F4 MDQJA+/(I'J>W^H!]W 5R&X*. _S=7)IA03)Y_9_FX]1%T4U&:J5 &E_R:@CY M]3<&IJ@/J(H I34>-9-@3@!K0< .G''1U%=XA*L85X4$$5D" MK1&00B&.!"+-55!Y! +AF;D$D[84;[//JH.I:L.T^7RZF[^D\6X(<1--)53X MRFQ\-2\,JO%%534=/+5)(8D,8:8R13A7[?LZ1.0\R+W$\ M#3RKZ^7#HRO6H1<=2TD<@5%6 !$96YN25G3TD21P@ WL;VM_3W'VXU:34W$U MZE/90([=$7A0 #Y_/Y@=&CV+IR.3$XTD=B"IKPQ3_!T8V;Y#46UL;3[?V=3U>8R] M7:FBJ\7HEB1PDAF37)&ZQM&;%G:.46N LG*$.6W+TES(]S?TCA&3KXGT_+\Q M^7$"F7F7Z>);>Q4RW)% 4H1P/R_R'[#PZ$/:O6'RY[EHZ=XZ+(T6*J::FJ#) MG*K,8N@@HI/%!!459BCGRS)X;ZY8TCD8<@1+HC!F+[ES;'*QJ&E'\ !^>*]O M^&GSZ+GLN;-T19+B01Q,,:B1CRX58D<23]PD*CZV.OGW-D8XBF?S/13M]?';N_KB"::NVUN"@H:*I:*JJJ*1YH'2 MGD=XLI3P8MJES2!UC61C>S:2 >=)C#ONW7#!"RAV& PI^53Y]%T_*V]6B%T5 MC&#Q1C]NJBDFGK^70Q="]T=R]>9'%Y# [FS65:*:/^*8;<8FR^$R#TDL<$:5 M5-2B*L:D99M)F1$EBE 902#[(=ZL-INHY1-#&K'@\9HPKZ5P3\CT+>7+_>+- MD03R-Y.LM2*X%10:J4P3UL'=9=R5.Z]K;:R<=-48FLJ*G%RY;'5:2I!1UE;/ M3WA^[C2.DR%&\-W54#-XBK/H8:?<*7EJ+:>6($.JG#>H^?IU,5JZ746M@0^G M-?6E?Y_ZAU:/L;(5-7@J&0PU)C\3S4JH68BD*PN(U13(]4R(-&@E2_CUEM3 M^SJRE=K="BL12H ]/,?/AD>=.@CN,<0N'HP!- U?4^?R_P!GTZ+YV5N+)XQ\ MKD#"[$L8Y5"+$CIXG#/'RLL?VJ/I-A8W&JP/L/BXE,LI8\2:_P"3_5\NA%;P M0B&*,>@(S7JA3Y*=9]H=T;@S$E'BZ>HIH-5&E7DJS6]2(EU1RM!14U/%'$ Q M2G#@K($8O?4NH8[)N5OM_A2.S,_$A5_S_P S^SHCWO:YMQ4H'0(.&HFE?D/\ M'\^BS[:^&6U:6OJINU-V/14]/X9)X\/_ ^)HZ>H4"%8)JFK5E=)/(\A6-S= MKR:RA?V)'YIO)$46=O0^IJ?Y4_U>709CY/L58M>W!8>@H,?(^7^JM>/1VNJ_ MB#\7T:EK5KMQ5]&&II,4L>\:P_9U<\RQI'+4T$M(\%372C0( T<7KT'.E?#E\?E/+%5K41&%80=+(R@HR$W *Y-RNXW,GB\> M*D8->-1P/2QK9E,:_3DQ@9(K7CY9K\Z]%U[&V'W=TVE5N?:FXGW)@\#/1TDE M!5/Y(VV\_BB99HX!(9Y7J/074?M?L_(^ M>>EZ2W"%/IV+#^!JUH/EZ_SZ)GDM\T_8$&3R])25.%FR)K)\CBZI 9L'G:2% MXJJDEC2F9HTD\:U/E!TMH4F9.0])@=?Q @4 R.! KY_SI3Y]09[CZEFAE0 H M0)E6 MZ7C&AQ;Z>Y2TD<%X>0S_ )>H:5R3W$M7-3C_ "8K]G3CE#+Y\;7QHW@CF2EB MFCF27[-:"0RP4A>-8RWV$;:(9#&#+$1?U @/$$ \*=78UH3PX?D.'^;KAF:2 M:BK\5N/'%(5RN/JLKH&B2%\A30?<9" 4X4@1UE/+Y/&WI!=DL ./*^H*M14^ MN>F)(C&4E45!&K'KYC\QUL(_\)S_ )/U.UOD=NGH'(91*3$]F8_8_:6U#425 M%164N_OCOFVS-7C\0S52Q12[UZ W/NS 3,RZI(J3'P$E4 ]K["J,\9(XZ@/F M./\ +_/T2[G")8EG4DT4H?L/#]AI^0'IU]%=6# ,I!5@&4CZ$$7!'^!'L]Z" M'7?OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z5&T,A]AFJ=6:T M-:#1R_TU2D&!OZ7$ZJ+_ (!/NKBHZLIH1T.'MGI[KWOW7NO>_=>Z G=5=]_F MZQP;QT[?9P_D:*047IAC4GI.^[=:Z][]U[KWOW7NO>_=> MZ][]U[KWOW7NO>_=>Z][]U[JEK^?7\R:3X?_ ,N_MZIQN46B[)[SHY/C_P!4 MTU/53TV3_O)O_'5IW3N2AGHI!64#["ZTHIDD6>6( M3SD3S)!'&?%&SB14D9;K&"VE>264 K;BWMT1Z:L =/D2>)\\=4\4L?#+ .>X M@>0K7)\O3KC(K53TL0C)>3TA4,DK:9758(S"%+>[K M3=Y7RK6OV'A^?0K;=HZ?%1QS5;((:6"NS-5IJ([S/C3]M04S: )4$M7):(AD M:91*P.AU][ ^6?EUMW 5B*Z!T&]9(]17Y.HJ:]9%J\E(T=#22!15!2^BLJ J M>.FA":;*;F[:18<^[2L=/:*&G$^7_%=(+7ND8NYH3\ \_M^6.C/]?1Q4U+0U M$,;+IA/FL_E22212A?4MPP8 Z#;@6MP+^P)?L7F8-PU=2IMM$M8V HU,T]?7 MH=]D87=F^9,GMG;<3"2>IH375P\@BH:6KJ1')-(T>J>9(T)M#$&:1[>FP)!+ M?RVUFL=Q]W+ZFUM,,676_ $\3YF@\AQ/5J'0NS M-E](PTKXC'T>3S?VTJ9"NS:4,F3@EIWCJC5BKJHVBAH+2>1:= K6!#%N3[ 6 MXW<^Y,WBR4BJ"$6M/V>9^?4L;-M=MM4?A6ZDO2C.WQ&GS\AZ#H2^P?YGW5_1 MN0R^WJ.:KW-O6-:F"EVCC8:&>3'5U4DA2GR^4R4U)B<"!4*A=)&+:)!) K"Q M]K-KY(W/=D2X4".S.3+)4 C'P@5+?Z@>BSF'GGECEZ5K*ZN'FW11_N- 6!X MA78D)&3Z,:T-0#T%]%_.7[7SD51_ L7U)M8G.TZ1QY+![Y[9R^,P5;1Y&L>2 MNK-N4N"H*&<4PF5((8C/HH9H]:J]V%4'(44"K6\EE(&="@"M?4@G_8ZCV7W) M>ZD(M]KBB6O:)9&9M/'(4(#^7F/F.A!V?\TN[.Y=R_PC96(^.?R K;?<4NV> MJMP9C8'9.7I:+$G/96DV3@.SX9J#>LD'WC4<$=/4J,K7SI'2B6:30J>?E6U3 MM%S*C@Y\158#[=-"/7%>C6QYRO9=+FPC>,Y_2=E8BE2RZJJ0*TJ2!D"O2Q3< M_3_:>T:/LO;,5)34B^>FJZK#_P"0YK!YN I'5[;WECB/OL?G8*F2HBG^[$3" M>*1=08:"%K_:+B R0S1%6&1Z,.((\B"*$=#K;]WLKZ!+B&<,AP3P*G-5;T(- M01ZUZ5/2O:,\]?C,,*B5J1\Q-%3*(E%(U-#%#3NRL%AI'J(O$G[B$NP8EOU: MB!]WL6C5Y2H#@ G_ "?/(Z&.U7D;GPQPJ:'UH/V=;''0^9FFVK3#(*OGEH*> MHCB=HF#+5*L\NI+>*U=%"&-P-%OR"/:?9;D0QRQOP.5!X9R?V]$N_P!KXMPK M)6@(J1\L?RKT&'9E/'_$*RFE\#T\<\A0-&)5E@8^9OVR\<*-J%AS8 WXY4$A MC!NV3RUG/Y_YNC:)RMJKBNHJ//TZK*^0V\J?!8S,4VV8XLCET6*%Z$1R4N%V M_3Y":.AI,]NVI@TOBL6M6TA3Q@RU'A<1*UG*R%M>S+,5::JQ\3II4^8 \JXZ M)+_=6A5XT >X;X5J<>533-,_ZAU0IW'4Y_=FV-_;\V9USF>TMJ=15\59W)W= MO)*RJV1C9ZOD1&@(4*#C@2<$D=% M9PFV^_:KXW;N^4G7W5B5_3W3];M;;/;._<5NFHV!N#9.2[6W1F\'L"NJ=LX7 M=V'W=N?9U3D,/)AX=TT]%)B),O++0#]^EJ!&-AR_;RPM/):*\!XEAJ%?,=U: M>1_G7J-6YJOX[J*V@W&1+P A0K%&HAPV=\L_E)\1\KM'! M[FQW9N)FW9CL5N6FP'==;65&TMU8[-P452V\>LNRJ>MIJROAR./D@CI(U:LH MY'D.2 2D@R6 X U&DHZTO &1?"TL4L,99HW/N"-WV2]V6[:TOHZ-Q4C@P\C M^8SZT()X]9#[9NFV;Y:1;IMTNJW+4()H58<5(&*@X-,:@:<#T"/9NPXL5ONI MKZ6FFHVW:\].4JI$>>EJGI[*#&S21PQZ@!%&HE*AW4,W "9';Z<0T[8R"!_J MS_J'5W31=>(AR^":_P"K\NJ#?GOAQ@\Y)A\D(0]"$$.J([QK42TARB-&?145%/5$K'HOID:6)9/R?U!=-_ M;,BGT-*T_9TIB=G0EOBIJ^WI:T.,J*S9I@A1DDM+E<%4%C'IK,::JGK:$1'T M^>2)VA8$$$(+GZ'VTBFA(&*Y'^3J^@/&V,Y8=/'QI[8K_C1\G^@.YJ"KIZ== MA]H;)W=DY34-14E5M.HSE-0;NP.2J32U?BP>9VM55M)5R+!(/LZMBH:P'M9 MQ$@=13R_EP_9_L]%EQ$GAL@X>OI7'\B:_GU]>OK3,Q;BZZV)G8!,L67VAMVO M5*B6.>=#4XFDE>.>>']J>5'8AG3TN1<<$>Q$N57[.@/(I61U/$$CI;^[=4Z] M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KM6*D,I*LI#*0;$$&X((^A M!]^Z]T8?%5HR.-HZT?6>!&>WT$H&B91;\+*K#_8>V"*$CI\&H!ZNM]022?;_3'77OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z^=K_PJ M1^6>%[Q^<.SOCSM/*Q9#;WQ8V//M_<,^/K/NH#VMV/546X=Y8^50YI*:;;NW M<3@Z5]"M,M:9XY?\VJJ3[@VJ15IVJ*G[>A3LT 2%F:NM_0>7Y_M_9UK2U5:U M1324\0&2=_%8*2%588[VNQ]H@HU4_%_@IT>, MS:*#X1P^?H/G_F^WIJ":0 0"5)])M^Y+ZO61I0@+)S^0 MCR?=BV37@?Y<.J MJA 'K_A/_%]/.,3Q5*R$R>5S&3(E@U-13G5+51W]23SJ56*X&E6N+DCW8 TX M4/6P!4T-?]5?Y_RZ4^8K'QVSJFI4%9]RY()2>1BR4V'Q"/!3O 1*\4E:UB6 M7211W'U]OQQU;Y XZ2WHVT*JC@,>=37))//T]@*^!\3!KGCZUZEC;U/T:D\*#JP3H'"0[8P57D: M^CS3U.39JJ"KQ4,\AIE:,FE1WA$GDG5BI8NI7Z<#D@!;],]S=11HZ>&O:0U. M/G^7V=29RK:"RM&DF1M;G6"M< C%?G]O39\FNU-R8W8V6I,+E)H,:E04D9J8ESLY188&.B:.5EE(C\;%E_+6V6\EY%-<1UAC-0H\S_A MH/3[1Y]- ]#GRZ WXG=*]6;@Q79([AS M. Q79>Z-K;AQ^PLUVIDJC";-QV?SN(K*6DRG\;RM(N#R6]7K9HY8ZJLK0M.@ M9PI?UK(4V_103JBPDVP%%,8!I3U4&H \@!3J)=MY4DN+:62:]5=Q2:9WK'FVQ@6 MX1+NW:8]H=Y -(.""A(.:XQ4'A3I'N'M]N=U+:R265RD*9>-8]6JAK574FOS MH2" .ML38GPK^.^[OY9/5/4WR73:S_)O9NS=Y[IINRNKL>^;W_U)OC>&\]U; MVQ^$BWET]@LSC,EAL+5Y1:2KI8)Y\(L<][VZ>1I'N8_J?(QF MORHU 0 2*YZ$&Q75E(KQF\BDC X*0=+$8:-@:E"<,",5'4E':KVR MFAN(5(+H*KD-I#96=*4632=2D$\"*XIT]].2)%VOM.CIGD2.7(4K-$"/(90' M-3Y(?&DCO$D5M12Y/*@VM[ V\J&VZX=A5@M*_+_9Z&FQ!OWA H.#FGV#S^>. MMJ[H[&UIVQCXI"6=8V6Z!G\<7JE6.^HNJE%'!%QR/P0 /M]J[)@4-?M_XJO0 MAW:6,.!BM!CY^OSZ;^P:&6'*0"4#QDR0!W;0PU D6N&]0E-KDZ@I_I[0-&89 MY:@U#>?[>MK5H R$9&*=$)[_ /CU+VCU]F-H;=I]Q;868[DW'OO?NQ*#%Y3> MF:R\L,6&V[M"N@RFXML5V.V8,"M7+79/'/6Y=HS%CZ:&.*KJ9&DO:MT@-NKB MIT#4 @J#Z!J'%!FN:4I3S 3G@5+N3ZB2@D 0#5H( '3P>!K=H4.]\%E*7,46ZMUP8#-R5E/2 M97(4*QY)JD+7I'.2VJ3Q)[&>V\U06\9MI+>85XNH!U$^@K7H![WR#>7NZ2;K M:W5LUN00D98@JOD":4(_P]4"4W\N3=FZZC:O^E?Y+]7;+Z]V/A-N;5I:[=_< MF8[)EV7UGE]Q[FW9D=O=2[!QN)DGIJ&FRV;R^;H\2?X-03Y7)33J_GJYI7%D M?-:W$$2>/ZS4U,ITPPL!0FKZ6E('"BA>%2:=)SX._#NLZ M]IZ+=ZQ[EV[5[AH**/,XS%8J@W)M+>3TE,\*;DQ](F9P^8V;GC2*K34Y:JI# M*6\8@?R*P YCW1=T'>P95)T' 917X?1@#P- ?MQU)/+NWG88Y(+< >(!XRCX M&<"FL Y4D<0*BOIT>#N'8,D.VGDIZ2J6JIIXJJ"7)X)L;6&2#U!8)!*T43-% M>X\LC$F]_P"H"4A;E-3U0U'[?]GH61 R(^!JI44-?R\NM=C^8+BIZJLR-/F: M*";[FFHZVAF: 03TF06)RU *R=D,:2RQ,9))2%=>%8GU";.061+8A&(8$^?$ M5P>H5]S;9M8>5!I=!IQYCR/#C\_+JE"@$DM?_ X*E9ZK2JK%&KO3+4RD1-2R MZ888E-6;+$\=U9K:2XY,RG3H66AH?V_YZCK'A0WBO;<6 _('TX#!/"G\^A%V M]Y&IE\2:':&8P2-SX7A83W(9-5YGC*.NB_YX/M._$#T/2Z&H08H?G_JX]"UL M?)+'20K+J7'R5%;-&XG1&HJR5&,DIF\ET M8)1FKY_SZ"_L[#,M+C*E2.HJHH MF_013:5-E ]WB_T4+4.*,/R/2&Z45C8?V9)C;_;9%?LSU]//^1=\AYODI_+% M^-F\LIFJ;,;HVG@\MU1NY8ZO[NMQV9ZTS%7M>FI\N"J2TU?D-OT=#D5C<7^V MK864LC(S".V?7"C5\N@1N[A3CQ_GU;I[?Z0=>]^Z]U[W[KW7O?N MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW0M[ K/+CZJB8W:DJ!(@)^D52I( '^$ ML;D_\&]M.,UZ=0X(Z7ONG5^D5ONK\&'2G!]594QH1_S:AO.Q_P!A(B?[?W=! MGJCG%.@<]N]-=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T"_R.[OV MO\:>@>Y_D'O1)9MK]+]9;U[+S%%3R)%696FV?@*[-KA,ZNVE68^0ZO&AD=$%:DTQGKX\O9_:>ZNZ^RNR^Y^PJ_^*[_[2WQN M3>^Y:Z&,K!+F]W9:MS&<>E#RRR04T555""FB8N4AL-5U]1#(2S\:$]Q'^#H< M6H1(JTX=H_P&G^#I*HB/5 )&6%$(S4O-)&RRU;HM**>)4TC1Y)"B:-11%#?1 M39K214DX(I3^?'T_V>E+,&<*JX7B3_$1IIC_ %"@ZY#]V265H4>/THB _KDN M;@%;@*[@EPI'ZB!;W0UU$DGIRAR>*_ZJ]3:.FFJ)$IT.J67R2*L:*SS3:3%% M#Q:WEETA0; K_A[>4X^7^KSZ;;AQ-?\O^;J+G9H\H[0PH?!2P)CA4F;P2*M M(&-0P>&[!JBH+I&R^GQ+^;W]JHV50*\>BVXC,[8X"HJ<<./S^0ZQXW%S55=0 M:Y)-46F&H,RLS/9BTGB5="L06U@UQO$D(4E0!6O MR 'E0?ZO/JQ?'?'7K/,8ML+1[3VXU,RBFFEKMLXK)4#RS!+KDL;4P"*NII6D MM+<,?]38D'V%GW.]#AC<-0&HTD@_+(/ET?+M5FL962TC*^C*I!^T$4/2?J_@ MQLW;)6:EV1F,9CJ)97IJS9$,>[MKH'<^6&KVGD*6ORM'!"TA:&GEA>"G(+0R M7L65)O-]*U9)E8UR7P?]Z! J?Y]%DFT[<*+!;(J_PCA3[""*>GITH>L_C?\ M'#8\]35QYNJIIJBM:LC2@PV.VO+'6OCFHJFMDA,+QT\KTDK?NFF1HY)G/U*."- M6BKI5IV\:3K) U;D),328J@F9Y'GC@I5IW8ECJ*EO>WN1&*GCP!Z:^GD<,92 M@S7X1_DK4^AKT5_Y@[\K-S8';]%E*:@HMO;2JJJLI*:/SUCY&ODQU12O*))R MTC46$CGE,6E= G<:0$%O9-<7E9XHK?SP2/M%.C*PVHQQ37,N7/ $#R\^&.JT MOCCM^FK^[R@9^-<_MIT$>.H]&V;5 U*P(IY4\QZT)Z!G?GQWI,O6RU$46.IR7E:.DDHJG+8R42R+)/$U+ M/)25E+#,&*RTPF-$\6D&"4JJ(.[?AKP72&RJP:9.M,+C")TF:HSD\>X MY)960I/4QK6YC+AU93('5H +L0.+CV17$K3'#LH\Z'_BNE::HP:SZF'HM/RX M?Y>AP@V32X2DA@Q<214T21EC%$E.FE2[+%'3T[+!^V#QS>WU 'M&P9 -)-/7 MI1%&9B2_Q&N#Y_[%?ET ';6$IJ_'UM'4QH3('$4I15TNUM7E55TNLBCEC=@1 MQP>61I,@U?+H[M[210"/L'I_Q76JK_,<'\"J\%3U"-1K6X_.T?\ $8_)5?P^ MMQE5 D$U72 Q?>T%? C4[DMJAUJZW/!F+D-@QO,X#*5'R-?V9_;U$GNM$4CV MR3@I#C5QH13B,8/#Y<>J'::OKZN&R^*\M0:$2QO+422H&61XR78$'5(?R#9UCVZF\A7IN-:D:3YT_ METO=NP1K25<2.AI:-:LJ\JE)5Q.@#$YO;=34TFB#2L>NFR. M'K::1&93(!*1F)0&22(DEF6H_TRGA]A!!_,];M MO_"1#NU<_P#'?Y6?'RKGJFK^M.W-I=J8Z"1*=:./ =N;3DVZT=(RJM5)419S MJBJ>H#E@@J(K6U$>S^R8%74>O^K_ "= _>(R&@E)XBGY#A^TUZV^_:[HEZ][ M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NEEL:J\&;$!/IK*::* MWXUQ@5"G_7"Q,/\ 8^Z.,5ZNAH>AF]M=.]!3V#4ZJV@I >(:9YR!^&J)-'/X MOII^/]?_ !]N(.)Z:?B!T'OMSJG7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K MW7O?NO=:R_\ PJC^13]5?R]L!TMBZQH-P?)CM?";9EABJW@F?9'7L7]^]U3F M!)HONZ;^+T>&I&5A(JO6HP76$8)+MM* >1/^#HTVN/5-(],JN/M/^Q4#Y]?. M-@B@KXA8 * C3N-1 ').CZ\7Y/]0?96%U58GCY_+_ &>A.3HTQC@N/]M_ ML?X>GNCHYJUJ"AB>")II))!/-*(HP/49ZF>2[.M/!'$SFP)TW^I(]MD@%BWP M_P"#I]5U")%(U5)_V>G^)*)U6FEUQ4Z,K*]V$E/11J6EM%2K,/3'220A5J3W$$#[:'_ =*GIG9)WE6+CY'6/7(D132 MKI'%&H9(V8C44C72"1R;$^RK=MQ^C>@6HIC[?/H[Y>VKZ^,DGSI2E:4X#I6[ MNVF-K[BKL.DRR4U-4 457>9(9(H(XXYHPDK2>+QU*D!2Q8BQM=B A@O?J8A+ M3CQ'^SY]&%[M9L;AX2P !JISP'E^1\NC#=75'@K<+$6C0K51AP0"H\($HUE@ M;#4> 2>1S^/97>+42-3R_P /0\Y?^*S6F=0X_+J\_P".F51_L*FC>2 MY!HPUHQ+*W^IBDE 74/2S W"_2)]UC(UQ\>/61FR6U8E<>8 _EY]7'=15L.3 MCG:5(RQGD6,*%T5/AI)/+50+(GC;2ZDC7=6%])'T +E084_'7HSN82FF@Q3- M?+/1NJ2**;PR4M*IDTTH(21TCCB2-%%RK+Z0JC5?DCCDI%3MZHR,SQR4U/(ZN 9V@36H159M1E4R+E=/''3L"P"1&QQQ7R^SSSU6/\ +# 5N;^TQV/_ 'JRIB2D$--&8EH) M&).5*26)>DAU1JKV4L+<"W*"RN:7"-*PTC.?\'0EE2/Z9XHQ3400>B3]7T== MA>Q*#&11@SQ5*K)XU&F84P /W#Z SLU2QL 06*WM];BNY*FU>0\"M1T7;>WA M7?A@XH:D?+_9ZV+^@*_,)'04YH*9<%#B::67)U-6%K),G,CAX*>A2)Q%%"B* M67J3TO=XUGDRTP:) M00T + Z@(QFNLV?+*%<1J8HF*J[1QQ,RQV!C ( (]/]7\^B@]BNTL%6=5F]5B1I=BH8^F MY'J(4<_@#_'V29UL:X_U?GT/K:!=-",'K5=_F\4*');,IX)2M7E)-Q%(8P1% M(DJX^2K=6)+-4:X &!N3KOZ5^LO>WTBI]4Q/:%2OVYX]0=[R0%5VN"/^T)DT MC_>:_GU2INS!?[@UO!)#-4M0K21JNH-Y=(E0D7;69-5N?H;_ %^DBV7SST#]0 *#@&_U'I?;>J*G;>:D9P)FQT$E!5T MTJK)+/#CJ*"AR,3*W!JDA5&CDL"'@0CVU(M5X4\^M1'0P/2#W+0ICY,/4I42 MU#QR5>%SK1HVEZNMP4*T%;1SD!IJ7.862$V* K+3, 6N&+0(752OD:?8:_D> M/7GH)(:$U!*L<^:XIZU%/V=;"'_"5+N.+K[^87OKJJOG--C?D+T/NG%XB.)) MY15[WZMS.#W_ (NF?PDQ4D(V;/N&;7,JAK!%:[6)MMTNI@I;.G]O_%4H>@YN M\9:W,@44# U'^KU:H_V.OHF^SGH,=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O? MNO=>]^Z]U[W[KW3EAZC[3*X^HO815D!?\?MF15D%_P 7C8^]-\)ZV,$=&&]L M=/\ 0';QG\VX*T W6$00+_AH@C+CC^DK-[>3X>F7^(])CW;JO7O?NO=>]^Z] MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=?.#_P"%0OR-W%VO_,>DZH8Z]JBFGW;V3B,?V!O'0/=5R1GY>M/\ 4>GB M=(X28%2*68DQ:I M&XT)(&"7(T_6]O80YI0F(RJJ9I"Y8RL G&@45J33_+Z=#;FC;'^GA555;<,TA(%2S4HN>&2>'F>@]ZKA\^ MNKFE2(43(HB](GCJ!=#95-XU41\7.EN/8BO6TJ%7-?/RIQZ:Y90.5DD/P&E/ M0_M_9Z]6_?'S;4[B2,2K#31PJ[@SL[2$>".5 M249#9M$E@$" M\FE?E\O\G3'O:*F2@F:-H55J:>5(;JL85%D(#A/HR2!E5C^H7(^H7VGW*%%4 MA* $7)Q92..K5Q$N@O4G[:-RX(87#CZ@L!BAI4"EJ*,NQ59$EFE"RS.00/*LRRCZWX-R M?Z%^W+K)%.X"GY]6W0Z*M)PKY'R'^"AZ6'9T;08\5:0K'-$AO$4",HU^EY&0 M%9/R+VM^/Q[0[U'HGBDI0E:,*4Q7!^?5MJ974H6)!;!_+A\N@6I-S9G!4$&2 MFI4K:=8(:B6)4,Y:FG(!M"GU(TVO] 2?ZV),Y:(*_A53]N.C86L4[-%XA4UH M#PH1Z="[LOL[86ZJ1#ALM1&>F>1:ZBCT2ST\Y;QLD]."6IV'(4E5)^BM[-+* MXLI$&A@I&6'V_+U^?1/?;9N=J298F,9^%_(^?Y_ZJ]#5B)L<8U*K AD)75<$ M&,L--R68J@!LS&P+\7 M<368A !TBO#\C_J_;T&KDS-45)IY=3YX8Y-91H[. M)"I,2^2-C<,ZRB157]ODK]+6-[\>S30KU( H>&/]GTZ;C=D*A@:BE:1_:.Z*BO;4$3Z:D8I(L5R>954O:P %@ ?97N$:F,D*/]7_ !70 MIV4,9 I)TCS\_P _LX=$B[$C$44\8D4,H=4T6\:%@4G6_.L,;6()-@0/J?81 MD0K2O^Q_Q74HVHU)JICY_P NM;7^9[M!\GEMFYBHU+08*6L(@IT666HDS533 M1*55X]""GG="]G9R'Y4 W]C[DJ_6+ZBWSXDF ?(:02?VCAU$7NI8"=MNN"U% MB\A3.LT_D>J6N_,=4X;&8$42JHFKY4I4T,I2&@Q]3+65*K(07@C =@Y-E8$< M6L)/Y>=)[N;!PN:>I(H.H*YPB>WLK4(14R8'R56J:<:4_GT67 5,L<=-%&2 MN5I'@1_47U2T]Y"XX#ZT%_Z>QZQ).>-.HG7(X'CBO$_/H2] _S&_AIV5/70 M8;$8+Y";+P6X\A45/VM%1;0[,J:CJ_=]35U321!*#'[F)"P(6W MLRM/TY8)-5=0I_L_F!_AZ(;M/&@N(OQ+4@?M%/G0G_!U];_V(N@?U[W[KW7O M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T.O\ &?\ :O\ F&_X MS]4_Y*_WW'MBA].GM7^"O0/9N4S9C*2'^U7U0%_KI69T2_)YTJ/;R_".FFXG MIK][ZUU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UQ=TB1Y972..-&>21V"( MB("SN[L0JHJBY)X ]^Z]U\>C^83\BJ;Y2?-'Y4?(#$9.?*[?[;[OW_FME9"? MRB2IZQH)(_P!7 M^ST;J.Q:G _U?ZOV]"-"B4[XFFK)8D>6>&6H>-)/VJ!*U99H%1@B1U'VRLK7 MOXK?4V('HHQ4FG_%])[A](%#1CP^?K^T=8UC*8ZNI5T2R-_$*M)/3(E93P/5 MT31A+ Q34YD)TMI*^34+FUEH*U'J.D,7&AH1)DJ#*8^HWWD:N)Z>6.J@E@BV]E>OUJA*D/'REQ<1-:!Q+=2:2I,6C_C2AO\ !U..YPJ([2+4KQ>*7'I\+%?E MQ-?RZKXV!5M3;FRM&0%CFR,DFBXMX]8''DY_;:]OZ'V/KFGTJ..(4= 78I/# MW&XB(HKN6_G\^K,ND9M5712K*+L\9E@LH,I"*C*%U,28U8$.0"@)/U ]QYNV M/$!X5(^761/+#:D3N^W[?]CJ]CH*M7QXL33+X?%"KQEXV_;3QQU#(#RDM.)& M-F"EI#Q]#:/YR':0'@6ZDB11X)*_%IQ_FZM!Z^KJ>&AA66=%>G6,1N2P5@5+ MB206=X[W&@K<6'J)8CV[;&-2-9 IPZC_ 'J-C(2%PV3^WY<>EUE]_P!331K% M10D0M$(=:%)8E8>AB?$[JLJN"/U!F_%@;>_3[@XHENO;3)XC^7GT'X]LB[C* MW>#7_549QT6_LS>F9IL575F4R=/CX*:"5JA8FC 1 &D8,"^@Z534+AFTB_UN M/:=(YKJ0AR"Y\O\ /TJC$$ "QH?M/^3JK#I[*[?[)W5V'NO-M3Y(U&?J7HA5 M*M504M/!)%%CJ6AAF*^*84BB6?R*!(S'DD*/9C/;):)%$P%0,_:#<1W*J :]P]?7]O5ZGPG[ M7PVZ]K4E?63+'HI85CC9')DDY$IF5"2 &0K9;@#38?TIM5U';W4Z75%8&BX/ MGTSS'8F:TAELR>_/S _XOHQ',@1/\ GZ*;CD#Z7O[3VGA-#J=E!\@?\O2ZY=UF;0#2O5<'R%P6Y.I] MR5G:W77WT$$4D-1N_$T E,3*6*?Q:C6/60\CJ1-&+"QUKR6NE;;HS.&C&C4 M:CA7_9Z$6T;DUQ;BRO"'0$A=5. \L^GD>/ET-?0'RXI]Y4%')/E(971A#(LT MDH=9D:,%)4=)4IZF$RZ3=-!/ZB/H'EN+JS=$E9JUI5B:$>1'ETFW'8;:F?E3HD.P.K*=*DC@:$_P"3IFW)NZDF618)]9FNMT\;*BM& 2J@:3ZK<$@# MB_%S[]CW:MG9=/B+0 ?/.?/TZ)SO[/1:90?U"-B4=P&-V.A-2$ M@*68FW))%S;Z^PW=/K"@#AQZ',<>B(L?3[.J$?YG.\4V[MS U-!32UU;G<_! MBHTB\LE)C,=CIHLQGL[7>/\ ;2)5IJ:GC;C5+-P;+P,N1K7ZJ>5V;2L0+9XE MB"JJ/YD_(?/J'?=*Z%K:VI"U,KZ*G@JJ0S,?3@ /F>J"OD]V56;CSFU,5*(U MJ4PR"<00QI'#09&"=F+K71K0O0?,C_ "]8 MR>X&]>)+MM@/B*:F^2L"*_GT"&W3&3223T\0 S-.^AI"L1UU]*WA=;#QQLL1 M4<@L#P0![%KBI(&>@#&QP2*5;@/MZ%3;;*U7)1,LTKX7<67@JT*Q/1^&1JVJ M,I6SZV>#6UQ?2L9/%@2V2, =/*ZFJ\2K$'_#TI#3O39W+&I&-KY,OC*W*SXZ MJK6:*IDA$E9-CK.1"S5LE%40J0VA96 )LRDI7>F*&E1PZ?B-"Y8Y/E]G^?HN M]-0'';_BH\+3Y"L^]ER%/MFGAHDJOLB=,]@TG;?3_5/:M @CH> MS.MMC=@T48D641TN\]L8O<=.GE14231%D@-0 !M< >Q*AJJGU%>@+*NB21/1 MB/V'H2O=NJ=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW2Z^Y M/VOEN;_W%^VOS]/XQ]G;Z_ZGC_?6]M_]!=7K_P =Z1=0VNHG?CUS2MQ]/4[' MCZ\<^[C@.J'.>L/O?7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NJP?YS_> M&8^//\KSYF=C[HZWKW;F7CJY:&LQ6:[?R^)ZHHLIBJJ"GJ98\WBW MWF:FALJZJN*,%X@3(C-:T\Z_9P_GU\F9X0\:1Q#2@E6GC]&E M8XHH[_X%5B"VM8 A?96K!*D^0K^W_/T)54/A?6@-*?ZJ#J4FC4(EO&%!*LH. MI4N/46L?W)6YM];_ .MQ0DTU')/'_-]G2M=.H(M1C%.-/G\ST,FR<>9UJ5AC M$DD6.KC5*1KGTZ=* MV:.GRZ@DS?;524,/[DJ4O\-2JFHH\;40PDSPU<;IK'DL"[&X*F_M]& [:])) M2,GBEGABEJI99:@TIDHZAJ::,&3[/.50J)6C*DN)42G!4D@L#R 3[ M5%2U*#'G_J^?1>KZ6:GPUK^1_P!7^?J/L;.0[8W]CI:EI_X>\M115K01&2J2 MB9GBEGCA'ZY85E66PY:QX_'LHW>T-Q87"H1XBT9:XS]N!FG1_P M;C]#O%I) M)_9-5&(&=)Q4#Y5K^WJQ+8N+L2OJ404T<]4M6M&"%-.U1^].C,X(C6 M&I)T$_J7_ CV(0H_=ZJ6J0M*^M.'[1T&+*8+OFI10:BU/2O^8]6'=&5X&1Q[ MJ6AD-92:)$9A&H1R;2R(25C<*0P ;4W].#[CS>P1K6E21_A^74\\K7.D1LI( M8,#_ *O\O5X?269CIF@$3,QJ$#M$[6>%DT>0 V4@:82RRCBUP PY,&?3JJKY'=W96MHL MBE+/,:>=71HR66-X)E "E9+!XW%]0^H(Y-[^S[;X%B;Q#D#A\_S]>O2L$@JJ M5;A6G5:-#WMN?K>ER[[>PM1++DY5>GE@M6XV68Z%3[ZECJ8J^$P21%F$08.# M=3_9!Q+96VYNGBRA0,G-#3T!H1GY\.@^-SN;!)!%!JU<*9'RJ*U'Y=(OEPQ^QM1 /I4?LX]6$_% M#Y8T.QL/1EZTU<4UXLA3,C1Y+#UHUQ3TV0Q>D5%)(K6!0@/&RL5#H0S$6X[: MT5P7\$DT)!4X^VIP?^*^SH56.Y07EI#&TH!&-)^(&O!EXC_5\NC1_(_YC[RA MV#BJCHK:\=XR8Z:CK(<=3PHM-0TJ2Q M35^1J +B*&8@L@VVTN[C7NLS0V48.MEIK8T[42M14G))P%!/$CJ]S/?VT?A; M5;)+=NP"AS^FH_$[D4- , @DT' 'H%.DNT_YFG:F[,/CNP-H[ VGM-\C"N0 MSE+293;LU'0M(_EFQV(J<[GLAE:N-$%D(@C+,MVL39%NMIRW!&?W9?7TLEAI4LFK5^0UO7\Z=7$4NW(#*5E?J;^(/XWCE%0TY"3M,LYUA5T+=H*9HFD8L@J7'CAU1^F/6 M&&JP+'4K>U\")?Q>"YHZ_"1D_L\^C:VW!U"R&,4P&'^KS]#T:3HOY.4.[L=# M3Q5THR%*@6JI*J2.&>)AH5G4D21@R$DN+VMZE)!/M)+:26SCQ 3YCS^?1O# M%>GIY@ >ZH SU2Y\]=UX&FV3ELUFJ*HJCBL3N&AHC! GB6HR>F*BHZR: M4B*)*R9(PJJ\DKJMPO!]R!R;;3RW4$=NU"TJLU3B@%3_ "_XOJ(/<7<+2#;Y M[B\BU!(9$44\VPHSZFGSZUCZVNFRN[L@'G>JEHQ!12RSNI:2:G@\4SK(Y/BI MH798T4<(@]Y-6D0BL(B0!K)8 8P3C\R,]8/WDYN=UF&HL4HA8YJ0*'[ #@?+ M[>ES0M+#M^FR T,[[FQB>.0_YUXI9IE1U(N\&J.QOQ;^IM[O3N^5#TX"5A5O M,N!^=>AABII8V/CCG() MI*F.6E1I0OEHWBF5P%$B2@@$V(3E:AZ#M\OLZ4$*JA@#PH?VY_:/\/0%T&8I MHMS[:SM?%-6T>U]PX/,RT@9J>2?&T6;H:R6FAGA$DM M? GC5E5S [*P!(]^ MBD,;C':<$?[/'IF6)9AQH000:?9_AZ^M?_+NH9,9\"?AACY::KHC2?%[HR"/ M'U[.];C*=.M]NBEQ=7))/4O+4XRFT4[OK;6T9(X-O8KA-8HS\NH]NUTW4ZTI M1R.CD>W.D_7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T_>;_ M ''Z+K_Q8?#;\_\ 'S_<6^OZOS_K>Z^?Y_Y.K>7Y?Y>F'W;JO7O?NO=>]^Z] MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=:Y7_"I/>=5M?^5K686%H30]A_(GI;:6 M;I9O&!78G%U&XNQVIDD>.5J>45^P:>194'DB,>M>0/:>Y-(C\S3]O2_;E5K@ MZO)=0_(CKYMFI8J5(U0$_=3U32,2\NB2*&,1>3@-'>*ZC2I!)N3?V6$EF/\ MJ_U4Z$"]BYR:USZ?YCUDI@ZS>1OUV+MH&L^3@1W/! 6YTJ/K]3[:DTZ !P\J M]*8:B34W$9-/Y?[ Z-5UW!!MS;6K7;$6:>=O-$J8Z:MI:K[:DJ!^W M%-51TJ4[*P9G-;Z1Z;AD(%X')S]O2XGL8^@].D;)&]'G<;21^..2FS(C>K>& M5XV7'TQJY(\&Y/U^A]^TH^N-AVMVM7]G^7I]VEM_ M#N(FHZ'4N?/CY>1IT=;XU[QR5;E*RLVQ35LE'G:?'1YW"XVAJ\E6TE52K--D MZ\8RB2HJEHJ.CHY*BMD"&..E5I9"B781QS'MW9]/*M9H]31MZK]O^K/V=3#R M9OSU:>T91;3:%F2E2KUI7U_SBAZ$KM#%Q4':F)RF/TRT61HH:&2MHD,./K6+P/.DL24]2NEE8*2/S]26;8[?NV>&0G6O< ]JN&HW?O62IBJ35PQ83:=)D(Y:/$0L[JIR9C\T68KUE6S2< M4T3-HB4G4Y5L+6WCTQ+J]7/%C_SZ!^T^?2%6DE2G,8T(Y467@*P(^I ]VMKA5JI^'CCJLRU0+3[. MB^TW5>X MBPV,IK125X]*O;72VX9L_0TL&*AHC,#/+52%9=15PJ)$5#!$FO<-];?0?0^W MX=TA8J/%)>OGTV-OD5AV #U KT=+KKX/XK=V^CLEE\6Z\,R@ M8J!6M/,\<=6U=1=8;+Q.VJW%8#9>-PB1UD*3T8>,01M3!O&%,X>I::.UU4LQ M"_I]/))!!)=J[**N#@DC_57I1<7"2GC MD@B6-HU4E784TL:S #26)NRLHOQS;@EN+=X6(8 ,/+USY=+8+I)$734K@G_- MCTZ:*[+N\\4,+^/QJ[MJC:)H&0K$5(-[I(X%F!'UO]+D(O$=6(_+I>JKI)9: MD_G_ *J= YV_U/A^Y]L9';.?D,D56*LQ3K&DS0U,H\9".W,>I5!!4\!1IM8' MV_:W\L$RR)EZU!&.'^QTV6CC31I["*'RQY]4&=H=%=O?%W?E.F/R=7G]HUV3 M>DHZ]1:>FC;U4BM6H56-*HWC4.5TR:+\.2!_;7]CNUN/&@"W(!K3@?7&>''H MG)O+.X62SG:2!C0!N*GR4_(UZ,7A.TM\X3'83*9ZCR-5@LNU+21Y.!)RU//+ MA0&4:L@ M>8_U?ZOLZ6RW#LE"/ET5_P"0OPIW'\G_ (Z=M;KQO9G775V.ZJJIQCK'3WEYEMK,)L;02-=/&)DD #(OQ :@#J&?/@.. M;E0JJ ,4I]O M6+.V/XCNSMW/4DGC4TZ&NJC^PV7AG="DK;JCK7E),B!(WHI((Y(3?48UJUU: M+-I8WM9?:%22[+3&G_(?\W1M* L* G@ZM7\_3Y="+LTTFZ,/DJ&IFC@R.U-U M3S05,I9XJ6BW93L(Y6FG+E:>FR5*I1&&EQ*06O:^RJI1V\Q^6*]6'ZFH$BJ- MYYI7/[.H4N9J)Z+^!9"9*:N2CEHVU5+YE_ +K- MLQ$M)V)T5C,1TKO2%6E9,K#L[$4F,VQNFF-0\D[19G"T:Q3EF8_?TE18Z=/L M26L@DB3U H1T"MTMS#KH?:GHMZ][]U[KWOW7NO>_=>Z][]U[ MKWOW7NO>_=>Z][]U[KWOW7NG#4OVUK\_P_3;_:OXKKM_R3S[KY_G_DZW7'Y? MY>F_W;K77O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=:R'_ JTPLV; M_EW]910T-77M1?*;:&0T4TT<24O@ZG[F27(URR(VN@I:664.=480NK%K @HK MYM,(/S'^'HTVE=5RPI7L/7SIZEWGECFF8R.X65G).MPJ(MI#R&L!8'VA3\=* M\>CYA4I6G"O[/7I]VQ1R5N3@C6.-ZF24&%9'=*="L@"M*Z@-XH_U-]/H;?CW M4BK X45Z=0,H+D=Y/#HSU+4^>;9^)IDI4B62:\18^I8[V_/M:A/YTZ M*4 $K*KN\]H==U57V?N+HO+]CYRI5^N-X[]RNUL72XJJCCB%9 M53_<,[I0UE[J.0 MQ*R(K#4 0W'22*D8/"@-,U-,=(]OE@$PBEU NP*L#0!@&%6R. 8YJ/D:TZ5W MR"W+T1FMH[;W?TQ)M#![3W'V=59C8.T-NU6>$&'V5DJRJ:'&XRBWA7UF\8XX MH)?/(*TQUU1(].Y"0?\@ZDK8G\*X:,GM:C"OY='!J]GYG%8=]Q4AU0 MTD:;M'(:ZL'T'^>G#I08/YK[%QS)3T>(K,C)-"28JEP M8&8E#,(XTB,@B9";H.;FUN;>U!Y*W*4$LZJ*^O1W:302D:YT6H]:XZ'K:_SQ MV)1F..39*^7PQ2*\=:E),6&IC)'((P%5'0W1O4 +7!TK[V.1[M0"900#Q Z$ M$<&U,M&W4*_'A@C^75A777\S3X_5D4.W]Q;:W!A)Z>@@\[T+05,,\U-5/3S4 M:2>>V+9H81.DFED"M96+@:C$74 M>V0$4]">-?\ BNEMNG^9M\?MBTI61J<+( (TFFJJQ\?KJ M61=#%8'(*W4@% ST>S16Z^'&#GB3Q)Z>BY'NKATEW7=DCC!RB@[AIZ1\I+L3;4U$B2MY( M,C" 5M)Y9$D7):"P_; ](\O[;8PM-'N+/ M&O$@J>'Y_P NO=4_S0NK^W-VX/9:1X+ 9W)5E)0X^:;?6(>E?/5)%'%2_;EH MZAWDF9O$(_*S!A$RH=3>ZW_)%_M\,ERZ2&$9)"D4'J3Y#_B^H^EW7;)&\/;] MUBFE)(* BH^5*Y_S]'IBV?%V#3R2YE4J)5J S4=39P)8 9^"HF0R!8KI;U$@ M&X'/LEK]/&L:?#Q'_%]6M9V9B_ ^>.@F[=ZDPV"V_A]MK"=4\CU[Q1B-C321 MSF?R02(?'3U$$S7CMK4N";BUO9:T[BXU@T?S^?E^SH\@D\6-G_#P'Y>?0)T5 M)-55M57,K''4E<\D5U.F6&FC1GC>XU^22I6.UK^F-KD?4^(**!3NI_J_ET^T MA. /GU2Y\VOYPG?73_7_ 'C_ "^NF*/:FW=M[L[,@W]G.Z\5-F*?LK'T>]^K MTV3V)U6^/-;)M/+8S*XFICAAJJRDDFQD;RF"/[I::KILL?:VS^GY/M_%@ >6 M5Y ?,K4 5-/5:\:<.L'O>C<6N.?[T1R_V,$J!-HQ4U M/3T4$<5T?[NMD"N06I*26:(H-1:UA$H%KM<_U]CBYU5+5J!@#Y]1Y8Z4T*!Z ML?RKT+F9FG?8M RQBK./R\V2E,1YCTTF((BG#7N7D1(KBX;3<\#E)&H:0"M" M?]D=&MT6:V# 9!!_93J7LK=$6'["GR-<*?\ AN;JJK;N[J.KC$U'_"JJ9%^Z MO'9A4X2259HM(5@8B%:S$#VI1P>&/\ -7J7 MV#1KM[/Q(DXEBT)3#(AY)RU9C:DO0Y8+/>95EIXH&<,-4@,I(N_MID/\-:BA MZ4LVC17A6@/V&H/0/Y,B=GD1$AECF%="%N?"693-2J=)6-8&U "W^QM:^H>U MJ5J"-+?Y#TS_=>Z][]U[KWOW M7NO>_=>Z][]U[KWOW7NO>_=>ZG>/]C5?_E!\EK?]7+Q6_P")]U\_S_R=;ICJ M)*NB21.?0[KS]?2Q'/\ CQ[L. ZUUP]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O? MNO=>]^Z]U2=_PH!ZOE[/_ET;VIJ7$T^5R&VM[;9RN/\ N:.2LCQ]9N3%[DZR M@R0$SA*GB>MC!(\P M!C[>'Y]#KLG_=E)3CPG&S5#Q-BWJ9Y9:61 M45L+BZRCK$QRU:H4@IZI$IP\GJDEI6=2VD,= <2#TZ#J.FA\S_*G^K[.BN;> M9AEZC&U"O&U11R&)3IC(D$CP5",&0_2.=B0?H1_4#VJ0@(6]*=%TO;,$88() M'[<]3MV/!,L=33Z5CKTQZK^XK%ZN.DI_H !XW,^O7_4GCZ>_1BLA;TZK,#X- M1Q8_S'#H**RECGAE@DB#AI5EE$EG#@SL(@%8:KJQY'JLP_P'LP7@.BAUJ2"/ M/S^WK'M&>3;>[\'E_P"Q]\8))$"W*U##RD*^KQ^1F4L2+&Y_//M+N$7CV5Q& M14Z=0^T9'^#IW;KCZ+<;6X(PKY'V]7===YV.KI=KYF&4$)!XIXY+/*T4H:-M M1"B-M!:]B 0E@/K+-!8W:G.FC#SS@\/ M3JXGX]9S;6_=J;JV3N#0T]91.\528HY/)+5XMJ".JAA;26!TIY; ,=9;]7'N M,;VWD@O(I1ZX^1!K3J4;28S0%5I48;T((X_RZLH^)%=5S;"J]IY2&6HKMO30 MX/(T4VEQ))A7E-#.VNQBDEIE5D8\DE3JM:Q;(-%S,5_LW[P/3U'Y'IR[2D4# MLP#*2-7VT'5>G\Q/XY/NZFW5G,16U>W,]-D,9)%F*+[6OQ-121I&R0/15 &?M'GY^G2#]U+NT;0I2KMX4N!W-G\AMW/S*ST/\ >?-5,^U-U.CQZ*;!Y'&T MTB)DZUB8! [1F.;AFTD'W+D-[97L1DM8T8@591AE_+C3Y] /F#E_F+E*YMK_ M '*2=K5W"+('8QD^5*&B,>%#0GT\^K9-E_RLMV9?KSL'<,>"P-5N_8593UZ[ M5>MS/W&>PD\='52TV!KLJ^-C;.+'7>?[=SS!3N$D:4*A9DM[D17=T(:1PJ&= M?.A\P/.E<_*O6X.=]J6\L[:^=Q'.6"RC.E@.T, < D4KZD>75A^_?Y)_5^0Z MEV+G^HX(,AF\GN[K[;V]1E,OFJ$C;N\,E%CLMOO!Y*CG:I2;:]94"I?'RW$\ M ])61>4-RFX06D5Y;LLI9T0I0"FLT#\#V@T!'&F1Z=$^W^XA_>-[9[E!IA6. M22)E.:H*Z&]21D?/IUW]_(9?;76F[-T](]T;^RN]MO;4S>=P?7^]:?%97';A MS.->><8"+/P4]#6TE3DL1&YHY3J1*QPC^D\M7,%VL#7)>)W4%G1596-..G)% M2/\ -TNV?WCG^N@MK^U*VKR!?%5M1 / T;R!^?SX8Z/1U7_(P^&^U-DM#V$- M\=T=A5^!TON?=V[LC2;?P^<:G$E/6X3:F$_AV,*1U"JO^5K4M%3'1ZY=3>W[ M?;:VRRW=Q_C3)JT145%-*A:FK-Z$X'1'N/O/S3<;A&+7PX]LCFS&ZAV=0:'4 M6X8X4\_YB#6?R;/B/F]C[(Q\VSZ+#;W\F*GW5N7%@S4&U99R+ER-:DU50>-,5)4?M/IU9_>?>;7==T MN/H(9-I5'6WA90K!^$;,ZY-2>X<*<,YZ*;\AOY/OPRV)M'MC?N9Q>=RC5>W< MW2]<[2;<,5%30YZIH(<7M7"4"H#)F,]+EI#4ZV6 ,SMN MK1VL9+BFFK4-%4G^D<8&?+I7M'N'S-SMNFSO-,M9#+3?= M4?VU75P5D,,]9(.))X/%'*$#221MOF\W,Z)$TA\+5JI4BM#^+\N'[>I\WVQV MW9!#90QJ960!W4 $+P(%*'N(X^8^WH['7&"SF'Q6WZ'?.3I-P[U@Q\$.Z,_C M=MQ;8H,_DZ=6DJ\GCMO"MR2X:DDEMXZ<5$]Q&6,A=F( UW)'+)+)'%X<18D) M75I'I4@5I^70=@#QPZ5D#4%-=*5/V"NG[*G[>BU=]9S[S=4\=(?//5PI1TJ0 M'S,07F6650P$<<7B3U$V 4&YNP'LD1-3,[>1_P!CH3V@5+2*,@AAQ'V]%5[B MW3M[J;K/.YS,58H,?A<+ELOEY9)%BE-'BJ.HR.1(+H;RRLLNDE; @#U?7V86 M%I/N-_:VEO&6FD<(H'J2 O\ /\^F=QO[?:]MO-QN7 MXHVD8UIA5+'^76BCV M)OO)]M]E[U[&RB>*LWKN?+;DDIY9&;[*/(UTLU/1!RQ:5:>G=%+$W8CFWU]Y MN[781[3MMCM\0[(8UCQYD#)_,]]WW'=K@_JW$[S$'RU,33\ACJ;A MI?MYJ9"6#4>-165@+EJF96)-@0R:G%U/N\]"K4XD_P"#JUH0LB!B>U/YD_[/ M0VPT,TW7QG0(NF.NK97D!D)H >'^H](H3J M9R>!^VM?\..EKF:F?.8>&AK)(YQ6Y;.*'[:=*PZR1^&]%E''YY[3]A_V.D'3M'53)&Z,RSQR4TW(1Q4/"\5 M.X4 Y.L.\(\33Y!Z!B:XB80$^=-39\LU_D#7U/7V8,+F,;N'#XG/X>JC MKL1G,909C%5L)U0UF-R=+%6T-5$WYCJ*:=74_P!#[,QG/0;(H2#QZ<_?NM=> M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T\>+_(M=S_ ,6?R_3_ *O_ M (;?ZWY]U\_S_P G5O+\O\O4;*1^')Y&+_CG75:?U_3/(HY/U^GO8X#K1XGJ M![WUKKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[HN_RUV!F>T/C3W7LG;60D MQ.Z MJS-.,! ZI)%@):.N1\>K@,*-HPP!N/9&AI'D<3Y=#.4484_".)^RO2/VE/)_ M$6DIPJ5D@9*)RO[45=6G[&FGEN& 6@I9I9AQ^M ;_CVXP& U>F8BSNY!HW&O MS.!^P=& VSFZ'%THRHH8X(:3(5T5')3K%'%5S0(S"A2&/6?$9+)UD<4L<=/DZ>*8U$E U3-3TB#(M'! M6K$YFERN0JWE@$2A4647T(VJA.#Y'IV-5)R/*G\NB1Y6IJ*;=B2Z3'+6UN1B M2-H-0B\\514H%A4( $G525^H ('/'M3!W(?EG/\ J].BR[)22%B3FH_RC'EG MI\W9%#/MRCK("5:HK\E/+" (XT,%3,L?AYU3^9;GT@Z H!^H]NH:.U3QITW- MFWJ/XJ_X>@YCB\P:9[%:ZD:0J;:PYD6GD 5?4--4HD''Z9+_ $/M4IQ3TZ+' MSW-P85_U?GTG,J!)0U"!-#P2*\9M9U;1XWY%M2CZW_'MP^728JI4D=67?''? ML66V[C*>9XP[I3-JD>4.E=21**N $%B)#H#6U '^G]8DYEV]HKF81KVYQCAY M?R/4^\B[R+BRBBDI6O$\:J.X>?V]6?=0[UJ=O9RDJ:2?PH*="DD1UL(;+)"H MLR!FIY2+?JN >!]/<7[C:++$X<9KGU!'4W[5>>#(E#V'\\'R_+J\KXQ;^IZG M+09**6:#^/QTOD,(26-JJQ5Z=%@,OB*NER<<+56X8F^U\KB2FADB=A'/(RN;0M3R.FH MG4FH7TV(]ZDVW:\I^!>)X=4-=Q;,JMER9<4^/ERFVHLG198T1BD MK),=/'4&2#[;Q1F4TJW8AHGUTH1)$N#I47[/N7C^$K2Z+H"@8&A-/GY'_#U) M>T[[ ;63:]Y@CGLF 4I,H=67^%P00WR/&N>E7MCYT[KH*7?NV\CO'=$-%V=@ M,9M_=TCYAILK#A<5CJC&T<.R-K:41DU !4Z:9'Q <#Z]% MNX_=5N;F=KZRYIMF)4@":-T!J*5)0O\ G0=6<[4_F6=2YC![B7+5V^\%E/X> M\V#QV Z(W_O"HJ*.KC.B:J-!59''*QITJ+/(\4 9%:[J&]F5MN>V7$-PTEY, MK@=L9A8Z@?FM0,5ZBO<_NX^XFVWMFD=GMTUN6[YOKX8P". <(YJ:8H3GI70 M?+WM?=])D?\ 1#T1W5NK;^5QCQ;)W3DNJJC9D]=.M!%)4904V?SE73RT<$-9 M%44SK"WTURQ^-M/NLM\/&;Z+;[ZXM:#PW\,)4@5(S7 'Y]7M_8^WMPAYKY_Y M?VZZ1JW5NMPURT8)(4514&HD4H32N*UZ)]NGYJ?)K9F/VWB.QL%!1YC::8+/ M8+/[MJ:;;V=:OPU/)A)\OEL3L:6'";EER+5TJR15A6"H9F;PW+$$<_,VY6CI M')M7AS ZH]3$:0,?".->&>IHVC[M?MWND37EMSA<3VCEHYEMT0JU0&HK2 F, MCCBI%>/J"DW8G9GR&W+05>3R61SF1IJG)2TE>50'>>H-.ZH)/$0OLAW'=+JY)GOYNVI*H,*,U-!^?4A6_+?)'MIMLMOR M]MR0NZ*LDKU>>?0 !XDK9;AD#2H/X:]'VZ]Q.-VQ0TU)% T5/CZ/PSA"VJ:< M$%IBB>1/)5N[$QJ2"UC_ %'L(_4F>=I)34>GH/+'4*;U+<7\\D[O621ZBO # MT\L#K/-DVR$V:SXBA6EI%J8X*B1E.FFC8Q&:)D4&\CQ'58'5;@"^KVAG;4'E MH-&:'JD$*PK! 7.IB"0/,_/_ %8ZKIS^X4RN^/?R;U.H\& MVP@XUD8&G^\J:_;3J"/?3FU;+:;;EFTF_P 8NQJFH>$*$5%/^&/C\F^SK79Q M,;15447CM:#61<'UO,)+,#8+98@+>\B&X$@]8HH-) Z64SBCR$KGA8JED;>'+K(R!_@(_P U.C"[;'WFP:56 MT.E7%E,3"X\IEQTTDJ5:B<1G1+]Y#4 Q6 :.2('FY'LLD8K*5],_ZOSZ$42^ M):)4=K C_+_.O01T$DWW'W0C!FCKIW>,@J14+53F076Y/DED+\\78_X>[.V: M5P ,_E_J_9TAB5V+,!G4:_;7J9GJBHPF7I*\(J*V,66IU69*O#U_EIJM6 N( MH8F :Y'I-R+#D.1()(W7YX^1'^?AU2=V@N4EX +W?Z4FA_9TF*BI6AJ$JDD, M)6=)UD8&1?2Z2P,=%W!62S:@#Q^>![N$\1"K"HI2G^$?Y.O2NL3@AJ FH)S7 MS'S^?0H;-VS5[S??]'C\959:"'8^X]\[M_A\L$$>,Z]V32S;QWQD*HS1F-6$ M-'#%3'\54B1HLDDD<;;MB5&FA)&/\W[*=:NO#[W9E\-Q4T/D.XX^=>OL"?%O M![GVQ\9?CIMK>])-C]Y[>Z)ZBP>[J"IEBGJ*'<^)Z_V]09^DGGIY)H)IJ;*T M\J,R.R,RD@D6/LZ7X5^SH(2_VDE.&H_X>AV][ZIU[W[KW7O?NO=>]^Z]U[W[ MKW7O?NO=>]^Z]U[W[KW2P^W_ ,@\?/\ QY_W'_KR_=?T^GNE?^/=6\OR_P O M4#=4/@S^26W#S),/Z'SPQS$C^OJ]VZKU[W[KW7O?NO=> M]^Z]U[W[KW7O?NO=>]^Z]UQ=$D1XY%5XY%9'1P&5T<%65E-PRLIL1^1[]U[K MY /\PG;E+L/YM_*S8E!7RY&@V/WOV/USA*B6HJJVK.V>NL_4;)VU#65E?%!D M*^MI<%@8(IZF=?-42Q-(Q=F+L1Z '=1\*&G0UUAX89*?J2+JQY8'17-JKHJ@ M8T45%7KIJ8R,ZJE16**>%K1@EFAB+$L =-[_ (N*RM5N.!CJ\,8 )(X\!^7^ M;H;:2HBH9(9H8#44N"BHFQ-!*HFI):^I,45'Y?&94GDJ'I?6$+N3,UF)1O;9 M/KYUZ5:1I50.T 4'^KUZ%3*PU$\5)MO)5[.Z2UE5N')3Q+4-)! E3E=S2NT9 M6GE>KD:6G3]:JTD^GZJ/;)-:L/\ 5_Q73ZG"KZ@U-/3)^7^H]%#[$20;GBD# M&.23+S9:42"1&IJ:1*N9-!8^0GQN 9+^IV(M]#[66RT1JFN*#_9Z*-P?5*@K MP.H_+'4W,P3Q[+PE4%,B4Z5PIAJ4HSRS51FDD/\ 9F8 (2+JE^+^[&C2+5N MTFF/EUH@K:ZOQ $C_5^?084;A8X&LMX:BFJHV5K6HJM"DU. ;ERQ@32?ZZB1 M?GVM/F1QI3\_7^?13@H P\P?R/'KK(4KQZJA9#)YD,B !;.2WAD#!M*^I7// M]>0./=QPI3JFG2,'H5>@]R38;(Y+$R32Q*-%=1ZF70L^L4\Q2Y)1)'MP;?7_ M %O8:YCMEEBA'53&I?EP!^RN.K7>OMWO5TT4D, MT8GA@@98_P!(991'JC+)]&-OH.&!-_IQ$&YV?ANYT]I)#?*G61FT;@98E9:: M@ 5_/_+U;I\2.SJ?*)2[=FJD#BIIXD@T."1*%41Q2,SWJ!/$PL=+ 2\$L![C M?<[)H)C)I[#Y^M/^+_EU).UWBW%K5C1P, ?S'1K.X>S*BA6MV+FS-C22-E)M)$R.-2\(A [H&&4KTLCE@C@' MVTX=+'<30@J?F/.E.BP[D^,N+WA63Y?;U4F&>6*"::AJHDC@6KJ',C2B&/2: M59W]+^'0K6U&Q#>Q-9[_ "VZ"*Y4O3 8'-/SX_GTHL;ZZM>!+Q@UTM7_ (L? MEU VC\;Y#_)?-4U+CMLMO7;>/IJ:**FIZO<0@S0>.):*CB-9FOOJK FE M1?M951--50"E,P1$DI Q<?1;;\L;*$$NX&S>[< MDR5CP:DEAV4UU-&!P0Q:AKW=9-N?'[_2'F(MP=I;[W3NS+T=-1XB>@FIZYF9 M(RVCVVVV]NMJ9#)$5HH0%0BDJ"S2. .+^9/RZ-S@ME8O:T6- MQ>U<+1XO%4M#I+Q#5)%-1 +CS65,C&LR#S(T[QAB%0(5.G5< Z[GN;EPSM5* MD_('RH//H)76Z37\D\U_.TDQ;SX9^+2."^0/3I5&:;)0XBE65Q42Q-4S()6F MFJ70L0Q/I#U&M;N+OV_X]O[;R64JIZ>EAJFJ*JKEJY#%##3 MPQ"J?(5,I58]%&LBGTZB$5N-0M[I;6KW%Q%#&E6) &?L'KGI9=WL=I"]Q*0 M$ ));@ !6OY=:9OR.[4JN]NY-Y=E"HF?'Y+(IA\ *B21WCVWBM=+B*B52 T9 MR*:J@J% 'F L"#[S Y(B7"?F1G\^@FI+OHGD4>@T\4L@LH)DFDCLH'UIV=E'W,9L=9HHY6(:Q$XEY9OI]1&;C\7]U48_/I0>/SIT//764>HH, MWMZ-8S6^'&YW#^12Y:KB5FJJ0IJ5)&DI+$ \:OP3;V6W"@D2*/,@_ECH_LY" M=4-,T##\QPZCR8135UU72)4?PZLB:NH7DU&8.=23TYD.DSO25\+Q.WU("D\- M?VC,R^2_+/\ J_9T^L)0R$#M)U?ZOSZ;M]T4N0K,1!0PI)-_#<=$GC&I8_!) M*)X8N+R-(6]-N")/\+^UL$@ 8UP>D%\A9XP%.H^?RZ#K(Q06EA@4B!%$='Y M!)%$L:B 3$%EU,0;'\J?SS[?CK7^D34TX=(Y!J&D#@*"OEC%>K2_Y*_1M-\E M_G[\?>B=S[@CP77&^MS05O<%-54*UM!OWKWJV1.ZX^G,@)-$)Q_;6X^M*+%5 ML;2('H1+Q*^B&1Z)?UV'X2/]7^KUZ33N5LW(!U#T]/+^?\A3S'7UA_9GT'>O M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[H7/X5);3I:W]Q_L+ M:3_P(U^2_P!?U:^;>VJ_X:].T/\ QFG2FIHTN?ZR0R2(W^VCT M>[(<$=5?CTAO=^J=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=-F9R:8;$Y' M*R125"X^BJ:L4T3(LM2\$3R)31-(RQK+.ZA%+$*";D@7/O1- 3UM14@=?(\_ MF;8F:A^?GRPQ4E8,QN"@[E[%J=Y5]-'4M2UF]*K<63R^_P"IH9:BJKZV;!T. MYJRLCI9)Y7E6BBC5V)34Q)D22D^;9I\NAI&%:&WTX B%/SZ)=A7D6JI_MF6. M>G$JP.R@MY:M/"[MKNGH@+!?H SDW'MF1B,GB>ET*@T'\'\_G^SH<< _\$&+ MJJM-1QM169BIAA3QM2^&,^>A%S()JW+&D_AM,D2A8_)*]AP2TQ(-#2GG7_9Z M>-%SQ'G^S_#Y="CC(I/[JY/.93(U5'F5U$%*P+9D 8K^$#C_D_ET\5*Q,1VEJ @>@R?L_U>G1.-RU MTV&K UQCH.SH MS3N'.>)/RXX^P#H5NUL;)@^H=CE:-J&62DHZ-UG\8:NGGQF/S%?5P:5-Q'29 M=$ U<%6# .&]^A8O<@5J./V>0ZBC\KEC22-"Q(( C MJ4!8HMA^T'D)N?R/Q[T==;!D:/>F*IYET-7BMQSR(Q*R3RTT M<\0-B KDTPO;@D#^MO95O,>O;Y7KE2K_ ,Z'^1Z,M@(7=[:-AEPR?:2*C^8Z M/AUWNR;&9&+%5@$XYW"W%Q"94;MIDCJ M9-FO7MYUAE.%.!P_R^?1^NF.TJW9V[Z2M2:)J66>!YT<&6-=$S,MS'JLSJX M*BP;^A-P =YVX/:UH2144\R#_FI4=2ML6Z&&\"2,/!;CZ _[/5M7S/G.?Z@Z MS[RVXP-1MJKI<%N&II)/(8<-FAY*2IJ3K,QH%KE36K:O&TS->S,/83V<^(9+ M9QW,"*'^)?\ 8Z$^X@P_K(Q'AN&K_1;C]H!IT&G5L_\ %<7!D*2H,(GIE^\B MDA+3QR J2_CCD8.(!))=@19D]1X ">YI&Y!%:'!\NCNP%PJ$1JYD%W6*0W>0OSI]0+>G_ (O$K6HQT:Z!6HI3H<=G=79)\ M='_#ZF:%IY7(,!>"G)C1:>H+4ZL&10]E52;2&1=5E8^U<34 "DU/^K_8Z2R. M@(UJ-(_U#_!7H7\7U1NB)8!33+)!+&DTKST5O'3 Z25LADDG2=_$R"Z("Q=0 MEF]^:)VTT&*<>J_4VZ:M7QE744Q:!55BI2:-E#B56FDT1ZE9@4:4QH4LOZ2Q-[7-J,25 !X&N>DF%:M!P MH?E_JSTE<@*+!BHSE42[4B)H:5VC>.4R.D!B#V$@64W8I8ZKG_7W'2-_%S49 MS_J\NFI2[@1 TK_@_P!GHDGS WS-C]L_92,9JK0\\+DY K^7EQZ5VI$-FS(.[^S/VG+=:RW\SGO;*;*ZH7 M;N"JVBK=^Y.KV%%/ [">EPR8N7*;FJ8@&6.6HFAJ8J02 ,+2GACRLJ>V>R17 MNZ_4W &FW7Q@/5JZ4_(4)ZB#WBYAGVSESZ2V-'NY#;%AQ"!=4E/FV%^RO6OY M11!+L2S1>*E#\ C28DTL6078*"/]A_3WD-C\^L4U% /Y]27CAA)CA)9'G5T4 MD@KX)1,$ /%@Z6X^M_?J#/#JQHIHO#J-E'A66%SJ96$B2L6!5@6<'D>L!0>? M\1[U_I>'6PP%"W#I<[7W$=M9^BS$R-+'32I!5I&53S4Y4QLBE@5%X:@A;@Z6 M4'ZCVE>+6A533SZ-(IC#,)*5I0'YT_U8Z'VB5H_X+DAY),=79%:FB9U!/G'C MDJZ.*,/*KR3(RS*MDBE"%+Z@?9%*C .*_=>Z][]U[KWOW7NO>_=>Z][]U[J310&JK*6F N:BI@@_I_G9%3Z_C M]7O1X'KPR0.C&Z$_U*_IT?I'Z/\ 4_3]/^'T]L=*.D!V#2ZZ&AK +FGJ'A8_ MD)4IJN?\ \ '^Q]W0YIU1Q@'H*/;O377O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U M[W[KW00]V[DCVML3*Y:>LH\914E'E*[+9G(S1T]!@<%B,)E,YG^0QBXF;N?L3 M?&>CA#5;Q55;55T=;N>NHJIXX(:B"OK72J!3J5=5!6E?MXDT!-%'_%5Z&6@BR&FBCIZ>>KJZYZ$H(X MZB\[S5,*4L\5-XUJJNJR MI)QCSKT2/";=&XMR;=VKY2U?NO.4-)F(Z+0[T.'AJ8ZW++!,]XO)#0JR$_0S MJ%-[*"(HNU25-0O"OJ>'S^?00E 8H&_M)&R/10:D?Y*^O0J_,/,44.Y=N==X M7(H^'VY2_P 7KW5(II,7FLO+6SSX:*)I/#)58NGK$@++(8!*DC.QL"SMJ"'E M)(UU4U3-(54IY5,B_MW M$00"&&&F-K*+%N;>UR5#9.*=%CY0>H/^K_!U'JY?)(SQV1*E"DD:W\8;0+:A MS:[GFW]?;BG'3$E22RC[0.H./K3CMP;?KH!9Z?*TPF4 J;--"L;^V;N,2VUS&WPF,_X#T_8L8+^QE!RLR\?M'^<]'USF$JZO&TNYL8K?Q#' M,LDL(MJGI^"X*K9B\>FX'X]Q5;3K'(]K)_9G@?+[/L/4VW=JTD27D(_60U(] M1Z?E_DZ$K9&[3DJ.FJ(G82THC#QEPDJ^,V!UM=-:$W(M8W^OY]I=QM0K/&1^ MFW#H[L+UI8HY%^-?GZ?MX]6O]7?("#(<&#U'D?\M/Y]2Q8[K#N%BL7TD2*)"H4ZV52% 8GFZ+>(07 M,P%*Y _R='&RSC0J<=)H?7R ZM;VQC(*J6*HD4*7= :8)JJ?(T:W"L4'@IU< M AF'DO<7U6N'!ZUZ$:LQ!'^QT;78=+0F.A$$CO)$5I=9L$8(3.Y]" U'A>/^KTKT9W!T-$*>*"21G>$JQ!>&>G: M=I5,OK0K$BI.A#JK$,2001<>SR#1H50QU#\Q6O\ D/0>F>0-4)VGY$&GE\\C MI?XS$T\L +T[JZL\44*G1#)&L/J?Q>75-%J32&*HB.VJY+ ^U\<6H D8]/\ M#T@FF96PP.,GSXXSZ_M]/+IYJ<=0111L(O(GW (F/JC(D$9$17RL?.S,= /) M"_5K^]2PQA5KD$\3TU'-*Y8%LTI3S_XKH-LK]LM2$B! E"F 1C5$6;T*%20$ MQN$5=0%C:Q('%B.5(]1T>?"@Q^P_+HVBD@*[+J86RFUMN2, M8Z>HR+9',JR@O44&#B7(ST^F1'TQ5%1XH'( 51(02>![1N0&\/&,M7Y9ITZA M+)(ZUU4HM/Z7#JDCY8]P3;Z[2K<;AT>JDHJ\X':])%4&*"HS#L88E!:[1Q4, M5DDDTA(51W&JP!>LH0XENIL*W<<<$&/Y^0_+I^:41+#9Q5:4#2!ZN>/^SZ9Z MH&_FW8'^[F-Z)P7W:S/%6[UJLC5RK(K5&0EQ>#:6LT,TTT2U+ZG13RL3HMA8 M@3#[32^/=[]+IH D04?+4V/M'^?J!_?>#Z6QY9@#U!FF9B?-M"9_//\ +JJ* M@!_A;3,J:Q0PTLR:1I:,!3 L8"J 2DEC];Z1>WN8R?U-/E6O6/Z'],MIS2A_ MR=1)(BC4\4BLBT-2KES8GQO/Y9!>U[%7_(]NUJ :\>J,*:4884_X37_+TSYA M 5FC!"*M3401F^ERH8G\C4=2\?[X>[K0@5XTZ:<98#A4@=/?W*54HJ)$7_*J M:**MB 41PUT4,,#3(% $45:L;.." S$7!]IVKG)J#C[.C*,A@'.:BC#T;_(" M/\O0H;)WFK\?.VHT\D,RJ_'Y7_7NCDC5 M]1(HQ_S=&EK*8PD9>L!.?EGCT-9PO@:')JU+6X;<,FJGKH(YJ1)T$53-H:*5 MZ713F<$K3+IJ*'B/2OK]O15<6?@:CEL ECZ^0_(9ZV'?^$^/1]1D?Y@&Z9UF MJ6V_\?\ I;!9;*U-7$V-7)[NW-BJ7%XJAI,-:7Q3;7BW)FONYFJ:IVR$IEE? MS2:8C*$'Q"I/8H_U4Z(-R_3MA4=[$+_EZWLD)**2+$JI('X) X_V'LR' =!D M]^O=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=*C9]+]SGJ0D72F66J?_ M \:%8S_ (6F=?=7-%ZLGQ#H_=>Z][]U[KWOW7NO>_=>Z][]U[JK M3^%VQN[[&.6.4D+L7 M(95)O&DDABF*JK%@K,3G2C?9TNV] ]S%7X0:GKY=&[5^XR^/Q,-141+LW"O3 MXS#5$K9*BQN;SVY*W+1;9III*N.$K3+E=<]1#$D,DU.2(]/K]E14::$FGD/\ MG0M4D.U?P@9'KTB=IT\E9GJ"BBCDE-35HM6L7[DLU%#()*J( AXI!(%)LRN& MD*W!'M-(0J@GATJCH6T@=U?/_5_JKT:GKVO3:FXJ;>F3CI7JJ2J$FW\=4O'! M1PR4P=4>.2\DE-3F-/"94C>H6"RQKYGU*1WLK3(T PIP:?X/R_U?,\L0L+BX M>A8'M!^7\Q7]OIGH0^\LCNOL/&4VX]P24^+P=%-]KA,3!!%0OD,K2T,44\&& MQXD.2FG=/'3YJ0 M,#3CU,U2\:,+2,%$J-54"B@ QZDG'_%=!F-:F2XD\CGY+_GZ*AN7+5&_-^9S M<^5A='S^=>6&EDE(6:-)TAHZ.$!$,=%0P(BR2, EU(75(Y(6 ^'$ .(6IIY8 M_F>B*15N+J29ZT9Z!3Y\ /L \SP\AGI-)5>;'Y(%3]XE=02K+&!&GA*Y3[A0 M6(>%C),@4+Z5"D#FWM7112G#ATEU AL=U0:_M_SCJ4[^2GG5#K*/&ZL#8D!= M/ %DO$NJ_!O^3[\IX8QU0_;TPULK)412H'!5J>5#9652M3%)&.3R^J,V_XH M3[L1J!!].J$E2&4FHH:_801U:EUI_E^ IPUIA447C:ZZB7D0DD(>+I?D&X-O M<+WJZ)Y2W'5_JSUD=LI\>SC8Y#(/YCI'R87)[3SE9/C0'@U7GI6) "D^0Z+ M JHTFUOQ>_M09DN(4604/D?]7^KSZ126L]GAJV-O!8V$T51+3& M6/Q2^-5CEHG8HWEJ8S9?$"E@>18D%Z.5+@*OBDN[78LR@#Z@D$2VS*2M.HB>2-(9X-$S)=74LL:-IT6NHN/SPF5 K>=:^?E3I5.@*.0M< M?;6O1Z=MWJ9:4,T4"F.H7'@>@Y*)""64E<&A)_P GF/EY=,>Z:J+P1_;O MK9E#>:9V+2TT/F,0, LT5[@H2$*Z;<$E0EO2"M5X^M>('^K'2K;P^LZO@!X M<#CSZ!>HR%%&9\C52K!%0N[!2 KRO&#^\SLJH8YK$!E-KBU^-1(6:,(\S8"G MAYG_ (ORZ/G644C4$ZADCR^7VCJH[Y7_ "CQ^V$W'F/;+9/] M^$]J_.G$_8,]5T=";2RFX,_4;VRE-4Y>LFYQS_N214DU7YG22-*D/JJZEHD$ MCDC4MP;)Q[5[Y=1J%L+<@1I0/C)('RI@?X>F]ELY75MQNNZ5O@KY DFM#YGJ MK3^=!1R4^XND*6HIH&D2MWPE55([/'53-1;75GT7956*,J."0;$DY5]F# M5M^-!J(.5P1V^+,:_[2/_ "=5$[;I/XEB,]$TBI)C*:DG1@-* M211UU/3Q3$N=:L\I5=(NWY/'N:IETO&P&*FO6/%N=<]CR4G:4LVDWGE M$XXTLCO&L4G-OH'%N#^?=C@]-E234^9)ZA4(-ZLH1JC@DC4. R.8GBU"1+V9 M0K#CZV)((]U:AT@^O^?IZ$T+T]*?X.GV"6+]IU0I33>C7S*E-(J(2E0R#R(G MJ)1V4*5L&Y^J5R0&7BX%:#B>/#_+3HQC*G20M(F-*G(!]":8^1/Y^?0]=9[R MW!M1C3FFBW)M&MR%'+FMO35(CTUE."*;(4-79GPV;IX&84U4%:&3F.021EHR M5LT4H 84\@?]7E\NCJV>YMS75JC/%3_JP0.!_P G5DNR-W[7R.QJ_96S-Q9[ M$8C=,^+JNP<%)!%3S02T^32JQ@KJ,29"=\;6U$@5LG1^6GEAD:&: S+YIJ*\ MUN:1M^F3P\CY_P ^C3_%KY0&:C4IZ%:GS'F#Z^76X1_PGMZIV3LKHONOSL7+V!3XC(55368C#[=P]1C\+)5X^LAAEQ%-N;-5>6R%(D8,4<4 MRT[-Y::6-#ZPE6:)G (D)[@>(^W[>@%S'#);7,<;#](+VL!AC7-/L_;UL7C@ M ?[UP/\ 8#\>S7H,=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T)O7 MM'QD*]A]3'1Q-_K?O3C_ 'F/VVYX#IQ!Q/0E^V^G.O>_=>Z+SEZ(X[)UM'8A M8:AQ%?ZF%_W("?\ $PNI]O@U /3!%"1TV^]]:Z][]U[KWOW7NO>_=>Z][]U[ MKWOW7NJ>/YQ-=/D>B-N]?P5-#0S]D[SGQ$55D,D<;#18WK'8>_N^,_65OCR6 M+GJ,+7S]8XO&5""41/'D66571M#I+DDKC!K3HTVOMG#TKIS_ )!_/KY=>,R= M%!@*K(S:9]PYC[NDH&JF9FI\744GAR.:J861#_%)9:O[>BM8JR2NUSI]H)>! M(4^@SZ<>A$IUJ"6HW'\O7_(.G+:+K2U'CIB[UM:BPTB(3$[>)C+*RRW"P#5I MO+<:;FQ!%_99+(QJ7I@_LZ,8,=H^(BG[.C#C"?PN2FJZB&FJ9Q20Q2EJN&:H ME:H4E3]Q+3B.FH$!9W81PQQHH-KJC$JNJZ-::NS>1%J$Q-61O/5Q^.,5=+LS&M9B3X9*]P$10C/ MK,+.T$;&244/DOSIY^5?\&>D%U>>*PMX6!U8U'A3U_TO[*]!-VAO"@>&AZ]V M573?W-PKTD4K37F;,5E-%)5UE;4SP%8LC6Y7,5$U3YY44+%))P%L MJ#K6>%?6@&!\^D,FA52!)*@-D@5!'&GS+'B3Y5^70&M11XZNUSR-*\-0DU6_ M.HU,LIDBI"S:7+4GFTLH%E;A?I[=$AD30@ J**/E05/Y]%KQ+%)KUUHU2?*I M.!^7G\^DA#$8?XV6'Z)6CC#&H2,R,20"&4W%^!^/;IR#3TZ3,:LH(X'_+U:1U-7-%2 M4E+Y&",(RIN/TN =0L2I"GD#_'CW#NYQYD<#-,=9%\MO2)(M1TTZ'2;;<>2' MD4%JB0Z6C)99I2K+(50#T@LI.E>5/TX/)(TNBO'@/,<.A8]D)IZ*;K;'B<2Q A MN%1_EZ6>U<_'410P5W^XJOCC6*&M5'?&SN6U)%4A0]13:]/ 0%;CFWU]ZGB5 MM1/>GUSPU]/%%2VJ+H/+X8GN9'D=XDD6G=47A2S,S:K@^PC<0 MM&Y.@@^8/V]#J&[BN8:*<\,?M^?GU9]M_L5S0(L2*]2:9(_*L'EB]3J#H:&] MG4MH:.QT @KR1G)+'3JKQI_J]:]<9-^2-6+4C(F:B;Q^ M<1212)3U"*]YA,UOMX]#+;5#J1Q8V)(.Y97 !$A+><*-,":G:*+08ETJY92&6-2Q :_ 1S7LY%" M[$5_XK'3\&WQ\1&.%2!\_4_EGJNWY2_,VCVO@)=M[:RM-59FN$HFE@EDG6DX M$*O+!32J:R+2ZMX;@2,.75;M[6;=M]UN!9IRT=JIQ7\9\P ?\/\ +HOW"^M] MK5TC57OCA1Y*/5OV\//[.J;J!-Q=P[XIJS,/5MB**=9(:29];3B*1Y355&DK M%%)//I;=KY9;GNB'!?+_8 MSDCSZM1ZLVS2[?QU*ZPR+21Q$)<(AGDG2,RU,MT8,1&2D*Z39':Y.HV 4C-) M([2$U/0Z2,I&J# ' =4/_P \+#0XO-]'9>*)IHQF][4,B*$EI-=3C<354DDS MZT9:BJ@IGU@"X$5M1(XG'V9<>-OL50',<9^>&:OY"HZQS^\%&39DBY!8KQ^3[G24 M5'6-]H=)(K0,,_8"">GN:FB&.FE9O)'39BFA60KZC25=33J9"[ 6+Q4H*ZK M&_U/'M+J(8+^*A_;T8,BA"3Y/_*HS^RG20ECG^^R5 ^IQ3Q5"0(Q$BR'QTY5 MQ8W]$BG_ YX]V=@J1N?,BI_.G3,2%Y)HN+!"13\NFFGCM6'2K:(W0%5%E6. MIC7T2CZZVE0BUC<#Z<>_2$::$\?\G5(S1U/'_5PZ=H%6!95"E8V=6-A< KK0 MGZ OI.FXXN""/\4TG=I(RX&!6G^K'2^%_##KP4G)XTI7_/GH0=J9I<+D8)9% M9Z(R.WRD0%964 M=?\ 5^WHT\ G1-"]36N,$?ZO M]5>'1_/B'\]?D3\<-\X.MV%/FL=N^JJ,3_"\OB(\=!_?O%0L'I]FY[!U4HV= MOG!9M:58XZ.%Z.NFE.K'N:X0I[5PNZ'Q8GH:_E]A'22[$%U$T-];ZU\FX$?, M'A7]GY];O_\ +R_FQ_'/YZT/]SL3G8=@_(/!1UE'NKIC>?VVV=Y5&2P$3+NB MJVWMROR%1DZ^CP\\#O50*9:BAB*F:WJ*B"WN4F%*]_F.H_O]MEM"9%!:V)PX MS2O"O5J7M3T6=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=#UMFA^PPM#"RZ M9)(_N9KBQ\E0?+9O]JC1@O\ R#[88U)/3RBBCI^]ZZMU[W[KW06]@8_1/29- M%],RFDG(''DCO)"Q/Y9XRP_UD'MQ#Q'33C(/0<^W.J=>]^Z]U[W[KW7O?NO= M>]^Z]U[W[KW5(7\YW)YG#]7;LRE!38^'^ _##YR[BPV;R,(JX*3C.PPKD5KK7 _.G\^OE MY4T02*%-3R!)-+.UB\\Q'(-S?TEK@ \<^RIR3PPQ7]@]>CZ%0=.HU74:_,^G M[>E1@Y:P9"&.AB^YR%2T<<,>A2(XD(*7+%$TKP[EB$ Y;CZ(I(B0J =@_F?/ M_,.C%' ?^F?Y#_9Z'#$S9/&@?]FDS=9*6-;N?*#QTK?-?3U^SI3[@V) MD]K=7Y;=L%!)C-MYDS9%M]9>G@H)1YF;Q M4Z*KSS2N12H9OIT.J4<0/(_X,>?IUZ:V:WMWN64K ?ET!V$Q9 MHZ&GW!%BS/)049DI37ZTI#N+*9!!3UI06:M_A5.D2"(E8_,LMPRZ@S5S<4D\ M*M!7N(] ,#_+^SIN"#],S^%WE3H#5IJ8\?G3 _;T&>ZJM9JA:*,L\-,KQM+, MZ S5S2K42UCE$MJ\\3MR2;'DEO9CMZ$*9F^)C@?+_9KT4[@06$-,+Z^IS]GE M_/I*RC335$SD@M,)-8TJDDJ@MJ93ZAP%'XN/I]?9DO$"G[>BIUP6]3UQH&LD MX.G6S"13< JZN%B8D,=-G^O^M[LPS6F.J(<-TVO$*N>M1P3YXJAR?2=!EJ2R M _@Z=&G_ &//MY!BGRZ3OEF/KT?CH[,O5;:BINY0NS+86,C$E].DUSE<$_/AT>O%@3 M4D-2A_5XHY)-(93P#'IM_J2M@Q)%P;WX]Q[/V2LM<<1_J^SJ6XAKC5Z9I0]* MJ;'ID:,AXX]<:WU>-=,RQ-8K(%7TNEC9KV8@D\7]IDGGB$B4( MZ#QMN04E?5WA?Q3?O,BJUXN?3(RCTZCJX('YOR/9@+N0H@KD=$;62B:2JG22 M<#I=;3>KQ,T:+4'[;6K1JZ+)&KM;CP3*Z+J;CZ?6_ ]MSR"1G2^R1[ M?M#=O$ _YN'1K^O^WDV;DJ&NK\36NT$ZQ&7%Y&6FAJ'202.TU'(S1II"D60^ M-KW9"?5[*I88YE((KY^7^KSZ$%KN,ML:YK\OYXZ/AM3YH86AI :&LR?G5Q(W MG@5ZE 1(JPRQM4 Q0F-S&MM0LOTN>"B3;K6M#J_P!7F.E% MD/G#M>DI)VA2OJ*FH"AZ"0XK%P,KLT@4M%/6SC3*;@)"2JDCD'CR;7#6A)(^ M0Z?&XR_*HQD]%[WI\EM\[XI:BEP-'CVA"5X(6F M4WY##D^WH[2SMF61HZOY:\],OE,8X^GITS!MIF;6X M-*U)/^4UJ>C?])]3QH\4;1+%$3#4Y6J<",I3262GHA8D2RS@$!?2VG4U^0?8 M4W"]9]+-]BK_ (3^70RL+:.W@44R>('IY='SI,%#0)11"%8O'8P)=B&2((@] M*,C2+#!=; H;_6XO[*@U?B.?/I]FJ"1U2M_-8^/^<[UAZPV)MW(X3"[FR_8- M+C]M5.:F^TPE;NW.8JKPFV\1F"<2UICX67/F!FE:8QY=:RF4 MP.YMF9K)[9WGMW/[4W3MNMEQN9V_N/&5F(S=!/23O25=#74-:J26\\,G(U(S M+=&(%SDP%26.J,"IX$>O^?K$ -)#(!(I5UX@\:>GV$=*G(QFHP],E)#=G-16 M2#@RUB4:32Q?4 (]'&AN5MK%C8L ?96>UGSW5I]G^?H02J9+<$' [OM'$=)> MLI3!FZ:I9AX*N 2B:*_C>*MIJ6ICOK%V_8E0B_Y_UO=9!J@D7\6#^SIBT_3O MH78_ID4) \B/^*Z35=3RX^O* AHTG#1@ HKG49 C\*K%7)_Q*GGVY&RS0]W$ MKG]GEU:> VMPR@=H:H/\Z'[.G9X0\XJ$'^1N'BGB4VDC>WDHS$/4&G!TIR;: M5N>!RF1J HZ@.,@^7HWY5J>E31H#XA_L2-+ <0>*T^? ?9QZ?\'KEJ*,-)3+ M'63JL$S:#3S1ZCY(IPRE00;!@UG0<\J?:*XC5 0BD$"A!\C\O]5#THMVUMSXV1DE0;:KFD MJH<=GE27]JF9O!6T[^)9HP 0433^$Q>5=41."*Z@?4_+Y]"BTM1,A$$_AW"K M70U-#C^B?)AY#@1BHZ:>JMU;8V9O_';5^0^ ?+_'W>.YJS;>:W'AZ-Z2DZ[W M#DI3%4YB2EDC7(;?-%+(E7F-N5H6::C1ZBD68($D-;-HV<*YH2,9J?D1Y,OS M'#SIT273R0%FTDQZB":=M:Y!!^$^94Y],5I>'M[^7WORD[JVQUOO+<>Z-J=\ M=68K)YGXC_,WJ2JR6/RF^SMQ:O+X+K7<"Y.:FW7FNUNL<-&:G;S3S5#YO (: M6:>IHUHC*<()/$4.:.!57 X_(_9T3S2Q- 2H!B.&4\5_PX_U>O6T;_+ ^]^Z]U[W[KW3M@J Y/*T5(1>-Y@\_P#3P1?N M3 G\:D4@?XD>],: ]; J:=&"]L=/]>]^Z]U[W[KW31G<<,IBJND !E:/R4Y- MA:HB]<7)^FIAI)_H3[V#0UZTPJ".B_D$$@@@@D$$6((X((/((/M_ICKKW[KW M7O?NO=>]^Z]U[W[KW7O?NO=:T?\ PI^[Q3I_X08+;]%_&:7=/[MA9NHH]5&@G>0A?+$/5[271T@>IP.C M3;/C/ #S/^&O0JG:-?MN27#2)!/GIZ"D&2*N)9,9)7.KRX]A"\C&L MD8I J+=I-4BHIT,P0>,TM6&(R<5\@/\ /T:K;?3Z(V-9Z5?U!-<$YX0I#1/B88(QCU ^?E7[>EMLD3SK%,*JI^$>;>2DC\*\6 XX M6O2PSD65^2_9&5J]TU-5C^LNMEHEIL":.-: 9.DQ\&%QE1EJ*@J31OEYC&7, M2#PTU.K1 GU:DTDJV%OHB_W)D'Q5S3CBO[/F<].B%MUNOU1_B<1^ C%> U#U M_D!CH%NS]TT4]-"\"K'A,9%28O T]% %I:V:**OCK]P3/^P\DMPT-*#8@2U$ MZJ&E+.CB1YI!&#W<23^6//\ U#I9>RQQQES\ H% \SD%O\@_,^?18XL-5&BD MS+:917&H-%26D>MFIZ9PE56:0CQT]'"Y"M)(RJS7TZOI[$H8JL<0P% !/V=! M(1:M/1R^@FG7'5='(-,=/D/OT2PLL62\D;&,Z25_>HGO M]?4W^O[ 7-J!+E& RR@5'R_XL=2OR'*SVKQG\$A/[:>?5CNRJ-ZG$PHITRJC M&,-])$&@L@U'2Q1@6"GF_P"D"]_<6;@0)V)X4%>IUL$U0 #C3'^H]+)E9:>, M.I3EHW<7]3J-)C5BH)$E[D'Z@\?D>T'G_@Z7LATZ2,\.G2"C%>(RWE6H6,4X MF?05J*5E-TD#\LU-XSZ3S?\ J#[:,HC)KD?Y>O"'6Q/XJ4KZCTK\NN=!AY6K M1$T7BG1IV\/#I*R$LCP$"V@J ?0+\W(X][>9= 96P?/TZ:$;&0)3/^K_ %8Z M%/'[3&8B$D)DCF!O*RR:'4RA@SEG!4*'C)YY/^''M UTT5:9'H?]CIG2 MF*P()JV*="=C.C8JB0:##&RLMFE7Q@6)>RRV$A&Q^TJ>G>E@HJ8R51F4+ 8V*21H"7EDDN["-([E[ E@H%R M>?:&2=V4ZF-.&.EJ1@,* !O*O1KMG=?1XRGIZ:5 \UUKJX>BU9*)7G,G[;$C M1(Z1)'K*H ?R/9>Y#G62:\ /3I47( H?ET)V:H'7[>6.% DZ(\"QZFJ$C]1 MB2VHQP.('#G3>W^U<^Z \:GJ@.#6M>JR/GAL==Y=8Y.EHZV:#+8]QFHLE3.T M%=25-!54];0Y&CF0(]/4T-9 LT#*JM'-$I47L/8QY3O'LMSMYU/)9)'-9M^8JEOW(W: M>LJFE@;4K*=4$<84_P"J4FQY]O749660E>UL_P L_L/2:S>MH@#59>W^>!^S MI@K?!4XU5>-HJC"SLC>*QA%"T\Q2?QZT8(T-0ZG^RH50/J![9%:XJ0<9_P!7 M'JK$5(90"K4-/,5.:?9UZ-6R"3.8TKW$)BK*5XQJJ8HY%22>FLIEIJF)RK H M=8O>Y5F!1-6)E &E:U##R_XOHXC;ZI-1[VII=3^*G$CS!^S_ "]1(%A4&*5) MD$%7!4+XHS),^.D BJ0L>DB6JIBB2)]!(=2DBXM5G#(#7+"A/H?\@/\ +JIB MT$J!\)!4>97_ "D4!^?#SZ>J:AJL=F*_$1%9_-51QU-&FN6CKX)X_NZ'*X_E M#)%-3U*302( _CE5E%B5-)3JBC,@RHPPXBF"I_V?]GIJ(TEE2.N6&I?+.01_ MJK_@ZL]V 4W7UO@**@GK8,Y0TE3+A,=D:>CS5!G,$C,,U20I-54&7KVBK*AU MFH(-%78DPO%+=P22J%=G/ \6&,^5>('V]"JS/U%ND:FDP!T*<@KYTR"<\5&? M2AZ*GV!V?F<5EZP_Y&\TU/5X;<6!R"Y#(;JTP#3C3!Z+KJY978T -"K DE77^ M%JFI \J]R_X=C'^4Y\P.NOE+UGLKX<[V[ W'UCW5U=OW:TGQDWON/<,F2R>' MQ-!]Q1=,KA]QY@-3;C["ZKW[D*';LV.88V/='7SX^E>"KEPTMQ-;R>,H5V'B M U!'GZ'Y?/H+3A8C++$A\&A#H>(%14$^=1D'UXU)/6PAV]!3];[!ZG^>VRL& MNP8NMI*#Y =A]482G@2FV5+D,Q0[>^:>SL8U)BL<:[*[[V#N'+>7"R_8T66W MOM#!Y.2F&5CEJO:\M32X^VG^'HHT:VDM7[G':K^HXJ?G_/!].KQT=9$21&#) M(JNC#Z,K ,K#_ @^U?1/UR]^Z]U[W[KW7O?NO=>]^Z]T*6P,;HAJLI(MC,?M M:_=>Z][]U[H%=Y M8HX_*M/&MJ;(:JB.PL%FN/N8^/R'8/\ ZS@?CVZAJ*=,L*'I(^[]5Z][]U[K MWOW7NO>_=>Z][]U[K4\_X5I;>RF0^)/0V>I(#/083M'/4.0_RVGC-)_%\3B* MVGKH\<]#)4UC(NWY8'EBJ(OMHYR&203$QHKPT$9^?1GMU:3T&:#/IUH1[+H7 M-74YZ6ZTF!965BA=%K3'YI*Q[@*T-&CQAN>9&5!RQ]DM],51($'?)_@\A^9Z M%&TQ!Y3=2DZ(ZT^T^9^P="SM>KRM;1UF19S#4U-;),]72F"DGIRT(FJI8I' M0Y84$9+2Z==/"4 ,Z@-( 5!.D"F?\ )\J]+3(:G/>34D8ICC]OSZ,+TQ@( M:;:.\=_1RUN/P>"V_4T^.RR+3THJ:VKR%-0OAHJJOHIY),KDZV=*$2TJ(J!9 MZAIM<*),CNWCU*M:L3PSZ8/I3I9;(^GQ4PF5!]?E7[?,?/I[V5L/,Y_:DE!A M)5QF(W+F,+CEDI9JBCER4U3$89Z)SOK'U^5WK! MMO\ 9H*5L^<#20Q5(;'024=8N%:ICD,WA%/CJ.!(W);Q HQ#6N?9_MZ+$CN? M[6E2?\GVDYZ#.X.;B3PPW8&T@?,&E?L 'V=+GNK;6+V131;6PM34TN'CAHZB MGQZB'^,9E(XDD_C&\Z^$1P8NGDG:1J:G823"*Q,:(48K(*EM3,":T!/^0>O5 M;M8HXQ&-6/(?9Q9O(=%,<5>>J7H,/"R4D#/][DE,BTR:6NX$Q'K:- &TWU%3 MP!?V:QKX0UR&K&E!T'G+74@CMXZ1CXG\OGG[/SZE5T=-215..HQJ2BH5BG8* M5\;5;*D3%G74T]6+D6!**#^3?W>,,QU.Y-BA646X!/(/(_(_'LP@3\1X<.BUZ5H!U95UYU6P^,76 M?R"V]#))#C.Q]]]/]E^.-FI\?5??8_AWR3=^!-X6KB33T-/(_ET938%>T:P4ZJK7U:A]66:.$1BFEG#F M.54$DI.LC3&54%C?2]AR2>>>#[2SO1FK4#RZW'%K"@*"?/\ U?MZ$#&X9I:J M(2QM,J^I)"H#J4NDKI,"LR(&TM$O)!N#8W/M$9".'^'I7],":D5-,'_9Z'[! M;'K4IJ>IQS13K((8ITKB4U%;$-%I)<+*'M( ND$_BX/M#)=IW(^*>8Z5+;O1 M2JUZ$_#;7RPDU'%LZPH2XI(Q(3!JQ0#BUP3<>VFEU_9Y?ZO/IQ25 %#PZ,%@L$OA2ID5T,:>>G, M;!HH?H O[J>,HX:Y%AI/J^O/MI<@D?#3B.FV8K@\3CJ)F#"[I35$3F=XY9:4 M+(R!H)#KDJ'4DF%VFU63ZB)1?@GWX?,=.4QJ\O/HI?;?71G2EIX]5S4%1Z;^SO:O$-Q&(LR$ MA54<22< >=?\_22]FB2WD:4@(J%G8X 4"I8D^@'0U?S&O@1AOC7_ "+^T.I: MBDH9MY[+VC1]L=AY"CBA>"N[2S?8>$W;N^:FENRM2X2>H3%TT@8WI<=&RFS> M\MN7+26RCVZ"=JR@ /3R)&1^5>L&>9=XAWK==WO($TVK,WAC^B/A^RM*]?/J MC@3'5]11U%F@J8I:%S+F-#+C*A*6635]O+))!5@$0 MY.@#E8YHBP22*94(NA 93=6' /NDL8=2"./\CU>WE:W=%)J%-0?XA_GI_F/2 MSJT!I(8\C0^?SZ$ 92@N$:L3#73S4^>?0^8]>NUJ9\A3XY':5J_&Q4])CZR.514& MB29WIJ!Y3^J3'3RL:?58K"YC!"QQJ'"_:0PP:U!X=,:"Q0C@H !%,4.!^7EZ M#JQGX^T+]DBOP63RM%09[)4D MFJ0LBU>JIIT=%*+MVM:/&M8P<4R0/L\QZ>7E@TZ$=A&;YF5I%$I&=0H"1YUI M@^O ^>1T7+Y#;3S&#R+S;GADKLJ##!4U,B1T&ZL2LT4S8],[3>"ECSD=7$A, M&56.7[N*RRSEM$86V;).@>$#1QIY'UI3A3T\O+HJW1)(787()>G$"C+QI7@& M^39!''TZ0/QP[ZK_ ([=H4F]TP^.W7M6OQM3MO?VS\G H7<6SZV>FJ*^BH*\ M0OE=M;CH*FBCK,9E\9-297&UL*24M3$_J]GL TAJKW'C\_G7H.'#5U?I4R,@ MT]",UI_L>?7T*>J>Q*;OW^6+\H.H5W!5=B[UI/BYW-N##Y/,Y/\ C.\^T>H_ MD/U#V%N7HCLS<2L0XH>/1+, )&IPJ?\)Z$+W?IKKWOW7NO>_=>Z MD4M-+65,%)"+RU$J0H#] SL%NQ%[*M[D_@#WXF@KU[C@=&&H:2*@I*>CA_S= M/$D2DBQ8J/4[6XU2-=C_ (GVG.<]/@4 '4KW[K?7O?NO=>]^Z]U[W[KW3!N3 M$_Q?%S0( :F+_**4_P#-Z,&\=_Z3(2O]+D'\>]J:&O56%1\^@'(()!!!!L0> M""/J"/P1[?Z9ZZ]^Z]U[W[KW7O?NO=>]^Z]U4O\ SQ>B:'OK^6'\I\4^W8-Q M9SKO8-=W'M>)Y9(*O'Y'K1&W%ELEC)H!YFR$.TJ?(K'3@^.M+?;R@Q2N"EO% M9K>0I36!45^72VP?1=1@UTMVFGSX?SZ^7/N3%Y#:& PFWYH3!-FOM\W41F82 M*8YE;[-'CT+H=$E=WU$MY7:]F]*ANWD:XEDD=@57 (_U?ZL=#R6%K*&"("C- M0T^W/_%_/J7C*[+92E.&QB1Z8X(EF:*,F2"BJ:U:2F266Q)-;E:_[F8^II)O M"+VB0*ZXTD5./+_+TP-3&BX^1'E_JST:'+[N2?9FWNM,)_D6#H9X3GZ4533O M-7O11M14,@'Y^9_ET;H]5 MCA6@C4TH#_JX>GJ>C=]3M4MD,3MBGJ\;CX]I]=TL5328^:G1Z/,;TI'RE;@Z MK.35"M1Y6EPM5JJG60-! ABB(J#Y?9%%"-4EQDEW-#G@O:#2G D?M^70E\5T M$<-5!2,"@\BPK0GR(!SZ#Y]5[;=Q6WF%5!BH%CU, ML"I.Z%M%YIV*DW@A^G3O-92,_P"8>O1'<3'<)M,?9:ZJ]QI@?B?C0?+/ID]9 M"$-XL[ >@K_JJ3UYW1:6NWJ\AXEZ4K]@-=*CCG/K3H-JBEO(N)A!DJ&J&J MLC,',S25TI8O-4S$D2M!&+* ;?7_ ]JXD:73I!SPKY#_)T62.(]2$@D9:F: MM\SY]*)J58(8HHE'[*@>D:FU C45;Z@76]_9N$55"@8 Z1ZP23YDY)ZV/_Y$ M6,V=W%L'Y8?&7L3&0YO9NZJW8^X\EAIF2-VPFZL-G]G9ZKQTTBLV/RN/R&$Q ME135"#5!5)')R1[)-YB5T4N*A@5(_P!6>C?:;QK:4M&U'!#CTK_LXZ#/Y$?% M[L?X9]SUW4^]_-EL8],VXNM=\Q4_AQO:77GWOVU!N2@DCU1)G,=(5H\U17\F M.R097'@FIW>&=XL6A=XI0=)-5;RH>'^R/V=9"\K[S%N$$=Q$1K%!(@X@CC7_ M "?SZ56VS%7TL9DB,M/*H)2<$->R,[E5OXEL+@C\C\<^P!<#PW8>8/E_JX]2 MS 5F0,H[3Z_SZ<:+#RTF35879DLYJ8RRQ'T&\=1#*#=)*74&"D\V-FYM[89E M="&&?+_5\^KQQZ'H.%C.."-A\/'CT-6'Q=/2B%HZ0!]*FH@E5Q60 M:D(41:M)?21Z5;](75<"X]ELIKAO+@?*O3XC4=H''H?-JF$TZ*L:O&IIR)FE M'WTSE69I#:.*GJ(XUN6)-^>=1%_:,T!)H.K>'IS7CZ=/$[)6,C222+!3S.B, M!&YF/5RA4<,D5/2AH<%"RK620+JE96B MF8) #'&@4 (B-XM)6Z&X'U5KO[>A2HJ2=J6D1HEI:5H6F+Q\ MBH>4>15"*#%]M($#/;D?0#GW<:@!B@_P_+IF0KJ8C+8_+Y_;TW_P53&U9-%& MB>*4O-.R-*%CL'29V.DQVCY(LITV''!LJEJ'RX=5:4@Z1Q]!PZLI^('Q+BV] MDL9W?V9B&I=P4L+S];;2R$)CFVZM5 8CO;.TD@5H=R5-'*T>,I7 ;'P2-42 M5$D:PSY[=\DRV2Q[]O$.FZ(K;0-Q4''B./)R/A'$#)SPQD]UO<6/7*FHD(/]DA\XU.6;@QP,"I##^=Y1+5_RN?FFRM&&/3F153]5&C*XF<@ M!02;>+@>YILF_P =M:Y[P/V]00!1),_A/\NOEC[VQ7VU2U0@(4R6+$ WXL;& M]M(/^O?_ %_H+IDHV3]M>D+'20!YY'2!S%&*A09D>05%&8ID+!XYO06BD'^T MR0W0_D,K7_'LEEA9#V\ :BG[:=&B2>,G>":BG^?H,Z;,3H\V&R8:HDHY*B*. MQ]LO%6C*:>?3"2L/TI,E217_5_A_V.EEMO M)U&-CJ(U\.))/C M&F2E0WE]E?\ 53I?:7,D!8!M<38*CB*_B%?,?SZF9%XL6U+44C&;'QM)"9O! M+%*BO5/)%'.DA)#0)(%0M=@JZ"6T@E*(!,&4XEXBE./^SY_MITN=C;>'*A)A MTK@&OIY?L/1POC1OK(+NNBFP>X$QN2C*Q)C93!]MG*:17IY(,<]8)*.#( M*C%XS)Z6OI/Y!+KNU#0RI.G U]/0_9T=[7>NLBR6\I# FB^H^5?/HSG>3+O M#:M-C-WTM0*O'4U13XW)4U$PR&'B=$&(P65GR!5*O9\,1$V+R%'-XI:&6P6<8H0",%:\ 2?P^A'ECRZJ MHSN&JL-7U&/F6-Y(:FJ@%3$QE@JV20C[:60B/36JRE4.F-]2Z)%N5/L4P7*R MQ!R"*4/V#U'R'F/S'0 N+=K9]/$:B PX'/PU]?GCT(\^K@O@C\V>U>O.N\1@ M=O;AQ$63V]C,[T)&=P[QR. I3U+V%%#+C\)E*5_+@JK%;>:HS#4$M1$[4\A" M,T4:1DN3RSQ3 J:ZA\\^1_V.E5K';W%LB.HUHV/Y$'\N'6[YL;^:9B=E9;:] M!\C^M-W=(S;]SFWL7BZ[>6 7&;0FIMROCJ;!YO$]D;>JMP;,S.('WR4\D]6, M33TZB(/4%GL32.]0:3(I6O"H]?GPZ#]QLK,KF"4.%K6AJ<>1'$=7+8;-XG<. M.I\MA,A29/'5(;PU='/'40LR,4DC+Q,RB2)P59;W4BQ]F:L&%5-1T'F1D8JX M(/SZ=/>^J]>]^Z]T)6P\1=IBO_JCQ43#^EAZ ?\ %O;;GRZ<0>?0 MG>V^G.O>_=>Z][]U[KWOW7NO>_=>Z][]U[H'MZX7[&M_B,"6I:]R9+#TQ5AN MT@_P$X!V[-M;/PM)$\]7 MF-TYW%[?Q=+!&"9)JC(9:JI*2&) +EF< #Z^_5\O/K8!/ $]$_SO\SO^6[MB MH-)G_GY\,L35@R TU9\FNF8YPT.GRJ8?[Y&0.A8 @B]S[T3IX];T-Z=9\'_, MR_ER;F=(\!\^/AGEI9&C5(:+Y-],33L\SB.*,0#>GE\CR'2%TW)XM[]7%MB-SP4]!G_,!^8/5W6WQ1WSF-J;_P"E=XY/L+$-L7;6,RW9>WVQ6?7>]+58 M?_(*##UE?EMY&>FGD$>/H0IJAJ\D\$"RRJAW&Y6WM)G%":$4)Z-MEL'N]QMH MW#JNL&H&:C( )P"?]0/7RRN_,K19#M3=]'BQ5?PK;%BG2G5$!BDIY$%[M9"&9F%R2V,06WB/#4*_MR/\G[>ACO$_BWLZC/AG2!\U M[2/L]/LSUSZWQACQ-?EJA&T.M#4P!?J\L8K1!$RN#"T+\$_34ST=A MZ>O^JO3=NH$2L1Y ]+;K*BILY5U6:R9K*FHRV<_A>/I:-_W1BJ?^(Y'=V8^Z M,+>*&FIHGIX.8SKDDDN%@]1;=MX:LITUTUSPR!0?SZ4[=JDE=V0GNT@CT%2Q M'\Z<.C<]4Y>)).R<]_$DQ&3SL=9 CK431TM%D\]34U31T$(IXY!6G%4DKK*B MF,TE+1(/(3,ZQL*GA+$@ .D #\O]7[3T9BJY.U M\EC:;(Q[2PT:28^"I;*5]=7I(YJ7EGU449QHDA@3Q0HDY2<2JD\A720B^Q/M M\)H9FXG ^7KT#=TF4/';1FJ+1F)\S3 I\N.>DG0Y(21+CZZOK!AU<5$])20I M$:Z6TIC>H5$DCG87,:R2W$*$A%0$@F:PFM57N/KT6M<$IX9E.BM=-,$_.G'' MKP^72LGWKEGP-9M/ 4T.&PF3GI9 ^SY]4DO7\,PQ +$::BN&/R)XD5\NF2BHTID\< M:DRFQ\@(#LYL&9C;]-N +V%O9DB! !^TG_5PZ+68FF<=.PIR7'HL+ -;D>D? MZH@#T@C^OM[03P.*YZ;!\R?RZO1_X3\&.O\ G+ENNY<@U'-V7T#V;#AU!,?W M6YNNZS;78V,IXRK#R2'$8+),HL2;$6O[*-Y5A:^(JFJL*_801TOL'_693\)4 M_P J'KBIMU;=^ MZ,<&3QE=3_Y-F,/.ZT>8QY:&4I(M/44X+O[2'<;<(Q%3E6 R#_JX_MZ%6T;O M<[)>1WEL05J!)&<*Z^8/V>1_SGK5^[;^,O;?Q%[7JNFNZL13T69:DJ\OM?<^ M'%3+L?LW:,-2:6GWIL#(U,:R5>->1DCK*.H(R.&JR:>KC1A'++#&_P"WW&WS M/'<)1JU4^1!KD=92DQ"Q%CZK?B]@E-.R5 X>70[B@5])(^71MMI[-ILA3QRS) M*\\$D!6HA*AX R?K*.AD.HV!!XLS:@2PL1RS4- ./KT;B&@4Z?SZ&RCV-F,7 MCXOM7^\H7FD66FB+I74TZ^(R-;TL&;S&X8'2""#_ $1/)J!8CCTZI130D5\O M3J?082HA,TTTHGGEE"4L$J^%CKOK8RF,)46L "#Z2>.!<(S2IKY8Z<-*@4^T M]"SLLF7&E8_ :B.K:&2D:H: 27=EB'E+*P)DN)0. G N2/;$GQGTZJXHV:TI M7I6KBAD*QJ9H?'4L?'+'2K)1S321EG;54J\L.@/I0!B/(OY%S[KC/J>GT/:I M!J..:'^5./0R8C;P:D6.OII?+"%2.!GC1%5525(XX/)(VBGD75J>\A_J%O[L M$J=1'2"5U5ZH<'C_ ,7\^GEZ1WL OU;A5N0 M/=@*GACY9KY<,\>FBP4$ ZF.2?3_ "8'KU8Y\:OB]3XA<1V/V=C4?-1&')[0 MV;6QJT6W[D3T>>W-32J4J=PKY/N<]X;OE_ERH%TC@/RZIV_GLYFGVU_*U M^6"U-1X9L]LJFV_2H[<2SY3-8RF$8!OJU+(;VY]J]O0F\M?0.#^S/6P5"REO MX&_U?Y.OF>[AH(\A&T#*=3IZ !^F,*-+M<_6[%K2JZD6*FWUY*+F$O$_;WKT]; MS%) @- 13_57H"=XXTQY+[E8WC$]%32,UK"HCD4HDAMZ&;05!YN& /'U]EBK MV_/TZ>N,2DTXCCTFZ2I0R:*BI:DJ8V++6MK^V=E4)HK$0AXE=1I,R!F L6!M M?VV5-: "GH?\G^;JJOZ\?ETK,7N++;?J)8JJ"HGQM7'X:ZBE<3DP2HSI/23N MSI]R@\DA85),1PP^1]/0@<.G:FJLQAZNAR MV+S7EHY)8ZK&U[Q:*>9XG63[2I:#PO#61FP<(R,";@CCVG$44N'CI(/+S_XK MI[Q;B%TDBF)C/PL>'V'T/KT>[:_=&7[ P;8QEIVSV'H8EK]KN[54N>H)(I9\ MADMN)]K)&:J4(SS0Q%):A[DQU3%E0AO+&.,J\:@+PK]GD?\ 5CH66.[27*F* M@UTIX?&HIDC[?Y_/HK6\UHX*S0E'']C)"C-!KJ8X6@E16B5-4KU5,:7_ '4= M;-"++H>P*?'UM#\0\ADJK$]J397<&V\U-\: M-Q[IGPN9V-NV;/8*.AQF]?C$U%G5HZ+>H1)L=MN;&U.2U8^BJ:K&F-N[0GA_ MB_F?X3Y?:OS\L=%NXP+= "H^N JH'!P*U ]'Q6G FM*$TZV%@00"#<'D$<@@ M_0@^S3H,=3\9CYLI74]%!^J9_4]KB*)?5+*WTX1 3_B>/J?>B:"O6P*FG1@: M6FAHZ:"E@73#3QK%&/S91:['B[,>2?R3[8XY/3P%,#J1[]UOKWOW7NO>_=>Z M][]U[KWOW7NO>_=>Z1O8>V\QO#8F[]K[=W34[%W'GMMYG%[S-#L/L7-=);$W/AY(Q48/<^& MVQTM1]6;)&@,OF:91XUB,KBFIY*BI<"52D-+3T\3/ M-42?M0Q@LU[:2BG<1@@+W?/A_L_Y>ED$)F():BUI0<2:5/V >9.!T93H3+TF MU?[X]LP14^-Q?5&UJT;0IX8C!/5[DKHTIX,I*!%%+-D,_FI*>.24,D@IK@$* MJ@@S>86FFL[#C+E7C4@^\!AE-*RP[CAC6I M$B&5#'DX$G(1AZ(@0!]"7W D85J<]&<)/T\>0,#CY<>GWK6#Q[0SE702N88 MLIG<%#-(2M4U!44=9C&1I0Z1@U--)523(45W9P!:W!?<*&G0-Q(5LM9#B,-NW)9:FF$TZ5N1JXL M?31U-73A8$AHJ2F5HA I6:8E;DHS$4N9&B ? !=5'V9J.E-O&DID0<5#%OM- M/\ \NB.9/&G+YK,Y6JUO/ELC556I2!$B&IE@:*,L&9:6+PJ$4L^N.G"+%L+I8ZR"Q)%E]/#D:0Q8<_X7O[?$0'$YZIJ'EU-BIF MCT:!&-%U!8"S64!V/#*5D+?2_P#O(]N!1Y =48X(Z@ZS''VH^=,]*[=@LT;&M*\ M?D?^+Z^H#_=N@RYECC I\OCIY81*MD?R02M&=!*J2I*DZ?R#<<^X^=*$/$>/ MQ _ZL'H[U::JXQZ_Y?GTB^WNB.IODSUS6=+=_;67/8.6H.1V_FJ.:/';PV)N M=*9J6AWOUWN8P5%3MO=5%&Q0LJR4M=3EJ:LAJ*9VB)??65IN]JUG>QU4CM88 M9#ZJ?(_R/1KLV];ER]N$6X[7/HF&&4Y21?-77S4_M'$=:XOR.^$7:7PYW+#1 M;L9]W=5Y[)&DZX[DPV-6@PV>J@IDIML[OHH9*C^Y78'V?+T$TC4E>4:;'33( M'B@@CFKEW<-@FU2CQ+!FHDZ\#\F'X''IP/D>LM.1.>-LYNM@EO2+=HUU36K' MN'JR'\<9]1D8# =/'5N/AGDIXWF9DF96$LGH1 RF_#Z=90_52WX^EA[ 4C%B M1]G4FU_34CHV5)C7Q-((X&@GB9(Y*A9(WG5B1(DL<+!E-]+L+N0H4F_YNE>8 ML<8IY]-H Y )S6GETEJS*8^CJ'B&+AEQ]4IAFC-(-:N!H26FD;S+$ZIP61!? M2OU(U>VZGS^SI7](\BDB6D@S_P 7PZS8V3$TM4S4%(M0DJ*9&E\IDBA.PF;IYI(X($6&2.19WN(4 M:5%_;2%V\=F:21E]7)TZK\\>Z A13IMK8A"2QH10]"G010Q(]1*ZK#' [553 M*33"&F#&1WFEOXX8T342[74HESQ[<2F3C3Y]%LS&OACC7M SG_+_ ).K _C1 MT#3TW\-[0WO0J:MDI\CLG;M53V7%)+&LE/N[+TT\:RG.5B-KHJ>0::.,B=E^ MX=/#._M_R,L AY@WB'_&#W6L##X/21@?QGBM?A&>/#&_W/\ <5[HS\L;#<4M MW"G+D',2$'$8X,?Q''PC)WY:DO"P]G&TA6OH5 ]3CY M#K3@""5B>[%/V]:0SP&612JE@%CTFZL7LHYL7!501IY'T'''L=E-7#HI9M(H MPQY=(3)T8QV:IZ@1!8][L ME-7<./2:I7)Z88:FKI9 OJ:,$H8)3)X1<@MXQ>T*AC?3PM^;>V2/+JVJA! Q MQZ4N'KQ3-,(4>IIJMUEGQ$XCDB:Z^N:(2,-3?ZETTR <&XM9-+'J [J,,!A_ M@/\ JITJAET$8U(X'@1^?KTK1)%9'MR10C0ZX M*FM1D'# _P"JG2[DW.^[L2=PUT8CW'352TN=$=/&E+F*J1)JV&JKJ&F\40AJ MA2U8,T6E@49'4V5P53P&"4 9A8U7U'R!_9Q_S]'45V+V(R.2+H?&:8;SJ12F M<\/SKTFL@*&@R1GQJ-5X.K1IZ.GK6:0/126>HP]:Z!"U;CR[0,XTZ@JRK8,O MMU:R)0XF#"I'$$\&^P_Y^DTB^ X9,PLII7@1YJ?F.'[#UARZTD=)!-03U"R0 MUCDCDA9S%744PTR*2 PD(!U(+^@ 9V21>X_PXH1Q^VO5+ M@E4#H^!_%0X/#]G[>KNOY(G\R7%?%7Y"[=ZO[ZK\7EOCWV^V'ZPW'D=P5U5E M,-UOA,W7Y:@DIL[B\@TNV,CU5GJC=-3%F*6LIW^P6I:M@:()5QU1I#VD(]2I MQW>?J*>G2"8F2$]X#KW+3B"*4.KRSPSU]%;XPQ9'8F*W9\>LQ6YG+CHW)8W& M;!W#G'BGK=R=);HHI,SU5,]:E35S9279-!'5[.GK:ES69&HVP]=/=ZO4RV E M=4).5X?Z4\/V]^Z]U[W[ MKW7O?NO=>]^Z]U[W[KW7O?NO=:\/_"@#^5(?G1T?%WWTSMU*WY3]!;>KI<3C MJ"#5D>W.L:.2KS&6ZZ"Q6FK-RX2HJ*G(;=4:F>JGJJ-5U5RR1&.W7?T\GAN? MT6.?D?7KU V">OF]UU/)%Y()X'CE@EDAD#J\/:"04/#KQ&?E\^D#G(3 MCX9J:G\BM6TYAR72N-PBE4R2.[_-]GKTMLBT^.^,OW$E3IDW=WE1X^M4P1&.:'";4I,Y' M!',D>M*=9*J"T0(5BC,WZ;@*2)JYCE ^&*V[1Y]S$$_MKT*=3Q\KQN"E* 'ZSQ6OZA[ M470T*KD5(S3SR1T66CEY#%D*QI4?8:4^VG[1TV:C:K=I[.KH7J*_'YZCW=B*.* MIIJVCBI-RU-9$DU+5T34UI(H&C24/EE0/+ MRJ#UZWC\%+VV8DL)!(JUK377-?.A! Z6'7F3I,7ENQ9'21(I=ET[.T$D;R-- M4SX>KS$@DC5I%5A'$UC+&7IR]S90C)[I/$$%*?'7^1_GT_:LJ-=,:@E/+[17 M^71;)\7X\ME)(DO#45U150MX_%'+%5M]S'/'I2)8XYXY00%15YL /Q)6U,KV M-L=7<% 8?,8SY^74=;G"8[ZY ':7+ GS!S_EZZ>B)9UT1Z=(2-V]=V('X-C/ MK_2 %!XX]F@1J\.D!XT\^LFSYYSUY:,@#]N["P*"ZC63Z;W%@I_/%K>[!.%?SZV 32IZG4].#X]*NC A1 MRQ52QL"RG4P))L.1?WYD].K>&" 1THJ.CG9)8Z2;PU$<<@BJHPXFI*PAOM*E M9%T\TTH#K8CU <^]HE#GAY].#MI0$'KZE?P^[AHOD=\6?CK\A,-*CS=F]/[( MW)F(U;]V'=4.(APN]J:=+EEJ*;>N)R$;JWJ!3_'W&UW;FUN+FW895BOY>7\N MCF-Q(H?R.:_X:=&KIYJ'-?L50,=9$;I*3I)<6)(;ZAA?Z^RJ6,2-K7$GG\_D M>G48QGNRG^#[.E#6X7";DVYF]B;]P.(WALWE,O5;YZ2BRN].EWDDR& M5VA65%1F-]]81N[SSFEG(:MWSL2G+DK4'7EL9'Q4"IB#5*P?SC[?3[9X^Z;$ M&FVRE7A^*2'SJ*9DCIY_$OG49ZRBY ]W+7?O VCF>6.WWH]L5P*+%/Z!O**4 M^GPMY$''2"I\.]3B894@7Q5"DHD=BLD7J)EIW7]NY47N+\6'/N***P&G-?3J M8HY5672S9'KY?:.DOE-A4^0QZ%7=?!<"-AXBC.HMJ9#HJ 0PY86+\CGWI8V( MU*:]+([MDDTZ:*?\ >C\AU!?NMSXFRP2Y_Q]Y#@:0 !CK%@L2Q]>L:3KR7( ']0221SR M>2;_ %]^/V]-&HX-CCTF\Q7555'+#1+=K$*2&*+8$>23^@!-[>]*3Q_P]>H2 M./Y?+K5Y_P"%#NT\7MWX+9[,5$D;9G%U M(6..6+58"VI0C65[:A]";>QZAJ17]AZ*'%5P/]7SZAYV@^^QY*\5:2>>./Z6 M<$&105%_6OU^MO=Y4#)\^/30%"*FAZ2F4QT.=Q=--!J&0AA'C939A+2DZ"Q4 MLXF5&8 V-[\^T%U!XJ=H_4' _9TK0E23Q%*&OSZ _,X2=51VC<>(:0H7@%R7 MTJ1JTAI 2!^G^@'Y*51A4$?ZO3J] U"#_JX](QJ.)J@K(BHM01#(Y'Z+>F-V MO:R*1SQ[H8P23ZCIL_$<]8L=MN.JR=%2>21&DK(XGEIXEFEC56)D:GBNJRN0 M" +A?S]![33J(8I'(X#IV$>)-&@XD\?Y_P"#H2WH*;%8Z-(T#RRY@FIDAJ"0 M9J4F-6IAPVFA5PHDM8R:@;@\$+SEFX^6*^G^ST*;>)5C*Z:]P8T/I_FZ1U53 M-14VYI:9I/'5# UD,L9:(P5E)FX2XD126BDDI)YU/(!U-S8^[HZN8%<9[EIY M$$?SX#I)<1/$9GC^$E7U#R.K^74>&K:99\?/)=ET2J\0-O((Q_E$-R/', VF M11Z77Z_0 4:+PBLJ+VUH:GY\/F/3TZVD[S!HG:IX]OJ!\0]#Y$#B/LZ4>/IO MO\48WC"2T[$"=!P()0+^0BR2HDFDG5S8\6^GM?!;Q7",0 '5OBZ3R3-"5U&@ M(X'.///^H=)B*FAAJ98S&ADCED6LBB9O#/- 07A !_922(%P5-F//UY+4VI* MI(>!T_9\_GGK<0CETE1QR0//_-CKZ:?_ G'[B[L^9'1^P>Y^SMG[GVQM[H' MJ<_%D[WRT]#5[?\ D?/M/([2RVQMS8J(BERM'E.GJ.ES6.R"JAIG[=S+205%!H-?.AQ_J^?2"^C2%?!K4EA(/E4$-_O6/V=;2?M5T6]>] M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=:-O_"C/^3?+ MLW*;I_F%?&7;M]F9_)-E?D[UYB(M/]T]Q9:I(J.Z,!0PQ*@VQN&OE W'$A,M M%DIQ7A'IJBL:B/=MO2P%M*V?P'_)_FZ]@ D#/6FS50F)6C()N2+Z>=7I)]?( M"G58@_ZWLQ91D'AZ]6PWGC[.DUD*&*KA:%U74 0C*" O!]2GD+(NJPYN?:21 M/(=:!TDE?]7Y>?3GNFF^Y^,F)IZ9U,NS/D'*^6IGJB97I-Z=;"GP58E"%!BI M::;9]="9VULTDH1-(1@P/GB:+FF0D=LUB-! \XY:,*^9[P:>70N\02\FP '] M2WW,^(*^4L(T'[*QD?;T6W*H,<[3PU532I-E4-%F(FCB;$U*$U\$%OEC_5\NBD5C.J-J*7%&%,'CGTSD>7F, M5'1YZ#M;'Y'K[K[N799BPO=W3'\0VMV%M&HIZ;178RIJ))\'NS$2+4BIRNWJ ME:ZH4Q>-ZC'RS2T[SS1-3LX?:T(DEM93JM9>Y&]/4'YC^?&G'H8)>"2S@OH% MIN5L=$L7\0-:,/53GU(R*G%9>4[BVKO+<^*WS0/%38S<6)FQVX]L@4Y;;63I M9,:YJ*.2H=!/@$O'465FHY%0:N"R26)]+7( MFV+<$34DI(7UXT)X?ECH+;O9NP4IEAY>9 K^T]+ R4Y59+PR0.Q:G9';UW/8N6Y2HTL"/+H,^%(/B3'D.N $7%V)=6U$?3RQB1E,JBW" M)-_9(LUOZ'VJ60,.'3+*M*\.N0B:0(JL"&-@1R2')9;-J*6,O]..#]/=@0W5 M:\*<>I<'CT)9[\FQ"#46N1:QY9C?@DDFPXO[W]O5@]*8'2DH#:0 A&6X5?6+ M%00+L6"KI+<^JUEO]?=T&>'5&8^M#G/6\#_PF_[X_O5\/NPNG:NMFJJCH_NO M-FA-1-Y?#MWMG&T^^,=2T(MBZG$50_W%*RB5B#Z;?3ZV/\ 3D?[;V&&6F0./D/7 M[.E()KIKTNL57"9%IJQ1J%U1S8#Z >K_ '-C_M^/;;1ALUH?+_9ZLK$&A%4 M\Q_E^WI7T-7/CY$='D\88%) 2"AXY4CE&L?IP;>Z1N0=-*$?MKUYU!^8/#Y_ MYCT6_MOXV83<\60W-UW0T>+SLQDK:_;$0AI<-F*HZWDJ*EPV9JF8^1!I MIJEC>T;DLT9W<%_X^X[#&L5\:M) ,)(>)*>2.?]Y/R/4T\B^ZMSM9M]JY MDF:7;!1([LU,D0. ).+21CR/Q*/4<"-TNW8Z6IK,7E*.7'5M#5STU90U\#P5 M=-.O#P5$$ZF>">FXNC @\-R+$PJ+5X7EAGB,LB3=I/ M%#!5A@@^O3'N;KC'UDC35'VHF$>LL],]U@%V&D%6='U( M/\"PN+?0)Y;)M5< _.HI^S[/SZ)*+4K6G'SZZZ:Z&RG1XXVIMD8&N$C31Y.NI"&KYHQKH*.2Y(J)8A[%W)G)TW,5 MX6G4KM<3?JO_ !'_ 'VIX5/F?PCYD=!#G[GV'E3;4-N5??)U(MX3G0.!F"*T@BM[>()"BA4110 # X =8?W-U<7D\]W=S-)< MRL7D=C4EFR23QJ>H2;?7GZ#V]7S/'TZ2ZJT'KPZAQO-6 M2BGBU>K^G!!/U^GXY_V'NI:HIY]6" "K8STKIZ*GQM E.@$M=6BX!TDA3^MV MXX1 UA_4_P"Q]V^$9KJ/3- 233'6F;_PI^[.A$GQBZ-IGM(^Y-^]K98:VM]K MA=NX_9&'4(K!"\E3N^L8W']CC\^Q1RU ?&N9?1 I_,U_P#JMR_Z"*!2K9I\A M_L]:CTU/#*%CD$BQB0#_/K@K2 MPNHGD$B+84\C/Y2X5&)@J66) 9PBWUZ5,HOP3?W>A %>'KTR:FI(Z320G'5T ML'&O6RS,!\NH>4P*U4_U_UO:1XT$L>FO&HZLC#X:4/2GZIV+7[XR\D5#(L!I:0S35$DB1-"LBE4CB M9N34O'%/(% U!(6(]A[>;KP( HH2Q I]G']F.CK:+(W5QJ5?A!SZ8Q^?$_ET MK\]LG(TNZ(L"8)J*BK6UP)-Z5%/Z)Z0@>HNLL$D;DH;S22 _4CV%9)_TFE.2 M!_Q?0HBLF:Z2(X#>9^?#_5Y]!#FL;.F0K:505/E,A2QT3T^HSM$(756LJ $ MBZD?2_M9!D-W:,78*:>=?45X4/[?V](^.(K5&41202RU$UH MW)?4IEDD\P) 94D07"\@#Z'V9:E\ *7!0*!7\@.BU4*R!E4ARV/\/GZ_X.E) MBJ^"!JBFDD C:HB=ED)2,C4"5+6N +^JW*CG\>UEB64:7�G\L'IFX,;DZ3 MPK0]6N_RDOY4_:7\TWY6T6P=OC*;6Z&V548K<_R([;I(J=$V?M!\A(:7 X"2 MLBFHZSL+?L=#/18B Q3B(K-6S1/2TDZERZC\:4Z3VGB?VC]O29)_I8@2>\?" M..<']G7UH>F.FNL?CSU3L+I'IG9^)V#U=UEMK'[3V7M+"1.E%B2:9 MYJS)9.NJ&DJ:ZNJI)JW(5LTM34RRSRR2,ZJA5"J,#HJ=VD9G_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZAY''8_,8 M^NQ.6H:/*8K*4=5CLGC,C2P5N/R./K8'IJVAKJ*I26FJZ.KII6CEBD5DD1BK M @D>_ TR./7NOG3?SU?Y)^3^#F[HK*_KO-5[,N!RCL\E([)C:UO.*6JR(CL+U;@"*7^V X^O^SUH" MA+ @#K6BJ*=XWTLK, ?(6*FY6Y"W;@OXP.">+C\?7VI>.N1Z=6I4?TN'2EVI M2X[*1[GV/E9DHZ+L/#X_;E/DIEII$PVZL=GJ/,[,R\TTREZ?'Q9@24M8\(,S M459,H5O85Y@BF@@@W:VB+36;F5T%:O$5*S* .+::,/FHZ$W+9M[J:ZV6]F$< M-]&(4E;@DRL&@=J\%U=K$9HQQT5O>^"S. R.2P>X,=4T61Q-1+BPM'=1L8Y$;B&&*'U^7J*'SZ16,R^1P=535E%&*M,?'-!334H"U]-1U M/JGHW51Y:G&58)9J:<%8RY:)X[('F M/FOR/Y$=>KP[ HI,;R!9J= S,LT6IO6MVYYU?4I?"_!<4) M4]K_ &^1K_EZ=:1<2VU0K9>/AP\Q]GJ.E8G:62GV_+M3/P0Y_!2-%44T.00I MEL341>;P38^O5UDD$/D=5$AD30Q "^VY+ %A);R>'*#BG _:/GT_%NA\/P;A M/$A/D<$?G\NFG'[R>DHY\>J33TU0T3M%4TE)4R&2#4*>3RS+,L,\2.\9="I9 M7L?Z>["T97\1"JL>-.'Y#T^75AN2:/"<,R>II7Y5->(X=*R+<]/48XSEIDJ? M(^LU$[24\E-X46,,7E$U)5TV@C4#^@@%R<\M1%2:ZB:"I'EZ'S_ #Z0;E:QJ#)%2GF>/Y8QZ="*B$+JMQ8$R FY8633Y+W& MHK<76ZC 'G_J_ M9UL(?\)V>S_[J_/++=/R5:PTWR*Z5WEMO&PRR^BJWQU4/]*VU***$D1FJJ=M M8GOY$4/\Z=+[-]#T-2"*8_E_EZW:Z+)5." MR:T]3?QL[#2X:\; \@@B]O3>_P#3V R0.TG'SZ,?Q:E/#_53H8:&6&MA6>%E MU$7!4@7M:_TO<_ZWU]T(Q4G%:&G7AGNSTJ:"KU#Q3CU@6%[BZBW!-CSSP?Q_ MK7]MLFL @]WKUNM#PZ4-'-XG9 QT8KGH@_P#H]W]NGL.7JJ;%UVV*[""CKMVY^6G^[HZ#;567 MCH:K#5;7H\K79TT\B8U49D4I))*JI"ZF(]LY1W:]WR79[V!XA%1II#D!#P*' M@QW,?MO;U!!C,3C89%IJ2'U'7*YFJJJIF;]VLR%;4,9:B=[R32$D_@ M#(/;MNM-KLX+&RBT6\8HH''YDGS).2?7K%O;? MGZV]MBK"M/SZ\@J<#'^K'2RQZ4N%I6KJFQ954J+"[N;%40'DDGC_ %_];VZE M$U,?A\_]1Z:-6[ ?/_B^H4]>Z15.5KI!')+&TGUL(*>-2P1=7 TCDDV]N(K. M0QP?]6.JNRJ M<#S]3U\Z_\ GD=S5?F@@7R4$X^9KU2LSF.1"MCJU M!1IU?YUBK.W^T:EM>W/'L^_+HO=N(I^WK-+31RH\+ K&Y0LT1(EB8,7AD'(O M)"RZ@1R2+?3CV[Q'503QZ3];JD?PR1Z:FCT&J10H26&5?VJF/F^B;3SI/#7' MX]L$5J#Q'7M5&)\N K_L=92Y1=5W9%1 &M]5OP+M9692;$FP/UL/;! KZBO3 MX)%#7-.DIN*BIZW'5 *1, K>LBS+>Q A*B^H?T^E_P >VIXPZ'&/]7^7IL:A M(IICY]9^AM[8W8%-EJR0X]\E/'F&,-72&MIHUJZ8T,$:QLLBMDDHFF@@N H> MI8EU&KW&>^5EN5 /8%H!6GG4_P"KY=#[EWPX+5W(!D+$M\@10#[:?X>A_P 1 M-0[^./KX'BR&1IMM9%<7(\B15-1E\UE*;%T CIYHE:]-//=3'<@@2,;1:5#% MU*R:8^ +9'R J?\ 5^7GT-;"!)@\ZJ-:Q-I)(^)B%7!^W_+Y=%ISFU*FNRU7 M4"I<9%-PUF,J%D5ONZ61-[Z@'MR.6'LQ#>'"@ P>'0?FA+R MDEN_45^S'[?+H&\S22T&1?$E2%PL,]/+$19X\JUQ/2W .@4]_ MYCGR#VO\?^D,9%#59""GW!V#OW,4E7)M/JG8M-.L.4WENV>E E$5IO!0T:,D M^3KI8H(RIDUH(H4/A1R!OB%:>G1#<%8M88&JFGVGKZS_ ,"_@ST=_+O^-NRO MC7T/AOM,!MV%]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O? MNO=>]^Z]U[W[KW7O?NO=>]^Z]TF=Y[,VEV+M+<>P]^;>S0U-KK,MNKH'(9>>..BVSO>0QM49#8U973 MK2X;/L\K>0QT61T534T^1$5E?)< 128F_D?L^?RZ]FM:5'I_J\NM<>2G4:XI M%+Q2*H>-]&I](U.'6P']2/P?I:_U>D4C/[.KBA&.'47>%=C,Y0QC=RC[F.GC MQ]-N2%$>I^TCM!!39VG"-4Y%*..2\4X7[J-%"ZV4$$'W.VS[6TL^T,/I')>2 MT:GM)S@]"U-VM][2"WW\'ZR-0D5Z@&O0O!9Q2LFBO:X[P* D M@9!'(;(&"A>FAJH\CCH*RJ/\7IJJ#)TLQ15<04T>,EE6&,,?]WR$>JWITD - M_O42REF1DET"D9!4C[=7F/ET8OL_T\)595DB5S^J""IX8 4X!^9Z#[(4M'!C MZB>6?2T$SST?)CG-3.Q\:4[QV9"+:F/T"@@\6N9Q3R-.J"/! #?8.-?\ Z)K MB&*.VED,AJK57YD\*''I4_\ %58<=5*U1+'D::GK(OW0):B,"GJ%9@X-0R$% M9&XTR(4>_)-^?:YT!4>&Y!KY?ZN'1;#(-1$JJ13B>'#_ %9Z;YJ01.[P/(D1 M?4$*M)'%$Y'C"LS,\R:CPYM?W8O$M53PQ(X:1_)3B MHUQDF)X@Y$T#V.H$E3<<'VML+5C*)%6BC@?7Y=4GF[66M6.*=&&73&J(SJ%' MB\ME"@$JBWC1KWL."+G41^+^Q,%H*=%I(S_@ZE4L,KM!(X:!_I#:QT0,2KEE M%T622+^I!07 _K[V!D?ZN/7F4 >HZ4M.IX(92%%B H 5-.D(ZZ3_ %LH(M< MV^OMY< ?Y.J>O1X_Y=7;E/T5\[OAOV_554E+C-F_)3J]; MJ\S!@J1C;F\JIF9C8JO(*W]LWB![2==->PFGS&1_@Z?A;42*G\_\G7U!.S^M MZ:O2>?'C354SR*KJH4LT+L+6']38^XRFB4AU/Q+BO1JCD@-7!\N@)VMG:K$9 M)\1DA)%)&VDJ]_JK6.B]Q8\'VDPI*$4/^QT_Z&O;YCUQT.5-*E0@D0V8\^C\ M@V(/];7_ -C_ +?W4@#\O7K5>X@C/3C'.UK G4OY)MJ"_2Y_U7!L?;;=P!'Q M]7!XYQUQJ]WPX>E5Y%>6H>04])21V^XJ:ER2E/&";!S8EB>$0%CP/>UD!!H> M_A^?6PC%@*T'J?(>O6#%35,CR5^2F$U?52>60IS!3*;&.GI0U],,"66_ZF)+ M'D^WHEI5SESY_P"3K3.#11A!C[?F?GT\5%<=))8G@\6XY'X _J?;A8*!U4!1 M6F.D\3)6.0+^,'Z\CZ_[P3?VV:N0:8X=;Q0DWE0!:$]O39)-0//'3:M4D#VK65E5MC-T.-9T!QM93^5/U:Y8'0V;@W53;_ (W[4C^& MOV],J:,",#KYXO\ .4P%)M+YKC:F.B$7\%Z%ZB>>-0;_ '>9KM]YF0LP8*TL MJUJ.?I^K\F_L;;$P^C9BU:R'_ .D]^>]8ZA)HEB,)")4HI$]+Y%80RJMB\3,5$NM;.LG"F_'-P&Z CAGKQ8U MJ#_J_P"*Z36ZI%@VSE:N !---)&\A*A=9LL8"C2RNS_0<.*$GC^0Z&'8^YY\+)29%:F5'F:6FCJVCA=R[>KT?.[ER&8RTHK%J:AJ9J:*GS,^8FK'!%#08+' M2M52SRD2-4+3QD"24(&7D;Q'1D)C I4'C4TI3S).,?,^72YHE:UCN(W'BN23 MJ_(U^0 S^SUZ47PV_EP=_?S"_D%B^B_C?MN2>N4TF=WSV9N:&OH-@]<[,>L= M:O>N]LK'25$RM4U"O!24,*RY'(U2&.&)BLSQG%E#)=4 7N'[!_L=!?1G;S-0/3H M^WOW377O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O? MNO=>]^Z]U[W[KW7O?NO=-&?V_@=UX/+[8W3A,1N7;6X<;6X;/[>S^-H\Q@\Y MA\E3R4F1Q67Q.1AJ:#)8VOI)7BF@FC>*6-BK*02/>P2""#0CKW6A3_.;_P"$ M[VY^B:OCL7)69/>O3\,M2DE;EMJS,,AF-U]6TB2 M.]0H2;+8&G4RRO44:35-*8_O+]%O'8#2"2Y] *YZ?@C^HEBA5:R,P55&*DFE M*^5?^*ZU6=Y;=H=OP4N.RN:MJM +)&C ^P3N&^27K2+:K(8>!;@"1Y*:"H]3P\NI"M-DCL &NA")Q4Z0 MVI@/G0DU]!D^O1?-JT826HK*5RBN /1>.?7[?G7RZ=D6W748R:_B? J">' 4'RZ!+*5=17RYJ MHHJ(_84!2BHHY")O(\55&E;.EE!DYS2GE@? MET#+V^$T\^E?TE.A!Y8.6_VW^;I,2T\;EWA6=3'(D>G3P+J7IS?@@QH"MB+@ MKR+\^U@4^G2#4O%<>5/EUD#S01FGE4NC(D9+M(&C43)*OC(-R&T@6X"W)'/N MKBGEU[55?Z/#IZQ--#43:I4CGC5TC598],@0.DC:C>[*-(X)/^)Y]U1J.@/" MO3@!*L<8X=&IP<.,6&F^WE5&?P:GDF"V"A0NKR-=1&MQI) 0'ZVY]BZ'PP%5 M3_/]G\NB\@9!]>GR,"9WF&KQ(R+2ZF4LJ@W:J8,;*)4!T!N;<\,19]17(X>7 M31!\O^+ZE0^6ZD*TBR:)V( ;4)"0797\>EF"W_P)_/MP TX_;U0FIIZ8Z?Z? M5I+60:"$3I8ON\5*+ MAX\M27J,=*& XD@K(HW4BX5@/Q[V2*'T(ZO&:'/ ]?71Z4[,I>[>@^DNY*5H M9:;MGJ#K;LB-H7\D3/O79>$W#.%<<-HJLA(I/^J4CW&EROA7,Z G#4/^7^?1 MI'E :C_5_L=);?6RH,E(:ZD58J^G.L,HTF5/J5NH!NI^G''^M[1RHK '\0Z> M0TXY!QTQ;8RDL9%+4$B6%FCD5^#=;<'\_7VF/%JGI]A3SQTM\IDJ/%T$N1JI M=$,2*=0NSN[%4CBBC4%I9I97"QHHU.[ 7]MG%*]>XD #->D7C*:KR5>^;R: M&.LG7QT=&2"N,HR5M%Z?0U94!09W_J BG2HOI$J[L0:GJ[LJJJJ:H,U]?/\ M9_Q?2_A4HH)Y 4<'\V8\VYL1]/:FM &(_9UH8#'Y5-.O>-ZJ3QK^C58^KB_' M^ O:W^P]LL23CJA;Y].\-,D(50WT Y_H+#^H%[CVH0444ZJRDC-=/E_E_/I/ M9>M>OJOX/2M:GBTMD9T)L01=:96']MKE2>MJ=(+G_:CUZ[ M,RPQI2TPT\! $'T4 @*!;ZV]NII! (SY=-M5L^1_R]-.]J9*3:=4.!))%(69 M@ Q+*;\GEOKQ]/;@ % ?(UZI6C?.O7SP/YX=1YOYC/8\*6/\.ZCZ!H&/*BYV M,V2.O202$_B/ '];?ZPYV&@L%/\ 3;_)_FZ8O3^LH'D@_P )ZJ08(SF742Y* MKSZ H()1V;2%9F'UO]/\?9V*9KT6D &GEUR"E/H-(UL&!4!]?]L2 6,;7YOQ MJO\ 6WMS'GU8T'E_J_P]<)%5RUM-_(+*$0*&_49-0_M7%[\WO]>3[TV:T&>M M$U/3964=-*4>6GBFU1Z)"ZCU+=B-D-O:@Q= M-M3,M!2()(XP8D9'"QS2R1JDA1')8VL!P2%-AQQ[17\<:VD^E,T(%,<>G(R0 MZY/&I^SHI]/5B%:R"=D,JN902#S!-)Y%L#8B-)&*V T@&Q]@.2(LT9R*>7SI M3H0Q3!0RX-1_+I6T>0>7&P1QR/%)%4NL_P!#JBE$:*Z(0"+%2&YL2?J.?9-< M6ZQW#DK566J_;Y]".WN!-9Q*#216HWS!H!3_ "];#7\HG^7U\@/YCV;DV%UE M@*W9G1NVZ$X3MCOG<6-KIMD;3GG>/*28G;RM)2#>?9%7%4K-3X:EE$5+%/'4 MU;TXJ?NT+K;:IKV<2' !J6\AY4_U?R'1G=[[:[=9>$160I0(#DGU^7V\/2I/ M7T@_AI\*/C[\#^F\1TI\?-H18'!TI%;N7<^1%)6;X[$W)(99*W=F_=Q04E') MG,W5SU$A0".*DHXF$%)#!3JD2C2WMXK:/PXACS/F?MZC2ZNYKR4RS-GR X#[ M.C9>W^DW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7 MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=:EG\XG_A,[UM\HZO=/R0^ M"5!M7I[Y#UHK6>1JRKRF DBA%#UAV3EF+AY= V_E:MEDJ MXZ&:6KR,J&^MFGA(BIJ'EZT\OE_JX=&VW7XMY0)ZF,_B\Q7S]3_JX]:(G=/4 MV].@>P]R=-=I=6*::'2Y+]JVR20/+,#6I ##-,:JCRJ* <,="/[M M;KI)IUK6*"O#I'9G#Q>&:?Q/Y82A<16#21:M))&DZ'5@.?\ 7_U_9;<0C26I MW#C_ *O7I1&PU '@<#IOHX N.;^Q"@*J W$=) >X?X*=9E:.RZ 2#K"^KU,;77UA M% ,AMQ;\G@CV^*'A^WIDDDUIGI[H[2Z#J9XRJQZK6E5M7&EB2L@L-.HCUFP M'^&ZTIC'7LTX=**@=@%&DI]2@!!5KL '#HALY!4$_3Z6_/O0/KQZ\!J-*_;U M])G^1!VH.S?Y4_QA$U6:NOZPI>P>DL@6P^I-_Z\DV]MT! M\OD>G48G!]/Y_P"3ICHHIF/MNFHAB.VO#_+T]_9G2OQ'C_J]/\/0CT5(JVXL!?\ 5R.+?[8_[;VZ M FR2#D=.00N;"Y'/-^>/SZ3Q[98UP.'^K]O5AD4.#\O]7ETZTT"1!;_J M/TMQ M![V'*D"M6\A_EZLHJIKP].F&*%*&G\"79V)::4\O)(W+._U)9F-_Z>WU73PS MYU_R]:>AT\*]..+I=F2?PUZ:NSB4V]5BQ]- M.U_R";'@@7^OMSR/D>J@Y&!2OGU\XW^FDH/JOV=5>H&9+LQ9]3K+Z38 / MR6#DN-0/^((_KS[.UR,<.'1>WX:>G7,*&!U(Y,BZ%!5KK(2ZDL &UC2.3_4^ MW ,\.O?8,]8W)^A"*SE[:"/VWTHI4)S>X7F_T(/OW'K5*"F?GU"J-2 -XRR M*H!<'R<"Q"C3XPS@BU^#_O-&%. _U?Y.O #U_/I*[MI0V!KO*D>O[=G0:>5T M 'T%@+E= '^(!M[37"ZHR*9ZNI&0H/1)ZA U4$=DBG#.B2AM))\ATJS$ ,WX M_P!;CGV"'70S@^O1NC*P3(!X?ZCUML?R9_\ A,IW?\N)-J?(/YPT6Z.@_C'4 M+1Y[;FP'CGP/=?=V-E;S4;1X^NIQ5];]?Y.$"092LB3*5]*R-CZ<05$61C9: MV28=Z]GH?\GIU=K]K<%(R#)ZC_+Z]?1IZT.F^E-A[;ZTZPV'BH M\-M39FU,?'CL1BJ-7>>>0JI>HK\GDJV:2JKJZIDFKA,]VZIU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>] M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW M7O?NO=>]^Z]U7;_,"_E=_$K^9#L7^[??FQTIM[8BBFI]B]T;/6CP_:6QIG6? MQ1T&=:EGBSFW_+4NTN(R<57CI#(SI''/HG2\;M&X=>/5@Y *U[?3_5Y]?.O_ M )G/\BWYB?RXMT+OVMP%3W?\;"U10+W[USALC48O 4?5: #'#CU3]-#$E M*?2OH0:0>56UU!N+FQ5CSR./Z>S%J'KQ8'"\.@RK(=4S >M)%82!>/3R&&E2 M=1XY^E[7]E=T H=J=M//J\-6< <:XZ:HJ,Q2TL,::S4.9(E$9#I K@F66/3= M6:1;#^O)'%C[#=M!))>$Y[ /WBHG\H'*Q$:20 2%_IW6,@@#UI\^-?ET2-5B68UZ4[H- M2E)F 4 NR )&2H5A>\@/UMH](!_V 6TX&O2=JT.*+7J)&R1R/XE5D(9#$&/ M U,SK_2]^.!.?MZ4- X0@N 2UM*J+L7;4$C9BY_U-AJEB4.6>%MR=6U#.0 MH"RR7)+/[!_,D0\:WEJ:E"M/+!R?MX=&%LVH$ 8IQ\^ME;+5D6/BGJ9I4BA@ M6262:5E6)(T!9I'D:P547ZDV'^/L+$9:HQTK6M0/.O08L]3NNL@K:U9(,/32 MK+CZ&0%7K9DYCR-;&;,BH#^S"?T_K<:](1L]^".P?X>G;^]MY@TX=; ] M:UZ=*>F$8O8&PN+_ .P(%C^..?;/'[.O"ISU"S&6BQ4'D8>2IF;124R6,DTI M_2 OX0']1^@'O3=H!I7-!UL"K#R''I.T-++ )*ZM8RY"L >9[\*. L,7/IBC M' X_/\ 7VXB:22P%3Z?X.MN*@ @ X)QQZSI&TTESP">#Q>YX L;#G\\^W MP)QQ(ZKHH/\ >E%11!&4 6M_AZ;6-OH;<^[JQ6H_U#IM@?3' ?ETE.T$_W MZ^18J+BGE(N!:UC^JP/I!'MQ16AKY^75 :$9Q7KYP?\ ./6-OYC7?X6_[V(Z M>DD4!F_LL88K8'7R0!&CJ$U+Z7!(!+7O M?^I%_I?V[FN3U>F14_ZOLZXOZ&M)PIY:,?3@@W+ W#/>X/X'U]^%:\<=>'EF ME1TWR1*?(0J@LUZ>VK2P+G6R@7-Q3JKXT]6;A['W#,D(S63IHUH=G[+Q]2)57,[XWCDGI=N[7QP6G<(U M541RU=DB=)=RQ0QL9'I7@/,]649Q6G#K>/_E1?\)GOC#\&JK =U_) M9=L_*+Y14,M+EL949#%/4])]39F K-%/U[M7.T<%1NO<-!4@-%N#.4RS1O'% M+14..F5G<)2LKNQ446O3^MJ4K]IZV_=>Z][]U[KWOW7NO>_=>Z][ M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NHU91TF1I*K'Y"EIJZ@KJ:>CK:* ML@BJJ2LI*J)H*FEJJ:=7AJ*:HA=D='4JZD@@@^_=>ZUF?YC?_"9#XH?*MMP= MC_%JNH?B7W7D7JEC!%$8H0$900'6-K+XT%B+Q:=*<#E2!P?S[ M7A111P'ICIHNXKG]G664*$9CY"P1[,-;%F4J%*ZOVV0*WX_LV(Y]VT@BG5"Q M\NH2!=06Q>_*JR>%&=2Y4N%0F%8EL; F]KD?CW4"AXYX_P"KTZ]QZFQ*WIO' MI )8?V5N!X=>^SI0T0T >K6SV5W1@X,C.MA(;$6 M<1@D"QL./H?;H(J*C[>MB@X];)?_ F:[@BV/\VNXNKLA6B"@[I^,VXJ^FCD MG$<1W#TKO# ;UIF=&!621MK9S-E?RH1C>U[D',48^@$P [9 N?(-_L@=*;/X MJ9KG_8_P];HM=4R[HJ$J:M3#A:699*&A(*/7S1D,E;7(>?&C6,$)%E-G>[:0 M@$8AQCX?\/1NH:.I_$1^SI0TD9;2MK#\+_3\"_T%[GW6@%%'6JXKY=*VCIQ$ MER!K //^/!^O^MQ_K^]Z0:5'6P3VDC'E7RZ=Z> $ZV7@?TL/R/Q^.?='.KM' M'AU:K, *?LZXY3)4V+I9*BH>RH"$4$$NYMIC0#U:C?\ I[;PM7/7B#BGKTC: M"FJ:ZI;,9($2R<4L!X2D@L"%5;<,PY8_U][123K?B> /D.O,:=JG/F>GIT9V M_%A8C_8@WL>?S[>%/+CUY0M 3Q\_\W4J*-8_J#_O! 'T%A]=)_VWO8 I4<3 MUJI9"//UZ=*0W=?S8C@_CFVF_-@+_P"/OQX?YNFQ\)KQZ3?9$8DVQ7J?H890 M0?I;03S[VCE10<>O* 3GKYM7\X202_S'OD@BC3]K)U70O<<%XNGMD%I!HM>. M/R"Q^I)L?I[D'8P?W;"2>+'A]IZ07^;FK?P#/Y=5HW)LK+"PN;D>H+"%_4H8 M EB;<7^G/LY&!2G2&@'#K..;,[G2;DK^I[:@ KM8DZF( L.1]/;HXX..G,<* M_P"KCT)'5/2O;O?6\J+KGI+K/>G:V]LJWFI]N[#VWE=T9<1>6.%LA5TN)IJE MJ#%4CSKYZJ;130)ZI'5;D4EDCB77(X5?4TZV5)/^K^?6V)\!?^$M&=RYP?8W M\P;?']V\5I95 M9/9'<[P!5;5<_P ;?Y!_G_9UL* :G)ZW"ND>A.F/C=L#$]6]$=:;1ZKV#AE7 M[/;>S\3!C*66H$,4$N2RE0H>OSN;JXX5^XKZV6HK:EAJEE=N?9')(\K%Y&)8 M^9ZMT+GNG7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z] M[]U[KWOW7NO>_=>Z][]U[KWOW7NF?<&WL!NS!Y7;.ZL'A]R[;SU!4XK.;?W! MC*+,X/,XRMB:"LQV5Q.1@J:#(T%7"Y26&:-XY%)# CWL$@@@YZ]UKL_-#_A, MK\%/D8^5W7T(^8^(?9-8TU4B["HH]R]/5U;,0[/D>J,K74(P\)""..+;^4PM M'"K,QII6M[,(-RGBH'[T^?']O^?JI53Y9ZU1?EO_ ,)_/YE'Q2?*9:GZ@_V8 MCKZB,D@WS\=)LAOJ<4QB2<2Y#KY,?C.SL>]-&Y^YE7#ST%.8W/W+QA9";P[C M;2\6TN?)L?SX=-^$1A<]4KU]#78JLK<;EJ>HQ]?CZB6FK*&OIYZ&IH:FCD>" M6EK*.589Z:6.9"CQNH9"IN%)]KP014''52./KTW2*$:S!C<-H0@*\L.C2-(6 M,AF4 _I%B/Q?CW4C/5:<>NZ2.S(UBL-Y':36)2IB"KK<>E#2%@=!"(P5Q>UU5'4 N_#&W-P/I_3Z#W8#KW5CO\J?LVFZF_F,_# MG>.0J8J?#5G=&"Z^W$\KA86V_P!O465ZGKEE:\:>**HWE!*=9MJA7@_3V7;O M#]1MEY'3.G4/M4ZO\G3]J_AR5!^1_/KZ13024\CT\RZ)::5H94L/3+&VB12# M>VEU(Y]QO@T-<<>C:M!PXX/2IQE(0%>0'_>/K>_ ^G 'O3 _8/\ 9ZMC@>E/ M##=A8@B][WX^O-Q^3_3ZGW5S0C^+_5_@Z\!J-3\74BNK(0K4;AKQ7U2,*.%O\C@8 K;5?S.#8%F'T MX]MJ#*=3+2(_?;QZ\] *4\O\ +UD:W Y^AL+_ (L >!8G MGWOS/7E!&H$?/J=1<-ZO\/\ "RWLIN+6M[T1@T/5,&I4_;TR]@('VU7 W$$ MA!M_:TFW _VWOPX$C[>MJ*E17SZ^:K_-^:0_S(OE%I9GT9SKY 01J1$Z>Z^) MC O_ &23_M1O_K>Y#V/&UVO^V_PGHMOB?J"/0?Y.D'\5?Y:WS@^9M112] ?' MGL#<^V:YI='869H!LOJR'P _[QS4^-Q>&FB*AHJYM1L4S[RQJMLE!ZMQ_9P MZ<"@?/Y=;2'Q^^,/Q\^*FRDZ]^.O4.QNHMJ7IY*VAV?A8**MSM52H\5/DMTY MZ;[C<&[LQ%#(R"MRE55U>@Z?)IL/9/+-+,VJ60L?G_D].K=#M[;Z]U[W[KW7 MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=%!^2OP#^&'S IY4^2'QOZN M[0R4R4\7][,E@%PW84-/2P_;P4E'V5M>7!]@4%"L-E,$&2CA8(NI3H6ST5Q- M#_92D#T\OV<.MUZU^OD1_P ),_BCO:6KRGQN[\[6Z)KI9)ZB';6],;B>Y=DT MR@RR4>+Q7DJ]C[UQU'&Q6/S5F7R\RH-161KZC"/=IA02H&^8P?\ -U0HIJ:9 MZH^[M_X3!?S.>K)ZF?KG&=/_ ")PY\M13R=;=D4.UL]'31LOHR6%[=I^NZ2/ M(.8O+X:*LR"LME#NYT!;'NELQ&K4OVC_ #=5T-Y$=51]J_ 7YM]"^>;N7XH_ M(#8.,A:5SGLSU;N\[4+4W-0L.[:+$U6V:OPQC4YCK90J'40%(8K4N8)/@F4_ MGG]G5"C#\)_+/^?HO&*SF1VMDL9N;%":/-;5R^+W/B2ITRKF]LY.ES>&=$4) MXW@RM!$6Y)#?2WT]O.NM60_"01^WK:L589(]>OJV=<[JQW:FTMF=HXF>*JP_ M9.R]H=CXR>-DDA>CW]MO%;NAT.A:-A''F0G!M=3[BJ1"C21G!5M/[#3H[4UT M^A%<="]!#91&H'X_K]#R?]M?_8>Z8%3U;XWU>5?MZ*CA:65P@0%B21P!_ MA:X8'VW2@)<]>)R0!CAT&M7/-N.N"^I,="]U4W F(;]1M]4!^@]M&LST_ .G M*:14"K_X.E;!"D")&BV"\#^EB?I]0+6''UY]J:"F.J C!IW=9E4D\WU&XY!% M@.+FX'%O?AY8SUZO&F6^?#K*0H%@/I_:)%_\&-^>+CWOSR3U0$EB3Q'7<%/4 MU,GCIH)JF2_,=/$\LAX!-HXD=K 6_'NRH[#M4D?*O5M2JE"0%KY]*K';6SM0 M$;[!Z=/H&J2E,5(MRT,A6>W_ ""?;RVD[ =M!\^F?'C6O?4]*"MZW7-43465 MR!@AEU).N.4-*\3#GQU%0@6*3G@F)P+#@^U"6 %"[Y^7^STP;FE-*\/7HJV" M_E=_ O#]Q[N^062^-NP-]=S;XR]%G=P;[[.I*GLBI_BN-Q>+PF-K<'@=XU.7 MVCM*IQ^+PU-%%)B<=12 QERQD=W8UCFFB@2W25A"N !CB:^7'IB1S+(9' U' M'1]X88J>**""*."""-(88846.*&*-0D<44:!4CCC10%4 6'MOJG63W[KW7 MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z] MU[W[KW7O?NO=>]^Z]U2K_,:_XN60_P"W*O\ GHO^WC7_ !NB[_[+)I_T4[+T_[+5_?' M_0%_Q;(]7^A33^[_ **?)J_@6O\ Y=WAMZ-'LCNM/CW%?#^,_'JU3_ %_3_O/M#)X> M/[/_ (W_ "Z?&K/Q?\9KTD=W:?L6U:_Q_P =?#?T_K\?.G^OXM[8FT^&>%*^ M6KU\^G4K\_Y>O^'IJP>C0G_ /Z+;_@1;_D#\7_U_?H=/9PX_TNMG5J--7P_T M>E7%X-1\GV'ZA;S_ ,2T_7G3]M_Q/^P]O]E_=>Z][]U[KWOW7NO>_= M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW 2OW7NO>_=>Z][]U[KWOW7NO_9 end GRAPHIC 35 jnj-20241229_g4.jpg begin 644 jnj-20241229_g4.jpg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end GRAPHIC 36 jnj-20241229_g5.jpg begin 644 jnj-20241229_g5.jpg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end GRAPHIC 37 jnj-20241229_g6.jpg begin 644 jnj-20241229_g6.jpg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
  • -WS76LH'7O*, L?,Q?^/' XJ9[6 M@N!^GNQUP7?W"BJU;?-"&B:CL08(33*ITN<2<2*AOV&<>E7-/1H'9/D=+\AN\2U"AG6;2Z/@N;4XBJOG3K9;\65; M\8)+5OU6:+^E:^_$D^U.?-%.6'L#]&>Z$WG9S'.6VE^P"W>C%'\#LF\N%3X, MP0RD+&DXA:R;\1A4381> 4+OW-%G5 VQ-JIZ\2)7W48HQ31(X@O%-00_GYJ MBGFG.VH"G@T#X&S0YB295)?B<>ZKJ78BF\)<+,3_$T ],I@KXQ:59]SAYAAL9C**T)&O:YFZ#F8 6LLK:6D[12_6IAV0F@]/DLT,=0M2CJ@N+-X9J;9>8[(B'79 U5?B^Y M^Z#P$BK*E99]7%;O\(1V2DNQZ2LP974L>PZ5."8P'>G8RHNS;,CHX>H1YMR("\Z%J (]E9W/6_I*H.AKAER.- )T)YKIJ#E24;C^<"6XL1?!: M+K4Y.J"FHC*'X" S[^S3_8#KB^'$3/B+U7+'.SFEN2L3I E,8?6K_"4H% M)BW\X"V><$L0<-<$ 4^V! %;@H!OD2#@#JV\'^OJ8K'2N7.3C+L/55*8S.4[ M7*U;8&2Y@K<41@$*XNJ6> %=*7-@&CA^R(Q#&('3''C,@2*.[<%SJ\1*E,8G MUGHN4<5Q;G7PLJXO"C"9LHC0[*];$Q.YZN.>R>'E-Q/-D8+KVXZA:#:W4J!6E%AJREV"MJLQ5 MC*IU0\%.U[(9ZUH484[N0[1\%54Z4/$AC=3YB(4TK7/.(JT8+*P&IO'<<&DS MNVG.WK5S_D]K9%:PRZ?BO:',0^@=ZNH,*SW/YV274B4-IT^(<*K(L8=5V6M/ MKT1J9 MQMGQ78H7'NUL\J?=EM*@#++21AO@G=/E[9;>2-[3KO.HWX="LT\#BSKYD4?_ MBV[4BVP9^2EFU>>VMGI&C:LR3KZ.,C*PP3*&M"N=Z1U$!9AZH@)Y'658?V;E MQR_C,8,>@PH$=ZKQCOW%#J@UW*FQDG*!PJ[-\\-AJR/O1I'Z31+,QT*5&GL< MJ9*TARD,(3T.\.73BI.-)+] ZCVMP4B'=L !F6XH2G/JISG+%Y)^T%@3'6H6 M(QH[RD;G((:EGS2 A%LYQ !WSJB>D]X>]J(=1R3<)'W <3TI[8HHM0MWM> ' MH(^@?>5J1\,156DO?)T?L;PVL5_&Y:XUM;D!S8PQ"SGE9N0ZZ<:Z "PQJ7W3Q;#U:"M?C]Z1&NNF:3CL(QQYN5/\K[ M=@PU4RMI;OVPJJGFTV7LW; M8A.0:,B%0+R38:C.)$W"A#O*.'Q!7(">_(:/^)!,.KL$,]$)\ZHAL[CK&\?K M1^N4ET2LS/A5-*6KZVPI#;'8,:?4)JF*V&3\1Y!0#7$]&9=E6Y5$/!@E<=[# M"Z1V1F$@(04OBLN\VJ67/%'29.Y,$0!^$ MBSEY])JY?;LTN1^AN@1-=\X4.<+DX?PX.6!$28[L&HPBHK(7@]E_TI,6K7A1 MTJW21]BR"]"7$;D:@1O2CL995%41-X^C0]I$W0I%3'2Q@K&N3T,VR.$5L.$0 M(?1#G.A%-":GIC%H4>&D2N^$. M]T"=*BCON- F;R14!$&HO4_!COI1-SEJG&:G\=&8.2V3EVS0\M;4W"&V'%ER MSJJ&^4[&7+"]VR7F8? %33Z*5?J-C++6'#9MZ-CN/>.F*""8XFPX\O.5!#BC M!C/R>1J9?<8,#%'6$\_1TJI[V%=RT;X/AJ:*XUA(*?J!'7J-?+UB^IIDNCRK MK?R<52.ECS,SUV1Q]1YR2S&)<03AC J30>MZ:UQIT-(N/"^G"'B:%LY4*D%4 M J37YQT4C#V#PP [@N'3Q1QG]L6+:@?_#8 D0F4#:DVTY]DVKM\RU]P'XI8M MLTV5(^![LFE^F6 M='&G2\F>0E7KFG[OK*SF^\8,=V0^=[74*1?#5<1KZYK$+M6@I 4F.85 +?42 MH%Z)*+JIJQ("WGZ8FRVGWM/-2U/A9DJDPT0ZNP)7X:,@O.]-Q%VJ_D(N78VI-,NX M-A1H&I9Q?E:PO7=[5O2RT[BXGO+N;OA=+417]-W5"N"$W-4:)#@-:$?29&=5 MN[!>]_!N->L?AOAUN<9%)&LC5*P Z _)'$'@*%]WAVDF$15X&G40<73],S0/ M)1)E@OEH(-A?_/"&7U"D6%M>A(.3'O* #=G;/9(6FP$/L7N(=-1%6PWN3:#X MG,YDI&$Z)6?LKU=X;+D)\'EN+E:&B3$Z_1:.DKN-_VE%%T\'2W@/1-#=B9W% M.K6?=B1XJ@?+KM]8&B[#L&@D;GC0<6*.ZR@5&5D1BGWD)%4N?OZ\^7.+Y18I%AKC=Q/"9!HO9 >R_C]<6M? MS=3D]N\!/D_S0 Q-9N#;,0ZPT^?.)?E1V*UI^!:YYOO/8'S MB<&-JOMFD:ZM)DH>1)FRA^L_&:[42RX(Y_Y'H*-HUH^;AOWR$U'ZGYOD M+44U=3HL2[VO./$+[\FX8UAJU67EOB(UVD H5G___?68W=F>'8O2MW>?"VUK/L"1$.L5BFNPCZ(6>8(G_EH2+V MLQQ21V#$YPZUZWK0JD>"(8N5F)>KD$ 899M'VE8LWG'%XN&V8G%;L?AE*;'' MWU!*[$9(X<^DQ*Y&H_YZ86;)[O$@>0\JJC$#:3;$/]X[0DZO[$"H^GPV1*0J M#*L:?H02'9DS=,@:MJ[?V'E5G$>, ZY-'[D(B"NNS20DD #EKT)%Q'(#&7!C15_[(XV8FXWI'O$^:3"VH<^NPY69M:'I)]*C* M8L%;:=_9.4*OQU296O*?^)_]GW7>N+T&:>]:^^/$W?TH(L"D'MJ+U&4'?>=% M'__,1E9W-+X3)$Q.-P/NK!?T9[,R]*:0\;M)]D,PO*>E#6CWXFOHFC)28,2M MW/T4??TS[$,#Z 01G6*.%^SEU'X+C>$"Z+@$W'V1A= -^K_;IU"-E#3W[)R8 MWF,I1:4;$V'M+B-!\=!R^0R8Z44N':=I35@0$K;^HM(30QT5)YX$"/?&"H.) M :)R/LV'NK[]_(W!;O%[)&'B291%NC142RG!N+.LR>DOPZI9[!C:#KME?*X] M>)1[<&O-C5204.-$PK&C9V:]6$H_\M0=B #@#NG"G5^)^-6^PS449. P,<&F M4;=7"1T*M3,TF\2G:Y//SE"G/%LI/Z!LK2R : Y-^Q!MD6/IP3+;)6;-C5:$ M-'8*5H%_6CA]4VH0:?U\E88$I,R' .5CE)/:2&Y7E!0Z:-,[(*9/@@U'R-6_ M0Z=NE>HH'U%S]Q6X;MPI.FS(&5@IC IV Z9]E'12:6IT/75C)!KOILLBY4=I M-9B[=X< F4B$\WD6H#,VWV==^ST_/ZY#,B1;9@!I AZR6P?I3 M).S<1.C*2EUW4%Z79*#:[E@NJ8@8;:\,_Z@X M[FDPF;-:D=;NPR@>YL&-3#-'2#O<+6( Z+$L59_H60@6O8LU6BHIN5TA3D0X M-=.%23,1+.?]2A.D_<)CG>1C+1%O2^6,X%5VUDW7"N&3[RI?40Y2V1B/,QD:;B:V?\'WVID98;M*DJR? 6UZ$E2:C)FF6]J#3A:%AN*T,AB%T M%%6IK)S!6NSH-J @.Z?(,K1[R*3;&6&PU$K L5%*ZE4L -PE>"T"_EPZGH.G MPR]BFA05DU_(-2:&_(9[,$.F9.X@5V.$\XE" R:P%"%&JK VVDH6HHVN9N;K MT6!+3[ 9/5U7Z5W4E#H?IFC4VU@7I,CJ*"M%CXFN,TX6$NLT<[ZL@V3=2MCI M(\47S7Z=,O3:[C]6BN6@R[3.3;OPL ,E):125*LZF!@3A9MB(,_@"XEO$-A- M>/,@>1&(XK-E,$.GU"&*(&"8O6X4W+B@S6U7N;"8!(TS=I,EV$?3NQIN$;%: MX3-("1"1-41(RC^#IZ2:T2*A-3O"MU857VZS= QGEU%:D>*(4_=(KAQ>JAVC MB<5R-%X,2.JW&]^C&(4[:4>_=7]VJH?AA+0#%WE#SK-8./:!%?>'ANP(CO%- M"^3NQ@MXC1M2M_.@G8$5CDLRE*Q ;.'GLK44;-8U;'KO,LF5+T<_\]@^3-1WE&/)7JRSTYZ(S5_LOK=F?]:.MM[M2"Q&X#IB\>, K+ M3;U::K=:"27O8 MT9RH_H,OC_+&O01%?=70&JRD:69,T00(LA8!=QJ73^=,D#RCF9-=TC-/T,$W* MS$X#I&%YDS4$N=%/3-NZAA%J H2954/GJ("^L)(?/]J?B$:WSBY\F"881@'V M5?B.0<4#L0X0M 475H]PK;[4.Q:_JVKQ<&2'%>2S+=#2;)?K#^UJ#,$]"!($_RT:";H8/DF (A>4',XTOR',6*S/CA.WCX,GQN37=%1(MH%[_GP5&Q-P(7 M4S='Z97)6^IJHS!@MZDJYLOW);SBS'[-2H2>Y+J,R-;] 03!W)1*=$/XW/X= M:X1RL"( H?TWP@X)K%J):@M/3N1>[RD+%P9+);FI#Y:8P+"SQ\>Z MA7-.[*NTI5#((OQ+_,)E;HJ1JW!6TD&VW$)7OJ4ESE1%&(5"'(\Y/U M<.R#"-HK.9))F]56F!@/*KYT\=3<57,V6(*L9N9#NCA*@QA/*V0/USO0O34% M,,Q>'BJ]D5P3,775]?W\/=F".[9%PMLBX;LM$C[Z&W(X?WT5_!2T6V0F2Q"T M8P"25C4")O^<8F8]X%2-4@K%WS?!,SBP%O@: =,DY+C3?$BO<99E9GT 1,JL M=LH"[=O#%=,3>D?%S"PG)CP?[Q8\ F:*&':)@:0^-XY3-)SJ:V+5Y%,/9\N5 MJ;GZ'9=EM[J-P/T5Y;7+J@0QS$56W.3A"U'@DM-WR0J!/6(BN3*.ME:+OZEJ M4Y$:S\<,@V23:;W6AME"OB]H(K-9QDAG[T13P!1M#[64H44['^]B^=Q1&@3V M49!T 1NX%8^&JH5*\NI\X#GTDE+,SL?")-=2&D3^0)$=&7WLQ6,TWGDG<]O/ MA9W$*$!KQ$ ;=FC$8&H'.8G0CW*A/>]:$T0$7R>/DXPX(&#( 70?ZC+]<#)' MJ8P-]P'AJ+N,E"[!.,='UNT5SO5'V')L$1$FP]%'7^)21-94CR?A_8Q[ZE.L M^GI/B0&/#M38Y(L$X^< 1>RZR:2G&8S/MG;M=@+[T85GU:46^['&_E*(0W/X M*R%Q9V+>4Q]YC2(@$2A8CXA4Z(PX\:T\+2><[2#*X;8H3:V2U*ZO/>6+.C]K M.5$[M;Z"*1C\53"'W=!OC"-PF@H%D/ %!1\)-0E(;6M&&_DVLR$>HSJ7W ?% M>$M#*<905U$\CL>!N*0.5=Q)1$J&5S@VZH",*H$\B2=CK:2*LM$=&4YI"<[7 M(3T::[ 2BN*NSWU+,$&+[=A?.\:05U-.(\8)LW4Y*-$K^T$VKM_R+& MJ+- "MP_C/69"1"X!QD3+R'KI/*-:&"DXY7LXLZJ*=_*1\ MB7.$P$SM!9+3O2+9]2+D/,2JMBL_4@ #E8%(DE$E5 Q$(/0DVPFU/ MD.SP>\)I$TVC/$#B) L?EI,E'#W](>>Q&JN &6D4_97-()+\(Y?28D70J=J? M52.@5J*.E8X<4@7OUZGLHQKT/_-"MR5#"76#M1NLZS.MA.V-Z6 "4Z91W MF3-YQ<3O]6OFN'4E')G[+U_KU(<4NP5Y46$*B*66 V/8D\)BU2K2AAS<\?HT MQA\$(%IT9W:S])@;!9* M_E$?2CX05('MR52D$PX[@9<[9!J[7_KJ4MN 3]::*J$^+!TFKL@RA_06^=Z' M=#I;AOW5J.AF%H4I&.'&>&F'L=\HU7]Z&2CWU$QSY95 )@(CFS<0%B(TNURGW,AA$1<1=)+414UW:*O5/7$.F?_=2+%\_6? M9W4.3SALVLH8@(Q(.'3(8*245B849<3] C:IP55=5Y-+ZF+5#O"4@ MB&#:[CC9J5;4ZM6(/21NO 99E#>!;-*6ZA[9T@SKUHYJJ4M,.F2(DZ*%>M$9 M6QE0T&VY9TRG@O"!T$\E1#.6\;QW4=ACUOQ[C_;VD@>OWQ\_9'YQ-&(T([?V MR3NLY0N-.8M!(3&[1DULK*ZW=&).EC 1[B_##IA^S@IF4=0YG-F%X][T.;5I M?.(,.C7EHXG[6)7'? V25]YMC[MJ^Y?_0P!=6&C4B2,;%^B/0 :?;EO M^27AZ6K5(+=?RHI%OG(D>#WQB>Z*:CAT7> 3UZA78I&:L//D0YE&3KP70_9\ M%2(M='+[!X^>)Z_,".9 \J)N)]#2%,-(WK$\8A/.T6O#:2"R/$!W42(D<_ONAV'?IK*GW IY)4"B\1 M=:'3G@B]*3C&D-F?%ER[L:5JWU)LW#G%QNZC+S.:L331_?C M%)Z@%K2BNC"? C5(807UJYUE129"+?!I]@/"T%G-^:F6S$"/F%6$0-$#GNW3 M<'V4 &&0D$]4$%79$+=4NZM9RWE8YV<<"6-FDX%C5HQ!"GESE9U$'4+9M6/0 MCD\<"+>/RG A5FP3!$PX+@P7MA0T>\KTTOR9"LY*&!V>&+M%/DA!-FI8)K=R M4*R](^4A#5?'F4\93IU:QBZ@2X]Z]>+8G8<%B$ F;.YX/"H7!FKEGOWW$,VB MM?=-E)6ZW!BE?-K5:G 'R:^&^^^Z-O7<]3!:8^-X+2LF MXLAD(ZXOB UDLO.HGK\_"ADCAUS"R 72Q397CQ:KYG+&M=$@$8(.'BI-X"8: M62%NI]\BDA5+3IM0: -+%>=R+V]U/<]*N##VN%28BH6HF9LF\3 ME\2$7P RJZ0$P3@O33>+C89:$-$,7=LH\2R1*WMQK1(B* X\,D@4'WG7ES'M MK?Y$P=-%IR"NHXJ= SLLLEP"KA @+?ML<#QQ0S2,Q^5<+H"HN7NME =4DNNE MM=)+L@_T;"T/R-W150R RU9H#$W"1MI1[3RO$&=WPT#1W*)N48#5EM)S,QN9 MN)G>]W+3,,/$^Y@TO?[*0:J$O?P4$M%4J"U_11N%W:/DEY6/,GDGU:XQD!&GM:34S/I$DO/-1 MQC,JI[2N,3B;QF/:_J4&.1Q""_!'UF8UAQV_YS"&4>"LT;K1,-HRITZBS-IA ME9[5"[@R?.N;-% $U/R'BOCP5FXG1Z6"=CN65FMW+8*.U,_LZHY-.6)^$G^+ MW-7)D#B$B="ZMK6"F3JK1J";N!AQ3UK'T@!F50JYV\M@)4CR\]N??CU]^ZL< MSM/D>68MH7?TO;X4[1G*II;=FL2CD M@MA-^;,=3?2V=.?3X>)"+]Q&2ZCJE@K!_&G10\I-69-#*-<*GJ2:. MRLQPT.WEKD9QH-:#K5=,B#ZG9CW:8)@UTV1<5!?*GY,MY(7Q=H\J(]QQG$:) MR[Y6E(//(SU+IEI'%JXZQX4AO>V65%CCZJ*D'-.<+627AQHJHZ#79!KDIT#F M??7 ^DVB=PX"%RA205M2.7'(5 698>$5ZK@336Q ]NXY=4BF^]AI M(<+PGJB>> ,-*%U=73>@=@W#_K.\T51"27<:*;NE+ /7B6LYBC/WSXT9!0 B7WE8'1:F*]W M/6R7KMYK\D#<-H&&TF>0%8O]XX<^[]MC$\+ 6RI3EK>T PFM9>F$_BM5:\ M5H>ZH4>-T3;-YHM.DJ8;QA ,V\5):>F[6)$1);CM6P4:9 57BGYCXKT>7&5 M R!=6]@OR?6>'0@*FX;Y>5[X3"'/O":^4[)J&PH@7)JAN8>"-516PE 8+9*[ M/9KT5D0_1T#BCP?E:)YWCC.N,1(Q!@-U[VP8W))8B,O/WL^U7=]2L\[F^2BR M:1!Z^4S([VJ+V\%24O3#P=[C1#Y]ELO7/QL?8K,*HZ2AK4^:7[YMQ.SHLNI! MMQUQD#D'2X7_?F+,4-G6-<;W8V7-MYB7Y9WS7A\,?WSS[F'R0"/A61W5_G?B MX. G!O#!BW HL4X4;IR,ZG:BK#+GNEKN)]6BC'A*2F+3&$Y4P+M_Q MUP3A2QUHHQO]JAF5! 3KH&(B;Z#ZHWT,V*! M6JS=OBL'JVC >\]^] _Y&I&L+=AC2[EQ]XP36\J-W@78W=TB)+[24I^(K0J5 MFGUBRY2"SU:0$9,\X44=NI0^$W 3KR.!OJ0>A9B42!MME,^Q9J&B7&^'G#&, M]W:1 1E875T%^]L Q$YQSY=:L7)2.7U-WPM8:E.7"Z,"HM*NN[)T:$#RY6]< M-%J5._:?SDCWC3)#"LCH"<&>!U^C^B0IJK$7*)^U,ZS&>C+POG/@^*%4; BA"V\'7<-Q$9D\E*+"TXJ93I;]0YD.!Z"3OTHH,<7U#$'*C1 M2\E<$&2O*8%@GYXUC1;]AUK078CUPXM1J/I#AF"W\%A MD4.&% EMC*$ >*Y0])499*7FH1,'_B?O"6;#J./3N@E%MI2SH##]E]H6(@J[ M#T&U I[>JF3VZ(52[5AY05Y5H^7W>>,B6AX P^F."/UR$@!>UEPLN,K,% JZ M&3C)UN4.+7]>\HSS!E@>Z]VBA2X]$2FX>#NP#7H(@]W8).EU M:@Q;X(?48UHY&Y/6+CK_C.CK>%?C'.%0DDEFT=8L M;CR\P9U^BLPV$9DIY CZ-2LIJT 7*%Y#E+C\"5=]3'&*;L9"C1G8FQ'I>\Q2#\IZQ M,!9P]QD^29U<0"QW6!K4!5%P,=,ZW4QF&Y+T<*. _W6K2FR44JK-ZL\Q>'%^ M*_@^J&#J\XAWLKL=FJNEDG+0<$IKD(I-A 4FS_U '#66G1M0 6ND,038<*%A MOWZ&R:X%%F6:W: WOZ:5:=!Z"C?NI^BX:A(@(+Y2'J-&F/77=VA!^5S-2BND M-M@H^SEY1'=EA>1G2%F%&^KX;(>&1U.#@#8R7TT+"#\<#R+GNM-%^-( B&NE4IUK MHK6O,*P'#JY.5/*N/2O ?6.5-GCC[*9/22WD4F:Y4CG&4!FR CR"VHI1A'W/ MJUI I53T>MFQ[%B&S,@+@BZQQ[7)']7$]JU&-K*:"$:\ />":#(,B AUS 16 M04\,=:BXMHVLD_"<^%X?VLQKDRY+T"DJL6K6GF[#H&"6&%KBEH_HZ#'W?KE8 MY[4PDL7?MU%TKWINE%+\QY@\HG2JB3L1K7I4W75NIT9NO7=*WR0WB+RC\]SN MZX/7[]X_C *]9]SKDXU"R$T/V]Z>,5<^?RQGW7S;&][GW:7Y1BVV;8MN74=UU. MO;DC-TLD0N9\FX.K\'R.4 M'D)EO)E7U0'BK$^YAYTLP[:_#"L6[* SRT+G-XT]7\;W N7%[E<($BH[W([K MP@B^QXW8:YOB'M,6]!70>>@R^+F5-IHG)_V5*(+=:3(LNV(4G(AMH<7GP/&8 M;+]%'O8/5MAYS4A&;G')(7TQC<7$"U!>U&-)(EI"_^G*D"-(7:<1*37_S)P98(^DF9*YR>QAFG!0SD9U M]/!V15TEATI*$K1<);:]X>;*J+0]42U0^,?+G[)RH0LPZH M/1C"VW6@5%"7AZ=H':C^FPLH-%(5](>2\Y!JX"3N2BI]F'UV)5V_0;[P(T@' M]_0FUQ%,J*W5J$^,ID*Y-);?F)%_."U:EXO.2]MB&9RF3;WQJ/@BH'./WG&1 M*]>8$AF1K!Y.P_O-8C?D;NJK$2^#V$BZ&T_[:G][5[V=UC43Q M^E;U""H5VFFE81HLNSJ-4PI=PH4T.#+%BGLO 0)WUI;Q&23Z=2K#/&<*9-<; M=4V;>TXB2<",>AE0%E+J4M^6"/6PZSNV8[1O[HQG[7HKSC4(1$4'\SR79F\: M:/@P-1JO#^7W3'(I)'=BKC,OUG^@Q*8] 4[>BI1CAKX>=D/]NX2Y2%X_OFLX15UL*,$[9+@2PW^FX7$/C>EW_'V$ M_%E2G2W6=.[N::OWS L-KADK&:;!/84\VKW3/#Y2@)&OJ,FBD:]+'*AQ^YUC#F<16%RX> MJ;1E*5WAA+ CF%#)>[H:7&=E_)Z[D%G ],[7+> \I?)BKB2T!Y1*\#I,O-Y" M0ERP%,6-C ?W6/'UOA%;X"!Y::6T-1&*@ANU,!:BZ%>F5!PG9B+!VP*M3&O7 MH=IFT%Y<(6M7T9ZM<5YJD(^I ["KUFLF=(1K7S&OYIX<)U!"8F89@J=).VH7 M15>AN*DJNS#,X=J$; 36XLFX3)7ZJ4%:E@8WAH!G01"4^9CM-XY?\XK;0T9T M0[%;Q-3OUC1=\OFJ%P[0$:%UPIOJ$[D+WU6:':QA5<\K'R>W[XYY?- EQEJU M(Z'0M7K5G7@>-JXL0VF9-E2:+<1PP0$>'&COW'DRUKZVATZ="3_4\/,$J7." M4U(RU7PA8I$Y$Q F-59\VX6E3K_682&Z?"O[1B 6K0/]'_ :1"]181(C)EW' MM8L02'@(Z$>IR M91"GE.YV=7;=$D#RUZCX#D,I.J6 #8M799X@K@6PDW9XL=3;#,_SZK)I5C(^ MI_#3N (I+Z>D7>5H!#$5NAM4"SU4[@=B5UD&S=0T\']F]_[B&T#\>&@#;:DB MH$4P>NK^^RD$^X-%JP"@C)QGPY 1-^74S5?*/:TA5KFU\ S9_0U;!)5(7-$1 M+6 $B;ZWS?.N'N3QW'X=VA OX&$^TR5EIPXD. ZB2!DS!!'881^%4/F;;45, MMXQP26%MF2^\E'_9>M/3?L@7F16O5]B!5UK<2^G,(! M;"/0DW9B0 ?[_[LN,R[8@R'-Q8.B IZ*E.]2)ZIDGX@ZBA8>6)H\_E]5?7]8 MA0G_\B=C'<,YQ'C*X2WGC?KJU%W_M>,FSW;>9<1#3W\['EN;&H1#$\)%!U4F M*-H@YT.6W]464.5$X)R,$+:H+ZNXB#J(*5M='Y-3BP"AE\-(TM>M\S'6-,D9 M%RW<5%>$O7)#$?N1X"-J^T1EL8![+$'4=65*J=U)]+M M[ZKL@IC2ES!)3!6.^?YA9JXI6'S?!0I]Z[Z.@@(_@2\F!G,*4NA!2#+/:HR)$&\7Q[_@UQ];AQ,W)TN1# M:RTF^_7?K7G^W]:*#%KFEY.E=0P>1,TD@A*8<07#TE7"2"C](5Q3#)5B!#+8 M#'VII>Q,4$73VI@=JIP9MK-6A%0\.WN5ZSG0^U8@/GKTOWWB!U2 Y]K.6SP% M7MV$3W'@GF1 7 6AVV81M%(.^\BP6T?WRLHL!,QG'OM(X19J')D/'1K6,#G= M#"8- MR#X#@"U)5SGW6=79"6GW&*&1F?IE=>N;:W[Q5D@7=*F1T#C;&N#P'1AA-$HV MPO)KC56S4'&Y\22DE@E;#_E8K0291LLRH[ZVWB/@Q(TT?".:^JMT;?#L@[%U M>.4& :%9Y&NE_Q >,2KYF^MB* F1M=VT?QQ56%*$D#_%!%QCE_:R:V9]O=3Q M=_'R-I1GR,#[E0GB MVW=[7?O9]1U<** @TY-',7J*R?,U=1V[/)5##VD8A6J0394W"#-HIYL>$%#H M@%A0))ZB M(&6>2'="#;:B%\F;ZWS9E3',K?=5<:("'8\[)0A!C@9][>R_W*)CM)G09Y # M-6<2VC!CLY9[S)Z#J/8O?#&M5$Z"<+N=(3,6R3^I#>5+C^4<%7M=OG,[\:_5WN@M5H0BY)-W3M;.+'L): ,"05M.$RVHX"\!BX%PZF,AW&SU^);Q C=*Y=R5XAPD/&I.[;F4,+?_Z:;U MA'RI<)TM?KCBAAW$&X8?Q87?@;]N_='!H;KQ:'51+G[8X=_=@5M.Q7Y/GMW- MCL3K\G1PN(\UX)Y?(JSXJKL,M2G/\[HJ@[ B2O&#(G4I06_='K8O.VP*\[1BW.VV.U-@FRECVM6@V%XY>QV3 MPLQDE%@+&R*['D9!5X^HFUQ7WVMF*M5J%?NE[Y&SJQ<>!,V0@_ YVP/SE0Y, ME^F;I56W#UW@_) ?@GPG$&(!P5\ D8P.!(03VC2MJUP.A$98T4Z=C8HBIF5Q M='N%.?<$'=NS\I7.RB@G.Y$;S#LQ0:YD'^1"'(FLON? M;7?QZZ@(;3;E.I2ZKO8$.16"D$NX+-6C9AK+[?7[:ANG7@>$(WLC[1Q!$NH0 MYO0]L#>N(9-5T[7:>$#44W1!;R*U?>#*ENT>?I4]G)C*;R/%'R(WV][(%F'. M4=YD#?>&TVZ%4EBB#H'46%R@RR$H_TG4CJU%!<(24]>5E:PS>RCF^ M^]0=;:6X<>M92>\A.?VN?OAMW,:SG:.Y^ MGIG%A3&='.G)U%XWBE/[\KDJX0-MRDAFAH3H?2,,7&;N_,K=QL63=>$1.N9U ME8W6U22XT"O7SZPI+]+B1"W9" O(! 'A*&/MZ<]J;DF[UH4/^IEK,("J??B) M(;TY!9H(L)J,0(R+#D$!"7"7/8#JZ7PK)\<].$B.?63;S3G(FNO M&\Z+:?/ MDO!]0% *O7&7H61>;:#3C45U*F[ L9RZ/CX=)DG'F^=)\ZY(HC5(7O'NS"C[ MTN,2>QI#.5*I-CR467- AFD@"NI<&B\UR@+/\Q&U6^6K5U0Y%UV7,ELB:#Q; M*D_"M"HH/>5NVRK+)>6\NN@!^/Z0PE2/AC1-S;M9-CZ- M.DEA4C*TX_G_HPDGX-:&M".^!;=?(-@<+HIJ4W,MLK.OYB_VX+A) 3I,A5V M":@<6B)DDSN35&4H_UW\@=C)M+5RY*:&1Y'D2YJ\,9_R8<42)RNS4<;R$[IP MB^'<4IG=-979P9;*;$MEMH6CWI8+-(.-I8I$8]S:.)/P'"[ UFNFD85"ZC?2 M*UK5H+%1)5A=T5ALK5/#>N&NZ%=Z9*5&?>SG&2'W0'G @)Z@L[NS(3EJJW9! M 0A:T8'(9QAG1;#H65L=6X.Y (UU)&)UPYT)CF!W8'1RWL:UR#ZFAAS>V+9[*UR=#7]Y-UUC3 MT\$+6![\ XX=(J_=>(1GVS/]40 !?,7\X\B<+0@FYEK&9T'G!6%8XMN+QN$\ M9WEH9^KP/CNGC_EV/#-9IU2*G#OO3BJ?$P=\:%!F65'S@EK=[T7=E-LU MXVG^*#)NBZ"*)29H1N27B]-CO]PB3H$Z,4=L9T]J-B1F!8FX>%HJ*VL!=B10 M)'.]L69@IAVPQ81=T@I$>FJ'CL:C['_1SAX24G-H3 H!VCCFERDKB+JVIN2M M D2Z1'3N$*XNOF^#%:+0V-<%25[0X"T(E;H=;9(U3_7^$?? ]IJ21XGOZ/YC MPWC20F-$]'S^)6G8ZT*++@*&RL_(FL^(EAM68]PA]44 ^+J?9*X<4H_:PPI4)_I9RT^8BR@)'GT=HH'?%6!%-$.>K(]9CWYK*% M<+.6W)Y@6"FLXUC7K&@>?IS4PC7G8[9RZ6D%D\8H6YX(-%R^SAI?5/8OM38; MSRBX)/?>M>;.*>8/P >"UR$[C\CAB/X&?S:7'()ICG!:2$PTJQ8Y,:UVQN9X MV"@JA-@P5?:*DJB"SIB#Y$U0=DVYFIJ%']9WWBX$(1<$F5DM53NLX[ ,(5I/ M:(ITO[(%26C[S[ELU"!Y/29RHQK$5$W3Z6Y ,I WF>"UXS%*3RA%F]/WA'54 M-O^234'C!MF8M+N4X2):7R%'L'8=*:QCI9789->L ^-3%&CSC(/R2"J?!CD4 MX1*;H)&.9#E6J8/)1FC+<&U6^(SQSAE[+:[^M)>C_EU)K^O@51F6C_2C0! M8B!T@/2J7/V;<^ 8U$Z4QL/X"10\]G63/;S)#P[Y64*IY-.UK$J;<..G,?VWL.1B204N9+=59@607F[9IJ:B),C_V .[8 MF=,G^#$!T@ZPSA6*4><1N9F1&&ON89WR9WJ>E<382\G('J%#O'E^C85=,7!Z MN,[&MPY> ;%:;R>?E)QL%!\POI$)R)P<4@08A8CR2+E^<,4[8E6:(GG3@BP' M.N7]G<*EXRHB:.5$G*K25=3V3:4Z*Z09&]UEIC#TY"0^UF-7)V77SY\-UXB9 M(C4=^C@ZQ'*MPFZ)+MV:!G"5-9),B$2B MT#KW60XQ5+6UU)GTC!IR.D+ZJ,>RYWU]\/K#PZ196NTY8YU5F@4YP%Y>QJ47,-0 M3R-..#?^M!]9D2JU$O,,T!L=Z6I,Z>9*(P7J\C#P UA>D8>]VF#5$RV$8*L^ M=M^LH=7B^^IQ9KY+@G%.%7',"<4 6P(>!%>SG!_W7QQ*MT37!(Q8F1>1(A0] M,$3K^%(V8S):+U!'BM6G68[H%=FY%6%QQUG[W?Y3$Y315J%0E&DS7(4,3NHE M+DV7<2_!#UZR[KKL0)KH[ B\9V$FM:L3ZAGNZOY%)S/NV1&V^J:(KRPIIY9& MZK-GPX\*V3)",B^=9QG'V '$S:Q9V424QP$VS]]3?RA3:AHN_Q3?AF%H"!TK MD7,4=@B.<'?"(6VY+T0G.>H:LX?/O1S7O06@;$G$MB1B=TPB]GB+VOA*9TT1 MNFD8H**FH]"9@^2Y&6:>C5T#&PLV$-B)9X7!IE=N_PK!C9"F)UGQH1UA,"([ MJII/T6'#T])SX(:T3\H$'@B7QM 1)5\)N")Z6TI [W&L-2,K(6[8[$UE!.Z" MT'P:^?P.F.&,-]"/A&HI=+8T91\VQ1BR^Z7$*@Z?+4MZ_+H+VUA(/_OF8Z?= MEB8LFXY9E)>:ZLS#/L)(I:[Q28!AQ2.<<_(LF88L4]2H.)M$J-8@H$+)"AAW MR"P$Q! 2!>WW2!!,((;/C7)-CN,4NS_&DVXE1G@DN3Z@D1-,B>>8@CD- PD, MQEEK!^MFK7B4<<=S?$0--WN [7&N,T6QT]W(:B$QZU*Y+7K/6!!A3G[,SZ6 MP%_#WLO;Q-.P*.CKL[L=6Z U6(*$>2!(V9UAT(=7U(RNF$-<0%#:[TBX6 MOQZUS7:IL+_P$(E&%Z9[$ ^B*NS(?2=>JCD5CB!01,#UF(EF)9X3D*_!NB:1 M$,6"OB3@$_6!\J:^C@61/XTLM''G'_QOB5'Y^#QW%F/FK9Z:LM(8%IG4)+K0 MSRB;P3"0G) _&G1U\G=%II(&^?X9Y+[5I1H#E?A4$"=5^YSZ*HAJH>LF MYJQ7+5Y&Q46OOJVEXX@+#Y\W-3@-:8]HCUAE^(VVQ(WD:6"D6\LT;X1!7R&2 M#$$'\7Q0(Q?MD @%"&O&>6:U8!37O@C)$EI7CM70WQD^S4=G&W3:5CW===73 MDVW5T[;JJ2=^!B&1C_[ON_S@[.!LM#<>C[-'NP=/S=.CW0.S>WBPFST>[NT> M[1W\^_'A=]],T&WW1@PLGX$L'U[I)KZV#E.R^WR0_%8"]5*<&X@?ZQ8Q7+Y< MW%,D<[\=_ZOUHX7?UAZP'DUWM;/U9/>[C=O"DT%R$@8H-@X\C[Z1,".SB7$$ MS-*&NS.9_-,/957^VL[LBX;::/V]&=NQ[NQ^EY39#,->CGZ(%@3/?^,>_XYS MZ:9Y5=7'[&25D]>4]!RCS^QQ.:(/VW]^8,L2A_.Y->,_?D>G:+SSV+[+-,-L MCG1%W9H;"8^O>3MN=^%>4U(8\;W5E=GKKDS76QE50^H_9[KY=<^ 0=O/%564 MA)6<,1OBW ^B/S//H/0RET[R03!/LM[4+L%9]IVP'K%N6?>J4K]Y#7-WSV,O M&5,8B*1F?$JN[3]:P=P'[,&3*EPK43U(_JK]?55DUB+A"5OQ^6GQPSC_9$8[ MM+6ZY?OQ)OL@;A=HI(%3/PM@49CZI9AKBEW;W!.]D -0!#PQ02G4 GC8U:/D M([3L"':8+JQVB-;KG]V?D]N2.A_@L[Y#6/,M@J^XD5:\B+"1X+671U=9[,=_ M#UGC%^YE.;&_N]I)/(A/(D>99;%]$;(B4()F\R19$,W0'!:"+W/T,5%L##>E MB^/.;0#@DB=)M8;'@:0:ZL@\X(C+87RL@=NFA["@" .E+\^@%%NA0>D./]2? M$O%9.>8;!1Y>)U+H"!3]J9I%[1LX8@6X:K$H@N(1CLDRTWKCOT#5,\**;)98-B=6A]FHD,&X+"K?_=BXF0;T8ST75J"!FPD;)3:&[ M'(:L+]?6G<%TEKJK$^[WTG^1E&6*NF)Y+!5D;^OW5B)5*)U;_I)_M,KW0]7] MU'L$,1&H7JP3Q6-[[KTL?D+'PQ[M#A-AWE#.,[O(F!Z22,[ZS02ZJ[ 9I]F( M\JO(">HXDX(&2M8#)ZV4>N\:22L?$PXP"&>;"CE9D??W"8+R'MA]Q<"2QF** M %BR^(1=J;\5O;'9SEUIHPS7M]:6%6E_EPPZ((H4FV(,QU M1N=::K&S.>%AIF3Q1(=?6?<<0&;%8W-9K["BR]6K]GG6+&<\3NVK[.&5O)"C M[_YY,LW-.'D="+.WP*]9 ?C@Y/5;ZCQ70=!;I664GZ5/,KW\!&I,2# W' _6 M7WW)J:Y1\+;3MP]7] (G=MVL6)!I*$S)*+.)0W;%4BP4PZM*.PA8J-.NH0N" M[7U.KFW,%7";A#5.&:-4@6V,]\)9 G;#4S9=X@4'.<"ZYAN]QK/?&->R;75W M;BD6])(,;^O_AHKB,F'VY%%?X$^K'[%$) $(N+FXL+];[HQQKM%AON'"9%?X MF/?; <+>:9?2DV@$KAS98D3?'C A:QB9??]Z.,UQ.A%F&E?#EM"/5AN"RIH0 MJ>+K PX8/@6_UK"=<#I,\SE_M2>8]->H[>=55H_>CE]8IY+,#Q=16MV+FX>G M[XO^/L-DZ;30%#?)*?[2+7:2_FU]VIX-]:=0"U7U)9N_O[+Y-Q^0Q";M"UG- M6'GEQ<%5[9PGE^4$G,C[*OJ;JUD^5+305U'F3PZ^^^=S/HOCQ%V]%85*!Y7# M2X9^0-"I)RS'R+T.;KJK74?TFF(911XII.*FQ";/>^]EG7B\%W/0G;8-(F9: MJ^=6(WGP_N3TY*$:''S/DU=C&X/*Y^? M)51>FG3;6;G D*:"/-=^*HT%R!E5 .&PIT[SZP7W>R['K5S@QQOF%N! 40DU M,<=IPU/ 4UNA7K '!WV=D?+@$\01\$Z7"9@"83.S>,.Y7CJD#(VWG6&1L#,D M]MZ@>WJ],,!BMO,1\:P3XI7> YIRC!N0N>@D2QB8GD%\E>]/VZ13L74GX.+> MG"B ;V6Q4G=/,0\NRQ!"DG6)-(G%H7G(D*RZ49@O<1F7,OJU,I%]QN2_Q 78 M A.WU;#;:M@[KH9]^E>B^6!A;=%\MP,%VQLD[YBRPQI/F^0S!0[!/Z@(I\E' MN90,W-5 MTN'3P<%!O^JYKDK:?338?WQT%SKI]F[$U>[S*9\K=SANI&1(8]R?*?'E>V4O M'TG:!V0E5FT#@_5A--//;**<=!*Y\T5B3;M\E&B$ZNYW^+,RCR5V65;")/[& MC-".R5QAMV\Z]5LY"L=(KW_1I _2)T=/KK/5F[*;;P"&'4[OP7V]C4TZVMV] MP7T471*<2QG?IFSB'Z[T\4.UR(JK7\>;S/R>;/91^N31T]7-CDW[^VT]_N$C M#FBVDUK3JL,8V['>>D2O&G(4PM@]TD_*M=:_HCGDHLE'#AS$[]L]^)*W[3U= M^[9-L^$=G:VNSUJ#^@R1MC^M]3TQ2&[.I_G0T\0OM.#H\/+ M@RY7C@0-GCZYWI/6_W[_Z/'6?K^6L?NC/];']EC? [O@UJ;VJ[84(BO^E;O3 MUYCC(\Q03L$F+\76I8F6(VIJ^^T[,WO[MS7'S]R'35^G]/!H[UMT^EZVB+;> M ]E^"WNTNSGB^S8\W,=[U_)P-^5$_F'0K:-,?D+? ^H_@BY3"C>!M]+A9]CD M,_OT[W1D#X\.O\4#>SQ&KY@T.4:K>7C#[S+"B7P3!W3W*@;"-W-"=].]Z\5V MMV'#S0T;/CFXQ6E>S?S=X-7Z!H*L08]!K:-;&]P3[!]J@LZJ<]-EX]5B[A* M+V#J*RI78?28]:>Y>U/PO Y0D$*#FQ<<70-PF)B2\,+ $ACJ$E)=H'B&6ZQ1 M$ZD"E:2I](59M^HH047L88+V3S-#$-D2C8+Q:+37JLH=ZD4?]!SC+IBHWAI( MS=#Z3>!ZW84IW3=6N!8,<34TKC.R@"_<@(&KW-!= T9:H;RCL($SH4Z*@NBC MF1):\#=8\TE5N?XUW)I'^)$W:14$BA#5Y%1>&C32H$@Z!8'2A?,:($"8\S?Y M2-C50K5KF?Q:+0R?C=VGR6F H(D:3J[+#.#;]-(3L.9914 0\5>N#)G"3_Q( M0>W22PDA=2B$'8U ^6Y.%/9TXXC"]@?)+]J=:6@,5.;&@<3",PC>"+NUJ%&@ M_!EJW3'/G/:]JNW^TLF %VSW_PRE#=(_3C587&9&C9:ILU=X0H]65^U>G<2G MCS;N)!X,DC>4!#IX]NIG#NT?SBX4NE<1R$=\7+=+9# />.*IA%_/CH3\J<=F!(_/!WLT=_7 MZ.W]0&\_>OSO=^_?/MK=M__OW_-\^.^?687_>Z17Z-_/T4AG:F_KXO<^E?[T MR<1RUF\1B#9X?"4-_:89)+\/@ATE507Z@M$U%B61]6 E.9]7>2GQ3NBDGA5' M/,/>Y3WKT3?1VVOS9T7QOHC\$1_>?2I!YB9X@W[BQ[IJY\G)U YBEI7! &EB:-'<'46"WZ(X?:$R8,J9G M!\WRCF<3ZE0$-JTBFTE$B)DT3JP>SJT*;*BQ$ULB\>_D@\^M9D8!9E[5S&G= M?0&/!!3!' =:1RF$+X2K-N8I/7J\@WEUB^F#1.LUM,DUL\Y=G7 SO?4(9UFU MSM%C_-\--->5GO)U=-?!]737BS9;5#]OU=9-U=;/5?:?UEX<6L;*W(1I+ MQ5GD&3P3 C\O5(6U[QO01?4@^7G VT1TNC.3]*Y!Y!V)*MFG]"AS[I( MD+9YS;J5(]FLSPLT4ZUCB77.Y[3:[A/TJ"T3I)ROH$L]#,2KKW=@R\V&IJ7+ M);TMW/2*I6H#^WAZ7'>5>L86SF><0]7V*]K=H\,CYEWZV>YE8\J=5\%8DM/! M\2!Y<#K/\O)A"FYYS4DO.TZ\T.Y!?WK/58/23="7&*YO3+**82 WZM)ZC>PT M61?,B^]Z_;ETGS#UC]N2>^5M%=[]47B/KZ?P7A$MEKWH+[=*[Z9*[R6:AYX9 M>X_=:EIG[6!#5-\-G346\)QX_7;4(CI%#/PV=M31M5:#16B'/OBS_IE_]3KG M[-&3E)N8<-MM]D<^(^,57J[NU4G5EHTIN-K5_OS"H"=*(V[2BSR;E!58\)MT MY2M(I ,5)GZ@T&@YMV3-XJ'9N M4+S=,71T]K>L?I)'R2%=APU30T^NIX;>M,444>9R]*^M'KJI'OI73;VX$K^8 M5@T=_AW4T$\M+/+WIJG:VLHQ#AQ^4UKI7X-@6Z^IECJK$RNHJT<0#P;)J?U MH)>&D5YZ[+H(D"ORT_LP;.;=D:"Q^+B%ZV&UEKVKCJO3/5.5EG NI'TT#59! M@4G"*Y97ZI,(7:W^_J?W?"A.N?U7V-SKG:D)8U8*MM8J0U-4<\?^,*LH6#HD M=]#%.ZF0@)_YWER@$>*WK(8V3?T\O9[Z>6_,:!OU^X*HW[1,3M!!"$GK-X,7 M \15Z#]/OO&<58],2I/W=,!>;+[F><%A0MG:M2[)WCZL])LMTE7=I"!O@V%T M^G*D"89*@^S$P?IUT"(YS1R#A]Z9XN; M/\4P#O^>D/K])^DPZ$.')R_?8F[VI5;5C':>MW4YS6;._[*ZV:#WA5TIZW8M M6JNP'I35A7X^T<_;-3U;-@\1]*R1,4M, Q!&WDSM:UR<#JB9;$[>$>'R6788 MZBW&KQE2^TSI=E5D"^@_[L]AC]5DJ7^_'8T6%X=]N:JYSH,N+^+:XGZWW-5; M[NH[YJX^NCY8=N-QKQMTY3<(=/?->3&'U_-B3H?363[ZL/5C;NK'?,AG"2]B MFCQ^O&*^;Z![TI?Q[A+A;JQW@BS[AX'LV)5C8IB-!\;RN#J=5]"<7 ?-!*X[L"=+.VODG;6-WRXXZ#.[YS(N=R\O%-!^B MZ>-*3"OT4WI!?FY]B -&^%\4],;NTQ;T=H_TQM$U]<9%AF.V#8#=/ "6S4R3 MR#I:W7'T;0>]UC;/_39TRL\#W?. G^R6&$4[R!3(G MM5U;]U'!@UM]^83QX(\>IX2?TRV@>-X5T6PQ+#O4E^_JZD\K[A18GGH0XNL/ M:7(*O)[_!0W[REN\U7SW1_/M/KJ>ZON0M?:@+[X%U7<[(O1VU*$IRWQLK_\O MUD#G%4Z3)[MKM<-MCOR>.5L^]<&YXI5&,FLTY;W3BPWI1;^A7^1O]35<> #! M2KU ._"NA]?3H2@QZN 43KHXA68]1LU!J1M#78)O!*G&2[O W^U$P[L@'&^>0[5'F:JN6[I%:VKV>6OK#E!-3;*%P-X?" M98MIO2P!YN6UO)Y3=JNZ],X=-81N2LHSOV6B.X@P=@_0)?M::+G[J)?^-?#[ M?$V/[3-+X_P8"?BEW)P".@MQUL[](-RX MS/XSY4:'>)>Z0B]+NZ%&G#3] 7K)O@60A\;Z0M:ADMJD2RN04.U$7R5"3%.V MM324C[PQJO)5>&!&Q;4@%T/O<1?'# *DQ%"XJGQ##>KP[]+2NG*;F#*-!O@. MC9]:FI3F CQQHW:XH"=Y;\[#'Z3Y-K-[N@."W[DRJ6WITWW4LGO7U+)5\?%; M\/SN#/77F/D47@$6LA=JOK$JTS-$;JI>Y#BF;,XUM>+*[*_O@?UD/J.+CD@7 M\9N,#\L]5PD;HK!!JO36^D35SIOAKR8OKJB+\D9U43O7-R;H/MHX@N['UNW/ZH_,B!Y0EOZ__\_AWN[39]P* MP;X1%/]P@DG[&4CD:O@1A)4&?2H6K@H@;YH67)MM/;26$5>4\W<1N+8&5=0_ M= /X4(]I"J_,6=W"1GR2(H#S.!6*T@O\S^[N06H/!'!0*++@5:&OR>+18JV8 ME\?25L%:7;=,=L]-E&$@(EG@NS0["OH?0MK[)PDV>^_1LQ,>[2E&F_)_DK=S M&M2[(I-22/XU)F'*AD=\/*D-D]_3@W:?W0IK_C.\3FXD?K&[I^,\Y8.T3-Y> ME&)=VQ>>6-F/<-9S4QIKZ9+)2W^G8;-CX&HQW\LQ/@V.\1L^QOQ*.O]V)B_Y M[$;SQ6*$"?R!3/MFQWKW2T3?.@G0E7EK),"W=ED_1(>?3>9Y79U;[Z6)+AD% M%:7^"@LO3/K)<*+G=NGX!G6*UTV]LQGJ+Q"FQ5J0V,,>Y^E,:,N_W(HKOU! MM5.?U-FLX08^M0DFQO3.*"Z3FT=/H_'NV&7:$9'%M]]\ B-C0_V9K O_LEZO15VF=>2]*V:ZV.$0) MD?S:(DBZ5HS>@W&B$'F:7=;+YQX,\IWH/'?*;F\ CQ&5_^P0>B*'T'0[>X/# M5>UT9D>*!WSWSP>[#Z\=$KKCQK*WMF?'YQ,JTQ\:BB2\R_(11 7]0"=N+"G_8>\I_N'H3XK^^;\95#_*U%O46.C7O M[:8'NWO;E?KL2OW/[I/]P95ZMO_=5XH""WO/MBMUHY6Z76_M;F2T$\2''0G] M:W7.LGOOX,HB^B^R&+[R5A_N[Z:' 2/9MS[?_]E]?#@X.OS;S/?J0N_;G>^W M(+J\A'KTZL82!NUWM_26^[I MV;FV?[T9JWU%@'6WL'@P.= ?S$H#T'W;X=[W^\89+>338(SC^BRLB6M((!^.1).@TG62326TF8,>WGW;",&DX M,KZ62B:$FR5<=%?N""H&&,0F&TH)'CJ+V<=PMVZ"W,W#/,=?!YNY*1#T<&_C M@*!/!L0>#>Z>M>G<;3W$EN=XRW-\MSS'>[L]$[ZU(H+#PPTN(KAG$O7I($ = M.TUC)=*P;1KH&2J&++-BV>2DF*RV;(L%_=,7H'-YH(-,#ZN24>,W54U'N]=7 M37>'4(XZ?T>5\UH^>4/0]8V,QL],:?]*4WIAFF&=,["VTZOH%B=X-_AK>9! MZ"-KCXI#%G$I:_(@L,4>)M/LW*"Z6 $7Q3+9W3],K0CA!YK9O*B6!C0-CG7) ME!-[PQP6V76FP.M&OO0W3699V8ZM14EEO.C-FQ6&C<8SM+)/K,$YH5\HJX,^ M MUV)>V]G62VMY6\&0L/W)S]1B&S"$4.\M'@N-_\(4Q+PNQU1#8[?&7G\#]'R:_&K:NFJ4^O)M.90/OVL+Z])@,W]:6@F^L"Y% MKE3))UD]RNT(K?@'@HC';U6V]9^;&>!NX;'+W?2I0&"$JJS\K,5A8-X)>[;L M>M7V 7EAZ@;\FR@PS_@']_D*/TVK9@[&S$9(R=QYM@=M;$@7X8^H.)K7@72R MZ\5+J[3-;CFY9*!QEP=VF%W1O(HN$*VWW"(JNY]GV)@T.6WKB:GM>G76Y(%] M_3F6NI"BIIH/O_7Q7J.1S+E].1=,G<)_@'I\*&7JI%#I?G*U0V/\.+HKB/;@ MX6K%ZQ.L*7ZD2=@K:M7OG*ZT3"A<.WDQRD7F4ZO-K::&VUJV-9T6]_PT,4LK M[5>7'B\:VLN2#WN=SGM^G8EH0'B/[(5Z88:\'6^RCT#1G;Q]\>8AKF#,:;"N ML_N#=[K8JW]\./BPCC"BZ8\R.+MKE9%A >99Q[E7&+H J&W1B(BP";%>GJ-K M%!5$=6((K&KJG'H[94.2]IGGD84&**"(0*[$[$+!LQ&HR.IL9JB 4DJ51EIW MU#/15"V1V['_">U46I6J,?X=&Z687I<:9H*5(K(C*;@WY"+2^+.Y M60A7E+ [^66U4YHF135D[6\7;$*,6VCX&-#S.RM@P)6%BUSJK*R4(@V H41C MH+?AJXBTU:[+9LE(53)H[%Q#@])T-CPOSZOBW'1>">8KL9E2^8@>_U&G?R5^ ME\]P1OG8V7>!!8OIM>S \3TO<^G*5$,KXXBR1/#%"-7E).S1+L#ZT>@ D)4+ MUC/A&X.GYUZS>\HMJQ-@ E'\KZX6T-$R[A8(VV+)O%[6BBSLWQ NL!^#3N[R MO/S#[[938RE5V\[P<^;IV+I!PZ8=#L7BPWZ1\: '2*T8GMA05QRMWDIK'E8E M3;)&M26"I+"*\:J#3Y5AL::W@+("7LR+Z P6JJN/FMS\ _)N\2[H/)TG+O"?(+U0Y9K MPJ:'@2&%%IOV31G]@PP0ZQJ-E,B=_B+\1/;'9L;I 'RNX#-OK3:[=RE7:=.; M&S7*^#5V@- ^F!Z#;N)+9S[A-MJ!4; 5.A;MS-V%&B6'S=H &Z4$?PU8#2$\Z9]FI+2(9/=FS<+:NW:CEE86-6KQ M"&-![+WO/?Y?32"1OVVEX>M2\DG_L_MTL)=8.ZG(I3\"RSUV&=;Y\7 +"I'U MLU61PLTSE4)S2*?;ZL^QV3'E%!$TT@EZC\2B<1\\1U&'@XA!50F]@-0]7^2L ME3N;[HX45H#5G-O\C3+F(=5ZPR^)C[S@U@QA!R-7"*M7F"XNT8^#Y&7T=9%> ME#O$9EOG2/P\&.=L5@4"%A>MK>>P+.TAF;2HY8=,L5(@@P\OHM2-$0^R3EOO MB&JR>)VU!-=R=$Z,:7V?EM>F>DRH7-Z/,9N(D0\OT3JTY=#N]R_$[C916\1N M"6( YQ29DK;I@6RB]JC6LVCP3T3O(R-EA5CD?<+MY$MN-5 I7 A\ M!_Y_]MZTN6TD21C^*XA^[1UZ X()\':_,Q%L6>Y1CP^M)'NFY\L$"!1)M$& MC4.RYM<_F5F%BP0I4*)( $3LQK1,$H6JO#,K#UG"F;&":(0$Q6\%1[GF@(2+HM.*YM%[-KE7>J[E:O!"1CM MWW.20<0]1J>M= ?]UWFQ\]R%%OJ/L^CB3AOV7O^,UR-B*66 '^3FG11;O Z[ M'":[;.Z9F[Y[Q^J[IQWB^OC8[>::OGNU' W\$MHM/]F!SW'?JTFJM@OA+YYH MSZ.Z!):4/_#H*"#*=NNL=U2FC]9.F,DM[/2W-@GOI+BG,QSUUEAE^%1>&;8S M[;_+KLE+23=CX\_0$IW^_Y>33)?CF.CX6"8GP27SN.=2I&-.S#R; M2*>7(IVNVM;V2#KJ.NEL9Q!UF(>BZ-/#(ZE(2O1/?_O?J-GCZO]>1C?<<38" M.* 3RTG%C73?Q_9]*3GSY)2L;I52LJ[SLM0J=Q\Q3N7=&>GNI!2GK%+4[H/K MI9,*76>W/$*,TV/?5 H&N>E* ![?Q7%%]"Q.E95\EA\JRV3DXAY@5PM);9_] M([I33J^*X2, =52$RUFNH\IB-M)Z]N1?]IO&=ZNM;)>*)P_%)1ATQ0#26$,#253JO$1"OAD-E MR%$51>UU7CBA1VDZ3OP8 J6O]%XG$^YY3@Y?W)ACLIU/C&=1R%_ ,,[*>E?[ M]J&#OJ)VRM: $C \*%OW4+6M:.JCF\H)V$0(=ER'%?]531ILWF2X^&W+9/RO M-Y))$?EW!2H.Z];>[;A]'HYY["*=KEZ$7?;9HNX% %BLQ< WUPX717I./KT% MEK8[Q-K22U'>LYHRD%G14T8K@50!1VSO6_B>/X97S<$41Q8_*TZ$/M' .))L^MYZ.%4 MH8?3X]B6JO3?--SZ# "VE=%A ?B2WLN!&H4=@-'+VRMLS=[=!]#+P2+YUX-= M)7;*#\:614SP/1'[\8WT?+#OX+4U=+X/@/>57D/GY:3S9^C,@AW=2G''=4O- MOX)4N4;ZTIY7F& 56F %E#\O.@2LWHC-//<^F%.EBB[*CNY8:M%V$*;A\:K;5[IY7W=$ 8/' ML/U - [48]%(RB'>0*96$G-+P25,@?(R,XR07VINQ_-<1QPA9>1B<_ ZH@2J MJHXO?&'U-$$H4@R8;-'U*G Z0Z6W!3CP]: @<'0INLW)I[OL-:RJC+)@VA^( MM!A$N?7F.;!:?;VH*18K\FOT.\L\4T?2-]W@/3QH 3@QDF31]W$N=; K(6Y: M U*I5"$>#3*%G9]1N@22$M:< 8(HS4*((JS.YVT[8EDEI[ASO0^ @ V28T_I MOI:EOC)\35COP!]R-! 5WFL_\*K4@#DOMH6NTH9WXD82IM: F%?VT70C;+H1 M'K\97].-,!\ G9P#UZ"THH0J(4[5\B-[(]W;0[H(L;T%KZJGOE0FMQ.XUD0S MH/UZ-6%+=!\#Z8TR7A8-=N-1[+J3T:RIQGYN:B,=49&"D\>$PV#MZO]+AAQ*?LL R]<^Y]8;^XYTM_9 B0SYO_) M6%8+IX]*8U&5H9$TQ_8-9J3U8,L=@L!.X$QO-UE(:Y,F?AR8*BKK;:<9^Y9^ M=J4;V%)%EL93#\2'@-HVLM >/0<_02;K,7L$M,_=Z13SH6%CVX_1 0U?*5,L MYKMT77486#:UK0OF'F/I=F))I[%,/QPTD:@W4-35CK<4B*UZQ$NV=T*;3"&U M%[&:*L!,^PAH&NB,"LFIG4>8-%?H9+>*-OR+[5(= OW0+E6QRRYY!=MV>8!J M[>X [)/!+OH!BSJ.425"%D3,TS.&G<>7(#L(1I4 MJ88H77T3F[/5;^V\I05MM2R>S9UTH^H0'FX48=^!THZDC;P:?L0HCS3UW(4P M30H9Q3V,OA8PB#2JTYWRZ9&L"F%]Y3-BTR]TCJ9AS/Q5AZB*G0, M=3?#>$A[$H&PG:*S\;IIWTN-H[.;XK&9AM1TU;$%]<]UY+@QN*G16Q87._AX M:A3"[)(EVH0.FP8SI6HPTSU$1/#8?56:!C.G%P4]EL/S2?_#]7+UR&HG?ZXP M=B@EK8HT[@R5=J=?OCK-3F^[8"_KIO:6&U/6 QY^4UI[5+Y-=?J/OOQTB@"* M%8^VWJ/,\\CE^[064#JI(MJF=GC/F82G 4*>78_6UCEYM2=(15^2/D$G#8>X MHFHG*#2%^5M9*S6MZT4KLI\/N^-GY!/47JD#>:CM,*S^M($UE-L][< Z\ 3[ M!FPP/U5%.V3YB%:T?*0BG0KRH?JZB 7?T*" 5EOI-B2X=Q)L*' G*;BQ'OUY MQ%"2 QZM=4H^],0A\Z!'F0#'MX?SI<;UQ:?+\_'[BR?SULK!GV3:Y0.O7$T* M"%JJW&_W&E 5 ]6P,RJ%#5P$[(])_QRPET/ZYP._I6K*<#?QOT6 /;_51H.8 M&#&JTFT04T;$E HOA[A *K]QK+Y\NWXK_2^/IR7)T8\/.)4I/54?O4 M#CPHT^51I?IH::*/5J=I1/8, ':CG@L-$)]!A=W-]F>C,5]08]Y>?!Q?GY22 M5-MRIZ^>V(F'O2*7<8V:W":@FGZ=SP)@9[/#U "PF,>I-2KR\"KR]OKBTX?? M3TI%=N3^X*3\R(ZL=AL_\GE&1O\H[=/K!L6AHC90W(.J[#6J\O"J\@N61^V6 M+%D?%7)*AU6+^,^-LMPLH 9=16V\H0:"1X0@#=;5?J[+R)LZ#&K /0)8DTZ\C=T;]!EQ%P=65N^JA@\-['6]1X?$57)5I MG'.33GXD M,^7B_=?K\>?;MYYE+ZT[RX,?G%207]8&1;H2U.C :J](VD-SL;$EU;#) FB@ M6 XH/J97&]7Y.D+<9/N4.=NGP4XZ M]J/$53 'T\5%KTX;DC@.PZHE2YYLTO,*I.=]/K^XOAV_7;!@_F OY\RQ3#W8 MT:PZU>RS?K=(<5P#J+\-AH>>^].D',52>5BHY*#)!3LX8GH-8DJ)F,[FF%F3 MH'+7\?2S=>;VXO/G\=O_W5Q]?'RR^>WXO/;Z\O/_QZ_O;V^^'9Y M?GM2'7RZLJ:=5.Y>MV @J[E9V7PUU22=[:$-B-)M@+B';(2F&^PQNL%>78^_ MC6^_G)+B4.7VH,B5?&T.W!\>>LQ*S:13K]_(^+U <=A <0^:\L!==1M-F:3N M[9AS4!L5HLKJH(BS5:,#]WJE&E)?04FE=9M!(\^$8'O?I0&G!L%.D[=7MKR] M+XY1M%=LDX3&XW1M>3#<\8[YE.&E#N1^H8$O3=;>BV% &32)80U-9+M9*<.& M)AJ:6*FK*%LL#@#T M3L3;I83^2%.*W(DU(&M ]KP&/2_&XW6[<'@_OO[W^./%OTXJZJZ>VARZD3SH MUJIYSC&Z)#?WRGO(!=04K8'B'OH$-+?SQVC<>OWQ8OS^I!*^-7DT*I+75:,# M=X9-*YWG@;#79'SO 8H#I=- <0\C6P^7MQ_FW\^\)>].2!V]LV>A+A_N_?;R]_'4MO]8GEZ0'S MX)B2;K"@6.>PVNB2?J=(KG%MCCMLHK#/O20:'KK;0>T@V#0T?W9A5--PXVAE MQ#N40-5&;8Q.2TMVAZ4*OVX 7;G3!4>:\E)%YR4_>%-YVDUD(GU:I8 M]RJT%ZZC>P_2WQ^6L#/F^!:LWM2B%@5C5]:&1?HR-N 2]Y;#@W=U;"KRTMFT M6C/2H:&)%9KH*FI#$PU-%#76FLK=8YMT&X(/5S=?/UW>EJYHK93>B":KA5SX M!E1_4^71H)GL<2S@MY5!45U93(8U0R3V6-"HC!KDE!0Y8,)LS$]L)GPG5[/?YV4JEWJCQ43ZHAN2KW"L7$FAR"S2#L/J)8FEOP(E#L*VH#Q9?4HXVJ M?$%WGG()\F]H3DF=:(5ZH];GN/U#-\JJF;P:-*IS#ZISV!1![T-UUF.<1ZUR M'LYUS[3<.]TW0EOWI+?2)Q;H$SB0OX!_D-9M+O2+7^CW^DW^PP[@Z@^:SN7' MO-WS@UN&MSDY9P.-57[N6SX::X[XNN.4PKT MJ[)::')WC0[<:?>;NXUG!92'3=.ZYP%PT/1F>&XVP,:17A52CT+-\W?G:/I: MW7A<.HY[IP?6'9,^,=,RX&?2C6XSO[BO^UQ %?.&7P =)8F=O>KUY5&AEJT- MP/<"\%Y7'O2*F%X>Z\#?2)S>"_ MIG7WM_\?_B?ZM=A$%R#W\]+UK42? M -S#8/,C"]V;64Z$QSZ\3GR"F(-_PJ]ICRMXAP/:^M)G[Z(_?H[.9SD$17KH MY^SJ>)@5C!+&^=?)%I4VWZ9P!L6;Q=<*?/5V_?.1IHRZ@]ROVHJ:^_FFI;K* ML-?9NM)ND=S"DC2%EE5..&QXMT,7AFVM*XT=)P1_])HM72^(>8&HM4 M"H M6.-]#H!>SH%SV#;]OW,O@<&,G4T\IG\_TZP*=_JQ$/ZS&Q[5;847.N0M':Y6(0.=6"4EIYKAD;@2S[&.Z1[YC'IE3I0 MAM+$LFWL=64Y$M*F+'ELZ3&?.0'0FJ1+)C, W#Z3W*FD*MIK2?>!.!=+W6.F M%+A2,&>PNN5ZT@/3/46ZA7_#,[@;?.3F]N+C^'HLM4(_8-\M)USHDS?1+F I MTP/1ZTB3!\F?PY*2[?H^K@? V!(9LCP)1>AYRX90&]B@0P&,.F>!#OT="?P M%>FC"^<1:\(KKR\^79Z/WU](++H3]IY;#,[& Y#L_ MQ,QS[X,Y+G@+*W[X?;RC=5H C3V0B04PF:.KD*C..HJ:(_PG@"Q_2?O? M<3'":\U"V,/WOI$Y!Y=Y:.:_]B(4M;AB]]M SF &>.ETL;" I!-YI 6AQ*Q_>CR6?(<_- M^![NX#T)$E*D#P3DT[/)>3@+G".?.P^P$Q <+ AP*P90&Z!+LH$B9_1.*73 M>*%W_I(L>N7![F@%P56$[R@$"_\<&P&^4&NW1PK\PP 3"+<*.US".9U O'&! M?^*CMCBM/O,8?>K+],YHD^S'DJ&$2[C;UD/'F',\;3\N8H++&'K5.B:Y=.Q) M]W/+F .,;5NRX+5PA-06Z%Y]\+.?B*((FE4B[5_R(15+52++"6-(O@&I%0!3 M+ODC*"-RX50'*X6!;YELPZ_1PD'B $J-Y+'K)2A%X@#$"V+C2RH _0CAB;S? M(-DYYD"]A7: >]:E:>A1?2%H,]"/@BG75$FE$'CI3!D>)02Y:_FDNW/5?T?I MKFM_/:V\-= PCRC\M*Z.57FR"*Q[_N7;Y?LS=23=Z09=N8 D8X"N2L'T,P/I MX!L6L_86JE[2);L,B[G3JH^!_H/TC^O? M?[F^^#;^? N 7%AWX(K@#^ QP+P=FEPI9AOARW14SYJ$04(#*PC:Q+-B"DTK M9PK-FPA=Y#S!J=@/V(%OW2'PR.J*AJ&"2S3Q0@"V-8D?FMGN)*5O\78<*=D/ M/81HE;AW0Q?G7''=53H1#S_"NYK2>9QW:>5$I )4YI+H0RBU%DC&L+KN<,H1 MS7^D%CA)[(>UU&=O5GSA[8Y21"HQ?6TX>'9-V,[OG_&MR7;>!KJIVSKX&&^J MA>EL[>K;I'+U+0?(!GNGGZ \8^=TE/9CNCB!HWC.C\%?+="E_;H%D%/ 1;JT M!/@9J.SU0'+0S ;;/?1AVP!.LIHG _F+:P 99=I>6!C BQL (N'>VEAN[$L(T]H/5#Z1XL,..^ MK'"B!2#2KUYUQ,GUPBT05M*N$2@+6(+@ (:_X8:X+FGQE?VA)H5G 20609M_ M#:Y9;+MQJ)"9!]H'L PVD$^_%CN,7& /'J;/02_9J&_@?6!/P)NF@$^' @_ M1J"E0-_P, 5+[0[?8%K"ST02FEL3<@J%W4F' :T<@,;DH*!/WL/^*,* 1'#E MN8")A60A&7]5;A1IR@"6H--F>#*'(@A+\2./_1E:9#G@&5/&!&R!8@]P(/1/ M?6OF6&!:Z B->+NNLQ%:*4#S6^4(VIO]G.8Z:L?K*+Q#TO9R&T476\,#7D>! MD6W:C*/E\/F/6O\0MTS[/)=:Z#(IF[]A+F6JIHW^,U.5 M/Y:SGT#B!7_]Z;>YBV_^'WVQ_%G\S;_-LJ0*IW\27:N]Y0\DGN,"HKE9>V$C MZCUW/KGGGPY"ZR8X@A00155I+1F/PV!,W@<5BDK)8S,P6@,7K":P.A:6ST.L M%/X487INMCCL7JB6E="HY9AQN!]_"#Z$'T0JS4=#=@H"V[WWWSW',*V$1M T M9= >[2=!H:>,M.T9"D67ZBN#8;]D*_64WFA?*_7;^=^\<";'_KA\6$AK7@F/ MYK.^8"2H6N=SML"=T4=K25P5/NIE+%*>=RB#KF=*=D3^K'PB;J8'NCC#PQ XL6(QAT&,_$H(=E2%\] MC*#9%F_89UB.N]#)'KQA-C,P4O+!FGCNQ(8'HKCP!]T \U*Z9AA$@C]^Q?N7 ML0ULP(U&[BRT;O_^Y?HEP9_/>;$C7! '_X35\0W^)O^HJ(,TU+3^6JI_<]Q" MQWU2$Y]-:QRTR>9Q1%V16]#]=8LL*RA61-^49!*YC2:_0653+JGBD/OB@=DH MX$@RJF<=Z>JCU )@WE[>?GU_<;;>=FVO0*L^!S<'WGL3U5,26_DI)R M/$#!NS7A1'>12QMOAL PFUD8)FM=@65[\?6F$5#-@1L!U0BHL@@H^#X64><7 M5W_?KXC:,P$WTJ/N!VY$U*F(**P8"B=&&.@.PTJ$A>M0*IB^?"#Q-8>GSCS+ M_R[Y"]>&@^/]Y9HD:XW_[^OEQW$CLDK#P2=WX!,061?OOUY3'KMGV4OK#M/C M"EUN5OSL.4;5DIF6'GB6$56Q^%)+.U,UR@'V)1!4;R@VQ2/H?[_\=MJ\T1RX M4C#EUJV4+I-A=+KFU0DPM6,M\?XE2=^: 06-KJ$CR]^_7 M7?QPL5.8 M=.GX"!SXQZ7'CU\^-]F#S8$;P;C+).2" /G[Y-#[K ME"[(<[KVR3[148JTE MR%5\.__5-JAIQQUVF,.)*TV"4#TD114/? KB*'<41JIVJ1%.R5?7S,>!"?#7 M>^J?+_*%KM_#FKTFDE0:OFV,D:+KL.'XQ!PY]^!U?_&E]WRL5#U9_'0% MQ0FPN!CE*:4G5#8_:'[!N'%$"0=*(HWKRY*F+HYOT!?2E M$TW?I*2WUU\:?Z,T?-OX&PWWOPSWK_@?4NM7G*-W>]DP?SV8 MOXH';N1438_^F-.T+HS&'\?_:F11>5CSY [M. /PJ4#K<[.+ [JND-E!-,2EU..HE#HS+KQU,_YXNTL@ MY;D@+282FK=46_SE3"!M9B _?>(E32X>[&?BI3+L;1]X^4*#'%-H23WB(24< M07CB%%=I[#@A",1KMG2]X!##DH\"@'RNU0:G,#BXFUU+[3YEW!#8\ZDE>U+OFXS7[(<&HA4G 0 &Y\QH[6B[PB8XLW<\M6 Y^88)"LQ5(WR/A1E>YK1?JJW"B\1R_?'-^4 MVETMNXM*;T M'UFZ( QZ<+@",- OKC9U'QJAP6I'^C&GZ'%%2XV'!*H%*I1(JR>GOYF[QO=['7Z7 MVHXB%>2&[LMR@]HN)#D_Z7_0N$8.J:FG.\;< J035(I.W\X]2B5LD2Y\H>XV M,GOSYYU1;R]6S4@9]/>UIUZW>[@]Y=@7$7X=UV$[_:J,YVOV1'MZ=*6]T4%- MQK"WWJ.X\\C$^,15K+_+[/5'7/,M8""#O#1P0&U^FL?N%#CVDT7E"8#PU@UT MFSRF\[GNS(HD;M<-!%\BF]4_;3B<"W=A-RB\B/Y)Q3Q3 =&GC75_ 7@^&COA M-2.A-V/>CG5AFX^;2V;:[B!K2R]%B6.\.'@6R%Z-Y&&W%T'L!5Z;?WO$XP&K MB'H"+1)HVP4I:TCYY>72(8!:G@4XI'(=\P1!U$GZN#ZKE M@J <3)!_\J[<'0ZWRL67L;!J!\;^0#T"& \6:*L>2EJ=S>9F0]-% +A%/S8 M+ + +0Y/F<1!W;2Y&.IX>LJ\)W=ZC3+?!QC[_4:9EPDEK;:RWOVUH>GB 1= MW@B&/5A$!Z;"FN::%(M??/&"N;O4F6D912KH*DML^:4E3_*\G=K66NK+/_4 MJMSO-"&6/8"QUS^&0]K8+)NC7DV$8!] /$;@L&9 ;#3Z<33Z/QS&3E*E][J] MAFN?#\9NK[DU*15*^LHQ'B[TT]/I';G='35L M^^Q;8WDT. 88&YV^Y2*_T]#U\X'8"(?&3:^H3K]9PD>R=(/-\7SI?_3%\F?I M"X[$/#TU#_I):P)N^P!C=]"H^3*A!(3KH$EX?!X U0: C7I_:K(CM0E\.=6^ MH2&,[IF6>Z?[1FCKGK1C-DJ!;?248:_ 3G*Z/V,I[%E'47-:&$YTG^$*6/&2 M4$S1=KV58Y=\U WD0;MDC3,:,5< ;WVYTSN)M*_&V-J\!.(<>L<9S+>*Y M6 >YB\G;Q)/O8K03N(O9X.;WNXTU\/Q YU!3M9\;>Z!D>/G?DS0&GGWJA@'+ M91&4WYVFG$HIFY)Q>E38&381L><#L:F,+!="^DT!P/.!.%0:,WL?P?+>"?O[ M+Z?4\Y,/OED^N-)U5N/YY^[):K??),M4$&_M0=--\E2,E0U#^922#6AL.+< MUIINDE7$6CW-L?('6\[A%[H12!^9XS/_[8G6LW;D0:=)X]H'&-M:8\.4"25M MI>F:NH>V%4V6TSX"+L-&PQ\AE2+T9KB/T]/JJMQ5&ZV^C_3$0=,SNE0HZ2C' M,+-J!L1N4[FQ%ZU^X'8?+Z+5]REKFE_5\U>/D) 87<_)-SV]7C!>:K1]6^DE M7X]Z^'^KP^U+8$[F!^INW4"WI4_,O&7&7+K1[4*MR_<$G$>$YAY14 Z9FX^" M5QU5'O9*UO1DO^2_KBNV,,%&#FZH;I_W*FT9R.*TB.[H?DM#P7NDX&[9VI8< M468>$.RO&_O@P*VUE))EKC1TWM#Y"P!\6T.C8UH&):.Y9WB[;P-]8K.HD#%5 M([K0O9GE1.#MPE[%)PA0_&>VB+2K=",*LAR3.<&[,_[97AW8GJ(])JLZF^LZ M-658L,7F_G8\++3?-"A'BC9"L%UY[,YR0]]^D#PV99['3"EP)=V7+IV >7< M8S@B>.HWKAWBGXF7WN R5:)[3%P.E3;ATMI:MUH8 M*W+^G_[VO]Q06/_?*^89L#5]QJ29QW2@82F8P][4=ONUY'J2XP;2@ND.'&L: MV@5!T\^"IG_H6G8Z\NV<27@)R[P':>KICC&W?";Y&#F3[IG'I%8C'SLS29=,9@!8X$%W*JG*Z#4LY2[PIQU%PC? ]_AJ?'YL MWL%;@)ZBM]Z#6%AZ%D "3B:9(4-1<3ZW'%VZ _&P8&?(&R;\QC5"CRW@I9)N M>*[O2[IM2Z 7@JGK+>!?#NJ.Q9(%%C*;A#OTX0D?7WOA,&_V0+^Y<$Q8*0 D M^K@[R^=;T($?8<$'.,/49X$T>0 < R@"CSFS8(Y'PW_C@(4IJ&,W>M\": ,> ME-@/9I PP]?]8KF^.)^.@(2-PG]7UW/8/1[+#(U ;#*ULU\]]QY^!A__RF#S M*"WS(>;!81W:+C/F#C7QDY;P2.#IM!W;SP=$! ME?!R@V,$?S,V#%O'_7". ZYA/B 27J)4C9^^>,'<7>K,M Q_(U-ICS&5$P,< MX:4IW36NFEH^*!!Z&']KAR:LKX.@9F>!M6"P'A!&B/\UW)E#JDB"+W!U Z37 M#+^Q"?O <0;H(QVV$M-CBL=2!TKQ&_P8$?=5N5&D^[EES"6N\.X84"7'-..X MO7<]V[RWS(V@$92SPBJK9!/3KL-TL(Z9MXB/" :B%R[IA*DS$;\FMHCN.$#E M*'LRVP"8!QX<.?0 ,ARRLYCW<* Y&C'8)M,'=D?DA,S<(A82SA0 &J/-8X&6 MT)< 7-V8RT3T,]N= /827N(O7=T S5_=S/*X_NWMU\\7R0YD:1D"$(.YYX:S M^2H\OEU\_/U&NG:!:0";NN];/G[K"TML^]82F<1GR-&^LKO139?C 0 #A ?4 M#!NV=8#[G$L.HJXUM;!Q?LW&H^>+>MP^)Q01?4(HV?Q( >%'#M**TPE"T-:7/GL7 M_?%SY%Q9#HDS>NCG[.HY/67(8N-?)UM4VGR;XB)2O%E\K??IN[^&82&N)O_FV6 M)54X_9/H6NTM?R#Q'!<0*23GA#_2_SOW$KS/0.B!$?']3)^"%GJGV_?Z@X^' M24L2 (AX<1^319\A\_@Q$ *X/Y8HJU0%^^&BB#'@SY31TZ+OJ0"NL.#6/#"T;A?Z'V"<)8<#BC'A@1G&I5:,F\3^2YLYE[!= MT*523^G1_J-_7U\I4M5\%UX*GS+-F2;6R/ ^__KMZX7T97P#%J]Z]AZXC\,,]Q3[.2W.T[AM;J]& MUJK_1LZ:DBG72OA/\"+'\>?6 :1TEU3\&TBQ%I]E" M ,("A^E.YYO9&.W(V^5CX9MM3!Y#;9UU+/.O/UG=27=B:M/I5&^KW0$;C-0N M4X==5>\9FCK2NO\!Q?73K@RG/BG@^)Y;SIN4?*>0&3=V=!N$-=& @<:+;9GD ML %]8$#1ER8,*!NAY-X)[@2\!_H/9$=B-!!T59(SYT\^)9'R*[6?4I-(2Z_4 MM$BBYX"(D,%\'AW!'Z'H03'E+T$14) "E 3&2Y8\N(L.,LDX^1EHH VJ0V7X MFMZI@D)_+4="2"* 5_Z M"A<$E$5+O/#FB;1Y/'%Z[OI!1K\#)YO$>3X894"FL@CA<#L%+3GP?U"A\E@C M^[$DJ^3=QI.O13M2WZW$4B8V*.Y"_W$61;*T8>_US^A.\P\Z_(-U_.?9)T\@G6$U2>=F MG1%YP#?+BH,[QZ.D1$_2@ R)?$VJB)+A\(U+GVTF8CLY1N>YYE':7^ MF&M:@ <,XW!3T;,^FC'6IORY;,88?78$K&([=JW_\_X3]HJ@) L7, @["(./ M[CWSDDCE^9=OE^_/U)%TIQL&7K;[X7)I/T@."^Y=[WN<'L!^6 $(.I]G(I%D M;+UJQW^#//-#7WK53B6N8"CC312RNQ2QPN@:!%\U"7WXC[^W[,X&\ULQ?Y7$ ME3,Y+2D<&X -P!AFX+K>0X)OQ&!4-AMAK>C=13&T'4%@Y42F&TH\""52=IIN M>2!T[!!E0T1P?L"69^&2KI':2C<6)2M)2C$)&NYB8CDBC]$PW%#<+_F^:_#$ MQ7LKF$OK$YFJH% 12A;X4\[,0O<##@4TJB_ #+7^RX\L@E'1M;/)+YSRU# % MQKM*+Q,%A\/.HRS!;#298R0U"4I*EH_B!(<#FHE->KVA(CORQ+3NB.=,9U2#NV*2@6+T#(Q MT,%MOE4-BC_Y!W/N0%O[###)URJG!,W'RS7S0<6!_8IR\SV[8[:[)-:KHCK( M',9KM8KY]]SY/0WB(_4K>*1, M6>D3&\%6]-R=ERV5W]M%#K^[/C2 TM>1G\1UY%IOAA:..FBP"8JOF;+ MR7/[)QSGZ.,%QCQ.XZROT92AIGU['&=; [@T-%!9>^*I&#F$["W6.RDG8K$1 M,6M-?AX_=_$6/CL=__D]HUZI';FG;1\(N@MVBS6&PD,^UCFIPD#5.H],_'@9 MB![PA#OTV=I^R&)=M"I,"Z]451[UMW3+CZKB"+##C55X+GP.S%BJ^B*#I'($;DGG3>PM>-^15>UP(U"J1F;M%YEL MLI7,2J\/]CM^X:75Q;;9"]XC%U>[^8[[:P#[8E2^80J".I"U3CD['>^UDW%1 M>[JRF%1'2OG^\@L MS%W07MEPW%-INPP8?"3-9L=#/BFH7R6"[RN#AMY/@MZKHE$W#EFIA%+]W[4. M52+IEY=Y[&&HSVYI-,TRY66%@O-P5O+;]SUIXYGY[=C@\TR!+X7+JN;2/!]RROWH&W98 6K 2(,>G%I+8 M#PV683\LOGRR5JKC/7-\7JT;M5]E4SRP&)'@L5D(9^!%NXNE;5&C2VY.P[%X MRTK>55W !!Y9Z)9#-90+*Q"E(+PD"5]C.9N#M7%)B&XM"$C,MCB,I#E@4?HS M!*$8\)U928)0TMV]LK46Z<*1QXKL9'TN+S)ZT/O\=^C2B!@$H":^*:#U+K=X95 M-M)OS//9 V_TS'L2O2%26EI+&NDDZ7SDS5'J !L2>@$2:J?KK*.A)-_._HD% MZ"DRV-18H9S",1]QE\[9E0#.1CEY"?K&\K@N;%U>71/PWK]Y)QT'W;AI@GNJ M\ETTJ0XRZM% \P^$.W4RFQ%J:43+#Q#K 0ZQP6XGW"&*N\WFE$U^&JAMJ36Q M7-^"<^C>FZB2/R(PT1L]LEG2% (??7+):)"N8!,+W6 A>1U1%Y8VZ72/-Y:% MCUU41+S0EII'<[CSI2U?O!EK_S.=6JP,0*()0O'OX0\'!-DTM,7D'MQVI1H# M\!;BK4MJPOLFJI.7I<\L>'5XEZT1^CK>\\*V)GIWA-I13.=DCIT(BL&]!<\<,7'3>TY-M2? M/$C1V;GXB_YU&;XH'2QV%@W+H/C$4CR]"HG'GZ AY?@P)L*#4G#!LWBP,''J"-]XK'BN=H MUMCJ G*&%\D(3I:+-T4%T[($!J\UBSN1>"'R*&\K&P0V*?>L/>^Y#[H=/(C& MT,W H&9@T+$'!G7:S<"@9F!0T])Q7PH^J]HY\#/Z/9I$L&J(1N-H0+G8:%EG MW=-1,MN @C=@[J7'&<8]WM:&IM*KJ/,#LF[M>S_T.XHZ[)6R-\(>E]K>\/>% MVO3NCY-V+_#^)2KPCJSYMQ>/I(X6.N^A4L1?I-5!%3J281.O21"73BI M7XMSM A!S$7#BX.5D=6+'0GG.K1- .:5)&YG*D%.MN*6I-SE"&RT;#7YKX> MKL/B"0,X[%E<5/*TIYKBKJHG:2OM6IRCMMQTL9:O8.MK@;.JHVY4#V9:#[!4 M]20'\@8/S4QTHUH+! '3#.M!:G 2K38GZ>^D@QZK#]IOVYX#<-VVSCU;4BCW M4&;V=% =G'@V-.'H)JT;3AD._4+1D]J# 4R)48XL*5B#]VCM1E>)QYC'M1OT MV5[%0T_1"I5/Y$<_-:HO*7('^W*W]X^7>XP4;12/),P;A4?I\-&$/5$*D*[M MHB0NW3:DA1X$#!YLW8"U_]D-&,_X4D=1[M4Y9A("&5-@ZH/EZ Y- ;L)X .> M?(UK+5R/228+=,OVWU!V/U]G)4DLWA(\I=^Y'F5D64[ ;,P4F[ >O$XF^]U $.@P3&_7O M2$YB_MPF:HUVLFUN;.@DLE*\+?=.D;\?RZ/Q0F%E T3FV]Z27W]U:;J>;^D M"8?PC7L@&.!R!*)'-A0MD%^>4ZER+$SOP!'4:^[$D8NQXGWQG.V5NK@\NX#F MZJHI?2G%:R3#>0LMTE:&R2+GNC^7)0/^E] -=!!W$EC0 %B>@)V00( ^&I#@ M*ZVK]%9J$@-Z/T/A/!6%CK@02'Y/G]$SG:@MSY;,L0RT??K1^.P[/175Z9J3#UY0V89W&.GH[2W MPN"5-HHZ$V^$;(<#=MMK4C.8^;&P80(XUIE?XB%22?L^\E<,] MEAN&/C_^-!1B*IFEG5;@]W/+F$L&J "&-H#T27^0.JJ<$#I*^AES "PX8M1; M@A0.0%2&\)?/GMP10GV2.G_/"Q,VU=)T"GEX7'))$S9%@SW0?Z1F;I93%F\J MAJ9SM%![O\D_3G:$*%+%*0KS;RN2^AI-ONU6OI"$3M*5 M^_TB8KV@-B__@3NJ/.P523VMP%':,GSQ7.15;^ZTJCXR%J=,\X"/ )Z>TGU1 M\-2I5T(4F6>ZA\E+?NI&MWK]$79HTU1^Z:9IK.]%A3;2LUHLRXQHMFP>>?I2DUVC91[7L1^;[[Z*D59R.$$BZ M;;M&E 8L$J)!/'@VT6@CM 3AY>[R4J]3/#CO(\6C%[?]T/=N\ MMTP699^O6^Y[F.-87A)_I?;E_G ?1;3E/ZO:D]O](I+IP),LRPNQP@9X#8Y: MU$!_%G&LW6<4@EB9+5AUJ R+7&D4)8T:W%%5'Z>#8A/#GX[3(EY+4[9?UK+] ME5K[P=-K[9]80%E/))>KTGV\P/EW6]SLN#V#%1>6K@S4HQJT]?JSU9^M%1>O ME&IR,EMM!K'6 F*]I4)/4:5,\>-@I=Q0QN&B2X;CK>&!S#ZRE=9Z7&>]UK5A M8T4R%1?B\+S\4NMD2G:JZ!G.QB=@BZIG^-$"5KX)7./[6EL*_G=.-3;60F[> MYF[UV!OJP9O)>?NJ=*-Y=]L'"A5="H?P;:^6>KEP8+3$JI(_0G$EL>[8<; ? MRS4#H1/L([I62@#D5_IWU)P#UWW,I/M_$%)](H]+\'MXQ,E^M=B/%#-\-&I5[1&3J"]>+^2UK>VF;D$;QP09+ M!\'2-2A8+XP&8T7AZL>YJM=PU7'<5FFF6\Y&!*UT)-3S.ZX*E*4='&.W 8J5 MB7:)$KSJ1[A6#K)35 NKA^*H%M;*O,[VS=PQH)59NPEHE44RI'IMHHN4[JZ= MF74HHECM->'1VMC,.[>CYYN4.EC5Y1G9(OIV-W10[L!F6JF+7J],^G;VS]5& MKHU/=$AT_MVBYK\[V=$IWHLY]\GH*D=\I*&VPYN7VJ9DD;%AV&!B@OP 1( # M805X ]+(A>,Y;K&")P?N,0<[)\15U'\KQ7" S-F//A!@M7<_@5/.=%P7LRT M03H:S"XZ4TD,T@JV:.C6]?_HB^7/[]^DH^'8JU[8ZMMNOK$INVL PL6(C068 M?]C/?0&J'(AF(7[O\][W=(,)?D" V7'1+%)88@FK8PH=^@H6[32TZ5Z++TK! M.#B%P3Q,O\+UP>Q<^*E->OJ2A8%E2#JZ&=SG$,>*?D[+^/B#E$=A(75.,>/- MA4.8EH]."A\H( 9[1WE]>!Q*8P,T .(L)UR%[M("6QA'T/@/CO% TS?N+ ^6 M;5W??'LCZ28<*AX7+C8E2W.&IP\L_M*_7WY+XX8?9.EA&M8/?,=:)"4W!R_C MM>?0#I]0X#$#<\ (S%E>%\C,Y*_&6:OXQ@M1V"\+/X 2[7AK_H!Y"\N)88.* MUF%H+.(O'1 L> MX^,$7G6[(VD137#8"C;*J>RT-_[Z')D#8>*Y)CSD8Y:X>2A@9P"<@F8*Q@!- M&F\!/_T#6"+QY=8 N#+88HX&_(0Q)SDNL+^XYLQB!6&B@T )X6LS0A_?V;T( M+7$QEL7,U T]$""K(R2:M,M]I5UBKJ2VEZQ+2N#YU((&:;K@Q5K,)-\S_OK3'\X?9\AZJJ:-_C-3E3^6LY\D MW0[^^M-OJ72)D(L^P+: UWJ:,9BN.%=,< Y.EK=O5J#>&G@/ U0*W)N'T2E*O M/D:=T8(DTT(8HCQ'Q)];Z#[>GA'-9>V5M2.MI.UTGLY:R5M90N;96T&(X<@[26"(9GIQ:'3V6M9WG-#'E>?>@?>.(7HX\JW^@Y%WST?.'#D4@D+A M/FY1P:937JL672>2K,"2.KI<$&XZ.;2)&*?;RA[>5L8WVL!#JJKT4E>6'^#D MZ.B'OI\3G%SSII<9D 4$,H]-P5&!)Q)R&VZG-OZCA.1R..OPNFNPR$RWKQ%4.= MZN!G7[JR<)R+='OO2N\MCZ-2%J):E$G"PP1<4U0XZB"0'6L1+E+(C[$.4D[M MO<;@@01L"':9Y<^3V81?O)GN1#$Q7.L"",1=6 :@XRPF$**&]^GHV)>+\_=O MTGO] "S-2)\'Y=PBK3AL(,'3 ",#H5T2SBG3#[JC^\^)K M[*3#G\E/20XS1S=PM=1;;3:S?)OO,1HDR0]GB6XP.@(QOA$C" :?P;QANP A&R\) M 5Z.A'YCP@ADS\44L8Y41?KGW,+*S!A @JUI,"7!"39QG["@CUNGJ93TN<=F M(=\&Z-R)+B9#&J%'EPNS$)@0M%C6ND0# P&T]8 J!60]'!'$R:%2_QCQV.N M:PC+_.M/5G?2G9C:=#K5VVIWP 8CMX:FCK3N?]1VYZ>=DV4V*A;1 M6?LIR3+]0M[R1^M/ #G6_R+Q&_K20F,%M*8;>D8%DW_B\W#A3Q_T*K*R,UZ5IFSC45WULJ._ZO%IU;>KNVKS::EF0W"]!V_U!$E1+ M4 M]GM5(T"/%@(**7,#$,+$J=%)$8AD)^5.U:),&-/Z8WZ^PHS:NWN M[F'&0H/^2COV;I([]NZ%1B/E=J79:<[!LWKOT.%)@NQY$@SUWQD\CO'CC'3X MORY/;]LLC\6$[CV->"P#ED&W[-)8LA)X)+1Q-P8U +FDPLW !/:?]F$Y^JC ML:4.E7Z1B9R50B2Z (1,&D,_>1!I$O7%8D=1ZX_$*0^[U!:);:5;.R1ROQFM M[+A[% 5^4$MZ;NC@29Y@&.VM3>?!;2-PR?;?C;3<-,#-H^Y3S*."'11+X69> M.O%M0S8X-=?-M5(K?AG$_;^XD&K%TUX+6M,5EYIN";?M]QV,7&;:'#[[Z@3C M<( [>1V#2?W]RIE*>I&R):""8:",[4<1RBF%4SK94 "&2<4=$F8*NM,F'-"$ M [:$ R[+$ Z(DZ\.I_74G;1>M2,")$@^@^T:)0[4R$0=*D5&_%8*4WB;Q[59 M-)4%59FX=C/_"$7: Z49WS^F2[%DV+]K?#^;1*UK<&'Q#<_@ MO0?=R,Y,]][AKTMWA-5W*=6CY7PIKW<,ND^\;L>ARES***&?OYV$/F8]18?E MK5ZGS*,K /U'@D RC9/%%C]U9[YX?"R356>,$2SW"RA9VJ_.2M$ MUZ_1!7C\;Z*HEQ1QQT!ID:'OU4)IZMH*<*H;!F^-O=0?R.@D$6887@@2P+9T M,%*X0U(OQ+94I5>G",M6U()^8N">1=B-,A5WQ>J+B/5]1W&.8-(6O/^H2R!G MNWN\0^"F*?-INJLWW=6/W%V]DW/@IC;F944FW6*A@Y=W%\G;[PR5OI0.+:;: M*%'R9!-=;**+94\V.NBL+VZ*M;K%+DY?(KQXM+&?T>T,M91?8EZ_%SS($C"O M\-+Q=H:"1"_IPQT>VRVU]Z*Y#L=#:-)-RYA>EID81P7HALOV2@;.C89$B MMLSTDV9IJ%%='TS-O/@K(;I>>&VIRK"V_+E;7+Y>B*TGPZ*@Y8U+L?X\[J94 M,]RI2J^&N#. ':T@*N63])G'1/Z*\*P>ZBA?VXI61_G*[YE:2>LN46H&*^"= MA)%%;>#I%L[5?*.Q\-.+XG,D%WA1%J7;^8$ZH*"_C MF4)%G5028&ZDZ%D%>DVHJ D5E3!4M#=. SE:T$FI2\B(C@U"P#*98U+(B 8U MSUW;Q,'3M;&0Z)PM[44+*8Z&/X\M0W V==Y(R>"#M2G5K%[X ^9LUQ!]Z&EF MPT/^G-P6,&EMUYF=86M0FKE>+W2VE6$-L;F"2>1"R5WRB#S[@;,*P8A[RQ9+ MVWU@O'T=2EOJ2:S_D"+.E?1[W3-K%@<4:'_!^N FY'!0A0H"N68*E9#ILR"P MXT9_ANO0QM#W02F<9&(3BZ\/S3A6]EQU%CUVR&6/'D/!"NL:!5XZ^8&78E78 M50J\W*8GDTDB^!$N,*#R7^Q>1NV!J$/@4@=4BJM9CTU#\*4*1UJZ>4>M1*2E M#[0_[.TEU(+#6AX)M1QKJ4=3+/SM@9KQ1/<[S M!,.]U.?1"ISGB*S\U*#J(2<0%#.HORHWBO2!F=0N=?]]AWO*L%=@'SEU!0C; M,U!C.6H2JS1Q!71SWF1U^9X"P^7RZ/A-8D<>JD52 BI^SJX\*,3]%3^F)JN] M(D&VD[97=A!AU F% K,?76RI0M9_"93B\RFETRW2B*'\Y] Z3ZC1+>,YU"+G M*)UQ8D[P_YYLG!R:J?F #63M)^N"QT]<$HIZU05E4(2H*G[.KCPJI/,J?DQ- M[@R*^)>-B-B'B/C@>O"A,+B8T7(RD, MM)5>\O6HA_]70C&2'VWB8F3[E<$>KI&>#JV#4VP^G%[UY8%:1*_5'Q)#N5=( MP]\Y-45%-&18,BKYGV_+CN29A'VD_GMS" M1.-%[&[%ZO23C?@71^.]4K-3AE?;:?+V^^VE>&6'VD%+X-+<>\])L!$ ML^+$?,61G)H5)CH8_\67'#=@V79AV91%JD( >+ ?5!@I2I=W:A0L/;X?U*/T MMHB6Z;6O5"W=$SD[SRC@PW]S<]C@J"XLNC(0?65*+DY!,^&G#NXX= @\S!3@Y^/T C(Q^$$& MR4$^;&S9#(K!H]P&7X:5>4=H:5"X&32'T7KV:C"W$&%3QB>,XL0I2A*!==', MH<7CI"DI5=XNY@4:MBMFNWW2'Z1.//<.*01/*N8) J"]I4M-XY"F M+9._&1N=.4$T7A5A'!719YMP8[GN&0,Z#.FH.&LX&>Z1# #CQ!T//8,S3RU! M\J;+B!-([B D<6$?!) U!=D)>Z!&; @TG)!F^=\YZ*(MP"\LPUK2H$4:-Y7W M>KYKWH'O 6'IZ3C^F Q'#G=@>^8ABL4L*SE!,-;,Z08^*'YI\1(IS!6W CRU MR%^:"TSS$\,>I3\< H0L! - M\6"XF Z24SI(/+*4E/AE90R 3K=0\R*?SD0DMYO3&"9=4PT#Y>_ "R[40 M9X$U2V9%KDS/30OWJ.GIZD_4%(>W7JF=U",X=A)@_H9*OKT[)L:&V@8 !P#K M^5(K:K8NJ:/G-EI_0[(COYO\PG6LP/5XX_&9[4[(W^!3^2)$T1GA?V?7EC6CRCI^)L=4HK(E,<8KI:"@/ M.EVYV^WRTAH_FF>>KM.0L5.OA"*(H2715B5D+_H]?Q'?&N(:G[G!9][(J)*V M[)",&[!NVJG%D*PR$AM_U%V99,>E4Z*Q@PUBGL[/9Z1&/YFX[G=Q#O%@A"T^ M3S'ZUT8R:=H [IB$A[W[M'V5.XZZPP.V 8R[<[YP3DJ^5]GI%D[J*$FNC?K8 MN5+CM:.S68N9Y'O&7W_ZP_GC#.TH5=-&_YFIRA_+V4^2;@=__>FW.6HCAQA4 M_,V_S;*D"J=_$EVKO>4/))[C J+I:/CR5:3,)P/: 5#!G]P]TE;LJWNRMPV4 MIN02I(PR."+'CTQ/\ F$3A-Z1\YJ%H[LZ"/WWD'MG3'CAB.E_SI: M0/A*8> '.LV:2BGG'%W+C>% ^BV$A;3(7B"EASW/ 38>J -N HC#4^/&U;DP MNN^[.!T -D=3O,6K.$RF-C,X_,@QQL'* 8]=D!X"6&UZF1]9'D;:KHR,97_. M6% YRVPSR:C&RJ:)X]M_CVYV^FG*"QOD'C:'!0!$_YN M--E4N=?IR,-.6^[VVMM)E1MOKSIJ:JX43I'?!+WDI;PQ.#]7P W U.G!JDWX M%GYQBYW%0YR$JGSYB MF8ZVO0 M"38U&_-:AY*<.-.&$2Y"FT22F!D!A. Q<"=]6%X"R>ZO2;K(20X7 M\/N_,[!3YE+4'8_C#_X'Q1Q7,BFD@=:(6=Y^D"-DTV\%N:T2YX:SBUD7YG8Y M/Z$8@A9# R,S1)5B?$HBD@4GZR54#L1A%9\P4(\3=)/F-9)X.\9.(!(YJC%=UO70$$WC-6PU@=O@)X23@ M$V%$@7$.X M+;0;G6&0=X94R 8$\01 Z'IG%]R*ND@(@ (O23A1'6IR1QO)O<>4:DSP:1UU MG@#@"@&@2%^7B44BCHP/;=I0?(3,,L3/.!;*!RHU>7P9V(PF09FQ5(T.[KAT MX8)LQX=&/3QN'EA^:NAJ1O:0+$;#*1L 3<^H3$N:+W%K-N".-]&DK$IQQB,U MGGF6&D(%[[3)NO! 9."\ '=BBR!S/#L+K(N$@^"A>)CGENNL=]*M*Y#_@&M@ M2Y=DY16^!14DFO:$%*?%JX+L_(UGH:(:X2_PZKI[JO8$-=[+?V3GI?98&5MH MJ0,G0Q3=_$#1.MOW7OKJD*::E>>O@>GSD$\[ZPB*ERM"E_,Y#=$PL57(\F"PG4"SZ2I-[AWAI5W' ]N1.O[V+#*R0F*M'52GYL-K/M3B+*H]&1:15%4[2 M[A1I;%H_\VL?A5QM;513F?.$L2HEQ%"=9(XF=X9/&)A2PI. S-&*='QH9$Z> MS.FV^S65.4]HR5Q"#-5+YFB%W)7RGV0T**+1&HF3)W&TGE93B5,/&[Y.$D?% M:H5:G&1T]!:/584<6+K]6MHX8TSDEAJY4\*S:)KJJQ _JG MOU-,YY1ZR#0-07:_D*LO)#J:#$S40 *,UHX\ZAZ[9^:)PKX[E(?#'/^T2L,^ M/E#=_H^H;#_IB,$3-(<[M,7X()*%EYZ[I%86U \@-50HZC^3:KNQ0V^ S4F= M3?'TCMFC5/+\Z("/0DMA'7;G&*F.*;2L2H8CL!'UQ1D[#N9$7S.U+GO/F7]3D7>GD.[YD(R=BCM(48^=JE4A1&G](8ZS MG\9RWW+\P MY"19HB(7N (GP-B/P>X-*<:)V9TE5!Y8<\+^IZ4O21DB1Q@86 M< # L#HN74_ '.I78SG8H,?U1HDW,HKZ#,%:J@YZ39>1PY[,4,# M6]/XJ(-_A2W T3TJ:>% X.44R0&P'XH[G?J,BO@"43:V_A!VD6.>_4 %(JE] M "@EM?V:BF485G6G2GZP>HP;#CPQ/&F9DE_W$1,N-8&Z=T/;Y$VC<*@OWP/\ M;0-%F=GV*JO%*1'BDF-.J(!'2^HCSVF>H<^H.I).8+*7.4%40KF?$ZSTJ+D$ MJK2H ,DWF /TX,HQ$B,<1AA<75/L;Y)' *O/YF,_KF_U&!*K+%:<8TLSQXUY MTXDH.NGQE>I#B$ND6+.J$HM8UQ?%EF!$XGE1AM@AUD9QGK52S)P14WY2*Y]_KRX2%=?\SOZ,5:*Y8]M'_J-.%D=O&@2)_(?*)]3YAML3LAM]!@Q#6(6*G3Q0), MFVR;1@(7[V_C2IOG/;?.;\9O^!XB,88-*>\XGE: D $I\#RY[P;HXWFC$<5 M]2!"<"ZXCUWZ>#=,^ 00SE=)0YN#R6$!]:!+=J)(-YD01O^YW0=),F\Z=V79 MCY,R*178(@@3ZP> Q8L&/8%LX4TJZ9-8N L=GNI3&W4OU3T/Q"[ #$%#-><9 MA9"T_\SM/Y)Z>VII[,8( E8WA>$F9"+\TN0--W5H U"-\ !@<[_:JBTI46D+JM*X"3[XT:N?CC!#@;4,3+J MR(IT1WUD0<0[V'+%#5'N.-\1^)YMWELF(W/AMQ DZGKWA:@;L0Y2Z%[J]+MG M)I#5.1<5'WA+V0?>.*:=L>*CEDH@NBV/FU3X"N%9\&X5/7RSH)*H"T*F>3&W M*GCO$OY*A$>J(ZR5$J*"C&[$CK\ 0SD(-RF)(UPC*;9NOGRX?B-=LRE#(Y+Q M3X'H1)NAY1)4*1%/RN^AEB+82P!67MH P^S/@"2H13'VW*6-31E+[S[9,2I& MM BB5@/5$J[4S2F%GYS.VR! MTFW!XS>L=!U/.H1S&-)O/'3.?30^3*G35=J\:Y88)\);\[:HY0>:"Z >A&R- M>\A1>"5:[4UT7OJ\T\Y=+M[%S>9EDY:RF_JB _(&[95NZ$.E-\ 'L.7Z&1,T M4"GB'HON("3.4J0&)BEJZ*F+G:VQ"5-L=NW04/UI@#AB\/6]A6V^TZ-K*H#" MK/$7-?G"SD"F.$[,)%';GWY\N;F_S1896KQE/,=C0XL=<_];+@9?3O;81@Q$ M)%ESR.Z@^%":1B 6 Y"X^.\JHW3'Z[2(@N\&[;7O.M6RQKZ 6:,[(4H-WCRT MQ^VG7UP,2F(S(+!^#&K>#C:MK7-;RF.S$ .O1AINHJ\H0">&B1R/WZ"1"1[8 M4UW^%K+W4C*\9FCK2NO]1V_V?ZG.Y MOE%IBD:'O1[XS_,!^\"VA\K''(_V9[H*,PJ3ODQR0JI5K')G<$$;]/ ?^4^(-[H4?8!>>$\3)]""V\R:@-B1!]0^X$" M5\L@:4J=W,RU?AV/K][P& !_0_K^VF?Y6_/0?_6B>XU%A@'%^U+/7;'G! C J(5)EYNTA6FO);RP.-(40(# M8L^FVPO*T*"6DA':,$3K>O0?C F9%O6QC:[C_=2NL_<5J0L.X:-3J"GN7YK* MU?C.'AYG$*(,YF,H@E_4P"-S> ,^L7#)-O8W( MB'@J2B3R=9LN=4" I9N[)N%:Q#WOEINZ"T>91I'H$)"'S)NOC\GDDT6 M<_(,(_3\Y#FZ%A>]OD6_\>BR?^:ZO-MKM':6W__B1U._1'JQV"!N('A8HA*T M'^(,ATX;5QJU)1,L($6ZPH%MG%"1\"*YX+$)OT7BP+#HQA5[PLMT#TTIS@M7 M]*8%TEW2'Q$$/1:$'GY _<=#D<$6[YXH?H;CHQPQ&@]+R@JZC,:7"X:).NF>VC?_- M&9Z83.G+ I^W!%^R *?0H3(W*!/@FI-0W,>:'X.K$JY8S.0@Z8[*="!9 B:! M]%M5S0A MCX;XF2L7_V(V9 XXN(SG6*+,P9D'7$!XB#]-TA6CT2*D+5(&VOW4MX"JRSY+!I,D>:Z@)"G@ \:8GD$<7:S2" 0A5#4308 MYW,B@N[QPIW]F%L34.&A$_IA_#(R!?%=N KB(;Z&,LG\D6-.(<;Q,LQ(YI28 M'4G*8\D,RGE!7/)[<51&XNA$1O_EX@YI)5(6JY9$"H+XG0>;K98H7*$!O&5% M,\Y/[L=(W"=#.)<9Q(H,"OY\DC=!%\\ZMQM-AIE6L;;@\RV8;1+>*9.!(P*Q MHF?4G$&Y$)?KWDV>$9QCSV9OTQ/GAR8S^-&M=D9W3F,:8R:W##(R*\D(S(!- MP"=/J^;X9EE_"]TM:19:_ X&,''$PILV@_^2AI.7#2K/+ MI@V?*?H(($22L2CPBEL&DC;]AL2LBA>5)F'.]7U&G8#X02\4%K&37%@_H5>R M0I'1P8WR'K*8CG[$5\Q%;GQIQ2]UTUD@Y(UG,T)5<0.L\Y(=O)GFEAU?VPR] M:*13:J*YF%O#K\OCF4@XYKQ2(N4J,E[19O9<,*W0X/!#P+(>XP,<=SXK.25R M,@0;91#KX'.B?>*2+(X<^T3[1#[KG6N'"W;&5=6*71UO0Y&^I7^V_H-U S!1 MB8)U:(%D5D]J#;%+QUQAO101DN9Q;3/RQ#-6)6G@>&#VNB.,% 96#V7$+&+# M?X+CD,"UP4@0T72^H4YB@P3+RI1LVWY[Z4[S"1I3(MR*F(6C,)"E+>><%$V M$R:;VL)3HI-%.UL776%/XL08O8\@ MCD=^1(.4LX7),.X$["!GV3NZ:B5?0(1+#88SAV!342Y9/'XI:PWF[2EFQLG*/D_&0L45)&P^7" M>A0\*UA%['T2Z_,/ YN*N)D!46C#^'#T6#D1FH4#\: M=XS*!*M'5O2(G G3I]U$TPTG ;C;42P@BI,EOQ#)9U'<=O(0.\"8_QI-9%V9 M!TH^(F8$PV8V5 OC>[)?E6QLKMHNQ Q;@A %S]&MK&[I#A15W=OLO6&W7_>E M#IG#=XQ)6)T7&H575#F*)<[P]^_4KM+-Z99U!(C\HMOD1>F;14(9=LE ;&!- MX\9-EA2\H(BNR#_=AQU6FJERO-I$N(>'89\2X/)*!-7>EIE3>&&C_Q(E(5J! M#6RJ"-&4X;:"D);VIC:.2IWD[@45=91YAQNE:[U&7.8?'KV5%YR)>*"SKB;F M;TN2:T[;G+:&IWVYX.01AAAD(SW22Y@BCU>G:D^O3FVI>S%&2M*Q_I7:E?O] M(OW^RW^6GB8/AO68=MKJJ8"601DFU.]A*$\/\%++Z;J),*-H=2VPU>_48X#2 ML%N/T7.M3J]7$SD@JRL.2SU9[181E94_:0L\KIXV*B* M*G]6=2"W>[E.3/1Z\?,.SXO>XU +51V MX4R-YBC-4?9TE"8YIDF.>;'D&$W6AJ-:<$YW (99/;1,JPOV=$^MB9>[GG]5 M.:OFA))CNO60!IV.5HMSM#K=FB3)K=Y3UDP(U"PUIB9Q[YH(@;J(@&H+@)/( MC='D4:=J)D#^6< A&/8'M3@*.@2]=N6NO3:$E=?3KRHG"DXU-Z9;CZ22=BU. MT5)K$B+H5#QI]D1S8^K!1:K;.O X M2F)#OE([<.=R:TNT6O,S=WYY7^_;D;S@-S)$RH@RJ2]X-/CLM M(AY6%EV9TY#IX8 G"BQX$S^/EHX]>523D[3@*,.:M* !^JIW>\HZ M%>*H6CT8J->M24U>K]>NB1A0AW46 C4KQ*F)&.C7I!*G7Y/\.DVKM@PXB5H< MN=^N&O?G'Z4O]_I5RQ;><,G0!Z14+NU^0XX88*66_D#]ZW#4FC2I[=2CSKC5 MJ5S?ZDU>9\5K=$^R%*=J1D+^*48U<1%&E3,/]E"M?YH%-M6M#P#G8E H,E?Y MDX+!/CR)@X)K,N@4BE%6_JC@&8]RQ=-*ZFS3F/:EUJB<8=@TIFV.TARE285I M4F$J0&R8"C.H6L!X@Q MS<9X\TBMG S8&%!N5UP,G&PJ3$TR9&N2T=/2:I(ANYIB54.!4,-4F*JUKM]P MBKHTI&W7I&9F)]N@:49[6KTV,9=FN,/TX_I" CR"41$)7'M M 9RNU-H:D_M M0;&>:+9+(]H3Z2):U4:T@W9WIT:T@VY[;XUHG]:'MK]GRBC6 @@@"K"3;O4? MS'^W?U0_:L2D^C**K02X%4GW6 )GI$=30J0LR"& ;Z:A8U)'0&PFJS_0GT@, MP9P!07@>\)OTP'2/L&MQLJ$O@7)".R BT9T'<#*F4P:_-I@T8<$]8X[T5;E1 MI%_'XZLH'(&=S' 9V!D\OG0]_"1+!B:#53S&?T-4X./.;$N?6#8P'O,5Z1;> M?NXNEOA:Y@?6@H@U[TE\6>K1Y/S,T8V 13N9A#&T%RB@(;*2EEYQ-5&MQS0%'HX%%G#JS SSAA M#IM:<$JDFQ HP MT :Y(6JY@;>K:M@N C"E$EN[GEC&7ED!5AF=-D' E\1I\ M'B@.OIF[MDF@7##=!^1@ES60+P$\$ 8)V4XM1W<,T&H )< 2_2J]UNH*2,&9 MW<(_O@/]PG+LQY)Q0G'AF.)S.)LN* >OX!7ID^[H,[[6!.0]NX/M!W,0?&GB MF8.D39'KO1O"81PW )B"_-4E_!A5L<0X/=&A8Y#]Q4\SG+MD'J=8F;OX4P(G M;#@Y>W282M-:/E.E61KQ:=M =J;E"T(P)9!7V#8Q:I(-R(M4D,2UCSJ0IIZ[ MD)!J+0< [Q XD63"B6^9ENZMB1K<#^)KZ;EWUNJ>^$X081MV@NNR/T.D$=C. M;[H3ZMX#E]=\1T.^HXA[-N\*6 4$+;TK7AVE/.A/^ WS8FI%:PGHP0J8_0"0 MM!R@2]A3]E3X'L?T\1%4P)83,OP[^GE$M]&+B))=GZWL+R%(1;JWPDTBFRSA1IC4S M<+YOH1X7@AG/0)(6X /,QB6SP=M21H(7%1D26: ##0!#/_-@#R,*_ M%ASO@"[=0VL:X1W;6"6%3+Z=^A&.8!-0;I@]E2X=4(/4S/.]^D* Q#M"Z1N;EHO8 M&/B?_V^HJ8.??>F/T)QQ6R66;+"32;0'6-@&EF6T1UF(=Y L-GB2P,8RO"@ M;<'9TF0@01>P"S,17.MZRD?<6C%NP7IRP]DG:2"#O?1^QQ$EG6.T?D^A934@>026HO#3V &;VI:N*;!PB $D1P% OE9/ M#?0^G6$C8[R$NE/EF:N:]Z#?RJ"N3$*>)02C(;8 M#$YME-:(?61T%(4_BJ:(B/&K.=/M8&[P:!H&OSP6A_IY> :.SB4V][LB M92 ">>VGJ0+PZ73+3L6I^.I58H2;P#6^2[\0WI#V@*R((DK$"O&MA4]N;K1# MH@>'RSS7L AC]Q;(>W)<@?[(;P5YBW(4G2G'#[R0(Q&PG="SH$\+S"KFW5D& MTLD83FP*B$:S(;Y3/>LRXF$;]B3,,59RVT G+!)P ^@%7W M;'?U>YEK%C\"JAD%#'+N9'RA0"B<0 3TRQY.,-REF&0$0"A6"\*@2 $4D#3 MHZ!XQ-^V-4W+ASL775*4!++D6?[WLZG'.*MQ%1?]#A@-A!)\\F Q&S;S@8_9 M)&L-2<&?XYM"AZ*G,>* [^S(,$?N Q&R#WS2' %]RY1GNN@])VY%#H*UI'[ M3HSS1-Q'<76\%XHO-0!J?!,\A,P];8F*0?@7>%%&]_C\?NHV0UV)),U9$7=% M-*KC;5SNJ:5[O2!YY@-'F"ZT8 P -".B;_1[,(SD6,X+"$9HB94*[H?N8W0K MWL4&/$EFZ,7V$VX=+6U.:XF<2)%2!*!'8;M_>&UAKC5UT]]-W40!/?@FY7P\ M4<\C+YN&(78*Y1M]9O?IC *P>1T7KYVWC[\MH2MYC1>(B,,43G=# M*>@T?KNDFR"PT;?:!!T:J7H[\N20SAX,>301QLTLN3HC1$GXA,_/< M>W Q/6'PYH4M,6$']\628 P!.Q6/B;?;$CF"RS@ A6[D&2Q[QMT%3K7D&6$@9T0^F3.U]23HEMD+SYUT4CF3 M<50Q.D>45H%LR1/P,%0OO+![C&;37BF7D$-H/9U"V,G"$TV2W1"48V_&<$.Z M+'UC#OMO".:M+-V&("WY+<'%[&$92*U)/,PY#HGXH&EA18P"XEV"A[0+'(*, M]@8M[CE@$HWU" "Z!SO7HVP!RFR<>XR=47ZV$2Y"X:U:&8A)?N@M=1(YJ,9$ M IEIY6>?8D#>"!(O9#7[U')2\H'$$O?R>8Q,L&\DQ%8$$Z9%W@E:T/'Z ?,< MN0B>T@T"ZHS#: A,G4DX.WQK0[XI$J13C M EQ_"P'WO%#B-U@(>$ZZFNO@M1LL)",-(''I&(K4$E^_ 9*R*>X5)X?H,QW# MC+%P P]N"706I3W_G>0K0>WOX0).>",BETAE]PPOBCBUG3,4K%PH?V( W"CZ MQ/]AF@QT%:_V'H2VD+:?VEUW+/G#U?)D"R**(- AP MU&5^_9N9584+"1( "4H$B-A9MRV10%5F5F967I[D7.=G,E'V F?91Y:C&;9- M?B*C$DYXNO)H8<@/UB0(%-H;2M/[HD03/_W%\H!*5T"729@:X3^? GVBG\F[K2KY#\LOA%VE^._F31H8*EA2L!HL,5W_5>0KOLCV<@S"(&R@]C M1##46Z O0J\B7.C(=T4NX=K*L M%%Y>>6:D+^5#P=-P96_'TPP>I%S_?D^*<[$<@=]!Z5(>7>"KG9O/UGPYYR$W M?DQ1LBB()L.#S!;A6&[,@10V'?(P<"UJIE ZD-# $!LWS']&17IPB*[@Z;9P M7<*=+18@]V(IO%@;B(Q5?E')WH0Y%H_LH8("5V".J:*PD(^#;DF&@D+U)LJU MY8V75K7J9+\OP24RS__XZ0$CF?(/TZO2ZJ] >9&E0":0OXN) 1(5D-1 EM+Q M38:LM9Q'TQ."@@[F*PQ&#GAY$Q0*DQ1 QKI%UX$TT)2DIYZKR=J9B;W2A_L+ MO2IL?$BTZ:VT0Z"-(2TBU(1H>O#+=#O2_K+I(>-X9#/6 M'^4QV/URU8,,*]Q#CT'R++&(9'L%OO9O<(%;HAY9"-M0J8,)JNMWT^.L!?[H M247BX7]$K]*VA8P=0GW230E"Z![&*J.W^7 (76K MYI%=KYSOWRG>J7PV_:!*V\BI,],T6FS'C<+,IS!O?,]D]F9]N8N6W*QM0PU: M)8%7O%C1 M/X:*4_9&B9=8/$[",\W)X!H5#HEN$^P!$FVB#N\;(8GA_6%TM9;7SPE^#FXJ MXA^4\_: :G;HS\H5T--1?:XUEXE0G.PP0W' R)E81]HWM,0W*B47OV)8SQ'7 M>H\"BA2QP?A.V.L8EK5AW,CUL:*"@@L_H\9M= =$RUV\V4TVS,4B%A&#J+;F MV>*% EBPLB0E0SV_7.1N,';F.(R')JA>2"[E(5RX@LV7%L5D*"XL[TV\)S_J M7\1*!QN;*BFX'"\,%HLWEZ"TO;#A-1: 6J5,?(LV,^GQ M7.0<$0MVJ7$;"T%XX)O?^,*P()ZMZ&"M4X+'RE_$%V1[)H\5R:/HL:B.88.R MR].[+_MP#4U5+/,Y_+CW+1^O#2Q#C >S$&7;8DY0%4C6\(S,L ;%D MQ>_:-LRH2@R$1+95ACTUR6!9N*M$"C],W",-/HO"F]9ZE1H) AQ>$2R5!;F1 M?/.(S$NR4VTUCHM-GR+3K+=T$"7IM]$ M'S%B41Q1O$Q86!G=Q">2@4_P!?DAI2QB2W6;NDR,@TEU$ 6DX]6EDB4HR512 MG>B]EG(7Y6K TB\]^06INU;+5?$A<#4*(U@Q362S!TO:&EZ @>$Y5YJR"$=< M#5_*O0UK/L+N1RFYT2O#=@1R_9L:D*8][ BZHYKVL%0"Q.;3G$[AQ*L; KV+ M88($Y N81+@%8*8.M2F%:4B?FT% J7_TP98>6 ,?LRL)_1HK3,"OBO1*LD4# MM!3^94XY%-'N/D$[H2K<093&(\R7\X\*34^YM;!0ES(JCB@2F+WX8 6 =-B2 M+-: %Q0>Z(^M,J6U>]6>R91BBHL454=4Y6Y"3(Y;>_#)W$1N?:5V)+I@@%7L"%L!2NNQJ$8_: M>,HO%EA+V*M)?[7=!Q*+.]%3F/ATV.) :<$OGZ[P^^3]/Z%?&2;T)\*_E&W[ MSN0#X2^ 7QO+Y45Y8A!MO+*I(+'LIW R1.G0 _B,X%N0^Q@M%"\[)/ISTUE] M7B@GF$M?24.%QR/$^ 'WU/(2]XP(1$&NB^^$R[SK1X'&8%\F9>#W0#H2)G4I,$=7M>A2P==CZEW M)^!WHS'=TVQSZ6 _P':2KE T(BC'8$!R"30>O!I1).41NRZ 'HH(F<:702<@ ME"JN";'Q;,RJ5U#_=14LI4JZ6#Z(*EX5^2^"LQ!%3F$2-Q:$Y0Q[=.U'?DKE M;4V>3_X ?IZW=&>KZ6J<@CUSYF'46Q4M8KS12S1(3H4>CF79Y^03^!]CM[8P M(2.2]/#+Z//K"#=T5'A8@*#$J*<&=0/^5Z@"P@_!5'8*J$V5N!ZWP*D(001P MDL!$26OP PIP.@KJ))6(4A4+F$IN%+V(:I+^ MGZS[H\R+C"5QLG,-3'$F:GF+82KYRASYC:MZ,CWLDHH#F&(H+QXH)?\T;*=] M9+:[X*%C-#QCE _R48DN5_?7BM%MG^OPOZZ:!+X**V!]%C]KL8JJ"+4-[83< M.(9PEU1CQZM)D32B36T=:X<:=T)"2[@V==7K6#I<_-R0%\*:"W@W>BX^BW?C M/^+FQ#'D%\@;\D?\(-"C$B>%!>N>8XT[:1+J&UT8;-GO(GPCX35,+*" M6: 7D ?%12&L-B+Y)*'U,+@)]X='"S'FG!BR $E!K-TSNNC )R@^/PVE9V&2 M/I5 7.)?53\,6;)T29$8!^\^Q$,080[ M22:%2JCP$>'/@"GXD-77(G"$Z=E8=(F+_!A*JBS?Y:])<.@CKV.C[\>K>Y$N M=)(P,K8,WP8W39-ZBN/Q=WFH^<-BSW\1$B$2Q3'P,PK-+RF[BE?/T%GEYO=C MG+V@01!>E?;ML1F"%\"_YNCNGF-" +;+@H 7BL$WA-A^_C=YR(%@Y6@E.6"7,.=,OCG@.('W>]P9Q1T!6K+WS1P0J2$DF=2WXH M;ESJ2@4;^.R8FHF;"<(!S:WHJ^0 MW*S"X[H+RP'Y4R,;09FM9W,>:W9/6"M5? )31012S&DSFFC!64!>AUXER5UIXBX 'R7R/B0\-_!#91"'IP72YP"8 M*A5*Z@WOK" P8)KAK>[X9T6XOYHHC"6*:2\<0\7"LFP_AA2 T;[_<;V?XO>? M9?%+5+WNO\Q'KJW\]NTW>:7XPD8> DPK/;I,=%5AS9[P#TTS5,WH2U/" 0WH M:XF%)$-Q:>E8:_+?9Y8Q,D83?3J=FFUX*.L/-8-I T,SNV-=&^K&/[7V\*RP M8 T.(%BKXS+2!8L.5O^JI?Q_,70O"? MIN/J8HP!3'X] />8%(R%9+%(![D>Z!K24BA3%I5Z>DQ.?P!MQDD8Q\6/*CU" MLRJJ"TS[Q;=\[IYM4OR1(0M;TF13XE?K7TL>B>86@C?\H6%;>IB%/Y>:5"2T M1<"30HM2=_*4X,<0*5HB,=R+JG_X7-P;CH,F8%'')!;R 7&LB%E,J! JZ!II]5H=[@U3T139>>R* 5,Q$Q M[#0J"L#V"]X4!V8*[(FYHQO?+MGKP ?F$##>58]A':Q,)>3 #,NXCU-5"6L$ M-J3;3C<[1-0 MF8[KL#-E!J[T?Y_]KSS*:85I5]_:W'-)F&%'UX MS9FM =.-7G-F*\J^3F>[:27T]>:0UH#+1K\YI%5EWW"[80U3_YLPZ^(*,TZNAVV6-Y,S2E=.SWN]LTMX[']]2#SF\GVCT2I^ M)+3VCC<%D181W(AE1L2.&Y7WYOPUM+/+E$(S41!+@$#8:R]Z7#S7YF/'(N\E MK%K>)6'VEI+1J((=1$73MGHWR:J6IJZN@;$1CSB"L]; V'0.6XPVJ$0Q6KZ2 MKK>;&K2Y(3_1@3_>7+D2MAJ\9D4:K9WH?A5L:,E.(,'R7TDX6(6^^8[CBU)# MU.\<<]/'A@T&[L%]B+%Q!^X'_Y?HQWVOO(O5G;_/*G*KF"'H]UM:?[OZSFU3 M6OU>>4\R2BB.6_?_5FJFVJAOQ7OV>$R*XB8MO%%SEW=T^JUNKK.#)R04W1T< MYTKNN)/8\5L45):W[4'.;5\10&M^5F_?;[X#DO,9.S%@SQO;ZS/@FC"J X&4 MNS,CLO?]6@=N?>/K?6HI'0DGN>$#775>?V_7F.,-^[JQ+./1M"D!3-Z0+]OP M\"/Z^QQ,/S1?K[!_?<]-_X<(47_Q^'P[FA!. >JE/SE;C5BWSQ"1W)J;MO_? M9^<]&^N.1/\S^>(?%?!M>EY" SY=P3!/U-X7R=<@9Z#"V9D9Y_LK70M M=)[[[;-+36WW!F]RG$MNHJXUM[:6DM)5U?S M3&<)QQIQO[%@QT/= >(;Z@";X!MEFBGI)1+>X(3O=T[$.[H1,\[2?:).XQ.M MBYLDV0M(65'QZH)XZ:J!K97-NY>%4;:'N=8YG;H%* C4'$W3Y5 M&Q5RY[$%SN@6\YO\&+)MY)[EB2/63KXS%(D@W&=.-[CHWR+1>/Q[1_.%O65J M>]!$5W*HEP.0'[OFU:Z6H=V/5^G$ MMMY(@,;0^[^'\5RF'\77:[ZF"8X4DWC,ASP]F#$8,V,**C&L,,HU"WY.8F M9T7.T "]* 898G)HP0=H(*3R^C7(R',->M.DX/&Y-IS,=TAD,*V?)8F+N_(# M#4LAP*IF1#@;KN3P>,KC"H8'AZ#>WR;N_!:!DN1 *7^3LN@V,9.TJ[RD'C=E M('"?G\48C%]==X)378I*8.?LLM-7>[OIA=HQ(#.64CX##&" H6K]_1R+ZJ@ M2:?FT.<[]+O*51>QYU2]W6X.=O;!WI7(/3B\/;7;/17[_0DAY+$_.3"?<<"4 M(P&UZ# K@^8 K\N6I-D-4>J'^1S:CJ+2ULZ/+(/SBZ' MJMX_E5(O"N#FC_;53JXRCG,LOOW-=<:[19.&E%@SLF+<)T+QC)->;Q>8MP]Z=F6S'F3 "$*)\%#&B=XM/IU*A&T]2!=GH: B\; F.# M1D^4WZ>ST]K<";^ZIICSYQ#.Y,)\H7:!&"9"ORZQGU*]M?N9ZP4_F#?_Q?4\ M]PGG113U&SIGEUUU.-BI J0*]"[3,RN!W)B/48WN?B6OU3G981.0.-*G*%0Y M6U+N.(5V*R :=BEXV]&:X&V!9I3]2-[#P&VOD]'^4Z>C3&/KBWF8M1.M[-., M5(K=/W>4KO[9Y4#M&AEI@1,A>O9Y+H?H!!2KZMJIG6F/C4QPO%7X2[#TA"^^ M\-RY2R.X3U'D-ISS/YT_I;A]YT3[SDEVY4SN0H(5E3M,V/35[J"IIMARV@]" M>JV-J9N>VFZ?D$M.9QXGES'')QQ=7F(]7]CN"V,*8=K")]P1K-5L-$"ZT?DL MR/6=4VMOXZ.U->Q,TO3U?OY3I'Z&R2^?^CK>S(=9K3"U4P--J551WSXL^=E= MUK L6NWW&^2(_,Y]"50WSB[UO4]X4Z-1=N?GSBFKDR@6R-!))1B^+LY[4COZ M3J'#4V-'AK(J@1T]'#VKZH/]8A"52VMOR@PZ#^N=-3:??!=VFHO*X75,"1;693#$ 0+[:J#/6%TJJ,3FBZ1$KI$ M8H:J>,^"UAZB*VT835OG+JTB^]$>6 V71^UD A6?MX0E$UV>0XIB:NWF_*>@ M"C#'AV=( *4[UP\\%E@>37 ?WH1#.G)(R\HRUT:71-<)[CLD"@T5K=$<><)O<7%;ER@,;0Z;/.9.@W6TGYJC,B?I"C,"$2K&*C]P7[PN37)3ER[\[D5S&EB M&<8>KN$;L'+FC$.H?D4;EI:HX#,."Y_)9]^Z<"S[O\\"#R=1K8ROBK: 4ZSB M&XB8/H27KK/[#7:CE; ;O;UQ-Q5TC].U15J[,\O;[EP%=9B[[[.BFZG7**@[ M3Z9L_, =_^3[);G4/RI/5C!SEX&R,#WE$8?E*>_,)?S(@S=,2*V"2O!]K%7; MJ"M\E'=_NT-R\^U+"KH\7]<]+HL.C7\5OCN?;6Q'BD7;HLTVK%![W17J&"4 M3N/_I^C E1]P/O&5-R.E-@9N$RQ*&??3D)SM\XU M#V(?8ALYB5TO]8M>D>NDZ=Y(YVYM2[]C'JF>PNJ+OYEX=6=ZM]Y]@!D\8EOT MS'4UU=TN-!N7DZ7O=UP.1F%:>12FLF">0OHR7JFDZ>\3)JUL&Q';U=X&HE_< MA!4@^M[+H]DM';V]FPW[J.SH1R254B=SAS?TFL*[&^Y)_(.MK,-+#A!+WN@T MOD.)X[LC_NPR)UKK:,08OVZ_OO$P:O-B,IW^UWV'U8-_PM)?$K"4NYHNLX67DZ^"O0]!L+ M;J<_S.?"^L9X,/DV^K.F%-^*+08-%N_KZ<.GW]=0@WUE@8MV2PDS/ M0;0D"N=)!!6]&<&'N@U(?ZEKJO2A^#2+E5_+5 ML[R-#/A&^KUNYD::^]PF99%@QVZ7C"'PH:OV&BB8/,IY?WH;;4[O7FGMEG6H M<_+WR1^?6K5-%D8KRJ:@)8<IS* MU6+E+- D=ZL,158ZY8[FC)2*11VK*KQR)NM'IK#X=\H8*E)?YAVH(K0+(=XU*%:P?+4RE#2F)YV@=$G:[S=>VU391UC"O6< M*H&+]9XD-Q0B_V(YIC,&OBJ45J8BQ.1%*;8S\4P#6;UP?8J'75"#J_7(/CY9 MDV F7AC_EA#F=O05(0E_ZF'PZ;F;E8-#!X;^.EMAJ\V4*FR7>+'[=@E]]6/^YT1IT]=3? MM%M:ZL\W/6FHMX;&8.NCR@V\S*W)Q&;E!UZ&N=2$891Q6W_-@)*6M:_.>M&D M-7]0?&],(*'G>ELW-%T?_O-!:_VY>#A33!LTUV\S/*W.?YKSQ4?Q=_[;Y)'4 M8/<[R;7673RC\+PM(6),3M&M\3]12:"ZMHR1,9KHT^G4;&M&G_6'FL&T@:&9 MW;&N#77CGU0W);XU\R)I>6#G([B _SPWI^#A7ICVD_GB(PGB^@?(*);; QV^ MCY[B&QQY'RY7-KO!;*0_2^MMLB1LI/4W<>D3UWZ;&-7+=13EPT@$%?DO_ZUR-2>\_V26^OU&ZUP7H]GKM3I:^J\* M6\U6O]?QT+>!/+?@7.<"#=\11(G+W$^G9OO1]V^3$W;J M[4,S^1S0>[@;TFUIO/1A!7"GW+D?+GOG![^=K^ZYC"%?60GH1^8LV1?/G6-# M&S[Q'U8PNQ;4!%O'(Y$X-A3^-]FA,L7HGET.!NI@;PC0*O*J$*OTM^=5#WC5 M5;7N3E@,I\2KSMOS"JL#ANHP*PE3[6[I?*R[QK(.=XI392;+,5QG8!N3*B.& M'D!BL^J7_>!V^JOK3BA(R[Q':\S\>R!C8;E$R-"^:O3KA>'Z^OJ^1)8@HF9/ M[79W&L1Y2BS)4.OEL:3;!I88:G>8,9#EZ,MU\S'A5\_U?53/4RLX@DO74:E> MHLT=D::P%&EGESU-[70K5]#U^NIT'S+K9Y?=@=IK5VYZTNNKR'W(C..BNVIG MN%]-2E5TXCVC"AY5F9O>3X9@,A1R-B=SR[%\N#-@NE9ASSA([>@Q"%]=:PKJ M_GPI+8)VA8/6L,^DEP)3,Z_'ILP4G67;4]J!SV M_EL$@E^/+3CHV5"U3@9;:J*W;YSS!2>6XFU2X=9\85I>LEKR9"1S\Z#K=*$, MA4]+$:X>QJNTRC7UOIX>WI6N"+*B[127K1E=-RC27>F*PT<&51]CE%<3\AX@ M 9I2"]$I!L*QW0;?.(] '2XR2*!=>Z9ZV#2B=E*\T6.'/CD$S3/\T=*(CMT> MJMZK'M[,(8B>X6UN)OHZ7;MGEVD-G!5#BRFH(<6=7E4(>E(C!B"$(Q M5L9KU$/&2M6EG)+B!O/-==P%PW"3\Y F9#UL@&^NB3FT92&R8NE/OPF*Y-"' MA<8_Q?4(OGIX4Y81P(YK%98@;V1W#[+TAXLWVLI*=)\& M->WX*ASHM\\N>VJOTW @19'NR(%U(FMGEP.MZK"FN5-)@;<F9Z#P@IMBXY.%"B.9RY4C^YZ-D!@S-H"AORY&QRT1-K1?JG MD6R1 )7*B(&-95C)^6CA2&DTN6+>,?RC1@'(4N_,$MU7]H-8SA)V?\MMJ.OX MOQ!58\-Z/S\'GNEZ0"/3>[D)V-PO!_:IC_BLX/,,UF&"3X]KF7?RXV%;CV?< MLX $3X)MF7?^XV$;UJ\,U4Y6.UU-C,3=-J,0#ZL.&I[$\H7:Q7%5(1W#,@+P=66X5VM\VZWR^"E&RD@BY=BC M)-3U=T;U&<[#9_C"*E#LUF&L@[S#6$^"/X74=6D,RJ%7>*_7(&5HU>DQJ9!6 M?TTF8>Q)[6;!>;S-#(LW0;V-VX?<^+='//4@WZ[+A!T#"D;R7%@@^_MXXI7G M0YF:?S\^#,XN.P@6MB^JS GP(4.Y[\>'(75)#E-&:EMF%93JI_3X8:W4:OE: M-37(D2,.(L,@*]*8$3R,26GGA(.'.ZKCDGFUSA/C['+0.L7ZIQV5]<$9TCV[ M;+=ZI8%/YP@"')>FWS8ITDF_=^57]Y6/CAS R98UR/+;))YIDMG;W96N/-T/ MH-ISTQWCLIW6(&,J8T/XO"H\-^$'Z%7G!#MIPG^EA_^.RRX5"^M,+)SPF6=6 MPC$=P>,*['SB--SH*0W1'O5/L/'JD*&=[437VQ1/TT\0%_V0P9TLHB,,/= M:/=;E<=0+X<7^ELR ^>,JMU.IU5YR-=RF-%Y0V9H;8X%T6UE^&CY+F^*"6UAF-=+F^K"U3_;^A+BUF[8OC5TZZ?M> MNV'7(>U!:>SJD$7H=5IYPGD?J'U4=C;"'Y*B<]-[L!S)MAX02OP$;UL]NF > M0*'3TRX(I'^\/=C:X<-5F<+O/(&K7+L.298)5%2^6([IC('SRGT /T@.AUK= MJWBFT85E+%S?0EI=>,RF^8H?GZQ),+O0VB0*L6\)TK2CKY@C6 P<>-7)Y2]L\^7"/Y/?FGD1Y1[8^!#&-@+SM8R4HH]%ZOU='2?U54 MH0];_=YVA?XV3S+*,#(YXY^'\F5S2/X@E^"CN3F"6$V9^^G4;#_ZCKGWV U+ MF(/CRVSD0.0JEF LM.DCJ10Y%J@573-*@EJI(A>.!6A%U[HE :W4G@L'A%G1 MM=ZA8%:J"&5QM*:"#S9+NTLH[VQ@^_LX:&.3!B^? 5]<#_[I*..EYS%G_*($ M'CS,IKK#(W#$C@H:DX3U.BZK7#\)&EX+$OY "O*W73F3'Q$]?S4M!W49GVCP MG8UMT_>M*9!'?M9\+JSG^H1HWMZIC>_XN;?GD.-M8]&.C9&(SZ;J*<, Z@%1 MN^?DY"IQD@\9&*Y[X:G3FFON>E3!"-XS,']68#'_HI(^ACYL#8Z8O'\X'C/Y MM.Z9:U.%XP.<.^'A*:9G^?BS"1_$N(!WN/7OP2K)]XAH^U=.6JG1;IU(JJ\X MA3\1@>^(OK*G)$5_Z5B*5$]WHLP@P6MR! MM:HI\]KI^P2&8@V4UZQ4UJ;:^ M1DI]U5>BTHTUG.TJ2^8K:&^4O#6G<_+GT@\PSXH-@5>WUS?@S-Z#T-U.(Q&- MY#'OD 5=/V66C&"1<0S*M' MT[*Q0D3(7\P%"45TF^?1:QSU/77YOASH-XYY.8YY&K3%3QAZ; +G?C5T_B/*KYAS'3OV[ M/HF_8OHKW83\Z?RY56/=X0]N^Y1P%^C/$Y]+AF3%#\Z2Y,VQBJF(5>26]:GK@<3* />: M@&^39OWLLIM5.5=5;KZ*47D+-A:K4NC@E&A52\&AKH?=*?7V6@-V8VVX.DAQ M%6MNH;";>#E'M#\6!#:1^P-6.P:F9>,_3D_8=RQRM!Q,G)(0WDZ%.%\YDV^N M(_Z1E&D4YK^;]I*^4"R.WLD;1S\)=NU=U+@WX]89A('GRB,XO5U2ZC7/4O]D M^:Y*<4S ]84)Q3U;B(!I4]QNOJWT\^"K-^!JEOB\AT<>%+3 M/-5K1JAVIO_P['*8%9JH*@->U+>V=8U_S JU<9O";O*,8V:&?@JS8U M"<=BJC[!MQX)+_[ M*:-P;&.UL)D8O2=WJ'9_7_4'335B2F=@U:-\UX%ZO M]E/*GT]0T/>P#MLDO7MV.2P=F#7GG-K\LT@K]Y1R9\,=@4%*!U6_3C-%)S'! MJDRH\91C*X\L_,M>(BGNL/ .NM6=D_N^RT54-K6+FW17UK5@[@5 [4=F>_*:1R M"@Y\GVTV;X?\5+/ 9H%'L< C&\RX=7C=CQE#G'T%D2$^O!.X'.\5QNM<<:Z6 MNSD6 (I&@=\J4PNUBO+"/-CIVIB&'&VO-/7%;S7#2'*M'-VP+@TN]=1T1 M<6B]!/&OO 1Q+UUXZ$S+AMWB**3>>O7K^_($\BUV!3?7SH$E\Q5W0Y>WC0+9 MVF=DY@'\%WK:JP^6KL1>K^;N$H>S@I3XL!O8([ID2=]K9H+#YKB!,F+, 4]L M;/H!%7 ]X]V2*>#"HFA:SA*^[BZ8QVN\FHG;K*0!K3@F6R]G%BK.[AZ\XL3M MN369V(RSY?6#OD;O-09IESJ[.&M?=&KY:&*Y-VO^H/C>F%H1S_'RI.GZ\)\/ M6NO/Q<.98MK!?Y_]-D,UYI!O(/[.?YL\DAKL?B>YUKJ+9Q2>MR7$08:'(^9- M,SS\[8>'UO[P2?UFDGET''^XX.<>08%%:1OZS@*XC;$)Z9G/X.S MR[ZAMG>#/:LX_PJQKWN4[,/L24J7WZ,M MO][<<2H;_@N471?>= W[)8!T4>:V\(E#-*F^.MP-F/^4N# \)!>,$^;"2HZF MV6?]]GF@IM4#YXPW8/^;_DR!-UL3YDQ\!8.LRKNMP8@[YMW/3(]M5^PWW[ZD MU.W/78='>H3=J1-D$\IY:Q7B*%N&>*C]]^7T;>^TCDK50T MD9#.,=HCJ0MK=.Q$TM3>H('2R6$\2Z-ZO^94SVU#FJW4TN*]MK$+:]BQ.X,Y M/E7N\:H,/*.*NZ ?T)356K"R3%L2]1#X/]PH-XM6^\:YY@E9LN4CTV>3ZQB% MOV,9BV\%3(P4Y*,"O[.Q^^#04W!P!RNL'7&6L6KT&C2(-(NT(1!V>":N\PEG M*_3K.G^UWGJ_JELI+I3>> 6EQ2M&8'&IN MK6LAJ*7>]F0M"5TX2+:NQB"!'DJE'_S.@ID[*2QMVMEE3VUW4CJ4R@=\/UX^ MU4@WUF@KA4Y/EIX_R.G1\YV>)@%8/%F+E4=;U#P;E5!-7DW_%SN)QU_4/AF>7AJ;VAEG) ME":<4.-ZXOJ7W)6)O[97(>L04RU=5>N6V-%62R[H&7TT^W%!.V$NG'"9[:GL MLRDG3BTGU@]33CS4L9RXGP+GUY039QG3L@I;AQTJ;.VG<*$>54'%;AT9QK,T MJALUIWJ]0_MN38RNJ&72PGUH8[73*.GW5[6J3C*2<>(K1T M9[WHNS%AS5:.0>_I:Y@41Z[W^JCWNOHZ1D4=37933IS?0A^B('(X.+OLJNWN M?NT@E:_AJI%NK-%6BOE(&7K^(*=GF._TU$19Y:PLVLE?+Q][T8T+T;>>E;GWJ]O_& MG,W'-!>T;7-A^,TY#3W_*AU.44*WB\LQYU.:?8\=2'7O8':3X'/:AB89& G ][CC1B(0U6Z'75@[%N\7DT.%C+GG;P#V=^& MEUJ;6B&[>M,*FF$S#*E);7D=30^5V60,C*W'D'D8G>.#--9&M7[-:=Z MO4/W-=I*37+?32/D[J;DR/J!.AJ-56FG8$S5@G-[&J2CZ8/L:$/@TW"_XN[C M95.]U7Y5MU+H[&2 (1Z;WM.Q5T+M#)H^R!H(:IEWO0,TJ@V[ME$H^D ML+51C?7<2C$7*4/-'^3TZ/E.3Y/[.Z8%-B-DFIKQ,B_.N\TNZ>B=L\NTWK): MD+=&5JB0$5K#[2Y'5(Q&5"JZE7R5,'RI*UX78G7A!OA7X7 )HWCJR]]"9]E8L\?'=9:'O#Y]D(6U M38[J!WJWK+*"/R2]YZ;W8#F2YST@H_@)1B?DIYV@0D8:[S=_29<@GO& M%,0,\)7 5:Y=A^3.#-A$^6(YX'^"7"CW ?R DCW)BK+87L4S#1#=CPO7ITS. MA<=L,X#[VL$->*FM?.Y=,B%=Y]0H7J^8CG* M[Q:875CW>X''IKW?:"_JHL9[O59'2_]5434^;/5[V]7XVSS)V,>T;/1[Q3G+ MF0W/^Y@WA($:Y#HS^X;O*KC? F@5M=BOOB-42:%='U6DFIIER!8I4\^=*^Z" M(3BG\Z#@K>D1/'NV^^#+XY& 5VD .^WMAF;@U)JAZ]\P6"QA<\ VW$[[A-MP MCV4Z;Z=SRG-A"W%A#SE;S>1AK"L=8Y8CG_Q!8@VU;4R6?.,5OR;_X#=ZHL/)3H MX(5^:3F!Z3Q8(SN7EW[\A96.=B#:/:Z63TJIP$ M];-&%A^"_%@7J!IUK0PLT[4X"/F[9Y<]=9@RQG@/A^/X-3(ELA7JADOT69^> MS&64=F#3X"^K38.%A0P+KU2MWYSQ['E4Y1"\3P1/ ?0[/8)G*-62"#X@@G?6 MYS-4JXFJ;GK^RO?A*OGD60$##CXUB!EKG>-(H)OYPK0\O(=?PVEX8'Z:A _/ M+HWV.D3"Z1$T:Q;[!HH64R@&1D75-$R*TR-XA@8OB> :$5S+\%$:#?[*962" MGYGIZH92%F^OAY MRUFRR2U/0+D.4@\S?;<.5J.ZOFG?3E,_F#X9:[M(=G.*9%694^HD[T.P)X<) M[&&1F3H<9(V1KRJ/2@U@O_H)ZI^>4@]KF1Z$8@>*$C 9=X@_C)8^?!S^7@_? MN$QTLD@4[X%F_NV4KI8^IECRADD,1/S4^GW#R=1E,T''^<%:"M#V*3)AS12\$A-P MK)7:ZV6=A+HIX&L@H14H"#+(?%[?-QZ[2ZQJ]=B868_4.6G:MON$"%+U\+M+ M=+OOI,WZXGJ?W.4HF"[M*T'!-#'#N5U-R#G3O]Y.UMQWZ&X3A=I%MQ85:BR1 MVA.#MRIE_W##<#"E9SDB)D$ZT[;,D653*7^(U,JF4S8.1-$_9?\X+@G_QL1Z M9'Y@!4NOJ?ZO_E9J6_T/WA7B=C.2]W7'H!;<+C,*)^GUB?'_WCA2;WX/B9:F M0?M8H-1$WG)X!KM2>'!VV=.;*U:.:%L^"A>\7@UY2=B> ;A*ZT_+>61.X'KY M$ SJ)G1%9>XFHE918>M1_:&FKQ815 M;Z)?>_BXI3+$H$%W1M/9MH=+7"I#NGA"VL/]&K$JI\(E43^\DV1^C]KW$GN$%U 4%E#JA>VGQ'IKP8@#^]6E M<*"/P/%&9B%+55EPD'1&7E:L4QN#1H,,::^;.I;4^O!.TBN'.FZ\ZYT50<)A M6!?!(1SXII5F;W6[AUO6;Y]==M7N(,,MJRH7#I-"/B0_*,@T[*^#'A4*==1D MM!M6R^>!F"N&A%C-P3'EPH(B%#%50DS8Y)>7/WRL-8M\AI"PA<47(W6&JN^- M&7H"/,IT4DSK8"K'GM+4385(VJ.BAF(0!+"VU=0U=DO\GQ2/,MRE _((BPS5=GO/>W-5%/T=@BRQB?"'@AE3)J)'/[6AG.JV M:Q'0*;>[A6CX!4B(K;>W4_C)9(D>)=L8->]CU+S?@+_E:7+9@;H8$.[6-!99 MJB+=A;H#C/6F6+$Z*LBK6$]*V+5"H<00JXYF+_++AC:H1X;QH#[O+Z$Y(< 7 MO)2+WTR*6NL!1KF[JI92GE,/1AS4LB]^K),,"#[NQDL/2MX 1-^[=HVHQ?XM],]Q&[8QK8@HYF_5#R >PAN M8!AHJ'92.N=/CQT%([Z'8 =B]6EJ+R6)5D>5+-#A_.5BX7J!8CYXC/&1QZ*J MZ*5)FZW>MX002D\ A?&'RPEYS^EX%9+Q1E9I[5X$-Z2VVF[3DY4'P?--&$1M MML-,9,G3X%!6_T Y'%IG0A>+KD^D\H$Z+91WEC.VE[A@96PNK 6]6_"01@C M3"I'H8,7 _%5OEF7"83MR#'1JCC;$I7>WTUYOD=C4!5>@K MR=> -;4#E]T]Q4-I22A6?Q(?O;"%*B:CRWIW/<>)EX(Y_GF"T(G>P(J+:[?2::':/)"LL M;%U*R9.TTJ)]3]99(_AZ"*K6[=8V.'BI45Q;Y^V>7/;7=6>_2JZ6F3?:" M^C/7"\X#YLV!ZJ,F>[VMC ))]0,H]0D(55C(!M3"I/=KFIL^6"G17D3'2&9' M[663OH(/:[98[,.IH-6K20;5=YR'2 MJ&%OON7[2QS""QOUF]+X;<;\1E#J=OH52+FS#!HH@[U>4WI=R'W-0_QM#86& M5O>IO8?R83=1?IW"/3!JI^>J)O5J+43I4)[J7GJ3>C6-;N,Q%714]R+Z@/H MNEFU&*=!] )NZEY$'V(2(>W:?P)>*D+JL6?FC2V>P*+,E>(NJ,OJ YLO;/>% M,>7)"F98A8"E,('YK,@.3W3+"@R?!C&U8):_##)T/ MJ6U:.)L6SOU;.+_(.L^M9A-F3A9@ MR4W64'92NQ\"'*H*_YU8CY?_!7]((HI-&UV@RL+EX*47'K--1'7]^&1-@MF% MUB9=$/L6Y\=%._J*.?)=>QEL_LK<]!XLYUQ\LP>O$S_!HC_X)WR:UKA2$@A, MMLV%SR[D7SXBZ+1MOEQ8#G&-OO0Q^73--1;0V.P]5'EFLRY-9G8C+/E]>OYC4$HEO3^ MW=3#5E>@Y'UI6?OJK%?76_,'Q??&=.3/];9N:+H^_.>#UOIS\7"FF#8X5;_- M7'SS?YKSQ4?Q=_[;Y)'48/<[R;7673RC\+PM(6),3M% \3]G7L3W!W8^\ICY M\]R&F7D][9Y;!!$\X(EQ8G=.ZLO]YOLOZY MHJ2'Y,'@9*"<.XF$EJQC)52D/.57JD)1!U#+@\P7]TPM8?D0$O7'D4(G[D)A%Y'O8Z)C":;$2 MF)*=E.E@LE)M&TVK2.X,V:$/2T<[46- CK90VQ8P"IBO+)8CVQJ#&0#2PF9. M3RB+5R'><-+=$>5N!>&*R%_=IR\=N@ W!P-R*.8.3@W5C?6ZLM/CP0ZEN'L? M N.TE##!*#4>]$XCKGXW)VQ?FU_WTOO2YUCE(WH./8M@L:JFU140H>QY5F4( M>]Z(4_5U:X0+70MA.@BZ:-Q\QQ WB&KY"EPZ@[/+E(+;>AS@)7Y =ND$(330LX"J&G[M#PE=!K\Z&,8?5!D1>G^;_7DZ96-*&;+G M\M@T*.__\YHN]WY@>>-0[8A,;1.Y/D#V*?3)-N["$8[#TBH/Y>W'*[&M!ZY:)MN.V)*4%KBY<<8>,WWVX=TGQO_V7K%.VHB4 MF+K<2VSO8/7N1/)'G;#9.+Y$>/G,N#L\N^ MVD^YE=:?RX$T==#,P M$TZ!4?J6I/#;,XJ/Y!JD7%)/CE&:<KP]#W/H M+)S/I.H-I-AFVU()-G:ITBQKR&K=\O@%[=&*R7EAIJ>\^^8&C.-&:#5+/QZY M=2HLX[U]+BPGQ;>#6J3"?$/H8$/5])WZP$Z*;P4=GN]2.OT&'7,8=Q> M$\:M1ABWES.,6R/3L%=TL#$.QQF,V!H7[#7]W96/[?::V&X]8KN]?+'=N@4% MTZONMP0%A:6I>S@PG2[_<316J;!X=_>YHE2><4=CB0KS[53BN/OS[:CBN+V< M<=ST>& G7SQP<[5C_@AXPJN M?+.58]W**72.D">[,&'EDZ5'$_AFC#NOH,\OZE]@%/G M@1]6"[5;[,:XW8&5A+D#=5;8'Z7IN,-A,\H]LU-J+S(/DG$72M/4V7ZO48V%5"-1>IV8'<0AVP^(K(+:<>S.&I*5)5A(P1](P%V\F[YQ=ME3^RD0K:='Z$QEN1^ENP@CU>TW ME,ZA+/>C=._LLJOJ>CY=6B!.GS,$?N"/G4:^.A%2]\ G^<48K>< M1S"HA$[I3$X J[*\*%FST\KM]!0"^S\0DF3IO< [W?%/FDV&(R)=3V'SA>V^ M,!Q3-E\PQR=7D(X]_ZB[H!\L;!,K)\5%FY3$0N #?XB>\60%LYEK3RAU8#XC M="%_BOED>I,3 )HJ(X"))<627_=(O1OBUA?7^RSH?!UCU94SH0_=$I_ND$UP M";J="L1.XE!A*X_I>+7;W>F:7W$.EC7PX8TY2 %LH[-O_5+M.;AE=,0;TE7=]/W6>"'T]_K;^7++!7XYCIXH[GU[DPO$/^(:<:_(Y%OIU=$ M8CDS6RMJT =M<,EZ:GO8>-7[!8M+X-;6)J5!WD&V#:631%9- '+>4U*'O:;^K"+%'Z-*'G%"5E<$CMXZ>[M."SH M^)GR^DH\DRG;%7G>8;A596-AO=4P(4*[=S9I\F,^)YU1/,;65NZ&G\SB< M'$=E^1BQ-V-W=MY4JFB# @VE!Z#8D9R'5[P3 %O@AW/788'IO21=F#+.2(\# M9.W5R%A?1K^B)=J+T=O-4]YYP@V3#VW<#GV:,1O35WO=/ 7:'P)S9#/X[\1Z MO/PO^$,2>VYZ#Y8C&=X#&HJ?((M[%% _@'&BIUU0/?5X.],(K>V>,05-DJ\$ MKG(-%@J%S@S81!'C DU;N0_@!_/$Y*%*[O6*RLU]9>$Q'W8C$NIZ6^]0_AS^ MHBLS\Y$ICALH(\8 &2ACTC/@?;5(K9VD@9L0(#3O3'A.LX2S_)TM7"](2NMN=ZJC M),!:UHP(8 Q3-IRBO.-_X@[0'%C&R!A-].ET:K8UH\_Z0\U@VL#0S.Y8UX:Z M\4\-I]B*;\V\B'(/['SD,?/GN3D-F'=AVD_FBX]"%S^T<*;$4GM8G+['X>8; M''D?+EZ M9X4)8NQBO3((TLE%$*TE4F7O14G7Z1Y.FC6%0^D$5^,Q6CPX MP'= SS%X1'B4?K'=\<_(UQF>*:%%NPK$S_"Q#/RB!1Y@;\FP"'4.5'G!(*8? MO0$NM_(5RD*\0_I,8KTKX@B_$Z_CE6OA,O"5*0O10\18% MD 9"RFC;8AG\:/RG.5]\E#\B+\Z"3_G+D6]-+-/#,/L[? !6_YC.R_N60MU' M8_[/Z+GXS<"#+7$W'W[@,879%NAG7&$+'F OYP[_H.<^^50Z:3D*V0]?F9LO MY#6"N50F2X9:S(,GH^UL*7?P0BS>QN'0Y%^2;PE6<[RT:?]+7Q1K@X56J:J; MODR4>5B"M[KB7JX>L J([B;=36;WF?W8>0'XF-XYX?33#_1^N9T_ M;V#Y;KGM2 =B()J%99,FF M[G@)WZ:![>$:Z&8&VX,#/%O"%L1JZ,M/S+;/1PS/]&Y"^X;G[V_,>02]='-W M^\%G"].+RL:SF@LK<"QO'>5W4, #E2[SJL(WJY*&L1FR$]9CP6E$$[-8CL G M -&8,H+,(?L ='F/LKRTR941DHAE]V"82$HW'FY_!I+JKQYM(W&V;[Y]67/3 MX#C<3JD,51[V>WH2KUR]<7Y$YJCPR<84^W"@]CN&:ACK%:D*7S-N"P\$D&DN M*_]5!81#Y*NWAN?!J-%ZUS:N9VS\FMY&&[\SO5N/HDL32E=%SUS?4N?LLMUJ MK]?B("HTWP_G)$9H]?9'(>_\90J]C7ZC?7RO*F:P32" *B7L7-_"T=LJTC<]W;1?1\L+I@60G]Q7/G-^(DW'":W1');@7% M\HGG,-H>W,*,UGILE1N=D67;\"^N]=GS&%6\T..)[1)DN#B[BOL(=)$?&;GN MSZCD G\J-4W2702EQOR ;!GO2%>>P*87HV%G.PT18S%X^9T%,QPXC*]#X_B= M<;2+7TW+^>KZ_JTC47\+DQ(!-%OK70,)4G+C9:)Q&V/0CZP;!G;PHW@ 3&MR M3@/G"8>CI5R%%!_;KB_.A""UNH&8[I.#>C:?0^20QELC9F+D36?; 0H]ZMOI M+;S8\V?6X@K#+ FM*<@%=\B07OVSR\&PM8[2\!>YQ<#%+DMW&@0;QVT28 MT M,7!!'IDUVV)\Q.-_B$U,+EZ[X#%U"Y5]+TX-'(&&1!RVE8@[,U?)A"7*! MTL-E*/V812X-DF!":L.2MRI8=.Q8%SU]O=33A[>1\(A%Y^Y^85L!& #QD]2S M-H2SUFZMF^R_D+*@!\I3MW;&@AE<@1_0[T8;,!-W!; W+>4+B(S[)-$.D[_E M1T_>%;A.*DJ'_D8ZR,GPZUJH@ [JMA'[*45G_V4C,9YF%MRPGI@71D)$[@JO MH.$1LT+[ IK<@_L/*:9I5'\H0A:I$YBXN9U9X 1Z&- 7SG!H"#"JAN$&Y:_\ M/A3>OM[QQ2T\]FBY2Q^TH,>B!-O6K_KL 5?[GH(MD=* 36VXD\B3+_A+R?C^ M1S\[;QF*$QT:^*G<5E)ZE'>^2(_@9U54G\W MV0K=2!SLV,4.^#(*>& E 5TC=TOX@1-F:V@QY18N8PY< MIM K$T*6;'R%G8[197R">P.H]/6[:K>MGUT&3^[Z3755S?L7RHWCN(]4^*#\ MSD!EPN_)?X9__&#C&;=!:1\2CT"Z4-0.K8+0&7%GP /I7@9PGDQL!8;WS>=+ M!QC[\*+"8Z<,5[;T43+AUXBR]8TM/=Q8(4^1N\]L7Z@()[&EG*7"&9:X>[)QH%9XUXPP[ ;W,8" MKN!)1=G@0:A@ZETP+B;_1_AY%_\UN*1":S)1/F@L-&_ ;,7$79 74]JNWL:R7=W_0;?6\W;_0A&&1 G= M%>7=#WC\][C-=KAI1;KQ>@J"59W)3#Q*]2%O $#4F,=JH""YQ8$TK>4V[> M5#!XB<70XO/2TRA\Z6PILKA6T?K$)'X=X67*\55DI/?7+$E37[I'?2D6A>JE ME)=2I>K@%>M+Y]9D8@MC_?K8(]WV:Y2-EKDO+5=U:!*/PIJ#VO#&%/ [1[6L MZ?KPGP]:Z\_%PQFH)7"A?INY%('!<(SX._]M\DB"5_.\DUQKW<4S"L_;$B)_ MJ>S1%KUNKC744VL-.UONZ)V4^D3\J5X-WSET.0648"W\Z&]4<2=<: J\?8)M M8F!#T8>41S&JY#@*+]HX;W&3R"_)CG[GS MAX0V'Q[ \>/B'/.IE7?WRU& GCD_^+K>/C?:[R]6OP)D75N,>'K%_')P#I<+ M"O^'/G;DA0F@=;ES\C:C.+XY!,@;=;5H8U2=ZA-ZG=+45?"NXE&Q.5668 MCUMWW4>F;Y$W'"WGR0)W=\04-IUR)YC^I MB9=(WUGXZH4>U6\IG^F20&>+E*"/#YQ; =7"[NQHTS8/X6E720RCN_(P/.6$ M[RVOR7TXA,KYV@4Y^NCFB_'6F\(1TF*+M=63!U8*&#S;5S#7]N!2A:>\5D4G M!W%L/7[&X=%CR[;HT6KBS*_H-RLV>X%7=$1YO^AWY[(X-'YU2YQCRX_N=\"R MM1,=3R#%3K@\K%D'TSC.LU=FH%-,JEV93[LQNFE4,8YYO3)VO$K:*U&*;9N^ M;TT)RPB$:P8? P&T+=C9)%:-P(T0-Y83E+NEQP&0*-_J,:;,X;4SGP)%F#"B MRCZ9I5\LO?',!--J^FOSVOE1W?'5H #P"&!PS$FN(ZPL3%W#TO/0X@,G?C(1 M\&!C\=QDJ3IU"/"V*.J;FIL_>:E3M#PZLK1&+,)E'ATNR_$#*^")$1Z[XV.6'*&%0.G'(>O4LN@W_6YZ6^' @<"^ MG@1YP-))AYX4 M[8,(ZX[@@LK+";"4V@.W$^E!Z?'HHRI2C;T(>BC3I3.1"1AXL(]J."(?T%P8 MM'??OU_Y[RMEN''%%$6E2!:(#B_BQ'31A%$<+2Q00;\1.?YK1-S[)'%O(^+R M0A-'3D-#'4W'@ 2S8/'2IK0O5B_];CG6?#F_#E=/A8*F;XHZIN^<8=]#?EU) M=J56,2$J4'N]B%=6,1VAQL84! MQ1CX$1,DQQPN(:*J!3YTO#+2VRXCR2)M.E]X:P*]B\I)W)/HQR6K<3S$TGA1 MZ"!=FV\/RQ?R:Z+B[XV^3#\EOM2O9J8VVFT]"W:0+?%-KDC3C-D3?M1)4E\2 M)I_GX436#/-R%WQL:]VT&/,1 M3A-*]CG8F7/JPELQX?P\1"6C.$IHSAMSD\6CH%E6EH:K%6L+FPM(PV)9'?@% M#I_S.1XOYZ+7E:HFZ==1Z(I?L>!RL[[4^"KE;\E@2C\L5AVZ?JSEASC:\L>H M9)-J^5Y2OH$U?0KHDWE+^9T4-1GO"<,?83D3MS/8Y0!>%.H5^?5Q=)DD/R#T MSX!-1&]2[;RB,+XI;H" X"LJBL3@G"'Q3:P=]9?C6;@.$9,*> XV61V/VBYI ME; :ASWY*POC?@?>_BR/5RC1O??/I4_ULHSJ6J,/@SC'I$'6TTH!5!4SNOJF M7 G34@N%].>=AXP.7G!80P 71+P<+K:JTT&*.AU44YW*S:LTUB<2I47(MPG6 M7(^M%"B 7%2FXG9YZO_PV71I?\7F* GV^P./70J-ASM3\VT4>@8A/29]#'*] M_&"#=\>K.3P3GWQ.(=\Y=7A1"#G&B:@M+5*I2Z(N.+N/47\R5T\7^UR&*I%Z M'_1:;2T]QUXT]ZYIK?Y@N$_N/1WW6YSE(TE@YY/J7Y86'^&%XCR2_PCE.G?6 M_E 4.2(HK*WJT$AK@4VW.E)'3MEZN?1DZ6&>)=226OOLLM->=7VY1:2$S*:, M^T%PR5Z?YE_)L4!'$:NN<=P<>AUA;J.V6&2[2.#P,!*(2!\;)/!6'($95SE(W_QVBD.1V0')W.TIK MD!#E+,A &)\=CM)*05>E(C.)-!2'+>"985&@@?&%)88%?7<:/)D"@BB&3T3N M/69&95&SA:7.J8<.Z[(9U7PLJ9.%M] ZC =;*2XB'DP]F)[BCG -^(_U9="= M&VLT,+5,G3G7X?(GT<=H=70AB<)#.2\3\AFRG/R!.1C(Q5X\A=G(9] '?-Z M=Q_^U-B2NL 0:)6LNPQ>8V#^W*8$J)B=2!VE/F;*,?4 8BG3QQQ.$]$W?0F6 M074/4]M]\EO*/]":2T>!/?(Z#$_AJ5A*X4=M4)CZ!3*Z]X)OBZ=#?1D6;"DWL2@A9G_# M;(0L,N.+D/ 3F(^A)#'OR$+TG%C#],1"I ML>(9O!D^(1!H^/*SZBD7Z)6IB M($-^ISSSU6R(1:07C1>(9\#DA*0%18!$G./!U)K-A S!K*"QDM=C_]I4'VQT1 M'-L+*1&^0%Q \+) BXLU$>+(;G>9N_&\CN#Y'==%F"B,:H_N^*M^X)M2?>:) M^1*)_" MCIGMP/<.LYKAV>5P?37P$9]0&!ZI?94G.:6R]]@(N1M6O"T7]!-P6 8!&QWG)FG*J)H.&#FVS:>1.?[) MFVW],$>]AN'T:'H6^>D(>F9-6 R=-9E5!VV^'$M<(=H$EZ&H=,KRHY,1=NI> MCDOILQ?[#K> KHDU+&[$9>ZU2!7L"BR/&KP RXDK&*D##RZ)<>* M1SE0ATH@3_@W7AM)50S2\IGH$5NPNX GPA$H.*HJBCD.,M[ 8P-Q7I.^F"]8 M8 6$WX&X)P\M\-V)8Q%0[U*6D$0V,=R(5&/H]-.&U#B@%[:H> +I9 $OI>*) M98"5%R3_C*+TIOWB6[Z4BS\Y(M?:/F2=(PHN(JKP#R#8B?=('2+\)AUO2J>F MI0AD*9+8&.*RD$^">9'%6Q(V.DBHRL7,!.TP)K075)D2(T2BLL.'_VC=M]18 MK2O^C)=T$(8+4('@961LB/_#HFV#F,Q]&3_A99E\@84@&[O]=,A&5(/B1 KV M?N?'\B M6X\VD/Q51Y. B!Z+( *2B?FH2F9=4CD6(YZ'F$6ADU3><_H: MWRI*)6DY#BN$)5/60[AU$J-_&3$3R5!++Q)69?Y^%4S3 :EF>:.": &6]R/_A2"#,GA#?T2$2 MC.#P7W''#7F#-9)$=7 CT9\)??;5EJ>4D3;).VP44:=F:E]6A">\P6DH8U@L MB;Y_0F>%;_,39!/T2?,3K?35HYGCFO+7JZL[Y6%I\0_P]Z]=]_B-B*)R*(E" MX-@S'$<$+-F\F,@1Q28/6YXD$0U(?E$P9QN2&^W/GN-!EB<8D5]X:P \&MWA MUF4"#8?;"T$Y.3TV@UQ(QN1G_SE>2 M5K.O1P.7=FHHV.65G>*O[.S[3LR:MM8!]K-_\!>.M$RA=42;YS='SFFXHU+I M%5;E"CT?[[P6S@YB/85_C69/5DK;ATX@][Z%QTQ%RF9X5,#+]TF/QJQ!0I>( MH^L#\T03+*\CYC>"R#&0LZ H0OZ(HYC8.7$T5&ECN-+PG>2R13>=$3,:[[E+?2\#6Y;2\)30!?QL.6!#=2S]<4@ZI^J!; M7 =M5K6%WDPC'')HHI41!8+'4<_A"IR4=6@#J0I*[&6[GUD+K'6YHM%C$:;A]$O_(X$(G(U ;N&L+UD3@1P4%KD:(@3GH8; T=JL77VV@=:9Z>]?9W%@W"] MC$%,NR]5PZ4.-B]U%1F(PY FO-(TZ[&F=?D"U5B A#>3Q95B)%YF)O69'[4]N].-EJRSPWUIR^5EKZ7L<(\ZT$KV MNUVM6W&>*4O#A"V[29ON])M,6:=;15,FMV55"Z\MMNR5UCQ>Y?(DT^P^P4'YQ;8$[XWQ#6C7?O-26?#0IO!5!X]0:%MT'A MK4?UJI%:O1I%8G*:[5]==X)UA> 9WSB!Z3Q80"+>N+[1D/>J:..^?"+)(/E8I)KBN=J!!#4#[1AB8UNLA8 MK/>O65[R"U$:!2O]9;8[.BJ4L8XX"'Y\2DE^-&R#4[J;#(ORV8W(EMAVKB(= M*DU(F;?)3_ AGO[>;(8J644>1:$1J=);IK3Q'[=(7\5@>D& M?)/)=)\XY$GXI<3(5=#\48>#Y0O0/TLT2_"#]"3U2Q@ D_"&<7!$G-%-*0%9 M8&Y&)92K;S%%'$[D/D4?2!+(:B(;+GQ_.5_$H$93:EK%$I>$""5K4].A&T5P M;Y-E!Z,'[JL%E.(0B1YCYS;J6F5FP6= _=+P'W@%?AT8*JS!8AF;0\?W0X53 MX;95;O6_XK,X*S744')(,.+#HKD6#^8-OK$/=^(?QL@"0O]<1PU!9(DC&A/, M3WBXDT)!N7^1(,9.88% )H&RHF*R- @T-6E"0/.)2D.6$$AL <+:6C-8->(S MCH49#2 6J/!308 R/;,6?M@T M05N>"'A^;N9#)G+!I>8L_+[E_Q1 G1P9%V/8[.$E&IF(%6:RO)2L?,#!?=<8 M(#$]L="(SSEW4]X[^I-'V$47-\Z-E*\$Z;I0WFGO.:\PHC['@P$O!EI( 1MC MH=*"X+[#RK+MP-[1#*U%U(OQ47FGOP]=E0!]M;3OANU7O!3*G'"DWWD(5X]Y M!;&^$.,4M^/#"SKB!2',::+>@3Q0A$--LS$?B9;O#$F+&)(JTA>>@'C#R+O5 MZ?3)QTEPY56GH;'DFYC]$"QG=)7S2V]8$BY (KG*11+.C6V&$9D>B+"T1:A6$F+1B!Y+**>-- M*"WENZP+_0->]N[[[1_OXTXR\5#Y*FR]G+X0-L-AI;]!AV\0M$E94<;7'T14B'K M29WLEQER.QM?E:,3BPP'L$AR*"JS3HC0DL!$X[=P[K7)JC8NLRC>$497?%WQ M\NUX*R7'M_TI'Q 6W)]0I\'WK/?($%_P%?@B6AZLT) M-@>%X+M4FOXUW)M/O0NR1-65ERGL70BPJ0X/FD#M9?$3P>M"Y>=7I7SE;'(( MHH#W=Z+K":MX"6LQ0R#[9)O],PZ4\,4]D[^HI=PF]74XNBK9.4HX[$F,4\)C MSV8NUK$SFS<.TKTIG- N4/?IE[+=5(Z8NI#V+9I!3EXA55([4D>@W'$!YRID M;OJ$KL2\1[Q/1_,E5-E5P(O@?+B.\H;J\$DI=W=5:@UX(%RIXD3BOW#.P[/" MP:W!@ZR2@HBS*6IZ0X:M&'%>@P/7!U";CVQFC6T:]&$ZRRGVEWH)?%%^E3(# M4Q&QU,1O23BX>XWZB1N?!9=;.J"N9 E9#!$]I MPA.R-PX(+E51I&=5?X2&@ M8TQNS^T4G!Y2GXG>\PMG.3^?N,&Y>%Q*F96!HS!:VEHM"]_USF5A6D996+E[ MZ*57["3WD%8OMJ'.6#2F)]R)ES?DL;2#+X4ITT?*K ^Q>%7N[K[Z01[9+,S7 M57W!RTJW<;=PH6FR8"^+0%B;5I@VPRWUTPX=NOBMY0U%4<"8^(5IO:V2=%]Q MW'E1VVI*]Q;)G5=EO)Y8-E6!#1!D%7 0&R#(="#(SDF4TG532^EZ>4OI1/\> M-G2&KN:F!$2WDD7P=V%+LMA>E2[N5P(0)(Z;$;M5C6W3FB?ST*J8/YY P:0( MCAJ/)<&S1F08*$04JRF(X C"7C&TB$&B=2<)Y#2&UU$90QB>2L&H(J0)G@B- MA?0PRHNX51XOJ(I5*!( M,3+$Z/IQ;.^0^DB +>2#9;FB=H0P;V3"%?Z$3<+#J!B+N(4P7HRX10/:$E'! M)(I)VBA.3DQ1O&>&2*)K@*.Y%UZE0[8:Q/29C9/!X9Y!(<(0W8G0H.R7<_?) M(639A:P2$A\<\V=PO!DA> 16*T55HAXDGR]J U5YFNE$LN9$9 P%3P?TPX9EDT F$5B^CJ_EKI=]JJ(A_+;UHU@N9(L]KSNF M5M0'G%*)H#Z4?'A$9*"[[4OSER.?@P5Q!,.U)XCIFM&0!W$@5Z&PN0N)A M=>PTM#<2$D78_I9R%9[HZ,$4M$<$EE@R-IE4XI5G48DT. /8-K:C.@B1J#B"*QXA1:@9<$NHXL+(>:.;"+AQ>AXCDPF"NECQO# M<(P[%FE-O.4#*MT)Y99]10S_L#$#MN3(.93*3@6)B59F.8^N#2L/GER:1@W\ M8>]#"01S)"P!!Z>)5VY:,L$=.Q-A4ITJQD2]:0RI$PNH)![?D^E-?%&42+$V M^;QP6#T(W%C4;'%8NP"Q^"Q1V>:SU?-(,'RQ/4D(T>B+6"J#.D%L5.XSCIVZ MZ?"O=J"+QG0)GQIXUF@ILJ!PFW-4 ;2^LD11&PP:@E25&M-31!7WQ;01O=T3 M.#I*$L]&%3>Q!R088@@380@IFN.NQT!T!)ZY0*&'M?[D_"#_8(6R'/[=B>\W MT@,3B7^=E'6DG8/G((:R&E>6,:KC%F*S8MA4Y'#3T(6V&P[TJ\VESY/=L>K" M$!0;ZYWBWQ/Y6U]FW+&['$>>AQ HR?+#*)9+/I98M"I!FL"EY[W"O-N%)_^Y MY(NBEW668_F6+U+5N0=Q&I6-LQF#EI$1'Z MPD/>Q(N)X0H+]&L9\Z%NYW2S$_:/E"=!U:?E_1J22!%9JL06OY,[ A;\0^BF M^&&[4*HWH+P#OR\X3[FKO/\_;Z9^WH9XUP0>$L,"1\C&^HI(#&1IHZ]X8A)P M*Z[$Y#:^$Q[L>[H7UTX.9.Q%F@P>HN$VI8#R\%BJ[C@QPC9N. *0 M79$969KSD1%DS8'=8IQH@D:T3(DA2P*'EZ<\Y^52I)!+I+\'V'IUO[\/;)Z:V%Z M/P5;)AF[)WV7XD!&0?U8*+]2D?0O FZ1E\6%8(L48P,Z8:VVX])(K$=K(B+9 M?_)V83.(6L9P](7'<,C"3IB=O43=YM7NVU MJ:-@G>C)XE2" 1G+'GDQ')+*Z'P9&?_VN]Y31E8T^ ;LXM$7CAA>3'I^Y6B5ZIYK91N6JW3,!5^6A)J6.3B%N[2H006,8LG09/),,KZ M"; %H&"8,(F23?_WZOOGKS]N,:US'CV(OO>+^0+O_2N#V_4,9\HI5[^JRLWO MOWS_X^\WUU?JMO?R!9[S?)5\WAW/.[Z,;6OL*U^_7M.,X:O1Z.]66%="W[R^ M^O[W__G;CQL53,M8Y+:C,[9QGU_9 Q8F_<*3F>YY^QZS5TJ>5J6%TXX2A/'$:V(X55*0(JGX=/7]_UU]_?Q_8QP@ MM_57YLS-D7+UX;ZI'&_P9"N )VLT>+(-GFP]BN![J47PD;^?LWSQ:D+<]"7D M_:9">)S;4+W2Q=CNJF33KWG5] JNDQEM)EGI)PJ?R,--5+#O-;O";RDQ\D6% MDD^N9T] X)D'?JN*9$\NEF<0.@LY/+)/>=4.C8%D0WXVZ M2YOB]M:[V,HWCPR!*_=EN]4K:PI+5N=DOC5U<$W;1@H7;K[.Z%+,MRQJ0NR7 M.%VEW%D6F-'Z83YOU%Z5;./AVU("\[E::&+Q=2)NPO;3ZFCUH\K.F4\9I#B8&(6*<*86K'QMQ29X_Y MC'$[#&VB]HD/%PR'#N)G1"#438!7K8SC#GMVTKY)*%.Q3NVH-<@Q.6@,K83R MBR%^(H$'ACC:XQ@R)WS8-I]BGR(T'A,V/@ZB7>19B,3YI'=4%]@%+[E+)P;E M@UL>,8=-K4#B58:X0? K>5=<8:*HA8P)C #I!AD;>]:(\;+0:+!P(,.-O+0_ MUJ!O!KSP-A+B"(XQ*M2,/VOU"81M&E\L_.,GH\G<:(/'0=B9Q'^._0E"CG . M;$OY/<+R'#';8H\22WZ< 'GU6;SAC%!OL1Z5VJO,<%JPPKAT)9$U_[0=B=+4"%DJY7HKC^)L[\I4K(.V[']>_7;U'B<297_"DT&7#8@-R MI\1,J!4<7I"GJ'!PM!@"T+M+WW[A7;-":4UBV,U3+K-A^X<"'I7))3X$ MO/US"8X_MF5RG?I'^J.DL7&].97%HXK@S93P%^P_> 0JA,-QT6T@O#Z3"R!\ M8R_>)2:] >7Q %XY$SQ^7#"J<#-^&(;1$.4EDTO^0J]*+OI&8Q[1!"X9OK"'^]:(ZPK^%4Z*P4 MH1R+0JV)ZWF];K4\BU!?TZ3R$&I]S>(+G2TRHK$B#7"QSKFND/64B^;K/Y_]MZT2VTD2QC^*SK,=$_5'!)K7^P>SDEOW>ZW MO+Q.U_293WT$!(G*(-&2<#K[US_W1D@@D$ ["!13T^E,T!)QM[C[M9EPIUGU MJ,<2?UMQQ$+<+FN;2Z5\] +*F3B#AJQHO!NU3:H7[N>-#*/1\#^ 'RNVPJ/L%V=$1D,!822+ MKZ)[,!V&?B*]^C4JD,,]4\05L<$296JLW>C.A-U6Q(-83I8P;K7_R.;;;U$1 M;RQN!KJKN6-2BM;GX0A:/P ,[^]INV V'S+>UXEVIUX,?[IA]F[6J92-<-A[ M'GO./E2V+H#8^O8/.N$2;&*['>X-IA/JIOYS&DZ'T&%[1(+<,4.RGCN"2C1? M]?H$1Q(?V69_DLXBE>^(GD?'A"#0WI(IH<%BA2F5!E/]6>MB=-K:45<1K )W M9H[MIYPA"YO5-&ZY/[FF72/:(RO9KRX_T'"C/,G(EC^^H*AU"B6?^,$TVRUJ M_KXUGG=CO6@%J.."F]11?'IO1>XJN%Y"#]>W5<,[W M&Y/ H8ARGS6DHUO%2:,K\3WH[ +I)'__.EMHS MNKXFEO%Y?J#S96D?=8 M34UQA&=6CN>]V^(O'F(BF+N*Z406WFYJR;;2,MB;CI9LB00XL_T9:]"T\U@? M@*=4(&)K6A#_ 56K8_$(0[G&>,0GDICMM,9>Y+C':SH\7X.>-1;LLK.1=('K!W IM-@(K M%L],*1D!QI8'!_5VL5&_@B"2$=@F"RE^AGD,_S=_%9LV.6 M].A<^.SN*A,2?F-=#3+3D>AQ^_AJ+^4P11$$4!4 M^=[M[O4)F[U'6XPE5DK[#=$"Z[C'8("!PPG>-626JDT-DBA,B3SY [\Z[& 8 M=W?9GC=LG!^*$,IH[*,95A5,G2B D&Q2-!3 #EIZSV2K%22;L$R=[1(.ILHF MK<]G86M9898'Z\\3!W10@I"FS6T]99'!F&B3'R] !CSB$ZN@*DY6-L M]C"_X]ZA [I&=KJ_@%5 M..[TL,'FO,1G!B?YPAJ:'K7WTBVKX;/K5&'CG6]GVD7-7!/S\H)K]C <%16( MKW1!UG8,5]22,ALXC.)9.\VHW=&Q,:U1M#"^+W;?;5L=4G4T?@\3!#';@BZ\ M?6\<(-PA93>F<#O-NZK7?"% M>V[(74^\Q)[@U>BAWKYA+]5EUR^0C3L+I@LRVRPQLR8"#VM5^0MSG='4I\@. MB:^(ID;3T7>[4/P1 2$>6K1'I 1[]#=GA:'4X^'GF;UK'6SH@[$EIL+/<$GP MZW [3Y)9.[KFO7T,JWY3NA7J\'P=1'NE7.@W#];;)MCU_>(BO1C@7"1R;A@R*]V IMOHD&H=MG M7%WWWC+:TQWF,#HN;> ?B5[,,#I+U[-&N/ >2QMJ ::.AI1JPE)80XJ4('UW M@T;!.*K],C MK49TG#^%/X4_A3_E#$_A.7V\D^.9.CGJO),C[^28D9Z(0@*-"T>=J).9/)_/ M;5%2#6)8DDHD4Y5L;2I+EJS^4](P\Z_C28V%K:%*LP9RK"&E$"O*4=9AN?@T MMI$X:"5Q[\X^TKZ$B-N';;U*AM5HI+/I3".=38?/'Z:[C-#$Q:@V;[5]8:)" M)JV:'X3AL]+#V (REB67;&A('K9OC]L)*@RS5?"[ZUAY^S%_51^)1CD5X_CGBJ4UHJSH(\/4.[8F M21S)8FY*0X9^$2,8&)R4NNK,&[1&JE[N2<<^ET>ZW$PA2A<)P1R9QNDG18KT MH8JE,:FPCW[?>V*_RQT*:+6;;''2K2\;1> PI1/M.P.)8[DV!Q2@9%+ N5-0 M+IBY5 R:;VS??\:.W*CT,MV137;O4B)/YZ'X>Z+M*87D7VVGR$#MRL<5Q\8) M;,05Q+,$4;^W'5_X7WNY(4?1HM\8&-!8B897X:\4& GCA3-X&5@R$X;"4-@9 MQNSOAX2Q>C,YH+DFXI;&^D!(M3(/Y-*9![IY.O/@;V0Y^^9]M$.DN^<=_95. ML[%HFHV4DXG D7H$J>? ::)G:E+-^!OK48&*QC[6Y\Y/,KO[-_&]#(1;(GIS M35F27U5!.==7KHY\4/&A>D]9V6!)7#9T!;G9[9[OP]AZJX9@F2.X*PC.BK5D MEF*>ENY*0>F>HYHV*>;Y5=VYJKU&0N>W/#YY[AUMO_F K;!I \ZT'=;,V"0.*E@)IWG.J,5S'$=E%?TT!LP"''+] M)9LLAH;*W-=H6(1/UAM_NF E''%3+TYSV31GY-2I->4MMJS!V!A*(I?8;6.F M2=5)%[OC\^5$< ;/K2Y*G$^;15$;_E==E#F:FD53(UY47>1>5'Y5=2_JY1?( MK[HBY_FYS:R/L)WGJ!1#F&_<&3>KCITV.5UP&C*K=%$=C/6A)"M<#RB*&;D+ M9A7W2%\E>U8WJW3.I\VBJ!VSRN!H:A9-#9E59C-FU55E*7QS5CAIF68%\*R$ MV^,V@4151XI[WJV3/RBJB)'$^;19%K:B(DLS1 MU"R:FE$1I88\[]WSQ1V;WC8)O=!>"K=)=MF;+E4(A^.FSZ%@29@3:@P54>^) M2,C&S3D.UV8U+.Z$NRP15.3/ZAJ6SAFU81RUHV(9%$^2R?'4%)Y*I8[J4HG4 MT1@4<>N<$YUSVAGP==;++BCTK^*RJU.N3^03_]7[\5_AL08=-R-[&N@X@4.Q M3PF?^Q^VLT39\][S'T#4O"63,*'3K3S8+&AQ;[P@?&T'3GD%W,*HC2EQD_Q, M&-MIX7_UO2! 51QV#2A$#?PU'4T;EG!YI0\99A?=:NYHY]Q:M/)A@MSZ<#73LB4>UI1D(B;UQ-ISF,FG.:%]1 MPF:W6CU,%8YL4#1>&+!=6"\J<0"16>\V1*J#GXO;#<5!6@Q M--_68UJ0,AW9V9D?TUV]HY2U+5VBD:V"@35U*(F5;&R.Z H*9AZ>RRF8JC@8 MJU(1!?,%?68LM!-'$HCX1\>-P:_"AJ-/\%C5F1;*#H ]=$UQJOTZ("_C7U[% MLLIQ*83H3:_VGY[AD:/89%^_>G)FX>*E)(HC0!+"-3JKHS='7X_@JQ?ISU5] M)!IRYE?B2"KYN6)II>XXMBA]9)CZ^=;4Y#E3:'^2.))%JV- MT:J7NY)QSZ7 M1[IL7",A%%J3.3*-TT_*-DW1L9ZV37WOB?TN=RC[I]B,\%_>H@SS \%QA8_. M<@D2-/BUKH=$-HK 80IRG?B=@80L8O?%?.=$)@6DK3+I*@>,-C=[/M+-A/N5 MMW'#,PUG/?NHY\[C(=FMY"\3_\7X-R\HDL_'*3F&X+L@!(TU)#,!^W\(U-@X M"D#]QC:/-I?P9WNU?B707Q/V%R>B,G",G$H[$^=8'5(Q1UUI<'0KY1A(J0_D M<^YV")7'S99SG:C28*P,E6HY=_R8OUSF7RLS<5&A*)$0K:JRA'<%00WT\!6+5K+R].X>WG5=:9Q9W/?)\^]HSW63O6# M:#61FX^Z.*, -2L/F4Y+27TPUF2YQ6S"-C*"^XW&9@T7HY;APOFOFOF1QH/9 M-B/V"P=5RRY5'.]C\/+7IO!0+OM%$\$,4\U>=*B@"MM7 LL)B."3]<:?+D ' M$NQ'GY!5P5A$/VGN3--@-6DP5H>*D9.-Q=6C3F&Y4?5(J^?7Y>QY#N^LIK3/ MI_U"42L^5DWE:&H6357]<13NFL+=Z09'/>2WHSPE!OSDFHZF*5* MCEG*S8!.H;%9,X![2<^&N%->4LULFQ'[A8.J7E(-O:1F7YI0M(^'H5-:4V8R1<'6H:RXVJ0SKW MBIX-<96]HKK2/I_V"T6M>$5UE:.I630UXQ75&_**7I5[[)NS0L\8=4EQE]CM M<4[%$?%9[*$/QJ '8;G$\-(F' M9K0XH^B@FJMSE^4T]+]-LJO?KZK7_2-QISU3O$H16;U1\1EZ5YKRI,'8J#0>DNM56 MHHI5&N=RUD30VCWUKPE/;:+IN.Z4QH0"W,<'PS>%B0JZT4E+PU2YI=$TCDHJ M1EH^@]R(7O0Y7!#_9-<_3FH'I-;X#/0T_6%//:X=71]R&_GG'YMF?\*MY,KF"QA1T? M&.@:$ )@A[/4SF:MJG+MK'S3M;/9""R5T&;E=#IO.Z'-H@EMIL%=BTVAOU3@ MM2;Z*P=>+:-'@=?Z.>]ET=14TIIE,N[L2QN/]C'52M*:19/66AO]5GC$.JO+! MBN\HC[_4U9%)"?;<1LDW:I%,06H.Z4^![(0G]85/HZ'MJ]W0]@R?>)X-T!"\ MBTU%O8FWM##>^R;@PM]21 IU1',H93%+%Y@R8H@86I*&9K6Z!$XF9U3@W'QTW1IX*\(@^073AG[$B@(K#2TD= MJ3&*''<&BWYYQSYK5#?01G)>4$ Y[AR445ON16;A=:;!*4UDBT$&[: M$$(/%!C6!$)PW!\D"%=,P_'I,#W/#\E,L$/!COUN0'5!2!6@V/,B/-J.&PB> M+RR](" ']SJN0&S?A;<'(V%?+3I*#'H?B$'N!#&8(Y$2PWW*]7Z8YI$BB;GM M^,(//%N$)R=<@' ZH @DDH@DMO>Y)!2\N1#:/^%3H V643+U5FN?+(@; /C^ M_!^2+KYR7/B0C X4:29N/FU6L/%I<0K26S8ALN \&+_? 0BV_(C9Q2YRUQY0 M,:MF K1A(PE%EL6QX3K"$P$< (^"7$9@;@+ H_"OC8=_3'SO.X!R#8")GAL MQ3ESH#YX)8.S-X&=_*!H=MSU)@PRX(NGBN-N;";/$Q".]J9B_"--\T_.+%R\ ME$1Z;"7NBA B[FZQ)W ,;\+CMQ1 961O[:D!@-*EO0[(R_B75[$1X+@4.?2F M5_M/SPCF4+'"OMXM<22R94:6<_3FZ.L1?/4B_;DECRS5R/Q*'$F9GQ][%%C! MFG+R2>T%!.-''*I'%^ H6915X=X%ZEP*7ZE(*1ULNQ8 I!1""@#-R-APAIZ5 M_+GP=S!X)'<3D-+?[^QY2/R7]O+)?@Z0?)+L!]P1O5178%4UV)0M=>*_&!\L MF_X\$#:1=JF9QIV\57TC47^HZQXJMP=1HH/@Q#?\'6'_>NE-O^_46* . LKM MFD0Y95T_4+XM" 4$:MO( I'FAB<#GJGP;3J"GC[&0^$MF9+5A/CLI)6MH4 9 M"P]X.X [ETOO*7A935F[(OEL:"-344O)Y^.?*Y;6B*2W1H9^6M(7_UQ3R^WN MU)I./ZGSV425;(K"A$W!@=,KA!H=D4/-T_5=NHS M*Y-HE_ U)1Q19"+A2RY/_\5R'=]&MAP:9BX1GL%R+^[L.[WU8JZ\TN"[?)*H M4MZ?6RNWXN/VT/\'Q=1GE_P?X&DO,:JT0T\=C(VA+%;*NN#H+^>G;0/[5=NV M&J+&,)^3#=?Y\[VX?*.6SU:\@=;L>YO'A3!W?K!/KNC(NT["O4<$ -U^8Y!_ M#X!'$@X.)%B:5/7!6.IMQ6/GT'5BF(8A&OFHNCF1LI,@6Z$2$I?+E+,1*9)F M1*7?B)LE4XIV'#!$L_<=!SJ'RR,ZSFD\6LW,+;E06MQEDM[*UW?S=(^ZZ1Z7 MLR(? "9+$D^">&N'I':-C0%K0ZM"JE1CPXFI$6+J!BV5IAR)44[.=(JLD-=5 MY09@*.>-MX*WQGDW@># _\C/*0D"EG'LN (L>;$=),K2+%;V'YXO3&SW^U;/ M]#8AC?X\>?YREFC4L8 7WOUK Q08/@NKY 1XQPU"?T-3?49"S^>V**D&,2Q))9*I2K8V ME25+5O\I:>J@;-A*JI0\])8%L(Y0@J04.G25$8O#E8MX?@!HNJ'G/\,:IDLO MV/@9$4Y)9IP.4"2S^S#Z#!^V'_>,'T9/^P,^VD-+J24^3!=DMEF2S_/M8J.$ MPR,!62D=D,V.$;--=)W'[QE7$N3'.9B'*.PB Y'%6^$+^$494M:(X,]RH9R MS'H1@-7-0"6!V O"@>4#_WCU'UIGIL:C@^8?G M?__@?F'0K$>%.E*A6 ]T]?UG:;@CV-+8C66/$[U202LX(4LD90:KXX4-A MC8^GSC(2OR W;)4519)9%*F9+69L[-KJ"XL'K-:G<(%1WVV7"'O7L1,#V3[P M*<,!UK+S$!P%@S^<%9P=/PA-)>*!C\9#7%:. M)GU4?:'MM+/49RP-E'(Z?7'<->!6LN2F48>U?58/PE"O-\X25\D"Z)/HKZ1Q M<"W'S)DI3JE'<24-<9UZ912)CW4JC"#UK @R&(+R1F/<@LCX:$\7\*'_?.A& MX(2828C:60G1!#W9JNJ_[2>"]+,BR ($F4/+R&D.? N2XHU':R48"EBJRZ// MF.,C4:<&R9\>3!6S:&1UR2=X_=,,>2&T:L >HVA810I5"WK MW8V V3&Q=L2[B^6JQX)\E9V$!Q"HY"3,A^(5GMZYE=H[3+Q-( )^7Q+\!0@_ M*N^GGQ]EBM+\H%*+0-;$YCS%G @JBKJ+$0%6/AA#TR@R&(2G*>9J@RXIXI#B M^6I7I$M62&!3L))#'&JU@G"<.JY $ZU"'.BSMX:F57X6T_4V3)G::R>DHV8P MBR8D/@E"@?Q<$S>@'>S7MA_&'?%I(AK\/DVZ\3"[S9XZR]T,EJW4'0D?#I^X M>QT=9Y3*BZ/M\Y4X.TX6GF )Y:1)7O8K6Q"V8PK>[!:310Y8S)'VA0DKEF@T M++FNG(ATF859L+"T;A@OC *OW-IR8IER0R/D=&1$0A.DC+)'[1$KG('LS1B#?[A_O$PN_!U;]X=X MU4G5]?,\@=H8Y5L46SL4XS3#45I&"I,F&*/=I:[R%2<=> -P"_)2CX\=G5!#- MU&-.%&#*#>VU-3^>0 UOV^-='-]"EL[*<>FU<]];,08/ I*3BPU?T/<=8@,/ MW9DSGP-VW2E*#EB."SN9D/")$)<^'B>ZL5>P46?X(OR3F(U3S,PS9F:OG-EL&15+G-\PU\QSC!1KB;)>SA2#-&5;N>ZC59*U6] MAI?12#O]C"HP.WW+22&X3*6:>K4:@Z&-++.IJK N3L-K0U?[)!V MC:=N(6S[CAWH [;C:#++?M9C7_<8JF4E*?J@[&J#O6\FL<;QU&Y1(:<3(;&<60 MCL2AFE<%> NE(ZG\/V5B\DJ$ MQDP\2-R[OADS>4CD)CMM45D*O MC)^:60E]A]7-9"5\VWK$KT^-:2KM0,[$FRATER++'5>Y!:+E4J;W#["Y\Y/, M[OY-?&][=HF[L\M$[J&:NVT3K,ZFILEY@[(XSA(XRVF[VSK.I,'8&LIY4WYO*M_A]-S'0M82]Q"T MY &Z,#?(=208QWAY^9?;N:9EA"N <'%HR8TD1A3I7G6E7J0CTK%&.E@]8#77 M3JS;GI6S"-64K[4^7ZF#L6(,]=9;SG$*.8<0;H% -" 0=2@5&A6SWU.A:.DT M_ADAZ@X%Z4M)':DQLE"A<\.7=^RS1@6J-I(+E)L?\][)([.@\ZZY%1^6D?#.RVU$UFV.T:TFEXQRJ43JNQ [#N*L6M@_< M.HGQN/2P61* @AH4N,NWY,OF67AX=N&/0)AL @!YP+H%8+\C;*W@S)VX$].! M"3)#4!Y\@N!#9A0FVZYL\*D'Q"38PAZ] E,[YR?=PMG!K!_B9LR!F-98UO MG@<1E0EKH!5O5K1I72]84.X$"YHCD;(@MMA:82\.9" G .98K7T'?6G8BR\S M02/=-RO9<:14LY1=*Y'X)$@W M'-=&<4W4QW1LD@J\LU XFW@^U 9!OR90* M.<8@LC7<98MANP&.(+6MO-CX;S' V?$=@?W*E/[("\)>S?+,K$GH-R)5]#3Q%04-P7 M1@ V#S0K);RU+ WJ _:_ZVWB&LFCX %3E#I,<3#6I)R\\K.665S%DY)AO#9$YQV)C920#V#9\%M= MKZ@E@I6IY;53YK@X*<*;P@4=$L*%=PWAW10FY.Q8094FXT4:'-Q<,"&NSVRV MUT1]E^1UO*6[W%FN/$/*Z:U6U35JL:9!NI4S8X230F>,5*,E2L V-\I0RY@7 MR"FADY10,.FF-"%H='"P+.9XI#/:V1RV7^AZ;XW<3A7;_D-1SP=JB.UZ08#6 M-/[ON&_8X4]0CI:;&0F$==015E@#4$C<2 $?9,_^V 3ABLZF!"0)]Q/'6Y$9 MA6/RC6.A8#,%/:N9PCG5&&PW@5T\V 78QP5XRGXD>_.TGF>)FX6V L+=G\G--7"!V;[[] M/+DGQA38'%EXXP6T@PAL<;:9PI<@K6>TBT@YW>ATQZ3DD*3/\\.F21DMD2P3 MY-\H;<<+43>D8*1-#=UX5&[.OMGVK_%)L"93[,6P?!X)AV-$ MA"DM&PI9'AKM2E_.UOL$#_[V1)8_R$=XRZ)@2V=]9Q3* M@[$Z%//CG/\#$_?;DU>:8+ \8JAR@NDGP2Q\0DJ3C HG MQM#D)--+DGGO;?S2%*,AQ>0&%3G%W";%P+6E*48O1#'-AJ$O$%Y^($3XY(5$ MD$QT>K.9(RZE+^H(!VC;[A3P+SR$\,$N6HPTA_" ;V8DM)UE<*S@CXT=352* M'$0N4O'F),BBQ:KHI$Y/F=AVT/_3OGLN@K"XN\6>P)XVX?%;.N=QKS@7P))' MEFHTXFE51Z:F7**W? (MA[+LO&$C)3).5>'>!>I<"E_)&D1,::?JM0 @V[&L M61D;SI)\B9^X Q2ECCI1)S-Y/I_;HJ0:Q+ DE4BF*MG:5)8L6?VGA*,#H[L6 M_@YRC^1NXA/[^YT]#XG_TEX^V<\!$EV2:8&GHJ7J"NRE!G.S#6*K_(/-E@K- M296D^%LF,HX@"<,)!7PH^B@::%XN$FP[_O_:RPV!-4R77H#R.2/4:Z0&S\!G MZ<$S^#3A!SY.6!$;'T8/C-29>!BYSDAPBIZ?\5:YRX%FRC#?$I.[-@&A!^:3 M[=-<'+@.P\ULC!?='BH6=)[7RG8QB0?'>I&?:XJ+^$S^88,.-G&6.)H(IQ'9 MP4*8XZ";(>9UP89A \GSE\:@#U_FP[?;^6'PE/D&CV,,=!-_&BUWFP[#)H@Y M_NQN;?OPUCB/C-Z)X6M4"@,X^UT/N)"^UW$%>_O6:51$Q))T]J QQ5EAVPO8 M^T$Y8.L+GN 434!C>YGO!-^S-PM'L>\]@9P-1L)K#V>"/:_9.N&$=M@4#)9: M,2-86,#"_\$.BL*"S!Y3>DFW:>Q^JW\MG_=GQ5$89P$5)R0!>[D!,"L=H)2@ MN;W+*:@3 *;UH^RK)*P!L0')@?%\)Q$B(%>B!Z3& DRT_VZ7A/ PU#OI;N/W MYT"N&*]Z\SGF[ASRZA0.=!OXX) +XA02W,>0 _Q M!JD7:]1*@!;-:HP0KVHT\B:^Z7-P_WO[)ABC'Y)G8P]3:X,SP$ %&8/P4J MGQ,L<.W4YH$O87OA MZ]\):S0, !?S,! +W+>]LNW@XIL2#ZW8B:=BL!UJPZ M(@YI+J23E>T5+GA[2":6N+8=.CYNC^-=V"K[Y.$^NI?)O)(5,N;I),8WVV7< M+T&IG3U_\0)XT?TC;/X1OMBJ85GYC-B/\X.8>B,=9I\*]SD% M(!0X0 Q;3H&UWZV)3]U&[C0Z%%';( *L!=/^IC8<&'OOW:DG5!P$3!XD>(UQ MF;<"/7@K%9QPP_PDE-T7-K +_+L$_3EDY_46&H^8HKZ_BQ&8I',D8:;S,1<% M !D/"6<.MB6*AJT0RI:^L:X^P_Z**W""48G!@$I 2\ MD#UQ;3^S/^*YK $YMM73G+Z/RX4]0P'+7$V,0^'>30B"R*42%->2?X .BZH9 M69_#4IN5!V^W O93M+5[NK,,?I)$X"=ME"YBK9P2+C:W-@G6)C:;#B[GI-27 M61Z8BM8)4728FIU%E/MGS'4398[4+P-9!1 OGTBR+TV4.84*9=:&M816QECI M.D294Z109GD:%KT6I\IKTHSOE\ND[IC4>6,;PY\QY1"Y:6(OZ=$:+ @<^WN' MSTAX<\R(R3+LMT\F]G015SXY;MI, ;9D%4]TNC-9$#CUZ4JQP&((SUT3QL"P MQ*<%H9?BZY.[.K0S4;F@%4=,06%M4QA2AXQ[YT+@14KJ\YIN('4E;!CUG%A& ML+JMY#;AM3OU K>V]0&QL>8>[-IF&C62#K.KKHEXOBUVS@/*I8#:0^4/H;!" M)0B(!<%)4) B"6&T*C8^]ZP7)FE!MJ->.27K""M[A,IH"&M IK%+B0@+6!HJ M" M'Q4OP8XWJPU3[8\S'8 B=);T!10HRV?J8]AQAF!3% 0)IP0%DD]U;S0SITL M$&B[#'=;7H^6'8"DCJ&/V$EL/LE_U\0J?Z4F/57CLPGDF!Z1\ SM8S,"R(Q, M4!"'OC/9,%L"G5J[F_:>>X!Q5C/%OH[KJ2(4[ 3RT\*94OI]%CP@#W\DI/82 MF8@IS]T!%X4+W]L\+A+>J/V.55N4(T *4V-$^2B+T$_":L.B>CPJ9K?R )N% M"2$&M8%/T]J#B.Y'2$C@M7, M";:!G:MBO#W7WT[FHQOXW<;W]L(A:"A'QO!LPTXHH!),6$'[ &F)NK4 ;K*H MJNRXRR+\^%B+WOM?0>(*RI2QUPZN<\+(]<_.4#!.@LTD<&8.J TD\C#$3@NZ M8"8/01+,-^XTNB5AC0@TRP'7Z)/99LIN_.$AA]%8%'6!4*]:0DCL!9RNS+>; M[Y>(E5:JASI;HI2WX&E8O@(]9)=*-$DA' ]\T>@#XP *%,PHREJ,A:V7?C,7$443K2/ACDH8.A M'JI51:P46^S)&%=^"":A9>T4#NKAVYD7/R*MKEP4_BT)IKZS9B7N7[>/GT9% M[WL8B_&TPXHQ&+OP<$&2T?$9+E+Q=B9;X"S:+%F$9J?V1) ZU'_IV1SO!KYG M!S@%-8/[RO[IK#8K84G<1Q!P^% 'D$/OV)[Q6ZPX+%)UJ-AM(V?P?3F ?62O M_XV^_?/\&[P[TL[CYI5[,,OL,T%AM8.BF=EH@@%T&"D!]/C:4ZT2 3H6T\B* M.'[;DIP &(@;:OC$7A[&V\"X@8/%F:-+UPZR0_A!)&O1]1L]X3&E#P)0$Z^: M$5CSBKIR053#"A@.45AI"B%(-]0XJG[+68LH=Y=N6JK$\F_U6HC:Z< ML;9R9K-EU/GAK(EI+.5)/$G-6C$/C3_QG\X?YQAWJ( M),O6/Q^ET1_KQP&<:B#5_K[ 0]3]L[U:OXI^9]_NLZ0$NZ]$UY*V_HG$8:E#[F$*!\@&FU/OW,L?=B[56!'XX&ZUIL_S;;[VEUWH,IW/AY& MP\PZR4KG\YW(S9,S<_.4J\C-FX/@ITE,4;P4^[* LKB"Q6W/OLB)NI=HMN?L M@L,V\DN4[B%T,I4!=0A<@_WSBMK#5#SY9'%D&%I#R>I23E>0HD\R1J*I=NQ) M^DA7FMF=/C+,<]0867ZFM^#:Q M_:A@MC<0^!#Y\2@(?F'.Y5][# _::C0-C.)@Z%7'(BXYZ1^]E9E]DP['I67? M(%%"3K9BC?&K+G<51^B-7=52A]A.#?:B;<^C%$JL^M[F_0WSJZUP?UWJ9,F? MP9]QMF=TWL55+$J.<4+A%XP4_HKY:0<5^1@%2TZ%*<+NW>CNS2^[37K]D)&[ MODVSXN1YM9=='7EFJU-_2V3*ER#&[C9G+%D)F9I@?:P2\EU4-X%)H*!NNV&< ML/)U6Z7TP7T7)3[N]V>D#6?N_DU\+Z,UHRQB8I I2_*K*NT\NX^0ZW*.&WZ!+BN(.CA(.C2XB[=4_(+S5=(4(O[F9IWLW2)?QR?TP)?TR7$,<=-R4<-UU" MW*U[>,II+&D73XH2XQ6$GW40SL"#@*ZZW0X2P;?EE/LI,* M)7MF-"3C"9\W<]G5T6SV6?,F?P8"S_^\_LMNA%KOMP.F'FG375_X94G%[7[S M]:B=ZUY#V+@)9(&.TC>A1);++%4NGEFJ\@A-$A\7SRQ5>> EB8^+9Y:JMQY/ M*8>/LV66JLI@+*D\_P1@?O'44I7'/"J@[>*II2H/923PH5X\M53E$8HD/BZ> M6JK>>N"A'#[.EEJJ8A1!20\#["',+YY:JO8LM;2@)^/^\YL/_2/'/&]$AV): M&G=;E'!;= EQW+]1PK_1)<1Q1T@)1\@%DC,T[C$IZ#'I$E=QUTKSKI4NX9?[ M8$KX8+J$..ZL*>&LZ1+BN%>GA%?G$GH*=_\4=/]TB:MX#BF_["8RG KED*8Z M O/TT=NX[$;(]7WNY&Y.HU=[V=71:/E0RVZ6/$T'Q7 +FRK/4DA[J K6"+WL MC7U/Q 4C($_IN75"(=?%P5CFZKBDUHBBU,:!-!BKLLZQ(*DU0B*UL2 /QHK" MD2"I-<(;)9%0V 35%>[826"H1HRC-INH@W$M4=6O<(5:(UQ1&U7:8&QP=I&T M&I&'VCC0!V/)O-&SO5QS RT51ZC0W* V/@PXY=-,T<,F!EJ-Z$!KQ[S)C_D$ MAFJ$"&KSB348YZ23<&]_OR[CPR!O["J.T!N[J@?.XUO,TR^G1J>]Q4VIT2Q7 MH(228(A9!N9MZ-(ED9)R'U\.*1)8G%K:XKP-M%S6G5P>&3*HT3S=J06GLP=CB#FA^V17G1F;G[_+VK[VX[.JH ME6?RUC\VSY?)6UBQ,7FWE"2&SI?G6QQ#O"U*$D/GRP$NCB'>_R2)H?,E"*/O^.7]5HON+$\V?$ MOV,L]1*X3PB\I3,38D:Z!1=:^7S&&E#IB,0J-R:I<9]:8R%#JYYG[?H1>5G/ M6W-XK.=_ZQL>SYU461R/];QTUX_'D@DR*3?>Q1)D+&4PUJQJJ>37C[;+NOV: M8[]ZSK^B>,QQ#O:-',Z=_5F<'.JY$'N&Q\9=C,WAL9ZCL6]X;-H1V1P>Z[DC MKQ^/Y;2CM+_RFB3X)O37^&3'C^"\3_\6. ME.A[.OJ4B+]5#>Y?>X&#('C)FBS_(*^>G%FX>"F)E/D3=T4O%7>WV!,09IOP M^"T%EDOQQV0E_$OKV*<.BX54/2F5_M/Q\T<"$LJ3-G7NR6.1+;, MB,6C-T=?C^"K%^G/+7EDJ4;F5^)(ROS\V*/4D:DI)Y_44N)J BV'A\QY??(* M@E\6956X=X'_EL)7LO;\<)]:JX4$.PF 5!8Z!8 N96PX2U0E?B[\'0P>R=W$ M)_;W.QO/PI?V\LE^#I!\DNP'W!&]5%=@5378])A483\/Q&E\YHK&G<)4!/B& MS.[#^%-UR;J3*JWNG-1['V TZ2V9DM6$^'_^#S ?7\G64*!4;;NS@Z\4 MB7ZE# 50?T!E68*6@WWM;1J8"H0GXA,:C +I-\,6^'@9 (>JBG8(GTWLI>U. M04XN" E9/WSX-/2$Z6:U87(;K@F<0+"WHR90-Q+FMN,+/^SEAM!N^B11T5#A M;+D*8:TH(TG62PGKXY^;:KD[CBU* KDORPTM2E/5IA8ER^6.M;,LJIN04K*_ M:OG8;DZTF86JHWZ#3P0G)"L,B:,<>I.40Z\C.?2 !W#5T\*9+NBU5,3, MHML#+$.ATW'JIIY:1: X)5C(U1DXOK%]_QF%_"[[ "'T-P:AWQQ[XBR=\/DL MH&G$D] <9'9'U@XV[_&<^E]Z3OV-37VAU+4;G"1\B(AI2Y<1@-EUQ8',[?L. MY!2A2I%PAI&)9'0BH:@8!?_R%E4='P6<\-%9+G$T40EGX.G-%XNOE09@MV1 MK!\+L=;,H5<%>K%AP:''::\3M,[#[=J]7[TS=VL[F9>>!<].1V"LT1L5SJTE$J%(!S+ M9;&PE MA1QRWB&#/4P79+99PBE*LYQV1VGPR0O?$F1+]*'?!Y&#\X,;A/Z&#H5_".$; M^MOG^7O'M=TI2)$OQ*>LYT[)O3O;?1QE7_SFL5RH;[@%U+I?+[WI]QT?PKE M@#O7&.[V-Z3S,=5O>Z%1%FET NK/)?,YF5+O[FP'5,'U0O@[!JM@!]MYXFCN/2,=S;CY^JZDA2S(X%X&2XP; ZMJC.ABKE MTY"ZD5!E53=\_38W'8LUQD_(*YL[]2"?=UK\B9I=L*GAM)OUB< M]C%$BZ Z JD/##Y;: E'('5;#KEC'M_=F0N:C/!V[\R-E!DAH?2)CE[S-R!]5R['>CHK)HOXE*9& .QGIZ!E&& MSS?M^9=8O>,Y>$8 ."'L\R*EE!P"D7 MV0GO6(;WK#\N,DD;J1)/G"_JC>H6_1IYQ^>4%G8ITI'[?I7+J? M1L5;\%&Y4^SB_("#4#Z4'81R MR_2W/RXFDP:9TS,;<#QJT$-_%O<&GBD__XP.ZW[B@E/RA?S:C7A,X2$7<)=> M:P9Z*6B=VPM9O4/4SLOS[B1O9RF?&>SG_8Q,-W=JA &DPEI3TR/NN)RQW0DY2[^.'>(;JT9A0-R'8!28J MY\//Z3Z.=V(NT@>2C-]&1L>5G(9?9.-IGZ3.9J:Q5CH?.KK M[>;=:<74J-$#NAW%1!V,+:U.N63/\5\._9VS3+3!6%?K6"871'\GA&I3RBEG MHQ)LE#-HL(LZR'E:[',BV1%)3I_P+A))T?[]!;*7[3X+"V\Y"P3R MKXT3/B=RAP+AR0D7 AQH,W@WH!(;=C@NS=W9M1P-:*;0D9N]39A[_TA(KF4% MQ^<&)'G6$\.%'0HSCQ8%+NP?I,#20B!*.!7@NTT@./ *Q\=G#05G#NM^'@KK M)7SA^=$5+&TY@ <'FV6(658T&NU- ,@_Z-/7@%NRO8Y&LX&A80TA$APCE5VZ ME3.#ER&[XBML(7 B[:?S,^*NMD%P!F"$P0;XH_V,ZLJ)LO=_[#A5;#B]Y[_ M %3^0*8;WPD=@ISEN5-GZ9RJ+)7,5$]?^ Q?> L9ROF,>JP^%/+AL7M1_7R.I=3O! M(*?Q\D?;_TZH*V[GD@42GC(*+MN)4[(&8W6H&@I/NVH[M=4HVH25L>&V]^HN M"R #?[(X&$O&U66EWB#V_G#_B#"7D)^'>1US&H6$JYCR@ZKL6^!A]_$+;,&; ME>5>64+N%<5T]@\G@*:#T3EM4?+$4<\2=%W%4W6/:WFE\*07P M5;YA=??>\G5+WC^9<_"AG6O8\U:FDUI_JNY2E$^Z.EG\P1'UE M>'J;0--.;Z2Y3%F23!V,=2O=>Y^CMAW-,56.TX3>KX'>;]52_'N.Q)HX;%+I M3V-7'XQE0^4<>A[DYA1$-2I[C<'8J.5MX9AM#K.%=7^S -8*I/2FAX0'JB-3*Y<>>.Q)ECRRU$82 ML HJ_"MG-EM&Z:_G;[.,8]=*!M$JA(R;W)>4MR^:K_LVWV6E&#WE>A:TM8_ MD7@N"X@$DK-D5.+GPM_A_9'<34!]^7YGS^& >VDOG^SG #>3E"0 D.C%N@(K MJR%QV%(Q_G:P[#B)/2DW([ELBL:=FLHSQT^UP;%[6!;ZB=6I5RL/>;XTSY?N M!_IXOG3%7(>_VR -_6>!9TMW$CVU.JGQ;.D;2DKBV=(\6YIG2_-L:9XMW9%5 M\FSI/I^NG>7R(\Q4 M2[4&\B,4<3!6]/3,N:O,BST_!FLB\'(9T0K-B);U.OT0.>([6:JBR+=4JG+E MJ#V2.5$2HTHAC/*DZANY[+Q)U5VS"FXUK[KSQD%.K]$FT_L43*V6;BF]K^/G ME)G3([24S8 YU1QUET9=2SG5BCX8UYK@P]';V8H6Q;BUBI8K1V[1Q&K%+("X MC*3%HME[^&<$^CO4$3&?28W![[C87??E'?NL444Q'=;)4A7KQSK;\_YGKS<) M2FLD6P@V[ ?LSVAH.QJURR+(+]X==-#GF$L$Y"Z).7,D4LPQ;#DN'4;!VEM/ M:4?I:31S??%16NAN\^U!< MJGO24ME3='ZR5N"?YP^A-_T.V@NFI-GPP9-+_&#AK.\Q_?K;KCGX5HK>R3LQ M:@W&UBCM\_P3&)PKVW$QU!F$]G?UC3! #L^7=1JVH2+49X ML@/8PFJ])"QE)=FT.L#VWS/A7QO;AX4AM6!N_4'3\9.%+AWL\_W9%3[:SX*D ML2:E0[KAN*4\;:L^$TI:G?L.-//PA(2'KP#9<&I_L==(,A%6K2U250QAC-)G MHS!A27."_?CHDT<[I$WEW:FS!NS85$6B/+Q]@;#&-]!6XC[0-PBKTIO13F_F MB^]-"9D%.&3A T +.>;S/+7%(M[!Q/ZE[/TS;HV! #MU22A,[6 !8&#+P.[K M$R)L IQB[OG"(P%> CC .;7V? JP#?P6X.R &/-&%N9W/& +;V-FB=P[,>?B M"IPP2'#:4= &"]LG01JZ>QTJ/GQZGQ00^-KWGL]>&K_S@3XH_JM@D$3<058& M0]>4AXIL#35-3%,86RCNC D+!,@*=D)EU+:+/6CK(%10R51 "(DH"/ID81G((9@>;#M(?T[B2_7$Y8>/ S$ MTI.+@R6>3V\%1TRG&-D<\Y1U.+L MDL]N)00G6$<9C,51NGYXGW7\E.)V./QH)-09,G!N(?Z^P>D*E,C+#B59T7A7 M-#MD6))2ZL#]O1)$A &9:6JF*CL+1[2UC%IXE;^E1(.7":77&F M.RY>[Q"9=4UP[@9PY3 6+XG!*KLY+G#I+OV6'A>,SH4GXA-Z&V-\*LJWRV*# M9?SH*J8<4WEP3KRR3&?'_;R=(/,%!\ADP@N;!F2H"TTBN.$5&]CFH R*$^BE MG)Z/XAE\!^I -H#H$0YOP"Y[+A;R>0%.W9DGN?_*Q.$.. XS6\A/ M)XP&$-%12$_>9CE#36FK%@*DP%8%-1+(!;TW.'8(^(%^$483L?!D=&PX1 #_ M(V'_+78D ^_0YIW%PYCHH*)84L+'FP!5!GC!9K5F\X[H@9MELI; MND30Y!!SN'1Z9V)UB:5\@(^G>*11@XTFXMT_O!%,601- 5[A$P+V*-"2L'! M'_2GBV?<%SS50Q?DOYDH<-PUZ#5,>81WLBW024[;G;*)4_11[$2(R''W6#B] M8M?X.N \A]O@F!3)D1,0?H!E3+1$N*\03J M]VMX/JZ*;0#(%9\+'^*<+$1,1+U[*V&B)=B Q/G7!FY>HDGAHGN(/1;(Z71X&84?-2LC/IWNQ(:]!!( _D1='Q@R7#)>QWEH=HB. M?13;/KOM^/'\!/*>#62SMXL0"*P O5%N4L.GL_6,5_& -;HG#^P$BEF@@P0& MX;4[JHK==?L@@V/-.S&\;N%,%Y23XTF":($$^RQ,+1+0X]$M$@4R3M\HR/MK M8*^W=Z&L[0@QYC]Y1'C&0@Z?SB0KA?@4" F.+;CC$:<:>CX3&PG+'][H(G^< M7I*"%X YO)UZ1Z77@;A.<,06RB =01V>@?QXQ*4!R.,)=2&9+ESG7_@TU*39 M^^G1&BO,L5&X=X8#%-!:0PV)3FZ$O?^QF3W&1$78J$;$]?5)O]T8.3R)XN.# M:ACTQ$&HTU,'!$-T<": 4VOHYO210"0W5U( M5S(V?,6=A:J,Q\VU<61+%H=Z_NCC4RK:UV;^)JN>TVG>UN=H8V4+%UAHZ+4)->>],_B M/9EZW#6".7E!58GK/@*$&LS?[KU M+E^WU6GF6&?(V-\08& 9UD)C1&"2+LCL$:,*B4C>2RXZ2G@@#IIESNW\3WLC+S+:1)FKU3 MI:G"S:"K'+9RILV5Q58**YHX&.MZNEZ/8^0(1JR\,I(R MTHM:'2UP:[R3TW:PO;-'Y6=/>6SE]!&L@ZW\1K@:ECH/5;/2Q.^>(BRG07%[ M[*5S]BJ/+>VB[&5P]BJ+,+UMS<\0X9OA5Y[BJ>!*& M.-)V 39+P_^N)@VC:)I1P>T6CTF6!-K914XVN,IY.ZVGUO)TD\Z6-%4<+S@Z3<]#"<\=X[M@5,E"=W+'Z1Q%/_C]S ED1 ME.4[0PT<TM$KCAWN*M3I99+49S>!5 F=.)6N(T63.:.?,)VL(:UAK,%04 MGG-V*U=Q5%W-53P]D"<:7#(]L+ZN5L_3S3%^YAS!AG0&;3!6AYJ:DU_"<=Z) M1,'Z3%[/"<\1?MYLP89XW. \?CTI@PWAW$1;T-)EGC>8["R*XP-;["[:]VP= M#BL.*PXK#JMK@=7591?>2.O0,Q(^WS'?,=_Q->WXZH0R[PM: !S-]@5]SX#Z M)AISGVE0?_+"MUM3[S[X&S/T$A?08[.B'XUG$#6?%MX24E/(,\7!6.--$AO+ M&[\T,YH\RZCYS/*S,:/,F;')U/.SX4T9C/7+Y*:?V[PN67A^,W3)K1&^8[[C MF]SQU4EF7E;=M#%V#OTO/CF?*RKVO/BZHU9V-F+3",2VSY723OJ)N[-8VG69 MDM=Q=]3:+LJ4!F?*SEG<17%G#L:&U@NK^_Z'[2SMR9(( &#A 0 A? X7Q!<^ MN#]($!;.U"I)M/RRFI?=4D."=__: $L*SH[BKJ\7@<)[$=0KNV%$\$"F&Y_Z M -__^.1DB69K,%8UB9^K356_9,.]L)X*NC374YNN3JF+$QZI:[R I*!XLF0N MGLJ9;'4Y(;](PU*P,$98X7[BYM6O:G@J(/2P;>=0EG2.JJ:TLC98BGMY&]?46N,H@W-4 ML\I=:Y@R!V-S:!K]R)MB[MI$]A3WUG;NLF(%X(R$&JP!OXCM\0:N@,42-Q3@ MU\"!G=G(?-=GA&C%C9"B&"Q6^UF%$#IR/OQG\2K9@NK=/M(E@ #'>K?4^+-@ M74*LBU:11CLO0K0IXD,;?L007=G^H^/&:-,!4-$GJ [ GQ$"QG^9^"_&^T=_ MB:E&*,WO=I_7X;&0M_'OG[U MY,S"Q4O+'(FZAFB.=,[HQ>Q;:004\"+]N:Z.%%'._$H<224_5T6]U!W'%B6! MDF=I#2U*T\RF%B4IULE'==ZX- L9EW_UO2 00D_X1$)AEW,E?"4@(Z; RWNJ M??<=((T!1A9Q9$@?MZW4;VU&)I)1PZP]MT7[RUL4T'X@.*[PT5DN@>*#7XMK M&Z?T7GI5PSQM ^SP&0@Z_YS/2Q_[EX2A9LQ;A-O/\]W'U+HEM<* MV91N/E.K,5V^'32QZ=I63EK,C0B--SZ9.:'PL%FO/3\4[A]]0FA2J_#+FX?[ M(N?&S5#F+^U($$J%6_JDXKF&9:E2&6*D+4N.JOI2I%E4:52.9%1F_'J+@B3" MR*?-"FZ?'J(@AOD?[A^'\'X([9"*G,_S]XYK@YUF+[]$,9!W/T/B!LYD2=ZY M^&!JOV'=C!-,EUY 9N^7]F,"Y'K>.N0S+<2(U3&T1.G38RJ(%C9._]T?]FU1 MT :9K&B"U,QQQG&05Q68V2#'<$=.\DDD^>+]1^M5J&NSR_'QRQ8]7=*L;#5O MXT:8IYYI65W?@!?C1(>\_DL<54V9ES50)0W&^E!4VAB'C'MM@!OT+R3U&KV;BMKT9*F MYIZ"Q@W.EH,#"6AGLJ<.-I#&[<[VI.@QP.-P,Z58!64)Z_-L\U)N\AD9V4Z( MGRE-OMK8$8(.9%0BDRE"D(HY1>D%AV_^ ML[U:OXI^9]_NLZ0$NZ]$UY*V_HG$>)M08.U>:?[3K5'@PYG@]S0V3 R=*6IC%=5O>DU MG7Y2P2.T^\F9N:>L(6RS_FJ;@\G;>RCO.:@#+@PDJ% MU_;2=J>DA-3HI#](*>^)R^NR&_O0/Q([V/C4H_H/)US\[GH36-X/U*H^N.M- M&.Q7@."?&]\'2+VV V>7XU5EJKHD2F:A:J].R_GZB"V#5UF^"KS2BEV0Y!RO M1?E5O0A>TZB3<9I?00?PM9\3;W;F+@E"@'T(5O$<("W\0/"4&2AZ(U283808 MBLLBP*<"!+A/?PSB']QW,;A/=&<'6I0&8]/D,J0H]HZ<#1=#'U;M6+U&7[E4 M".40?SCB 'Z[."*QKB>C^.HLJ1+==J?>PZ;H.7N9KD=*C:Y'>OG6J]UEM 9. MN=-M+G8>[V\^+'-.?)_,$L'T#R[R%YEE\H\*_).1%=8G2=C$0=84AHJV[03, M:;WOVUD>>ZECK'7^T@=CHU#+F.NW6;[8SS0#^ 5M!WD3%DHY):D=._F(F?Q MPG#)4JXS"<_(G!_5EVS?"MAKR7U5$7WF8*RE*PDX^JJ*]C.C#[V,Z5X#I:R2 M%CNR=MAJ>>?.,J(CUV.ZM-"PM;LZ/G"YZ M%D]4Y$+QQ#)=00\R$/'/"+-W>+"_E-21&F/7<6>P[9=W[+-&SVMM)-?*;@&,7H'\G)(UI6QO+I#43%'\M-29*8OM#R<#&CXZ MG4Q8L02GH?"T<*8+"HNC<) HZ(YFXY;?>R5?6[--?Q7UF-C?@28#(((RJI9N M?)O,+G>"VB>U''(B6-Y XK/P9^&J*7K+28BMGEO%9. F#1F(Z M9KO/2\ F1TUL2@:P]] 3OOA>2 !_C\Y/%"^'4).;@5K.9.%S0$T5!V,CHUE2 M):C=3QQO16:C-&,(!17+3@31'@@1/@'^@]A!A>>008NEYW%GHF/NK@59@I0& M&-F^_XRA.'OE;?!8=".*<:G3F4(LBM()#PM"PC*"FK?]*%G;39MU&(W4+&,' MD=-UU.VGRQY&)B[ (WAT"/$Y^H-S^MTQD'&MJ MHA2J-C9&45^30IWI=DVU)G%KN8U/D%1>+[WI]\2IF6X2@A_BDPB])Z#VC-9S28"66M[#=$%FFR5MO#H)/[@!O(L&2+)6FM:W\&48S4POYFHJNR32ROZFRIG/V4[NZ#A@=R4R]U #&KN?O'S10 MNUS>?F,(>C>?,Q\KU0"_@LU*?_D31UJ'D5:REQ)'T!5R5=&V/JTTC&JY_6C) MELGN!N-&:=>JE72M?OCT/LO$VUE.'Z(<%<0&[4,^^T)\'/T-!O?6:XJABZU1 MI S&XDC7TGF+?V*N0V&V(=2_GO9\7F#\[5'PD4T:=OF]OI.@>V]/R3WU<6:Z MEU6LHTI#Z>-'X=W&]X2R>-U?6P9>WWL^[-Q]$V4EO?O).E\B8FGYX9(:M])V MK6)BK1BF'DFBE5YN"YD 12HIY!J5%$KI2HKVVY%U-[.Z9.#&.LTAOWGNXS?B MKY!3RA0EJWJMHN3J>)3+XU$4NHO->J>%6ORLV)[ER>,B!]][QXAQ'.'9FD\% M=J.($CN(IB(J#Y=-)653WNF]+YLR9) Y&)M*SJ#G\ZJ;V4Y8N8:#^112VBYQ MS#V8>RZ,]PFXKC#.$KH6U=W3[<>XQ"TO<=L+=G??R-POO6S>R-2P8^,HR\9D ME'I-AN;C9)V&7TZ%4AE#4Y, 5F*FH?G7UU_*VYER>W:FAC6/&,I))]C>MIW9 MD0#&F>MP\PJTJQJ+FM)>!RLY$QDWI65(%S+Y-+6BR5=+QZC";$W$ >HCMC,! M@'.+C9S#,<^.T[3!6,^;IGRFAIX],-5N5D[*+5MCF@YT.LKHM79!858I WA:%$>27<6Z8)P M[ =SY50:YS&7+G+FJLA<:LO,I4L=9JY>:QY:NYJ'+F, 0..*1UW9F-.L(%"^G:4TMWC-$QGNUPE9]Y3VS9=XSI [S7J_5EI:+G0P<]SFR=L&_H'6:N/BL>-26C953D(O8;-1?HFKI>AHN.LLQ M4!NBD]8Z=51T]H/W2N7QEN0]D_I+5(G[*BOP7MN9K:;48=[KM=K2A5C MEA2AM=U'I!A"Y+&$CLL:7IM_;9< M76'1-)$,O3FK:XW)]=+3IT6I$HN2WD-+IMY#BWONZW)1&_)3H6S43?G9#]XK M58%1EO=4QGL\FZ<"[[5=H&%I'>:]7NLN+1=H6+0925;"08;N8G'=Y;3\+%6E MD2$BL5JFGG)RK5VM>B##VZX4L;"KR4@Z-MF6-UGC3=: "DL5LV2(*(N+J-L5 M42T7U$BBV#T1Q=5,Q'R[!362* W&ZLC,R@^!)\.-&Y^KF85E>.5A+/EFNB12 M%YF44;+-S?1R7-2&_%0H&W6S@5,O>$\I5713N+>U))YHDLP9+X_QE$8+:]7JLM[=;JP/^A#9F5 MK91VQ>!41*Z[G)*?I;+H2\I/*7+%I(.S7'Z6XZ(VY"=UQ5AR)^5G/WBO5%YY M<5>,Q%TQ=1BOT33K$JX8B;MBNJO3[.6.*DUK-/I@K(SDDQI-K-#(G9X9FE6/ MJN0D1)>H1Y4D+-K+FADJO/O]:^EJ5.5T1G#U6E1),F^S])EKT=DG>;VQ"I)D M 5EGC-7B%6*\%K4Y>5;?9I!%>E!U,\NZ'Y*F]Z T4D&7M):>GZ(VZCEV.1%H2C(B*/R-VL#>L%PZO!>(T6+)2(X2D& MC^%UU:^BMES+H- \,3UW[HBB59@[LK_X.[-TXIV56"B60HW2RM7K:G,@F3[M9FO10\?"P-M8S3 M@">"\D30RL=K"T:D2D=[Z>DV>EU06/LAB"H7CQ411!HM?-?2Q8%<$/&9)94U MKS8$D=YA0=1KR[EJ+4(ANUDUL!!!*>;LUX6KJYE3&ZR94\W!V,RJF:M6-)># MV#JFE'6;ACLWI;(UF)I%E:E";4+*DH_)$U+ M17/:B>HK'G#+9;Q+%+9=0:=9@K!4<5(C&(M<^3@G(FF54NC@86U8M *_-J3ZZP7BO M5N9 7WFO[:D^NMEAWNNUWM)R)9Q.W6-FB6Z6)E=@3@O14J4J:3EIB(.Q;ITU MOXH;H&<3Y&U7B!C2$7[F/C+N(]M28:DBE@P1)7,1=;LBJNW:$4/IGHCBNB9B M7FM7US2HCTS-:+J0$8KE:F:.#*^9QF]H&.=0N#%>DTW:$)#4$:;R$9&78ZY2 MF>L9S&5PYJK(7(UFIV24E*R9 MBVZ*8 BHZ:I3;D9>$V448N<6!+E)Y]'KZ4.6>[JXIVM+A34S^DV9BZC;%5%M M%QV82O=$%-=C*_ MJ5,6Z6;&22^82Z^9*6]BM:/*2XG+,Y?>=AJZ:7:8N?JL>.@MIZ&;U,F5EAD2?96-;:>96]1O9':S1*MW#,6,:4,2X;RW%(&[)1 MIRS2SO%8]6&]);%FWK5:@AO7HP??8* M^M'K=?O1[X9[R2+.9\L:[56A&7T.4JLWHY=%B3>C[].)7"J+O5S%N2SBC+BA MJ/"Y7KQ7?3WMI>6,?UE46'OD3FHO_1!$[?2J!ZV#]ZJOP7@7ZE4OBQKO5=]9 MBZ+=0@%9I.571CIK[\"5R5O5YXC44N4!974[VDW(,G@GK[H,U(8Z0VNLC&ZF MG_2#]TKEO9?E/8OQ'H_ 5N"]EG/.94GL,._U6FUI-^=9J\^*A]%NSKDLL;EE&:.N#S0/WM(I1SC62SJ7)6,P-E0^?JPN MB[0A'-GXL6ZFI_2#N>HEGPP<_5:\V@WZ5R6)2QS ME'.SSC5>9Y\C'.MEG%\D@W*W+ZP5SULLYE&7T>,L\Z MK\!<+6>=R[+68>:BFL>+T)XLR?;@@V4BC!QW8T+/0F\Y28\?LM^GJ2>E2=)=[%[A3\C_AW M8&FO _(R_N75S G62_OYI>-2VJ$WO=I_>D:N(P4\^WJWQ)'(EAEI;M&;HZ]' M\-6+].=8>"]G?B..I,S/CSW)DD>6:IY\5+-ZYV6>.)$TK)?R.?ZZI:B-BU!S)1C-KDD>&H?,UG75-II']394UG?,L MO3(?3;M#/V19QVDOF7-Q4Q5ZFLK]-*=-R7I#/V29MFSC3NRZ;-*&*6E2/NEF M^+P?S-52"9!L\1*@&HQWJ1(@1>0E0)U56EHN 5)H8$G-#2SI/+"4(U/;K %2 M6'UW1MDL%ZOE.*@%?4:A<:>,]L!=D)W]X+TV:X 4E?)>1I4DY[UDMYU99/H<+XM>E]=N5/36+:!0=\_SYV)V;%'^-EOF4L>B,3EITUTJI M-RN\S)I%2HHY&.NUYF)<*TGTID) MB--7W5/XLI-4'C:3T OM90$VSM]LCC98"5IGYZCL7(\RHE8J)6E+FJ@JE@7( M0S6C,*T1'%YC9\ LE%7N#*@6[PQ8#)K=."A*DG7V02&U76ZKTG8/RO&TX OK M!&79*'TNG5OCR<;[G[BL:$)62,4[X?;F\"M5[EOV\,,9.<90R0AA<8+FAU_+ MAU_;Y=0J#2Y9QP-__/#CAU]W9$7FX7"G@5FCWES>:_4_7A/A-+$5CI1+ABMI+ *(CM-L!2'"2 MZ!9)E!-G)=2X.N+,&(QE;6B:7)QQVNT0)$ZUBRG:IP#_C)YWA_3T4E)':@Q= MQYT!O[R\8Y\UJEIJ([F /S()>N^96;!9:;Q*4UDBV$&S_H!>0F6## MBNU'(I#85R[X=DA&J=FF/<:7 CAKZGM M^\]PG?##7FZ(X,%.Z.=SV_'CS^;4$R$\V8%03JO<4RK-6*G\P_WCY3NZB,_S M-]'K_Q??]!E>_A[>R_Z8[Z46)X8XJR8&/M,Q?6'B+)>X)MN=E5RHG+_2W<)@ ME?O+/KY2BPYR/K'2D *;P((!RG,''R$\$]NGHI!NY.!#92CX)%BS4V_Y?,!K MZ=YVY1L^G2EP1A6]]WM4AJ#8]WY1FB-!")C!8W\3(*7"JK^34%C[#F!F*#PM MG.E">"(^$+/G^Q[H?/3BR;/PKXU'?_.][T#6[ 8*U "XU)D#Q[JAX&$1D^!- M8 <_:).NSL "0V5/*XZ$G!)M)$,(V024'Y7?C M(P20U#;N+$#R<['IH;<)A(GM?@^$)\]?SIZ<&1D)'USA[QN74$H<4MS$;P@( M&("HA0DN>1(47;V;V<_"&_C("87W]M19.N$SOJ44$^Y7:EHI$Q0V#?*"OB1^ MQT?[I[/:K%XCVI^ --[8:_@F?,[B10U'OQ]GQ9B.R,^U@\UX/)<=:@P$&CW9 M- 0*2]00I@O .< -C6)7Q_ _F:1_)PR:""J!/O1)P33/ 0'X1RPVXA#"0\O M1M-:>/C\_JL L" X+YX(F HB>'Y$GO9ZO01R1?*,R!^)/&!K1(0OE]X3YE>S?<"%SF>B%[+S(EVGI7 MQBI [H\+;Q,F16NP$[A,R";I/9*H %Y@J 78'@G^6CK_VC@SI/>0/9AA'V!) M_"DRW=I>QPH2P]Q(>%AX?LB$7()V\-WTWOT\ D3A@5"T5][&#=ER ).^]Y/* MQ^5SR5-/S#[UDBE*VYA=!D-)@['>[#%\1&$HNB"9ML"O<-JFL+]WQ K?LK%R MY+AJ% >QX^W-EJ"^(#V=@H*".D=Z+&5[:*FP1LS/.(4IQSV%D>&65WRRLATJ MIT"R'C(=O6KI(9*W;(9:@8,RW*7ZD;UDG(FG)'"Q[3OD^@[^F#0I!4[LI8W' MATUE?[:)#1"8+C1$Y_;U'2%VTO7O.6G<\;>J7OVSF1.9V8"IZ;C5M5T]<*? M*.5F[ ( N?$CW6I?\/]EKX5U:O'RZ?13Q-D>IH :IR]G&Q_4P5E W,2:C<$X M?/*$%;Q@$1QVSMX7E;GT&#L,*M.C<@9Z/&)L7IP>\VFCHWEZ MS$F'+DZ/NGB2'O=%^:DU22GBF2[(;+,$F^,CVR4<#9_GR4#8-]2?48*_AD/F M>V)-\"P"\%W#TV!#I%+;Y7,>(O>/H. _(B&NMEO-4#N]R=)YI,=F=-:Z4SQ1 MV5FMH6GPLL[1>14MGB5MI.GEFONVW^)94D>F7*[I/E\47U3^HDX3>F;2GM6A MY/U#/WEVUMTO;U&V@ T(@NPC.\^#7YO/WN_A997:(9")9)RAS+$Q\L&SKW*% MT,%F*W5$N$* Z1Q@Y0!F<("5 YC) 58.8!8'6 F W>/X'2$%MN;*&,X/FUKE M'W*K"?0[ _PK6=O/-!+U>?[%=\ 7=O+#^XG>.ZW)[+\03Y2/T#IQ%1=KE$P MV A:FZN^N$;2N1CE_!^Q_6]/7GF"P2C+T+(XP?218!8^(>5)1H6#=JB8Z; 7 M)YF;)YGWWL8O3S'8PGHH&YQB^D@QSH\*,D:GI=*JRBFF3Q1#S9'J1(-56?)0 M4W-FB!R9I9RH_)0/$ M7X(6(]A0Z!93!0[\%NT-0R7>FOB;X.H M;N $(<9:;S]RJI>/ M2\?!9 4\9#[F670AL] M>D:[QTC;Q)5MX/T^>AC%ZO;%#XYSAVQ.VZL1W[TG0#CV,F4FE#9+#9%ZOZI- M+NB(L#^S1T$^,X9P0NS0$"OY)_N)(>7,&)*9![F2/["D_#Z\O ]7W<*1]B%9 M#G5#9UL+1YOGPPO]F RU"+^/??(LM8GPR*^G6K-_ZFS^E!UK$C3DX M?ZFE.6";,/@M7:S..#!RTS0F""W4:#4E+0A;*$>\%92EE(GSXLS$^;I#54W; MB1QGQ?6+,^-,8KG[U7#&O:*]. >Y5S37DMZR)W/I'&7/# [$3FW:\;'-7&36 M/N;*XT09C'6IY[I'DV9R#52H8!%G]"KMNSU\RN\YBZ#=G%'<72IMU*C!'MYO/)%W?:2J502-&>U_F^% /+.CG-3 /68BUJU MHX930 L&U[DIP$ #3#//8H"==VK495S"7T[5G_1\H%3C>8Z-N2%,F@0B7W(6 M6H]G?C8>MVR,+BS:BT2I9!YSNC@_7>38@4W1A47SH2VSN3AINI9WOW;WL* T M494804O%BL'T9*1MH>"?]LLW(X(1=[?8$R"-37C\EELI?[3DD:4:C93UJ2-3 M.UUJV%+!7@(MARQ[@<);VLG^W@5J70I?"T#7MK+)_LY0/))LA]P1_12'>OB:[ I6^K$?W%0 MF;ZM3S]6&BYGEX8K@\I5[>_BL9%;V8Q-T;\2> .%J(K.%;6;EU==V^ RVIM M^T[ &M4[VYX!..P(3Z1X, K&_J-Y&*$=;D+/?Z[:GWY?64J-'RB"@/NX#.(A M7LS>Q8.L%O:6?.+L/K+2RRP4,\"S-/]4ZWW'34^JB<8F1--1Y"$. DH,+/KS M?YBR9+P*$N-1$=L4E4Z HQCF'LZ+"HIV'4C/VKR68Y=W'>A@UP'>3^!J*LQY M/X$^;7N_G\ -=0HXGNM8=M3\_V/OVYO41I)]OXJ"L M]\S8OK9G-^Y?&VHH0#-"8O3H=L^GOYE5$@@D0!*2$%"Q$;-N$*6J_&5E96;E MXU(KD_UG*Y&03-'YQ0_#]X&_?..G58XVEP,_D9D?;+0G$KZ%?X1 BT(7!UY\ M:_DR9!4OABZS.'7?K@4;P;BJCXO>#HO*R;?#M\H"S3LN.P*>7@KKXA&G]]5% M%O9 7>Q53&$-GDOBJZJS'-Y"&T-)Y9EAS5Z!=8.>2=$3>5[?.>5];?3PCE,= M&EK^H*]I@EQ [$8Q@N_LP*/]OQ\H<7>C-QK,\NLO%SQJ[V8NR@(8M-7?ZB0.]O!VX_V*OW,&_YV:O MS%;9DC)>MO:@/QMHH;]?F+O&X&&Z1"78/XLZYP, N6?D@ M1\X%77+![FG<.1>8* M*I'IV$)(H<@EMY,@= M%-N6 F:CEQ%';T ]Q]N%$.J*7M *_A'7Z M.CR%;@+Y9AP#I^.=O5N9.=_)].XO$OC%?" -QC0]1G[-'04G%HAE00I9M\%V MP8G+<1G(W&5PQ&50=I-^0<*3Z3<_C02%ISYY6\XE]NOBW8GMBD;Y&% NI2_P M?#Z1%93!6!R5B /GK' ^YT%'K*"BZMZ='^EJ[$R\!R=':M=>'A-W?@F.EU#D MWIO^XD\R1:A)6,RL&C)K/BB9VYF7=P]=#7B=.QCZ ?SI]\_5@#>*-96+,R?/ M$=KWP(IA45LR7-@!N4.S;$I+EA OI&AFV>=^_,KW]JY\[UU7\*,%":Y(C^G,<[_,0& Q=Q2*T1$KZ42YFJLNIK8O0:?%Z4 M25K,W7C1H5659Q7Y[Y(SJ\HN]8@0OE7>K7,JEV=>O/BH?/-Q,O/6.JPY'W5^ MV)?G(YT*P;SWX*Q\5%!6O4*UY/3U=RAJ7TGJ2$WYP/&FH.R\NF.?-7KP:R.Y M1'WP?3%3\L@LF675W(QWZY06SS=+2FLD6TBV?=EK0D!F+G CK8[M+%? 2B%6 M,\\\X7C"[W'@A%-GPCYXA-A\)7&.@O$K _L%3W3\2=._%R*#PMG,F"5N(69O:C']!"VFQV> ^" M Q=4[K9#@15R)U,VQW0"F\FR+8)/CX22I;WU6V!6N1?,:H[$A%DG;CP%AD( M/1*MH9_13W[^\,NW#PC[D/Z9)-W^)>S_/Y-@ M INN^*@T!F.U(,WRARU9D?0&V%FS4K#FD8#$604P=Q!\4^2W(&1L";PS :$W M!Q8)@.-@K#A$VCP0UW\:U9,UY\'_@Y>#?TC7G31/$!;V5%AB);9D[\ !L8#? M$]I8;^>LR!)YE\##A)(P?1QCO=F>8"B2;=< 6VV"ZLL4S@,@4J%5D9)J3Y??GH/'86 M/;"Z^"D!LC2"-=*]ATP6AZ>M5^]PO=9@;.R-\SFZ7F +V T+UJAQ@7O/G0CP M_HBP1@*436"MP TT"B4<"3_A\XPQ4#P#\VP8)@*9G]G):VF>MFW9IJHL_2"\ MP#?/XH >$X['5H]3#@D1/OKP,\G:]!/QJ!I-#X+WCF>#G(+ET(E1)]W+NGK& M>?;^/9S&3$?<[,F\,-BC?SV!4(V]5&%[3DYME('/@DOF3L@TDD1.ANS,?4)U MT?& GFQ$BOMG!_M&"-^>?)Q$B$(F.?L3B?!?X?K8W=%-J>9H4Q:@BBV\'H;8 MJ_XFVF2)OC#!UBDT$N[=T-_I/9,A3RJYYL3#=]%9P'F%/ $/4RXLT!O6.D7D MI\(U]&,XWZ94<\% 5=!?XBATIB2_$>@S3KB]\N/9*"?0 (Z*_))GL U<8#DX M)&(W$+9%=G3U!"IL6?9(O)@(7TGPZ$R(\.+# MEZ\OZ1HGH,?:L+9M36Z+$=A)#0,*V/?,88V=\!W9]Z*DH*8)97=_-@M!UP1F MQ>?62,#:[8W3?;TIJG ?3F,GI96N8Q]7#N'GX8H1WWT>'@>H")Q+$CL%*F>1 M^H5'6$V5LZ&4C2K*IT(S*O/E"^[90*4JW [SD#CZ,@P WV,9PQ@$< M++U8(*X4U+:\W'1@E^(AN'GVHMCIP];!-?/Q+!?^C&&GDXR6D:4EVYG3$E+( MCD%0IUVDUQW') 5^&OCQ?(%_Z(D@@%T,$I#)@ )/1D+KF@WDL$EX5W:4(A4G M!_^ 8A9.G(U@HTK /IFZS;GT%*BJQQJ']=C->G=:%7Y_PT[82O6X,TJM(F/D MQ#Z?:ZK4IO() "BGJ)\ST6&Q96;E< 98QF+.[",WP8M&?^G$IJ9D0 M0C;*ZN"4\(@(U5N6]I32/QUNF_)A_ *IP.&.@D+)5OB^'"*H<%7/=BA$V;? M8(<@%\)D'#IGW#V@( :)SA60NR5LI9CIS(D^E_,% MOL+)V=<[AP?#B)GJ^U MB5#(JBAD\R+FAWW-*VW6VC?/^D-ZGH-BBM;"+-%7 ML9_EFD+U^UKN.+]%ZEC>=G[3S[IM]TMW#1)&UE\W[\DNLVFWZ6*,3 5I<(+/ M1MI3QA\9\&VR4X"K[NE&@G_\A%LL9;Q/LS=LH[&OW\;DF_^%^,'<]IR_"HI" ME#D!M4-9/.D)B.RVR5I!:>UBBM#VWDXV/[ UTP02@RNSWU.VW?B8UU)DR)RM MZ1N*3Y@6['U4=)*U)J]&56>CX)P"]6&EILQY_;,#8O1^Z<=>R5+J661U1/:8 M@Q(0H_8$^)KUN2HWX<:9;3>PIU M\F_V[?:6E&#UM?A:TE;?D7G.2X@,R 5A-]G_+H(-[G-R]P"'Z1]W]@SDXBO; M?;*?0UQ,5I( 09(7ZZ# G")QV%0?@A_'.].F_]V1F^N^5[IYI[#C$;XBT_MH M_;%Z: :7HJCG;9/7 MWG(9[565CVH_W''"ME8V3,'&"SITDH#A2V]RCP8K/ *A=QWQ=8(4O-/NZJWN M[NH5L\Q=?1)SD6'ZHY?RN8OW[)U[95>,U80_F6T)2ZRN*\S*J!@!FS[VA[L44TN71[)5S=;:_[FFJHU8;<9(5I2& MYJ186N_F9%G%[SCGG)K$3F_"X"[9<;CP,:N,F8L.>!*7WJ/<_N7*]9_)QL+U M']S$Q-Y?%_:*^*?K_O3BX3;31;?;Z6>)HR-;90OLWI^2(HDID.G?:SL_TSA: MQ5@VX]26XNT"W9R/5H3QR6J(F8WBC(8&U*^MDOSN#7[V)5P06M"LB(7J!C.4$M M6[(* #T[375:!1CT%CT/A95K>Q'U?I,_8V>%5Q!\1S5?=_8TP9JYN/F<(/<9 M<8-M]"Y%K7"W:(.QJ91H L,A;@?B\E*S-L3Z8&R)QUI%7X,,^]GWIT\.%M? M/-9U,$@9$YSS\KG$50H:L/$F?H=I"+M_EXM.R+*^ :;Z4-9+=#;B/-$C^=8J M3YB#L324M5L0B%]H'.M;86*OG"C)J4\R3[DQ6TV(%6;-;&6)?"$AL8/) ICV M+7DDKD]/Y#<;TE=G56LP5H>*E>_]P*77.4W:<_""AL4 AIJ5K_[)#=O#,A"@ M"!Y)DGI%!>(ZI\AI0S>\$MX_W:F74AXVP?UD$L0P4G6VEU $JFH^JY6+P OQ MZC7"!C)*/U/B;KV*6'_P'N'@\6G: +V:YO*N(7FWIFPAORIX1YPW.[G0ZJ70 M.HPEEE70\F68N.0Y"%A2A-R;"ZX?AMNQ]EP(-22$UD3^!6C\)DOBZD>L-AC+ M0YD;FYM8U[[*X>M->]ELV!9")8I M\BW6\CU9HZCIV%-XJ!=XF-N\&#O;NOILB.G MUJDEAVM]5&=["=E>,_,&/H\1.*_LZXH!9#1^C *%L$VYMZ[WU;7<^]4))\1U M;8_X<;A=Z>663N=VW3)8YZ,Z(RHT,D6JE5K$!=$9/# ,Y@(D58RJ[=3]?PTN MXVW1A%62BCM2'E5I6SGP,_K.$=0;>Q/C3E4Q-Q;QG7#KS.U8'%"H9#R3CF]N+ MGDO-KKEAT0F-,6.U(C M*2?GDY*XF1(V"<27=0X4EUT[8'32+F;^3'@\Z:@XE7KE(&\!H\XW?C% K9XT M'TG)EDW9C8YW#=I0,FN%>W*N:(0K^F@.&VH#YC!GC [%154UH9:X0/>_/-2- M?*<'SA7]%!<=&>-Z!6-\I\W45M^*WG>1V&JW&M\,"]5+MNRDWU#:VF8./PZCPG:>6)DBGRO$UFH'A"Z\F!H^ MO 7>P5+K-YU^_0,I2*P.!EWJ,?2F/GT+70UMS 23=[!7S=:( KS,\:<,@@B288R0=FM!8?/(FH.N>PL5\B)2/ND*AX-M.KJ6;=]RN5TQ#7VD MRE8S;3%'AMZWQB$XI\,C]3YBN9OV#[VO'H^=3"XGUJ?1WB6W52__)SP>/2J' M9[3%5E.UK/N@O#=1X/XUJ>5L*W $)K,#8*/#=7 M5]?N<^ _.F&UDNS7P3D'XO;R/))CHS7=BKC'% =C5;OMG+VF^A:?C 7V&-%N M8"?_1IT.5=LK7 D#G<0_&_!F#&D1=L<*/P@OT ME?K)WS^Z#GPY97[:/GBZ3F(YI5O]X#Y#V+<9HA8RG#X8%USAW8@LJ [,:9I_ M)60P[40ZSIP>M/JOL3K#15HMYUF ]Y&T]P7VLSC2?K))&=P29M6 M*9=TB=@2_#NY_;79 )E[WH0H*M[!IL+X%;U/=A[)YNKUA^W[\H0OQ,U/[ ?@ M@#C:_Y-KN5"VY)&E&HU89(![SY%.X]X$Y7^$)6 M?A!M1R74TWE[28"<+*($T*V"!1=M[,Q_%\&&!G-R]Q 0^X\[>Q:1X)7M/MG/ M(;)/=OO![DA>JBLPJQ.V*9OJ0_#C>&?::0Q/5MBD\DS6S3MU4#7$9[(@T]@E MGV:_>1A%-?.<>$02CTBZY&4KM[ELF0=B\4"L\E;O'IVLLJ5K25B# M4C5K%>#GP5>-!E\UABGM6674ZUG%,:WFD5<[PE2A#85/=,A?Q-'PP9N 01V" MN96QL-A]?42/"FIAK2\O>J#U]2)ZYPC'K:GZA82QB[E)[P-_R>Z%H\\T@PB> M_GSH2LA2!V/)Z*(3WI4 54_>-X$4WN,K770.NQ*DE+,AI0_&FGRDN.G52O45 MD"A(\Q>Y5&^* S\C64OR'U[SRUQ2G$6F5\')!(G>23/B*\&I28E>!2>\.59O M0)Z_);8O'*F3A?KI M2&%Q0O58,D<%;*: M+5C0Z((+A$Y$=RW(L-^.F7?*&U(,.*3[$(\N,!')\H$$K'6K; T%FMP4 M;=5/G@KV:A7XWX%D$9;R/47.FZ5Q2Z"Q,M!@[^]17I +#RR:'1>T-ZMDNW8S MS!%5IE!XB$,@31@*-ISE,\?%A!7X54"B./!HJ+R'>&()X E6 *:%AO'9)+C* M906F:6'D>(K9*_ 3(-8\P$&?P, 6;!P":(S38\^M;>V1@"8XO"UF2>!.D&";K;'ZZ_AD\;F1^*XO;Y 2: M,UK,'(_5=1:6J(?>L= S+* Q P*L8%]@^+(-U&$>"$8ANL(O7QE=DY+5/K8P MQ5G0TC-;!:R1Q/B3F8,\ L_$ 0SR9VP'$:,R\O!.I>9^;\8/Z7J7]N] ]^W5 M/L$79&M+YKB7,4F*L!T!($M*Q!6AA:TS[#GWA0=[\D?*:Q0@0%?94]NCH'A!&B)Z(^TB$)5!A 5-^QI]2+MCL M T24CKJU\NTIV1X<5LX*]P1LJ!SOH;=N=ZQZ90N&-5V+%2/H) 2#;KL.*DZT9,59RU-AA;^3BV M=-(4]FKSKAM!5''>.G:+S6OH0D8T)LI!JK[(*E5M%;HF3!T;IEJ7\PB' ^/$ MB'9F8ZT>J"B:3((XNX&>@(V[\'(4$N2>S:;Z:6( ;QKY,+CMTZ0ZU@WNK/72 M"F:/07QZ?O8'L4Y15H9LD5M0[Q0!*"PV@F]WU ?U82K/9C-;E%2#&):D$LE4 M)5N;R)(EJ_^6L/)KQ?-$4NL<*&]96OJ>,T522IG;UHA1HUI- Q3/L!$I<;XP MR?_&#Z/P9Z8$Y"L8J)(U2//WR?0^2C_$H;<+&[P#A=%_)F1]HO@/KC-/[]IV MJ\)D4=M3M(&]I631!BP ELX@6=BGS?OWE&=0Y4LKSW ?,7V/^:J3K;+>))N_ ME:% #N"QZ0KD>XG:YU%_$WWP)]O%HD'"UP7!YD!/L,5K%FLPL*X/\US=H:?_ ME62FOBOLY>-%K^[PDTLIZ&!H(]W4>ECR@)=AN- R#%>4O\^K-=Q"V8+/H#W@ M&9V:ACRANOG*!\>+0L(+IHD.G@#R&8[L)._NWIM^]+W$I7U"ATE5IJ41+/V4 M2I&WC'K#11X[ IW63CB:$7<- 8*?P?()2.0$U/=81:3UY!SKF$6/R*5/Z.?= MIND.UP*[9EBSB'.KLRLV;AA:]2)";A/&(Y+F/#"J%$;]!O(&D;3,-N=2IP&I MLTW.U#&9\N=S,]RI447H6.T9CEII(=,):CJBILGYBYRKDREI"7!Z;9_Z=SEO MGE9T/^LK/\*9!)B8E:]R?AHDY&!\S9LL[<"XVT/T;O1A=7P]L M7=-4,>M/#X:]A]N1-]LHJS2UG5%)Z*B'CJY@WH M+;]@7&U:V7 =;;2RG_%BCY^5-2TBYAR$X["4*9\:\%M.PP*NE 9CS9*Y1M.4 M!=0.2C(F:3:BXUQWLM^!X @65Y-TZA6 BG>)A.*Y1!>9?%AUIV6VV G>!T7! M4UP^UDF I\V&.M#L:#;\PEAV=5NBMM8%5;P&%H%RN!Z59C/L!V[NQ6A M/:09!8XW<>,I#)^$_[E308KACEB9\"&VE9ANT*SPT# MI3.=NDD8;Z>M].AY8XA=] YLQ',G$ R:L4(&LES/!WE0T ;GWR0W9_,%PA5(C"(5'.W P83\3J)4D,-(X M5$JJ8:)*8-+IE*D_*2V'ZP^0)H'S$$>IUH6IDHZ7D,^;DJ6'32V3 9\6SF0! MO\'DYZ6/*8N)9AH*3W[@3F%O[60\@CJVSI.E2=;174%PV1#SYK&;)M8:(" L M%Q-0A8:8?FF[KD! XM'<[-]&7T=INA,.,LU,@$X>*!? VH .F$>QJQ#U&^A? M:88QJX* Y,]<1R6YIDAW!/%9F.,_/:3A7<(3\#FMR6 OUZ2 'X3KB@L[*@O**P\$:RT(_[!!/ 3/ M@H3IDI)&2;MAOP<[W"0 I2-0MY?Q.MR*)!"F<4#;P<*#K@V4/BA496QZF[\2 MR5[=LM3Z+<,#J#1Y!>^!W34-B9<1J.9@/ --G64$[DK%=*D[XH&FS*\+=;!< M0JP$F1;:P._?8WD+X1[8"TY7X;/]3*<3N_;+$:5Z.5*S[&8@K\J,&M!;)C&S M7;&>PURPA:DSFQ%ZQ9&\8$/ZM;V[16Y6TQ9/_FW4Y\D91/H9.F/-SGT2?[Q M9MR]#$@9+06\:"_+^F550/BP)>O#^"%TIHY-R^\L;("4'KH)9=C).X,_V%D M9QQ:X$ Y5EXFB,.(@@D<$K/J"52NQ<%D0;<5&V8>^/&*'?KV)"DL$1 D:OH# M=E1/+VK+9!6.-;IRVI$B.#I'6R!$4:;I[=_33OLF)46Q(;57^VX;'H M"6Y6E#\;E0V'VU9O=HZG G5_E-/OZW2J_TA2*X6F=>_+>U:L"\M[AG4E756 M&BG=4.D+UV6Q$HC7"LR.(9"%@+'X'B#6OLN=&A.INY+M"]]U_2<\WO'@]CU4 MP6OF2%^28] 825*U#.'VY(Z=TCV%6,YU2QN^M0 MD6JE*W-H*T*K-KTML;Z\<6KR)\>N#'9:T]BIQ?60.7;-8ZV;S/BLH2VG=*UW;&/A_*$J\IS<%G7BTQ R*$)*K0P"#3MD2K4TS1N%H+*^ M>!0""=-2CD!P)0KCN[0A&>N]*"29&DF"YRTQ7:66X354R)327RBA/WF;A-_* MZHHFTX*)>MZFN:"6!ITC5EFE;!(Q]/T4]K?EB#6H8C:)F$H1TSABK6JDAQ K M $4;C/,V&@>D0?VT(B Z!Z1E;;4B(,9@G#>A7UZCZGJ_]&$B?ZV;Z*X")Y.- M11--.1^6UU\Q_1;^5:)*38;NGV:?D>H9#_R;@$R=8K/*!+/*S)M57%I4T%G; M1\GB*)VLI[:.DBYRE$[63=M'"?MR<8Q.45?;QTCF&)VHP;:/D3(8Y\MS5E)J MTX1,&(#LQXH_=6E/78DM\V7=M%T [HYMW-."ZX.9%PHOYK9S4LSX[9OYMIVN5<#1 - K/QM-=\JK5LJQY#1!V-=XUW8NC=. MC@%C8-L!CDOG!LDQ7$RP0C@NW1LAQW!!;YA\)'#S2G30-W$0V8Z+)1A8S9V0 M1)%+2S+P0) & T$VNOY'$B'_(?N]C-(N'5,2F;.=S*]^XL$?B&""I:$IWVB M;AK'MH-'FMMRZG&/[Y5CU7)82?M[3BNYYWK5Y>YLVO?>PIG"BPF]&"G#_+P= M63-=[3J+I0'4/R>@9\K!%FXG'93] DN4LT5G;-%9[$X%KC &8]VH%Z/,N>(< M7%'?GJG %29P!1<5%]+0LH;!5($5+'3XU[J)X:QP!E:H;'*59P53'(S58\WJ M.2OTAA4JFW056 %[Q"M'W) 7WZL6>W!LI0.L6P!@NH"WU^!R0F&%'4B\B+4\ MQ3X"(=!>P%<(3D26Q9U/OT;P?\MD^'=VX $WAL+3@@0DZ5]0W$6(M4>P:7.D ME1_ 4-D^:8@A2V_PI_$$'H07P@-?8()V,%G0FYHI>22NOZ+O)M]Q9#(4OA(7 M)CP?"@#$'R2B+8[@67NZ=#PGC +:5C5]G+9IF0IHA9)TYK/ 7PI3)UPWJ1-\ M(!CK\3ND](-I1?9W$@K.;-T(.&GN%9*5':QS,_Z7>(\Q&0GWKIN08M..X3 8 MK -,BH8-T-@!?3&KE?T"".4ORCU\ 1[ MZ<=>TKMB@HO;-I8!@GSX#^2R^HJ]9L7;*+>:(P;I6H2 M]99V"]DT:]GJ)$@I;;.K7"3D8]*JR4Z:- 5D"2,BS[/..&M!0%N#V0 5#C,2 MWL.?;$#*")Z/\7=T7VR:4<&XS\?>YSHSMIU-GEG'07LG0VGO(MF6V"QU MN\^)@SU26!-$UFHO[5>V]SQA'=4.M]F6L[W?X-S 4OBPDD^S-WX0.%,_^#3[ M.2# @O"/7ZD$H3VU/LUVDL_NY,RY@C67S!Y@(&Y-R."QXSD9._V022GBD M3;O@L[2]=$+CR21>)JW:5EN-/M>B8M-]'"A/^['%W@:M'-UA9^)V9]W%6%O" M9'XUV>JB-M[G7*)<^.-6Z[PV]AV>8%A8 L6W,W%@R2A%6>NUR%F2% E6?2+M MU#82\I--YUI^]Y2:;_H*D+>S>-VESG&QUR@^67,!O/]Y>VV.:-=RHY'&+=A* M7>FP_WFV3W@ZQ*[!<@;10)NLW7O G2YHF*C'=-$H_2P$*&X<;DC5FX;WMOWW M@=[3[K:&)LP/B<^IW;FQ-O.\;9SO.W%0.B9+K4%(4^A#X5#&7I?BB>B>B7BV1 MU+WM?'YCNQ.\, ;:% =%O4W0_ )@%M]DJX.Q.E+RQ478%>,N ]1B? J8V#3[ MGX[6#YR]6V9O^>SLK2%[F_D4NU;9^Q!<94XFSFF5.4TY.Z=AWM)(S:>H<$Z[ M+DY3S\YI6-MH5-"]BG/:=7&:=G9.,Y'3U'R@(^>TZ^(T_>RBGH,IL*'!2,J7:.!, MT1-K\AQ,H5*K,I^5S9FB)X;?.9A"P^-#SW<=:)4IKL3"0ZIB6I[C30)BAP3S M/K;[#YD&!6O"OTP5@9&4TK5=SFNQ1^;/L" MM2H_&I0?\T6"^='=$\OO?*QAHGM*Y*I^#UBC[2O*JJQA(6L4U/3DK-$3*_!< MK*&)(F>-OK!&VY> 55E#HJS1L:YQ)1;A.UJAB6 A(&]^AS65Z'T?&HD!B>+ M$Y)"-TD)(JZ*G]TT3"'[!1#[!H!]H3A]\O:7H=)$>3 VFK^(X>;AI?!DV^9A M'9Y4*$]R$[$'[-&VB5B'/=161%;S['&ACR7Z2_I]PC\*JZW3XWGSQ[I@B\M1 M:XM3>]/$UD_K,IC-=TKBC_7JL=M(P7S+LRX[U(N,QO2BY*&-/#IVT:V)6ITP M3IYPR3F[#&>;Y^1L'3E;,WL5P\^9K'DFL\[)9"SYK:)[@3/9A3&9(HKG9#*: M]Z95#$;C3'9Q3-:<3[\&DUDT-II+LFMGLN:<]-693!)IK'7%^_7SYE4>:X]V M*39]@M^*.N +SG[-Z_QP 55E=1E;7 MZZ7TUV?U4Q0__8?IBP9K\/M6DVL)>EV@US@ MDM !N@+EL&US@.U]GAWB3O&O1_C)NH$;/K& UPE_QC:V^AQF(L-GSG?:Q1D; M3,/_A5$0TV;/K+DO_#YVZ>\+ID,G$$;XWG6#Z6F\Z=],0\Q=QZ;]11V2#)FL M\[]"84FBA3\%\LZ?T3V2KL[)]"G%=K;.5@FK&%O;KM\2KF!?S)P)_,-?3PT7 M!Y.QM\B1MIBF_5+_:STM(*,=+H29ZS^%%]7?]MLB;<4,\+&%[XGOS[;GV_!$ MTCL\Q0*?#,.TR?.8/M[(?"W/4?;-=- M&T-OAMQN[LPZ.Z\"_W.'X?;W[FN/V'=R?%GK$?S M2-CFA)K-(O].;#=:O(&M@O&RWV"#3E'15+:IH%Q.%TE#&^FFUK,.>];( MT _W!S[/G Z/U/OPUG*=:_Z^V2,-=VP[0('>->\ITQ[J"I>]W>3INGH6%1M! M?]][)*Q/#3P8/'B/\$SLH-561H7WU(=I>T4&IE35E[9'L;EGN'V$D=\[:#S^ M/\"MV(PT!V-KI%2L E:%[Z_@&HSS<54^KNJ=.YV/K<%84D96_2+I5\+(O=?! M*D1M1+[PM' FS)^Q>S8YX?IX@N> VW 0X04Z29;TQ_CH2YZ]W/21\UM"X#U; M5BK-Q3X4\E?D#LR8(P?]:V MF*^8K\>OO[9V<4EW:GZ7(CQ[=N@7AE6ZC]>?9W8K5BH757/W@HC?FEXVV\AM M\XW20[XI<>]9\^KB(XG>Q]Z43+]&=A3OO;&057;F.EY,IO=1^B&.?/$7&5C% M!%U0T4)P//C_);MQ#(AK1TS[QQ/A(2E*X*]OU-?733/;"81'VXW)^C*4U=L2 M[$B84<.2>K;N\"A!UR?])3H#J>_+WJOH%WNOHBLCJ7?W*L9(-*N-Q.?4ISD93=P_G5(BPRKC29D0#)3H MS:W&EXWL:>0^ZQ)I\(F*XK1P39X,O7>;E5OFB[;]9W_5T@PA3,19R)^M[[?G"E>])N%[_3*BY=W4S^Z2P9=7[;H&7^3-A@KTM!0 M\]59;@FH:CA99\!)AY/7&BH%@1$4([$- ;1H!"=06P^ (E$9 :QH!#,\H: 1\C>?*V>Q MQ@ZZ;.OIRJJ6H@S&TE MB!GE"#5V$)Z&D$H14KB8;O&@W$:H 3LV"[FRWMQ M"!H[*8]"@#X6Z3:.2J2'L+)Q,@Z\.J+4#9R'F";N9 G]TS,^ M\WF#0R%?&H.QD>]PP4%J[/AL B030.*F9HLG:&60LFH0+(H"J61/!*SN_[)?&FM*P4Y\_&SFI:Z6U-V$KL)W$!0N,63SRH M0Y@V_*LZ5 60R(.QG@.CP2#*_J/1\H%\PG91^';IX+P] 2#UO,(J?!B;CM>^%)P?:RXERZXN?EH(U,K,:77*S]TD.:O:(Z4\TA>8YC9G3*2 M"C)^'NR0X @@A:6-F&,Y;#>PERH>/965@S5W_ R\\0LP1F4_JZJAGU56\Z8\ M/Y5:4!$: P=@D-1YW?X)V@1I^!5 (DQ&"L6!^0$K:%A0#"2JJ MR=5J"6\= M+-3K1'% PB34V5ZN7@OVY,_88!_:@S8/H2;"N:;E8R2X9EC57]&' M#:EQ=V!S_HU.MZ$,)MI-7""\B8/(=ESJ&1IB:9;(I:4%MG0:C)8(8E #L27& M+3%N,\X$Y-PLG>^]Z=<-H>&O+UGZ%O(C!L\5-(>YJ6/AU&.],3#4P5A6\K;G M38'1V!E=!8L*)Z_&3]X:>^; T7OBGM%!KU6.Z;77Y!](%)-06-G.E/7AP4IA ME^<24&[0)=#V)4)>:TVXY3,P2V7_M&;@A8(I6]H>\_)\[N$T%B;F!5Y"@NJ"Q3PI308ZR:_R>_D)K\I MS# BL$!9NB7(VCYVFX(*_5XWKM9V=U!$^MG89ES,M736N(?.7*W;4 4N?;KKC48\6:;4;WQ8MTK-DF#A6I5L(V M9Y-&V*3WE?UT_93*?IQ+.N<2113/P"6T7ITJUTHOYDQR!B8Y0U%#W2Q5U+!$ M\QS\.VEO8[,!,AU3$J*H>"V1O[18-S'Y8;OY3<(7XN8G]@-P0!SM_TF)?CD7 MT9I%'9F:W$Q/>'EDJ6:'3>&7SG3JDO;OZ(IWG"%7OMHZ\]VC=&Q=M.O2=N\L M9SD7PF!"KW'OL,Z]),O6O^?2Z/?5?"#8+@B ?RQ\?#.-]DG^S;[=WI(2K+X6 M7TO:ZCLRSWD)D0&Y2$9E_KL(-KC/R=U#0.P_[NQ91()7MOMD/X>XF*PD 8(D M+]85F-D)$H=-]2'X<;PS;?K?';F9Z1=V)PWV?JTJQIV2;RB&'ZL5)LB[59TF M7?O:A8G/J=R<3NI65=P?()%^_?-9'>M_00M'W=.N>[4;7^PLOE:#!3[&98UQ M7;OD0%&U3$?*=;O*TUMB= 98'\SD\S33> ]P_1/1^C2CV8\4Q^JVLH4!CT-= M/,4Y>\LPM]R*HQF4#9$Z5U4K'R_$4>Y!(X\]*!< "=:3R4'L99N/\B#*@[%1 MQCEY^2%B-"??Q3;5<> )+[! S4L!!LXTP^8Q$LW6?'&_4&)_\DXY+Q0:]"OQ M J$MQFDWAY8*I_O0TFX[5*SE2+']:!4 @I63> 7D%@.S*Z&A QI'=*8K.6[? M^$MXX[/ JZ.W<\#N% !^MURY_C,)"KG.@"-4Y@T26CQ JZ"!64R\,%J;!V05 M-#!WB;>::_. K("&*0[&NL7[B/"3LNG:Y%0EJ]Z;PI1X Y%V3\Z3T)%YYY . M"I670J=\H1&3ES#OK(1YT]"=N;AYUV=TIF3++7%FVYG$&;(>]I>8Z+TJZ"MW M4]F,;1?I*(\&>J^,&Z_ST'I7Z$(P*HAH@Y^NG?2./A4G\P;[A&0K@ N\^/)@[%6T.V9*R'-E/ON: M:O,YWVW6^ MNT)2OD%%9D^ITITXLLO18WC%TC;O'4ZJ>FDIO%1I!UZ0IM!2>8W2#HJE[4.K M !"-%R=MO3AI!3AT7I64WR54.&6K];6F/+A3EN]; +-WJ=9[J!V?90!GWOI= M0V>';$V,S,%8EVLE'=TH1"> MJPQI,T7?+K>H6]ME1!O)8]9%B6:K*]8I]?]N'>I+J$N@BW)#=0DXTJV5\RR; M\*R+RF!LU0H9Y4#VJ?R +JK'RP_<0N6<][$W)5A?RX[B4#A9\;C^@@QG4CHH M3%\I2HRUJY]#6+Q\*!XKU\ A/I.RT0#".KWJT4\]GVX5X4J^Q@(MHWSCCP:P MIN7#CS?XY& W W9]QW(38-,RX.+16\'K4EB*<;M?^K$7A<(7,O'G'OQNBL4Q MHP41DI(!5(D*$KPM":'IDZ(3T-@4>9GZ6F>^Z_A.NND][AH_1 M\S&N:YL5VP4??>]N0GV_4?GJ5C=UK#12*[.R(;!VSF<:3(0 5H)5]:/%&HSU MH:CR2GQ=W,=4M@J:AEL249.PK"/]XCCK.R'K 3WX1LWZ;0(:8YUVZ[* M)K$^FG\ P"C[[8120R EH M=F*>;<.$^+]L:%_(DAAVK/"XR0:U@Y: 4C%'_L83HD[U_'4"E :JFY;W[7*@ M:A_*+0&E U %93JO,D8YZR?@Q_$9CN,,,YYB%V*-SZ%9\SKA5J%L^,!N"$J3 MWO-*(H?R?$=Z0U!B2YNA:7#M[(R'?C-0RMBW9JB+)ZH%5Q+__,V/:"^-W2L\ MO*3#!=D1?/:0W-^%>'_' Z-['Z.4W,QN+F8_>,D5++V!K;YEI&8"EFX9\[:O M)YJ&7&XF@NF6(>\LBJEQ\)6&0IHX^AV$-36.OLICG ['.-U/)O$R=JEN1%57 M&O$4D 4JM(]$^.!-_"5) YV8PL2BG00>Z,3'Z##0J8<;;8_WDD2"C0V84.X* MV-/OE/UQ,@B].E_:B6\J?[YLI!T5=ENRCHDZ0 ]SD4-,1B;A3P1.'/+-_E[] MZ*&9$9;8;-S\+7##B>9%+YE!IQ%2>K,14IP9&K0[3F"& KP-[!E4J^$D1[L+ M.Z-9M/%R1+N1#E&!XP<"_/;1F:!9$$;"BTE ID[$;P_.I[%05+XR4-X )F\H M(B><5Q:ZS,2"EKD<+4NP66/53?^OX?.*\]Q_V<0!3'I MEI1K0NDP[SR%KNBL9E%5#W3I0F1_%P@M('VEP=AG"G(ZSIDG6'DL"ENKY7N^ M&@C/?P:?@" -OC9NIL;T6:HU5D.P "2L>6#6*L=YHQ!53VX^$2(5PZ75(Y&? MR;&=TBM9GT(5E :U'?Y8_K%K"U/?$X>5B;A*F%O(*)D\)OV2U+7DTPU^E0]W M50+US!R:)@]/O@3MK@' L72W.)24? )6WP#OY2C5#^C+C)/D8_1SC$(M13;J M.G;@K:QA:/K[I1W,'>^."=%7*HR0?(+SPS^3%]SA:*\D=:2F+W&\*?&B5W?L MLT95&VTD'_,6*?M;?TON5J;L9FJ?EF26F-9 O)]FU!,O&[+^88 M!?3R1Y?& :&P%S:9G;3!:HAQ]+(HJX(-VAK\0Q&>2$"$50!'0 #S%:8!D,(3 M'IX%UG$M3%,3ITXXP:A\UH)M)&PW/+UMII![P13F2*1,\78-(>+VO\1[C(D0 MDI4=4"U@Q)$K:MQ[5N32O3QS4 FC-E2XLT\=;^+&4]B/]FH5^-]AOT8$]FLE M V*/&Z.X_W5.?:37#3,2!&3ZS?\Y\./5O>?%3O3\!EZ"KR]4(3&I3@?[&!X 01\')*!"'K?Y;Z.O(^&K M[8(4A\>3''\V R3#SJ:OG]A6&Z9+][ZKHNB%G2<7]D^#1L,12M6ULF#9'00X=X8 MD? 8JIT,L+/86R&8PIF(,U&S3%0K%_7XJOMUWU"8]XU)JI]A/'_J3-9G$D:J M4MVQ(!.EE/'-&*EZUJUQZXED5=6%>D1CVCB8&Q(I]8=X2Q26[FY !;! KAF_V//KH5%<^(9;/<\QG-1J]/&&Y.9,8&OH"[KM_5P1["8TDS.!K:-+_C9JY?"">S7.JII>G6(O9F$I MI\,Z=?E*&YK!RZBT>$W4.M(%B)H@G&[[(&KTAJA/F]7BF[7QJZ,>X:N+M]7R M?-?YL=K2-5Z@LO%28,H&9^\VG2!9($Y6H6O4GM0E,)7-(Q6L.>H-7PZ='77T M\YH:1[U3_\C945>*]%..>9MNDK-CKA[%_$I4FG>T.B$J,^0[2[9FN=6WQ-\- MW^)@#B@CZZ?9NX2H7Y"FA9RF#<:WWEJZD7N5:E37X22OUVKJ1JF^Q^E0C>H& M4)W3_%1'P &:5S#=S69,]RL))&55>S%\X<<7#E5#7NYT1O=IBM=DJ]DG>W*8 MJ?;+HX)*%YT[0^Q$:<5QHW,>5A,QQ-2HUTF$LT&W,16G85^Q&H=!.P5)5BU? M >>,[BY%VI *!D:,7D"UPFN!ON9]22O0HX=0.BT2-$$O*8"5SY2Z*HUK6\?R M]J8%8Y)]@0;&DNR=BDGVIY*VW/9K <">;,^V5#=6>6%3=^'#GJ2X=+ONV=0G M'-L*;>-HG93JRKFK1QIA\RQ5P#7J8*Q)IYSWG&5ZI"IVPC(:&(XZ9YE+89DC M*F8G+(-%&(ZYK*EJ^6-D/[AD7641GL?E.%YL)S_(?9(IOYH02=6PTFJNG.F3 M,XT6KR214C#SJX1/Q,U/[ ?@B#C:_Y/M.J_Z=IU7G54GQW7L<.0$B^6M0O(J M_-1E.F/7F^/KN7+KU*.9%]OIC@2V303Y3QY<_+U"+[Z,?^Y M)8\LU2C\2AQ)A9_O&TH=F9IR<*26+ATSL.SNU&XM R4MTR9@/52P#[Z0E1]L M@JDV=4.O@P YV40)8"@%"R[:VIG_+H(-#>;D[B$@]A]W]BPBP2O;?;*?0V2? M[/:#W9&\5%=@5B=L4S;5A^#'\=*&05A+!177]"[>LY]N' FJ(CX1XV1S("%E)'3P?\$22%?IV'F#Y'QUW:4Q@' M3B@X]\@2WD +/J_@V(WH I<$NQ##Q%W?F]_!W):91L0ASAN_I+09">]],-MA MY]DP3?K1D,X;-JK@A(+G@WF/!%G"HE?T6)N0H6"'ZX?@S8\.5IWV? '.6,]? M;MP#(P#""\F?,?$B6M(X \T"Q@@)['E8\"HA< +7PH[H.O'EC(:EB\GOW0-= M[UK&$G%:M:*J!Q6&G!UNF.96PGGZFSMNRTFVBZFO5/;FKWD8[P$="<[2Y*R%[D?/.:C M@&&_$-HQYYN?*Q<.>N-[VPG^:;LQ^32C'79HK]5O>!H@+_T$N_V/S%JM@4" M!"N2]'KM.SO3LO.@T/E/N-^9WI?H=2%E\43.A9$=Q6OQDO#]?^7$[-_LY>JU M\-'W[C:?;0N /+;)&_"+V$O^V/E-)+PE$[)\( %C$$4:;NKC%WZE;#/)JU-$ MS$5HP[(VTDVM$6W8& $?GVFD_9^;:K5?\-7U9W6Z)?=O=:;9A,57Z,Z1M./^ MG./%F7O6%8"*^D9Z(EPE>0H,A3IARX4$TX^4Z[B;^JX+FY$H:K;I[F@M:J"WR,T#/A2#Z2/WL; %2V M/AL P,(&$$-)X^7N6K0?3\?)HM4E+*N6"^?:Z%_90FR _NBA&8K*D1:_U_ECW3QV&X7V3[QFO:"Z*$J;" M@,D"=O5?79%0!V-U*(FUVMM=/$!MQP@W@(\V&"MUK\EOKL)X RV?"CP4>RH8 MMX.WON^ZM\$^$U<#5K*H'RO+F?<_?:I\)L.F *M5.Q:"P2$Z M8+:V#9&"AJNAU@H'*PO1B8T-^H]TPZ9KVYBK^V[7FVBIVT9+VWX5]UC*$=@:Q,P9MVF0SV[S#\03R?4)" M6F%A;V(Q%L[\@ 0^S7D=SQYK^EM?*S@\([*MV)[LAB\[C/(^D0 M02GP+R# H<"2\(/WCJX]FS9]/Y\'!+XGI4)2K UOR>)@K(WR3DKA@=7['%[. MTM?W]N46+@W&^BA_;J4+K]X'Y)QKWY-+7[!L&0S<44'[DS7>V6X00^PH@7TL M"#:WG24-7:I31KJ@#:$TNR'.N/2*&T)M?$.<<>WE-P2&*AQ8]M$-H=3IJY.2 MX.MD0::Q"[-\]WV5Q>JS_8RMO/?USS%D_=KZYVR.Y%D:=\J1;Q?Y]WX<5 9>H?5LC6.U M&SCP?0;>>:R^XQ6) F_5*I;&@3\[\ CZ>P=Q118(ORU(0.Q91&J( %:K5Q6/ MQ#H>L7G2:T+X/=F/.7_JTI[BL-_D4S>28?@I'U+QM_^0=/$U#_-NK;!.Y;3T MBMZ.@B-.&8Q5O=7TQ*L'^9P8KQT:!=!BQ:23BA%P:,\.+?-9%("K ;C**;8I M!_?AP)L#3QO^;Z]5&P;="Z8F.JJ'>O75"+' MJU3X.>:D94+/PPCFM5[DN^7*]9])\ 9^&S@/,0VVWQ>'KEA7'X>^=#QG&2\I M+=?T$"*?/AU[,U;;-MBY!!X)\*:0"/;2CS%X?>H+GA\)CC=QXRGFJ#WC:R?X M,]^S@^?=X1=)HD$2ZRXL[6>!N# Q?//2_H-@&"8^P&8YX@'N/""9SXG/B0>X M\P!W'N#. ]QY@#L/<.+_O/%OALL%;N>M7.#Q=GB MABS^67BF5W-2XM;I M M#MR;%?")-AB;Q[JW7GSQPW?V9"&L6/DK5GS0"04?V"0DQ!,>G@5;<'V@#4"S M7#I11(C@!\*#;P=3=E?DA+10%=AL#E[FS.!;O!W"(6S7%>PI7F.%4; I<>AX MCR2,Z(V5/V/1?/3^*S.)<"1\\ ![@ 9_[LVS/UH!RT\<$@X%.BR9P[_IP',? M&&4H$%Q2P70G.$?8.Z$P RA]ZF_%2S$8?I@L,IU#$+O)F &98QTPM$E?)P]% M]O?MC^U'VW'M!\=UHF!"_8O"DN)YJ,7KX6DNN^D!;LQ+=0FB&M7@N4N/B93>5 $P,A'-F(#M8(4O7^3-V MILF"&5V E__ LI5(MJVO'^P0S/LX"(@W>1X)]_#D[WZ0?%E45RN%@5) L , M$3["57GD20"Z H&2%^&7)-GY^, #/.O=S7WDF823/B,31?C]!A@VZBH V1+ MADKFBR/^"/SB L.2Z9#5! 5J1<#80!V'P@+S0A]]^KP >_T.)@2+Q0M5=^LE M80RL:(?"@DSG": [%Z8H+5#J.5YL,_&2D1?)3E7Q>G/EA_0-KV B-J*\N=7\ M8?OR.Q$OXN8G]@,<$W&T_R=762I9H>W3TMG.G63,(;NO7&& MNL.6M;HO'W0P-KPNZ=BZZ/&V'2SN+.="&$RH!G&'-44E6;;^/9=&OZ_F \%V MH_\9_&/AXYO_9B]7KY-_LV^WMZ0$JZ_%UY*V^H[,3E21 D.3%N@(S.T'BL*D^!#^.=Z:=EKO,RLU4 M;5,5XTYCBB1\1:;WT?IC?5"[2.:]BT<BG/Y"8KWA%EY5(JCX!28Y.SD)KAGU/A& MY2&EQ.8XJ7(M7%'Q A%YAE7^RP_<*>P.(F2J$WTN69VHR5I0%Q :(*OE?8[M M%\^Z!((IG(F.A,QU6#NQ:0%3SH'\[L\8/4S%^=Y MU^!CBH?8="#4Z6#\P#FW1C?<7]89V=B:LRZG-# MV_/\"G8Q?U2P#_F&/,>&E+K8D"K?D'Q#\@W9R@E97V75^*[LYZYL,)5 DO>% MD26.ND*]_"V+D=H79BB76M/;)&9_'7$^LYU >,2.V/A7D=)>(^CK' %R-'QE M86/8N4!"Q,D)%X3%@#\1U[V;^I,8PQW@LU7@8X=P&O"6S6+8$",<">\WE'%" M&B0_%>(53/?/V,=!6#P]!JE/,-GA";-5TEP#EXR$#[,D4#UY!#,=Z$]9<#M6 M_5H_/8!_!(Z.?P/= 1DQ?P[TT1.0HK;C M"7!"V=[$H0D0813$+ %BXLBZ2:8!P/KH*4Z-N(/^!'0 M"@BY5C)/@RCP;,7)4J0>A]ASU/54/@GW4\O/M[_\^5&YON,9.O]RXI)@C;E/N/" MV=DL^$^@;V+Z'ZOTZ$V'6(XR9D(IDT0V9*'>"^)ABI@SW?R(*;KXAG !H,&0 M 'X$3\-;1L(E$?6^4+:M ^4GF(((W/07V^T9KGW,BX"=LW?#9HSI6?8@;)-U M;F4(QQU-N_.BM/1G1E:R/42#+"^*3]^O"Z$Z*$'8AEZE*N,V[;8/)RH]TB33 M;*I=0HHIGA\9@5*2*NHV5?#/Q(BX0UOAE22.S-30=*C6\^J.?=:M_SO)Y3%E M67]=T62K\GHZVBN0_*XS.0KG-J6,D:D@5;["T1'=H=Z0S8>E*9 M3OP@US$9 M3S>N_%IX8X<+*KT2=3O,3GBCP>"!0UEIFFHF$]Q3,7-LDB.1&H&A+#4;TA!=M<@0T[923\BYK1V1V0V%2IJ4PW MA)>R/WO),'?9.7G#??U61>NR 05@71=ST.F M=F5<"BP9/BVJCD(A7A,1_Y]9^L.=Q:.&MB$559]#P,RU P&,;/0/ A_ H!-J M&6+M<)1T\/L)"M 9)O!1JA;[+>C\[?6D"Q:XC]S/NS3FHJ&<#? M=@['C;&98?O#!B>N9MOJ'"49WJEK-BNW4U?9,WI9R<8.S1Y;-=U8G$E/9E+F MD]B^FSTO@V9G1'D2Q&T /)M3PBM>AVDGN=QL2'-**>&6Q]BJXT'I@1B/U M1+!(V>$:)RWUM"H14L^ K+ M<>G%Y;B,^N6X\O%PX5NP)4$UC^%\**C(I5UB1:[=;H'T# 3/F(6Q6Y]E?\J M<1V&9P88"&_)A*"+)+&@X>19E^\J_$HI6Z%+O5CY+IDC4SW<;>P<7=ETI6]5 MP_21J%8KL;G_<]UJIEAGDW/B=.)TXG2Z:#IIO%I?C5)2_Y6*/WKUZ2\-V@@].\/Z%3!B3=4T^\2:?9U$YU%:4)= ^Q?Z]L&1BQZX] ) MB6I80(RJ9Z;?/@VS#_/\+7-[U.N);O-99NOG-K28_R4+83[!779"M+) M_9TO>/'R+2]>::&S=W\>NT1@6#F1 B66MY>_J4*ZO!HSK\;,F8@ST?EIPIF( M,Q%G(LY$YZ<)9Z*3F*C#;@PM++I<(9\2B9Z\3/AQ,OYGE<[(BF04MT;>7S$* MJ\U0#V*V@]T ;W.6=O0_ ^=[]&KF?"?3N[](X!?U0]8,%L@JR:][4C+\-&G2 M9XG4;9]M13(;XJ8"KC$'8RE?%?D6CI6N0;3: Q$;!4@21[%]%.4]/>\;0%$7 M!V-3MCB*': H=7X\Z]+^XYDCW#S"BBIH:NH1%'M_.UV.YF7K&+7:*OHB^4_K7@/13M) ;A0GO7N<=(Y3 M=9S:<*EZ\?)NZD=WR<"%8!F#L3$TS7RC. [5/JB:\E=6A0K[O0XM#E4%J)KR M2E:0?A:7?I5Q4IKR.Y;'R1 Y3M4,;;[DRUURM=W8AO^XQ %G2%P7J0I5&X[@ M,E#)I721*_$2["LYRMEQEQV;\BU6.,<5?HY7QZDI[V$%G%2.4W6H^?-$X$+[(<=J'4QN.MB,X MF1RG&S61;W#)U79C&[[4,@> M;-@G>FD%#+&(PE M:2@K/ [CY(W6.E8FQ4HWC^RK(QZ7M"DF_)[LQXP_Q9^Z[J>NQ#&9[1S/1?8^ MD=U];+C%G9(U<.H\-MP4N5.R!DZMU84U16DP-DT.15DH]-:*NYHB^A5Y!E)Y M*)IRU1= H6#):[XMRF/1E"^^ MU,+:X;Z,\%'M\[9T[IDQ1PXL2T>3>^?+@ M[?'.GP$\FA(K6[R.R,D[KV5/E2D:N,\4D5^]G+S/6H?*Q%VE*OI)/L6D1B^C M<;9,;T+93 U?<:1MOK8T_%\/VQ(=[:N-K;1G@(#P6+*#=D,D*M>VJ D@^M'8 MJ!B(:HV-]/-4WC#*>;(#3$D:C"5M"(*5<\J%<,IYDA-,2::<8IS4FHIS2I>< MTMZ5@H3.4[V6WX!S0O><8+1WHR&IP D*YX1+X80]%RK=.Q\E#1A'',I&+="Z S\(X^&%MUTS,XZ_1'[+2NM!J#L:(,E7I7')Q3^B-D6N<4DW** M+AZ1*=1M_V-D/[@$_G_J/([_&_Z3TG%I!W/'2[%4@3S))X@>_IF@=8<.O%>2 M.E)3Q!QO"O+QU1W[K%%/O#:2CWDT%?&'URL_='"]KP+B4K']&B=])X_,59Z) M[)#@ (/Q"^EE1==KB1F;I>:;):4UDBTDV[<%$1"V1ZPX!RP@1/#!+^21N(*2 MA'0*3BAX/FPC6(@S@T5Y$7W2=EWAF=A!**P"$@(89#I:0T^!3ACC8[R$^4X. M *]O Z\W#.A1![6"VPY)\<9?PEN?_RL46%!KLFT$W"BA8 <$-B,FWY.I0+Y/ MR(I1XK?1UQ%S;T]VOT(]P! M2_B_KY$_^4.8.@'0R'T6%L2="HXGK "I5"P\V6$U)I'V6-6H#V>X(=F#(9L) MGD7<8'=D: M7^.H#^K#5)[-9K8HJ08Q+$DEDJE*MC:1)4M6_RUAY81CY_?.9I!J'8.*) "6:Y<_YF0<"1D)P!ZZV1!X'P65B28P!CVG(HY8D\6Z]_0 M"'OC=4AA#)R'&(E._PIA#OCB)R=:T%G!#!Z=D'X-H]!/4.[A4?^T<";LH71< M5(_2"<*T_,AVMR>&*]A^)Q A'13$* &MHIK8*774OLF\$IGZC1_" !,?E+B_ MR+10T*B#L5R0VI=*FF'%:9:S3&K,$YN(Z$VJ+U(Y5:O&5'68JI8WD=93A3-U MYN#O$E4:#R(FO>DJX!_RCJY2055)=JRJH2&5LU:>G&FT>"6)5(/(_"H1,^+F M)_8#F-!QM/\G)004M0!W3'@05*Z]"LFK]!^OTPPYQZ,BA_[H]?;H6MZZH@8A M^WHSQ9'(IIF$C"5O3KX>P5<_YC]71Z8F%WXCCJ3"S_>-9,DC2S4/#M5L]M_2 MF4Y=PF#I/BP- R>VV/)X<&752+N&UR4=6Y>2#UIREG,A#"947[C#G2K)LO7O MN33Z?34?@#T,:L$_%C[5K%&G3O[-OMW>DA*LOA9?2]KJ.S+/>0F1 ;G OY/] M;Q4-4UEKF(M@PRUS"5[3[9SR&2("M_@(S)='54$$^04VR! M#\&/.]K:Y:B^:T'QFZTL,Y'1ZII )2,@NB\#&KS+&/%AL).@BQ MWW63%PO05&XP']AE59(MM\(7]TL_Q@P"$"*_,D,D%-XQ?_;VZH6O"SM@TN;; MPH_AG=/P97,9-)FKNLP]'GF0<-YM7]0U1DY&H_+WHX>7>Q,D8PQ8([^G\KI[ M52GE)]NEKB\[$OYA@Z(#VTRFUKY\"]S38CY;2+=@SJVS?2FE'-1Y$^]\,E"9 MVW EHT9:6*= ')I&K01Y#FVU?"KIR&WC%K#T%J9R?(."+>>LH7@K/>=2;_;$ M7ZZ(%S(;#&TX9ESX*_H!=5G?4@;MBZHB1SDL3A1W2F[@)BRH(DABQ44%B8S[B=_QDZ MT]5Q086"=>& MBL&K6905&O*1M)"\VI&B@S>%OY)HX9?$*2LW5"QE+!Y+&2EO/EU&^8/2!E02 M[%)-RSX]_/@2PHN;D4ER5T:4H@W&FJ@/9?64-&P.;P6!=B1$HPD[2@?+6!KJ MUFTTZ>)V5$-VU!&ITX8=9="$;4W.%Z+G=E3=(*\6["@3S%U *>^7X7;4U?)D M59W%[-".LL".DH:BR>VHTFK'GI(<&+Y1QH;Z2*)/LV_V]\JR0Q5I1SGC-GRZ M_TN\QY@(=(M@NA*-'!%>?/0C(LC2R6>:7$B0]FJV-9HN4T&8*$='.> MG32;25"X;Z?E"W*I,]&F#,:&) ^-DXH@<7A/3TYL4H*I *HVU/73VH%=BHCB MOIV&?#N=NW94C;IV1)E?D3>69MB\9T?%9+FA8G+/S@VQ9%5C3.O.LZ,RA[!D M\B8"Y=MRGP7OT MLRI12*=9A1:S"JV".S<.<%O!TY6CF"I+8TUDAJ&9#W8\5ASNLFJ&W<_G 9G; M4>)E#WRG6F)(CA@75*$#EJI\@%\WZ9O3$?">7R&EQ?B MJ0[&ZLC*GTI882BY4=LNW9+ @JXA^'+*B@EM5GFL^M_>Y M7)\R/%Y:9^]"E'86@N%E(S7O5#ZX$'FWXE^_=\PG;R==4!M2Z?"3;P=4/K!R M V?YJ!Y.%P$2@AK6TZ",+WP4ECFXTH 5H=()-_WA/'@(6)VRR M7UR4K 3DOY)5Q$P?B:U99N"G-<9LS_-CL)*F\"F<&DX4%O$%U3T>*5^P31%L MO$])P378W#'8X('S%U8LR[X":+Q^.%[AGQ6+@VYW=3)3S@F#B+D1-ZZPSVPN M]\E,R)1E"DMKQK$RC ,VOS8JD&$/27&MI'C;IJAKL9+&BLGE"4(K7*) =TD$ ME)M2+R<=,1$G,R<((^%/8*\(X(%1DZJ+6?XJ+M!5MB2.=5%%%Y5:E6<0'MB_ MQ MIZ7L@.,$0E8)B+=CS/5>#1K/R-6CN)Y-X"<(/8?-I(=])]B5P(N!;A!>N M'V(Y@R-E:MD0::Q2S[-,C.@SO""1?X"+]]7E@9;JN^4I=E7'X>MOX@L MNG]M8)L+[?Z%"\Y5>=JK5+,E&+D^A)CX7OX5V'X M5.*T>O=G[$3/P)QNC-3X[ ?XHON(%1NG)J+_T?=H$7G0&^"1#U@QD811Y9LY M7:)=!$6I7B0<9XAJ,72*D4MU:ID?"B#'/ ..=B=HYSH(]VSW*Q@E98CY>&W. M#BVP@YF+M.A^\ZO8IB]?3X/CW4+ M-[SW8]1\,I0U/()9Y64X?/'/_*G2D:" M7HII\I%$U"816)+R!5FTG9\IN;2,/4+FT+53[3!K70<1,C2L>@?*K4*6JY%R M$F0%J!B@UN7C)VX*DFJ(',GN;F?OF+AW3)'7"2F/TY$ZS[4WC(5>D%I5YFX2 M"/E(+F!=' QQ,"X(LKS!\@>\FF4W1W$N/ZU?)IJ![EDX) H:&%>TV#E/E.:) MKLWV MAE4.!.]LASR$M#WO4M30'DRF!L6ASS[C __TV,@0V6E6,- #CF36$N MY\R'GIWVZ)"5AY9^3 QPA^S%/'5=#EF%.V2/GBME[WQ;<2H9.B:>RK=>L[H2 M8M:1!/C:W@QTP]ZV4ZG:UK'.>I=A4'^L4M#@[::V3D7(VK[+,- UJ_(Z;16T MW+,>0*8X&*M#0SUV %V)7I34U/Y*5G9 DQA^_/#YTRVQYHFZT39'%MM1;\D$ M2]"0]X&_A'_['C52*;6KLZ>$[&G>>''^O_V'*4MRKGKX-2_Y1$7D9#XM8$5T M\A9$3E1 I;_D_C]7L0J^3RIJ&IV+$@FOS,&Z'B=_*Z,GERX4+_\R*9* MDWHDM9XIRWFB#D]T?;=0 #M>'W#$.T.\Y[$C)BV?+A;4'N0LT19+G#]TQ#0& M8\7@<02=85[69WTN*6#2.V7M:#C1E3CDDHM*]18O*JO)JES,4Q?>88OFBXA' M6IQQG#(X[6F.>>K%BB6">L!A* W#$5]';1C0(5U@J-T2$)4.7!CBG/=;EDQO MB8UZ =E7 UFEO9/3BAO:.MA#T#SB0.>AV[Z6>I@; [5HZ$8G*=Z9$#WG*)/F5I<,5:6E%ZO21 KCXT M)0#>B.867+2Q,_]=!!L:S,G=0T#L/^[L&8B;5[;[9#^'R#[9[0>[(WFICAUR M3MBF;*I8HGIGVFD/FGVM7^3BUB]*[UN_L+Y.M &"7:Y;#W:M@D]#XN&#'EFW M@:&B%?M?V=\%9[D"F3X2DOX#PB3I/2!$F[X#@A,*GA\)]O3W.,0?PD&2O@3& M(*'PM,!^A$Z4#!W2#E@$3AOL50.//L+YLR3)]!T\D#PZ,NRV,'X(G:EC!PX) MZ3182R3<5,D34Q+9CAMB*[/"=8:$)&VKTDA)F.+7"/YOF7;*V7*>"LQ[>EDM M[=YNB!!@;[@P=&8@59!$\&%,L.;EP+YO@+*D"'NC?I=[GI"E;0IA+#5 M$**0)*S'(VJ00!;8D"@:8+(K8@0>+8%1EG10955$DA3;*XC9<9Z@)L\!? M"BQQ;90G=<&Q4:X[(>B8%]6=4*W5G3!1)-(>1C"5B>N'<5#4M<\JZD]H%?0G M_+"E,A3I*$>;$A:R%7U7WX]^H.B6-@;,C4U+LXJ3X(/\AF^].97GOG?WV^AK M A_KG)42#1[>;H>ZL+$)+I 7M/.T)RI^#TAM2.VP)J .W3K[M#P!+=9_C7C*T+J_EAMHN_I'-\6CB3!1UR"N<13HW* M3_PQ^VIA@TJSL*=4*00!"_]@V@^J.@'50G'*Z?#X!YH: E!SZ>.PF_:D*SO$ MB04@A6G+\"$^Q'1:FRXQLH%Y8#DKYFY):4$[!<]<_XFM'77D1/!O4>^9ZK7T M\Z7]NP_*RG-!J]4L)?-#H Y>3-OGRU)D/U#1FZ8T48;=QU!#X<$&)68"Y^B" M@(ZRI@69S4!T[QRYP!XVXP5J= "!R]E)K)MM\CU]0T3/"]Q%Z[]#.#U" 5=# M3XL$Y;6106V,#3,XZ7&$#VV.I-D!&PMG 1 3ZMY;JPQ; X$I%[O,GEG_$.@W M(7C0>3NT2F:,"W$=^\%QF89L1^LUPGZD$:#)7J%'I+]15^BS,*4(^!49D3XU M3'?QC/(S;D9DTXAI/ =WM/#B/I@3E,'V4/@6!W^09_K.?X*^^5<,9N/+$:BN MP)M>(L6R?8-].,P7.XV#U9VVSF[HIW-/3-1$***B!N.]FS^OJ!)6,$W& SM" M=H>@*5EPY,,K96PY2!P,B8H6;MDHJ!VS\TQ2+DO@?8E-5>,(S*7G\6&?Z7+N-DM<-.QKL;^>PXJS+%E Y==J@""IZ/E@NG38%JMK,RUY"GSISS),O"/-;SQS8 MZ=C>'*)46J$]]$CJ>3?[-OM+2G!ZFOQM:2MOB/SG)<0Y>^AJKA@M$'O;Z\NP3>D MU?(-O4M\I9])\'5A%[F$+(S531K-]3\P2'\F6KD(\5(C3F&_&=&G@]W#G M\[2L!]5JD@81BW-VROTK=^.J0DT)O71$M"16/CP6VU_:YJE21 M/>@=E'<5XDW"*5:E>[-&Z-,:(!B70IL,GKBIQ(Q*#*:7-C+SCL$=LR\!N ;/ M4TC$DIQ_6@?FZ^[B7(M_Y-892$<&JE^?X MV0?FX]K[4>WT*WG 7/MT-8'56/K[K$1LU3JF$>*> %:S V1SJO*]3P2=0Z<)(X M&(LC/9]=>8-UE+_YD>WN.\;NF!N85U,\WTE7>&=1R-32'I.,HW?&0Z@\?%AJ M2QF9M8H%@[6/>ANUS#Q.QYX2=$C1E#:.J<>II(@?5D$N?'M>O M#3%*'8[BTW:9[U]T:#)-R/TQQNO13S/*B.&G#=$3IJQ6$L"2L"'O4!6-T1&F MY9@=B&'L&C0-0=,4973;39VJ@J:<%31:G%Z7M=$16_%*CH?/?D18CDUR0)#O M))@X(0VZB+TIVA=8!D7P5Q2\%6:WTR :1S0S!7;?>,OE[['V':[CDRJ MO9#I9_L9'[X/ HSXIP'ZA4QK8"&)4;Z2.@>J]MG0$E+F8&RIHUH5[6X6J2,' M0DM(T?ZNXC&HKN08^(6$X:OT" C(*@XF"UJ]@1T!$39&BX/GY"Q8DFCA3V^) M9?<7&*MT#/SN_?Z*<>>_,)?VC1^[TY_(EPV]?T-R?TNH3>N/_4II7<2ALC@8 M_W_VWK:Y;6-) _TK*.8F-V<+HH&9P9M=EU6*K20Z:ULN6?'9[)[8Z>Z9IY_VO&[Q7+9!#*X](+-B MW:\7&K?3\X.2$)*@V6&AKQ<:V+QSW&YQ\[52VYD#.5(XGDE+Q5MN$^5<ZD[_/N MAAX_!Y+AO-M0!/42!C1QP.J@,<^;=MFQ'5,\U*!HKD3F,NHAW@C="ZPB+V793H'LN6W@46L9X.OM/)STZB:[/<0:C^7^8RYD9?: M-]LE-:IFT+57>=)F$2I]>9VY<$5@#G9R982@+@+S.@0%9& ES9[+'-IL/&;W M'V2Z.A6*;?,A?%'!+GV'ON\P/O7>4J\FV^8&(=FF\0&6=V+/.(#GE%;HV#:Z2 M7&5YDLP^9WV5G[M)DQ@TL*>W<:8K/3LPOXO3O^6]/L;#AV1)75YM'01O)MG/ MSJDGDY8*ZK%YP;$>R]11&=;@,7EN6W22VT^V$7IW_S!5=E74'LR$L4K=,&BK ME-$Y$;55=MHZ(KNJXVA>HV'YG9[@W>+QQ^$8UN$+O)2;E'"\/=E4 )M@VU32 M[])3=DLA8"A];I#>KK^3WNYS\Z6S:P K&4W4R)UGDOIJ[(2N6<4W&@=^ID5-^+V6WR(S7UCV> MKM2W76S4U+=63W$8TDM <7Y8U9 77(DS/^V=>7+K4PT;?)NRB7FK^91]V]RQ ME7S@*^#X?)4+YR09E4[VJ-,;CY+"9+=BU6L@LX4C=>>+%@'WG@V ZAWR?CRZ M.;I(TCOH8@F58O):N*&L8XZ[^[N?.)>M_ M??V7)-_N!RFH.8VL8QG8#RWF*WA9USH>#JT8.JI,K)^74@+HV"W-'_*%_.$ MZVS^R#1$@9 UIX$'5>_]0R8'L6I^ TV4DG\_0) M[8_M/KAHI7;9BPI;QP_1VG,HYVJ],6!,.Z)^OBHAF/3=F%GD-5CVW),H7LO9E]0[/$S5]EZ$Y MRXQNCL67#=:'^/LOR2F V?_\)@K[IXWJBGJ3ZZ(HM1E>9];(Q>]L9<]?*]Y?C MQW@P5!7OJE7:P_1AAM!D6[>=^7A3O>[L^7X=I[_!8Y4.MP>^H+B5]=R(*QO" M9*0:T67=(C(PH&5$'D++\+E1#?8@CER(?Z'_=K:V08?6RR090;^]%%I'SPPI M:PXWZYL!^\8JQ8)MXI D:TU7?5KY$F?;#58W+GMQIS@] MSQ' AXE5(_"BH)B3X^B%J9JS>2RWIJ*[9-;[#3^]M1G'MK( MW(P@$I]URLP_-'EJK@J_J1:NLCP1YDG]-G]R=S\@WC0YY&M6Z?KMGK$9X'\(U@S@WRT?XNOZV&!SE2B M3[\8*9HP+>IZ8"C8](O39BGQJ#QW;'5-MD_R=/@-<>WLA+P/V7QQBTQ]YC&! M0O)YK_,PFIMYQ2"KNN]P:@#DXWB4W6F6FR@V[/S[L#G_<3S],Y&_.KOYZ@!Y MRJ$[18+=KNZFCI5FMT3H9049.G7$7JV-MJ>WQ9& 9KNM(O*M3^IJ7]#YQ M1^YERC+NYXF$S%2SW&,,^>S4AE'NN?DQO_G+ZS^3G73!%[ MY1SYO#[7N(KO!_*QLCAN8MW'Z10"MH%\\M%TG'[/W)#,T ?R8:X'5_$(4G49 M @[SB39IW,[$+(R=)-/I$,09;;W:.$4?]SFMO2:JZE >U-,B$UNGKFW8B$8[G8%GF_>QA1L(:9AV/I'4. MK?/D?IQ.=31&W\L E#<*AP*CP@-O:!)N;+OO-9065DYIX1ONH!R1G,>V"TF) M;452^CQ_W-HD#[=PXSE?8WUT))R@](CD7R$*>+,+)HA^E!@#.4?$^I&M4IT@JXH'XS!H_ I4]B^1F44EVVJ#N-U,3V# $ M86VG1.J/+_*^Y-*4#4)Y_'43] MM]RDE0MB\^MXD#Z7?:AC_)QQF1WA0]H.IGD7Y^?2Q67A00TKO/[+,+[Z^^CS MU>T8POS\>^#+,]]T-^XGPVR=>,C"C:?/YSC/I3#**7*5 MYE_Y$;<-2V^B]O,>QQ!/#R%*E^D!')/#$7ALR:\9 > M?I>6/9$)&,0O:H&#C&O^F^1%V8_"R3Q<\C0S!C)%&"S]+OQ$E@.J,^$F<3/R5DWP?)4$:,#^ECHD@?U]? Y,DGGC2>E1.DTH:0-*RD_S!,%=:ZPT3WOJ\;7KU_BZANQ M]^*+;LA8+7LO43?PU^^];/^Z)\1!W]/Z;]IRCVK/$DVU%<_#C&Z.,E6=C\W; M^=BLDIB5S#=NTK%,"X_RV[M6__?F()0$SA<"\97FP&H2?A* M(ZH_;J,G\:(!V"0(0)-F51)DRJR).CW>#581 6G6T*S9\ZSA!LZ:0!%=L:?3,"3:2)_\)M\-;-GCUL-FR>/F&GQ[H1 M31^:/J9/GSWL9&R>/J YU UH^FS:YB@*CL^'JR^FNL]C/D]U/P9NZV#Z?16] M/70:1F\_MJ21RKOX_LQHSP2?H;+BN00H$UE6U4>K%+ '$RNO_P!R;S(;N2X9J"2KA^VP/D5#0D-"0T)#0D-"0T)#8N:0 M'':=UZQ_PW,G+XN[61GS?FC^B -O^K[LB@::B\*UY>?C=?8CV4ZKE\]M\JD> M2,QFO$CX)R/",:+=!!=PE37F+&E);6&62*L'O-.#I:C([:Z[N-OI>L^P1Q[\KS%N?TGP#IM1VY1^HAL: \VA*>B-7F)NM)F?P_M';R@ M&Q7[.S3?CIZ^_M +$&9>Y*FY"1&?UPW7SS6[ N!A9'TCWSVD3P*N648_3]*8 MS<8=EGOH=.?805!LEE5+E@7Z 1=I]C9Q01C:-VR>P4] M((9)_Y6&XK]FJ#VDR0OB<: 7VX%7K-6G];EIZW.) M/51>H:&!DL^ZHF@/)IC#BU?H3?S=QNW.K.A'43R4F?%*,8GS>K(G!/"TKRGE ML%5U+X[I!SN1DQWL^&S#;BH9HE&&N-OAD&/JX5 $YXM"E.FUD!4VU JK=J8U MYX I@J-*V]VT)&Y1E6-V)VQK7WYQ<+SI"ZW._M,4&:I,2&=^] O*G9MYXGK3J959MIQHJT@Z>!J-[G@7IR MXE6802/-FMI"0'?/4&.QT]V@WQ_F%9#ZKCIJ+A<"# MNQMKDE[]?YV_1G\=P4QU&8O^[\;M_G5_T['BH5P9_GD[5LVOH.U5_O?LW<4I MZ_^&QC/?@?BL-N+\LHR8)MJFE6&?OPPO1VGT![[#ZCTG3M#@WK? MR2_?%U*5+8LN[O I:?L=$WLE\D]'Q :J+YC:L M%JNAMZU\%HWU2]SM1MPSK)[7Q"Y#+NMZD7&%S[SK<-^PFS(6O;TT,J]O4=QC MA;CK;3,.T$XV28T9B?D:\1<^?]3 QS]Y=G"5&,1F5P=5>O;$4@&/I2*>;;9< MZZ#=[Y-=7]_<6>HI;^:8;#ZZ?++&^>_"Z;(N[*-FI M@2$_8MVP&&&"+"E\@?0H[C^V3L%I!JT3YE!_7UR;#)]A9HUI,U8EL\9L%SLT MJK(8>=>QQC)%L=-1]%9;.,4-G/?CKTF:_6UP-YB6GC\KWJM3QGNUCG9K?:WU M$?^XO]_XB"$\HML-U]3U;/195(6)7ATF=JL&W]%P,MK0V?5#"2;[^5]P6F\! /096? M;53E9W*L.CVG&];9=H$,J78GO@5=6INU+5SR2W(S&('I_1(/H83"+7I$:6-N MYA%QJ(]D9TWUA7/;@;OY0FE:C'PA+6%+]E6TJW5+6/F2Q;=;LG37QS4I\V0& M99X249!;<+VN7TS+=L\\-3[BQLQ3/B(P\%C4]8HEQB_//%MX_$598 "]0?PZL\#6F$-%E\&;G7=$QN1556E\Q&VRJEQ>+U@CKT=957V.+VAF5L4B%E53KBH*#1616#C3O?Z7).:\?A.9<:LBK&.SUALYJU$%ML'Z8L)C4D M54QLCD\IJ5J/>&A44L5@D\T77;_.I$KC(VZ15#%@=OE>-URSHE%259_?BQJ: M5 ';*[*Y,+/YB/$&LBJI"AN<5(6=GD])E8XX*&IV4A5E+J;F6JX6&XM)SJ6& MI(H[JB++8T0 /+#5I(:LBKMY#+[A'!.KJ6\SL/]CG;#^-9\C *LHJ-R97X-#6H7-)28EM-?_AG#O81 MI"^O7=$5,\ '\DE'T]='V6NUYC!%:=>R9@@OEW:M[XZ7=2G+[W=^**,NBV#8 M9B*Y5\]QDC4<7"=6.HN@0-9$GC*Q@AB6.<&Y$RG/&UM3XS:+". \A M-?"6;3]O]P6C4=$J&&NH5< VN1O:?LGROYM5E#]Z(ZQ".& 5!8W!;,U0IK'4 M]U+;4:(6<2\BY[?M%,G2MD"^.A%&0*Q$O7B8? MO;R$;-DF:RGX#JYNK4?YIC669F') MWWL$:[Y7G4HGUO16VKJR->LZ'=^M=YN"E6OS[F*^ZH\O\KZD%\S:IKJESN]. MWL'MG,UZ-"'U"E;C&&MFMF::B?Y]"_Y]7*L\HA ]5*4%I!8B9P6\IIXT_#5 MMWIM.WQ?QVE_DHSF1E!F"-/;-$F.8-0*0SD_5IF-=ZU/R^,WR:(8-;S0(7HP MO;6F7\=6\F\9APV_YW-/OG,SECAD&_U4[E, M6L.Q3'?EB-[EW:G53]V.AS)DE+-S^I".7EMQ_Z^'"7SS6-Z<&BOY0?D<$ LJ MH'. 89V:)?HKOTY93!:=C90/! SS!\QB2GF[\.7R]^03S $-?VT U.$FJ.5W M222&0^M1QJFVI>)W:SR2CPV-HK/]A3F+L!?6N*(7'^61Q/)8+.@"G7[\=;OD MH3@TE^N&YAQL;B('"-J,2??]Y+&/V-R0R$RHV +\Q[F5;_NG$L8\E0=U:4[9 M<^6V.I4.-YE:SU:^8DF<3>GE@*76EJS'$!4-IM\O(.8JM%F53^,VK,WJ<=Y4 M]?MLN%?$$FN")YAL:E#D/_NY4U')L14K;U3>?=4:R#5/_EBBEN'+9#C^6FS( MVI ^JU[8]8)J#< U=,4,93Y7[:M6O\ZC:FUDU][4^J^B5IW;G&DUID75?*-. MZ$PUEYRI$;+^6$C VCLP\Y'JJI'9,#=FRZ#T=\GJ$=K_I^@Q3/H4/89)GZ+' M,.E3[7@,O3T?==?:IT5.TG-U#$K%)R3TU%V'E!]4HA.S[9M>9 M3*0)"^.RB9180=#IA4XQ%_E'JU;&M[")/DSZK^0S<@7-!>T+)=_ MC?Y"G 4CG&\H(UDR3L](* %LI]+91F&T>D.FLAK:"; M*@[GMF:2L:T5&!MI\ ]U)^LL( W75UJ^[H:"^I.:Y6=6RP'N?U=IHR'#\D& M,N(3>3N>["@WR[;04-:PM[54M:/>?!=/DU_E2'R!@2@KW?'AR$D$9)UF(YJ@LHEX^]DFL_3O+2@+V\)YJR:F%DQR^)D7E6A M)"=P7]Z.]&7PEEPCY3\?!_UDU%\H<1F-IUF9BX1OS;K05^&]^L1C1D%_J@/9 M^I8&:E=U\]*R*14N[PNB85OH BI&BO;AS]F'U^F%);T<++FV#^5?-JPB&U8/ MHY_<[_1\IRA$/WORS0O&AH7"Z(URUQJB\(,WAS1R2 '#IP MNB7B]]N%&?+MJX=A#%/L.<8HGZ\+00>$"4DL0X-\_E[)L1F/Y%/F-9N+04E6 M=I1%)DU;O)[7JHEZ:E7&6:P8S1Y;CH8:E?+E+"M[A:CH3HUX'DDM1&YK0[U\ ML&B<&P]LIG%NU *^.YS)0EX*ZV0AM+)Y5 [9QO.2JO_5P?8!I M;;V-T^%8W8R:I];=N)\,R^]U31WC[A$H:THH$H!Z==FZL6L$VIPG5\E[L=SU M)1$H;\S#RU0]*IZ[S0>@U9+3$J$X&)S!*)N NRSQ/56,M=)1Y$NT@'+2HBS? M4Q7ICXN%O_F/.L^7Q)>3\?!ANOJ2+6ZW$;6Q$>M&(JBE>%1T0X_OHW9T#I;E M/?$]! :J>OIX- *!@_/D?IQ.MVY)U;0!*%1.J@$(W9('+ML)G_L3G@"6H8&X M%)=]=GU]'3NN")(@YE: J1:3Q9J<4^TY*8]R]S]P$_678GS'@%B%^EHQA_G06RD^0^ MSL1I9F']6^GH83"LWY-X.+U]'KY!%A+G'GMZ.Y#1_[\?XG2:R72 V[;S;\AT MC083&?E_M<;I33P"147Y#>NT2R899JR@H[=!N^1)?#*3V1G=S, O*L^,'NZ> ME&=*$EROTYM^'1?CE5099^9]\^]^;9V.1N/'+._XD/0'5W*0E(7)?UPD5[?9 M%G3^<0AB'H;2'&]EEFM=)LE(OG(53Z8JAXF'PV>-KK%\YWHH YX\U54F!F@] MJ0A-GI%2X]RX+#>_[Y]^".7:^V9B7=T.DNO9\\DG!;0G*I^*_Y:V]?/;LW\,TM M6?ZRS/ID_CL#4O[&^ X@E,"!5LTW0$P".+Z"3%'"/'Y(K^3G?Y8?'#XH&>#D M[GXX_IXD\CNO!R.9_@WBH:U^5*Y8 \A8GR[[Q_->Q^P'[].D/[Z#ZT"0*I^# M<18-P#V %:E$.1W++Y@IB\%]2]N9R%Q')3; MDM08S1RU](,C>?LPD7< ONREXQ UA\8\ 4,6%FDL'2DY65)[;JQJV/\Z3OH.PSYCL,I M@RY?"TX_?CS[+_M']W#5AYIE;3UN1:"C6$PW/D\=D])#\FH[O9KT- M_S68WL[V:D^^Y2>@Q^HD,>E?Q-^VJXN=IQ"J)J$V]XI%/ 3U3J73I4A[!B = M*J2]DJ:$A'1]2/L&(*U:O-H.WR#H5R?2K!K2CF4NWJMU>59T?UI^Y"\>'U>?(/V@ XO'C+091;!!L4: M OI%0(<& W-LVUODS01 ?TBH",#@!8@*1Q&&A.P PIVJH?E 7Y8[G5ZSM[# M\IKW0 _(9BJ;3(@6(/LR@7.ZQ6)=BI!1(^1_C=-A_^N@GY OKQ;!W;(ZNT314@O(KU!C$L+TK!O'=J.5]20)J3K0WJ#XH<6I&'?VKI/Z.P7(QJT1JTS&Q0J0([?3\VD'66]\G-V6!'2< ME;Z_ED^4I/"I3N_\Y,/IV^-W1'&DZ\VYOB7SDKA6=8>W&S3==(2W$4C5V8Y# M_!M,H W@U$6@H&^[@@YT,($V@%(706, 6Y1(&%.^BI&O!&<[4;>XW&LWFE:%Q];)-Y"-FY!3K<^I8K"72_QFT.E%='"#"20& M@:T$R%"USB(D$9'$8*B5(!F!AD>1GD"!+$9,XF/')*[C='J<=XO"^!3(-M5H MT.ELK@--,D,3C*8U@2PQ^)'<)@;?M^ V78=U>B*B @120^#;5:")._T/$%[ M\YA(8K#)2I 4G5[ -++%6AV51/A1B=?I1=TB)XPBV8;:C(?..W,=7T:RO%M< MSBF2):9]@SSF_EFYK@-,>[NLRS,!71_0^^>GN YLYMHAZ<.@ KU_?HKKP%ZO MS77R4UH=[C#T<,<%FCWK%H_4*$9NJM&@\IY-T]Y-T_4]=U,^Y]2#7$F$#O7_O2=3/N M/=/(9&DAT/N71W-=Q;UW?=(XU9./+$M'(N0C7J?'*8<]()O!I[FY/MB, 0)< MK0F.B;"$Y%/WKT3INNJHQW6(FH\)]/Z5*%U7'?4XI"V+";2_?YDTUXT4T%2A MJD4=Q\.2CY2W W%.<;KN1QV'S*4> 4T%'9A &\!U8T(!'5+!JY:=0']9-K+^G4"F MI/@-T. @FZDE./:767/U68I?WK2!@N-]<9\N3MX?GQ/9B:XWY_J63$LB.]4= MW!K [V3 M!!H UAM+ *@>:CQ8/: 4H_JZ2JZ M9J3+U8&. ;479#/UI*M8K95=[H+\0=&74[I*/"?#YTJI.S6 .\R97'QM7[@4 M-R$";0"AC7, .HRH[ ,3: ,(;5P T)PZQVD*D/&U*+D'_<"*YW,4()MA,Y5- M!HT;QT%^WR_IV4 1,K&=#)XH9;XT,( SS*$*P+&Y3^$Q)M(&\-IXJ) ./2KX MP$3: &(;CSJ]R X823YIB8\#?(5+X71ZPH3*1[*96N+C *NSLBO<%3W-*#[> M$^'IXOSDPZ]_$N&)KC?G^I9,2R(\U1W=&L#F%ZH^1U##752@#6"VB:P^ASK. MH0)M +--*'6G4%!]CI;<8UELMK[< _HINQEF1]7G[UD9SG%8US* M58GM9/AD*?6E!I"'A5)U8HR")DR@M31<=D78Z441=>C 1%)+PV571)U>J%.F MMLWQRK(096WQBN?(A+2L\0;%MTVVEV5Z6WWVDO7<*/)1*;XEKI+!$Z7441K M^_4R)G] I:Z(0(<&D-(\Q>2GG5]6HGSQ29 M';*76NPE7":VU6
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�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�$3F0'#H4&SLA]";P4N[8[S2-E M_8XM^8"D;R/7/NRNT^&G3\/Q"0'[US#.-7"T3*KR13LN:.^J<)1S%GP.$;A5 MP-L":2[B%OZ)N-K6YHS[\^QW$Z/0N3/^9* M7ZP(T;@$FO.:?TV;G"=S Y(5F$7,0HO6J43W83H2 Z 7"GHXK+^-;XEN^6)L M@*\G7_T^; _COK=E]%YU:4!'+VGP]^!4V3"9:>4K01%.'AWX0C_%E%FR+)+/ MVWJ/>1AUN>$H;XTO\C*/NT_Q6V9>:T+2\SR&BIE74 M.C "$T','**5!0)MO%[[E/W:AGF[7;.Z%];APPMMN;QU_:HM$8V#$.]K@Y/Y MVR"+1'H'&%BI:E:*%. 56>$N&FLDE\J&%I&'RP&/Q-K878@-T[LN05PHU"8P M&D85K@U]^#C"CL*_2=\>DFL<+K@.ATEF(H8"D@E!6Y0*$% 7,+0(>4V+DLP; M'=P]-(%K0@)M^=M&8(UY^Y4D=79^M@021!"65I DM .54FW41TL+H>&&*2'< MVMYXFS+WS:"']>AW%GO70F:-]\%?PY?K0'RQ4@<'FM5&UC&%VF4Q 0M%!RDY MYV:CW/W[R+L^Z!,D;V>9]6#POIMT9 3,OKX;A?&,C*V:VS4WM9Y__4B/F"\P MS'F7$BTP6=;]O9C:+X(I4"QXR7QPUK4V>#> =22&4%]$]) +?2?$"O#"YM\$ M8D_!EPW@/4S\I3FUFZK.GKP<W:2[ )M$,=!SVT)=*,POM48T_Y M'^+\YSI$*6G-0@9))59[R=,Z:92J=22E4D9H\N:>NFIL?^K3OV9L(?9^;-&: M6G$+X=(Q=U8F38:4\8J3-24U>,T#%&%-"HQSK5N?!ZY'] A.>'8E[[;9V4KR M/1@8'\[C=)B'8?+U0QCAVS*_^C9_$8R(B9M0;P]R F;10Z,=*&SIM*T@\7 M?7BM]R.50AIDL8!RLGKK@H,OVD,0VI#;GK,VS7,:'TA;[KML\E#*L@T%/2C) MFW=OEUF76+RVV=1.ZE-&:F:R'6AH9$ M;3+R"YZ$T:MYXZ^%)J?L&0L)K*YE(1,39"ZY1/,+F"1:H].Z$^G[N[3<&/!( MS(-]17F;U;VZ)BY0++>:#7!LL.UOVA?O(;;SO<5_JPO>'K)KN +?PB,S$XSE M#(&YVDLH)W#:"\@JN(0N(ZY-_GP,'-ZQR?9&X38B:WQU\]]Q_/F\EG=91J13 MD=S4CGI.:5#2^^.,"3]"%R^ L :CS$M:29X\2:G$WH[F1R8D-B%KU["?(UMXB:IR) M]?;/,4ZFI\-/BW/%&*+-P8-EW- B$1EX%3F4&$,QQH: +7+HOAGT2*R6_81Y MF]6=F_E^ V29"; !E(9)KC>&/WRBZQY$K*)S#RGV];I>0/(H.!H3:1FJ/I.8 MU\C4M<^$4TSG0K_>Z!3C,1"Z)O&U'SZW$5[/UHR2.9B<&9!Q1ILV9D6^K^/5 M1"O)HXOY)H^/RYK96[QK#)IM9-,XU?5#.L5\7B,7B_IWB\JT;\:?<5$:^?:G MB#6\,5=3(00*0;L(%HVU7@898D9JD-(%82,*5!OU4[CGW=P'XQ'MO0>C:L5* ML)>.W07LXBW:!%K#K7L]FL/OY(>CM>N5DL9VP#T(#4^9WAQ#"VZF'=(;VB%3 MB6"1DTO!R"?$C3J&/D)E66,E/$9=V8:)GFT,:;DH)2H0W"901=+.'((&H:TQ MAH<@@GGL-D9+::\Q.;8150_9",^F4YS-*^)/%[*L"NI-\86) M%&01NC9!"L MX""R"M+88I1K79-N%8XC,1F:B7K%2[OW(>%-4$N#>@-8/>4X>3HSO0&>Y#9QS ;J6\:7]BI8HZ2/$'#/Y5LJFU/K&Q"&5X)[T@4/I MP#92;KQ]_V\JYHWKO@^TA/O98]3N9UWO.\^Y;[W RATU; M*'J3:/*U1P-T]M2<#(PVCX?S'_@\18NW2]';\<3C]UTS :V$"* M;A(#F66A[;%:6YQ HW"1D6^'4;:^:;,MQJ/2I%X)ZJ$4R?5%$B=5,F2VORU7 MN0%EAI/K]E9V/A+C"LC<\J"2\Q!16RB.B80A!L^:=^K<$N-1*52O!/5R@_S2 M$IN;7V_/9]-9&-?^=@/.O',6:YE3PZK#I\GUTP6L5J*8DH/9K";9;H;P33A' MI2:MQ-[PXE^=]:6:7NGNAT^CX8SVTXM/!M+H8*P5X%.J[518!)]E!&ZD9\DE M,LAN*,7*\,O](QT%WST(M>'5CHKNU9=T6HN[W5ZT[ERRF(TI\*Q!QQ1K 3@. MKDA![IG/T7 NF=BD6=#V(Q^-2O0L](:9M,L%:QG9>8^?NLF\U^FR,Q8IKR]< MUKATJ.L5]PR"Y$A +29?%$/>VF:]&\U1J$ACH;?,UKJZN_J)UC"?K9"Z,%^>325W9>$'O2#=I'ZO31YIY%,% \,K%$'1TL7E[\,V@ M'96F]$%''Z?Z&^*\;,/WMBR^63W[;G$:]JKV]IT.Z65X-3X_PX5$!Y9E%2P& M$*+.SE@)SIL,2+-5 NE'O5&B:7L]VWHNWZ-B]DOX"DW>.3Y<9791AOA%-QH1 M[$D8S6WX, T7&_E[_%Q/6VG9/I_01C_%9R<3G$]O@-IG[IT%XZ(#Q1Q"<*X MEUGQ;+T11FU@.^V.X"BTZX DK-"=%B'EU34,?Y]B.1_],BPX*%(QX[R#H&N= M(1EE3>A2(%*M \!$<-CZ!',#6$>A/7W1L$)5=HX@U^E7#1[/3\1*-SFKR^?5 MNODN?)T7O<0)"2$I+W(.#F3V) 3K!*V%@KP$E2(*J9*/>8-%9=/QCD()>A/P M"BW8.>Q;03Y+:7*.^3U&6N:F[W%V/AG7MGBDO6==13H="&:9S2Y 9$HNZIVZ MZ"4$5M4S2B',)OS?/]+1,-]8J"LXWSDR6^'5*/(%JMH0:/(9!QJEMT(G\$D7 M4#YZ\#H(*$$+F[.PSML-.+[]Y*/A=$^AK>!PKU@JJ5(9SNKQT85!\K&;(QQ8 MKD.NQ0--K%W$JPD2;0WG.!.4%!%M3ALP>=?SCX;/)@)

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Ș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

      &..*'H$I[ $!\YTN)"G@Z8.R_*( MM[_+6MC3-OWLX)^%T"Y+I&&8G^V&'1#6PL-Z#"0&*EO1<)1&SOG\"#/S8Q2"E MJC1)4^*Y3OMET9N.1\$M[LH_&+VN%+K81"#@4CEJ(:*ML@7LU MI;BC,V>\7KQGKL=^/^W.7CA6R:3NI.IP9N#T"SG2"#C]; Z@ADN(-K.6G3L3 MM9X.5]Y\%%A7U]IT3:,Y^Y3_L*]%?NNNQY4/-3TU,F%%?RVYH_*0^P#W?U5> MSJ"'5NCV%/_QXL^=E4Z%"^:,I_/OLI?\N@0;E1.P!P7P@>GB9[N''()C8R"@ M%#L=9ER;4[C'.720[H?3>E4MOEFA,3TWR+QM:WTGQ M"I,Z<]\=:7S6^\LN\]+1*FY4-"9A\%J< R@[P)9,!#3Y4]'*")A$D]*/0;@$ M"24T1OO2T)E^8I?WR<&RFESCL3.! NI#C]ZC]T;O",]^H_\#HT?I@S*F5-,^ M**"#Z2.*?R(O\GZ7"KL@!MPH7<4&9$]^=AQ/43K9K656>GSOJ*IWX/T!;\*) M'='<6QCR(^@>'#EI$LYE\1'K@":Q7U\6-&'X+1B&BX9K23A#%\T)I@Z6 M:_U2##^KJ^.V,OCEIU9@9+NV^2<4/[>Q@9SI+F,VMZO)!7+60D!XM7-9V#9$ MULHC@N*8,>A]QE'VT;!+9%Q3JJV:33-MM5 /'L#AXMBFKU@:/XL'/,"NL3ZZ MN&(M]XY1JT\4;,=C8U)B^@70?$ABM%F$R:LZNSY7NGIN?]GOAU'==;BC;B/CVH^4POR.W/[DQ M-W$?!G\L6A_0+$RPUN&,8.L)=ZTP2V+I%L*(MH4F:J>FOF9+2VNPR;!/8Y') M<[TA[Y#TNOL-UUC/T?NXE1&/%P%U JBL1,5,&U)>MZ*PHJA+5(4.4Y/9& N48AI MDV.KL06$J.LB_#:)"U\:1"$LN]P,]I;P^#!_PPQG&,Z#(Q=@Z3>V(30HHYTC M]#@XLA2X387?[5A/4;$8!_6B*WR((6A"!M(J+1"]/VWVJ$=/4^LI53-BSHZ. M)W=V.'.#BAUK%WH'H/H;-N'3_?9J;0DNW[IKRSP&;OG*EHE#&T(;)4!\: AI?U 4[C;5E_S#4?$I;T" M5_(H'1/[=ZD5Z(WSP(D[4D]A,$DT:5&:H\=]=?^B$EK>X0THQB[JLY!;^T1? M/Y_UHFFBJ:4CD?1Q-60*4"NA*@UFO;,<.JI;VZP*01=A\%U8NB-6 HV'-YQ] MSL QL[TWH3DPQ<.I:6BML+^E<84%09ZA+\9()SYO&ECE0ZDE7KOK"0K09QX MC&'($7+GNN4?.SH0V"0LW@'D N=)1T*@*YM:< MMS'[H2.=[U%K2R9(/%3BEWVG('#._F?J7=#Y%9>QD8(SHPXHK.T<=T.">P4]V2YD;WY M5Y>GS'4(I9*BO)(PTTUERW,CFX*_G_I\]$54AOKH9L0MZ3 LGAC4E]CN%K>M MF0G[T\"DL.]5<8QF'!F6E(>9YX!JDO[O2H^>PY6*V3S'=G?OU85V6+M/9V16 ME1J4"Z_F$,,.(EC"M(-_PPW=&PH6OBUX9E,7D!^MKI7Q>;NH)AZQ?8-P_Y^N MD%7A4HKY04V,! BCQ#_&-3:U._IW=5WY^(B-D.P\P=0;AE$TV.4HF;*K\U]7 MJ3^@FSVF6-@?T=3:R;=_&T0TG0 5FL>!<,6"9,2J8F^3&RR]X<7[VIH-6>9X/1DB%XAOR;AO_? MG,VBTS!X'0SYP114_)K1(BF264A?<1$;&(RD1 @O]"=52'ST]]N_S%ES\HYX#2IWQA[(LF=W UK/PUB@I0.YX1\:C?S*KGQ_$4M4? M/?@-[5@]ES-:;.?A(?0,L@>B7!ZFU%KOH/I?*:G]Z>4(>7,]RSMV,89<"15J MA";A&FE6S]F97/,="KB1#2GK:;^GP M+M7,U' $XECR.PGK+67I7#=;"A.)ABLY,_@'?+*;;E<2*A&UG\KN13NFO&O= MH/A&!RI-TP:?B(K>FAJ#J5@+(X69]P%MZN+,-H3Z\.[4!25&3:J^D?--X;@A M-^.J(;V]C_?=S&GZX*DLP-\4_> J\Z6QU]L%6=[)0\F66420H,.&=AX\';#$(N T6..8#3+ M%>6, QHH@AVA])9S$]<6EMU&0<$WI.K"0]4.L8Z^C^-0B0Z?WQ>I[Z/P1XQ; MZ/"2UP&M0E"IG/O.#:[+O8PZD;,4T:NGWX?MQG^X1F!-G%E;/GX"[QF4Z1#]N]#J(G.KWT4[IV(5QL7D=8 MHU!P,^[DX+L!M?38%*.&@-# R'L7OAP-*@Z=A3@>JE[7R$I0>/J.]PZ=< ]& M'N<:G=VZ5.7H.MH1RL Y_I MG+)YYK42+\WSD SG!6"4PL3&G%2H6(=Y:.EWBSU%>YZ^6#$13R,W-*489^L$ MN/:\>%%Q9UIH8N<4D((!#B^"DNY4#"BS3(8GH85!*_8SFA4_?RK*6:NR A-R MWB5ZSXN]>\Q&2M-/[BX]>M'7[,. (3S*U09*W(;'P#))<%I>!X>CN3,9 $F5+;=&>WC]! M^TWDE3$XL;OPAJW(O?RPG[G[[S\M5;TOP![DDFQ3'+D51S^!W1I=[>Y0TNUCCQ JN*,9G;=@ECAPQL33FT?W"?:Y MM20&;PA"%H>)J/7DV"'FA)578[/F)%4U'6;#GD_6)#X_S0 M[B]EN1($^9JRD&=B>+8^1V1'!K23\Z&%M WIA0':+J ,CB.!36EC+WVRQMZN M7B7IO9_;51!RM;18ZXFJ0/"I>]C+]%(AW$T,GHM0R$DP 1PY]];9%H;8>08+ MX"Y60D:X777GTH&W:*+(J]<,76_2J:&?;T8/=N19RCXL/7%72+8+?)%@?9+[ MV@^<;DQC*BC=S@QK9#] "W-&%8-[(T00BAV1X/'.=Z-:[6T35U\$(M>H,VJ[ M,]];$3[\R72M/EXH,H:RYU;WX Q>X'K)Q*!Y#%XWJE-VZ200Q9%*/56;UU?> MUE2LX/9-=^-T7R$4D77-K[8O3W9^*RM>UPZ"-N/",?JU'%!:=RFX=S$56J=/ M&^0&6LUAT(/+F@].AO_\K2^,1/1 KTQL6MZ^@JRBO7[RYDA%KT;N 0/BUTJZ M?(4!IR^4%)^=7X9_%5J0.SOK>[S.%R_)=WKIW*Z*.\,0""_I]7]S60+-KH-= M6A0#XUL*"2K\&T9$.3LY@R.SHB\A%$W"_/4]LB[X^B->OZ;Z2R08^G>L[*(I M,/F0%L68TL #V:NC7TWJH:L"^-U7Q&UW)\'KHK_A&KW6&NA$YOWAK@_42OWZ ML.%37F>GPM55XG'7N8C^F#KQGPCWQ)??J@V:OT66?:J Z8;4' =8+ .4._MI M4V\9,&5O$+KQWK/7I]%M,8@Z((/MO1?2&GYW"8^M=:/P,47KR M:8Y*EH3?-N2VZ_W9-Z!O^(&K_Z#5?Q6GZ[SY+V\:'!CN-1[Z$!$A[*"1*6LV MXA!T^3J$M[RZC$SHWH:DXQJULVEH)5"%[O&MM7)^7YJ>^]=D YX\+[/SI0H* M,:I[L^-D_FYR/<$?[JQP (W8#V2)U-A^ST:&2Q\?#[5U8] [A+9R]2U/'#_( MO"BV=?RFM^FE-\W(5%#*D"- TY#D3HQ&?MIMRI#!PW?#*.$XZ(F)H"YW0.): M?,=GQM1*>L6+NW80G@0(6__?DSX%J6_25-0/B9K-9?.>(B>^S>3Q=!-X7SV0(*3; MAPD5 W3TU[ZR#G*&L0+;D""7C%L%=6+I:!.$G$5$HOK8[]##JJ&4C1-Q&S42 M!T*IY^(&UIY6"(M=V[F^L@R?+>0(85E^ M;AC4CJ\8C-&SJH%];4P_WGZ2\43E69Z%(N3OP?0_ZLR;W#[^RJUJB.,2S0Q2 M1#>4!X5J'44AJI3;M%.M$)1CCLX[_!_G MV<@<&I?K\O&QG^"NP+.V(0*88&)F,=?Z-(XID.TOU3VR0C(J/-(Y'KX+:FU' ME5F,WO5E>?U+0L50QSH-O[/QR\[?AEQTD0<"*)@!):STCPL&C*R.*1_^1)"/ MXO@TV*-D5.K>M4QQWGK-_5U!JLT$DE( #?+W>/J?J1WG\Q+]T8=+05SI!*9Y M/8YAA#8!6NCSJ!L48=]%H;G9OJCF]#@OFLC!2E\G-]+-R]%\3K=]$0:Z\3+_ M@931YAC\0;0(9P%+=X^X"Q6W/@:,<818# )^]/LV1 %E2ZD4D>H-/HL(H86K M:*4E&;>;W#CJ%RSO"J]K KA<#2MT] 1&*,H:FCTY8WSS^AF8##4'/M_'3-/_W[4(],(*A M+:KV-QY"I,P\!#UB$,'H=1ZA+\CI-&W5C2C=?'MTAJIZ'5D<7.<*]W MOYKDOZDARB&ANPI)"3D/9;R:4)6,5.J.(OSN+. >2Y4[87QJ&A\76?$S^)GP M6B":<7EAP #U8S!<2.^$?3YDWZ=#]_]8YLQGSV5_2]CY?L=+;@UG7'@HC%S7 MM0= L/11D1.@*1W3#5=$\=(7"04^OL^2^A07:JRVIFXTR%A.ZI[W7+#C_W)U M&X+N[&4689F=[ HO6XIHZ?9GY!\BE9^ M[-<6PY?,:*#0Y,M!=-M;SZS6 M:VHW4APS\\R'$.MP;=")C04#Z1B.X IK+W@>P"E$I&'W82*@(N!9X$ZTFDQ< M1-.]PX?5//F_N37C@MQ2?]:BBXS788V8M9SGG)E%>B3AGK4LD+2$Z5N$] :P MU$FK&6_! XPG;;*EAEHM$>*)CFD/,[I/?BVVNMAQHX6>#F'5,,W9=[N.H8

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a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ε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�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end XML 171 jnj-20241229_htm.xml IDEA: XBRL DOCUMENT 0000200406 2024-01-01 2024-12-29 0000200406 us-gaap:CommonStockMember 2024-01-01 2024-12-29 0000200406 jnj:A1.150NotesDueNovember2028Member 2024-01-01 2024-12-29 0000200406 jnj:A3.20NotesDueNovember2032Member 2024-01-01 2024-12-29 0000200406 jnj:A1.650NotesDue2035Member 2024-01-01 2024-12-29 0000200406 jnj:A3.350NotesDueNovember2036Member 2024-01-01 2024-12-29 0000200406 jnj:A3.550NotesDueNovember2044Member 2024-01-01 2024-12-29 0000200406 2024-06-30 0000200406 2025-02-06 0000200406 2024-12-29 0000200406 2023-12-31 0000200406 2023-01-02 2023-12-31 0000200406 2022-01-03 2023-01-01 0000200406 2022-01-02 0000200406 us-gaap:RetainedEarningsMember 2022-01-02 0000200406 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-02 0000200406 us-gaap:CommonStockMember 2022-01-02 0000200406 us-gaap:TreasuryStockCommonMember 2022-01-02 0000200406 us-gaap:RetainedEarningsMember 2022-01-03 2023-01-01 0000200406 us-gaap:TreasuryStockCommonMember 2022-01-03 2023-01-01 0000200406 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-03 2023-01-01 0000200406 2023-01-01 0000200406 us-gaap:RetainedEarningsMember 2023-01-01 0000200406 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 0000200406 us-gaap:CommonStockMember 2023-01-01 0000200406 us-gaap:TreasuryStockCommonMember 2023-01-01 0000200406 us-gaap:RetainedEarningsMember 2023-01-02 2023-12-31 0000200406 us-gaap:TreasuryStockCommonMember 2023-01-02 2023-12-31 0000200406 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-02 2023-12-31 0000200406 us-gaap:RetainedEarningsMember 2023-12-31 0000200406 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0000200406 us-gaap:CommonStockMember 2023-12-31 0000200406 us-gaap:TreasuryStockCommonMember 2023-12-31 0000200406 us-gaap:RetainedEarningsMember 2024-01-01 2024-12-29 0000200406 us-gaap:TreasuryStockCommonMember 2024-01-01 2024-12-29 0000200406 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-12-29 0000200406 us-gaap:RetainedEarningsMember 2024-12-29 0000200406 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-12-29 0000200406 us-gaap:CommonStockMember 2024-12-29 0000200406 us-gaap:TreasuryStockCommonMember 2024-12-29 0000200406 us-gaap:IPOMember jnj:KenvueIncMember 2023-05-08 2023-05-08 0000200406 jnj:KenvueIncMember 2023-05-08 0000200406 2023-05-08 2023-05-08 0000200406 jnj:KenvueIncMember jnj:JohnsonJohnsonMember 2023-05-08 2023-05-08 0000200406 jnj:KenvueIncMember jnj:JohnsonJohnsonMember 2023-07-02 0000200406 jnj:KenvueIncMember 2023-08-23 2023-08-23 0000200406 jnj:KenvueIncMember jnj:JohnsonJohnsonMember 2023-08-23 2023-08-23 0000200406 srt:MaximumMember us-gaap:BuildingAndBuildingImprovementsMember 2024-12-29 0000200406 srt:MinimumMember jnj:LandAndLeaseholdImprovementsMember 2024-12-29 0000200406 srt:MaximumMember jnj:LandAndLeaseholdImprovementsMember 2024-12-29 0000200406 srt:MinimumMember us-gaap:MachineryAndEquipmentMember 2024-12-29 0000200406 srt:MaximumMember us-gaap:MachineryAndEquipmentMember 2024-12-29 0000200406 srt:MinimumMember us-gaap:SoftwareDevelopmentMember 2024-12-29 0000200406 srt:MaximumMember us-gaap:SoftwareDevelopmentMember 2024-12-29 0000200406 srt:MinimumMember 2024-01-01 2024-12-29 0000200406 srt:MaximumMember 2024-01-01 2024-12-29 0000200406 jnj:PharmaceuticalMember 2024-12-29 0000200406 jnj:PharmaceuticalMember 2023-12-31 0000200406 us-gaap:ShippingAndHandlingMember 2024-01-01 2024-12-29 0000200406 us-gaap:ShippingAndHandlingMember 2023-01-02 2023-12-31 0000200406 us-gaap:ShippingAndHandlingMember 2021-01-04 2022-01-02 0000200406 us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:ProductConcentrationRiskMember 2024-01-01 2024-12-29 0000200406 us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:ProductConcentrationRiskMember 2023-01-02 2023-12-31 0000200406 us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:ProductConcentrationRiskMember 2022-01-03 2023-01-01 0000200406 jnj:YellowJerseyTherapeuticsMember 2024-01-01 2024-12-29 0000200406 2018-12-31 2019-12-29 0000200406 2019-12-30 2021-01-03 0000200406 us-gaap:CashMember us-gaap:HeldtomaturitySecuritiesMember 2024-12-29 0000200406 us-gaap:SovereignDebtSecuritiesMember us-gaap:HeldtomaturitySecuritiesMember 2024-12-29 0000200406 us-gaap:RepurchaseAgreementsMember us-gaap:HeldtomaturitySecuritiesMember 2024-12-29 0000200406 us-gaap:MoneyMarketFundsMember us-gaap:HeldtomaturitySecuritiesMember 2024-12-29 0000200406 us-gaap:CorporateDebtSecuritiesMember us-gaap:HeldtomaturitySecuritiesMember 2024-12-29 0000200406 us-gaap:BankTimeDepositsMember us-gaap:HeldtomaturitySecuritiesMember 2024-12-29 0000200406 us-gaap:HeldtomaturitySecuritiesMember 2024-12-29 0000200406 us-gaap:USTreasuryAndGovernmentMember us-gaap:AvailableforsaleSecuritiesMember 2024-12-29 0000200406 jnj:OtherSovereignSecuritiesMember us-gaap:AvailableforsaleSecuritiesMember 2024-12-29 0000200406 us-gaap:CorporateDebtSecuritiesMember us-gaap:AvailableforsaleSecuritiesMember 2024-12-29 0000200406 us-gaap:AvailableforsaleSecuritiesMember 2024-12-29 0000200406 us-gaap:CashMember us-gaap:HeldtomaturitySecuritiesMember 2023-12-31 0000200406 us-gaap:SovereignDebtSecuritiesMember us-gaap:HeldtomaturitySecuritiesMember 2023-12-31 0000200406 us-gaap:RepurchaseAgreementsMember us-gaap:HeldtomaturitySecuritiesMember 2023-12-31 0000200406 us-gaap:CorporateDebtSecuritiesMember us-gaap:HeldtomaturitySecuritiesMember 2023-12-31 0000200406 us-gaap:MoneyMarketFundsMember us-gaap:HeldtomaturitySecuritiesMember 2023-12-31 0000200406 us-gaap:BankTimeDepositsMember us-gaap:HeldtomaturitySecuritiesMember 2023-12-31 0000200406 us-gaap:HeldtomaturitySecuritiesMember 2023-12-31 0000200406 us-gaap:USTreasuryAndGovernmentMember us-gaap:AvailableforsaleSecuritiesMember 2023-12-31 0000200406 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:AvailableforsaleSecuritiesMember 2023-12-31 0000200406 jnj:OtherSovereignSecuritiesMember us-gaap:AvailableforsaleSecuritiesMember 2023-12-31 0000200406 us-gaap:CorporateDebtSecuritiesMember us-gaap:AvailableforsaleSecuritiesMember 2023-12-31 0000200406 us-gaap:AvailableforsaleSecuritiesMember 2023-12-31 0000200406 jnj:LandAndLeaseholdImprovementsMember 2024-12-29 0000200406 jnj:LandAndLeaseholdImprovementsMember 2023-12-31 0000200406 us-gaap:BuildingAndBuildingImprovementsMember 2024-12-29 0000200406 us-gaap:BuildingAndBuildingImprovementsMember 2023-12-31 0000200406 us-gaap:MachineryAndEquipmentMember 2024-12-29 0000200406 us-gaap:MachineryAndEquipmentMember 2023-12-31 0000200406 us-gaap:ConstructionInProgressMember 2024-12-29 0000200406 us-gaap:ConstructionInProgressMember 2023-12-31 0000200406 jnj:PatentsAndTrademarksMember 2024-12-29 0000200406 jnj:PatentsAndTrademarksMember 2023-12-31 0000200406 us-gaap:OtherIntangibleAssetsMember 2024-12-29 0000200406 us-gaap:OtherIntangibleAssetsMember 2023-12-31 0000200406 us-gaap:TrademarksMember 2024-12-29 0000200406 us-gaap:TrademarksMember 2023-12-31 0000200406 jnj:PurchasedInProcessResearchAndDevelopmentMember 2024-12-29 0000200406 jnj:PurchasedInProcessResearchAndDevelopmentMember 2023-12-31 0000200406 us-gaap:TrademarksMember 2024-09-30 0000200406 jnj:InnovativeMedicineMember 2023-01-01 0000200406 jnj:MedTechMember 2023-01-01 0000200406 jnj:InnovativeMedicineMember 2023-01-02 2023-12-31 0000200406 jnj:MedTechMember 2023-01-02 2023-12-31 0000200406 jnj:InnovativeMedicineMember 2023-12-31 0000200406 jnj:MedTechMember 2023-12-31 0000200406 jnj:InnovativeMedicineMember 2024-01-01 2024-12-29 0000200406 jnj:MedTechMember 2024-01-01 2024-12-29 0000200406 jnj:InnovativeMedicineMember 2024-12-29 0000200406 jnj:MedTechMember 2024-12-29 0000200406 us-gaap:ForeignExchangeContractMember 2024-12-29 0000200406 us-gaap:ForeignExchangeContractMember 2023-12-31 0000200406 us-gaap:CrossCurrencyInterestRateContractMember 2024-12-29 0000200406 us-gaap:InterestRateSwapMember 2024-12-29 0000200406 us-gaap:CrossCurrencyInterestRateContractMember 2023-12-31 0000200406 us-gaap:InterestRateSwapMember 2023-12-31 0000200406 us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:SalesMember 2024-01-01 2024-12-29 0000200406 us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:CostOfSalesMember 2024-01-01 2024-12-29 0000200406 us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-01 2024-12-29 0000200406 us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember jnj:InterestIncomeExpenseNetMember 2024-01-01 2024-12-29 0000200406 us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember jnj:OtherIncomeExpenseNetMember 2024-01-01 2024-12-29 0000200406 us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:SalesMember 2023-01-02 2023-12-31 0000200406 us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:CostOfSalesMember 2023-01-02 2023-12-31 0000200406 us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-02 2023-12-31 0000200406 us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember jnj:InterestIncomeExpenseNetMember 2023-01-02 2023-12-31 0000200406 us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember jnj:OtherIncomeExpenseNetMember 2023-01-02 2023-12-31 0000200406 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:FairValueHedgingMember us-gaap:SalesMember 2024-01-01 2024-12-29 0000200406 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:FairValueHedgingMember us-gaap:CostOfSalesMember 2024-01-01 2024-12-29 0000200406 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:FairValueHedgingMember us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-01 2024-12-29 0000200406 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:FairValueHedgingMember jnj:InterestIncomeExpenseNetMember 2024-01-01 2024-12-29 0000200406 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:FairValueHedgingMember jnj:OtherIncomeExpenseNetMember 2024-01-01 2024-12-29 0000200406 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:FairValueHedgingMember us-gaap:SalesMember 2023-01-02 2023-12-31 0000200406 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:FairValueHedgingMember us-gaap:CostOfSalesMember 2023-01-02 2023-12-31 0000200406 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:FairValueHedgingMember us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-02 2023-12-31 0000200406 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:FairValueHedgingMember jnj:InterestIncomeExpenseNetMember 2023-01-02 2023-12-31 0000200406 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:FairValueHedgingMember jnj:OtherIncomeExpenseNetMember 2023-01-02 2023-12-31 0000200406 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:SalesMember 2024-01-01 2024-12-29 0000200406 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:CostOfSalesMember 2024-01-01 2024-12-29 0000200406 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-01 2024-12-29 0000200406 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember jnj:InterestIncomeExpenseNetMember 2024-01-01 2024-12-29 0000200406 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember jnj:OtherIncomeExpenseNetMember 2024-01-01 2024-12-29 0000200406 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:SalesMember 2023-01-02 2023-12-31 0000200406 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:CostOfSalesMember 2023-01-02 2023-12-31 0000200406 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-02 2023-12-31 0000200406 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember jnj:InterestIncomeExpenseNetMember 2023-01-02 2023-12-31 0000200406 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember jnj:OtherIncomeExpenseNetMember 2023-01-02 2023-12-31 0000200406 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:SalesMember 2024-01-01 2024-12-29 0000200406 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:CostOfSalesMember 2024-01-01 2024-12-29 0000200406 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-01 2024-12-29 0000200406 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember jnj:InterestIncomeExpenseNetMember 2024-01-01 2024-12-29 0000200406 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember jnj:OtherIncomeExpenseNetMember 2024-01-01 2024-12-29 0000200406 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:SalesMember 2023-01-02 2023-12-31 0000200406 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:CostOfSalesMember 2023-01-02 2023-12-31 0000200406 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-02 2023-12-31 0000200406 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember jnj:InterestIncomeExpenseNetMember 2023-01-02 2023-12-31 0000200406 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember jnj:OtherIncomeExpenseNetMember 2023-01-02 2023-12-31 0000200406 us-gaap:LongTermDebtMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-12-29 0000200406 us-gaap:LongTermDebtMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-12-31 0000200406 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2024-01-01 2024-12-29 0000200406 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2023-01-02 2023-12-31 0000200406 jnj:OtherIncomeExpenseNetMember 2024-09-30 2024-12-29 0000200406 jnj:OtherIncomeExpenseNetMember 2023-10-02 2023-12-31 0000200406 us-gaap:CrossCurrencyInterestRateContractMember 2024-01-01 2024-12-29 0000200406 us-gaap:CrossCurrencyInterestRateContractMember 2023-01-02 2023-12-31 0000200406 us-gaap:CrossCurrencyInterestRateContractMember jnj:OtherIncomeExpenseNetMember 2024-09-30 2024-12-29 0000200406 us-gaap:CrossCurrencyInterestRateContractMember jnj:OtherIncomeExpenseNetMember 2023-10-02 2023-12-31 0000200406 us-gaap:EquitySecuritiesMember jnj:EquityInvestmentswithReadilyDeterminableValueMember 2023-12-31 0000200406 us-gaap:EquitySecuritiesMember jnj:EquityInvestmentswithReadilyDeterminableValueMember 2024-01-01 2024-12-29 0000200406 us-gaap:EquitySecuritiesMember jnj:EquityInvestmentswithReadilyDeterminableValueMember 2024-12-29 0000200406 us-gaap:EquitySecuritiesMember jnj:EquityInvestmentswithoutReadilyDeterminableValueMember 2023-12-31 0000200406 us-gaap:EquitySecuritiesMember jnj:EquityInvestmentswithoutReadilyDeterminableValueMember 2024-01-01 2024-12-29 0000200406 us-gaap:EquitySecuritiesMember jnj:EquityInvestmentswithoutReadilyDeterminableValueMember 2024-12-29 0000200406 us-gaap:EquitySecuritiesMember jnj:EquityInvestmentswithReadilyDeterminableValueMember 2023-01-01 0000200406 us-gaap:EquitySecuritiesMember jnj:EquityInvestmentswithReadilyDeterminableValueMember 2023-01-02 2023-12-31 0000200406 us-gaap:EquitySecuritiesMember jnj:EquityInvestmentswithoutReadilyDeterminableValueMember 2023-01-01 0000200406 us-gaap:EquitySecuritiesMember jnj:EquityInvestmentswithoutReadilyDeterminableValueMember 2023-01-02 2023-12-31 0000200406 2024-05-15 0000200406 2024-05-15 2024-05-15 0000200406 2024-05-17 0000200406 2024-05-17 2024-05-17 0000200406 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel1Member 2024-12-29 0000200406 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel2Member 2024-12-29 0000200406 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel3Member 2024-12-29 0000200406 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel2Member 2023-12-31 0000200406 us-gaap:InterestRateContractMember us-gaap:FairValueInputsLevel1Member 2024-12-29 0000200406 us-gaap:InterestRateContractMember us-gaap:FairValueInputsLevel2Member 2024-12-29 0000200406 us-gaap:InterestRateContractMember us-gaap:FairValueInputsLevel3Member 2024-12-29 0000200406 us-gaap:InterestRateContractMember 2024-12-29 0000200406 us-gaap:InterestRateContractMember us-gaap:FairValueInputsLevel2Member 2023-12-31 0000200406 us-gaap:FairValueInputsLevel1Member 2024-12-29 0000200406 us-gaap:FairValueInputsLevel2Member 2024-12-29 0000200406 us-gaap:FairValueInputsLevel3Member 2024-12-29 0000200406 us-gaap:FairValueInputsLevel2Member 2023-12-31 0000200406 us-gaap:FairValueInputsLevel1Member 2023-12-31 0000200406 us-gaap:FairValueInputsLevel3Member 2023-12-31 0000200406 us-gaap:OtherNoncurrentLiabilitiesMember 2024-12-29 0000200406 us-gaap:OtherNoncurrentLiabilitiesMember 2023-12-31 0000200406 us-gaap:OtherNoncurrentLiabilitiesMember 2023-01-01 0000200406 us-gaap:OtherCurrentLiabilitiesMember 2023-01-01 0000200406 jnj:ProteologixMember 2024-12-29 0000200406 jnj:AbiomedMember 2023-01-01 0000200406 jnj:A0.650NotesDue2024Member 2024-12-29 0000200406 jnj:A0.650NotesDue2024Member 2023-12-31 0000200406 jnj:A5.50NotesDue2024Member 2024-12-29 0000200406 jnj:A5.50NotesDue2024Member 2023-12-31 0000200406 jnj:A2.625Notesdue2025Member 2024-12-29 0000200406 jnj:A2.625Notesdue2025Member 2023-12-31 0000200406 jnj:A055NotesDue2025Member 2024-12-29 0000200406 jnj:A055NotesDue2025Member 2023-12-31 0000200406 jnj:A2.45Notesdue2026Member 2024-12-29 0000200406 jnj:A2.45Notesdue2026Member 2023-12-31 0000200406 jnj:A2.95Notesdue2027Member 2024-12-29 0000200406 jnj:A2.95Notesdue2027Member 2023-12-31 0000200406 jnj:A095NotesDue2027Member 2024-12-29 0000200406 jnj:A095NotesDue2027Member 2023-12-31 0000200406 jnj:A1.150NotesDue2028Member 2024-12-29 0000200406 jnj:A1.150NotesDue2028Member 2023-12-31 0000200406 jnj:A2.900Notesdue2028Member 2024-12-29 0000200406 jnj:A2.900Notesdue2028Member 2023-12-31 0000200406 jnj:A6.95Notesdue2029Member 2024-12-29 0000200406 jnj:A6.95Notesdue2029Member 2023-12-31 0000200406 jnj:A4.80DebenturesDue2029Member 2024-12-29 0000200406 jnj:A4.80DebenturesDue2029Member 2023-12-31 0000200406 jnj:A130NotesDue2030Member 2024-12-29 0000200406 jnj:A130NotesDue2030Member 2023-12-31 0000200406 jnj:A4.90DebenturesDue2031Member 2024-12-29 0000200406 jnj:A4.90DebenturesDue2031Member 2023-12-31 0000200406 jnj:A3.20DebenturesDue2032Member 2024-12-29 0000200406 jnj:A3.20DebenturesDue2032Member 2023-12-31 0000200406 jnj:A4.95Debenturesdue2033Member 2024-12-29 0000200406 jnj:A4.95Debenturesdue2033Member 2023-12-31 0000200406 jnj:A4.375Notesdue2033Member 2024-12-29 0000200406 jnj:A4.375Notesdue2033Member 2023-12-31 0000200406 jnj:A4.95DebenturesDue2034Member 2024-12-29 0000200406 jnj:A4.95DebenturesDue2034Member 2023-12-31 0000200406 jnj:A1.650NotesDue2035Member 2024-12-29 0000200406 jnj:A1.650NotesDue2035Member 2023-12-31 0000200406 jnj:A3.35DebenturesDue2036Member 2024-12-29 0000200406 jnj:A3.35DebenturesDue2036Member 2023-12-31 0000200406 jnj:A3.55Notesdue2036Member 2024-12-29 0000200406 jnj:A3.55Notesdue2036Member 2023-12-31 0000200406 jnj:A5.95Notesdue2037Member 2024-12-29 0000200406 jnj:A5.95Notesdue2037Member 2023-12-31 0000200406 jnj:A3.625Notesdue2037Member 2024-12-29 0000200406 jnj:A3.625Notesdue2037Member 2023-12-31 0000200406 jnj:A5.85Debenturesdue2038Member 2024-12-29 0000200406 jnj:A5.85Debenturesdue2038Member 2023-12-31 0000200406 jnj:A3.400Notesdue2038Member 2024-12-29 0000200406 jnj:A3.400Notesdue2038Member 2023-12-31 0000200406 jnj:A4.50Debenturesdue2040Member 2024-12-29 0000200406 jnj:A4.50Debenturesdue2040Member 2023-12-31 0000200406 jnj:A210NotesDue2040Member 2024-12-29 0000200406 jnj:A210NotesDue2040Member 2023-12-31 0000200406 jnj:A4.85Notesdue2041Member 2024-12-29 0000200406 jnj:A4.85Notesdue2041Member 2023-12-31 0000200406 jnj:A4.50Notesdue2043Member 2024-12-29 0000200406 jnj:A4.50Notesdue2043Member 2023-12-31 0000200406 jnj:A3.55DebenturesDue2044Member 2024-12-29 0000200406 jnj:A3.55DebenturesDue2044Member 2023-12-31 0000200406 jnj:A3.70Notesdue2046Member 2024-12-29 0000200406 jnj:A3.70Notesdue2046Member 2023-12-31 0000200406 jnj:A3.75Notesdue2047Member 2024-12-29 0000200406 jnj:A3.75Notesdue2047Member 2023-12-31 0000200406 jnj:A3.500Notesdue2048Member 2024-12-29 0000200406 jnj:A3.500Notesdue2048Member 2023-12-31 0000200406 jnj:A2250NotesDue2050Member 2024-12-29 0000200406 jnj:A2250NotesDue2050Member 2023-12-31 0000200406 jnj:A5.25DebenturesDue2054Member 2024-12-29 0000200406 jnj:A5.25DebenturesDue2054Member 2023-12-31 0000200406 jnj:A2450NotesDue2060Member 2024-12-29 0000200406 jnj:A2450NotesDue2060Member 2023-12-31 0000200406 us-gaap:OtherDebtSecuritiesMember 2024-12-29 0000200406 us-gaap:OtherDebtSecuritiesMember 2023-12-31 0000200406 us-gaap:CommercialPaperMember 2024-12-29 0000200406 us-gaap:CommercialPaperMember 2024-01-01 2024-12-29 0000200406 us-gaap:CommercialPaperMember 2023-12-31 0000200406 us-gaap:CommercialPaperMember 2023-01-02 2023-12-31 0000200406 jnj:TalcMember jnj:ConsumerMember 2024-01-01 2024-12-29 0000200406 jnj:TalcMember jnj:ConsumerMember 2023-01-02 2023-12-31 0000200406 2023-10-02 2023-12-31 0000200406 us-gaap:StateAndLocalJurisdictionMember 2024-01-01 2024-12-29 0000200406 jnj:TalcMember jnj:ConsumerMember 2022-01-03 2023-01-01 0000200406 srt:MaximumMember us-gaap:PensionPlansDefinedBenefitMember 2024-01-01 2024-12-29 0000200406 us-gaap:PensionPlansDefinedBenefitMember 2024-01-01 2024-12-29 0000200406 us-gaap:PensionPlansDefinedBenefitMember 2023-01-02 2023-12-31 0000200406 us-gaap:PensionPlansDefinedBenefitMember 2022-01-03 2023-01-01 0000200406 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2024-01-01 2024-12-29 0000200406 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2023-01-02 2023-12-31 0000200406 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2022-01-03 2023-01-01 0000200406 us-gaap:PensionPlansDefinedBenefitMember 2024-12-29 0000200406 us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000200406 us-gaap:PensionPlansDefinedBenefitMember 2023-01-01 0000200406 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2024-12-29 0000200406 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2023-12-31 0000200406 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2023-01-01 0000200406 country:US 2024-01-01 2024-12-29 0000200406 us-gaap:ForeignPlanMember 2024-01-01 2024-12-29 0000200406 jnj:QualifiedPlansMember country:US 2024-12-29 0000200406 jnj:QualifiedPlansMember country:US 2023-12-31 0000200406 jnj:NonQualifiedPlansMember country:US 2024-12-29 0000200406 jnj:NonQualifiedPlansMember country:US 2023-12-31 0000200406 jnj:FundedPlansMember us-gaap:ForeignPlanMember 2024-12-29 0000200406 jnj:FundedPlansMember us-gaap:ForeignPlanMember 2023-12-31 0000200406 jnj:UnfundedPlansMember us-gaap:ForeignPlanMember 2024-12-29 0000200406 jnj:UnfundedPlansMember us-gaap:ForeignPlanMember 2023-12-31 0000200406 us-gaap:EquitySecuritiesMember 2024-12-29 0000200406 us-gaap:EquitySecuritiesMember 2023-12-31 0000200406 us-gaap:DebtSecuritiesMember 2024-12-29 0000200406 us-gaap:DebtSecuritiesMember 2023-12-31 0000200406 jnj:ShortTermInvestmentFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:PensionPlansDefinedBenefitMember 2024-12-29 0000200406 jnj:ShortTermInvestmentFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000200406 jnj:ShortTermInvestmentFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:PensionPlansDefinedBenefitMember 2024-12-29 0000200406 jnj:ShortTermInvestmentFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000200406 jnj:ShortTermInvestmentFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:PensionPlansDefinedBenefitMember 2024-12-29 0000200406 jnj:ShortTermInvestmentFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000200406 jnj:ShortTermInvestmentFundsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:PensionPlansDefinedBenefitMember 2024-12-29 0000200406 jnj:ShortTermInvestmentFundsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000200406 us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:PensionPlansDefinedBenefitMember 2024-12-29 0000200406 us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000200406 us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:PensionPlansDefinedBenefitMember 2024-12-29 0000200406 us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000200406 us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:PensionPlansDefinedBenefitMember 2024-12-29 0000200406 us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000200406 us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:PensionPlansDefinedBenefitMember 2024-12-29 0000200406 us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000200406 us-gaap:DebtSecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:PensionPlansDefinedBenefitMember 2024-12-29 0000200406 us-gaap:DebtSecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000200406 us-gaap:DebtSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:PensionPlansDefinedBenefitMember 2024-12-29 0000200406 us-gaap:DebtSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000200406 us-gaap:DebtSecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:PensionPlansDefinedBenefitMember 2024-12-29 0000200406 us-gaap:DebtSecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000200406 us-gaap:DebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:PensionPlansDefinedBenefitMember 2024-12-29 0000200406 us-gaap:DebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000200406 us-gaap:EquitySecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:PensionPlansDefinedBenefitMember 2024-12-29 0000200406 us-gaap:EquitySecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000200406 us-gaap:EquitySecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:PensionPlansDefinedBenefitMember 2024-12-29 0000200406 us-gaap:EquitySecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000200406 us-gaap:EquitySecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:PensionPlansDefinedBenefitMember 2024-12-29 0000200406 us-gaap:EquitySecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000200406 us-gaap:EquitySecuritiesMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:PensionPlansDefinedBenefitMember 2024-12-29 0000200406 us-gaap:EquitySecuritiesMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000200406 jnj:CommingledFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:PensionPlansDefinedBenefitMember 2024-12-29 0000200406 jnj:CommingledFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000200406 jnj:CommingledFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:PensionPlansDefinedBenefitMember 2024-12-29 0000200406 jnj:CommingledFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000200406 jnj:CommingledFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:PensionPlansDefinedBenefitMember 2024-12-29 0000200406 jnj:CommingledFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000200406 jnj:CommingledFundsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:PensionPlansDefinedBenefitMember 2024-12-29 0000200406 jnj:CommingledFundsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000200406 us-gaap:OtherAssetsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:PensionPlansDefinedBenefitMember 2024-12-29 0000200406 us-gaap:OtherAssetsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000200406 us-gaap:OtherAssetsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:PensionPlansDefinedBenefitMember 2024-12-29 0000200406 us-gaap:OtherAssetsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000200406 us-gaap:OtherAssetsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:PensionPlansDefinedBenefitMember 2024-12-29 0000200406 us-gaap:OtherAssetsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000200406 us-gaap:OtherAssetsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:PensionPlansDefinedBenefitMember 2024-12-29 0000200406 us-gaap:OtherAssetsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000200406 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:PensionPlansDefinedBenefitMember 2024-12-29 0000200406 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000200406 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:PensionPlansDefinedBenefitMember 2024-12-29 0000200406 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000200406 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:PensionPlansDefinedBenefitMember 2024-12-29 0000200406 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000200406 us-gaap:FairValueMeasurementsRecurringMember us-gaap:PensionPlansDefinedBenefitMember 2024-12-29 0000200406 us-gaap:FairValueMeasurementsRecurringMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000200406 jnj:CommingledFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2024-12-29 0000200406 jnj:CommingledFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2023-12-31 0000200406 us-gaap:SubsequentEventMember 2025-01-02 2025-01-02 0000200406 jnj:December172018ShareRepurchaseProgramMember 2022-09-14 0000200406 us-gaap:AccumulatedTranslationAdjustmentMember 2022-01-02 0000200406 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2022-01-02 0000200406 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2022-01-02 0000200406 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2022-01-02 0000200406 us-gaap:AccumulatedTranslationAdjustmentMember 2022-01-03 2023-01-01 0000200406 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2022-01-03 2023-01-01 0000200406 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2022-01-03 2023-01-01 0000200406 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2022-01-03 2023-01-01 0000200406 us-gaap:AccumulatedTranslationAdjustmentMember 2023-01-01 0000200406 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2023-01-01 0000200406 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2023-01-01 0000200406 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2023-01-01 0000200406 us-gaap:AccumulatedTranslationAdjustmentMember 2023-01-02 2023-12-31 0000200406 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2023-01-02 2023-12-31 0000200406 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2023-01-02 2023-12-31 0000200406 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2023-01-02 2023-12-31 0000200406 us-gaap:AccumulatedTranslationAdjustmentMember 2023-12-31 0000200406 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2023-12-31 0000200406 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2023-12-31 0000200406 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2023-12-31 0000200406 us-gaap:AccumulatedTranslationAdjustmentMember 2024-01-01 2024-12-29 0000200406 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2024-01-01 2024-12-29 0000200406 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2024-01-01 2024-12-29 0000200406 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2024-01-01 2024-12-29 0000200406 us-gaap:AccumulatedTranslationAdjustmentMember 2024-12-29 0000200406 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2024-12-29 0000200406 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2024-12-29 0000200406 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2024-12-29 0000200406 2021-01-04 2022-01-02 0000200406 jnj:A2022LongTermIncentivePlanMember 2024-12-29 0000200406 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-12-29 0000200406 srt:MinimumMember us-gaap:EmployeeStockOptionMember 2024-01-01 2024-12-29 0000200406 srt:MaximumMember us-gaap:EmployeeStockOptionMember 2024-01-01 2024-12-29 0000200406 jnj:ExercisePriceRangeOneMember 2024-01-01 2024-12-29 0000200406 jnj:ExercisePriceRangeOneMember 2024-12-29 0000200406 jnj:ExercisePriceRangeTwoMember 2024-01-01 2024-12-29 0000200406 jnj:ExercisePriceRangeTwoMember 2024-12-29 0000200406 jnj:ExercisePriceRangeThreeMember 2024-01-01 2024-12-29 0000200406 jnj:ExercisePriceRangeThreeMember 2024-12-29 0000200406 jnj:ExercisePriceRangeFourMember 2024-01-01 2024-12-29 0000200406 jnj:ExercisePriceRangeFourMember 2024-12-29 0000200406 jnj:ExercisePriceRangeFiveMember 2024-01-01 2024-12-29 0000200406 jnj:ExercisePriceRangeFiveMember 2024-12-29 0000200406 srt:MinimumMember us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-12-29 0000200406 srt:MaximumMember us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-12-29 0000200406 us-gaap:PerformanceSharesMember 2024-01-01 2024-12-29 0000200406 srt:MinimumMember us-gaap:PerformanceSharesMember 2024-01-01 2024-12-29 0000200406 srt:MaximumMember us-gaap:PerformanceSharesMember 2024-01-01 2024-12-29 0000200406 us-gaap:RestrictedStockUnitsRSUMember 2023-12-31 0000200406 us-gaap:PerformanceSharesMember 2023-12-31 0000200406 us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-12-29 0000200406 us-gaap:RestrictedStockUnitsRSUMember 2024-12-29 0000200406 us-gaap:PerformanceSharesMember 2024-12-29 0000200406 us-gaap:RestrictedStockUnitsRSUMember 2023-01-02 2023-12-31 0000200406 us-gaap:RestrictedStockUnitsRSUMember 2022-01-03 2023-01-01 0000200406 us-gaap:PerformanceSharesMember 2023-01-02 2023-12-31 0000200406 us-gaap:PerformanceSharesMember 2022-01-03 2023-01-01 0000200406 country:US jnj:InnovativeMedicineMember jnj:ImmunologyMember 2024-01-01 2024-12-29 0000200406 country:US jnj:InnovativeMedicineMember jnj:ImmunologyMember 2023-01-02 2023-12-31 0000200406 country:US jnj:InnovativeMedicineMember jnj:ImmunologyMember 2022-01-03 2023-01-01 0000200406 us-gaap:NonUsMember jnj:InnovativeMedicineMember jnj:ImmunologyMember 2024-01-01 2024-12-29 0000200406 us-gaap:NonUsMember jnj:InnovativeMedicineMember jnj:ImmunologyMember 2023-01-02 2023-12-31 0000200406 us-gaap:NonUsMember jnj:InnovativeMedicineMember jnj:ImmunologyMember 2022-01-03 2023-01-01 0000200406 jnj:InnovativeMedicineMember jnj:ImmunologyMember 2024-01-01 2024-12-29 0000200406 jnj:InnovativeMedicineMember jnj:ImmunologyMember 2023-01-02 2023-12-31 0000200406 jnj:InnovativeMedicineMember jnj:ImmunologyMember 2022-01-03 2023-01-01 0000200406 jnj:RemicadeMember country:US jnj:InnovativeMedicineMember jnj:ImmunologyMember 2024-01-01 2024-12-29 0000200406 jnj:RemicadeMember country:US jnj:InnovativeMedicineMember jnj:ImmunologyMember 2023-01-02 2023-12-31 0000200406 jnj:RemicadeMember country:US jnj:InnovativeMedicineMember jnj:ImmunologyMember 2022-01-03 2023-01-01 0000200406 jnj:RemicadeMember jnj:UNITEDSTATESExportsMember jnj:InnovativeMedicineMember jnj:ImmunologyMember 2024-01-01 2024-12-29 0000200406 jnj:RemicadeMember jnj:UNITEDSTATESExportsMember jnj:InnovativeMedicineMember jnj:ImmunologyMember 2023-01-02 2023-12-31 0000200406 jnj:RemicadeMember jnj:UNITEDSTATESExportsMember jnj:InnovativeMedicineMember jnj:ImmunologyMember 2022-01-03 2023-01-01 0000200406 jnj:RemicadeMember us-gaap:NonUsMember jnj:InnovativeMedicineMember jnj:ImmunologyMember 2024-01-01 2024-12-29 0000200406 jnj:RemicadeMember us-gaap:NonUsMember jnj:InnovativeMedicineMember jnj:ImmunologyMember 2023-01-02 2023-12-31 0000200406 jnj:RemicadeMember us-gaap:NonUsMember jnj:InnovativeMedicineMember jnj:ImmunologyMember 2022-01-03 2023-01-01 0000200406 jnj:RemicadeMember jnj:InnovativeMedicineMember jnj:ImmunologyMember 2024-01-01 2024-12-29 0000200406 jnj:RemicadeMember jnj:InnovativeMedicineMember jnj:ImmunologyMember 2023-01-02 2023-12-31 0000200406 jnj:RemicadeMember jnj:InnovativeMedicineMember jnj:ImmunologyMember 2022-01-03 2023-01-01 0000200406 jnj:SimponiSimponiAriaMember country:US jnj:InnovativeMedicineMember jnj:ImmunologyMember 2024-01-01 2024-12-29 0000200406 jnj:SimponiSimponiAriaMember country:US jnj:InnovativeMedicineMember jnj:ImmunologyMember 2023-01-02 2023-12-31 0000200406 jnj:SimponiSimponiAriaMember country:US jnj:InnovativeMedicineMember jnj:ImmunologyMember 2022-01-03 2023-01-01 0000200406 jnj:SimponiSimponiAriaMember us-gaap:NonUsMember jnj:InnovativeMedicineMember jnj:ImmunologyMember 2024-01-01 2024-12-29 0000200406 jnj:SimponiSimponiAriaMember us-gaap:NonUsMember jnj:InnovativeMedicineMember jnj:ImmunologyMember 2023-01-02 2023-12-31 0000200406 jnj:SimponiSimponiAriaMember us-gaap:NonUsMember jnj:InnovativeMedicineMember jnj:ImmunologyMember 2022-01-03 2023-01-01 0000200406 jnj:SimponiSimponiAriaMember jnj:InnovativeMedicineMember jnj:ImmunologyMember 2024-01-01 2024-12-29 0000200406 jnj:SimponiSimponiAriaMember jnj:InnovativeMedicineMember jnj:ImmunologyMember 2023-01-02 2023-12-31 0000200406 jnj:SimponiSimponiAriaMember jnj:InnovativeMedicineMember jnj:ImmunologyMember 2022-01-03 2023-01-01 0000200406 jnj:StelaraMember country:US jnj:InnovativeMedicineMember jnj:ImmunologyMember 2024-01-01 2024-12-29 0000200406 jnj:StelaraMember country:US jnj:InnovativeMedicineMember jnj:ImmunologyMember 2023-01-02 2023-12-31 0000200406 jnj:StelaraMember country:US jnj:InnovativeMedicineMember jnj:ImmunologyMember 2022-01-03 2023-01-01 0000200406 jnj:StelaraMember us-gaap:NonUsMember jnj:InnovativeMedicineMember jnj:ImmunologyMember 2024-01-01 2024-12-29 0000200406 jnj:StelaraMember us-gaap:NonUsMember jnj:InnovativeMedicineMember jnj:ImmunologyMember 2023-01-02 2023-12-31 0000200406 jnj:StelaraMember us-gaap:NonUsMember jnj:InnovativeMedicineMember jnj:ImmunologyMember 2022-01-03 2023-01-01 0000200406 jnj:StelaraMember jnj:InnovativeMedicineMember jnj:ImmunologyMember 2024-01-01 2024-12-29 0000200406 jnj:StelaraMember jnj:InnovativeMedicineMember jnj:ImmunologyMember 2023-01-02 2023-12-31 0000200406 jnj:StelaraMember jnj:InnovativeMedicineMember jnj:ImmunologyMember 2022-01-03 2023-01-01 0000200406 jnj:TremfyaMember country:US jnj:InnovativeMedicineMember jnj:ImmunologyMember 2024-01-01 2024-12-29 0000200406 jnj:TremfyaMember country:US jnj:InnovativeMedicineMember jnj:ImmunologyMember 2023-01-02 2023-12-31 0000200406 jnj:TremfyaMember country:US jnj:InnovativeMedicineMember jnj:ImmunologyMember 2022-01-03 2023-01-01 0000200406 jnj:TremfyaMember us-gaap:NonUsMember jnj:InnovativeMedicineMember jnj:ImmunologyMember 2024-01-01 2024-12-29 0000200406 jnj:TremfyaMember us-gaap:NonUsMember jnj:InnovativeMedicineMember jnj:ImmunologyMember 2023-01-02 2023-12-31 0000200406 jnj:TremfyaMember us-gaap:NonUsMember jnj:InnovativeMedicineMember jnj:ImmunologyMember 2022-01-03 2023-01-01 0000200406 jnj:TremfyaMember jnj:InnovativeMedicineMember jnj:ImmunologyMember 2024-01-01 2024-12-29 0000200406 jnj:TremfyaMember jnj:InnovativeMedicineMember jnj:ImmunologyMember 2023-01-02 2023-12-31 0000200406 jnj:TremfyaMember jnj:InnovativeMedicineMember jnj:ImmunologyMember 2022-01-03 2023-01-01 0000200406 jnj:OtherImmunologyMember country:US jnj:InnovativeMedicineMember jnj:ImmunologyMember 2024-01-01 2024-12-29 0000200406 jnj:OtherImmunologyMember country:US jnj:InnovativeMedicineMember jnj:ImmunologyMember 2023-01-02 2023-12-31 0000200406 jnj:OtherImmunologyMember country:US jnj:InnovativeMedicineMember jnj:ImmunologyMember 2022-01-03 2023-01-01 0000200406 jnj:OtherImmunologyMember us-gaap:NonUsMember jnj:InnovativeMedicineMember jnj:ImmunologyMember 2024-01-01 2024-12-29 0000200406 jnj:OtherImmunologyMember us-gaap:NonUsMember jnj:InnovativeMedicineMember jnj:ImmunologyMember 2023-01-02 2023-12-31 0000200406 jnj:OtherImmunologyMember us-gaap:NonUsMember jnj:InnovativeMedicineMember jnj:ImmunologyMember 2022-01-03 2023-01-01 0000200406 jnj:OtherImmunologyMember jnj:InnovativeMedicineMember jnj:ImmunologyMember 2024-01-01 2024-12-29 0000200406 jnj:OtherImmunologyMember jnj:InnovativeMedicineMember jnj:ImmunologyMember 2023-01-02 2023-12-31 0000200406 jnj:OtherImmunologyMember jnj:InnovativeMedicineMember jnj:ImmunologyMember 2022-01-03 2023-01-01 0000200406 country:US jnj:InnovativeMedicineMember jnj:InfectiousDiseasesMember 2024-01-01 2024-12-29 0000200406 country:US jnj:InnovativeMedicineMember jnj:InfectiousDiseasesMember 2023-01-02 2023-12-31 0000200406 country:US jnj:InnovativeMedicineMember jnj:InfectiousDiseasesMember 2022-01-03 2023-01-01 0000200406 us-gaap:NonUsMember jnj:InnovativeMedicineMember jnj:InfectiousDiseasesMember 2024-01-01 2024-12-29 0000200406 us-gaap:NonUsMember jnj:InnovativeMedicineMember jnj:InfectiousDiseasesMember 2023-01-02 2023-12-31 0000200406 us-gaap:NonUsMember jnj:InnovativeMedicineMember jnj:InfectiousDiseasesMember 2022-01-03 2023-01-01 0000200406 jnj:InnovativeMedicineMember jnj:InfectiousDiseasesMember 2024-01-01 2024-12-29 0000200406 jnj:InnovativeMedicineMember jnj:InfectiousDiseasesMember 2023-01-02 2023-12-31 0000200406 jnj:InnovativeMedicineMember jnj:InfectiousDiseasesMember 2022-01-03 2023-01-01 0000200406 jnj:COVID19Member country:US jnj:InnovativeMedicineMember jnj:InfectiousDiseasesMember 2024-01-01 2024-12-29 0000200406 jnj:COVID19Member country:US jnj:InnovativeMedicineMember jnj:InfectiousDiseasesMember 2023-01-02 2023-12-31 0000200406 jnj:COVID19Member country:US jnj:InnovativeMedicineMember jnj:InfectiousDiseasesMember 2022-01-03 2023-01-01 0000200406 jnj:COVID19Member us-gaap:NonUsMember jnj:InnovativeMedicineMember jnj:InfectiousDiseasesMember 2024-01-01 2024-12-29 0000200406 jnj:COVID19Member us-gaap:NonUsMember jnj:InnovativeMedicineMember jnj:InfectiousDiseasesMember 2023-01-02 2023-12-31 0000200406 jnj:COVID19Member us-gaap:NonUsMember jnj:InnovativeMedicineMember jnj:InfectiousDiseasesMember 2022-01-03 2023-01-01 0000200406 jnj:COVID19Member jnj:InnovativeMedicineMember jnj:InfectiousDiseasesMember 2024-01-01 2024-12-29 0000200406 jnj:COVID19Member jnj:InnovativeMedicineMember jnj:InfectiousDiseasesMember 2023-01-02 2023-12-31 0000200406 jnj:COVID19Member jnj:InnovativeMedicineMember jnj:InfectiousDiseasesMember 2022-01-03 2023-01-01 0000200406 jnj:EDURANTrilpivirineMember country:US jnj:InnovativeMedicineMember jnj:InfectiousDiseasesMember 2024-01-01 2024-12-29 0000200406 jnj:EDURANTrilpivirineMember country:US jnj:InnovativeMedicineMember jnj:InfectiousDiseasesMember 2023-01-02 2023-12-31 0000200406 jnj:EDURANTrilpivirineMember country:US jnj:InnovativeMedicineMember jnj:InfectiousDiseasesMember 2022-01-03 2023-01-01 0000200406 jnj:EDURANTrilpivirineMember us-gaap:NonUsMember jnj:InnovativeMedicineMember jnj:InfectiousDiseasesMember 2024-01-01 2024-12-29 0000200406 jnj:EDURANTrilpivirineMember us-gaap:NonUsMember jnj:InnovativeMedicineMember jnj:InfectiousDiseasesMember 2023-01-02 2023-12-31 0000200406 jnj:EDURANTrilpivirineMember us-gaap:NonUsMember jnj:InnovativeMedicineMember jnj:InfectiousDiseasesMember 2022-01-03 2023-01-01 0000200406 jnj:EDURANTrilpivirineMember jnj:InnovativeMedicineMember jnj:InfectiousDiseasesMember 2024-01-01 2024-12-29 0000200406 jnj:EDURANTrilpivirineMember jnj:InnovativeMedicineMember jnj:InfectiousDiseasesMember 2023-01-02 2023-12-31 0000200406 jnj:EDURANTrilpivirineMember jnj:InnovativeMedicineMember jnj:InfectiousDiseasesMember 2022-01-03 2023-01-01 0000200406 jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember country:US jnj:InnovativeMedicineMember jnj:InfectiousDiseasesMember 2024-01-01 2024-12-29 0000200406 jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember country:US jnj:InnovativeMedicineMember jnj:InfectiousDiseasesMember 2023-01-02 2023-12-31 0000200406 jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember country:US jnj:InnovativeMedicineMember jnj:InfectiousDiseasesMember 2022-01-03 2023-01-01 0000200406 jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember us-gaap:NonUsMember jnj:InnovativeMedicineMember jnj:InfectiousDiseasesMember 2024-01-01 2024-12-29 0000200406 jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember us-gaap:NonUsMember jnj:InnovativeMedicineMember jnj:InfectiousDiseasesMember 2023-01-02 2023-12-31 0000200406 jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember us-gaap:NonUsMember jnj:InnovativeMedicineMember jnj:InfectiousDiseasesMember 2022-01-03 2023-01-01 0000200406 jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember jnj:InnovativeMedicineMember jnj:InfectiousDiseasesMember 2024-01-01 2024-12-29 0000200406 jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember jnj:InnovativeMedicineMember jnj:InfectiousDiseasesMember 2023-01-02 2023-12-31 0000200406 jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember jnj:InnovativeMedicineMember jnj:InfectiousDiseasesMember 2022-01-03 2023-01-01 0000200406 jnj:OtherInfectiousDiseasesMember country:US jnj:InnovativeMedicineMember jnj:InfectiousDiseasesMember 2024-01-01 2024-12-29 0000200406 jnj:OtherInfectiousDiseasesMember country:US jnj:InnovativeMedicineMember jnj:InfectiousDiseasesMember 2023-01-02 2023-12-31 0000200406 jnj:OtherInfectiousDiseasesMember country:US jnj:InnovativeMedicineMember jnj:InfectiousDiseasesMember 2022-01-03 2023-01-01 0000200406 jnj:OtherInfectiousDiseasesMember us-gaap:NonUsMember jnj:InnovativeMedicineMember jnj:InfectiousDiseasesMember 2024-01-01 2024-12-29 0000200406 jnj:OtherInfectiousDiseasesMember us-gaap:NonUsMember jnj:InnovativeMedicineMember jnj:InfectiousDiseasesMember 2023-01-02 2023-12-31 0000200406 jnj:OtherInfectiousDiseasesMember us-gaap:NonUsMember jnj:InnovativeMedicineMember jnj:InfectiousDiseasesMember 2022-01-03 2023-01-01 0000200406 jnj:OtherInfectiousDiseasesMember jnj:InnovativeMedicineMember jnj:InfectiousDiseasesMember 2024-01-01 2024-12-29 0000200406 jnj:OtherInfectiousDiseasesMember jnj:InnovativeMedicineMember jnj:InfectiousDiseasesMember 2023-01-02 2023-12-31 0000200406 jnj:OtherInfectiousDiseasesMember jnj:InnovativeMedicineMember jnj:InfectiousDiseasesMember 2022-01-03 2023-01-01 0000200406 country:US jnj:InnovativeMedicineMember jnj:NeuroscienceMember 2024-01-01 2024-12-29 0000200406 country:US jnj:InnovativeMedicineMember jnj:NeuroscienceMember 2023-01-02 2023-12-31 0000200406 country:US jnj:InnovativeMedicineMember jnj:NeuroscienceMember 2022-01-03 2023-01-01 0000200406 us-gaap:NonUsMember jnj:InnovativeMedicineMember jnj:NeuroscienceMember 2024-01-01 2024-12-29 0000200406 us-gaap:NonUsMember jnj:InnovativeMedicineMember jnj:NeuroscienceMember 2023-01-02 2023-12-31 0000200406 us-gaap:NonUsMember jnj:InnovativeMedicineMember jnj:NeuroscienceMember 2022-01-03 2023-01-01 0000200406 jnj:InnovativeMedicineMember jnj:NeuroscienceMember 2024-01-01 2024-12-29 0000200406 jnj:InnovativeMedicineMember jnj:NeuroscienceMember 2023-01-02 2023-12-31 0000200406 jnj:InnovativeMedicineMember jnj:NeuroscienceMember 2022-01-03 2023-01-01 0000200406 jnj:CONCERTAMethylphenidateMember country:US jnj:InnovativeMedicineMember jnj:NeuroscienceMember 2024-01-01 2024-12-29 0000200406 jnj:CONCERTAMethylphenidateMember country:US jnj:InnovativeMedicineMember jnj:NeuroscienceMember 2023-01-02 2023-12-31 0000200406 jnj:CONCERTAMethylphenidateMember country:US jnj:InnovativeMedicineMember jnj:NeuroscienceMember 2022-01-03 2023-01-01 0000200406 jnj:CONCERTAMethylphenidateMember us-gaap:NonUsMember jnj:InnovativeMedicineMember jnj:NeuroscienceMember 2024-01-01 2024-12-29 0000200406 jnj:CONCERTAMethylphenidateMember us-gaap:NonUsMember jnj:InnovativeMedicineMember jnj:NeuroscienceMember 2023-01-02 2023-12-31 0000200406 jnj:CONCERTAMethylphenidateMember us-gaap:NonUsMember jnj:InnovativeMedicineMember jnj:NeuroscienceMember 2022-01-03 2023-01-01 0000200406 jnj:CONCERTAMethylphenidateMember jnj:InnovativeMedicineMember jnj:NeuroscienceMember 2024-01-01 2024-12-29 0000200406 jnj:CONCERTAMethylphenidateMember jnj:InnovativeMedicineMember jnj:NeuroscienceMember 2023-01-02 2023-12-31 0000200406 jnj:CONCERTAMethylphenidateMember jnj:InnovativeMedicineMember jnj:NeuroscienceMember 2022-01-03 2023-01-01 0000200406 jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember country:US jnj:InnovativeMedicineMember jnj:NeuroscienceMember 2024-01-01 2024-12-29 0000200406 jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember country:US jnj:InnovativeMedicineMember jnj:NeuroscienceMember 2023-01-02 2023-12-31 0000200406 jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember country:US jnj:InnovativeMedicineMember jnj:NeuroscienceMember 2022-01-03 2023-01-01 0000200406 jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember us-gaap:NonUsMember jnj:InnovativeMedicineMember jnj:NeuroscienceMember 2024-01-01 2024-12-29 0000200406 jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember us-gaap:NonUsMember jnj:InnovativeMedicineMember jnj:NeuroscienceMember 2023-01-02 2023-12-31 0000200406 jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember us-gaap:NonUsMember jnj:InnovativeMedicineMember jnj:NeuroscienceMember 2022-01-03 2023-01-01 0000200406 jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember jnj:InnovativeMedicineMember jnj:NeuroscienceMember 2024-01-01 2024-12-29 0000200406 jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember jnj:InnovativeMedicineMember jnj:NeuroscienceMember 2023-01-02 2023-12-31 0000200406 jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember jnj:InnovativeMedicineMember jnj:NeuroscienceMember 2022-01-03 2023-01-01 0000200406 jnj:SPRAVATOMember country:US jnj:InnovativeMedicineMember jnj:NeuroscienceMember 2024-01-01 2024-12-29 0000200406 jnj:SPRAVATOMember country:US jnj:InnovativeMedicineMember jnj:NeuroscienceMember 2023-01-02 2023-12-31 0000200406 jnj:SPRAVATOMember country:US jnj:InnovativeMedicineMember jnj:NeuroscienceMember 2022-01-03 2023-01-01 0000200406 jnj:SPRAVATOMember us-gaap:NonUsMember jnj:InnovativeMedicineMember jnj:NeuroscienceMember 2024-01-01 2024-12-29 0000200406 jnj:SPRAVATOMember us-gaap:NonUsMember jnj:InnovativeMedicineMember jnj:NeuroscienceMember 2023-01-02 2023-12-31 0000200406 jnj:SPRAVATOMember us-gaap:NonUsMember jnj:InnovativeMedicineMember jnj:NeuroscienceMember 2022-01-03 2023-01-01 0000200406 jnj:SPRAVATOMember jnj:InnovativeMedicineMember jnj:NeuroscienceMember 2024-01-01 2024-12-29 0000200406 jnj:SPRAVATOMember jnj:InnovativeMedicineMember jnj:NeuroscienceMember 2023-01-02 2023-12-31 0000200406 jnj:SPRAVATOMember jnj:InnovativeMedicineMember jnj:NeuroscienceMember 2022-01-03 2023-01-01 0000200406 jnj:OTHERNEUROSCIENCEMember country:US jnj:InnovativeMedicineMember jnj:NeuroscienceMember 2024-01-01 2024-12-29 0000200406 jnj:OTHERNEUROSCIENCEMember country:US jnj:InnovativeMedicineMember jnj:NeuroscienceMember 2023-01-02 2023-12-31 0000200406 jnj:OTHERNEUROSCIENCEMember country:US jnj:InnovativeMedicineMember jnj:NeuroscienceMember 2022-01-03 2023-01-01 0000200406 jnj:OTHERNEUROSCIENCEMember us-gaap:NonUsMember jnj:InnovativeMedicineMember jnj:NeuroscienceMember 2024-01-01 2024-12-29 0000200406 jnj:OTHERNEUROSCIENCEMember us-gaap:NonUsMember jnj:InnovativeMedicineMember jnj:NeuroscienceMember 2023-01-02 2023-12-31 0000200406 jnj:OTHERNEUROSCIENCEMember us-gaap:NonUsMember jnj:InnovativeMedicineMember jnj:NeuroscienceMember 2022-01-03 2023-01-01 0000200406 jnj:OTHERNEUROSCIENCEMember jnj:InnovativeMedicineMember jnj:NeuroscienceMember 2024-01-01 2024-12-29 0000200406 jnj:OTHERNEUROSCIENCEMember jnj:InnovativeMedicineMember jnj:NeuroscienceMember 2023-01-02 2023-12-31 0000200406 jnj:OTHERNEUROSCIENCEMember jnj:InnovativeMedicineMember jnj:NeuroscienceMember 2022-01-03 2023-01-01 0000200406 country:US jnj:InnovativeMedicineMember jnj:OncologyMember 2024-01-01 2024-12-29 0000200406 country:US jnj:InnovativeMedicineMember jnj:OncologyMember 2023-01-02 2023-12-31 0000200406 country:US jnj:InnovativeMedicineMember jnj:OncologyMember 2022-01-03 2023-01-01 0000200406 us-gaap:NonUsMember jnj:InnovativeMedicineMember jnj:OncologyMember 2024-01-01 2024-12-29 0000200406 us-gaap:NonUsMember jnj:InnovativeMedicineMember jnj:OncologyMember 2023-01-02 2023-12-31 0000200406 us-gaap:NonUsMember jnj:InnovativeMedicineMember jnj:OncologyMember 2022-01-03 2023-01-01 0000200406 jnj:InnovativeMedicineMember jnj:OncologyMember 2024-01-01 2024-12-29 0000200406 jnj:InnovativeMedicineMember jnj:OncologyMember 2023-01-02 2023-12-31 0000200406 jnj:InnovativeMedicineMember jnj:OncologyMember 2022-01-03 2023-01-01 0000200406 jnj:CARVYKTIMember country:US jnj:InnovativeMedicineMember jnj:OncologyMember 2024-01-01 2024-12-29 0000200406 jnj:CARVYKTIMember country:US jnj:InnovativeMedicineMember jnj:OncologyMember 2023-01-02 2023-12-31 0000200406 jnj:CARVYKTIMember country:US jnj:InnovativeMedicineMember jnj:OncologyMember 2022-01-03 2023-01-01 0000200406 jnj:CARVYKTIMember us-gaap:NonUsMember jnj:InnovativeMedicineMember jnj:OncologyMember 2024-01-01 2024-12-29 0000200406 jnj:CARVYKTIMember us-gaap:NonUsMember jnj:InnovativeMedicineMember jnj:OncologyMember 2023-01-02 2023-12-31 0000200406 jnj:CARVYKTIMember us-gaap:NonUsMember jnj:InnovativeMedicineMember jnj:OncologyMember 2022-01-03 2023-01-01 0000200406 jnj:CARVYKTIMember jnj:InnovativeMedicineMember jnj:OncologyMember 2024-01-01 2024-12-29 0000200406 jnj:CARVYKTIMember jnj:InnovativeMedicineMember jnj:OncologyMember 2023-01-02 2023-12-31 0000200406 jnj:CARVYKTIMember jnj:InnovativeMedicineMember jnj:OncologyMember 2022-01-03 2023-01-01 0000200406 jnj:DARZALEXMember country:US jnj:InnovativeMedicineMember jnj:OncologyMember 2024-01-01 2024-12-29 0000200406 jnj:DARZALEXMember country:US jnj:InnovativeMedicineMember jnj:OncologyMember 2023-01-02 2023-12-31 0000200406 jnj:DARZALEXMember country:US jnj:InnovativeMedicineMember jnj:OncologyMember 2022-01-03 2023-01-01 0000200406 jnj:DARZALEXMember us-gaap:NonUsMember jnj:InnovativeMedicineMember jnj:OncologyMember 2024-01-01 2024-12-29 0000200406 jnj:DARZALEXMember us-gaap:NonUsMember jnj:InnovativeMedicineMember jnj:OncologyMember 2023-01-02 2023-12-31 0000200406 jnj:DARZALEXMember us-gaap:NonUsMember jnj:InnovativeMedicineMember jnj:OncologyMember 2022-01-03 2023-01-01 0000200406 jnj:DARZALEXMember jnj:InnovativeMedicineMember jnj:OncologyMember 2024-01-01 2024-12-29 0000200406 jnj:DARZALEXMember jnj:InnovativeMedicineMember jnj:OncologyMember 2023-01-02 2023-12-31 0000200406 jnj:DARZALEXMember jnj:InnovativeMedicineMember jnj:OncologyMember 2022-01-03 2023-01-01 0000200406 jnj:ErleadaMember country:US jnj:InnovativeMedicineMember jnj:OncologyMember 2024-01-01 2024-12-29 0000200406 jnj:ErleadaMember country:US jnj:InnovativeMedicineMember jnj:OncologyMember 2023-01-02 2023-12-31 0000200406 jnj:ErleadaMember country:US jnj:InnovativeMedicineMember jnj:OncologyMember 2022-01-03 2023-01-01 0000200406 jnj:ErleadaMember us-gaap:NonUsMember jnj:InnovativeMedicineMember jnj:OncologyMember 2024-01-01 2024-12-29 0000200406 jnj:ErleadaMember us-gaap:NonUsMember jnj:InnovativeMedicineMember jnj:OncologyMember 2023-01-02 2023-12-31 0000200406 jnj:ErleadaMember us-gaap:NonUsMember jnj:InnovativeMedicineMember jnj:OncologyMember 2022-01-03 2023-01-01 0000200406 jnj:ErleadaMember jnj:InnovativeMedicineMember jnj:OncologyMember 2024-01-01 2024-12-29 0000200406 jnj:ErleadaMember jnj:InnovativeMedicineMember jnj:OncologyMember 2023-01-02 2023-12-31 0000200406 jnj:ErleadaMember jnj:InnovativeMedicineMember jnj:OncologyMember 2022-01-03 2023-01-01 0000200406 jnj:IMBRUVICAMember country:US jnj:InnovativeMedicineMember jnj:OncologyMember 2024-01-01 2024-12-29 0000200406 jnj:IMBRUVICAMember country:US jnj:InnovativeMedicineMember jnj:OncologyMember 2023-01-02 2023-12-31 0000200406 jnj:IMBRUVICAMember country:US jnj:InnovativeMedicineMember jnj:OncologyMember 2022-01-03 2023-01-01 0000200406 jnj:IMBRUVICAMember us-gaap:NonUsMember jnj:InnovativeMedicineMember jnj:OncologyMember 2024-01-01 2024-12-29 0000200406 jnj:IMBRUVICAMember us-gaap:NonUsMember jnj:InnovativeMedicineMember jnj:OncologyMember 2023-01-02 2023-12-31 0000200406 jnj:IMBRUVICAMember us-gaap:NonUsMember jnj:InnovativeMedicineMember jnj:OncologyMember 2022-01-03 2023-01-01 0000200406 jnj:IMBRUVICAMember jnj:InnovativeMedicineMember jnj:OncologyMember 2024-01-01 2024-12-29 0000200406 jnj:IMBRUVICAMember jnj:InnovativeMedicineMember jnj:OncologyMember 2023-01-02 2023-12-31 0000200406 jnj:IMBRUVICAMember jnj:InnovativeMedicineMember jnj:OncologyMember 2022-01-03 2023-01-01 0000200406 jnj:TECVAYLIMember country:US jnj:PharmaceuticalMember jnj:OncologyMember 2024-01-01 2024-12-29 0000200406 jnj:TECVAYLIMember country:US jnj:PharmaceuticalMember jnj:OncologyMember 2023-01-02 2023-12-31 0000200406 jnj:TECVAYLIMember country:US jnj:PharmaceuticalMember jnj:OncologyMember 2022-01-03 2023-01-01 0000200406 jnj:TECVAYLIMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:OncologyMember 2024-01-01 2024-12-29 0000200406 jnj:TECVAYLIMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:OncologyMember 2023-01-02 2023-12-31 0000200406 jnj:TECVAYLIMember us-gaap:NonUsMember jnj:PharmaceuticalMember jnj:OncologyMember 2022-01-03 2023-01-01 0000200406 jnj:TECVAYLIMember jnj:PharmaceuticalMember jnj:OncologyMember 2024-01-01 2024-12-29 0000200406 jnj:TECVAYLIMember jnj:PharmaceuticalMember jnj:OncologyMember 2023-01-02 2023-12-31 0000200406 jnj:TECVAYLIMember jnj:PharmaceuticalMember jnj:OncologyMember 2022-01-03 2023-01-01 0000200406 jnj:ZYTIGAMember country:US jnj:InnovativeMedicineMember jnj:OncologyMember 2024-01-01 2024-12-29 0000200406 jnj:ZYTIGAMember country:US jnj:InnovativeMedicineMember jnj:OncologyMember 2023-01-02 2023-12-31 0000200406 jnj:ZYTIGAMember country:US jnj:InnovativeMedicineMember jnj:OncologyMember 2022-01-03 2023-01-01 0000200406 jnj:ZYTIGAMember us-gaap:NonUsMember jnj:InnovativeMedicineMember jnj:OncologyMember 2024-01-01 2024-12-29 0000200406 jnj:ZYTIGAMember us-gaap:NonUsMember jnj:InnovativeMedicineMember jnj:OncologyMember 2023-01-02 2023-12-31 0000200406 jnj:ZYTIGAMember us-gaap:NonUsMember jnj:InnovativeMedicineMember jnj:OncologyMember 2022-01-03 2023-01-01 0000200406 jnj:ZYTIGAMember jnj:InnovativeMedicineMember jnj:OncologyMember 2024-01-01 2024-12-29 0000200406 jnj:ZYTIGAMember jnj:InnovativeMedicineMember jnj:OncologyMember 2023-01-02 2023-12-31 0000200406 jnj:ZYTIGAMember jnj:InnovativeMedicineMember jnj:OncologyMember 2022-01-03 2023-01-01 0000200406 jnj:OtherOncologyMember country:US jnj:InnovativeMedicineMember jnj:OncologyMember 2024-01-01 2024-12-29 0000200406 jnj:OtherOncologyMember country:US jnj:InnovativeMedicineMember jnj:OncologyMember 2023-01-02 2023-12-31 0000200406 jnj:OtherOncologyMember country:US jnj:InnovativeMedicineMember jnj:OncologyMember 2022-01-03 2023-01-01 0000200406 jnj:OtherOncologyMember us-gaap:NonUsMember jnj:InnovativeMedicineMember jnj:OncologyMember 2024-01-01 2024-12-29 0000200406 jnj:OtherOncologyMember us-gaap:NonUsMember jnj:InnovativeMedicineMember jnj:OncologyMember 2023-01-02 2023-12-31 0000200406 jnj:OtherOncologyMember us-gaap:NonUsMember jnj:InnovativeMedicineMember jnj:OncologyMember 2022-01-03 2023-01-01 0000200406 jnj:OtherOncologyMember jnj:InnovativeMedicineMember jnj:OncologyMember 2024-01-01 2024-12-29 0000200406 jnj:OtherOncologyMember jnj:InnovativeMedicineMember jnj:OncologyMember 2023-01-02 2023-12-31 0000200406 jnj:OtherOncologyMember jnj:InnovativeMedicineMember jnj:OncologyMember 2022-01-03 2023-01-01 0000200406 country:US jnj:InnovativeMedicineMember jnj:PulmonaryHypertensionMember 2024-01-01 2024-12-29 0000200406 country:US jnj:InnovativeMedicineMember jnj:PulmonaryHypertensionMember 2023-01-02 2023-12-31 0000200406 country:US jnj:InnovativeMedicineMember jnj:PulmonaryHypertensionMember 2022-01-03 2023-01-01 0000200406 us-gaap:NonUsMember jnj:InnovativeMedicineMember jnj:PulmonaryHypertensionMember 2024-01-01 2024-12-29 0000200406 us-gaap:NonUsMember jnj:InnovativeMedicineMember jnj:PulmonaryHypertensionMember 2023-01-02 2023-12-31 0000200406 us-gaap:NonUsMember jnj:InnovativeMedicineMember jnj:PulmonaryHypertensionMember 2022-01-03 2023-01-01 0000200406 jnj:InnovativeMedicineMember jnj:PulmonaryHypertensionMember 2024-01-01 2024-12-29 0000200406 jnj:InnovativeMedicineMember jnj:PulmonaryHypertensionMember 2023-01-02 2023-12-31 0000200406 jnj:InnovativeMedicineMember jnj:PulmonaryHypertensionMember 2022-01-03 2023-01-01 0000200406 jnj:OPSUMITMember country:US jnj:InnovativeMedicineMember jnj:PulmonaryHypertensionMember 2024-01-01 2024-12-29 0000200406 jnj:OPSUMITMember country:US jnj:InnovativeMedicineMember jnj:PulmonaryHypertensionMember 2023-01-02 2023-12-31 0000200406 jnj:OPSUMITMember country:US jnj:InnovativeMedicineMember jnj:PulmonaryHypertensionMember 2022-01-03 2023-01-01 0000200406 jnj:OPSUMITMember us-gaap:NonUsMember jnj:InnovativeMedicineMember jnj:PulmonaryHypertensionMember 2024-01-01 2024-12-29 0000200406 jnj:OPSUMITMember us-gaap:NonUsMember jnj:InnovativeMedicineMember jnj:PulmonaryHypertensionMember 2023-01-02 2023-12-31 0000200406 jnj:OPSUMITMember us-gaap:NonUsMember jnj:InnovativeMedicineMember jnj:PulmonaryHypertensionMember 2022-01-03 2023-01-01 0000200406 jnj:OPSUMITMember jnj:InnovativeMedicineMember jnj:PulmonaryHypertensionMember 2024-01-01 2024-12-29 0000200406 jnj:OPSUMITMember jnj:InnovativeMedicineMember jnj:PulmonaryHypertensionMember 2023-01-02 2023-12-31 0000200406 jnj:OPSUMITMember jnj:InnovativeMedicineMember jnj:PulmonaryHypertensionMember 2022-01-03 2023-01-01 0000200406 jnj:UPTRAVIMember country:US jnj:InnovativeMedicineMember jnj:PulmonaryHypertensionMember 2024-01-01 2024-12-29 0000200406 jnj:UPTRAVIMember country:US jnj:InnovativeMedicineMember jnj:PulmonaryHypertensionMember 2023-01-02 2023-12-31 0000200406 jnj:UPTRAVIMember country:US jnj:InnovativeMedicineMember jnj:PulmonaryHypertensionMember 2022-01-03 2023-01-01 0000200406 jnj:UPTRAVIMember us-gaap:NonUsMember jnj:InnovativeMedicineMember jnj:PulmonaryHypertensionMember 2024-01-01 2024-12-29 0000200406 jnj:UPTRAVIMember us-gaap:NonUsMember jnj:InnovativeMedicineMember jnj:PulmonaryHypertensionMember 2023-01-02 2023-12-31 0000200406 jnj:UPTRAVIMember us-gaap:NonUsMember jnj:InnovativeMedicineMember jnj:PulmonaryHypertensionMember 2022-01-03 2023-01-01 0000200406 jnj:UPTRAVIMember jnj:InnovativeMedicineMember jnj:PulmonaryHypertensionMember 2024-01-01 2024-12-29 0000200406 jnj:UPTRAVIMember jnj:InnovativeMedicineMember jnj:PulmonaryHypertensionMember 2023-01-02 2023-12-31 0000200406 jnj:UPTRAVIMember jnj:InnovativeMedicineMember jnj:PulmonaryHypertensionMember 2022-01-03 2023-01-01 0000200406 jnj:OtherPulmonaryHypertensionMember country:US jnj:InnovativeMedicineMember jnj:PulmonaryHypertensionMember 2024-01-01 2024-12-29 0000200406 jnj:OtherPulmonaryHypertensionMember country:US jnj:InnovativeMedicineMember jnj:PulmonaryHypertensionMember 2023-01-02 2023-12-31 0000200406 jnj:OtherPulmonaryHypertensionMember country:US jnj:InnovativeMedicineMember jnj:PulmonaryHypertensionMember 2022-01-03 2023-01-01 0000200406 jnj:OtherPulmonaryHypertensionMember us-gaap:NonUsMember jnj:InnovativeMedicineMember jnj:PulmonaryHypertensionMember 2024-01-01 2024-12-29 0000200406 jnj:OtherPulmonaryHypertensionMember us-gaap:NonUsMember jnj:InnovativeMedicineMember jnj:PulmonaryHypertensionMember 2023-01-02 2023-12-31 0000200406 jnj:OtherPulmonaryHypertensionMember us-gaap:NonUsMember jnj:InnovativeMedicineMember jnj:PulmonaryHypertensionMember 2022-01-03 2023-01-01 0000200406 jnj:OtherPulmonaryHypertensionMember jnj:InnovativeMedicineMember jnj:PulmonaryHypertensionMember 2024-01-01 2024-12-29 0000200406 jnj:OtherPulmonaryHypertensionMember jnj:InnovativeMedicineMember jnj:PulmonaryHypertensionMember 2023-01-02 2023-12-31 0000200406 jnj:OtherPulmonaryHypertensionMember jnj:InnovativeMedicineMember jnj:PulmonaryHypertensionMember 2022-01-03 2023-01-01 0000200406 country:US jnj:InnovativeMedicineMember jnj:CardiovascularMetabolismOtherMember 2024-01-01 2024-12-29 0000200406 country:US jnj:InnovativeMedicineMember jnj:CardiovascularMetabolismOtherMember 2023-01-02 2023-12-31 0000200406 country:US jnj:InnovativeMedicineMember jnj:CardiovascularMetabolismOtherMember 2022-01-03 2023-01-01 0000200406 us-gaap:NonUsMember jnj:InnovativeMedicineMember jnj:CardiovascularMetabolismOtherMember 2024-01-01 2024-12-29 0000200406 us-gaap:NonUsMember jnj:InnovativeMedicineMember jnj:CardiovascularMetabolismOtherMember 2023-01-02 2023-12-31 0000200406 us-gaap:NonUsMember jnj:InnovativeMedicineMember jnj:CardiovascularMetabolismOtherMember 2022-01-03 2023-01-01 0000200406 jnj:InnovativeMedicineMember jnj:CardiovascularMetabolismOtherMember 2024-01-01 2024-12-29 0000200406 jnj:InnovativeMedicineMember jnj:CardiovascularMetabolismOtherMember 2023-01-02 2023-12-31 0000200406 jnj:InnovativeMedicineMember jnj:CardiovascularMetabolismOtherMember 2022-01-03 2023-01-01 0000200406 jnj:XareltoMember country:US jnj:InnovativeMedicineMember jnj:CardiovascularMetabolismOtherMember 2024-01-01 2024-12-29 0000200406 jnj:XareltoMember country:US jnj:InnovativeMedicineMember jnj:CardiovascularMetabolismOtherMember 2023-01-02 2023-12-31 0000200406 jnj:XareltoMember country:US jnj:InnovativeMedicineMember jnj:CardiovascularMetabolismOtherMember 2022-01-03 2023-01-01 0000200406 jnj:XareltoMember us-gaap:NonUsMember jnj:InnovativeMedicineMember jnj:CardiovascularMetabolismOtherMember 2024-01-01 2024-12-29 0000200406 jnj:XareltoMember us-gaap:NonUsMember jnj:InnovativeMedicineMember jnj:CardiovascularMetabolismOtherMember 2023-01-02 2023-12-31 0000200406 jnj:XareltoMember us-gaap:NonUsMember jnj:InnovativeMedicineMember jnj:CardiovascularMetabolismOtherMember 2022-01-03 2023-01-01 0000200406 jnj:XareltoMember jnj:InnovativeMedicineMember jnj:CardiovascularMetabolismOtherMember 2024-01-01 2024-12-29 0000200406 jnj:XareltoMember jnj:InnovativeMedicineMember jnj:CardiovascularMetabolismOtherMember 2023-01-02 2023-12-31 0000200406 jnj:XareltoMember jnj:InnovativeMedicineMember jnj:CardiovascularMetabolismOtherMember 2022-01-03 2023-01-01 0000200406 jnj:OtherMember country:US jnj:InnovativeMedicineMember jnj:CardiovascularMetabolismOtherMember 2024-01-01 2024-12-29 0000200406 jnj:OtherMember country:US jnj:InnovativeMedicineMember jnj:CardiovascularMetabolismOtherMember 2023-01-02 2023-12-31 0000200406 jnj:OtherMember country:US jnj:InnovativeMedicineMember jnj:CardiovascularMetabolismOtherMember 2022-01-03 2023-01-01 0000200406 jnj:OtherMember us-gaap:NonUsMember jnj:InnovativeMedicineMember jnj:CardiovascularMetabolismOtherMember 2024-01-01 2024-12-29 0000200406 jnj:OtherMember us-gaap:NonUsMember jnj:InnovativeMedicineMember jnj:CardiovascularMetabolismOtherMember 2023-01-02 2023-12-31 0000200406 jnj:OtherMember us-gaap:NonUsMember jnj:InnovativeMedicineMember jnj:CardiovascularMetabolismOtherMember 2022-01-03 2023-01-01 0000200406 jnj:OtherMember jnj:InnovativeMedicineMember jnj:CardiovascularMetabolismOtherMember 2024-01-01 2024-12-29 0000200406 jnj:OtherMember jnj:InnovativeMedicineMember jnj:CardiovascularMetabolismOtherMember 2023-01-02 2023-12-31 0000200406 jnj:OtherMember jnj:InnovativeMedicineMember jnj:CardiovascularMetabolismOtherMember 2022-01-03 2023-01-01 0000200406 country:US jnj:InnovativeMedicineMember 2024-01-01 2024-12-29 0000200406 country:US jnj:InnovativeMedicineMember 2023-01-02 2023-12-31 0000200406 country:US jnj:InnovativeMedicineMember 2022-01-03 2023-01-01 0000200406 us-gaap:NonUsMember jnj:InnovativeMedicineMember 2024-01-01 2024-12-29 0000200406 us-gaap:NonUsMember jnj:InnovativeMedicineMember 2023-01-02 2023-12-31 0000200406 us-gaap:NonUsMember jnj:InnovativeMedicineMember 2022-01-03 2023-01-01 0000200406 jnj:InnovativeMedicineMember 2022-01-03 2023-01-01 0000200406 country:US jnj:MedTechMember jnj:CardiovascularMember 2024-01-01 2024-12-29 0000200406 country:US jnj:MedTechMember jnj:CardiovascularMember 2023-01-02 2023-12-31 0000200406 country:US jnj:MedTechMember jnj:CardiovascularMember 2022-01-03 2023-01-01 0000200406 us-gaap:NonUsMember jnj:MedTechMember jnj:CardiovascularMember 2024-01-01 2024-12-29 0000200406 us-gaap:NonUsMember jnj:MedTechMember jnj:CardiovascularMember 2023-01-02 2023-12-31 0000200406 us-gaap:NonUsMember jnj:MedTechMember jnj:CardiovascularMember 2022-01-03 2023-01-01 0000200406 jnj:MedTechMember jnj:CardiovascularMember 2024-01-01 2024-12-29 0000200406 jnj:MedTechMember jnj:CardiovascularMember 2023-01-02 2023-12-31 0000200406 jnj:MedTechMember jnj:CardiovascularMember 2022-01-03 2023-01-01 0000200406 jnj:ELECTROPHYSIOLOGYMember country:US jnj:MedTechMember jnj:CardiovascularMember 2024-01-01 2024-12-29 0000200406 jnj:ELECTROPHYSIOLOGYMember country:US jnj:MedTechMember jnj:CardiovascularMember 2023-01-02 2023-12-31 0000200406 jnj:ELECTROPHYSIOLOGYMember country:US jnj:MedTechMember jnj:CardiovascularMember 2022-01-03 2023-01-01 0000200406 jnj:ELECTROPHYSIOLOGYMember us-gaap:NonUsMember jnj:MedTechMember jnj:CardiovascularMember 2024-01-01 2024-12-29 0000200406 jnj:ELECTROPHYSIOLOGYMember us-gaap:NonUsMember jnj:MedTechMember jnj:CardiovascularMember 2023-01-02 2023-12-31 0000200406 jnj:ELECTROPHYSIOLOGYMember us-gaap:NonUsMember jnj:MedTechMember jnj:CardiovascularMember 2022-01-03 2023-01-01 0000200406 jnj:ELECTROPHYSIOLOGYMember jnj:MedTechMember jnj:CardiovascularMember 2024-01-01 2024-12-29 0000200406 jnj:ELECTROPHYSIOLOGYMember jnj:MedTechMember jnj:CardiovascularMember 2023-01-02 2023-12-31 0000200406 jnj:ELECTROPHYSIOLOGYMember jnj:MedTechMember jnj:CardiovascularMember 2022-01-03 2023-01-01 0000200406 jnj:AbiomedMember country:US jnj:MedTechMember jnj:CardiovascularMember 2024-01-01 2024-12-29 0000200406 jnj:AbiomedMember country:US jnj:MedTechMember jnj:CardiovascularMember 2023-01-02 2023-12-31 0000200406 jnj:AbiomedMember country:US jnj:MedTechMember jnj:CardiovascularMember 2022-01-03 2023-01-01 0000200406 jnj:AbiomedMember us-gaap:NonUsMember jnj:MedTechMember jnj:CardiovascularMember 2024-01-01 2024-12-29 0000200406 jnj:AbiomedMember us-gaap:NonUsMember jnj:MedTechMember jnj:CardiovascularMember 2023-01-02 2023-12-31 0000200406 jnj:AbiomedMember us-gaap:NonUsMember jnj:MedTechMember jnj:CardiovascularMember 2022-01-03 2023-01-01 0000200406 jnj:AbiomedMember jnj:MedTechMember jnj:CardiovascularMember 2024-01-01 2024-12-29 0000200406 jnj:AbiomedMember jnj:MedTechMember jnj:CardiovascularMember 2023-01-02 2023-12-31 0000200406 jnj:AbiomedMember jnj:MedTechMember jnj:CardiovascularMember 2022-01-03 2023-01-01 0000200406 jnj:ShockwaveMedicalInc.Member country:US jnj:MedTechMember jnj:CardiovascularMember 2024-01-01 2024-12-29 0000200406 jnj:ShockwaveMedicalInc.Member country:US jnj:MedTechMember jnj:CardiovascularMember 2023-01-02 2023-12-31 0000200406 jnj:ShockwaveMedicalInc.Member country:US jnj:MedTechMember jnj:CardiovascularMember 2022-01-03 2023-01-01 0000200406 jnj:ShockwaveMedicalInc.Member us-gaap:NonUsMember jnj:MedTechMember jnj:CardiovascularMember 2024-01-01 2024-12-29 0000200406 jnj:ShockwaveMedicalInc.Member us-gaap:NonUsMember jnj:MedTechMember jnj:CardiovascularMember 2023-01-02 2023-12-31 0000200406 jnj:ShockwaveMedicalInc.Member us-gaap:NonUsMember jnj:MedTechMember jnj:CardiovascularMember 2022-01-03 2023-01-01 0000200406 jnj:ShockwaveMedicalInc.Member jnj:MedTechMember jnj:CardiovascularMember 2024-01-01 2024-12-29 0000200406 jnj:ShockwaveMedicalInc.Member jnj:MedTechMember jnj:CardiovascularMember 2023-01-02 2023-12-31 0000200406 jnj:ShockwaveMedicalInc.Member jnj:MedTechMember jnj:CardiovascularMember 2022-01-03 2023-01-01 0000200406 jnj:OtherCardiovascularMember country:US jnj:MedTechMember jnj:CardiovascularMember 2024-01-01 2024-12-29 0000200406 jnj:OtherCardiovascularMember country:US jnj:MedTechMember jnj:CardiovascularMember 2023-01-02 2023-12-31 0000200406 jnj:OtherCardiovascularMember country:US jnj:MedTechMember jnj:CardiovascularMember 2022-01-03 2023-01-01 0000200406 jnj:OtherCardiovascularMember us-gaap:NonUsMember jnj:MedTechMember jnj:CardiovascularMember 2024-01-01 2024-12-29 0000200406 jnj:OtherCardiovascularMember us-gaap:NonUsMember jnj:MedTechMember jnj:CardiovascularMember 2023-01-02 2023-12-31 0000200406 jnj:OtherCardiovascularMember us-gaap:NonUsMember jnj:MedTechMember jnj:CardiovascularMember 2022-01-03 2023-01-01 0000200406 jnj:OtherCardiovascularMember jnj:MedTechMember jnj:CardiovascularMember 2024-01-01 2024-12-29 0000200406 jnj:OtherCardiovascularMember jnj:MedTechMember jnj:CardiovascularMember 2023-01-02 2023-12-31 0000200406 jnj:OtherCardiovascularMember jnj:MedTechMember jnj:CardiovascularMember 2022-01-03 2023-01-01 0000200406 country:US jnj:MedTechMember jnj:OrthopaedicsMember 2024-01-01 2024-12-29 0000200406 country:US jnj:MedTechMember jnj:OrthopaedicsMember 2023-01-02 2023-12-31 0000200406 country:US jnj:MedTechMember jnj:OrthopaedicsMember 2022-01-03 2023-01-01 0000200406 us-gaap:NonUsMember jnj:MedTechMember jnj:OrthopaedicsMember 2024-01-01 2024-12-29 0000200406 us-gaap:NonUsMember jnj:MedTechMember jnj:OrthopaedicsMember 2023-01-02 2023-12-31 0000200406 us-gaap:NonUsMember jnj:MedTechMember jnj:OrthopaedicsMember 2022-01-03 2023-01-01 0000200406 jnj:MedTechMember jnj:OrthopaedicsMember 2024-01-01 2024-12-29 0000200406 jnj:MedTechMember jnj:OrthopaedicsMember 2023-01-02 2023-12-31 0000200406 jnj:MedTechMember jnj:OrthopaedicsMember 2022-01-03 2023-01-01 0000200406 jnj:HIPSMember country:US jnj:MedTechMember jnj:OrthopaedicsMember 2024-01-01 2024-12-29 0000200406 jnj:HIPSMember country:US jnj:MedTechMember jnj:OrthopaedicsMember 2023-01-02 2023-12-31 0000200406 jnj:HIPSMember country:US jnj:MedTechMember jnj:OrthopaedicsMember 2022-01-03 2023-01-01 0000200406 jnj:HIPSMember us-gaap:NonUsMember jnj:MedTechMember jnj:OrthopaedicsMember 2024-01-01 2024-12-29 0000200406 jnj:HIPSMember us-gaap:NonUsMember jnj:MedTechMember jnj:OrthopaedicsMember 2023-01-02 2023-12-31 0000200406 jnj:HIPSMember us-gaap:NonUsMember jnj:MedTechMember jnj:OrthopaedicsMember 2022-01-03 2023-01-01 0000200406 jnj:HIPSMember jnj:MedTechMember jnj:OrthopaedicsMember 2024-01-01 2024-12-29 0000200406 jnj:HIPSMember jnj:MedTechMember jnj:OrthopaedicsMember 2023-01-02 2023-12-31 0000200406 jnj:HIPSMember jnj:MedTechMember jnj:OrthopaedicsMember 2022-01-03 2023-01-01 0000200406 jnj:KNEESMember country:US jnj:MedTechMember jnj:OrthopaedicsMember 2024-01-01 2024-12-29 0000200406 jnj:KNEESMember country:US jnj:MedTechMember jnj:OrthopaedicsMember 2023-01-02 2023-12-31 0000200406 jnj:KNEESMember country:US jnj:MedTechMember jnj:OrthopaedicsMember 2022-01-03 2023-01-01 0000200406 jnj:KNEESMember us-gaap:NonUsMember jnj:MedTechMember jnj:OrthopaedicsMember 2024-01-01 2024-12-29 0000200406 jnj:KNEESMember us-gaap:NonUsMember jnj:MedTechMember jnj:OrthopaedicsMember 2023-01-02 2023-12-31 0000200406 jnj:KNEESMember us-gaap:NonUsMember jnj:MedTechMember jnj:OrthopaedicsMember 2022-01-03 2023-01-01 0000200406 jnj:KNEESMember jnj:MedTechMember jnj:OrthopaedicsMember 2024-01-01 2024-12-29 0000200406 jnj:KNEESMember jnj:MedTechMember jnj:OrthopaedicsMember 2023-01-02 2023-12-31 0000200406 jnj:KNEESMember jnj:MedTechMember jnj:OrthopaedicsMember 2022-01-03 2023-01-01 0000200406 jnj:TRAUMAMember country:US jnj:MedTechMember jnj:OrthopaedicsMember 2024-01-01 2024-12-29 0000200406 jnj:TRAUMAMember country:US jnj:MedTechMember jnj:OrthopaedicsMember 2023-01-02 2023-12-31 0000200406 jnj:TRAUMAMember country:US jnj:MedTechMember jnj:OrthopaedicsMember 2022-01-03 2023-01-01 0000200406 jnj:TRAUMAMember us-gaap:NonUsMember jnj:MedTechMember jnj:OrthopaedicsMember 2024-01-01 2024-12-29 0000200406 jnj:TRAUMAMember us-gaap:NonUsMember jnj:MedTechMember jnj:OrthopaedicsMember 2023-01-02 2023-12-31 0000200406 jnj:TRAUMAMember us-gaap:NonUsMember jnj:MedTechMember jnj:OrthopaedicsMember 2022-01-03 2023-01-01 0000200406 jnj:TRAUMAMember jnj:MedTechMember jnj:OrthopaedicsMember 2024-01-01 2024-12-29 0000200406 jnj:TRAUMAMember jnj:MedTechMember jnj:OrthopaedicsMember 2023-01-02 2023-12-31 0000200406 jnj:TRAUMAMember jnj:MedTechMember jnj:OrthopaedicsMember 2022-01-03 2023-01-01 0000200406 jnj:SPINESPORTSOTHERMember country:US jnj:MedTechMember jnj:OrthopaedicsMember 2024-01-01 2024-12-29 0000200406 jnj:SPINESPORTSOTHERMember country:US jnj:MedTechMember jnj:OrthopaedicsMember 2023-01-02 2023-12-31 0000200406 jnj:SPINESPORTSOTHERMember country:US jnj:MedTechMember jnj:OrthopaedicsMember 2022-01-03 2023-01-01 0000200406 jnj:SPINESPORTSOTHERMember us-gaap:NonUsMember jnj:MedTechMember jnj:OrthopaedicsMember 2024-01-01 2024-12-29 0000200406 jnj:SPINESPORTSOTHERMember us-gaap:NonUsMember jnj:MedTechMember jnj:OrthopaedicsMember 2023-01-02 2023-12-31 0000200406 jnj:SPINESPORTSOTHERMember us-gaap:NonUsMember jnj:MedTechMember jnj:OrthopaedicsMember 2022-01-03 2023-01-01 0000200406 jnj:SPINESPORTSOTHERMember jnj:MedTechMember jnj:OrthopaedicsMember 2024-01-01 2024-12-29 0000200406 jnj:SPINESPORTSOTHERMember jnj:MedTechMember jnj:OrthopaedicsMember 2023-01-02 2023-12-31 0000200406 jnj:SPINESPORTSOTHERMember jnj:MedTechMember jnj:OrthopaedicsMember 2022-01-03 2023-01-01 0000200406 country:US jnj:MedTechMember jnj:SurgeryMember 2024-01-01 2024-12-29 0000200406 country:US jnj:MedTechMember jnj:SurgeryMember 2023-01-02 2023-12-31 0000200406 country:US jnj:MedTechMember jnj:SurgeryMember 2022-01-03 2023-01-01 0000200406 us-gaap:NonUsMember jnj:MedTechMember jnj:SurgeryMember 2024-01-01 2024-12-29 0000200406 us-gaap:NonUsMember jnj:MedTechMember jnj:SurgeryMember 2023-01-02 2023-12-31 0000200406 us-gaap:NonUsMember jnj:MedTechMember jnj:SurgeryMember 2022-01-03 2023-01-01 0000200406 jnj:MedTechMember jnj:SurgeryMember 2024-01-01 2024-12-29 0000200406 jnj:MedTechMember jnj:SurgeryMember 2023-01-02 2023-12-31 0000200406 jnj:MedTechMember jnj:SurgeryMember 2022-01-03 2023-01-01 0000200406 jnj:ADVANCEDMember country:US jnj:MedTechMember jnj:SurgeryMember 2024-01-01 2024-12-29 0000200406 jnj:ADVANCEDMember country:US jnj:MedTechMember jnj:SurgeryMember 2023-01-02 2023-12-31 0000200406 jnj:ADVANCEDMember country:US jnj:MedTechMember jnj:SurgeryMember 2022-01-03 2023-01-01 0000200406 jnj:ADVANCEDMember us-gaap:NonUsMember jnj:MedTechMember jnj:SurgeryMember 2024-01-01 2024-12-29 0000200406 jnj:ADVANCEDMember us-gaap:NonUsMember jnj:MedTechMember jnj:SurgeryMember 2023-01-02 2023-12-31 0000200406 jnj:ADVANCEDMember us-gaap:NonUsMember jnj:MedTechMember jnj:SurgeryMember 2022-01-03 2023-01-01 0000200406 jnj:ADVANCEDMember jnj:MedTechMember jnj:SurgeryMember 2024-01-01 2024-12-29 0000200406 jnj:ADVANCEDMember jnj:MedTechMember jnj:SurgeryMember 2023-01-02 2023-12-31 0000200406 jnj:ADVANCEDMember jnj:MedTechMember jnj:SurgeryMember 2022-01-03 2023-01-01 0000200406 jnj:GENERALMember country:US jnj:MedTechMember jnj:SurgeryMember 2024-01-01 2024-12-29 0000200406 jnj:GENERALMember country:US jnj:MedTechMember jnj:SurgeryMember 2023-01-02 2023-12-31 0000200406 jnj:GENERALMember country:US jnj:MedTechMember jnj:SurgeryMember 2022-01-03 2023-01-01 0000200406 jnj:GENERALMember us-gaap:NonUsMember jnj:MedTechMember jnj:SurgeryMember 2024-01-01 2024-12-29 0000200406 jnj:GENERALMember us-gaap:NonUsMember jnj:MedTechMember jnj:SurgeryMember 2023-01-02 2023-12-31 0000200406 jnj:GENERALMember us-gaap:NonUsMember jnj:MedTechMember jnj:SurgeryMember 2022-01-03 2023-01-01 0000200406 jnj:GENERALMember jnj:MedTechMember jnj:SurgeryMember 2024-01-01 2024-12-29 0000200406 jnj:GENERALMember jnj:MedTechMember jnj:SurgeryMember 2023-01-02 2023-12-31 0000200406 jnj:GENERALMember jnj:MedTechMember jnj:SurgeryMember 2022-01-03 2023-01-01 0000200406 country:US jnj:MedTechMember jnj:VisionMember 2024-01-01 2024-12-29 0000200406 country:US jnj:MedTechMember jnj:VisionMember 2023-01-02 2023-12-31 0000200406 country:US jnj:MedTechMember jnj:VisionMember 2022-01-03 2023-01-01 0000200406 us-gaap:NonUsMember jnj:MedTechMember jnj:VisionMember 2024-01-01 2024-12-29 0000200406 us-gaap:NonUsMember jnj:MedTechMember jnj:VisionMember 2023-01-02 2023-12-31 0000200406 us-gaap:NonUsMember jnj:MedTechMember jnj:VisionMember 2022-01-03 2023-01-01 0000200406 jnj:MedTechMember jnj:VisionMember 2024-01-01 2024-12-29 0000200406 jnj:MedTechMember jnj:VisionMember 2023-01-02 2023-12-31 0000200406 jnj:MedTechMember jnj:VisionMember 2022-01-03 2023-01-01 0000200406 jnj:CONTACTLENSESOTHERMember country:US jnj:MedTechMember jnj:VisionMember 2024-01-01 2024-12-29 0000200406 jnj:CONTACTLENSESOTHERMember country:US jnj:MedTechMember jnj:VisionMember 2023-01-02 2023-12-31 0000200406 jnj:CONTACTLENSESOTHERMember country:US jnj:MedTechMember jnj:VisionMember 2022-01-03 2023-01-01 0000200406 jnj:CONTACTLENSESOTHERMember us-gaap:NonUsMember jnj:MedTechMember jnj:VisionMember 2024-01-01 2024-12-29 0000200406 jnj:CONTACTLENSESOTHERMember us-gaap:NonUsMember jnj:MedTechMember jnj:VisionMember 2023-01-02 2023-12-31 0000200406 jnj:CONTACTLENSESOTHERMember us-gaap:NonUsMember jnj:MedTechMember jnj:VisionMember 2022-01-03 2023-01-01 0000200406 jnj:CONTACTLENSESOTHERMember jnj:MedTechMember jnj:VisionMember 2024-01-01 2024-12-29 0000200406 jnj:CONTACTLENSESOTHERMember jnj:MedTechMember jnj:VisionMember 2023-01-02 2023-12-31 0000200406 jnj:CONTACTLENSESOTHERMember jnj:MedTechMember jnj:VisionMember 2022-01-03 2023-01-01 0000200406 jnj:SURGICALMember country:US jnj:MedTechMember jnj:VisionMember 2024-01-01 2024-12-29 0000200406 jnj:SURGICALMember country:US jnj:MedTechMember jnj:VisionMember 2023-01-02 2023-12-31 0000200406 jnj:SURGICALMember country:US jnj:MedTechMember jnj:VisionMember 2022-01-03 2023-01-01 0000200406 jnj:SURGICALMember us-gaap:NonUsMember jnj:MedTechMember jnj:VisionMember 2024-01-01 2024-12-29 0000200406 jnj:SURGICALMember us-gaap:NonUsMember jnj:MedTechMember jnj:VisionMember 2023-01-02 2023-12-31 0000200406 jnj:SURGICALMember us-gaap:NonUsMember jnj:MedTechMember jnj:VisionMember 2022-01-03 2023-01-01 0000200406 jnj:SURGICALMember jnj:MedTechMember jnj:VisionMember 2024-01-01 2024-12-29 0000200406 jnj:SURGICALMember jnj:MedTechMember jnj:VisionMember 2023-01-02 2023-12-31 0000200406 jnj:SURGICALMember jnj:MedTechMember jnj:VisionMember 2022-01-03 2023-01-01 0000200406 country:US jnj:MedTechMember 2024-01-01 2024-12-29 0000200406 country:US jnj:MedTechMember 2023-01-02 2023-12-31 0000200406 country:US jnj:MedTechMember 2022-01-03 2023-01-01 0000200406 us-gaap:NonUsMember jnj:MedTechMember 2024-01-01 2024-12-29 0000200406 us-gaap:NonUsMember jnj:MedTechMember 2023-01-02 2023-12-31 0000200406 us-gaap:NonUsMember jnj:MedTechMember 2022-01-03 2023-01-01 0000200406 jnj:MedTechMember 2022-01-03 2023-01-01 0000200406 country:US 2024-01-01 2024-12-29 0000200406 country:US 2023-01-02 2023-12-31 0000200406 country:US 2022-01-03 2023-01-01 0000200406 us-gaap:NonUsMember 2024-01-01 2024-12-29 0000200406 us-gaap:NonUsMember 2023-01-02 2023-12-31 0000200406 us-gaap:NonUsMember 2022-01-03 2023-01-01 0000200406 us-gaap:OperatingSegmentsMember jnj:InnovativeMedicineMember 2024-01-01 2024-12-29 0000200406 us-gaap:OperatingSegmentsMember jnj:MedTechMember 2024-01-01 2024-12-29 0000200406 us-gaap:OperatingSegmentsMember jnj:InnovativeMedicineMember 2023-01-02 2023-12-31 0000200406 us-gaap:OperatingSegmentsMember jnj:MedTechMember 2023-01-02 2023-12-31 0000200406 us-gaap:OperatingSegmentsMember jnj:InnovativeMedicineMember 2022-01-03 2023-01-01 0000200406 us-gaap:OperatingSegmentsMember jnj:MedTechMember 2022-01-03 2023-01-01 0000200406 us-gaap:OperatingSegmentsMember 2024-01-01 2024-12-29 0000200406 us-gaap:OperatingSegmentsMember 2023-01-02 2023-12-31 0000200406 us-gaap:OperatingSegmentsMember 2022-01-03 2023-01-01 0000200406 us-gaap:OperatingSegmentsMember jnj:InnovativeMedicineMember 2024-12-29 0000200406 us-gaap:OperatingSegmentsMember jnj:InnovativeMedicineMember 2023-12-31 0000200406 us-gaap:OperatingSegmentsMember jnj:MedTechMember 2024-12-29 0000200406 us-gaap:OperatingSegmentsMember jnj:MedTechMember 2023-12-31 0000200406 jnj:SegmentsTotalMember 2024-12-29 0000200406 jnj:SegmentsTotalMember 2023-12-31 0000200406 us-gaap:CorporateNonSegmentMember jnj:GeneralCorporateMember 2024-12-29 0000200406 us-gaap:CorporateNonSegmentMember jnj:GeneralCorporateMember 2023-12-31 0000200406 jnj:SegmentsTotalMember 2024-01-01 2024-12-29 0000200406 jnj:SegmentsTotalMember 2023-01-02 2023-12-31 0000200406 jnj:SegmentsTotalMember 2022-01-03 2023-01-01 0000200406 jnj:ConsumerMember 2024-01-01 2024-12-29 0000200406 jnj:ConsumerMember 2023-01-02 2023-12-31 0000200406 jnj:ConsumerMember 2022-01-03 2023-01-01 0000200406 us-gaap:CorporateNonSegmentMember jnj:GeneralCorporateMember 2024-01-01 2024-12-29 0000200406 us-gaap:CorporateNonSegmentMember jnj:GeneralCorporateMember 2023-01-02 2023-12-31 0000200406 us-gaap:CorporateNonSegmentMember jnj:GeneralCorporateMember 2022-01-03 2023-01-01 0000200406 us-gaap:OperatingSegmentsMember country:US 2024-01-01 2024-12-29 0000200406 us-gaap:OperatingSegmentsMember country:US 2023-01-02 2023-12-31 0000200406 us-gaap:OperatingSegmentsMember country:US 2022-01-03 2023-01-01 0000200406 us-gaap:OperatingSegmentsMember country:US 2024-12-29 0000200406 us-gaap:OperatingSegmentsMember country:US 2023-12-31 0000200406 us-gaap:OperatingSegmentsMember srt:EuropeMember 2024-01-01 2024-12-29 0000200406 us-gaap:OperatingSegmentsMember srt:EuropeMember 2023-01-02 2023-12-31 0000200406 us-gaap:OperatingSegmentsMember srt:EuropeMember 2022-01-03 2023-01-01 0000200406 us-gaap:OperatingSegmentsMember srt:EuropeMember 2024-12-29 0000200406 us-gaap:OperatingSegmentsMember srt:EuropeMember 2023-12-31 0000200406 us-gaap:OperatingSegmentsMember jnj:WesternHemisphereExcludingUSMember 2024-01-01 2024-12-29 0000200406 us-gaap:OperatingSegmentsMember jnj:WesternHemisphereExcludingUSMember 2023-01-02 2023-12-31 0000200406 us-gaap:OperatingSegmentsMember jnj:WesternHemisphereExcludingUSMember 2022-01-03 2023-01-01 0000200406 us-gaap:OperatingSegmentsMember jnj:WesternHemisphereExcludingUSMember 2024-12-29 0000200406 us-gaap:OperatingSegmentsMember jnj:WesternHemisphereExcludingUSMember 2023-12-31 0000200406 us-gaap:OperatingSegmentsMember jnj:AsiaPacificAfricaMember 2024-01-01 2024-12-29 0000200406 us-gaap:OperatingSegmentsMember jnj:AsiaPacificAfricaMember 2023-01-02 2023-12-31 0000200406 us-gaap:OperatingSegmentsMember jnj:AsiaPacificAfricaMember 2022-01-03 2023-01-01 0000200406 us-gaap:OperatingSegmentsMember jnj:AsiaPacificAfricaMember 2024-12-29 0000200406 us-gaap:OperatingSegmentsMember jnj:AsiaPacificAfricaMember 2023-12-31 0000200406 us-gaap:OperatingSegmentsMember 2024-12-29 0000200406 us-gaap:OperatingSegmentsMember 2023-12-31 0000200406 us-gaap:CorporateNonSegmentMember 2024-12-29 0000200406 us-gaap:CorporateNonSegmentMember 2023-12-31 0000200406 jnj:Wholesaler1Member us-gaap:SalesRevenueNetMember jnj:WholesalerConcentrationRiskMember 2024-01-01 2024-12-29 0000200406 jnj:Wholesaler2Member us-gaap:SalesRevenueNetMember jnj:WholesalerConcentrationRiskMember 2024-01-01 2024-12-29 0000200406 jnj:Wholesaler3Member us-gaap:SalesRevenueNetMember jnj:WholesalerConcentrationRiskMember 2024-01-01 2024-12-29 0000200406 jnj:Wholesaler1Member us-gaap:SalesRevenueNetMember jnj:WholesalerConcentrationRiskMember 2023-01-02 2023-12-31 0000200406 jnj:Wholesaler2Member us-gaap:SalesRevenueNetMember jnj:WholesalerConcentrationRiskMember 2023-01-02 2023-12-31 0000200406 jnj:Wholesaler3Member us-gaap:SalesRevenueNetMember jnj:WholesalerConcentrationRiskMember 2023-01-02 2023-12-31 0000200406 jnj:Wholesaler1Member us-gaap:SalesRevenueNetMember jnj:WholesalerConcentrationRiskMember 2022-01-03 2023-01-01 0000200406 jnj:Wholesaler2Member us-gaap:SalesRevenueNetMember jnj:WholesalerConcentrationRiskMember 2022-01-03 2023-01-01 0000200406 jnj:Wholesaler3Member us-gaap:SalesRevenueNetMember jnj:WholesalerConcentrationRiskMember 2022-01-03 2023-01-01 0000200406 jnj:BabyPowderMember jnj:TalcMember 2024-01-01 2024-12-29 0000200406 jnj:BabyPowderMember jnj:TalcMember 2023-01-02 2023-12-31 0000200406 jnj:MomentaMember jnj:InnovativeMedicineMember 2024-01-01 2024-12-29 0000200406 jnj:VWaveLtd.Member jnj:MedTechMember 2024-01-01 2024-12-29 0000200406 jnj:MomentaMember jnj:InnovativeMedicineMember 2023-01-02 2023-12-31 0000200406 jnj:LaminarMember jnj:MedTechMember 2023-01-02 2023-12-31 0000200406 jnj:BermekimabMember us-gaap:InProcessResearchAndDevelopmentMember 2022-01-03 2023-01-01 0000200406 us-gaap:PropertyPlantAndEquipmentMember 2024-12-29 0000200406 us-gaap:PropertyPlantAndEquipmentMember 2023-12-31 0000200406 us-gaap:OtherIntangibleAssetsMember 2024-12-29 0000200406 us-gaap:OtherIntangibleAssetsMember 2023-12-31 0000200406 srt:ScenarioForecastMember jnj:IntraCellularTherapiesInc.Member 2025-02-13 0000200406 srt:ScenarioForecastMember jnj:IntraCellularTherapiesInc.Member 2025-01-01 2025-02-13 0000200406 jnj:ProteologixMember 2024-06-20 2024-06-20 0000200406 jnj:ProteologixMember 2024-06-20 0000200406 srt:MinimumMember jnj:ProteologixMember 2024-06-20 0000200406 srt:MaximumMember jnj:ProteologixMember 2024-06-20 0000200406 jnj:ProteologixMember 2024-01-01 2024-12-29 0000200406 jnj:ShockwaveMedicalInc.Member 2024-05-31 0000200406 jnj:ShockwaveMedicalInc.Member 2024-12-29 0000200406 jnj:ShockwaveMedicalInc.Member 2024-06-01 2024-06-29 0000200406 jnj:ShockwaveMedicalInc.Member 2024-06-20 0000200406 jnj:ShockwaveMedicalInc.Member 2024-05-31 2024-05-31 0000200406 jnj:ShockwaveMedicalInc.Member 2024-01-01 2024-12-29 0000200406 srt:MinimumMember jnj:ShockwaveMedicalInc.Member 2024-05-31 0000200406 jnj:AmbrxMember 2024-01-01 2024-12-29 0000200406 jnj:AmbrxMember 2024-12-29 0000200406 srt:MinimumMember jnj:AmbrxMember 2024-12-29 0000200406 srt:MaximumMember jnj:AmbrxMember 2024-12-29 0000200406 jnj:AbiomedMember 2022-12-22 0000200406 jnj:AbiomedMember 2022-12-22 2022-12-22 0000200406 jnj:NonTradeableContingentValueRightMember jnj:AbiomedMember 2022-12-22 2022-12-22 0000200406 2022-12-22 0000200406 jnj:ImpellaMember jnj:AbiomedMember 2022-12-22 0000200406 jnj:ClassIRecommendationForImpellaMember 2022-12-22 0000200406 jnj:AbiomedMember 2024-12-29 0000200406 jnj:AbiomedMember 2024-01-01 2024-12-29 0000200406 srt:MinimumMember jnj:AbiomedMember 2022-12-22 0000200406 srt:MaximumMember jnj:AbiomedMember 2022-12-22 0000200406 jnj:VWaveLtd.Member 2024-10-08 2024-10-08 0000200406 srt:MaximumMember jnj:VWaveLtd.Member 2024-10-08 2024-10-08 0000200406 jnj:VWaveLtd.Member 2024-10-08 0000200406 jnj:YellowJerseyTherapeuticsMember 2024-07-11 2024-07-11 0000200406 jnj:YellowJerseyTherapeuticsMember 2024-07-11 0000200406 jnj:LaminarMember 2023-01-02 2023-12-31 0000200406 jnj:LaminarMember 2023-12-31 0000200406 jnj:AcclarentMember 2024-01-01 2024-12-29 0000200406 jnj:PonvoryMember 2024-01-01 2024-12-29 0000200406 jnj:InghamVsJohnsonJohnsonMember 2018-07-01 2018-07-31 0000200406 jnj:InghamVsJohnsonJohnsonMember 2020-06-01 2020-06-30 0000200406 jnj:InghamVsJohnsonJohnsonMember 2021-06-01 2021-06-30 0000200406 jnj:TalcMember 2024-05-01 2024-05-01 0000200406 jnj:TalcMember 2024-05-01 0000200406 jnj:TalcMember 2024-09-20 2024-09-20 0000200406 jnj:MesotheliomaAndStateClaimsMember 2024-05-01 2024-05-01 0000200406 jnj:TalcMember 2024-09-30 2024-12-29 0000200406 jnj:TalcMember 2024-12-29 0000200406 jnj:OpioidMember 2024-12-29 0000200406 jnj:OpioidMember 2021-07-04 0000200406 jnj:TalcMember 2024-12-29 0000200406 jnj:AsrMember 2024-12-29 0000200406 jnj:PinnacleAcetabularCupSystemMember 2024-12-29 0000200406 jnj:PelvicMeshesMember 2024-12-29 0000200406 jnj:PhysiomeshMember 2024-12-29 0000200406 jnj:RisperdalMember 2024-12-29 0000200406 jnj:ElmironMember 2024-12-29 0000200406 jnj:DePuyASRU.S.Member us-gaap:SettledLitigationMember 2024-12-29 0000200406 jnj:PhysiomeshMember us-gaap:PendingLitigationMember 2021-05-31 0000200406 jnj:PhysiomeshMember us-gaap:PendingLitigationMember 2021-09-30 0000200406 us-gaap:JudicialRulingMember 2019-10-01 2019-10-31 0000200406 us-gaap:JudicialRulingMember 2020-01-01 2020-01-31 0000200406 jnj:RDRestructuringPlanMember 2024-01-01 2024-12-29 0000200406 jnj:RDRestructuringPlanMember 2023-01-02 2023-12-31 0000200406 jnj:RDRestructuringPlanMember 2024-12-29 0000200406 jnj:OrthopaedicsRestructuringPlanMember 2024-01-01 2024-12-29 0000200406 jnj:OrthopaedicsRestructuringPlanMember 2023-01-02 2023-12-31 0000200406 jnj:OrthopaedicsRestructuringPlanMember 2024-12-29 0000200406 srt:MinimumMember jnj:OrthopaedicsRestructuringPlanMember 2024-12-29 0000200406 srt:MaximumMember jnj:OrthopaedicsRestructuringPlanMember 2024-12-29 0000200406 us-gaap:RestructuringChargesMember jnj:InnovativeMedicineMember 2023-01-02 2023-12-31 0000200406 jnj:CostsOfGoodsAndServicesSoldMember jnj:InnovativeMedicineMember 2023-01-02 2023-12-31 0000200406 us-gaap:RestructuringChargesMember jnj:MedTechMember 2024-01-01 2024-12-29 0000200406 jnj:CostsOfGoodsAndServicesSoldMember jnj:MedTechMember 2024-01-01 2024-12-29 0000200406 us-gaap:RestructuringChargesMember jnj:MedTechMember 2023-01-02 2023-12-31 0000200406 jnj:CostsOfGoodsAndServicesSoldMember jnj:MedTechMember 2023-01-02 2023-12-31 0000200406 jnj:KenvueIncMember 2023-08-23 2023-08-23 0000200406 jnj:KenvueIncMember 2023-08-23 2023-08-23 0000200406 2023-08-23 0000200406 jnj:KenvueIncMember jnj:JohnsonJohnsonMember 2023-08-23 0000200406 jnj:KenvueIncMember jnj:JohnsonJohnsonMember 2024-12-29 0000200406 jnj:ConsumerHealthMember 2023-08-23 0000200406 jnj:ConsumerHealthMember 2023-08-23 2023-08-23 0000200406 jnj:KenvueIncMember jnj:ConsumerHealthMember jnj:JohnsonJohnsonMember 2023-08-23 0000200406 2023-08-23 2023-08-23 0000200406 srt:MinimumMember 2023-08-23 2023-08-23 0000200406 srt:MaximumMember 2023-08-23 2023-08-23 0000200406 2024-09-30 2024-12-29 iso4217:USD shares iso4217:USD shares jnj:Employee pure jnj:Segment iso4217:EUR iso4217:GBP jnj:StockBasedCompensationPlans jnj:segment jnj:claimant jnj:cases 0000200406 2024 FY false Johnson & Johnson http://fasb.org/us-gaap/2024#OtherAssetsNoncurrent http://fasb.org/us-gaap/2024#OtherAssetsNoncurrent http://fasb.org/us-gaap/2024#AccruedLiabilitiesCurrent http://fasb.org/us-gaap/2024#AccruedLiabilitiesCurrent http://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrent http://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrent http://fasb.org/us-gaap/2024#AccountsPayableCurrent http://fasb.org/us-gaap/2024#AccountsPayableCurrent P25Y http://fasb.org/us-gaap/2024#OtherNonoperatingIncomeExpense http://fasb.org/us-gaap/2024#OtherNonoperatingIncomeExpense http://fasb.org/us-gaap/2024#OtherNonoperatingIncomeExpense 10-K true 2024-12-29 --12-29 false 1-3215 NJ 22-1024240 One Johnson & Johnson Plaza New Brunswick NJ 08933 732 524-0400 Common Stock, Par Value $1.00 JNJ NYSE 1.150% Notes Due November 2028 JNJ28 NYSE 3.20% Notes Due November 2032 JNJ32 NYSE 1.650% Notes Due May 2035 JNJ35 NYSE 3.350% Notes Due November 2036 JNJ36A NYSE 3.550% Notes Due November 2044 JNJ44 NYSE Yes No Yes Yes Large Accelerated Filer false false true false false 352000000000 2407616693 <div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:110%">DOCUMENTS INCORPORATED BY REFERENCE</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.647%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.153%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:7.5pt;font-weight:400;line-height:130%">Part III:</span></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:7.5pt;font-weight:400;line-height:130%">Portions of the registrant’s proxy statement for its 2025 annual meeting of shareholders to be filed within 120 days after the close of the registrant’s fiscal year (the “Proxy Statement”), are incorporated by reference to this report on Form 10-K (this “Report”).</span></div></td></tr></table></div> <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company has documented cybersecurity policies and standards, assesses risks from cybersecurity threats, and monitors information systems for potential cybersecurity issues. To protect the Company’s information systems from cybersecurity threats, the Company uses various security tools supporting protection, detection, and response capabilities. The Company maintains a cybersecurity incident response plan to help ensure a timely, consistent response to actual or attempted cybersecurity incidents impacting the Company. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company also identifies and assesses third-party risks within the enterprise, and through the Company's use of third-party service providers, across a range of areas including data security and supply chain through a structured third-party risk management program. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company maintains a formal information security training program for all employees that includes training on matters such as phishing and email security best practices. Employees are also required to complete mandatory training on data privacy.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">To evaluate and enhance its cybersecurity program, the Company periodically utilizes third-party experts to undertake maturity assessments of the Company’s information security program.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">To date, the Company is not aware of any cybersecurity incident that has had or is reasonably likely to have a material impact on the Company’s business or operations; however, because of the frequently changing attack techniques, along with the increased volume and sophistication of the attacks, there is the potential for the Company to be adversely impacted. This impact could result in reputational, competitive, operational or other business harm as well as financial costs and regulatory action. Refer to the risk factor captioned An information security incident, including a cybersecurity breach, could have a negative impact to the Company’s business or reputation in Part I, Item 1A. Risk factors for additional description of cybersecurity risks and potential related impacts on the Company.</span></div> The Company has documented cybersecurity policies and standards, assesses risks from cybersecurity threats, and monitors information systems for potential cybersecurity issues. To protect the Company’s information systems from cybersecurity threats, the Company uses various security tools supporting protection, detection, and response capabilities. The Company maintains a cybersecurity incident response plan to help ensure a timely, consistent response to actual or attempted cybersecurity incidents impacting the Company. true true true false <div style="margin-bottom:6pt;margin-top:16pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Governance - management’s responsibility</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company takes a risk-based approach to cybersecurity and has implemented cybersecurity controls designed to address cybersecurity threats and risks. The Chief Information Officer (CIO), who is a member of the Company’s Executive Committee, and the Chief Information Security Officer (CISO) are responsible for assessing and managing cybersecurity risks, including security incident detection, response, and recovery.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company’s CISO, in coordination with the CIO, is responsible for leading the Company’s cybersecurity program and management of cybersecurity risk. The current CISO has over twenty-five years of experience in information security, and his background includes technical experience, strategy and architecture focused roles, cyber and threat experience, and various leadership roles.</span></div> <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company takes a risk-based approach to cybersecurity and has implemented cybersecurity controls designed to address cybersecurity threats and risks. The Chief Information Officer (CIO), who is a member of the Company’s Executive Committee, and the Chief Information Security Officer (CISO) are responsible for assessing and managing cybersecurity risks, including security incident detection, response, and recovery.</span></div> true The current CISO has over twenty-five years of experience in information security, and his background includes technical experience, strategy and architecture focused roles, cyber and threat experience, and various leadership roles. <div style="margin-bottom:6pt;margin-top:16pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Governance - board oversight</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company’s Board of Directors oversees the overall risk management process, including cybersecurity risks, directly and through its committees. The Regulatory Compliance &amp; Sustainability Committee (RCSC) of the board is primarily responsible for oversight of risk from cybersecurity threats and oversees compliance with applicable laws, regulations and Company policies related to, among others, privacy and cybersecurity. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">RCSC meetings include discussions of specific risk areas throughout the year including, among others, those relating to cybersecurity. The CISO provides quarterly updates each year to RCSC on cybersecurity matters. These reports include an overview of the cybersecurity threat landscape, key cybersecurity initiatives to improve the Company’s risk posture, changes in the legal and regulatory landscape relative to cybersecurity, and overviews of certain cybersecurity incidents that have occurred within the Company and within the industry.</span></div> The Company’s Board of Directors oversees the overall risk management process, including cybersecurity risks, directly and through its committees. The Regulatory Compliance &amp; Sustainability Committee (RCSC) of the board is primarily responsible for oversight of risk from cybersecurity threats and oversees compliance with applicable laws, regulations and Company policies related to, among others, privacy and cybersecurity. The Company’s Board of Directors oversees the overall risk management process, including cybersecurity risks, directly and through its committees. The Regulatory Compliance &amp; Sustainability Committee (RCSC) of the board is primarily responsible for oversight of risk from cybersecurity threats and oversees compliance with applicable laws, regulations and Company policies related to, among others, privacy and cybersecurity. true <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">RCSC meetings include discussions of specific risk areas throughout the year including, among others, those relating to cybersecurity. The CISO provides quarterly updates each year to RCSC on cybersecurity matters. These reports include an overview of the cybersecurity threat landscape, key cybersecurity initiatives to improve the Company’s risk posture, changes in the legal and regulatory landscape relative to cybersecurity, and overviews of certain cybersecurity incidents that have occurred within the Company and within the industry.</span></div> 238 24105000000 21859000000 417000000 1068000000 167000000 166000000 14842000000 14873000000 12444000000 11181000000 4085000000 4514000000 55893000000 53495000000 20518000000 19898000000 37618000000 34175000000 44200000000 36558000000 10461000000 9279000000 11414000000 14153000000 180104000000 167558000000 5983000000 3451000000 10311000000 9632000000 8549000000 10212000000 17580000000 16001000000 4126000000 3993000000 3772000000 2993000000 50321000000 46282000000 30651000000 25881000000 2448000000 3193000000 7255000000 7149000000 390000000 2881000000 17549000000 13398000000 108614000000 98784000000 2000000 2000000 0 0 1.00 1.00 4320000000 4320000000 3119843000 3119843000 3120000000 3120000000 -11741000000 -12527000000 155791000000 153843000000 712921000 712765000 75680000000 75662000000 71490000000 68774000000 180104000000 167558000000 88821000000 85159000000 79990000000 27471000000 26553000000 24596000000 61350000000 58606000000 55394000000 22869000000 21512000000 20246000000 17232000000 15085000000 14135000000 211000000 313000000 783000000 1332000000 1261000000 490000000 755000000 772000000 276000000 -4694000000 -6634000000 -810000000 234000000 489000000 275000000 16687000000 15062000000 19359000000 2621000000 1736000000 2989000000 14066000000 13326000000 16370000000 0 21827000000 1571000000 14066000000 35153000000 17941000000 5.84 5.26 6.23 0 8.62 0.60 5.84 13.88 6.83 5.79 5.20 6.14 0 8.52 0.59 5.79 13.72 6.73 2407300000 2533500000 2625200000 2429400000 2560400000 2663900000 14066000000 35153000000 17941000000 1708000000 -3221000000 -1796000000 2000000 26000000 -24000000 0 0 0 2000000 26000000 -24000000 154000000 149000000 160000000 -541000000 1183000000 -1854000000 0 -23000000 0 -62000000 90000000 -111000000 -449000000 1399000000 -1805000000 -511000000 422000000 454000000 862000000 569000000 348000000 -1373000000 -147000000 106000000 786000000 -4741000000 91000000 14852000000 30412000000 18032000000 -1100000000 797000000 -460000000 -86000000 289000000 -461000000 -365000000 -39000000 30000000 74023000000 123060000000 -13058000000 3120000000 -39099000000 17941000000 17941000000 4.45 11682000000 11682000000 2466000000 -974000000 3440000000 6035000000 6035000000 91000000 91000000 76804000000 128345000000 -12967000000 3120000000 -41694000000 35153000000 35153000000 4.70 11770000000 11770000000 2193000000 -336000000 2529000000 5054000000 5054000000 25000000 -25000000 -23786000000 2451000000 5181000000 -31418000000 -4741000000 -4741000000 68774000000 153843000000 -12527000000 3120000000 -75662000000 14066000000 14066000000 4.91 11823000000 11823000000 2094000000 -295000000 2389000000 2407000000 2407000000 786000000 786000000 71490000000 155791000000 -11741000000 3120000000 -75680000000 14066000000 35153000000 17941000000 7339000000 7486000000 6970000000 1176000000 1162000000 1138000000 405000000 1295000000 1216000000 1841000000 483000000 0 0 20984000000 0 226000000 117000000 380000000 -2183000000 -4194000000 -1663000000 11000000 0 -17000000 406000000 624000000 1290000000 1128000000 1323000000 2527000000 1621000000 2346000000 1098000000 -1717000000 3480000000 -687000000 33000000 5588000000 -1979000000 24266000000 22791000000 21194000000 4424000000 4543000000 4009000000 675000000 358000000 543000000 15146000000 0 17652000000 1783000000 470000000 0 1726000000 10906000000 32384000000 2462000000 19390000000 41609000000 1517000000 -2963000000 -249000000 174000000 -12000000 229000000 -18599000000 878000000 -12371000000 11823000000 11770000000 11682000000 2432000000 5054000000 6035000000 15277000000 13743000000 16134000000 9463000000 22973000000 6550000000 6660000000 0 2000000 1453000000 1551000000 2134000000 838000000 1094000000 1329000000 272000000 -219000000 -28000000 970000000 0 0 0 8047000000 0 0 4241000000 0 0 1114000000 0 -38000000 -269000000 93000000 -3132000000 -15825000000 -8871000000 -289000000 -112000000 -312000000 2246000000 7732000000 -360000000 21859000000 12889000000 13309000000 0 1238000000 1178000000 21859000000 14127000000 14487000000 24105000000 21859000000 12889000000 0 0 1238000000 24105000000 21859000000 14127000000 1990000000 1836000000 982000000 1911000000 1766000000 933000000 6714000000 8574000000 5223000000 1551000000 1435000000 2114000000 16091000000 0 18710000000 1632000000 0 1058000000 14459000000 0 17652000000 Summary of significant accounting policies<div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Principles of consolidation</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The consolidated financial statements include the accounts of Johnson &amp; Johnson and its subsidiaries (the Company). Intercompany accounts and transactions are eliminated. Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Description of the company</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company has approximately 138,100 employees worldwide engaged in the research and development, manufacture and sale of a broad range of products in the healthcare field. The Company conducts business in virtually all countries of the world and its primary focus is on products related to human health and well-being.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Kenvue IPO/separation and discontinued operations</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">On May 8, 2023, Kenvue, completed an initial public offering (the IPO) resulting in the issuance of 198,734,444 shares of its common stock, par value $0.01 per share (the “Kenvue Common Stock”), at an initial public offering of $22.00 per share for net proceeds of $4.2 billion. The excess of the net proceeds from the IPO over the net book value of the Johnson &amp; Johnson divested interest was $2.5 billion and was recorded to additional paid-in capital. As of the closing of the IPO, Johnson &amp; Johnson owned approximately 89.6% of the total outstanding shares of Kenvue Common Stock and at July 2, 2023, the <br/>non-controlling interest of $1.3 billion associated with Kenvue was reflected in equity attributable to non-controlling interests in the consolidated balance sheet in the fiscal second quarter of 2023. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">On August 23, 2023, Johnson &amp; Johnson completed the disposition of an additional 80.1% ownership of the shares of Kenvue through an exchange offer. Following the exchange offer, the Company owned 9.5% of the shares of Kenvue which were accounted for as an equity investment carried at fair value within continuing operations. The historical results of the Consumer Health business (which previously represented the Consumer Health business segment) are reflected as discontinued operations in the Company’s Consolidated Financial Statements through the date of the exchange offer (see Note 21 for additional details). Unless otherwise indicated, the information in the notes to the Consolidated Financial Statements refer only to Johnson &amp; Johnson’s continuing operations. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">In the fiscal second quarter of 2024 the Company completed a debt for equity exchange of the retained stake in Kenvue. Upon completion of the debt for equity exchange, the Company no longer owns any shares of Kenvue Common Stock.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Business segments</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company is organized into two business segments: Innovative Medicine and MedTech. The Innovative Medicine segment is focused on the following therapeutic areas: Immunology, Infectious Diseases, Neuroscience, Oncology, Pulmonary Hypertension, and Cardiovascular and Metabolic. Products in this segment are distributed directly to retailers, wholesalers, distributors, hospitals and healthcare professionals for prescription use. The MedTech segment includes a broad portfolio of products used in the Orthopaedic, Surgery, Cardiovascular (previously referred to as Interventional Solutions) and Vision fields. These products are distributed to wholesalers, hospitals and retailers, and used principally in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. </span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%">New accounting standards</span></div><div style="margin-bottom:6pt;margin-top:10pt"><span style="color:#000000;font-family:'Johnson Display',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently adopted accounting standards</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">ASU 2023-07: Segment Reporting (Topic 280) – Improvements to Reportable Segment Disclosures</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company adopted the standard in the fiscal year 2024, which requires expanded annual and interim disclosures for significant segment expenses that are regularly provided to the chief operating decision maker and included within each reported measure of segment profit or loss. The standard was applied retrospectively to all periods presented in the financial statements. As this accounting standard only impacts disclosures, it did not have a material impact on the Company’s Consolidated Financial Statements. See Note 17 for the required disclosures.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Recently issued accounting standards</span></div><div style="margin-bottom:6pt;margin-top:10pt"><span style="color:#000000;font-family:'Johnson Display',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Not adopted as of December 29, 2024</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">ASU 2024-03: Income Statement – Reporting Comprehensive Income – Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">This update requires disclosure of disaggregated information about certain income statement expense line items on an annual and interim basis. This update will be effective for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. As this accounting standard only impacts disclosures, it will not have a material impact on the Company’s Consolidated Financial Statements.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">ASU 2023-09: Income Taxes (Topic 740) - Improvements to Income Tax Disclosures</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">This update standardizes categories for the effective tax rate reconciliation, requires disaggregation of income taxes and additional income tax-related disclosures. This update is required to be effective for the Company for fiscal periods beginning after December 15, 2024. As this accounting standard only impacts disclosures, it will not have a material impact on the Company’s Consolidated Financial Statements. </span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Cash equivalents</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company classifies all highly liquid investments with stated maturities of three months or less from date of purchase as cash equivalents and all highly liquid investments with stated maturities of greater than three months from the date of purchase as current marketable securities. The Company has a policy of making investments only with commercial institutions that have at least an investment grade credit rating. The Company invests its cash primarily in government securities and obligations, corporate debt securities, money market funds and reverse repurchase agreements (RRAs).</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">RRAs are collateralized by deposits in the form of Government Securities and Obligations for an amount not less than 102% of their value. The Company does not record an asset or liability as the Company is not permitted to sell or repledge the associated collateral. The Company has a policy that the collateral has at least an A (or equivalent) credit rating. The Company utilizes a third party custodian to manage the exchange of funds and ensure that collateral received is maintained at 102% of the value of the RRAs on a daily basis. RRAs with stated maturities of greater than three months from the date of purchase are classified as marketable securities.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Investments</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Investments classified as held to maturity investments are reported at amortized cost and realized gains or losses are reported in earnings. Investments classified as available-for-sale debt securities are carried at estimated fair value with unrealized gains and losses recorded as a component of accumulated other comprehensive income. Available-for-sale securities available for current operations are classified as current assets; otherwise, they are classified as long term. Management determines the appropriate classification of its investment in debt and equity securities at the time of purchase and re-evaluates such determination at each balance sheet date. The Company reviews its investments for impairment and adjusts these investments to fair value through earnings, as required. </span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Property, plant and equipment and depreciation</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Property, plant and equipment are stated at cost. The Company utilizes the straight-line method of depreciation over the estimated useful lives of the assets:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:86.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.789%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Building and building equipment</span></div></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">30 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Land and leasehold improvements</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">10 - 20 years</span></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Machinery and equipment</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">2 - 13 years</span></div></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company capitalizes certain computer software and development costs, included in machinery and equipment, when incurred in connection with developing or obtaining computer software for internal use. Capitalized software costs are amortized over the estimated useful lives of the software, which generally range from 3 to 8 years.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company reviews long-lived assets to assess recoverability using undiscounted cash flows. When certain events or changes in operating or economic conditions occur, an impairment assessment may be performed on the recoverability of the carrying value of these assets. If the asset is determined to be impaired, the loss is measured based on the difference between the asset’s fair value and its carrying value. If quoted market prices are not available, the Company will estimate fair value using a discounted value of estimated future cash flows.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Revenue recognition</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company recognizes revenue from product sales when obligations under the terms of a contract with the customer are satisfied; generally, this occurs with the transfer of control of the goods to customers. The Company's global payment terms are typically between 30 to 90 days. Provisions for certain rebates, sales incentives, trade promotions, coupons, product returns, discounts to customers and governmental clawback provisions are accounted for as variable consideration and recorded as a reduction in sales. The liability is recognized within Accrued rebates, returns, and promotions on the consolidated balance sheet.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Product discounts granted are based on the terms of arrangements with direct, indirect and other market participants, as well as market conditions, including consideration of competitor pricing. Rebates and discounts are estimated based on contractual terms, historical experience, patient outcomes, trend analysis and projected market conditions in the various markets served. A significant portion of the liability related to rebates is from the sale of the Company's pharmaceutical products within the U.S., primarily the Managed Care, Medicare and Medicaid programs, which amounted to $12.3 billion and $11.5 billion as of December 29, 2024 and December 31, 2023, respectively. The Company evaluates market conditions for products or groups of products primarily through the analysis of wholesaler and other third-party sell-through and market research data, as well as internally generated information.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Sales returns are estimated and recorded based on historical sales and returns information. Products that have lost patent exclusivity, or that otherwise exhibit unusual sales or return patterns due to dating, competition or other marketing matters are specifically investigated and analyzed as part of the accounting for sales return accruals.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Sales returns allowances represent a reserve for products that may be returned due to expiration, destruction in the field, or in specific areas, product recall. In accordance with the Company’s accounting policies, the Company generally issues credit to customers for returned goods. The Company’s sales returns reserves are accounted for in accordance with the U.S. GAAP guidance for revenue recognition when right of return exists. Sales returns reserves are recorded at full sales value. Sales returns in the Innovative Medicine segment are almost exclusively not resalable. Sales returns for certain franchises in the MedTech segment are typically resalable but are not material. The Company infrequently exchanges products from inventory for returned products. The sales returns reserve for the total Company has been approximately 1.0% of annual net trade sales during each of the fiscal years 2024, 2023 and 2022.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Promotional programs, such as product listing allowances are recorded in the same period as related sales and include <br/>volume-based sales incentive programs. Volume-based incentive programs are based on the estimated sales volumes for the incentive period and are recorded as products are sold. These arrangements are evaluated to determine the appropriate amounts to be deferred or recorded as a reduction of revenue. The Company also earns profit-share payments through collaborative arrangements of certain products, which are included in sales to customers. Profit-share payments were less than 2.0% of the total revenues in the fiscal year 2024 and 2023, respectively, and less than 3.0% of total revenues in the fiscal year 2022 and are included in sales to customers.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">See Note 17 to the Consolidated Financial Statements for further disaggregation of revenue.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Shipping and handling</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Shipping and handling costs incurred were $0.9 billion, $0.9 billion and $0.8 billion in fiscal years 2024, 2023 and 2022, respectively, and are included in selling, marketing and administrative expense. The amount of revenue received for shipping and handling is less than 1.0% of sales to customers for all periods presented.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Inventories</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Inventories are stated at the lower of cost or net realizable value determined by the first-in, first-out method.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Intangible assets and goodwill</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The authoritative literature on U.S. GAAP requires that goodwill and intangible assets with indefinite lives be assessed annually for impairment. The Company completed its annual impairment test for 2024 in the fiscal fourth quarter. Future impairment tests will be performed annually in the fiscal fourth quarter, or sooner if warranted. In-process research and development purchased as part of a business combination is accounted for as an indefinite lived intangible asset until the underlying project is completed, at which point the intangible asset will be accounted for as a definite lived intangible asset. If warranted the purchased in-process research and development could be written off or partially impaired depending on the underlying program.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Intangible assets that have finite useful lives continue to be amortized over their useful lives and are reviewed for impairment when warranted by economic conditions. See Note 5 for further details on Intangible Assets and Goodwill.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Financial instruments</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">As required by U.S. GAAP, all derivative instruments are recorded on the balance sheet at fair value. Fair value is the exit price that would be received to sell an asset or paid to transfer a liability. Fair value is a market-based measurement determined using assumptions that market participants would use in pricing an asset or liability. The authoritative literature establishes a three-level hierarchy to prioritize the inputs used in measuring fair value, with Level 1 having the highest priority and Level 3 having the lowest. Changes in the fair value of derivatives are recorded each period in current earnings or other comprehensive income, depending on whether the derivative is designated as part of a hedge transaction, and if so, the type of hedge transaction.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company documents all relationships between hedged items and derivatives. The overall risk management strategy includes reasons for undertaking hedge transactions and entering into derivatives. The objectives of this strategy are: (1) minimize foreign currency exposure’s impact on the Company’s financial performance; (2) protect the Company’s cash flow from adverse movements in foreign exchange rates; (3) ensure the appropriateness of financial instruments; and (4) manage the enterprise risk associated with financial institutions. See Note 6 for additional information on Financial Instruments.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Leases</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company determines whether an arrangement is a lease at contract inception by establishing if the contract conveys the right to control the use of identified property, plant, or equipment for a period of time in exchange for consideration. Right of Use (ROU) Assets and Lease Liabilities for operating leases are included in <span style="-sec-ix-hidden:f-539"><span style="-sec-ix-hidden:f-540">Other assets</span></span>, <span style="-sec-ix-hidden:f-541"><span style="-sec-ix-hidden:f-542">Accrued liabilities</span></span>, and <span style="-sec-ix-hidden:f-543"><span style="-sec-ix-hidden:f-544">Other liabilities</span></span> on the consolidated balance sheet. The ROU Assets represent the right to use an underlying asset for the lease term and lease liabilities represent an obligation to make lease payments arising from the lease. Commitments under finance leases are not significant, and are included in Property, plant and equipment, Loans and notes payable, and Long-term debt on the consolidated balance sheet.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">ROU Assets and Lease Liabilities are recognized at the lease commencement date based on the present value of all minimum lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments, when the implicit rate is not readily determinable. Lease terms may include options to extend or terminate the lease. These options are included in the lease term when it is reasonably certain that the Company will exercise that option. Operating lease expense is recognized on a straight-line basis over the lease term. The Company has elected the following policy elections on adoption: use of portfolio approach on leases of assets under master service agreements, exclusion of short term leases on the balance sheet, and not separating lease and non-lease components. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company primarily has operating lease for space, vehicles, manufacturing equipment and data processing equipment. The ROU asset pertaining to leases from continuing operations was $1.1 billion and $1.0 billion in fiscal years 2024 and 2023, respectively. The lease liability from continuing operations was $1.2 billion and $1.1 billion in fiscal years 2024 and 2023, respectively. The operating lease costs from continuing operations were $0.2 billion in fiscal years 2024, 2023 and 2022. Cash paid for amounts included in the measurement of lease liabilities from continuing operations were $0.2 billion in fiscal years 2024, 2023 and 2022.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Product liability</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Accruals for product liability claims are recorded, on an undiscounted basis, when it is probable that a liability has been incurred and the amount of the liability can be reasonably estimated based on existing information and actuarially determined estimates where applicable. The accruals are adjusted periodically as additional information becomes available. The Company accrues an estimate of the legal defense costs needed to defend each matter when those costs are probable and can be reasonably estimated. To the extent adverse verdicts have been rendered against the Company, the Company does not record an accrual until a loss is determined to be probable and can be reasonably estimated.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company has self insurance through a wholly-owned captive insurance company. In addition to accruals in the self insurance program, claims that exceed the insurance coverage are accrued when losses are probable and amounts can be reasonably estimated.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Research and development</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Research and development expenses are expensed as incurred in accordance with ASC 730, Research and Development. Upfront and milestone payments made to third parties in connection with research and development collaborations are expensed as incurred up to the point of regulatory approval. Payments made to third parties subsequent to regulatory approval are capitalized and amortized over the remaining useful life of the related product. Amounts capitalized for such payments are included in other intangibles, net of accumulated amortization.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company enters into collaborative arrangements, typically with other pharmaceutical or biotechnology companies, to develop and commercialize drug candidates or intellectual property. These arrangements typically involve two (or more) parties who are active participants in the collaboration and are exposed to significant risks and rewards dependent on the commercial success of the activities. These collaborations usually involve various activities by one or more parties, including research and development, marketing and selling and distribution. Often, these collaborations require upfront, milestone and royalty or profit share payments, contingent upon the occurrence of certain future events linked to the success of the asset in development. Amounts due from collaborative partners related to development activities are generally reflected as a reduction of research and development expense because the performance of contract development services is not central to the Company’s operations. In general, the income statement presentation for these collaborations is as follows:</span></div><div style="margin-bottom:4pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.453%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.157%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">Nature/Type of Collaboration</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">Statement of Earnings Presentation</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Third-party sale of product &amp; profit share payments received</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Sales to customers</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Royalties/milestones paid to collaborative partner (post-regulatory approval)*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Cost of products sold</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Royalties received from collaborative partner</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Other income (expense), net</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Upfront payments &amp; milestones paid to collaborative partner (pre-regulatory approval)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Research and development expense</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Research and development payments to collaborative partner</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Research and development expense</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Research and development payments received from collaborative partner or government entity</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Reduction of Research and development expense</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%">*    Milestones are capitalized as intangible assets and amortized to cost of products sold over the useful life.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">For all years presented, there was no individual project that represented greater than 5% of the total annual consolidated research and development expense other than the acquired in-process research &amp; development expense of $1.25 billion to secure the global rights to the NM26 bispecific antibody (Yellow Jersey acquisition) in fiscal year 2024.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company has a number of products and compounds developed in collaboration with strategic partners including XARELTO, co-developed with Bayer HealthCare AG, IMBRUVICA, developed in collaboration and co-marketed with Pharmacyclics LLC, an AbbVie company and CARVYKTI, licensed and developed in collaboration with Legend Biotech USA Inc. and Legend Biotech Ireland Limited.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Separately, the Company has a number of licensing arrangements for products and compounds including DARZALEX, licensed from Genmab A/S.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Advertising</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Costs associated with advertising are expensed in the year incurred and are included in selling, marketing and administrative expenses. Advertising expenses worldwide, which comprised television, radio, print media and Internet advertising, were $0.6 billion, $0.5 billion and $0.7 billion in fiscal years 2024, 2023 and 2022, respectively.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Income taxes</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Income taxes are recorded based on amounts refundable or payable for the current year and include the results of any difference between U.S. GAAP accounting and tax reporting, recorded as deferred tax assets or liabilities. The Company estimates deferred tax assets and liabilities based on enacted tax regulations and rates. Future changes in tax laws and rates may affect recorded deferred tax assets and liabilities in the future. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company has unrecognized tax benefits for uncertain tax positions. The Company follows U.S. GAAP which prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. Management believes that changes in these estimates would not have a material effect on the Company's results of operations, cash flows or financial position. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">In 2017, the United States enacted into law new U.S. tax legislation, the U.S. Tax Cuts and Jobs Act (TCJA). This law included provisions for a comprehensive overhaul of the corporate income tax code, including a reduction of the statutory corporate tax rate from 35% to 21%, effective on January 1, 2018. The TCJA included a provision for a tax on all previously undistributed earnings of U.S. companies located in foreign jurisdictions. Undistributed earnings in the form of cash and cash equivalents were taxed at a rate of 15.5% and all other earnings were taxed at a rate of 8.0%. This tax is payable over 8 years and will not accrue interest. These payments began in fiscal year 2018 and will continue through 2025. The final payment of $2.5 billion will be made in fiscal year 2025. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The TCJA also includes provisions for a tax on global intangible low-taxed income (GILTI). GILTI is described as the excess of a U.S. shareholder’s total net foreign income over a deemed return on tangible assets, as provided by the TCJA. In January 2018, the FASB issued guidance that allows companies to elect as an accounting policy whether to record the tax effects of GILTI in the period the tax liability is generated (i.e., “period cost”) or provide for deferred tax assets and liabilities related to basis differences that exist and are expected to affect the amount of GILTI inclusion in future years upon reversal (i.e., “deferred method”). The Company has elected to account for GILTI under the deferred method. The deferred tax amounts recorded are based on the evaluation of temporary differences that are expected to reverse as GILTI is incurred in future periods. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company has recorded deferred tax liabilities on all undistributed earnings prior to December 31, 2017 from its international subsidiaries. The Company has not provided deferred taxes on the undistributed earnings subsequent to January 1, 2018 from certain international subsidiaries where the earnings are considered to be indefinitely reinvested. The Company intends to continue to reinvest these earnings in those international operations. If the Company decides at a later date to repatriate these earnings to the U.S., the Company would be required to provide for the net tax effects on these amounts. The Company estimates that the tax effect of this repatriation would be approximately $0.5 billion under currently enacted tax laws and regulations and at current currency exchange rates. This amount does not include the possible benefit of U.S. foreign tax credits, which may substantially offset this cost.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">See Note 8 to the Consolidated Financial Statements for further information regarding income taxes.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Net earnings per share</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Basic earnings per share is computed by dividing net earnings available to common shareholders by the weighted average number of common shares outstanding for the period. Diluted earnings per share reflects the potential dilution that could occur if securities were exercised or converted into common stock using the treasury stock method.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Use of estimates</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the U.S. requires management to make estimates and assumptions that affect the amounts reported. Estimates are used when accounting for sales discounts, rebates, allowances and incentives, product liabilities, income taxes, withholding taxes, depreciation, amortization, employee benefits, contingencies and intangible asset and liability valuations. Actual results may or may not differ from those estimates. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company follows the provisions of U.S. GAAP when recording litigation related contingencies. A liability is recorded when a loss is probable and can be reasonably estimated. The best estimate of a loss within a range is accrued; however, if no estimate in the range is better than any other, the minimum amount is accrued.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Supplier finance program obligations</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company has agreements for supplier finance programs with third-party financial institutions. These programs provide participating suppliers the ability to finance payment obligations from the Company with the third-party financial institutions. The Company is not a party to the arrangements between the suppliers and the third-party financial institutions. The Company’s obligations to its suppliers, including amounts due, and scheduled payment dates (which have general payment terms of 90 days), are not affected by a participating supplier’s decision to participate in the program. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Confirmed obligations under the program as of December 29, 2024, and December 31, 2023, were $0.8 billion and $0.7 billion, respectively. The obligations are presented as <span style="-sec-ix-hidden:f-579"><span style="-sec-ix-hidden:f-580">Accounts payable</span></span> on the Consolidated Balance Sheets.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The rollforward of the Company's valid obligations under the program were as follows:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:86.697%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.139%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.764%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Confirmed obligations - beginning of the year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">$704</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Invoices confirmed during the year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">3,048</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Confirmed invoices paid during the year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">2,964</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Confirmed obligations - end of the year</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">$788</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Annual closing date</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company follows the concept of a fiscal year, which ends on the Sunday nearest to the end of the month of December. Normally each fiscal year consists of 52 weeks, but every five or six years the fiscal year consists of 53 weeks, and therefore includes additional shipping days, as was the case in fiscal year 2020, and will be the case again in fiscal year 2026.</span></div> <div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Principles of consolidation</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The consolidated financial statements include the accounts of Johnson &amp; Johnson and its subsidiaries (the Company). Intercompany accounts and transactions are eliminated. Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures.</span></div> 138100 198734444 0.01 22.00 4200000000 2500000000 0.896 1300000000 0.801 0.095 <div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Business segments</span></div>The Company is organized into two business segments: Innovative Medicine and MedTech. The Innovative Medicine segment is focused on the following therapeutic areas: Immunology, Infectious Diseases, Neuroscience, Oncology, Pulmonary Hypertension, and Cardiovascular and Metabolic. Products in this segment are distributed directly to retailers, wholesalers, distributors, hospitals and healthcare professionals for prescription use. The MedTech segment includes a broad portfolio of products used in the Orthopaedic, Surgery, Cardiovascular (previously referred to as Interventional Solutions) and Vision fields. These products are distributed to wholesalers, hospitals and retailers, and used principally in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. 2 <div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%">New accounting standards</span></div><div style="margin-bottom:6pt;margin-top:10pt"><span style="color:#000000;font-family:'Johnson Display',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently adopted accounting standards</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">ASU 2023-07: Segment Reporting (Topic 280) – Improvements to Reportable Segment Disclosures</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company adopted the standard in the fiscal year 2024, which requires expanded annual and interim disclosures for significant segment expenses that are regularly provided to the chief operating decision maker and included within each reported measure of segment profit or loss. The standard was applied retrospectively to all periods presented in the financial statements. As this accounting standard only impacts disclosures, it did not have a material impact on the Company’s Consolidated Financial Statements. See Note 17 for the required disclosures.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Recently issued accounting standards</span></div><div style="margin-bottom:6pt;margin-top:10pt"><span style="color:#000000;font-family:'Johnson Display',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Not adopted as of December 29, 2024</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">ASU 2024-03: Income Statement – Reporting Comprehensive Income – Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">This update requires disclosure of disaggregated information about certain income statement expense line items on an annual and interim basis. This update will be effective for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. As this accounting standard only impacts disclosures, it will not have a material impact on the Company’s Consolidated Financial Statements.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">ASU 2023-09: Income Taxes (Topic 740) - Improvements to Income Tax Disclosures</span></div>This update standardizes categories for the effective tax rate reconciliation, requires disaggregation of income taxes and additional income tax-related disclosures. This update is required to be effective for the Company for fiscal periods beginning after December 15, 2024. As this accounting standard only impacts disclosures, it will not have a material impact on the Company’s Consolidated Financial Statements. <div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Cash equivalents</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company classifies all highly liquid investments with stated maturities of three months or less from date of purchase as cash equivalents and all highly liquid investments with stated maturities of greater than three months from the date of purchase as current marketable securities. The Company has a policy of making investments only with commercial institutions that have at least an investment grade credit rating. The Company invests its cash primarily in government securities and obligations, corporate debt securities, money market funds and reverse repurchase agreements (RRAs).</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">RRAs are collateralized by deposits in the form of Government Securities and Obligations for an amount not less than 102% of their value. The Company does not record an asset or liability as the Company is not permitted to sell or repledge the associated collateral. The Company has a policy that the collateral has at least an A (or equivalent) credit rating. The Company utilizes a third party custodian to manage the exchange of funds and ensure that collateral received is maintained at 102% of the value of the RRAs on a daily basis. RRAs with stated maturities of greater than three months from the date of purchase are classified as marketable securities.</span></div> 1.02 1.02 <div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Investments</span></div>Investments classified as held to maturity investments are reported at amortized cost and realized gains or losses are reported in earnings. Investments classified as available-for-sale debt securities are carried at estimated fair value with unrealized gains and losses recorded as a component of accumulated other comprehensive income. Available-for-sale securities available for current operations are classified as current assets; otherwise, they are classified as long term. Management determines the appropriate classification of its investment in debt and equity securities at the time of purchase and re-evaluates such determination at each balance sheet date. The Company reviews its investments for impairment and adjusts these investments to fair value through earnings, as required. <div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Property, plant and equipment and depreciation</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Property, plant and equipment are stated at cost. The Company utilizes the straight-line method of depreciation over the estimated useful lives of the assets:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:86.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.789%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Building and building equipment</span></div></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">30 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Land and leasehold improvements</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">10 - 20 years</span></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Machinery and equipment</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">2 - 13 years</span></div></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company capitalizes certain computer software and development costs, included in machinery and equipment, when incurred in connection with developing or obtaining computer software for internal use. Capitalized software costs are amortized over the estimated useful lives of the software, which generally range from 3 to 8 years.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company reviews long-lived assets to assess recoverability using undiscounted cash flows. When certain events or changes in operating or economic conditions occur, an impairment assessment may be performed on the recoverability of the carrying value of these assets. If the asset is determined to be impaired, the loss is measured based on the difference between the asset’s fair value and its carrying value. If quoted market prices are not available, the Company will estimate fair value using a discounted value of estimated future cash flows.</span></div> <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Property, plant and equipment are stated at cost. The Company utilizes the straight-line method of depreciation over the estimated useful lives of the assets:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:86.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.789%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Building and building equipment</span></div></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">30 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Land and leasehold improvements</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">10 - 20 years</span></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Machinery and equipment</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">2 - 13 years</span></div></td></tr></table></div> P30Y P10Y P20Y P2Y P13Y P3Y P8Y <div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Revenue recognition</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company recognizes revenue from product sales when obligations under the terms of a contract with the customer are satisfied; generally, this occurs with the transfer of control of the goods to customers. The Company's global payment terms are typically between 30 to 90 days. Provisions for certain rebates, sales incentives, trade promotions, coupons, product returns, discounts to customers and governmental clawback provisions are accounted for as variable consideration and recorded as a reduction in sales. The liability is recognized within Accrued rebates, returns, and promotions on the consolidated balance sheet.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Product discounts granted are based on the terms of arrangements with direct, indirect and other market participants, as well as market conditions, including consideration of competitor pricing. Rebates and discounts are estimated based on contractual terms, historical experience, patient outcomes, trend analysis and projected market conditions in the various markets served. A significant portion of the liability related to rebates is from the sale of the Company's pharmaceutical products within the U.S., primarily the Managed Care, Medicare and Medicaid programs, which amounted to $12.3 billion and $11.5 billion as of December 29, 2024 and December 31, 2023, respectively. The Company evaluates market conditions for products or groups of products primarily through the analysis of wholesaler and other third-party sell-through and market research data, as well as internally generated information.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Sales returns are estimated and recorded based on historical sales and returns information. Products that have lost patent exclusivity, or that otherwise exhibit unusual sales or return patterns due to dating, competition or other marketing matters are specifically investigated and analyzed as part of the accounting for sales return accruals.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Sales returns allowances represent a reserve for products that may be returned due to expiration, destruction in the field, or in specific areas, product recall. In accordance with the Company’s accounting policies, the Company generally issues credit to customers for returned goods. The Company’s sales returns reserves are accounted for in accordance with the U.S. GAAP guidance for revenue recognition when right of return exists. Sales returns reserves are recorded at full sales value. Sales returns in the Innovative Medicine segment are almost exclusively not resalable. Sales returns for certain franchises in the MedTech segment are typically resalable but are not material. The Company infrequently exchanges products from inventory for returned products. The sales returns reserve for the total Company has been approximately 1.0% of annual net trade sales during each of the fiscal years 2024, 2023 and 2022.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Promotional programs, such as product listing allowances are recorded in the same period as related sales and include <br/>volume-based sales incentive programs. Volume-based incentive programs are based on the estimated sales volumes for the incentive period and are recorded as products are sold. These arrangements are evaluated to determine the appropriate amounts to be deferred or recorded as a reduction of revenue. The Company also earns profit-share payments through collaborative arrangements of certain products, which are included in sales to customers. Profit-share payments were less than 2.0% of the total revenues in the fiscal year 2024 and 2023, respectively, and less than 3.0% of total revenues in the fiscal year 2022 and are included in sales to customers.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">See Note 17 to the Consolidated Financial Statements for further disaggregation of revenue.</span></div> P30D P90D 12300000000 11500000000 0.010 0.010 0.010 0.020 0.020 0.030 <div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Shipping and handling</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Shipping and handling costs incurred were $0.9 billion, $0.9 billion and $0.8 billion in fiscal years 2024, 2023 and 2022, respectively, and are included in selling, marketing and administrative expense. The amount of revenue received for shipping and handling is less than 1.0% of sales to customers for all periods presented.</span></div> 900000000 900000000 800000000 0.010 0.010 0.010 <div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Inventories</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Inventories are stated at the lower of cost or net realizable value determined by the first-in, first-out method.</span></div> <div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Intangible assets and goodwill</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The authoritative literature on U.S. GAAP requires that goodwill and intangible assets with indefinite lives be assessed annually for impairment. The Company completed its annual impairment test for 2024 in the fiscal fourth quarter. Future impairment tests will be performed annually in the fiscal fourth quarter, or sooner if warranted. In-process research and development purchased as part of a business combination is accounted for as an indefinite lived intangible asset until the underlying project is completed, at which point the intangible asset will be accounted for as a definite lived intangible asset. If warranted the purchased in-process research and development could be written off or partially impaired depending on the underlying program.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Intangible assets that have finite useful lives continue to be amortized over their useful lives and are reviewed for impairment when warranted by economic conditions. See Note 5 for further details on Intangible Assets and Goodwill.</span></div> <div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Financial instruments</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">As required by U.S. GAAP, all derivative instruments are recorded on the balance sheet at fair value. Fair value is the exit price that would be received to sell an asset or paid to transfer a liability. Fair value is a market-based measurement determined using assumptions that market participants would use in pricing an asset or liability. The authoritative literature establishes a three-level hierarchy to prioritize the inputs used in measuring fair value, with Level 1 having the highest priority and Level 3 having the lowest. Changes in the fair value of derivatives are recorded each period in current earnings or other comprehensive income, depending on whether the derivative is designated as part of a hedge transaction, and if so, the type of hedge transaction.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company documents all relationships between hedged items and derivatives. The overall risk management strategy includes reasons for undertaking hedge transactions and entering into derivatives. The objectives of this strategy are: (1) minimize foreign currency exposure’s impact on the Company’s financial performance; (2) protect the Company’s cash flow from adverse movements in foreign exchange rates; (3) ensure the appropriateness of financial instruments; and (4) manage the enterprise risk associated with financial institutions. See Note 6 for additional information on Financial Instruments.</span></div> <div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Leases</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company determines whether an arrangement is a lease at contract inception by establishing if the contract conveys the right to control the use of identified property, plant, or equipment for a period of time in exchange for consideration. Right of Use (ROU) Assets and Lease Liabilities for operating leases are included in <span style="-sec-ix-hidden:f-539"><span style="-sec-ix-hidden:f-540">Other assets</span></span>, <span style="-sec-ix-hidden:f-541"><span style="-sec-ix-hidden:f-542">Accrued liabilities</span></span>, and <span style="-sec-ix-hidden:f-543"><span style="-sec-ix-hidden:f-544">Other liabilities</span></span> on the consolidated balance sheet. The ROU Assets represent the right to use an underlying asset for the lease term and lease liabilities represent an obligation to make lease payments arising from the lease. Commitments under finance leases are not significant, and are included in Property, plant and equipment, Loans and notes payable, and Long-term debt on the consolidated balance sheet.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">ROU Assets and Lease Liabilities are recognized at the lease commencement date based on the present value of all minimum lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments, when the implicit rate is not readily determinable. Lease terms may include options to extend or terminate the lease. These options are included in the lease term when it is reasonably certain that the Company will exercise that option. Operating lease expense is recognized on a straight-line basis over the lease term. The Company has elected the following policy elections on adoption: use of portfolio approach on leases of assets under master service agreements, exclusion of short term leases on the balance sheet, and not separating lease and non-lease components. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company primarily has operating lease for space, vehicles, manufacturing equipment and data processing equipment. The ROU asset pertaining to leases from continuing operations was $1.1 billion and $1.0 billion in fiscal years 2024 and 2023, respectively. The lease liability from continuing operations was $1.2 billion and $1.1 billion in fiscal years 2024 and 2023, respectively. The operating lease costs from continuing operations were $0.2 billion in fiscal years 2024, 2023 and 2022. Cash paid for amounts included in the measurement of lease liabilities from continuing operations were $0.2 billion in fiscal years 2024, 2023 and 2022.</span></div> 1100000000 1000000000 1200000000 1100000000 200000000 200000000 200000000 200000000 200000000 200000000 <div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Product liability</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Accruals for product liability claims are recorded, on an undiscounted basis, when it is probable that a liability has been incurred and the amount of the liability can be reasonably estimated based on existing information and actuarially determined estimates where applicable. The accruals are adjusted periodically as additional information becomes available. The Company accrues an estimate of the legal defense costs needed to defend each matter when those costs are probable and can be reasonably estimated. To the extent adverse verdicts have been rendered against the Company, the Company does not record an accrual until a loss is determined to be probable and can be reasonably estimated.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company has self insurance through a wholly-owned captive insurance company. In addition to accruals in the self insurance program, claims that exceed the insurance coverage are accrued when losses are probable and amounts can be reasonably estimated.</span></div> <div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Research and development</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Research and development expenses are expensed as incurred in accordance with ASC 730, Research and Development. Upfront and milestone payments made to third parties in connection with research and development collaborations are expensed as incurred up to the point of regulatory approval. Payments made to third parties subsequent to regulatory approval are capitalized and amortized over the remaining useful life of the related product. Amounts capitalized for such payments are included in other intangibles, net of accumulated amortization.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company enters into collaborative arrangements, typically with other pharmaceutical or biotechnology companies, to develop and commercialize drug candidates or intellectual property. These arrangements typically involve two (or more) parties who are active participants in the collaboration and are exposed to significant risks and rewards dependent on the commercial success of the activities. These collaborations usually involve various activities by one or more parties, including research and development, marketing and selling and distribution. Often, these collaborations require upfront, milestone and royalty or profit share payments, contingent upon the occurrence of certain future events linked to the success of the asset in development. Amounts due from collaborative partners related to development activities are generally reflected as a reduction of research and development expense because the performance of contract development services is not central to the Company’s operations. In general, the income statement presentation for these collaborations is as follows:</span></div><div style="margin-bottom:4pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.453%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.157%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">Nature/Type of Collaboration</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">Statement of Earnings Presentation</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Third-party sale of product &amp; profit share payments received</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Sales to customers</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Royalties/milestones paid to collaborative partner (post-regulatory approval)*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Cost of products sold</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Royalties received from collaborative partner</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Other income (expense), net</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Upfront payments &amp; milestones paid to collaborative partner (pre-regulatory approval)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Research and development expense</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Research and development payments to collaborative partner</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Research and development expense</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Research and development payments received from collaborative partner or government entity</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Reduction of Research and development expense</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%">*    Milestones are capitalized as intangible assets and amortized to cost of products sold over the useful life.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">For all years presented, there was no individual project that represented greater than 5% of the total annual consolidated research and development expense other than the acquired in-process research &amp; development expense of $1.25 billion to secure the global rights to the NM26 bispecific antibody (Yellow Jersey acquisition) in fiscal year 2024.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company has a number of products and compounds developed in collaboration with strategic partners including XARELTO, co-developed with Bayer HealthCare AG, IMBRUVICA, developed in collaboration and co-marketed with Pharmacyclics LLC, an AbbVie company and CARVYKTI, licensed and developed in collaboration with Legend Biotech USA Inc. and Legend Biotech Ireland Limited.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Separately, the Company has a number of licensing arrangements for products and compounds including DARZALEX, licensed from Genmab A/S.</span></div> 0.05 0.05 0.05 1250000000 <div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Advertising</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Costs associated with advertising are expensed in the year incurred and are included in selling, marketing and administrative expenses. Advertising expenses worldwide, which comprised television, radio, print media and Internet advertising, were $0.6 billion, $0.5 billion and $0.7 billion in fiscal years 2024, 2023 and 2022, respectively.</span></div> 600000000 500000000 700000000 <div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Income taxes</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Income taxes are recorded based on amounts refundable or payable for the current year and include the results of any difference between U.S. GAAP accounting and tax reporting, recorded as deferred tax assets or liabilities. The Company estimates deferred tax assets and liabilities based on enacted tax regulations and rates. Future changes in tax laws and rates may affect recorded deferred tax assets and liabilities in the future. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company has unrecognized tax benefits for uncertain tax positions. The Company follows U.S. GAAP which prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. Management believes that changes in these estimates would not have a material effect on the Company's results of operations, cash flows or financial position. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">In 2017, the United States enacted into law new U.S. tax legislation, the U.S. Tax Cuts and Jobs Act (TCJA). This law included provisions for a comprehensive overhaul of the corporate income tax code, including a reduction of the statutory corporate tax rate from 35% to 21%, effective on January 1, 2018. The TCJA included a provision for a tax on all previously undistributed earnings of U.S. companies located in foreign jurisdictions. Undistributed earnings in the form of cash and cash equivalents were taxed at a rate of 15.5% and all other earnings were taxed at a rate of 8.0%. This tax is payable over 8 years and will not accrue interest. These payments began in fiscal year 2018 and will continue through 2025. The final payment of $2.5 billion will be made in fiscal year 2025. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The TCJA also includes provisions for a tax on global intangible low-taxed income (GILTI). GILTI is described as the excess of a U.S. shareholder’s total net foreign income over a deemed return on tangible assets, as provided by the TCJA. In January 2018, the FASB issued guidance that allows companies to elect as an accounting policy whether to record the tax effects of GILTI in the period the tax liability is generated (i.e., “period cost”) or provide for deferred tax assets and liabilities related to basis differences that exist and are expected to affect the amount of GILTI inclusion in future years upon reversal (i.e., “deferred method”). The Company has elected to account for GILTI under the deferred method. The deferred tax amounts recorded are based on the evaluation of temporary differences that are expected to reverse as GILTI is incurred in future periods. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company has recorded deferred tax liabilities on all undistributed earnings prior to December 31, 2017 from its international subsidiaries. The Company has not provided deferred taxes on the undistributed earnings subsequent to January 1, 2018 from certain international subsidiaries where the earnings are considered to be indefinitely reinvested. The Company intends to continue to reinvest these earnings in those international operations. If the Company decides at a later date to repatriate these earnings to the U.S., the Company would be required to provide for the net tax effects on these amounts. The Company estimates that the tax effect of this repatriation would be approximately $0.5 billion under currently enacted tax laws and regulations and at current currency exchange rates. This amount does not include the possible benefit of U.S. foreign tax credits, which may substantially offset this cost.</span></div> 0.35 0.21 0.155 0.080 P8Y 2500000000 500000000 <div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Net earnings per share</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Basic earnings per share is computed by dividing net earnings available to common shareholders by the weighted average number of common shares outstanding for the period. Diluted earnings per share reflects the potential dilution that could occur if securities were exercised or converted into common stock using the treasury stock method.</span></div> <div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Use of estimates</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the U.S. requires management to make estimates and assumptions that affect the amounts reported. Estimates are used when accounting for sales discounts, rebates, allowances and incentives, product liabilities, income taxes, withholding taxes, depreciation, amortization, employee benefits, contingencies and intangible asset and liability valuations. Actual results may or may not differ from those estimates. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company follows the provisions of U.S. GAAP when recording litigation related contingencies. A liability is recorded when a loss is probable and can be reasonably estimated. The best estimate of a loss within a range is accrued; however, if no estimate in the range is better than any other, the minimum amount is accrued.</span></div> <div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Supplier finance program obligations</span></div>The Company has agreements for supplier finance programs with third-party financial institutions. These programs provide participating suppliers the ability to finance payment obligations from the Company with the third-party financial institutions. The Company is not a party to the arrangements between the suppliers and the third-party financial institutions. The Company’s obligations to its suppliers, including amounts due, and scheduled payment dates (which have general payment terms of 90 days), are not affected by a participating supplier’s decision to participate in the program. P90D 800000000 700000000 <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The rollforward of the Company's valid obligations under the program were as follows:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:86.697%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.139%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.764%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Confirmed obligations - beginning of the year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">$704</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Invoices confirmed during the year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">3,048</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Confirmed invoices paid during the year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">2,964</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Confirmed obligations - end of the year</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">$788</span></td></tr></table></div> 704000000 3048000000 2964000000 788000000 <div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Annual closing date</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company follows the concept of a fiscal year, which ends on the Sunday nearest to the end of the month of December. Normally each fiscal year consists of 52 weeks, but every five or six years the fiscal year consists of 53 weeks, and therefore includes additional shipping days, as was the case in fiscal year 2020, and will be the case again in fiscal year 2026.</span></div> Cash, cash equivalents and current marketable securities<div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">At the end of the fiscal year 2024 and 2023, cash, cash equivalents and current marketable securities comprised:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.072%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.209%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.465%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.627%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.875%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td></tr><tr style="height:35pt"><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Carrying<br/> Amount</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrecognized<br/>Gain</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Estimated<br/> Fair Value</span></td><td colspan="6" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cash &amp; Cash<br/>Equivalents</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Current<br/> Marketable<br/> Securities</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$2,918</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,918</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,918</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Non-U.S. Sovereign Securities</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">120</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">120</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">120</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. Reverse repurchase agreements</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7,100</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7,100</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7,100</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Money market funds</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,123</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,123</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,123</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Time deposits</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,045</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,045</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,045</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Subtotal </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$17,306</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">—</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">17,306</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">17,186</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">120</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. Gov't Securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$6,815</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,816</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,796</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">20</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other Sovereign Securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">176</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">176</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">83</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">93</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Corporate and other debt securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">224</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">224</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">40</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">184</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Subtotal available for sale</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$7,215</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">1</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">7,216</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">6,919</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">297</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:64.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total cash, cash equivalents and current marketable securities</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$24,105</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">417</span></td></tr></table></div><div style="margin-bottom:4pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.072%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:10.209%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.465%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.627%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.875%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr style="height:35pt"><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrecognized<br/>Loss</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Estimated Fair Value</span></td><td colspan="6" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cash &amp; Cash Equivalents</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Current Marketable Securities</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$3,340</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,340</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,340</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Non-U.S. Sovereign Securities</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">522</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">522</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">174</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">348</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. Reverse repurchase agreements</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,377</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,377</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,377</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Corporate debt securities</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">338</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">338</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">189</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">149</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Money market funds</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,814</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,814</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,814</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Time deposits</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">662</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">662</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">662</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Subtotal </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">14,053</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">14,053</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">13,556</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">497</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. Gov't Securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$8,562</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8,562</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8,259</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">303</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. Gov't Agencies</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">71</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">70</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">70</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other Sovereign Securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Corporate and other debt securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">237</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">237</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">43</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">194</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Subtotal available for sale</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$8,875</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">8,874</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">8,303</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">571</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:64.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total cash, cash equivalents and current marketable securities</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$21,859</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">1,068</span></td></tr></table></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:9.29pt">Held to maturity investments are reported at amortized cost and realized gains or losses are reported in earnings. </span></div><div style="margin-bottom:6pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.09pt">Available for sale debt securities are reported at fair value with unrealized gains and losses reported net of taxes in other comprehensive income.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Fair value of government securities and obligations and corporate debt securities were estimated using quoted broker prices and significant other observable inputs.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The contractual maturities of the available for sale debt securities at December 29, 2024 are as follows:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.834%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.764%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cost Basis</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Due within one year</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">$7,204</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">7,205</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Due after one year through five years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">11</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">11</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Due after five years through ten years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">—</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total debt securities</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%">$7,215</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%">7,216</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company invests its excess cash in both deposits with major banks throughout the world and other high-quality money market instruments. The Company has a policy of making investments only with commercial institutions that have at least an investment grade credit rating.</span></div> <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">At the end of the fiscal year 2024 and 2023, cash, cash equivalents and current marketable securities comprised:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.072%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.209%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.465%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.627%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.875%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td></tr><tr style="height:35pt"><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Carrying<br/> Amount</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrecognized<br/>Gain</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Estimated<br/> Fair Value</span></td><td colspan="6" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cash &amp; Cash<br/>Equivalents</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Current<br/> Marketable<br/> Securities</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$2,918</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,918</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,918</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Non-U.S. Sovereign Securities</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">120</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">120</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">120</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. Reverse repurchase agreements</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7,100</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7,100</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7,100</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Money market funds</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,123</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,123</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,123</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Time deposits</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,045</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,045</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,045</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Subtotal </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$17,306</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">—</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">17,306</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">17,186</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">120</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. Gov't Securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$6,815</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,816</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,796</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">20</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other Sovereign Securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">176</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">176</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">83</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">93</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Corporate and other debt securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">224</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">224</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">40</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">184</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Subtotal available for sale</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$7,215</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">1</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">7,216</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">6,919</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">297</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:64.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total cash, cash equivalents and current marketable securities</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$24,105</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">417</span></td></tr></table></div><div style="margin-bottom:4pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.072%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:10.209%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.465%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.627%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.875%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr style="height:35pt"><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrecognized<br/>Loss</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Estimated Fair Value</span></td><td colspan="6" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cash &amp; Cash Equivalents</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Current Marketable Securities</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$3,340</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,340</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,340</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Non-U.S. Sovereign Securities</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">522</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">522</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">174</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">348</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. Reverse repurchase agreements</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,377</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,377</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,377</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Corporate debt securities</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">338</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">338</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">189</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">149</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Money market funds</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,814</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,814</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,814</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Time deposits</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">662</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">662</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">662</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Subtotal </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">14,053</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">14,053</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">13,556</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">497</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. Gov't Securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$8,562</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8,562</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8,259</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">303</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. Gov't Agencies</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">71</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">70</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">70</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other Sovereign Securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Corporate and other debt securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">237</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">237</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">43</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">194</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Subtotal available for sale</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$8,875</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">8,874</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">8,303</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">571</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:64.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total cash, cash equivalents and current marketable securities</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$21,859</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">1,068</span></td></tr></table></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:9.29pt">Held to maturity investments are reported at amortized cost and realized gains or losses are reported in earnings. </span></div><div style="margin-bottom:6pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.09pt">Available for sale debt securities are reported at fair value with unrealized gains and losses reported net of taxes in other comprehensive income.</span></div> 2918000000 0 2918000000 2918000000 0 120000000 0 120000000 0 120000000 7100000000 0 7100000000 7100000000 0 6123000000 0 6123000000 6123000000 0 1045000000 0 1045000000 1045000000 0 17306000000 0 17306000000 17186000000 120000000 6815000000 1000000 6816000000 6796000000 20000000 176000000 0 176000000 83000000 93000000 224000000 0 224000000 40000000 184000000 7215000000 1000000 7216000000 6919000000 297000000 24105000000 417000000 3340000000 0 3340000000 3340000000 0 522000000 0 522000000 174000000 348000000 4377000000 0 4377000000 4377000000 0 338000000 0 338000000 189000000 149000000 4814000000 0 4814000000 4814000000 0 662000000 0 662000000 662000000 0 14053000000 0 14053000000 13556000000 497000000 8562000000 0 8562000000 8259000000 303000000 71000000 1000000 70000000 0 70000000 5000000 0 5000000 1000000 4000000 237000000 237000000 43000000 194000000 8875000000 1000000 8874000000 8303000000 571000000 21859000000 1068000000 <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The contractual maturities of the available for sale debt securities at December 29, 2024 are as follows:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.834%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.764%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cost Basis</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Due within one year</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">$7,204</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">7,205</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Due after one year through five years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">11</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">11</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Due after five years through ten years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">—</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total debt securities</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%">$7,215</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%">7,216</span></td></tr></table></div> 7204000000 7205000000 11000000 11000000 0 0 7215000000 7216000000 Inventories<div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">At the end of fiscal years 2024 and 2023, inventories comprised:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.685%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.764%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Raw materials and supplies</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$2,337</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,355</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Goods in process</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,815</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,952</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Finished goods</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7,292</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,874</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total inventories</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$12,444</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">11,181</span></td></tr></table></div> <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">At the end of fiscal years 2024 and 2023, inventories comprised:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.685%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.764%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Raw materials and supplies</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$2,337</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,355</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Goods in process</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,815</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,952</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Finished goods</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7,292</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,874</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total inventories</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$12,444</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">11,181</span></td></tr></table></div> 2337000000 2355000000 2815000000 1952000000 7292000000 6874000000 12444000000 11181000000 Property, plant and equipment<div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">At the end of fiscal years 2024 and 2023, property, plant and equipment at cost and accumulated depreciation were:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.685%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.764%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Land and land improvements</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$718</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">795</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Buildings and building equipment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">12,317</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">12,375</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Machinery and equipment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">29,444</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">28,979</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Construction in progress</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,289</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,627</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total property, plant and equipment, gross</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$48,768</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">47,776</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Less accumulated depreciation</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">28,250</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">27,878</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total property, plant and equipment, net</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$20,518</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">19,898</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company capitalizes interest expense as part of the cost of construction of facilities and equipment. Interest expense capitalized in fiscal years 2024, 2023 and 2022 was $79 million, $70 million and $49 million, respectively.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Depreciation expense, including the amortization of capitalized interest in fiscal years 2024, 2023 and 2022 was $2.8 billion, $2.6 billion and $2.4 billion, respectively. </span></div><div style="margin-bottom:40pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Upon retirement or other disposal of property, plant and equipment, the costs and related amounts of accumulated depreciation or amortization are eliminated from the asset and accumulated depreciation accounts, respectively. The difference, if any, between the net asset value and the proceeds are recorded in earnings.</span></div> <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">At the end of fiscal years 2024 and 2023, property, plant and equipment at cost and accumulated depreciation were:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.685%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.764%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Land and land improvements</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$718</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">795</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Buildings and building equipment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">12,317</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">12,375</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Machinery and equipment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">29,444</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">28,979</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Construction in progress</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,289</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,627</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total property, plant and equipment, gross</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$48,768</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">47,776</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Less accumulated depreciation</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">28,250</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">27,878</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total property, plant and equipment, net</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$20,518</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">19,898</span></td></tr></table></div> 718000000 795000000 12317000000 12375000000 29444000000 28979000000 6289000000 5627000000 48768000000 47776000000 28250000000 27878000000 20518000000 19898000000 79000000 70000000 49000000 2800000000 2600000000 2400000000 Intangible assets and goodwill<div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:125%">At the end of fiscal years 2024 and 2023, the gross and net amounts of intangible assets were:</span></div><div style="margin-bottom:4pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.764%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Intangible assets with definite lives:</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"> </span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"> </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Patents and trademarks — gross</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">$44,695</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">40,417</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Less accumulated amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(26,124)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(24,808)</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Patents and trademarks — net</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%">$18,571</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%">15,609</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Customer relationships and other intangibles — gross</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">$20,310</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">20,322</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Less accumulated amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(13,544)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(12,685)</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Customer relationships and other intangibles — net</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%">$6,766</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%">7,637</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Intangible assets with indefinite lives:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"> </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Trademarks</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,714</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Purchased in-process research and development</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">12,281</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">9,215</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total intangible assets with indefinite lives</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%">$12,281</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%">10,929</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total intangible assets — net</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%">$37,618</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%">34,175</span></td></tr></table></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:125%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:125%;padding-left:9.29pt">In September 2024, the Company announced changes to its MedTech brand identity and the $1.7 billion of trademarks associated with the DePuy Synthes business were reclassified from indefinite lived to definite lived and will be amortized over a <span style="-sec-ix-hidden:f-767">25 year</span> period.</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:125%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:125%;padding-left:8.09pt">The majority is comprised of customer relationships</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Goodwill as of December 29, 2024 and December 31, 2023, as allocated by segment of business, was as follows:</span></div><div style="margin-bottom:4pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.822%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.465%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.316%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.139%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.575%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Innovative <br/>Medicine</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">MedTech</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Goodwill at January 1, 2023</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$10,184</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">25,863</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">36,047</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Goodwill, related to acquisitions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Goodwill, related to divestitures</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Currency translation/other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">223</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">288</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">511</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Goodwill at December 31, 2023</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10,407</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">26,151</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">36,558</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Goodwill, related to acquisitions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">640</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7,569</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8,209</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Goodwill, related to divestitures</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(56)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(56)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Currency translation/other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(355)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(156)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(511)</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Goodwill at December 29, 2024</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$10,692</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">33,508</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">44,200</span></td></tr></table></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%">*    Includes purchase price allocation adjustments for Abiomed </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:125%">The weighted average amortization period for patents and trademarks is approximately 12 years. The weighted average amortization period for customer relationships and other intangible assets is approximately 18 years. The amortization expense of amortizable assets included in Cost of products sold was $4.5 billion, $4.5 billion and $3.9 billion before tax, for the fiscal years ended December 29, 2024, December 31, 2023 and January 1, 2023, respectively. Intangible asset write-downs are included in Other (income) expense, net.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:125%">The estimated amortization expense related to intangible assets for approved products, before tax, for the five succeeding years is approximately:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"><tr><td style="width:1.0%"></td><td style="width:18.302%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.302%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.302%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.302%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.308%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:13pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:130%">(Dollars in Millions)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2027</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2028</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2029</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$4,000</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,400</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,800</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,200</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,200</span></td></tr></table></div><div style="margin-bottom:4pt;margin-top:4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%">See Note 18 to the Consolidated Financial Statements for additional details related to acquisitions and divestitures.</span></div> <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:125%">At the end of fiscal years 2024 and 2023, the gross and net amounts of intangible assets were:</span></div><div style="margin-bottom:4pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.764%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Intangible assets with definite lives:</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"> </span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"> </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Patents and trademarks — gross</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">$44,695</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">40,417</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Less accumulated amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(26,124)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(24,808)</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Patents and trademarks — net</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%">$18,571</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%">15,609</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Customer relationships and other intangibles — gross</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">$20,310</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">20,322</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Less accumulated amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(13,544)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(12,685)</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Customer relationships and other intangibles — net</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%">$6,766</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%">7,637</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Intangible assets with indefinite lives:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"> </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Trademarks</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,714</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Purchased in-process research and development</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">12,281</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">9,215</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total intangible assets with indefinite lives</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%">$12,281</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%">10,929</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total intangible assets — net</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%">$37,618</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%">34,175</span></td></tr></table></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:125%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:125%;padding-left:9.29pt">In September 2024, the Company announced changes to its MedTech brand identity and the $1.7 billion of trademarks associated with the DePuy Synthes business were reclassified from indefinite lived to definite lived and will be amortized over a <span style="-sec-ix-hidden:f-767">25 year</span> period.</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:125%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:125%;padding-left:8.09pt">The majority is comprised of customer relationships</span></div> 44695000000 40417000000 26124000000 24808000000 18571000000 15609000000 20310000000 20322000000 13544000000 12685000000 6766000000 7637000000 0 1714000000 12281000000 9215000000 12281000000 10929000000 37618000000 34175000000 1700000000 <div style="margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Goodwill as of December 29, 2024 and December 31, 2023, as allocated by segment of business, was as follows:</span></div><div style="margin-bottom:4pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.822%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.465%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.316%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.139%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.575%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Innovative <br/>Medicine</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">MedTech</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Goodwill at January 1, 2023</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$10,184</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">25,863</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">36,047</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Goodwill, related to acquisitions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Goodwill, related to divestitures</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Currency translation/other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">223</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">288</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">511</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Goodwill at December 31, 2023</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10,407</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">26,151</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">36,558</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Goodwill, related to acquisitions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">640</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7,569</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8,209</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Goodwill, related to divestitures</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(56)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(56)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Currency translation/other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(355)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(156)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(511)</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Goodwill at December 29, 2024</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$10,692</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">33,508</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">44,200</span></td></tr></table></div>*    Includes purchase price allocation adjustments for Abiomed 10184000000 25863000000 36047000000 0 0 0 0 0 0 223000000 288000000 511000000 10407000000 26151000000 36558000000 640000000 7569000000 8209000000 0 56000000 56000000 -355000000 -156000000 -511000000 10692000000 33508000000 44200000000 P12Y P18Y 4500000000 4500000000 3900000000 <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:125%">The estimated amortization expense related to intangible assets for approved products, before tax, for the five succeeding years is approximately:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"><tr><td style="width:1.0%"></td><td style="width:18.302%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.302%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.302%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.302%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.308%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:13pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:130%">(Dollars in Millions)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2027</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2028</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2029</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$4,000</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,400</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,800</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,200</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,200</span></td></tr></table></div> 4000000000 3400000000 2800000000 2200000000 2200000000 Fair value measurements<div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company uses forward foreign exchange contracts to manage its exposure to the variability of cash flows, primarily related to the foreign exchange rate changes of future intercompany products and third-party purchases of materials denominated in a foreign currency. The Company uses cross currency interest rate swaps to manage currency risk primarily related to borrowings. Both types of derivatives are designated as cash flow hedges.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Additionally, the Company uses interest rate swaps as an instrument to manage interest rate risk related to fixed rate borrowings. These derivatives are designated as fair value hedges. The Company uses cross currency interest rate swaps and forward foreign exchange contracts designated as net investment hedges. Additionally, the Company uses forward foreign exchange contracts to offset its exposure to certain foreign currency assets and liabilities. These forward foreign exchange contracts are not designated as hedges and therefore, changes in the fair values of these derivatives are recognized in earnings, thereby offsetting the current earnings effect of the related foreign currency assets and liabilities. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company does not enter into derivative financial instruments for trading or speculative purposes, or that contain credit risk related contingent features. The Company maintains credit support agreements (CSA) with certain derivative counterparties establishing collateral thresholds based on respective credit ratings and netting agreements. As of December 29, 2024 and December 31, 2023, the total amount of cash collateral paid by the Company under the CSA amounted to $2.2 billion and $4.0 billion net respectively, related to net investment and cash flow hedges. On an ongoing basis, the Company monitors counter-party credit ratings. The Company considers credit non-performance risk to be low, because the Company primarily enters into agreements with commercial institutions that have at least an investment grade credit rating. Refer to the table on significant financial assets and liabilities measured at fair value contained in this footnote for receivables and payables with these commercial institutions. As of December 29, 2024, the Company had notional amounts outstanding for forward foreign exchange contracts, cross currency interest rate swaps and interest rate swaps of $45.1 billion, $40.5 billion and $9.0 billion, respectively. As of December 31, 2023, the Company had notional amounts outstanding for forward foreign exchange contracts, cross currency interest rate swaps and interest rate swaps of $42.9 billion, $39.7 billion and $10.0 billion, respectively.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">All derivative instruments are recorded on the balance sheet at fair value. Changes in the fair value of derivatives are recorded each period in current earnings or other comprehensive income, depending on whether the derivative is designated as part of a hedge transaction, and if so, the type of hedge transaction. Cash exchanged for derivatives is primarily in cash flows from operating activities.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The designation as a cash flow hedge is made at the entrance date of the derivative contract. At inception, all derivatives are expected to be highly effective. Foreign exchange contracts designated as cash flow hedges are accounted for under the forward method and all gains/losses associated with these contracts will be recognized in the income statement when the hedged item impacts earnings. Changes in the fair value of these derivatives are recorded in accumulated other comprehensive income until the underlying transaction affects earnings, and are then reclassified to earnings in the same account as the hedged transaction.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Gains and losses associated with interest rate swaps and changes in fair value of hedged debt attributable to changes in interest rates are recorded to interest expense in the period in which they occur. Gains and losses on net investment hedges are accounted through the currency translation account within accumulated other comprehensive income. The portion excluded from effectiveness testing is recorded through interest (income) expense using the spot method. On an ongoing basis, the Company assesses whether each derivative continues to be highly effective in offsetting changes of hedged items. If and when a derivative is no longer expected to be highly effective, hedge accounting is discontinued.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company designated its Euro denominated notes with due dates ranging from 2024 to 2044 as a net investment hedge of the Company's investments in certain of its international subsidiaries that use the Euro as their functional currency in order to reduce the volatility caused by changes in exchange rates. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">As of December 29, 2024, the balance of deferred net loss on derivatives included in accumulated other comprehensive income was $1.7 billion after-tax. For additional information, see the Consolidated Statements of Comprehensive Income and Note 13. The Company expects that substantially all of the amounts related to forward foreign exchange contracts will be reclassified into earnings over the next 12 months as a result of transactions that are expected to occur over that period. The maximum length of time over which the Company is hedging transaction exposure is 18 months, excluding interest rate contracts and net investment hedges. The amount ultimately realized in earnings may differ as foreign exchange rates change. Realized gains and losses are ultimately determined by actual exchange rates at maturity of the derivative.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The following table is a summary of the activity related to derivatives and hedges for the fiscal years ended December 29, 2024 and December 31, 2023, net of tax:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:20.775%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.108%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.084%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.084%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.638%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.436%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.703%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.679%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.388%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 29, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Sales</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cost of<br/>Products<br/> Sold</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">R&amp;D<br/> Expense</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Interest<br/>(Income)<br/> Expense</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Other<br/>(Income)<br/>Expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Sales</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cost of<br/>Products<br/>Sold</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">R&amp;D<br/>Expense</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Interest<br/>(Income)<br/>Expense</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Other<br/>(Income)<br/>Expense</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The effects of fair value, net investment and cash flow hedging:</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Gain (Loss) on fair value hedging relationship:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Interest rate swaps contracts:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Hedged items</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$—</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">64</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">168</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Derivatives designated as hedging instruments</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(64)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(168)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Gain (Loss) on net investment hedging relationship:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cross currency interest rate swaps contracts:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$—</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">148</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">130</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amount of gain or (loss) recognized in AOCI</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">148</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">130</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Gain (Loss) on cash flow hedging relationship:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Forward foreign exchange contracts:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amount of gain or (loss) reclassified from AOCI into income</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">426</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">33</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">186</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(37)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amount of gain or (loss) recognized in AOCI</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(7)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(156)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">80</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">21</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">447</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(18)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Cross currency interest rate swaps contracts:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amount of gain or (loss) reclassified from AOCI into income</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">247</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">275</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amount of gain or (loss) recognized in AOCI</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$—</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(597)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(156)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">As of December 29, 2024 and December 31, 2023, the following amounts were recorded on the consolidated balance sheet related to cumulative basis adjustment for fair value hedges:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.126%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.822%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.227%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.822%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.230%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Line item in the Consolidated Balance Sheet<br/>in which the hedged item is included</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Carrying Amount of the Hedged Liability</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cumulative Amount of Fair Value Hedging<br/>Adjustment Included in the Carrying<br/>Amount of the Hedged Liability</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 29, 2024</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2023</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 29, 2024</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2023</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Long-term Debt</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$7,935</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$8,862</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$(1,132)</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$(1,216)</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The following table is the effect of derivatives not designated as hedging instrument for the fiscal years ended <br/>December 29, 2024 and December 31, 2023:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.138%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.179%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.822%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.229%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Location of Gain /(Loss)<br/>Recognized in Income on<br/>Derivative</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gain/(Loss)<br/>Recognized In<br/>Income on Derivative</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Derivatives Not Designated as Hedging Instruments</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 29, 2024</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2023</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Foreign Exchange Contracts</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:f-905"><span style="-sec-ix-hidden:f-906">Other (income) expense</span></span></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$8</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(60)</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The following table is the effect of net investment hedges for the fiscal years ended December 29, 2024 and <br/>December 31, 2023:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.417%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.822%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.227%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.161%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.822%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.231%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gain/(Loss)<br/>Recognized In<br/>Accumulated OCI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Location of Gain or<br/>(Loss) Reclassified<br/>from Accumulated Other Comprehensive Income Into Income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gain/(Loss)<br/>Reclassified from<br/>Accumulated OCI<br/>Into Income</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 29, 2024</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 29, 2024</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Debt</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$282</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(131)</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Interest (income) expense</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cross Currency interest rate swaps</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$955</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">642</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Interest (income) expense</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company holds equity investments with readily determinable fair values and equity investments without readily determinable fair values. The Company measures equity investments that do not have readily determinable fair values at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The following table is a summary of the activity related to equity investments for the fiscal years ended December 29, 2024 and December 31, 2023:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.792%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.334%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.658%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 29, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Carrying Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Changes in Fair</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Value Reflected in</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Net Income</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Sales/</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Purchases/</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Other</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Carrying Value</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Non-Current<br/>Other Assets</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Equity Investments with readily determinable value *</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$4,473</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(17)</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4,005)</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">451</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">451</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Equity Investments without readily determinable value</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$696</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(197)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">274</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">773</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">773</span></td></tr></table></div><div style="margin-bottom:4pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.792%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.334%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.658%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">January 1, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Carrying Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Changes in Fair</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Value Reflected in</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Net Income</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Sales/</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Purchases/</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Other</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Carrying Value</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Non-Current<br/>Other Assets</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Equity Investments with readily determinable value *</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$576</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(368)</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,265</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,473</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,473</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Equity Investments without readily determinable value</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$613</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">82</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">696</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">696</span></td></tr></table></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:9.29pt">Recorded in Other Income/Expense</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.09pt">Other includes impact of currency</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%">*    The December 31, 2023 balance includes the 9.5% remaining stake in Kenvue. A debt-for-equity exchange was completed in the fiscal second quarter of 2024.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">On May 15, 2024, the Company issued $3.6 billion aggregate principal amount of commercial paper and received $3.6 billion of net cash proceeds to be used for general corporate purposes. On May 17, 2024, the Company completed a Debt-for-Equity Exchange of its remaining 182,329,550 shares of Kenvue Common Stock for the outstanding Commercial Paper. Upon completion of the Debt-for-Equity Exchange, the Commercial Paper was satisfied and discharged, and the Company no longer owns any shares of Kenvue Common Stock. This exchange resulted in a loss of approximately $0.4 billion recorded in Other (income) expense. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">For the fiscal years ended December 29, 2024 and December 31, 2023 for equity investments without readily determinable market values, $171 million and $1 million, respectively, of the changes in fair value reflected in net income were the result of impairments. There were impacts of $26 million and $27 million, respectively, of changes in the fair value reflected in net income due to changes in observable prices and gains on the disposal of investments. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Fair value is the exit price that would be received to sell an asset or paid to transfer a liability. Fair value is a market-based measurement determined using assumptions that market participants would use in pricing an asset or liability. In accordance with ASC 820, a three-level hierarchy to prioritize the inputs used in measuring fair value. The levels within the hierarchy are described below with Level 1 having the highest priority and Level 3 having the lowest.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The fair value of a derivative financial instrument (i.e., forward foreign exchange contracts, interest rate contracts) is the aggregation by currency of all future cash flows discounted to its present value at the prevailing market interest rates and subsequently converted to the U.S. Dollar at the current spot foreign exchange rate. The Company does not believe that fair values of these derivative instruments materially differ from the amounts that could be realized upon settlement or maturity, or that the changes in fair value will have a material effect on the Company’s results of operations, cash flows or financial position. The Company also holds equity investments which are classified as Level 1 and debt securities which are classified as Level 2. The Company holds acquisition related contingent liabilities based upon certain regulatory and commercial events, which are classified as Level 3, whose values are determined using discounted cash flow methodologies or similar techniques for which the determination of fair value requires significant judgment or estimations.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The following three levels of inputs are used to measure fair value:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Level 1 — Quoted prices in active markets for identical assets and liabilities.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Level 2 — Significant other observable inputs.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Level 3 — Significant unobservable inputs.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company’s significant financial assets and liabilities measured at fair value as of the fiscal year ended December 29, 2024 and December 31, 2023 were as follows:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.209%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.895%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Derivatives designated as hedging instruments:</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"> </span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"> </span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"> </span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"> </span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"> </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"> </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Forward foreign exchange contracts </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">660</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">660</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">539</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Interest rate contracts</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,484</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,484</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">988</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$—</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2,144</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">—</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2,144</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">1,527</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Liabilities:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Forward foreign exchange contracts</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">794</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">794</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">624</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Interest rate contracts</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,753</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,753</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,338</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$—</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">4,547</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">—</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">4,547</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">5,962</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Derivatives not designated as hedging instruments:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Forward foreign exchange contracts </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">50</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">50</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">64</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Liabilities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Forward foreign exchange contracts</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">17</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">17</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">75</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Available For Sale Other Investments:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Equity investments</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">451</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">451</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,473</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Debt securities</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7,216</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7,216</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8,874</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Other Liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Contingent Consideration</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,217</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,217</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,092</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.065%"><tr><td style="width:1.0%"></td><td style="width:64.302%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.895%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.558%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.139%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross to Net Derivative Reconciliation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total Gross Assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$2,194</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,591</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Credit Support Agreements (CSA)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2,172)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,575)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total Net Asset</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">22</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">16</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total Gross Liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,564</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,037</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Credit Support Agreements (CSA)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4,412)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5,604)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total Net Liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$152</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">433</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Summarized information about changes in liabilities for contingent consideration is as follows:</span></div><div style="margin-bottom:4pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.822%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.764%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Beginning Balance</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">$1,092</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,120</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">533</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Changes in estimated fair value </span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">88</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">29</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(194)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Additions</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:130%;position:relative;top:-3.15pt;vertical-align:baseline">(6)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">112</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">792</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Payments/Other</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(75)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(57)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(11)</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Ending Balance</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:130%;position:relative;top:-3.15pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">$1,217</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,092</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,120</span></td></tr></table></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:9.29pt">2023 assets and liabilities are all classified as Level 2 with the exception of equity investments of $4,473 million, which are classified as Level 1 and contingent consideration of $1,092 million, classified as Level 3.</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.09pt">Includes cross currency interest rate swaps and interest rate swaps.</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8pt">Classified as non-current other assets.</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:7.89pt">Classified as cash equivalents and current marketable securities.</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:7.99pt">Includes $1,217 million, $1,092 million and $1,116 million, classified as non-current other liabilities as of December 29, 2024, <br/>December 31, 2023 and January 1, 2023, respectively. Includes $4 million classified as current liabilities as of January 1, 2023.</span></div><div style="margin-bottom:6pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline">(6)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8pt">In fiscal year 2024, the Company recorded $105 million of contingent consideration related to Proteologix. In fiscal year 2022, the Company recorded $704 million of contingent consideration related to Abiomed. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">See Notes 2 and 7 for financial assets and liabilities held at carrying amount on the Consolidated Balance Sheet.</span></div> 2200000000 4000000000.0 45100000000 40500000000 9000000000.0 42900000000 39700000000 10000000000.0 -1700000000 next 12 months P18M <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The following table is a summary of the activity related to derivatives and hedges for the fiscal years ended December 29, 2024 and December 31, 2023, net of tax:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:20.775%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.108%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.084%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.084%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.638%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.436%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.703%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.679%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.388%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 29, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Sales</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cost of<br/>Products<br/> Sold</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">R&amp;D<br/> Expense</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Interest<br/>(Income)<br/> Expense</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Other<br/>(Income)<br/>Expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Sales</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cost of<br/>Products<br/>Sold</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">R&amp;D<br/>Expense</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Interest<br/>(Income)<br/>Expense</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Other<br/>(Income)<br/>Expense</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The effects of fair value, net investment and cash flow hedging:</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Gain (Loss) on fair value hedging relationship:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Interest rate swaps contracts:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Hedged items</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$—</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">64</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">168</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Derivatives designated as hedging instruments</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(64)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(168)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Gain (Loss) on net investment hedging relationship:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cross currency interest rate swaps contracts:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$—</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">148</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">130</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amount of gain or (loss) recognized in AOCI</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">148</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">130</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Gain (Loss) on cash flow hedging relationship:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Forward foreign exchange contracts:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amount of gain or (loss) reclassified from AOCI into income</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">426</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">33</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">186</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(37)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amount of gain or (loss) recognized in AOCI</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(7)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(156)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">80</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">21</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">447</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(18)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Cross currency interest rate swaps contracts:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amount of gain or (loss) reclassified from AOCI into income</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">247</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">275</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amount of gain or (loss) recognized in AOCI</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$—</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(597)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(156)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">As of December 29, 2024 and December 31, 2023, the following amounts were recorded on the consolidated balance sheet related to cumulative basis adjustment for fair value hedges:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.126%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.822%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.227%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.822%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.230%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Line item in the Consolidated Balance Sheet<br/>in which the hedged item is included</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Carrying Amount of the Hedged Liability</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cumulative Amount of Fair Value Hedging<br/>Adjustment Included in the Carrying<br/>Amount of the Hedged Liability</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 29, 2024</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2023</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 29, 2024</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2023</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Long-term Debt</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$7,935</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$8,862</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$(1,132)</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$(1,216)</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div> 0 0 0 64000000 0 0 0 0 168000000 0 0 0 0 -64000000 0 0 0 0 -168000000 0 0 0 0 148000000 0 0 0 0 130000000 0 0 0 0 148000000 0 0 0 0 130000000 0 2000000 426000000 33000000 0 6000000 7000000 186000000 -37000000 0 8000000 -7000000 -156000000 80000000 0 21000000 10000000 447000000 -18000000 0 9000000 0 0 0 247000000 0 0 0 0 275000000 0 0 0 0 -597000000 0 0 0 0 -156000000 0 7935000000 8862000000 -1132000000 -1216000000 <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The following table is the effect of derivatives not designated as hedging instrument for the fiscal years ended <br/>December 29, 2024 and December 31, 2023:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.138%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.179%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.822%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.229%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Location of Gain /(Loss)<br/>Recognized in Income on<br/>Derivative</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gain/(Loss)<br/>Recognized In<br/>Income on Derivative</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Derivatives Not Designated as Hedging Instruments</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 29, 2024</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2023</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Foreign Exchange Contracts</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:f-905"><span style="-sec-ix-hidden:f-906">Other (income) expense</span></span></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$8</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(60)</span></td></tr></table></div> 8000000 -60000000 <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The following table is the effect of net investment hedges for the fiscal years ended December 29, 2024 and <br/>December 31, 2023:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.417%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.822%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.227%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.161%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.822%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.231%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gain/(Loss)<br/>Recognized In<br/>Accumulated OCI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Location of Gain or<br/>(Loss) Reclassified<br/>from Accumulated Other Comprehensive Income Into Income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gain/(Loss)<br/>Reclassified from<br/>Accumulated OCI<br/>Into Income</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 29, 2024</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 29, 2024</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Debt</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$282</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(131)</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Interest (income) expense</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cross Currency interest rate swaps</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$955</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">642</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Interest (income) expense</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td></tr></table></div> 282000000 -131000000 0 0 955000000 642000000 0 0 <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The following table is a summary of the activity related to equity investments for the fiscal years ended December 29, 2024 and December 31, 2023:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.792%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.334%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.658%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 29, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Carrying Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Changes in Fair</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Value Reflected in</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Net Income</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Sales/</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Purchases/</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Other</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Carrying Value</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Non-Current<br/>Other Assets</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Equity Investments with readily determinable value *</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$4,473</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(17)</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4,005)</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">451</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">451</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Equity Investments without readily determinable value</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$696</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(197)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">274</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">773</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">773</span></td></tr></table></div><div style="margin-bottom:4pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.792%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.334%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.658%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">January 1, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Carrying Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Changes in Fair</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Value Reflected in</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Net Income</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Sales/</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Purchases/</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Other</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Carrying Value</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Non-Current<br/>Other Assets</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Equity Investments with readily determinable value *</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$576</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(368)</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,265</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,473</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,473</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Equity Investments without readily determinable value</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$613</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">82</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">696</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">696</span></td></tr></table></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:9.29pt">Recorded in Other Income/Expense</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.09pt">Other includes impact of currency</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%">*    The December 31, 2023 balance includes the 9.5% remaining stake in Kenvue. A debt-for-equity exchange was completed in the fiscal second quarter of 2024.</span></div> 4473000000 -17000000 -4005000000 451000000 451000000 696000000 -197000000 274000000 773000000 773000000 576000000 -368000000 4265000000 4473000000 4473000000 613000000 1000000 82000000 696000000 696000000 0.095 3600000000 3600000000 182329550 400000000 -171000000 -1000000 -26000000 27000000 <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company’s significant financial assets and liabilities measured at fair value as of the fiscal year ended December 29, 2024 and December 31, 2023 were as follows:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.209%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.895%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Derivatives designated as hedging instruments:</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"> </span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"> </span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"> </span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"> </span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"> </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"> </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Forward foreign exchange contracts </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">660</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">660</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">539</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Interest rate contracts</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,484</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,484</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">988</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$—</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2,144</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">—</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2,144</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">1,527</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Liabilities:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Forward foreign exchange contracts</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">794</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">794</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">624</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Interest rate contracts</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,753</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,753</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,338</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$—</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">4,547</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">—</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">4,547</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">5,962</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Derivatives not designated as hedging instruments:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Forward foreign exchange contracts </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">50</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">50</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">64</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Liabilities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Forward foreign exchange contracts</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">17</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">17</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">75</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Available For Sale Other Investments:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Equity investments</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">451</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">451</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,473</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Debt securities</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7,216</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7,216</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8,874</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Other Liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Contingent Consideration</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,217</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,217</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,092</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.065%"><tr><td style="width:1.0%"></td><td style="width:64.302%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.895%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.558%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.139%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross to Net Derivative Reconciliation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total Gross Assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$2,194</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,591</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Credit Support Agreements (CSA)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2,172)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,575)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total Net Asset</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">22</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">16</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total Gross Liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,564</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,037</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Credit Support Agreements (CSA)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4,412)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5,604)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total Net Liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$152</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">433</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Summarized information about changes in liabilities for contingent consideration is as follows:</span></div><div style="margin-bottom:4pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.822%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.764%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Beginning Balance</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">$1,092</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,120</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">533</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Changes in estimated fair value </span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">88</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">29</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(194)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Additions</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:130%;position:relative;top:-3.15pt;vertical-align:baseline">(6)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">112</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">792</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Payments/Other</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(75)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(57)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(11)</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Ending Balance</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:130%;position:relative;top:-3.15pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">$1,217</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,092</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,120</span></td></tr></table></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:9.29pt">2023 assets and liabilities are all classified as Level 2 with the exception of equity investments of $4,473 million, which are classified as Level 1 and contingent consideration of $1,092 million, classified as Level 3.</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.09pt">Includes cross currency interest rate swaps and interest rate swaps.</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8pt">Classified as non-current other assets.</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:7.89pt">Classified as cash equivalents and current marketable securities.</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:7.99pt">Includes $1,217 million, $1,092 million and $1,116 million, classified as non-current other liabilities as of December 29, 2024, <br/>December 31, 2023 and January 1, 2023, respectively. Includes $4 million classified as current liabilities as of January 1, 2023.</span></div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline">(6)</span>In fiscal year 2024, the Company recorded $105 million of contingent consideration related to Proteologix. In fiscal year 2022, the Company recorded $704 million of contingent consideration related to Abiomed. 0 660000000 0 660000000 539000000 0 1484000000 0 1484000000 988000000 0 2144000000 0 2144000000 1527000000 0 794000000 0 794000000 624000000 0 3753000000 0 3753000000 5338000000 0 4547000000 0 4547000000 5962000000 0 50000000 0 50000000 64000000 0 17000000 0 17000000 75000000 451000000 0 0 451000000 4473000000 0 7216000000 0 7216000000 8874000000 1217000000 1217000000 1092000000 2194000000 1591000000 2172000000 1575000000 Total Net Asset Total Net Asset 22000000 16000000 4564000000 6037000000 4412000000 5604000000 Total Net Liabilities Total Net Liabilities 152000000 433000000 1092000000 1120000000 533000000 88000000 29000000 -194000000 112000000 0 792000000 75000000 57000000 11000000 1217000000 1092000000 1120000000 4473000000 1092000000 1217000000 1092000000 1116000000 4000000 105000000 704000000 Borrowings<div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The components of long-term debt are as follows:</span></div><div style="margin-bottom:4pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.155%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.275%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.776%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.275%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.776%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.275%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.776%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.778%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Effective<br/>Rate<br/>%</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Effective<br/>Rate<br/>%</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.650% Notes due 2024 </span></div><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(750MM Euro 1.1090)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">$—</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #eb1700;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">— </span></td><td style="border-top:1pt solid #eb1700;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">%</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">$831</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:130%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="border-top:1pt solid #eb1700;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">0.68 </span></td><td style="border-top:1pt solid #eb1700;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">%</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5.50% Notes due 2024 </span></div><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(500MM GBP 1.2756)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">637</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:130%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">6.75 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2.625% Notes due 2025</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">750</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">2.63 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">750</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">2.63 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.55% Notes due 2025</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">999</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">0.57 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">950</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">0.57 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2.46% Notes due 2026</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,999</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">2.47 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,997</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">2.47 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2.95% Notes due 2027</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">927</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">2.96 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">900</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">2.96 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.95% Notes due 2027</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,458</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">0.96 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,419</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">0.96 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1.150% Notes due 2028<br/>(750MM Euro 1.0401)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">/(750MM Euro 1.1090)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">777</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:130%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1.21 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">828</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:130%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1.21 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2.90% Notes due 2028</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,498</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">2.91 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,497</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">2.91 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6.95% Notes due 2029</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">298</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"> </span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">7.14 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">298</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"> </span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">7.14 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.80% Debentures due 2029</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,146</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">4.83 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1.30% Notes due 2030</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,646</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1.30 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,630</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1.30 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.90% Debentures due 2031</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,145</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">4.92 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.20% Debenture due 2032</span></div><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(700M EUR 1.0401)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">725</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:130%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">3.21 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.95% Debentures due 2033</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">499</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"> </span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">4.95 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">499</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"> </span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">4.95 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.375% Notes due 2033</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">854</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">4.24 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">854</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">4.24 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">4.95% Debentures due 2034</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">846</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">4.96 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1.650% Notes due 2035<br/>(1.5B Euro 1.0401)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">/(1.5B Euro 1.1090)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,550</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:130%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1.68 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,652</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:130%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1.68 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.35% Debentures due 2036 </span></div><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(800MM EUR 1.0401)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">827</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:130%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">3.37 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.587% Notes due 2036</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">869</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">3.59 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">864</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">3.59 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5.95% Notes due 2037</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">994</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"> </span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">5.99 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">994</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"> </span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">5.99 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.625% Notes due 2037</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,358</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">3.64 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,357</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">3.64 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5.85% Debentures due 2038</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">697</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"> </span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">5.85 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">697</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"> </span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">5.85 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.40% Notes due 2038</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">993</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">3.42 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">993</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">3.42 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.50% Debentures due 2040</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">541</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"> </span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">4.63 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">541</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"> </span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">4.63 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2.10% Notes due 2040</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">845</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">2.14 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">849</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">2.14 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.85% Notes due 2041</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">297</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">4.89 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">297</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">4.89 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.50% Notes due 2043</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">496</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">4.52 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">496</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">4.52 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.55% Debentures due 2044</span></div><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1B EUR 1.0401)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,030</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:130%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">3.58 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.73% Notes due 2046</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,978</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">3.74 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,977</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">3.74 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.75% Notes due 2047</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">822</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">3.76 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">832</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">3.76 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.500% Notes due 2048</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">744</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">3.52 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">743</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">3.52 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2.250% Notes due 2050</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">808</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">2.29 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">826</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">2.29 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:4pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.155%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.275%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.776%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.275%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.776%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.275%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.776%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.778%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5.25% Debentures due 2054</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">843</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">5.26 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2.450% Notes due 2060</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,058</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">2.49 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,073</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">2.49 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">83</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"> </span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">69</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"> </span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Subtotal</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%">32,400</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:130%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%">3.36</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"> </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%">%</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:130%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%">27,350</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:130%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%">2.98</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"> </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%">%</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:130%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Less current portion</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,749</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,469</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"> </span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total long-term debt</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%">$30,651</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%"> </span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%"> </span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%"> </span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%">$25,881</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%"> </span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%"> </span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:9.29pt">Weighted average effective rate.</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.09pt">Translation rate at December 29, 2024.</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8pt">Translation rate at December 31, 2023.</span></div><div style="margin-bottom:6pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:7.89pt">The excess of the carrying value over the fair value of debt was $2.0 billion and $1.0 billion at the end of fiscal year 2024 and fiscal year 2023, respectively.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Fair value of the long-term debt was estimated using market prices, which were corroborated by quoted broker prices and significant other observable inputs.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company has access to substantial sources of funds at numerous banks worldwide. In June 2024, the Company secured a new 364-day Credit Facility of $10 billion, which expires on June 25, 2025. Interest charged on borrowings under the credit line agreement is based on either the Term SOFR Reference Rate or other applicable market rates as allowed under the terms of the agreement, plus applicable margins. Commitment fees under the agreements are not material.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Throughout fiscal years 2024 and 2023, the Company continued to have access to liquidity through the commercial paper market. Short-term borrowings and the current portion of long-term debt amounted to approximately $6.0 billion and $3.5 billion at the end of fiscal years 2024 and 2023, respectively. The current portion of the long-term debt was $1.7 billion and $1.5 billion in 2024 and 2023, respectively, and the remainder is commercial paper and local borrowing by international subsidiaries.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The current debt balance as of December 29, 2024 includes $4.1 billion of commercial paper which has a weighted average interest rate of 4.46% and a weighted average maturity of approximately two months. The current debt balance as of December 31, 2023 includes $2.0 billion of commercial paper which has a weighted average interest rate of 5.37% and a weighted average maturity of approximately two months.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Aggregate maturities of long-term debt obligations commencing in 2025 are:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.822%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.822%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.822%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.822%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.826%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2027</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2028</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2029</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">After 2029</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$1,749</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,999</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,385</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,275</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,444</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">22,548</span></td></tr></table></div> <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The components of long-term debt are as follows:</span></div><div style="margin-bottom:4pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.155%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.275%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.776%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.275%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.776%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.275%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.776%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.778%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Effective<br/>Rate<br/>%</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Effective<br/>Rate<br/>%</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.650% Notes due 2024 </span></div><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(750MM Euro 1.1090)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">$—</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #eb1700;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">— </span></td><td style="border-top:1pt solid #eb1700;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">%</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">$831</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:130%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="border-top:1pt solid #eb1700;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">0.68 </span></td><td style="border-top:1pt solid #eb1700;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">%</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5.50% Notes due 2024 </span></div><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(500MM GBP 1.2756)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">637</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:130%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">6.75 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2.625% Notes due 2025</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">750</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">2.63 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">750</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">2.63 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.55% Notes due 2025</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">999</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">0.57 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">950</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">0.57 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2.46% Notes due 2026</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,999</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">2.47 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,997</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">2.47 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2.95% Notes due 2027</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">927</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">2.96 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">900</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">2.96 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.95% Notes due 2027</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,458</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">0.96 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,419</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">0.96 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1.150% Notes due 2028<br/>(750MM Euro 1.0401)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">/(750MM Euro 1.1090)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">777</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:130%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1.21 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">828</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:130%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1.21 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2.90% Notes due 2028</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,498</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">2.91 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,497</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">2.91 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6.95% Notes due 2029</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">298</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"> </span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">7.14 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">298</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"> </span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">7.14 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.80% Debentures due 2029</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,146</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">4.83 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1.30% Notes due 2030</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,646</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1.30 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,630</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1.30 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.90% Debentures due 2031</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,145</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">4.92 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.20% Debenture due 2032</span></div><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(700M EUR 1.0401)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">725</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:130%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">3.21 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.95% Debentures due 2033</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">499</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"> </span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">4.95 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">499</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"> </span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">4.95 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.375% Notes due 2033</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">854</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">4.24 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">854</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">4.24 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">4.95% Debentures due 2034</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">846</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">4.96 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1.650% Notes due 2035<br/>(1.5B Euro 1.0401)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">/(1.5B Euro 1.1090)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,550</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:130%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1.68 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,652</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:130%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1.68 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.35% Debentures due 2036 </span></div><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(800MM EUR 1.0401)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">827</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:130%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">3.37 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.587% Notes due 2036</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">869</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">3.59 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">864</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">3.59 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5.95% Notes due 2037</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">994</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"> </span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">5.99 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">994</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"> </span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">5.99 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.625% Notes due 2037</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,358</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">3.64 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,357</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">3.64 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5.85% Debentures due 2038</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">697</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"> </span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">5.85 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">697</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"> </span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">5.85 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.40% Notes due 2038</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">993</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">3.42 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">993</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">3.42 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.50% Debentures due 2040</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">541</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"> </span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">4.63 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">541</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"> </span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">4.63 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2.10% Notes due 2040</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">845</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">2.14 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">849</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">2.14 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.85% Notes due 2041</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">297</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">4.89 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">297</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">4.89 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.50% Notes due 2043</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">496</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">4.52 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">496</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">4.52 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.55% Debentures due 2044</span></div><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1B EUR 1.0401)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,030</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:130%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">3.58 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.73% Notes due 2046</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,978</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">3.74 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,977</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">3.74 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.75% Notes due 2047</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">822</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">3.76 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">832</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">3.76 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.500% Notes due 2048</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">744</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">3.52 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">743</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">3.52 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2.250% Notes due 2050</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">808</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">2.29 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">826</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">2.29 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:4pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.155%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.275%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.776%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.275%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.776%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.275%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.776%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.778%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5.25% Debentures due 2054</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">843</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">5.26 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2.450% Notes due 2060</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,058</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">2.49 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,073</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">2.49 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">83</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"> </span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">69</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"> </span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Subtotal</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%">32,400</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:130%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%">3.36</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"> </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%">%</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:130%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%">27,350</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:130%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%">2.98</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"> </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%">%</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:130%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Less current portion</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,749</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,469</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%"> </span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total long-term debt</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%">$30,651</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%"> </span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%"> </span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%"> </span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%">$25,881</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%"> </span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%"> </span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:9.29pt">Weighted average effective rate.</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.09pt">Translation rate at December 29, 2024.</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8pt">Translation rate at December 31, 2023.</span></div><div style="margin-bottom:6pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:7.89pt">The excess of the carrying value over the fair value of debt was $2.0 billion and $1.0 billion at the end of fiscal year 2024 and fiscal year 2023, respectively.</span></div> 0.00650 750000000 1.1090 0 0 831000000 0.0068 0.0550 500000000 1.2756 0 0 637000000 0.0675 0.02625 750000000 0.0263 750000000 0.0263 0.0055 999000000 0.0057 950000000 0.0057 0.0246 1999000000 0.0247 1997000000 0.0247 0.0295 927000000 0.0296 900000000 0.0296 0.0095 1458000000 0.0096 1419000000 0.0096 0.01150 750000000 1.0401 750000000 1.1090 777000000 0.0121 828000000 0.0121 0.0290 1498000000 0.0291 1497000000 0.0291 0.0695 298000000 0.0714 298000000 0.0714 0.0480 1146000000 0.0483 0 0 0.0130 1646000000 0.0130 1630000000 0.0130 0.0490 1145000000 0.0492 0 0 0.0320 700000000 1.0401 725000000 0.0321 0 0 0.0495 499000000 0.0495 499000000 0.0495 0.04375 854000000 0.0424 854000000 0.0424 0.0495 846000000 0.0496 0 0 0.01650 1500000000 1.0401 1500000000 1.1090 1550000000 0.0168 1652000000 0.0168 0.0335 800000000 1.0401 827000000 0.0337 0 0 0.03587 869000000 0.0359 864000000 0.0359 0.0595 994000000 0.0599 994000000 0.0599 0.03625 1358000000 0.0364 1357000000 0.0364 0.0585 697000000 0.0585 697000000 0.0585 0.0340 993000000 0.0342 993000000 0.0342 0.0450 541000000 0.0463 541000000 0.0463 0.0210 845000000 0.0214 849000000 0.0214 0.0485 297000000 0.0489 297000000 0.0489 0.0450 496000000 0.0452 496000000 0.0452 0.0355 1000000000 1.0401 1030000000 0.0358 0 0 0.0373 1978000000 0.0374 1977000000 0.0374 0.0375 822000000 0.0376 832000000 0.0376 0.03500 744000000 0.0352 743000000 0.0352 0.02250 808000000 0.0229 826000000 0.0229 0.0525 843000000 0.0526 0 0 0.02450 1058000000 0.0249 1073000000 0.0249 83000000 0 69000000 0 32400000000 0.0336 27350000000 0.0298 1749000000 1469000000 30651000000 25881000000 2000000000.0 1000000000.0 10000000000 6000000000.0 3500000000 1700000000 1500000000 4100000000 0.0446 P2M 2000000000 0.0537 P2M <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Aggregate maturities of long-term debt obligations commencing in 2025 are:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.822%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.822%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.822%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.822%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.826%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2027</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2028</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2029</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">After 2029</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$1,749</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,999</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,385</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,275</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,444</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">22,548</span></td></tr></table></div> 1749000000 1999000000 2385000000 2275000000 1444000000 22548000000 Income taxes<div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The provision for taxes on income on continuing operations consists of:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.822%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.764%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Currently payable:</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. taxes</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$2,200</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,705</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,274</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International taxes</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,604</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,090</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,295</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total currently payable</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,804</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,795</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,569</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Deferred:</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. taxes</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2,539)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3,440)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,990)</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International taxes</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">356</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(619)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">410</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total deferred</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2,183)</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4,059)</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,580)</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Provision for taxes on income</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$2,621</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">1,736</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2,989</span></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">A comparison of income tax expense at the U.S. statutory rate of 21% in fiscal years 2024, 2023 and 2022, to the Company’s effective tax rate is as follows:</span></div><div style="margin-bottom:4pt;margin-top:4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.822%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.764%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. </span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$(458)</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2,033)</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,606</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">17,145</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">17,095</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">14,753</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Earnings before taxes on income:</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$16,687</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">15,062</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">19,359</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Tax rates:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. statutory rate</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">21.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">21.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">21.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International operations</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5.2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(8.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. tax settlements</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. taxes on international income</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(0.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. state taxes</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1.5 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.3 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Tax benefits on share-based compensation</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(0.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(0.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">All other</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.6 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1.7 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1.6 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Effective Rate</span></td><td colspan="2" style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">15.7 </span></td><td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11.5 </span></td><td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">15.4 </span></td><td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:9.29pt">International operations reflect the impacts of operations in jurisdictions with statutory tax rates different than the U.S., particularly Ireland, Switzerland, and Belgium, which is a favorable impact on the effective tax rate as compared with the U.S. statutory rate. </span></div><div style="margin-bottom:6pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.09pt">Includes the net impact of the GILTI tax, the Foreign-Derived Intangible Income deduction and other foreign income that is taxable under the U.S. tax code as well as related foreign tax credits.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:128%">The fiscal year 2024 effective tax rate increased 4.2% as compared to the fiscal year 2023 effective tax rate. The primary drivers of this change are discussed below.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:128%">In fiscal year 2024, The Company had more income in higher tax jurisdictions compared to fiscal year 2023, primarily in the U.S. where the Company recorded a charge of approximately $5.1 billion in the fiscal year of 2024 versus approximately $7.0 billion in the fiscal year of 2023, both for the talc matters in the United States. Both charges were recorded at an effective U.S. tax rate of approximately 21% (for further information see Note 19 to the Consolidated Financial Statements). </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:128%">Additionally in the fiscal year 2024, the effective tax rate was unfavorably impacted by legislative changes that went into effect for Pillar Two in some of the Company's foreign jurisdictions which are reflected in International operations on the Company’s effective tax rate reconciliation. Also in fiscal year 2024, the Company generated incremental U.S. foreign tax credits related to income sourced and taxed outside the United States and is reflected in U.S. taxes on international income on the Company’s effective tax rate reconciliation. In 2024, the Company finalized multi-year transfer pricing agreements with the U.S. Internal Revenue Service (IRS) and certain other foreign jurisdictions. The U.S portion of the agreements were partially offset by the related tax adjustments in the foreign jurisdictions which are reflected in U.S tax settlements and International operations, respectively, on the Company’s effective rate reconciliation.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:128%">The fiscal year 2023 effective tax rate decreased 3.9% as compared to the fiscal year 2022 effective tax rate as the Company recorded certain non-recurring favorable tax items in fiscal year 2023 when compared to the prior fiscal year.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:128%">In the fiscal fourth quarter of 2023, the Company settled the U.S. Internal Revenue Service audit for tax years 2013 through 2016 which resulted in a favorable impact to the rate of 3.0%. This settlement was partially offset by the Company recording a $0.4 billion decrease in expected U.S. foreign tax credits, an unfavorable effective rate impact of 2.6%, which has been reflected as a current tax expense in U.S. taxes on international income on the Company’s effective tax rate reconciliation.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:128%">In the fiscal year 2023, the Company had certain non-recurring impacts as a result of legislative tax elections made in certain international subsidiaries which resulted in a change in the Company’s tax basis in certain assets resulting in deferred tax re-measurements. The net impact of these non-recurring items is a net benefit of 3.4% to the Company’s annual effective tax rate, comprised of the following items:</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:10.8pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:128%">•</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:128%;padding-left:7.83pt">approximately $0.3 billion of tax benefit on local deferred tax assets to record the remeasurement of the increased tax basis, this benefit has been reflected as International operations on the Company’s effective tax rate reconciliation. This benefit was offset by approximately $0.1 billion of U.S. deferred tax expense on the GILTI deferred tax liability resulting from the remeasurement of these deferred tax assets. This has been reflected in the “U.S. tax on international income” on the Company’s effective tax rate reconciliation.</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:10.8pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">•</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%;padding-left:7.83pt">approximately $0.3 billion of U.S. deferred tax benefit on the GILTI deferred tax related to an election made by an international subsidiary resulting in a decrease in local deferred tax assets. This has been reflected in the U.S. taxes on international income on the Company’s effective tax rate reconciliation.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company also had lower income in higher tax jurisdictions vs. fiscal year 2022, primarily in the U.S. where the Company recorded an approximately $7.0 billion charge related to talc matters in the United States at an effective tax rate of 21.1% (for further information see Note 19 to the Consolidated Financial Statements).</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Temporary differences and carryforwards at the end of fiscal years 2024 and 2023 were as follows:</span></div><div style="margin-bottom:4pt;margin-top:9pt;padding-right:4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.292%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.236%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024 Deferred Tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023 Deferred Tax</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Asset</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Liability</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Asset</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Liability</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Employee related obligations</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$372</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">586</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Stock based compensation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">717</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">686</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Depreciation of property, plant and equipment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(833)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(902)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Goodwill and intangibles</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3,261)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,252)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">R&amp;D capitalized for tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,398</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,595</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Reserves &amp; liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,444</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,816</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Inventory related</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">371</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">359</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Operating loss carryforwards</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,298</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,145</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Undistributed foreign earnings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,931</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,492)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,801</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,695)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Global intangible low-taxed income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,589)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2,731)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Miscellaneous international</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,212</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">831</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Miscellaneous U.S. </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,083</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4)</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total deferred income taxes</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">16,826</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(7,175)</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13,819</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(6,584)</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Valuation allowances</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,638)</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,149)</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total deferred income taxes net of valuation allowances</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">15,188</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(7,175)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">12,670</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(6,584)</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company has wholly-owned international subsidiaries that have cumulative net losses. The Company believes that it is more likely than not that these subsidiaries will generate future taxable income sufficient to partially utilize these deferred tax assets. In certain jurisdictions, valuation allowances have been recorded against deferred tax assets for loss carryforwards that are not more likely than not to be realized. The net operating loss carryforwards for these international subsidiaries that do not have an indefinite carryforward period will begin to expire in 2025 for various amounts.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The following table summarizes the activity related to valuation allowances for continuing operations:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.429%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.764%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Beginning of year</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$1,149</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">775</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Provision</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">451</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">355</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Utilization</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(116)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Foreign currency translation</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(46)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">25</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net acquisitions / (dispositions/liquidations)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">84</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">110</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">End of year</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$1,638</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$1,149</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The following table summarizes the activity related to unrecognized tax benefits for continuing operations:</span></div><div style="margin-bottom:6pt;margin-top:4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.822%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.764%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Beginning of year</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$2,485</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,716</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,210</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Increases related to current year tax positions</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">176</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">239</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">523</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Increases related to prior period tax positions</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">129</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">244</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">143</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Decreases related to prior period tax positions</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(147)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(781)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(148)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Settlements</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(583)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(880)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Lapse of statute of limitations</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(40)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(53)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(11)</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">End of year</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$2,020</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2,485</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">3,716</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">As of December 29, 2024 the Company had approximately $2.0 billion of unrecognized tax benefits. The Company conducts business and files tax returns in numerous countries and currently has tax audits in progress with a number of tax authorities. With respect to the United States, the Internal Revenue Service (IRS) has completed its audit for the tax years through 2016 and has commenced the audit for tax years 2017 through 2020. The Company recently finalized multi-year transfer pricing agreements with the IRS and certain other foreign jurisdictions in the fiscal fourth quarter of 2024.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">In other major jurisdictions where the Company conducts business, the years that remain open to tax audits go back to the year 2013. The Company believes it is possible that some tax audits may be completed over the next twelve months by taxing authorities in some jurisdictions. The Company anticipates a change in uncertain tax positions of approximately $200 million in certain jurisdictions in the next twelve months due to the expected expiration of the statute of limitations. However, generally the Company is not able to provide a reasonably reliable estimate of the timing of any other future tax payments, audit settlements, or changes in uncertain tax positions. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company classifies liabilities for unrecognized tax benefits and related interest and penalties as long-term liabilities. Interest expense and penalties related to unrecognized tax benefits are classified as income tax expense. The Company recognized after tax interest expense of $217 million, $99 million and $136 million in fiscal years 2024, 2023 and 2022, respectively. The total amount of accrued interest was $274 million and $264 million in fiscal years 2024 and 2023, respectively.</span></div> <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The provision for taxes on income on continuing operations consists of:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.822%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.764%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Currently payable:</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. taxes</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$2,200</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,705</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,274</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International taxes</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,604</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,090</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,295</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total currently payable</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,804</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,795</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,569</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Deferred:</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. taxes</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2,539)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3,440)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,990)</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International taxes</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">356</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(619)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">410</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total deferred</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2,183)</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4,059)</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,580)</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Provision for taxes on income</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$2,621</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">1,736</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2,989</span></td><td colspan="3" style="display:none"></td></tr></table></div> 2200000000 2705000000 2274000000 2604000000 3090000000 2295000000 4804000000 5795000000 4569000000 -2539000000 -3440000000 -1990000000 356000000 -619000000 410000000 -2183000000 -4059000000 -1580000000 2621000000 1736000000 2989000000 <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">A comparison of income tax expense at the U.S. statutory rate of 21% in fiscal years 2024, 2023 and 2022, to the Company’s effective tax rate is as follows:</span></div><div style="margin-bottom:4pt;margin-top:4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.822%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.764%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. </span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$(458)</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2,033)</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,606</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">17,145</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">17,095</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">14,753</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Earnings before taxes on income:</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$16,687</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">15,062</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">19,359</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Tax rates:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. statutory rate</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">21.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">21.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">21.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International operations</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5.2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(8.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. tax settlements</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. taxes on international income</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(0.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. state taxes</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1.5 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.3 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Tax benefits on share-based compensation</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(0.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(0.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">All other</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.6 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1.7 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1.6 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Effective Rate</span></td><td colspan="2" style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">15.7 </span></td><td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11.5 </span></td><td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">15.4 </span></td><td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:9.29pt">International operations reflect the impacts of operations in jurisdictions with statutory tax rates different than the U.S., particularly Ireland, Switzerland, and Belgium, which is a favorable impact on the effective tax rate as compared with the U.S. statutory rate. </span></div><div style="margin-bottom:6pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.09pt">Includes the net impact of the GILTI tax, the Foreign-Derived Intangible Income deduction and other foreign income that is taxable under the U.S. tax code as well as related foreign tax credits.</span></div> 0.21 0.21 -458000000 -2033000000 4606000000 17145000000 17095000000 14753000000 16687000000 15062000000 19359000000 0.210 0.210 0.210 -0.052 -0.081 -0.050 0.010 -0.030 0 -0.026 -0.003 -0.011 0.015 0.010 0.003 -0.006 -0.008 -0.014 0.006 0.017 0.016 0.157 0.115 0.154 0.042 5100000000 7000000000 -0.039 0.030 400000000 0.026 0.034 300000000 100000000 300000000 7000000000 0.211 <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Temporary differences and carryforwards at the end of fiscal years 2024 and 2023 were as follows:</span></div><div style="margin-bottom:4pt;margin-top:9pt;padding-right:4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.292%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.236%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024 Deferred Tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023 Deferred Tax</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Asset</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Liability</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Asset</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Liability</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Employee related obligations</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$372</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">586</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Stock based compensation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">717</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">686</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Depreciation of property, plant and equipment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(833)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(902)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Goodwill and intangibles</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3,261)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,252)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">R&amp;D capitalized for tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,398</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,595</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Reserves &amp; liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,444</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,816</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Inventory related</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">371</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">359</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Operating loss carryforwards</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,298</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,145</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Undistributed foreign earnings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,931</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,492)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,801</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,695)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Global intangible low-taxed income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,589)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2,731)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Miscellaneous international</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,212</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">831</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Miscellaneous U.S. </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,083</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4)</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total deferred income taxes</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">16,826</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(7,175)</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13,819</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(6,584)</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Valuation allowances</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,638)</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,149)</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total deferred income taxes net of valuation allowances</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">15,188</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(7,175)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">12,670</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(6,584)</span></td></tr></table></div> 372000000 586000000 717000000 686000000 833000000 902000000 3261000000 1252000000 4398000000 3595000000 4444000000 3816000000 371000000 359000000 2298000000 2145000000 1931000000 1492000000 1801000000 1695000000 1589000000 2731000000 1212000000 831000000 1083000000 4000000 16826000000 7175000000 13819000000 6584000000 1638000000 1149000000 15188000000 7175000000 12670000000 6584000000 <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The following table summarizes the activity related to valuation allowances for continuing operations:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.429%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.764%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Beginning of year</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$1,149</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">775</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Provision</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">451</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">355</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Utilization</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(116)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Foreign currency translation</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(46)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">25</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net acquisitions / (dispositions/liquidations)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">84</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">110</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">End of year</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$1,638</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$1,149</span></td></tr></table></div> 1149000000 775000000 451000000 355000000 0 -116000000 -46000000 25000000 84000000 110000000 1638000000 1149000000 <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The following table summarizes the activity related to unrecognized tax benefits for continuing operations:</span></div><div style="margin-bottom:6pt;margin-top:4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.822%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.764%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Beginning of year</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$2,485</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,716</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,210</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Increases related to current year tax positions</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">176</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">239</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">523</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Increases related to prior period tax positions</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">129</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">244</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">143</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Decreases related to prior period tax positions</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(147)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(781)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(148)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Settlements</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(583)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(880)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Lapse of statute of limitations</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(40)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(53)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(11)</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">End of year</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$2,020</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2,485</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">3,716</span></td></tr></table></div> 2485000000 3716000000 3210000000 176000000 239000000 523000000 129000000 244000000 143000000 147000000 781000000 148000000 583000000 880000000 1000000 40000000 53000000 11000000 2020000000 2485000000 3716000000 2000000000.0 200000000 217000000 99000000 136000000 274000000 264000000 Employee related obligations<div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">At the end of fiscal 2024 and fiscal 2023, employee related obligations recorded on the Consolidated Balance Sheets were:</span></div><div style="margin-bottom:6pt;margin-top:7pt;padding-left:18pt;text-indent:-18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.685%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.764%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Pension benefits</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$2,968</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,129</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Postretirement benefits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,920</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,963</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Postemployment benefits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,910</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,527</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Deferred compensation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">49</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">68</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total employee obligations</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7,847</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7,687</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Less current benefits payable</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">592</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">538</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Employee related obligations — non-current</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$7,255</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">7,149</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Prepaid employee related obligations of $6,046 million and $4,992 million for 2024 and 2023, respectively, are included in Other assets on the Consolidated Balance Sheets.</span></div> <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">At the end of fiscal 2024 and fiscal 2023, employee related obligations recorded on the Consolidated Balance Sheets were:</span></div><div style="margin-bottom:6pt;margin-top:7pt;padding-left:18pt;text-indent:-18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.685%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.764%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Pension benefits</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$2,968</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,129</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Postretirement benefits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,920</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,963</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Postemployment benefits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,910</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,527</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Deferred compensation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">49</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">68</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total employee obligations</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7,847</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7,687</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Less current benefits payable</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">592</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">538</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Employee related obligations — non-current</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$7,255</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">7,149</span></td></tr></table></div> 2968000000 3129000000 1920000000 1963000000 2910000000 2527000000 49000000 68000000 7847000000 7687000000 592000000 538000000 7255000000 7149000000 6046000000 4992000000 Pensions and other benefit plans<div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company sponsors various retirement and pension plans, including defined benefit, defined contribution and termination indemnity plans, which cover most employees worldwide. The Company also provides post-retirement benefits, primarily healthcare, to all eligible U.S. retired employees and their dependents.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Many international employees are covered by government-sponsored programs and the cost to the Company is not significant.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">In the U.S., non-union pension benefits for employees hired before January 1, 2015 are primarily based on the employee’s compensation during the last five years before retirement and the number of years of service (the Final Average Pay formula). U.S. pension benefits for employees hired after 2014, are calculated using a different formula based on employee compensation over total years of service (the Retirement Value formula).</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">In January 2021, the Company announced that, effective on January 1, 2026, all eligible U.S. non-union employees, regardless of hire date, will earn benefits under the Retirement Value formula. This amendment does not affect the benefits accrued under the Final Average Pay formula for service before January 1, 2026. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">International subsidiaries have plans under which funds are deposited with trustees, annuities are purchased under group contracts, or reserves are provided.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company does not fund retiree healthcare benefits in advance and has the right to modify these plans in the future.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">In 2024 and 2023 the Company used December 31, 2024 and December 31, 2023, respectively, as the measurement date for all U.S. and international retirement and other benefit plans.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Net periodic benefit costs for the Company’s defined benefit retirement plans and other benefit plans for 2024, 2023 and 2022 include the following components:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.114%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.792%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Retirement Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Other Benefit Plans</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Service cost</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$948</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">893</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,319</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">277</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">264</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">320</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Interest cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,402</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,437</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">908</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">209</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">214</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">104</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Expected return on plan assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2,560)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2,716)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2,756)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(7)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(7)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(8)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amortization of prior service cost </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(184)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(184)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(184)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5)</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Recognized actuarial losses (gains)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">174</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(199)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">650</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">53</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">23</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">122</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Curtailments and settlements</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">93</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net periodic benefit cost (credit)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$(222)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(676)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(62)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">530</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">487</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">533</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The service cost component of net periodic benefit cost is presented in the same line items on the Consolidated Statement of Earnings where other employee compensation costs are reported, including Cost of products sold, Research and development expense, Selling, marketing and administrative expenses, and Net earnings from discontinued operations, net of taxes if related to the separation of Kenvue. All other components of net periodic benefit cost are presented as part of Other (income) expense, net on the Consolidated Statement of Earnings, with the exception of certain amounts for curtailments and settlements, which are reported in Net earnings from discontinued operations, net of taxes if related to the separation of Kenvue (as noted above).</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Unrecognized gains and losses for the U.S. pension plans are amortized over the average remaining future service for each plan. For plans with no active employees, they are amortized over the average life expectancy. The amortization of gains and losses for the other U.S. benefit plans is determined by using a 10% corridor of the greater of the market value of assets or the accumulated postretirement benefit obligation. Total unamortized gains and losses in excess of the corridor are amortized over the average remaining future service.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Prior service costs/benefits for the U.S. pension plans are amortized over the average remaining future service of plan participants at the time of the plan amendment. Prior service cost/benefit for the other U.S. benefit plans is amortized over the average remaining service to full eligibility age of plan participants at the time of the plan amendment.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The following table represents the weighted-average actuarial assumptions:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.114%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.792%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Retirement Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Other Benefit Plans</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Worldwide Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">Net Periodic Benefit Cost</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Service cost discount rate</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #959595;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.39 </span></td><td style="border-top:0.5pt solid #959595;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #959595;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.85 </span></td><td style="border-top:0.5pt solid #959595;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #959595;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2.46 </span></td><td style="border-top:0.5pt solid #959595;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #959595;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5.09 </span></td><td style="border-top:0.5pt solid #959595;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #959595;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5.40 </span></td><td style="border-top:0.5pt solid #959595;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #959595;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2.59 </span></td><td style="border-top:0.5pt solid #959595;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Interest cost discount rate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.95 </span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5.25 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2.80 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5.12 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5.43 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2.64 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Rate of increase in compensation levels</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.70 </span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.71 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.02 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.22 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.22 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.21 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Expected long-term rate of return on plan assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7.25 </span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7.21 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7.25 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Benefit Obligation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Discount rate</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #959595;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.95 </span></td><td style="border-top:0.5pt solid #959595;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #959595;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.58 </span></td><td style="border-top:0.5pt solid #959595;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #959595;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5.01 </span></td><td style="border-top:0.5pt solid #959595;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #959595;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5.54 </span></td><td style="border-top:0.5pt solid #959595;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #959595;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5.11 </span></td><td style="border-top:0.5pt solid #959595;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #959595;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5.42 </span></td><td style="border-top:0.5pt solid #959595;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Rate of increase in compensation levels</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.70 </span></td><td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.69 </span></td><td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.00 </span></td><td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.22 </span></td><td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.22 </span></td><td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.21 </span></td><td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company’s discount rates are determined by considering current yield curves representing high quality, long-term fixed income instruments. The resulting discount rates are consistent with the duration of plan liabilities. The Company's methodology in determining service and interest cost uses duration specific spot rates along that yield curve to the plans' liability cash flows.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The expected rates of return on plan asset assumptions represent the Company's assessment of long-term returns on diversified investment portfolios globally. The assessment is determined using projections from external financial sources, long-term historical averages, actual returns by asset class and the various asset class allocations by market. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The following table displays the assumed healthcare cost trend rates, for all individuals:</span></div><div style="margin-bottom:3pt;margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.685%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.764%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Healthcare Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Healthcare cost trend rate assumed for next year</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #eb1700;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9.33 </span></td><td style="border-top:1pt solid #eb1700;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #eb1700;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13.90 </span></td><td style="border-top:1pt solid #eb1700;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Rate to which the cost trend rate is assumed to decline (ultimate trend)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.02 </span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.00 </span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Year the rate reaches the ultimate trend rate</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2048 </span></td><td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2048 </span></td><td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The following table sets forth information related to the benefit obligation and the fair value of plan assets at fiscal year-end 2024 and 2023 for the Company’s defined benefit retirement plans and other post-retirement plans:</span></div><div style="margin-bottom:6pt;margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.185%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.084%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.084%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.084%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.087%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Retirement Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Other Benefit Plans</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Change in Benefit Obligation</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Projected benefit obligation — beginning of year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$31,744</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">29,390</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,108</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,192</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Service cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">948</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">893</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">277</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">264</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Interest cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,402</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,437</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">209</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">214</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Plan participant contributions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">75</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">73</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amendments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(6)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Actuarial (gains) losses</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,245)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,068</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">398</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">469</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Divestitures &amp; acquisitions</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(352)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Curtailments, settlements &amp; restructuring</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(121)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(238)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(332)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Benefits paid from plan</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,801)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2,122)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(556)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(702)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Effect of exchange rates</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(685)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">601</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(11)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Projected benefit obligation — end of year</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$30,317</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">31,744</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">4,425</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">4,108</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.185%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.084%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.084%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.084%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.087%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Change in Plan Assets</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Plan assets at fair value — beginning of year</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$33,607</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">31,496</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">86</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">78</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Actual return (loss) on plan assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,113</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,951</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">15</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">16</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Company contributions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">229</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">268</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">548</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">694</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Plan participant contributions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">75</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">73</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Settlements</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(114)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(176)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Divestitures &amp; acquisitions</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(509)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Benefits paid from plan assets</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,801)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2,122)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(556)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(702)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Effect of exchange rates</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(714)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">626</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Plan assets at fair value — end of year</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$33,395</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">33,607</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">93</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">86</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Funded status — end of year</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$3,078</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">1,863</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(4,332)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(4,022)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Amounts Recognized in the Company’s Balance Sheet consist of the following:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Non-current assets</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$6,046</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,992</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Current liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(136)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(119)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(453)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(416)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Non-current liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2,832)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3,010)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3,879)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3,606)</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total recognized in the consolidated balance sheet — end of year</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$3,078</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">1,863</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(4,332)</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(4,022)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Amounts Recognized in Accumulated Other Comprehensive Income consist of the following:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net actuarial loss</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$3,903</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,962</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">691</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">354</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Prior service cost (credit)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,051)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,236)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(6)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Unrecognized net transition obligation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total before tax effects</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$2,852</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">3,726</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">687</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">348</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Accumulated Benefit Obligations — end of year</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$28,883</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">30,139</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:9.29pt">The actuarial (gains)/losses for retirement plans in 2024 and 2023 were primarily driven by changes in the discount rates. </span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.09pt">Driven by the Kenvue separation.</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8pt">The fiscal years 2024 and 2023 includes approximately $400 million and $800 million, respectively, transferred to a group annuity contract issued by a third-party insurer for the U.S. Salaried Pension Plan.</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Retirement Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Other Benefit Plans</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Amounts Recognized in Net Periodic Benefit Cost and Other Comprehensive Income</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net periodic benefit cost (credit)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$(222)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(676)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">530</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">487</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net actuarial (gain) loss</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(807)</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">711</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">389</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">136</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amortization of net actuarial loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(172)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">199</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(53)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(22)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Prior service cost (credit)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amortization of prior service (cost) credit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">184</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">185</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Effect of exchange rates</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(79)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">103</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total loss/(income) recognized in other comprehensive income, before tax</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$(874)</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">1,195</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">339</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">116</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total recognized in net periodic benefit cost and other comprehensive income</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$(1,096)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">519</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">869</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">603</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:3pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company plans to continue to fund its U.S. Qualified Plans to comply with the Pension Protection Act of 2006. International Plans are funded in accordance with local regulations. Additional discretionary contributions are made when deemed appropriate to meet the long-term obligations of the plans. For certain plans, funding is not a common practice, as funding provides no economic benefit. Consequently, the Company has several pension plans that are not funded. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">In 2024, the Company contributed $122 million and $107 million to its U.S. and international pension plans, respectively.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The following table displays the funded status of the Company's U.S. Qualified &amp; Non-Qualified pension plans and international funded and unfunded pension plans at December 31, 2024 and December 31, 2023, respectively:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.685%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.679%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.679%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.679%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.679%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.679%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.679%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.679%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.688%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-bottom:1pt solid #eb1700;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">U.S. Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-bottom:1pt solid #eb1700;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">International Plans</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Qualified Plans</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Non-Qualified Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Funded Plans</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unfunded Plans</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Plan Assets</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$22,250</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">22,298</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11,145</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11,309</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Projected Benefit Obligation</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">18,146</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">19,152</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,990</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,037</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10,069</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10,431</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">112</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">124</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accumulated Benefit Obligation</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">17,726</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">18,557</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,949</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,982</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9,115</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9,498</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">93</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">102</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Over (Under) Funded Status</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Projected Benefit Obligation</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$4,104</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,146</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,990)</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2,037)</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,076</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">878</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(112)</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(124)</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accumulated Benefit Obligation</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,524</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,741</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,949)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,982)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,030</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,811</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(93)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(102)</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Plans with accumulated benefit obligations in excess of plan assets have an accumulated benefit obligation, projected benefit obligation and plan assets of $5.8 billion, $6.1 billion and $3.2 billion, respectively, at the end of 2024, and $5.8 billion, $6.1 billion and $3.1 billion, respectively, at the end of 2023.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The following table displays the projected future benefit payments from the Company’s retirement and other benefit plans:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.286%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.620%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2027</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2028</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2029</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2030-2034</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Projected future benefit payments</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Retirement plans</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$1,480</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,503</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,604</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,702</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,797</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10,401</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other benefit plans </span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$464</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">478</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">432</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">445</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">462</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,537</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The following table displays the projected future minimum contributions to the unfunded retirement plans. These amounts do not include any discretionary contributions that the Company may elect to make in the future.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.286%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.620%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2027</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2028</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2029</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2030-2034</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Projected future contributions</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$133</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">135</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">140</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">145</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">150</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">815</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Each pension plan is overseen by a local committee or board that is responsible for the overall administration and investment of the pension plans. In determining investment policies, strategies and goals, each committee or board considers factors including, local pension rules and regulations; local tax regulations; availability of investment vehicles (separate accounts, commingled accounts, insurance funds, etc.); funded status of the plans; ratio of actives to retirees; duration of liabilities; and other relevant factors including: diversification, liquidity of local markets and liquidity of base currency. A majority of the Company’s pension funds are open to new entrants and are expected to be on-going plans. Permitted investments are primarily liquid and/or listed, with little reliance on illiquid and non-traditional investments such as hedge funds.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company’s retirement plan asset allocation at the end of 2024 and 2023 and target allocations for 2025 are as follows:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.078%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.764%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Percent of<br/>Plan Assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Target<br/>Allocation</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Worldwide Retirement Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Equity securities</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #eb1700;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">55 </span></td><td style="border-top:1pt solid #eb1700;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #eb1700;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">58 </span></td><td style="border-top:1pt solid #eb1700;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #eb1700;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">54 </span></td><td style="border-top:1pt solid #eb1700;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Debt securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">45 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">42 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">46 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total plan assets</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">100</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></td><td style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">%</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">100</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></td><td style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">%</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">100</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></td><td style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">%</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Determination of fair value of plan assets</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Plan has an established and well-documented process for determining fair values. Fair value is based upon quoted market prices, where available. If listed prices or quotes are not available, fair value is based upon models that primarily use, as inputs, market-based or independently sourced market parameters, including yield curves, interest rates, volatilities, equity or debt prices, foreign exchange rates and credit curves.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">While the Plan believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different estimate of fair value at the reporting date.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Valuation hierarchy</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The authoritative literature establishes a three-level hierarchy to prioritize the inputs used in measuring fair value. The levels within the hierarchy are described in the table below with Level 1 having the highest priority and Level 3 having the lowest.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Net Asset Value (NAV) is based on the value of the underlying assets owned by the fund, minus its liabilities, and then divided by the number of shares outstanding. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">A financial instrument’s categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Following is a description of the valuation methodologies used for the investments measured at fair value.</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:10.8pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">•</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:130%;padding-left:7.83pt">Short-term investment funds</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"> — Cash and quoted short-term instruments are valued at the closing price or the amount held on deposit by the custodian bank. Other investments are through investment vehicles valued using the NAV provided by the administrator of the fund. The NAV is a quoted price in a market that is not active and classified as Level 2.</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:10.8pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">•</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:130%;padding-left:7.83pt">Government and agency securities</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"> — A limited number of these investments are valued at the closing price reported on the major market on which the individual securities are traded. Where quoted prices are available in an active market, the investments are classified within Level 1 of the valuation hierarchy. If quoted market prices are not available for the specific security, then fair values are estimated by using pricing models, quoted prices of securities with similar characteristics or discounted cash flows. When quoted market prices for a security are not available in an active market, they are classified as Level 2.</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:10.8pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">•</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:130%;padding-left:7.83pt">Debt instruments</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"> — A limited number of these investments are valued at the closing price reported on the major market on which the individual securities are traded. Where quoted prices are available in an active market, the investments are classified as Level 1. If quoted market prices are not available for the specific security, then fair values are estimated by using pricing models, quoted prices of securities with similar characteristics or discounted cash flows and are classified as Level 2. Level 3 debt instruments are priced based on unobservable inputs.</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:10.8pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">•</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:130%;padding-left:7.83pt">Equity securities</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"> — Equity securities are valued at the closing price reported on the major market on which the individual securities are traded. Substantially all equity securities are classified within Level 1 of the valuation hierarchy.</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:10.8pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">•</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:130%;padding-left:7.83pt">Commingled funds</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"> — These investment vehicles are valued using the NAV provided by the fund administrator. Assets in the Level 2 category have a quoted market price.</span></div><div style="margin-bottom:6pt;margin-top:4pt;padding-left:10.8pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">•</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:130%;padding-left:7.83pt">Other assets</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"> — Other assets are represented primarily by limited partnerships. These investment vehicles are valued using the NAV provided by the fund administrator. Other assets that are exchange listed and actively traded are classified as Level 1, while inactively traded assets are classified as Level 2. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The following table sets forth the Retirement Plans' investments measured at fair value as of December 31, 2024 and December 31, 2023:</span></div><div style="margin-bottom:4pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.840%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.638%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.042%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.042%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.042%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.042%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.042%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.042%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.042%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.042%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.054%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Quoted Prices<br/>in Active<br/>Markets for<br/>Identical Assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Significant<br/>Other<br/>Observable<br/>Inputs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Significant</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unobservable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Inputs</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Investments<br/>Measured at Net<br/>Asset Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Level 1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Level 2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Level 3)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total Assets</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Short-term investment funds</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #eb1700;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$— </span></td><td style="border-top:1pt solid #eb1700;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">12</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">511</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">829</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">511</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">841</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Government and agency securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7,885</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,985</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7,885</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,985</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Debt instruments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,321</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,899</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,321</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,899</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Equity securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7,144</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7,764</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7,144</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7,764</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Commingled funds</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,004</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,967</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">37</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">43</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,190</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,672</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11,231</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11,682</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">88</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">49</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">128</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">92</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,087</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,295</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,303</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,436</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Investments at fair value</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$7,144</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></td><td style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">7,776</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">15,809</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">15,729</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">165</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">135</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">10,277</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">9,967</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">33,395</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">33,607</span></td></tr></table></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:9.29pt">The activity for the Level 3 assets is not significant for all years presented.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company's Other Benefit Plans are unfunded except for U.S. commingled funds (Level 2) of $93 million and $86 million at December 31, 2024 and December 31, 2023, respectively. </span></div>The fair value of Johnson &amp; Johnson Common Stock directly held in plan assets was $13 million at December 31, 2024 and $14 million at December 31, 2023. P5Y <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Net periodic benefit costs for the Company’s defined benefit retirement plans and other benefit plans for 2024, 2023 and 2022 include the following components:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.114%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.792%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Retirement Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Other Benefit Plans</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Service cost</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$948</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">893</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,319</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">277</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">264</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">320</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Interest cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,402</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,437</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">908</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">209</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">214</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">104</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Expected return on plan assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2,560)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2,716)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2,756)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(7)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(7)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(8)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amortization of prior service cost </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(184)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(184)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(184)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5)</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Recognized actuarial losses (gains)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">174</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(199)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">650</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">53</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">23</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">122</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Curtailments and settlements</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">93</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net periodic benefit cost (credit)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$(222)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(676)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(62)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">530</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">487</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">533</span></td></tr></table></div> 948000000 893000000 1319000000 277000000 264000000 320000000 1402000000 1437000000 908000000 209000000 214000000 104000000 2560000000 2716000000 2756000000 7000000 7000000 8000000 -184000000 -184000000 -184000000 -2000000 -2000000 -5000000 -174000000 199000000 -650000000 -53000000 -23000000 -122000000 2000000 -93000000 -1000000 0 5000000 0 -222000000 -676000000 -62000000 530000000 487000000 533000000 0.10 <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The following table represents the weighted-average actuarial assumptions:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.114%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.792%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Retirement Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Other Benefit Plans</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Worldwide Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">Net Periodic Benefit Cost</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Service cost discount rate</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #959595;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.39 </span></td><td style="border-top:0.5pt solid #959595;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #959595;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.85 </span></td><td style="border-top:0.5pt solid #959595;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #959595;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2.46 </span></td><td style="border-top:0.5pt solid #959595;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #959595;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5.09 </span></td><td style="border-top:0.5pt solid #959595;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #959595;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5.40 </span></td><td style="border-top:0.5pt solid #959595;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #959595;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2.59 </span></td><td style="border-top:0.5pt solid #959595;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Interest cost discount rate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.95 </span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5.25 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2.80 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5.12 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5.43 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2.64 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Rate of increase in compensation levels</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.70 </span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.71 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.02 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.22 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.22 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.21 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Expected long-term rate of return on plan assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7.25 </span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7.21 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7.25 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Benefit Obligation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Discount rate</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #959595;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.95 </span></td><td style="border-top:0.5pt solid #959595;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #959595;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.58 </span></td><td style="border-top:0.5pt solid #959595;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #959595;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5.01 </span></td><td style="border-top:0.5pt solid #959595;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #959595;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5.54 </span></td><td style="border-top:0.5pt solid #959595;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #959595;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5.11 </span></td><td style="border-top:0.5pt solid #959595;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #959595;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5.42 </span></td><td style="border-top:0.5pt solid #959595;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Rate of increase in compensation levels</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.70 </span></td><td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.69 </span></td><td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.00 </span></td><td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.22 </span></td><td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.22 </span></td><td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.21 </span></td><td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 0.0439 0.0485 0.0246 0.0509 0.0540 0.0259 0.0495 0.0525 0.0280 0.0512 0.0543 0.0264 0.0370 0.0371 0.0402 0.0422 0.0422 0.0421 0.0725 0.0721 0.0725 0.0495 0.0458 0.0501 0.0554 0.0511 0.0542 0.0370 0.0369 0.0400 0.0422 0.0422 0.0421 <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The following table displays the assumed healthcare cost trend rates, for all individuals:</span></div><div style="margin-bottom:3pt;margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.685%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.764%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Healthcare Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Healthcare cost trend rate assumed for next year</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #eb1700;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9.33 </span></td><td style="border-top:1pt solid #eb1700;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #eb1700;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13.90 </span></td><td style="border-top:1pt solid #eb1700;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Rate to which the cost trend rate is assumed to decline (ultimate trend)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.02 </span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.00 </span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Year the rate reaches the ultimate trend rate</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2048 </span></td><td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2048 </span></td><td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 0.0933 0.1390 0.0402 0.0400 2048 2048 <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The following table sets forth information related to the benefit obligation and the fair value of plan assets at fiscal year-end 2024 and 2023 for the Company’s defined benefit retirement plans and other post-retirement plans:</span></div><div style="margin-bottom:6pt;margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.185%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.084%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.084%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.084%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.087%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Retirement Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Other Benefit Plans</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Change in Benefit Obligation</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Projected benefit obligation — beginning of year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$31,744</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">29,390</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,108</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,192</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Service cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">948</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">893</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">277</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">264</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Interest cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,402</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,437</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">209</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">214</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Plan participant contributions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">75</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">73</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amendments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(6)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Actuarial (gains) losses</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,245)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,068</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">398</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">469</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Divestitures &amp; acquisitions</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(352)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Curtailments, settlements &amp; restructuring</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(121)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(238)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(332)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Benefits paid from plan</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,801)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2,122)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(556)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(702)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Effect of exchange rates</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(685)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">601</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(11)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Projected benefit obligation — end of year</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$30,317</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">31,744</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">4,425</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">4,108</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.185%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.084%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.084%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.084%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.087%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Change in Plan Assets</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Plan assets at fair value — beginning of year</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$33,607</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">31,496</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">86</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">78</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Actual return (loss) on plan assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,113</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,951</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">15</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">16</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Company contributions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">229</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">268</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">548</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">694</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Plan participant contributions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">75</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">73</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Settlements</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(114)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(176)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Divestitures &amp; acquisitions</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(509)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Benefits paid from plan assets</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,801)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2,122)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(556)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(702)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Effect of exchange rates</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(714)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">626</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Plan assets at fair value — end of year</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$33,395</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">33,607</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">93</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">86</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Funded status — end of year</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$3,078</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">1,863</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(4,332)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(4,022)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Amounts Recognized in the Company’s Balance Sheet consist of the following:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Non-current assets</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$6,046</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,992</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Current liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(136)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(119)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(453)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(416)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Non-current liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2,832)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3,010)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3,879)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3,606)</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total recognized in the consolidated balance sheet — end of year</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$3,078</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">1,863</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(4,332)</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(4,022)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Amounts Recognized in Accumulated Other Comprehensive Income consist of the following:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net actuarial loss</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$3,903</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,962</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">691</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">354</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Prior service cost (credit)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,051)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,236)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(6)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Unrecognized net transition obligation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total before tax effects</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$2,852</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">3,726</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">687</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">348</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Accumulated Benefit Obligations — end of year</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$28,883</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">30,139</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:9.29pt">The actuarial (gains)/losses for retirement plans in 2024 and 2023 were primarily driven by changes in the discount rates. </span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.09pt">Driven by the Kenvue separation.</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8pt">The fiscal years 2024 and 2023 includes approximately $400 million and $800 million, respectively, transferred to a group annuity contract issued by a third-party insurer for the U.S. Salaried Pension Plan.</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Retirement Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Other Benefit Plans</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Amounts Recognized in Net Periodic Benefit Cost and Other Comprehensive Income</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net periodic benefit cost (credit)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$(222)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(676)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">530</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">487</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net actuarial (gain) loss</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(807)</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">711</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">389</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">136</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amortization of net actuarial loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(172)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">199</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(53)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(22)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Prior service cost (credit)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amortization of prior service (cost) credit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">184</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">185</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Effect of exchange rates</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(79)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">103</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total loss/(income) recognized in other comprehensive income, before tax</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$(874)</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">1,195</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">339</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">116</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total recognized in net periodic benefit cost and other comprehensive income</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$(1,096)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">519</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">869</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">603</span></td></tr></table></div> 31744000000 29390000000 4108000000 4192000000 948000000 893000000 277000000 264000000 1402000000 1437000000 209000000 214000000 75000000 73000000 0 0 0 -6000000 0 0 1245000000 -2068000000 -398000000 -469000000 0 -352000000 0 1000000 121000000 238000000 0 332000000 1801000000 2122000000 556000000 702000000 685000000 -601000000 11000000 -2000000 30317000000 31744000000 4425000000 4108000000 33607000000 31496000000 86000000 78000000 2113000000 3951000000 15000000 16000000 229000000 268000000 548000000 694000000 75000000 73000000 0 0 114000000 176000000 0 0 0 -509000000 0 0 1801000000 2122000000 556000000 702000000 -714000000 626000000 0 0 33395000000 33607000000 93000000 86000000 3078000000 1863000000 -4332000000 -4022000000 6046000000 4992000000 0 0 136000000 119000000 453000000 416000000 2832000000 3010000000 3879000000 3606000000 3078000000 1863000000 -4332000000 -4022000000 -3903000000 -4962000000 -691000000 -354000000 -1051000000 -1236000000 -4000000 -6000000 0 0 0 2852000000 3726000000 687000000 348000000 28883000000 30139000000 400000000 800000000 -222000000 -676000000 530000000 487000000 807000000 -711000000 -389000000 -136000000 -172000000 199000000 -53000000 -22000000 0 -2000000 0 0 -184000000 -185000000 -2000000 -2000000 -79000000 103000000 1000000 0 -874000000 1195000000 339000000 116000000 -1096000000 519000000 869000000 603000000 122000000 107000000 <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The following table displays the funded status of the Company's U.S. Qualified &amp; Non-Qualified pension plans and international funded and unfunded pension plans at December 31, 2024 and December 31, 2023, respectively:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.685%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.679%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.679%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.679%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.679%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.679%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.679%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.679%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.688%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-bottom:1pt solid #eb1700;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">U.S. Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-bottom:1pt solid #eb1700;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">International Plans</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Qualified Plans</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Non-Qualified Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Funded Plans</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unfunded Plans</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Plan Assets</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$22,250</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">22,298</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11,145</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11,309</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Projected Benefit Obligation</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">18,146</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">19,152</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,990</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,037</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10,069</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10,431</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">112</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">124</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accumulated Benefit Obligation</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">17,726</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">18,557</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,949</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,982</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9,115</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9,498</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">93</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">102</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Over (Under) Funded Status</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Projected Benefit Obligation</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$4,104</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,146</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,990)</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2,037)</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,076</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">878</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(112)</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(124)</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accumulated Benefit Obligation</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,524</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,741</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,949)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,982)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,030</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,811</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(93)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(102)</span></td></tr></table></div> 22250000000 22298000000 0 0 11145000000 11309000000 0 0 18146000000 19152000000 1990000000 2037000000 10069000000 10431000000 112000000 124000000 17726000000 18557000000 1949000000 1982000000 9115000000 9498000000 93000000 102000000 4104000000 3146000000 -1990000000 -2037000000 1076000000 878000000 -112000000 -124000000 4524000000 3741000000 -1949000000 -1982000000 2030000000 1811000000 -93000000 -102000000 5800000000 6100000000 3200000000 5800000000 6100000000 3100000000 <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The following table displays the projected future benefit payments from the Company’s retirement and other benefit plans:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.286%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.620%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2027</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2028</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2029</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2030-2034</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Projected future benefit payments</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Retirement plans</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$1,480</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,503</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,604</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,702</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,797</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10,401</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other benefit plans </span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$464</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">478</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">432</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">445</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">462</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,537</span></td></tr></table></div> 1480000000 1503000000 1604000000 1702000000 1797000000 10401000000 464000000 478000000 432000000 445000000 462000000 2537000000 <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The following table displays the projected future minimum contributions to the unfunded retirement plans. These amounts do not include any discretionary contributions that the Company may elect to make in the future.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.286%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.620%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2027</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2028</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2029</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2030-2034</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Projected future contributions</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$133</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">135</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">140</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">145</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">150</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">815</span></td></tr></table></div> 133000000 135000000 140000000 145000000 150000000 815000000 <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company’s retirement plan asset allocation at the end of 2024 and 2023 and target allocations for 2025 are as follows:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.078%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.764%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Percent of<br/>Plan Assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Target<br/>Allocation</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Worldwide Retirement Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Equity securities</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #eb1700;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">55 </span></td><td style="border-top:1pt solid #eb1700;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #eb1700;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">58 </span></td><td style="border-top:1pt solid #eb1700;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #eb1700;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">54 </span></td><td style="border-top:1pt solid #eb1700;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Debt securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">45 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">42 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">46 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total plan assets</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">100</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></td><td style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">%</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">100</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></td><td style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">%</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">100</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></td><td style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">%</span></td></tr></table></div> 0.55 0.58 0.54 0.45 0.42 0.46 1 1 1 <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The following table sets forth the Retirement Plans' investments measured at fair value as of December 31, 2024 and December 31, 2023:</span></div><div style="margin-bottom:4pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.840%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.638%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.042%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.042%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.042%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.042%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.042%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.042%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.042%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.042%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.054%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Quoted Prices<br/>in Active<br/>Markets for<br/>Identical Assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Significant<br/>Other<br/>Observable<br/>Inputs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Significant</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unobservable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Inputs</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Investments<br/>Measured at Net<br/>Asset Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Level 1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Level 2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Level 3)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total Assets</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Short-term investment funds</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #eb1700;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$— </span></td><td style="border-top:1pt solid #eb1700;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">12</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">511</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">829</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">511</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">841</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Government and agency securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7,885</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,985</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7,885</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,985</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Debt instruments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,321</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,899</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,321</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,899</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Equity securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7,144</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7,764</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7,144</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7,764</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Commingled funds</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,004</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,967</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">37</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">43</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,190</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,672</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11,231</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11,682</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">88</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">49</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">128</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">92</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,087</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,295</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,303</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,436</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Investments at fair value</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$7,144</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></td><td style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">7,776</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">15,809</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">15,729</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">165</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">135</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">10,277</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">9,967</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">33,395</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">33,607</span></td></tr></table></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:9.29pt">The activity for the Level 3 assets is not significant for all years presented.</span></div> 0 12000000 511000000 829000000 0 0 511000000 841000000 0 0 7885000000 5985000000 0 0 7885000000 5985000000 0 0 2321000000 3899000000 0 0 2321000000 3899000000 7144000000 7764000000 0 0 0 0 7144000000 7764000000 0 0 5004000000 4967000000 37000000 43000000 6190000000 6672000000 11231000000 11682000000 0 0 88000000 49000000 128000000 92000000 4087000000 3295000000 4303000000 3436000000 7144000000 7776000000 15809000000 15729000000 165000000 135000000 10277000000 9967000000 33395000000 33607000000 93000000 86000000 13000000 14000000 Savings plan<div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company has voluntary 401(k) savings plans designed to enhance the existing retirement programs covering eligible employees. The Company matches a percentage of each employee’s contributions consistent with the provisions of the plan for which the employee is eligible. Total Company matching contributions to the plans were $282 million, $263 million and $257 million in fiscal years 2024, 2023 and 2022, respectively.</span></div> 282000000 263000000 257000000 Capital and treasury stock<div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Changes in treasury stock were:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.685%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.764%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Treasury Stock</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Amounts in Millions Except Treasury Stock Shares in Thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amount</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Balance at January 2, 2022</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">490,878</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$39,099</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Employee compensation and stock option plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(20,007)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3,440)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Repurchase of common stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">35,375</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,035</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Balance at January 1, 2023</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">506,246</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">41,694</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Employee compensation and stock option plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(15,521)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2,529)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Repurchase of common stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">31,085</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,079</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Kenvue share exchange (Note 21)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">190,955 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">31,418</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Balance at December 31, 2023</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">712,765</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">75,662</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Employee compensation and stock option plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(15,027)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2,389)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Repurchase of common stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">15,183</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,407</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Balance at December 29, 2024</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">712,921</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$75,680</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Aggregate shares of common stock issued were approximately 3,119,843,000 shares at the end of fiscal years 2024, 2023 and 2022.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Cash dividends paid were $4.91 per share in fiscal year 2024, compared with dividends of $4.70 per share in fiscal year 2023, and $4.45 per share in fiscal year 2022. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">On January 2, 2025, the Board of Directors declared a regular cash dividend of $1.24 per share, payable on March 4, 2025 to shareholders of record as of February 18, 2025.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">On September 14, 2022, the Company announced that its Board of Directors approved a share repurchase program, authorizing the Company to purchase up to $5.0 billion of the Company's shares of common stock. The repurchase program was completed during the fiscal first quarter of 2023.</span></div> <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Changes in treasury stock were:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.685%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.764%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Treasury Stock</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Amounts in Millions Except Treasury Stock Shares in Thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amount</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Balance at January 2, 2022</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">490,878</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$39,099</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Employee compensation and stock option plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(20,007)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3,440)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Repurchase of common stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">35,375</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,035</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Balance at January 1, 2023</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">506,246</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">41,694</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Employee compensation and stock option plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(15,521)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2,529)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Repurchase of common stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">31,085</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,079</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Kenvue share exchange (Note 21)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">190,955 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">31,418</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Balance at December 31, 2023</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">712,765</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">75,662</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Employee compensation and stock option plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(15,027)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2,389)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Repurchase of common stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">15,183</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,407</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Balance at December 29, 2024</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">712,921</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$75,680</span></td></tr></table></div> 490878000 39099000000 20007000 3440000000 35375000 6035000000 506246000 41694000000 15521000 2529000000 31085000 5079000000 190955000 31418000000 712765000 75662000000 15027000 2389000000 15183000 2407000000 712921000 75680000000 3119843000 3119843000 3119843000 4.91 4.70 4.45 1.24 5000000000.0 Accumulated other comprehensive income (loss)<div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Components of other comprehensive income (loss) consist of the following:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.334%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.436%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.402%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Foreign<br/>Currency<br/>Translation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gain/<br/>(Loss) On<br/>Securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Employee<br/>Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gain/<br/>(Loss) On<br/>Derivatives<br/>&amp; Hedges</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total<br/>Accumulated<br/>Other<br/>Comprehensive<br/>Income (Loss)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">January 2, 2022</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$(10,017)</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3)</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2,702)</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(336)</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(13,058)</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net 2022 changes</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,796)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(24)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,805</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">106</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">91</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">January 1, 2023</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(11,813)</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(27)</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(897)</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(230)</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(12,967)</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net 2023 changes</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3,221)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">26</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,399)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(147)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4,741)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Kenvue Separation/IPO</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,885</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">296</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,181</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">December 31, 2023</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(10,149)</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2,000)</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(377)</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(12,527)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net 2024 changes</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,708</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">449</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,373)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">786</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">December 29, 2024</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$(8,441)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,551)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,750)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(11,741)</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Amounts in accumulated other comprehensive income are presented net of the related tax impact. Foreign currency translation is not adjusted for income taxes where it relates to permanent investments in international subsidiaries. For additional details on comprehensive income see the Consolidated Statements of Comprehensive Income. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Details on reclassifications out of Accumulated Other Comprehensive Income:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Gain/(Loss) On Securities - reclassifications released to Other (income) expense, net.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Employee Benefit Plans - reclassifications are included in net periodic benefit cost. See Note 10 for additional details.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Gain/(Loss) On Derivatives &amp; Hedges - reclassifications to earnings are recorded in the same account as the hedged transaction. See Note 6 for additional details.</span></div>*    Includes impact of curtailments and settlements in connection with separation from Kenvue. <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Components of other comprehensive income (loss) consist of the following:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.334%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.436%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.402%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Foreign<br/>Currency<br/>Translation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gain/<br/>(Loss) On<br/>Securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Employee<br/>Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gain/<br/>(Loss) On<br/>Derivatives<br/>&amp; Hedges</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total<br/>Accumulated<br/>Other<br/>Comprehensive<br/>Income (Loss)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">January 2, 2022</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$(10,017)</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3)</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2,702)</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(336)</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(13,058)</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net 2022 changes</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,796)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(24)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,805</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">106</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">91</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">January 1, 2023</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(11,813)</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(27)</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(897)</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(230)</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(12,967)</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net 2023 changes</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3,221)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">26</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,399)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(147)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4,741)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Kenvue Separation/IPO</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,885</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">296</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,181</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">December 31, 2023</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(10,149)</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2,000)</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(377)</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(12,527)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net 2024 changes</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,708</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">449</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,373)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">786</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">December 29, 2024</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$(8,441)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,551)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,750)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(11,741)</span></td></tr></table></div> -10017000000 -3000000 -2702000000 -336000000 -13058000000 -1796000000 -24000000 1805000000 106000000 91000000 -11813000000 -27000000 -897000000 -230000000 -12967000000 -3221000000 26000000 -1399000000 -147000000 -4741000000 4885000000 296000000 5181000000 -10149000000 -1000000 -2000000000 -377000000 -12527000000 1708000000 2000000 449000000 -1373000000 786000000 -8441000000 1000000 -1551000000 -1750000000 -11741000000 International currency translation<div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">For translation of its subsidiaries operating in non-U.S. Dollar currencies, the Company has determined that the local currencies of its international subsidiaries are the functional currencies except those in highly inflationary economies, which are defined as those which have had compound cumulative rates of inflation of 100% or more during the past three years, or where a substantial portion of its cash flows are not in the local currency. For the majority of the Company's subsidiaries the local currency is the functional currency. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">In consolidating international subsidiaries, balance sheet currency effects are recorded as a component of accumulated other comprehensive income. The other current and non-current assets line within the Statement of Cash flows includes the impact of foreign currency translation. This equity account includes the results of translating certain balance sheet assets and liabilities at current exchange rates and some accounts at historical rates, except for those located in highly inflationary economies (Argentina, Turkey and Venezuela). Beginning in the fiscal fourth quarter of 2024, the Company also accounted for operations in Egypt as highly inflationary. The translation of balance sheet accounts for highly inflationary economies are reflected in the operating results.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">A rollforward of the changes during fiscal years 2024, 2023 and 2022 for foreign currency translation adjustments is included in Note 13. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Net currency transaction gains and losses included in Other (income) expense were losses of $214 million, $366 million and $286 million in fiscal years 2024, 2023 and 2022, respectively.</span></div> -214000000 -366000000 -286000000 Earnings per share<div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The following is a reconciliation of basic net earnings per share to diluted net earnings per share for the fiscal years ended December 29, 2024, December 31, 2023 and January 1, 2023:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.096%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.426%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(In Millions Except Per Share Amounts)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Basic net earnings per share from continuing operations</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #eb1700;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$5.84 </span></td><td style="border-top:1pt solid #eb1700;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5.26</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6.23</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Basic net earnings per share from discontinued operations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8.62</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.60</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total net earnings per share - basic</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5.84</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13.88</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6.83</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Average shares outstanding — basic</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,407.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,533.5</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,625.2</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Potential shares exercisable under stock option plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">77.7</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">94.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">140.1</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Less: shares repurchased under treasury stock method</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(55.6)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(67.2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(101.4)</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Adjusted average shares outstanding — diluted</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,429.4</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,560.4</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,663.9</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Diluted net earnings per share from continuing operations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5.79 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5.20</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6.14</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Diluted net earnings per share from discontinuing operations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8.52</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.59</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total net earnings per share - diluted</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #959595;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$5.79 </span></td><td style="border-top:0.5pt solid #959595;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13.72</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6.73</span></td></tr><tr style="height:17pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Shares in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The diluted net earnings per share calculation excluded the following number of shares related to stock options, as the exercise price of these options was greater than the average market value of the Company’s stock. </span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #eb1700;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">54.1 </span></td><td style="border-top:1pt solid #eb1700;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #eb1700;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">43.0 </span></td><td style="border-top:1pt solid #eb1700;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.0</span></td></tr></table></div> <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The following is a reconciliation of basic net earnings per share to diluted net earnings per share for the fiscal years ended December 29, 2024, December 31, 2023 and January 1, 2023:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.096%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.426%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(In Millions Except Per Share Amounts)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Basic net earnings per share from continuing operations</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #eb1700;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$5.84 </span></td><td style="border-top:1pt solid #eb1700;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5.26</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6.23</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Basic net earnings per share from discontinued operations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8.62</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.60</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total net earnings per share - basic</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5.84</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13.88</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6.83</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Average shares outstanding — basic</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,407.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,533.5</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,625.2</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Potential shares exercisable under stock option plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">77.7</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">94.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">140.1</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Less: shares repurchased under treasury stock method</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(55.6)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(67.2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(101.4)</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Adjusted average shares outstanding — diluted</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,429.4</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,560.4</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,663.9</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Diluted net earnings per share from continuing operations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5.79 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5.20</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6.14</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Diluted net earnings per share from discontinuing operations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8.52</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.59</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total net earnings per share - diluted</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #959595;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$5.79 </span></td><td style="border-top:0.5pt solid #959595;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13.72</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6.73</span></td></tr><tr style="height:17pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Shares in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The diluted net earnings per share calculation excluded the following number of shares related to stock options, as the exercise price of these options was greater than the average market value of the Company’s stock. </span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #eb1700;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">54.1 </span></td><td style="border-top:1pt solid #eb1700;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #eb1700;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">43.0 </span></td><td style="border-top:1pt solid #eb1700;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.0</span></td></tr></table></div> 5.84 5.26 6.23 0 8.62 0.60 5.84 13.88 6.83 2407300000 2533500000 2625200000 77700000 94100000 140100000 55600000 67200000 101400000 2429400000 2560400000 2663900000 5.79 5.20 6.14 0 8.52 0.59 5.79 13.72 6.73 54.1 43.0 0.0 Common stock, stock option plans and stock compensation agreements<div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">At December 29, 2024, the Company had one active stock-based compensation plan, the 2022 Long-Term Incentive Plan. The shares outstanding are for contracts under the Company's 2012 Long-Term Incentive Plan and 2022 Long-Term Incentive Plan. The 2012 Long-Term Incentive Plan expired on April 26, 2022. All awards (stock options, restricted shares units and performance share units) granted subsequent to that date were under the 2022 Long-Term Incentive Plan. Under the 2022 Long-Term Incentive Plan, the Company may issue up to 150 million shares of common stock, of which up to 110 million shares of common stock may be issued subject to stock options or stock appreciation rights and up to 40 million shares of common stock may be issued subject to full value awards. Awards will generally be counted on a 1-for-1 basis against the share reserve, provided that if more than 40 million full value awards are granted, each full value award in excess of 40 million will be counted on a 5-for-1 basis against the share reserve. Shares available for future grants under the 2022 Long-Term Incentive Plan were 111 million at the end of fiscal year 2024.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The compensation cost that has been charged against income for these plans was $1,176 million, $1,087 million and $1,028 million for fiscal years 2024, 2023 and 2022, respectively. The total income tax benefit recognized in the income statement for share-based compensation costs was $251 million, $221 million and $177 million for fiscal years 2024, 2023 and 2022, respectively. The Company also recognized additional income tax benefits of $94 million, $126 million and $267 million for fiscal years 2024, 2023 and 2022, respectively, for which options were exercised or restricted shares were vested. The total unrecognized compensation cost was $1,002 million, $907 million and $866 million for fiscal years 2024, 2023 and 2022, respectively. The weighted average period for this cost to be recognized was 1.81 years, 1.80 years and 1.80 years for fiscal years 2024, 2023, and 2022, respectively. Share-based compensation costs capitalized as part of inventory were insignificant in all periods.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company settles employee benefit equity issuances with treasury shares. Treasury shares are replenished through market purchases throughout the year for the number of shares used to settle employee benefit equity issuances. </span></div><div style="margin-bottom:6pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Stock options</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Stock options expire 10 years from the date of grant and vest over service periods that range from 6 months to 4 years. Options granted under the 2012 Long-Term Incentive Plan were granted at the average of the high and low prices of the Company’s Common Stock on the New York Stock Exchange on the date of grant. Options granted under the 2022 Long-Term incentive Plan were granted at the closing price of the Company’s Common Stock on the New York Stock Exchange on the date of grant.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The fair value of each option award was estimated on the date of grant using the Black-Scholes option valuation model that uses the assumptions noted in the following table. For 2024, 2023, and 2022 grants, expected volatility represents a blended rate of 10-year weekly historical overall volatility rate, and a 5-week average implied volatility rate based on at-the-money traded Johnson &amp; Johnson options with a life of 2 years. For all grants, historical data is used to determine the expected life of the option. The risk-free rate was based on the U.S. Treasury yield curve in effect at the time of grant.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The average fair value of options granted was $27.67, $27.85 and $23.23, in fiscal years 2024, 2023 and 2022, respectively. The fair value was estimated based on the weighted average assumptions of:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.822%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.764%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Risk-free rate</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.15 </span></td><td style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.74 </span></td><td style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1.98 </span></td><td style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Expected volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">17.85 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">17.69 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">18.00 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Expected life (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7.0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7.0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7.0</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Expected dividend yield</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.10 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2.90 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2.70 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">A summary of option activity under the Plan as of December 29, 2024, is presented below:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.780%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.780%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.569%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Shares in Thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Outstanding<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted<br/>Average Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Aggregate<br/>Intrinsic<br/>Value<br/>(Dollars in Millions) </span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Shares at December 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">112,238</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$139.88</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$2,239</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Options granted</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13,917</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">157.92</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Options exercised</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(10,771)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">107.06</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Options canceled/forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2,755)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">162.45</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Shares at December 29, 2024</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">112,629</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$144.69</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$1,129</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The total intrinsic value of options exercised was $560 million, $729 million and $1,228 million in fiscal years 2024, 2023 and 2022, respectively.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The following table summarizes stock options outstanding and exercisable at December 29, 2024:</span></div><div style="margin-bottom:4pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.590%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.036%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.593%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Shares in Thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Outstanding</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exercisable</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exercise Price Range</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Options</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Average Life</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted<br/>Average<br/>Exercise Price</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Options</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted<br/>Average<br/>Exercise Price</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$100.06 - $101.87</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13,016</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.8</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$101.29</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13,016</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$101.29</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$115.67 - $129.51</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">18,252</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2.6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">122.49</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">18,252</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">122.49</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$131.94 - $151.41</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">25,624</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">142.87</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">25,624</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">142.87</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$157.92 - $162.75</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">26,391</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8.6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">160.33</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,269</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">162.75</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$164.62 - $165.89</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">29,346</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6.6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">165.29</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13,522</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">164.64</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">112,629</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">5.3</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$144.69</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">74,683</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$135.72</span></td></tr></table></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:9.29pt">Average contractual life remaining in years.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Stock options outstanding at December 31, 2023 and January 1, 2023 were 112,238 and an average life of 5.5 years and 118,672 and an average life of 5.8 years, respectively. Stock options exercisable at December 31, 2023 and January 1, 2023 were 66,998 at an average price of $123.39 and 63,661 at an average price of $113.06, respectively. </span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Restricted share units and performance share units</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company grants restricted share units which vest over service periods that range from 6 months to 3 years. The Company also grants performance share units, which are paid in shares of Johnson &amp; Johnson Common Stock after the end of a three-year performance period. Performance shares were granted with two equally-weighted goals that directly align with or help drive long-term total shareholder return: adjusted operational earnings per share and relative total shareholder return. The number of shares actually earned at the end of the three-year period will vary, based only on actual performance, from 0% to 200% of the target number of performance share units granted. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">A summary of the restricted share units and performance share units activity under the Plans as of December 29, 2024 is presented below:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.395%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Shares in Thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Outstanding<br/>Restricted Share Units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Outstanding<br/>Performance Share Units</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Shares at December 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">12,938</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,037</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,331</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">906</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Issued</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5,454)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(808)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Canceled/forfeited/adjusted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(774)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(122)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Shares at December 29, 2024</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13,041</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,013</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The average fair value of the restricted share units granted was $147.51, $152.63 and $153.67 in fiscal years 2024, 2023 and 2022, respectively, using the fair market value at the date of grant. The fair value of restricted share units was discounted for dividends, which are not paid on the restricted share units during the vesting period. The fair value of restricted share units issued was $833 million, $605 million and $591 million in 2024, 2023 and 2022, respectively.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The weighted average fair value of the performance share units granted was $133.76, $145.17 and $170.46 in fiscal years 2024, 2023 and 2022, calculated using the weighted average fair market value for each of the component goals at the date of grant.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The fair values for the earnings per share goals of each performance share unit were estimated on the date of grant using the fair market value of the shares at the time of the award discounted for dividends, which are not paid on the performance share units during the vesting period. The fair value for the relative total shareholder return goal of each performance share unit was estimated on the date of grant using the Monte Carlo valuation model. The fair value of performance share units issued was $146 million, $140 million and $94 million in fiscal years 2024, 2023 and 2022, respectively.</span></div> 1 150000000 110000000 40000000 40000000 40000000 111000000 1176000000 1087000000 1028000000 251000000 221000000 177000000 94000000 126000000 267000000 1002000000 907000000 866000000 P1Y9M21D P1Y9M18D P1Y9M18D P10Y P6M P4Y <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The average fair value of options granted was $27.67, $27.85 and $23.23, in fiscal years 2024, 2023 and 2022, respectively. The fair value was estimated based on the weighted average assumptions of:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.822%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.764%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Risk-free rate</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.15 </span></td><td style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.74 </span></td><td style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1.98 </span></td><td style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Expected volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">17.85 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">17.69 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">18.00 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Expected life (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7.0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7.0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7.0</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Expected dividend yield</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.10 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2.90 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2.70 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr></table></div> 27.67 27.85 23.23 0.0415 0.0374 0.0198 0.1785 0.1769 0.1800 P7Y P7Y P7Y 0.0310 0.0290 0.0270 <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">A summary of option activity under the Plan as of December 29, 2024, is presented below:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.780%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.780%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.569%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Shares in Thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Outstanding<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted<br/>Average Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Aggregate<br/>Intrinsic<br/>Value<br/>(Dollars in Millions) </span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Shares at December 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">112,238</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$139.88</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$2,239</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Options granted</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13,917</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">157.92</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Options exercised</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(10,771)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">107.06</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Options canceled/forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2,755)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">162.45</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Shares at December 29, 2024</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">112,629</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$144.69</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$1,129</span></td></tr></table></div> 112238000 139.88 2239000000 13917000 157.92 10771000 107.06 2755000 162.45 112629000 144.69 1129000000 560000000 729000000 1228000000 <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The following table summarizes stock options outstanding and exercisable at December 29, 2024:</span></div><div style="margin-bottom:4pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.590%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.036%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.593%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Shares in Thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Outstanding</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exercisable</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exercise Price Range</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Options</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Average Life</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted<br/>Average<br/>Exercise Price</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Options</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted<br/>Average<br/>Exercise Price</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$100.06 - $101.87</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13,016</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.8</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$101.29</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13,016</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$101.29</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$115.67 - $129.51</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">18,252</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2.6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">122.49</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">18,252</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">122.49</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$131.94 - $151.41</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">25,624</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">142.87</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">25,624</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">142.87</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$157.92 - $162.75</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">26,391</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8.6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">160.33</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,269</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">162.75</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$164.62 - $165.89</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">29,346</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6.6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">165.29</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13,522</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">164.64</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">112,629</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">5.3</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$144.69</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">74,683</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$135.72</span></td></tr></table></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:9.29pt">Average contractual life remaining in years.</span></div> 100.06 101.87 13016000 P0Y9M18D 101.29 13016000 101.29 115.67 129.51 18252000 P2Y7M6D 122.49 18252000 122.49 131.94 151.41 25624000 P4Y7M6D 142.87 25624000 142.87 157.92 162.75 26391000 P8Y7M6D 160.33 4269000 162.75 164.62 165.89 29346000 P6Y7M6D 165.29 13522000 164.64 112629000 P5Y3M18D 144.69 74683000 135.72 112238000 P5Y6M 118672000 P5Y9M18D 66998000 123.39 63661000 113.06 P6M P3Y P3Y P3Y 0 2 <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">A summary of the restricted share units and performance share units activity under the Plans as of December 29, 2024 is presented below:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.395%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Shares in Thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Outstanding<br/>Restricted Share Units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Outstanding<br/>Performance Share Units</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Shares at December 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">12,938</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,037</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,331</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">906</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Issued</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5,454)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(808)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Canceled/forfeited/adjusted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(774)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(122)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Shares at December 29, 2024</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13,041</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,013</span></td></tr></table></div> 12938000 2037000 6331000 906000 5454000 808000 774000 122000 13041000 2013000 147.51 152.63 153.67 833000000 605000000 591000000 133.76 145.17 170.46 146000000 140000000 94000000 Segments of business and geographic areas<div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Following the separation of the Consumer Health business in the fiscal third quarter of 2023, the Company is now organized into two reportable segments: Innovative Medicine and MedTech. The segment results have been recast for all periods to reflect the continuing operations of the Company.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company’s chief operating decision maker (CODM) is the Chief Executive Officer (Principal Executive Officer). For the Innovative Medicine and MedTech segments, the CODM uses segment income before tax to allocate resources (including employees, financial, and capital resources) for each segment predominantly in the annual forecasting process. The CODM considers planning-to-actual variances on a quarterly basis to assess performance and make decisions about allocating resources to the segments. </span></div><div style="margin-bottom:4pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.953%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.953%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.655%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.655%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.358%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.958%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Sales to Customers </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">% Change</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="border-bottom:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">’24 vs. ’23</span></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">’23 vs. ’22</span></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">INNOVATIVE MEDICINE</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Immunology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$11,355</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11,539</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11,036</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,473</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,513</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,899</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(0.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">17,828</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">18,052</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">16,935</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">REMICADE</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,009</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,143</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,417</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(11.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(19.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. Exports</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">98</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">147</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">204</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(33.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(28.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">497</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">549</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">722</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(9.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(23.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,605</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,839</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,343</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(12.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(21.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">SIMPONI / SIMPONI ARIA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,082</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,124</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,166</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,108</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,073</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,017</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,190</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,197</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,184</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">STELARA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,720</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,966</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,388</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,641</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,892</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,335</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(6.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">16.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10,361</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10,858</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9,723</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">TREMFYA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,443</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,147</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,844</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">16.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,227</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">999</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">824</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">22.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">21.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,670</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,147</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,668</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">16.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">17.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">OTHER IMMUNOLOGY</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">17</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(74.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(33.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">17</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(74.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(33.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Infectious Diseases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,354</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,500</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,680</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(9.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(10.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,042</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,918</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,769</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(30.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(22.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,396</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,418</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,449</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(23.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(18.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">COVID-19 VACCINE</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">120</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">198</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,117</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">2,059</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(82.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(45.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:4pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.953%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.953%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.655%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.655%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.358%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.958%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Sales to Customers </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">% Change</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="border-bottom:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">’24 vs. ’23</span></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">’23 vs. ’22</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">198</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,117</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">2,179</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(82.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(48.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">EDURANT / rilpivirine</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">31</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">35</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">36</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(10.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(3.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,241</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,115</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">972</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">11.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">14.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,272</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,150</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,008</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">10.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">14.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">PREZISTA / PREZCOBIX</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> /</span></div><div style="padding-left:12pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">REZOLSTA / SYMTUZA</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,311</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,446</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,494</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(9.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(3.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">401</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">408</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">449</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(1.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(9.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,712</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,854</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,943</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(7.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(4.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">OTHER INFECTIOUS DISEASES</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">11</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">19</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">30</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(41.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(34.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">203</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">278</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">289</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(26.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(3.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">214</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">297</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">318</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(27.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(6.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Neuroscience</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">4,398</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">4,065</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">3,570</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">8.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">13.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">2,718</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">3,076</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">3,323</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(11.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(7.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">7,115</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">7,140</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">6,893</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(0.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">3.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">CONCERTA / methylphenidate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">134</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">230</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">151</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(41.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">52.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">507</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">554</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">493</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(8.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">12.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">641</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">783</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">644</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(18.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">21.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">3,125</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">2,897</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">2,714</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">7.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">6.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,097</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,218</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,426</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(9.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(14.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">4,222</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">4,115</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">4,140</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">2.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(0.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">SPRAVATO</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">929</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">589</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">328</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">57.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">79.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">148</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">100</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">46</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">48.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,077</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">689</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">374</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">56.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">84.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">OTHER NEUROSCIENCE</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">210</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">349</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">376</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(39.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(7.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">965</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,204</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,358</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(19.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(11.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,175</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,553</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,734</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(24.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(10.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Oncology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">10,854</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">8,462</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">6,930</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">28.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">22.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">9,926</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">9,199</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">9,052</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">7.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">20,781</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">17,661</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">15,983</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">17.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">10.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">CARVYKTI</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">869</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">469</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">133</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">85.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">94</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">30</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:4pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.953%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.953%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.655%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.655%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.358%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.958%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Sales to Customers </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">% Change</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="border-bottom:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">’24 vs. ’23</span></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">’23 vs. ’22</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">963</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">500</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">133</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">92.7</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">DARZALEX</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,588</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,277</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,210</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">24.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">25.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,082</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,467</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,767</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">18.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11,670</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9,744</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7,977</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">19.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">22.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">ERLEADA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,282</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,065</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">968</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">20.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,717</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,322</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">913</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">29.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">44.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,999</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,387</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,881</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">25.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">26.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">IMBRUVICA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,051</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,390</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(24.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,018</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,214</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,394</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(8.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(7.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,038</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,264</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,784</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(6.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(13.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">TECVAYLI</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">418</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">334</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">12</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">25.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">131</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">61</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">549</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">395</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">15</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">38.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">ZYTIGA /abiraterone acetate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">34</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">50</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">74</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(32.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(32.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">597</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">837</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,696</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(28.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(50.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">631</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">887</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,770</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(28.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(49.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">OTHER ONCOLOGY</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">643</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">215</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">144</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">49.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">288</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">269</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">280</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">931</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">484</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">423</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">92.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">14.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Pulmonary Hypertension</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,143</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,697</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,346</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">16.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">15.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,140</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,117</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,071</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,282</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,815</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,417</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">12.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%;text-decoration:underline">OPSUMIT</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,520</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,292</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,132</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">17.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">14.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">664</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">681</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">651</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,184</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,973</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,783</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">UPTRAVI</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,511</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,326</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,104</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">20.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">307</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">255</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">218</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">20.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">17.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,817</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,582</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,322</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">14.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">19.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">OTHER PULMONARY HYPERTENSION</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">112</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">79</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">110</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">41.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(28.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">169</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">182</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">202</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(6.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(10.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">281</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">260</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">313</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(16.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:4pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.953%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.953%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.655%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.655%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.358%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.958%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Sales to Customers </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">% Change</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="border-bottom:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">’24 vs. ’23</span></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">’23 vs. ’22</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Cardiovascular / Metabolism / Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,866</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,906</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,042</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">696</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">765</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">845</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(9.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(9.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,562</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,671</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,887</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">XARELTO</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,373</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,365</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,473</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,373</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,365</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,473</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">OTHER</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">494</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">541</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">569</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(8.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">696</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">765</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">845</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(9.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(9.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,189</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,306</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,414</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(8.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(7.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">TOTAL INNOVATIVE MEDICINE</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">33,970</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">31,169</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">28,604</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">22,994</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">23,590</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">23,959</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">56,964</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">54,759</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">52,563</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">MEDTECH</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Cardiovascular </span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,513</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,633</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,169</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">24.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">67.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,194</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,717</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,131</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">17.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">27.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7,707</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,350</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,300</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">21.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">47.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">ELECTROPHYSIOLOGY</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,738</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,458</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,036</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">20.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,529</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,230</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,901</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">17.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,267</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,688</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,937</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">12.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">19.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">ABIOMED</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,213</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,066</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">31</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">284</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">240</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">18.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,496</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,306</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">31</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">14.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">SHOCKWAVE</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">442</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">122</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">564</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">OTHER CARDIOVASCULAR</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">120</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">109</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">102</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">260</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">247</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">230</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">380</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">356</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">332</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Orthopaedics</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,689</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,525</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,321</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,470</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,417</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,267</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9,158</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8,942</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8,587</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:4pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.953%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.953%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.655%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.655%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.358%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.958%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Sales to Customers </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">% Change</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="border-bottom:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">’24 vs. ’23</span></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">’23 vs. ’22</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">HIPS</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,057</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">996</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">943</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">581</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">564</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">571</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,638</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,560</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,514</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">KNEES</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">922</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">896</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">851</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">623</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">559</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">508</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,545</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,456</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,359</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">TRAUMA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,013</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,949</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,882</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,036</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,030</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">989</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,049</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,979</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,871</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">SPINE, SPORTS &amp; OTHER</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,696</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,684</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,645</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,230</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,263</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,198</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,926</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,947</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,843</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(0.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Surgery</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,003</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,031</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,897</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(0.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,842</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,006</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,793</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9,845</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10,037</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9,690</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">ADVANCED</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,838</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,833</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,784</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,650</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,837</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,785</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(6.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,488</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,671</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,569</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">GENERAL</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,165</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,198</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,113</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,192</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,168</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,008</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,358</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,366</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,121</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Vision</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,128</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,086</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,990</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,018</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,986</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,859</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,146</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,072</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,849</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">CONTACT LENSES / OTHER</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,684</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,626</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,522</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,049</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,076</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,733</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,702</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,543</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">SURGICAL</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">444</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">460</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">468</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">969</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">910</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">837</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,413</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,370</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,306</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:4pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.953%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.953%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.655%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.655%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.358%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.958%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Sales to Customers </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">% Change</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="border-bottom:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">’24 vs. ’23</span></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">’23 vs. ’22</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">TOTAL MEDTECH</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">16,332</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">15,275</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13,377</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">14.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">15,525</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">15,125</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">14,050</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">31,857</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">30,400</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">27,427</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">WORLDWIDE</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">50,302</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">46,444</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">41,981</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">38,519</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">38,715</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">38,009</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(0.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$88,821</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">85,159</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">79,990</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.3 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6.5 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%">*    percentage greater than 100% or not meaningful</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:9.29pt">Previously referred to as Interventional Solutions</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.09pt">Acquired on December 22, 2022</span></div><div style="margin-bottom:6pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8pt">Acquired on May 31, 2024</span></div><div style="margin-bottom:4pt;margin-top:4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.263%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.679%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.679%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.084%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.275%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.679%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.042%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.275%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.679%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.750%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="border-bottom:1pt solid #eb1700;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Income Before Tax by Segment</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024 </span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span></div></td><td colspan="9" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023 </span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span></div></td><td colspan="9" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022 </span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(5)</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Innovative<br/>Medicine</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">MedTech</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Innovative<br/>Medicine</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">MedTech</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Innovative<br/>Medicine</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">MedTech</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Sales to customers</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$56,964</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">31,857</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">54,759</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">30,400</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">52,563</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">27,427</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cost of products sold</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">14,036</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13,345</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13,715</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">12,722</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">14,066</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10,397</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Selling, marketing and administrative </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10,906</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10,812</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9,842</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10,476</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9,714</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9,537</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Research and development expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13,529</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,703</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11,963</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,122</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11,642</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,493</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other segment items </span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(426)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">257</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">993</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(589)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,494</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">553</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Segment income before tax</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$18,919</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,740</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">22,659</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">18,246</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,669</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">22,915</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">15,647</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,447</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">20,094</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Less: Expense not allocated to segments </span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,972</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7,853</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">735</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Worldwide total</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$16,687</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">15,062</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">19,359</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.644%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.764%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Identifiable Assets</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Innovative Medicine</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$57,070</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">58,324</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">MedTech</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">84,322</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">74,710</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">141,392</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">133,034</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">General corporate </span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(6)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">38,712</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">34,524</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Worldwide total</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$180,104</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">167,558</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.465%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.873%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Additions to Property,<br/>Plant &amp; Equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Depreciation and<br/>Amortization</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Innovative Medicine</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$1,710</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,653</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,374</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$3,760</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,847</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,687</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">MedTech</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,443</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,372</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,120</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,237</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,943</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,302</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Segments total</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,153</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,025</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,494</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,997</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,790</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,989</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Discontinued operations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">162</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">303</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">383</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">641</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">General corporate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">271</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">356</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">212</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">342</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">313</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">340</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Worldwide total</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$4,424</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">4,543</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">4,009</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$7,339</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">7,486</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">6,970</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.989%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.614%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.467%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Sales to Customers </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Long-Lived Assets </span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(7)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">United States</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$50,302</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">46,444</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">41,981</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$70,670</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">54,832</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">20,212</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">20,410</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">20,664</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">27,267</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">31,616</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Western Hemisphere excluding U.S. </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,714</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,549</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,108</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,728</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,491</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Asia-Pacific, Africa</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13,593</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13,756</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13,237</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,454</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,500</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Segments total</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">88,821</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">85,159</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">79,990</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">101,119</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">89,439</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">General corporate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,217</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,192</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other non long-lived assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">77,768</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">76,927</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Worldwide total</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$88,821</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">85,159</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">79,990</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$180,104</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">167,558</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:125%">See Note 1 for a description of the segments in which the Company operates. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Export sales are not significant. In fiscal year 2024, the Company utilized three wholesalers distributing products for both segments that represented approximately 20.5%, 15.6% and 12.3% of the total gross revenues. In fiscal year 2023, the Company had three wholesalers distributing products for both segments that represented approximately 18.2%, 15.1% and 14.2% of the total gross revenues. In fiscal year 2022, the Company had three wholesalers distributing products for all three segments that represented approximately 18.9%, 15.0%, and 13.8% of the total gross revenues. </span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:125%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:125%;padding-left:8.64pt"><span style="-sec-ix-hidden:f-2949">Other segment expenses</span> for each reportable segment include charges related to other income and expenses, restructuring activities and impairment charges related to in-process research and development.</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:125%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:125%;padding-left:7.29pt">Amounts not allocated to segments include interest (income)/expense and general corporate (income)/expense. The fiscal years 2024 and 2023 include charges for talc matters of approximately $5.1 billion and $7 billion, respectively (See Note 19, Legal proceedings, for additional details). The fiscal year 2024 includes a loss of approximately $0.4 billion related to the debt to equity exchange of the Company's remaining shares of Kenvue Common Stock. The fiscal year 2023 includes the unfavorable change in the fair value of the retained stake in Kenvue of approximately $0.4 billion.</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:125%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:125%;padding-left:7.19pt">Innovative Medicine segment income before tax includes:</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:125%">•</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:125%;padding-left:8.25pt">Acquired in-process research &amp; development expense of $1.25 billion to secure the global rights to the NM26 bispecific antibody (Yellow Jersey acquisition)</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:125%">•</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:125%;padding-left:8.25pt">Monetization of royalty rights of $0.3 billion</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:125%">•</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:125%;padding-left:8.25pt">Litigation expense of $0.3 billion primarily related to Risperdal Gynecomastia</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:125%">•</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:125%;padding-left:8.25pt">An intangible asset impairment charge of approximately $0.2 billion associated with the M710 (biosimilar) asset acquired as part of the acquisition of Momenta Pharmaceuticals in 2020.</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:125%">•</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:125%;padding-left:8.25pt">A restructuring related charge of $0.1 billion</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:125%">•</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:125%;padding-left:8.25pt">One-time COVID-19 Vaccine manufacturing exit related costs of $0.1 billion</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:125%">•</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:125%;padding-left:8.25pt">Favorable changes in the fair value of securities of $0.1 billion</span></div><div style="padding-left:14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:125%">MedTech segment income before tax includes:</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:125%">•</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:125%;padding-left:8.25pt">Acquisition and integration related costs of $1.0 billion primarily related to the acquisition of Shockwave </span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%">•</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.25pt">Acquired in-process research and development expense of $0.5 billion from the V-Wave acquisition</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%">•</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.25pt">A gain of $0.2 billion related to the Acclarent divestiture</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%">•</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.25pt">A Medical Device Regulation charge of $0.2 billion</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%">•</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.25pt">A restructuring related charge of $0.2 billion</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:130%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:7.07pt">Innovative Medicine segment income before tax includes:</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:130%">•</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.16pt">One-time COVID-19 Vaccine manufacturing exit related costs of $0.7 billion </span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:130%">•</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.16pt">A restructuring related charge of $0.5 billion</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:130%">•</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.16pt">Unfavorable changes in the fair value of securities of $0.4 billion </span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:130%">•</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.16pt">Favorable litigation related items of $0.1 billion</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:130%">•</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.16pt">Loss on divestiture of $0.2 billion. </span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:130%">•</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.16pt">An intangible asset impairment charge of approximately $0.2 billion related to market dynamics associated with a non-strategic asset (M710) acquired as part of the acquisition of Momenta Pharmaceuticals in 2020.</span></div><div style="padding-left:14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:112%">MedTech segment income before tax includes:</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:130%">•</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.16pt">Acquired in-process research and development expense of $0.4 billion related to the Laminar acquisition in 2023</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:130%">•</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.16pt">A restructuring related charge of $0.3 billion</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:130%">•</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.16pt">Acquisition and integration related costs of $0.2 billion primarily related to the acquisition of Abiomed</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:130%">•</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.16pt">A Medical Device Regulation charge of $0.3 billion</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:130%">•</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.16pt">Income from litigation settlements of $0.1 billion</span></div><div style="padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:112%;position:relative;top:-3.15pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:112%;padding-left:7.17pt">Innovative Medicine segment income before tax includes:</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:130%">•</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.16pt">One-time COVID-19 Vaccine manufacturing exit related costs of $1.5 billion</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:130%">•</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.16pt">An intangible asset impairment charge of approximately $0.8 billion related to an in-process research and development asset, bermekimab (JnJ-77474462), an investigational drug for the treatment of Atopic Dermatitis (AD) and Hidradenitis Suppurativa (HS) acquired with the acquisition of XBiotech, Inc. in the fiscal year 2020. Additional information regarding efficacy of the AD and HS indications became available which led the Company to the decision to terminate the development of bermekimab for AD and HS</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:130%">•</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.16pt">Litigation expense of $0.1 billion </span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:130%">•</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.16pt">Unfavorable changes in the fair value of securities of $0.7 billion </span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:130%">•</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.16pt">A restructuring related charge of $0.1 billion </span></div><div style="padding-left:14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:112%">MedTech segment income before tax includes:</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:130%">•</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.16pt">Litigation expense of $0.6 billion primarily for pelvic mesh related costs</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:130%">•</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.16pt">A restructuring related charge of $0.3 billion </span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:130%">•</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.16pt">Acquisition and integration related costs of $0.3 billion primarily related to the acquisition of Abiomed</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%">•</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.25pt">A Medical Device Regulation charge of $0.3 billion</span></div><div style="margin-bottom:4pt;margin-top:4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:130%;position:relative;top:-3.15pt;vertical-align:baseline">(6)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"> </span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%"> General corporate includes cash, cash equivalents, marketable securities and other corporate assets. </span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:130%;position:relative;top:-3.15pt;vertical-align:baseline">(7)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:7.64pt">Long-lived assets include property, plant and equipment, net for fiscal years 2024, and 2023 of $20,518 and $19,898, respectively, and intangible assets and goodwill, net for fiscal years 2024 and 2023 of $81,818 and $70,733, respectively.</span></div> 2 <div style="margin-bottom:4pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.953%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.953%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.655%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.655%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.358%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.958%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Sales to Customers </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">% Change</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="border-bottom:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">’24 vs. ’23</span></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">’23 vs. ’22</span></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">INNOVATIVE MEDICINE</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Immunology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$11,355</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11,539</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11,036</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,473</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,513</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,899</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(0.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">17,828</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">18,052</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">16,935</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">REMICADE</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,009</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,143</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,417</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(11.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(19.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. Exports</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">98</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">147</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">204</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(33.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(28.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">497</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">549</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">722</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(9.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(23.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,605</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,839</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,343</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(12.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(21.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">SIMPONI / SIMPONI ARIA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,082</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,124</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,166</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,108</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,073</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,017</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,190</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,197</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,184</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">STELARA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,720</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,966</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,388</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,641</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,892</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,335</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(6.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">16.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10,361</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10,858</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9,723</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">TREMFYA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,443</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,147</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,844</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">16.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,227</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">999</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">824</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">22.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">21.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,670</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,147</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,668</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">16.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">17.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">OTHER IMMUNOLOGY</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">17</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(74.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(33.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">17</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(74.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(33.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Infectious Diseases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,354</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,500</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,680</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(9.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(10.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,042</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,918</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,769</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(30.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(22.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,396</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,418</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,449</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(23.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(18.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">COVID-19 VACCINE</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">120</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">198</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,117</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">2,059</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(82.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(45.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:4pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.953%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.953%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.655%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.655%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.358%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.958%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Sales to Customers </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">% Change</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="border-bottom:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">’24 vs. ’23</span></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">’23 vs. ’22</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">198</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,117</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">2,179</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(82.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(48.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">EDURANT / rilpivirine</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">31</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">35</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">36</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(10.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(3.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,241</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,115</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">972</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">11.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">14.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,272</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,150</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,008</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">10.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">14.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">PREZISTA / PREZCOBIX</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> /</span></div><div style="padding-left:12pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">REZOLSTA / SYMTUZA</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,311</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,446</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,494</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(9.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(3.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">401</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">408</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">449</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(1.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(9.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,712</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,854</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,943</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(7.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(4.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">OTHER INFECTIOUS DISEASES</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">11</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">19</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">30</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(41.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(34.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">203</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">278</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">289</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(26.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(3.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">214</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">297</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">318</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(27.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(6.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Neuroscience</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">4,398</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">4,065</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">3,570</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">8.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">13.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">2,718</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">3,076</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">3,323</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(11.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(7.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">7,115</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">7,140</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">6,893</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(0.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">3.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">CONCERTA / methylphenidate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">134</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">230</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">151</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(41.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">52.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">507</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">554</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">493</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(8.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">12.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">641</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">783</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">644</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(18.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">21.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">3,125</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">2,897</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">2,714</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">7.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">6.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,097</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,218</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,426</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(9.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(14.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">4,222</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">4,115</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">4,140</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">2.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(0.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">SPRAVATO</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">929</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">589</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">328</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">57.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">79.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">148</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">100</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">46</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">48.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,077</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">689</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">374</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">56.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">84.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">OTHER NEUROSCIENCE</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">210</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">349</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">376</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(39.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(7.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">965</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,204</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,358</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(19.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(11.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,175</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,553</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,734</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(24.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(10.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Oncology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">10,854</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">8,462</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">6,930</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">28.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">22.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">9,926</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">9,199</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">9,052</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">7.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">20,781</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">17,661</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">15,983</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">17.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">10.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">CARVYKTI</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">869</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">469</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">133</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">85.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">94</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">30</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:4pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.953%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.953%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.655%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.655%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.358%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.958%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Sales to Customers </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">% Change</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="border-bottom:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">’24 vs. ’23</span></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">’23 vs. ’22</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">963</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">500</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">133</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">92.7</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">DARZALEX</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,588</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,277</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,210</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">24.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">25.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,082</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,467</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,767</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">18.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11,670</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9,744</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7,977</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">19.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">22.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">ERLEADA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,282</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,065</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">968</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">20.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,717</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,322</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">913</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">29.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">44.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,999</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,387</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,881</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">25.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">26.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">IMBRUVICA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,051</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,390</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(24.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,018</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,214</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,394</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(8.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(7.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,038</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,264</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,784</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(6.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(13.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">TECVAYLI</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">418</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">334</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">12</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">25.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">131</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">61</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">549</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">395</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">15</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">38.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">ZYTIGA /abiraterone acetate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">34</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">50</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">74</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(32.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(32.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">597</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">837</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,696</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(28.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(50.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">631</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">887</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,770</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(28.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(49.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">OTHER ONCOLOGY</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">643</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">215</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">144</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">49.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">288</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">269</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">280</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">931</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">484</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">423</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">92.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">14.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Pulmonary Hypertension</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,143</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,697</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,346</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">16.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">15.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,140</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,117</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,071</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,282</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,815</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,417</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">12.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%;text-decoration:underline">OPSUMIT</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,520</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,292</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,132</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">17.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">14.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">664</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">681</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">651</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,184</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,973</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,783</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">UPTRAVI</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,511</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,326</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,104</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">20.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">307</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">255</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">218</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">20.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">17.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,817</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,582</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,322</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">14.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">19.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">OTHER PULMONARY HYPERTENSION</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">112</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">79</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">110</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">41.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(28.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">169</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">182</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">202</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(6.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(10.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">281</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">260</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">313</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(16.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:4pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.953%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.953%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.655%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.655%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.358%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.958%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Sales to Customers </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">% Change</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="border-bottom:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">’24 vs. ’23</span></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">’23 vs. ’22</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Cardiovascular / Metabolism / Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,866</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,906</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,042</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">696</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">765</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">845</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(9.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(9.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,562</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,671</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,887</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">XARELTO</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,373</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,365</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,473</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,373</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,365</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,473</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">OTHER</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">494</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">541</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">569</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(8.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">696</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">765</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">845</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(9.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(9.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,189</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,306</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,414</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(8.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(7.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">TOTAL INNOVATIVE MEDICINE</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">33,970</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">31,169</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">28,604</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">22,994</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">23,590</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">23,959</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">56,964</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">54,759</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">52,563</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">MEDTECH</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Cardiovascular </span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,513</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,633</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,169</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">24.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">67.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,194</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,717</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,131</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">17.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">27.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7,707</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,350</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,300</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">21.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">47.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">ELECTROPHYSIOLOGY</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,738</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,458</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,036</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">20.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,529</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,230</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,901</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">17.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,267</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,688</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,937</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">12.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">19.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">ABIOMED</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,213</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,066</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">31</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">284</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">240</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">18.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,496</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,306</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">31</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">14.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">SHOCKWAVE</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">442</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">122</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">564</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">OTHER CARDIOVASCULAR</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">120</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">109</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">102</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">260</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">247</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">230</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">380</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">356</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">332</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Orthopaedics</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,689</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,525</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,321</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,470</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,417</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,267</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9,158</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8,942</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8,587</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:4pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.953%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.953%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.655%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.655%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.358%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.958%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Sales to Customers </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">% Change</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="border-bottom:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">’24 vs. ’23</span></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">’23 vs. ’22</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">HIPS</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,057</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">996</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">943</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">581</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">564</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">571</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,638</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,560</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,514</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">KNEES</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">922</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">896</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">851</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">623</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">559</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">508</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,545</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,456</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,359</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">TRAUMA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,013</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,949</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,882</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,036</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,030</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">989</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,049</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,979</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,871</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">SPINE, SPORTS &amp; OTHER</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,696</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,684</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,645</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,230</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,263</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,198</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,926</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,947</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,843</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(0.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Surgery</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,003</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,031</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,897</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(0.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,842</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,006</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,793</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9,845</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10,037</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9,690</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">ADVANCED</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,838</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,833</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,784</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,650</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,837</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,785</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(6.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,488</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,671</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,569</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">GENERAL</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,165</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,198</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,113</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,192</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,168</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,008</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,358</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,366</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,121</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Vision</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,128</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,086</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,990</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,018</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,986</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,859</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,146</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,072</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,849</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">CONTACT LENSES / OTHER</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,684</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,626</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,522</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,049</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,076</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,733</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,702</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,543</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">SURGICAL</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">444</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">460</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">468</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">969</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">910</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">837</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,413</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,370</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,306</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:4pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.953%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.953%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.655%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.655%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.358%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.958%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Sales to Customers </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">% Change</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="border-bottom:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">’24 vs. ’23</span></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #eb1700;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">’23 vs. ’22</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">TOTAL MEDTECH</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">16,332</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">15,275</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13,377</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">14.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">15,525</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">15,125</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">14,050</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">31,857</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">30,400</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">27,427</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">WORLDWIDE</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">50,302</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">46,444</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">41,981</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">38,519</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">38,715</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">38,009</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(0.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$88,821</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">85,159</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">79,990</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.3 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6.5 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%">*    percentage greater than 100% or not meaningful</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:9.29pt">Previously referred to as Interventional Solutions</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.09pt">Acquired on December 22, 2022</span></div><div style="margin-bottom:6pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8pt">Acquired on May 31, 2024</span></div> 11355000000 11539000000 11036000000 -0.016 0.046 6473000000 6513000000 5899000000 -0.006 0.104 17828000000 18052000000 16935000000 -0.012 0.066 1009000000 1143000000 1417000000 -0.117 -0.193 98000000 147000000 204000000 -0.330 -0.280 497000000 549000000 722000000 -0.095 -0.239 1605000000 1839000000 2343000000 -0.128 -0.215 1082000000 1124000000 1166000000 -0.038 -0.036 1108000000 1073000000 1017000000 0.033 0.054 2190000000 2197000000 2184000000 -0.003 0.006 6720000000 6966000000 6388000000 -0.035 0.090 3641000000 3892000000 3335000000 -0.064 0.167 10361000000 10858000000 9723000000 -0.046 0.117 2443000000 2147000000 1844000000 0.137 0.165 1227000000 999000000 824000000 0.228 0.212 3670000000 3147000000 2668000000 0.166 0.179 3000000 11000000 17000000 -0.741 -0.338 0 0 0 0 3000000 11000000 17000000 -0.741 -0.338 1354000000 1500000000 1680000000 -0.098 -0.107 2042000000 2918000000 3769000000 -0.300 -0.226 3396000000 4418000000 5449000000 -0.231 -0.189 0 0 120000000 0 198000000 1117000000 2059000000 -0.824 -0.458 198000000 1117000000 2179000000 -0.824 -0.488 31000000 35000000 36000000 -0.100 -0.037 1241000000 1115000000 972000000 0.112 0.148 1272000000 1150000000 1008000000 0.106 0.141 1311000000 1446000000 1494000000 -0.094 -0.032 401000000 408000000 449000000 -0.017 -0.092 1712000000 1854000000 1943000000 -0.077 -0.046 11000000 19000000 30000000 -0.410 -0.345 203000000 278000000 289000000 -0.267 -0.038 214000000 297000000 318000000 -0.276 -0.067 4398000000 4065000000 3570000000 0.082 0.139 2718000000 3076000000 3323000000 -0.116 -0.075 7115000000 7140000000 6893000000 -0.004 0.036 134000000 230000000 151000000 -0.417 0.525 507000000 554000000 493000000 -0.084 0.122 641000000 783000000 644000000 -0.181 0.216 3125000000 2897000000 2714000000 0.079 0.067 1097000000 1218000000 1426000000 -0.099 -0.146 4222000000 4115000000 4140000000 0.026 -0.006 929000000 589000000 328000000 0.578 0.797 148000000 100000000 46000000 0.482 1077000000 689000000 374000000 0.564 0.841 210000000 349000000 376000000 -0.398 -0.073 965000000 1204000000 1358000000 -0.198 -0.113 1175000000 1553000000 1734000000 -0.243 -0.104 10854000000 8462000000 6930000000 0.283 0.221 9926000000 9199000000 9052000000 0.079 0.016 20781000000 17661000000 15983000000 0.177 0.105 869000000 469000000 133000000 0.852 94000000 30000000 0 963000000 500000000 133000000 0.927 6588000000 5277000000 4210000000 0.248 0.254 5082000000 4467000000 3767000000 0.138 0.186 11670000000 9744000000 7977000000 0.198 0.222 1282000000 1065000000 968000000 0.203 0.100 1717000000 1322000000 913000000 0.298 0.448 2999000000 2387000000 1881000000 0.256 0.269 1020000000 1051000000 1390000000 -0.030 -0.244 2018000000 2214000000 2394000000 -0.088 -0.075 3038000000 3264000000 3784000000 -0.069 -0.137 418000000 334000000 12000000 0.253 131000000 61000000 3000000 549000000 395000000 15000000 0.388 34000000 50000000 74000000 -0.322 -0.321 597000000 837000000 1696000000 -0.286 -0.507 631000000 887000000 1770000000 -0.288 -0.499 643000000 215000000 144000000 0.493 288000000 269000000 280000000 0.071 -0.039 931000000 484000000 423000000 0.925 0.144 3143000000 2697000000 2346000000 0.165 0.150 1140000000 1117000000 1071000000 0.020 0.043 4282000000 3815000000 3417000000 0.123 0.116 1520000000 1292000000 1132000000 0.177 0.141 664000000 681000000 651000000 -0.024 0.046 2184000000 1973000000 1783000000 0.107 0.106 1511000000 1326000000 1104000000 0.139 0.201 307000000 255000000 218000000 0.201 0.173 1817000000 1582000000 1322000000 0.149 0.197 112000000 79000000 110000000 0.418 -0.286 169000000 182000000 202000000 -0.069 -0.103 281000000 260000000 313000000 0.079 -0.167 2866000000 2906000000 3042000000 -0.014 -0.045 696000000 765000000 845000000 -0.091 -0.094 3562000000 3671000000 3887000000 -0.030 -0.055 2373000000 2365000000 2473000000 0.003 -0.044 0 0 0 0 0 2373000000 2365000000 2473000000 0.003 -0.044 494000000 541000000 569000000 -0.088 -0.050 696000000 765000000 845000000 -0.091 -0.094 1189000000 1306000000 1414000000 -0.089 -0.076 33970000000 31169000000 28604000000 0.090 0.090 22994000000 23590000000 23959000000 -0.025 -0.015 56964000000 54759000000 52563000000 0.040 0.042 4513000000 3633000000 2169000000 0.242 0.675 3194000000 2717000000 2131000000 0.176 0.275 7707000000 6350000000 4300000000 0.214 0.477 2738000000 2458000000 2036000000 0.114 0.207 2529000000 2230000000 1901000000 0.134 0.173 5267000000 4688000000 3937000000 0.123 0.191 1213000000 1066000000 31000000 0.137 284000000 240000000 0 0.182 1496000000 1306000000 31000000 0.145 442000000 0 0 122000000 0 0 564000000 0 0 120000000 109000000 102000000 0.107 0.067 260000000 247000000 230000000 0.053 0.073 380000000 356000000 332000000 0.069 0.071 5689000000 5525000000 5321000000 0.030 0.038 3470000000 3417000000 3267000000 0.015 0.046 9158000000 8942000000 8587000000 0.024 0.041 1057000000 996000000 943000000 0.062 0.056 581000000 564000000 571000000 0.030 -0.012 1638000000 1560000000 1514000000 0.050 0.030 922000000 896000000 851000000 0.029 0.053 623000000 559000000 508000000 0.113 0.102 1545000000 1456000000 1359000000 0.061 0.071 2013000000 1949000000 1882000000 0.033 0.036 1036000000 1030000000 989000000 0.006 0.041 3049000000 2979000000 2871000000 0.023 0.038 1696000000 1684000000 1645000000 0.007 0.024 1230000000 1263000000 1198000000 -0.026 0.054 2926000000 2947000000 2843000000 -0.007 0.037 4003000000 4031000000 3897000000 -0.007 0.034 5842000000 6006000000 5793000000 -0.027 0.037 9845000000 10037000000 9690000000 -0.019 0.036 1838000000 1833000000 1784000000 0.002 0.028 2650000000 2837000000 2785000000 -0.066 0.019 4488000000 4671000000 4569000000 -0.039 0.022 2165000000 2198000000 2113000000 -0.015 0.040 3192000000 3168000000 3008000000 0.008 0.053 5358000000 5366000000 5121000000 -0.002 0.048 2128000000 2086000000 1990000000 0.020 0.048 3018000000 2986000000 2859000000 0.011 0.045 5146000000 5072000000 4849000000 0.015 0.046 1684000000 1626000000 1522000000 0.036 0.068 2049000000 2076000000 2022000000 -0.013 0.027 3733000000 3702000000 3543000000 0.008 0.045 444000000 460000000 468000000 -0.034 -0.018 969000000 910000000 837000000 0.065 0.086 1413000000 1370000000 1306000000 0.032 0.049 16332000000 15275000000 13377000000 0.069 0.142 15525000000 15125000000 14050000000 0.026 0.077 31857000000 30400000000 27427000000 0.048 0.108 50302000000 46444000000 41981000000 0.083 0.106 38519000000 38715000000 38009000000 -0.005 0.019 88821000000 85159000000 79990000000 0.043 0.065 <div style="margin-bottom:4pt;margin-top:4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.263%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.679%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.679%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.084%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.275%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.679%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.042%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.275%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.679%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.750%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="border-bottom:1pt solid #eb1700;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Income Before Tax by Segment</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024 </span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span></div></td><td colspan="9" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023 </span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span></div></td><td colspan="9" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022 </span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(5)</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Innovative<br/>Medicine</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">MedTech</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Innovative<br/>Medicine</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">MedTech</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Innovative<br/>Medicine</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">MedTech</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Sales to customers</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$56,964</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">31,857</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">54,759</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">30,400</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">52,563</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">27,427</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cost of products sold</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">14,036</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13,345</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13,715</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">12,722</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">14,066</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10,397</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Selling, marketing and administrative </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10,906</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10,812</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9,842</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10,476</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9,714</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9,537</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Research and development expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13,529</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,703</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11,963</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,122</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11,642</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,493</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other segment items </span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(426)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">257</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">993</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(589)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,494</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">553</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Segment income before tax</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$18,919</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,740</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">22,659</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">18,246</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,669</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">22,915</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">15,647</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,447</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">20,094</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Less: Expense not allocated to segments </span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,972</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7,853</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">735</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Worldwide total</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$16,687</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">15,062</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">19,359</span></td></tr></table></div> 56964000000 31857000000 54759000000 30400000000 52563000000 27427000000 14036000000 13345000000 13715000000 12722000000 14066000000 10397000000 10906000000 10812000000 9842000000 10476000000 9714000000 9537000000 13529000000 3703000000 11963000000 3122000000 11642000000 2493000000 -426000000 257000000 993000000 -589000000 1494000000 553000000 18919000000 3740000000 22659000000 18246000000 4669000000 22915000000 15647000000 4447000000 20094000000 5972000000 7853000000 735000000 16687000000 15062000000 19359000000 <div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.644%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.764%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Identifiable Assets</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Innovative Medicine</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$57,070</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">58,324</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">MedTech</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">84,322</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">74,710</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">141,392</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">133,034</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">General corporate </span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(6)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">38,712</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">34,524</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Worldwide total</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$180,104</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">167,558</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.465%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.873%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Additions to Property,<br/>Plant &amp; Equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Depreciation and<br/>Amortization</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Innovative Medicine</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$1,710</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,653</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,374</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$3,760</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,847</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,687</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">MedTech</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,443</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,372</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,120</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,237</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,943</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,302</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Segments total</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,153</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,025</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,494</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,997</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,790</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,989</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Discontinued operations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">162</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">303</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">383</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">641</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">General corporate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">271</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">356</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">212</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">342</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">313</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">340</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Worldwide total</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$4,424</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">4,543</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">4,009</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$7,339</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">7,486</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">6,970</span></td></tr></table></div> 57070000000 58324000000 84322000000 74710000000 141392000000 133034000000 38712000000 34524000000 180104000000 167558000000 1710000000 1653000000 1374000000 3760000000 3847000000 3687000000 2443000000 2372000000 2120000000 3237000000 2943000000 2302000000 4153000000 4025000000 3494000000 6997000000 6790000000 5989000000 0 162000000 303000000 0 383000000 641000000 271000000 356000000 212000000 342000000 313000000 340000000 4424000000 4543000000 4009000000 7339000000 7486000000 6970000000 <div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.989%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.614%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.467%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Sales to Customers </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Long-Lived Assets </span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(7)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">United States</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$50,302</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">46,444</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">41,981</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$70,670</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">54,832</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">20,212</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">20,410</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">20,664</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">27,267</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">31,616</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Western Hemisphere excluding U.S. </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,714</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,549</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,108</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,728</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,491</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Asia-Pacific, Africa</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13,593</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13,756</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13,237</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,454</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,500</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Segments total</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">88,821</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">85,159</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">79,990</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">101,119</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">89,439</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">General corporate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,217</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,192</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other non long-lived assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">77,768</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">76,927</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Worldwide total</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$88,821</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">85,159</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">79,990</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$180,104</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">167,558</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:125%">See Note 1 for a description of the segments in which the Company operates. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Export sales are not significant. In fiscal year 2024, the Company utilized three wholesalers distributing products for both segments that represented approximately 20.5%, 15.6% and 12.3% of the total gross revenues. In fiscal year 2023, the Company had three wholesalers distributing products for both segments that represented approximately 18.2%, 15.1% and 14.2% of the total gross revenues. In fiscal year 2022, the Company had three wholesalers distributing products for all three segments that represented approximately 18.9%, 15.0%, and 13.8% of the total gross revenues. </span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:125%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:125%;padding-left:8.64pt"><span style="-sec-ix-hidden:f-2949">Other segment expenses</span> for each reportable segment include charges related to other income and expenses, restructuring activities and impairment charges related to in-process research and development.</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:125%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:125%;padding-left:7.29pt">Amounts not allocated to segments include interest (income)/expense and general corporate (income)/expense. The fiscal years 2024 and 2023 include charges for talc matters of approximately $5.1 billion and $7 billion, respectively (See Note 19, Legal proceedings, for additional details). The fiscal year 2024 includes a loss of approximately $0.4 billion related to the debt to equity exchange of the Company's remaining shares of Kenvue Common Stock. The fiscal year 2023 includes the unfavorable change in the fair value of the retained stake in Kenvue of approximately $0.4 billion.</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:125%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:125%;padding-left:7.19pt">Innovative Medicine segment income before tax includes:</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:125%">•</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:125%;padding-left:8.25pt">Acquired in-process research &amp; development expense of $1.25 billion to secure the global rights to the NM26 bispecific antibody (Yellow Jersey acquisition)</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:125%">•</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:125%;padding-left:8.25pt">Monetization of royalty rights of $0.3 billion</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:125%">•</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:125%;padding-left:8.25pt">Litigation expense of $0.3 billion primarily related to Risperdal Gynecomastia</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:125%">•</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:125%;padding-left:8.25pt">An intangible asset impairment charge of approximately $0.2 billion associated with the M710 (biosimilar) asset acquired as part of the acquisition of Momenta Pharmaceuticals in 2020.</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:125%">•</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:125%;padding-left:8.25pt">A restructuring related charge of $0.1 billion</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:125%">•</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:125%;padding-left:8.25pt">One-time COVID-19 Vaccine manufacturing exit related costs of $0.1 billion</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:125%">•</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:125%;padding-left:8.25pt">Favorable changes in the fair value of securities of $0.1 billion</span></div><div style="padding-left:14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:125%">MedTech segment income before tax includes:</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:125%">•</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:125%;padding-left:8.25pt">Acquisition and integration related costs of $1.0 billion primarily related to the acquisition of Shockwave </span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%">•</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.25pt">Acquired in-process research and development expense of $0.5 billion from the V-Wave acquisition</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%">•</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.25pt">A gain of $0.2 billion related to the Acclarent divestiture</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%">•</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.25pt">A Medical Device Regulation charge of $0.2 billion</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%">•</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.25pt">A restructuring related charge of $0.2 billion</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:130%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:7.07pt">Innovative Medicine segment income before tax includes:</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:130%">•</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.16pt">One-time COVID-19 Vaccine manufacturing exit related costs of $0.7 billion </span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:130%">•</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.16pt">A restructuring related charge of $0.5 billion</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:130%">•</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.16pt">Unfavorable changes in the fair value of securities of $0.4 billion </span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:130%">•</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.16pt">Favorable litigation related items of $0.1 billion</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:130%">•</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.16pt">Loss on divestiture of $0.2 billion. </span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:130%">•</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.16pt">An intangible asset impairment charge of approximately $0.2 billion related to market dynamics associated with a non-strategic asset (M710) acquired as part of the acquisition of Momenta Pharmaceuticals in 2020.</span></div><div style="padding-left:14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:112%">MedTech segment income before tax includes:</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:130%">•</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.16pt">Acquired in-process research and development expense of $0.4 billion related to the Laminar acquisition in 2023</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:130%">•</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.16pt">A restructuring related charge of $0.3 billion</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:130%">•</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.16pt">Acquisition and integration related costs of $0.2 billion primarily related to the acquisition of Abiomed</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:130%">•</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.16pt">A Medical Device Regulation charge of $0.3 billion</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:130%">•</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.16pt">Income from litigation settlements of $0.1 billion</span></div><div style="padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:112%;position:relative;top:-3.15pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:112%;padding-left:7.17pt">Innovative Medicine segment income before tax includes:</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:130%">•</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.16pt">One-time COVID-19 Vaccine manufacturing exit related costs of $1.5 billion</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:130%">•</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.16pt">An intangible asset impairment charge of approximately $0.8 billion related to an in-process research and development asset, bermekimab (JnJ-77474462), an investigational drug for the treatment of Atopic Dermatitis (AD) and Hidradenitis Suppurativa (HS) acquired with the acquisition of XBiotech, Inc. in the fiscal year 2020. Additional information regarding efficacy of the AD and HS indications became available which led the Company to the decision to terminate the development of bermekimab for AD and HS</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:130%">•</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.16pt">Litigation expense of $0.1 billion </span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:130%">•</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.16pt">Unfavorable changes in the fair value of securities of $0.7 billion </span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:130%">•</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.16pt">A restructuring related charge of $0.1 billion </span></div><div style="padding-left:14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:112%">MedTech segment income before tax includes:</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:130%">•</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.16pt">Litigation expense of $0.6 billion primarily for pelvic mesh related costs</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:130%">•</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.16pt">A restructuring related charge of $0.3 billion </span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:130%">•</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.16pt">Acquisition and integration related costs of $0.3 billion primarily related to the acquisition of Abiomed</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:25.2pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%">•</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.25pt">A Medical Device Regulation charge of $0.3 billion</span></div><div style="margin-bottom:4pt;margin-top:4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:130%;position:relative;top:-3.15pt;vertical-align:baseline">(6)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%"> </span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%"> General corporate includes cash, cash equivalents, marketable securities and other corporate assets. </span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:130%;position:relative;top:-3.15pt;vertical-align:baseline">(7)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:7.64pt">Long-lived assets include property, plant and equipment, net for fiscal years 2024, and 2023 of $20,518 and $19,898, respectively, and intangible assets and goodwill, net for fiscal years 2024 and 2023 of $81,818 and $70,733, respectively.</span></div> 50302000000 46444000000 41981000000 70670000000 54832000000 20212000000 20410000000 20664000000 27267000000 31616000000 4714000000 4549000000 4108000000 1728000000 1491000000 13593000000 13756000000 13237000000 1454000000 1500000000 88821000000 85159000000 79990000000 101119000000 89439000000 1217000000 1192000000 77768000000 76927000000 88821000000 85159000000 79990000000 180104000000 167558000000 0.205 0.156 0.123 0.182 0.151 0.142 3 0.189 0.150 0.138 5100000000 7000000000 -400000000 -400000000 1250000000 300000000 300000000 200000000 100000000 100000000 100000000 1000000000 500000000 200000000 200000000 200000000 700000000 500000000 -400000000 100000000 -200000000 200000000 400000000 300000000 200000000 300000000 100000000 1500000000 800000000 100000000 -700000000 100000000 600000000 300000000 300000000 300000000 20518000000 19898000000 81818000000 70733000000 Acquisitions and divestitures<div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Subsequent to the fiscal year end 2024, the Company announced it has entered into a definitive agreement to acquire Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, for $132.00 per share in cash for a total equity value of approximately $14.6 billion. The Company expects to fund the transaction through a combination of cash on hand and debt. The closing of the transaction is expected to occur later this year subject to applicable regulatory approvals, approval by Intra-Cellular Therapies’ stockholders and other customary closing conditions for a transaction of this type. The results of operations will be included in the Innovative Medicine segment beginning on the acquisition date.</span></div><div><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Business combinations</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Acquisitions of a business are accounted for as business combinations applying the acquisition method of accounting. Under this method, the assets acquired and liabilities assumed are recorded at their respective fair values as of the acquisition date in the Company’s consolidated financial statements. The excess of the purchase price over the fair value of the acquired net assets, where applicable, is recorded as goodwill. The results of operations of these acquisitions have been included in the Company’s financial statements from their respective dates of acquisition. </span></div><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">During the fiscal year 2024, certain businesses were acquired for $15.1 billion, net of cash acquired. The fiscal year 2024 acquisitions primarily included; Ambrx Biopharma, Inc., Shockwave Medical Inc., and Proteologix, Inc. The remaining acquisitions were not material.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">On June 20, 2024, the Company completed the acquisition of Proteologix, Inc., a privately held biotechnology company focused on bispecific antibodies for immune-mediated diseases, for approximately $0.8 billion net of cash acquired, with potential for an additional milestone payment. The results of operations are included in the Innovative Medicine segment as of the acquisition date. The fair value of the acquisition was allocated to assets acquired of $1.2 billion, primarily non-amortizable intangible assets, inclusive of purchased IPR&amp;D, for $0.9 billion, goodwill for $0.3 billion, and $0.3 billion of liabilities assumed which included $0.1 billion related to a contingent consideration. The preliminary purchase price allocation is subject to any subsequent valuation adjustments within the measurement period. A probability of success factor ranging from 30% to 45% was used in the fair value calculation to reflect inherent regulatory and commercial risk of the IPR&amp;D. The discount rate applied was approximately 16%. The goodwill is primarily attributable to synergies expected to arise from the business acquisition and is not expected to be deductible for tax purposes. Acquisition related costs before tax for the fiscal 2024 were not material. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">On May 31, 2024, the Company completed the acquisition of Shockwave Medical Inc. (SWAV)(Shockwave), a leading, first-to-market provider of innovative intravascular lithotripsy (IVL) technology for the treatment of calcified coronary artery disease (CAD) and peripheral artery disease (PAD) in an all-cash merger transaction. The Company acquired all the outstanding shares of Shockwave’s common stock for $335.00 per share through a merger of Shockwave with a subsidiary of the Company. The results of operations were included in the MedTech segment as of the acquisition date.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Details of the fair value amounts recognized for assets acquired and liabilities assumed as of the purchase date and at the end of fiscal year 2024, which includes measurement period adjustments, are included in the table below. As the acquisition occurred in May 2024, the Company is still finalizing the allocation of the purchase price to the individual assets acquired and liabilities assumed. The allocation of the purchase price included in the current period balance sheet is based on the best estimate of management and is preliminary and subject to change.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.584%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.060%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Billions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">May 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 29, 2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">Assets acquired:</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">$1.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">$1.1</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Goodwill</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">7.5</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">7.6</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amortizable intangibles</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">5.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">5.3</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">IPR&amp;D</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">0.6</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">0.6</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Inventory</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">0.5</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">0.5</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">0.5</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">0.4</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total assets acquired</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">$15.5</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">$15.5</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Liabilities assumed:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Deferred taxes</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">$1.5</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">$1.5</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Notes payable*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1.0</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1.0</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accrued liabilities**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">0.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">0.4</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total liabilities assumed</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">$2.9</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">$2.9</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net assets acquired</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">$12.6</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">$12.6</span></td></tr><tr style="height:6pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net assets acquired as of May 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">$12.6</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Less: Cash acquired</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Equity awards settled</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">0.6</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Settlement of Note payable*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1.0</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total enterprise value as of June 30, 2024</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">$13.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%">*    Represents the convertible debt which was subsequently paid in the fiscal second quarter of 2024.</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%">**    Includes $0.2 billion of equity awards</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The goodwill is primarily attributable to synergies expected to arise from the business acquisition and is not expected to be deductible for tax purposes. Acquisition related costs before tax for the fiscal 2024 were $0.9 billion of which $0.4 billion was related to the fair value of the inventory step-up and was recorded in Cost of products sold and $0.5 billion primarily related to equity awards and was recorded in Other (income) expense. The amortizable intangible assets were primarily comprised of already in-market CAD and PAD IVL products with the average weighted lives of 14 years. The IPR&amp;D assets were valued for technology programs for unapproved products. The value of the IPR&amp;D was calculated using a probability-adjusted cash flow projection discounted for the risk inherent in such projects with the weighted average probability of success factors of approximately 50%. The discount rate applied was 9.0%.</span></div><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">On March 7, 2024, the Company completed the acquisition of Ambrx Biopharma, Inc., (Ambrx), a clinical-stage biopharmaceutical company with a proprietary synthetic biology technology platform to design and develop next-generation antibody drug conjugates (ADCs), in an all-cash merger transaction for a total equity value of approximately $2.0 billion, or $1.8 billion net of cash acquired. The Company acquired all of the outstanding shares of Ambrx’s common stock for $28.00 per share through a merger of Ambrx with a subsidiary of the Company. The results of operations were included in the Innovative Medicine segment as of the acquisition date. The fair value of the acquisition was allocated to assets acquired of $2.3 billion, primarily non-amortizable intangible assets, inclusive of purchased IPR&amp;D, for $1.9 billion, goodwill for $0.3 billion and liabilities assumed of $0.5 billion, which includes deferred taxes of $0.4 billion. The preliminary purchase price allocation is subject to any subsequent valuation adjustments within the measurement period. A probability of success factor ranging from 40% to </span></div><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">70% was used in the fair value calculation to reflect inherent regulatory and commercial risk of the IPR&amp;D. The discount rate applied was approximately 17%. The goodwill is primarily attributable to synergies expected to arise from the business acquisition and is not expected to be deductible for tax purposes. Acquisition related costs before tax for the fiscal year 2024 were not material.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">During the fiscal year 2023, the Company did not make any acquisitions that qualified as a business combination. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">During the fiscal year 2022, certain businesses were acquired for $17.7 billion, net of cash acquired. The fiscal year 2022 acquisitions primarily included Abiomed, Inc. (Abiomed). The remaining acquisitions were not material.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">On December 22, 2022, the Company completed the acquisition of Abiomed, a leading, first-to-market provider of cardiovascular medical technology with a first-in-kind portfolio for the treatment of coronary artery disease and heart failure which also has an extensive innovation pipeline of life-saving technologies. The transaction broadens the Company’s position as a growing cardiovascular innovator, advancing the standard of care in heart failure and recovery, one of healthcare’s largest areas of unmet need. The results of operations were included in the MedTech segment as of the date of the acquisition. The acquisition was completed through a tender offer for all outstanding shares. The consideration paid in the acquisition consisted of an upfront payment of $380.00 per share in cash, amounting to $17.1 billion, net of cash acquired, as well as a non-tradeable contingent value right (“CVR”) entitling the holder to receive up to $35.00 per share in cash (which with respect to the CVRs total approximately $1.6 billion in the aggregate) if certain commercial and clinical milestones are achieved. The corresponding enterprise value (without taking into account the CVRs) of approximately $16.5 billion includes cash, cash equivalents and marketable securities acquired.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The milestones of the CVR consist of:</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">a.</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%;padding-left:7.65pt">$17.50 per share, payable if net sales for Abiomed products exceeds $3.7 billion during Johnson &amp; Johnson’s fiscal second quarter of 2027 through fiscal first quarter of 2028, or if this threshold is not met during this period and is subsequently met during any rolling four quarter period up to the end of Johnson &amp; Johnson’s fiscal first quarter of 2029, $8.75 per share;</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">b.</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%;padding-left:7.23pt">$7.50 per share payable upon FDA premarket application approval of the use of Impella® products in ST-elevated myocardial infarction (STEMI) patients without cardiogenic shock by January 1, 2028; and</span></div><div style="margin-bottom:6pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">c.</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%;padding-left:7.49pt">$10.00 per share payable upon the first publication of a Class I recommendation for the use of Impella® products in high risk PCI or STEMI with or without cardiogenic shock within four years from their respective clinical endpoint publication dates, but in all cases no later than December 31, 2029.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">During the fiscal fourth quarter of 2023, the Company finalized the purchase price allocation. In fiscal 2023, there were purchase price allocation adjustments netting to approximately $0.2 billion with an offsetting increase to goodwill. The fair value of the acquisition was allocated to assets acquired of $20.1 billion (net of $0.3 billion cash acquired), primarily to goodwill for $11.1 billion, amortizable intangible assets for $6.6 billion, IPR&amp;D for $1.1 billion, marketable securities of $0.6 billion and liabilities assumed of $3.0 billion, which includes the fair value of the contingent consideration mentioned above for $0.7 billion and deferred taxes of $2.0 billion. The goodwill is primarily attributable to the commercial acceleration and expansion of the portfolio and is not expected to be deductible for tax purposes. The contingent consideration was recorded in Other Liabilities and adjusted to fair value through the fiscal year end 2024 on the Consolidated Balance Sheet.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The amortizable intangible assets were primarily comprised of already in-market products of the Impella® platform with an average weighted life of 14 years. The IPR&amp;D assets were valued for technology programs for unapproved products. The value of the IPR&amp;D was calculated using probability-adjusted cash flow projections discounted for the risk inherent in such projects. The probability of success factor ranged from 52% to 70%. The discount rate applied was 9.5%. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">In the fiscal years 2024, 2023 and 2022, the Company recorded acquisition related costs before tax of approximately $0.3 billion, $0.2 billion and $0.3 billion, which was primarily recorded in Other (income)/expense.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">In accordance with U.S. GAAP standards related to business combinations, and goodwill and other intangible assets, supplemental pro forma information for fiscal years 2024, 2023 and 2022 is not provided, as the impact of the aforementioned acquisitions did not have a material effect on the Company’s results of operations.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Asset acquisitions</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Acquired In-process research and development (IPR&amp;D) in an asset acquisition is immediately expensed as research and development expense in the Company's consolidated financial statements. Milestone payments incurred prior to regulatory approval are expensed as research and development expense when the milestone event occurs.</span></div><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The fiscal year 2024 asset acquisitions expensed as research and development included V-Wave Ltd. and the global rights to the NM26 bispecific antibody (Yellow Jersey acquisition). The remaining activity was not material.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">On October 8, 2024, the Company completed the acquisition of V-Wave Ltd, a privately-held company focused on developing innovative treatment options for patients with heart failure, for an upfront payment of $0.6 billion, with the potential for additional regulatory and commercial milestone payments up to approximately $1.1 billion. The Company recorded an IPR&amp;D charge of approximately $0.5 billion, net of a gain recorded on the Company's existing investment in V-Wave and the results of operations are included in the MedTech segment as of the acquisition date. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">On July 11, 2024, the Company completed the acquisition of Yellow Jersey, a demerged subsidiary of Numab Therapeutics AG, to secure the global rights to NM26, a novel, investigational first-in-class bispecific antibody targeting two clinically proven pathways in atopic dermatitis (AD), in an all-cash transaction for approximately $1.25 billion. The Company recorded an IPR&amp;D charge of approximately $1.25 billion, and the results of operations are included in the Innovative Medicine segment as of the acquisition date.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The fiscal year 2023 asset acquisitions expensed as research and development included Laminar Inc. The remaining activity was not material.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">During the fiscal year 2023, the Company completed the acquisition of Laminar Inc., a privately-held medical device company focused on eliminating the left atrial appendage (LAA) in patients with non-valvular atrial fibrillation (AFib), for an upfront payment of $0.4 billion. The Company recorded an IPR&amp;D charge of approximately $0.4 billion and the results of operations are included in the MedTech segment as of the acquisition date. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">There were no significant asset acquisitions in 2022.</span></div><div><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Divestitures</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">During the fiscal year 2024, the Company completed the divestiture of Acclarent resulting in approximately $0.3 billion in proceeds and the divestiture of Ponvory outside of the U.S. resulting in approximately $0.2 billion in proceeds. All other divestitures were not material.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">During the fiscal year 2023, the Company executed divestitures resulting in approximately $0.2 billion in proceeds resulting in gains or losses that were not material. At fiscal year end 2023, the Company held assets, primarily intangibles, on its Consolidated Balance Sheet of approximately $0.3 billion, primarily related to Acclarent and Ponvory, that were subsequently divested in fiscal 2024.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">During fiscal year 2022, the Company did not make any material divestitures.</span></div> 132.00 14600000000 15100000000 800000000 1200000000 900000000 300000000 300000000 100000000 0.30 0.45 0.16 0 335.00 <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Details of the fair value amounts recognized for assets acquired and liabilities assumed as of the purchase date and at the end of fiscal year 2024, which includes measurement period adjustments, are included in the table below. As the acquisition occurred in May 2024, the Company is still finalizing the allocation of the purchase price to the individual assets acquired and liabilities assumed. The allocation of the purchase price included in the current period balance sheet is based on the best estimate of management and is preliminary and subject to change.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.584%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.060%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Billions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">May 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 29, 2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">Assets acquired:</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">$1.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">$1.1</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Goodwill</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">7.5</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">7.6</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amortizable intangibles</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">5.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">5.3</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">IPR&amp;D</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">0.6</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">0.6</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Inventory</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">0.5</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">0.5</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">0.5</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">0.4</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total assets acquired</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">$15.5</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">$15.5</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Liabilities assumed:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Deferred taxes</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">$1.5</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">$1.5</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Notes payable*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1.0</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1.0</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accrued liabilities**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">0.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">0.4</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total liabilities assumed</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">$2.9</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">$2.9</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net assets acquired</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">$12.6</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">$12.6</span></td></tr><tr style="height:6pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net assets acquired as of May 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">$12.6</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Less: Cash acquired</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Equity awards settled</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">0.6</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Settlement of Note payable*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1.0</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total enterprise value as of June 30, 2024</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">$13.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%">*    Represents the convertible debt which was subsequently paid in the fiscal second quarter of 2024.</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%">**    Includes $0.2 billion of equity awards</span></div> 1100000000 1100000000 7500000000 7600000000 5300000000 5300000000 600000000 600000000 500000000 500000000 500000000 400000000 15500000000 15500000000 1500000000 1500000000 1000000000.0 1000000000.0 400000000 400000000 2900000000 2900000000 12600000000 12600000000 12600000000 1100000000 600000000 1000000000.0 13100000000 200000000 900000000 400000000 500000000 P14Y 0.50 0.090 2000000000 1800000000 28.00 2300000000 1900000000 300000000 500000000 400000000 0.40 0.70 0.17 17700000000 380.00 17100000000 35.00 1600000000 16500000000 17.50 3700000000 8.75 7.50 10.00 200000000 20100000000 300000000 11100000000 6600000000 1100000000 600000000 3000000000 700000000 2000000000 P14Y 0.52 0.70 0.095 300000000 200000000 300000000 600000000 1100000000 500000000 1250000000 1250000000 400000000 400000000 300000000 200000000 200000000 300000000 0 Legal proceedings<div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Johnson &amp; Johnson and certain of its subsidiaries are involved in various lawsuits and claims regarding product liability; intellectual property; commercial; indemnification and other matters; governmental investigations; and other legal proceedings that arise from time to time in the ordinary course of their business.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company records accruals for loss contingencies associated with these legal matters when it is probable that a liability will be incurred, and the amount of the loss can be reasonably estimated. As of December 29, 2024, the Company has determined that the liabilities associated with certain litigation matters are probable and can be reasonably estimated. The Company has accrued for these matters and will continue to monitor each related legal issue and adjust accruals as might be warranted based on new information and further developments in accordance with ASC 450-20-25. For these and other litigation and regulatory matters discussed below for which a loss is probable or reasonably possible, the Company is unable to estimate the possible loss or range of loss beyond the amounts accrued. Amounts accrued for legal contingencies often result from a complex series of judgments about future events and uncertainties that rely heavily on estimates and assumptions including timing of related payments. The ability to make such estimates and judgments can be affected by various factors including, among other things, whether damages sought in the proceedings are unsubstantiated or indeterminate; scientific and legal discovery has not commenced or is not complete; proceedings are in early stages; matters present legal uncertainties; there are significant facts in dispute; procedural or jurisdictional issues; the uncertainty and unpredictability of the number of </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">potential claims; ability to achieve comprehensive multi-party settlements; complexity of related cross-claims and counterclaims; and/or there are numerous parties involved. To the extent adverse awards, judgments or verdicts have been rendered against the Company, the Company does not record an accrual until a loss is determined to be probable and can be reasonably estimated.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">In the Company’s opinion, based on its examination of these matters, its experience to date and discussions with counsel, the ultimate outcome of legal proceedings, net of liabilities accrued in the Company’s balance sheet, is not expected to have a material adverse effect on the Company’s financial position. However, the resolution of, or increase in accruals for, one or more of these matters in any reporting period may have a material adverse effect on the Company’s results of operations and cash flows for that period.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Matters concerning talc</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">A significant number of personal injury claims alleging that talc causes cancer have been asserted against the Company and its affiliates arising out of the use of body powders containing talc, primarily JOHNSON’S Baby Powder. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">In talc cases that have gone to trial, the Company has obtained a number of defense verdicts, but there also have been verdicts against the Company, many of which have been reversed on appeal. In June 2020, the Missouri Court of Appeals reversed in part and affirmed in part a July 2018 verdict of $4.7 billion in Ingham v. Johnson &amp; Johnson, et al., No. ED 207476 (Mo. App.), reducing the overall award to $2.1 billion. An application for transfer of the case to the Missouri Supreme Court was subsequently denied, and in June 2021, a petition for certiorari, seeking a review of the Ingham decision by the United States Supreme Court, was denied. In June 2021, the Company paid the award, which, including interest, totaled approximately $2.5 billion. The facts and circumstances, including the terms of the award, were unique to the Ingham decision and not representative of other claims brought against the Company. The Company continues to believe that it has strong legal grounds to contest the other talc verdicts that it has appealed. Notwithstanding the Company’s confidence in the safety of its talc products, in certain circumstances the Company has settled cases. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">In June 2014, the Mississippi Attorney General filed a complaint against the Company alleging violation of the Mississippi Consumer Protection Act by failing to disclose alleged health risks associated with female consumers’ use of talc contained in JOHNSON’S Baby Powder and JOHNSON’S Shower to Shower (a product divested in 2012). The Company has reached an agreement to resolve this matter. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">In January 2020, the State of New Mexico filed a consumer protection case alleging that the Company deceptively marketed and sold its talcum powder products by making misrepresentations about the safety of the products and the presence of carcinogens, including asbestos. The Company has reached an agreement to resolve this matter. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Forty-two states and the District of Columbia commenced a joint investigation into the Company’s marketing of its talcum powder products. In January 2024, the Company reached an agreement in principle with the multi-state group of state Attorneys General, subject to ongoing negotiation of non-monetary terms. In June 2024, the settlements were finalized. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">In October 2021, Johnson &amp; Johnson Consumer Inc. (Old JJCI) implemented a corporate restructuring (the 2021 Corporate Restructuring). As a result of that restructuring, Old JJCI ceased to exist and three new entities were created: (a) LTL Management LLC, a North Carolina limited liability company (LTL or Debtor); (b) Royalty A&amp;M LLC, a North Carolina limited liability company and a direct subsidiary of LTL (RAM); and (c) the Debtor’s direct parent, Johnson &amp; Johnson Consumer Inc., a New Jersey company (New JJCI). The Debtor received certain of Old JJCI’s assets and became solely responsible for the talc-related liabilities of Old JJCI, including all liabilities related in any way to injury or damage, or alleged injury or damage, sustained or incurred in the purchase or use of, or exposure to, talc, including talc contained in any product, or to the risk of, or responsibility for, any such damage or injury, except for any liabilities for which the exclusive remedy is provided under a workers’ compensation statute or act (the Talc-Related Liabilities).</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">In October 2021, notwithstanding the Company’s confidence in the safety of its talc products, the Debtor filed a voluntary petition with the United States Bankruptcy Court for the Western District of North Carolina, Charlotte Division, seeking relief under Chapter 11 of the Bankruptcy Code (the LTL Bankruptcy Case). All litigation against LTL, Old JJCI, New JJCI, the Company, other of their corporate affiliates, identified retailers, insurance companies, and certain other parties (the Protected Parties) was stayed. The LTL Bankruptcy Case was transferred to the United States Bankruptcy Court for the District of New Jersey. Claimants filed motions to dismiss the LTL Bankruptcy Case and, following a multiple day hearing, the New Jersey Bankruptcy Court denied those motions in March 2022. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The claimants subsequently filed notices of appeal as to the denial of the motions to dismiss the LTL Bankruptcy Case and the extension of the stay to the Protected Parties. On January 30, 2023, the Third Circuit reversed the Bankruptcy Court’s ruling and remanded to the Bankruptcy Court to dismiss the LTL bankruptcy. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">In April 2023, the New Jersey Bankruptcy Court dismissed the LTL Bankruptcy Case, effectively lifting the stay as to all parties and returning the talc litigation to the tort system. LTL re-filed in the United States Bankruptcy Court for the District of New Jersey seeking relief under Chapter 11 of the Bankruptcy Code (the LTL 2 Bankruptcy Case). As a result of the new filing, all talc claims against LTL were again automatically stayed pursuant to section 362 of the Bankruptcy Code. Additionally, the New Jersey Bankruptcy Court issued a temporary restraining order staying all litigation as to LTL, Old JJCI, New JJCI, the Company, identified retailers, and certain other parties (the New Protected Parties). </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Also in April 2023, the New Jersey Bankruptcy Court issued a decision that granted limited injunctive relief to the Company and the New Protected Parties (the LTL 2 Preliminary Injunction). The LTL 2 Preliminary Injunction remained in force until late August 2023, following the Bankruptcy Court’s extension of the initial LTL 2 Preliminary Injunction in June 2023. Under the LTL 2 Preliminary Injunction, except for those cases filed in the federal court ovarian cancer multi-district litigation, discovery in all personal injury and wrongful death matters was permitted to proceed. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Furthermore, in April 2023, the Talc Claimants' Committee filed a motion to dismiss the LTL 2 Bankruptcy followed by similar motions from other claimants. Hearings on the motions to dismiss occurred in June 2023. In July 2023, the court dismissed the LTL 2 Bankruptcy case and, the same day, the Company stated its intent to appeal the decision and to continue its efforts to obtain a resolution of the talc claims. In September 2023, the Bankruptcy Court entered an order granting LTL leave to seek a direct appeal to the Third Circuit Court of Appeals. In October 2023, the Third Circuit granted LTL’s petition for a direct appeal. In July 2024, the Third Circuit issued a non-precedential opinion affirming the Bankruptcy Court's decision to dismiss the LTL Bankruptcy case.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">In October 2023, the Company stated that it was pursuing the following four parallel and alternative pathways to achieve a comprehensive and final resolution of the talc claims: (i) the appeal of the LTL 2 dismissal decision; (ii) pursuing a consensual “prepackaged” bankruptcy case, as “strongly encouraged” by the Bankruptcy Court in its dismissal decision; (iii) aggressively litigating the talc claims in the tort system; and (iv) pursuing affirmative claims against experts for false and defamatory narratives regarding the Company’s talc powder products. In December 2023, LTL changed its state of formation to Texas and its name to LLT Management LLC ("LLT").</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Following the dismissal of LTL 2, new lawsuits were filed, cases across the country that had been stayed were reactivated, and trials have commenced. The majority of the cases are pending in federal court, organized in a multi-district litigation (MDL) in the United States District Court for the District of New Jersey. In the MDL, case-specific discovery proceeded. The MDL proceedings have been stayed by order of the bankruptcy court in the Red River Bankruptcy case discussed below. In March 2024, the court granted the Company's motion for a renewed Daubert hearing prior to the trial. The briefing on the renewed Daubert issues was completed in August 2024.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">In May 2024, the Company commenced a three-month solicitation period of its proposed consensual “prepackaged” Chapter 11 bankruptcy plan (the “Proposed Plan”) for the comprehensive and final resolution of all current and future claims related to cosmetic talc in the United States, excluding claims related to mesothelioma or State consumer protection claims, in exchange for the payment by the Company of present value of approximately $6.475 billion payable over 25 years (nominal value of approximately $8.0 billion, discounted at a rate of 4.4%). The claims encompassed by the Proposed Plan constitute 99.75% of pending lawsuits against the Company relating to its talc powder products. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">In August 2024, LLT engaged in a restructuring that resulted in the creation of three new Texas limited liability companies: (a) Red River Talc, LLC ("Red River"); (b) Pecos River Talc LLC ("Pecos River"); and (3) New Holdco (Texas) LLC. As a result of this restructuring, all claims related to ovarian and other gynecological cancers were separated and allocated to Red River, and mesothelioma, governmental unit and certain other claims were allocated to Pecos River.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">In September 2024, while reiterating the Company's continued confidence in the safety of its talc products, Red River filed a voluntary petition with the United States Bankruptcy Court for the Southern District of Texas, seeking relief under Chapter 11 of the Bankruptcy Code (the Red River Bankruptcy Case), in furtherance of the Company's consensual "prepackaged" Proposed Plan. Red River also filed a motion for a temporary restraining order, seeking to extend the automatic stay to additional non-debtor entities. Prior to filing, the initial proposed plan was amended to, among other things, increase the proposed resolution by $1.75 billion.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Shortly after Red River filed its Chapter 11 petition, the U.S. Trustee's office filed a motion to transfer venue in the New Jersey Bankruptcy Court, and thereafter, a motion to transfer venue and a motion to dismiss in the Texas Bankruptcy Court. A coalition of six plaintiff law firms also filed a motion to transfer venue and a motion to dismiss in the Texas Bankruptcy Court. In September 2024, the Texas Bankruptcy Court entered a temporary order enjoining the commencement or prosecution of all claims against Red River and certain non-debtor entities, including the Company, until October 11, 2024. The temporary order was extended in October 2024 and again in December 2024. The commencement and prosecution of all claims against Red River and certain non-debtor entities are currently enjoined until March 15, 2025. Also in September 2024, the New Jersey Bankruptcy Court denied the U.S. Trustee's motion to transfer venue without prejudice. In October 2024, the Texas Bankruptcy Court denied the motion to transfer venue from Texas to New Jersey Bankruptcy Court. A consolidated hearing to address, among other things, the motions to dismiss and plan confirmation is currently scheduled to begin on February 18, 2025. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Mesothelioma and State consumer protection claims are being addressed outside the Proposed Plan. The Company separately has resolved 95% of the mesothelioma lawsuits filed to date and has resolved the State claims.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">To account for these settlements and the contemplated comprehensive resolution through the Proposed Plan, the Company recorded a cumulative incremental charge of approximately $5.0 billion, through the fourth fiscal quarter 2024. As of December 29, 2024, the total present value of the reserve is approximately $11.6 billion (or nominal value of approximately $13.5 billion), net of payments made in fiscal 2024. Approximately ten percent of the reserve is recorded as a current liability. The recorded amount remains the Company's best estimate of probable loss.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">In February 2019, the Company’s talc supplier, Imerys Talc America, Inc. and two of its affiliates, Imerys Talc Vermont, Inc. and Imerys Talc Canada, Inc. (collectively, Imerys) filed a voluntary petition for relief under Chapter 11 of the United States Code (the Bankruptcy Code) in the United States Bankruptcy Court for the District of Delaware (Imerys Bankruptcy). The Imerys Bankruptcy relates to Imerys’s potential liability for personal injury from exposure to talcum powder sold by Imerys. In its bankruptcy, Imerys alleges it has claims against the Company for indemnification and rights to joint insurance proceeds. In its bankruptcy, Imerys proposed a Chapter 11 plan (the Imerys Plan) that contemplated all talc-related claims against it being channeled to a trust along with its alleged indemnification rights against the Company. Following confirmation and consummation of the plan, the trust would pay talc claims pursuant to proposed trust distribution procedures (the TDP) and then seek indemnification from the Company.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">In February 2021, Cyprus Mines Corporation (Cyprus), which had owned certain Imerys talc mines, filed a voluntary petition for relief under Chapter 11 of the Bankruptcy Code and filed its Disclosure Statement and Plan (the Cyprus Plan). The Cyprus Plan contemplates a settlement with Imerys and talc claimants where Cyprus would make a monetary contribution to a trust established under the Imerys Plan in exchange for an injunction against talc claims asserted against it and certain affiliated parties. Cyprus also asserts it has claims for indemnity against the Company arising out of talc personal injury claims. Under the Cyprus Plan, Cyprus would also contribute its alleged indemnification rights to the trust. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">In September 2023, Imerys and Cyprus filed amended plans of reorganization. The amended plans contemplate a similar construct as the prior Imerys and Cyprus Plans, including all talc claims against Imerys and Cyprus (and certain other protected parties) being channeled to a trust along with Imerys’s and Cyprus’s alleged indemnification rights against the Company. The Company opposed both plans on the basis that the plans inflated Imerys’s and Cyprus’s liability for talc claims and had the potential effect of imposing those inflated liabilities on the Company through the Company’s alleged indemnification obligations.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">In July 2024, the Company, Imerys, and Cyprus and certain of their affiliates (including their parent entities), and the tort claimants' committees and future claimants' representatives appointed in their respective Chapter 11 cases entered into a global settlement agreement (the Imerys Settlement Agreement) to resolve their ongoing disputes, including disputes raised in the Imerys and Cyprus bankruptcies. In August 2024, Imerys and Cyprus filed amended Chapter 11 plans and disclosure statements incorporating the terms of the settlement with the Company. In October 2024, the Imerys Bankruptcy Court entered an order approving the Imerys Settlement Agreement (the Settlement Order). The effectiveness of certain provisions of the settlement, including mutual releases, are subject to certain conditions, including the Imerys and Cyprus Plans being accepted by a sufficient number and amount of voting creditors to be confirmed under the Bankruptcy Code. Certain insurers have appealed the Settlement Order and sought a stay of the order pending appeal, which the Court denied on January 13, 2025. The briefing of the appeal in the District Court is scheduled to be completed in April 2025. On January 5, 2025, Imerys and Cyprus each filed a certification of voting results, indicating that their respective plan had been accepted by each voting class of creditors. A joint confirmation hearing for the plans is scheduled for April 2025.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:128%">In February 2018, a securities class action lawsuit was filed against the Company and certain named officers in the United States District Court for the District of New Jersey, alleging that the Company violated the federal securities laws by failing to disclose alleged asbestos contamination in body powders containing talc, primarily JOHNSON’S Baby Powder, and that purchasers of the Company’s shares suffered losses as a result. In April 2019, the Company moved to dismiss the complaint. In December 2019, the Court denied, in part, the motion to dismiss. The case was stayed in May 2022 pursuant to the LTL Bankruptcy Case and was reopened in May 2023. In December 2023, the Court granted Plaintiff’s motion for class certification. In January 2024, Defendants filed a petition with the Third Circuit under Federal Rule of Civil Procedure 23(f) for permission to appeal the Court’s order granting class certification, and in February 2024, the Third Circuit granted Defendants' petition. In February 2024, fact discovery closed, the Court ordered the parties to mediate, and stayed the case pending mediation. In May 2024, the parties participated in an unsuccessful mediation. In June 2024, at the parties' request, the Court lifted the stay for certain limited discovery, but otherwise kept the stay in place pending a decision from the Third Circuit on the 23(f) petition. Briefing on the 23(f) petition was completed in September 2024. In January 2025, the Third Circuit listed the appeal for oral argument in March 2025.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:129%">Matters concerning opioids</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:128%">Beginning in 2014 and continuing to the present, the Company and Janssen Pharmaceuticals, Inc. (JPI), along with other pharmaceutical companies, have been named in close to 3,500 lawsuits related to the marketing of opioids, including DURAGESIC, NUCYNTA and NUCYNTA ER. Similar lawsuits have also been filed by private plaintiffs and organizations, including but not limited to the following: individual plaintiffs on behalf of children born with Neonatal Abstinence Syndrome (NAS); hospitals; and health insurers/payors. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:128%">To date, the Company and JPI have litigated two of the cases to judgment and have prevailed in both, either at trial or on appeal. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:128%">In July 2021, the Company announced finalization of an agreement to settle the state and subdivision claims for up to $5.0 billion. Approximately 70% of the all-in settlement was paid by the end of fiscal fourth quarter 2024. A few government entities opted out of the settlement. In September 2024, the Company reached an agreement to resolve the hospital cases.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:128%">The Company and JPI continue to defend the cases brought by the remaining government entity litigants as well as the cases brought by private litigants. In total, there are approximately 35 remaining opioid cases against the Company and JPI in various state courts, 390 remaining cases in the Ohio multi-district litigation (MDL), and 4 additional cases in other federal courts.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:128%">In addition, the Province of British Columbia filed suit against the Company and its Canadian affiliate Janssen Inc., and many other industry members, in Canada. That action was certified as an opt in class action on behalf of other provincial/territorial and the federal governments in Canada in January 2025. Additional proposed class actions have been filed in Canada against the Company and Janssen Inc., and many other industry members, by and on behalf of people who used opioids (for personal injuries), municipalities and First Nations bands. The proposed class action in Quebec on behalf of residents diagnosed with opioid use disorder was authorized to proceed against Janssen Inc. and other industry members in April 2024; and leave to appeal was denied in October 2024.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:128%">Starting in November 2019, a series of shareholder derivative complaints were filed against the Company as the nominal defendant and certain current and former directors and officers as defendants in the Superior Court of New Jersey. The complaint alleges breaches of fiduciary duties related to the marketing of opioids, and that the Company has suffered damages as a result of those alleged breaches. As of September 2024, all the complaints had been dismissed, and all appeals exhausted.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Product liability</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:128%">The Company and certain of its subsidiaries are involved in numerous product liability claims and lawsuits involving multiple products. Claimants in these cases seek substantial compensatory and, where available, punitive damages. While the Company believes it has substantial defenses, it is not feasible to predict the ultimate outcome of litigation. From time to time, even if it has substantial defenses, the Company considers isolated settlements based on a variety of circumstances. The Company has accrued for these matters and will continue to monitor each related legal issue and adjust accruals as might be warranted based on new information and further developments in accordance with ASC 450-20-25, Contingencies. The Company accrues an estimate of the legal defense costs needed to defend each matter when those costs are probable and can be reasonably estimated. For certain of these matters, the Company has accrued additional amounts such as estimated costs associated with settlements, damages and other losses. Product liability accruals can represent projected product liability for thousands of claims around the world, each in different litigation environments and with different fact patterns. Changes to the accruals may be required in the future as additional information becomes available.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The table below contains the most significant of these cases and provides the approximate number of plaintiffs in the United States with direct claims in pending lawsuits regarding injuries allegedly due to the relevant product or product category as of December 29, 2024:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:81.340%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.419%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Product or product category</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of plaintiffs </span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Body powders containing talc, primarily JOHNSON’S Baby Powder</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #eb1700;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">62,830 </span></td><td style="border-top:1pt solid #eb1700;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">DePuy ASR XL Acetabular System and DePuy ASR Hip Resurfacing System</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">60 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">PINNACLE Acetabular Cup System</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">910 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Pelvic meshes</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,990 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">ETHICON PHYSIOMESH Flexible Composite Mesh</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">130 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">RISPERDAL</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">ELMIRON</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,170 </span></td><td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The number of pending lawsuits is expected to fluctuate as certain lawsuits are settled or dismissed and additional lawsuits are filed. There may be additional claims that have not yet been filed.</span></div><div style="margin-bottom:6pt;margin-top:10pt"><span style="color:#000000;font-family:'Johnson Display',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MedTech</span></div><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">DePuy ASR XL Acetabular System and ASR Hip Resurfacing System</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">In August 2010, DePuy Orthopaedics, Inc. (DePuy) announced a worldwide voluntary recall of its ASR XL Acetabular System and DePuy ASR Hip Resurfacing System (ASR Hip) used in hip replacement surgery. Claims for personal injury have been made against DePuy and the Company. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Northern District of Ohio. Litigation has also been filed in countries outside of the United States, primarily in the United Kingdom, Ireland, India and Italy. In November 2013, DePuy reached an agreement with a Court-appointed committee of lawyers representing ASR Hip plaintiffs to establish a program to settle claims with eligible ASR Hip patients in the United States. This settlement program has resolved more than 10,000 claims, thereby bringing to resolution significant ASR Hip litigation activity in the United States. However, lawsuits in the United States remain, and the settlement program does not address litigation outside of the United States. The Company continues to receive information with respect to potential additional costs associated with this recall on a worldwide basis. The Company has established accruals for the costs associated with the United States settlement program and ASR Hip-related product liability litigation.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">DePuy PINNACLE Acetabular Cup System </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Claims for personal injury have also been made against DePuy Orthopaedics, Inc. and the Company (collectively, DePuy) relating to the PINNACLE Acetabular Cup System used in hip replacement surgery. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. Most cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Northern District of Texas (Texas MDL). Beginning on June 1, 2022, the Judicial Panel on Multidistrict Litigation ceased transfer of new cases into the Texas MDL, and there are now cases pending in federal court outside the Texas MDL. Litigation also has been filed in state courts and in countries outside of the United States. During the first quarter of 2019, DePuy established a United States settlement program to resolve these cases. As part of the settlement program, adverse verdicts have been settled. The Company has established an accrual for product liability litigation associated with the PINNACLE Acetabular Cup System and the related settlement program.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:130%">Ethicon Pelvic Mesh </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Claims for personal injury have been made against Ethicon, Inc. (Ethicon) and the Company arising out of Ethicon’s pelvic mesh devices used to treat stress urinary incontinence and pelvic organ prolapse. The Company continues to receive information with respect to potential costs and additional cases. Cases filed in federal courts in the United States had been organized as a multi-district litigation (MDL) in the United States District Court for the Southern District of West Virginia. In March 2021, the MDL Court entered an order closing the MDL. The MDL Court has remanded cases for trial to the jurisdictions where the case was originally filed and additional pelvic mesh lawsuits have been filed, and remain, outside of the MDL. The Company has settled or otherwise resolved the majority of the United States cases and the estimated costs associated with these settlements and the remaining cases are reflected in the Company’s accruals. In addition, class actions and individual personal injury cases or claims seeking damages for alleged injury resulting from Ethicon’s pelvic mesh devices have been commenced in </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">various countries outside of the United States, including claims and cases in the United Kingdom, the Netherlands, and Ireland, and class actions in Israel, Australia, Canada and South Africa. The vast majority of these actions are now resolved. The Company has established accruals with respect to product liability litigation associated with Ethicon’s pelvic mesh products.</span></div><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Ethicon Physiomesh</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Following a June 2016 worldwide market withdrawal of Ethicon Physiomesh Flexible Composite Mesh (Physiomesh), claims for personal injury have been made against Ethicon, Inc. (Ethicon) and the Company alleging personal injury arising out of the use of this hernia mesh device. Cases filed in federal courts in the United States have been organized as a multi-district litigation (MDL) in the United States District Court for the Northern District of Georgia. A multi-county litigation (MCL) also has been formed in New Jersey state court and assigned to Atlantic County for cases pending in New Jersey. In addition to the matters in the MDL and MCL, there are additional lawsuits pending in the United States District Court for the Southern District of Ohio, which are part of the MDL for polypropylene mesh devices manufactured by C.R. Bard, Inc., and lawsuits pending in two New Jersey MCLs formed for Proceed/Proceed Ventral Patch and Prolene Hernia systems, and lawsuits pending outside the United States. In May 2021, Ethicon and lead counsel for the plaintiffs entered into a term sheet to resolve approximately 3,600 Physiomesh cases (covering approximately 4,300 plaintiffs) pending in the MDL and MCL at that time. A master settlement agreement (MSA) was entered into in September 2021 and includes 3,729 cases in the MDL and MCL. Other than a small number of cases still pending in the MDL, all Physiomesh matters in the United States have been resolved or are undergoing formal review for purposes of settlement.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Claims have also been filed against Ethicon and the Company alleging personal injuries arising from the PROCEED Mesh and PROCEED Ventral Patch hernia mesh products. In March 2019, the New Jersey Supreme Court entered an order consolidating these cases pending in New Jersey as an MCL in Atlantic County Superior Court. Additional cases have been filed in various federal and state courts in the United States, and in jurisdictions outside the United States. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Ethicon and the Company also have been subject to claims for personal injuries arising from the PROLENE Polypropylene Hernia System. In January 2020, the New Jersey Supreme Court created an MCL in Atlantic County Superior Court to handle such cases. Cases involving this product have also been filed in other federal and state courts in the United States. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">In October 2022, an agreement in principle, subject to various conditions, was reached to settle the majority of the pending cases involving Proceed, Proceed Ventral Patch, Prolene Hernia System and related multi-layered mesh products, as well as a number of unfiled claims. All litigation activities in the two New Jersey MCLs are stayed pending effectuation of the proposed settlement. Future cases that are filed in the New Jersey MCLs will be subject to docket control orders requiring early expert reports and discovery requirements.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company has established accruals with respect to product liability litigation associated with Ethicon Physiomesh Flexible Composite Mesh, PROCEED Mesh and PROCEED Ventral Patch, and PROLENE Polypropylene Hernia System products.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Display',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Innovative Medicine</span></div><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">RISPERDAL</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Claims for personal injury have been made against Janssen Pharmaceuticals, Inc. and the Company arising out of the use of RISPERDAL, and related compounds, indicated for the treatment of schizophrenia, acute manic or mixed episodes associated with bipolar I disorder and irritability associated with autism. Lawsuits primarily have been filed in state courts in Pennsylvania, California, and Missouri. Other actions are pending in various courts in the United States and Canada. The Company continues to defend RISPERDAL product liability lawsuits, and continues to evaluate potential costs related to those claims. The Company has successfully defended a number of these cases but there have been verdicts against the Company, including a verdict in October 2019 of $8.0 billion of punitive damages related to one plaintiff, which the trial judge reduced to $6.8 million in January 2020. In September 2021, the Company entered into a settlement in principle with the counsel representing plaintiffs in this matter and in substantially all of the outstanding cases in the United States. The costs associated with this and other settlements are reflected in the Company's accruals.</span></div><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">ELMIRON</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Claims for personal injury have been made against a number of Johnson &amp; Johnson companies, including Janssen Pharmaceuticals, Inc. and the Company, arising out of the use of ELMIRON, a prescription medication indicated for the relief of bladder pain or discomfort associated with interstitial cystitis. These lawsuits, which allege that ELMIRON contributes to the development of permanent retinal injury and vision loss, have been filed in both state and federal courts across the United States. In December 2020, lawsuits filed in federal courts in the United States, including putative class action cases seeking medical monitoring, were organized as a multi-district litigation in the United States District Court for the District of New </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Jersey (MDL). In addition, cases have been filed in various state courts of New Jersey, which have been coordinated in a multi-county litigation in Bergen County, as well as the Court of Common Pleas in Philadelphia, which have been coordinated and granted mass tort designation. In addition, three class action lawsuits have been filed in Canada. The Company continues to defend ELMIRON product liability lawsuits and continues to evaluate potential costs related to those claims. All U.S. based ELMIRON matters have been resolved or are undergoing formal review for purposes of settlement. The Company has established accruals for defense and indemnity costs associated with ELMIRON related product liability litigation.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Intellectual property</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Certain subsidiaries of the Company are subject, from time to time, to legal proceedings and claims related to patent, trademark and other intellectual property matters arising out of their businesses. Many of these matters involve challenges to the scope and/or validity of patents that relate to various products and allegations that certain of the Company’s products infringe the intellectual property rights of third parties. Although these subsidiaries believe that they have substantial defenses to these challenges and allegations with respect to all significant patents, there can be no assurance as to the outcome of these matters. A loss in any of these cases could adversely affect the ability of these subsidiaries to sell their products, result in loss of sales due to loss of market exclusivity, require the payment of past damages and future royalties, and may result in a non-cash impairment charge for any associated intangible asset. </span></div><div style="margin-bottom:6pt;margin-top:10pt"><span style="color:#000000;font-family:'Johnson Display',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Innovative Medicine - litigation against filers of abbreviated new drug applications (ANDAs)</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company’s subsidiaries have brought lawsuits against generic companies that have filed ANDAs with the U.S. FDA (or similar lawsuits outside of the United States) seeking to market generic versions of products sold by various subsidiaries of the Company prior to expiration of the applicable patents covering those products. These lawsuits typically include allegations of non-infringement and/or invalidity of patents listed in FDA’s publication “Approved Drug Products with Therapeutic Equivalence Evaluations” (commonly known as the Orange Book). In each of these lawsuits, the Company’s subsidiaries are seeking an order enjoining the defendant from marketing a generic version of a product before the expiration of the relevant patents (Orange Book Listed Patents). In the event the Company’s subsidiaries are not successful in an action, or any automatic statutory stay expires before the court rulings are obtained, the generic companies involved would have the ability, upon regulatory approval, to introduce generic versions of their products to the market, resulting in the potential for substantial market share and revenue losses for the applicable products, and which may result in a non-cash impairment charge in any associated intangible asset. In addition, from time to time, the Company’s subsidiaries may settle these types of actions and such settlements can involve the introduction of generic versions of the products at issue to the market prior to the expiration of the relevant patents. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Inter Partes Review (IPR) process with the United States Patent and Trademark Office (USPTO), created under the 2011 America Invents Act, is also being used at times by generic companies in conjunction with ANDAs and lawsuits to challenge the applicable patents.</span></div><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">XARELTO</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Beginning in March 2021, Janssen Pharmaceuticals, Inc.; Bayer Pharma AG; Bayer AG; and Bayer Intellectual Property GmbH filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of XARELTO before expiration of certain Orange Book Listed Patents. The following entities are named defendants: Dr. Reddy’s Laboratories, Inc.; Dr. Reddy’s Laboratories, Ltd.; Lupin Limited; Lupin Pharmaceuticals, Inc.; Taro Pharmaceutical Industries Ltd.; Taro Pharmaceuticals U.S.A., Inc.; Teva Pharmaceuticals USA, Inc.; Mylan Pharmaceuticals Inc.; Mylan Inc.; Mankind Pharma Limited; Apotex Inc.; Apotex Corp.; Auson Pharmaceuticals Inc.; Shanghai Auson Pharmaceuticals Co. Ltd.; Cipla Ltd.; Cipla USA Inc.; InvaGen Pharmaceuticals, Inc.; Prinston Pharmaceuticals, Inc.; Ascent Pharmaceuticals, Inc.; and Hetero Labs Limited. In October 2024, the Company entered into a confidential settlement agreement with Auson Pharmaceuticals Inc. and Shanghai Auson Pharmaceuticals Co., Ltd. and the case was dismissed. In November 2024, the Company entered into confidential settlement agreements with Ascent Pharmaceuticals Inc. that resulted in dismissal of litigation against Ascent Pharmaceuticals, Inc. and Hetero Labs Limited. In January 2025, the Company entered into a confidential settlement agreement with Prinston Pharmaceutical, Inc. (as to U.S. Patent No. 9,539,218). The following U.S. patents are included in one or more cases: 9,539,218 and 10,828,310. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">U.S. Patent No. 10,828,310 was also under consideration by the USPTO in an IPR proceeding. In July 2023, the USPTO issued a final written decision finding the claims of the patent invalid. In September 2023, Bayer Pharma AG filed an appeal to the U.S. Court of Appeals for the Federal Circuit.</span></div><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">INVEGA SUSTENNA </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Beginning in January 2018, Janssen Pharmaceutica NV and Janssen Pharmaceuticals, Inc. filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of INVEGA SUSTENNA before expiration of the Orange Book Listed Patent. The following entities are named defendants: Teva Pharmaceuticals USA, Inc.; Mylan Laboratories Limited; Pharmascience Inc.; Mallinckrodt PLC; Specgx LLC; Tolmar, Inc.; Accord Healthcare, Inc.; Qilu Pharmaceutical Co. Ltd.; and Qilu Pharma Inc. The following U.S. patent is included in one or more cases: 9,439,906. In October 2020, the district court issued a decision in the case against Teva Pharmaceuticals USA, Inc., finding that United States Patent No. 9,439,906 is not invalid. Teva previously stipulated to infringement. Teva appealed the decision, and, in April 2024, the United States Court of Appeals for the Federal Circuit vacated and remanded the case to the district court for further proceedings. In November 2024, the district court issued its decision on remand, finding that United States Patent No. 9,439,906 is not invalid. Teva appealed to the Court of Appeals for the Federal Circuit, and oral argument is scheduled for April 2025. In February 2024, the district court issued a decision in the case against Tolmar Inc. finding that United States Patent No. 9,439,906 is not invalid. Tolmar previously stipulated to infringement. Tolmar has appealed the decision.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Beginning in February 2018, Janssen Inc. and Janssen Pharmaceutica NV initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against generic manufacturers who have filed ANDSs seeking approval to market generic versions of INVEGA SUSTENNA before expiration of the listed patent. The following entities are named defendants: Pharmascience Inc. and Apotex Inc. The following Canadian patent is included in one or more cases: 2,655,335. In June 2024, the Supreme Court dismissed the Apotex case. In September 2024, the Supreme Court granted Pharmascience's motion to appeal the Federal Court's decision that the 2,655,335 Patent is not invalid.</span></div><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">INVEGA TRINZA </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Beginning in September 2020, Janssen Pharmaceuticals, Inc., Janssen Pharmaceutica NV, and Janssen Research &amp; Development, LLC filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of INVEGA TRINZA before expiration of the Orange Book Listed Patent. The following entities are named defendants: Mylan Laboratories Limited; Mylan Pharmaceuticals Inc.; and Mylan Institutional LLC. The following U.S. patent is included in one or more cases: 10,143,693. In May 2023, the District Court issued a decision finding that Mylan’s proposed generic product infringes the asserted patent and that the patent is not invalid. Mylan has appealed the decision. Oral argument before the Court of Appeals for the Federal Circuit was held in February 2025.</span></div><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">SYMTUZA </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Beginning in November 2021, Janssen Products, L.P., Janssen Sciences Ireland Unlimited Company, Gilead Sciences, Inc. and Gilead Sciences Ireland UC filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of SYMTUZA before expiration of certain Orange Book Listed Patents. The following entities are named defendants: Lupin Limited; Lupin Pharmaceuticals, Inc.; MSN Laboratories Private Ltd.; MSN Life Sciences Private Ltd.; MSN Pharmaceuticals Inc.; Apotex Inc.; and Apotex Corp. The following U.S. patents are included in one or more cases: 10,039,718 and 10,786,518. A trial is scheduled to begin in February 2025.</span></div><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">ERLEADA </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Beginning in May 2022, Aragon Pharmaceuticals, Inc., Janssen Biotech, Inc. (collectively, Janssen), Sloan Kettering Institute for Cancer Research (SKI) and The Regents of the University of California filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of ERLEADA before expiration of certain Orange Book Listed Patents. The following entities are named defendants: Zydus Worldwide DMCC; Zydus Pharmaceuticals (USA), Inc.; Zydus Lifesciences Limited; Hetero Labs Limited Unit V; and Hetero USA, Inc. The following U.S. patents are included in one or more cases: 9,481,663; 9,884,054; 10,052,314 (which reissued as RE49,353); 10,702,508; 10,849,888; 8,445,507; 8,802,689; 9,388,159; 9,987,261; RE49,353; and 11,963,952. In October 2024, Janssen, The Regents of the University of California, SKI, Hetero Labs Limited Unit V, and Hetero USA, Inc. entered into a confidential settlement, and the case was dismissed. In November 2024, Janssen, The Regents of the University of California, Zydus Worldwide DMCC, Zydus Pharmaceuticals (USA), Inc., and Zydus Lifesciences Limited entered into confidential settlements, and the cases were dismissed. </span></div><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">SPRAVATO </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Beginning in May 2023, Janssen Pharmaceuticals, Inc. and Janssen Pharmaceutica NV filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of SPRAVATO before expiration of certain Orange Book Listed Patents. The following entities are named defendants: Sandoz </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Inc.; Hikma Pharmaceuticals Inc. USA; Hikma Pharmaceuticals PLC; and Alkem Laboratories Ltd. The following U.S. patents are included in one or more cases: 10,869,844; 11,173,134; 11,311,500; and 11,446,260. </span></div><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">INVOKANA </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Beginning in January 2024, Janssen Inc. and Mitsubishi Tanabe Pharma Corporation initiated Statements of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against generic manufacturers who filed ANDSs seeking approval to market generic versions of INVOKANA before expiration of the listed patents. The following entities are named defendants: Jamp Pharma Corporation and Apotex Inc. The following Canadian patents are included in one or more cases: 2,534,024 and 2,671,357. Trial in the Jamp action is scheduled for September 2025, and trial in the Apotex action is scheduled for December 2025.</span></div><div style="margin-bottom:6pt;margin-top:10pt"><span style="color:#000000;font-family:'Johnson Display',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MedTech </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">In March 2016, Abiomed, Inc. (Abiomed) filed a declaratory judgment action against Maquet Cardiovascular LLC (Maquet) in U.S. District Court for the District of Massachusetts seeking a declaration that the Impella does not infringe certain Maquet patents, currently U.S. Patent Nos. 7,022,100 (’100); 8,888,728; 9,327,068; 9,545,468; 9,561,314; and 9,597,437. Maquet counterclaimed for infringement of each of those patents. After claim construction, Maquet alleged infringement of only the ’100 patent. In September 2021, the court granted Abiomed’s motion for summary judgment of non-infringement of the ’100 patent, and in September 2023, the district court entered final judgment in favor of Abiomed on all patents-in-suit. Maquet appealed.</span></div><div><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:142%">Government proceedings</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Like other companies in the pharmaceutical and medical technologies industries, the Company and certain of its subsidiaries are subject to extensive regulation by national, state and local government agencies in the United States and other countries in which they operate. Such regulation has been the basis of government investigations and litigations. The most significant litigation brought by, and investigations conducted by, government agencies are listed below. It is possible that criminal charges and substantial fines and/or civil penalties or damages could result from government investigations or litigation.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Display',sans-serif;font-size:10pt;font-weight:700;line-height:130%">MedTech</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">In July 2018, the Public Prosecution Service in Rio de Janeiro and representatives from the Brazilian antitrust authority CADE inspected the offices of more than 30 companies including Johnson &amp; Johnson do Brasil Indústria e Comércio de Produtos para Saúde Ltda. The authorities appear to be investigating allegations of possible anti-competitive behavior and possible improper payments in the medical device industry. The Company continues to respond to inquiries regarding the Foreign Corrupt Practices Act from the United States Department of Justice (DOJ) and the United States Securities and Exchange Commission. The Company has been informed DOJ has closed its investigation.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">In July 2023, the DOJ issued Civil Investigative Demands to the Company, Johnson &amp; Johnson Surgical Vision, Inc., and Johnson &amp; Johnson Vision Care, Inc. (collectively, J&amp;J Vision) in connection with a civil investigation under the False Claims Act relating to free or discounted intraocular lenses and equipment used in eye surgery, such as phacoemulsification and laser systems. J&amp;J Vision has begun producing documents and information responsive to the Civil Investigative Demands. J&amp;J Vision is in ongoing discussions with the DOJ regarding its inquiry.</span></div><div><span style="color:#000000;font-family:'Johnson Display',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Innovative Medicine</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">In July 2016, the Company and Janssen Products, LP were served with a qui tam complaint pursuant to the False Claims Act filed in the United States District Court for the District of New Jersey alleging the off-label promotion of two HIV products, PREZISTA and INTELENCE, and anti-kickback violations in connection with the promotion of these products. The complaint was filed under seal in December 2012. The federal and state governments have declined to intervene, and the lawsuit is being prosecuted by the relators. The Court denied summary judgment on all claims in December 2021. Daubert motions were granted in part and denied in part in January 2022, and trial commenced in May 2024. On June 13, 2024, a jury found no liability regarding the anti-kickback violations but found liability for a portion of the off-label promotion claims. The Company is pursuing post-trial briefing challenging the verdict on the off-label claims.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">In March 2017, Janssen Biotech, Inc. (JBI) received a Civil Investigative Demand from the United States Department of Justice regarding a False Claims Act investigation concerning management and advisory services provided to rheumatology and gastroenterology practices that purchased REMICADE or SIMPONI ARIA. In August 2019, the United States Department of Justice notified JBI that it was closing the investigation. Subsequently, the United States District Court for the District of Massachusetts unsealed a qui tam False Claims Act complaint, which was served on the Company. The Department of Justice </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">had declined to intervene in the qui tam lawsuit in August 2019. The Company filed a motion to dismiss, which was granted in part and denied in part. Discovery is underway. </span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#eb1700;font-family:'Johnson Display',sans-serif;font-size:12pt;font-weight:700;line-height:120%">General litigation</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The Company or its subsidiaries are also parties to various proceedings brought under the Comprehensive Environmental Response, Compensation, and Liability Act, commonly known as Superfund, and comparable state, local or foreign laws in which the primary relief sought is the Company’s agreement to implement remediation activities at designated hazardous waste sites or to reimburse the government or third parties for the costs they have incurred in performing remediation as such sites.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">In October 2017, certain United States service members and their families brought a complaint against a number of pharmaceutical and medical devices companies, including Johnson &amp; Johnson and certain of its subsidiaries in United States District Court for the District of Columbia, alleging that the defendants violated the United States Anti-Terrorism Act. The complaint alleges that the defendants provided funding for terrorist organizations through their sales practices pursuant to pharmaceutical and medical device contracts with the Iraqi Ministry of Health. In July 2020, the District Court dismissed the complaint. In January 2022, the United States Court of Appeals for the District of Columbia Circuit reversed the District Court’s decision. In June 2023, defendants filed a petition for a writ of certiorari to the United States Supreme Court. In June 2024, the Supreme Court vacated the D.C. Circuit's decision and remanded the case to the D.C. Circuit. Oral argument was held in November 2024. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">In February 2024, a putative class action was filed against the Company, the Pension &amp; Benefits Committee of Johnson &amp; Johnson (Committee), and certain named officers and employees, in United States District Court for the District of New Jersey. In May 2024, the plaintiff filed an amended complaint against the Company and the Committee. The complaint alleges that defendants breached fiduciary duties under the Employee Retirement Income Security Act (ERISA) by allegedly mismanaging the Company’s prescription-drug benefits program. The complaint seeks damages and other relief. In January 2025, the Court granted in part and denied in part defendants’ motion to dismiss.</span></div><div style="margin-bottom:6pt;margin-top:10pt"><span style="color:#000000;font-family:'Johnson Display',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MedTech</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">In October 2020, Fortis Advisors LLC (Fortis), in its capacity as representative of the former stockholders of Auris Health Inc. (Auris), filed a complaint against the Company, Ethicon Inc., and certain named officers and employees (collectively, Ethicon) in the Court of Chancery of the State of Delaware. The complaint alleges breach of contract, fraud, and other causes of action against Ethicon in connection with Ethicon’s acquisition of Auris in 2019. The complaint seeks damages and other relief. In December 2021, the Court granted in part and denied in part defendants’ motion to dismiss certain causes of action. All claims against the individual defendants were dismissed. The trial occurred in January 2024. In September 2024, the court found liability with respect to certain claims and no liability with respect to other claims. The Company has appealed the decision. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">In October 2019, Innovative Health, LLC filed a complaint against Biosense Webster, Inc (BWI) in the United States District Court for the Central District of California. The complaint alleges that certain of BWI's business practices and contractual terms violate the antitrust laws of the United States and the State of California by restricting competition in the sale of High Density Mapping Catheters and Ultrasound Catheters. Trial is scheduled for April 2025. </span></div><div style="margin-bottom:6pt;margin-top:10pt"><span style="color:#000000;font-family:'Johnson Display',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Innovative Medicine</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">In June 2019, the United States Federal Trade Commission (FTC) issued a Civil Investigative Demand to the Company and Janssen Biotech, Inc. (collectively, Janssen) in connection with its investigation of whether Janssen’s REMICADE contracting practices violate federal antitrust laws. The Company has produced documents and information responsive to the Civil Investigative Demand. Janssen is in ongoing discussions with the FTC staff regarding its inquiry. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">In February 2022, the United States Federal Trade Commission (FTC) issued Civil Investigative Demands to Johnson &amp; Johnson and Janssen Biotech, Inc. (collectively, Janssen) in connection with its investigation of whether advertising practices for REMICADE violate federal law. Janssen has produced documents and information responsive to the Civil Investigative Demands. In January 2025, the FTC Bureau of Consumer Protection informed Janssen that it was closing its investigation.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:125%">In October 2018, two separate putative class actions were filed against Actelion Pharmaceutical Ltd., Actelion Pharmaceuticals U.S., Inc., and Actelion Clinical Research, Inc. (collectively Actelion) in United States District Court for the District of Maryland and United States District Court for the District of Columbia. The complaints allege that Actelion violated state and federal antitrust and unfair competition laws by allegedly refusing to supply generic pharmaceutical manufacturers with samples of TRACLEER. TRACLEER is subject to a Risk Evaluation and Mitigation Strategy required by the U.S. Food and Drug Administration, which imposes restrictions on distribution of the product. In January 2019, the plaintiffs dismissed the District of Columbia case and filed a consolidated complaint in the United States District Court for the District of Maryland. In September 2024, the district court granted plaintiff's motion for class certification. Trial is scheduled for March 2026.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:125%">In December 2023, a putative class action lawsuit was filed against the Company and Janssen Biotech Inc. (collectively Janssen) in the United States District Court for the Eastern District of Virginia. The complaint alleges that Janssen violated federal and state antitrust laws and other state laws by delaying biosimilar competition with STELARA through Janssen's enforcement of patent rights covering STELARA. The complaint seeks damages and other relief. In February 2024, plaintiffs filed an amended complaint, which Janssen moved to dismiss in March 2024. In August 2024, the court granted in part and denied in part Janssen's motion to dismiss. </span></div>In December 2018, Janssen Biotech, Inc., Janssen Oncology, Inc., Janssen Research &amp; Development, LLC, and Johnson &amp; Johnson (collectively, Janssen) were served with a qui tam complaint on behalf of the United States, certain states, and the District of Columbia. The complaint alleges that Janssen violated the federal False Claims Act and state law when providing pricing information for ZYTIGA to the government in connection with direct sales and reimbursement programs. At this time, the federal and state governments have declined to intervene. In December 2021, the United States District Court for the District of New Jersey denied Janssen's motion to dismiss. 4700000000 2100000000 2500000000 P3M 6475000000 P25Y 8000000000 0.044 0.9975 1750000000 0.95 5000000000 11600000000 13500000000 3500 5000000000 0.70 <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The table below contains the most significant of these cases and provides the approximate number of plaintiffs in the United States with direct claims in pending lawsuits regarding injuries allegedly due to the relevant product or product category as of December 29, 2024:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:81.340%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.419%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Product or product category</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of plaintiffs </span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Body powders containing talc, primarily JOHNSON’S Baby Powder</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #eb1700;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">62,830 </span></td><td style="border-top:1pt solid #eb1700;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">DePuy ASR XL Acetabular System and DePuy ASR Hip Resurfacing System</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">60 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">PINNACLE Acetabular Cup System</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">910 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Pelvic meshes</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,990 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">ETHICON PHYSIOMESH Flexible Composite Mesh</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">130 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">RISPERDAL</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">ELMIRON</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,170 </span></td><td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 62830 60 910 5990 130 7 2170 10000 3600 4300 3729 8000000000 6800000 Restructuring<div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:125%">In fiscal 2023, the Company commenced restructuring actions within its Innovative Medicine and MedTech segments. The amounts and details of the current year programs are included below.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:125%">In fiscal 2023, the Company completed a prioritization of its research and development (R&amp;D) investment within its Innovative Medicine segment to focus on the most promising medicines with the greatest benefit to patients. This resulted in the exit of certain programs within certain therapeutic areas. The R&amp;D program exits are primarily in infectious diseases and vaccines including the discontinuation of its respiratory syncytial virus (RSV) adult vaccine program, hepatitis and HIV development. Pre-tax Restructuring expenses of $0.1 billion in the fiscal year 2024, included the termination of partnered and non-partnered development program costs, asset impairments and asset divestments. Pre-tax Restructuring expenses of $0.5 billion in the fiscal year 2023, included the termination of partnered and non-partnered development program costs and asset impairments. Total project costs of approximately $0.6 billion have been recorded since the restructuring was announced. The program was completed in the fiscal fourth quarter of 2024.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:125%">In fiscal 2023, the Company initiated a restructuring program of its Orthopaedics franchise within the MedTech segment to streamline operations by exiting certain markets, product lines and distribution network arrangements. The pre-tax restructuring expense of $0.2 billion in the fiscal year 2024 primarily included costs related to market and product exits. The pre-tax restructuring expense of $0.3 billion in the fiscal year 2023 primarily included inventory and instrument charges related to market and product exits. Total project costs of approximately $0.5 billion have been recorded since the restructuring was announced. The estimated costs of the total program are between $0.7 billion - $0.8 billion and is expected to be completed by the end of fiscal year 2025.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:125%">The following table summarizes the restructuring expenses for the fiscal years 2024 and 2023:</span></div><div style="margin-bottom:4pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:77.173%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.764%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Pre-tax Dollars in Millions)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Innovative Medicine Segment</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$102</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">479</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">MedTech Segment</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">167</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">319</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total Programs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$269</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$798</span></td></tr></table></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:9.29pt">The fiscal year of 2024 included $102 million in Restructuring on the Consolidated Statement of Earnings. The fiscal year of 2023 included $449 million in Restructuring and $30 million in Cost of products sold on the Consolidated Statement of Earnings.</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.09pt">The fiscal year of 2024 included $132 million in Restructuring and $35 million in Cost of products sold on the Consolidated Statement of Earnings. The fiscal year of 2023 Included $40 million in Restructuring and $279 million in Cost of products sold on the Consolidated Statement of Earnings.</span></div>Restructuring reserves as of December 29, 2024 and December 31, 2023 were insignificant. 100000000 500000000 600000000 200000000 300000000 500000000 700000000 800000000 <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:125%">The following table summarizes the restructuring expenses for the fiscal years 2024 and 2023:</span></div><div style="margin-bottom:4pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:77.173%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.764%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Pre-tax Dollars in Millions)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Innovative Medicine Segment</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$102</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">479</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">MedTech Segment</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">167</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">319</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total Programs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$269</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$798</span></td></tr></table></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:9.29pt">The fiscal year of 2024 included $102 million in Restructuring on the Consolidated Statement of Earnings. The fiscal year of 2023 included $449 million in Restructuring and $30 million in Cost of products sold on the Consolidated Statement of Earnings.</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:8.09pt">The fiscal year of 2024 included $132 million in Restructuring and $35 million in Cost of products sold on the Consolidated Statement of Earnings. The fiscal year of 2023 Included $40 million in Restructuring and $279 million in Cost of products sold on the Consolidated Statement of Earnings.</span></div> 102000000 479000000 167000000 319000000 269000000 798000000 102000000 449000000 30000000 132000000 35000000 40000000 279000000 Kenvue separation and discontinued operations<div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The results of the Consumer Health business (previously reported as a separate business segment) have been reflected as discontinued operations in the Company’s consolidated statements of earnings as Net earnings from discontinued operations, net of taxes through August 23, 2023, the date of the exchange offer. Prior periods have been recast to reflect this presentation. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">On May 15, 2024, the Company issued $3.6 billion aggregate principal amount of commercial paper and received $3.6 billion of net cash proceeds to be used for general corporate purposes. On May 17, 2024, the Company completed a Debt-for-Equity Exchange of its remaining 182,329,550 shares of Kenvue Common Stock for the outstanding Commercial Paper. Upon completion of the Debt-for-Equity Exchange, the Commercial Paper was satisfied and discharged and the Company no longer owns any shares of Kenvue Common Stock. This exchange resulted in a loss of approximately $0.4 billion recorded in Other (income) expense. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">On May 8, 2023, Kenvue, completed an initial public offering (the IPO) resulting in the issuance of 198,734,444 shares of its common stock, par value $0.01 per share (the “Kenvue Common Stock”), at an initial public offering of $22.00 per share for net proceeds of $4.2 billion. The excess of the net proceeds from the IPO over the net book value of the Johnson &amp; Johnson divested interest was $2.5 billion and was recorded to additional paid-in capital. As of the closing of the IPO, Johnson &amp; Johnson owned approximately 89.6% of the total outstanding shares of Kenvue Common Stock and at July 2, 2023, the non-controlling interest of $1.3 billion associated with Kenvue was reflected in equity attributable to non-controlling interests in the consolidated balance sheet in the fiscal second quarter of 2023. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">On August 23, 2023, Johnson &amp; Johnson completed the disposition of an additional 80.1% ownership of Kenvue Common Stock through an exchange offer, which resulted in Johnson &amp; Johnson acquiring 190,955,436 shares of the Company’s common stock in exchange for 1,533,830,450 shares of Kenvue Common Stock. The $31.4 billion of Johnson &amp; Johnson common stock received in the exchange offer is recorded in Treasury stock. Following the exchange offer, the Company owned 9.5% of the total outstanding shares of Kenvue Common Stock that was recorded in other assets within continuing operations at the fair market value of $4.3 billion as of August 23, 2023. Subsequent changes are reflected in other income/expense and amounted to $0.4 billion expense through December 31, 2023.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Johnson &amp; Johnson divested net assets of $11.6 billion as of August 23, 2023, and the accumulated other comprehensive loss attributable to the Consumer Health business at that date was $4.3 billion. Additionally, at the date of the exchange offer, Johnson &amp; Johnson decreased the non-controlling interest by $1.2 billion to record the deconsolidation of Kenvue. This resulted in a non-cash gain on the exchange offer of $21.0 billion that was recorded in Net earnings from discontinued operations, net of taxes in the consolidated statements of earnings for the fiscal third quarter of 2023. This one-time gain includes a gain of $2.8 billion on the Kenvue Common Stock retained by Johnson &amp; Johnson. The gain on the exchange offer qualifies as a tax-free transaction for U.S. federal income tax purposes.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Also in connection with the separation, Johnson &amp; Johnson and Kenvue entered into a separation agreement and also entered into various other agreements that provide for certain transactions to effect the transfer of the assets and liabilities of the Consumer Health business to Kenvue and to govern various interim and ongoing relationships between Kenvue and Johnson &amp; Johnson following the completion of the Kenvue IPO, including transition services agreements (TSAs), transition manufacturing agreements (TMAs), trademark agreements, intellectual property agreements, an employee matters agreement, and a tax matters agreement. Under the TSAs, Johnson &amp; Johnson will provide Kenvue various services and, similarly, Kenvue will provide Johnson &amp; Johnson various services. The provision of services under the TSAs generally will terminate within 24 months following the Kenvue IPO. Additionally, Johnson &amp; Johnson and Kenvue entered into TMAs pursuant to which Johnson &amp; Johnson will manufacture and supply to Kenvue certain products and, similarly, Kenvue will manufacture and supply to Johnson &amp; Johnson certain products. The terms of the TMAs range in initial duration from 3 months to 5 years.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Amounts related to the TSAs and TMAs included in the consolidated statements of earnings were immaterial for both fiscal years 2024 and 2023. Additionally, the amounts due to and from Kenvue for the above agreements was not material as of December 31, 2023.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The results of the Consumer Health business (previously reported as a separate business segment), as well as the associated gain, have been reflected as discontinued operations in the Company’s consolidated statements of earnings as Net earnings from discontinued operations, net of taxes. As a result of the separation of Kenvue, Johnson &amp; Johnson incurred separation costs of $145 million in the fiscal year 2024, which was included in Net Earnings and incurred separation costs of $986 million and $1,089 million in the fiscal years 2023 and 2022, respectively, which were included in Net earnings from discontinued operations, net of taxes. These costs were primarily related to external advisory, legal, accounting, contractor and other </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">incremental costs directly related to separation activities. In the fiscal 2022, as part of the planned separation of the Company’s Consumer Health business, the Company recognized approximately $0.5 billion in net incremental tax costs. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Details of Net Earnings from Discontinued Operations, net of taxes are as follows:</span></div><div style="margin-bottom:4pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.280%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.765%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"> 2023</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Sales to customers</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">$10,036</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">14,953</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cost of products sold</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">4,369</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">6,494</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Gross profit</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">5,667</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">8,459</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Selling, marketing and administrative expenses</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">3,085</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">4,519</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Research and development expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">258</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">468</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Interest Income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(117)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">—</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Interest expense, net of portion capitalized</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">199</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">—</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other (income) expense, net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,092</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,060</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Gain) on separation of Kenvue</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(20,984)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">—</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Restructuring</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">—</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">46</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Earnings from Discontinued Operations Before Provision for Taxes on Income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">22,134</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">2,366</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Provision for taxes on income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">307</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">795</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Net earnings from Discontinued Operations</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%">$21,827</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%">1,571</span></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:9.29pt">The Company ceased consolidating the results of the Consumer Health business on August 23, 2023, the date of the exchange offer, but continued to reflect any separation costs incurred as part of discontinued operations through the end of the fiscal fourth quarter.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The following table presents depreciation, amortization and capital expenditures of the discontinued operations related to Kenvue:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:77.173%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.764%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"> 2023</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Depreciation and Amortization</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$383</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">641</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Capital expenditures</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$162</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">303</span></td><td colspan="3" style="display:none"></td></tr></table></div> 3600000000 3600000000 182329550 400000000 198734444 0.01 22.00 4200000000 2500000000 0.896 1300000000 0.801 190955436 1533830450 31400000000 0.095 4300000000 400000000 11600000000 -4300000000 1200000000 21000000000 2800000000 P24M P3M P5Y 145000000 986000000 1089000000 500000000 <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">Details of Net Earnings from Discontinued Operations, net of taxes are as follows:</span></div><div style="margin-bottom:4pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.280%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.765%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"> 2023</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Sales to customers</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">$10,036</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">14,953</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cost of products sold</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">4,369</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">6,494</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Gross profit</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">5,667</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">8,459</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Selling, marketing and administrative expenses</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">3,085</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">4,519</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Research and development expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">258</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">468</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Interest Income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(117)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">—</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Interest expense, net of portion capitalized</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">199</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">—</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other (income) expense, net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,092</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">1,060</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Gain) on separation of Kenvue</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">(20,984)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">—</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Restructuring</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">—</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">46</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Earnings from Discontinued Operations Before Provision for Taxes on Income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">22,134</span></td><td colspan="3" style="border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">2,366</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Provision for taxes on income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">307</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">795</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Net earnings from Discontinued Operations</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%">$21,827</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:0.5pt solid #959595;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:130%">1,571</span></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:4pt;padding-left:14.4pt;text-indent:-14.4pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:400;line-height:130%;padding-left:9.29pt">The Company ceased consolidating the results of the Consumer Health business on August 23, 2023, the date of the exchange offer, but continued to reflect any separation costs incurred as part of discontinued operations through the end of the fiscal fourth quarter.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:130%">The following table presents depreciation, amortization and capital expenditures of the discontinued operations related to Kenvue:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:77.173%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.764%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Dollars in Millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%"> 2023</span><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Depreciation and Amortization</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$383</span></td><td colspan="3" style="border-top:1pt solid #eb1700;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">641</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Johnson Text',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Capital expenditures</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$162</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">303</span></td><td colspan="3" style="display:none"></td></tr></table></div> 10036000000 14953000000 4369000000 6494000000 5667000000 8459000000 3085000000 4519000000 258000000 468000000 117000000 0 199000000 0 -1092000000 -1060000000 20984000000 0 0 46000000 22134000000 2366000000 307000000 795000000 21827000000 1571000000 383000000 641000000 162000000 303000000 PricewaterhouseCoopers LLP Florham Park, New Jersey false false false false true

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

  •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Ð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�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

    @XJDT-T/HM M5(VAU%0?)-D&?62+7>;T4S =D+494 I&J:E/YDL*#FD*'K86"O7:;#?']'&L MG[B'4BY*3&B70>U\R ;HB&JC&4FFJ& M1/MH>&'YZ]=?D5XQUKR \CQ4C:'45"\DST=T\7F$Y5?47ZFF@[(V!$KM*#75 M$$GM$4WM U9?QDUBM*SUE Z%>:@:0ZFI!IV]LW;L!Y$C:#4*H6HI5(VAU%2K)$;'V/W9+T\)<3]"T[%8^P!%:)2:ZH-$ MZ'@X0B/FC7Y\I@.R-@.*SR@UU0R)S_'PHO?7KY5BO?"M>0$E9:@:0ZFI7DA2 MCH>7O5&+JO[GD>F@K V!\C!*337D[&MC:![^<=MPH=LXE3#!J9^SQUHNP"Z, M^8;N!H>JI5 UAE)3K9$D'2=CK[N@+_R"JJ50-8924ZV2.!YC-XP3TXOASOL(+6T[?D'54J@:0ZFI)DG$3\9&_ 2*^%"U%*K&4&JJ51+QDV^% M^$D_XM.Q6/L 17R4FNJ#1/SDFR)^TH_X=$#69D 1'Z6FFB$1/Z$1?^ D8ZR2 MT]+6(Q>4_:%J#*6FFB39/QF[2IY J^10M12JQE!JJE7RKD#RK:KDB>$+BW2> M,;2:=[_:)Z5CML[P*-\[>_;%L]^T3)[H%7 3IAQ:=;X72LLS]OMIQR#S1))Y M0I/YP)G!6&&DI:V'&RBS0]482DW]%F')[/.Q=Z_/H;O7H6HI5(VAU%2K),[/ MO]7N]7G_[G4Z%FL?H,2.4E-]D,0^_Z:[U^?Z]^9J9D"9'*K&4&H',Z;U ^=- MFC79]>6&5VN^X$713AN[K9!O+3K]U:GX??M=?A&PO=V]R:W-H965T#9+/[8;$?&*EU02312])V NR/'U(B556GBM6GR)?Y,&,K MIY\J]W0V/L^5D_GEX M6O^;F_GB<;9:_W5Q>[[\O!AFU\\;/3Z<%]-I<_XXNW\ZNWC__+,?%Q?OYU]6 M#_=/PX^+;/GE\7&V^./C\##_]N$L/]O]X*?[V[O5Y@?G%^\_SVZ'GX?5+Y]_ M7*S_=OY*N;Y_')Z6]_.G;#'_Z.BFFQV>*YY+_NAV]+Z\_9YG?Y=3[_ M;?.7'ZX_G$TW4QH>AJO5AC%;_]_7X7)X>-B@UA/YORWU['70S8;VGW=T>O[M MU[_-K[/E<#E_^._[Z]7=A[/N++L>;F9?'E8_S;_]^[#]C>H-[VK^L'S^W^S; MMG9ZEEU]6:[FC]N-US-XO']Z^?_9[]L]86U0%'LV*+8;%-(-RNT&I72#:KM! M)=V@WFY02S=HMALTS_O^96<][VDU6\TNWB_FW[+%IGI-V_SA.:[GK=<[^/YI M\]'Z>;58_]O[]7:KBX_SQ7J+^Z?;9?:W[.?U!_?ZR\.0S6^R?\R?;O^V&A:/ MF1I^764_/"U7BR_KS]1JF;U1PVIV_[!\F_WU3UW95-]G]T_9I_N'A_5'9?G= M^H=Y4[*?_=G^Z_OSU7KFF_'/K[:S_/@RRV+/+/,B^S1_6MTM,_UT/5R[@//U M+_#Z>Q>[W_MC$26JX6J2%?UWV?J_BBK[Y6>5O?GSV\#$+@68,G_&E!&,2IF- M_N6G[,UVUX9@.F5.8S!*@?W;QQ\WL$V^;R,AE*\?OO(97NZ%.Y^L['_^L2[( M?E@-C\O_#7U(7FA5F+8Y"+];?IY=#1_.UD?9Y;#X.IQ=;"8[_3X4+!*FD#"- MA!$(YN1;O>9;Q>@7YAARO4XZE.C+]O7S]INSX->+LJBFT_?G7^VH_*JB+6M6 MI:)S23 M:5DV+(YP7=%W+! A3PMY-%[G[*'F=0\U\4_IL%RN3[6+Q>80]'F^V'0\H=W3 M>)_"O*UZMF\"157#BE1T/JF?5"2,0# GA_8UAS::PW_.5[.'[&'TF/%":>QC MQK2IJ5'1&J4D@802".4ETKTET\6/&[U>;_R;67>#5;+'X8]T= M9E]G#U_6?>'789'=S.X7N[_?[$VI\_?_U#NP1Z>1>@Y&PC021B"8DV7_FF4O MS-+.;9,CSW9_EM$14ONNWOM@Y-X'0R%'U$@8@6!.EOG4K-:FT32GDZ:>_B7[ MYWPU++/K=6K/"X8W;3W]]"G37Q;S+)_DTW[Z]DT9:O8_QO&I44)I"DK34!JA M:&[LUB(]ARZ4MCA4S$B:@M(TE$8HFAMS86(NCEPO;0%V?\G/J8&2KN1]3WPB MR2$@:82BN2$8)Y%'E\0I"Z8M:7-PV!]'&5RU3!N^6A+ M!1&@D)W]Y@E?1Y? MT_^\6N^,:W??9&]FRVR6?1X65^NC4_C$4^V94,WW%W+EK:3#:NBPA**Y&9DE M?QY?\S^?+NY?3Q??K5N_JR&;/2IJ TO:7EI?7) M:+E3(M28;I#&3.1Q-4'SQ7!_^[2U$U=_9,/O5W>SI]OA^3^[[[+58O:T?)CM M,Q9Q>G*:+[2\LEOW3;?)#V10O2$K#ONE_GQMKN>;MKN MC13/)T5;-WN[;J09N(32%)2FH31"T=SDC07).VS7C90&EU":@M(TE$8HFANS M$21YW) (NNY^O.OV2YJRY4=&J-: T@A%<[^--6*CB(N-A*Y[2XIVW;L:UOO[E "FI3 2%+J[QPB (KKR/+3KWE+YA&K>=,='3SW6"$?5T%$)17,3,FOW M(KYV'^VY-U^:!S-"+IXOH30%I6DHC;:TW#[DUI9(=G,TR_\BOOP_LN6.TY/3 M+$--[:;5Y(5X&BN3$8AU'$'49*=]V&K[)I2IZ)L%!)"[6TD 2%[HXR2_XB?N7#H7WV M"S5O^(0*K].&KNK%XVKHN(2BN2F9%7L17[%/)[6L-X!>N "E*2A-0VF$HKD7 M!1L74$ZAO4$)O:@!2E-0FH;2"$5S8S9.HXP[C?'>8 NP3_M]SZ^X#!5YO4%\ M*LDQ0,4%BN;&8,1%&1<7";W!EN1]FUJW/!-AH9(6:FDA"0K='67=K! W P?V M!N6>K^(]"1Q!MLJ?Z$^"U7\>&3#SW" M835T6$+1W(R,-2CCUJ"8]-P:M,%0H-8 2E-0FH;2"$5S;S4UUJ#"6H,*:@V@ M- 6E:2B-4#0W9F,-JF.M0140 @4_"X6*O+N0XE-)C@%J#5 T-P9C#2J8-:C" M*_*BYR\W8B/GSR@4S:0WY?TS!0O^>?"E0"X$T7N?N.;.*K^.K^&+2!V^W[X+["?J RA- M06D:2B,4S*320X":A]0-#<(8Q_JD6= )O2^_9XO@+PSC[!020NUM) $A>Z#@,V2 MO(D_A># WK<)W_=?> \'AJZYA:-JZ*B$HKD)F=5T$U]--YNOZ@+M01_,!?H8 M1"A-06D:2B,4S-- G*$!I"DK34!JA:&[,1C0T<=$PWAYL TD0)-7 H&H&CHJH6AN0D9#M'$-D4]* M=CE/.0U& C404)J"TC241BB:&Z\Q$"W60+10 P&E*2A-0VF$HKDQ&P/1'FL@ M6E\NY(W7!P2K2G[>B4\F.0BH@T#1W"",@VAA#J(-K]5SW@D(ZY2P3@OK:+S. MW4?&'K0GL0=M>.7N[R^H+Q".JJ&C$HKF)F0,03MF"/J0(=B\?">0"]000&D* M2M-0&J%H;L;6.RJQAJ"%&@(H34%I&DHC%,V-V1B"]EA#T 8- ;_8,5#EM050 M0P"E$8KFIF ,00LS!.V>17U?\$0$AD *TP(8Q6O<][,:0]"=Q!!T>];J_$*% M^.BIQQGAJ!HZ*J%H;D+&$'1Q0U!.BF S4 1S@6H"*$U!:1I*(Q3-S=AH@@ZK M"3JH)H#2%)2FH31"T=R8C2;HCM4$G2\ 6N_1SX$B?N*)3R0Y!*@B0-'<$(PB MZ&"*H LOP4OO_IU=8:P7D,*T $;Q&G?/&#'0G40,=.$E>LD;IOCHR8<9V:@: M.BJA:&Y"1@QT<3%P^.TZ<7#R&0-J";8T]T8<_@PE#1V34#0W2+/Z[^)/-CCR MMIXM??RVGO@TDH,2#JNAPQ**YF9EEO!=? E?F2N%_2Z\#,8#?7\CE*:@- VE M$8KF!FTL0==CNW#HXQ*@- 6E:2B-4#0GYMXHCSZN/,:[\"W ;K K[]$QDB(5 MGTIJ#% :H6AN#,9K]'&OD="']^'W0%;>$V:DA4I:J*6%)"AT=Y21 WW\@0,' MMN5]^,;^P$Z#+O^EPVKHL(2BN1F9E7T?7]E7D[)E3_X+MP9Q3NHY TI34)J& MT@A%<_,UTJ"OH*U!'W40R3$C:0I*TU :H6ANS,: ]'$#(F@-:N^LW]45/Z(* MBE1\*LDQ0#4'BN;&8#1'']<<*:U!$S[=%%XFPD(E+=320A(4NCO*:(0^KA$. M;0VVZWCVMK^JY"\BOXR/GWSDD8ZKH>,2BN:F9 1"+Q (@6_PJF V4'< I2DH M34-IA**Y&1MWT&/=00]U!U":@M(TE$8HFA-S/C7R8//GXUJ$'<$Y_7N7^H:J M^%=&(W-)30*+(QB.99%;6< 4P@[EKTO]8/+Q+_/$."W!T4@1VT&%M8-.H@YV MV'%W,#*!U"./>&"-'9A@.!95:445-PCYI.$/]BWKW8-]\TG]T7^NK_W3V&-] M1X9./=E@<0J+TU@MCQ8&E#Y0,6I[$X@N%8VK65]K$&8D=P M+ABN^7,K+X-E35UX)S*HAL#B"(9C>316'C 5L4-Y]ZHT_+Y9<:425VIQ)4DJ MV?YJK?UU$B.QP_IS\CL.J)(0#ZRQ Q,,QZ+JK*CB6N+PBXE&R.FG&*BEV.&< MZXGRVKN@2%A'L.FQI'HKJ?CM"T=>+;3#CU\NM*?2?PRP&*FE2!(4NCLPMQ;M M>7S17D[*H($+OM)[!);\Z8;B%!:GL3B"X5C4EA/([[+OA+,4)5GO.)SR4]"ZS!0.%8%I;!R.,&(Z55SL-O M6RA+/YA28..D."W!T4@1VT'62CZ/KAX/[HVW6/^W\WKC^ 32#S["@35V8(+A M6%36,CR/+\./Z(WCY/3S"?2NB1W.Z7D[OS6&CDHP',O36L;G\67\L1WT%B_H MH.,32<]+.+#&#DPP'(O,,@EYW"24D[IKF1#?TZ]#'XV Q2DL3F-Q!,.QF"T+ MD7?@?AWK'J XA<5I+(Y@.):V93+RN,F0].N]WZ\W_.+[-M%*)*[6XDB25;']9;J&(7V]P: ._Q?+K MWLKU"<[;>5A](!Y98TWY%N*A*C -1!0G,+B-!9',!R+ MV3(0!=A %%@# <4I+$YC<03#L;0M U$<;2 *WRWDZQ63=YP-EO&WB8[,)ST/ MK(- X=P\2LM!E#@'4>Y9VW/QP.(W%$0S'HK9D1 F6$2561D!Q"HO36!S! M<"QM2T:41\N(TK<,?<_?N22J4B.S24\#JR)0.#>-RE(1%4Y%5'N6^!5_ZK6X M4HDKM;B2))5L?UDJHCJ-BJC"STXH/8L3'S_Y8"0<5V/')1B.!65IB"JN(:I) M/=VG(:K@ZT9'B,FG%2A.87$:BR,8CN5M:8@*K"$JK(: XA06I[$X@N%8VI:& MJ([6$)4O&.K*NW1=4J5&9I.>!E9#H' L#4M#5#@-4867]U7C]7?22B6NU.)* MDE2R_65IB.HT&J+:\U!%ST+$QT\_&,G&U=AQ"89C05D2HHI+B&*2L^<3[6L= ML/X!BE-8G,;B"(9C*5O^H0+[APKK'Z XA<5I+(Y@.):VY1^JH_U#%;C1(G"0 M#55YU^K%9Y.>!M8_H'!N&K7E'VJ.74=9!5]E/L))/IE <0J+ MTU@H]J_G.NPM#6JG$E5I<29)*MK\LZU"?QCK4>U;__L4/ M\0FD'XV$ VOLP 3#L:@L[U#'OX<:ZQV@.(7%:2R.8#B6MN4=ZJ.]0^T;A<"S^B55:F0VZ6E@O0,*YZ;1 M6-ZAP7F')KR>K_B#I2_%E4I^QHGIY]0L/IABW/?=3#U'_P*'99@.!:HY16:^$LNCGWP MZQ8O>/!K?"+I@0D'UMB!"89CD5ERH(G+@7+2EDSXA9_[&N>D_Q<'?8DF%J>Q M.(+AW)1;2SJT4VS#WF+?R@'%*2Q.8W$$P[&T+672QI6)H&'?$IR&O6^]OC!< MYGU?&)]/>AY8,X+"L3PL,]+&S4A*S]Z&W\E9MMZE1M)*):[4XDJ25++]9>F% M-OYNBT-;^';/BRE:[PKO^ 32CT?"@35V8(+A6%26&VCC;F#=/O"+C<(/;8MS MTD\H2)S"XC061S <2]F2#FT-;A^PK^6 XA06I[$X@N%8VI9!:>,&1=(^-%Y? MT!7>EU*AJM+[0BH^F_0TL)($A6-I6)*DC4N2I.8A_'K-LO6^RI56*G&E%E>2 MI)+M+\M!M'$'<7#ST.V9D^?_XA-(/QH)!];8@0F&8U%9[J$=6?.C \J'#R@O]I(6JG$E5I<29)*MK\L M]="=1CUT>PR USS$QT\_&,G&U=AQ"89C05GBH8N+AV)2\"N5Z_ =TG%0^MD$ M:QZ@.(W%$0S'8K;,0P3G@;6/*!P+ W+/'0X\]"%5_1%X=WF)*U4XDHMKB1))=M?EGGH3F,> MNK */QGQ<BLLQ#%SM\K=-PK7(:JO MB MXW-)SP+K'E XEH7E'GJ<>^C#:_J:-VV7KY712Y6E."W!T4@1VT&6;.A/(QOZ M\**_]AN&^ 32#S["@35V8(+A6%26;NC'=$/%=4,3U@UQ4/KI ZL;H#B-Q1$, MQV*V=$,/U@T]5C= <0J+TU@IQPZ/CD;FD9P&5"S < MRZ*PLH#)A1TJML:_E!0I29&6%-%(T#<-*S5:SB_>/P^)VN!P>'I;9 MU>;^V,TQR?IIMAAN-J>A=W\OSLZ]GW_,WUWF@9_K_!T]__S?Y[=#I]F MB]O[IV7V,-RLAYI.-A#?,KH?%IF#] M[V_FZZ7R]B^; ;[-%[\]_SH7_P)02P,$% @ [(!-6O,Z5NG& P F \ M !D !X;"]W;W)K&ULK5==C]HX%/TK5K9:M5([ M^0[#%) *V6J[ZJQ&'77[4/7!)!>(FMA9VT#GW^^UDPD!,MD9%!X@<>XYON?8 MN?A.]ES\E!L 17X5.9-3:Z-4>6/;,ME 0>45+X'ADQ47!55X*]:V+ 70U("* MW/8<)[(+FC%K-C%C=V(VX5N59PSN!)';HJ#B80XYWT\MUWH<^)*M-TH/V+-) M2==P#^IK>2?PSFY8TJP )C/.B(#5U/K@WL2NIP$FXI\,]K)U3;24)><_]J7_JJ-: '< MZ F 5P.\4\!3,_@UP'\N(*@!@7&FDF)\B*FBLXG@>R)T-++I"V.F0:/\C.EU MOU<"GV:(4[,Y%XC(V%J2=^1O*@35ZT!>QZ!HELLW./KU/B:O7[TAKTC&R&V6 MY[A>XP4="2V> ?== _<[X'$__*\M0[C3-?N1&K]9"=_P^4_PW6^X4.\4 MB(+$L%3D^V<,()\4%/)'E]L56]#-ILO%C2QI E,+ZX$$L0-K]OMO;N2\[W)J M2+)X(+(C%X/&Q:"/_;"?24)QDDP]D"UN-T$2 6FFR K'X0;L<#,_RC-II5LZRAJC(F>L8<@K7>.<8,7!8@D MHSDI:8F#I>!K08LN$RKRJ+U8HS,3.H+.3>A-\T(31HT)HUX3/G/*JMW N *) MLA_H,H'XVC\1?![D!Z%[(K@WI0L%7S>"KWL%+PY+?*>7N$MI+\-+ M*\209/% 9$?.C1OGQH/^=P%'.&>N5JIG81#=RS(M,1 MY9W5X[@_JTM5MPZ@;J]JO67>DKTYH&/-I3L0V'#@61,W%$A%\$3:;4%]L'5; MZIPK)PBB4Q>Z T-_=&I$;Z*7&N$=C/#^UPB4+9788F.%GN@WJE-Y/X]'"G/. M[GI;+H?&_="7NF.W6A8LNVO3^DG\G]TR574 S6C37GXP3=7)^-R]651-XH&F MZEEOJ5BCG22'%5(Z5R-\#T35!E8WBI>F,5IRA6V6N=Q@ZPQ"!^#S%2KGS:P( &,& 9 >&PO=V]R:W-H M965TFILS:FOG9= MG:VA9/I*UE#A3"Y5R0QV5>'J6@%;-:)2N-3S0K=DO'+2I!F[4VDB-T;P"NX4 MT9NR9.KO#(3<39V1\S)PSXNUL0-NFM2L@ Q79]L^ 7AYW>:Q-;R5+*)]OYMIHZG@T$ C)C'1@^MG +0E@CC/&G\W1Z MI!7NMU_9>[KY"5T]@_3(I=/-+=MU: MSR'91AM9=F),4/*J?;+G;A_V!)0>$=!.0)O<+:A).6>&I8F2.Z+L:G2SC:;4 M1HWA>&7_E >C<):CSJ0SJ5#!JT*32W)3% H*9H LF-DH;CAH(G/R758%^0FJ M)#^6@N,"W$]-SN=@&!?Z@IP17I$%%\*.)Z[!7-;=S;H,LS8#/9)A#MD5H9-/ MA'K4)X\/A]?B?\N \_?L\]Q;T(AC*UJJ!1V1.W34>1 M/TG<[0#+[UG^*58XQ&I5X3YK,CG""GI6<(H5#;&" Q8=Q\$P*^Q9X2E6/,0* M#UDT.L**>E9TBC498D6'>^C[_C K[EGQNZR;'-]>*H%Y*CSKB(T4.V5UG:,K)MK9"D-7DI-&ULK5?;;MLX%/P50EL4+=!8=\G*V@*::(M-@0!!DW2? M&>G8%D*1+DG;R=\O22FJ+=%&@/K%%LF9X9G#BXYF.\:?Q0I HI>&4#%W5E*N M+UU7E"MHL)BP-5 ULF"\P5(U^=(5:PZX,J2&N('G)6Z#:^KD,]-WQ_,9VTA2 M4[CC2&R:!O/7*R!L-W=\YZWC1[U<2=WAYK,U7L(]R,?U'5IZ@:HJ!E% M'!9SYZM_6?B&8! _:]B)O6>DK3PQ]JP;-]7<\71$0*"46@*KORU< R%:2<7Q MJQ-U^CDUF#JI@@3=$_F"[?Z$S%&N]DA%A M?M&NQ::)@\J-D*SIR"J"IJ;M/W[I$K%'\(\1@HX0# G1$4+8$<+W$J*.$)G, MM%9,'@HL<3[C;(>X1BLU_6"2:=C*?DWUNM]+KD9KQ9/Y#2U9 TCB%Q#H MUQ MMJW-FJHMA;K!!S/XJ0"):R(^*]CC?8$^??B,/J":HMN:$,40,U>J@+2L6W:3 M7[63!T$%D"NGX' M/?0-/;30B]/T[YA.D&>E'[@)^\4)C5YX1.]ZPSE025[1&K_B)P*7MARW&I%= M0]\;EV*-2Y@[ZF(0P+?@Y!__\A/O;UM^SBE6G$GL('=1G[OHE'K^.+F?M-O: MEK.6&QNNOAJW>:!NRIF[W<^%!91Z\2&HL"FE40\ZB#WN8X]/QGY#)7"*]<6( MR7$3K4BR/W7B10,38U#H90.GA44IR&*[B:0WD9PT\<"D"KX<;F&;D60T?30= M&1F#XC0;KH9%*4XRNY&T-Y*>/(4%+$"9J*R'+SWGX3NG6'$FL8.43?N43?_@ M\$U'BW01Q&$V6&\+*HRBX!/W0U1OEIF Q-6;2RZ?!"UK1M0[*U MJ?*>F%0UHWE\ X!J@QA>,R;>&GJ#_LLC_!U!+ P04 " #L@$U:K=2/ M]>0$ "0&0 &0 'AL+W=OUTBZ)\P9T@$2;H-U)U:IVW3X;,!#=)&:V*>V_G^V$D*1."%/VI9X$CZQT M#>10EH1\ES??UE/#DA[A&*^XI$#BWQM^P'$LF80?_^2D1O%-"2Q?G]@7:O!B M,$O$\ .)_X[6?#B!(!^ \#. 78=X#8 G!S@= 6X.<#M"O!R@-<5X.< 7VF?B:64 M#A!'LPDE1T"EM6"3%RI<"BT$CE*962^1P/'9MW1%$@PX>L<,? 4/)-DC M&C$1<[(!^"^?4E #=?;L$7$*7@,8ICD5=L8G(Q!NF)N^E M:[RN$IAB\(4"]DF!>[N5,<"K ;#'OP#;LEV-0P\=X Y4<$<##]KAOZ-T *QF M>-@%[B@XU, 7G<<.QRU:.D4V.8K/:> KI<\?Y?0!X;N8"AD&\T])-*\D49$Z M\R7C5$P[N@S)?'#U/LBI^([MT0I/#3'7,DS?L#'[Z0?H6[_JHMLG6= G6=@G MV:(GLDI6N$56N->SOPY>!HWNWF>$GB*4B^/;[*OKC2;F6SET&B/;WIM/<_I2+T_=&PIKW&RK-\NZ:]QFKL>..:]JT#NE;[GL@JV@\+ M[8>M*XM<&*A8&-B=3MAAGRM"GV1!GV1AGV2+GL@JT1P5T1RU5I*<_ $K-@(R ML+JP9B30*B6Y-9#[G$J]=+(*.EF%G:P66BOG/#M6-!D7FHR[S]Q M(Y476OW MR.U,-][ MGZ\U>7V!>!H /7 X.(7+3TP; 5>F[,]D57B ZUSJV1=SEHQS0.& M.8^QZ*^YOH.Q=/EAU?/VPM=NG"9- ^T':IG]&377LY!0UT5GT[VN[YU3KWQ%;5^=QOP];&36V+ECC%FXBKTF [ M1/%7>=2V!J(L9-.MZD2K?SNU2/+&\KB('#65QP4D'+A-Y=%K.]P76S5LYX88 MMO: LWDL5GB^PU0;%U>?R'Z]+O1V<%@OC :[>@_<[O/5"O\?73 \M\&PO0\^ MGT8^-VPN20 M\NQ$M7A:_*PP5X?IM>?W\N<&=4!]ILE^JWA$=!NE#,1X(RBMP5 ,@&;'_]D- M)WMU7+TDG)-$7>XP6F,J#<3[#2'\=",_4/P(,_L74$L#!!0 ( .R 35I: MK6EWRP4 "(E 9 >&PO=V]R:W-H965TOUR^Q1-T]1]Y#WI$7WJZY^"(7 (J\9"F3=YV%4LN;;E=&"\BHO.1+8/K+ MC(N,*OTJYEVY%$#C7"E+NY[C#+L935AG?)NW?1#C6[Y2:<+@@R!RE654?+V' ME*_O.FYGT_ QF2^4:>B.;Y=T#D^@/B\_"/W6W:+$209,)IP1 ;.[SAOW)O0< MHY!+_); 6NX\$S.4*>=?S,M#?-=Q3(\@A4@9"*I_GF$":6J0=#_^*D$[6YM& M#F5()$Y[^GL1J<=>YZI 89G25JH]\_1;* 0T,7L13F?\EZU+6 MZ9!H)17/2F7=@RQAQ2]]*1VQHZ!QVA6\4L%K*@P/*/1*A5Y3H7] H5\J](]5 M&)0*@V,5AJ7",/=]X:SE-!?$ZVG MQ@\LXAD015] DM?D5RH$-5R3,Q\435)YKEL_/_GD[-4Y>4421MXG::KGA+SM M*FW?H'2CTM9]8F\S^GO/BNA# M=$EZ[@7Q'*_7UJ$CU+WK7+W?HNY_F_7 KOZ.LDOB'%8/CU'W=B;U M ;Q/](5,!,2)(A,]B[[JJ+>F(B9_/&I!\J @DW^VS9D"M=^.:@+KC5S2 M".XZ.G)*$,_0&?_T@SMT?F[C"Q/,QP0+,,%")+ :S_TMSWT;^CB8S2!/!SH8 M;&('T4$#=**).(N2-*$F:5R8[SK921U+8BB>SB_($D0$3+7-A,*NZ^2&34I\ M'CN7CI[:S[L4EU)N7:KOU<5\^R#.>I?7SH_G;419%4\E"@FL1M1@2]3 .D:_ M=+H)VGHQZAS+> M]4XXD55TY#,2@=";+59*D7BEHRK7\52?&"A+_L[C:1O9H[WUVMM;K]9.GLKT M$08#3(,A$EB-P*LM@5=(F>Z7A\=/#Q>$9GS5OBJMAD[=Y%SMD> V2? Q#0:8 M8"$26(W1ZRVCUU9&'_9W)";&QKLK59,ZUL8TV"(!%9CW76J0ZYCY?TS,RMV MKD-I2?(4&,P.;()*K%WG>/VK02.LMDDY7G,9'H45E%*UL#IR&RD[;)/RW,IB MW3<[!0#W__G&;. 5:#H4X6PW!,++$IB$5M]9;9TZY4NTFO?<4=/%^T+7UTT' M[\NXO3W_(O6]SH-7\>#A\@"2T"@2J]92RGUI;7>V>,-^]9L.;A%J M(@7VP9T:+;#0ZE14E0S7>H"V4:%WW@F/VXZVK22@%C=*M!JE>XD?U62 BA9B MH=5IK0H7KOW0_Z3,WHVRF#SR2&?U=RN1R#B)#NVN[7 GLX>)YJ.B!:AH(19: MG>:J[.$.ODLATL6L'TQ0T7Q4M 5+<1"J]-=U4I<>[&D.J4=/)XQ4&T1VVS] M-SK6FHJ]!R?/C/8236\O[Z*655#10BRT.N=59<6UEU8^T30B_Y )9W*5@2!O M@:9JT4H=9C5B@HKFHZ(%J&@A%EJ=X*KRXEY]GQB.6FA!1?-1T0)4M! +K4YW M599Q[769QT0E\SQ86P^7J/64$FUW-SW8KZ.U2(V MO0AR?#G3?)"@5 J9SHC6U&BW>2HGJ&@^*EI0HC72MN>Z#9:QK!8L=W>N=NA, M-\\OX4@2F4)S<<]AV[J]Z/,FO][2:)^X-T%Q7:>"*6X/O:=BGC!)4IAI2.=R MI*>Q*"[D%"^*+_,+)%.N%,_RQP70&(01T-]GG*O-BS&PO18U_A=02P,$% M @ [(!-6NGDVGHD!0 :A@ !D !X;"]W;W)K&ULM9EM;]LV$,>_"N$510O4L2A9#VX= VVT=1U6K&B:[C4MTPY12E1).D[V MZ7=ZB&6+-)$*3E[$DGQWNM^)//XISW="_E"WE&ITG_-"78YNM2[?3B8JNZ4Y M41>BI 5\LQ8R)QI.Y6:B2DG)JG;*^<3WO&B2$U:,%O/ZVA>YF(NMYJR@7R12 MVSPG\N$#Y6)W.<*CQPM?V>965Q@]?IOZM4-M\9W1G3HX1A7*4H@?U7(JS*BG&:Z"D'@XXY>4"_\M6^O9RE(S0BJ[)ENNO8ON0$DT6P,^*ZKG?JTE?,O 3R\^%9G(*=+DGBHT M1M]H7@H) P"E;+VFDA897"?%"ET1*1]@G.V(7"GT*J6:,*Y>@\_-=8I>O7B- M7B!6H,^,:C[1D%UUCTG69O*AR<0_D4E*LPODS]X@W_.G%O>K)[@'N'8/ M+.ZIV_TO4EP@S^H^@9+NZ^KOZ^K7\8(3\=XK1;6M"(W;U.Y6S?*WJB09O1S! M-%94WM'1XN5O./+>V4IRSF#IF8(=E2O8ERMP15_\GI=[RF363P.C,:R!ON>4,G[]>7)"_?I2@C)=.$L_^ M&QI*U7MLR*&!,PUF28_9- K"6=B#=J8U$#K:0T=NZ":B:@+6%4"W,:R#U M;$\]D_PS4QG(5%)0L54@>3251=VW";>*'L]$\G%_K;)8)?WBI.[$AH(?*$7\ MZ_&/JW%S<7UQ4F!\:.,?E<)+@GXI!F1Q6M2<*]IQS3H5B)VJZ5%>2PJJ6G?K M'2JWLA3*WO_;D$=EBA(_ZM?)8@9K0+\UNA,<6H!.UV&WL/M.^)8T.SP.>TQ2 M[2>LT(%!,\91T.^+5C,\-:!-[3>.XZY_'L-T@@V[%=LW ;JEVE52*>%ALL.] M4P%[=+%&=T_E-=4:#G%B\%K,_"CV^KS/H>MP)^QPZ-SL_-T*F@6E3E(*6MM M31DX3@*CHUJL9I[?'T//H19Q)Q>Q6R]^%&*U8YS7T+"JDF+#EOS$Y#$UX3CP MH[Z8L)EA/S3 GT,]XDX^8K=^_'4EA4UU.(8>:&@*FUED[([Z=CJ8#CWBRYLIE%86+4Y:QR M&]BQC2D9$B[)^U;L46HN\/KRE9$5E90#? MKX70CR?5V^/]SPN+_P%02P,$% @ [(!-6IK0-],1 P V@@ !D !X M;"]W;W)K&ULK9;?;]HP$,?_%2NKIE9:&_*# !U$ M*NVF]:$3:M7N8=J#FQQ@U;&I;:#LK]_9@8R2$.UA+^ ?=]_[W"7V9;B6ZD7/ M 0QY*[C0(V]NS.+2]W4VAX+J"[D @3M3J0IJ<*IFOEXHH+ES*K@?=CJ)7U F MO'3HUB8J'3VP]L[@B<%:[XV)S>19RA<[N.@0'W&( MM@Z12[0DAGTEN1R0*(H6^@ MR3EYHGQ)77VO.#Y@*C(@5[;2S&S(Z0T8RK@^0\/'AQMR>G)&3@@3Y(YQCCYZ MZ!M$LL)^M@T_+L.'1\('(;F3PLPU^2)RR-\+^)A+E5"X2V@0'9!PL$G M$G;"N 'H^A_Q=^G'5?IQFWHZAAD3@HD9D5.R :J: MLBTEND["WCJK- CBP=!?[6=1-^KUNI7-.[AN!==MA9LHN6+V.FJ"*EV3O7AQ M-SA@JMM$W2-,2<64M#(]&L;9;_?&-%$EM8B= Z:ZQ7D0),U0O0JJUPJ%KRI> MAP+O(Z5 9!MB%!6:'Z7LU1GBY("S;A,>*5V_HNRW4G['GD>SUR4^4@NFB4]. M/.UG8Y!_70D4?\ MJ\%H_PB57/Y>FRA S5SWU"232V'*"[9:K1KTE>M+!^MC;-QEG_TK4W;].ZKP MP&O"88J2G8L>(JFRDY83(Q>N&3U+@ZW-#>?X\0'*&N#^5$JSF]@ U>=,^@=0 M2P,$% @ [(!-6J^?"'Y^ P I0L !D !X;"]W;W)K&ULK5;O;]LV$/U7"*TH6J"-?MJ6,UM ;&U8BP4(DF7[S$AGFRA% MJB0=)_OK1U**8DNTUJ+]8HG4O*LKDTMLI55_ZOBQV M4&%YP6M@^LF&BPHKO11;7]8"<&E!%?6C()CZ%2;,RQ9V[T9D"[Y7E#"X$4CN MJPJ+YQ50?EAZH?>R<4NV.V4V_&Q1XRW<@;JO;X1>^1U+22I@DG"&!&R6WE5X MF8>! =B(OPD./]B%I_*I1<814"A4(8"Z\LCK(%2PZ1U?&U)O>Y, M SR^?V'_W9K79AZPA#6G_Y!2[99>ZJ$2-GA/U2T__ &MH8GA*SB5]A<=VMC M0\5>*EZU8*V@(JRYXJ <'H&$+6 J ](S@#B%A!_*R!I 8G-3&/%YB'' M"F<+P0](F&C-9FYL,BU:VR?,U/U."?V4:)S*/K&"5X 4?@*)/J*[IOR(;]"5 MJ0A1S^@6*%90(L71/1-0\"TC_^KU7_@)K8#!ABB)WN6@,*'RO2:YO\O1NS?O MT1M$&+HFE.H"RX6OM%QSJ%^TTE:-M.B,M#!"UYRIG42_L1+*4P)?^^S,1B]F M5]$H8P[%!8KF'U 41(E#T/H;X'%HX;$#GH_#/V-V@0(G_,1-W)4NMGSQ&;ZC M6NV/ZZ)KB1[:NKBRWK F;E;39RYEC0M8>KJ12!"/X&5O?PFGP:^NC/U,LOPG MD9UD,^FRF8RQ9RO8$L8(VYI\/@,6KM0U%!-+83KJ8Q8EZ63A/QZG9!@4S\+I M:5#N"(K"H LZL3#I+$Q&+>AW6;=^J5]D\?K*%GLA@"EKR?XU:BZ).O=&-@=, MCV2%LY[T]3 FBN<]>\.8B?G/N]Q-.W?3[W=7"\(%JD%?RO]W-QVZBWK*U\.8 M*$EZ[AP\R1EWL\[=;-2=[BT_ZFXV4/4Q3&8]>XZ@61KV_#F94K?!M#.8CAK4 M$X2BH"<&=U-*AT=.TK@GWA&4ID%/O",H=$N?=]+GH]+_Q+4$TQ:DPFJO["TE M%=&K<[68#T4D/:%K1\RDYSAWQ(1GW(3!ZR<_&/6C/Z=C3:Y%GW2Y(.JK=T4- M>F'NB#IIAHT#_VA^J4!L[1PH4<'W3#5?]VZWFS6O[(35VU^9&=3.1:\TS0![ MC87N[Q)1V&C*X&*F)8EF)FP6BM=V2GK@2L]<]G:GYV@0)D _WW"N7A;F@&XR MS_X#4$L#!!0 ( .R 35K7)Z;+ @, "() 9 >&PO=V]R:W-H965T M[";!^'V/GW/\Q6#-Q8M< "CTFK%<#JV%4L6U M;M19/2EX">%M6P](Y-)POF+:7R;#BW' )D(1/^M8 2,F4 :XV\= MTVJ&-,;V\R;ZES)WG4M")(PX^T6G:C&T0@M-84:63#WR]5>H\_%-O)0S6?ZB M=:UU+)0NI>)9;=8$&W>MMW6A6FJ@YOJX#*>]TYU+C?5N:L@GD,*.JBZ-&M 77:^!ZQ^&X MG@)05( ^6=11QBI0T!K>C;"SP]@E"KQN1K]A]-]EA'(AO7L4/D MXWXW8] P!D<9QS #(?0"3WFF+PA9[O NPF!O\%ZTP[# M*\(0;,ZBUA'5A=C?&[\?]OH[D!VB(#Q0Q+#!#(]BWH.4^LS6=6Q-,RK(&TD8 M=)&&>Q!^A'= .S3>@7)=TE//8F5\=&VWH/O;] MG00Z1&YO=]O;K1O,?#T\$#&G^HIA,-,VYZJO_:*ZD:N&XD5YJ25&PO=V]R:W-H965TYCV0.R;&!6,!R1N_WZ '2O5DJH/>S%B!KJ.S.1BI!C0W5ENA: 2T\2' 2!L&$",HJ MG,9^;:'26.X,9Q4L%-([(:AZO@4NFP0/\6%AR;:E<0LDC6NZA168AWJA;$1Z MEH()J#23%5*P2?#-<)9%+M\G_�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end XML 163 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 164 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 166 FilingSummary.xml IDEA: XBRL DOCUMENT 3.25.0.1 html 1035 694 1 false 239 0 false 12 false false R1.htm 0000001 - Document - Cover Page Sheet http://www.jnj.com/role/CoverPage Cover Page Cover 1 false false R2.htm 0000002 - Document - Audit Information Sheet http://www.jnj.com/role/AuditInformation Audit Information Cover 2 false false R3.htm 9952151 - Statement - Consolidated Balance Sheets Sheet http://www.jnj.com/role/ConsolidatedBalanceSheets Consolidated Balance Sheets Statements 3 false false R4.htm 9952152 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://www.jnj.com/role/ConsolidatedBalanceSheetsParenthetical Consolidated Balance Sheets (Parenthetical) Statements 4 false false R5.htm 9952153 - Statement - Consolidated Statements of Earnings Sheet http://www.jnj.com/role/ConsolidatedStatementsofEarnings Consolidated Statements of Earnings Statements 5 false false R6.htm 9952154 - Statement - Consolidated Statements of Comprehensive Income Sheet http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome Consolidated Statements of Comprehensive Income Statements 6 false false R7.htm 9952155 - Statement - Consolidated Statements of Comprehensive Income (Parenthetical) Sheet http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncomeParenthetical Consolidated Statements of Comprehensive Income (Parenthetical) Statements 7 false false R8.htm 9952156 - Statement - Consolidated Statements of Equity Sheet http://www.jnj.com/role/ConsolidatedStatementsofEquity Consolidated Statements of Equity Statements 8 false false R9.htm 9952157 - Statement - Consolidated Statements of Equity (Parenthetical) Sheet http://www.jnj.com/role/ConsolidatedStatementsofEquityParenthetical Consolidated Statements of Equity (Parenthetical) Statements 9 false false R10.htm 9952158 - Statement - Consolidated Statements of Cash Flows Sheet http://www.jnj.com/role/ConsolidatedStatementsofCashFlows Consolidated Statements of Cash Flows Statements 10 false false R11.htm 9952159 - Disclosure - Summary of significant accounting policies Sheet http://www.jnj.com/role/Summaryofsignificantaccountingpolicies Summary of significant accounting policies Notes 11 false false R12.htm 9952160 - Disclosure - Cash, cash equivalents and current marketable securities Sheet http://www.jnj.com/role/Cashcashequivalentsandcurrentmarketablesecurities Cash, cash equivalents and current marketable securities Notes 12 false false R13.htm 9952161 - Disclosure - Inventories Sheet http://www.jnj.com/role/Inventories Inventories Notes 13 false false R14.htm 9952162 - Disclosure - Property, plant and equipment Sheet http://www.jnj.com/role/Propertyplantandequipment Property, plant and equipment Notes 14 false false R15.htm 9952163 - Disclosure - Intangible assets and goodwill Sheet http://www.jnj.com/role/Intangibleassetsandgoodwill Intangible assets and goodwill Notes 15 false false R16.htm 9952164 - Disclosure - Fair value measurements Sheet http://www.jnj.com/role/Fairvaluemeasurements Fair value measurements Notes 16 false false R17.htm 9952165 - Disclosure - Borrowings Sheet http://www.jnj.com/role/Borrowings Borrowings Notes 17 false false R18.htm 9952166 - Disclosure - Income taxes Sheet http://www.jnj.com/role/Incometaxes Income taxes Notes 18 false false R19.htm 9952167 - Disclosure - Employee related obligations Sheet http://www.jnj.com/role/Employeerelatedobligations Employee related obligations Notes 19 false false R20.htm 9952168 - Disclosure - Pensions and other benefit plans Sheet http://www.jnj.com/role/Pensionsandotherbenefitplans Pensions and other benefit plans Notes 20 false false R21.htm 9952169 - Disclosure - Savings plan Sheet http://www.jnj.com/role/Savingsplan Savings plan Notes 21 false false R22.htm 9952170 - Disclosure - Capital and treasury stock Sheet http://www.jnj.com/role/Capitalandtreasurystock Capital and treasury stock Notes 22 false false R23.htm 9952171 - Disclosure - Accumulated other comprehensive income (loss) Sheet http://www.jnj.com/role/Accumulatedothercomprehensiveincomeloss Accumulated other comprehensive income (loss) Notes 23 false false R24.htm 9952172 - Disclosure - International currency translation Sheet http://www.jnj.com/role/Internationalcurrencytranslation International currency translation Notes 24 false false R25.htm 9952173 - Disclosure - Earnings per share Sheet http://www.jnj.com/role/Earningspershare Earnings per share Notes 25 false false R26.htm 9952174 - Disclosure - Common stock, stock option plans and stock compensation agreements Sheet http://www.jnj.com/role/Commonstockstockoptionplansandstockcompensationagreements Common stock, stock option plans and stock compensation agreements Notes 26 false false R27.htm 9952175 - Disclosure - Segments of business and geographic areas Sheet http://www.jnj.com/role/Segmentsofbusinessandgeographicareas Segments of business and geographic areas Notes 27 false false R28.htm 9952176 - Disclosure - Acquisitions and divestitures Sheet http://www.jnj.com/role/Acquisitionsanddivestitures Acquisitions and divestitures Notes 28 false false R29.htm 9952177 - Disclosure - Legal proceedings Sheet http://www.jnj.com/role/Legalproceedings Legal proceedings Notes 29 false false R30.htm 9952178 - Disclosure - Restructuring Sheet http://www.jnj.com/role/Restructuring Restructuring Notes 30 false false R31.htm 9952179 - Disclosure - Kenvue separation and discontinued operations Sheet http://www.jnj.com/role/Kenvueseparationanddiscontinuedoperations Kenvue separation and discontinued operations Notes 31 false false R32.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Notes 32 false false R33.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 33 false false R34.htm 995447 - Disclosure - Insider Trading Policies and Procedures Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc Insider Trading Policies and Procedures Notes 34 false false R35.htm 995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure Sheet http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure Cybersecurity Risk Management and Strategy Disclosure Notes 35 false false R36.htm 9955511 - Disclosure - Summary of significant accounting policies (Policies) Sheet http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesPolicies Summary of significant accounting policies (Policies) Policies 36 false false R37.htm 9955512 - Disclosure - Summary of significant accounting policies (Tables) Sheet http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesTables Summary of significant accounting policies (Tables) Tables http://www.jnj.com/role/Summaryofsignificantaccountingpolicies 37 false false R38.htm 9955513 - Disclosure - Cash, cash equivalents and current marketable securities (Tables) Sheet http://www.jnj.com/role/CashcashequivalentsandcurrentmarketablesecuritiesTables Cash, cash equivalents and current marketable securities (Tables) Tables http://www.jnj.com/role/Cashcashequivalentsandcurrentmarketablesecurities 38 false false R39.htm 9955514 - Disclosure - Inventories (Tables) Sheet http://www.jnj.com/role/InventoriesTables Inventories (Tables) Tables http://www.jnj.com/role/Inventories 39 false false R40.htm 9955515 - Disclosure - Property, plant and equipment (Tables) Sheet http://www.jnj.com/role/PropertyplantandequipmentTables Property, plant and equipment (Tables) Tables http://www.jnj.com/role/Propertyplantandequipment 40 false false R41.htm 9955516 - Disclosure - Intangible assets and goodwill (Tables) Sheet http://www.jnj.com/role/IntangibleassetsandgoodwillTables Intangible assets and goodwill (Tables) Tables http://www.jnj.com/role/Intangibleassetsandgoodwill 41 false false R42.htm 9955517 - Disclosure - Fair value measurements (Tables) Sheet http://www.jnj.com/role/FairvaluemeasurementsTables Fair value measurements (Tables) Tables http://www.jnj.com/role/Fairvaluemeasurements 42 false false R43.htm 9955518 - Disclosure - Borrowings (Tables) Sheet http://www.jnj.com/role/BorrowingsTables Borrowings (Tables) Tables http://www.jnj.com/role/Borrowings 43 false false R44.htm 9955519 - Disclosure - Income taxes (Tables) Sheet http://www.jnj.com/role/IncometaxesTables Income taxes (Tables) Tables http://www.jnj.com/role/Incometaxes 44 false false R45.htm 9955520 - Disclosure - Employee related obligations (Tables) Sheet http://www.jnj.com/role/EmployeerelatedobligationsTables Employee related obligations (Tables) Tables http://www.jnj.com/role/Employeerelatedobligations 45 false false R46.htm 9955521 - Disclosure - Pensions and other benefit plans (Tables) Sheet http://www.jnj.com/role/PensionsandotherbenefitplansTables Pensions and other benefit plans (Tables) Tables http://www.jnj.com/role/Pensionsandotherbenefitplans 46 false false R47.htm 9955522 - Disclosure - Capital and treasury stock (Tables) Sheet http://www.jnj.com/role/CapitalandtreasurystockTables Capital and treasury stock (Tables) Tables http://www.jnj.com/role/Capitalandtreasurystock 47 false false R48.htm 9955523 - Disclosure - Accumulated other comprehensive income (loss) (Tables) Sheet http://www.jnj.com/role/AccumulatedothercomprehensiveincomelossTables Accumulated other comprehensive income (loss) (Tables) Tables http://www.jnj.com/role/Accumulatedothercomprehensiveincomeloss 48 false false R49.htm 9955524 - Disclosure - Earnings per share (Tables) Sheet http://www.jnj.com/role/EarningspershareTables Earnings per share (Tables) Tables http://www.jnj.com/role/Earningspershare 49 false false R50.htm 9955525 - Disclosure - Common stock, stock option plans and stock compensation agreements (Tables) Sheet http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsTables Common stock, stock option plans and stock compensation agreements (Tables) Tables http://www.jnj.com/role/Commonstockstockoptionplansandstockcompensationagreements 50 false false R51.htm 9955526 - Disclosure - Segments of business and geographic areas (Tables) Sheet http://www.jnj.com/role/SegmentsofbusinessandgeographicareasTables Segments of business and geographic areas (Tables) Tables http://www.jnj.com/role/Segmentsofbusinessandgeographicareas 51 false false R52.htm 9955527 - Disclosure - Acquisitions and divestitures (Tables) Sheet http://www.jnj.com/role/AcquisitionsanddivestituresTables Acquisitions and divestitures (Tables) Tables http://www.jnj.com/role/Acquisitionsanddivestitures 52 false false R53.htm 9955528 - Disclosure - Legal proceedings (Tables) Sheet http://www.jnj.com/role/LegalproceedingsTables Legal proceedings (Tables) Tables http://www.jnj.com/role/Legalproceedings 53 false false R54.htm 9955529 - Disclosure - Restructuring (Tables) Sheet http://www.jnj.com/role/RestructuringTables Restructuring (Tables) Tables http://www.jnj.com/role/Restructuring 54 false false R55.htm 9955530 - Disclosure - Kenvue separation and discontinued operations (Tables) Sheet http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsTables Kenvue separation and discontinued operations (Tables) Tables http://www.jnj.com/role/Kenvueseparationanddiscontinuedoperations 55 false false R56.htm 9955531 - Disclosure - Summary of significant accounting policies - Narrative (Details) Sheet http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails Summary of significant accounting policies - Narrative (Details) Details 56 false false R57.htm 9955532 - Disclosure - Summary of significant accounting policies - Estimated Useful Lives of Assets (Details) Sheet http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesEstimatedUsefulLivesofAssetsDetails Summary of significant accounting policies - Estimated Useful Lives of Assets (Details) Details 57 false false R58.htm 9955533 - Disclosure - Summary of significant accounting policies - Supplier Finance Program (Details) Sheet http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesSupplierFinanceProgramDetails Summary of significant accounting policies - Supplier Finance Program (Details) Details 58 false false R59.htm 9955534 - Disclosure - Cash, cash equivalents and current marketable securities - Cash and Cash Equivalent Composition (Details) Sheet http://www.jnj.com/role/CashcashequivalentsandcurrentmarketablesecuritiesCashandCashEquivalentCompositionDetails Cash, cash equivalents and current marketable securities - Cash and Cash Equivalent Composition (Details) Details 59 false false R60.htm 9955535 - Disclosure - Cash, cash equivalents and current marketable securities - Contractual Maturities of Available for Sale Securities (Details) Sheet http://www.jnj.com/role/CashcashequivalentsandcurrentmarketablesecuritiesContractualMaturitiesofAvailableforSaleSecuritiesDetails Cash, cash equivalents and current marketable securities - Contractual Maturities of Available for Sale Securities (Details) Details 60 false false R61.htm 9955536 - Disclosure - Inventories (Details) Sheet http://www.jnj.com/role/InventoriesDetails Inventories (Details) Details http://www.jnj.com/role/InventoriesTables 61 false false R62.htm 9955537 - Disclosure - Property, plant and equipment - Property, Plant and Equipment at Cost and Accumulated Depreciation (Details) Sheet http://www.jnj.com/role/PropertyplantandequipmentPropertyPlantandEquipmentatCostandAccumulatedDepreciationDetails Property, plant and equipment - Property, Plant and Equipment at Cost and Accumulated Depreciation (Details) Details 62 false false R63.htm 9955538 - Disclosure - Property, plant and equipment - Narrative (Details) Sheet http://www.jnj.com/role/PropertyplantandequipmentNarrativeDetails Property, plant and equipment - Narrative (Details) Details 63 false false R64.htm 9955539 - Disclosure - Intangible assets and goodwil - Schedule of Intangible Assets and Goodwill (Details) Sheet http://www.jnj.com/role/IntangibleassetsandgoodwilScheduleofIntangibleAssetsandGoodwillDetails Intangible assets and goodwil - Schedule of Intangible Assets and Goodwill (Details) Details 64 false false R65.htm 9955540 - Disclosure - Intangible assets and goodwill - Goodwill (Details) Sheet http://www.jnj.com/role/IntangibleassetsandgoodwillGoodwillDetails Intangible assets and goodwill - Goodwill (Details) Details 65 false false R66.htm 9955541 - Disclosure - Intangible assets and goodwill - Narrative (Details) Sheet http://www.jnj.com/role/IntangibleassetsandgoodwillNarrativeDetails Intangible assets and goodwill - Narrative (Details) Details 66 false false R67.htm 9955542 - Disclosure - Intangible assets and goodwill - Estimated Amortization of Intangible Assets (Details) Sheet http://www.jnj.com/role/IntangibleassetsandgoodwillEstimatedAmortizationofIntangibleAssetsDetails Intangible assets and goodwill - Estimated Amortization of Intangible Assets (Details) Details 67 false false R68.htm 9955543 - Disclosure - Fair value measurements - Narrative (Details) Sheet http://www.jnj.com/role/FairvaluemeasurementsNarrativeDetails Fair value measurements - Narrative (Details) Details 68 false false R69.htm 9955544 - Disclosure - Fair value measurements - Summary of Derivative Activity (Details) Sheet http://www.jnj.com/role/FairvaluemeasurementsSummaryofDerivativeActivityDetails Fair value measurements - Summary of Derivative Activity (Details) Details 69 false false R70.htm 9955545 - Disclosure - Fair value measurements - Schedule of Derivatives Recorded in Consolidated Balance Sheets (Details) Sheet http://www.jnj.com/role/FairvaluemeasurementsScheduleofDerivativesRecordedinConsolidatedBalanceSheetsDetails Fair value measurements - Schedule of Derivatives Recorded in Consolidated Balance Sheets (Details) Details 70 false false R71.htm 9955546 - Disclosure - Fair value measurements - Schedule of Effect of Derivatives not Designated as Hedging Instruments (Details) Sheet http://www.jnj.com/role/FairvaluemeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails Fair value measurements - Schedule of Effect of Derivatives not Designated as Hedging Instruments (Details) Details 71 false false R72.htm 9955547 - Disclosure - Fair value measurements - Schedule of Effect of Net Investment Hedges (Details) Sheet http://www.jnj.com/role/FairvaluemeasurementsScheduleofEffectofNetInvestmentHedgesDetails Fair value measurements - Schedule of Effect of Net Investment Hedges (Details) Details 72 false false R73.htm 9955548 - Disclosure - Fair value measurements - Summary of Activity Related to Equity Investments (Details) Sheet http://www.jnj.com/role/FairvaluemeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails Fair value measurements - Summary of Activity Related to Equity Investments (Details) Details 73 false false R74.htm 9955549 - Disclosure - Fair value measurements - Financial Assets and Liabilities at Fair Value (Details) Sheet http://www.jnj.com/role/FairvaluemeasurementsFinancialAssetsandLiabilitiesatFairValueDetails Fair value measurements - Financial Assets and Liabilities at Fair Value (Details) Details 74 false false R75.htm 9955550 - Disclosure - Borrowings - Schedule of Long-term Debt Instruments (Details) Sheet http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails Borrowings - Schedule of Long-term Debt Instruments (Details) Details 75 false false R76.htm 9955551 - Disclosure - Borrowings - Narrative (Details) Sheet http://www.jnj.com/role/BorrowingsNarrativeDetails Borrowings - Narrative (Details) Details 76 false false R77.htm 9955552 - Disclosure - Borrowings - Aggregate Maturities of Long Term Obligations (Details) Sheet http://www.jnj.com/role/BorrowingsAggregateMaturitiesofLongTermObligationsDetails Borrowings - Aggregate Maturities of Long Term Obligations (Details) Details 77 false false R78.htm 9955553 - Disclosure - Income taxes - Provision for Income Taxes (Details) Sheet http://www.jnj.com/role/IncometaxesProvisionforIncomeTaxesDetails Income taxes - Provision for Income Taxes (Details) Details 78 false false R79.htm 9955554 - Disclosure - Income taxes - Comparison of Income Taxes at Statutory Rate and Company's Effective Tax Rate (Details) Sheet http://www.jnj.com/role/IncometaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails Income taxes - Comparison of Income Taxes at Statutory Rate and Company's Effective Tax Rate (Details) Details 79 false false R80.htm 9955555 - Disclosure - Income taxes - Narrative (Details) Sheet http://www.jnj.com/role/IncometaxesNarrativeDetails Income taxes - Narrative (Details) Details 80 false false R81.htm 9955556 - Disclosure - Income taxes - Temporary Differences and Carryforwards (Details) Sheet http://www.jnj.com/role/IncometaxesTemporaryDifferencesandCarryforwardsDetails Income taxes - Temporary Differences and Carryforwards (Details) Details 81 false false R82.htm 9955557 - Disclosure - Income taxes - Valuation Allowance Activity (Details) Sheet http://www.jnj.com/role/IncometaxesValuationAllowanceActivityDetails Income taxes - Valuation Allowance Activity (Details) Details 82 false false R83.htm 9955558 - Disclosure - Income taxes - Summary of Activity Related to Unrecognized Tax Benefits (Details) Sheet http://www.jnj.com/role/IncometaxesSummaryofActivityRelatedtoUnrecognizedTaxBenefitsDetails Income taxes - Summary of Activity Related to Unrecognized Tax Benefits (Details) Details 83 false false R84.htm 9955559 - Disclosure - Employee related obligations - Employee Related Obligations (Details) Sheet http://www.jnj.com/role/EmployeerelatedobligationsEmployeeRelatedObligationsDetails Employee related obligations - Employee Related Obligations (Details) Details 84 false false R85.htm 9955560 - Disclosure - Employee related obligations - Narrative (Details) Sheet http://www.jnj.com/role/EmployeerelatedobligationsNarrativeDetails Employee related obligations - Narrative (Details) Details 85 false false R86.htm 9955561 - Disclosure - Pensions and other benefit plans - Narrative (Details) Sheet http://www.jnj.com/role/PensionsandotherbenefitplansNarrativeDetails Pensions and other benefit plans - Narrative (Details) Details 86 false false R87.htm 9955562 - Disclosure - Pensions and other benefit plans - Components of Net Periodic Benefit Cost (Details) Sheet http://www.jnj.com/role/PensionsandotherbenefitplansComponentsofNetPeriodicBenefitCostDetails Pensions and other benefit plans - Components of Net Periodic Benefit Cost (Details) Details 87 false false R88.htm 9955563 - Disclosure - Pensions and other benefit plans - Rates Used to Develop Actuarial Present Value of Projected Benefit Obligation (Details) Sheet http://www.jnj.com/role/PensionsandotherbenefitplansRatesUsedtoDevelopActuarialPresentValueofProjectedBenefitObligationDetails Pensions and other benefit plans - Rates Used to Develop Actuarial Present Value of Projected Benefit Obligation (Details) Details 88 false false R89.htm 9955564 - Disclosure - Pensions and other benefit plans - Assumed Health Care Cost Trend Rates (Details) Sheet http://www.jnj.com/role/PensionsandotherbenefitplansAssumedHealthCareCostTrendRatesDetails Pensions and other benefit plans - Assumed Health Care Cost Trend Rates (Details) Details 89 false false R90.htm 9955565 - Disclosure - Pensions and other benefit plans - Schedule of Net Funded Status (Details) Sheet http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofNetFundedStatusDetails Pensions and other benefit plans - Schedule of Net Funded Status (Details) Details 90 false false R91.htm 9955566 - Disclosure - Pensions and other benefit plans - Information Related to the Benefit Obligation and the Fair Value of Plan Assets (Details) Sheet http://www.jnj.com/role/PensionsandotherbenefitplansInformationRelatedtotheBenefitObligationandtheFairValueofPlanAssetsDetails Pensions and other benefit plans - Information Related to the Benefit Obligation and the Fair Value of Plan Assets (Details) Details 91 false false R92.htm 9955567 - Disclosure - Pensions and other benefit plans - Projected Future Benefit Payments from Company's Retirement and Other Benefit Plans (Details) Sheet http://www.jnj.com/role/PensionsandotherbenefitplansProjectedFutureBenefitPaymentsfromCompanysRetirementandOtherBenefitPlansDetails Pensions and other benefit plans - Projected Future Benefit Payments from Company's Retirement and Other Benefit Plans (Details) Details 92 false false R93.htm 9955568 - Disclosure - Pensions and other benefit plans - Projected Future Minimum Contributions to the Company's U.S. and International Unfunded Retirement Plans (Details) Sheet http://www.jnj.com/role/PensionsandotherbenefitplansProjectedFutureMinimumContributionstotheCompanysUSandInternationalUnfundedRetirementPlansDetails Pensions and other benefit plans - Projected Future Minimum Contributions to the Company's U.S. and International Unfunded Retirement Plans (Details) Details 93 false false R94.htm 9955569 - Disclosure - Pensions and other benefit plans - Company' Retirement Plan Asset Allocation and Target Allocations (Details) Sheet http://www.jnj.com/role/PensionsandotherbenefitplansCompanyRetirementPlanAssetAllocationandTargetAllocationsDetails Pensions and other benefit plans - Company' Retirement Plan Asset Allocation and Target Allocations (Details) Details 94 false false R95.htm 9955570 - Disclosure - Pensions and other benefit plans - Schedule of Defined Benefit Plans Disclosures (Details) Sheet http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofDefinedBenefitPlansDisclosuresDetails Pensions and other benefit plans - Schedule of Defined Benefit Plans Disclosures (Details) Details 95 false false R96.htm 9955571 - Disclosure - Savings plan (Details) Sheet http://www.jnj.com/role/SavingsplanDetails Savings plan (Details) Details http://www.jnj.com/role/Savingsplan 96 false false R97.htm 9955572 - Disclosure - Capital and treasury stock - Changes in Treasury Stock (Details) Sheet http://www.jnj.com/role/CapitalandtreasurystockChangesinTreasuryStockDetails Capital and treasury stock - Changes in Treasury Stock (Details) Details 97 false false R98.htm 9955573 - Disclosure - Capital and treasury stock - Narrative (Details) Sheet http://www.jnj.com/role/CapitalandtreasurystockNarrativeDetails Capital and treasury stock - Narrative (Details) Details 98 false false R99.htm 9955574 - Disclosure - Accumulated other comprehensive income (loss) (Details) Sheet http://www.jnj.com/role/AccumulatedothercomprehensiveincomelossDetails Accumulated other comprehensive income (loss) (Details) Details http://www.jnj.com/role/AccumulatedothercomprehensiveincomelossTables 99 false false R100.htm 9955575 - Disclosure - International currency translation (Details) Sheet http://www.jnj.com/role/InternationalcurrencytranslationDetails International currency translation (Details) Details http://www.jnj.com/role/Internationalcurrencytranslation 100 false false R101.htm 9955576 - Disclosure - Earnings per share - Reconciliation of Basic Net Earnings per Share to Diluted Net Earnings per Share (Details) Sheet http://www.jnj.com/role/EarningspershareReconciliationofBasicNetEarningsperSharetoDilutedNetEarningsperShareDetails Earnings per share - Reconciliation of Basic Net Earnings per Share to Diluted Net Earnings per Share (Details) Details 101 false false R102.htm 9955577 - Disclosure - Earnings per share - Narrative (Details) Sheet http://www.jnj.com/role/EarningspershareNarrativeDetails Earnings per share - Narrative (Details) Details 102 false false R103.htm 9955578 - Disclosure - Common stock, stock option plans and stock compensation agreements - Narrative (Details) Sheet http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsNarrativeDetails Common stock, stock option plans and stock compensation agreements - Narrative (Details) Details http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsTables 103 false false R104.htm 9955579 - Disclosure - Common stock, stock option plans and stock compensation agreements - Schedule Valuation Assumptions (Details) Sheet http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsScheduleValuationAssumptionsDetails Common stock, stock option plans and stock compensation agreements - Schedule Valuation Assumptions (Details) Details 104 false false R105.htm 9955580 - Disclosure - Common stock, stock option plans and stock compensation agreements - Summary of Stock Option Activity (Details) Sheet http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsSummaryofStockOptionActivityDetails Common stock, stock option plans and stock compensation agreements - Summary of Stock Option Activity (Details) Details 105 false false R106.htm 9955581 - Disclosure - Common stock, stock option plans and stock compensation agreements - Summary of Options Outstanding (Details) Sheet http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsSummaryofOptionsOutstandingDetails Common stock, stock option plans and stock compensation agreements - Summary of Options Outstanding (Details) Details 106 false false R107.htm 9955582 - Disclosure - Common stock, stock option plans and stock compensation agreements - Summary of Restricted Share Units (Details) Sheet http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsSummaryofRestrictedShareUnitsDetails Common stock, stock option plans and stock compensation agreements - Summary of Restricted Share Units (Details) Details 107 false false R108.htm 9955583 - Disclosure - Segments of Business and Geographic Areas - Sales by Segment of Business (Details) Sheet http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails Segments of Business and Geographic Areas - Sales by Segment of Business (Details) Details 108 false false R109.htm 9955584 - Disclosure - Segments of Business and Geographic Areas - Income Before Tax by Segment (Details) Sheet http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasIncomeBeforeTaxbySegmentDetails Segments of Business and Geographic Areas - Income Before Tax by Segment (Details) Details 109 false false R110.htm 9955585 - Disclosure - Segments of Business and Geographic Areas - Schedule of Segment Reporting Information (Details) Sheet http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails Segments of Business and Geographic Areas - Schedule of Segment Reporting Information (Details) Details 110 false false R111.htm 9955586 - Disclosure - Segments of Business and Geographic Areas - Schedule of Segment Reporting By Geographic Area (Details) Sheet http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingByGeographicAreaDetails Segments of Business and Geographic Areas - Schedule of Segment Reporting By Geographic Area (Details) Details 111 false false R112.htm 9955587 - Disclosure - Acquisitions and divestitures - Narrative (Details) Sheet http://www.jnj.com/role/AcquisitionsanddivestituresNarrativeDetails Acquisitions and divestitures - Narrative (Details) Details 112 false false R113.htm 9955588 - Disclosure - Acquisitions and divestitures (Details) Sheet http://www.jnj.com/role/AcquisitionsanddivestituresDetails Acquisitions and divestitures (Details) Details http://www.jnj.com/role/AcquisitionsanddivestituresTables 113 false false R114.htm 9955589 - Disclosure - Legal proceedings - Narrative (Details) Sheet http://www.jnj.com/role/LegalproceedingsNarrativeDetails Legal proceedings - Narrative (Details) Details 114 false false R115.htm 9955590 - Disclosure - Legal proceedings - Product Liabilities (Details) Sheet http://www.jnj.com/role/LegalproceedingsProductLiabilitiesDetails Legal proceedings - Product Liabilities (Details) Details 115 false false R116.htm 9955591 - Disclosure - Restructuring - Narrative (Details) Sheet http://www.jnj.com/role/RestructuringNarrativeDetails Restructuring - Narrative (Details) Details 116 false false R117.htm 9955592 - Disclosure - Restructuring - Schedule of Restructuring Reserve (Details) Sheet http://www.jnj.com/role/RestructuringScheduleofRestructuringReserveDetails Restructuring - Schedule of Restructuring Reserve (Details) Details 117 false false R118.htm 9955593 - Disclosure - Kenvue separation and discontinued operations - Details (Details) Sheet http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsDetailsDetails Kenvue separation and discontinued operations - Details (Details) Details http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsTables 118 false false R119.htm 9955594 - Disclosure - Kenvue separation and discontinued operations - Net Earnings from Discontinued Operation (Details) Sheet http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsNetEarningsfromDiscontinuedOperationDetails Kenvue separation and discontinued operations - Net Earnings from Discontinued Operation (Details) Details 119 false false R120.htm 9955595 - Disclosure - Kenvue separation and discontinued operations - Depreciation and Amortization of Discontinued Operation (Details) Sheet http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsDepreciationandAmortizationofDiscontinuedOperationDetails Kenvue separation and discontinued operations - Depreciation and Amortization of Discontinued Operation (Details) Details 120 false false All Reports Book All Reports jnj-20241229.htm jnj-20241229.xsd jnj-20241229_cal.xml jnj-20241229_def.xml jnj-20241229_lab.xml jnj-20241229_pre.xml jnj-20241229_g1.jpg jnj-20241229_g10.jpg jnj-20241229_g11.jpg jnj-20241229_g12.jpg jnj-20241229_g13.jpg jnj-20241229_g14.jpg jnj-20241229_g15.jpg jnj-20241229_g16.jpg jnj-20241229_g17.jpg jnj-20241229_g18.jpg jnj-20241229_g19.jpg jnj-20241229_g2.jpg jnj-20241229_g20.jpg jnj-20241229_g21.jpg jnj-20241229_g22.jpg jnj-20241229_g23.jpg jnj-20241229_g24.jpg jnj-20241229_g25.jpg jnj-20241229_g26.jpg jnj-20241229_g3.jpg jnj-20241229_g4.jpg jnj-20241229_g5.jpg jnj-20241229_g6.jpg jnj-20241229_g7.jpg jnj-20241229_g8.jpg jnj-20241229_g9.jpg http://fasb.org/srt/2024 http://fasb.org/us-gaap/2024 http://xbrl.sec.gov/cyd/2024 http://xbrl.sec.gov/dei/2024 http://xbrl.sec.gov/ecd/2024 true true JSON 169 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "jnj-20241229.htm": { "nsprefix": "jnj", "nsuri": "http://www.jnj.com/20241229", "dts": { "inline": { "local": [ "jnj-20241229.htm" ] }, "schema": { "local": [ "jnj-20241229.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd", "https://xbrl.sec.gov/cyd/2024/cyd-af-2024.xsd", "https://xbrl.sec.gov/cyd/2024/cyd-af-sub-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" ] }, "calculationLink": { "local": [ "jnj-20241229_cal.xml" ] }, "definitionLink": { "local": [ "jnj-20241229_def.xml" ] }, "labelLink": { "local": [ "jnj-20241229_lab.xml" ] }, "presentationLink": { "local": [ "jnj-20241229_pre.xml" ] } }, "keyStandard": 569, "keyCustom": 125, "axisStandard": 47, "axisCustom": 0, "memberStandard": 74, "memberCustom": 151, "hidden": { "total": 17, "http://xbrl.sec.gov/dei/2024": 5, "http://fasb.org/us-gaap/2024": 12 }, "contextCount": 1035, "entityCount": 1, "segmentCount": 239, "elementCount": 1265, "unitCount": 12, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 2595, "http://xbrl.sec.gov/dei/2024": 53, "http://xbrl.sec.gov/cyd/2024": 15, "http://xbrl.sec.gov/ecd/2024": 5, "http://fasb.org/srt/2024": 1 }, "report": { "R1": { "role": "http://www.jnj.com/role/CoverPage", "longName": "0000001 - Document - Cover Page", "shortName": "Cover Page", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.jnj.com/role/AuditInformation", "longName": "0000002 - Document - Audit Information", "shortName": "Audit Information", "isDefault": "false", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "2", "firstAnchor": { "contextRef": "c-1", "name": "dei:AuditorName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:AuditorName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true } }, "R3": { "role": "http://www.jnj.com/role/ConsolidatedBalanceSheets", "longName": "9952151 - Statement - Consolidated Balance Sheets", "shortName": "Consolidated Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "c-10", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-10", "name": "us-gaap:AccountsReceivableNetCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "unique": true } }, "R4": { "role": "http://www.jnj.com/role/ConsolidatedBalanceSheetsParenthetical", "longName": "9952152 - Statement - Consolidated Balance Sheets (Parenthetical)", "shortName": "Consolidated Balance Sheets (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "c-10", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-10", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true } }, "R5": { "role": "http://www.jnj.com/role/ConsolidatedStatementsofEarnings", "longName": "9952153 - Statement - Consolidated Statements of Earnings", "shortName": "Consolidated Statements of Earnings", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:GrossProfit", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "unique": true } }, "R6": { "role": "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome", "longName": "9952154 - Statement - Consolidated Statements of Comprehensive Income", "shortName": "Consolidated Statements of Comprehensive Income", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "unique": true } }, "R7": { "role": "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncomeParenthetical", "longName": "9952155 - Statement - Consolidated Statements of Comprehensive Income (Parenthetical)", "shortName": "Consolidated Statements of Comprehensive Income (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-8", "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-8", "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true } }, "R8": { "role": "http://www.jnj.com/role/ConsolidatedStatementsofEquity", "longName": "9952156 - Statement - Consolidated Statements of Equity", "shortName": "Consolidated Statements of Equity", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "8", "firstAnchor": { "contextRef": "c-14", "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-15", "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "unique": true } }, "R9": { "role": "http://www.jnj.com/role/ConsolidatedStatementsofEquityParenthetical", "longName": "9952157 - Statement - Consolidated Statements of Equity (Parenthetical)", "shortName": "Consolidated Statements of Equity (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "9", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CommonStockDividendsPerShareCashPaid", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true }, "uniqueAnchor": null }, "R10": { "role": "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows", "longName": "9952158 - Statement - Consolidated Statements of Cash Flows", "shortName": "Consolidated Statements of Cash Flows", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "10", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ShareBasedCompensation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "unique": true } }, "R11": { "role": "http://www.jnj.com/role/Summaryofsignificantaccountingpolicies", "longName": "9952159 - Disclosure - Summary of significant accounting policies", "shortName": "Summary of significant accounting policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.jnj.com/role/Cashcashequivalentsandcurrentmarketablesecurities", "longName": "9952160 - Disclosure - Cash, cash equivalents and current marketable securities", "shortName": "Cash, cash equivalents and current marketable securities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.jnj.com/role/Inventories", "longName": "9952161 - Disclosure - Inventories", "shortName": "Inventories", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.jnj.com/role/Propertyplantandequipment", "longName": "9952162 - Disclosure - Property, plant and equipment", "shortName": "Property, plant and equipment", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.jnj.com/role/Intangibleassetsandgoodwill", "longName": "9952163 - Disclosure - Intangible assets and goodwill", "shortName": "Intangible assets and goodwill", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.jnj.com/role/Fairvaluemeasurements", "longName": "9952164 - Disclosure - Fair value measurements", "shortName": "Fair value measurements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.jnj.com/role/Borrowings", "longName": "9952165 - Disclosure - Borrowings", "shortName": "Borrowings", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.jnj.com/role/Incometaxes", "longName": "9952166 - Disclosure - Income taxes", "shortName": "Income taxes", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.jnj.com/role/Employeerelatedobligations", "longName": "9952167 - Disclosure - Employee related obligations", "shortName": "Employee related obligations", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CompensationRelatedCostsGeneralTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CompensationRelatedCostsGeneralTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.jnj.com/role/Pensionsandotherbenefitplans", "longName": "9952168 - Disclosure - Pensions and other benefit plans", "shortName": "Pensions and other benefit plans", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.jnj.com/role/Savingsplan", "longName": "9952169 - Disclosure - Savings plan", "shortName": "Savings plan", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "c-1", "name": "jnj:SavingsPlanTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "jnj:SavingsPlanTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.jnj.com/role/Capitalandtreasurystock", "longName": "9952170 - Disclosure - Capital and treasury stock", "shortName": "Capital and treasury stock", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:TreasuryStockTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:TreasuryStockTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.jnj.com/role/Accumulatedothercomprehensiveincomeloss", "longName": "9952171 - Disclosure - Accumulated other comprehensive income (loss)", "shortName": "Accumulated other comprehensive income (loss)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.jnj.com/role/Internationalcurrencytranslation", "longName": "9952172 - Disclosure - International currency translation", "shortName": "International currency translation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "24", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ForeignCurrencyDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ForeignCurrencyDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.jnj.com/role/Earningspershare", "longName": "9952173 - Disclosure - Earnings per share", "shortName": "Earnings per share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "25", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.jnj.com/role/Commonstockstockoptionplansandstockcompensationagreements", "longName": "9952174 - Disclosure - Common stock, stock option plans and stock compensation agreements", "shortName": "Common stock, stock option plans and stock compensation agreements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "26", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.jnj.com/role/Segmentsofbusinessandgeographicareas", "longName": "9952175 - Disclosure - Segments of business and geographic areas", "shortName": "Segments of business and geographic areas", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "27", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.jnj.com/role/Acquisitionsanddivestitures", "longName": "9952176 - Disclosure - Acquisitions and divestitures", "shortName": "Acquisitions and divestitures", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "28", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.jnj.com/role/Legalproceedings", "longName": "9952177 - Disclosure - Legal proceedings", "shortName": "Legal proceedings", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "29", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:LegalMattersAndContingenciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:LegalMattersAndContingenciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.jnj.com/role/Restructuring", "longName": "9952178 - Disclosure - Restructuring", "shortName": "Restructuring", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "30", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.jnj.com/role/Kenvueseparationanddiscontinuedoperations", "longName": "9952179 - Disclosure - Kenvue separation and discontinued operations", "shortName": "Kenvue separation and discontinued operations", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "31", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true } }, "R32": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "32", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true }, "uniqueAnchor": null }, "R33": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "33", "firstAnchor": { "contextRef": "c-1035", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ecd:NonRule10b51ArrAdoptedFlag", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1035", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ecd:NonRule10b51ArrAdoptedFlag", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true } }, "R34": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc", "longName": "995447 - Disclosure - Insider Trading Policies and Procedures", "shortName": "Insider Trading Policies and Procedures", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "34", "firstAnchor": { "contextRef": "c-1", "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true } }, "R35": { "role": "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure", "longName": "995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure", "shortName": "Cybersecurity Risk Management and Strategy Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "35", "firstAnchor": { "contextRef": "c-1", "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true } }, "R36": { "role": "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesPolicies", "longName": "9955511 - Disclosure - Summary of significant accounting policies (Policies)", "shortName": "Summary of significant accounting policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "36", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ConsolidationPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ConsolidationPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true } }, "R37": { "role": "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesTables", "longName": "9955512 - Disclosure - Summary of significant accounting policies (Tables)", "shortName": "Summary of significant accounting policies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "37", "firstAnchor": { "contextRef": "c-1", "name": "jnj:EstimatedUsefulLivesOfAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "jnj:EstimatedUsefulLivesOfAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true } }, "R38": { "role": "http://www.jnj.com/role/CashcashequivalentsandcurrentmarketablesecuritiesTables", "longName": "9955513 - Disclosure - Cash, cash equivalents and current marketable securities (Tables)", "shortName": "Cash, cash equivalents and current marketable securities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "38", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true } }, "R39": { "role": "http://www.jnj.com/role/InventoriesTables", "longName": "9955514 - Disclosure - Inventories (Tables)", "shortName": "Inventories (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "39", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true } }, "R40": { "role": "http://www.jnj.com/role/PropertyplantandequipmentTables", "longName": "9955515 - Disclosure - Property, plant and equipment (Tables)", "shortName": "Property, plant and equipment (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "40", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true } }, "R41": { "role": "http://www.jnj.com/role/IntangibleassetsandgoodwillTables", "longName": "9955516 - Disclosure - Intangible assets and goodwill (Tables)", "shortName": "Intangible assets and goodwill (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "41", "firstAnchor": { "contextRef": "c-1", "name": "jnj:ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "jnj:ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true } }, "R42": { "role": "http://www.jnj.com/role/FairvaluemeasurementsTables", "longName": "9955517 - Disclosure - Fair value measurements (Tables)", "shortName": "Fair value measurements (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "42", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true } }, "R43": { "role": "http://www.jnj.com/role/BorrowingsTables", "longName": "9955518 - Disclosure - Borrowings (Tables)", "shortName": "Borrowings (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "43", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true } }, "R44": { "role": "http://www.jnj.com/role/IncometaxesTables", "longName": "9955519 - Disclosure - Income taxes (Tables)", "shortName": "Income taxes (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "44", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true } }, "R45": { "role": "http://www.jnj.com/role/EmployeerelatedobligationsTables", "longName": "9955520 - Disclosure - Employee related obligations (Tables)", "shortName": "Employee related obligations (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "45", "firstAnchor": { "contextRef": "c-1", "name": "jnj:EmployeeRelatedObligationsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "jnj:EmployeeRelatedObligationsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true } }, "R46": { "role": "http://www.jnj.com/role/PensionsandotherbenefitplansTables", "longName": "9955521 - Disclosure - Pensions and other benefit plans (Tables)", "shortName": "Pensions and other benefit plans (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "46", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true } }, "R47": { "role": "http://www.jnj.com/role/CapitalandtreasurystockTables", "longName": "9955522 - Disclosure - Capital and treasury stock (Tables)", "shortName": "Capital and treasury stock (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "47", "firstAnchor": { "contextRef": "c-1", "name": "jnj:ChangesInTreasuryStockTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "jnj:ChangesInTreasuryStockTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true } }, "R48": { "role": "http://www.jnj.com/role/AccumulatedothercomprehensiveincomelossTables", "longName": "9955523 - Disclosure - Accumulated other comprehensive income (loss) (Tables)", "shortName": "Accumulated other comprehensive income (loss) (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "48", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true } }, "R49": { "role": "http://www.jnj.com/role/EarningspershareTables", "longName": "9955524 - Disclosure - Earnings per share (Tables)", "shortName": "Earnings per share (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "49", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true } }, "R50": { "role": "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsTables", "longName": "9955525 - Disclosure - Common stock, stock option plans and stock compensation agreements (Tables)", "shortName": "Common stock, stock option plans and stock compensation agreements (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "50", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true } }, "R51": { "role": "http://www.jnj.com/role/SegmentsofbusinessandgeographicareasTables", "longName": "9955526 - Disclosure - Segments of business and geographic areas (Tables)", "shortName": "Segments of business and geographic areas (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "51", "firstAnchor": { "contextRef": "c-1", "name": "jnj:SalesBySegmentOfBusinessTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "jnj:SalesBySegmentOfBusinessTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true } }, "R52": { "role": "http://www.jnj.com/role/AcquisitionsanddivestituresTables", "longName": "9955527 - Disclosure - Acquisitions and divestitures (Tables)", "shortName": "Acquisitions and divestitures (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "52", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true } }, "R53": { "role": "http://www.jnj.com/role/LegalproceedingsTables", "longName": "9955528 - Disclosure - Legal proceedings (Tables)", "shortName": "Legal proceedings (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "53", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfLossContingenciesByContingencyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfLossContingenciesByContingencyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true } }, "R54": { "role": "http://www.jnj.com/role/RestructuringTables", "longName": "9955529 - Disclosure - Restructuring (Tables)", "shortName": "Restructuring (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "54", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true } }, "R55": { "role": "http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsTables", "longName": "9955530 - Disclosure - Kenvue separation and discontinued operations (Tables)", "shortName": "Kenvue separation and discontinued operations (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "55", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true } }, "R56": { "role": "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails", "longName": "9955531 - Disclosure - Summary of significant accounting policies - Narrative (Details)", "shortName": "Summary of significant accounting policies - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "c-1", "name": "jnj:NumberOfEmployeesEngagedInCompanyActivitiesWorldwide", "unitRef": "employee", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "jnj:NumberOfEmployeesEngagedInCompanyActivitiesWorldwide", "unitRef": "employee", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true } }, "R57": { "role": "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesEstimatedUsefulLivesofAssetsDetails", "longName": "9955532 - Disclosure - Summary of significant accounting policies - Estimated Useful Lives of Assets (Details)", "shortName": "Summary of significant accounting policies - Estimated Useful Lives of Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "c-49", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "td", "tr", "table", "div", "jnj:EstimatedUsefulLivesOfAssetsTableTextBlock", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-49", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "td", "tr", "table", "div", "jnj:EstimatedUsefulLivesOfAssetsTableTextBlock", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true } }, "R58": { "role": "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesSupplierFinanceProgramDetails", "longName": "9955533 - Disclosure - Summary of significant accounting policies - Supplier Finance Program (Details)", "shortName": "Summary of significant accounting policies - Supplier Finance Program (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "c-11", "name": "us-gaap:SupplierFinanceProgramObligationCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:SupplierFinanceProgramTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SupplierFinanceProgramObligationIncrease", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:SupplierFinanceProgramTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "unique": true } }, "R59": { "role": "http://www.jnj.com/role/CashcashequivalentsandcurrentmarketablesecuritiesCashandCashEquivalentCompositionDetails", "longName": "9955534 - Disclosure - Cash, cash equivalents and current marketable securities - Cash and Cash Equivalent Composition (Details)", "shortName": "Cash, cash equivalents and current marketable securities - Cash and Cash Equivalent Composition (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "c-10", "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-74", "name": "us-gaap:HeldToMaturitySecurities", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "unique": true } }, "R60": { "role": "http://www.jnj.com/role/CashcashequivalentsandcurrentmarketablesecuritiesContractualMaturitiesofAvailableforSaleSecuritiesDetails", "longName": "9955535 - Disclosure - Cash, cash equivalents and current marketable securities - Contractual Maturities of Available for Sale Securities (Details)", "shortName": "Cash, cash equivalents and current marketable securities - Contractual Maturities of Available for Sale Securities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "c-10", "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-10", "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true } }, "R61": { "role": "http://www.jnj.com/role/InventoriesDetails", "longName": "9955536 - Disclosure - Inventories (Details)", "shortName": "Inventories (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "c-10", "name": "us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-10", "name": "us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true } }, "R62": { "role": "http://www.jnj.com/role/PropertyplantandequipmentPropertyPlantandEquipmentatCostandAccumulatedDepreciationDetails", "longName": "9955537 - Disclosure - Property, plant and equipment - Property, Plant and Equipment at Cost and Accumulated Depreciation (Details)", "shortName": "Property, plant and equipment - Property, Plant and Equipment at Cost and Accumulated Depreciation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "c-10", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-10", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true } }, "R63": { "role": "http://www.jnj.com/role/PropertyplantandequipmentNarrativeDetails", "longName": "9955538 - Disclosure - Property, plant and equipment - Narrative (Details)", "shortName": "Property, plant and equipment - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:InterestCostsCapitalized", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:InterestCostsCapitalized", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true } }, "R64": { "role": "http://www.jnj.com/role/IntangibleassetsandgoodwilScheduleofIntangibleAssetsandGoodwillDetails", "longName": "9955539 - Disclosure - Intangible assets and goodwil - Schedule of Intangible Assets and Goodwill (Details)", "shortName": "Intangible assets and goodwil - Schedule of Intangible Assets and Goodwill (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "64", "firstAnchor": { "contextRef": "c-10", "name": "us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "jnj:ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-10", "name": "us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "jnj:ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true } }, "R65": { "role": "http://www.jnj.com/role/IntangibleassetsandgoodwillGoodwillDetails", "longName": "9955540 - Disclosure - Intangible assets and goodwill - Goodwill (Details)", "shortName": "Intangible assets and goodwill - Goodwill (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "65", "firstAnchor": { "contextRef": "c-11", "name": "us-gaap:Goodwill", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfGoodwillTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfGoodwillTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "unique": true } }, "R66": { "role": "http://www.jnj.com/role/IntangibleassetsandgoodwillNarrativeDetails", "longName": "9955541 - Disclosure - Intangible assets and goodwill - Narrative (Details)", "shortName": "Intangible assets and goodwill - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "66", "firstAnchor": { "contextRef": "c-971", "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:AmortizationOfIntangibleAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-8", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "unique": true } }, "R67": { "role": "http://www.jnj.com/role/IntangibleassetsandgoodwillEstimatedAmortizationofIntangibleAssetsDetails", "longName": "9955542 - Disclosure - Intangible assets and goodwill - Estimated Amortization of Intangible Assets (Details)", "shortName": "Intangible assets and goodwill - Estimated Amortization of Intangible Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "67", "firstAnchor": { "contextRef": "c-10", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-10", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true } }, "R68": { "role": "http://www.jnj.com/role/FairvaluemeasurementsNarrativeDetails", "longName": "9955543 - Disclosure - Fair value measurements - Narrative (Details)", "shortName": "Fair value measurements - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "68", "firstAnchor": { "contextRef": "c-10", "name": "us-gaap:AociLossCashFlowHedgeCumulativeGainLossAfterTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-8", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-10", "name": "us-gaap:AociLossCashFlowHedgeCumulativeGainLossAfterTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-8", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true } }, "R69": { "role": "http://www.jnj.com/role/FairvaluemeasurementsSummaryofDerivativeActivityDetails", "longName": "9955544 - Disclosure - Fair value measurements - Summary of Derivative Activity (Details)", "shortName": "Fair value measurements - Summary of Derivative Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "69", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-124", "name": "us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "unique": true } }, "R70": { "role": "http://www.jnj.com/role/FairvaluemeasurementsScheduleofDerivativesRecordedinConsolidatedBalanceSheetsDetails", "longName": "9955545 - Disclosure - Fair value measurements - Schedule of Derivatives Recorded in Consolidated Balance Sheets (Details)", "shortName": "Fair value measurements - Schedule of Derivatives Recorded in Consolidated Balance Sheets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "70", "firstAnchor": { "contextRef": "c-10", "name": "us-gaap:DerivativeFairValueOfDerivativeLiability", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-164", "name": "us-gaap:DerivativeFairValueOfDerivativeLiability", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "unique": true } }, "R71": { "role": "http://www.jnj.com/role/FairvaluemeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails", "longName": "9955546 - Disclosure - Fair value measurements - Schedule of Effect of Derivatives not Designated as Hedging Instruments (Details)", "shortName": "Fair value measurements - Schedule of Effect of Derivatives not Designated as Hedging Instruments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "71", "firstAnchor": { "contextRef": "c-166", "name": "us-gaap:DerivativeGainLossOnDerivativeNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-166", "name": "us-gaap:DerivativeGainLossOnDerivativeNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true } }, "R72": { "role": "http://www.jnj.com/role/FairvaluemeasurementsScheduleofEffectofNetInvestmentHedgesDetails", "longName": "9955547 - Disclosure - Fair value measurements - Schedule of Effect of Net Investment Hedges (Details)", "shortName": "Fair value measurements - Schedule of Effect of Net Investment Hedges (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "72", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true } }, "R73": { "role": "http://www.jnj.com/role/FairvaluemeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails", "longName": "9955548 - Disclosure - Fair value measurements - Summary of Activity Related to Equity Investments (Details)", "shortName": "Fair value measurements - Summary of Activity Related to Equity Investments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "73", "firstAnchor": { "contextRef": "c-10", "name": "us-gaap:OtherAssetsNoncurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-176", "name": "us-gaap:MarketableSecuritiesNoncurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "unique": true } }, "R74": { "role": "http://www.jnj.com/role/FairvaluemeasurementsFinancialAssetsandLiabilitiesatFairValueDetails", "longName": "9955549 - Disclosure - Fair value measurements - Financial Assets and Liabilities at Fair Value (Details)", "shortName": "Fair value measurements - Financial Assets and Liabilities at Fair Value (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "74", "firstAnchor": { "contextRef": "c-10", "name": "us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-10", "name": "us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true } }, "R75": { "role": "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails", "longName": "9955550 - Disclosure - Borrowings - Schedule of Long-term Debt Instruments (Details)", "shortName": "Borrowings - Schedule of Long-term Debt Instruments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "75", "firstAnchor": { "contextRef": "c-10", "name": "us-gaap:LongTermDebt", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-10", "name": "us-gaap:LongTermDebt", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true } }, "R76": { "role": "http://www.jnj.com/role/BorrowingsNarrativeDetails", "longName": "9955551 - Disclosure - Borrowings - Narrative (Details)", "shortName": "Borrowings - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "76", "firstAnchor": { "contextRef": "c-8", "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-9", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-8", "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-9", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true } }, "R77": { "role": "http://www.jnj.com/role/BorrowingsAggregateMaturitiesofLongTermObligationsDetails", "longName": "9955552 - Disclosure - Borrowings - Aggregate Maturities of Long Term Obligations (Details)", "shortName": "Borrowings - Aggregate Maturities of Long Term Obligations (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "77", "firstAnchor": { "contextRef": "c-10", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-10", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true } }, "R78": { "role": "http://www.jnj.com/role/IncometaxesProvisionforIncomeTaxesDetails", "longName": "9955553 - Disclosure - Income taxes - Provision for Income Taxes (Details)", "shortName": "Income taxes - Provision for Income Taxes (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "78", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true } }, "R79": { "role": "http://www.jnj.com/role/IncometaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails", "longName": "9955554 - Disclosure - Income taxes - Comparison of Income Taxes at Statutory Rate and Company's Effective Tax Rate (Details)", "shortName": "Income taxes - Comparison of Income Taxes at Statutory Rate and Company's Effective Tax Rate (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "79", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true } }, "R80": { "role": "http://www.jnj.com/role/IncometaxesNarrativeDetails", "longName": "9955555 - Disclosure - Income taxes - Narrative (Details)", "shortName": "Income taxes - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "80", "firstAnchor": { "contextRef": "c-287", "name": "jnj:EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-287", "name": "jnj:EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true } }, "R81": { "role": "http://www.jnj.com/role/IncometaxesTemporaryDifferencesandCarryforwardsDetails", "longName": "9955556 - Disclosure - Income taxes - Temporary Differences and Carryforwards (Details)", "shortName": "Income taxes - Temporary Differences and Carryforwards (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "81", "firstAnchor": { "contextRef": "c-10", "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-10", "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true } }, "R82": { "role": "http://www.jnj.com/role/IncometaxesValuationAllowanceActivityDetails", "longName": "9955557 - Disclosure - Income taxes - Valuation Allowance Activity (Details)", "shortName": "Income taxes - Valuation Allowance Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "82", "firstAnchor": { "contextRef": "c-11", "name": "us-gaap:DeferredTaxAssetsValuationAllowance", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "jnj:ValuationAllowanceDeferredTaxAssetsProvision", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:SummaryOfValuationAllowanceTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "unique": true } }, "R83": { "role": "http://www.jnj.com/role/IncometaxesSummaryofActivityRelatedtoUnrecognizedTaxBenefitsDetails", "longName": "9955558 - Disclosure - Income taxes - Summary of Activity Related to Unrecognized Tax Benefits (Details)", "shortName": "Income taxes - Summary of Activity Related to Unrecognized Tax Benefits (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "83", "firstAnchor": { "contextRef": "c-11", "name": "us-gaap:UnrecognizedTaxBenefits", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "unique": true } }, "R84": { "role": "http://www.jnj.com/role/EmployeerelatedobligationsEmployeeRelatedObligationsDetails", "longName": "9955559 - Disclosure - Employee related obligations - Employee Related Obligations (Details)", "shortName": "Employee related obligations - Employee Related Obligations (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "84", "firstAnchor": { "contextRef": "c-10", "name": "us-gaap:DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "jnj:EmployeeRelatedObligationsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-10", "name": "us-gaap:DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "jnj:EmployeeRelatedObligationsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true } }, "R85": { "role": "http://www.jnj.com/role/EmployeerelatedobligationsNarrativeDetails", "longName": "9955560 - Disclosure - Employee related obligations - Narrative (Details)", "shortName": "Employee related obligations - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "85", "firstAnchor": { "contextRef": "c-10", "name": "us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true }, "uniqueAnchor": null }, "R86": { "role": "http://www.jnj.com/role/PensionsandotherbenefitplansNarrativeDetails", "longName": "9955561 - Disclosure - Pensions and other benefit plans - Narrative (Details)", "shortName": "Pensions and other benefit plans - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "86", "firstAnchor": { "contextRef": "c-10", "name": "jnj:PercentageOfCorridorOfGreaterOfMarketValueOfAssets", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-10", "name": "jnj:PercentageOfCorridorOfGreaterOfMarketValueOfAssets", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true } }, "R87": { "role": "http://www.jnj.com/role/PensionsandotherbenefitplansComponentsofNetPeriodicBenefitCostDetails", "longName": "9955562 - Disclosure - Pensions and other benefit plans - Components of Net Periodic Benefit Cost (Details)", "shortName": "Pensions and other benefit plans - Components of Net Periodic Benefit Cost (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "87", "firstAnchor": { "contextRef": "c-291", "name": "us-gaap:DefinedBenefitPlanServiceCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-291", "name": "us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "unique": true } }, "R88": { "role": "http://www.jnj.com/role/PensionsandotherbenefitplansRatesUsedtoDevelopActuarialPresentValueofProjectedBenefitObligationDetails", "longName": "9955563 - Disclosure - Pensions and other benefit plans - Rates Used to Develop Actuarial Present Value of Projected Benefit Obligation (Details)", "shortName": "Pensions and other benefit plans - Rates Used to Develop Actuarial Present Value of Projected Benefit Obligation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "88", "firstAnchor": { "contextRef": "c-291", "name": "us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "4", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAssumptionsUsedTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-291", "name": "us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "4", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAssumptionsUsedTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true } }, "R89": { "role": "http://www.jnj.com/role/PensionsandotherbenefitplansAssumedHealthCareCostTrendRatesDetails", "longName": "9955564 - Disclosure - Pensions and other benefit plans - Assumed Health Care Cost Trend Rates (Details)", "shortName": "Pensions and other benefit plans - Assumed Health Care Cost Trend Rates (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "89", "firstAnchor": { "contextRef": "c-10", "name": "us-gaap:DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "4", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfHealthCareCostTrendRatesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-10", "name": "us-gaap:DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "4", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfHealthCareCostTrendRatesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true } }, "R90": { "role": "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofNetFundedStatusDetails", "longName": "9955565 - Disclosure - Pensions and other benefit plans - Schedule of Net Funded Status (Details)", "shortName": "Pensions and other benefit plans - Schedule of Net Funded Status (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "90", "firstAnchor": { "contextRef": "c-10", "name": "us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "jnj:DefinedBenefitPlanBenefitObligationTransferredToGroupAnnuityContract", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "unique": true } }, "R91": { "role": "http://www.jnj.com/role/PensionsandotherbenefitplansInformationRelatedtotheBenefitObligationandtheFairValueofPlanAssetsDetails", "longName": "9955566 - Disclosure - Pensions and other benefit plans - Information Related to the Benefit Obligation and the Fair Value of Plan Assets (Details)", "shortName": "Pensions and other benefit plans - Information Related to the Benefit Obligation and the Fair Value of Plan Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "91", "firstAnchor": { "contextRef": "c-305", "name": "us-gaap:DefinedBenefitPlanFairValueOfPlanAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "jnj:InformationRelatedToBenefitObligationAndFairValueOfPlanAssetsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-305", "name": "us-gaap:DefinedBenefitPlanFairValueOfPlanAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "jnj:InformationRelatedToBenefitObligationAndFairValueOfPlanAssetsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true } }, "R92": { "role": "http://www.jnj.com/role/PensionsandotherbenefitplansProjectedFutureBenefitPaymentsfromCompanysRetirementandOtherBenefitPlansDetails", "longName": "9955567 - Disclosure - Pensions and other benefit plans - Projected Future Benefit Payments from Company's Retirement and Other Benefit Plans (Details)", "shortName": "Pensions and other benefit plans - Projected Future Benefit Payments from Company's Retirement and Other Benefit Plans (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "92", "firstAnchor": { "contextRef": "c-297", "name": "us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfExpectedBenefitPaymentsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-297", "name": "us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfExpectedBenefitPaymentsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true } }, "R93": { "role": "http://www.jnj.com/role/PensionsandotherbenefitplansProjectedFutureMinimumContributionstotheCompanysUSandInternationalUnfundedRetirementPlansDetails", "longName": "9955568 - Disclosure - Pensions and other benefit plans - Projected Future Minimum Contributions to the Company's U.S. and International Unfunded Retirement Plans (Details)", "shortName": "Pensions and other benefit plans - Projected Future Minimum Contributions to the Company's U.S. and International Unfunded Retirement Plans (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "93", "firstAnchor": { "contextRef": "c-10", "name": "jnj:DefinedBenefitPlanExpectedFutureBenefitContributionInYearOne", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "jnj:ScheduleOfEstimatedFutureEmployerContributionsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-10", "name": "jnj:DefinedBenefitPlanExpectedFutureBenefitContributionInYearOne", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "jnj:ScheduleOfEstimatedFutureEmployerContributionsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true } }, "R94": { "role": "http://www.jnj.com/role/PensionsandotherbenefitplansCompanyRetirementPlanAssetAllocationandTargetAllocationsDetails", "longName": "9955569 - Disclosure - Pensions and other benefit plans - Company' Retirement Plan Asset Allocation and Target Allocations (Details)", "shortName": "Pensions and other benefit plans - Company' Retirement Plan Asset Allocation and Target Allocations (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "94", "firstAnchor": { "contextRef": "c-10", "name": "us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAllocationOfPlanAssetsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-10", "name": "us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAllocationOfPlanAssetsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true } }, "R95": { "role": "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofDefinedBenefitPlansDisclosuresDetails", "longName": "9955570 - Disclosure - Pensions and other benefit plans - Schedule of Defined Benefit Plans Disclosures (Details)", "shortName": "Pensions and other benefit plans - Schedule of Defined Benefit Plans Disclosures (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "95", "firstAnchor": { "contextRef": "c-297", "name": "us-gaap:DefinedBenefitPlanFairValueOfPlanAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-371", "name": "us-gaap:DefinedBenefitPlanFairValueOfPlanAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDefinedBenefitPlansDisclosuresTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "unique": true } }, "R96": { "role": "http://www.jnj.com/role/SavingsplanDetails", "longName": "9955571 - Disclosure - Savings plan (Details)", "shortName": "Savings plan (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "96", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DefinedContributionPlanCostRecognized", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DefinedContributionPlanCostRecognized", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true } }, "R97": { "role": "http://www.jnj.com/role/CapitalandtreasurystockChangesinTreasuryStockDetails", "longName": "9955572 - Disclosure - Capital and treasury stock - Changes in Treasury Stock (Details)", "shortName": "Capital and treasury stock - Changes in Treasury Stock (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "97", "firstAnchor": { "contextRef": "c-11", "name": "us-gaap:TreasuryStockCommonShares", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "jnj:ChangesInTreasuryStockTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-14", "name": "us-gaap:TreasuryStockCommonShares", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "jnj:ChangesInTreasuryStockTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "unique": true } }, "R98": { "role": "http://www.jnj.com/role/CapitalandtreasurystockNarrativeDetails", "longName": "9955573 - Disclosure - Capital and treasury stock - Narrative (Details)", "shortName": "Capital and treasury stock - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "98", "firstAnchor": { "contextRef": "c-10", "name": "us-gaap:CommonStockSharesIssued", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "us-gaap:CommonStockSharesIssued", "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-22", "name": "us-gaap:CommonStockSharesIssued", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "us-gaap:CommonStockSharesIssued", "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "unique": true } }, "R99": { "role": "http://www.jnj.com/role/AccumulatedothercomprehensiveincomelossDetails", "longName": "9955574 - Disclosure - Accumulated other comprehensive income (loss) (Details)", "shortName": "Accumulated other comprehensive income (loss) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "99", "firstAnchor": { "contextRef": "c-11", "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-377", "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "unique": true } }, "R100": { "role": "http://www.jnj.com/role/InternationalcurrencytranslationDetails", "longName": "9955575 - Disclosure - International currency translation (Details)", "shortName": "International currency translation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "100", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ForeignCurrencyTransactionGainLossBeforeTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ForeignCurrencyTransactionGainLossBeforeTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true } }, "R101": { "role": "http://www.jnj.com/role/EarningspershareReconciliationofBasicNetEarningsperSharetoDilutedNetEarningsperShareDetails", "longName": "9955576 - Disclosure - Earnings per share - Reconciliation of Basic Net Earnings per Share to Diluted Net Earnings per Share (Details)", "shortName": "Earnings per share - Reconciliation of Basic Net Earnings per Share to Diluted Net Earnings per Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "101", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeLossFromContinuingOperationsPerBasicShare", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "unique": true } }, "R102": { "role": "http://www.jnj.com/role/EarningspershareNarrativeDetails", "longName": "9955577 - Disclosure - Earnings per share - Narrative (Details)", "shortName": "Earnings per share - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "102", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true }, "uniqueAnchor": null }, "R103": { "role": "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsNarrativeDetails", "longName": "9955578 - Disclosure - Common stock, stock option plans and stock compensation agreements - Narrative (Details)", "shortName": "Common stock, stock option plans and stock compensation agreements - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "103", "firstAnchor": { "contextRef": "c-10", "name": "jnj:NumberOfStockBasedCompensationPlans", "unitRef": "stockbasedcompensationplans", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-10", "name": "jnj:NumberOfStockBasedCompensationPlans", "unitRef": "stockbasedcompensationplans", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true } }, "R104": { "role": "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsScheduleValuationAssumptionsDetails", "longName": "9955579 - Disclosure - Common stock, stock option plans and stock compensation agreements - Schedule Valuation Assumptions (Details)", "shortName": "Common stock, stock option plans and stock compensation agreements - Schedule Valuation Assumptions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "104", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "4", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "4", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true } }, "R105": { "role": "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsSummaryofStockOptionActivityDetails", "longName": "9955580 - Disclosure - Common stock, stock option plans and stock compensation agreements - Summary of Stock Option Activity (Details)", "shortName": "Common stock, stock option plans and stock compensation agreements - Summary of Stock Option Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "105", "firstAnchor": { "contextRef": "c-11", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-11", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true } }, "R106": { "role": "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsSummaryofOptionsOutstandingDetails", "longName": "9955581 - Disclosure - Common stock, stock option plans and stock compensation agreements - Summary of Options Outstanding (Details)", "shortName": "Common stock, stock option plans and stock compensation agreements - Summary of Options Outstanding (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "106", "firstAnchor": { "contextRef": "c-10", "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-10", "name": "us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "unique": true } }, "R107": { "role": "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsSummaryofRestrictedShareUnitsDetails", "longName": "9955582 - Disclosure - Common stock, stock option plans and stock compensation agreements - Summary of Restricted Share Units (Details)", "shortName": "Common stock, stock option plans and stock compensation agreements - Summary of Restricted Share Units (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "107", "firstAnchor": { "contextRef": "c-425", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-425", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true } }, "R108": { "role": "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails", "longName": "9955583 - Disclosure - Segments of Business and Geographic Areas - Sales by Segment of Business (Details)", "shortName": "Segments of Business and Geographic Areas - Sales by Segment of Business (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "108", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NumberOfOperatingSegments", "unitRef": "segment2", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "jnj:PercentageChangeInSalesBySegmentOfBusiness", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "unique": true } }, "R109": { "role": "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasIncomeBeforeTaxbySegmentDetails", "longName": "9955584 - Disclosure - Segments of Business and Geographic Areas - Income Before Tax by Segment (Details)", "shortName": "Segments of Business and Geographic Areas - Income Before Tax by Segment (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "109", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SegmentReportingOtherItemAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "unique": true } }, "R110": { "role": "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails", "longName": "9955585 - Disclosure - Segments of Business and Geographic Areas - Schedule of Segment Reporting Information (Details)", "shortName": "Segments of Business and Geographic Areas - Schedule of Segment Reporting Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "110", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SegmentExpenditureAdditionToLongLivedAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "unique": true } }, "R111": { "role": "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingByGeographicAreaDetails", "longName": "9955586 - Disclosure - Segments of Business and Geographic Areas - Schedule of Segment Reporting By Geographic Area (Details)", "shortName": "Segments of Business and Geographic Areas - Schedule of Segment Reporting By Geographic Area (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "111", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-12", "name": "us-gaap:GainLossRelatedToLitigationSettlement", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-8", "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "unique": true } }, "R112": { "role": "http://www.jnj.com/role/AcquisitionsanddivestituresNarrativeDetails", "longName": "9955587 - Disclosure - Acquisitions and divestitures - Narrative (Details)", "shortName": "Acquisitions and divestitures - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "112", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:PaymentsToAcquireBusinessesGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-8", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:PaymentsToAcquireBusinessesGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-8", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true } }, "R113": { "role": "http://www.jnj.com/role/AcquisitionsanddivestituresDetails", "longName": "9955588 - Disclosure - Acquisitions and divestitures (Details)", "shortName": "Acquisitions and divestitures (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "113", "firstAnchor": { "contextRef": "c-10", "name": "us-gaap:Goodwill", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfGoodwillTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-958", "name": "us-gaap:Goodwill", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-8", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "unique": true } }, "R114": { "role": "http://www.jnj.com/role/LegalproceedingsNarrativeDetails", "longName": "9955589 - Disclosure - Legal proceedings - Narrative (Details)", "shortName": "Legal proceedings - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "114", "firstAnchor": { "contextRef": "c-998", "name": "jnj:ProductLiabilityContingencyNumberOfClaimant", "unitRef": "claimant", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfLossContingenciesByContingencyTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-996", "name": "jnj:ProductLiabilityContingencyNumberOfClaimant", "unitRef": "claimant", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "unique": true } }, "R115": { "role": "http://www.jnj.com/role/LegalproceedingsProductLiabilitiesDetails", "longName": "9955590 - Disclosure - Legal proceedings - Product Liabilities (Details)", "shortName": "Legal proceedings - Product Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "115", "firstAnchor": { "contextRef": "c-998", "name": "jnj:ProductLiabilityContingencyNumberOfClaimant", "unitRef": "claimant", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfLossContingenciesByContingencyTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-999", "name": "jnj:ProductLiabilityContingencyNumberOfClaimant", "unitRef": "claimant", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfLossContingenciesByContingencyTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "unique": true } }, "R116": { "role": "http://www.jnj.com/role/RestructuringNarrativeDetails", "longName": "9955591 - Disclosure - Restructuring - Narrative (Details)", "shortName": "Restructuring - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "116", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RestructuringCharges", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1012", "name": "us-gaap:RestructuringAndRelatedCostCostIncurredToDate1", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-8", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "unique": true } }, "R117": { "role": "http://www.jnj.com/role/RestructuringScheduleofRestructuringReserveDetails", "longName": "9955592 - Disclosure - Restructuring - Schedule of Restructuring Reserve (Details)", "shortName": "Restructuring - Schedule of Restructuring Reserve (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "117", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RestructuringCharges", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1018", "name": "us-gaap:RestructuringCharges", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "unique": true } }, "R118": { "role": "http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsDetailsDetails", "longName": "9955593 - Disclosure - Kenvue separation and discontinued operations - Details (Details)", "shortName": "Kenvue separation and discontinued operations - Details (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "118", "firstAnchor": { "contextRef": "c-184", "name": "us-gaap:CommercialPaper", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-8", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1026", "name": "jnj:ExchangeOfStockCommonStockValueReceived", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-8", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "unique": true } }, "R119": { "role": "http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsNetEarningsfromDiscontinuedOperationDetails", "longName": "9955594 - Disclosure - Kenvue separation and discontinued operations - Net Earnings from Discontinued Operation (Details)", "shortName": "Kenvue separation and discontinued operations - Net Earnings from Discontinued Operation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "119", "firstAnchor": { "contextRef": "c-12", "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-12", "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true } }, "R120": { "role": "http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsDepreciationandAmortizationofDiscontinuedOperationDetails", "longName": "9955595 - Disclosure - Kenvue separation and discontinued operations - Depreciation and Amortization of Discontinued Operation (Details)", "shortName": "Kenvue separation and discontinued operations - Depreciation and Amortization of Discontinued Operation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "120", "firstAnchor": { "contextRef": "c-12", "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-12", "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "jnj-20241229.htm", "first": true, "unique": true } } }, "tag": { "jnj_A0.650NotesDue2024Member": { "xbrltype": "domainItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "A0.650NotesDue2024Member", "presentation": [ "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "0.650% Notes due 2024 (750MM Euro 1.1090)(3)", "label": "0.650% Notes Due 2024 [Member]", "documentation": "0.650% Notes Due 2024 [Member]" } } }, "auth_ref": [] }, "jnj_A055NotesDue2025Member": { "xbrltype": "domainItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "A055NotesDue2025Member", "presentation": [ "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "0.55% Notes due 2025", "label": "0.55% Notes due 2025 [Member]", "documentation": "0.55% Notes due 2025" } } }, "auth_ref": [] }, "jnj_A095NotesDue2027Member": { "xbrltype": "domainItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "A095NotesDue2027Member", "presentation": [ "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "0.95% Notes due 2027", "label": "0.95% Notes due 2027 [Member]", "documentation": "0.95% Notes due 2027" } } }, "auth_ref": [] }, "jnj_A1.150NotesDue2028Member": { "xbrltype": "domainItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "A1.150NotesDue2028Member", "presentation": [ "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails", "http://www.jnj.com/role/CoverPage" ], "lang": { "en-us": { "role": { "verboseLabel": "1.150% Notes Due November 2028", "terseLabel": "1.150% Notes due 2028\u2028(750MM Euro 1.0401)(2)/(750MM Euro 1.1090)(3)", "label": "1.150% Notes Due 2028 [Member]", "documentation": "1.150% Notes Due 2028 [Member]" } } }, "auth_ref": [] }, "jnj_A1.150NotesDueNovember2028Member": { "xbrltype": "domainItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "A1.150NotesDueNovember2028Member", "presentation": [ "http://www.jnj.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "1.150% Notes Due November 2028", "label": "1.150% Notes Due November 2028 [Member]", "documentation": "1.150% Notes Due November 2028" } } }, "auth_ref": [] }, "jnj_A1.650NotesDue2035Member": { "xbrltype": "domainItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "A1.650NotesDue2035Member", "presentation": [ "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails", "http://www.jnj.com/role/CoverPage" ], "lang": { "en-us": { "role": { "verboseLabel": "1.650% Notes Due May 2035", "terseLabel": "1.650% Notes due 2035\u2028(1.5B Euro 1.0401)(2)/(1.5B Euro 1.1090)(3)", "label": "1.650% Notes Due 2035 [Member]", "documentation": "1.650% Notes Due 2035 [Member]" } } }, "auth_ref": [] }, "jnj_A130NotesDue2030Member": { "xbrltype": "domainItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "A130NotesDue2030Member", "presentation": [ "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "1.30% Notes due 2030", "label": "1.30% Notes due 2030 [Member]", "documentation": "1.30% Notes due 2030" } } }, "auth_ref": [] }, "jnj_A2.45Notesdue2026Member": { "xbrltype": "domainItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "A2.45Notesdue2026Member", "presentation": [ "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2.46% Notes due 2026", "label": "2.45% Notes due 2026 [Member]", "documentation": "2.45% Notes due 2026 [Member]" } } }, "auth_ref": [] }, "jnj_A2.625Notesdue2025Member": { "xbrltype": "domainItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "A2.625Notesdue2025Member", "presentation": [ "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2.625% Notes due 2025", "label": "2.625 Notes due 2025 [Member]", "documentation": "2.625 Notes due 2025 [Member]" } } }, "auth_ref": [] }, "jnj_A2.900Notesdue2028Member": { "xbrltype": "domainItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "A2.900Notesdue2028Member", "presentation": [ "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2.90%\u00a0Notes due 2028", "label": "2.900% Notes due 2028 [Member]", "documentation": "2.900% Notes due 2028 [Member]" } } }, "auth_ref": [] }, "jnj_A2.95Notesdue2027Member": { "xbrltype": "domainItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "A2.95Notesdue2027Member", "presentation": [ "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2.95% Notes due 2027", "label": "2.95% Notes due 2027 [Member]", "documentation": "2.95% Notes due 2027 [Member]" } } }, "auth_ref": [] }, "jnj_A2022LongTermIncentivePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "A2022LongTermIncentivePlanMember", "presentation": [ "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2022 Long-Term Incentive Plan", "label": "2022 Long-Term Incentive Plan [Member]", "documentation": "2022 Long-Term Incentive Plan" } } }, "auth_ref": [] }, "jnj_A210NotesDue2040Member": { "xbrltype": "domainItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "A210NotesDue2040Member", "presentation": [ "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2.10% Notes due 2040", "label": "2.10% Notes due 2040 [Member]", "documentation": "2.10% Notes due 2040" } } }, "auth_ref": [] }, "jnj_A2250NotesDue2050Member": { "xbrltype": "domainItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "A2250NotesDue2050Member", "presentation": [ "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2.250% Notes due 2050", "label": "2.250% Notes due 2050 [Member]", "documentation": "2.250% Notes due 2050" } } }, "auth_ref": [] }, "jnj_A2450NotesDue2060Member": { "xbrltype": "domainItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "A2450NotesDue2060Member", "presentation": [ "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2.450% Notes due 2060", "label": "2.450% Notes due 2060 [Member]", "documentation": "2.450% Notes due 2060" } } }, "auth_ref": [] }, "jnj_A3.20DebenturesDue2032Member": { "xbrltype": "domainItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "A3.20DebenturesDue2032Member", "presentation": [ "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "3.20% Debentures due 2032", "label": "3.20% Debentures due 2032 [Member]", "documentation": "3.20% Debentures due 2032" } } }, "auth_ref": [] }, "jnj_A3.20NotesDueNovember2032Member": { "xbrltype": "domainItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "A3.20NotesDueNovember2032Member", "presentation": [ "http://www.jnj.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "3.20% Notes Due November 2032", "label": "3.20% Notes Due November 2032 [Member]", "documentation": "3.20% Notes Due November 2032" } } }, "auth_ref": [] }, "jnj_A3.350NotesDueNovember2036Member": { "xbrltype": "domainItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "A3.350NotesDueNovember2036Member", "presentation": [ "http://www.jnj.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "3.350% Notes Due November 2036", "label": "3.350% Notes Due November 2036 [Member]", "documentation": "3.350% Notes Due November 2036" } } }, "auth_ref": [] }, "jnj_A3.35DebenturesDue2036Member": { "xbrltype": "domainItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "A3.35DebenturesDue2036Member", "presentation": [ "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "3.35% Debentures due 2036", "label": "3.35% Debentures due 2036 [Member]", "documentation": "3.35% Debentures due 2036" } } }, "auth_ref": [] }, "jnj_A3.400Notesdue2038Member": { "xbrltype": "domainItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "A3.400Notesdue2038Member", "presentation": [ "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "3.40%\u00a0Notes due 2038", "label": "3.400% Notes due 2038 [Member]", "documentation": "3.400% Notes due 2038 [Member]" } } }, "auth_ref": [] }, "jnj_A3.500Notesdue2048Member": { "xbrltype": "domainItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "A3.500Notesdue2048Member", "presentation": [ "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "3.500% Notes due 2048", "label": "3.500% Notes due 2048 [Member]", "documentation": "3.500% Notes due 2048 [Member]" } } }, "auth_ref": [] }, "jnj_A3.550NotesDueNovember2044Member": { "xbrltype": "domainItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "A3.550NotesDueNovember2044Member", "presentation": [ "http://www.jnj.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "3.550% Notes Due November 2044", "label": "3.550% Notes Due November 2044 [Member]", "documentation": "3.550% Notes Due November 2044" } } }, "auth_ref": [] }, "jnj_A3.55DebenturesDue2044Member": { "xbrltype": "domainItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "A3.55DebenturesDue2044Member", "presentation": [ "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "3.55% Debentures due 2044", "label": "3.55% Debentures due 2044 [Member]", "documentation": "3.55% Debentures due 2044" } } }, "auth_ref": [] }, "jnj_A3.55Notesdue2036Member": { "xbrltype": "domainItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "A3.55Notesdue2036Member", "presentation": [ "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "3.587% Notes due 2036", "label": "3.55% Notes due 2036 [Member]", "documentation": "3.55% Notes due 2036 [Member]" } } }, "auth_ref": [] }, "jnj_A3.625Notesdue2037Member": { "xbrltype": "domainItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "A3.625Notesdue2037Member", "presentation": [ "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "3.625% Notes due 2037", "label": "3.625% Notes due 2037 [Member]", "documentation": "3.625% Notes due 2037 [Member]" } } }, "auth_ref": [] }, "jnj_A3.70Notesdue2046Member": { "xbrltype": "domainItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "A3.70Notesdue2046Member", "presentation": [ "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "3.73% Notes due 2046", "label": "3.70% Notes due 2046 [Member]", "documentation": "3.70% Notes due 2046 [Member]" } } }, "auth_ref": [] }, "jnj_A3.75Notesdue2047Member": { "xbrltype": "domainItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "A3.75Notesdue2047Member", "presentation": [ "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "3.75% Notes due 2047", "label": "3.75% Notes due 2047 [Member]", "documentation": "3.75% Notes due 2047 [Member]" } } }, "auth_ref": [] }, "jnj_A4.375Notesdue2033Member": { "xbrltype": "domainItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "A4.375Notesdue2033Member", "presentation": [ "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "4.375% Notes due 2033", "label": "4.375% Notes due 2033 [Member]", "documentation": "4.375% Notes due 2033 [Member]" } } }, "auth_ref": [] }, "jnj_A4.50Debenturesdue2040Member": { "xbrltype": "domainItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "A4.50Debenturesdue2040Member", "presentation": [ "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "4.50%\u00a0Debentures due 2040", "label": "4.50% Debentures due 2040 [Member]", "documentation": "4.50% Debentures due 2040 [Member]" } } }, "auth_ref": [] }, "jnj_A4.50Notesdue2043Member": { "xbrltype": "domainItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "A4.50Notesdue2043Member", "presentation": [ "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "4.50% Notes due 2043", "label": "4.50% Notes due 2043 [Member]", "documentation": "4.50% Notes due 2043 [Member]" } } }, "auth_ref": [] }, "jnj_A4.80DebenturesDue2029Member": { "xbrltype": "domainItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "A4.80DebenturesDue2029Member", "presentation": [ "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "4.80% Debentures due 2029", "label": "4.80% Debentures due 2029 [Member]", "documentation": "4.80% Debentures due 2029" } } }, "auth_ref": [] }, "jnj_A4.85Notesdue2041Member": { "xbrltype": "domainItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "A4.85Notesdue2041Member", "presentation": [ "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "4.85% Notes due 2041", "label": "4.85% Notes due 2041 [Member]", "documentation": "4.85% Notes due 2041 [Member]" } } }, "auth_ref": [] }, "jnj_A4.90DebenturesDue2031Member": { "xbrltype": "domainItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "A4.90DebenturesDue2031Member", "presentation": [ "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "4.90% Debentures due 2031", "label": "4.90% Debentures due 2031 [Member]", "documentation": "4.90% Debentures due 2031" } } }, "auth_ref": [] }, "jnj_A4.95DebenturesDue2034Member": { "xbrltype": "domainItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "A4.95DebenturesDue2034Member", "presentation": [ "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "4.95% Debentures due 2034", "label": "4.95% Debentures due 2034 [Member]", "documentation": "4.95% Debentures due 2034" } } }, "auth_ref": [] }, "jnj_A4.95Debenturesdue2033Member": { "xbrltype": "domainItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "A4.95Debenturesdue2033Member", "presentation": [ "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "4.95%\u00a0Debentures due 2033", "label": "4.95% Debentures due 2033 [Member]", "documentation": "4.95% Debentures due 2033 [Member]" } } }, "auth_ref": [] }, "jnj_A5.25DebenturesDue2054Member": { "xbrltype": "domainItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "A5.25DebenturesDue2054Member", "presentation": [ "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "5.25% Debentures due 2054", "label": "5.25% Debentures due 2054 [Member]", "documentation": "5.25% Debentures due 2054" } } }, "auth_ref": [] }, "jnj_A5.50NotesDue2024Member": { "xbrltype": "domainItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "A5.50NotesDue2024Member", "presentation": [ "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "5.50%\u00a0Notes due 2024 (500MM GBP 1.2756)(3)", "label": "5.50% Notes Due 2024 [Member]", "documentation": "5.50% Notes Due 2024 [Member]" } } }, "auth_ref": [] }, "jnj_A5.85Debenturesdue2038Member": { "xbrltype": "domainItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "A5.85Debenturesdue2038Member", "presentation": [ "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "5.85%\u00a0Debentures due 2038", "label": "5.85% Debentures due 2038 [Member]", "documentation": "5.85% Debentures due 2038 [Member]" } } }, "auth_ref": [] }, "jnj_A5.95Notesdue2037Member": { "xbrltype": "domainItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "A5.95Notesdue2037Member", "presentation": [ "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "5.95%\u00a0Notes due 2037", "label": "5.95% Notes due 2037 [Member]", "documentation": "5.95% Notes due 2037 [Member]" } } }, "auth_ref": [] }, "jnj_A6.95Notesdue2029Member": { "xbrltype": "domainItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "A6.95Notesdue2029Member", "presentation": [ "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "6.95%\u00a0Notes due 2029", "label": "6.95% Notes due 2029 [Member]", "documentation": "6.95% Notes due 2029 [Member]" } } }, "auth_ref": [] }, "jnj_ADVANCEDMember": { "xbrltype": "domainItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "ADVANCEDMember", "presentation": [ "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "ADVANCED", "label": "ADVANCED [Member]", "documentation": "ADVANCED [Member]" } } }, "auth_ref": [] }, "jnj_AbiomedMember": { "xbrltype": "domainItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "AbiomedMember", "presentation": [ "http://www.jnj.com/role/AcquisitionsanddivestituresNarrativeDetails", "http://www.jnj.com/role/FairvaluemeasurementsFinancialAssetsandLiabilitiesatFairValueDetails", "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Abiomed", "label": "Abiomed [Member]", "documentation": "Abiomed" } } }, "auth_ref": [] }, "jnj_AcclarentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "AcclarentMember", "presentation": [ "http://www.jnj.com/role/AcquisitionsanddivestituresNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Acclarent", "label": "Acclarent [Member]", "documentation": "Acclarent" } } }, "auth_ref": [] }, "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Accounting Policies [Abstract]", "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://www.jnj.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.jnj.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "verboseLabel": "Accounts payable", "label": "Accounts Payable, Current", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r149", "r1219" ] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "calculation": { "http://www.jnj.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.jnj.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "verboseLabel": "Accounts receivable trade, less allowances $167 (2023, $166)", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": [ "r1438" ] }, "us-gaap_AccruedIncomeTaxesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedIncomeTaxesCurrent", "crdr": "credit", "calculation": { "http://www.jnj.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.jnj.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "verboseLabel": "Accrued taxes on income", "label": "Accrued Income Taxes, Current", "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations." } } }, "auth_ref": [ "r152", "r236" ] }, "us-gaap_AccruedIncomeTaxesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedIncomeTaxesNoncurrent", "crdr": "credit", "calculation": { "http://www.jnj.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.jnj.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term taxes payable", "label": "Accrued Income Taxes, Noncurrent", "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due beyond one year or the operating cycle, whichever is longer. Alternate captions include income taxes payable, noncurrent." } } }, "auth_ref": [ "r157", "r236" ] }, "us-gaap_AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.jnj.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.jnj.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "verboseLabel": "Accrued liabilities", "label": "Accrued Liabilities, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r152" ] }, "jnj_AccruedRebatesReturnsAndPromotions": { "xbrltype": "monetaryItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "AccruedRebatesReturnsAndPromotions", "crdr": "credit", "calculation": { "http://www.jnj.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.jnj.com/role/ConsolidatedBalanceSheets", "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Accrued rebates, returns and promotions", "label": "Accrued Rebates Returns And Promotions", "documentation": "Reflects the estimated obligations due within one year for rebates, returns and promotions. Reserves include such items related to Medicaid rebates, product returns due to expiration, product recalls, current portion of coupons and volume-based sales incentives programs." } } }, "auth_ref": [] }, "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedDefinedBenefitPlansAdjustmentMember", "presentation": [ "http://www.jnj.com/role/AccumulatedothercomprehensiveincomelossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Employee Benefit Plans", "label": "Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]", "documentation": "Accumulated other comprehensive (income) loss related to defined benefit plans attributable to the parent." } } }, "auth_ref": [ "r7", "r8", "r21", "r41", "r173", "r1406", "r1407", "r1408" ] }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.jnj.com/role/PropertyplantandequipmentPropertyPlantandEquipmentatCostandAccumulatedDepreciationDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.jnj.com/role/PropertyplantandequipmentPropertyPlantandEquipmentatCostandAccumulatedDepreciationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Less accumulated depreciation", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } } }, "auth_ref": [ "r67", "r319", "r974" ] }, "us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedGainLossNetCashFlowHedgeParentMember", "presentation": [ "http://www.jnj.com/role/AccumulatedothercomprehensiveincomelossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gain/ (Loss) On Derivatives & Hedges", "label": "Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]", "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent." } } }, "auth_ref": [ "r346", "r356", "r357", "r802", "r1153", "r1406" ] }, "us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedNetUnrealizedInvestmentGainLossMember", "presentation": [ "http://www.jnj.com/role/AccumulatedothercomprehensiveincomelossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gain/ (Loss) On Securities", "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Parent [Member]", "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent." } } }, "auth_ref": [ "r341", "r342", "r343", "r346", "r356", "r357", "r1406" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "presentation": [ "http://www.jnj.com/role/AccumulatedothercomprehensiveincomelossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r355", "r356", "r858", "r860", "r861", "r862", "r863", "r865" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://www.jnj.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.jnj.com/role/ConsolidatedBalanceSheets", "http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsDetailsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Accumulated other comprehensive income (loss)", "negatedTerseLabel": "Accumulated other comprehensive loss", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": [ "r40", "r41", "r174", "r331", "r970", "r1011", "r1012" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "presentation": [ "http://www.jnj.com/role/AccumulatedothercomprehensiveincomelossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]", "label": "Accumulated Other Comprehensive Income (Loss) [Table]", "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss)." } } }, "auth_ref": [ "r355", "r356", "r858", "r860", "r861", "r862", "r863", "r865" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": [ "http://www.jnj.com/role/AccumulatedothercomprehensiveincomelossDetails", "http://www.jnj.com/role/ConsolidatedStatementsofEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income (Loss)", "label": "AOCI Attributable to Parent [Member]", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r5", "r21", "r41", "r812", "r815", "r882", "r1007", "r1008", "r1406", "r1407", "r1408", "r1424", "r1425", "r1426", "r1428" ] }, "us-gaap_AccumulatedTranslationAdjustmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedTranslationAdjustmentMember", "presentation": [ "http://www.jnj.com/role/AccumulatedothercomprehensiveincomelossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign Currency Translation", "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]", "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent." } } }, "auth_ref": [ "r6", "r21", "r41", "r171", "r172", "r356", "r357", "r860", "r861", "r862", "r863", "r865", "r1406" ] }, "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife", "presentation": [ "http://www.jnj.com/role/AcquisitionsanddivestituresNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average useful life", "label": "Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life", "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r524", "r1141" ] }, "us-gaap_AcquisitionCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AcquisitionCosts", "crdr": "debit", "presentation": [ "http://www.jnj.com/role/AcquisitionsanddivestituresNarrativeDetails", "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingByGeographicAreaDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Acquisition costs, period cost", "label": "Oil and Gas, Full Cost Method, Capitalized Cost Excluded from Amortization, Acquisition Cost, Period Cost", "documentation": "Amount of capitalized acquisition cost incurred during period and excluded from amortization for oil- and gas-producing activities accounted for under full cost method. Excludes exploration and development costs and capitalized interest." } } }, "auth_ref": [ "r1602", "r1603" ] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Additional402vDisclosureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Additional 402(v) Disclosure", "label": "Additional 402(v) Disclosure [Text Block]" } } }, "auth_ref": [ "r1311" ] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation, Amount", "label": "Adjustment to Compensation Amount" } } }, "auth_ref": [ "r1324" ] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation:", "label": "Adjustment to Compensation [Axis]" } } }, "auth_ref": [ "r1324" ] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote", "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]" } } }, "auth_ref": [ "r1324" ] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToPeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment To PEO Compensation, Footnote", "label": "Adjustment To PEO Compensation, Footnote [Text Block]" } } }, "auth_ref": [ "r1324" ] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": [ "http://www.jnj.com/role/ConsolidatedStatementsofEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Employee compensation and stock option plans", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": [ "r88", "r89", "r706" ] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Adjustments to reconcile net earnings to cash flows from operating activities:", "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AdvertisingCostsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdvertisingCostsPolicyTextBlock", "presentation": [ "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Advertising", "label": "Advertising Cost [Policy Text Block]", "documentation": "Disclosure of accounting policy for advertising cost." } } }, "auth_ref": [ "r258" ] }, "us-gaap_AdvertisingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdvertisingExpense", "crdr": "debit", "presentation": [ "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Advertising expense", "label": "Advertising Expense", "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line." } } }, "auth_ref": [ "r743", "r1201" ] }, "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table", "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]" } } }, "auth_ref": [ "r1369" ] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Amount", "label": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r1282", "r1293", "r1303", "r1336" ] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined", "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]" } } }, "auth_ref": [ "r1285", "r1296", "r1306", "r1339" ] }, "ecd_AggtPnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtPnsnAdjsSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Pension Adjustments Service Cost", "label": "Aggregate Pension Adjustments Service Cost [Member]" } } }, "auth_ref": [ "r1370" ] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllAdjToCompMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Adjustments to Compensation", "label": "All Adjustments to Compensation [Member]" } } }, "auth_ref": [ "r1324" ] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllExecutiveCategoriesMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Executive Categories", "label": "All Executive Categories [Member]" } } }, "auth_ref": [ "r1331" ] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllIndividualsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Individuals", "label": "All Individuals [Member]" } } }, "auth_ref": [ "r1286", "r1297", "r1307", "r1331", "r1340", "r1344", "r1352" ] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllTradingArrangementsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "All Trading Arrangements", "label": "All Trading Arrangements [Member]" } } }, "auth_ref": [ "r1350" ] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": [ "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation cost charged for Long term incentive plan", "label": "Share-Based Payment Arrangement, Expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": [ "r736", "r741" ] }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "crdr": "credit", "presentation": [ "http://www.jnj.com/role/ConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "verboseLabel": "Allowances for doubtful accounts", "label": "Accounts Receivable, Allowance for Credit Loss, Current", "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current." } } }, "auth_ref": [ "r332", "r454", "r493" ] }, "jnj_AmbrxMember": { "xbrltype": "domainItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "AmbrxMember", "presentation": [ "http://www.jnj.com/role/AcquisitionsanddivestituresNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ambrx", "label": "Ambrx [Member]", "documentation": "Ambrx" } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://www.jnj.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_AmortizationOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AmortizationOfIntangibleAssets", "crdr": "debit", "presentation": [ "http://www.jnj.com/role/IntangibleassetsandgoodwillNarrativeDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Amortization expense of amortizable intangible assets", "label": "Amortization of Intangible Assets", "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": [ "r14", "r521", "r528", "r1175" ] }, "us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax", "crdr": "debit", "presentation": [ "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofNetFundedStatusDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total recognized in net periodic benefit cost and other comprehensive\u00a0income", "label": "Defined Benefit Plan, Amount Recognized in Net Periodic Benefit Cost (Credit) and Other Comprehensive (Income) Loss, before Tax", "documentation": "Amount recognized in net periodic benefit cost (credit) and other comprehensive (income) loss." } } }, "auth_ref": [ "r1189" ] }, "us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTaxAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTaxAbstract", "presentation": [ "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofNetFundedStatusDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Defined Benefit Plan, Amount Recognized in Net Periodic Benefit Cost (Credit) and Other Comprehensive (Income) Loss, before Tax [Abstract]", "label": "Defined Benefit Plan, Amount Recognized in Net Periodic Benefit Cost (Credit) and Other Comprehensive (Income) Loss, before Tax [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://www.jnj.com/role/EarningspershareNarrativeDetails", "http://www.jnj.com/role/EarningspershareReconciliationofBasicNetEarningsperSharetoDilutedNetEarningsperShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive securities excluded from computation of earnings per share (in shares)", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r402" ] }, "us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AociLossCashFlowHedgeCumulativeGainLossAfterTax", "crdr": "credit", "presentation": [ "http://www.jnj.com/role/FairvaluemeasurementsNarrativeDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Deferred net losses (gains) on derivatives included in accumulated other comprehensive income", "label": "AOCI, Cash Flow Hedge, Cumulative Gain (Loss), after Tax", "documentation": "Amount, after tax, of accumulated gain (loss) on derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness." } } }, "auth_ref": [ "r344" ] }, "jnj_AsiaPacificAfricaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "AsiaPacificAfricaMember", "presentation": [ "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingByGeographicAreaDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Asia-Pacific, Africa", "label": "Asia-Pacific, Africa [Member]", "documentation": "Asia-Pacific, Africa [Member]" } } }, "auth_ref": [] }, "jnj_AsrMember": { "xbrltype": "domainItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "AsrMember", "presentation": [ "http://www.jnj.com/role/LegalproceedingsProductLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "ASR", "label": "ASR [Member]", "documentation": "ASR." } } }, "auth_ref": [] }, "us-gaap_AssetAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetAcquisitionAxis", "presentation": [ "http://www.jnj.com/role/AcquisitionsanddivestituresNarrativeDetails", "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails", "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Asset Acquisition [Axis]", "label": "Asset Acquisition [Axis]", "documentation": "Information by asset acquisition." } } }, "auth_ref": [ "r522", "r523", "r524", "r525", "r526", "r1562" ] }, "us-gaap_AssetAcquisitionConsiderationTransferred": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetAcquisitionConsiderationTransferred", "crdr": "credit", "presentation": [ "http://www.jnj.com/role/AcquisitionsanddivestituresNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Consideration transferred", "label": "Asset Acquisition, Consideration Transferred", "documentation": "Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer." } } }, "auth_ref": [ "r1204", "r1563", "r1564", "r1565" ] }, "us-gaap_AssetAcquisitionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetAcquisitionDomain", "presentation": [ "http://www.jnj.com/role/AcquisitionsanddivestituresNarrativeDetails", "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails", "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Asset Acquisition [Domain]", "label": "Asset Acquisition [Domain]", "documentation": "Asset acquisition." } } }, "auth_ref": [ "r522", "r523", "r524", "r525", "r526", "r1562" ] }, "jnj_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredIntangibleAssetsOtherThanGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "AssetAcquisitionRecognizedIdentifiableAssetsAcquiredIntangibleAssetsOtherThanGoodwill", "crdr": "debit", "presentation": [ "http://www.jnj.com/role/AcquisitionsanddivestituresNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "IPR&D charge", "label": "Asset Acquisition, Recognized Identifiable Assets Acquired, Intangible Assets, Other than Goodwill", "documentation": "Asset Acquisition, Recognized Identifiable Assets Acquired, Intangible Assets, Other than Goodwill" } } }, "auth_ref": [] }, "us-gaap_AssetImpairmentCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetImpairmentCharges", "crdr": "debit", "calculation": { "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 12.0 } }, "presentation": [ "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Asset write-downs", "label": "Asset Impairment Charges", "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill." } } }, "auth_ref": [ "r14", "r66" ] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.jnj.com/role/ConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.jnj.com/role/ConsolidatedBalanceSheets", "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingByGeographicAreaDetails", "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "verboseLabel": "Identifiable Assets", "terseLabel": "Assets", "label": "Assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": [ "r233", "r249", "r323", "r370", "r407", "r415", "r440", "r444", "r490", "r571", "r572", "r574", "r575", "r576", "r577", "r578", "r580", "r581", "r800", "r804", "r847", "r965", "r1071", "r1166", "r1167", "r1219", "r1256", "r1496", "r1497", "r1593" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsAbstract", "presentation": [ "http://www.jnj.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "verboseLabel": "Assets", "label": "Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://www.jnj.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.jnj.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": [ "r314", "r335", "r370", "r490", "r571", "r572", "r574", "r575", "r576", "r577", "r578", "r580", "r581", "r800", "r804", "r847", "r1219", "r1496", "r1497", "r1593" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": [ "http://www.jnj.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "verboseLabel": "Current assets:", "label": "Assets, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsHeldForSaleNotPartOfDisposalGroup": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsHeldForSaleNotPartOfDisposalGroup", "crdr": "debit", "presentation": [ "http://www.jnj.com/role/AcquisitionsanddivestituresNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Asset, held-for-sale, not part of disposal group", "label": "Asset, Held-for-Sale, Not Part of Disposal Group", "documentation": "Amount of assets held-for-sale that are not part of a disposal group." } } }, "auth_ref": [ "r200" ] }, "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperation", "crdr": "debit", "presentation": [ "http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsDetailsDetails", "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingByGeographicAreaDetails", "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net assets divested", "label": "Disposal Group, Including Discontinued Operation, Assets", "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of." } } }, "auth_ref": [ "r4", "r129", "r143", "r202", "r312", "r313" ] }, "dei_AuditorFirmId": { "xbrltype": "nonemptySequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditorFirmId", "presentation": [ "http://www.jnj.com/role/AuditInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Auditor Firm ID", "label": "Auditor Firm ID", "documentation": "PCAOB issued Audit Firm Identifier" } } }, "auth_ref": [ "r1265", "r1266", "r1289" ] }, "jnj_AuditorInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "AuditorInformationAbstract", "lang": { "en-us": { "role": { "label": "Auditor Information [Abstract]", "documentation": "Auditor Information" } } }, "auth_ref": [] }, "dei_AuditorLocation": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditorLocation", "presentation": [ "http://www.jnj.com/role/AuditInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Auditor Location", "label": "Auditor Location" } } }, "auth_ref": [ "r1265", "r1266", "r1289" ] }, "dei_AuditorName": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditorName", "presentation": [ "http://www.jnj.com/role/AuditInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Auditor Name", "label": "Auditor Name" } } }, "auth_ref": [ "r1265", "r1266", "r1289" ] }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "crdr": "credit", "presentation": [ "http://www.jnj.com/role/CashcashequivalentsandcurrentmarketablesecuritiesCashandCashEquivalentCompositionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Available-for-sale, unrealized gain", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax", "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r459" ] }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "crdr": "debit", "presentation": [ "http://www.jnj.com/role/CashcashequivalentsandcurrentmarketablesecuritiesCashandCashEquivalentCompositionDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Available-for-sale, unrecognized loss", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax", "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r460" ] }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "crdr": "debit", "presentation": [ "http://www.jnj.com/role/CashcashequivalentsandcurrentmarketablesecuritiesCashandCashEquivalentCompositionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Carrying Amount, available-for-sale", "label": "Debt Securities, Available-for-Sale, Amortized Cost", "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r456", "r500", "r964" ] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost", "crdr": "debit", "presentation": [ "http://www.jnj.com/role/CashcashequivalentsandcurrentmarketablesecuritiesContractualMaturitiesofAvailableforSaleSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Due after five years through ten years", "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10", "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r1450" ] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue", "crdr": "debit", "presentation": [ "http://www.jnj.com/role/CashcashequivalentsandcurrentmarketablesecuritiesContractualMaturitiesofAvailableforSaleSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Due after five years through ten years", "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10", "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r465", "r960" ] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost", "crdr": "debit", "presentation": [ "http://www.jnj.com/role/CashcashequivalentsandcurrentmarketablesecuritiesContractualMaturitiesofAvailableforSaleSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Due after one year through five years", "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five", "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r1449" ] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue", "crdr": "debit", "presentation": [ "http://www.jnj.com/role/CashcashequivalentsandcurrentmarketablesecuritiesContractualMaturitiesofAvailableforSaleSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Due after one year through five years", "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five", "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r464", "r959" ] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract", "presentation": [ "http://www.jnj.com/role/CashcashequivalentsandcurrentmarketablesecuritiesContractualMaturitiesofAvailableforSaleSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value", "label": "Debt Securities, Available-for-Sale, Fair Value, Fiscal Year Maturity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate", "crdr": "debit", "presentation": [ "http://www.jnj.com/role/CashcashequivalentsandcurrentmarketablesecuritiesContractualMaturitiesofAvailableforSaleSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total debt securities", "label": "Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Fair Value", "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date." } } }, "auth_ref": [ "r1446", "r1447", "r1607" ] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis", "crdr": "debit", "presentation": [ "http://www.jnj.com/role/CashcashequivalentsandcurrentmarketablesecuritiesContractualMaturitiesofAvailableforSaleSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total debt securities", "label": "Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Amortized Cost", "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date." } } }, "auth_ref": [ "r1446", "r1447", "r1606" ] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract", "presentation": [ "http://www.jnj.com/role/CashcashequivalentsandcurrentmarketablesecuritiesContractualMaturitiesofAvailableforSaleSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cost Basis", "label": "Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Amortized Cost [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost", "crdr": "debit", "presentation": [ "http://www.jnj.com/role/CashcashequivalentsandcurrentmarketablesecuritiesContractualMaturitiesofAvailableforSaleSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Due within one year", "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One", "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r1448" ] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue", "crdr": "debit", "presentation": [ "http://www.jnj.com/role/CashcashequivalentsandcurrentmarketablesecuritiesContractualMaturitiesofAvailableforSaleSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Due within one year", "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One", "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r463", "r958" ] }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtSecurities", "crdr": "debit", "presentation": [ "http://www.jnj.com/role/CashcashequivalentsandcurrentmarketablesecuritiesCashandCashEquivalentCompositionDetails", "http://www.jnj.com/role/FairvaluemeasurementsFinancialAssetsandLiabilitiesatFairValueDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Fair value, available-for-sale", "terseLabel": "Debt securities", "label": "Debt Securities, Available-for-Sale", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r457", "r500", "r823", "r952", "r1206", "r1210", "r1440", "r1575", "r1576", "r1577" ] }, "us-gaap_AvailableforsaleSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableforsaleSecuritiesMember", "presentation": [ "http://www.jnj.com/role/CashcashequivalentsandcurrentmarketablesecuritiesCashandCashEquivalentCompositionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Available-for-sale Securities", "label": "Available-for-Sale Securities [Member]", "documentation": "Investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r254" ] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardExrcPrice", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise Price", "label": "Award Exercise Price" } } }, "auth_ref": [ "r1347" ] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardGrantDateFairValue", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value as of Grant Date", "label": "Award Grant Date Fair Value" } } }, "auth_ref": [ "r1348" ] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]" } } }, "auth_ref": [ "r1343" ] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing, How MNPI Considered", "label": "Award Timing, How MNPI Considered [Text Block]" } } }, "auth_ref": [ "r1343" ] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Method", "label": "Award Timing Method [Text Block]" } } }, "auth_ref": [ "r1343" ] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Considered", "label": "Award Timing MNPI Considered [Flag]" } } }, "auth_ref": [ "r1343" ] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Disclosure", "label": "Award Timing MNPI Disclosure [Text Block]" } } }, "auth_ref": [ "r1343" ] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgPredtrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Predetermined", "label": "Award Timing Predetermined [Flag]" } } }, "auth_ref": [ "r1343" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": [ "http://www.jnj.com/role/AcquisitionsanddivestituresNarrativeDetails", "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsNarrativeDetails", "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsSummaryofRestrictedShareUnitsDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type [Axis]", "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r710", "r711", "r712", "r713", "r714", "r715", "r716", "r717", "r718", "r719", "r720", "r721", "r722", "r723", "r724", "r725", "r726", "r727", "r728", "r729", "r730", "r731", "r732", "r733", "r734", "r735" ] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardUndrlygSecuritiesAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Securities", "label": "Award Underlying Securities Amount" } } }, "auth_ref": [ "r1346" ] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Awards Close in Time to MNPI Disclosures, Individual Name" } } }, "auth_ref": [ "r1345" ] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures", "label": "Awards Close in Time to MNPI Disclosures [Table]" } } }, "auth_ref": [ "r1344" ] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures, Table", "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]" } } }, "auth_ref": [ "r1344" ] }, "jnj_BabyPowderMember": { "xbrltype": "domainItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "BabyPowderMember", "presentation": [ "http://www.jnj.com/role/LegalproceedingsNarrativeDetails", "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingByGeographicAreaDetails", "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Baby Powder", "label": "Baby Powder [Member]", "documentation": "Baby Powder [Member]" } } }, "auth_ref": [] }, "us-gaap_BalanceSheetLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BalanceSheetLocationAxis", "presentation": [ "http://www.jnj.com/role/FairvaluemeasurementsFinancialAssetsandLiabilitiesatFairValueDetails", "http://www.jnj.com/role/FairvaluemeasurementsScheduleofDerivativesRecordedinConsolidatedBalanceSheetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statement of Financial Position Location, Balance [Axis]", "label": "Statement of Financial Position Location, Balance [Axis]", "documentation": "Information by location in statement of financial position where disaggregated cumulative balance has been reported." } } }, "auth_ref": [ "r544", "r1614", "r1615" ] }, "us-gaap_BalanceSheetLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BalanceSheetLocationDomain", "presentation": [ "http://www.jnj.com/role/FairvaluemeasurementsFinancialAssetsandLiabilitiesatFairValueDetails", "http://www.jnj.com/role/FairvaluemeasurementsScheduleofDerivativesRecordedinConsolidatedBalanceSheetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statement of Financial Position Location, Balance [Domain]", "label": "Statement of Financial Position Location, Balance [Domain]", "documentation": "Location in statement of financial position where disaggregated cumulative balance has been reported." } } }, "auth_ref": [ "r110", "r114", "r544", "r1614", "r1615" ] }, "us-gaap_BankTimeDepositsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BankTimeDepositsMember", "presentation": [ "http://www.jnj.com/role/CashcashequivalentsandcurrentmarketablesecuritiesCashandCashEquivalentCompositionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Time deposits", "label": "Bank Time Deposits [Member]", "documentation": "Certificates of deposit (CD) or savings accounts with a fixed term or understanding the customer can only withdraw by giving advanced notice with a bank or other financial institution. A CD is a short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest." } } }, "auth_ref": [ "r245" ] }, "jnj_BermekimabMember": { "xbrltype": "domainItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "BermekimabMember", "presentation": [ "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingByGeographicAreaDetails" ], "lang": { "en-us": { "role": { "terseLabel": "bermekimab", "label": "bermekimab [Member]", "documentation": "bermekimab" } } }, "auth_ref": [] }, "us-gaap_BuildingAndBuildingImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BuildingAndBuildingImprovementsMember", "presentation": [ "http://www.jnj.com/role/PropertyplantandequipmentPropertyPlantandEquipmentatCostandAccumulatedDepreciationDetails", "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesEstimatedUsefulLivesofAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Building and building equipment", "label": "Building and Building Improvements [Member]", "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities and any addition, improvement, or renovation to the structure, for example, but not limited to, interior masonry, interior flooring, electrical, and plumbing." } } }, "auth_ref": [] }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionAcquireeDomain", "presentation": [ "http://www.jnj.com/role/AcquisitionsanddivestituresDetails", "http://www.jnj.com/role/AcquisitionsanddivestituresNarrativeDetails", "http://www.jnj.com/role/FairvaluemeasurementsFinancialAssetsandLiabilitiesatFairValueDetails", "http://www.jnj.com/role/IncometaxesNarrativeDetails", "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingByGeographicAreaDetails", "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition, Acquiree [Domain]", "label": "Business Acquisition, Acquiree [Domain]", "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree." } } }, "auth_ref": [ "r522", "r523", "r524", "r525", "r526", "r793", "r1191", "r1194" ] }, "us-gaap_BusinessAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionAxis", "presentation": [ "http://www.jnj.com/role/AcquisitionsanddivestituresDetails", "http://www.jnj.com/role/AcquisitionsanddivestituresNarrativeDetails", "http://www.jnj.com/role/FairvaluemeasurementsFinancialAssetsandLiabilitiesatFairValueDetails", "http://www.jnj.com/role/IncometaxesNarrativeDetails", "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingByGeographicAreaDetails", "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition [Axis]", "label": "Business Acquisition [Axis]", "documentation": "Information by business combination or series of individually immaterial business combinations." } } }, "auth_ref": [ "r91", "r92", "r522", "r523", "r524", "r525", "r526", "r793", "r1191", "r1194" ] }, "jnj_BusinessAcquisitionDiscountRate": { "xbrltype": "percentItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "BusinessAcquisitionDiscountRate", "presentation": [ "http://www.jnj.com/role/AcquisitionsanddivestituresNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Discount rate", "label": "Business Acquisition, Discount Rate", "documentation": "Business Acquisition, Discount Rate" } } }, "auth_ref": [] }, "us-gaap_BusinessAcquisitionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionLineItems", "presentation": [ "http://www.jnj.com/role/AcquisitionsanddivestituresDetails", "http://www.jnj.com/role/AcquisitionsanddivestituresNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition [Line Items]", "label": "Business Acquisition [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r793" ] }, "us-gaap_BusinessAcquisitionSharePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionSharePrice", "presentation": [ "http://www.jnj.com/role/AcquisitionsanddivestituresNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Acquisition price (in dollars per share)", "label": "Business Acquisition, Share Price", "documentation": "Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination." } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationAcquisitionRelatedCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationAcquisitionRelatedCosts", "crdr": "debit", "presentation": [ "http://www.jnj.com/role/AcquisitionsanddivestituresNarrativeDetails", "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Acquisition related costs", "label": "Business Combination, Acquisition Related Costs", "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities." } } }, "auth_ref": [ "r90" ] }, "jnj_BusinessCombinationAcquisitionRelatedCostsEquityAwards": { "xbrltype": "monetaryItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "BusinessCombinationAcquisitionRelatedCostsEquityAwards", "crdr": "debit", "presentation": [ "http://www.jnj.com/role/AcquisitionsanddivestituresNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity awards", "label": "Business Combination, Acquisition Related Costs, Equity Awards", "documentation": "Business Combination, Acquisition Related Costs, Equity Awards" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationAndAssetAcquisitionAbstract", "lang": { "en-us": { "role": { "label": "Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable", "crdr": "credit", "presentation": [ "http://www.jnj.com/role/AcquisitionsanddivestituresNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity interests issued and issuable", "label": "Business Combination, Consideration Transferred, Equity Interests Issued and Issuable", "documentation": "Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination." } } }, "auth_ref": [ "r1", "r2" ] }, "us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationConsiderationTransferredLiabilitiesIncurred", "crdr": "credit", "presentation": [ "http://www.jnj.com/role/FairvaluemeasurementsFinancialAssetsandLiabilitiesatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Additions", "label": "Business Combination, Consideration Transferred, Liabilities Incurred", "documentation": "Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination." } } }, "auth_ref": [ "r1", "r2", "r96", "r796" ] }, "us-gaap_BusinessCombinationContingentConsiderationLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationContingentConsiderationLiability", "crdr": "credit", "presentation": [ "http://www.jnj.com/role/AcquisitionsanddivestituresNarrativeDetails", "http://www.jnj.com/role/FairvaluemeasurementsFinancialAssetsandLiabilitiesatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contingent Consideration", "label": "Business Combination, Contingent Consideration, Liability", "documentation": "Amount of liability recognized arising from contingent consideration in a business combination." } } }, "auth_ref": [ "r97", "r226", "r797", "r825", "r826", "r827" ] }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationDisclosureTextBlock", "presentation": [ "http://www.jnj.com/role/Acquisitionsanddivestitures" ], "lang": { "en-us": { "role": { "verboseLabel": "Acquisitions and divestitures", "label": "Business Combination Disclosure [Text Block]", "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable)." } } }, "auth_ref": [ "r225", "r794" ] }, "jnj_BusinessCombinationProbabilityOfSuccessFactor": { "xbrltype": "percentItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "BusinessCombinationProbabilityOfSuccessFactor", "presentation": [ "http://www.jnj.com/role/AcquisitionsanddivestituresNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Probability of success factor", "label": "Business Combination, Probability Of Success Factor", "documentation": "Business Combination, Probability Of Success Factor" } } }, "auth_ref": [] }, "jnj_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities", "crdr": "credit", "calculation": { "http://www.jnj.com/role/AcquisitionsanddivestituresDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.jnj.com/role/AcquisitionsanddivestituresDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued liabilities", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Accrued Liabilities", "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Accrued Liabilities" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "crdr": "debit", "calculation": { "http://www.jnj.com/role/AcquisitionsanddivestituresDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.jnj.com/role/AcquisitionsanddivestituresDetails", "http://www.jnj.com/role/AcquisitionsanddivestituresNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other assets assumed", "totalLabel": "Other assets assumed", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets", "documentation": "Amount of assets acquired at the acquisition date." } } }, "auth_ref": [ "r94" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract", "presentation": [ "http://www.jnj.com/role/AcquisitionsanddivestituresDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Assets acquired:", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "crdr": "debit", "calculation": { "http://www.jnj.com/role/AcquisitionsanddivestituresDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.jnj.com/role/AcquisitionsanddivestituresDetails", "http://www.jnj.com/role/AcquisitionsanddivestituresNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and equivalents", "verboseLabel": "Less: Cash acquired", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r94" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities", "crdr": "debit", "presentation": [ "http://www.jnj.com/role/AcquisitionsanddivestituresNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Marketable securities assumed", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Marketable Securities", "documentation": "Amount of investments in debt and equity securities, including, but not limited to, held-to-maturity, trading and available-for-sale expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date." } } }, "auth_ref": [ "r94" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities", "crdr": "credit", "calculation": { "http://www.jnj.com/role/AcquisitionsanddivestituresDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.jnj.com/role/AcquisitionsanddivestituresDetails", "http://www.jnj.com/role/AcquisitionsanddivestituresNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred taxes", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date." } } }, "auth_ref": [ "r94" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill", "crdr": "debit", "calculation": { "http://www.jnj.com/role/AcquisitionsanddivestituresDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.jnj.com/role/AcquisitionsanddivestituresDetails", "http://www.jnj.com/role/AcquisitionsanddivestituresNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible assets assumed", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill", "documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date." } } }, "auth_ref": [ "r94" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles", "crdr": "debit", "calculation": { "http://www.jnj.com/role/AcquisitionsanddivestituresDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.jnj.com/role/AcquisitionsanddivestituresDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortizable intangibles", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles", "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date." } } }, "auth_ref": [ "r93", "r94" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory", "crdr": "debit", "calculation": { "http://www.jnj.com/role/AcquisitionsanddivestituresDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.jnj.com/role/AcquisitionsanddivestituresDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Inventory", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory", "documentation": "The amount of inventory recognized as of the acquisition date." } } }, "auth_ref": [ "r93", "r94" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "crdr": "credit", "calculation": { "http://www.jnj.com/role/AcquisitionsanddivestituresDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.jnj.com/role/AcquisitionsanddivestituresDetails", "http://www.jnj.com/role/AcquisitionsanddivestituresNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total liabilities assumed", "totalLabel": "Total liabilities assumed", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities", "documentation": "Amount of liabilities assumed at the acquisition date." } } }, "auth_ref": [ "r94" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract", "presentation": [ "http://www.jnj.com/role/AcquisitionsanddivestituresDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Liabilities assumed:", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "crdr": "debit", "calculation": { "http://www.jnj.com/role/AcquisitionsanddivestituresDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.jnj.com/role/AcquisitionsanddivestituresDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net assets acquired", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net", "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed." } } }, "auth_ref": [ "r93", "r94" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt", "crdr": "credit", "calculation": { "http://www.jnj.com/role/AcquisitionsanddivestituresDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.jnj.com/role/AcquisitionsanddivestituresDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Notes payable", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-Term Debt", "documentation": "Amount of long-term debt due after one year or the normal operating cycle, if longer, assumed at the acquisition date." } } }, "auth_ref": [ "r94" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets", "crdr": "debit", "calculation": { "http://www.jnj.com/role/AcquisitionsanddivestituresDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.jnj.com/role/AcquisitionsanddivestituresDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other assets", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets", "documentation": "Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date." } } }, "auth_ref": [ "r94" ] }, "jnj_BusinessCombinationSettlementOfEquityAwards": { "xbrltype": "monetaryItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "BusinessCombinationSettlementOfEquityAwards", "crdr": "credit", "presentation": [ "http://www.jnj.com/role/AcquisitionsanddivestituresDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity awards settled", "label": "Business Combination, Settlement Of Equity Awards", "documentation": "Business Combination, Settlement Of Equity Awards" } } }, "auth_ref": [] }, "jnj_BusinessCombinationSettlementOfNotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "BusinessCombinationSettlementOfNotesPayable", "crdr": "credit", "presentation": [ "http://www.jnj.com/role/AcquisitionsanddivestituresDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Settlement of notes payable", "label": "Business Combination, Settlement Of Notes Payable", "documentation": "Business Combination, Settlement Of Notes Payable" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementLoss", "crdr": "debit", "presentation": [ "http://www.jnj.com/role/AcquisitionsanddivestituresNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity interest in acquiree, remeasurement loss", "label": "Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Loss", "documentation": "In a business combination achieved in stages, this element represents the amount of loss recognized by the entity as a result of remeasuring to fair value the equity interest in the acquiree it held before the business combination." } } }, "auth_ref": [] }, "jnj_CARVYKTIMember": { "xbrltype": "domainItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "CARVYKTIMember", "presentation": [ "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "CARVYKTI", "label": "CARVYKTI [Member]", "documentation": "CARVYKTI" } } }, "auth_ref": [] }, "jnj_CONCERTAMethylphenidateMember": { "xbrltype": "domainItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "CONCERTAMethylphenidateMember", "presentation": [ "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "CONCERTA/Methylphenidate", "label": "CONCERTA/Methylphenidate [Member]", "documentation": "CONCERTA/Methylphenidate [Member]" } } }, "auth_ref": [] }, "jnj_CONTACTLENSESOTHERMember": { "xbrltype": "domainItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "CONTACTLENSESOTHERMember", "presentation": [ "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "CONTACT LENSES/OTHER", "label": "CONTACT LENSES/OTHER [Member]", "documentation": "CONTACT LENSES/OTHER [Member]" } } }, "auth_ref": [] }, "jnj_COVID19Member": { "xbrltype": "domainItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "COVID19Member", "presentation": [ "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "COVID-19", "label": "COVID-19 [Member]", "documentation": "COVID-19" } } }, "auth_ref": [] }, "us-gaap_CapitalExpenditureDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CapitalExpenditureDiscontinuedOperations", "crdr": "debit", "presentation": [ "http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsDepreciationandAmortizationofDiscontinuedOperationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Capital expenditures", "label": "Capital Expenditure, Discontinued Operations", "documentation": "Amount of capital expenditure attributable to discontinued operations." } } }, "auth_ref": [ "r142" ] }, "jnj_CardiovascularMember": { "xbrltype": "domainItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "CardiovascularMember", "presentation": [ "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cardiovascular", "label": "Cardiovascular [Member]", "documentation": "Cardiovascular [Member]" } } }, "auth_ref": [] }, "jnj_CardiovascularMetabolismOtherMember": { "xbrltype": "domainItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "CardiovascularMetabolismOtherMember", "presentation": [ "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cardiovascular/Metabolism/Other", "label": "Cardiovascular/Metabolism/Other [Member]", "documentation": "Cardiovascular/Metabolism/Other [Member]" } } }, "auth_ref": [] }, "us-gaap_CashAcquiredFromAcquisition": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAcquiredFromAcquisition", "crdr": "debit", "presentation": [ "http://www.jnj.com/role/AcquisitionsanddivestituresNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash acquired from acquisition", "label": "Cash Acquired from Acquisition", "documentation": "The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business)." } } }, "auth_ref": [ "r43" ] }, "us-gaap_CashAndCashEquivalentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Cash and Cash Equivalents [Abstract]", "label": "Cash and Cash Equivalents [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.jnj.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.jnj.com/role/CashcashequivalentsandcurrentmarketablesecuritiesCashandCashEquivalentCompositionDetails", "http://www.jnj.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "verboseLabel": "Cash and cash equivalents", "terseLabel": "Cash & Cash Equivalents", "label": "Cash and Cash Equivalents, at Carrying Value", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r46", "r317", "r1146" ] }, "us-gaap_CashAndCashEquivalentsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsLineItems", "presentation": [ "http://www.jnj.com/role/CashcashequivalentsandcurrentmarketablesecuritiesCashandCashEquivalentCompositionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and Cash Equivalents [Line Items]", "label": "Cash and Cash Equivalents [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsPolicyTextBlock", "presentation": [ "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Cash equivalents", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value." } } }, "auth_ref": [ "r47" ] }, "us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsAndMarketableSecuritiesTextBlock", "presentation": [ "http://www.jnj.com/role/Cashcashequivalentsandcurrentmarketablesecurities" ], "lang": { "en-us": { "role": { "terseLabel": "Cash, cash equivalents and current marketable securities", "label": "Cash, Cash Equivalents, and Marketable Securities [Text Block]", "documentation": "The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss)." } } }, "auth_ref": [ "r1439" ] }, "us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsAndShortTermInvestmentsAbstract", "presentation": [ "http://www.jnj.com/role/CashcashequivalentsandcurrentmarketablesecuritiesCashandCashEquivalentCompositionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash, Cash Equivalents, and Short-term Investments [Abstract]", "label": "Cash, Cash Equivalents, and Short-Term Investments [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": [ "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "periodStartLabel": "Cash and cash equivalents, beginning of year", "periodEndLabel": "Cash and cash equivalents, end of year", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r46", "r190", "r367" ] }, "jnj_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsContinuingOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsContinuingOperations", "crdr": "debit", "presentation": [ "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "periodStartLabel": "Cash and cash equivalents from continuing operations, beginning of period", "periodEndLabel": "Cash and cash equivalents from continuing operations, end of period", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations", "documentation": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations" } } }, "auth_ref": [] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "crdr": "debit", "presentation": [ "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "periodStartLabel": "Cash and cash equivalents from discontinued operations, beginning of period", "periodEndLabel": "Cash and cash equivalents from discontinued operations, end of period", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r46", "r190", "r367" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Increase/(Decrease) in cash and cash equivalents", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r3", "r190" ] }, "us-gaap_CashFlowHedgingMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashFlowHedgingMember", "presentation": [ "http://www.jnj.com/role/FairvaluemeasurementsSummaryofDerivativeActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash Flow Hedging", "label": "Cash Flow Hedging [Member]", "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk." } } }, "auth_ref": [ "r108" ] }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "presentation": [ "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Supplemental schedule of non-cash investing and financing activities", "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CashMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashMember", "presentation": [ "http://www.jnj.com/role/CashcashequivalentsandcurrentmarketablesecuritiesCashandCashEquivalentCompositionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash", "label": "Cash [Member]", "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits." } } }, "auth_ref": [ "r317" ] }, "jnj_CashPaidDuringTheYearAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "CashPaidDuringTheYearAbstract", "presentation": [ "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Cash paid during the year for:", "label": "Cash Paid During The Year [Abstract]", "documentation": "Cash Paid During The Year [Abstract]" } } }, "auth_ref": [] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChangedPeerGroupFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Changed Peer Group, Footnote", "label": "Changed Peer Group, Footnote [Text Block]" } } }, "auth_ref": [ "r1322" ] }, "jnj_ChangesInTreasuryStockRollForward": { "xbrltype": "stringItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "ChangesInTreasuryStockRollForward", "presentation": [ "http://www.jnj.com/role/CapitalandtreasurystockChangesinTreasuryStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Changes in treasury stock", "label": "Changes In Treasury Stock [Roll Forward]", "documentation": "Changes in treasury stock." } } }, "auth_ref": [] }, "jnj_ChangesInTreasuryStockTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "ChangesInTreasuryStockTableTextBlock", "presentation": [ "http://www.jnj.com/role/CapitalandtreasurystockTables" ], "lang": { "en-us": { "role": { "terseLabel": "Changes in Treasury Stock", "label": "Changes In Treasury Stock [Table Text Block]", "documentation": "Changes in treasury stock." } } }, "auth_ref": [] }, "jnj_ChangesinTreasuryStockSharesOutstandingRollForward": { "xbrltype": "stringItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "ChangesinTreasuryStockSharesOutstandingRollForward", "presentation": [ "http://www.jnj.com/role/CapitalandtreasurystockChangesinTreasuryStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Changes in Treasury Stock Shares Outstanding [Roll Forward]", "label": "Changes in Treasury Stock Shares Outstanding [Roll Forward]", "documentation": "Changes in Treasury Stock Shares Outstanding [Roll Forward]" } } }, "auth_ref": [] }, "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year", "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]" } } }, "auth_ref": [ "r1319" ] }, "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested", "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]" } } }, "auth_ref": [ "r1317" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [ "http://www.jnj.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "jnj_ClassIRecommendationForImpellaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "ClassIRecommendationForImpellaMember", "presentation": [ "http://www.jnj.com/role/AcquisitionsanddivestituresNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class I Recommendation For Impella", "label": "Class I Recommendation For Impella [Member]", "documentation": "Class I Recommendation For Impella" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockDomain", "presentation": [ "http://www.jnj.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock [Domain]", "label": "Class of Stock [Domain]", "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": [ "r269", "r328", "r329", "r330", "r370", "r393", "r397", "r399", "r401", "r409", "r410", "r490", "r571", "r574", "r575", "r576", "r580", "r581", "r611", "r612", "r613", "r614", "r616", "r847", "r1020", "r1021", "r1022", "r1023", "r1027", "r1028", "r1029", "r1030", "r1031", "r1032", "r1033", "r1034", "r1035", "r1036", "r1037", "r1038", "r1058", "r1080", "r1099", "r1122", "r1123", "r1124", "r1125", "r1126", "r1374", "r1418", "r1429" ] }, "us-gaap_ClassOfTreasuryStockTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfTreasuryStockTable", "presentation": [ "http://www.jnj.com/role/CapitalandtreasurystockChangesinTreasuryStockDetails", "http://www.jnj.com/role/CapitalandtreasurystockNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Treasury Stock [Table]", "label": "Class of Treasury Stock [Table]", "documentation": "Disclosure of information about treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock." } } }, "auth_ref": [ "r72", "r73", "r74", "r75" ] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Amount", "label": "Company Selected Measure Amount" } } }, "auth_ref": [ "r1323" ] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Name", "label": "Company Selected Measure Name" } } }, "auth_ref": [ "r1323" ] }, "us-gaap_CollateralAlreadyPostedAggregateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CollateralAlreadyPostedAggregateFairValue", "crdr": "debit", "presentation": [ "http://www.jnj.com/role/FairvaluemeasurementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Collateral paid", "label": "Collateral Already Posted, Aggregate Fair Value", "documentation": "The aggregate fair value of assets that are already posted, at the end of the reporting period, as collateral for derivative instruments with credit-risk-related contingent features." } } }, "auth_ref": [ "r118" ] }, "us-gaap_CommercialPaper": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommercialPaper", "crdr": "credit", "presentation": [ "http://www.jnj.com/role/FairvaluemeasurementsNarrativeDetails", "http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsDetailsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Commercial paper", "label": "Commercial Paper", "documentation": "Carrying value as of the balance sheet date of short-term borrowings using unsecured obligations issued by banks, corporations and other borrowers to investors. The maturities of these money market securities generally do not exceed 270 days." } } }, "auth_ref": [ "r148", "r234", "r1609" ] }, "us-gaap_CommercialPaperMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommercialPaperMember", "presentation": [ "http://www.jnj.com/role/BorrowingsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Commercial Paper", "label": "Commercial Paper [Member]", "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds." } } }, "auth_ref": [ "r209", "r570", "r1245", "r1246", "r1247", "r1250" ] }, "jnj_CommingledFundsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "CommingledFundsMember", "presentation": [ "http://www.jnj.com/role/PensionsandotherbenefitplansNarrativeDetails", "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofDefinedBenefitPlansDisclosuresDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Commingled funds", "label": "Commingled Funds [Member]", "documentation": "Commingled funds." } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingencies", "crdr": "credit", "calculation": { "http://www.jnj.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.jnj.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies", "label": "Commitments and Contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": [ "r158", "r239", "r967", "r1057" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies Disclosure [Abstract]", "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommonStockDividendsPerShareCashPaid": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockDividendsPerShareCashPaid", "presentation": [ "http://www.jnj.com/role/CapitalandtreasurystockNarrativeDetails", "http://www.jnj.com/role/ConsolidatedStatementsofEquityParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Cash dividends paid (in dollars per share)", "label": "Common Stock, Dividends, Per Share, Cash Paid", "documentation": "Aggregate dividends paid during the period for each share of common stock outstanding." } } }, "auth_ref": [ "r212" ] }, "us-gaap_CommonStockDividendsPerShareDeclared": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockDividendsPerShareDeclared", "presentation": [ "http://www.jnj.com/role/CapitalandtreasurystockNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash dividend (in dollars per share)", "label": "Common Stock, Dividends, Per Share, Declared", "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding." } } }, "auth_ref": [ "r212" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": [ "http://www.jnj.com/role/ConsolidatedStatementsofEquity", "http://www.jnj.com/role/CoverPage" ], "lang": { "en-us": { "role": { "verboseLabel": "Common Stock, Par Value $1.00", "terseLabel": "Common Stock Issued Amount", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r1241", "r1242", "r1243", "r1245", "r1246", "r1247", "r1250", "r1424", "r1425", "r1428", "r1571", "r1646", "r1648" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://www.jnj.com/role/ConsolidatedBalanceSheetsParenthetical", "http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsDetailsDetails", "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Common stock, par value per share (in usd per share)", "terseLabel": "Common Stock, Par or Stated Value Per Share", "label": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r161" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://www.jnj.com/role/ConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "verboseLabel": "Common stock, shares authorized (in shares)", "label": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r161", "r1058" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": [ "http://www.jnj.com/role/CapitalandtreasurystockNarrativeDetails", "http://www.jnj.com/role/ConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "verboseLabel": "Common stock, shares issued (in shares)", "label": "Common Stock, Shares, Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r161" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://www.jnj.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.jnj.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "verboseLabel": "Common stock\u00a0\u2014 par value $1.00 per share (Note\u00a012) (authorized 4,320,000,000\u00a0shares; issued 3,119,843,000\u00a0shares)", "label": "Common Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r161", "r969", "r1219" ] }, "us-gaap_CommonStockValueOutstanding": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValueOutstanding", "crdr": "credit", "presentation": [ "http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsDetailsDetails", "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, value", "label": "Common Stock, Value, Outstanding", "documentation": "Value of common shares held by shareholders. Excludes common shares repurchased and held as treasury shares." } } }, "auth_ref": [ "r161", "r1058" ] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Company Selected Measure", "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]" } } }, "auth_ref": [ "r1328" ] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Net Income", "label": "Compensation Actually Paid vs. Net Income [Text Block]" } } }, "auth_ref": [ "r1327" ] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Other Measure", "label": "Compensation Actually Paid vs. Other Measure [Text Block]" } } }, "auth_ref": [ "r1329" ] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return", "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]" } } }, "auth_ref": [ "r1326" ] }, "jnj_ComparisonOfIncomeTaxExpenseAtStatutoryRateAndCompanysTaxRateAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "ComparisonOfIncomeTaxExpenseAtStatutoryRateAndCompanysTaxRateAbstract", "presentation": [ "http://www.jnj.com/role/IncometaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Comparison Of Income Tax Expense At Statutory Rate And Company's Tax Rate Abstract", "label": "Comparison Of Income Tax Expense At Statutory Rate And Company's Tax Rate Abstract", "documentation": "Comparison of income tax expense at the Statutory rate and Company's tax rate." } } }, "auth_ref": [] }, "us-gaap_CompensationAndRetirementDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CompensationAndRetirementDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Retirement Benefits [Abstract]", "label": "Retirement Benefits [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CompensationRelatedCostsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CompensationRelatedCostsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Compensation Related Costs [Abstract]", "label": "Compensation Related Costs [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CompensationRelatedCostsGeneralTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CompensationRelatedCostsGeneralTextBlock", "presentation": [ "http://www.jnj.com/role/Employeerelatedobligations" ], "lang": { "en-us": { "role": { "terseLabel": "Employee related obligations", "label": "Compensation Related Costs, General [Text Block]", "documentation": "The entire disclosure for compensation costs, including compensated absences accruals, compensated absences liability, deferred compensation arrangements and income statement compensation items. Deferred compensation arrangements may include a description of an arrangement with an individual employee, which is generally an employment contract between the entity and a selected officer or key employee containing a promise by the employer to pay certain amounts at designated future dates, usually including a period after retirement, upon compliance with stipulated requirements. This type of arrangement is distinguished from broader based employee benefit plans as it is usually tailored to the employee. Disclosure also typically includes the amount of related compensation expense recognized during the reporting period, the number of shares (units) issued during the period under such arrangements, and the carrying amount as of the balance sheet date of the related liability." } } }, "auth_ref": [ "r620", "r621" ] }, "us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract", "presentation": [ "http://www.jnj.com/role/IncometaxesTemporaryDifferencesandCarryforwardsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Components of Deferred Tax Assets and Liabilities [Abstract]", "label": "Components of Deferred Tax Assets and Liabilities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome" ], "lang": { "en-us": { "role": { "totalLabel": "Comprehensive income", "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r103", "r227", "r351", "r353", "r359", "r954", "r980" ] }, "us-gaap_ComprehensiveIncomeNoteTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNoteTextBlock", "presentation": [ "http://www.jnj.com/role/Accumulatedothercomprehensiveincomeloss" ], "lang": { "en-us": { "role": { "verboseLabel": "Accumulated other comprehensive income (loss)", "label": "Comprehensive Income (Loss) Note [Text Block]", "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income." } } }, "auth_ref": [ "r170", "r358", "r953", "r978" ] }, "jnj_ConcentrationOfCreditRiskLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "ConcentrationOfCreditRiskLineItems", "presentation": [ "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration of Credit Risk [Line Items]", "label": "Concentration of Credit Risk [Line Items]", "documentation": "Concentration of credit risk." } } }, "auth_ref": [] }, "jnj_ConcentrationOfCreditRiskTable": { "xbrltype": "stringItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "ConcentrationOfCreditRiskTable", "presentation": [ "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration of Credit Risk [Table]", "label": "Concentration of Credit Risk [Table]", "documentation": "Concentration of Credit Risk [Table]" } } }, "auth_ref": [] }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskBenchmarkDomain", "presentation": [ "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingByGeographicAreaDetails", "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Benchmark [Domain]", "label": "Concentration Risk Benchmark [Domain]", "documentation": "The denominator in a calculation of a disclosed concentration risk percentage." } } }, "auth_ref": [ "r54", "r55", "r125", "r126", "r452", "r1129" ] }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskByBenchmarkAxis", "presentation": [ "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingByGeographicAreaDetails", "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Benchmark [Axis]", "label": "Concentration Risk Benchmark [Axis]", "documentation": "Information by benchmark of concentration risk." } } }, "auth_ref": [ "r54", "r55", "r125", "r126", "r452", "r1014", "r1129" ] }, "us-gaap_ConcentrationRiskByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskByTypeAxis", "presentation": [ "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingByGeographicAreaDetails", "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Type [Axis]", "label": "Concentration Risk Type [Axis]", "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender." } } }, "auth_ref": [ "r54", "r55", "r125", "r126", "r452", "r1129", "r1384" ] }, "us-gaap_ConcentrationRiskPercentage1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskPercentage1", "presentation": [ "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingByGeographicAreaDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration risk (as a percent)", "label": "Concentration Risk, Percentage", "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division." } } }, "auth_ref": [ "r54", "r55", "r125", "r126", "r452" ] }, "jnj_ConcentrationRiskThresholdPercentage": { "xbrltype": "pureItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "ConcentrationRiskThresholdPercentage", "presentation": [ "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration risk, threshold percentage (as a percent)", "label": "Concentration Risk, Threshold Percentage", "documentation": "Concentration Risk, Threshold Percentage" } } }, "auth_ref": [] }, "us-gaap_ConcentrationRiskTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskTypeDomain", "presentation": [ "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingByGeographicAreaDetails", "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Type [Domain]", "label": "Concentration Risk Type [Domain]", "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration." } } }, "auth_ref": [ "r54", "r55", "r125", "r126", "r452", "r1129" ] }, "srt_ConsolidationItemsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ConsolidationItemsAxis", "presentation": [ "http://www.jnj.com/role/RestructuringScheduleofRestructuringReserveDetails", "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasIncomeBeforeTaxbySegmentDetails", "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingByGeographicAreaDetails", "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Consolidation Items [Axis]", "label": "Consolidation Items [Axis]", "documentation": "Information by components, eliminations, non-segment corporate-level activity and reconciling items used in consolidating a parent entity and its subsidiaries or its operating segments." } } }, "auth_ref": [ "r247", "r270", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r374", "r407", "r417", "r438", "r439", "r440", "r441", "r442", "r444", "r445", "r446", "r571", "r572", "r573", "r574", "r576", "r577", "r578", "r579", "r580", "r1166", "r1167", "r1400", "r1401", "r1496", "r1497" ] }, "srt_ConsolidationItemsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ConsolidationItemsDomain", "presentation": [ "http://www.jnj.com/role/RestructuringScheduleofRestructuringReserveDetails", "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasIncomeBeforeTaxbySegmentDetails", "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingByGeographicAreaDetails", "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Consolidation Items [Domain]", "label": "Consolidation Items [Domain]", "documentation": "Components, elimination, non-segment corporate-level activity and reconciling items used in consolidating a parent entity and its subsidiaries or its operating segments." } } }, "auth_ref": [ "r247", "r270", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r374", "r407", "r417", "r438", "r439", "r440", "r441", "r442", "r444", "r445", "r446", "r571", "r572", "r573", "r574", "r576", "r577", "r578", "r579", "r580", "r1166", "r1167", "r1400", "r1401", "r1496", "r1497" ] }, "us-gaap_ConsolidationPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConsolidationPolicyTextBlock", "presentation": [ "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Principles of consolidation", "label": "Consolidation, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary." } } }, "auth_ref": [ "r101", "r1154" ] }, "us-gaap_ConstructionInProgressMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConstructionInProgressMember", "presentation": [ "http://www.jnj.com/role/PropertyplantandequipmentPropertyPlantandEquipmentatCostandAccumulatedDepreciationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Construction in progress", "label": "Construction in Progress [Member]", "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service." } } }, "auth_ref": [] }, "jnj_ConsumerHealthMember": { "xbrltype": "domainItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "ConsumerHealthMember", "presentation": [ "http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsDetailsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Consumer Health Business", "label": "Consumer Health [Member]", "documentation": "Consumer Health" } } }, "auth_ref": [] }, "jnj_ConsumerMember": { "xbrltype": "domainItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "ConsumerMember", "presentation": [ "http://www.jnj.com/role/IncometaxesNarrativeDetails", "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Consumer Health", "label": "Consumer [Member]", "documentation": "Consumer." } } }, "auth_ref": [] }, "us-gaap_CorporateDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CorporateDebtSecuritiesMember", "presentation": [ "http://www.jnj.com/role/CashcashequivalentsandcurrentmarketablesecuritiesCashandCashEquivalentCompositionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Corporate debt securities", "label": "Corporate Debt Securities [Member]", "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment." } } }, "auth_ref": [ "r1187", "r1189", "r1206", "r1220", "r1238", "r1643" ] }, "us-gaap_CorporateNonSegmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CorporateNonSegmentMember", "presentation": [ "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingByGeographicAreaDetails", "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segment Reporting, Reconciling Item, Corporate Nonsegment", "label": "Segment Reporting, Reconciling Item, Corporate Nonsegment [Member]", "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment." } } }, "auth_ref": [ "r28", "r439", "r440", "r441", "r442", "r445", "r1434" ] }, "us-gaap_CostOfGoodsAndServicesSold": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfGoodsAndServicesSold", "crdr": "debit", "calculation": { "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": { "parentTag": "us-gaap_GrossProfit", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.jnj.com/role/ConsolidatedStatementsofEarnings", "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasIncomeBeforeTaxbySegmentDetails", "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cost of products sold", "label": "Cost of Goods and Services Sold", "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities." } } }, "auth_ref": [ "r179", "r180", "r917" ] }, "us-gaap_CostOfSalesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfSalesMember", "presentation": [ "http://www.jnj.com/role/FairvaluemeasurementsSummaryofDerivativeActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cost of Products Sold", "label": "Cost of Sales [Member]", "documentation": "Primary financial statement caption encompassing cost of sales." } } }, "auth_ref": [] }, "jnj_CostsOfGoodsAndServicesSoldMember": { "xbrltype": "domainItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "CostsOfGoodsAndServicesSoldMember", "presentation": [ "http://www.jnj.com/role/RestructuringScheduleofRestructuringReserveDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Costs of Goods and Services Sold", "label": "Costs of Goods and Services Sold [Member]", "documentation": "Costs of Goods and Services Sold" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "terseLabel": "Cover page.", "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "us-gaap_CrossCurrencyInterestRateContractMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CrossCurrencyInterestRateContractMember", "presentation": [ "http://www.jnj.com/role/FairvaluemeasurementsNarrativeDetails", "http://www.jnj.com/role/FairvaluemeasurementsScheduleofEffectofNetInvestmentHedgesDetails", "http://www.jnj.com/role/FairvaluemeasurementsSummaryofDerivativeActivityDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Cross currency interest rate swaps", "terseLabel": "Cross currency interest rate swaps contracts:", "label": "Cross Currency Interest Rate Contract [Member]", "documentation": "Derivative instrument whose primary underlying risk is tied to interest rates and foreign exchange rates." } } }, "auth_ref": [ "r1507", "r1570" ] }, "us-gaap_CurrentFederalTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CurrentFederalTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.jnj.com/role/IncometaxesProvisionforIncomeTaxesDetails": { "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.jnj.com/role/IncometaxesProvisionforIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "U.S. taxes", "label": "Current Federal Tax Expense (Benefit)", "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [ "r1386", "r1421", "r1557" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://www.jnj.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_CurrentForeignTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CurrentForeignTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.jnj.com/role/IncometaxesProvisionforIncomeTaxesDetails": { "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.jnj.com/role/IncometaxesProvisionforIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "International taxes", "label": "Current Foreign Tax Expense (Benefit)", "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations." } } }, "auth_ref": [ "r1386", "r1421" ] }, "us-gaap_CurrentIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CurrentIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.jnj.com/role/IncometaxesProvisionforIncomeTaxesDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.jnj.com/role/IncometaxesProvisionforIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total currently payable", "label": "Current Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations." } } }, "auth_ref": [ "r777", "r1421" ] }, "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract", "presentation": [ "http://www.jnj.com/role/IncometaxesProvisionforIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Currently payable:", "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]" } } }, "auth_ref": [] }, "jnj_CurtailmentsAndSettlementsAndRestructuring": { "xbrltype": "monetaryItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "CurtailmentsAndSettlementsAndRestructuring", "crdr": "debit", "presentation": [ "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofNetFundedStatusDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Curtailments, settlements\u00a0& restructuring", "label": "Curtailments And Settlements And Restructuring", "documentation": "The amount of increase or decrease related to curtailments, settlements and restructuring." } } }, "auth_ref": [] }, "cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]" } } }, "auth_ref": [ "r1274", "r1363" ] }, "cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskBoardOfDirectorsOversightTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Board of Directors Oversight [Text Block]" } } }, "auth_ref": [ "r1274", "r1363" ] }, "cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Expertise of Management Responsible [Text Block]" } } }, "auth_ref": [ "r1276", "r1365" ] }, "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Positions or Committees Responsible [Flag]" } } }, "auth_ref": [ "r1276", "r1365" ] }, "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]" } } }, "auth_ref": [ "r1278", "r1367" ] }, "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Positions or Committees Responsible [Text Block]" } } }, "auth_ref": [ "r1276", "r1365" ] }, "cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]" } } }, "auth_ref": [ "r1269", "r1358" ] }, "cyd_CybersecurityRiskManagementProcessesIntegratedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementProcessesIntegratedFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Processes Integrated [Flag]" } } }, "auth_ref": [ "r1270", "r1359" ] }, "cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementProcessesIntegratedTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Processes Integrated [Text Block]" } } }, "auth_ref": [ "r1270", "r1359" ] }, "cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementStrategyAndGovernanceAbstract", "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management, Strategy, and Governance [Abstract]" } } }, "auth_ref": [ "r1268", "r1357" ] }, "cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementStrategyAndGovernanceLineItems", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management, Strategy, and Governance [Line Items]" } } }, "auth_ref": [ "r1268", "r1357" ] }, "cyd_CybersecurityRiskManagementStrategyAndGovernanceTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementStrategyAndGovernanceTable", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management, Strategy, and Governance [Table]" } } }, "auth_ref": [ "r1268", "r1357" ] }, "cyd_CybersecurityRiskManagementThirdPartyEngagedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementThirdPartyEngagedFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Third Party Engaged [Flag]" } } }, "auth_ref": [ "r1271", "r1360" ] }, "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]" } } }, "auth_ref": [ "r1273", "r1362" ] }, "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]" } } }, "auth_ref": [ "r1273", "r1362" ] }, "cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]" } } }, "auth_ref": [ "r1274", "r1363" ] }, "cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]" } } }, "auth_ref": [ "r1277", "r1366" ] }, "cyd_CybersecurityRiskRoleOfManagementTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskRoleOfManagementTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Role of Management [Text Block]" } } }, "auth_ref": [ "r1275", "r1364" ] }, "cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]" } } }, "auth_ref": [ "r1272", "r1361" ] }, "jnj_DARZALEXMember": { "xbrltype": "domainItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "DARZALEXMember", "presentation": [ "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "DARZALEX", "label": "DARZALEX [Member]", "documentation": "DARZALEX [Member]" } } }, "auth_ref": [] }, "jnj_DePuyASRU.S.Member": { "xbrltype": "domainItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "DePuyASRU.S.Member", "presentation": [ "http://www.jnj.com/role/LegalproceedingsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "DePuy ASR U.S.", "label": "DePuy ASR U.S. [Member]", "documentation": "DePuy ASR U.S. [Member]" } } }, "auth_ref": [] }, "us-gaap_DebtCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtCurrent", "crdr": "credit", "presentation": [ "http://www.jnj.com/role/BorrowingsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Short-term borrowings and the current portion of long-term debt", "label": "Debt, Current", "documentation": "Amount of debt and lease obligation, classified as current." } } }, "auth_ref": [ "r326" ] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Debt Disclosure [Abstract]", "label": "Debt Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureTextBlock", "presentation": [ "http://www.jnj.com/role/Borrowings" ], "lang": { "en-us": { "role": { "terseLabel": "Borrowings", "label": "Debt Disclosure [Text Block]", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } }, "auth_ref": [ "r208", "r369", "r539", "r540", "r541", "r542", "r543", "r569", "r570", "r582", "r588", "r589", "r590", "r591", "r592", "r593", "r598", "r605", "r606", "r608", "r869" ] }, "jnj_DebtForEquityExchangeLossOnSharesExchanged": { "xbrltype": "monetaryItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "DebtForEquityExchangeLossOnSharesExchanged", "crdr": "debit", "presentation": [ "http://www.jnj.com/role/FairvaluemeasurementsNarrativeDetails", "http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsDetailsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss on shares exchanged", "label": "Debt For Equity Exchange, Loss On Shares Exchanged", "documentation": "Debt For Equity Exchange, Loss On Shares Exchanged" } } }, "auth_ref": [] }, "jnj_DebtForEquityExchangeSharesExchanged": { "xbrltype": "sharesItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "DebtForEquityExchangeSharesExchanged", "presentation": [ "http://www.jnj.com/role/FairvaluemeasurementsNarrativeDetails", "http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsDetailsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt for equity exchange, shares exchanged (in shares)", "label": "Debt For Equity Exchange, Shares Exchanged", "documentation": "Debt For Equity Exchange, Shares Exchanged" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentAxis", "presentation": [ "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Axis]", "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": [ "r34", "r151", "r152", "r235", "r238", "r374", "r583", "r584", "r585", "r586", "r587", "r589", "r594", "r595", "r596", "r597", "r599", "r600", "r601", "r602", "r603", "r604", "r1178", "r1179", "r1180", "r1181", "r1182", "r1217", "r1419", "r1483", "r1484", "r1485", "r1591", "r1592" ] }, "us-gaap_DebtInstrumentFaceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentFaceAmount", "crdr": "credit", "presentation": [ "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt instrument, face amount", "label": "Debt Instrument, Face Amount", "documentation": "Face (par) amount of debt instrument at time of issuance." } } }, "auth_ref": [ "r583", "r869", "r870", "r1179", "r1180", "r1217" ] }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentInterestRateEffectivePercentage", "presentation": [ "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Effective interest rate", "label": "Debt Instrument, Interest Rate, Effective Percentage", "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium." } } }, "auth_ref": [ "r154", "r610", "r869", "r870", "r1217" ] }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": [ "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stated interest rate (as a percent)", "label": "Debt Instrument, Interest Rate, Stated Percentage", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } } }, "auth_ref": [ "r154", "r584" ] }, "us-gaap_DebtInstrumentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentLineItems", "presentation": [ "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Line Items]", "label": "Debt Instrument [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r374", "r583", "r584", "r585", "r586", "r587", "r589", "r594", "r595", "r596", "r597", "r599", "r600", "r601", "r602", "r603", "r604", "r607", "r1178", "r1179", "r1180", "r1181", "r1182", "r1217", "r1419", "r1591", "r1592" ] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentNameDomain", "presentation": [ "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Name [Domain]", "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": [ "r34", "r374", "r583", "r584", "r585", "r586", "r587", "r589", "r594", "r595", "r596", "r597", "r599", "r600", "r601", "r602", "r603", "r604", "r1178", "r1179", "r1180", "r1181", "r1182", "r1217", "r1419", "r1483", "r1484", "r1485", "r1591", "r1592" ] }, "us-gaap_DebtInstrumentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentTable", "presentation": [ "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Long-term Debt Instruments [Table]", "label": "Schedule of Long-Term Debt Instruments [Table]", "documentation": "Disclosure of information about long-term debt instrument or arrangement." } } }, "auth_ref": [ "r34", "r69", "r70", "r127", "r210", "r211", "r374", "r583", "r584", "r585", "r586", "r587", "r589", "r594", "r595", "r596", "r597", "r599", "r600", "r601", "r602", "r603", "r604", "r607", "r1178", "r1179", "r1180", "r1181", "r1182", "r1217", "r1419", "r1591", "r1592" ] }, "us-gaap_DebtInstrumentTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentTerm", "presentation": [ "http://www.jnj.com/role/BorrowingsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt instrument, term", "label": "Debt Instrument, Term", "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleRealizedGainLoss", "crdr": "credit", "presentation": [ "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingByGeographicAreaDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Realized gain (loss)", "label": "Debt Securities, Available-for-Sale, Realized Gain (Loss)", "documentation": "Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r1452" ] }, "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleTableTextBlock", "presentation": [ "http://www.jnj.com/role/CashcashequivalentsandcurrentmarketablesecuritiesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Contractual Maturities of Available for Sale Securities", "label": "Debt Securities, Available-for-Sale [Table Text Block]", "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r1441", "r1442", "r1443", "r1444", "r1445", "r1446", "r1447", "r1448", "r1449", "r1450", "r1451", "r1452" ] }, "us-gaap_DebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesMember", "presentation": [ "http://www.jnj.com/role/PensionsandotherbenefitplansCompanyRetirementPlanAssetAllocationandTargetAllocationsDetails", "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofDefinedBenefitPlansDisclosuresDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt securities", "verboseLabel": "Debt instruments", "label": "Debt Securities [Member]", "documentation": "Debt instrument issued by corporations, governments and governmental agencies, municipalities, and other institutions." } } }, "auth_ref": [ "r65", "r1243", "r1650" ] }, "us-gaap_DebtWeightedAverageInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtWeightedAverageInterestRate", "presentation": [ "http://www.jnj.com/role/BorrowingsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt, weighted average interest rate", "label": "Debt, Weighted Average Interest Rate", "documentation": "Weighted average interest rate of debt outstanding." } } }, "auth_ref": [] }, "jnj_December172018ShareRepurchaseProgramMember": { "xbrltype": "domainItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "December172018ShareRepurchaseProgramMember", "presentation": [ "http://www.jnj.com/role/CapitalandtreasurystockNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "December 17, 2018 Share Repurchase Program", "label": "December 17, 2018 Share Repurchase Program [Member]", "documentation": "December 17, 2018 Share Repurchase Program [Member]" } } }, "auth_ref": [] }, "us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredCompensationLiabilityCurrentAndNoncurrent", "crdr": "credit", "calculation": { "http://www.jnj.com/role/EmployeerelatedobligationsEmployeeRelatedObligationsDetails": { "parentTag": "jnj_EmployeeObligations", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.jnj.com/role/EmployeerelatedobligationsEmployeeRelatedObligationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred compensation", "label": "Deferred Compensation Liability, Current and Noncurrent", "documentation": "Aggregate carrying value as of the balance sheet date of the liabilities for all deferred compensation arrangements. Represents currently earned compensation under compensation arrangements that is not actually paid until a later date." } } }, "auth_ref": [] }, "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredFederalIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.jnj.com/role/IncometaxesProvisionforIncomeTaxesDetails": { "parentTag": "jnj_DeferredIncomeTaxExpenseBenefitNetOfDiscontinuedOperations", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.jnj.com/role/IncometaxesProvisionforIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "U.S. taxes", "label": "Deferred Federal Income Tax Expense (Benefit)", "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [ "r1421", "r1556", "r1557" ] }, "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredForeignIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.jnj.com/role/IncometaxesProvisionforIncomeTaxesDetails": { "parentTag": "jnj_DeferredIncomeTaxExpenseBenefitNetOfDiscontinuedOperations", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.jnj.com/role/IncometaxesProvisionforIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "International taxes", "label": "Deferred Foreign Income Tax Expense (Benefit)", "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations." } } }, "auth_ref": [ "r1421", "r1556" ] }, "us-gaap_DeferredIncomeTaxAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredIncomeTaxAssetsNet", "crdr": "debit", "calculation": { "http://www.jnj.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.jnj.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "verboseLabel": "Deferred taxes on income", "label": "Deferred Income Tax Assets, Net", "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting." } } }, "auth_ref": [ "r750", "r751" ] }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Deferred tax provision", "label": "Deferred Income Tax Expense (Benefit)", "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations." } } }, "auth_ref": [ "r14", "r267", "r1421" ] }, "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract", "presentation": [ "http://www.jnj.com/role/IncometaxesProvisionforIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred:", "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]" } } }, "auth_ref": [] }, "jnj_DeferredIncomeTaxExpenseBenefitNetOfDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "DeferredIncomeTaxExpenseBenefitNetOfDiscontinuedOperations", "crdr": "debit", "calculation": { "http://www.jnj.com/role/IncometaxesProvisionforIncomeTaxesDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.jnj.com/role/IncometaxesProvisionforIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total deferred", "label": "Deferred Income Tax Expense (Benefit), Net Of Discontinued Operations", "documentation": "Deferred Income Tax Expense (Benefit), Net Of Discontinued Operations" } } }, "auth_ref": [] }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredIncomeTaxLiabilitiesNet", "crdr": "credit", "calculation": { "http://www.jnj.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.jnj.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "verboseLabel": "Deferred taxes on income", "label": "Deferred Income Tax Liabilities, Net", "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting." } } }, "auth_ref": [ "r750", "r751", "r966" ] }, "us-gaap_DeferredTaxAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsGross", "crdr": "debit", "calculation": { "http://www.jnj.com/role/IncometaxesTemporaryDifferencesandCarryforwardsDetails": { "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.jnj.com/role/IncometaxesTemporaryDifferencesandCarryforwardsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Income reported for tax purposes", "label": "Deferred Tax Assets, Gross", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards." } } }, "auth_ref": [ "r770" ] }, "jnj_DeferredTaxAssetsInternationalResearchAndDevelopmentCapitalized": { "xbrltype": "monetaryItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "DeferredTaxAssetsInternationalResearchAndDevelopmentCapitalized", "crdr": "debit", "calculation": { "http://www.jnj.com/role/IncometaxesTemporaryDifferencesandCarryforwardsDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://www.jnj.com/role/IncometaxesTemporaryDifferencesandCarryforwardsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "R&D capitalized for tax", "label": "Deferred Tax Assets International Research And Development Capitalized", "documentation": "Deferred tax assets international research and development capitalized." } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsInventory": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsInventory", "crdr": "debit", "calculation": { "http://www.jnj.com/role/IncometaxesTemporaryDifferencesandCarryforwardsDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.jnj.com/role/IncometaxesTemporaryDifferencesandCarryforwardsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Inventory related", "label": "Deferred Tax Assets, Inventory", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory." } } }, "auth_ref": [ "r1554" ] }, "us-gaap_DeferredTaxAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsNet", "crdr": "debit", "calculation": { "http://www.jnj.com/role/IncometaxesTemporaryDifferencesandCarryforwardsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.jnj.com/role/IncometaxesTemporaryDifferencesandCarryforwardsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total deferred income taxes net of valuation allowances", "label": "Deferred Tax Assets, Net of Valuation Allowance", "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards." } } }, "auth_ref": [ "r1549" ] }, "us-gaap_DeferredTaxAssetsNetAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsNetAbstract", "presentation": [ "http://www.jnj.com/role/IncometaxesTemporaryDifferencesandCarryforwardsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Asset", "label": "Deferred Tax Assets, Net [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "crdr": "debit", "calculation": { "http://www.jnj.com/role/IncometaxesTemporaryDifferencesandCarryforwardsDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.jnj.com/role/IncometaxesTemporaryDifferencesandCarryforwardsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating loss carryforwards", "label": "Deferred Tax Assets, Operating Loss Carryforwards", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards." } } }, "auth_ref": [ "r1554" ] }, "us-gaap_DeferredTaxAssetsOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsOther", "crdr": "debit", "calculation": { "http://www.jnj.com/role/IncometaxesTemporaryDifferencesandCarryforwardsDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.jnj.com/role/IncometaxesTemporaryDifferencesandCarryforwardsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Miscellaneous international", "label": "Deferred Tax Assets, Other", "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other." } } }, "auth_ref": [ "r1554" ] }, "jnj_DeferredTaxAssetsOtherDomestic": { "xbrltype": "monetaryItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "DeferredTaxAssetsOtherDomestic", "crdr": "debit", "calculation": { "http://www.jnj.com/role/IncometaxesTemporaryDifferencesandCarryforwardsDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.jnj.com/role/IncometaxesTemporaryDifferencesandCarryforwardsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Miscellaneous U.S.", "label": "Deferred Tax Assets Other Domestic", "documentation": "Deferred tax assets other domestic." } } }, "auth_ref": [] }, "jnj_DeferredTaxAssetsTaxBasisIncreaseOfCertainAssetsDueToReorganization": { "xbrltype": "monetaryItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "DeferredTaxAssetsTaxBasisIncreaseOfCertainAssetsDueToReorganization", "crdr": "debit", "presentation": [ "http://www.jnj.com/role/IncometaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred tax assets, tax basis increase of certain assets due to reorganization", "label": "Deferred Tax Assets, Tax Basis Increase of Certain Assets due to Reorganization", "documentation": "Deferred Tax Assets, Tax Basis Increase of Certain Assets due to Reorganization" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits", "crdr": "debit", "calculation": { "http://www.jnj.com/role/IncometaxesTemporaryDifferencesandCarryforwardsDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.jnj.com/role/IncometaxesTemporaryDifferencesandCarryforwardsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Employee related obligations", "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Employee Benefits", "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from employee benefits, classified as other." } } }, "auth_ref": [ "r1554" ] }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost", "crdr": "debit", "calculation": { "http://www.jnj.com/role/IncometaxesTemporaryDifferencesandCarryforwardsDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.jnj.com/role/IncometaxesTemporaryDifferencesandCarryforwardsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock based compensation", "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation." } } }, "auth_ref": [ "r1554" ] }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals", "crdr": "debit", "calculation": { "http://www.jnj.com/role/IncometaxesTemporaryDifferencesandCarryforwardsDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.jnj.com/role/IncometaxesTemporaryDifferencesandCarryforwardsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reserves\u00a0& liabilities", "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals." } } }, "auth_ref": [ "r1554" ] }, "jnj_DeferredTaxAssetsUndistributedForeignEarnings": { "xbrltype": "monetaryItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "DeferredTaxAssetsUndistributedForeignEarnings", "crdr": "debit", "calculation": { "http://www.jnj.com/role/IncometaxesTemporaryDifferencesandCarryforwardsDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.jnj.com/role/IncometaxesTemporaryDifferencesandCarryforwardsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Undistributed foreign earnings", "label": "Deferred Tax Assets, Undistributed Foreign Earnings", "documentation": "Deferred Tax Assets, Undistributed Foreign Earnings" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsValuationAllowance", "crdr": "credit", "calculation": { "http://www.jnj.com/role/IncometaxesTemporaryDifferencesandCarryforwardsDetails": { "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.jnj.com/role/IncometaxesTemporaryDifferencesandCarryforwardsDetails", "http://www.jnj.com/role/IncometaxesValuationAllowanceActivityDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Valuation allowances", "periodStartLabel": "Beginning of year", "periodEndLabel": "End of year", "label": "Deferred Tax Assets, Valuation Allowance", "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized." } } }, "auth_ref": [ "r771" ] }, "us-gaap_DeferredTaxLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxLiabilities", "crdr": "credit", "calculation": { "http://www.jnj.com/role/IncometaxesTemporaryDifferencesandCarryforwardsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.jnj.com/role/IncometaxesTemporaryDifferencesandCarryforwardsDetails" ], "lang": { "en-us": { "role": { "negatedTotalLabel": "Total deferred income taxes net of valuation allowances", "label": "Deferred Tax Liabilities, Net", "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting." } } }, "auth_ref": [ "r1549" ] }, "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets", "crdr": "credit", "calculation": { "http://www.jnj.com/role/IncometaxesTemporaryDifferencesandCarryforwardsDetails": { "parentTag": "us-gaap_DeferredTaxLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.jnj.com/role/IncometaxesTemporaryDifferencesandCarryforwardsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Goodwill and intangibles", "label": "Deferred Tax Liabilities, Intangible Assets", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill." } } }, "auth_ref": [ "r1554" ] }, "us-gaap_DeferredTaxLiabilitiesNetAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxLiabilitiesNetAbstract", "presentation": [ "http://www.jnj.com/role/IncometaxesTemporaryDifferencesandCarryforwardsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Liability", "label": "Deferred Tax Liabilities, Net [Abstract]" } } }, "auth_ref": [] }, "jnj_DeferredTaxLiabilitiesOtherDomestic": { "xbrltype": "monetaryItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "DeferredTaxLiabilitiesOtherDomestic", "crdr": "credit", "calculation": { "http://www.jnj.com/role/IncometaxesTemporaryDifferencesandCarryforwardsDetails": { "parentTag": "us-gaap_DeferredTaxLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.jnj.com/role/IncometaxesTemporaryDifferencesandCarryforwardsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Miscellaneous U.S.", "label": "Deferred Tax Liabilities, Other Domestic", "documentation": "Deferred Tax Liabilities, Other Domestic" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.jnj.com/role/IncometaxesTemporaryDifferencesandCarryforwardsDetails": { "parentTag": "us-gaap_DeferredTaxLiabilities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.jnj.com/role/IncometaxesTemporaryDifferencesandCarryforwardsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Depreciation of property, plant and equipment", "label": "Deferred Tax Liabilities, Property, Plant and Equipment", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment." } } }, "auth_ref": [ "r1554" ] }, "us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxLiabilitiesUndistributedForeignEarnings", "crdr": "credit", "calculation": { "http://www.jnj.com/role/IncometaxesTemporaryDifferencesandCarryforwardsDetails": { "parentTag": "us-gaap_DeferredTaxLiabilities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.jnj.com/role/IncometaxesTemporaryDifferencesandCarryforwardsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Undistributed foreign earnings", "label": "Deferred Tax Liabilities, Undistributed Foreign Earnings", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from undistributed earnings of subsidiary and other recognized entity not within country of domicile. Includes, but is not limited to, other basis differences." } } }, "auth_ref": [ "r1554" ] }, "jnj_DeferredTaxLiabilityGlobalIntangibleLowTaxedIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "DeferredTaxLiabilityGlobalIntangibleLowTaxedIncome", "crdr": "credit", "calculation": { "http://www.jnj.com/role/IncometaxesTemporaryDifferencesandCarryforwardsDetails": { "parentTag": "us-gaap_DeferredTaxLiabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.jnj.com/role/IncometaxesTemporaryDifferencesandCarryforwardsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Global intangible low-taxed income", "label": "Deferred Tax Liability, Global Intangible Low-Taxed Income", "documentation": "Deferred Tax Liability, Global Intangible Low-Taxed Income" } } }, "auth_ref": [] }, "us-gaap_DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities", "crdr": "credit", "calculation": { "http://www.jnj.com/role/EmployeerelatedobligationsEmployeeRelatedObligationsDetails": { "parentTag": "jnj_EmployeeObligations", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.jnj.com/role/EmployeerelatedobligationsEmployeeRelatedObligationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Pension benefits", "label": "Liability, Defined Benefit Pension Plan", "documentation": "Amount of liability, recognized in statement of financial position, for defined benefit pension plan. Excludes other postretirement benefit plan." } } }, "auth_ref": [ "r77", "r78", "r237" ] }, "us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanAccumulatedBenefitObligation", "crdr": "credit", "presentation": [ "http://www.jnj.com/role/PensionsandotherbenefitplansInformationRelatedtotheBenefitObligationandtheFairValueofPlanAssetsDetails", "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofNetFundedStatusDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Benefit Obligation", "label": "Defined Benefit Plan, Accumulated Benefit Obligation", "documentation": "Amount of actuarial present value of benefits attributed to employee service rendered, excluding assumptions about future compensation level." } } }, "auth_ref": [ "r656" ] }, "us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax", "crdr": "debit", "calculation": { "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofNetFundedStatusDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofNetFundedStatusDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total before tax effects", "label": "Defined Benefit Plan, Accumulated Other Comprehensive (Income) Loss, before Tax", "documentation": "Amount, before tax, of accumulated other comprehensive (income) loss for defined benefit plan, that has not been recognized in net periodic benefit cost (credit)." } } }, "auth_ref": [ "r7", "r8", "r41", "r173", "r1510" ] }, "us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax", "crdr": "credit", "calculation": { "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofNetFundedStatusDetails": { "parentTag": "us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofNetFundedStatusDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Net actuarial loss", "label": "Defined Benefit Plan, Accumulated Other Comprehensive Income (Loss), Gain (Loss), before Tax", "documentation": "Amount, before tax, of accumulated other comprehensive income (loss) for gain (loss) of defined benefit plan, that has not been recognized in net periodic benefit (cost) credit." } } }, "auth_ref": [ "r41", "r668" ] }, "us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax", "crdr": "debit", "calculation": { "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofNetFundedStatusDetails": { "parentTag": "us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofNetFundedStatusDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prior service cost (credit)", "label": "Defined Benefit Plan, Accumulated Other Comprehensive (Income) Loss, Prior Service Cost (Credit), before Tax", "documentation": "Amount, before tax, of accumulated other comprehensive (income) loss for cost (credit) of benefit change attributable to participants' prior service from plan amendment or plan initiation of defined benefit plan, that has not been recognized in net periodic benefit cost (credit)." } } }, "auth_ref": [ "r41", "r668" ] }, "us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetTransitionAssetsObligationsBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetTransitionAssetsObligationsBeforeTax", "crdr": "credit", "calculation": { "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofNetFundedStatusDetails": { "parentTag": "us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofNetFundedStatusDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrecognized net transition obligation", "label": "Defined Benefit Plan, Accumulated Other Comprehensive Income (Loss), Transition Asset (Obligation), before Tax", "documentation": "Amount, before tax, of accumulated other comprehensive income (loss) for transition asset (obligation) of defined benefit plan, that has not been recognized in net periodic benefit (cost) credit." } } }, "auth_ref": [ "r8", "r41", "r668" ] }, "us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanActualReturnOnPlanAssets", "crdr": "debit", "presentation": [ "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofNetFundedStatusDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Actual return on plan assets", "label": "Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss)", "documentation": "Amount of increase (decrease) in plan assets of defined benefit plan from actual return (loss) determined by change in fair value of plan assets adjusted for contributions, benefit payments, and other expenses." } } }, "auth_ref": [ "r638", "r1189" ] }, "us-gaap_DefinedBenefitPlanActuarialGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanActuarialGainLoss", "crdr": "credit", "presentation": [ "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofNetFundedStatusDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Actuarial (gains) losses", "label": "Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss)", "documentation": "Amount of gain (loss) from change in actuarial assumptions which (increases) decreases benefit obligation of defined benefit plan. Assumptions include, but are not limited to, interest, mortality, employee turnover, salary, and temporary deviation from substantive plan." } } }, "auth_ref": [ "r631" ] }, "jnj_DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets", "crdr": "debit", "presentation": [ "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofDefinedBenefitPlansDisclosuresDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Investments Measured at Net Asset Value", "label": "Defined Benefit Plan, Alternative Investments, Fair Value of Plan Assets", "documentation": "Defined Benefit Plan, Alternative Investments, Fair Value of Plan Assets" } } }, "auth_ref": [] }, "us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanAmortizationOfGainsLosses", "crdr": "credit", "calculation": { "http://www.jnj.com/role/PensionsandotherbenefitplansComponentsofNetPeriodicBenefitCostDetails": { "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.jnj.com/role/PensionsandotherbenefitplansComponentsofNetPeriodicBenefitCostDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Recognized actuarial losses (gains)", "label": "Defined Benefit Plan, Amortization of Gain (Loss)", "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit of defined benefit plan." } } }, "auth_ref": [ "r625", "r663", "r689", "r1189", "r1190" ] }, "us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanAmortizationOfPriorServiceCostCredit", "crdr": "debit", "calculation": { "http://www.jnj.com/role/PensionsandotherbenefitplansComponentsofNetPeriodicBenefitCostDetails": { "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.jnj.com/role/PensionsandotherbenefitplansComponentsofNetPeriodicBenefitCostDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Amortization of prior service cost", "label": "Defined Benefit Plan, Amortization of Prior Service Cost (Credit)", "documentation": "Amount of prior service cost (credit) recognized in net periodic benefit cost (credit) of defined benefit plan." } } }, "auth_ref": [ "r625", "r664", "r690", "r1189", "r1190" ] }, "us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanAmountsRecognizedInBalanceSheet", "crdr": "debit", "calculation": { "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofNetFundedStatusDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofNetFundedStatusDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total recognized in the consolidated balance sheet\u00a0\u2014 end of year", "label": "Defined Benefit Plan, Amounts for Asset (Liability) Recognized in Statement of Financial Position", "documentation": "Amount of asset (liability), recognized in statement of financial position, for defined benefit pension and other postretirement plans." } } }, "auth_ref": [ "r77", "r78" ] }, "us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract", "presentation": [ "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofNetFundedStatusDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amounts Recognized in the Company\u2019s Balance Sheet consist of the\u00a0following:", "label": "Defined Benefit Plan, Amounts for Asset (Liability) Recognized in Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract", "presentation": [ "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofNetFundedStatusDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Defined Benefit Plan, Amounts Recognized in Other Comprehensive Income (Loss) [Abstract]", "label": "Defined Benefit Plan, Amounts Recognized in Other Comprehensive Income (Loss) [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent", "crdr": "debit", "calculation": { "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofNetFundedStatusDetails": { "parentTag": "us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.jnj.com/role/EmployeerelatedobligationsNarrativeDetails", "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofNetFundedStatusDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Prepaid employee related obligations", "terseLabel": "Non-current assets", "label": "Assets for Plan Benefits, Defined Benefit Plan", "documentation": "Amount of asset, recognized in statement of financial position, for overfunded defined benefit pension and other postretirement plans." } } }, "auth_ref": [ "r232", "r623", "r624", "r646", "r1070", "r1189", "r1608" ] }, "us-gaap_DefinedBenefitPlanAssumedHealthCareCostTrendRatesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanAssumedHealthCareCostTrendRatesAbstract", "presentation": [ "http://www.jnj.com/role/PensionsandotherbenefitplansAssumedHealthCareCostTrendRatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Defined Benefit Plan, Assumed Health Care Cost Trend Rates [Abstract]", "label": "Defined Benefit Plan, Assumed Health Care Cost Trend Rates [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate", "presentation": [ "http://www.jnj.com/role/PensionsandotherbenefitplansRatesUsedtoDevelopActuarialPresentValueofProjectedBenefitObligationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Discount rate", "label": "Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate", "documentation": "Weighted average rate for present value of future retirement benefits cash flows, used to determine benefit obligation of defined benefit plan." } } }, "auth_ref": [ "r670" ] }, "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease", "presentation": [ "http://www.jnj.com/role/PensionsandotherbenefitplansRatesUsedtoDevelopActuarialPresentValueofProjectedBenefitObligationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Rate of increase in compensation levels", "label": "Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Rate of Compensation Increase", "documentation": "Weighted average rate increase of compensation, used to determine benefit obligation of defined benefit plan. Plan includes, but is not limited to, pay-related defined benefit plan." } } }, "auth_ref": [ "r671" ] }, "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate", "presentation": [ "http://www.jnj.com/role/PensionsandotherbenefitplansRatesUsedtoDevelopActuarialPresentValueofProjectedBenefitObligationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Service cost discount rate", "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate", "documentation": "Weighted average rate for present value of future retirement benefits cash flows, used to determine net periodic benefit cost of defined benefit plan." } } }, "auth_ref": [ "r670" ] }, "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets", "presentation": [ "http://www.jnj.com/role/PensionsandotherbenefitplansRatesUsedtoDevelopActuarialPresentValueofProjectedBenefitObligationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected long-term rate of return on plan assets", "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-Term Rate of Return on Plan Assets", "documentation": "Weighted average rate of return on plan assets, reflecting average rate of earnings expected on existing plan assets and expected contributions, used to determine net periodic benefit cost of defined benefit plan." } } }, "auth_ref": [ "r672", "r694" ] }, "jnj_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate": { "xbrltype": "percentItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate", "presentation": [ "http://www.jnj.com/role/PensionsandotherbenefitplansRatesUsedtoDevelopActuarialPresentValueofProjectedBenefitObligationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest cost discount rate", "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Interest Cost, Discount Rate", "documentation": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Interest Cost, Discount Rate" } } }, "auth_ref": [] }, "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease", "presentation": [ "http://www.jnj.com/role/PensionsandotherbenefitplansRatesUsedtoDevelopActuarialPresentValueofProjectedBenefitObligationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Rate of increase in compensation levels", "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Rate of Compensation Increase", "documentation": "Weighted average rate of compensation increase used to determine net periodic benefit cost of defined benefit plan. Plan includes, but is not limited to, pay-related defined benefit plan." } } }, "auth_ref": [ "r671" ] }, "us-gaap_DefinedBenefitPlanBenefitObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanBenefitObligation", "crdr": "credit", "calculation": { "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofNetFundedStatusDetails": { "parentTag": "us-gaap_DefinedBenefitPlanFundedStatusOfPlan", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.jnj.com/role/PensionsandotherbenefitplansInformationRelatedtotheBenefitObligationandtheFairValueofPlanAssetsDetails", "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofNetFundedStatusDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Projected benefit obligation - beginning of year", "periodEndLabel": "Projected benefit obligation - end of year", "terseLabel": "Projected Benefit Obligation", "label": "Defined Benefit Plan, Benefit Obligation", "documentation": "Amount of actuarial present value of benefits attributed to service rendered by employee for defined benefit plan." } } }, "auth_ref": [ "r626" ] }, "us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanBenefitObligationBenefitsPaid", "crdr": "credit", "presentation": [ "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofNetFundedStatusDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Benefits paid from plan", "label": "Defined Benefit Plan, Benefit Obligation, Benefits Paid", "documentation": "Amount of payment to participant of defined benefit plan which decreases benefit obligation. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services." } } }, "auth_ref": [ "r633", "r697" ] }, "jnj_DefinedBenefitPlanBenefitObligationBusinessCombinationandDivestitureIncreaseDecrease": { "xbrltype": "monetaryItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "DefinedBenefitPlanBenefitObligationBusinessCombinationandDivestitureIncreaseDecrease", "crdr": "credit", "presentation": [ "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofNetFundedStatusDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Divestitures & acquisitions", "label": "Defined Benefit Plan, Benefit Obligation, Business Combination and Divestiture, Increase (Decrease)", "documentation": "Defined Benefit Plan, Benefit Obligation, Business Combination and Divestiture, Increase (Decrease)" } } }, "auth_ref": [] }, "us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant", "crdr": "debit", "presentation": [ "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofNetFundedStatusDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Plan participant contributions", "label": "Defined Benefit Plan, Benefit Obligation, Contributions by Plan Participant", "documentation": "Amount of contributions received by defined benefit plan from participant which increase benefit obligation." } } }, "auth_ref": [ "r630" ] }, "jnj_DefinedBenefitPlanBenefitObligationTransferredToGroupAnnuityContract": { "xbrltype": "monetaryItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "DefinedBenefitPlanBenefitObligationTransferredToGroupAnnuityContract", "crdr": "credit", "presentation": [ "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofNetFundedStatusDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Transferred to group annuity contract", "label": "Defined Benefit Plan, Benefit Obligation, Transferred To Group Annuity Contract", "documentation": "Defined Benefit Plan, Benefit Obligation, Transferred To Group Annuity Contract" } } }, "auth_ref": [] }, "us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanByPlanAssetCategoriesAxis", "presentation": [ "http://www.jnj.com/role/PensionsandotherbenefitplansCompanyRetirementPlanAssetAllocationandTargetAllocationsDetails", "http://www.jnj.com/role/PensionsandotherbenefitplansNarrativeDetails", "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofDefinedBenefitPlansDisclosuresDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Defined Benefit Plan, Plan Assets, Category [Axis]", "terseLabel": "Defined Benefit Plan, Plan Assets, Category [Axis]", "label": "Defined Benefit Plan, Plan Assets, Category [Axis]", "documentation": "Information by defined benefit plan asset investment." } } }, "auth_ref": [ "r647", "r648", "r650", "r651", "r652", "r653", "r654", "r655", "r675", "r1187", "r1188", "r1189" ] }, "us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanChangeInBenefitObligationRollForward", "presentation": [ "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofNetFundedStatusDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Change in Benefit Obligation", "label": "Defined Benefit Plan, Change in Benefit Obligation [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward", "presentation": [ "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofNetFundedStatusDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]", "label": "Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_DefinedBenefitPlanContributionsByEmployer": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanContributionsByEmployer", "crdr": "debit", "presentation": [ "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofNetFundedStatusDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Company contributions", "label": "Defined Benefit Plan, Plan Assets, Contributions by Employer", "documentation": "Amount of contribution received by defined benefit plan from employer which increases plan assets." } } }, "auth_ref": [ "r640", "r650", "r693", "r1187", "r1188", "r1189", "r1190" ] }, "us-gaap_DefinedBenefitPlanDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanDisclosureLineItems", "presentation": [ "http://www.jnj.com/role/PensionsandotherbenefitplansCompanyRetirementPlanAssetAllocationandTargetAllocationsDetails", "http://www.jnj.com/role/PensionsandotherbenefitplansComponentsofNetPeriodicBenefitCostDetails", "http://www.jnj.com/role/PensionsandotherbenefitplansInformationRelatedtotheBenefitObligationandtheFairValueofPlanAssetsDetails", "http://www.jnj.com/role/PensionsandotherbenefitplansNarrativeDetails", "http://www.jnj.com/role/PensionsandotherbenefitplansProjectedFutureBenefitPaymentsfromCompanysRetirementandOtherBenefitPlansDetails", "http://www.jnj.com/role/PensionsandotherbenefitplansRatesUsedtoDevelopActuarialPresentValueofProjectedBenefitObligationDetails", "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofDefinedBenefitPlansDisclosuresDetails", "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofNetFundedStatusDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Defined Benefit Plan Disclosure [Line Items]", "label": "Defined Benefit Plan Disclosure [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInFiveFiscalYearsThereafter": { "xbrltype": "monetaryItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "DefinedBenefitPlanExpectedFutureBenefitContributionInFiveFiscalYearsThereafter", "crdr": "credit", "presentation": [ "http://www.jnj.com/role/PensionsandotherbenefitplansProjectedFutureMinimumContributionstotheCompanysUSandInternationalUnfundedRetirementPlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2029-2033", "label": "Defined Benefit Plan Expected Future Benefit Contribution In Five Fiscal Years Thereafter", "documentation": "Defined benefit plan expected future benefit contribution in five fiscal years thereafter." } } }, "auth_ref": [] }, "jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "DefinedBenefitPlanExpectedFutureBenefitContributionInYearFive", "crdr": "credit", "presentation": [ "http://www.jnj.com/role/PensionsandotherbenefitplansProjectedFutureMinimumContributionstotheCompanysUSandInternationalUnfundedRetirementPlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2028", "label": "Defined Benefit Plan Expected Future Benefit Contribution In Year Five", "documentation": "Defined benefit plan expected future benefit contribution in year five." } } }, "auth_ref": [] }, "jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "DefinedBenefitPlanExpectedFutureBenefitContributionInYearFour", "crdr": "credit", "presentation": [ "http://www.jnj.com/role/PensionsandotherbenefitplansProjectedFutureMinimumContributionstotheCompanysUSandInternationalUnfundedRetirementPlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Defined Benefit Plan Expected Future Benefit Contribution In Year Four", "documentation": "Defined benefit plan expected future benefit contribution in year four." } } }, "auth_ref": [] }, "jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearOne": { "xbrltype": "monetaryItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "DefinedBenefitPlanExpectedFutureBenefitContributionInYearOne", "crdr": "credit", "presentation": [ "http://www.jnj.com/role/PensionsandotherbenefitplansProjectedFutureMinimumContributionstotheCompanysUSandInternationalUnfundedRetirementPlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2024", "label": "Defined Benefit Plan Expected Future Benefit Contribution In Year One", "documentation": "Defined benefit plan expected future benefit contribution in year one." } } }, "auth_ref": [] }, "jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "DefinedBenefitPlanExpectedFutureBenefitContributionInYearThree", "crdr": "credit", "presentation": [ "http://www.jnj.com/role/PensionsandotherbenefitplansProjectedFutureMinimumContributionstotheCompanysUSandInternationalUnfundedRetirementPlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Defined Benefit Plan Expected Future Benefit Contribution In Year Three", "documentation": "Defined benefit plan expected future benefit contribution in year three." } } }, "auth_ref": [] }, "jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "DefinedBenefitPlanExpectedFutureBenefitContributionInYearTwo", "crdr": "credit", "presentation": [ "http://www.jnj.com/role/PensionsandotherbenefitplansProjectedFutureMinimumContributionstotheCompanysUSandInternationalUnfundedRetirementPlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Defined Benefit Plan Expected Future Benefit Contribution In Year Two", "documentation": "Defined benefit plan expected future benefit contribution in year two." } } }, "auth_ref": [] }, "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter", "crdr": "credit", "presentation": [ "http://www.jnj.com/role/PensionsandotherbenefitplansProjectedFutureBenefitPaymentsfromCompanysRetirementandOtherBenefitPlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2029-2033", "label": "Defined Benefit Plan, Expected Future Benefit Payment, after Year Five for Next Five Years", "documentation": "Amount of benefit for defined benefit plan expected to be paid in five fiscal years after fifth fiscal year following current fiscal year." } } }, "auth_ref": [ "r657" ] }, "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths", "crdr": "credit", "presentation": [ "http://www.jnj.com/role/PensionsandotherbenefitplansProjectedFutureBenefitPaymentsfromCompanysRetirementandOtherBenefitPlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2024", "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year One", "documentation": "Amount of benefit for defined benefit plan expected to be paid in next fiscal year following current fiscal year." } } }, "auth_ref": [ "r657" ] }, "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive", "crdr": "credit", "presentation": [ "http://www.jnj.com/role/PensionsandotherbenefitplansProjectedFutureBenefitPaymentsfromCompanysRetirementandOtherBenefitPlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2028", "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Five", "documentation": "Amount of benefit for defined benefit plan expected to be paid in fifth fiscal year following current fiscal year." } } }, "auth_ref": [ "r657" ] }, "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour", "crdr": "credit", "presentation": [ "http://www.jnj.com/role/PensionsandotherbenefitplansProjectedFutureBenefitPaymentsfromCompanysRetirementandOtherBenefitPlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Four", "documentation": "Amount of benefit for defined benefit plan expected to be paid in fourth fiscal year following current fiscal year." } } }, "auth_ref": [ "r657" ] }, "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree", "crdr": "credit", "presentation": [ "http://www.jnj.com/role/PensionsandotherbenefitplansProjectedFutureBenefitPaymentsfromCompanysRetirementandOtherBenefitPlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Three", "documentation": "Amount of benefit for defined benefit plan expected to be paid in third fiscal year following current fiscal year." } } }, "auth_ref": [ "r657" ] }, "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo", "crdr": "credit", "presentation": [ "http://www.jnj.com/role/PensionsandotherbenefitplansProjectedFutureBenefitPaymentsfromCompanysRetirementandOtherBenefitPlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Two", "documentation": "Amount of benefit for defined benefit plan expected to be paid in second fiscal year following current fiscal year." } } }, "auth_ref": [ "r657" ] }, "us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanExpectedReturnOnPlanAssets", "crdr": "credit", "calculation": { "http://www.jnj.com/role/PensionsandotherbenefitplansComponentsofNetPeriodicBenefitCostDetails": { "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.jnj.com/role/PensionsandotherbenefitplansComponentsofNetPeriodicBenefitCostDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Expected return on plan assets", "label": "Defined Benefit Plan, Expected Return (Loss) on Plan Assets", "documentation": "Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan." } } }, "auth_ref": [ "r625", "r662", "r688", "r1189", "r1190" ] }, "us-gaap_DefinedBenefitPlanFairValueOfPlanAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanFairValueOfPlanAssets", "crdr": "debit", "calculation": { "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofNetFundedStatusDetails": { "parentTag": "us-gaap_DefinedBenefitPlanFundedStatusOfPlan", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.jnj.com/role/PensionsandotherbenefitplansInformationRelatedtotheBenefitObligationandtheFairValueofPlanAssetsDetails", "http://www.jnj.com/role/PensionsandotherbenefitplansNarrativeDetails", "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofDefinedBenefitPlansDisclosuresDetails", "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofNetFundedStatusDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Plan Assets", "periodStartLabel": "Plan assets at fair value\u00a0\u2014 beginning of year", "periodEndLabel": "Plan assets at fair value\u00a0- End of year", "label": "Defined Benefit Plan, Plan Assets, Amount", "documentation": "Amount of asset segregated and restricted to provide benefit under defined benefit plan. Asset includes, but is not limited to, stock, bond, other investment, earning from investment, and contribution by employer and employee." } } }, "auth_ref": [ "r637", "r648", "r650", "r651", "r1187", "r1188", "r1189" ] }, "us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation", "crdr": "credit", "presentation": [ "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofNetFundedStatusDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Effect of exchange rates", "label": "Defined Benefit Plan, Benefit Obligation, Foreign Currency Translation Gain (Loss)", "documentation": "Amount of foreign currency translation gain (loss) which (increases) decreases benefit obligation of defined benefit plan." } } }, "auth_ref": [ "r632" ] }, "us-gaap_DefinedBenefitPlanFundedStatusOfPlan": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanFundedStatusOfPlan", "crdr": "debit", "calculation": { "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofNetFundedStatusDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.jnj.com/role/PensionsandotherbenefitplansInformationRelatedtotheBenefitObligationandtheFairValueofPlanAssetsDetails", "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofNetFundedStatusDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Funded status - end of year", "terseLabel": "Projected Benefit Obligation", "label": "Defined Benefit Plan, Funded (Unfunded) Status of Plan", "documentation": "Amount of funded (unfunded) status of defined benefit plan, measured as difference between fair value of plan assets and benefit obligation. Includes, but is not limited to, overfunded (underfunded) status." } } }, "auth_ref": [ "r623", "r646", "r1189" ] }, "us-gaap_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear", "presentation": [ "http://www.jnj.com/role/PensionsandotherbenefitplansAssumedHealthCareCostTrendRatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Healthcare cost trend rate assumed for next year", "label": "Defined Benefit Plan, Health Care Cost Trend Rate Assumed, Next Fiscal Year", "documentation": "Assumed rate, for next fiscal year, based on annual change in cost of health care cost benefits used to measure expected cost of benefits covered by defined benefit postretirement plan. Factors include, but are not limited to, estimate of health care inflation, change in health care utilization or delivery pattern, technological advances, and change in health status of participant. Excludes factors for change in composition of plan population by age and dependency status." } } }, "auth_ref": [ "r674" ] }, "us-gaap_DefinedBenefitPlanInterestCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanInterestCost", "crdr": "debit", "calculation": { "http://www.jnj.com/role/PensionsandotherbenefitplansComponentsofNetPeriodicBenefitCostDetails": { "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.jnj.com/role/PensionsandotherbenefitplansComponentsofNetPeriodicBenefitCostDetails", "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofNetFundedStatusDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Interest cost", "terseLabel": "Interest cost", "label": "Defined Benefit Plan, Interest Cost", "documentation": "Amount of cost recognized for passage of time related to defined benefit plan." } } }, "auth_ref": [ "r625", "r629", "r661", "r687", "r1189", "r1190" ] }, "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanNetPeriodicBenefitCost", "crdr": "debit", "calculation": { "http://www.jnj.com/role/PensionsandotherbenefitplansComponentsofNetPeriodicBenefitCostDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.jnj.com/role/PensionsandotherbenefitplansComponentsofNetPeriodicBenefitCostDetails", "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofNetFundedStatusDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net periodic benefit cost (credit)", "terseLabel": "Net periodic benefit cost (credit)", "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit)", "documentation": "Amount of net periodic benefit cost (credit) for defined benefit plan." } } }, "auth_ref": [ "r659", "r685", "r1189", "r1190" ] }, "jnj_DefinedBenefitPlanOverUnderFundedStatusABO": { "xbrltype": "monetaryItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "DefinedBenefitPlanOverUnderFundedStatusABO", "crdr": "debit", "presentation": [ "http://www.jnj.com/role/PensionsandotherbenefitplansInformationRelatedtotheBenefitObligationandtheFairValueofPlanAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Benefit Obligation", "label": "Defined Benefit Plan Over (Under) Funded Status ABO", "documentation": "Defined benefit plan over (under) funded status ABO" } } }, "auth_ref": [] }, "us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation", "crdr": "credit", "presentation": [ "http://www.jnj.com/role/PensionsandotherbenefitplansNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated benefit obligation unfunded plans", "label": "Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Accumulated Benefit Obligation", "documentation": "Amount of accumulated benefit obligation for defined benefit plan with accumulated benefit obligation in excess of plan assets." } } }, "auth_ref": [ "r682", "r683", "r1189" ] }, "us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets", "crdr": "debit", "presentation": [ "http://www.jnj.com/role/PensionsandotherbenefitplansNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Plan with accumulated benefit obligation in excess of plan assets, plan assets", "label": "Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Plan Assets", "documentation": "Amount of plan asset for defined benefit plan with accumulated benefit obligation in excess of plan assets." } } }, "auth_ref": [ "r682", "r683", "r1189" ] }, "us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation", "crdr": "credit", "presentation": [ "http://www.jnj.com/role/PensionsandotherbenefitplansNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Projected benefit obligation, unfunded plans", "label": "Defined Benefit Plan, Pension Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Projected Benefit Obligation", "documentation": "Amount of projected benefit obligation for defined benefit pension plan with accumulated benefit obligation in excess of plan assets." } } }, "auth_ref": [ "r1511" ] }, "us-gaap_DefinedBenefitPlanPlanAmendments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanPlanAmendments", "crdr": "credit", "presentation": [ "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofNetFundedStatusDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amendments", "label": "Defined Benefit Plan, Benefit Obligation, Increase (Decrease) for Plan Amendment", "documentation": "Amount of increase (decrease) in benefit obligation of defined benefit plan from change in terms of existing plan or initiation of new plan." } } }, "auth_ref": [ "r634" ] }, "us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanPlanAssetsBenefitsPaid", "crdr": "credit", "presentation": [ "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofNetFundedStatusDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Benefits paid from plan assets", "label": "Defined Benefit Plan, Plan Assets, Benefits Paid", "documentation": "Amount of payment to participant under defined benefit plan which decreases plan assets. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services." } } }, "auth_ref": [ "r642", "r1513" ] }, "jnj_DefinedBenefitPlanPlanAssetsBusinessCombinationandDivestitureIncreaseDecrease": { "xbrltype": "monetaryItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "DefinedBenefitPlanPlanAssetsBusinessCombinationandDivestitureIncreaseDecrease", "crdr": "debit", "presentation": [ "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofNetFundedStatusDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Divestitures & acquisitions", "label": "Defined Benefit Plan, Plan Assets, Business Combination and Divestiture, Increase (Decrease)", "documentation": "Defined Benefit Plan, Plan Assets, Business Combination and Divestiture, Increase (Decrease)" } } }, "auth_ref": [] }, "us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant", "crdr": "debit", "presentation": [ "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofNetFundedStatusDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Plan participant contributions", "label": "Defined Benefit Plan, Plan Assets, Contributions by Plan Participant", "documentation": "Amount of contributions received by defined benefit plan from participant which increases plan assets." } } }, "auth_ref": [ "r641" ] }, "us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss", "crdr": "credit", "presentation": [ "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofNetFundedStatusDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Effect of exchange rates", "label": "Defined Benefit Plan, Plan Assets, Foreign Currency Translation Gain (Loss)", "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) plan assets of defined benefit plan." } } }, "auth_ref": [ "r639" ] }, "us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanPlanAssetsTargetAllocationPercentage", "presentation": [ "http://www.jnj.com/role/PensionsandotherbenefitplansCompanyRetirementPlanAssetAllocationandTargetAllocationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Target Allocation", "label": "Defined Benefit Plan, Plan Assets, Target Allocation, Percentage", "documentation": "Percentage of target investment allocation to total plan assets. Includes, but is not limited to, percentage on weighted-average basis if more than one plan." } } }, "auth_ref": [ "r647", "r1189" ] }, "us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1", "crdr": "credit", "calculation": { "http://www.jnj.com/role/PensionsandotherbenefitplansComponentsofNetPeriodicBenefitCostDetails": { "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://www.jnj.com/role/PensionsandotherbenefitplansComponentsofNetPeriodicBenefitCostDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Curtailments and settlements", "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement and Curtailment", "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit from settlement and curtailment." } } }, "auth_ref": [ "r1505", "r1508", "r1512" ] }, "us-gaap_DefinedBenefitPlanServiceCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanServiceCost", "crdr": "debit", "calculation": { "http://www.jnj.com/role/PensionsandotherbenefitplansComponentsofNetPeriodicBenefitCostDetails": { "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.jnj.com/role/PensionsandotherbenefitplansComponentsofNetPeriodicBenefitCostDetails", "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofNetFundedStatusDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Service cost", "terseLabel": "Service cost", "label": "Defined Benefit Plan, Service Cost", "documentation": "Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan." } } }, "auth_ref": [ "r627", "r660", "r686", "r1189", "r1190" ] }, "us-gaap_DefinedBenefitPlanSettlementsPlanAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanSettlementsPlanAssets", "crdr": "credit", "presentation": [ "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofNetFundedStatusDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Settlements", "label": "Defined Benefit Plan, Plan Assets, Payment for Settlement", "documentation": "Amount of payment, which decreases plan assets of defined benefit plan, for irrevocable action relieving primary responsibility for benefit obligation and eliminating risk for obligation and assets used to effect settlement. Transaction constituting settlement includes, but is not limited to, making lump-sum cash payment to participant in exchange for their rights to receive specified benefits and purchasing nonparticipating annuity contract." } } }, "auth_ref": [ "r645" ] }, "us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanUltimateHealthCareCostTrendRate1", "presentation": [ "http://www.jnj.com/role/PensionsandotherbenefitplansAssumedHealthCareCostTrendRatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Rate to which the cost trend rate is assumed to decline (ultimate trend)", "label": "Defined Benefit Plan, Ultimate Health Care Cost Trend Rate", "documentation": "Ultimate trend rate for health care cost for defined benefit postretirement plan." } } }, "auth_ref": [ "r674" ] }, "us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanWeightedAverageAssetAllocations", "presentation": [ "http://www.jnj.com/role/PensionsandotherbenefitplansCompanyRetirementPlanAssetAllocationandTargetAllocationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percent of Plan Assets", "label": "Defined Benefit Plan, Plan Assets, Actual Allocation, Percentage", "documentation": "Percentage of actual investment allocation to total plan assets. Includes, but is not limited to, percentage on weighted-average basis if more than one plan." } } }, "auth_ref": [ "r1506" ] }, "us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract", "presentation": [ "http://www.jnj.com/role/PensionsandotherbenefitplansRatesUsedtoDevelopActuarialPresentValueofProjectedBenefitObligationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Benefit Obligation", "label": "Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Benefit Obligation [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract", "presentation": [ "http://www.jnj.com/role/PensionsandotherbenefitplansRatesUsedtoDevelopActuarialPresentValueofProjectedBenefitObligationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net Periodic Benefit Cost", "label": "Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Net Periodic Benefit Cost [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate": { "xbrltype": "gYearListItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate", "presentation": [ "http://www.jnj.com/role/PensionsandotherbenefitplansAssumedHealthCareCostTrendRatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Year the rate reaches the ultimate trend rate", "label": "Defined Benefit Plan, Year Health Care Cost Trend Rate Reaches Ultimate Trend Rate", "documentation": "Year ultimate health care cost trend rate is expected to be reached, in YYYY format." } } }, "auth_ref": [ "r674" ] }, "us-gaap_DefinedContributionPlanCostRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedContributionPlanCostRecognized", "crdr": "debit", "presentation": [ "http://www.jnj.com/role/SavingsplanDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Matching contributions", "label": "Defined Contribution Plan, Cost", "documentation": "Amount of cost for defined contribution plan." } } }, "auth_ref": [ "r698" ] }, "us-gaap_DepreciationDepletionAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepreciationDepletionAndAmortization", "crdr": "debit", "calculation": { "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows", "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Depreciation and amortization of property and intangibles", "terseLabel": "Depreciation and Amortization", "label": "Depreciation, Depletion and Amortization", "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets." } } }, "auth_ref": [ "r14", "r407", "r420", "r444", "r1166", "r1167" ] }, "jnj_DepreciationExpenseIncludingAmortizationOfCapitalizedInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "DepreciationExpenseIncludingAmortizationOfCapitalizedInterest", "crdr": "debit", "presentation": [ "http://www.jnj.com/role/PropertyplantandequipmentNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation expense, including the amortization of capitalized interest", "label": "Depreciation Expense Including Amortization Of Capitalized Interest", "documentation": "Depreciation expense including the amortization of capitalized interest." } } }, "auth_ref": [] }, "us-gaap_DerivativeAssetFairValueGrossLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeAssetFairValueGrossLiability", "crdr": "credit", "calculation": { "http://www.jnj.com/role/FairvaluemeasurementsFinancialAssetsandLiabilitiesatFairValueDetails": { "parentTag": "us-gaap_DerivativeAssets", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.jnj.com/role/FairvaluemeasurementsFinancialAssetsandLiabilitiesatFairValueDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Credit Support Agreements (CSA)", "label": "Derivative Asset, Subject to Master Netting Arrangement, Liability Offset", "documentation": "Fair value of liability associated with financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset." } } }, "auth_ref": [ "r27", "r33", "r228", "r229", "r1116", "r1117" ] }, "jnj_DerivativeAssetStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag": { "xbrltype": "stringItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "DerivativeAssetStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag", "presentation": [ "http://www.jnj.com/role/FairvaluemeasurementsFinancialAssetsandLiabilitiesatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Asset, Statement Of Financial Position, Extensible Enumeration, Not Disclosed Flag", "label": "Derivative Asset, Statement Of Financial Position, Extensible Enumeration, Not Disclosed Flag", "documentation": "Derivative Asset, Statement Of Financial Position, Extensible Enumeration, Not Disclosed Flag" } } }, "auth_ref": [] }, "us-gaap_DerivativeAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeAssets", "crdr": "debit", "calculation": { "http://www.jnj.com/role/FairvaluemeasurementsFinancialAssetsandLiabilitiesatFairValueDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.jnj.com/role/FairvaluemeasurementsFinancialAssetsandLiabilitiesatFairValueDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total Net Asset", "label": "Derivative Asset", "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset." } } }, "auth_ref": [ "r337", "r338", "r823", "r824", "r837", "r846", "r1039", "r1040", "r1041", "r1042", "r1043", "r1045", "r1046", "r1047", "r1048", "r1049", "r1064", "r1065", "r1111", "r1114", "r1115", "r1116", "r1118", "r1119", "r1152", "r1206", "r1210", "r1243", "r1575", "r1576", "r1577", "r1647" ] }, "us-gaap_DerivativeContractTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeContractTypeDomain", "presentation": [ "http://www.jnj.com/role/FairvaluemeasurementsFinancialAssetsandLiabilitiesatFairValueDetails", "http://www.jnj.com/role/FairvaluemeasurementsNarrativeDetails", "http://www.jnj.com/role/FairvaluemeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails", "http://www.jnj.com/role/FairvaluemeasurementsScheduleofEffectofNetInvestmentHedgesDetails", "http://www.jnj.com/role/FairvaluemeasurementsSummaryofDerivativeActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Contract [Domain]", "label": "Derivative Contract [Domain]", "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset." } } }, "auth_ref": [ "r1047", "r1049", "r1063", "r1064", "r1065", "r1066", "r1067", "r1068", "r1069", "r1072", "r1073", "r1074", "r1075", "r1086", "r1087", "r1088", "r1089", "r1092", "r1093", "r1094", "r1095", "r1111", "r1112", "r1115", "r1118", "r1241", "r1243", "r1578", "r1579", "r1580", "r1581", "r1582", "r1583", "r1585", "r1586" ] }, "us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeExcludedComponentGainLossRecognizedInEarnings", "crdr": "credit", "presentation": [ "http://www.jnj.com/role/FairvaluemeasurementsSummaryofDerivativeActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing", "label": "Derivative, Excluded Component, Gain (Loss), Recognized in Earnings", "documentation": "Amount of gain (loss) from excluded component of derivative hedge, recognized in earnings. Excludes recognition under systematic and rational method." } } }, "auth_ref": [ "r255", "r1569" ] }, "us-gaap_DerivativeFairValueOfDerivativeAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeFairValueOfDerivativeAsset", "crdr": "debit", "calculation": { "http://www.jnj.com/role/FairvaluemeasurementsFinancialAssetsandLiabilitiesatFairValueDetails": { "parentTag": "us-gaap_DerivativeAssets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.jnj.com/role/FairvaluemeasurementsFinancialAssetsandLiabilitiesatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total Gross Assets", "label": "Derivative Asset, Subject to Master Netting Arrangement, before Offset", "documentation": "Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement." } } }, "auth_ref": [ "r30", "r169", "r228", "r229", "r336", "r1152" ] }, "us-gaap_DerivativeFairValueOfDerivativeLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeFairValueOfDerivativeLiability", "crdr": "credit", "calculation": { "http://www.jnj.com/role/FairvaluemeasurementsFinancialAssetsandLiabilitiesatFairValueDetails": { "parentTag": "us-gaap_DerivativeLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.jnj.com/role/FairvaluemeasurementsFinancialAssetsandLiabilitiesatFairValueDetails", "http://www.jnj.com/role/FairvaluemeasurementsScheduleofDerivativesRecordedinConsolidatedBalanceSheetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Carrying Amount of the Hedged Liability", "verboseLabel": "Total Gross Liabilities", "label": "Derivative Liability, Subject to Master Netting Arrangement, before Offset", "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement." } } }, "auth_ref": [ "r30", "r169", "r228", "r229", "r336", "r1152" ] }, "us-gaap_DerivativeGainLossOnDerivativeNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeGainLossOnDerivativeNet", "crdr": "credit", "presentation": [ "http://www.jnj.com/role/FairvaluemeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gain/(Loss) Recognized In Income on Derivative", "label": "Derivative, Gain (Loss) on Derivative, Net", "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement." } } }, "auth_ref": [ "r1568" ] }, "us-gaap_DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration", "presentation": [ "http://www.jnj.com/role/FairvaluemeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]", "label": "Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]", "documentation": "Indicates line item in statement of income or comprehensive income that includes gain (loss) from derivative." } } }, "auth_ref": [ "r1568" ] }, "us-gaap_DerivativeInstrumentDetailAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentDetailAbstract", "presentation": [ "http://www.jnj.com/role/FairvaluemeasurementsFinancialAssetsandLiabilitiesatFairValueDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Financial assets and liabilities at fair value", "label": "Derivative Instrument Detail [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DerivativeInstrumentRiskAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentRiskAxis", "presentation": [ "http://www.jnj.com/role/FairvaluemeasurementsFinancialAssetsandLiabilitiesatFairValueDetails", "http://www.jnj.com/role/FairvaluemeasurementsNarrativeDetails", "http://www.jnj.com/role/FairvaluemeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails", "http://www.jnj.com/role/FairvaluemeasurementsScheduleofEffectofNetInvestmentHedgesDetails", "http://www.jnj.com/role/FairvaluemeasurementsSummaryofDerivativeActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instrument [Axis]", "label": "Derivative Instrument [Axis]", "documentation": "Information by type of derivative contract." } } }, "auth_ref": [ "r111", "r115", "r117", "r230", "r1047", "r1049", "r1063", "r1064", "r1065", "r1066", "r1067", "r1068", "r1069", "r1072", "r1073", "r1074", "r1075", "r1086", "r1087", "r1088", "r1089", "r1092", "r1093", "r1094", "r1095", "r1111", "r1112", "r1115", "r1118", "r1152", "r1241", "r1243", "r1578", "r1579", "r1580", "r1581", "r1582", "r1583", "r1585", "r1586" ] }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis", "presentation": [ "http://www.jnj.com/role/FairvaluemeasurementsSummaryofDerivativeActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hedging Relationship [Axis]", "label": "Hedging Relationship [Axis]", "documentation": "Information by type of hedging relationship." } } }, "auth_ref": [ "r23", "r111", "r115" ] }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable", "presentation": [ "http://www.jnj.com/role/FairvaluemeasurementsScheduleofDerivativesRecordedinConsolidatedBalanceSheetsDetails", "http://www.jnj.com/role/FairvaluemeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails", "http://www.jnj.com/role/FairvaluemeasurementsScheduleofEffectofNetInvestmentHedgesDetails", "http://www.jnj.com/role/FairvaluemeasurementsSummaryofDerivativeActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments, Gain (Loss) [Table]", "label": "Derivative Instruments, Gain (Loss) [Table]", "documentation": "Disclosure of information about the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments." } } }, "auth_ref": [ "r23", "r111", "r115", "r117", "r122", "r123", "r808" ] }, "us-gaap_DerivativeInstrumentsGainLossLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentsGainLossLineItems", "presentation": [ "http://www.jnj.com/role/FairvaluemeasurementsScheduleofDerivativesRecordedinConsolidatedBalanceSheetsDetails", "http://www.jnj.com/role/FairvaluemeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails", "http://www.jnj.com/role/FairvaluemeasurementsScheduleofEffectofNetInvestmentHedgesDetails", "http://www.jnj.com/role/FairvaluemeasurementsSummaryofDerivativeActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments, Gain (Loss) [Line Items]", "label": "Derivative Instruments, Gain (Loss) [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r808" ] }, "us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred", "crdr": "credit", "presentation": [ "http://www.jnj.com/role/FairvaluemeasurementsScheduleofEffectofNetInvestmentHedgesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gain/(Loss) Reclassified from Accumulated OCI Into Income", "label": "Derivative Instruments, Gain (Loss) Reclassification from Accumulated OCI to Income, Estimated Net Amount to be Transferred", "documentation": "The estimated value of gains (losses), net anticipated to be transferred in the future from accumulated other comprehensive income into earnings." } } }, "auth_ref": [ "r817" ] }, "us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentsInHedgesAssetsAtFairValue", "crdr": "debit", "presentation": [ "http://www.jnj.com/role/FairvaluemeasurementsFinancialAssetsandLiabilitiesatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivatives designated as hedging instruments : Assets", "label": "Derivative Instruments in Hedges, Assets, at Fair Value", "documentation": "Aggregate fair value of all derivative assets designated as hedging instruments. Includes instruments designated as cash flow hedges, fair value hedges, and hedges of net investments in foreign operations." } } }, "auth_ref": [] }, "us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentsInHedgesLiabilitiesAtFairValue", "crdr": "credit", "presentation": [ "http://www.jnj.com/role/FairvaluemeasurementsFinancialAssetsandLiabilitiesatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivatives designated as hedging instruments : Liabilities", "label": "Derivative Instruments in Hedges, Liabilities, at Fair Value", "documentation": "Aggregate fair value of all derivative liabilities designated as hedging instruments. Includes instruments designated as cash flow hedges, fair value hedges, and hedges of net investments in foreign operations." } } }, "auth_ref": [] }, "us-gaap_DerivativeLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeLiabilities", "crdr": "credit", "calculation": { "http://www.jnj.com/role/FairvaluemeasurementsFinancialAssetsandLiabilitiesatFairValueDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.jnj.com/role/FairvaluemeasurementsFinancialAssetsandLiabilitiesatFairValueDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total Net Liabilities", "label": "Derivative Liability", "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset." } } }, "auth_ref": [ "r337", "r338", "r823", "r824", "r837", "r846", "r1039", "r1040", "r1041", "r1042", "r1045", "r1046", "r1047", "r1048", "r1049", "r1072", "r1074", "r1075", "r1112", "r1113", "r1114", "r1115", "r1116", "r1118", "r1119", "r1152", "r1575", "r1576", "r1577", "r1647" ] }, "us-gaap_DerivativeLiabilityFairValueGrossAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeLiabilityFairValueGrossAsset", "crdr": "debit", "calculation": { "http://www.jnj.com/role/FairvaluemeasurementsFinancialAssetsandLiabilitiesatFairValueDetails": { "parentTag": "us-gaap_DerivativeLiabilities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.jnj.com/role/FairvaluemeasurementsFinancialAssetsandLiabilitiesatFairValueDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Credit Support Agreements (CSA)", "label": "Derivative Liability, Subject to Master Netting Arrangement, Asset Offset", "documentation": "Fair value of asset associated with financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset." } } }, "auth_ref": [ "r27", "r33", "r228", "r229", "r1116", "r1117", "r1151" ] }, "jnj_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag": { "xbrltype": "stringItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag", "presentation": [ "http://www.jnj.com/role/FairvaluemeasurementsFinancialAssetsandLiabilitiesatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Liability, Statement Of Financial Position, Extensible Enumeration, Not Disclosed Flag", "label": "Derivative Liability, Statement Of Financial Position, Extensible Enumeration, Not Disclosed Flag", "documentation": "Derivative Liability, Statement Of Financial Position, Extensible Enumeration, Not Disclosed Flag" } } }, "auth_ref": [] }, "us-gaap_DerivativeLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeLineItems", "presentation": [ "http://www.jnj.com/role/FairvaluemeasurementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative [Line Items]", "label": "Derivative [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r818" ] }, "us-gaap_DerivativeNotionalAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeNotionalAmount", "presentation": [ "http://www.jnj.com/role/FairvaluemeasurementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative, notional amount", "label": "Derivative, Notional Amount", "documentation": "Nominal or face amount used to calculate payment on derivative." } } }, "auth_ref": [ "r1566", "r1567" ] }, "us-gaap_DerivativeTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeTable", "presentation": [ "http://www.jnj.com/role/FairvaluemeasurementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative [Table]", "label": "Derivative [Table]", "documentation": "Disclosure of information about derivative instrument or group of derivative instruments, including, but not limited to, type of derivative instrument, risk being hedged, notional amount, hedge designation, related hedged item, inception date, and maturity date." } } }, "auth_ref": [ "r23", "r104", "r105", "r106", "r109", "r112", "r115", "r119", "r121", "r123", "r818" ] }, "us-gaap_DerivativesFairValueLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativesFairValueLineItems", "presentation": [ "http://www.jnj.com/role/FairvaluemeasurementsFinancialAssetsandLiabilitiesatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivatives, Fair Value [Line Items]", "label": "Derivatives, Fair Value [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_DerivativesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativesPolicyTextBlock", "presentation": [ "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Financial instruments", "label": "Derivatives, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities." } } }, "auth_ref": [ "r23", "r104", "r105", "r109", "r120", "r373", "r388" ] }, "us-gaap_DescriptionOfReclassificationOfCashFlowHedgeGainLoss": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DescriptionOfReclassificationOfCashFlowHedgeGainLoss", "presentation": [ "http://www.jnj.com/role/FairvaluemeasurementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Description of reclassification of cash flow hedge gain (loss)", "label": "Description of Reclassification of Cash Flow Hedge Gain (Loss)", "documentation": "Description of the transactions or other events that will result in the reclassification into earnings of gains or losses reported in accumulated other comprehensive income. May include the time period over which gains or losses will be reclassified to earnings." } } }, "auth_ref": [ "r124" ] }, "us-gaap_DesignatedAsHedgingInstrumentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DesignatedAsHedgingInstrumentMember", "presentation": [ "http://www.jnj.com/role/FairvaluemeasurementsScheduleofDerivativesRecordedinConsolidatedBalanceSheetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Designated as Hedging Instrument", "label": "Designated as Hedging Instrument [Member]", "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP)." } } }, "auth_ref": [ "r23" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": [ "http://www.jnj.com/role/Commonstockstockoptionplansandstockcompensationagreements" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, stock option plans and stock compensation agreements", "label": "Share-Based Payment Arrangement [Text Block]", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": [ "r704", "r709", "r737", "r738", "r740", "r1198" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Disclosure of Compensation Related Costs, Share-based Payments [Abstract]", "label": "Share-Based Payment Arrangement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax", "crdr": "credit", "calculation": { "http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsNetEarningsfromDiscontinuedOperationDetails": { "parentTag": "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax", "weight": 1.0, "order": 7.0 }, "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 14.0 } }, "presentation": [ "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows", "http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsNetEarningsfromDiscontinuedOperationDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "(Gain) on separation of Kenvue", "label": "Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of Tax", "documentation": "Amount after tax of gain (loss) not previously recognized resulting from the disposal of a discontinued operation." } } }, "auth_ref": [ "r130", "r132", "r134", "r145" ] }, "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax", "crdr": "credit", "calculation": { "http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsNetEarningsfromDiscontinuedOperationDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsNetEarningsfromDiscontinuedOperationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Earnings from Discontinued Operations Before Provision for Taxes on Income", "label": "Discontinued Operation, Income (Loss) from Discontinued Operation, before Income Tax", "documentation": "Amount before tax of income (loss) from a discontinued operation. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal." } } }, "auth_ref": [ "r130", "r131", "r132", "r133", "r134", "r140", "r178", "r1611" ] }, "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare", "calculation": { "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": { "parentTag": "us-gaap_EarningsPerShareBasic", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.jnj.com/role/ConsolidatedStatementsofEarnings", "http://www.jnj.com/role/EarningspershareReconciliationofBasicNetEarningsperSharetoDilutedNetEarningsperShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Basic net earnings per share from discontinued operations (in dollars per share)", "label": "Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Basic Share", "documentation": "Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation." } } }, "auth_ref": [] }, "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare", "calculation": { "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": { "parentTag": "us-gaap_EarningsPerShareDiluted", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.jnj.com/role/ConsolidatedStatementsofEarnings", "http://www.jnj.com/role/EarningspershareReconciliationofBasicNetEarningsperSharetoDilutedNetEarningsperShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Diluted net earnings per share from discontinuing operations (in dollars per share)", "label": "Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Diluted Share", "documentation": "Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation." } } }, "auth_ref": [] }, "jnj_DiscontinuedOperationIncrementalTaxCost": { "xbrltype": "monetaryItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "DiscontinuedOperationIncrementalTaxCost", "crdr": "debit", "presentation": [ "http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsDetailsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Incremental tax cost", "label": "Discontinued Operation, Incremental Tax Cost", "documentation": "Discontinued Operation, Incremental Tax Cost" } } }, "auth_ref": [] }, "us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DiscontinuedOperationTaxEffectOfDiscontinuedOperation", "crdr": "debit", "presentation": [ "http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsNetEarningsfromDiscontinuedOperationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Provision for taxes on income", "label": "Discontinued Operation, Tax Effect of Discontinued Operation", "documentation": "Amount of tax expense (benefit) related to a discontinued operation. Includes, but is not limited to, tax expense (benefit) related to income (loss) from operations during the phase-out period, tax expense (benefit) related to gain (loss) on disposal, tax expense (benefit) related to gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and tax expense (benefit) related to adjustments of a prior period gain (loss) on disposal." } } }, "auth_ref": [ "r131", "r132", "r133", "r134", "r140", "r145", "r752", "r782", "r784" ] }, "jnj_DiscontinuedOperationTransitionManufacturingAgreementTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "DiscontinuedOperationTransitionManufacturingAgreementTerm", "presentation": [ "http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsDetailsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Transition manufacturing agreement, term", "label": "Discontinued Operation, Transition Manufacturing Agreement, Term", "documentation": "Discontinued Operation, Transition Manufacturing Agreement, Term" } } }, "auth_ref": [] }, "us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DiscontinuedOperationsAndDisposalGroupsAbstract", "lang": { "en-us": { "role": { "label": "Discontinued Operations and Disposal Groups [Abstract]" } } }, "auth_ref": [] }, "jnj_DiscontinuedOperationsSeparationCostsIncurred": { "xbrltype": "monetaryItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "DiscontinuedOperationsSeparationCostsIncurred", "crdr": "debit", "presentation": [ "http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsDetailsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Separation costs incurred", "label": "Discontinued Operations, Separation Costs Incurred", "documentation": "Discontinued Operations, Separation Costs Incurred" } } }, "auth_ref": [] }, "jnj_DiscontinuedOperationsTransitionServiceAgreementTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "DiscontinuedOperationsTransitionServiceAgreementTerm", "presentation": [ "http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsDetailsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Transition service agreement, term", "label": "Discontinued Operations, Transition Service Agreement, Term", "documentation": "Discontinued Operations, Transition Service Agreement, Term" } } }, "auth_ref": [] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold", "crdr": "debit", "calculation": { "http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsNetEarningsfromDiscontinuedOperationDetails": { "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsNetEarningsfromDiscontinuedOperationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cost of products sold", "label": "Disposal Group, Including Discontinued Operation, Costs of Goods Sold", "documentation": "Amount of costs of goods sold attributable to disposal group, including, but not limited to, discontinued operation." } } }, "auth_ref": [ "r141", "r313" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization", "crdr": "debit", "presentation": [ "http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsDepreciationandAmortizationofDiscontinuedOperationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation and Amortization", "label": "Disposal Group, Including Discontinued Operation, Depreciation and Amortization", "documentation": "Amount of depreciation and amortization expense attributable to disposal group, including, but not limited to, discontinued operation." } } }, "auth_ref": [ "r141" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsNetEarningsfromDiscontinuedOperationDetails": { "parentTag": "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsNetEarningsfromDiscontinuedOperationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Selling, marketing and administrative expenses", "label": "Disposal Group, Including Discontinued Operation, General and Administrative Expense", "documentation": "Amount of general and administrative expense attributable to disposal group, including, but not limited to, discontinued operation." } } }, "auth_ref": [ "r141" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss", "crdr": "credit", "calculation": { "http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsNetEarningsfromDiscontinuedOperationDetails": { "parentTag": "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsNetEarningsfromDiscontinuedOperationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Gross profit", "label": "Disposal Group, Including Discontinued Operation, Gross Profit (Loss)", "documentation": "Amount of gross profit attributable to disposal group, including, but not limited to, discontinued operation." } } }, "auth_ref": [ "r141", "r313" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationInterestExpense", "crdr": "debit", "calculation": { "http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsNetEarningsfromDiscontinuedOperationDetails": { "parentTag": "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsNetEarningsfromDiscontinuedOperationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest expense, net of portion capitalized", "label": "Disposal Group, Including Discontinued Operation, Interest Expense", "documentation": "Amount of interest expense attributable to disposal group, including, but not limited to, discontinued operation." } } }, "auth_ref": [ "r35", "r36", "r38", "r141" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationInterestIncome", "crdr": "credit", "calculation": { "http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsNetEarningsfromDiscontinuedOperationDetails": { "parentTag": "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsNetEarningsfromDiscontinuedOperationDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Interest Income", "label": "Disposal Group, Including Discontinued Operation, Interest Income", "documentation": "Amount of interest income attributable to disposal group, including, but not limited to, discontinued operation." } } }, "auth_ref": [ "r141" ] }, "jnj_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet", "crdr": "credit", "calculation": { "http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsNetEarningsfromDiscontinuedOperationDetails": { "parentTag": "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsNetEarningsfromDiscontinuedOperationDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other (income) expense, net", "label": "Disposal Group, Including Discontinued Operation, Other Income (Expense), Net", "documentation": "Disposal Group, Including Discontinued Operation, Other Income (Expense), Net" } } }, "auth_ref": [] }, "jnj_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsNetEarningsfromDiscontinuedOperationDetails": { "parentTag": "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsNetEarningsfromDiscontinuedOperationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research and development expense", "label": "Disposal Group, Including Discontinued Operation, Research and Development Expense", "documentation": "Disposal Group, Including Discontinued Operation, Research and Development Expense" } } }, "auth_ref": [] }, "jnj_DisposalGroupIncludingDiscontinuedOperationRestructuringExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "DisposalGroupIncludingDiscontinuedOperationRestructuringExpense", "crdr": "debit", "calculation": { "http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsNetEarningsfromDiscontinuedOperationDetails": { "parentTag": "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsNetEarningsfromDiscontinuedOperationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring", "label": "Disposal Group, Including Discontinued Operation, Restructuring Expense", "documentation": "Disposal Group, Including Discontinued Operation, Restructuring Expense" } } }, "auth_ref": [] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationRevenue", "crdr": "credit", "calculation": { "http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsNetEarningsfromDiscontinuedOperationDetails": { "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsNetEarningsfromDiscontinuedOperationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sales to customers", "label": "Disposal Group, Including Discontinued Operation, Revenue", "documentation": "Amount of revenue attributable to disposal group, including, but not limited to, discontinued operation." } } }, "auth_ref": [ "r141", "r313" ] }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "presentation": [ "http://www.jnj.com/role/Kenvueseparationanddiscontinuedoperations" ], "lang": { "en-us": { "role": { "terseLabel": "Kenvue separation and discontinued operations", "label": "Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]", "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component." } } }, "auth_ref": [ "r128", "r199" ] }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain", "presentation": [ "http://www.jnj.com/role/AcquisitionsanddivestituresNarrativeDetails", "http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsDetailsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group Name [Domain]", "label": "Disposal Group Name [Domain]", "documentation": "Name of disposal group." } } }, "auth_ref": [ "r1191", "r1194" ] }, "us-gaap_DividendsCommonStockCash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DividendsCommonStockCash", "crdr": "debit", "presentation": [ "http://www.jnj.com/role/ConsolidatedStatementsofEquity" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Cash dividends paid", "label": "Dividends, Common Stock, Cash", "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash." } } }, "auth_ref": [ "r212" ] }, "us-gaap_DividendsPayableAmountPerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DividendsPayableAmountPerShare", "presentation": [ "http://www.jnj.com/role/AcquisitionsanddivestituresNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Dividends payable, amount per share (in dollars per share)", "label": "Dividends Payable, Amount Per Share", "documentation": "The per share amount of a dividend declared, but not paid, as of the financial reporting date." } } }, "auth_ref": [ "r49" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAnnualReport", "presentation": [ "http://www.jnj.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Annual Report", "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r1265", "r1266", "r1289" ] }, "dei_DocumentFinStmtErrorCorrectionFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFinStmtErrorCorrectionFlag", "presentation": [ "http://www.jnj.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Financial Statement Error Correction", "label": "Document Financial Statement Error Correction [Flag]", "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction." } } }, "auth_ref": [ "r1265", "r1266", "r1289", "r1332" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://www.jnj.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://www.jnj.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationLineItems", "presentation": [ "http://www.jnj.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Information [Line Items]", "label": "Document Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_DocumentInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationTable", "presentation": [ "http://www.jnj.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Information [Table]", "label": "Document Information [Table]", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.jnj.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": [ "http://www.jnj.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Transition Report", "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r1310" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [ "http://www.jnj.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://www.jnj.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Documents Incorporated by Reference", "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r1263" ] }, "us-gaap_DomesticPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DomesticPlanMember", "presentation": [ "http://www.jnj.com/role/PensionsandotherbenefitplansInformationRelatedtotheBenefitObligationandtheFairValueofPlanAssetsDetails", "http://www.jnj.com/role/PensionsandotherbenefitplansNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Domestic Plan", "label": "Domestic Plan [Member]", "documentation": "Location of employer sponsoring plan, designed to provide retirement benefits, determined as principal place of business. Includes, but is not limited to, defined benefit and defined contribution plans." } } }, "auth_ref": [ "r1514", "r1515", "r1516" ] }, "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year", "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]" } } }, "auth_ref": [ "r1321" ] }, "jnj_EDURANTrilpivirineMember": { "xbrltype": "domainItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "EDURANTrilpivirineMember", "presentation": [ "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "EDURANT/rilpivirine", "label": "EDURANT/rilpivirine [Member]", "documentation": "EDURANT/rilpivirine [Member]" } } }, "auth_ref": [] }, "jnj_ELECTROPHYSIOLOGYMember": { "xbrltype": "domainItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "ELECTROPHYSIOLOGYMember", "presentation": [ "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "ELECTROPHYSIOLOGY", "label": "ELECTROPHYSIOLOGY [Member]", "documentation": "ELECTROPHYSIOLOGY" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareAbstract", "presentation": [ "http://www.jnj.com/role/ConsolidatedStatementsofEarnings" ], "lang": { "en-us": { "role": { "verboseLabel": "Net earnings per share", "terseLabel": "Earnings Per Share [Abstract]", "label": "Earnings Per Share [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "calculation": { "http://www.jnj.com/role/EarningspershareReconciliationofBasicNetEarningsperSharetoDilutedNetEarningsperShareDetails": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 2.0 }, "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.jnj.com/role/ConsolidatedStatementsofEarnings", "http://www.jnj.com/role/EarningspershareReconciliationofBasicNetEarningsperSharetoDilutedNetEarningsperShareDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Basic (in dollars per share)", "verboseLabel": "Basic net earnings per share (in dollars per share)", "label": "Earnings Per Share, Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r360", "r380", "r381", "r382", "r383", "r384", "r385", "r391", "r393", "r399", "r400", "r401", "r406", "r791", "r799", "r820", "r821", "r955", "r981", "r1158" ] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "calculation": { "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.jnj.com/role/ConsolidatedStatementsofEarnings", "http://www.jnj.com/role/EarningspershareReconciliationofBasicNetEarningsperSharetoDilutedNetEarningsperShareDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Diluted (in dollars per share)", "terseLabel": "Diluted net earnings per share (in dollars per share)", "label": "Earnings Per Share, Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r360", "r380", "r381", "r382", "r383", "r384", "r385", "r393", "r399", "r400", "r401", "r406", "r791", "r799", "r820", "r821", "r955", "r981", "r1158" ] }, "us-gaap_EarningsPerSharePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerSharePolicyTextBlock", "presentation": [ "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Net earnings per share", "label": "Earnings Per Share, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements." } } }, "auth_ref": [ "r52", "r53", "r403" ] }, "us-gaap_EarningsPerShareReconciliationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareReconciliationAbstract", "presentation": [ "http://www.jnj.com/role/EarningspershareReconciliationofBasicNetEarningsperSharetoDilutedNetEarningsperShareDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Reconciliation of basic net earnings per share to diluted net earnings per share", "label": "Earnings Per Share Reconciliation [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareTextBlock", "presentation": [ "http://www.jnj.com/role/Earningspershare" ], "lang": { "en-us": { "role": { "verboseLabel": "Earnings per share", "label": "Earnings Per Share [Text Block]", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r390", "r402", "r404", "r405" ] }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "calculation": { "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Effect of exchange rate changes on cash and cash equivalents", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations", "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r856" ] }, "jnj_EffectOfExchangeRates": { "xbrltype": "monetaryItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "EffectOfExchangeRates", "crdr": "debit", "presentation": [ "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofNetFundedStatusDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Effect of exchange rates", "label": "Effect Of Exchange Rates", "documentation": "Effect Of Exchange Rates." } } }, "auth_ref": [] }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateContinuingOperations", "calculation": { "http://www.jnj.com/role/IncometaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.jnj.com/role/IncometaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Effective Rate", "label": "Effective Income Tax Rate Reconciliation, Percent", "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r754", "r1203" ] }, "us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract", "presentation": [ "http://www.jnj.com/role/IncometaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tax rates:", "label": "Effective Income Tax Rate Reconciliation, Percent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "calculation": { "http://www.jnj.com/role/IncometaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.jnj.com/role/IncometaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails", "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "U.S. statutory rate", "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent", "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)." } } }, "auth_ref": [ "r372", "r754", "r780", "r1203" ] }, "jnj_EffectiveIncomeTaxRateReconciliationConsumerHealthSeparation": { "xbrltype": "percentItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "EffectiveIncomeTaxRateReconciliationConsumerHealthSeparation", "calculation": { "http://www.jnj.com/role/IncometaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.jnj.com/role/IncometaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "U.S. tax settlements", "label": "Effective Income Tax Rate Reconciliation, Consumer Health Separation", "documentation": "Effective Income Tax Rate Reconciliation, Consumer Health Separation" } } }, "auth_ref": [] }, "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential", "calculation": { "http://www.jnj.com/role/IncometaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.jnj.com/role/IncometaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "International operations", "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile." } } }, "auth_ref": [ "r755", "r758", "r1203", "r1422", "r1544" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationGiltiAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateReconciliationGiltiAmount", "crdr": "debit", "presentation": [ "http://www.jnj.com/role/IncometaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Effective income tax rate reconciliation, GILTI, amount", "label": "Effective Income Tax Rate Reconciliation, GILTI, Amount", "documentation": "Amount of reported income tax expense from difference to expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations, attributable to global intangible low-taxed income (GILTI)." } } }, "auth_ref": [ "r1203", "r1544", "r1546" ] }, "jnj_EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent": { "xbrltype": "percentItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent", "presentation": [ "http://www.jnj.com/role/IncometaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Effective income tax rate reconciliation, increase (decrease), percent", "label": "Effective Income Tax Rate Reconciliation, Increase (Decrease), Percent", "documentation": "Effective Income Tax Rate Reconciliation, Increase (Decrease), Percent" } } }, "auth_ref": [] }, "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost", "calculation": { "http://www.jnj.com/role/IncometaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.jnj.com/role/IncometaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tax benefits on share-based compensation", "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent", "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement." } } }, "auth_ref": [ "r1203", "r1422", "r1544", "r1546" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments", "calculation": { "http://www.jnj.com/role/IncometaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.jnj.com/role/IncometaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "All other", "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments." } } }, "auth_ref": [ "r1203", "r1422", "r1544", "r1545" ] }, "jnj_EffectiveIncomeTaxRateReconciliationRelatedToDomesticTaxOnInternationalIncome": { "xbrltype": "percentItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "EffectiveIncomeTaxRateReconciliationRelatedToDomesticTaxOnInternationalIncome", "calculation": { "http://www.jnj.com/role/IncometaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.jnj.com/role/IncometaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "U.S. taxes on international income", "label": "Effective Income Tax Rate Reconciliation Related To Domestic Tax On International Income", "documentation": "Effective income tax rate reconciliation related to domestic tax on international income." } } }, "auth_ref": [] }, "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes", "calculation": { "http://www.jnj.com/role/IncometaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.jnj.com/role/IncometaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "U.S. state taxes", "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)." } } }, "auth_ref": [ "r757", "r1203", "r1422", "r1544" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsForeign", "presentation": [ "http://www.jnj.com/role/IncometaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Decrease in foreign tax credits, percent", "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Foreign, Percent", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign tax credit." } } }, "auth_ref": [ "r1422", "r1544", "r1546" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateReconciliationTaxSettlements", "presentation": [ "http://www.jnj.com/role/IncometaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Effective income tax rate reconciliation, tax settlement, percent", "label": "Effective Income Tax Rate Reconciliation, Tax Settlement, Percent", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income tax settlements. Including, but not limited to, domestic tax settlement, foreign tax settlement, state and local tax settlement, and other tax settlements." } } }, "auth_ref": [ "r1422", "r1544", "r1545" ] }, "jnj_EffectiveTaxRateReconciliationNetIncreaseDecreaseInTaxRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "EffectiveTaxRateReconciliationNetIncreaseDecreaseInTaxRatePercent", "presentation": [ "http://www.jnj.com/role/IncometaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Effective tax rate reconciliation, net increase (decrease) in tax rate, percent", "label": "Effective Tax Rate Reconciliation, Net Increase (Decrease) In Tax Rate, Percent", "documentation": "Effective Tax Rate Reconciliation, Net Increase (Decrease) In Tax Rate, Percent" } } }, "auth_ref": [] }, "jnj_ElmironMember": { "xbrltype": "domainItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "ElmironMember", "presentation": [ "http://www.jnj.com/role/LegalproceedingsProductLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Elmiron", "label": "Elmiron [Member]", "documentation": "Elmiron" } } }, "auth_ref": [] }, "jnj_EmployeeCompensationPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "EmployeeCompensationPeriod", "presentation": [ "http://www.jnj.com/role/PensionsandotherbenefitplansNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Retirement plan benefits employee compensation period", "label": "Employee Compensation Period", "documentation": "Employee Compensation Period." } } }, "auth_ref": [] }, "jnj_EmployeeObligations": { "xbrltype": "monetaryItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "EmployeeObligations", "crdr": "credit", "calculation": { "http://www.jnj.com/role/EmployeerelatedobligationsEmployeeRelatedObligationsDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.jnj.com/role/EmployeerelatedobligationsEmployeeRelatedObligationsDetails_1": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.jnj.com/role/EmployeerelatedobligationsEmployeeRelatedObligationsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total employee obligations", "label": "Employee Obligations", "documentation": "Total employee obligations current and non current." } } }, "auth_ref": [] }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.jnj.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.jnj.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "verboseLabel": "Accrued compensation and employee related obligations", "label": "Employee-related Liabilities, Current", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r152" ] }, "us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeRelatedLiabilitiesCurrentAndNoncurrentAbstract", "presentation": [ "http://www.jnj.com/role/EmployeerelatedobligationsEmployeeRelatedObligationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Employee-related Liabilities [Abstract]", "label": "Employee-related Liabilities [Abstract]" } } }, "auth_ref": [] }, "jnj_EmployeeRelatedObligationsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "EmployeeRelatedObligationsTableTextBlock", "presentation": [ "http://www.jnj.com/role/EmployeerelatedobligationsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Employee Related Obligations", "label": "Employee Related Obligations [Table Text Block]", "documentation": "Employee related obligations." } } }, "auth_ref": [] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "crdr": "debit", "presentation": [ "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total compensation cost not yet recognized for option", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement." } } }, "auth_ref": [ "r739" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": [ "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average period for total compensation cost not yet recognized", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r739" ] }, "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense", "crdr": "credit", "presentation": [ "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total income tax benefit recognized", "label": "Share-Based Payment Arrangement, Expense, Tax Benefit", "documentation": "Amount of tax benefit for recognition of expense of award under share-based payment arrangement." } } }, "auth_ref": [ "r736" ] }, "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions", "crdr": "credit", "presentation": [ "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise of options, tax benefit", "label": "Share-Based Payment Arrangement, Exercise of Option, Tax Benefit", "documentation": "Amount of tax benefit from exercise of option under share-based payment arrangement." } } }, "auth_ref": [ "r264" ] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOptionMember", "presentation": [ "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsNarrativeDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Employee Stock Option", "label": "Share-Based Payment Arrangement, Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.jnj.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.jnj.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.jnj.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.jnj.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.jnj.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1262" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://www.jnj.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Common Stock, Shares Outstanding", "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://www.jnj.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Current Reporting Status", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityDomain", "presentation": [ "http://www.jnj.com/role/FairvaluemeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails", "http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsDetailsDetails", "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Entity [Domain]", "label": "Entity [Domain]", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.jnj.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1262" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [ "http://www.jnj.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": [ "http://www.jnj.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r1262" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.jnj.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://www.jnj.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Interactive Data Current", "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r1372" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://www.jnj.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Public Float", "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [ "http://www.jnj.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1262" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": [ "http://www.jnj.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r1262" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": [ "http://www.jnj.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Small Business", "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r1262" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.jnj.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1262" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityVoluntaryFilers", "presentation": [ "http://www.jnj.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Voluntary Filers", "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://www.jnj.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Well-known Seasoned Issuer", "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r1373" ] }, "ecd_EqtyAwrdsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Adjustments, Footnote", "label": "Equity Awards Adjustments, Footnote [Text Block]" } } }, "auth_ref": [ "r1315" ] }, "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table", "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]" } } }, "auth_ref": [ "r1368" ] }, "ecd_EqtyAwrdsAdjsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Adjustments", "label": "Equity Awards Adjustments [Member]" } } }, "auth_ref": [ "r1368" ] }, "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table", "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]" } } }, "auth_ref": [ "r1368" ] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "terseLabel": "Equity [Abstract]", "label": "Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EquityClassOfTreasuryStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityClassOfTreasuryStockLineItems", "presentation": [ "http://www.jnj.com/role/CapitalandtreasurystockChangesinTreasuryStockDetails", "http://www.jnj.com/role/CapitalandtreasurystockNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity, Class of Treasury Stock [Line Items]", "label": "Equity, Class of Treasury Stock [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": [ "http://www.jnj.com/role/AccumulatedothercomprehensiveincomelossDetails", "http://www.jnj.com/role/CapitalandtreasurystockChangesinTreasuryStockDetails", "http://www.jnj.com/role/ConsolidatedStatementsofEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Component [Domain]", "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r22", "r309", "r355", "r356", "r357", "r375", "r376", "r377", "r379", "r384", "r386", "r388", "r408", "r491", "r492", "r536", "r617", "r778", "r779", "r788", "r789", "r790", "r792", "r798", "r799", "r811", "r812", "r813", "r814", "r815", "r816", "r819", "r858", "r860", "r861", "r862", "r863", "r865", "r871", "r873", "r882", "r978", "r1007", "r1008", "r1009", "r1027", "r1099" ] }, "us-gaap_EquityFairValueAdjustment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityFairValueAdjustment", "crdr": "credit", "presentation": [ "http://www.jnj.com/role/FairvaluemeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity, fair value adjustment", "label": "Equity, Fair Value Adjustment", "documentation": "Amount of addition (reduction) to the amount at which an instrument classified in shareholders' equity could be incurred (settled) in a current transaction between willing parties." } } }, "auth_ref": [] }, "jnj_EquityFairValueAdjustmentChangeinObservablePrices": { "xbrltype": "monetaryItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "EquityFairValueAdjustmentChangeinObservablePrices", "crdr": "credit", "presentation": [ "http://www.jnj.com/role/FairvaluemeasurementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity, fair value adjustment, change in observable prices", "label": "Equity, Fair Value Adjustment, Change in Observable Prices", "documentation": "Equity, Fair Value Adjustment, Change in Observable Prices" } } }, "auth_ref": [] }, "jnj_EquityFairValueAdjustmentImpairmentLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "EquityFairValueAdjustmentImpairmentLoss", "crdr": "debit", "presentation": [ "http://www.jnj.com/role/FairvaluemeasurementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity, fair value adjustment, impairment loss", "label": "Equity, Fair Value Adjustment, Impairment Loss", "documentation": "Equity, Fair Value Adjustment, Impairment Loss" } } }, "auth_ref": [] }, "jnj_EquityInvestmentRollForward": { "xbrltype": "stringItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "EquityInvestmentRollForward", "presentation": [ "http://www.jnj.com/role/FairvaluemeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Investment [Roll Forward]", "label": "Equity Investment [Roll Forward]", "documentation": "Equity Investment [Roll Forward]" } } }, "auth_ref": [] }, "jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod": { "xbrltype": "monetaryItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod", "crdr": "debit", "presentation": [ "http://www.jnj.com/role/FairvaluemeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity investments, increase (decrease) from acquisition (sale) during period", "label": "Equity Investments, Increase (Decrease) from Acquisition (Sale) During Period", "documentation": "Equity Investments, Increase (Decrease) from Acquisition (Sale) During Period" } } }, "auth_ref": [] }, "jnj_EquityInvestmentswithReadilyDeterminableValueMember": { "xbrltype": "domainItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "EquityInvestmentswithReadilyDeterminableValueMember", "presentation": [ "http://www.jnj.com/role/FairvaluemeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Investments with readily determinable value", "label": "Equity Investments with Readily Determinable Value [Member]", "documentation": "Equity Investments with Readily Determinable Value [Member]" } } }, "auth_ref": [] }, "jnj_EquityInvestmentswithoutReadilyDeterminableValueMember": { "xbrltype": "domainItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "EquityInvestmentswithoutReadilyDeterminableValueMember", "presentation": [ "http://www.jnj.com/role/FairvaluemeasurementsNarrativeDetails", "http://www.jnj.com/role/FairvaluemeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Investments without readily determinable value", "label": "Equity Investments without Readily Determinable Value [Member]", "documentation": "Equity Investments without Readily Determinable Value [Member]" } } }, "auth_ref": [] }, "srt_EquityMethodInvesteeNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "EquityMethodInvesteeNameDomain", "presentation": [ "http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsDetailsDetails", "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Investment, Name [Domain]", "label": "Investment, Name [Domain]", "documentation": "Name of investment including named security. Excludes entity that is consolidated." } } }, "auth_ref": [ "r487", "r488", "r489", "r787", "r1376", "r1377", "r1378", "r1558", "r1559", "r1560", "r1561" ] }, "us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityMethodInvestmentRealizedGainLossOnDisposal", "crdr": "credit", "presentation": [ "http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsDetailsDetails", "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Realized gain (loss) on investment", "label": "Equity Method Investment, Realized Gain (Loss) on Disposal", "documentation": "Amount of gain (loss) on sale or disposal of an equity method investment." } } }, "auth_ref": [ "r1410", "r1411", "r1415" ] }, "us-gaap_EquitySecuritiesFvNi": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquitySecuritiesFvNi", "crdr": "debit", "presentation": [ "http://www.jnj.com/role/FairvaluemeasurementsFinancialAssetsandLiabilitiesatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity investments", "label": "Equity Securities, FV-NI, Current", "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current." } } }, "auth_ref": [ "r324", "r845", "r1148" ] }, "us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquitySecuritiesFvNiCurrentAndNoncurrent", "crdr": "debit", "presentation": [ "http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsDetailsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity securities, fair market value", "label": "Equity Securities, FV-NI", "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)." } } }, "auth_ref": [ "r324", "r823", "r845", "r962", "r963", "r1206", "r1237", "r1240", "r1575", "r1576", "r1577" ] }, "us-gaap_EquitySecuritiesFvNiGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquitySecuritiesFvNiGainLoss", "crdr": "credit", "presentation": [ "http://www.jnj.com/role/FairvaluemeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails", "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingByGeographicAreaDetails", "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Equity securities, FV-NI, gain (loss)", "terseLabel": "Equity securities, FV-NI, gain (loss)", "label": "Equity Securities, FV-NI, Gain (Loss)", "documentation": "Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)." } } }, "auth_ref": [ "r983", "r1456" ] }, "us-gaap_EquitySecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquitySecuritiesMember", "presentation": [ "http://www.jnj.com/role/FairvaluemeasurementsNarrativeDetails", "http://www.jnj.com/role/FairvaluemeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails", "http://www.jnj.com/role/PensionsandotherbenefitplansCompanyRetirementPlanAssetAllocationandTargetAllocationsDetails", "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofDefinedBenefitPlansDisclosuresDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity securities", "label": "Equity Securities [Member]", "documentation": "Ownership interest or right to acquire or dispose of ownership interest in corporations and other legal entities for which ownership interest is represented by shares of common or preferred stock, convertible securities, stock rights, or stock warrants." } } }, "auth_ref": [ "r65", "r1220", "r1251", "r1252", "r1253", "r1650" ] }, "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueAmount", "crdr": "debit", "presentation": [ "http://www.jnj.com/role/FairvaluemeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity securities without readily determinable fair value, amount", "label": "Equity Securities without Readily Determinable Fair Value, Amount", "documentation": "Amount of investment in equity security without readily determinable fair value." } } }, "auth_ref": [ "r486" ] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Valuation Assumption Difference, Footnote", "label": "Equity Valuation Assumption Difference, Footnote [Text Block]" } } }, "auth_ref": [ "r1325" ] }, "jnj_ErleadaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "ErleadaMember", "presentation": [ "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "ERLEADA", "label": "Erleada [Member]", "documentation": "Erleada" } } }, "auth_ref": [] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompAnalysisTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Erroneous Compensation Analysis", "label": "Erroneous Compensation Analysis [Text Block]" } } }, "auth_ref": [ "r1282", "r1293", "r1303", "r1336" ] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompRecoveryTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Erroneously Awarded Compensation Recovery", "label": "Erroneously Awarded Compensation Recovery [Table]" } } }, "auth_ref": [ "r1279", "r1290", "r1300", "r1333" ] }, "jnj_EstimatedUsefulLivesOfAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "EstimatedUsefulLivesOfAssetsTableTextBlock", "presentation": [ "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Estimated Useful Lives of Assets", "label": "Estimated Useful Lives Of Assets [Table Text Block]", "documentation": "Estimated useful lives of the assets." } } }, "auth_ref": [] }, "srt_EuropeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "EuropeMember", "presentation": [ "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingByGeographicAreaDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Europe", "label": "Europe [Member]", "documentation": "Continent of Europe." } } }, "auth_ref": [ "r1396", "r1397", "r1398", "r1399", "r1649", "r1651", "r1652", "r1653" ] }, "jnj_ExcessOfCarryingValueOverFairValueOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "ExcessOfCarryingValueOverFairValueOfDebt", "crdr": "credit", "presentation": [ "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Excess of carrying value over fair value of debt", "label": "Excess Of Carrying Value Over Fair Value Of Debt", "documentation": "Excess Of Carrying Value Over Fair Value Of Debt" } } }, "auth_ref": [] }, "jnj_ExcessOfFairValueOverCarryingValueOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "ExcessOfFairValueOverCarryingValueOfDebt", "crdr": "credit", "presentation": [ "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Excess of fair value over carrying value of debt", "label": "Excess Of Fair Value Over Carrying Value Of Debt", "documentation": "Excess of fair value over carrying value of debt." } } }, "auth_ref": [] }, "jnj_ExchangeOfStockCommonStockValueReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "ExchangeOfStockCommonStockValueReceived", "crdr": "debit", "presentation": [ "http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsDetailsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock received in exchange offer", "label": "Exchange Of Stock, Common Stock, Value, Received", "documentation": "Exchange Of Stock, Common Stock, Value, Received" } } }, "auth_ref": [] }, "jnj_ExchangeOfStockPercentageOwnershipAfterTransaction": { "xbrltype": "percentItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "ExchangeOfStockPercentageOwnershipAfterTransaction", "presentation": [ "http://www.jnj.com/role/FairvaluemeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails", "http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsDetailsDetails", "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage ownership after transaction", "label": "Exchange of Stock, Percentage Ownership After Transaction", "documentation": "Exchange of Stock, Percentage Ownership After Transaction" } } }, "auth_ref": [] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ExecutiveCategoryAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Executive Category:", "label": "Executive Category [Axis]" } } }, "auth_ref": [ "r1331" ] }, "jnj_ExercisePriceRangeFiveMember": { "xbrltype": "domainItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "ExercisePriceRangeFiveMember", "presentation": [ "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsSummaryofOptionsOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "$164.62 - $165.89", "label": "Exercise Price Range Five [Member]", "documentation": "Exercise Price Range." } } }, "auth_ref": [] }, "jnj_ExercisePriceRangeFourMember": { "xbrltype": "domainItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "ExercisePriceRangeFourMember", "presentation": [ "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsSummaryofOptionsOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "$157.92 - $162.75", "label": "Exercise Price Range Four [Member]", "documentation": "Exercise Price Range." } } }, "auth_ref": [] }, "jnj_ExercisePriceRangeOneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "ExercisePriceRangeOneMember", "presentation": [ "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsSummaryofOptionsOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "$100.06 - $101.87", "label": "Exercise Price Range One Member", "documentation": "Exercise price range." } } }, "auth_ref": [] }, "jnj_ExercisePriceRangeThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "ExercisePriceRangeThreeMember", "presentation": [ "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsSummaryofOptionsOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "$131.94 - $151.41", "label": "Exercise Price Range Three [Member]", "documentation": "Exercise Price Range." } } }, "auth_ref": [] }, "jnj_ExercisePriceRangeTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "ExercisePriceRangeTwoMember", "presentation": [ "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsSummaryofOptionsOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "$115.67 - $129.51", "label": "Exercise Price Range Two [Member]", "documentation": "Exercise Price Range." } } }, "auth_ref": [] }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain", "presentation": [ "http://www.jnj.com/role/FairvaluemeasurementsNarrativeDetails", "http://www.jnj.com/role/FairvaluemeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Asset Class [Domain]", "label": "Asset Class [Domain]", "documentation": "Class of asset." } } }, "auth_ref": [ "r828", "r829", "r830", "r831", "r832", "r833", "r838", "r1208" ] }, "us-gaap_FairValueByAssetClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByAssetClassAxis", "presentation": [ "http://www.jnj.com/role/FairvaluemeasurementsNarrativeDetails", "http://www.jnj.com/role/FairvaluemeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Asset Class [Axis]", "label": "Asset Class [Axis]", "documentation": "Information by class of asset." } } }, "auth_ref": [ "r828", "r829", "r830", "r831", "r832", "r833", "r838", "r1208" ] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": [ "http://www.jnj.com/role/FairvaluemeasurementsFinancialAssetsandLiabilitiesatFairValueDetails", "http://www.jnj.com/role/PensionsandotherbenefitplansNarrativeDetails", "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofDefinedBenefitPlansDisclosuresDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]", "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r596", "r650", "r651", "r652", "r653", "r654", "r655", "r822", "r824", "r825", "r826", "r827", "r836", "r837", "r839", "r887", "r888", "r889", "r1179", "r1180", "r1187", "r1188", "r1189", "r1206", "r1210" ] }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByMeasurementFrequencyAxis", "presentation": [ "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofDefinedBenefitPlansDisclosuresDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Frequency [Axis]", "label": "Measurement Frequency [Axis]", "documentation": "Information by measurement frequency." } } }, "auth_ref": [ "r823", "r824", "r825", "r827", "r1206", "r1576", "r1587" ] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "terseLabel": "Fair Value Disclosures [Abstract]", "label": "Fair Value Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresTextBlock", "presentation": [ "http://www.jnj.com/role/Fairvaluemeasurements" ], "lang": { "en-us": { "role": { "verboseLabel": "Fair value measurements", "label": "Fair Value Disclosures [Text Block]", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": [ "r832", "r834", "r835", "r836", "r839", "r840", "r841", "r842", "r843", "r950", "r1206", "r1211" ] }, "us-gaap_FairValueHedgingMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueHedgingMember", "presentation": [ "http://www.jnj.com/role/FairvaluemeasurementsSummaryofDerivativeActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hedging", "label": "Fair Value Hedging [Member]", "documentation": "A hedge of the exposure to changes in the fair value of a recognized asset or liability, or of an unrecognized firm commitment, that are attributable to a particular risk." } } }, "auth_ref": [ "r107" ] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel1Member", "presentation": [ "http://www.jnj.com/role/FairvaluemeasurementsFinancialAssetsandLiabilitiesatFairValueDetails", "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofDefinedBenefitPlansDisclosuresDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Level 1", "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": [ "r596", "r650", "r655", "r824", "r837", "r887", "r1187", "r1188", "r1189", "r1206" ] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel2Member", "presentation": [ "http://www.jnj.com/role/FairvaluemeasurementsFinancialAssetsandLiabilitiesatFairValueDetails", "http://www.jnj.com/role/PensionsandotherbenefitplansNarrativeDetails", "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofDefinedBenefitPlansDisclosuresDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Level 2", "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": [ "r596", "r650", "r655", "r824", "r825", "r837", "r888", "r1179", "r1180", "r1187", "r1188", "r1189", "r1206" ] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel3Member", "presentation": [ "http://www.jnj.com/role/FairvaluemeasurementsFinancialAssetsandLiabilitiesatFairValueDetails", "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofDefinedBenefitPlansDisclosuresDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Level 3", "label": "Fair Value, Inputs, Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r596", "r650", "r651", "r652", "r653", "r654", "r655", "r824", "r825", "r826", "r827", "r837", "r889", "r1179", "r1180", "r1187", "r1188", "r1189", "r1206", "r1210" ] }, "us-gaap_FairValueMeasurementFrequencyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementFrequencyDomain", "presentation": [ "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofDefinedBenefitPlansDisclosuresDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Measurement Frequency [Domain]", "label": "Measurement Frequency [Domain]", "documentation": "Measurement frequency." } } }, "auth_ref": [ "r823", "r824", "r825", "r827", "r1206", "r1576", "r1587" ] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements", "crdr": "debit", "presentation": [ "http://www.jnj.com/role/FairvaluemeasurementsFinancialAssetsandLiabilitiesatFairValueDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Payments/Other", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements", "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r831", "r838" ] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "crdr": "credit", "presentation": [ "http://www.jnj.com/role/FairvaluemeasurementsFinancialAssetsandLiabilitiesatFairValueDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning Balance", "periodEndLabel": "Ending Balance", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value", "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r828", "r838" ] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [ "http://www.jnj.com/role/FairvaluemeasurementsFinancialAssetsandLiabilitiesatFairValueDetails", "http://www.jnj.com/role/PensionsandotherbenefitplansNarrativeDetails", "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofDefinedBenefitPlansDisclosuresDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Fair Value, Measurements, Fair Value Hierarchy [Domain]", "terseLabel": "Fair Value Hierarchy and NAV [Domain]", "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r596", "r650", "r651", "r652", "r653", "r654", "r655", "r822", "r824", "r825", "r826", "r827", "r836", "r837", "r839", "r887", "r888", "r889", "r1179", "r1180", "r1187", "r1188", "r1189", "r1206", "r1210" ] }, "us-gaap_FairValueMeasurementsRecurringMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsRecurringMember", "presentation": [ "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofDefinedBenefitPlansDisclosuresDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Measurements, Recurring", "label": "Fair Value, Recurring [Member]", "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value." } } }, "auth_ref": [ "r1206", "r1573", "r1574", "r1575", "r1576", "r1577", "r1587" ] }, "jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue", "crdr": "debit", "presentation": [ "http://www.jnj.com/role/FairvaluemeasurementsFinancialAssetsandLiabilitiesatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Changes in estimated fair value", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Change In Estimated Fair Value", "documentation": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Change In Estimated Fair Value" } } }, "auth_ref": [] }, "jnj_FairValueOfCompanysCommonStockDirectlyHeldInPlanAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "FairValueOfCompanysCommonStockDirectlyHeldInPlanAssets", "crdr": "debit", "presentation": [ "http://www.jnj.com/role/PensionsandotherbenefitplansNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value of company's common stock directly held in plan assets", "label": "Fair Value Of Company's Common Stock Directly Held In Plan Assets", "documentation": "Fair value of company's common stock directly held in plan assets." } } }, "auth_ref": [] }, "us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable", "presentation": [ "http://www.jnj.com/role/FairvaluemeasurementsFinancialAssetsandLiabilitiesatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]", "label": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]", "documentation": "Disclosure of information about location and fair value of derivative instrument and nonderivative instrument designated as hedging instrument." } } }, "auth_ref": [ "r110", "r112", "r122" ] }, "us-gaap_FinancialInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancialInstrumentAxis", "presentation": [ "http://www.jnj.com/role/CashcashequivalentsandcurrentmarketablesecuritiesCashandCashEquivalentCompositionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Instrument [Axis]", "label": "Financial Instrument [Axis]", "documentation": "Information by type of financial instrument." } } }, "auth_ref": [ "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r494", "r495", "r497", "r498", "r499", "r501", "r502", "r503", "r607", "r615", "r818", "r844", "r884", "r885", "r886", "r887", "r888", "r889", "r890", "r891", "r892", "r893", "r894", "r895", "r896", "r897", "r898", "r900", "r901", "r902", "r903", "r904", "r905", "r906", "r907", "r908", "r909", "r910", "r911", "r912", "r913", "r914", "r979", "r1173", "r1206", "r1208", "r1210", "r1211", "r1212", "r1213", "r1214", "r1215", "r1216", "r1220", "r1388", "r1389", "r1390", "r1391", "r1392", "r1393", "r1394", "r1452", "r1453", "r1454", "r1455", "r1572", "r1575", "r1576", "r1577", "r1584", "r1587" ] }, "jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems", "presentation": [ "http://www.jnj.com/role/IntangibleassetsandgoodwilScheduleofIntangibleAssetsandGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived And Indefinite-Lived Intangible Assets [Line Items]", "label": "Finite-Lived And Indefinite-Lived Intangible Assets [Line Items]", "documentation": "Finite-Lived And Indefinite-Lived Intangible Assets [Line Items]" } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetUsefulLife", "presentation": [ "http://www.jnj.com/role/AcquisitionsanddivestituresNarrativeDetails", "http://www.jnj.com/role/IntangibleassetsandgoodwilScheduleofIntangibleAssetsandGoodwillDetails", "http://www.jnj.com/role/IntangibleassetsandgoodwillNarrativeDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Intangible assets useful life", "label": "Finite-Lived Intangible Asset, Useful Life", "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "crdr": "credit", "calculation": { "http://www.jnj.com/role/IntangibleassetsandgoodwilScheduleofIntangibleAssetsandGoodwillDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.jnj.com/role/IntangibleassetsandgoodwilScheduleofIntangibleAssetsandGoodwillDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Less accumulated amortization", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r321", "r507", "r527", "r1175" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "crdr": "debit", "presentation": [ "http://www.jnj.com/role/IntangibleassetsandgoodwillEstimatedAmortizationofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r529", "r1141", "r1175" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock", "presentation": [ "http://www.jnj.com/role/IntangibleassetsandgoodwillTables" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible Asset Amortization Expense", "label": "Finite-Lived Intangible Assets Amortization Expense [Table Text Block]", "documentation": "Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive", "crdr": "debit", "presentation": [ "http://www.jnj.com/role/IntangibleassetsandgoodwillEstimatedAmortizationofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2029", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r529", "r1141", "r1175" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "crdr": "debit", "presentation": [ "http://www.jnj.com/role/IntangibleassetsandgoodwillEstimatedAmortizationofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2028", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r529", "r1141", "r1175" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "crdr": "debit", "presentation": [ "http://www.jnj.com/role/IntangibleassetsandgoodwillEstimatedAmortizationofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r529", "r1141", "r1175" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "crdr": "debit", "presentation": [ "http://www.jnj.com/role/IntangibleassetsandgoodwillEstimatedAmortizationofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r529", "r1141", "r1175" ] }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": [ "http://www.jnj.com/role/IncometaxesNarrativeDetails", "http://www.jnj.com/role/IntangibleassetsandgoodwilScheduleofIntangibleAssetsandGoodwillDetails", "http://www.jnj.com/role/IntangibleassetsandgoodwillNarrativeDetails", "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingByGeographicAreaDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "documentation": "Information by major type or class of finite-lived intangible assets." } } }, "auth_ref": [ "r520", "r522", "r523", "r524", "r526", "r527", "r531", "r532", "r918", "r919", "r1141" ] }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsGross", "crdr": "debit", "calculation": { "http://www.jnj.com/role/IntangibleassetsandgoodwilScheduleofIntangibleAssetsandGoodwillDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.jnj.com/role/IntangibleassetsandgoodwilScheduleofIntangibleAssetsandGoodwillDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Finite lived intangible assets gross", "label": "Finite-Lived Intangible Assets, Gross", "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r507", "r527", "r919", "r1175" ] }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsLineItems", "presentation": [ "http://www.jnj.com/role/IntangibleassetsandgoodwillNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets [Line Items]", "label": "Finite-Lived Intangible Assets [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r520", "r527", "r531", "r532", "r535", "r918", "r1141", "r1175" ] }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": [ "http://www.jnj.com/role/IncometaxesNarrativeDetails", "http://www.jnj.com/role/IntangibleassetsandgoodwilScheduleofIntangibleAssetsandGoodwillDetails", "http://www.jnj.com/role/IntangibleassetsandgoodwillNarrativeDetails", "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingByGeographicAreaDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "auth_ref": [ "r520", "r522", "r523", "r524", "r526", "r527", "r531", "r532", "r1141" ] }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsNet", "crdr": "debit", "calculation": { "http://www.jnj.com/role/IntangibleassetsandgoodwilScheduleofIntangibleAssetsandGoodwillDetails": { "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.jnj.com/role/IntangibleassetsandgoodwilScheduleofIntangibleAssetsandGoodwillDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Finite lived intangible assets net", "label": "Finite-Lived Intangible Assets, Net", "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r918", "r1479" ] }, "us-gaap_FiniteLivedIntangibleAssetsNetAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsNetAbstract", "presentation": [ "http://www.jnj.com/role/IntangibleassetsandgoodwilScheduleofIntangibleAssetsandGoodwillDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Intangible assets with definite lives:", "label": "Finite-Lived Intangible Assets, Net [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FinitelivedIntangibleAssetsAcquired1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinitelivedIntangibleAssetsAcquired1", "crdr": "debit", "presentation": [ "http://www.jnj.com/role/AcquisitionsanddivestituresNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-lived intangible assets acquired", "label": "Finite-Lived Intangible Assets Acquired", "documentation": "Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition." } } }, "auth_ref": [ "r522" ] }, "jnj_FiscalPeriodPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "FiscalPeriodPolicyTextBlock", "presentation": [ "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Annual closing date", "label": "Fiscal Period [Policy Text Block]", "documentation": "Fiscal period policy." } } }, "auth_ref": [] }, "us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue", "crdr": "debit", "presentation": [ "http://www.jnj.com/role/FairvaluemeasurementsFinancialAssetsandLiabilitiesatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivatives not designated as hedging instruments : Assets", "label": "Foreign Currency Derivative Instruments Not Designated as Hedging Instruments, Asset at Fair Value", "documentation": "Fair value as of the balance sheet date of all foreign currency derivative assets not designated as hedging instruments." } } }, "auth_ref": [ "r113" ] }, "us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue", "crdr": "credit", "presentation": [ "http://www.jnj.com/role/FairvaluemeasurementsFinancialAssetsandLiabilitiesatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivatives not designated as hedging instruments : Liabilities", "label": "Foreign Currency Derivative Instruments Not Designated as Hedging Instruments, Liability at Fair Value", "documentation": "Fair value as of the balance sheet date of all foreign currency derivative liabilities not designated as hedging instruments." } } }, "auth_ref": [ "r113" ] }, "us-gaap_ForeignCurrencyDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignCurrencyDisclosureTextBlock", "presentation": [ "http://www.jnj.com/role/Internationalcurrencytranslation" ], "lang": { "en-us": { "role": { "terseLabel": "International currency translation", "label": "Foreign Currency Disclosure [Text Block]", "documentation": "The entire disclosure for foreign currency transactions and translation. This may include description of foreign currency transactions, foreign currency gains and losses, explanation of change in cumulative translation adjustment, description of effect of subsequent foreign currency exchange rate change, cumulative translation adjustment movement, foreign currency translation adjustment by component movement, translation adjustment for net investment hedge movement, adjustment for long-term intercompany transactions, schedule of long-term intercompany balances and any other foreign currency transactions and translation related items." } } }, "auth_ref": [ "r848", "r867", "r1257", "r1258", "r1259", "r1260", "r1379" ] }, "us-gaap_ForeignCurrencyExchangeRateTranslation1": { "xbrltype": "pureItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignCurrencyExchangeRateTranslation1", "presentation": [ "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign currency exchange rate, translation", "label": "Foreign Currency Exchange Rate, Translation", "documentation": "Foreign exchange rate used to translate amounts denominated in functional currency to reporting currency." } } }, "auth_ref": [ "r866", "r867" ] }, "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignCurrencyTransactionGainLossBeforeTax", "crdr": "credit", "presentation": [ "http://www.jnj.com/role/InternationalcurrencytranslationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign currency transaction gain (loss), before tax", "label": "Gain (Loss), Foreign Currency Transaction, before Tax", "documentation": "Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction." } } }, "auth_ref": [ "r849", "r851", "r853", "r855", "r1096" ] }, "us-gaap_ForeignCurrencyTranslationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignCurrencyTranslationAbstract", "lang": { "en-us": { "role": { "terseLabel": "Foreign Currency Translation [Abstract]", "label": "Foreign Currency Translation [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ForeignExchangeContractMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignExchangeContractMember", "presentation": [ "http://www.jnj.com/role/FairvaluemeasurementsFinancialAssetsandLiabilitiesatFairValueDetails", "http://www.jnj.com/role/FairvaluemeasurementsNarrativeDetails", "http://www.jnj.com/role/FairvaluemeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails", "http://www.jnj.com/role/FairvaluemeasurementsSummaryofDerivativeActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign exchange contracts", "verboseLabel": "Forward foreign exchange contracts:", "label": "Foreign Exchange Contract [Member]", "documentation": "Derivative instrument whose primary underlying risk is tied to foreign exchange rates." } } }, "auth_ref": [ "r1152", "r1187", "r1205", "r1206" ] }, "us-gaap_ForeignPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignPlanMember", "presentation": [ "http://www.jnj.com/role/PensionsandotherbenefitplansInformationRelatedtotheBenefitObligationandtheFairValueofPlanAssetsDetails", "http://www.jnj.com/role/PensionsandotherbenefitplansNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "International Plans", "label": "Foreign Plan [Member]", "documentation": "Location of employer sponsoring plan, designed to provide retirement benefits, not determined as principal place of business. Includes, but is not limited to, defined benefit and defined contribution plans." } } }, "auth_ref": [ "r1514", "r1515", "r1516" ] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": [ "r1286", "r1297", "r1307", "r1340" ] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount", "label": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": [ "r1286", "r1297", "r1307", "r1340" ] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount", "label": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": [ "r1286", "r1297", "r1307", "r1340" ] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery, Explanation of Impracticability", "label": "Forgone Recovery, Explanation of Impracticability [Text Block]" } } }, "auth_ref": [ "r1286", "r1297", "r1307", "r1340" ] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Forgone Recovery, Individual Name" } } }, "auth_ref": [ "r1286", "r1297", "r1307", "r1340" ] }, "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year", "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]" } } }, "auth_ref": [ "r1320" ] }, "jnj_FundedPlansMember": { "xbrltype": "domainItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "FundedPlansMember", "presentation": [ "http://www.jnj.com/role/PensionsandotherbenefitplansInformationRelatedtotheBenefitObligationandtheFairValueofPlanAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Funded Plans", "label": "Funded Plans [Member]", "documentation": "Funded plans." } } }, "auth_ref": [] }, "jnj_GENERALMember": { "xbrltype": "domainItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "GENERALMember", "presentation": [ "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "GENERAL", "label": "GENERAL [Member]", "documentation": "GENERAL [Member]" } } }, "auth_ref": [] }, "us-gaap_GainLossOnSaleOfBusiness": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainLossOnSaleOfBusiness", "crdr": "credit", "presentation": [ "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingByGeographicAreaDetails", "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gain (loss) on divestiture", "label": "Gain (Loss) on Disposition of Business", "documentation": "Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant." } } }, "auth_ref": [ "r803", "r1415" ] }, "us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainLossOnSalesOfAssetsAndAssetImpairmentCharges", "crdr": "credit", "calculation": { "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Net gain on sale of assets/businesses", "label": "Gain (Loss) on Sale of Assets and Asset Impairment Charges", "documentation": "Amount of gain (loss) from the difference between the sale price or salvage price and the book value of an asset that was sold or retired, and gain (loss) from the write down of assets from their carrying value to fair value." } } }, "auth_ref": [ "r1415" ] }, "us-gaap_GainLossRelatedToLitigationSettlement": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainLossRelatedToLitigationSettlement", "crdr": "credit", "presentation": [ "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingByGeographicAreaDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gain (loss) related to litigation settlement", "label": "Gain (Loss) from Litigation Settlement", "documentation": "Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process." } } }, "auth_ref": [ "r1166", "r1489" ] }, "jnj_GeneralCorporateMember": { "xbrltype": "domainItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "GeneralCorporateMember", "presentation": [ "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingByGeographicAreaDetails", "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "General Corporate", "label": "General Corporate [Member]", "documentation": "General corporate member." } } }, "auth_ref": [] }, "us-gaap_Goodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Goodwill", "crdr": "debit", "calculation": { "http://www.jnj.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 }, "http://www.jnj.com/role/AcquisitionsanddivestituresDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.jnj.com/role/AcquisitionsanddivestituresDetails", "http://www.jnj.com/role/ConsolidatedBalanceSheets", "http://www.jnj.com/role/IntangibleassetsandgoodwillGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill", "periodStartLabel": "Goodwill beginning of period", "periodEndLabel": "Goodwill end of period", "label": "Goodwill", "documentation": "Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } } }, "auth_ref": [ "r320", "r508", "r951", "r1167", "r1174", "r1207", "r1219", "r1462", "r1469" ] }, "us-gaap_GoodwillAcquiredDuringPeriod": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillAcquiredDuringPeriod", "crdr": "debit", "presentation": [ "http://www.jnj.com/role/AcquisitionsanddivestituresNarrativeDetails", "http://www.jnj.com/role/IntangibleassetsandgoodwillGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill, related to acquisitions", "label": "Goodwill, Acquired During Period", "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination." } } }, "auth_ref": [ "r511", "r1174" ] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]", "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "presentation": [ "http://www.jnj.com/role/Intangibleassetsandgoodwill" ], "lang": { "en-us": { "role": { "verboseLabel": "Intangible assets and goodwill", "label": "Goodwill and Intangible Assets Disclosure [Text Block]", "documentation": "The entire disclosure for goodwill and intangible assets." } } }, "auth_ref": [ "r1460", "r1472" ] }, "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock", "presentation": [ "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible assets and goodwill", "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets." } } }, "auth_ref": [ "r1460", "r1472" ] }, "us-gaap_GoodwillLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillLineItems", "presentation": [ "http://www.jnj.com/role/IntangibleassetsandgoodwillGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill [Line Items]", "label": "Goodwill [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r1174" ] }, "us-gaap_GoodwillOtherIncreaseDecrease": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillOtherIncreaseDecrease", "crdr": "debit", "presentation": [ "http://www.jnj.com/role/IntangibleassetsandgoodwillGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Currency translation/other", "label": "Goodwill, Other Increase (Decrease)", "documentation": "Amount of increase (decrease) of asset representing future economic benefit from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized, classified as other." } } }, "auth_ref": [ "r516" ] }, "us-gaap_GoodwillPurchaseAccountingAdjustments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillPurchaseAccountingAdjustments", "crdr": "debit", "presentation": [ "http://www.jnj.com/role/AcquisitionsanddivestituresNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill, measurement period adjustment", "label": "Goodwill, Measurement Period Adjustment", "documentation": "Amount of increase (decrease) from measurement period adjustment of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } } }, "auth_ref": [ "r0", "r1468" ] }, "us-gaap_GoodwillRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillRollForward", "presentation": [ "http://www.jnj.com/role/IntangibleassetsandgoodwillGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill [Roll Forward]", "label": "Goodwill [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillWrittenOffRelatedToSaleOfBusinessUnit", "crdr": "credit", "presentation": [ "http://www.jnj.com/role/IntangibleassetsandgoodwillGoodwillDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Goodwill, related to divestitures", "label": "Goodwill, Written off Related to Sale of Business Unit", "documentation": "Amount of divestiture of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } } }, "auth_ref": [ "r513", "r1174" ] }, "us-gaap_GrossProfit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GrossProfit", "crdr": "credit", "calculation": { "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.jnj.com/role/ConsolidatedStatementsofEarnings" ], "lang": { "en-us": { "role": { "totalLabel": "Gross profit", "label": "Gross Profit", "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity." } } }, "auth_ref": [ "r175", "r181", "r248", "r370", "r490", "r571", "r572", "r574", "r575", "r576", "r577", "r578", "r580", "r581", "r847", "r1160", "r1166", "r1431", "r1433", "r1435", "r1436", "r1437", "r1496" ] }, "jnj_HIPSMember": { "xbrltype": "domainItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "HIPSMember", "presentation": [ "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "HIPS", "label": "HIPS [Member]", "documentation": "HIPS [Member]" } } }, "auth_ref": [] }, "us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease", "crdr": "credit", "presentation": [ "http://www.jnj.com/role/FairvaluemeasurementsScheduleofDerivativesRecordedinConsolidatedBalanceSheetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cumulative Amount of Fair Value Hedging Adjustment Included in the Carrying Amount of the Hedged Liability", "label": "Hedged Liability, Fair Value Hedge, Cumulative Increase (Decrease)", "documentation": "Amount of cumulative increase (decrease) in fair value of hedged liability in fair value hedge, attributable to hedged risk." } } }, "auth_ref": [ "r809" ] }, "us-gaap_HedgingDesignationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "HedgingDesignationAxis", "presentation": [ "http://www.jnj.com/role/FairvaluemeasurementsScheduleofDerivativesRecordedinConsolidatedBalanceSheetsDetails", "http://www.jnj.com/role/FairvaluemeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hedging Designation [Axis]", "label": "Hedging Designation [Axis]", "documentation": "Information by designation of purpose of derivative instrument." } } }, "auth_ref": [ "r23", "r808" ] }, "us-gaap_HedgingDesignationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "HedgingDesignationDomain", "presentation": [ "http://www.jnj.com/role/FairvaluemeasurementsScheduleofDerivativesRecordedinConsolidatedBalanceSheetsDetails", "http://www.jnj.com/role/FairvaluemeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hedging Designation [Domain]", "label": "Hedging Designation [Domain]", "documentation": "Designation of purpose of derivative instrument." } } }, "auth_ref": [ "r23" ] }, "us-gaap_HedgingRelationshipDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "HedgingRelationshipDomain", "presentation": [ "http://www.jnj.com/role/FairvaluemeasurementsSummaryofDerivativeActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hedging Relationship [Domain]", "label": "Hedging Relationship [Domain]", "documentation": "Nature or intent of a hedge." } } }, "auth_ref": [ "r23" ] }, "us-gaap_HeldToMaturitySecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "HeldToMaturitySecurities", "crdr": "debit", "presentation": [ "http://www.jnj.com/role/CashcashequivalentsandcurrentmarketablesecuritiesCashandCashEquivalentCompositionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Carrying Amount, held-to-maturity", "label": "Debt Securities, Held-to-Maturity, Amortized Cost, before Allowance for Credit Loss", "documentation": "Amount, before allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity)." } } }, "auth_ref": [ "r250", "r468", "r497", "r1458" ] }, "us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain", "crdr": "credit", "presentation": [ "http://www.jnj.com/role/CashcashequivalentsandcurrentmarketablesecuritiesCashandCashEquivalentCompositionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Held-to-maturity, unrecognized gain", "label": "Debt Securities, Held-to-Maturity, Accumulated Unrecognized Gain", "documentation": "Amount of accumulated unrecognized gain on investment in debt security measured at amortized cost (held-to-maturity)." } } }, "auth_ref": [ "r252", "r478" ] }, "us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss", "crdr": "debit", "presentation": [ "http://www.jnj.com/role/CashcashequivalentsandcurrentmarketablesecuritiesCashandCashEquivalentCompositionDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Held-to-maturity, unrecognized loss", "label": "Debt Securities, Held-to-Maturity, Accumulated Unrecognized Loss", "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at amortized cost (held-to-maturity)." } } }, "auth_ref": [ "r253", "r479" ] }, "us-gaap_HeldToMaturitySecuritiesFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "HeldToMaturitySecuritiesFairValue", "crdr": "debit", "presentation": [ "http://www.jnj.com/role/CashcashequivalentsandcurrentmarketablesecuritiesCashandCashEquivalentCompositionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value, held-to-maturity", "label": "Debt Securities, Held-to-Maturity, Fair Value", "documentation": "Fair value of investment in debt security measured at amortized cost (held-to-maturity)." } } }, "auth_ref": [ "r251", "r477", "r824", "r836", "r952", "r964" ] }, "us-gaap_HeldtomaturitySecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "HeldtomaturitySecuritiesMember", "presentation": [ "http://www.jnj.com/role/CashcashequivalentsandcurrentmarketablesecuritiesCashandCashEquivalentCompositionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Held-to-maturity Securities", "label": "Held-to-Maturity Securities [Member]", "documentation": "Investments in debt securities classified as held-to-maturity." } } }, "auth_ref": [ "r254" ] }, "jnj_IMBRUVICAMember": { "xbrltype": "domainItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "IMBRUVICAMember", "presentation": [ "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "IMBRUVICA", "label": "IMBRUVICA [Member]", "documentation": "IMBRUVICA [Member]" } } }, "auth_ref": [] }, "jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember": { "xbrltype": "domainItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "INVEGASUSTENNAXEPLIONTRINZATREVICTAMember", "presentation": [ "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "INVEGA SUSTENNA/XEPLION/TRINZA/TREVICTA", "label": "INVEGA SUSTENNA/XEPLION/TRINZA/TREVICTA [Member]", "documentation": "INVEGA SUSTENNA/XEPLION/TRINZA/TREVICTA [Member]" } } }, "auth_ref": [] }, "us-gaap_IPOMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IPOMember", "presentation": [ "http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsDetailsDetails", "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "IPO", "label": "IPO [Member]", "documentation": "First sale of stock by a private company to the public." } } }, "auth_ref": [] }, "dei_IcfrAuditorAttestationFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "IcfrAuditorAttestationFlag", "presentation": [ "http://www.jnj.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "ICFR Auditor Attestation Flag", "label": "ICFR Auditor Attestation Flag" } } }, "auth_ref": [ "r1265", "r1266", "r1289" ] }, "jnj_ImmunologyMember": { "xbrltype": "domainItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "ImmunologyMember", "presentation": [ "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Immunology", "label": "Immunology [Member]", "documentation": "Immunology [Member]" } } }, "auth_ref": [] }, "us-gaap_ImpairmentIntangibleAssetStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ImpairmentIntangibleAssetStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration", "presentation": [ "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingByGeographicAreaDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Impairment, Intangible Asset, Statement of Income or Comprehensive Income [Extensible Enumeration]", "label": "Impairment, Intangible Asset, Statement of Income or Comprehensive Income [Extensible Enumeration]", "documentation": "Indicates line item in statement of income or comprehensive income that includes impairment of intangible asset. Includes, but is not limited to, finite-lived and indefinite-lived intangible assets." } } }, "auth_ref": [ "r534" ] }, "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ImpairmentOfIntangibleAssetsExcludingGoodwill", "crdr": "debit", "presentation": [ "http://www.jnj.com/role/IncometaxesNarrativeDetails", "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingByGeographicAreaDetails", "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Impairment of intangible assets, excluding goodwill", "label": "Impairment of Intangible Assets (Excluding Goodwill)", "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value." } } }, "auth_ref": [ "r14", "r521", "r533" ] }, "jnj_ImpellaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "ImpellaMember", "presentation": [ "http://www.jnj.com/role/AcquisitionsanddivestituresNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Impella", "label": "Impella [Member]", "documentation": "Impella" } } }, "auth_ref": [] }, "us-gaap_InProcessResearchAndDevelopmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InProcessResearchAndDevelopmentMember", "presentation": [ "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingByGeographicAreaDetails" ], "lang": { "en-us": { "role": { "terseLabel": "In Process Research and Development", "label": "In Process Research and Development [Member]", "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process." } } }, "auth_ref": [ "r1473", "r1474", "r1475", "r1476", "r1477", "r1478", "r1479", "r1480", "r1481", "r1482" ] }, "us-gaap_IncomeLossFromContinuingOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperations", "crdr": "credit", "calculation": { "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.jnj.com/role/ConsolidatedStatementsofEarnings" ], "lang": { "en-us": { "role": { "totalLabel": "Net earnings from continuing operations", "label": "Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent", "documentation": "Amount after tax of income (loss) from continuing operations attributable to the parent." } } }, "auth_ref": [ "r100", "r177", "r195", "r380", "r381", "r382", "r383", "r384", "r398", "r401", "r799" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "crdr": "credit", "calculation": { "http://www.jnj.com/role/IncometaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.jnj.com/role/IncometaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "U.S.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic", "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations." } } }, "auth_ref": [ "r371", "r753" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": { "parentTag": "us-gaap_IncomeLossFromContinuingOperations", "weight": 1.0, "order": 2.0 }, "http://www.jnj.com/role/IncometaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.jnj.com/role/ConsolidatedStatementsofEarnings", "http://www.jnj.com/role/IncometaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails", "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasIncomeBeforeTaxbySegmentDetails", "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Earnings before provision for taxes on income", "terseLabel": "Earnings before provision for taxes on income", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r176", "r242", "r248", "r956", "r976", "r1160", "r1166", "r1431", "r1433", "r1435", "r1436", "r1437" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign", "crdr": "credit", "calculation": { "http://www.jnj.com/role/IncometaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.jnj.com/role/IncometaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "International", "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign", "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile." } } }, "auth_ref": [ "r371", "r753" ] }, "us-gaap_IncomeLossFromContinuingOperationsPerBasicShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsPerBasicShare", "calculation": { "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": { "parentTag": "us-gaap_EarningsPerShareBasic", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.jnj.com/role/ConsolidatedStatementsofEarnings", "http://www.jnj.com/role/EarningspershareReconciliationofBasicNetEarningsperSharetoDilutedNetEarningsperShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Basic net earnings per share from continuing operations (in dollars per share)", "label": "Income (Loss) from Continuing Operations, Per Basic Share", "documentation": "The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r177", "r243", "r360", "r378", "r380", "r381", "r382", "r383", "r384", "r393", "r399", "r400", "r791", "r799", "r821", "r955", "r1612" ] }, "us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsPerDilutedShare", "calculation": { "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": { "parentTag": "us-gaap_EarningsPerShareDiluted", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.jnj.com/role/ConsolidatedStatementsofEarnings", "http://www.jnj.com/role/EarningspershareReconciliationofBasicNetEarningsperSharetoDilutedNetEarningsperShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Diluted net earnings per share from continuing operations (in dollars per share)", "label": "Income (Loss) from Continuing Operations, Per Diluted Share", "documentation": "The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r177", "r360", "r378", "r380", "r381", "r382", "r383", "r384", "r393", "r399", "r400", "r401", "r799", "r821", "r955", "r1612" ] }, "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest", "crdr": "debit", "presentation": [ "http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsNetEarningsfromDiscontinuedOperationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net earnings from Discontinued Operations", "label": "Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Noncontrolling Interest", "documentation": "Amount after tax of income (loss) from a discontinued operation attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal." } } }, "auth_ref": [ "r98", "r130", "r131", "r132", "r133", "r134", "r140", "r145", "r227" ] }, "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity", "crdr": "credit", "calculation": { "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.jnj.com/role/ConsolidatedStatementsofEarnings" ], "lang": { "en-us": { "role": { "terseLabel": "Net earnings from discontinued operations", "label": "Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent", "documentation": "Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal." } } }, "auth_ref": [ "r130", "r131", "r132", "r133", "r134", "r140", "r145", "r227" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Statement [Abstract]", "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis", "presentation": [ "http://www.jnj.com/role/AcquisitionsanddivestituresNarrativeDetails", "http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsDetailsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group Name [Axis]", "label": "Disposal Group Name [Axis]", "documentation": "Information by name of disposal group." } } }, "auth_ref": [ "r1191", "r1194" ] }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems", "presentation": [ "http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsDetailsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]", "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable", "presentation": [ "http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsDetailsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal Groups, Including Discontinued Operations [Table]", "label": "Disposal Groups, Including Discontinued Operations [Table]", "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component." } } }, "auth_ref": [ "r17", "r26", "r37", "r129", "r135", "r136", "r137", "r138", "r139", "r144", "r146", "r147", "r203" ] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationAxis", "presentation": [ "http://www.jnj.com/role/FairvaluemeasurementsScheduleofEffectofNetInvestmentHedgesDetails", "http://www.jnj.com/role/FairvaluemeasurementsSummaryofDerivativeActivityDetails", "http://www.jnj.com/role/RestructuringNarrativeDetails", "http://www.jnj.com/role/RestructuringScheduleofRestructuringReserveDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statement of Income Location, Balance [Axis]", "label": "Statement of Income Location, Balance [Axis]", "documentation": "Information by location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": [ "r537", "r544", "r555", "r829", "r833", "r838", "r1004", "r1006", "r1083", "r1141", "r1209", "r1616" ] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationDomain", "presentation": [ "http://www.jnj.com/role/FairvaluemeasurementsScheduleofEffectofNetInvestmentHedgesDetails", "http://www.jnj.com/role/FairvaluemeasurementsSummaryofDerivativeActivityDetails", "http://www.jnj.com/role/RestructuringNarrativeDetails", "http://www.jnj.com/role/RestructuringScheduleofRestructuringReserveDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statement of Income Location, Balance [Domain]", "label": "Statement of Income Location, Balance [Domain]", "documentation": "Location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": [ "r544", "r555", "r829", "r833", "r838", "r1004", "r1006", "r1083", "r1141", "r1209", "r1616" ] }, "us-gaap_IncomeTaxAuthorityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxAuthorityAxis", "presentation": [ "http://www.jnj.com/role/IncometaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Tax Jurisdiction [Axis]", "label": "Income Tax Jurisdiction [Axis]", "documentation": "Information by income tax jurisdiction." } } }, "auth_ref": [ "r366", "r754", "r755", "r762", "r774", "r1203", "r1553" ] }, "us-gaap_IncomeTaxAuthorityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxAuthorityDomain", "presentation": [ "http://www.jnj.com/role/IncometaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Tax Jurisdiction [Domain]", "label": "Income Tax Jurisdiction [Domain]", "documentation": "Income tax jurisdiction." } } }, "auth_ref": [ "r366", "r754", "r755", "r762", "r774", "r1203", "r1553" ] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Tax Disclosure [Abstract]", "label": "Income Tax Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureTextBlock", "presentation": [ "http://www.jnj.com/role/Incometaxes" ], "lang": { "en-us": { "role": { "verboseLabel": "Income taxes", "label": "Income Tax Disclosure [Text Block]", "documentation": "The entire disclosure for income tax." } } }, "auth_ref": [ "r372", "r746", "r754", "r759", "r760", "r761", "r768", "r773", "r781", "r783", "r785", "r786", "r1025", "r1203" ] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": { "parentTag": "us-gaap_IncomeLossFromContinuingOperations", "weight": -1.0, "order": 1.0 }, "http://www.jnj.com/role/IncometaxesProvisionforIncomeTaxesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.jnj.com/role/ConsolidatedStatementsofEarnings", "http://www.jnj.com/role/IncometaxesProvisionforIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Provision for taxes on income", "totalLabel": "Provision for taxes on income", "label": "Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r256", "r268", "r387", "r388", "r407", "r423", "r444", "r752", "r754", "r782", "r984", "r1203" ] }, "us-gaap_IncomeTaxPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxPolicyTextBlock", "presentation": [ "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Income taxes", "label": "Income Tax, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements." } } }, "auth_ref": [ "r354", "r748", "r749", "r768", "r769", "r772", "r776", "r1019" ] }, "us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxReconciliationRepatriationOfForeignEarnings", "crdr": "debit", "presentation": [ "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Repatriation of foreign earnings amount", "label": "Effective Income Tax Rate Reconciliation, Repatriation of Foreign Earnings, Amount", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to repatriation of foreign earnings." } } }, "auth_ref": [ "r1544", "r1545" ] }, "us-gaap_IncomeTaxReconciliationTaxCreditsForeign": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxReconciliationTaxCreditsForeign", "crdr": "credit", "presentation": [ "http://www.jnj.com/role/IncometaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Decrease in foreign tax credits", "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Foreign, Amount", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign tax credit." } } }, "auth_ref": [ "r1544", "r1546" ] }, "us-gaap_IncomeTaxesPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxesPaid", "crdr": "credit", "presentation": [ "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Income taxes, inclusive of discontinued operations", "label": "Income Taxes Paid", "documentation": "Amount, before refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax." } } }, "auth_ref": [ "r48", "r194", "r1417", "r1551", "r1552" ] }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "crdr": "debit", "calculation": { "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Increase in accounts payable and accrued liabilities", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid." } } }, "auth_ref": [ "r13" ] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "calculation": { "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Increase in accounts receivable", "label": "Increase (Decrease) in Accounts Receivable", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": [ "r13" ] }, "jnj_IncreaseDecreaseInDeferredTaxLiabilitiesGlobalIntangibleLowTaxedIncomeGILTI": { "xbrltype": "monetaryItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "IncreaseDecreaseInDeferredTaxLiabilitiesGlobalIntangibleLowTaxedIncomeGILTI", "crdr": "credit", "presentation": [ "http://www.jnj.com/role/IncometaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (decrease) in deferred tax liabilities, global intangible low-taxed income (GILTI)", "label": "Increase (Decrease) in Deferred Tax Liabilities, Global Intangible Low-Taxed Income (GILTI)", "documentation": "Increase (Decrease) in Deferred Tax Liabilities, Global Intangible Low-Taxed Income (GILTI)" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInInventories", "crdr": "credit", "calculation": { "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 8.0 } }, "presentation": [ "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Increase in inventories", "label": "Increase (Decrease) in Inventories", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": [ "r13" ] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Changes in assets and liabilities, net of effects from acquisitions and divestitures:", "label": "Increase (Decrease) in Operating Capital [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOtherOperatingAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOtherOperatingAssets", "crdr": "credit", "calculation": { "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 9.0 } }, "presentation": [ "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Decrease/(Increase) in other current and non-current assets", "label": "Increase (Decrease) in Other Operating Assets", "documentation": "Amount of increase (decrease) in operating assets classified as other." } } }, "auth_ref": [ "r13" ] }, "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOtherOperatingLiabilities", "crdr": "debit", "calculation": { "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Increase/(Decrease) in other current and non-current liabilities", "label": "Increase (Decrease) in Other Operating Liabilities", "documentation": "Amount of increase (decrease) in operating liabilities classified as other." } } }, "auth_ref": [ "r13" ] }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "calculation": { "http://www.jnj.com/role/EarningspershareReconciliationofBasicNetEarningsperSharetoDilutedNetEarningsperShareDetails": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.jnj.com/role/EarningspershareReconciliationofBasicNetEarningsperSharetoDilutedNetEarningsperShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Potential shares exercisable under stock option plans (in shares)", "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements", "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method." } } }, "auth_ref": [ "r394", "r395", "r396", "r401", "r708" ] }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": [ "http://www.jnj.com/role/IntangibleassetsandgoodwilScheduleofIntangibleAssetsandGoodwillDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Indefinite-lived Intangible Assets by Major Class [Axis]", "label": "Indefinite-Lived Intangible Assets [Axis]", "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit." } } }, "auth_ref": [ "r520", "r525", "r530", "r1175" ] }, "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill", "crdr": "debit", "calculation": { "http://www.jnj.com/role/IntangibleassetsandgoodwilScheduleofIntangibleAssetsandGoodwillDetails": { "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.jnj.com/role/IntangibleassetsandgoodwilScheduleofIntangibleAssetsandGoodwillDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Indefinite lived intangible assets", "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill)", "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit." } } }, "auth_ref": [ "r507", "r530", "r1175" ] }, "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract", "presentation": [ "http://www.jnj.com/role/IntangibleassetsandgoodwilScheduleofIntangibleAssetsandGoodwillDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Intangible assets with indefinite lives:", "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill) [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": [ "http://www.jnj.com/role/IntangibleassetsandgoodwilScheduleofIntangibleAssetsandGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]", "label": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company." } } }, "auth_ref": [ "r520", "r525", "r530", "r1175" ] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "IndividualAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Individual:", "label": "Individual [Axis]" } } }, "auth_ref": [ "r1286", "r1297", "r1307", "r1331", "r1340", "r1344", "r1352" ] }, "jnj_InfectiousDiseasesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "InfectiousDiseasesMember", "presentation": [ "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Infectious Diseases", "label": "Infectious Diseases [Member]", "documentation": "Infectious Diseases [Member]" } } }, "auth_ref": [] }, "us-gaap_InformationByCategoryOfDebtSecurityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InformationByCategoryOfDebtSecurityAxis", "presentation": [ "http://www.jnj.com/role/CashcashequivalentsandcurrentmarketablesecuritiesCashandCashEquivalentCompositionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Security Category [Axis]", "label": "Debt Security Category [Axis]", "documentation": "Information by category of debt security, either available-for-sale or held-to-maturity." } } }, "auth_ref": [] }, "jnj_InformationRelatedToBenefitObligationAndFairValueOfPlanAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "InformationRelatedToBenefitObligationAndFairValueOfPlanAssetsTableTextBlock", "presentation": [ "http://www.jnj.com/role/PensionsandotherbenefitplansTables" ], "lang": { "en-us": { "role": { "terseLabel": "Information Related to the Benefit Obligation and the Fair Value of Plan Assets", "label": "Information Related To Benefit Obligation And Fair Value Of Plan Assets [Table Text Block]", "documentation": "Information related to the benefit obligation and the fair value of plan assets." } } }, "auth_ref": [] }, "jnj_InghamVsJohnsonJohnsonMember": { "xbrltype": "domainItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "InghamVsJohnsonJohnsonMember", "presentation": [ "http://www.jnj.com/role/LegalproceedingsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ingham vs. Johnson & Johnson", "label": "Ingham vs. Johnson & Johnson [Member]", "documentation": "Ingham vs. Johnson & Johnson" } } }, "auth_ref": [] }, "jnj_InnovativeMedicineMember": { "xbrltype": "domainItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "InnovativeMedicineMember", "presentation": [ "http://www.jnj.com/role/IntangibleassetsandgoodwillGoodwillDetails", "http://www.jnj.com/role/RestructuringScheduleofRestructuringReserveDetails", "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasIncomeBeforeTaxbySegmentDetails", "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails", "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingByGeographicAreaDetails", "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Innovative Medicine", "label": "Innovative Medicine [Member]", "documentation": "Innovative Medicine" } } }, "auth_ref": [] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]" } } }, "auth_ref": [ "r1350" ] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]" } } }, "auth_ref": [ "r1267", "r1356" ] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Adopted", "label": "Insider Trading Policies and Procedures Adopted [Flag]" } } }, "auth_ref": [ "r1267", "r1356" ] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Not Adopted", "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]" } } }, "auth_ref": [ "r1267", "r1356" ] }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IntangibleAssetsNetExcludingGoodwill", "crdr": "debit", "calculation": { "http://www.jnj.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 5.0 }, "http://www.jnj.com/role/IntangibleassetsandgoodwilScheduleofIntangibleAssetsandGoodwillDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.jnj.com/role/ConsolidatedBalanceSheets", "http://www.jnj.com/role/IntangibleassetsandgoodwilScheduleofIntangibleAssetsandGoodwillDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Intangible assets, net", "totalLabel": "Total intangible assets - net", "label": "Intangible Assets, Net (Excluding Goodwill)", "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges." } } }, "auth_ref": [ "r520", "r1479", "r1480" ] }, "us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IntangibleAssetsNetExcludingGoodwillAbstract", "presentation": [ "http://www.jnj.com/role/IntangibleassetsandgoodwilScheduleofIntangibleAssetsandGoodwillDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Intangible assets and Goodwill", "label": "Intangible Assets, Net (Excluding Goodwill) [Abstract]" } } }, "auth_ref": [] }, "us-gaap_InterestCostsCapitalized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestCostsCapitalized", "crdr": "debit", "presentation": [ "http://www.jnj.com/role/PropertyplantandequipmentNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest expense capitalized", "label": "Interest Costs Capitalized", "documentation": "Amount of interest capitalized during the period." } } }, "auth_ref": [ "r868" ] }, "us-gaap_InterestExpenseNonoperating": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpenseNonoperating", "crdr": "debit", "calculation": { "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://www.jnj.com/role/ConsolidatedStatementsofEarnings" ], "lang": { "en-us": { "role": { "terseLabel": "Interest expense, net of portion capitalized", "label": "Interest Expense, Nonoperating", "documentation": "Amount of interest expense classified as nonoperating." } } }, "auth_ref": [ "r419", "r1412" ] }, "jnj_InterestIncomeExpenseNetMember": { "xbrltype": "domainItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "InterestIncomeExpenseNetMember", "presentation": [ "http://www.jnj.com/role/FairvaluemeasurementsSummaryofDerivativeActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest (Income) Expense", "label": "Interest Income Expense Net Member", "documentation": "Interest Income Expense Net Member." } } }, "auth_ref": [] }, "us-gaap_InterestPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestPaid", "crdr": "credit", "presentation": [ "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Interest", "label": "Interest Paid, Including Capitalized Interest, Operating and Investing Activities", "documentation": "Amount of cash paid for interest, including, but not limited to, capitalized interest and payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount; classified as operating and investing activities." } } }, "auth_ref": [ "r1416" ] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestPaidNet", "crdr": "credit", "presentation": [ "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Interest, net of amount capitalized", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": [ "r362", "r364", "r365" ] }, "us-gaap_InterestRateContractMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestRateContractMember", "presentation": [ "http://www.jnj.com/role/FairvaluemeasurementsFinancialAssetsandLiabilitiesatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest rate swaps contracts:", "label": "Interest Rate Contract [Member]", "documentation": "Derivative instrument whose primary underlying risk is tied to the right to receive or pay a sum of money at a given interest rate." } } }, "auth_ref": [ "r1143", "r1152", "r1187", "r1206" ] }, "us-gaap_InterestRateSwapMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestRateSwapMember", "presentation": [ "http://www.jnj.com/role/FairvaluemeasurementsNarrativeDetails", "http://www.jnj.com/role/FairvaluemeasurementsSummaryofDerivativeActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest Rate Swap", "label": "Interest Rate Swap [Member]", "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period." } } }, "auth_ref": [ "r1143", "r1248", "r1249" ] }, "jnj_IntraCellularTherapiesInc.Member": { "xbrltype": "domainItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "IntraCellularTherapiesInc.Member", "presentation": [ "http://www.jnj.com/role/AcquisitionsanddivestituresNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Intra-Cellular Therapies, Inc.", "label": "Intra-Cellular Therapies, Inc. [Member]", "documentation": "Intra-Cellular Therapies, Inc." } } }, "auth_ref": [] }, "us-gaap_InventoryDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Inventory Disclosure [Abstract]", "label": "Inventory Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_InventoryDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryDisclosureTextBlock", "presentation": [ "http://www.jnj.com/role/Inventories" ], "lang": { "en-us": { "role": { "verboseLabel": "Inventories", "label": "Inventory Disclosure [Text Block]", "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory." } } }, "auth_ref": [ "r504" ] }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryFinishedGoodsNetOfReserves", "crdr": "debit", "calculation": { "http://www.jnj.com/role/InventoriesDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.jnj.com/role/InventoriesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Finished goods", "label": "Inventory, Finished Goods, Net of Reserves", "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale." } } }, "auth_ref": [ "r198", "r1149" ] }, "us-gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryNet", "crdr": "debit", "calculation": { "http://www.jnj.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 }, "http://www.jnj.com/role/InventoriesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.jnj.com/role/ConsolidatedBalanceSheets", "http://www.jnj.com/role/InventoriesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Inventories", "totalLabel": "Total inventories", "label": "Inventory, Net", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r334", "r1147", "r1219" ] }, "us-gaap_InventoryNetAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryNetAbstract", "presentation": [ "http://www.jnj.com/role/InventoriesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Summary of Inventories", "label": "Inventory, Net [Abstract]" } } }, "auth_ref": [] }, "us-gaap_InventoryPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryPolicyTextBlock", "presentation": [ "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Inventories", "label": "Inventory, Policy [Policy Text Block]", "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost." } } }, "auth_ref": [ "r257", "r316", "r333", "r504", "r505", "r506", "r916", "r1155" ] }, "us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryRawMaterialsAndSuppliesNetOfReserves", "crdr": "debit", "calculation": { "http://www.jnj.com/role/InventoriesDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.jnj.com/role/InventoriesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Raw materials and supplies", "label": "Inventory, Raw Materials and Supplies, Net of Reserves", "documentation": "Aggregated amount of unprocessed materials to be used in manufacturing or production process and supplies that will be consumed. This amount is net of valuation reserves and adjustments." } } }, "auth_ref": [ "r198", "r1404" ] }, "us-gaap_InventoryWorkInProcessNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryWorkInProcessNetOfReserves", "crdr": "debit", "calculation": { "http://www.jnj.com/role/InventoriesDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.jnj.com/role/InventoriesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Goods in process", "label": "Inventory, Work in Process, Net of Reserves", "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing." } } }, "auth_ref": [ "r198", "r1150" ] }, "us-gaap_InvestmentIncomeInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentIncomeInterest", "crdr": "credit", "calculation": { "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.jnj.com/role/ConsolidatedStatementsofEarnings" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Interest income", "label": "Investment Income, Interest", "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities." } } }, "auth_ref": [ "r407", "r418", "r444", "r1166", "r1409" ] }, "us-gaap_InvestmentPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentPolicyTextBlock", "presentation": [ "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Investments", "label": "Investment, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for investment in financial asset." } } }, "auth_ref": [ "r982", "r1015", "r1016", "r1017", "r1018", "r1104", "r1105" ] }, "jnj_JohnsonJohnsonMember": { "xbrltype": "domainItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "JohnsonJohnsonMember", "presentation": [ "http://www.jnj.com/role/FairvaluemeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails", "http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsDetailsDetails", "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Johnson & Johnson", "label": "Johnson & Johnson [Member]", "documentation": "Johnson & Johnson" } } }, "auth_ref": [] }, "us-gaap_JudicialRulingMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "JudicialRulingMember", "presentation": [ "http://www.jnj.com/role/LegalproceedingsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Judicial Ruling", "label": "Judicial Ruling [Member]", "documentation": "Litigation outcome that occurs as a result of judicial intervention, supervision, or approval." } } }, "auth_ref": [ "r1489" ] }, "jnj_KNEESMember": { "xbrltype": "domainItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "KNEESMember", "presentation": [ "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "KNEES", "label": "KNEES [Member]", "documentation": "KNEES [Member]" } } }, "auth_ref": [] }, "jnj_KenvueIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "KenvueIncMember", "presentation": [ "http://www.jnj.com/role/FairvaluemeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails", "http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsDetailsDetails", "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Kenvue Inc.", "label": "Kenvue Inc. [Member]", "documentation": "Kenvue Inc." } } }, "auth_ref": [] }, "jnj_LaminarMember": { "xbrltype": "domainItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "LaminarMember", "presentation": [ "http://www.jnj.com/role/AcquisitionsanddivestituresNarrativeDetails", "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Laminar", "label": "Laminar [Member]", "documentation": "Laminar" } } }, "auth_ref": [] }, "jnj_LandAndLeaseholdImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "LandAndLeaseholdImprovementsMember", "presentation": [ "http://www.jnj.com/role/PropertyplantandequipmentPropertyPlantandEquipmentatCostandAccumulatedDepreciationDetails", "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesEstimatedUsefulLivesofAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Land and leasehold improvements", "label": "Land And Leasehold Improvements [Member]", "documentation": "Land and leasehold improvements." } } }, "auth_ref": [] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LegalEntityAxis", "presentation": [ "http://www.jnj.com/role/FairvaluemeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails", "http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsDetailsDetails", "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Legal Entity [Axis]", "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "us-gaap_LegalMattersAndContingenciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LegalMattersAndContingenciesTextBlock", "presentation": [ "http://www.jnj.com/role/Legalproceedings" ], "lang": { "en-us": { "role": { "verboseLabel": "Legal proceedings", "label": "Legal Matters and Contingencies [Text Block]", "documentation": "The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies." } } }, "auth_ref": [ "r207" ] }, "jnj_LegalProceedingTextualsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "LegalProceedingTextualsAbstract", "presentation": [ "http://www.jnj.com/role/LegalproceedingsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Legal Proceeding (Textuals)", "label": "Legal Proceeding (Textuals) [Abstract]", "documentation": "Legal Proceeding Textuals Abstract." } } }, "auth_ref": [] }, "us-gaap_LesseeLeasesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeLeasesPolicyTextBlock", "presentation": [ "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Leases", "label": "Lessee, Leases [Policy Text Block]", "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee." } } }, "auth_ref": [ "r878" ] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://www.jnj.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.jnj.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label": "Liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } }, "auth_ref": [ "r34", "r151", "r152", "r153", "r156", "r157", "r158", "r159", "r370", "r490", "r571", "r572", "r574", "r575", "r576", "r577", "r578", "r580", "r581", "r801", "r804", "r805", "r847", "r1056", "r1159", "r1256", "r1496", "r1593", "r1594" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://www.jnj.com/role/ConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.jnj.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities and shareholders\u2019 equity", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r165", "r240", "r972", "r1219", "r1420", "r1457", "r1588" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://www.jnj.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "verboseLabel": "Liabilities and Shareholders\u2019 Equity", "label": "Liabilities and Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.jnj.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.jnj.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r153", "r315", "r370", "r490", "r571", "r572", "r574", "r575", "r576", "r577", "r578", "r580", "r581", "r801", "r804", "r805", "r847", "r1219", "r1496", "r1593", "r1594" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://www.jnj.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "verboseLabel": "Current liabilities", "label": "Liabilities, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "crdr": "credit", "presentation": [ "http://www.jnj.com/role/BorrowingsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Borrowing capacity under credit facility", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility." } } }, "auth_ref": [ "r150", "r155" ] }, "srt_LitigationCaseAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "LitigationCaseAxis", "presentation": [ "http://www.jnj.com/role/IncometaxesNarrativeDetails", "http://www.jnj.com/role/LegalproceedingsNarrativeDetails", "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingByGeographicAreaDetails", "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Litigation Case [Axis]", "label": "Litigation Case [Axis]", "documentation": "Information by type of judicial proceeding, alternative dispute resolution or claim." } } }, "auth_ref": [] }, "srt_LitigationCaseTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "LitigationCaseTypeDomain", "presentation": [ "http://www.jnj.com/role/IncometaxesNarrativeDetails", "http://www.jnj.com/role/LegalproceedingsNarrativeDetails", "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingByGeographicAreaDetails", "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Litigation Case Type [Domain]", "label": "Litigation Case [Domain]", "documentation": "Judicial proceeding, alternative dispute resolution or claim. For example, but not limited to, name of case, category of litigation, or other differentiating information." } } }, "auth_ref": [] }, "jnj_LitigationSettlementByCompaniesAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "LitigationSettlementByCompaniesAxis", "presentation": [ "http://www.jnj.com/role/LegalproceedingsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Litigation Settlement By Companies", "label": "Litigation Settlement By Companies [Axis]", "documentation": "Litigation settlement by companies." } } }, "auth_ref": [] }, "jnj_LitigationSettlementByCompaniesDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "LitigationSettlementByCompaniesDomain", "presentation": [ "http://www.jnj.com/role/LegalproceedingsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Litigation Settlement By Companies", "label": "Litigation Settlement By Companies [Domain]", "documentation": "Litigation settlement by companies." } } }, "auth_ref": [] }, "us-gaap_LitigationSettlementExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LitigationSettlementExpense", "crdr": "debit", "presentation": [ "http://www.jnj.com/role/IncometaxesNarrativeDetails", "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingByGeographicAreaDetails", "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Litigation expense", "label": "Litigation Settlement, Fee Expense", "documentation": "Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees." } } }, "auth_ref": [ "r1387" ] }, "us-gaap_LitigationStatusAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LitigationStatusAxis", "presentation": [ "http://www.jnj.com/role/LegalproceedingsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Litigation Status [Axis]", "label": "Litigation Status [Axis]", "documentation": "Information by status of pending, threatened, or settled litigation." } } }, "auth_ref": [ "r1483", "r1484", "r1485", "r1489" ] }, "us-gaap_LitigationStatusDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LitigationStatusDomain", "presentation": [ "http://www.jnj.com/role/LegalproceedingsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Litigation Status [Domain]", "label": "Litigation Status [Domain]", "documentation": "Status of pending, threatened, or settled litigation." } } }, "auth_ref": [ "r1483", "r1484", "r1485", "r1489" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [ "http://www.jnj.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LongTermCommercialPaperCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermCommercialPaperCurrent", "crdr": "credit", "presentation": [ "http://www.jnj.com/role/BorrowingsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Borrowed under the commercial paper program", "label": "Long-Term Commercial Paper, Current", "documentation": "Carrying value as of the balance sheet date of the current portion of long-term unsecured obligations issued by corporations and other borrowers to investors (with maturities initially due after one year or beyond the operating cycle if longer)." } } }, "auth_ref": [ "r151", "r152" ] }, "us-gaap_LongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebt", "crdr": "credit", "calculation": { "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Long-term debt", "label": "Long-Term Debt", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation." } } }, "auth_ref": [ "r34", "r238", "r595", "r609", "r1179", "r1180", "r1217", "r1610" ] }, "us-gaap_LongTermDebtByMaturityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtByMaturityAbstract", "presentation": [ "http://www.jnj.com/role/BorrowingsAggregateMaturitiesofLongTermObligationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate maturities of long-term obligations", "label": "Long-Term Debt, Fiscal Year Maturity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LongTermDebtCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtCurrent", "crdr": "credit", "calculation": { "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Less current portion", "label": "Long-Term Debt, Current Maturities", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation." } } }, "auth_ref": [ "r325" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive", "crdr": "credit", "presentation": [ "http://www.jnj.com/role/BorrowingsAggregateMaturitiesofLongTermObligationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "After 2029", "label": "Long-Term Debt, Maturity, after Year Five", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r16", "r374", "r1499" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "crdr": "credit", "presentation": [ "http://www.jnj.com/role/BorrowingsAggregateMaturitiesofLongTermObligationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Long-Term Debt, Maturity, Year One", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r16", "r374", "r600" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive", "crdr": "credit", "presentation": [ "http://www.jnj.com/role/BorrowingsAggregateMaturitiesofLongTermObligationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2029", "label": "Long-Term Debt, Maturity, Year Five", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r16", "r374", "r600" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour", "crdr": "credit", "presentation": [ "http://www.jnj.com/role/BorrowingsAggregateMaturitiesofLongTermObligationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2028", "label": "Long-Term Debt, Maturity, Year Four", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r16", "r374", "r600" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "crdr": "credit", "presentation": [ "http://www.jnj.com/role/BorrowingsAggregateMaturitiesofLongTermObligationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Long-Term Debt, Maturity, Year Three", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r16", "r374", "r600" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "crdr": "credit", "presentation": [ "http://www.jnj.com/role/BorrowingsAggregateMaturitiesofLongTermObligationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Long-Term Debt, Maturity, Year Two", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r16", "r374", "r600" ] }, "us-gaap_LongTermDebtMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMember", "presentation": [ "http://www.jnj.com/role/FairvaluemeasurementsScheduleofDerivativesRecordedinConsolidatedBalanceSheetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term Debt", "label": "Long-Term Debt [Member]", "documentation": "Debt arrangement having an initial term longer than one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": [] }, "us-gaap_LongTermDebtNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtNoncurrent", "crdr": "credit", "calculation": { "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 2.0 }, "http://www.jnj.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails", "http://www.jnj.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term debt", "verboseLabel": "Total long-term debt", "label": "Long-Term Debt, Excluding Current Maturities", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation." } } }, "auth_ref": [ "r327" ] }, "us-gaap_LossContingenciesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingenciesLineItems", "presentation": [ "http://www.jnj.com/role/LegalproceedingsNarrativeDetails", "http://www.jnj.com/role/LegalproceedingsProductLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss Contingencies [Line Items]", "label": "Loss Contingencies [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r563", "r564", "r565", "r568", "r742", "r1177", "r1490", "r1492" ] }, "us-gaap_LossContingenciesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingenciesTable", "presentation": [ "http://www.jnj.com/role/LegalproceedingsNarrativeDetails", "http://www.jnj.com/role/LegalproceedingsProductLiabilitiesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Product Liability Contingencies [Table]", "terseLabel": "Loss Contingencies [Table]", "label": "Loss Contingencies [Table]", "documentation": "Disclosure of information about loss contingency. Excludes environmental contingency, warranty, and unconditional purchase obligation." } } }, "auth_ref": [ "r563", "r564", "r565", "r568", "r742", "r1177", "r1490", "r1492" ] }, "us-gaap_LossContingencyAccrualAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingencyAccrualAtCarryingValue", "crdr": "credit", "presentation": [ "http://www.jnj.com/role/LegalproceedingsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amount reserved for settlement", "label": "Loss Contingency Accrual", "documentation": "Amount of loss contingency liability." } } }, "auth_ref": [ "r563", "r1375" ] }, "jnj_LossContingencyAccrualNominalValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "LossContingencyAccrualNominalValue", "crdr": "credit", "presentation": [ "http://www.jnj.com/role/LegalproceedingsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrual, nominal value", "label": "Loss Contingency Accrual, Nominal Value", "documentation": "Loss Contingency Accrual, Nominal Value" } } }, "auth_ref": [] }, "jnj_LossContingencyAccrualPaymentPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "LossContingencyAccrualPaymentPercentage", "presentation": [ "http://www.jnj.com/role/LegalproceedingsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss contingency accrual, payment percentage", "label": "Loss contingency accrual, payment percentage", "documentation": "Loss contingency accrual, payment percentage" } } }, "auth_ref": [] }, "us-gaap_LossContingencyAccrualProvision": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingencyAccrualProvision", "crdr": "debit", "presentation": [ "http://www.jnj.com/role/LegalproceedingsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Incremental charges", "label": "Loss Contingency Accrual, Provision", "documentation": "Amount charged against operating income increasing loss contingency liability, after adjustments to reduce previously estimated charges." } } }, "auth_ref": [ "r1489" ] }, "jnj_LossContingencyClaimsSettledPercent": { "xbrltype": "percentItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "LossContingencyClaimsSettledPercent", "presentation": [ "http://www.jnj.com/role/LegalproceedingsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Claims settled, percent", "label": "Loss Contingency, Claims Settled, Percent", "documentation": "Loss Contingency, Claims Settled, Percent" } } }, "auth_ref": [] }, "us-gaap_LossContingencyDamagesAwardedValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingencyDamagesAwardedValue", "crdr": "debit", "presentation": [ "http://www.jnj.com/role/LegalproceedingsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Damages awarded", "label": "Loss Contingency, Damages Awarded, Value", "documentation": "Amount of damages awarded to the plaintiff in the legal matter." } } }, "auth_ref": [ "r1489", "r1490", "r1492" ] }, "us-gaap_LossContingencyDamagesPaidValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingencyDamagesPaidValue", "crdr": "credit", "presentation": [ "http://www.jnj.com/role/LegalproceedingsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss contingency, damages paid, value", "label": "Loss Contingency, Damages Paid, Value", "documentation": "Amount of damages paid to the plaintiff in the legal matter." } } }, "auth_ref": [ "r1489", "r1490", "r1492" ] }, "jnj_LossContingencyDamagesSoughtNominalValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "LossContingencyDamagesSoughtNominalValue", "crdr": "debit", "presentation": [ "http://www.jnj.com/role/LegalproceedingsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Damages sought, nominal value", "label": "Loss Contingency, Damages Sought, Nominal Value", "documentation": "Loss Contingency, Damages Sought, Nominal Value" } } }, "auth_ref": [] }, "us-gaap_LossContingencyDamagesSoughtValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingencyDamagesSoughtValue", "crdr": "debit", "presentation": [ "http://www.jnj.com/role/LegalproceedingsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Litigation contingency", "label": "Loss Contingency, Damages Sought, Value", "documentation": "The value (monetary amount) of the award the plaintiff seeks in the legal matter." } } }, "auth_ref": [ "r1489", "r1490", "r1492" ] }, "jnj_LossContingencyDamagesSoughtValueIncrease": { "xbrltype": "monetaryItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "LossContingencyDamagesSoughtValueIncrease", "crdr": "debit", "presentation": [ "http://www.jnj.com/role/LegalproceedingsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Increase in damages sought", "label": "Loss Contingency, Damages Sought, Value, Increase", "documentation": "Loss Contingency, Damages Sought, Value, Increase" } } }, "auth_ref": [] }, "jnj_LossContingencyDiscountRate": { "xbrltype": "percentItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "LossContingencyDiscountRate", "presentation": [ "http://www.jnj.com/role/LegalproceedingsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Bankruptcy loss contingency, discount rate", "label": "Loss Contingency, Discount Rate", "documentation": "Loss Contingency, Discount Rate" } } }, "auth_ref": [] }, "us-gaap_LossContingencyLossInPeriod": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingencyLossInPeriod", "crdr": "debit", "presentation": [ "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingByGeographicAreaDetails", "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss contingency, loss in period", "label": "Loss Contingency, Loss in Period", "documentation": "The amount of loss pertaining to the specified contingency that was charged against earnings in the period, including the effects of revisions in previously reported estimates." } } }, "auth_ref": [ "r1489" ] }, "jnj_LossContingencyNumberOfClaimsWithinSettlementAgreement": { "xbrltype": "integerItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "LossContingencyNumberOfClaimsWithinSettlementAgreement", "presentation": [ "http://www.jnj.com/role/LegalproceedingsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of claims within settlement agreement", "label": "Loss Contingency, Number of Claims within Settlement Agreement", "documentation": "Loss Contingency, Number of Claims within Settlement Agreement" } } }, "auth_ref": [] }, "jnj_LossContingencyPaymentPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "LossContingencyPaymentPeriod", "presentation": [ "http://www.jnj.com/role/LegalproceedingsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss contingency, payment period", "label": "Loss Contingency, Payment Period", "documentation": "Loss Contingency, Payment Period" } } }, "auth_ref": [] }, "us-gaap_LossContingencyPendingClaimsNumber": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingencyPendingClaimsNumber", "presentation": [ "http://www.jnj.com/role/LegalproceedingsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of pending claims", "label": "Loss Contingency, Pending Claims, Number", "documentation": "Number of pending claims pertaining to a loss contingency." } } }, "auth_ref": [ "r1490", "r1492" ] }, "jnj_LossContingencySolicitationPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "LossContingencySolicitationPeriod", "presentation": [ "http://www.jnj.com/role/LegalproceedingsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Solicitation period", "label": "Loss Contingency, Solicitation Period", "documentation": "Loss Contingency, Solicitation Period" } } }, "auth_ref": [] }, "us-gaap_MachineryAndEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MachineryAndEquipmentMember", "presentation": [ "http://www.jnj.com/role/PropertyplantandequipmentPropertyPlantandEquipmentatCostandAccumulatedDepreciationDetails", "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesEstimatedUsefulLivesofAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Machinery and equipment", "label": "Machinery and Equipment [Member]", "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment." } } }, "auth_ref": [] }, "srt_MajorCustomersAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MajorCustomersAxis", "presentation": [ "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingByGeographicAreaDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer [Axis]", "label": "Customer [Axis]", "documentation": "Information by name or description of a single external customer or a group of external customers." } } }, "auth_ref": [ "r452", "r1186", "r1230", "r1235", "r1501", "r1613", "r1617", "r1618", "r1620", "r1621", "r1622", "r1623", "r1624", "r1625", "r1626", "r1627", "r1628", "r1629", "r1630", "r1631", "r1632", "r1633", "r1634", "r1635", "r1636", "r1637", "r1638", "r1639", "r1640", "r1641", "r1642", "r1644", "r1645" ] }, "us-gaap_MarketableSecuritiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MarketableSecuritiesCurrent", "crdr": "debit", "calculation": { "http://www.jnj.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.jnj.com/role/CashcashequivalentsandcurrentmarketablesecuritiesCashandCashEquivalentCompositionDetails", "http://www.jnj.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "verboseLabel": "Marketable securities", "terseLabel": "Current Marketable Securities", "label": "Marketable Securities, Current", "documentation": "Amount of investment in marketable security, classified as current." } } }, "auth_ref": [ "r1403" ] }, "us-gaap_MarketableSecuritiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MarketableSecuritiesNoncurrent", "crdr": "debit", "presentation": [ "http://www.jnj.com/role/FairvaluemeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Marketable securities, noncurrent", "label": "Marketable Securities, Noncurrent", "documentation": "Amount of investment in marketable security, classified as noncurrent." } } }, "auth_ref": [ "r1403" ] }, "us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MaximumLengthOfTimeForeignCurrencyCashFlowHedge", "presentation": [ "http://www.jnj.com/role/FairvaluemeasurementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum length of time for hedging transaction exposure", "label": "Maximum Length of Time, Foreign Currency Cash Flow Hedge", "documentation": "Maximum period of hedging exposure to variability in future cash flows for forecasted transaction of foreign currency cash flow hedge, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Excludes forecasted transaction for payment of variable interest on existing financial instrument." } } }, "auth_ref": [ "r19" ] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MaximumMember", "presentation": [ "http://www.jnj.com/role/AcquisitionsanddivestituresNarrativeDetails", "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsNarrativeDetails", "http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsDetailsDetails", "http://www.jnj.com/role/PensionsandotherbenefitplansNarrativeDetails", "http://www.jnj.com/role/RestructuringNarrativeDetails", "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesEstimatedUsefulLivesofAssetsDetails", "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum", "label": "Maximum [Member]", "documentation": "Upper limit of the provided range." } } }, "auth_ref": [ "r271", "r273", "r275", "r276", "r278", "r307", "r308", "r564", "r565", "r566", "r567", "r701", "r742", "r827", "r915", "r1003", "r1005", "r1013", "r1048", "r1049", "r1102", "r1106", "r1108", "r1109", "r1120", "r1139", "r1140", "r1172", "r1183", "r1197", "r1210", "r1211", "r1215", "r1216", "r1231", "r1498", "r1595", "r1596", "r1597", "r1598", "r1599", "r1600" ] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Measure:", "label": "Measure [Axis]" } } }, "auth_ref": [ "r1323" ] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Measure Name" } } }, "auth_ref": [ "r1323" ] }, "jnj_MedTechMember": { "xbrltype": "domainItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "MedTechMember", "presentation": [ "http://www.jnj.com/role/AcquisitionsanddivestituresNarrativeDetails", "http://www.jnj.com/role/IntangibleassetsandgoodwillGoodwillDetails", "http://www.jnj.com/role/RestructuringNarrativeDetails", "http://www.jnj.com/role/RestructuringScheduleofRestructuringReserveDetails", "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasIncomeBeforeTaxbySegmentDetails", "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails", "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingByGeographicAreaDetails", "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "MedTech", "verboseLabel": "MedTech", "label": "MedTech [Member]", "documentation": "MedTech [Member]" } } }, "auth_ref": [] }, "jnj_MesotheliomaAndStateClaimsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "MesotheliomaAndStateClaimsMember", "presentation": [ "http://www.jnj.com/role/LegalproceedingsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Mesothelioma and State Claims", "label": "Mesothelioma and State Claims [Member]", "documentation": "Mesothelioma and State Claims" } } }, "auth_ref": [] }, "jnj_MinimumCollateralValueasaPercentReverseRepurchaseAgreement": { "xbrltype": "percentItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "MinimumCollateralValueasaPercentReverseRepurchaseAgreement", "presentation": [ "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Minimum reverse repurchase agreement collateral (as a percent)", "label": "Minimum Collateral Value as a Percent, Reverse Repurchase Agreement", "documentation": "Minimum Collateral Value as a Percent, Reverse Repurchase Agreement" } } }, "auth_ref": [] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MinimumMember", "presentation": [ "http://www.jnj.com/role/AcquisitionsanddivestituresNarrativeDetails", "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsNarrativeDetails", "http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsDetailsDetails", "http://www.jnj.com/role/RestructuringNarrativeDetails", "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesEstimatedUsefulLivesofAssetsDetails", "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Minimum", "label": "Minimum [Member]", "documentation": "Lower limit of the provided range." } } }, "auth_ref": [ "r271", "r273", "r275", "r276", "r278", "r307", "r308", "r564", "r565", "r566", "r567", "r701", "r742", "r827", "r915", "r1003", "r1005", "r1013", "r1048", "r1049", "r1102", "r1106", "r1108", "r1109", "r1120", "r1139", "r1140", "r1172", "r1183", "r1197", "r1210", "r1211", "r1215", "r1231", "r1498", "r1595", "r1596", "r1597", "r1598", "r1599", "r1600" ] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MnpiDiscTimedForCompValFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "MNPI Disclosure Timed for Compensation Value", "label": "MNPI Disclosure Timed for Compensation Value [Flag]" } } }, "auth_ref": [ "r1343" ] }, "jnj_MomentaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "MomentaMember", "presentation": [ "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingByGeographicAreaDetails", "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Momenta", "label": "Momenta [Member]", "documentation": "Momenta" } } }, "auth_ref": [] }, "us-gaap_MoneyMarketFundsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MoneyMarketFundsMember", "presentation": [ "http://www.jnj.com/role/CashcashequivalentsandcurrentmarketablesecuritiesCashandCashEquivalentCompositionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Money market funds", "label": "Money Market Funds [Member]", "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities." } } }, "auth_ref": [ "r1507" ] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Material Terms of Trading Arrangement", "label": "Material Terms of Trading Arrangement [Text Block]" } } }, "auth_ref": [ "r1351" ] }, "srt_NameOfMajorCustomerDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "NameOfMajorCustomerDomain", "presentation": [ "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingByGeographicAreaDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer [Domain]", "label": "Customer [Domain]", "documentation": "Single external customer or group of external customers." } } }, "auth_ref": [ "r452", "r1186", "r1230", "r1235", "r1501", "r1613", "r1617", "r1618", "r1620", "r1621", "r1622", "r1623", "r1624", "r1625", "r1626", "r1627", "r1628", "r1629", "r1630", "r1631", "r1632", "r1633", "r1634", "r1635", "r1636", "r1637", "r1638", "r1639", "r1640", "r1641", "r1642", "r1644", "r1645" ] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Named Executive Officers, Footnote", "label": "Named Executive Officers, Footnote [Text Block]" } } }, "auth_ref": [ "r1324" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used by financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r363" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Cash flows from financing activities", "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash (used by)/from investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r363" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Cash flows from investing activities", "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash flows from operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r190", "r191", "r195" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Cash flows from operating activities", "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 2.0 }, "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 11.0 }, "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows", "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome", "http://www.jnj.com/role/ConsolidatedStatementsofEarnings", "http://www.jnj.com/role/ConsolidatedStatementsofEquity", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "totalLabel": "Net earnings", "terseLabel": "Net earnings", "verboseLabel": "Net earnings", "label": "Net Income (Loss) Attributable to Parent", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r182", "r195", "r244", "r313", "r349", "r352", "r357", "r370", "r378", "r380", "r381", "r382", "r383", "r384", "r387", "r388", "r398", "r490", "r571", "r572", "r574", "r575", "r576", "r577", "r578", "r580", "r581", "r791", "r799", "r821", "r847", "r977", "r1079", "r1097", "r1098", "r1254", "r1496" ] }, "jnj_NeuroscienceMember": { "xbrltype": "domainItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "NeuroscienceMember", "presentation": [ "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Neuroscience", "label": "Neuroscience [Member]", "documentation": "Neuroscience [Member]" } } }, "auth_ref": [] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "New accounting standards and Recently issued accounting standards", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-GAAP Measure Description", "label": "Non-GAAP Measure Description [Text Block]" } } }, "auth_ref": [ "r1323" ] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonNeosMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-NEOs", "label": "Non-NEOs [Member]" } } }, "auth_ref": [ "r1286", "r1297", "r1307", "r1331", "r1340" ] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount", "label": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": [ "r1314" ] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Total Compensation Amount", "label": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": [ "r1313" ] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO", "label": "Non-PEO NEO [Member]" } } }, "auth_ref": [ "r1331" ] }, "jnj_NonQualifiedPlansMember": { "xbrltype": "domainItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "NonQualifiedPlansMember", "presentation": [ "http://www.jnj.com/role/PensionsandotherbenefitplansInformationRelatedtotheBenefitObligationandtheFairValueofPlanAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Qualified Plans", "label": "Non Qualified Plans [Member]", "documentation": "Non qualified plans." } } }, "auth_ref": [] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted", "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r1351" ] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated", "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r1351" ] }, "jnj_NonTradeableContingentValueRightMember": { "xbrltype": "domainItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "NonTradeableContingentValueRightMember", "presentation": [ "http://www.jnj.com/role/AcquisitionsanddivestituresNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Tradeable Contingent Value Right", "label": "Non-Tradeable Contingent Value Right [Member]", "documentation": "Non-Tradeable Contingent Value Right" } } }, "auth_ref": [] }, "us-gaap_NonUsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonUsMember", "presentation": [ "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-US", "label": "Non-US [Member]", "documentation": "Countries excluding the United States of America (US)." } } }, "auth_ref": [ "r1649", "r1651", "r1652", "r1653" ] }, "us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1", "crdr": "debit", "calculation": { "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash paid for acquisitions (Note 18)", "label": "Noncash or Part Noncash Acquisition, Net Nonmonetary Assets Acquired (Liabilities Assumed)", "documentation": "The net book value of a nonmonetary asset transferred or exchanged in connection with the acquisition of a business or asset in a noncash transaction. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. Nonmonetary assets and liabilities are assets and liabilities that will not result in cash receipts or cash payments in the future." } } }, "auth_ref": [ "r49", "r50", "r51" ] }, "us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract", "presentation": [ "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Acquisitions", "label": "Noncash or Part Noncash Acquisition, Net Nonmonetary Assets Acquired (Liabilities Assumed) [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1", "crdr": "debit", "calculation": { "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Fair value of assets acquired", "label": "Noncash or Part Noncash Acquisition, Value of Assets Acquired", "documentation": "The value of an asset or business acquired in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": [ "r49", "r50", "r51" ] }, "us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1", "crdr": "credit", "calculation": { "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Fair value of liabilities assumed", "label": "Noncash or Part Noncash Acquisition, Value of Liabilities Assumed", "documentation": "The total amount of [all] liabilities that an Entity assumes in acquiring a business or in consideration for an asset received in a noncash (or part noncash) acquisition. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": [ "r49", "r50", "r51" ] }, "jnj_NoncashOrPartNoncashTransactionGainOnExchangeOfStock": { "xbrltype": "monetaryItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "NoncashOrPartNoncashTransactionGainOnExchangeOfStock", "crdr": "debit", "presentation": [ "http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsDetailsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Noncash gain on exchange offer", "label": "Noncash Or Part Noncash Transaction, Gain On Exchange Of Stock", "documentation": "Noncash Or Part Noncash Transaction, Gain On Exchange Of Stock" } } }, "auth_ref": [] }, "us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NoncontrollingInterestDecreaseFromDeconsolidation", "crdr": "debit", "presentation": [ "http://www.jnj.com/role/AccumulatedothercomprehensiveincomelossDetails", "http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsDetailsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Kenvue Separation/IPO", "terseLabel": "Decrease in noncontrolling interest", "label": "Noncontrolling Interest, Decrease from Deconsolidation", "documentation": "The amount of the reduction or elimination during the period of a noncontrolling interest resulting from the parent's loss of control and deconsolidation of the entity in which one or more outside parties had a noncontrolling interest." } } }, "auth_ref": [ "r20", "r71" ] }, "us-gaap_NoncurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NoncurrentAssets", "crdr": "debit", "presentation": [ "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingByGeographicAreaDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-Lived Assets", "label": "Long-Lived Assets", "documentation": "Long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets." } } }, "auth_ref": [ "r451" ] }, "us-gaap_NondesignatedMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NondesignatedMember", "presentation": [ "http://www.jnj.com/role/FairvaluemeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Not Designated as Hedging Instrument", "label": "Not Designated as Hedging Instrument [Member]", "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP)." } } }, "auth_ref": [ "r23" ] }, "jnj_NumberOfEmployeesEngagedInCompanyActivitiesWorldwide": { "xbrltype": "integerItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "NumberOfEmployeesEngagedInCompanyActivitiesWorldwide", "presentation": [ "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of employees", "label": "Number Of Employees Engaged In Company Activities Worldwide", "documentation": "Number of employees engaged in company activities worldwide." } } }, "auth_ref": [] }, "us-gaap_NumberOfOperatingSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NumberOfOperatingSegments", "presentation": [ "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails", "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingByGeographicAreaDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of segments", "label": "Number of Operating Segments", "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues." } } }, "auth_ref": [ "r1167", "r1432" ] }, "us-gaap_NumberOfReportableSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NumberOfReportableSegments", "presentation": [ "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of business segments", "label": "Number of Reportable Segments", "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements." } } }, "auth_ref": [ "r1161", "r1171", "r1432" ] }, "jnj_NumberOfStockBasedCompensationPlans": { "xbrltype": "integerItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "NumberOfStockBasedCompensationPlans", "presentation": [ "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of stock-based compensation plans", "label": "Number Of Stock Based Compensation Plans", "documentation": "Number of stock-based compensation plans." } } }, "auth_ref": [] }, "jnj_Numberofpatientsinsettlement": { "xbrltype": "integerItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "Numberofpatientsinsettlement", "presentation": [ "http://www.jnj.com/role/LegalproceedingsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of patients in settlement", "label": "Number of patients in settlement", "documentation": "Number of patients in settlement" } } }, "auth_ref": [] }, "jnj_OPSUMITMember": { "xbrltype": "domainItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "OPSUMITMember", "presentation": [ "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "OPSUMIT", "label": "OPSUMIT [Member]", "documentation": "OPSUMIT [Member]" } } }, "auth_ref": [] }, "jnj_OTHERNEUROSCIENCEMember": { "xbrltype": "domainItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "OTHERNEUROSCIENCEMember", "presentation": [ "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "OTHER NEUROSCIENCE", "label": "OTHER NEUROSCIENCE [Member]", "documentation": "OTHER NEUROSCIENCE [Member]" } } }, "auth_ref": [] }, "jnj_OncologyMember": { "xbrltype": "domainItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "OncologyMember", "presentation": [ "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Oncology", "label": "Oncology [Member]", "documentation": "Oncology [Member]" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseCost", "crdr": "debit", "presentation": [ "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease costs", "label": "Operating Lease, Cost", "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability." } } }, "auth_ref": [ "r879", "r1218" ] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiability", "crdr": "credit", "presentation": [ "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Operating lease liabilities", "label": "Operating Lease, Liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": [ "r875" ] }, "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList", "presentation": [ "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]", "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes current operating lease liability." } } }, "auth_ref": [ "r876" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList", "presentation": [ "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]", "label": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes noncurrent operating lease liability." } } }, "auth_ref": [ "r876" ] }, "us-gaap_OperatingLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeasePayments", "crdr": "credit", "presentation": [ "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash paid for operating leases", "label": "Operating Lease, Payments", "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use." } } }, "auth_ref": [ "r877", "r880" ] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "presentation": [ "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease, right-of-use asset", "label": "Operating Lease, Right-of-Use Asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r874" ] }, "us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList", "presentation": [ "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]", "label": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes operating lease right-of-use asset." } } }, "auth_ref": [ "r876" ] }, "us-gaap_OperatingSegmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingSegmentsMember", "presentation": [ "http://www.jnj.com/role/RestructuringScheduleofRestructuringReserveDetails", "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasIncomeBeforeTaxbySegmentDetails", "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingByGeographicAreaDetails", "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Segments", "label": "Operating Segments [Member]", "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": [ "r438", "r439", "r440", "r441", "r442", "r445", "r1166", "r1167" ] }, "jnj_OpioidMember": { "xbrltype": "domainItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "OpioidMember", "presentation": [ "http://www.jnj.com/role/LegalproceedingsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Opioid", "label": "opioid [Member]", "documentation": "Opioid" } } }, "auth_ref": [] }, "jnj_OrthopaedicsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "OrthopaedicsMember", "presentation": [ "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Orthopaedics", "label": "Orthopaedics [Member]", "documentation": "Orthopaedics [Member]" } } }, "auth_ref": [] }, "jnj_OrthopaedicsRestructuringPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "OrthopaedicsRestructuringPlanMember", "presentation": [ "http://www.jnj.com/role/RestructuringNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Orthopaedics Restructuring Plan", "label": "Orthopaedics Restructuring Plan [Member]", "documentation": "Orthopaedics Restructuring Plan" } } }, "auth_ref": [] }, "us-gaap_OtherAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsMember", "presentation": [ "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofDefinedBenefitPlansDisclosuresDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other assets", "label": "Other Assets [Member]", "documentation": "Primary financial statement caption encompassing other assets." } } }, "auth_ref": [ "r110", "r122" ] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://www.jnj.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.jnj.com/role/ConsolidatedBalanceSheets", "http://www.jnj.com/role/FairvaluemeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Other assets", "terseLabel": "Other assets, noncurrent", "label": "Other Assets, Noncurrent", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": [ "r322" ] }, "jnj_OtherCardiovascularMember": { "xbrltype": "domainItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "OtherCardiovascularMember", "presentation": [ "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "other cardiovascular", "label": "other cardiovascular [Member]", "documentation": "other cardiovascular" } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract", "presentation": [ "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome" ], "lang": { "en-us": { "role": { "terseLabel": "Securities:", "label": "Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax", "crdr": "debit", "presentation": [ "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofNetFundedStatusDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prior service cost (credit)", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), before Tax", "documentation": "Amount, before tax, of cost (credit) of benefit change attributable to participants' prior service from plan amendment or plan initiation of defined benefit plan, that has not been recognized in net periodic benefit cost (credit)." } } }, "auth_ref": [ "r7", "r174", "r667" ] }, "us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract", "presentation": [ "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome" ], "lang": { "en-us": { "role": { "terseLabel": "Employee benefit plans:", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract", "presentation": [ "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome" ], "lang": { "en-us": { "role": { "terseLabel": "Derivatives & hedges:", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeFinalizationOfPensionAndNonPensionPostretirementPlanValuationTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeFinalizationOfPensionAndNonPensionPostretirementPlanValuationTax", "crdr": "debit", "calculation": { "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Consumer settlement/ curtailment", "label": "Other Comprehensive Income (Loss), Defined Benefit Plan, Adjustment for Settlement or Curtailment Gain (Loss), Tax", "documentation": "Amount of tax expense (benefit) for increase (decrease) to other comprehensive income from settlement and curtailment gain (loss) of defined benefit plan." } } }, "auth_ref": [ "r9", "r227" ] }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax", "crdr": "credit", "calculation": { "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign currency translation", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss), before Reclassification and Tax", "documentation": "Amount before tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature." } } }, "auth_ref": [ "r6", "r174", "r850", "r852", "r857" ] }, "us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax", "crdr": "credit", "presentation": [ "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofNetFundedStatusDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Amortization of prior service (cost) credit", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), Reclassification Adjustment from AOCI, before Tax", "documentation": "Amount, before tax, of reclassification adjustment from accumulated other comprehensive (income) loss for prior service cost (credit) of defined benefit plan." } } }, "auth_ref": [ "r11", "r174", "r348", "r667" ] }, "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax", "crdr": "credit", "calculation": { "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome" ], "lang": { "en-us": { "role": { "totalLabel": "Net change", "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax", "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale." } } }, "auth_ref": [ "r341", "r342", "r344", "r978" ] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax", "crdr": "credit", "calculation": { "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome" ], "lang": { "en-us": { "role": { "totalLabel": "Net change", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax", "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness." } } }, "auth_ref": [ "r339", "r344", "r978" ] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax", "crdr": "debit", "presentation": [ "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncomeParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Derivatives & hedges", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax", "documentation": "Amount, after reclassification, of tax expense (benefit) for gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness." } } }, "auth_ref": [ "r345" ] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax", "crdr": "credit", "calculation": { "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome", "http://www.jnj.com/role/FairvaluemeasurementsSummaryofDerivativeActivityDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Unrealized gain (loss) arising during period", "terseLabel": "Amount of gain or (loss) recognized in AOCI", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax", "documentation": "Amount, after tax and before reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness." } } }, "auth_ref": [ "r339", "r344" ] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax", "crdr": "debit", "calculation": { "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome", "http://www.jnj.com/role/FairvaluemeasurementsSummaryofDerivativeActivityDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Reclassifications to earnings", "terseLabel": "Amount of gain or (loss) reclassified from AOCI into income", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax", "documentation": "Amount, after tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness." } } }, "auth_ref": [ "r344", "r347" ] }, "us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax", "crdr": "credit", "presentation": [ "http://www.jnj.com/role/FairvaluemeasurementsSummaryofDerivativeActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amount of gain or (loss) recognized in AOCI", "label": "Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, after Tax", "documentation": "Amount, after tax and before adjustments, of gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method." } } }, "auth_ref": [ "r340", "r344", "r806", "r810" ] }, "us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax", "crdr": "credit", "presentation": [ "http://www.jnj.com/role/FairvaluemeasurementsScheduleofEffectofNetInvestmentHedgesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gain/(Loss) Recognized In Accumulated OCI", "label": "Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments and Tax", "documentation": "Amount, before tax and adjustments, of gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method." } } }, "auth_ref": [ "r340", "r344", "r806", "r807", "r810" ] }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax", "crdr": "debit", "presentation": [ "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncomeParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign currency translation", "label": "Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax", "documentation": "Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature." } } }, "auth_ref": [ "r6", "r9", "r854", "r864" ] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.jnj.com/role/AccumulatedothercomprehensiveincomelossDetails", "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome", "http://www.jnj.com/role/ConsolidatedStatementsofEquity" ], "lang": { "en-us": { "role": { "totalLabel": "Other comprehensive income (loss)", "verboseLabel": "Other comprehensive income (loss), net of tax", "terseLabel": "Net change", "label": "Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss)." } } }, "auth_ref": [ "r22", "r32", "r350", "r353", "r358", "r384", "r858", "r859", "r865", "r953", "r978", "r1406", "r1407" ] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "presentation": [ "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome" ], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive income (loss), net of tax", "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]" } } }, "auth_ref": [] }, "jnj_OtherComprehensiveIncomeLossPensionAndOtherEffectsOfExchangeRateNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "OtherComprehensiveIncomeLossPensionAndOtherEffectsOfExchangeRateNetOfTax", "crdr": "debit", "calculation": { "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Effect of exchange rates", "label": "Other comprehensive income (loss), pension and other, effects of exchange rate net of tax", "documentation": "other comprehensive income loss, pension and other , effects of exchange rate net of tax" } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax", "crdr": "debit", "presentation": [ "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofNetFundedStatusDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total loss/(income) recognized in other comprehensive income, before tax", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, before Tax", "documentation": "Amount, before tax, after reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan." } } }, "auth_ref": [ "r7", "r8", "r173", "r174", "r978", "r1189", "r1509" ] }, "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax", "crdr": "debit", "calculation": { "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome" ], "lang": { "en-us": { "role": { "negatedTotalLabel": "Net change", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax", "documentation": "Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan." } } }, "auth_ref": [ "r7", "r8", "r173", "r174", "r978" ] }, "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax", "crdr": "credit", "presentation": [ "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofNetFundedStatusDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Net actuarial (gain) loss", "label": "Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, before Tax", "documentation": "Amount, before tax, of gain (loss) for (increase) decrease in value of benefit obligation for change in actuarial assumptions and increase (decrease) in value of plan assets from experience different from that assumed of defined benefit plan, that has not been recognized in net periodic benefit (cost) credit." } } }, "auth_ref": [ "r173", "r174", "r214" ] }, "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax", "crdr": "credit", "presentation": [ "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncomeParenthetical" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Employee benefits", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, Tax", "documentation": "Amount, after reclassification adjustment, of tax (expense) benefit for (increase) decrease in accumulated other comprehensive income of defined benefit plan." } } }, "auth_ref": [ "r7", "r8", "r9", "r173", "r227" ] }, "jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax": { "xbrltype": "monetaryItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax", "crdr": "debit", "calculation": { "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Prior service credit (cost), net of amortization", "label": "Other Comprehensive (Income) Loss, Pension and Other Postretirement Benefit Plans, Net Prior Service Cost (Credit), Net of Amortization, Arising During Period, Net of Tax", "documentation": "Other Comprehensive (Income) Loss, Pension and Other Postretirement Benefit Plans, Net Prior Service Cost (Credit), Net of Amortization, Arising During Period, Net of Tax" } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax", "crdr": "debit", "calculation": { "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Reclassifications to earnings", "label": "Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax", "documentation": "Amount after tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities." } } }, "auth_ref": [ "r11", "r174", "r348", "r485" ] }, "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax", "crdr": "debit", "presentation": [ "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofNetFundedStatusDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization of net actuarial loss", "label": "Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), Reclassification Adjustment from AOCI, before Tax", "documentation": "Amount, before tax, of reclassification adjustment from accumulated other comprehensive income (loss) for gain (loss) of defined benefit plan." } } }, "auth_ref": [ "r11", "r174", "r348", "r667" ] }, "jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax": { "xbrltype": "monetaryItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax", "crdr": "debit", "calculation": { "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Gain (loss), net of amortization", "label": "Other Comprehensive (Income) Loss, Reclassification Adjustment from AOCI Pension and Other Postretirement Benefit Plans for Net Gain Loss, Net of Amortization, Net of Tax", "documentation": "Other Comprehensive (Income) Loss, Reclassification Adjustment from AOCI Pension and Other Postretirement Benefit Plans for Net Gain Loss, Net of Amortization, Net of Tax" } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "crdr": "credit", "calculation": { "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome" ], "lang": { "en-us": { "role": { "terseLabel": "Unrealized holding gain (loss) arising during period", "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax", "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale." } } }, "auth_ref": [ "r341", "r344", "r485" ] }, "us-gaap_OtherCurrentLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherCurrentLiabilitiesMember", "presentation": [ "http://www.jnj.com/role/FairvaluemeasurementsFinancialAssetsandLiabilitiesatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Current Liabilities", "label": "Other Current Liabilities [Member]", "documentation": "Primary financial statement caption encompassing other current liabilities." } } }, "auth_ref": [] }, "us-gaap_OtherDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherDebtSecuritiesMember", "presentation": [ "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Other Debt Obligations [Member]", "documentation": "Investments in debt securities classified as other." } } }, "auth_ref": [ "r1459", "r1507" ] }, "jnj_OtherImmunologyMember": { "xbrltype": "domainItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "OtherImmunologyMember", "presentation": [ "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Immunology", "label": "Other Immunology [Member]", "documentation": "Other Immunology [Member]" } } }, "auth_ref": [] }, "jnj_OtherIncomeExpenseNetMember": { "xbrltype": "domainItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "OtherIncomeExpenseNetMember", "presentation": [ "http://www.jnj.com/role/FairvaluemeasurementsScheduleofEffectofNetInvestmentHedgesDetails", "http://www.jnj.com/role/FairvaluemeasurementsSummaryofDerivativeActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other (Income) Expense", "label": "Other Income Expense Net [Member]", "documentation": "Other Income Expense Net [Member]" } } }, "auth_ref": [] }, "jnj_OtherInfectiousDiseasesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "OtherInfectiousDiseasesMember", "presentation": [ "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Infectious Diseases", "label": "Other Infectious Diseases [Member]", "documentation": "Other Infectious Diseases [Member]" } } }, "auth_ref": [] }, "us-gaap_OtherIntangibleAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherIntangibleAssetsMember", "presentation": [ "http://www.jnj.com/role/IntangibleassetsandgoodwilScheduleofIntangibleAssetsandGoodwillDetails", "http://www.jnj.com/role/IntangibleassetsandgoodwillNarrativeDetails", "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingByGeographicAreaDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Customer relationships and other intangible assets", "terseLabel": "Other Intangible Assets", "label": "Other Intangible Assets [Member]", "documentation": "Intangible assets classified as other." } } }, "auth_ref": [ "r1175", "r1473", "r1474", "r1475", "r1476", "r1477", "r1478", "r1479", "r1480", "r1481", "r1482" ] }, "us-gaap_OtherInvestmentNotReadilyMarketableAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherInvestmentNotReadilyMarketableAxis", "presentation": [ "http://www.jnj.com/role/FairvaluemeasurementsNarrativeDetails", "http://www.jnj.com/role/FairvaluemeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Investment Not Readily Marketable [Axis]", "label": "Other Investment Not Readily Marketable [Axis]", "documentation": "Information by investment not readily marketable." } } }, "auth_ref": [ "r1604" ] }, "us-gaap_OtherInvestmentNotReadilyMarketableLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherInvestmentNotReadilyMarketableLineItems", "presentation": [ "http://www.jnj.com/role/FairvaluemeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Investment Not Readily Marketable [Line Items]", "label": "Other Investment Not Readily Marketable [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r1604" ] }, "us-gaap_OtherInvestmentNotReadilyMarketableNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherInvestmentNotReadilyMarketableNameDomain", "presentation": [ "http://www.jnj.com/role/FairvaluemeasurementsNarrativeDetails", "http://www.jnj.com/role/FairvaluemeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Investment Not Readily Marketable, Name [Domain]", "label": "Other Investment Not Readily Marketable, Name [Domain]", "documentation": "Name of the investment category or actual investment title." } } }, "auth_ref": [ "r1604" ] }, "us-gaap_OtherInvestmentNotReadilyMarketableTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherInvestmentNotReadilyMarketableTable", "presentation": [ "http://www.jnj.com/role/FairvaluemeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Investment Not Readily Marketable [Table]", "label": "Other Investment Not Readily Marketable [Table]", "documentation": "Disclosure of information about investment not readily marketable." } } }, "auth_ref": [ "r1604" ] }, "us-gaap_OtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://www.jnj.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.jnj.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "verboseLabel": "Other liabilities", "label": "Other Liabilities, Noncurrent", "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r157" ] }, "jnj_OtherMember": { "xbrltype": "domainItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "OtherMember", "presentation": [ "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Other [Member]", "documentation": "Other [Member]" } } }, "auth_ref": [] }, "jnj_OtherNonLongLivedAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "OtherNonLongLivedAssets", "crdr": "debit", "presentation": [ "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingByGeographicAreaDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other non long-lived assets", "label": "Other Non Long Lived Assets", "documentation": "Other non long lived assets." } } }, "auth_ref": [] }, "us-gaap_OtherNoncurrentLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNoncurrentLiabilitiesMember", "presentation": [ "http://www.jnj.com/role/FairvaluemeasurementsFinancialAssetsandLiabilitiesatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Noncurrent Liabilities", "label": "Other Noncurrent Liabilities [Member]", "documentation": "Primary financial statement caption encompassing other noncurrent liabilities." } } }, "auth_ref": [] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.jnj.com/role/ConsolidatedStatementsofEarnings", "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasIncomeBeforeTaxbySegmentDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other (income) expense, net", "terseLabel": "Other (income) expense, net", "label": "Other Nonoperating Income (Expense)", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": [ "r184" ] }, "jnj_OtherOncologyMember": { "xbrltype": "domainItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "OtherOncologyMember", "presentation": [ "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Oncology", "label": "Other Oncology [Member]", "documentation": "Other Oncology [Member]" } } }, "auth_ref": [] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OtherPerfMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Other Performance Measure, Amount", "label": "Other Performance Measure, Amount" } } }, "auth_ref": [ "r1323" ] }, "us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherPostretirementBenefitPlansDefinedBenefitMember", "presentation": [ "http://www.jnj.com/role/PensionsandotherbenefitplansComponentsofNetPeriodicBenefitCostDetails", "http://www.jnj.com/role/PensionsandotherbenefitplansNarrativeDetails", "http://www.jnj.com/role/PensionsandotherbenefitplansProjectedFutureBenefitPaymentsfromCompanysRetirementandOtherBenefitPlansDetails", "http://www.jnj.com/role/PensionsandotherbenefitplansRatesUsedtoDevelopActuarialPresentValueofProjectedBenefitObligationDetails", "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofNetFundedStatusDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Other Benefit Plans", "terseLabel": "Other benefit plans", "label": "Other Postretirement Benefits Plan [Member]", "documentation": "Plan designed to provide other postretirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes pension benefits." } } }, "auth_ref": [ "r623", "r626", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r640", "r641", "r642", "r643", "r644", "r645", "r646", "r647", "r648", "r650", "r651", "r652", "r653", "r654", "r655", "r657", "r658", "r659", "r660", "r661", "r662", "r663", "r664", "r665", "r666", "r667", "r668", "r670", "r672", "r673", "r675", "r678", "r681", "r685", "r686", "r687", "r688", "r689", "r690", "r691", "r692", "r693", "r694", "r698", "r699", "r700", "r1189", "r1190", "r1191", "r1192", "r1193" ] }, "us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherPostretirementDefinedBenefitPlanLiabilitiesCurrentAndNoncurrent", "crdr": "credit", "calculation": { "http://www.jnj.com/role/EmployeerelatedobligationsEmployeeRelatedObligationsDetails": { "parentTag": "jnj_EmployeeObligations", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.jnj.com/role/EmployeerelatedobligationsEmployeeRelatedObligationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Postretirement benefits", "label": "Liability, Other Postretirement Defined Benefit Plan", "documentation": "Amount of liability, recognized in statement of financial position, for defined benefit other postretirement plan. Excludes pension plan." } } }, "auth_ref": [ "r77", "r78", "r237" ] }, "jnj_OtherPulmonaryHypertensionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "OtherPulmonaryHypertensionMember", "presentation": [ "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Pulmonary Hypertension", "label": "Other Pulmonary Hypertension [Member]", "documentation": "Other Pulmonary Hypertension" } } }, "auth_ref": [] }, "jnj_OtherSovereignSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "OtherSovereignSecuritiesMember", "presentation": [ "http://www.jnj.com/role/CashcashequivalentsandcurrentmarketablesecuritiesCashandCashEquivalentCompositionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Sovereign Securities", "label": "Other Sovereign Securities [Member]", "documentation": "Other Sovereign Securities" } } }, "auth_ref": [] }, "us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain", "presentation": [ "http://www.jnj.com/role/CashcashequivalentsandcurrentmarketablesecuritiesCashandCashEquivalentCompositionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other than Temporary Impairment, Credit Losses Recognized in Earnings, Categories of Investments [Domain]", "label": "Other than Temporary Impairment, Credit Losses Recognized in Earnings, Categories of Investments [Domain]", "documentation": "Provides the categories of debt securities, available-for-sale or held-to-maturity, on which an entity may recognize other than temporary impairments (OTTI) for which a portion related to credit losses has been recognized in earnings and a portion related to all other factors has been recognized in other comprehensive income." } } }, "auth_ref": [ "r31" ] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingAggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount", "label": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r1284", "r1295", "r1305", "r1338" ] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Amount", "label": "Outstanding Recovery Compensation Amount" } } }, "auth_ref": [ "r1287", "r1298", "r1308", "r1341" ] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Outstanding Recovery, Individual Name" } } }, "auth_ref": [ "r1287", "r1298", "r1308", "r1341" ] }, "srt_OwnershipAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "OwnershipAxis", "presentation": [ "http://www.jnj.com/role/FairvaluemeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails", "http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsDetailsDetails", "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ownership [Axis]", "label": "Ownership [Axis]", "documentation": "Information by name of entity in which ownership interest is disclosed. Excludes equity method investee and named security investment." } } }, "auth_ref": [] }, "srt_OwnershipDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "OwnershipDomain", "presentation": [ "http://www.jnj.com/role/FairvaluemeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails", "http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsDetailsDetails", "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ownership [Domain]", "label": "Ownership [Domain]", "documentation": "Name of entity in which ownership interest is disclosed. Excludes equity method investee and named security investment." } } }, "auth_ref": [] }, "jnj_OwnershipPercentageSplitOffPercent": { "xbrltype": "percentItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "OwnershipPercentageSplitOffPercent", "presentation": [ "http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsDetailsDetails", "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Split-off percentage", "label": "Ownership Percentage, Split-Off Percent", "documentation": "Ownership Percentage, Split-Off Percent" } } }, "auth_ref": [] }, "jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember": { "xbrltype": "domainItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "PREZISTAPREZCOBIXREZOLSTASYMTUZAMember", "presentation": [ "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA", "label": "PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA [Member]", "documentation": "PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA [Member]" } } }, "auth_ref": [] }, "jnj_PatentsAndTrademarksMember": { "xbrltype": "domainItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "PatentsAndTrademarksMember", "presentation": [ "http://www.jnj.com/role/IntangibleassetsandgoodwilScheduleofIntangibleAssetsandGoodwillDetails", "http://www.jnj.com/role/IntangibleassetsandgoodwillNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Patents And Trademarks", "label": "Patents And Trademarks [Member]", "documentation": "Patents And Trademarks [Member]" } } }, "auth_ref": [] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]" } } }, "auth_ref": [ "r1312" ] }, "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForProceedsFromOtherInvestingActivities", "crdr": "credit", "calculation": { "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Other (including capitalized licenses and milestones)", "label": "Payments for (Proceeds from) Other Investing Activities", "documentation": "Amount of cash (inflow) outflow from investing activities classified as other." } } }, "auth_ref": [ "r1381", "r1413" ] }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForRepurchaseOfCommonStock", "crdr": "credit", "calculation": { "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Repurchase of common stock", "label": "Payments for Repurchase of Common Stock", "documentation": "The cash outflow to reacquire common stock during the period." } } }, "auth_ref": [ "r188" ] }, "jnj_PaymentsMadeInBusinessSeparation": { "xbrltype": "monetaryItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "PaymentsMadeInBusinessSeparation", "crdr": "credit", "calculation": { "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 11.0 } }, "presentation": [ "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Cash transferred to Kenvue at separation", "label": "Payments Made In Business Separation", "documentation": "Payments Made In Business Separation" } } }, "auth_ref": [] }, "us-gaap_PaymentsOfOrdinaryDividends": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsOfOrdinaryDividends", "crdr": "credit", "calculation": { "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 8.0 } }, "presentation": [ "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Dividends to shareholders", "label": "Payments of Ordinary Dividends", "documentation": "Cash outflow in the form of ordinary dividends to common shareholders, preferred shareholders and noncontrolling interests, generally out of earnings." } } }, "auth_ref": [ "r188" ] }, "us-gaap_PaymentsToAcquireBusinessesGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireBusinessesGross", "crdr": "credit", "presentation": [ "http://www.jnj.com/role/AcquisitionsanddivestituresNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Payments to acquire businesses, gross", "label": "Payments to Acquire Businesses, Gross", "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price." } } }, "auth_ref": [ "r44", "r795" ] }, "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired", "crdr": "credit", "calculation": { "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.jnj.com/role/AcquisitionsanddivestituresNarrativeDetails", "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Acquisitions, net of cash acquired", "terseLabel": "Acquisitions, net of cash acquired (Note 18)", "label": "Payments to Acquire Businesses, Net of Cash Acquired", "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase." } } }, "auth_ref": [ "r44" ] }, "us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireInProcessResearchAndDevelopment", "crdr": "credit", "presentation": [ "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails", "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Payments to Acquire in Process Research and Development", "label": "Payments to Acquire in Process Research and Development", "documentation": "The cash outflows from the purchase of net carrying value allocated to in-process research and development costs and materials acquired in a business combination." } } }, "auth_ref": [ "r44" ] }, "us-gaap_PaymentsToAcquireInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireInvestments", "crdr": "credit", "calculation": { "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 8.0 } }, "presentation": [ "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Purchases of investments", "label": "Payments to Acquire Investments", "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period." } } }, "auth_ref": [ "r186" ] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Additions to property, plant and equipment", "label": "Payments to Acquire Property, Plant, and Equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r187" ] }, "jnj_PaymentsToAcquiredInProcessResearchAndDevelopmentAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "PaymentsToAcquiredInProcessResearchAndDevelopmentAssets", "crdr": "credit", "calculation": { "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Purchases of in-process research and development assets", "label": "Payments To Acquired In-Process Research And Development Assets", "documentation": "Payments To Acquired In-Process Research And Development Assets" } } }, "auth_ref": [] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupIssuersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Issuers, Footnote", "label": "Peer Group Issuers, Footnote [Text Block]" } } }, "auth_ref": [ "r1322" ] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Total Shareholder Return Amount", "label": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": [ "r1322" ] }, "jnj_PelvicMeshesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "PelvicMeshesMember", "presentation": [ "http://www.jnj.com/role/LegalproceedingsProductLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Pelvic Meshes", "label": "Pelvic Meshes [Member]", "documentation": "Pelvic meshes." } } }, "auth_ref": [] }, "us-gaap_PendingLitigationMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PendingLitigationMember", "presentation": [ "http://www.jnj.com/role/LegalproceedingsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Pending Litigation", "label": "Pending Litigation [Member]", "documentation": "Risk of loss associated with the outcome of pending litigation against the entity, for example, but not limited to, litigation in arbitration or within the trial process." } } }, "auth_ref": [ "r1489" ] }, "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "presentation": [ "http://www.jnj.com/role/Pensionsandotherbenefitplans" ], "lang": { "en-us": { "role": { "verboseLabel": "Pensions and other benefit plans", "label": "Retirement Benefits [Text Block]", "documentation": "The entire disclosure for retirement benefits." } } }, "auth_ref": [ "r622", "r647", "r649", "r655", "r674", "r676", "r677", "r678", "r679", "r680", "r695", "r696", "r698", "r1189" ] }, "us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities", "crdr": "credit", "calculation": { "http://www.jnj.com/role/EmployeerelatedobligationsEmployeeRelatedObligationsDetails_1": { "parentTag": "jnj_EmployeeObligations", "weight": 1.0, "order": 1.0 }, "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofNetFundedStatusDetails": { "parentTag": "us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.jnj.com/role/EmployeerelatedobligationsEmployeeRelatedObligationsDetails", "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofNetFundedStatusDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Less current benefits payable", "negatedLabel": "Current liabilities", "label": "Liability, Defined Benefit Plan, Current", "documentation": "Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as current." } } }, "auth_ref": [ "r152", "r623", "r624", "r646", "r1189" ] }, "us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://www.jnj.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 }, "http://www.jnj.com/role/EmployeerelatedobligationsEmployeeRelatedObligationsDetails_1": { "parentTag": "jnj_EmployeeObligations", "weight": 1.0, "order": 2.0 }, "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofNetFundedStatusDetails": { "parentTag": "us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.jnj.com/role/ConsolidatedBalanceSheets", "http://www.jnj.com/role/EmployeerelatedobligationsEmployeeRelatedObligationsDetails", "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofNetFundedStatusDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Employee related obligations", "terseLabel": "Employee related obligations\u00a0\u2014 non-current", "negatedLabel": "Non-current liabilities", "label": "Liability, Defined Benefit Plan, Noncurrent", "documentation": "Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as noncurrent." } } }, "auth_ref": [ "r157", "r623", "r624", "r646", "r1189" ] }, "us-gaap_PensionContributions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PensionContributions", "crdr": "credit", "presentation": [ "http://www.jnj.com/role/PensionsandotherbenefitplansNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contribution to pension plans", "label": "Payment for Pension Benefits", "documentation": "Amount of cash outflow for pension benefit. Includes, but is not limited to, employer contribution to fund plan asset and payment to retiree. Excludes other postretirement benefit." } } }, "auth_ref": [ "r12" ] }, "us-gaap_PensionPlansDefinedBenefitMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PensionPlansDefinedBenefitMember", "presentation": [ "http://www.jnj.com/role/PensionsandotherbenefitplansComponentsofNetPeriodicBenefitCostDetails", "http://www.jnj.com/role/PensionsandotherbenefitplansNarrativeDetails", "http://www.jnj.com/role/PensionsandotherbenefitplansProjectedFutureBenefitPaymentsfromCompanysRetirementandOtherBenefitPlansDetails", "http://www.jnj.com/role/PensionsandotherbenefitplansRatesUsedtoDevelopActuarialPresentValueofProjectedBenefitObligationDetails", "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofDefinedBenefitPlansDisclosuresDetails", "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofNetFundedStatusDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Retirement Plans", "terseLabel": "Retirement plans", "label": "Pension Plan [Member]", "documentation": "Plan designed to provide participant with pension benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes other postretirement benefits." } } }, "auth_ref": [ "r623", "r626", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r640", "r641", "r642", "r643", "r644", "r645", "r646", "r647", "r648", "r650", "r651", "r652", "r653", "r654", "r655", "r656", "r657", "r658", "r659", "r660", "r661", "r662", "r663", "r664", "r665", "r666", "r667", "r668", "r670", "r672", "r673", "r675", "r678", "r681", "r685", "r686", "r687", "r688", "r689", "r690", "r691", "r692", "r693", "r694", "r698", "r699", "r703", "r1189", "r1190", "r1194", "r1195", "r1196" ] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoActuallyPaidCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Actually Paid Compensation Amount", "label": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": [ "r1314" ] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO", "label": "PEO [Member]" } } }, "auth_ref": [ "r1331" ] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Name", "label": "PEO Name" } } }, "auth_ref": [ "r1324" ] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Total Compensation Amount", "label": "PEO Total Compensation Amount" } } }, "auth_ref": [ "r1313" ] }, "jnj_PercentageChangeInSalesBySegmentOfBusiness": { "xbrltype": "percentItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "PercentageChangeInSalesBySegmentOfBusiness", "presentation": [ "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "% Change", "label": "Percentage Change In Sales By Segment Of Business", "documentation": "Percentage change in sales by segment of business." } } }, "auth_ref": [] }, "jnj_PercentageOfCorridorOfGreaterOfMarketValueOfAssets": { "xbrltype": "percentItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "PercentageOfCorridorOfGreaterOfMarketValueOfAssets", "presentation": [ "http://www.jnj.com/role/PensionsandotherbenefitplansNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of corridor of greater of market value of assets", "label": "Percentage Of Corridor Of Greater Of Market Value Of Assets", "documentation": "Percentage of corridor of greater of market value of assets." } } }, "auth_ref": [] }, "us-gaap_PerformanceSharesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PerformanceSharesMember", "presentation": [ "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsNarrativeDetails", "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsSummaryofRestrictedShareUnitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Performance Shares", "label": "Performance Shares [Member]", "documentation": "Share-based payment arrangement awarded for meeting performance target." } } }, "auth_ref": [] }, "jnj_PharmaceuticalMember": { "xbrltype": "domainItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "PharmaceuticalMember", "presentation": [ "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails", "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingByGeographicAreaDetails", "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Pharmaceutical", "terseLabel": "Pharmaceutical", "label": "Pharmaceutical [Member]", "documentation": "Pharmaceutical." } } }, "auth_ref": [] }, "jnj_PhysiomeshMember": { "xbrltype": "domainItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "PhysiomeshMember", "presentation": [ "http://www.jnj.com/role/LegalproceedingsNarrativeDetails", "http://www.jnj.com/role/LegalproceedingsProductLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Physiomesh", "label": "Physiomesh [Member]", "documentation": "Physiomesh [Member]" } } }, "auth_ref": [] }, "jnj_PinnacleAcetabularCupSystemMember": { "xbrltype": "domainItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "PinnacleAcetabularCupSystemMember", "presentation": [ "http://www.jnj.com/role/LegalproceedingsProductLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Pinnacle Acetabular Cup System", "label": "Pinnacle Acetabular Cup System [Member]", "documentation": "Pinnacle Acetabular cup system." } } }, "auth_ref": [] }, "us-gaap_PlanAssetCategoriesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanAssetCategoriesDomain", "presentation": [ "http://www.jnj.com/role/PensionsandotherbenefitplansCompanyRetirementPlanAssetAllocationandTargetAllocationsDetails", "http://www.jnj.com/role/PensionsandotherbenefitplansNarrativeDetails", "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofDefinedBenefitPlansDisclosuresDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Defined Benefit Plan, Plan Assets, Category [Domain]", "label": "Defined Benefit Plan, Plan Assets, Category [Domain]", "documentation": "Defined benefit plan asset investment." } } }, "auth_ref": [ "r647", "r648", "r650", "r651", "r652", "r653", "r654", "r655", "r675", "r1187", "r1188", "r1189" ] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameAxis", "presentation": [ "http://www.jnj.com/role/PensionsandotherbenefitplansInformationRelatedtotheBenefitObligationandtheFairValueofPlanAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Plan Name [Axis]", "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": [ "r1517", "r1518", "r1519", "r1520", "r1521", "r1522", "r1523", "r1524", "r1525", "r1526", "r1527", "r1528", "r1529", "r1530", "r1531", "r1532", "r1533", "r1534", "r1535", "r1536", "r1537", "r1538", "r1539", "r1540", "r1541", "r1542" ] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameDomain", "presentation": [ "http://www.jnj.com/role/PensionsandotherbenefitplansInformationRelatedtotheBenefitObligationandtheFairValueofPlanAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Plan Name [Domain]", "label": "Plan Name [Domain]", "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": [ "r1517", "r1518", "r1519", "r1520", "r1521", "r1522", "r1523", "r1524", "r1525", "r1526", "r1527", "r1528", "r1529", "r1530", "r1531", "r1532", "r1533", "r1534", "r1535", "r1536", "r1537", "r1538", "r1539", "r1540", "r1541", "r1542" ] }, "ecd_PnsnAdjsPrrSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsPrrSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pension Adjustments Prior Service Cost", "label": "Pension Adjustments Prior Service Cost [Member]" } } }, "auth_ref": [ "r1315" ] }, "ecd_PnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pension Adjustments Service Cost", "label": "Pension Adjustments Service Cost [Member]" } } }, "auth_ref": [ "r1371" ] }, "ecd_PnsnBnftsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnBnftsAdjFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pension Benefits Adjustments, Footnote", "label": "Pension Benefits Adjustments, Footnote [Text Block]" } } }, "auth_ref": [ "r1314" ] }, "jnj_PonvoryMember": { "xbrltype": "domainItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "PonvoryMember", "presentation": [ "http://www.jnj.com/role/AcquisitionsanddivestituresNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ponvory", "label": "Ponvory [Member]", "documentation": "Ponvory" } } }, "auth_ref": [] }, "us-gaap_PostemploymentBenefitsLiabilityCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PostemploymentBenefitsLiabilityCurrentAndNoncurrent", "crdr": "credit", "calculation": { "http://www.jnj.com/role/EmployeerelatedobligationsEmployeeRelatedObligationsDetails": { "parentTag": "jnj_EmployeeObligations", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.jnj.com/role/EmployeerelatedobligationsEmployeeRelatedObligationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Postemployment benefits", "label": "Postemployment Benefits Liability", "documentation": "The carrying amount as of the balance sheet date of the obligations recognized for the various benefits provided to former or inactive employees, their beneficiaries, and covered dependents after employment but before retirement." } } }, "auth_ref": [ "r237", "r1503", "r1504" ] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesAuthorized", "presentation": [ "http://www.jnj.com/role/ConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares authorized (in shares)", "label": "Preferred Stock, Shares Authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r160", "r1058" ] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockValue", "crdr": "credit", "calculation": { "http://www.jnj.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.jnj.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock\u00a0\u2014 without par value (authorized and unissued 2,000,000\u00a0shares)", "label": "Preferred Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r160", "r968", "r1219" ] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "calculation": { "http://www.jnj.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.jnj.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "verboseLabel": "Prepaid expenses and other receivables", "label": "Prepaid Expense and Other Assets, Current", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r1405" ] }, "us-gaap_ProceedsFromDivestitureOfBusinesses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromDivestitureOfBusinesses", "crdr": "debit", "presentation": [ "http://www.jnj.com/role/AcquisitionsanddivestituresNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from divestiture of brands", "label": "Proceeds from Divestiture of Businesses", "documentation": "The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period." } } }, "auth_ref": [ "r43" ] }, "jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits": { "xbrltype": "monetaryItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits", "crdr": "debit", "calculation": { "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Proceeds from the exercise of stock options/employee withholding tax on stock awards, net", "label": "Proceeds From The Exercise Of Stock Options And Excess Tax Benefits", "documentation": "Proceeds From The Exercise Of Stock Options And Excess Tax Benefits" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIssuanceInitialPublicOffering": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceInitialPublicOffering", "crdr": "debit", "calculation": { "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows", "http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsDetailsDetails", "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from Kenvue initial public offering", "label": "Proceeds from Issuance Initial Public Offering", "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public." } } }, "auth_ref": [ "r10" ] }, "us-gaap_ProceedsFromIssuanceOfCommercialPaper": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfCommercialPaper", "crdr": "debit", "presentation": [ "http://www.jnj.com/role/FairvaluemeasurementsNarrativeDetails", "http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsDetailsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from issuance of commercial paper", "label": "Proceeds from Issuance of Commercial Paper", "documentation": "The cash inflow from borrowing by issuing commercial paper." } } }, "auth_ref": [ "r45" ] }, "us-gaap_ProceedsFromIssuanceOfLongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfLongTermDebt", "crdr": "debit", "calculation": { "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Proceeds from long-term debt, net of issuance costs", "label": "Proceeds from Issuance of Long-Term Debt", "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer." } } }, "auth_ref": [ "r45", "r1020" ] }, "jnj_ProceedsFromIssuanceOfLongTermDebtTransferredInBusinessSeparation": { "xbrltype": "monetaryItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "ProceedsFromIssuanceOfLongTermDebtTransferredInBusinessSeparation", "crdr": "debit", "calculation": { "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds of short and long-term debt, net of issuance cost, related to the debt that transferred to Kenvue at separation", "label": "Proceeds From Issuance Of Long-Term Debt, Transferred In Business Separation", "documentation": "Proceeds From Issuance Of Long-Term Debt, Transferred In Business Separation" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromPaymentsForOtherFinancingActivities", "crdr": "debit", "calculation": { "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Proceeds from (Payments for) Other Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities classified as other." } } }, "auth_ref": [ "r1382", "r1414" ] }, "us-gaap_ProceedsFromRoyaltiesReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromRoyaltiesReceived", "crdr": "debit", "presentation": [ "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from Royalties Received", "label": "Proceeds from Royalties Received", "documentation": "Cash received for royalties during the current period." } } }, "auth_ref": [ "r192", "r193" ] }, "us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromSaleMaturityAndCollectionsOfInvestments", "crdr": "debit", "calculation": { "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Sales of investments", "label": "Proceeds from Sale, Maturity and Collection of Investments", "documentation": "The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period." } } }, "auth_ref": [ "r42" ] }, "us-gaap_ProceedsFromSaleOfProductiveAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromSaleOfProductiveAssets", "crdr": "debit", "calculation": { "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Proceeds from the disposal of assets/businesses, net", "label": "Proceeds from Sale of Productive Assets", "documentation": "The cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets." } } }, "auth_ref": [ "r185" ] }, "us-gaap_ProceedsFromShortTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromShortTermDebt", "crdr": "debit", "calculation": { "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Proceeds from short-term debt", "label": "Proceeds from Short-Term Debt", "documentation": "The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r45" ] }, "jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities", "crdr": "debit", "calculation": { "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Credit support agreements activity, net", "label": "Proceeds (Payments) from (to) Credit Support Agreements, Financing Activities", "documentation": "Proceeds (Payments) from (to) Credit Support Agreements, Financing Activities" } } }, "auth_ref": [] }, "jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities", "crdr": "debit", "calculation": { "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Credit support agreements activity, net", "label": "Proceeds (Payments) from (to) Credit Support Agreements, Investing Activities", "documentation": "Proceeds (Payments) from (to) Credit Support Agreements, Investing Activities" } } }, "auth_ref": [] }, "us-gaap_ProductConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProductConcentrationRiskMember", "presentation": [ "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Project Concentration Risk", "label": "Product Concentration Risk [Member]", "documentation": "Reflects the percentage that revenues during the period from a specified product are to a specified benchmark, such as total net revenues, segment revenues or product line revenues. May also reflect the percentage contribution the product made to operating results. Risk is materially adverse effects of a loss of sales of a significant product or line of products, which could occur upon loss of rights to sell, distribute or license others; loss of patent or copyright protection; or technological obsolescence." } } }, "auth_ref": [ "r197" ] }, "jnj_ProductLiabilityContingencyNumberOfClaimant": { "xbrltype": "integerItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "ProductLiabilityContingencyNumberOfClaimant", "presentation": [ "http://www.jnj.com/role/LegalproceedingsNarrativeDetails", "http://www.jnj.com/role/LegalproceedingsProductLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product liability contingency, number of claimants", "label": "Product Liability Contingency Number Of Claimant", "documentation": "Product liability contingency number of claimant." } } }, "auth_ref": [] }, "jnj_ProductLiabilityPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "ProductLiabilityPolicyTextBlock", "presentation": [ "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Product liability", "label": "Product Liability [Policy Text Block]", "documentation": "Product liability." } } }, "auth_ref": [] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductOrServiceAxis", "presentation": [ "http://www.jnj.com/role/AcquisitionsanddivestituresNarrativeDetails", "http://www.jnj.com/role/LegalproceedingsNarrativeDetails", "http://www.jnj.com/role/LegalproceedingsProductLiabilitiesDetails", "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails", "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingByGeographicAreaDetails", "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails", "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Axis]", "label": "Product and Service [Axis]", "documentation": "Information by product and service, or group of similar products and similar services." } } }, "auth_ref": [ "r280", "r281", "r282", "r283", "r284", "r285", "r305", "r448", "r917", "r996", "r997", "r998", "r999", "r1000", "r1001", "r1002", "r1144", "r1184", "r1229", "r1231", "r1232", "r1236", "r1239", "r1402", "r1493", "r1494", "r1501", "r1613", "r1617", "r1618", "r1619", "r1620", "r1621", "r1622", "r1623", "r1624", "r1625", "r1626", "r1627", "r1628", "r1629", "r1630", "r1631", "r1632", "r1633", "r1634", "r1635", "r1636", "r1637", "r1638", "r1639", "r1640", "r1641", "r1642", "r1644", "r1645" ] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductsAndServicesDomain", "presentation": [ "http://www.jnj.com/role/AcquisitionsanddivestituresNarrativeDetails", "http://www.jnj.com/role/LegalproceedingsNarrativeDetails", "http://www.jnj.com/role/LegalproceedingsProductLiabilitiesDetails", "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails", "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingByGeographicAreaDetails", "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails", "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Domain]", "label": "Product and Service [Domain]", "documentation": "Product or service, or a group of similar products or similar services." } } }, "auth_ref": [ "r280", "r281", "r282", "r283", "r284", "r285", "r305", "r448", "r917", "r996", "r997", "r998", "r999", "r1000", "r1001", "r1002", "r1144", "r1184", "r1229", "r1231", "r1232", "r1236", "r1239", "r1402", "r1493", "r1494", "r1501", "r1613", "r1617", "r1618", "r1619", "r1620", "r1621", "r1622", "r1623", "r1624", "r1625", "r1626", "r1627", "r1628", "r1629", "r1630", "r1631", "r1632", "r1633", "r1634", "r1635", "r1636", "r1637", "r1638", "r1639", "r1640", "r1641", "r1642", "r1644", "r1645" ] }, "jnj_ProfitLossPercentToSales": { "xbrltype": "percentItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "ProfitLossPercentToSales", "presentation": [ "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of profit share payments (less than)", "label": "Profit Loss Percent To Sales", "documentation": "Profit loss percent to sales." } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentAbstract", "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment [Abstract]", "label": "Property, Plant and Equipment [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": [ "http://www.jnj.com/role/PropertyplantandequipmentPropertyPlantandEquipmentatCostandAccumulatedDepreciationDetails", "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingByGeographicAreaDetails", "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesEstimatedUsefulLivesofAssetsDetails", "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment, Type [Axis]", "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": [ "r15", "r881" ] }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "presentation": [ "http://www.jnj.com/role/Propertyplantandequipment" ], "lang": { "en-us": { "role": { "terseLabel": "Property, plant and equipment", "label": "Property, Plant and Equipment Disclosure [Text Block]", "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [ "r199", "r261", "r265", "r266" ] }, "us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentGross", "crdr": "debit", "calculation": { "http://www.jnj.com/role/PropertyplantandequipmentPropertyPlantandEquipmentatCostandAccumulatedDepreciationDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.jnj.com/role/PropertyplantandequipmentPropertyPlantandEquipmentatCostandAccumulatedDepreciationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total property, plant and equipment, gross", "label": "Property, Plant and Equipment, Gross", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r201", "r318", "r975" ] }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentLineItems", "presentation": [ "http://www.jnj.com/role/PropertyplantandequipmentPropertyPlantandEquipmentatCostandAccumulatedDepreciationDetails", "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesEstimatedUsefulLivesofAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment [Line Items]", "label": "Property, Plant and Equipment [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r881" ] }, "us-gaap_PropertyPlantAndEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentMember", "presentation": [ "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingByGeographicAreaDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment", "label": "Property, Plant and Equipment [Member]", "documentation": "Physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://www.jnj.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 }, "http://www.jnj.com/role/PropertyplantandequipmentPropertyPlantandEquipmentatCostandAccumulatedDepreciationDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.jnj.com/role/ConsolidatedBalanceSheets", "http://www.jnj.com/role/PropertyplantandequipmentPropertyPlantandEquipmentatCostandAccumulatedDepreciationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Property, plant and equipment, net", "totalLabel": "Total property, plant and equipment, net", "label": "Property, Plant and Equipment, Net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r15", "r881", "r961", "r975", "r1219" ] }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "presentation": [ "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Property, plant and equipment and depreciation", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [ "r15", "r261", "r265", "r973" ] }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": [ "http://www.jnj.com/role/PropertyplantandequipmentTables" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment at Cost and Accumulated Depreciation", "label": "Property, Plant and Equipment [Table Text Block]", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r15" ] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": [ "http://www.jnj.com/role/PropertyplantandequipmentPropertyPlantandEquipmentatCostandAccumulatedDepreciationDetails", "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingByGeographicAreaDetails", "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesEstimatedUsefulLivesofAssetsDetails", "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment, Type [Domain]", "label": "Long-Lived Tangible Asset [Domain]", "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": [ "r201", "r881" ] }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentUsefulLife", "presentation": [ "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesEstimatedUsefulLivesofAssetsDetails", "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Estimated useful lives of the assets", "label": "Property, Plant and Equipment, Useful Life", "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment." } } }, "auth_ref": [] }, "jnj_ProteologixMember": { "xbrltype": "domainItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "ProteologixMember", "presentation": [ "http://www.jnj.com/role/AcquisitionsanddivestituresNarrativeDetails", "http://www.jnj.com/role/FairvaluemeasurementsFinancialAssetsandLiabilitiesatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proteologix", "label": "Proteologix [Member]", "documentation": "Proteologix" } } }, "auth_ref": [] }, "us-gaap_ProvisionForDoubtfulAccounts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProvisionForDoubtfulAccounts", "crdr": "debit", "calculation": { "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Credit losses and accounts receivable allowances", "label": "Accounts Receivable, Credit Loss Expense (Reversal)", "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable." } } }, "auth_ref": [ "r361", "r496" ] }, "jnj_PulmonaryHypertensionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "PulmonaryHypertensionMember", "presentation": [ "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Pulmonary Hypertension", "label": "Pulmonary Hypertension [Member]", "documentation": "Pulmonary Hypertension [Member]" } } }, "auth_ref": [] }, "jnj_PurchasedInProcessResearchAndDevelopmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "PurchasedInProcessResearchAndDevelopmentMember", "presentation": [ "http://www.jnj.com/role/IncometaxesNarrativeDetails", "http://www.jnj.com/role/IntangibleassetsandgoodwilScheduleofIntangibleAssetsandGoodwillDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Purchased in-process research and development", "terseLabel": "Purchased in-process research and development(1)", "label": "Purchased In-Process Research And Development [Member]", "documentation": "Purchased In-Process Research And Development [Member]" } } }, "auth_ref": [] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure", "label": "Pay vs Performance Disclosure [Table]" } } }, "auth_ref": [ "r1312" ] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure, Table", "label": "Pay vs Performance [Table Text Block]" } } }, "auth_ref": [ "r1312" ] }, "jnj_QualifiedPlansMember": { "xbrltype": "domainItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "QualifiedPlansMember", "presentation": [ "http://www.jnj.com/role/PensionsandotherbenefitplansInformationRelatedtotheBenefitObligationandtheFairValueofPlanAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Qualified Plans", "label": "Qualified Plans [Member]", "documentation": "Qualified plans." } } }, "auth_ref": [] }, "jnj_RDRestructuringPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "RDRestructuringPlanMember", "presentation": [ "http://www.jnj.com/role/RestructuringNarrativeDetails", "http://www.jnj.com/role/RestructuringScheduleofRestructuringReserveDetails" ], "lang": { "en-us": { "role": { "terseLabel": "R&D Restructuring Plan", "label": "R&D Restructuring Plan [Member]", "documentation": "R&D Restructuring Plan" } } }, "auth_ref": [] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": [ "http://www.jnj.com/role/AcquisitionsanddivestituresNarrativeDetails", "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsNarrativeDetails", "http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsDetailsDetails", "http://www.jnj.com/role/PensionsandotherbenefitplansNarrativeDetails", "http://www.jnj.com/role/RestructuringNarrativeDetails", "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesEstimatedUsefulLivesofAssetsDetails", "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Range [Axis]", "label": "Statistical Measurement [Axis]", "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median." } } }, "auth_ref": [ "r271", "r273", "r275", "r276", "r278", "r307", "r308", "r564", "r565", "r566", "r567", "r647", "r701", "r732", "r733", "r734", "r742", "r827", "r890", "r899", "r915", "r1003", "r1005", "r1013", "r1048", "r1049", "r1102", "r1106", "r1108", "r1109", "r1120", "r1139", "r1140", "r1172", "r1183", "r1197", "r1210", "r1211", "r1215", "r1216", "r1231", "r1243", "r1487", "r1498", "r1576", "r1596", "r1597", "r1598", "r1599", "r1600" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": [ "http://www.jnj.com/role/AcquisitionsanddivestituresNarrativeDetails", "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsNarrativeDetails", "http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsDetailsDetails", "http://www.jnj.com/role/PensionsandotherbenefitplansNarrativeDetails", "http://www.jnj.com/role/RestructuringNarrativeDetails", "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesEstimatedUsefulLivesofAssetsDetails", "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Range [Domain]", "label": "Statistical Measurement [Domain]", "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median." } } }, "auth_ref": [ "r271", "r273", "r275", "r276", "r278", "r307", "r308", "r564", "r565", "r566", "r567", "r647", "r701", "r732", "r733", "r734", "r742", "r827", "r890", "r899", "r915", "r1003", "r1005", "r1013", "r1048", "r1049", "r1102", "r1106", "r1108", "r1109", "r1120", "r1139", "r1140", "r1172", "r1183", "r1197", "r1210", "r1211", "r1215", "r1216", "r1231", "r1243", "r1487", "r1498", "r1576", "r1596", "r1597", "r1598", "r1599", "r1600" ] }, "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract", "presentation": [ "http://www.jnj.com/role/AccumulatedothercomprehensiveincomelossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]", "label": "AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable", "presentation": [ "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasIncomeBeforeTaxbySegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]", "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]", "documentation": "Disclosure of information about the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment." } } }, "auth_ref": [ "r62", "r63" ] }, "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "presentation": [ "http://www.jnj.com/role/SegmentsofbusinessandgeographicareasTables" ], "lang": { "en-us": { "role": { "terseLabel": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated", "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]", "documentation": "Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment." } } }, "auth_ref": [ "r62", "r63" ] }, "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward", "presentation": [ "http://www.jnj.com/role/IncometaxesSummaryofActivityRelatedtoUnrecognizedTaxBenefitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of unrecognized tax benefits", "label": "Unrecognized Tax Benefits [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]" } } }, "auth_ref": [ "r1279", "r1290", "r1300", "r1333" ] }, "jnj_RegulationCharge": { "xbrltype": "monetaryItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "RegulationCharge", "crdr": "debit", "presentation": [ "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingByGeographicAreaDetails", "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Regulation charge", "label": "Regulation charge", "documentation": "Regulation charge" } } }, "auth_ref": [] }, "jnj_RemicadeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "RemicadeMember", "presentation": [ "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Remicade", "label": "Remicade [Member]", "documentation": "Remicade [Member]" } } }, "auth_ref": [] }, "us-gaap_RepaymentsOfLongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RepaymentsOfLongTermDebt", "crdr": "credit", "calculation": { "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 10.0 } }, "presentation": [ "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Repayment of long-term debt", "label": "Repayments of Long-Term Debt", "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": [ "r189", "r1023" ] }, "us-gaap_RepaymentsOfShortTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RepaymentsOfShortTermDebt", "crdr": "credit", "calculation": { "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 12.0 } }, "presentation": [ "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Repayment of short-term debt", "label": "Repayments of Short-Term Debt", "documentation": "The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r189" ] }, "us-gaap_RepurchaseAgreementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RepurchaseAgreementsMember", "presentation": [ "http://www.jnj.com/role/CashcashequivalentsandcurrentmarketablesecuritiesCashandCashEquivalentCompositionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "U.S. Reverse repurchase agreements", "label": "Repurchase Agreements [Member]", "documentation": "Investments represented by an agreement between the entity and another party for the sale and repurchase of identical or substantially the same securities at a date certain for a specified price. Such agreements are generally short-term in nature." } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 13.0 } }, "presentation": [ "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Charges for acquired in-process research and development assets", "label": "Research and Development Expense", "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity." } } }, "auth_ref": [ "r745", "r1141", "r1166", "r1601" ] }, "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost", "crdr": "debit", "calculation": { "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.jnj.com/role/ConsolidatedStatementsofEarnings", "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasIncomeBeforeTaxbySegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research and development expense", "label": "Research and Development Expense (Excluding Acquired in Process Cost)", "documentation": "Amount of expense for research and development. Excludes cost for computer software product to be sold, leased, or otherwise marketed, writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both, and write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity." } } }, "auth_ref": [ "r1543" ] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": [ "http://www.jnj.com/role/FairvaluemeasurementsSummaryofDerivativeActivityDetails", "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "R&D Expense", "label": "Research and Development Expense [Member]", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpensePolicy", "presentation": [ "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Research and development", "label": "Research and Development Expense, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process." } } }, "auth_ref": [ "r744" ] }, "jnj_ResearchAndDevelopmentInProcess1": { "xbrltype": "monetaryItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "ResearchAndDevelopmentInProcess1", "crdr": "debit", "calculation": { "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.jnj.com/role/AcquisitionsanddivestituresNarrativeDetails", "http://www.jnj.com/role/ConsolidatedStatementsofEarnings", "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingByGeographicAreaDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "In-process research and development impairments", "terseLabel": "Research and development in process", "label": "Research and Development In Process1", "documentation": "Research and Development In Process1" } } }, "auth_ref": [] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDateAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date:", "label": "Restatement Determination Date [Axis]" } } }, "auth_ref": [ "r1280", "r1291", "r1301", "r1334" ] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDeterminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date", "label": "Restatement Determination Date" } } }, "auth_ref": [ "r1281", "r1292", "r1302", "r1335" ] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement does not require Recovery", "label": "Restatement Does Not Require Recovery [Text Block]" } } }, "auth_ref": [ "r1288", "r1299", "r1309", "r1342" ] }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedStockUnitsRSUMember", "presentation": [ "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsNarrativeDetails", "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsSummaryofRestrictedShareUnitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted Stock Units (RSUs)", "label": "Restricted Stock Units (RSUs) [Member]", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": [] }, "us-gaap_RestructuringAndRelatedActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringAndRelatedActivitiesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Restructuring and Related Activities [Abstract]", "label": "Restructuring and Related Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock", "presentation": [ "http://www.jnj.com/role/Restructuring" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring", "label": "Restructuring and Related Activities Disclosure [Text Block]", "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled." } } }, "auth_ref": [ "r551", "r552", "r554", "r557", "r562" ] }, "us-gaap_RestructuringAndRelatedCostCostIncurredToDate1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringAndRelatedCostCostIncurredToDate1", "crdr": "debit", "presentation": [ "http://www.jnj.com/role/RestructuringNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring and Related Cost, Cost Incurred to Date", "label": "Restructuring and Related Cost, Cost Incurred to Date", "documentation": "Amount of costs incurred to date for the specified restructuring cost." } } }, "auth_ref": [ "r553", "r556", "r559", "r561" ] }, "us-gaap_RestructuringAndRelatedCostExpectedCost1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringAndRelatedCostExpectedCost1", "crdr": "debit", "presentation": [ "http://www.jnj.com/role/RestructuringNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-tax restructuring charges", "label": "Restructuring and Related Cost, Expected Cost", "documentation": "Amount expected to be recognized in earnings for the specified restructuring cost." } } }, "auth_ref": [ "r553", "r556", "r559", "r561" ] }, "us-gaap_RestructuringCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringCharges", "crdr": "debit", "calculation": { "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0, "order": 8.0 } }, "presentation": [ "http://www.jnj.com/role/ConsolidatedStatementsofEarnings", "http://www.jnj.com/role/RestructuringNarrativeDetails", "http://www.jnj.com/role/RestructuringScheduleofRestructuringReserveDetails", "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingByGeographicAreaDetails", "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring", "verboseLabel": "Restructuring charges", "label": "Restructuring Charges", "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation." } } }, "auth_ref": [ "r14", "r558", "r559", "r1488" ] }, "us-gaap_RestructuringChargesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringChargesMember", "presentation": [ "http://www.jnj.com/role/RestructuringNarrativeDetails", "http://www.jnj.com/role/RestructuringScheduleofRestructuringReserveDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Charges", "label": "Restructuring Charges [Member]", "documentation": "Primary financial statement caption in which the reported facts about restructuring charges have been included." } } }, "auth_ref": [ "r204", "r206" ] }, "us-gaap_RestructuringCostAndReserveLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringCostAndReserveLineItems", "presentation": [ "http://www.jnj.com/role/RestructuringNarrativeDetails", "http://www.jnj.com/role/RestructuringScheduleofRestructuringReserveDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Cost and Reserve [Line Items]", "label": "Restructuring Cost and Reserve [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r553", "r554", "r555", "r556", "r559", "r560", "r561" ] }, "us-gaap_RestructuringPlanAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringPlanAxis", "presentation": [ "http://www.jnj.com/role/RestructuringNarrativeDetails", "http://www.jnj.com/role/RestructuringScheduleofRestructuringReserveDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Plan [Axis]", "label": "Restructuring Plan [Axis]", "documentation": "Information by individual restructuring plan." } } }, "auth_ref": [] }, "us-gaap_RestructuringPlanDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringPlanDomain", "presentation": [ "http://www.jnj.com/role/RestructuringNarrativeDetails", "http://www.jnj.com/role/RestructuringScheduleofRestructuringReserveDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Plan [Domain]", "label": "Restructuring Plan [Domain]", "documentation": "Identification of the individual restructuring plans." } } }, "auth_ref": [] }, "us-gaap_RestructuringReserveRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringReserveRollForward", "presentation": [ "http://www.jnj.com/role/RestructuringScheduleofRestructuringReserveDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Reserve [Roll Forward]", "label": "Restructuring Reserve [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://www.jnj.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.jnj.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "verboseLabel": "Retained earnings and Additional-paid-in-capital", "label": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r162", "r212", "r971", "r1010", "r1012", "r1024", "r1059", "r1219" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": [ "http://www.jnj.com/role/ConsolidatedStatementsofEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Retained Earnings and Additional paid-in capital", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r309", "r375", "r376", "r377", "r379", "r384", "r386", "r388", "r491", "r492", "r536", "r778", "r779", "r788", "r789", "r790", "r792", "r798", "r799", "r811", "r813", "r814", "r816", "r819", "r871", "r873", "r1007", "r1009", "r1027", "r1648" ] }, "us-gaap_RetirementPlanSponsorLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetirementPlanSponsorLocationAxis", "presentation": [ "http://www.jnj.com/role/PensionsandotherbenefitplansInformationRelatedtotheBenefitObligationandtheFairValueofPlanAssetsDetails", "http://www.jnj.com/role/PensionsandotherbenefitplansNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Retirement Plan Sponsor Location [Axis]", "label": "Retirement Plan Sponsor Location [Axis]", "documentation": "Information by location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans." } } }, "auth_ref": [ "r626", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r640", "r641", "r642", "r643", "r644", "r645", "r646", "r647", "r648", "r650", "r651", "r652", "r653", "r654", "r655", "r656", "r657", "r658", "r659", "r660", "r661", "r662", "r663", "r664", "r665", "r666", "r667", "r668", "r670", "r671", "r672", "r673", "r675", "r678", "r682", "r683", "r684", "r685", "r686", "r687", "r688", "r689", "r690", "r691", "r692", "r693", "r694", "r1514", "r1515", "r1516" ] }, "us-gaap_RetirementPlanSponsorLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetirementPlanSponsorLocationDomain", "presentation": [ "http://www.jnj.com/role/PensionsandotherbenefitplansInformationRelatedtotheBenefitObligationandtheFairValueofPlanAssetsDetails", "http://www.jnj.com/role/PensionsandotherbenefitplansNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Retirement Plan Sponsor Location [Domain]", "label": "Retirement Plan Sponsor Location [Domain]", "documentation": "Location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans." } } }, "auth_ref": [ "r626", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r640", "r641", "r642", "r643", "r644", "r645", "r646", "r647", "r648", "r650", "r651", "r652", "r653", "r654", "r655", "r656", "r657", "r658", "r659", "r660", "r661", "r662", "r663", "r664", "r665", "r666", "r667", "r668", "r670", "r671", "r672", "r673", "r675", "r678", "r682", "r683", "r684", "r685", "r686", "r687", "r688", "r689", "r690", "r691", "r692", "r693", "r694", "r1514", "r1515", "r1516" ] }, "us-gaap_RetirementPlanTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetirementPlanTypeAxis", "presentation": [ "http://www.jnj.com/role/PensionsandotherbenefitplansComponentsofNetPeriodicBenefitCostDetails", "http://www.jnj.com/role/PensionsandotherbenefitplansNarrativeDetails", "http://www.jnj.com/role/PensionsandotherbenefitplansProjectedFutureBenefitPaymentsfromCompanysRetirementandOtherBenefitPlansDetails", "http://www.jnj.com/role/PensionsandotherbenefitplansRatesUsedtoDevelopActuarialPresentValueofProjectedBenefitObligationDetails", "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofDefinedBenefitPlansDisclosuresDetails", "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofNetFundedStatusDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Retirement Plan Type [Axis]", "label": "Retirement Plan Type [Axis]", "documentation": "Information by type of retirement benefit plan. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement." } } }, "auth_ref": [ "r623", "r626", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r640", "r641", "r642", "r643", "r644", "r645", "r646", "r647", "r648", "r650", "r651", "r652", "r653", "r654", "r655", "r656", "r657", "r658", "r659", "r660", "r661", "r662", "r663", "r664", "r665", "r666", "r667", "r668", "r670", "r672", "r673", "r675", "r678", "r681", "r685", "r686", "r687", "r688", "r689", "r690", "r691", "r692", "r693", "r694", "r698", "r699", "r700", "r703", "r1189", "r1190", "r1191", "r1192", "r1193", "r1194", "r1195", "r1196" ] }, "us-gaap_RetirementPlanTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetirementPlanTypeDomain", "presentation": [ "http://www.jnj.com/role/PensionsandotherbenefitplansComponentsofNetPeriodicBenefitCostDetails", "http://www.jnj.com/role/PensionsandotherbenefitplansNarrativeDetails", "http://www.jnj.com/role/PensionsandotherbenefitplansProjectedFutureBenefitPaymentsfromCompanysRetirementandOtherBenefitPlansDetails", "http://www.jnj.com/role/PensionsandotherbenefitplansRatesUsedtoDevelopActuarialPresentValueofProjectedBenefitObligationDetails", "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofDefinedBenefitPlansDisclosuresDetails", "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofNetFundedStatusDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Retirement Plan Type [Domain]", "label": "Retirement Plan Type [Domain]", "documentation": "Type of plan designed to provide participants with retirement benefits. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement." } } }, "auth_ref": [ "r623", "r626", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r640", "r641", "r642", "r643", "r644", "r645", "r646", "r647", "r648", "r650", "r651", "r652", "r653", "r654", "r655", "r656", "r657", "r658", "r659", "r660", "r661", "r662", "r663", "r664", "r665", "r666", "r667", "r668", "r670", "r672", "r673", "r675", "r678", "r681", "r685", "r686", "r687", "r688", "r689", "r690", "r691", "r692", "r693", "r694", "r698", "r699", "r700", "r703", "r1189", "r1190", "r1191", "r1192", "r1193", "r1194", "r1195", "r1196" ] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "calculation": { "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": { "parentTag": "us-gaap_GrossProfit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.jnj.com/role/ConsolidatedStatementsofEarnings", "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasIncomeBeforeTaxbySegmentDetails", "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails", "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingByGeographicAreaDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Sales to customers", "terseLabel": "Sales to Customers", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": [ "r246", "r247", "r407", "r416", "r417", "r438", "r444", "r448", "r450", "r452", "r618", "r619", "r917" ] }, "jnj_RevenuePerformanceObligationPaymentTerms": { "xbrltype": "durationItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "RevenuePerformanceObligationPaymentTerms", "presentation": [ "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue, performance obligation, payment terms", "label": "Revenue, Performance Obligation, Payment Terms", "documentation": "Revenue, Performance Obligation, Payment Terms" } } }, "auth_ref": [] }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueRecognitionPolicyTextBlock", "presentation": [ "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue recognition", "label": "Revenue [Policy Text Block]", "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources." } } }, "auth_ref": [ "r1081", "r1142", "r1156" ] }, "jnj_RevenuesContingentConsideration": { "xbrltype": "monetaryItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "RevenuesContingentConsideration", "crdr": "credit", "presentation": [ "http://www.jnj.com/role/AcquisitionsanddivestituresNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contingent consideration", "label": "Revenues, Contingent Consideration", "documentation": "Revenues, Contingent Consideration" } } }, "auth_ref": [] }, "us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenuesFromExternalCustomersAndLongLivedAssetsLineItems", "presentation": [ "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingByGeographicAreaDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenues from External Customers and Long-Lived Assets [Line Items]", "label": "Revenues from External Customers and Long-Lived Assets [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "jnj_RisperdalMember": { "xbrltype": "domainItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "RisperdalMember", "presentation": [ "http://www.jnj.com/role/IncometaxesNarrativeDetails", "http://www.jnj.com/role/LegalproceedingsNarrativeDetails", "http://www.jnj.com/role/LegalproceedingsProductLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Risperdal", "label": "Risperdal [Member]", "documentation": "Risperdal." } } }, "auth_ref": [] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Adopted", "label": "Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r1351" ] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Terminated", "label": "Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r1351" ] }, "jnj_SPINESPORTSOTHERMember": { "xbrltype": "domainItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "SPINESPORTSOTHERMember", "presentation": [ "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "SPINE,SPORTS & OTHER", "label": "SPINE, SPORTS & OTHER [Member]", "documentation": "SPINE & OTHER [Member]" } } }, "auth_ref": [] }, "jnj_SPRAVATOMember": { "xbrltype": "domainItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "SPRAVATOMember", "presentation": [ "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "SPRAVATO", "label": "SPRAVATO [Member]", "documentation": "SPRAVATO" } } }, "auth_ref": [] }, "jnj_SURGICALMember": { "xbrltype": "domainItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "SURGICALMember", "presentation": [ "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "SURGICAL", "label": "SURGICAL [Member]", "documentation": "SURGICAL [Member]" } } }, "auth_ref": [] }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": [ "http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsDetailsDetails", "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sale of Stock [Domain]", "label": "Sale of Stock [Domain]", "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "presentation": [ "http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsDetailsDetails", "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sale of stock, number of shares issued in transaction (in shares)", "label": "Sale of Stock, Number of Shares Issued in Transaction", "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockPercentageOfOwnershipAfterTransaction", "presentation": [ "http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsDetailsDetails", "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage ownership after transaction", "label": "Sale of Stock, Percentage of Ownership after Transaction", "documentation": "Percentage of subsidiary's or equity investee's stock owned by parent company after stock transaction." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockPricePerShare", "presentation": [ "http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsDetailsDetails", "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sale of stock (in USD per share)", "label": "Sale of Stock, Price Per Share", "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction." } } }, "auth_ref": [] }, "jnj_SalesBySegmentOfBusinessTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "SalesBySegmentOfBusinessTableTextBlock", "presentation": [ "http://www.jnj.com/role/SegmentsofbusinessandgeographicareasTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Sales by Segment of Business", "label": "Sales By Segment Of Business [Table Text Block]", "documentation": "Sales by segment of business." } } }, "auth_ref": [] }, "us-gaap_SalesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SalesMember", "presentation": [ "http://www.jnj.com/role/FairvaluemeasurementsSummaryofDerivativeActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sales", "label": "Sales [Member]", "documentation": "Primary financial statement caption encompassing revenue from sale of goods and services rendered in the normal course of business." } } }, "auth_ref": [ "r29" ] }, "jnj_SalesReturnReserve": { "xbrltype": "percentItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "SalesReturnReserve", "presentation": [ "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sales return reserve (as a percent)", "label": "Sales Return Reserve", "documentation": "Sales return reserve" } } }, "auth_ref": [] }, "us-gaap_SalesRevenueNetMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SalesRevenueNetMember", "presentation": [ "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingByGeographicAreaDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sales Revenue, Net", "label": "Revenue Benchmark [Member]", "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation." } } }, "auth_ref": [ "r452", "r1383" ] }, "jnj_SavingsPlanAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "SavingsPlanAbstract", "lang": { "en-us": { "role": { "terseLabel": "Savings Plan [Abstract]", "label": "Savings Plan [Abstract]", "documentation": "Savings Plan." } } }, "auth_ref": [] }, "jnj_SavingsPlanTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "SavingsPlanTextBlock", "presentation": [ "http://www.jnj.com/role/Savingsplan" ], "lang": { "en-us": { "role": { "terseLabel": "Savings plan", "label": "Savings Plan [Text Block]", "documentation": "Savings Plan." } } }, "auth_ref": [] }, "srt_ScenarioForecastMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ScenarioForecastMember", "presentation": [ "http://www.jnj.com/role/AcquisitionsanddivestituresNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Forecast", "label": "Forecast [Member]", "documentation": "Information reported for future period. Excludes information expected to be reported in future period for effect on historical fact." } } }, "auth_ref": [ "r702", "r1395", "r1427" ] }, "srt_ScenarioUnspecifiedDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ScenarioUnspecifiedDomain", "presentation": [ "http://www.jnj.com/role/AcquisitionsanddivestituresNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Scenario [Domain]", "label": "Scenario [Domain]", "documentation": "Scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts." } } }, "auth_ref": [ "r306", "r389", "r702", "r1375", "r1427" ] }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "presentation": [ "http://www.jnj.com/role/AccumulatedothercomprehensiveincomelossTables" ], "lang": { "en-us": { "role": { "verboseLabel": "Components of Accumulated Other Comprehensive Income", "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss)." } } }, "auth_ref": [ "r41", "r1589", "r1590" ] }, "us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAllocationOfPlanAssetsTableTextBlock", "presentation": [ "http://www.jnj.com/role/PensionsandotherbenefitplansTables" ], "lang": { "en-us": { "role": { "terseLabel": "Company' Retirement Plan Asset Allocation and Target Allocations", "label": "Schedule of Allocation of Plan Assets [Table Text Block]", "documentation": "Tabular disclosure of the major categories of plan assets of pension plans and/or other employee benefit plans. This information may include, but is not limited to, the target allocation of plan assets, the fair value of each major category of plan assets, and the level within the fair value hierarchy in which the fair value measurements fall." } } }, "auth_ref": [ "r215" ] }, "us-gaap_ScheduleOfAssumptionsUsedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAssumptionsUsedTableTextBlock", "presentation": [ "http://www.jnj.com/role/PensionsandotherbenefitplansTables" ], "lang": { "en-us": { "role": { "terseLabel": "Rates Used to Develop Actuarial Present Value of Projected Benefit Obligation", "label": "Defined Benefit Plan, Assumptions [Table Text Block]", "documentation": "Tabular disclosure of assumption used to determine benefit obligation and net periodic benefit cost of defined benefit plan. Includes, but is not limited to, discount rate, rate of compensation increase, expected long-term rate of return on plan assets and interest crediting rate." } } }, "auth_ref": [ "r669" ] }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "presentation": [ "http://www.jnj.com/role/FairvaluemeasurementsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Activity Related to Equity Investments", "label": "Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]", "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "presentation": [ "http://www.jnj.com/role/AcquisitionsanddivestituresDetails", "http://www.jnj.com/role/AcquisitionsanddivestituresNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]", "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "documentation": "Disclosure of information about business combination. Includes, but is not limited to, recognized asset and liability." } } }, "auth_ref": [ "r91", "r92", "r793" ] }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "presentation": [ "http://www.jnj.com/role/AcquisitionsanddivestituresTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Business Acquisitions, by Acquisition", "label": "Schedule of Business Acquisitions, by Acquisition [Table Text Block]", "documentation": "Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts." } } }, "auth_ref": [ "r91", "r92" ] }, "us-gaap_ScheduleOfCashAndCashEquivalentsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfCashAndCashEquivalentsTable", "presentation": [ "http://www.jnj.com/role/CashcashequivalentsandcurrentmarketablesecuritiesCashandCashEquivalentCompositionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and Cash Equivalent [Table]", "label": "Cash and Cash Equivalent [Table]", "documentation": "Disclosure of information about cash and cash equivalent by type. Excludes restricted cash and cash equivalent." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "presentation": [ "http://www.jnj.com/role/CashcashequivalentsandcurrentmarketablesecuritiesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and Cash Equivalent Composition", "label": "Cash, Cash Equivalents and Investments [Table Text Block]", "documentation": "Tabular disclosure of the components of cash, cash equivalents, and investments." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "presentation": [ "http://www.jnj.com/role/IncometaxesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Provision for Income Taxes", "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]", "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years." } } }, "auth_ref": [ "r1555" ] }, "us-gaap_ScheduleOfDebtInstrumentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDebtInstrumentsTextBlock", "presentation": [ "http://www.jnj.com/role/BorrowingsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Long-term Debt Instruments", "label": "Schedule of Long-Term Debt Instruments [Table Text Block]", "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer." } } }, "auth_ref": [ "r34", "r69", "r70", "r127", "r210", "r211", "r1179", "r1181", "r1423", "r1591" ] }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "presentation": [ "http://www.jnj.com/role/IncometaxesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Temporary Differences and Carryforwards", "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]", "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets." } } }, "auth_ref": [ "r1549" ] }, "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable", "presentation": [ "http://www.jnj.com/role/PensionsandotherbenefitplansCompanyRetirementPlanAssetAllocationandTargetAllocationsDetails", "http://www.jnj.com/role/PensionsandotherbenefitplansComponentsofNetPeriodicBenefitCostDetails", "http://www.jnj.com/role/PensionsandotherbenefitplansInformationRelatedtotheBenefitObligationandtheFairValueofPlanAssetsDetails", "http://www.jnj.com/role/PensionsandotherbenefitplansNarrativeDetails", "http://www.jnj.com/role/PensionsandotherbenefitplansProjectedFutureBenefitPaymentsfromCompanysRetirementandOtherBenefitPlansDetails", "http://www.jnj.com/role/PensionsandotherbenefitplansRatesUsedtoDevelopActuarialPresentValueofProjectedBenefitObligationDetails", "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofDefinedBenefitPlansDisclosuresDetails", "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofNetFundedStatusDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Defined Benefit Plan [Table]", "label": "Defined Benefit Plan [Table]", "documentation": "Disclosure of information about individual defined benefit pension plan or other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": [ "r18", "r79", "r80", "r81", "r82" ] }, "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTextBlock", "presentation": [ "http://www.jnj.com/role/PensionsandotherbenefitplansTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Defined Benefit Plans Disclosures", "label": "Schedule of Defined Benefit Plans Disclosures [Table Text Block]", "documentation": "Tabular disclosure of one or more of the entity's defined benefit pension plans or one or more other defined benefit postretirement plans, separately for pension plans and other postretirement benefit plans including the entity's schedule of fair value of plan assets for defined benefit or other postretirement plans." } } }, "auth_ref": [ "r18", "r79", "r80", "r81", "r82" ] }, "us-gaap_ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock", "presentation": [ "http://www.jnj.com/role/FairvaluemeasurementsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Effect of Net Investment Hedges", "label": "Schedule of Derivative Instruments, Effect on Other Comprehensive Income (Loss) [Table Text Block]", "documentation": "Tabular disclosure of the effective portion of the gains and losses on derivative instruments designated (and non-derivative instruments) designated and qualifying in cash flow hedges and net investment hedges that was recognized in other comprehensive income (loss) during the current period." } } }, "auth_ref": [ "r231" ] }, "us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "presentation": [ "http://www.jnj.com/role/FairvaluemeasurementsTables" ], "lang": { "en-us": { "role": { "verboseLabel": "Summary of Derivative Activity", "label": "Derivative Instruments, Gain (Loss) [Table Text Block]", "documentation": "Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments." } } }, "auth_ref": [ "r111", "r115", "r808" ] }, "us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "presentation": [ "http://www.jnj.com/role/FairvaluemeasurementsTables" ], "lang": { "en-us": { "role": { "verboseLabel": "Financial Assets and Liabilities at Fair Value", "label": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]", "documentation": "Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position." } } }, "auth_ref": [ "r112" ] }, "us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "presentation": [ "http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal Groups, Including Discontinued Operations", "label": "Disposal Groups, Including Discontinued Operations [Table Text Block]", "documentation": "Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component." } } }, "auth_ref": [ "r17", "r26", "r37", "r129", "r135", "r136", "r137", "r138", "r139", "r144", "r146", "r147", "r203" ] }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": [ "http://www.jnj.com/role/EarningspershareTables" ], "lang": { "en-us": { "role": { "verboseLabel": "Reconciliation of Basic Net Earnings per Share to Diluted Net Earnings per Share", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": [ "r1430" ] }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "presentation": [ "http://www.jnj.com/role/IncometaxesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Comparison of Income Taxes at Statutory Rate and Company's Effective Tax Rate", "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]", "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations." } } }, "auth_ref": [ "r756", "r1203", "r1544" ] }, "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "presentation": [ "http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsDetailsDetails", "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Investment, Name [Axis]", "label": "Investment, Name [Axis]", "documentation": "Information by name of investment including named security. Excludes entity that is consolidated." } } }, "auth_ref": [ "r487", "r488", "r489", "r787", "r1376", "r1377", "r1378", "r1558", "r1559", "r1560", "r1561" ] }, "jnj_ScheduleOfEstimatedFutureEmployerContributionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "ScheduleOfEstimatedFutureEmployerContributionsTableTextBlock", "presentation": [ "http://www.jnj.com/role/PensionsandotherbenefitplansTables" ], "lang": { "en-us": { "role": { "terseLabel": "Projected Future Minimum Contributions to the Company's U.S. and International Unfunded Retirement Plans", "label": "Schedule Of Estimated Future Employer Contributions [Table Text Block]", "documentation": "Schedule of estimated future employer contributions." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfExpectedBenefitPaymentsTableTextBlock", "presentation": [ "http://www.jnj.com/role/PensionsandotherbenefitplansTables" ], "lang": { "en-us": { "role": { "terseLabel": "Projected Future Benefit Payments from Company's Retirement and Other Benefit Plans", "label": "Schedule of Expected Benefit Payments [Table Text Block]", "documentation": "Tabular disclosure of benefits expected to be paid by pension plans and/or other employee benefit plans in each of the next five fiscal years and in the aggregate for the five fiscal years thereafter." } } }, "auth_ref": [ "r216" ] }, "jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock", "presentation": [ "http://www.jnj.com/role/IntangibleassetsandgoodwillTables" ], "lang": { "en-us": { "role": { "verboseLabel": "Schedule of Intangible Assets and Goodwill", "label": "Schedule of Finite and Indefinite-Lived Intangible Assets Excluding Goodwill by Major Class [Table Text Block]", "documentation": "Schedule of Finite and Indefinite-Lived Intangible Assets Excluding Goodwill by Major Class [Table Text Block]" } } }, "auth_ref": [] }, "jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable": { "xbrltype": "stringItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable", "presentation": [ "http://www.jnj.com/role/IntangibleassetsandgoodwilScheduleofIntangibleAssetsandGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Finite-Lived And Indefinite-Lived Intangible Assets By Major Class [Table]", "label": "Schedule of Finite-Lived And Indefinite-Lived Intangible Assets By Major Class [Table]", "documentation": "Schedule of Finite-Lived And Indefinite-Lived Intangible Assets By Major Class [Table]" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "presentation": [ "http://www.jnj.com/role/IntangibleassetsandgoodwillNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Finite-Lived Intangible Assets by Major Class [Table]", "label": "Intangible Asset, Finite-Lived [Table]", "documentation": "Disclosure of information about finite-lived intangible asset. Excludes indefinite-lived intangible asset." } } }, "auth_ref": [ "r520", "r527", "r531", "r532", "r535", "r918", "r1141", "r1175" ] }, "us-gaap_ScheduleOfGoodwillTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfGoodwillTable", "presentation": [ "http://www.jnj.com/role/IntangibleassetsandgoodwillGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill [Table]", "label": "Goodwill [Table]", "documentation": "Disclosure of information about goodwill, including, but not limited to, change from acquisition, sale, impairment, and other reason." } } }, "auth_ref": [ "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r1174" ] }, "us-gaap_ScheduleOfGoodwillTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfGoodwillTextBlock", "presentation": [ "http://www.jnj.com/role/IntangibleassetsandgoodwillTables" ], "lang": { "en-us": { "role": { "verboseLabel": "Goodwill", "label": "Schedule of Goodwill [Table Text Block]", "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule." } } }, "auth_ref": [ "r1174", "r1461", "r1462", "r1463", "r1464", "r1465", "r1466", "r1467", "r1468", "r1469", "r1470", "r1471" ] }, "us-gaap_ScheduleOfHealthCareCostTrendRatesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfHealthCareCostTrendRatesTableTextBlock", "presentation": [ "http://www.jnj.com/role/PensionsandotherbenefitplansTables" ], "lang": { "en-us": { "role": { "terseLabel": "Assumed Health Care Cost Trend Rates", "label": "Schedule of Health Care Cost Trend Rates [Table Text Block]", "documentation": "Tabular disclosure of the assumed health care cost trend rates for the next year used to measure the expected cost of benefits covered by the plans, including the ultimate trend rate(s) and when that rate is expected to be achieved." } } }, "auth_ref": [ "r218" ] }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfInventoryCurrentTableTextBlock", "presentation": [ "http://www.jnj.com/role/InventoriesTables" ], "lang": { "en-us": { "role": { "verboseLabel": "Summary of Inventories", "label": "Schedule of Inventory, Current [Table Text Block]", "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process." } } }, "auth_ref": [ "r39", "r166", "r167", "r168" ] }, "us-gaap_ScheduleOfLossContingenciesByContingencyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfLossContingenciesByContingencyTextBlock", "presentation": [ "http://www.jnj.com/role/LegalproceedingsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Loss Contingencies by Contingency", "label": "Schedule of Loss Contingencies by Contingency [Table Text Block]", "documentation": "Tabular disclosure of the loss contingencies that were reported in the period or disclosed as of the balance sheet date." } } }, "auth_ref": [ "r1489", "r1491", "r1493", "r1495" ] }, "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "presentation": [ "http://www.jnj.com/role/BorrowingsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Maturities of Long Term Obligations", "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]", "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt." } } }, "auth_ref": [ "r16" ] }, "us-gaap_ScheduleOfNetBenefitCostsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfNetBenefitCostsTableTextBlock", "presentation": [ "http://www.jnj.com/role/PensionsandotherbenefitplansTables" ], "lang": { "en-us": { "role": { "verboseLabel": "Components of Net Periodic Benefit Cost", "label": "Schedule of Net Benefit Costs [Table Text Block]", "documentation": "Tabular disclosure of the components of net benefit costs for pension plans and/or other employee benefit plans including service cost, interest cost, expected return on plan assets, gain (loss), prior service cost or credit, transition asset or obligation, and gain (loss) recognized due to settlements or curtailments." } } }, "auth_ref": [ "r217" ] }, "us-gaap_ScheduleOfNetFundedStatusTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfNetFundedStatusTableTextBlock", "presentation": [ "http://www.jnj.com/role/PensionsandotherbenefitplansTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Net Funded Status", "label": "Schedule of Net Funded Status [Table Text Block]", "documentation": "Tabular disclosure of net funded status of pension plans and/or other employee benefit plans." } } }, "auth_ref": [ "r78" ] }, "us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "presentation": [ "http://www.jnj.com/role/FairvaluemeasurementsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Effect of Derivatives not Designated as Hedging Instruments", "label": "Derivatives Not Designated as Hedging Instruments [Table Text Block]", "documentation": "Tabular disclosure of derivative instrument not designated or qualifying as hedging instrument." } } }, "auth_ref": [ "r116", "r1385" ] }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "presentation": [ "http://www.jnj.com/role/PropertyplantandequipmentPropertyPlantandEquipmentatCostandAccumulatedDepreciationDetails", "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesEstimatedUsefulLivesofAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment [Table]", "label": "Property, Plant and Equipment [Table]", "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r15", "r881" ] }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRestructuringAndRelatedCostsTable", "presentation": [ "http://www.jnj.com/role/RestructuringNarrativeDetails", "http://www.jnj.com/role/RestructuringScheduleofRestructuringReserveDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Cost [Table]", "label": "Restructuring Cost [Table]", "documentation": "Disclosure of information about restructuring cost. Includes, but is not limited to, expected cost, cost incurred, statement of income caption that includes restructuring cost recognized, and amount of restructuring reserve." } } }, "auth_ref": [ "r553", "r554", "r555", "r556", "r559", "r560", "r561" ] }, "us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "presentation": [ "http://www.jnj.com/role/RestructuringTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Severance Charges and Associated Spending", "label": "Schedule of Restructuring Reserve by Type of Cost [Table Text Block]", "documentation": "Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period." } } }, "auth_ref": [ "r68", "r205" ] }, "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock", "presentation": [ "http://www.jnj.com/role/SegmentsofbusinessandgeographicareasTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas", "label": "Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]", "documentation": "Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries." } } }, "auth_ref": [ "r64", "r175" ] }, "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable", "presentation": [ "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingByGeographicAreaDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]", "label": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]", "documentation": "Disclosure of information about revenue from external customer and long-lived asset by geographical area. Long-lived asset excludes financial instrument, customer relationship with financial institution, mortgage and other servicing right, deferred policy acquisition cost, and deferred tax asset." } } }, "auth_ref": [ "r64", "r175" ] }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "presentation": [ "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails", "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]", "label": "Schedule of Segment Reporting Information, by Segment [Table]", "documentation": "Disclosure of information about profit (loss) and total assets by reportable segment." } } }, "auth_ref": [ "r59", "r60", "r61" ] }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "presentation": [ "http://www.jnj.com/role/SegmentsofbusinessandgeographicareasTables" ], "lang": { "en-us": { "role": { "verboseLabel": "Schedule of Segment Reporting Information", "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]", "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss." } } }, "auth_ref": [ "r59", "r60", "r61" ] }, "us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationActivityTableTextBlock", "presentation": [ "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Restricted Share Units", "label": "Share-Based Payment Arrangement, Activity [Table Text Block]", "documentation": "Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value." } } }, "auth_ref": [ "r24", "r25", "r222" ] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": [ "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsNarrativeDetails", "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsSummaryofRestrictedShareUnitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": [ "r705", "r707", "r710", "r711", "r712", "r713", "r714", "r715", "r716", "r717", "r718", "r719", "r720", "r721", "r722", "r723", "r724", "r725", "r726", "r727", "r728", "r729", "r730", "r731", "r732", "r733", "r734", "r735" ] }, "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable", "presentation": [ "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsSummaryofOptionsOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table]", "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Table]", "documentation": "Disclosure of information about share-based payment arrangement by range of exercise prices." } } }, "auth_ref": [ "r83" ] }, "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock", "presentation": [ "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Options Outstanding", "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block]", "documentation": "Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms." } } }, "auth_ref": [ "r83" ] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": [ "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Stock Option Activity", "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": [ "r24", "r25", "r219" ] }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "presentation": [ "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule Valuation Assumptions", "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions." } } }, "auth_ref": [ "r224" ] }, "us-gaap_ScheduleOfShortTermDebtTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShortTermDebtTable", "presentation": [ "http://www.jnj.com/role/BorrowingsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Short-term Debt [Table]", "label": "Short-Term Debt [Table]", "documentation": "Disclosure of information about short-term debt arrangement. Includes, but is not limited to, description of arrangement, lender, repayment term, weighted-average interest rate, borrowed amount, and description and amount of refinancing of short-term obligation when obligation is excluded from current liability." } } }, "auth_ref": [ "r151" ] }, "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "presentation": [ "http://www.jnj.com/role/IncometaxesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Unrecognized Tax Benefits Roll Forward", "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]", "documentation": "Tabular disclosure of the change in unrecognized tax benefits." } } }, "auth_ref": [ "r763", "r1202" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [ "http://www.jnj.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1261" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [ "http://www.jnj.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r1264" ] }, "us-gaap_SegmentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentDomain", "presentation": [ "http://www.jnj.com/role/AcquisitionsanddivestituresNarrativeDetails", "http://www.jnj.com/role/IncometaxesNarrativeDetails", "http://www.jnj.com/role/IntangibleassetsandgoodwillGoodwillDetails", "http://www.jnj.com/role/RestructuringNarrativeDetails", "http://www.jnj.com/role/RestructuringScheduleofRestructuringReserveDetails", "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasIncomeBeforeTaxbySegmentDetails", "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails", "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingByGeographicAreaDetails", "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails", "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segments [Domain]", "label": "Segments [Domain]", "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": [ "r246", "r247", "r248", "r249", "r407", "r412", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r428", "r429", "r430", "r438", "r439", "r440", "r441", "r442", "r444", "r445", "r446", "r452", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r535", "r556", "r561", "r985", "r986", "r987", "r988", "r989", "r990", "r991", "r992", "r993", "r994", "r995", "r1163", "r1166", "r1167", "r1174", "r1234", "r1613", "r1617", "r1618", "r1619", "r1620", "r1621", "r1622", "r1623", "r1624", "r1625", "r1626", "r1627", "r1628", "r1629", "r1630", "r1631", "r1632", "r1633", "r1634", "r1635", "r1636", "r1637", "r1638", "r1639", "r1640", "r1641", "r1642", "r1644", "r1645" ] }, "us-gaap_SegmentExpenditureAdditionToLongLivedAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentExpenditureAdditionToLongLivedAssets", "crdr": "debit", "presentation": [ "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Additions to Property, Plant & Equipment", "label": "Segment, Expenditure, Addition to Long-Lived Assets", "documentation": "Amount of expenditure for addition to long-lived assets included in determination of segment assets by chief operating decision maker (CODM) or otherwise regularly provided to CODM. Excludes expenditure for addition to financial instrument, long-term customer relationship of financial institution, mortgage and other servicing rights, deferred policy acquisition cost, and deferred tax assets." } } }, "auth_ref": [ "r407", "r426", "r444", "r1166", "r1167" ] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "SegmentGeographicalDomain", "presentation": [ "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails", "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingByGeographicAreaDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Geographical [Domain]", "label": "Geographical [Domain]", "documentation": "Geographical area." } } }, "auth_ref": [ "r272", "r274", "r277", "r279", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r450", "r451", "r920", "r921", "r922", "r923", "r924", "r925", "r926", "r927", "r928", "r929", "r930", "r931", "r932", "r933", "r934", "r935", "r936", "r937", "r938", "r939", "r940", "r941", "r942", "r943", "r944", "r945", "r946", "r947", "r948", "r949", "r1041", "r1044", "r1046", "r1103", "r1107", "r1110", "r1121", "r1128", "r1130", "r1131", "r1132", "r1133", "r1134", "r1135", "r1136", "r1137", "r1138", "r1145", "r1185", "r1221", "r1222", "r1223", "r1224", "r1225", "r1226", "r1227", "r1228", "r1233", "r1243", "r1501", "r1613", "r1617", "r1618", "r1620", "r1621", "r1622", "r1623", "r1624", "r1625", "r1626", "r1627", "r1628", "r1629", "r1630", "r1631", "r1632", "r1633", "r1634", "r1635", "r1636", "r1637", "r1638", "r1639", "r1640", "r1641", "r1642", "r1644", "r1645" ] }, "us-gaap_SegmentReportingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingAbstract", "lang": { "en-us": { "role": { "terseLabel": "Segment Reporting [Abstract]", "label": "Segment Reporting [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SegmentReportingDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingDisclosureTextBlock", "presentation": [ "http://www.jnj.com/role/Segmentsofbusinessandgeographicareas" ], "lang": { "en-us": { "role": { "verboseLabel": "Segments of business and geographic areas", "label": "Segment Reporting Disclosure [Text Block]", "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments." } } }, "auth_ref": [ "r249", "r407", "r411", "r412", "r413", "r414", "r415", "r427", "r429", "r430", "r442", "r443", "r444", "r445", "r446", "r448", "r449", "r452", "r1161", "r1164", "r1165", "r1166", "r1168", "r1170", "r1171" ] }, "us-gaap_SegmentReportingInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingInformationLineItems", "presentation": [ "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails", "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segment Reporting Information [Line Items]", "label": "Segment Reporting Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_SegmentReportingOtherItemAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingOtherItemAmount", "crdr": "debit", "presentation": [ "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasIncomeBeforeTaxbySegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Less: Expense not allocated to segments", "label": "Segment Reporting, Other Segment Item, Amount", "documentation": "Amount of other expense (income) and loss (gain) calculated as difference between segment revenue and separately disclosed expense category to arrive at segment profit (loss)." } } }, "auth_ref": [ "r407", "r429", "r430", "r444", "r1166" ] }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingPolicyPolicyTextBlock", "presentation": [ "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Business segments", "label": "Segment Reporting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for segment reporting." } } }, "auth_ref": [ "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r447", "r450", "r1162", "r1163", "r1169" ] }, "us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems", "presentation": [ "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasIncomeBeforeTaxbySegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]", "label": "Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "jnj_SegmentsTotalMember": { "xbrltype": "domainItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "SegmentsTotalMember", "presentation": [ "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segments Total", "label": "Segments Total [Member]", "documentation": "Segments Total" } } }, "auth_ref": [] }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingGeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.jnj.com/role/ConsolidatedStatementsofEarnings", "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasIncomeBeforeTaxbySegmentDetails", "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Selling, marketing and administrative expenses", "label": "Selling, General and Administrative Expense", "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc." } } }, "auth_ref": [ "r183" ] }, "us-gaap_SettledLitigationMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SettledLitigationMember", "presentation": [ "http://www.jnj.com/role/LegalproceedingsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Settled Litigation", "label": "Settled Litigation [Member]", "documentation": "Agreement reached between parties in a litigation that occurs without judicial intervention, supervision or approval." } } }, "auth_ref": [ "r1489" ] }, "jnj_SettlementOfConvertibleDebtAcquiredFromShockwave": { "xbrltype": "monetaryItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "SettlementOfConvertibleDebtAcquiredFromShockwave", "crdr": "credit", "calculation": { "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 13.0 } }, "presentation": [ "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Settlement of convertible debt acquired from Shockwave", "label": "Settlement of convertible debt acquired from Shockwave", "documentation": "Settlement of convertible debt acquired from Shockwave" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Stock based compensation", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r13" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "presentation": [ "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Award vesting period", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period", "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition." } } }, "auth_ref": [ "r1198" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract", "presentation": [ "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsSummaryofRestrictedShareUnitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]" } } }, "auth_ref": [] }, "jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCanceledForfeitedandAdjustedDuringthePeriod": { "xbrltype": "sharesItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCanceledForfeitedandAdjustedDuringthePeriod", "presentation": [ "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsSummaryofRestrictedShareUnitsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Canceled/forfeited/adjusted (in shares)", "label": "Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Canceled, Forfeited and Adjusted During the Period", "documentation": "Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Canceled, Forfeited and Adjusted During the Period" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": [ "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsSummaryofRestrictedShareUnitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Granted (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r724" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Average fair value of RSU's and PSU's granted (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r724" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": [ "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsSummaryofRestrictedShareUnitsDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance (in shares)", "periodEndLabel": "Ending balance (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": [ "r721", "r722" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "presentation": [ "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsSummaryofRestrictedShareUnitsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Issued (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period." } } }, "auth_ref": [ "r725" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue", "crdr": "debit", "presentation": [ "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value of RSU or PSU units settled", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value", "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash." } } }, "auth_ref": [ "r728" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract", "presentation": [ "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsScheduleValuationAssumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average assumptions of fair value of options", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "presentation": [ "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsScheduleValuationAssumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected dividend yield", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term." } } }, "auth_ref": [ "r733" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "presentation": [ "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsScheduleValuationAssumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected volatility", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": [ "r732" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "presentation": [ "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsScheduleValuationAssumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Risk-free rate", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [ "r734" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [ "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsNarrativeDetails", "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsSummaryofRestrictedShareUnitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r705", "r707", "r710", "r711", "r712", "r713", "r714", "r715", "r716", "r717", "r718", "r719", "r720", "r721", "r722", "r723", "r724", "r725", "r726", "r727", "r728", "r729", "r730", "r731", "r732", "r733", "r734", "r735" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward", "presentation": [ "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsSummaryofRestrictedShareUnitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonTradeableContingentValueRight": { "xbrltype": "monetaryItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonTradeableContingentValueRight", "crdr": "credit", "presentation": [ "http://www.jnj.com/role/AcquisitionsanddivestituresNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-tradeable contingent value right", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Tradeable Contingent Value Right", "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Tradeable Contingent Value Right" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "presentation": [ "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of shares authorized for issuance under long-term incentive plan (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized", "documentation": "Number of shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": [ "r1200" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "presentation": [ "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shares available for future grants under long-term incentive plan", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant", "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable." } } }, "auth_ref": [ "r83" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract", "presentation": [ "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsSummaryofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of option activity under the Plan", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "presentation": [ "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock options exercisable (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number", "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan." } } }, "auth_ref": [ "r715" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "presentation": [ "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock options average price (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan." } } }, "auth_ref": [ "r715" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "crdr": "debit", "presentation": [ "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total intrinsic value of options exercised", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value", "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares." } } }, "auth_ref": [ "r728" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "presentation": [ "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsSummaryofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Options canceled/forfeited (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period", "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan." } } }, "auth_ref": [ "r719" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "presentation": [ "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsSummaryofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Options granted (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures", "documentation": "Net number of share options (or share units) granted during the period." } } }, "auth_ref": [ "r1524" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Average fair value of option granted (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology." } } }, "auth_ref": [ "r727" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": [ "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsSummaryofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate intrinsic value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } }, "auth_ref": [ "r83" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": [ "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsSummaryofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Options outstanding beginning of period (in shares)", "periodEndLabel": "Options outstanding end of period (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": [ "r713", "r714" ] }, "jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToFullValueAwards": { "xbrltype": "sharesItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToFullValueAwards", "presentation": [ "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shares subject to full value awards (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number, May Be Issued Subject To Full Value Awards", "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number, May Be Issued Subject To Full Value Awards" } } }, "auth_ref": [] }, "jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToFullValueAwardsExcess": { "xbrltype": "sharesItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToFullValueAwardsExcess", "presentation": [ "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shares subject to full value award, excess (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number, May Be Issued Subject To Full Value Awards, Excess", "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number, May Be Issued Subject To Full Value Awards, Excess" } } }, "auth_ref": [] }, "jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToStockOptionsOrStockAppreciationRights": { "xbrltype": "sharesItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToStockOptionsOrStockAppreciationRights", "presentation": [ "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shares issued subject to stock options or stock appreciation rights (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number, May Be Issued Subject To Stock Options Or Stock Appreciation Rights", "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number, May Be Issued Subject To Stock Options Or Stock Appreciation Rights" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "presentation": [ "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsSummaryofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding Shares", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": [ "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsSummaryofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Options exercise price beginning of period (in dollars per share)", "periodEndLabel": "Options exercise price end of period (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": [ "r713", "r714" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "presentation": [ "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsSummaryofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Exercise Price", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]" } } }, "auth_ref": [] }, "jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesNonTradeableContingentValueRight": { "xbrltype": "perShareItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesNonTradeableContingentValueRight", "presentation": [ "http://www.jnj.com/role/AcquisitionsanddivestituresNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-tradeable contingent value right (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Shares, Non-Tradeable Contingent Value Right", "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Shares, Non-Tradeable Contingent Value Right" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://www.jnj.com/role/AcquisitionsanddivestituresNarrativeDetails", "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsNarrativeDetails", "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsSummaryofRestrictedShareUnitsDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type [Domain]", "label": "Award Type [Domain]", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r710", "r711", "r712", "r713", "r714", "r715", "r716", "r717", "r718", "r719", "r720", "r721", "r722", "r723", "r724", "r725", "r726", "r727", "r728", "r729", "r730", "r731", "r732", "r733", "r734", "r735" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsSummaryofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Options exercised, average exercise price (in dollars per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares." } } }, "auth_ref": [ "r718" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsSummaryofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Options canceled/forfeited, average exercise price (in dollars per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated." } } }, "auth_ref": [ "r719" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsSummaryofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Options granted, average exercise price (in dollars per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": [ "r717" ] }, "jnj_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract", "presentation": [ "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsSummaryofOptionsOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock options outstanding and exercisable", "label": "Share Based Compensation Shares Authorized Under Stock Option Plans By Exercise Price Range [Abstract]", "documentation": "Share based compensation shares authorized under stock option plans by exercise price range." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis", "presentation": [ "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsSummaryofOptionsOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Axis]", "label": "Exercise Price Range [Axis]", "documentation": "Information by range of option prices pertaining to options granted." } } }, "auth_ref": [ "r86" ] }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain", "presentation": [ "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsSummaryofOptionsOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Domain]", "label": "Exercise Price Range [Domain]", "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices." } } }, "auth_ref": [ "r87" ] }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems", "presentation": [ "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsSummaryofOptionsOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]", "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit", "presentation": [ "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsSummaryofOptionsOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Price Range, Minimum (in dollars per share)", "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit", "documentation": "The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range." } } }, "auth_ref": [ "r87" ] }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions", "presentation": [ "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsSummaryofOptionsOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercisable number of Options (in shares)", "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable", "documentation": "The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied." } } }, "auth_ref": [ "r85" ] }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions", "presentation": [ "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsNarrativeDetails", "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsSummaryofOptionsOutstandingDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Stock options outstanding (in shares)", "terseLabel": "Outstanding number of Options (in shares)", "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding", "documentation": "The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices." } } }, "auth_ref": [ "r220", "r221" ] }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit", "presentation": [ "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsSummaryofOptionsOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Price Range, Maximum (in dollars per share)", "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit", "documentation": "The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range." } } }, "auth_ref": [ "r87" ] }, "srt_ShareRepurchaseProgramAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ShareRepurchaseProgramAxis", "presentation": [ "http://www.jnj.com/role/CapitalandtreasurystockNarrativeDetails", "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share Repurchase Program [Axis]", "label": "Share Repurchase Program [Axis]", "documentation": "Information by share repurchase program." } } }, "auth_ref": [ "r1500" ] }, "srt_ShareRepurchaseProgramDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ShareRepurchaseProgramDomain", "presentation": [ "http://www.jnj.com/role/CapitalandtreasurystockNarrativeDetails", "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share Repurchase Program [Domain]", "label": "Share Repurchase Program [Domain]", "documentation": "Name of share repurchase program." } } }, "auth_ref": [ "r1500" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage", "presentation": [ "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vesting percentage", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage", "documentation": "Percentage of vesting of award under share-based payment arrangement." } } }, "auth_ref": [ "r1517" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "presentation": [ "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Stock options expiration period", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period", "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r1199" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": [ "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsScheduleValuationAssumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected life (in years)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term", "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r731" ] }, "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1", "presentation": [ "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsSummaryofOptionsOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercisable, Average Exercise Price (in dollars per share)", "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price", "documentation": "Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding." } } }, "auth_ref": [ "r84" ] }, "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1", "presentation": [ "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsSummaryofOptionsOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding Average Exercise Price (in dollars per share)", "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price", "documentation": "The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices." } } }, "auth_ref": [ "r220", "r221" ] }, "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2", "presentation": [ "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsNarrativeDetails", "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsSummaryofOptionsOutstandingDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Stock option average life", "terseLabel": "Outstanding, Average Life", "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r223" ] }, "jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod": { "xbrltype": "sharesItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod", "calculation": { "http://www.jnj.com/role/EarningspershareReconciliationofBasicNetEarningsperSharetoDilutedNetEarningsperShareDetails": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.jnj.com/role/EarningspershareReconciliationofBasicNetEarningsperSharetoDilutedNetEarningsperShareDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Less: shares repurchased under treasury stock method (in shares)", "label": "Shares Which Could Be Repurchased Under Treasury Stock Method", "documentation": "Common stock assumed to be purchased using the proceeds that could be obtained upon exercise of potential shares exercisable under stock option plans, at the average market price during the period." } } }, "auth_ref": [] }, "us-gaap_ShippingAndHandlingCostPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShippingAndHandlingCostPolicyTextBlock", "presentation": [ "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Shipping and handling", "label": "Shipping and Handling Cost, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the classification of shipping and handling costs, including whether the costs are included in cost of sales or included in other income statement accounts. If shipping and handling fees are significant and are not included in cost of sales, disclosure includes both the amounts of such costs and the line item on the income statement which includes such costs." } } }, "auth_ref": [] }, "us-gaap_ShippingAndHandlingMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShippingAndHandlingMember", "presentation": [ "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shipping and Handling", "label": "Shipping and Handling [Member]", "documentation": "Packing and transport of product." } } }, "auth_ref": [ "r1502" ] }, "jnj_ShippingandHandlingCostsasaPercentofSales": { "xbrltype": "percentItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "ShippingandHandlingCostsasaPercentofSales", "presentation": [ "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shipping and handling costs as a percent of sales", "label": "Shipping and Handling Costs as a Percent of Sales", "documentation": "Shipping and Handling Costs as a Percent of Sales" } } }, "auth_ref": [] }, "jnj_ShockwaveMedicalInc.Member": { "xbrltype": "domainItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "ShockwaveMedicalInc.Member", "presentation": [ "http://www.jnj.com/role/AcquisitionsanddivestituresDetails", "http://www.jnj.com/role/AcquisitionsanddivestituresNarrativeDetails", "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shockwave Medical, Inc.", "label": "Shockwave Medical, Inc. [Member]", "documentation": "Shockwave Medical, Inc." } } }, "auth_ref": [] }, "us-gaap_ShortTermBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermBorrowings", "crdr": "credit", "calculation": { "http://www.jnj.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.jnj.com/role/BorrowingsNarrativeDetails", "http://www.jnj.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Loans and notes payable", "verboseLabel": "Loans and notes payable", "label": "Short-Term Debt", "documentation": "Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r149", "r235", "r1219", "r1609" ] }, "us-gaap_ShortTermDebtLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermDebtLineItems", "presentation": [ "http://www.jnj.com/role/BorrowingsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Short-term Debt [Line Items]", "label": "Short-Term Debt [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_ShortTermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermDebtTypeAxis", "presentation": [ "http://www.jnj.com/role/BorrowingsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Short-term Debt, Type [Axis]", "label": "Short-Term Debt, Type [Axis]", "documentation": "Information by type of short-term debt arrangement." } } }, "auth_ref": [ "r151", "r1483", "r1484", "r1485" ] }, "us-gaap_ShortTermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermDebtTypeDomain", "presentation": [ "http://www.jnj.com/role/BorrowingsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Short-term Debt, Type [Domain]", "label": "Short-Term Debt, Type [Domain]", "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing." } } }, "auth_ref": [ "r149", "r1483", "r1484", "r1485" ] }, "jnj_ShortTermInvestmentFundsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "ShortTermInvestmentFundsMember", "presentation": [ "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofDefinedBenefitPlansDisclosuresDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Short-term investment funds", "label": "Short Term Investment Funds [Member]", "documentation": "Short term investment funds." } } }, "auth_ref": [] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": [ "http://www.jnj.com/role/Summaryofsignificantaccountingpolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of significant accounting policies", "label": "Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r196", "r368" ] }, "jnj_SimponiSimponiAriaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "SimponiSimponiAriaMember", "presentation": [ "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Simponi/Simponi Aria", "label": "Simponi/Simponi Aria [Member]", "documentation": "Simponi/Simponi Aria [Member]" } } }, "auth_ref": [] }, "us-gaap_SoftwareDevelopmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SoftwareDevelopmentMember", "presentation": [ "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Software Development", "label": "Software Development [Member]", "documentation": "Internally developed software for sale, licensing or long-term internal use." } } }, "auth_ref": [] }, "us-gaap_SovereignDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SovereignDebtSecuritiesMember", "presentation": [ "http://www.jnj.com/role/CashcashequivalentsandcurrentmarketablesecuritiesCashandCashEquivalentCompositionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-U.S. Sovereign Securities", "label": "Sovereign Debt Securities [Member]", "documentation": "Debt security issued by foreign government (not within the country of domicile of the entity)." } } }, "auth_ref": [] }, "us-gaap_StateAndLocalJurisdictionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StateAndLocalJurisdictionMember", "presentation": [ "http://www.jnj.com/role/IncometaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "State and Local Jurisdiction", "label": "State and Local Jurisdiction [Member]", "documentation": "Designated state or local jurisdiction entitled to levy and collect income tax." } } }, "auth_ref": [ "r754" ] }, "us-gaap_StatementBusinessSegmentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementBusinessSegmentsAxis", "presentation": [ "http://www.jnj.com/role/AcquisitionsanddivestituresNarrativeDetails", "http://www.jnj.com/role/IncometaxesNarrativeDetails", "http://www.jnj.com/role/IntangibleassetsandgoodwillGoodwillDetails", "http://www.jnj.com/role/RestructuringNarrativeDetails", "http://www.jnj.com/role/RestructuringScheduleofRestructuringReserveDetails", "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasIncomeBeforeTaxbySegmentDetails", "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails", "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingByGeographicAreaDetails", "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails", "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Segments [Axis]", "terseLabel": "Segments [Axis]", "label": "Segments [Axis]", "documentation": "Information by business segments." } } }, "auth_ref": [ "r246", "r247", "r248", "r249", "r311", "r407", "r412", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r428", "r429", "r430", "r438", "r439", "r440", "r441", "r442", "r444", "r445", "r446", "r452", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r535", "r538", "r556", "r561", "r985", "r986", "r987", "r988", "r989", "r990", "r991", "r992", "r993", "r994", "r995", "r1163", "r1166", "r1167", "r1174", "r1234", "r1613", "r1617", "r1618", "r1619", "r1620", "r1621", "r1622", "r1623", "r1624", "r1625", "r1626", "r1627", "r1628", "r1629", "r1630", "r1631", "r1632", "r1633", "r1634", "r1635", "r1636", "r1637", "r1638", "r1639", "r1640", "r1641", "r1642", "r1644", "r1645" ] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementClassOfStockAxis", "presentation": [ "http://www.jnj.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock [Axis]", "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": [ "r269", "r328", "r329", "r330", "r370", "r393", "r397", "r399", "r401", "r409", "r410", "r490", "r571", "r574", "r575", "r576", "r580", "r581", "r611", "r612", "r613", "r614", "r616", "r847", "r1020", "r1021", "r1022", "r1023", "r1027", "r1028", "r1029", "r1030", "r1031", "r1032", "r1033", "r1034", "r1035", "r1036", "r1037", "r1038", "r1058", "r1080", "r1099", "r1122", "r1123", "r1124", "r1125", "r1126", "r1374", "r1418", "r1429" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://www.jnj.com/role/AccumulatedothercomprehensiveincomelossDetails", "http://www.jnj.com/role/CapitalandtreasurystockChangesinTreasuryStockDetails", "http://www.jnj.com/role/ConsolidatedStatementsofEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Components [Axis]", "verboseLabel": "Equity Components [Axis]", "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r22", "r161", "r163", "r164", "r309", "r355", "r356", "r357", "r375", "r376", "r377", "r379", "r384", "r386", "r388", "r408", "r491", "r492", "r536", "r617", "r778", "r779", "r788", "r789", "r790", "r792", "r798", "r799", "r811", "r812", "r813", "r814", "r815", "r816", "r819", "r858", "r860", "r861", "r862", "r863", "r865", "r871", "r873", "r882", "r978", "r1007", "r1008", "r1009", "r1027", "r1099" ] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StatementGeographicalAxis", "presentation": [ "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails", "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingByGeographicAreaDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Geographical [Axis]", "label": "Geographical [Axis]", "documentation": "Information by geographical components." } } }, "auth_ref": [ "r272", "r274", "r277", "r279", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r450", "r451", "r920", "r921", "r922", "r923", "r924", "r925", "r926", "r927", "r928", "r929", "r930", "r931", "r932", "r933", "r934", "r935", "r936", "r937", "r938", "r939", "r940", "r941", "r942", "r943", "r944", "r945", "r946", "r947", "r948", "r949", "r1041", "r1044", "r1046", "r1103", "r1107", "r1110", "r1121", "r1128", "r1130", "r1131", "r1132", "r1133", "r1134", "r1135", "r1136", "r1137", "r1138", "r1145", "r1185", "r1221", "r1222", "r1223", "r1224", "r1225", "r1226", "r1227", "r1228", "r1233", "r1243", "r1501", "r1613", "r1617", "r1618", "r1620", "r1621", "r1622", "r1623", "r1624", "r1625", "r1626", "r1627", "r1628", "r1629", "r1630", "r1631", "r1632", "r1633", "r1634", "r1635", "r1636", "r1637", "r1638", "r1639", "r1640", "r1641", "r1642", "r1644", "r1645" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": [ "http://www.jnj.com/role/ConsolidatedStatementsofEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Line Items]", "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r375", "r376", "r377", "r408", "r873", "r917", "r1015", "r1038", "r1050", "r1051", "r1052", "r1053", "r1054", "r1055", "r1058", "r1061", "r1062", "r1063", "r1064", "r1065", "r1066", "r1067", "r1068", "r1069", "r1072", "r1073", "r1074", "r1075", "r1076", "r1078", "r1081", "r1082", "r1084", "r1085", "r1086", "r1087", "r1088", "r1089", "r1090", "r1091", "r1092", "r1093", "r1094", "r1095", "r1099", "r1244" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Cash Flows [Abstract]", "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Financial Position [Abstract]", "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Comprehensive Income [Abstract]", "label": "Statement of Comprehensive Income [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Stockholders' Equity [Abstract]", "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "srt_StatementScenarioAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StatementScenarioAxis", "presentation": [ "http://www.jnj.com/role/AcquisitionsanddivestituresNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Scenario [Axis]", "label": "Scenario [Axis]", "documentation": "Information by scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts." } } }, "auth_ref": [ "r306", "r389", "r702", "r1375", "r1380", "r1427" ] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": [ "http://www.jnj.com/role/ConsolidatedStatementsofEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Table]", "label": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": [ "r375", "r376", "r377", "r408", "r453", "r873", "r917", "r1015", "r1038", "r1050", "r1051", "r1052", "r1053", "r1054", "r1055", "r1058", "r1061", "r1062", "r1063", "r1064", "r1065", "r1066", "r1067", "r1068", "r1069", "r1072", "r1073", "r1074", "r1075", "r1076", "r1078", "r1081", "r1082", "r1084", "r1085", "r1086", "r1087", "r1088", "r1089", "r1090", "r1091", "r1092", "r1093", "r1094", "r1095", "r1099", "r1244" ] }, "jnj_StelaraMember": { "xbrltype": "domainItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "StelaraMember", "presentation": [ "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stelara", "label": "Stelara [Member]", "documentation": "Stelara [Member]" } } }, "auth_ref": [] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Price or TSR Estimation Method", "label": "Stock Price or TSR Estimation Method [Text Block]" } } }, "auth_ref": [ "r1283", "r1294", "r1304", "r1337" ] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockAppreciationRightsSARSMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Appreciation Rights (SARs)", "label": "Stock Appreciation Rights (SARs) [Member]", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "jnj_StockIssuedDuringPeriodSharesExchangeOffer": { "xbrltype": "sharesItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "StockIssuedDuringPeriodSharesExchangeOffer", "presentation": [ "http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsDetailsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock issued in exchange offer (in shares)", "label": "Stock Issued During Period, Shares, Exchange Offer", "documentation": "Stock Issued During Period, Shares, Exchange Offer" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesOther": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesOther", "presentation": [ "http://www.jnj.com/role/CapitalandtreasurystockChangesinTreasuryStockDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Employee compensation and stock option plans (shares)", "label": "Stock Issued During Period, Shares, Other", "documentation": "Number of shares of stock issued attributable to transactions classified as other." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": [ "http://www.jnj.com/role/CommonstockstockoptionplansandstockcompensationagreementsSummaryofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Options exercised (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": [ "r22", "r160", "r161", "r212", "r718" ] }, "us-gaap_StockIssuedDuringPeriodValueOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueOther", "crdr": "credit", "presentation": [ "http://www.jnj.com/role/CapitalandtreasurystockChangesinTreasuryStockDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Employee compensation and stock option plans", "label": "Stock Issued During Period, Value, Other", "documentation": "Value of shares of stock issued attributable to transactions classified as other." } } }, "auth_ref": [] }, "srt_StockRepurchaseProgramAuthorizedAmount1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StockRepurchaseProgramAuthorizedAmount1", "crdr": "credit", "presentation": [ "http://www.jnj.com/role/CapitalandtreasurystockNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock repurchase program, authorized amount", "label": "Share Repurchase Program, Authorized, Amount", "documentation": "Amount authorized for purchase of share under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership." } } }, "auth_ref": [ "r1500" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityAbstract", "presentation": [ "http://www.jnj.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "verboseLabel": "Shareholders\u2019 equity", "label": "Equity, Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.jnj.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.jnj.com/role/AccumulatedothercomprehensiveincomelossDetails", "http://www.jnj.com/role/ConsolidatedBalanceSheets", "http://www.jnj.com/role/ConsolidatedStatementsofEquity" ], "lang": { "en-us": { "role": { "totalLabel": "Total shareholders\u2019 equity", "periodStartLabel": "Beginning Balance", "periodEndLabel": "Ending Balance", "label": "Equity, Including Portion Attributable to Noncontrolling Interest", "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": [ "r98", "r99", "r102", "r309", "r310", "r356", "r375", "r376", "r377", "r379", "r384", "r386", "r491", "r492", "r536", "r617", "r778", "r779", "r788", "r789", "r790", "r792", "r798", "r799", "r811", "r812", "r813", "r814", "r815", "r816", "r819", "r858", "r860", "r865", "r872", "r882", "r1008", "r1009", "r1026", "r1060", "r1077", "r1100", "r1101", "r1127", "r1255", "r1420", "r1457", "r1588", "r1648" ] }, "us-gaap_StockholdersEquityNoteSpinoffTransaction": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteSpinoffTransaction", "crdr": "credit", "presentation": [ "http://www.jnj.com/role/ConsolidatedStatementsofEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Kenvue Separation /IPO", "label": "Stockholders' Equity Note, Spinoff Transaction", "documentation": "The change in equity as a result of a spin-off transaction (a regular or reverse spin-off) which is based on the recorded amounts." } } }, "auth_ref": [ "r76" ] }, "us-gaap_StockholdersEquityOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityOther", "crdr": "debit", "presentation": [ "http://www.jnj.com/role/ConsolidatedStatementsofEquity" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other", "label": "Stockholders' Equity, Other", "documentation": "This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy." } } }, "auth_ref": [] }, "us-gaap_SubsegmentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsegmentsAxis", "presentation": [ "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsegments [Axis]", "label": "Subsegments [Axis]", "documentation": "Information by business subsegments." } } }, "auth_ref": [] }, "us-gaap_SubsegmentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsegmentsDomain", "presentation": [ "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsegments [Domain]", "label": "Subsegments [Domain]", "documentation": "Divisions of a component of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": [] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventMember", "presentation": [ "http://www.jnj.com/role/CapitalandtreasurystockNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event", "label": "Subsequent Event [Member]", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r866", "r883" ] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeAxis", "presentation": [ "http://www.jnj.com/role/CapitalandtreasurystockNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event Type [Axis]", "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r866", "r883" ] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeDomain", "presentation": [ "http://www.jnj.com/role/CapitalandtreasurystockNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event Type [Domain]", "label": "Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r866", "r883" ] }, "us-gaap_SubsidiarySaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsidiarySaleOfStockAxis", "presentation": [ "http://www.jnj.com/role/KenvueseparationanddiscontinuedoperationsDetailsDetails", "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sale of Stock [Axis]", "label": "Sale of Stock [Axis]", "documentation": "Information by type of sale of the entity's stock." } } }, "auth_ref": [] }, "us-gaap_SummaryOfValuationAllowanceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SummaryOfValuationAllowanceTextBlock", "presentation": [ "http://www.jnj.com/role/IncometaxesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Valuation Allowance", "label": "Summary of Valuation Allowance [Table Text Block]", "documentation": "Tabular disclosure of valuation allowances to reduce deferred tax assets to net realizable value, including identification of the deferred tax asset more likely than not will not be fully realized and the corresponding amount of the valuation allowance." } } }, "auth_ref": [ "r1550" ] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalCashFlowInformationAbstract", "presentation": [ "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Supplemental cash flow data", "label": "Supplemental Cash Flow Information [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SupplierFinanceProgramObligationCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplierFinanceProgramObligationCurrent", "crdr": "credit", "presentation": [ "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails", "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesSupplierFinanceProgramDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Supplier finance program, obligation, current", "periodStartLabel": "Confirmed obligations - beginning of the year", "periodEndLabel": "Confirmed obligations - end of the year", "label": "Supplier Finance Program, Obligation, Current", "documentation": "Amount of obligation for supplier finance program, classified as current." } } }, "auth_ref": [ "r546", "r547", "r550" ] }, "us-gaap_SupplierFinanceProgramObligationCurrentStatementOfFinancialPositionExtensibleEnumeration": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplierFinanceProgramObligationCurrentStatementOfFinancialPositionExtensibleEnumeration", "presentation": [ "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Supplier Finance Program, Obligation, Current, Statement of Financial Position [Extensible Enumeration]", "label": "Supplier Finance Program, Obligation, Current, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes obligation for supplier finance program, classified as current." } } }, "auth_ref": [ "r547" ] }, "us-gaap_SupplierFinanceProgramObligationDecreaseSettlement": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplierFinanceProgramObligationDecreaseSettlement", "crdr": "debit", "presentation": [ "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesSupplierFinanceProgramDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Confirmed invoices paid during the year", "label": "Supplier Finance Program, Obligation, Settlement", "documentation": "Amount of decrease in obligation for supplier finance program from settlement." } } }, "auth_ref": [ "r549", "r1176" ] }, "us-gaap_SupplierFinanceProgramObligationIncrease": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplierFinanceProgramObligationIncrease", "crdr": "credit", "presentation": [ "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesSupplierFinanceProgramDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Invoices confirmed during the year", "label": "Supplier Finance Program, Obligation, Addition", "documentation": "Amount of increase in obligation for supplier finance program." } } }, "auth_ref": [ "r548", "r1176" ] }, "us-gaap_SupplierFinanceProgramObligationRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplierFinanceProgramObligationRollForward", "presentation": [ "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesSupplierFinanceProgramDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Supplier Finance Program, Obligation [Roll Forward]", "label": "Supplier Finance Program, Obligation [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_SupplierFinanceProgramPaymentTimingPeriod": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplierFinanceProgramPaymentTimingPeriod", "presentation": [ "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Supplier finance program, payment timing, period", "label": "Supplier Finance Program, Payment Timing, Period", "documentation": "Period when payment is expected to be made to finance provider or intermediary in supplier finance program, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r545" ] }, "jnj_SupplierFinanceProgramPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "SupplierFinanceProgramPolicyTextBlock", "presentation": [ "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Supplier finance program obligations", "label": "Supplier Finance Program [Policy Text Block]", "documentation": "Supplier Finance Program" } } }, "auth_ref": [] }, "us-gaap_SupplierFinanceProgramTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplierFinanceProgramTableTextBlock", "presentation": [ "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Supplier Finance Program", "label": "Supplier Finance Program [Table Text Block]", "documentation": "Tabular disclosure of supplier finance program." } } }, "auth_ref": [ "r1176", "r1486" ] }, "us-gaap_SuppliesExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SuppliesExpense", "crdr": "debit", "presentation": [ "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingByGeographicAreaDetails", "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Supplies expense", "label": "Supplies Expense", "documentation": "Amount of expense associated with supplies that were used during the current accounting period." } } }, "auth_ref": [ "r241" ] }, "jnj_SurgeryMember": { "xbrltype": "domainItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "SurgeryMember", "presentation": [ "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Surgery", "label": "Surgery [Member]", "documentation": "Surgery [Member]" } } }, "auth_ref": [] }, "jnj_TECVAYLIMember": { "xbrltype": "domainItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "TECVAYLIMember", "presentation": [ "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "TECVAYLI", "label": "TECVAYLI [Member]", "documentation": "TECVAYLI" } } }, "auth_ref": [] }, "jnj_TRAUMAMember": { "xbrltype": "domainItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "TRAUMAMember", "presentation": [ "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "TRAUMA", "label": "TRAUMA [Member]", "documentation": "TRAUMA [Member]" } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TabularListTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Tabular List, Table", "label": "Tabular List [Table Text Block]" } } }, "auth_ref": [ "r1330" ] }, "jnj_TalcMember": { "xbrltype": "domainItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "TalcMember", "presentation": [ "http://www.jnj.com/role/IncometaxesNarrativeDetails", "http://www.jnj.com/role/LegalproceedingsNarrativeDetails", "http://www.jnj.com/role/LegalproceedingsProductLiabilitiesDetails", "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingByGeographicAreaDetails", "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Talc", "label": "Talc [Member]", "documentation": "Talc [Member]" } } }, "auth_ref": [] }, "us-gaap_TaxCreditCarryforwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TaxCreditCarryforwardLineItems", "presentation": [ "http://www.jnj.com/role/IncometaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tax Credit Carryforward [Line Items]", "label": "Tax Credit Carryforward [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r775" ] }, "us-gaap_TaxCreditCarryforwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TaxCreditCarryforwardTable", "presentation": [ "http://www.jnj.com/role/IncometaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tax Credit Carryforward [Table]", "label": "Tax Credit Carryforward [Table]", "documentation": "Disclosure of information about tax credit carryforward available to reduce future taxable income. Includes, but is not limited to, description, amount, expiration date, limitation on use, and related deferred tax asset and valuation allowance." } } }, "auth_ref": [ "r775" ] }, "jnj_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiabilityNoncurrent", "crdr": "credit", "presentation": [ "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "TJCA , provisional liability, non-current", "label": "Tax Cuts And Jobs Act Of 2017, Incomplete Accounting, Provisional Liability, Noncurrent", "documentation": "Tax Cuts And Jobs Act Of 2017, Incomplete Accounting, Provisional Liability, Current" } } }, "auth_ref": [] }, "jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsCashAndCashEquivalentsTaxRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "TaxCutsAndJobsActOf2017UndistributedForeignEarningsCashAndCashEquivalentsTaxRatePercent", "presentation": [ "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "TCJA, undistributed foreign earnings percent related to cash and cash equivalents", "label": "Tax Cuts And Jobs Act Of 2017, Undistributed Foreign Earnings, Cash And Cash Equivalents, Tax Rate, Percent", "documentation": "Tax Cuts And Jobs Act Of 2017, Undistributed Foreign Earnings, Cash And Cash Equivalents, Tax Rate, Percent" } } }, "auth_ref": [] }, "jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsOtherThanCashAndCashEquivalentsTaxRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "TaxCutsAndJobsActOf2017UndistributedForeignEarningsOtherThanCashAndCashEquivalentsTaxRatePercent", "presentation": [ "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "TCJA, undistributed foreign earnings percent related to earnings other than cash and cash equivalents", "label": "Tax Cuts And Jobs Act Of 2017, Undistributed Foreign Earnings, Other Than Cash And Cash Equivalents, Tax Rate, Percent", "documentation": "Tax Cuts And Jobs Act Of 2017, Undistributed Foreign Earnings, Other Than Cash And Cash Equivalents, Tax Rate, Percent" } } }, "auth_ref": [] }, "jnj_TaxCutsAndJobsActTransitionTaxForAccumulatedForeignEarningsPaymentPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "TaxCutsAndJobsActTransitionTaxForAccumulatedForeignEarningsPaymentPeriod", "presentation": [ "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "TCJA, transition tax for accumulated foreign earnings, payment period", "label": "Tax Cuts and Jobs Act, Transition Tax for Accumulated Foreign Earnings, Payment Period", "documentation": "Tax Cuts and Jobs Act, Transition Tax for Accumulated Foreign Earnings, Payment Period" } } }, "auth_ref": [] }, "jnj_TotalClaimsAgainstCompanyPercent": { "xbrltype": "percentItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "TotalClaimsAgainstCompanyPercent", "presentation": [ "http://www.jnj.com/role/LegalproceedingsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total claims against company, percent", "label": "Total Claims Against Company, Percent", "documentation": "Total Claims Against Company, Percent" } } }, "auth_ref": [] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Amount", "label": "Total Shareholder Return Amount" } } }, "auth_ref": [ "r1322" ] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Vs Peer Group", "label": "Total Shareholder Return Vs Peer Group [Text Block]" } } }, "auth_ref": [ "r1329" ] }, "us-gaap_TrademarksMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TrademarksMember", "presentation": [ "http://www.jnj.com/role/IntangibleassetsandgoodwilScheduleofIntangibleAssetsandGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Trademarks", "label": "Trademarks [Member]", "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style." } } }, "auth_ref": [ "r95", "r1175", "r1473", "r1474", "r1475", "r1476", "r1477", "r1478", "r1479", "r1480", "r1481", "r1482" ] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangement:", "label": "Trading Arrangement [Axis]" } } }, "auth_ref": [ "r1350" ] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrByIndTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangements, by Individual", "label": "Trading Arrangements, by Individual [Table]" } } }, "auth_ref": [ "r1352" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [ "http://www.jnj.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "presentation": [ "http://www.jnj.com/role/CashcashequivalentsandcurrentmarketablesecuritiesCashandCashEquivalentCompositionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Instruments [Domain]", "label": "Financial Instruments [Domain]", "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "auth_ref": [ "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r607", "r615", "r818", "r844", "r884", "r885", "r886", "r887", "r888", "r889", "r890", "r891", "r892", "r893", "r894", "r895", "r896", "r897", "r898", "r900", "r901", "r902", "r903", "r904", "r905", "r906", "r907", "r908", "r909", "r910", "r911", "r912", "r913", "r914", "r979", "r1206", "r1208", "r1210", "r1211", "r1212", "r1213", "r1214", "r1215", "r1216", "r1220", "r1388", "r1389", "r1390", "r1391", "r1392", "r1393", "r1394", "r1452", "r1453", "r1454", "r1455", "r1572", "r1575", "r1576", "r1577", "r1584", "r1587" ] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrAdoptionDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Adoption Date", "label": "Trading Arrangement Adoption Date" } } }, "auth_ref": [ "r1353" ] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrDuration", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Arrangement Duration", "label": "Trading Arrangement Duration" } } }, "auth_ref": [ "r1354" ] }, "ecd_TrdArrExpirationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrExpirationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Expiration Date", "label": "Trading Arrangement Expiration Date" } } }, "auth_ref": [ "r1354" ] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Trading Arrangement, Individual Name" } } }, "auth_ref": [ "r1352" ] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndTitle", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Title", "label": "Trading Arrangement, Individual Title" } } }, "auth_ref": [ "r1352" ] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Available", "label": "Trading Arrangement, Securities Aggregate Available Amount" } } }, "auth_ref": [ "r1355" ] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrTerminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Termination Date", "label": "Trading Arrangement Termination Date" } } }, "auth_ref": [ "r1353" ] }, "us-gaap_TreasuryStockCommonMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockCommonMember", "presentation": [ "http://www.jnj.com/role/CapitalandtreasurystockChangesinTreasuryStockDetails", "http://www.jnj.com/role/ConsolidatedStatementsofEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Treasury Stock Amount", "label": "Treasury Stock, Common [Member]", "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r72" ] }, "us-gaap_TreasuryStockCommonShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockCommonShares", "presentation": [ "http://www.jnj.com/role/CapitalandtreasurystockChangesinTreasuryStockDetails", "http://www.jnj.com/role/ConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Treasury stock (in shares)", "periodStartLabel": "Treasury Stock, beginning balance (shares)", "periodEndLabel": "Treasury Stock, ending balance (shares)", "label": "Treasury Stock, Common, Shares", "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r72" ] }, "jnj_TreasuryStockIssuedForEmployeeCompensationAndStockOptionPlansNetOfCashProceeds": { "xbrltype": "monetaryItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "TreasuryStockIssuedForEmployeeCompensationAndStockOptionPlansNetOfCashProceeds", "crdr": "credit", "presentation": [ "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Treasury stock issued for employee compensation and stock option plans, net of cash proceeds/ employee withholding tax on stock awards", "label": "Treasury Stock Issued For Employee Compensation And Stock Option Plans Net Of Cash Proceeds", "documentation": "Treasury stock issued for employee compensation and stock option plans, net of cash proceeds." } } }, "auth_ref": [] }, "us-gaap_TreasuryStockSharesAcquired": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockSharesAcquired", "presentation": [ "http://www.jnj.com/role/CapitalandtreasurystockChangesinTreasuryStockDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Repurchase of common stock (shares)", "label": "Treasury Stock, Shares, Acquired", "documentation": "Number of shares that have been repurchased during the period and are being held in treasury." } } }, "auth_ref": [ "r22", "r161", "r212" ] }, "us-gaap_TreasuryStockTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockTextBlock", "presentation": [ "http://www.jnj.com/role/Capitalandtreasurystock" ], "lang": { "en-us": { "role": { "terseLabel": "Capital and treasury stock", "label": "Treasury Stock [Text Block]", "documentation": "The entire disclosure for treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock." } } }, "auth_ref": [ "r213" ] }, "us-gaap_TreasuryStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockValue", "crdr": "debit", "calculation": { "http://www.jnj.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.jnj.com/role/CapitalandtreasurystockChangesinTreasuryStockDetails", "http://www.jnj.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "verboseLabel": "Less: common stock held in treasury, at cost (Note\u00a012) (712,921,000\u00a0shares and 712,765,000\u00a0shares)", "periodStartLabel": "Treasury Stock, Balance", "periodEndLabel": "Treasury Stock, Ending Balance", "label": "Treasury Stock, Value", "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury." } } }, "auth_ref": [ "r72", "r75", "r161", "r163" ] }, "us-gaap_TreasuryStockValueAcquiredCostMethod": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockValueAcquiredCostMethod", "crdr": "debit", "presentation": [ "http://www.jnj.com/role/CapitalandtreasurystockChangesinTreasuryStockDetails", "http://www.jnj.com/role/ConsolidatedStatementsofEquity" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Repurchase of common stock", "terseLabel": "Repurchase of common stock", "label": "Treasury Stock, Value, Acquired, Cost Method", "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method." } } }, "auth_ref": [ "r22", "r72", "r212" ] }, "jnj_TreasuryStockValueAcquiredCostMethodNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "TreasuryStockValueAcquiredCostMethodNetOfTax", "crdr": "debit", "presentation": [ "http://www.jnj.com/role/CapitalandtreasurystockChangesinTreasuryStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Repurchase of common stock", "label": "Treasury Stock, Value, Acquired, Cost Method, Net Of Tax", "documentation": "Treasury Stock, Value, Acquired, Cost Method, Net Of Tax" } } }, "auth_ref": [] }, "jnj_TremfyaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "TremfyaMember", "presentation": [ "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tremfya", "label": "Tremfya [Member]", "documentation": "Tremfaya" } } }, "auth_ref": [] }, "jnj_UNITEDSTATESExportsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "UNITEDSTATESExportsMember", "presentation": [ "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "UNITED STATES Exports", "label": "UNITED STATES Exports [Member]", "documentation": "UNITED STATES Exports [Member]" } } }, "auth_ref": [] }, "jnj_UPTRAVIMember": { "xbrltype": "domainItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "UPTRAVIMember", "presentation": [ "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "UPTRAVI", "label": "UPTRAVI [Member]", "documentation": "UPTRAVI [Member]" } } }, "auth_ref": [] }, "country_US": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2024", "localname": "US", "presentation": [ "http://www.jnj.com/role/PensionsandotherbenefitplansInformationRelatedtotheBenefitObligationandtheFairValueofPlanAssetsDetails", "http://www.jnj.com/role/PensionsandotherbenefitplansNarrativeDetails", "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails", "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingByGeographicAreaDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "U.S. Plans", "terseLabel": "United States", "label": "UNITED STATES" } } }, "auth_ref": [] }, "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "USGovernmentAgenciesDebtSecuritiesMember", "presentation": [ "http://www.jnj.com/role/CashcashequivalentsandcurrentmarketablesecuritiesCashandCashEquivalentCompositionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "U.S. Gov't Agencies", "label": "US Government Agencies Debt Securities [Member]", "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB)." } } }, "auth_ref": [ "r1157", "r1187", "r1605" ] }, "us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "USGovernmentCorporationsAndAgenciesSecuritiesMember", "presentation": [ "http://www.jnj.com/role/PensionsandotherbenefitplansScheduleofDefinedBenefitPlansDisclosuresDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Government and agency securities", "label": "US Government Corporations and Agencies Securities [Member]", "documentation": "This category includes information about debt issued by US Government Corporations and Agencies. Investments in such US Government Corporations may include debt securities issued by the Government National Mortgage Association (Ginnie Mae) and by the Federal National Mortgage Association (Fannie Mae) and the Federal Home Loan Mortgage Corporation (Freddie Mac)." } } }, "auth_ref": [ "r1605" ] }, "us-gaap_USTreasuryAndGovernmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "USTreasuryAndGovernmentMember", "presentation": [ "http://www.jnj.com/role/CashcashequivalentsandcurrentmarketablesecuritiesCashandCashEquivalentCompositionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "U.S. Gov't Securities", "label": "US Treasury and Government [Member]", "documentation": "This category includes investments in debt securities issued by the United States Department of the Treasury, US Government Agencies and US Government-sponsored Enterprises. Such securities may include treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years), debt securities issued by the Government National Mortgage Association (Ginnie Mae) and debt securities issued by the Federal National Mortgage Association (Fannie Mae) or the Federal Home Loan Mortgage Corporation (Freddie Mac)." } } }, "auth_ref": [ "r957", "r1187", "r1220", "r1238", "r1643" ] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Security Market Price Change", "label": "Underlying Security Market Price Change, Percent" } } }, "auth_ref": [ "r1349" ] }, "jnj_UnfundedPlansMember": { "xbrltype": "domainItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "UnfundedPlansMember", "presentation": [ "http://www.jnj.com/role/PensionsandotherbenefitplansInformationRelatedtotheBenefitObligationandtheFairValueofPlanAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unfunded Plans", "label": "Unfunded Plans [Member]", "documentation": "Unfunded plans." } } }, "auth_ref": [] }, "us-gaap_UnrecognizedTaxBenefits": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrecognizedTaxBenefits", "crdr": "credit", "presentation": [ "http://www.jnj.com/role/IncometaxesNarrativeDetails", "http://www.jnj.com/role/IncometaxesSummaryofActivityRelatedtoUnrecognizedTaxBenefitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrecognized tax benefits", "periodStartLabel": "Beginning of year", "periodEndLabel": "End of year", "label": "Unrecognized Tax Benefits", "documentation": "Amount of unrecognized tax benefits." } } }, "auth_ref": [ "r747", "r763", "r1202" ] }, "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions", "crdr": "debit", "presentation": [ "http://www.jnj.com/role/IncometaxesSummaryofActivityRelatedtoUnrecognizedTaxBenefitsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Decreases related to prior period tax positions", "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions", "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns." } } }, "auth_ref": [ "r764", "r1202" ] }, "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities", "crdr": "debit", "presentation": [ "http://www.jnj.com/role/IncometaxesSummaryofActivityRelatedtoUnrecognizedTaxBenefitsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Settlements", "label": "Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities", "documentation": "Amount of decrease in unrecognized tax benefits resulting from settlements with taxing authorities." } } }, "auth_ref": [ "r766", "r1202" ] }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions", "crdr": "credit", "presentation": [ "http://www.jnj.com/role/IncometaxesSummaryofActivityRelatedtoUnrecognizedTaxBenefitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Increases related to current year tax positions", "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions", "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return." } } }, "auth_ref": [ "r765", "r1202" ] }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions", "crdr": "credit", "presentation": [ "http://www.jnj.com/role/IncometaxesSummaryofActivityRelatedtoUnrecognizedTaxBenefitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Increases related to prior period tax positions", "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions", "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns." } } }, "auth_ref": [ "r764", "r1202" ] }, "us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued", "crdr": "credit", "presentation": [ "http://www.jnj.com/role/IncometaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrecognized tax benefits, interest on income taxes accrued", "label": "Unrecognized Tax Benefits, Interest on Income Taxes Accrued", "documentation": "Amount of interest expense accrued for an underpayment of income taxes." } } }, "auth_ref": [ "r1547" ] }, "us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense", "crdr": "debit", "presentation": [ "http://www.jnj.com/role/IncometaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrecognized tax benefits, interest on income tax expense", "label": "Unrecognized Tax Benefits, Interest on Income Taxes Expense", "documentation": "Amount of interest expense for an underpayment of income taxes." } } }, "auth_ref": [ "r1547" ] }, "us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrecognizedTaxBenefitsPeriodIncreaseDecrease", "presentation": [ "http://www.jnj.com/role/IncometaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrecognized tax benefits, period increase (decrease)", "label": "Unrecognized Tax Benefits, Period Increase (Decrease)", "documentation": "Amount of increase (decrease) in unrecognized tax benefits attributable to uncertain tax positions taken in tax returns." } } }, "auth_ref": [ "r1548" ] }, "us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations", "crdr": "debit", "presentation": [ "http://www.jnj.com/role/IncometaxesSummaryofActivityRelatedtoUnrecognizedTaxBenefitsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Lapse of statute of limitations", "label": "Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations", "documentation": "Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations." } } }, "auth_ref": [ "r767" ] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UseOfEstimates", "presentation": [ "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Use of estimates", "label": "Use of Estimates, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r56", "r57", "r58", "r259", "r260", "r262", "r263" ] }, "jnj_VWaveLtd.Member": { "xbrltype": "domainItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "VWaveLtd.Member", "presentation": [ "http://www.jnj.com/role/AcquisitionsanddivestituresNarrativeDetails", "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "V-Wave Ltd.", "label": "V-Wave Ltd. [Member]", "documentation": "V-Wave Ltd." } } }, "auth_ref": [] }, "jnj_ValuationAllowanceDeferredTaxAssetForeignCurrencyTranslation": { "xbrltype": "monetaryItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "ValuationAllowanceDeferredTaxAssetForeignCurrencyTranslation", "crdr": "credit", "presentation": [ "http://www.jnj.com/role/IncometaxesValuationAllowanceActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign currency translation", "label": "Valuation Allowance, Deferred Tax Asset, Foreign Currency Translation", "documentation": "Valuation Allowance, Deferred Tax Asset, Foreign Currency Translation" } } }, "auth_ref": [] }, "jnj_ValuationAllowanceDeferredTaxAssetsAcquisitionsDispositions": { "xbrltype": "monetaryItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "ValuationAllowanceDeferredTaxAssetsAcquisitionsDispositions", "crdr": "credit", "presentation": [ "http://www.jnj.com/role/IncometaxesValuationAllowanceActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net acquisitions / (dispositions/liquidations)", "label": "Valuation Allowance, Deferred Tax Assets, Acquisitions (Dispositions)", "documentation": "Valuation Allowance, Deferred Tax Assets, Acquisitions (Dispositions)" } } }, "auth_ref": [] }, "jnj_ValuationAllowanceDeferredTaxAssetsProvision": { "xbrltype": "monetaryItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "ValuationAllowanceDeferredTaxAssetsProvision", "crdr": "credit", "presentation": [ "http://www.jnj.com/role/IncometaxesValuationAllowanceActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Provision", "label": "Valuation Allowance, Deferred Tax Assets, Provision", "documentation": "Valuation Allowance, Deferred Tax Assets, Provision" } } }, "auth_ref": [] }, "jnj_ValuationAllowanceDeferredTaxAssetsUtilization": { "xbrltype": "monetaryItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "ValuationAllowanceDeferredTaxAssetsUtilization", "crdr": "debit", "presentation": [ "http://www.jnj.com/role/IncometaxesValuationAllowanceActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Utilization", "label": "Valuation Allowance, Deferred Tax Assets, Utilization", "documentation": "Valuation Allowance, Deferred Tax Assets, Utilization" } } }, "auth_ref": [] }, "jnj_ValuationAllowanceRollForward": { "xbrltype": "stringItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "ValuationAllowanceRollForward", "presentation": [ "http://www.jnj.com/role/IncometaxesValuationAllowanceActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Valuation Allowance [Roll Forward]", "label": "Valuation Allowance [Roll Forward]", "documentation": "Valuation Allowance" } } }, "auth_ref": [] }, "jnj_VisionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "VisionMember", "presentation": [ "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vision", "label": "Vision [Member]", "documentation": "Vision[Member]" } } }, "auth_ref": [] }, "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year", "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]" } } }, "auth_ref": [ "r1318" ] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "calculation": { "http://www.jnj.com/role/EarningspershareReconciliationofBasicNetEarningsperSharetoDilutedNetEarningsperShareDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.jnj.com/role/ConsolidatedStatementsofEarnings", "http://www.jnj.com/role/EarningspershareReconciliationofBasicNetEarningsperSharetoDilutedNetEarningsperShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Diluted (in shares)", "totalLabel": "Average shares outstanding - diluted (in shares)", "label": "Weighted Average Number of Shares Outstanding, Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r392", "r401" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "presentation": [ "http://www.jnj.com/role/ConsolidatedStatementsofEarnings" ], "lang": { "en-us": { "role": { "verboseLabel": "Average shares outstanding", "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "calculation": { "http://www.jnj.com/role/EarningspershareReconciliationofBasicNetEarningsperSharetoDilutedNetEarningsperShareDetails": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.jnj.com/role/ConsolidatedStatementsofEarnings", "http://www.jnj.com/role/EarningspershareReconciliationofBasicNetEarningsperSharetoDilutedNetEarningsperShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Basic (in shares)", "verboseLabel": "Average shares outstanding\u00a0\u2014 basic (in shares)", "label": "Weighted Average Number of Shares Outstanding, Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r391", "r401" ] }, "jnj_WesternHemisphereExcludingUSMember": { "xbrltype": "domainItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "WesternHemisphereExcludingUSMember", "presentation": [ "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingByGeographicAreaDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Western Hemisphere excluding U.S.", "label": "Western Hemisphere, excluding U.S. [Member]", "documentation": "Western Hemisphere, excluding U.S. [Member]" } } }, "auth_ref": [] }, "jnj_Wholesaler1Member": { "xbrltype": "domainItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "Wholesaler1Member", "presentation": [ "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingByGeographicAreaDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Wholesaler 1", "label": "Wholesaler 1 [Member]", "documentation": "Wholesaler 1 [Member]" } } }, "auth_ref": [] }, "jnj_Wholesaler2Member": { "xbrltype": "domainItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "Wholesaler2Member", "presentation": [ "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingByGeographicAreaDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Wholesaler 2", "label": "Wholesaler 2 [Member]", "documentation": "Wholesaler 2 [Member]" } } }, "auth_ref": [] }, "jnj_Wholesaler3Member": { "xbrltype": "domainItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "Wholesaler3Member", "presentation": [ "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingByGeographicAreaDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Wholesaler 3", "label": "Wholesaler 3 [Member]", "documentation": "Wholesaler 3 [Member]" } } }, "auth_ref": [] }, "jnj_WholesalerConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "WholesalerConcentrationRiskMember", "presentation": [ "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingByGeographicAreaDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Wholesaler Concentration Risk", "label": "Wholesaler Concentration Risk [Member]", "documentation": "Wholesaler Concentration Risk" } } }, "auth_ref": [] }, "jnj_XareltoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "XareltoMember", "presentation": [ "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "XARELTO", "label": "Xarelto [Member]", "documentation": "Xarelto [Member]" } } }, "auth_ref": [] }, "jnj_YellowJerseyTherapeuticsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "YellowJerseyTherapeuticsMember", "presentation": [ "http://www.jnj.com/role/AcquisitionsanddivestituresNarrativeDetails", "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails", "http://www.jnj.com/role/SummaryofsignificantaccountingpoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Yellow Jersey Therapeutics", "label": "Yellow Jersey Therapeutics [Member]", "documentation": "Yellow Jersey Therapeutics" } } }, "auth_ref": [] }, "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested", "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]" } } }, "auth_ref": [ "r1316" ] }, "jnj_ZYTIGAMember": { "xbrltype": "domainItemType", "nsuri": "http://www.jnj.com/20241229", "localname": "ZYTIGAMember", "presentation": [ "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "ZYTIGA/abiraterone acetate", "label": "ZYTIGA [Member]", "documentation": "ZYTIGA [Member]" } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "16", "SubTopic": "10", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479405/805-10-25-16" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "7", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479637/805-30-30-7" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "8", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479637/805-30-30-8" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "SubTopic": "20", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-10" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(j)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(k)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-12" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-15" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(g)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "470", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-1" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "20", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "20", "Topic": "715", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "30", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-1" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(2)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-2" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "SubTopic": "20", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "SubTopic": "10", "Topic": "280", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-4" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(c)(2)", "SubTopic": "20", "Topic": "860", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4D" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "SubTopic": "10", "Topic": "320", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-8" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482739/220-10-55-15" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "SubTopic": "20", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-8" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "205", "SubTopic": "20", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-6" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "205", "SubTopic": "20", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-7" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "205", "SubTopic": "20", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-3" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "205", "SubTopic": "20", "Section": "S99", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480781/205-20-S99-3" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "12", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "30", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "41", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "320", "Publisher": "FASB", "URI": "https://asc.fasb.org/320/tableOfContent" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-4" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "420", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481549/505-30-45-1" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-2" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-3" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "60", "Section": "25", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481423/505-60-25-2" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480535/715-20-45-2" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-2" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-3" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-4" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "25", "Paragraph": "23", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479405/805-10-25-23" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "55", "Paragraph": "37", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-37" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "30", "Section": "25", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479668/805-30-25-5" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "30", "Section": "25", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479668/805-30-25-6" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-15" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-16" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-18" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4I", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4I" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1A" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1B" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-2" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-2" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4C", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4H", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4H" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-5" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-7" }, "r121": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8" }, "r122": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "55", "Paragraph": "182", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-182" }, "r123": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "25", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480238/815-25-50-1" }, "r124": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "30", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-1" }, "r125": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-20" }, "r126": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21" }, "r127": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3" }, "r128": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/205-20/tableOfContent" }, "r129": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-11" }, "r130": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-3" }, "r131": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-3A" }, "r132": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-3B" }, "r133": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-4" }, "r134": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1" }, "r135": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-3A" }, "r136": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-4A" }, "r137": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-4B" }, "r138": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5A" }, "r139": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5B" }, "r140": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5B" }, "r141": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5B" }, "r142": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5B" }, "r143": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5B" }, "r144": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5C" }, "r145": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5C" }, "r146": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5D" }, "r147": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r148": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r149": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r150": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r151": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r152": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r153": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r154": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r155": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r156": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r157": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r158": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r159": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r160": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r161": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r162": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r163": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r164": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r165": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r166": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r167": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r168": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r169": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-7" }, "r170": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/220/tableOfContent" }, "r171": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r172": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r173": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r174": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r175": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r176": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r177": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r178": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r179": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r180": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r181": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r182": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r183": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r184": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r185": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r186": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r187": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r188": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r189": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r190": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r191": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r192": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r193": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r194": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r195": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r196": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/235/tableOfContent" }, "r197": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r198": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.BB)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480581/330-10-S99-2" }, "r199": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/360/tableOfContent" }, "r200": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "15", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482309/360-10-15-4" }, "r201": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r202": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r203": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3A" }, "r204": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.P.3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-1" }, "r205": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.b.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r206": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r207": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/450/tableOfContent" }, "r208": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/470/tableOfContent" }, "r209": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481573/470-10-45-12A" }, "r210": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6" }, "r211": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7" }, "r212": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r213": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/505-30/tableOfContent" }, "r214": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r215": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "715", "SubTopic": "20", "Subparagraph": "(d)(5)", "Name": "Accounting Standards Codification", "Paragraph": "1", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r216": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "715", "SubTopic": "20", "Subparagraph": "(f)", "Name": "Accounting Standards Codification", "Paragraph": "1", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r217": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "715", "SubTopic": "20", "Subparagraph": "(h)", "Name": "Accounting Standards Codification", "Paragraph": "1", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r218": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "715", "SubTopic": "20", "Subparagraph": "(l)", "Name": "Accounting Standards Codification", "Paragraph": "1", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r219": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r220": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r221": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r222": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r223": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r224": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(f)(2)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r225": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/805/tableOfContent" }, "r226": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479613/805-30-35-1" }, "r227": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r228": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r229": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r230": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r231": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r232": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r233": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r234": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r235": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r236": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r237": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r238": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r239": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r240": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r241": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r242": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r243": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r244": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r245": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "230", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479024/942-230-45-1" }, "r246": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r247": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r248": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r249": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r250": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-7A" }, "r251": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r252": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r253": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r254": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-8B" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(b)", "SubTopic": "20", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480627/815-20-45-1A" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "270", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482989/270-10-45-6" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "SubTopic": "35", "Topic": "720", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483406/720-35-50-1" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "04", "Paragraph": "a", "Publisher": "SEC" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12", "Paragraph": "Column A", "Footnote": "2", "Publisher": "SEC" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12", "Paragraph": "Column C", "Footnote": "5", "Publisher": "SEC" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12A", "Paragraph": "Column A", "Footnote": "2", "Publisher": "SEC" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12A", "Paragraph": "Column C", "Footnote": "4", "Publisher": "SEC" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12B", "Paragraph": "Column A", "Subparagraph": "(a)", "Footnote": "4", "Publisher": "SEC" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12B", "Paragraph": "Column A", "Subparagraph": "(b)", "Footnote": "4", "Publisher": "SEC" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12B", "Paragraph": "Column C", "Footnote": "2", "Publisher": "SEC" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "14", "Paragraph": "Column A", "Footnote": "2", "Publisher": "SEC" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "14", "Paragraph": "Column F", "Footnote": "7", "Publisher": "SEC" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column A", "Publisher": "SEC" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column B", "Publisher": "SEC" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column C", "Publisher": "SEC" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column D", "Publisher": "SEC" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column E", "Publisher": "SEC" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column F", "Publisher": "SEC" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column A", "Footnote": "2", "Publisher": "SEC" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column B", "Publisher": "SEC" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column C", "Publisher": "SEC" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column D", "Publisher": "SEC" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column E", "Publisher": "SEC" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column F", "Publisher": "SEC" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column G", "Publisher": "SEC" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column H", "Publisher": "SEC" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column I", "Publisher": "SEC" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "29", "Paragraph": "Column A", "Footnote": "4", "Publisher": "SEC" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "01", "Paragraph": "a", "Subparagraph": "(4)(i)", "Publisher": "SEC" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "01", "Paragraph": "a", "Subparagraph": "(4)(iii)(A)", "Publisher": "SEC" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "01", "Paragraph": "a", "Subparagraph": "(4)(iii)(B)", "Publisher": "SEC" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "01", "Paragraph": "a", "Subparagraph": "(4)(iv)", "Publisher": "SEC" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "02", "Paragraph": "a", "Subparagraph": "(4)(i)", "Publisher": "SEC" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "02", "Paragraph": "a", "Subparagraph": "(4)(iii)(A)", "Publisher": "SEC" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "02", "Paragraph": "a", "Subparagraph": "(4)(iii)(B)", "Publisher": "SEC" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "02", "Paragraph": "a", "Subparagraph": "(4)(iii)(C)", "Publisher": "SEC" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "02", "Paragraph": "a", "Subparagraph": "(4)(iv)", "Publisher": "SEC" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Staff Accounting Bulletin (SAB)", "Number": "Topic 11", "Section": "L", "Publisher": "SEC" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Staff Accounting Bulletin (SAB)", "Number": "Topic 11", "Section": "M", "Paragraph": "Question 2", "Publisher": "SEC" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Staff Accounting Bulletin (SAB)", "Number": "Topic 5", "Section": "Y", "Paragraph": "Question 2", "Publisher": "SEC" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Staff Accounting Bulletin (SAB)", "Number": "Topic 5", "Section": "Y", "Paragraph": "Question 4", "Publisher": "SEC" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5C" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-10" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(dd)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-12" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-15" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-17A" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(n))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/260/tableOfContent" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-22" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-23" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-28A" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/280/tableOfContent" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "34", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "36", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-4" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479344/326-20-45-1" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479130/326-30-45-1" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/330/tableOfContent" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-1" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-4" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480265/350-10-S45-1" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-1" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1A" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-2" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479468/405-50-50-3" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479468/405-50-50-3" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479468/405-50-50-3" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479468/405-50-50-3" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479468/405-50-50-3" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479468/405-50-50-4" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/420/tableOfContent" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.P.3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-1" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.b.1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.b.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-3" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "710", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/710/tableOfContent" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "710", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482969/710-10-50-1" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/715/tableOfContent" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480535/715-20-45-2" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480535/715-20-45-3" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480535/715-20-45-3A" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(10)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r629": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r631": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r632": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r633": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r634": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r635": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(8)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r636": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(9)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r637": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r638": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r639": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r640": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r641": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r642": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r643": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r644": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r645": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(8)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r646": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r647": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r648": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r649": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r650": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r651": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r652": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r653": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r654": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r655": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r656": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r657": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r658": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r659": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r660": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r661": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r662": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r663": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r664": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r665": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r666": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r667": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r668": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r669": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r670": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r671": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r672": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r673": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r674": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r675": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r676": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(o)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r677": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(p)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r678": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(q)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r679": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(r)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r680": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(r)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r681": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-2" }, "r682": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-3" }, "r683": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-3" }, "r684": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-4" }, "r685": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r686": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r687": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r688": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r689": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r690": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r691": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r692": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r693": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r694": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-8" }, "r695": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480126/715-20-S99-2" }, "r696": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480266/715-60-50-3" }, "r697": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480266/715-60-50-4" }, "r698": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "70", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480794/715-70-50-1" }, "r699": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480606/715-80-35-1" }, "r700": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11" }, "r701": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r702": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r703": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-9" }, "r704": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/718/tableOfContent" }, "r705": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D" }, "r706": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2" }, "r707": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3" }, "r708": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480454/718-10-45-1" }, "r709": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r710": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r711": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r712": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r713": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r714": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r715": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r716": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r717": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r718": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r719": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r720": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r721": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r722": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r723": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r724": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r725": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r726": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r727": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r728": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r729": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r730": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r731": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r732": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r733": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r734": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r735": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r736": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r737": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r738": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r739": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r740": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r741": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r742": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1" }, "r743": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "35", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483406/720-35-50-1" }, "r744": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1" }, "r745": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1" }, "r746": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/740/tableOfContent" }, "r747": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-10B" }, "r748": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25" }, "r749": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28" }, "r750": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-4" }, "r751": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-6" }, "r752": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10" }, "r753": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10A" }, "r754": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r755": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r756": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r757": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r758": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r759": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B" }, "r760": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C" }, "r761": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14" }, "r762": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15" }, "r763": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A" }, "r764": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A" }, "r765": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A" }, "r766": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A" }, "r767": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A" }, "r768": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17" }, "r769": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19" }, "r770": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2" }, "r771": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2" }, "r772": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20" }, "r773": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21" }, "r774": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23" }, "r775": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3" }, "r776": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r777": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r778": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r779": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r780": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.1.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r781": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r782": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r783": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2" }, "r784": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2" }, "r785": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1" }, "r786": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2" }, "r787": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478758/740-323-25-1" }, "r788": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r789": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r790": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r791": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r792": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r793": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5" }, "r794": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5" }, "r795": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r796": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r797": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r798": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r799": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r800": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r801": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r802": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r803": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1B" }, "r804": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r805": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r806": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r807": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4CCC", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4CCC" }, "r808": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4E" }, "r809": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4EE", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4EE" }, "r810": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480627/815-20-45-3" }, "r811": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r812": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r813": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r814": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r815": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r816": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r817": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-6" }, "r818": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5" }, "r819": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r820": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r821": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r822": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r823": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r824": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r825": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r826": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r827": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r828": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r829": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r830": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r831": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r832": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r833": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r834": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r835": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r836": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r837": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r838": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r839": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r840": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r841": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r842": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r843": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r844": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B" }, "r845": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482736/825-10-45-1A" }, "r846": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10" }, "r847": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r848": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/830/tableOfContent" }, "r849": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481839/830-10-45-17" }, "r850": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481839/830-10-45-9" }, "r851": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482014/830-20-35-1" }, "r852": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482014/830-20-35-3" }, "r853": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481956/830-20-45-1" }, "r854": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481956/830-20-45-5" }, "r855": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481926/830-20-50-1" }, "r856": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "230", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r857": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-12" }, "r858": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r859": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r860": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r861": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r862": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r863": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r864": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-21" }, "r865": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r866": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2" }, "r867": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479424/830-30-S99-1" }, "r868": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483013/835-20-50-1" }, "r869": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r870": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r871": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r872": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r873": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "12A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" }, "r874": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r875": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r876": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-2" }, "r877": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5" }, "r878": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1" }, "r879": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r880": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r881": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r882": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r883": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r884": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r885": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r886": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r887": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r888": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r889": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r890": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r891": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r892": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r893": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r894": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r895": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r896": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r897": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1" }, "r898": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r899": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r900": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r901": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r902": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r903": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(4)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r904": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r905": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r906": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r907": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r908": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r909": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r910": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r911": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r912": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r913": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r914": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r915": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6" }, "r916": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "912", "SubTopic": "330", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478411/912-330-50-1" }, "r917": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, "r918": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5" }, "r919": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "928", "SubTopic": "340", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1" }, "r920": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1" }, "r921": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r922": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r923": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r924": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19" }, "r925": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r926": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r927": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r928": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r929": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r930": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r931": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r932": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r933": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r934": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r935": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r936": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r937": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r938": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r939": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r940": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r941": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r942": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r943": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6" }, "r944": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7" }, "r945": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r946": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r947": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r948": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "280", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1" }, "r949": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1" }, "r950": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "940", "SubTopic": "820", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1" }, "r951": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r952": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r953": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r954": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r955": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r956": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r957": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2" }, "r958": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3A" }, "r959": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3A" }, "r960": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3A" }, "r961": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1" }, "r962": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r963": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r964": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r965": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r966": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(15)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r967": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r968": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r969": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r970": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r971": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r972": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r973": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r974": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r975": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r976": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r977": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r978": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r979": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r980": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r981": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r982": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r983": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(3)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r984": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r985": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r986": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r987": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r988": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r989": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r990": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r991": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r992": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r993": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r994": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column J))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r995": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column K))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r996": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r997": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r998": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r999": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r1000": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r1001": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r1002": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E" }, "r1003": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1004": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1005": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1006": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9" }, "r1007": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r1008": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r1009": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r1010": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r1011": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r1012": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r1013": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.W.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1" }, "r1014": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "825", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B" }, "r1015": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r1016": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(f)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r1017": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(f)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r1018": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(f)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r1019": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(h)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r1020": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r1021": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r1022": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r1023": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r1024": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r1025": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13" }, "r1026": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3" }, "r1027": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r1028": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2" }, "r1029": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27" }, "r1030": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r1031": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r1032": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r1033": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r1034": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r1035": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r1036": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r1037": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r1038": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4" }, "r1039": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r1040": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r1041": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r1042": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r1043": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-12" }, "r1044": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2" }, "r1045": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r1046": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r1047": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r1048": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r1049": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r1050": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1051": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1052": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1053": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1054": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1055": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1056": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1057": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1058": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1059": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1060": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1061": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1062": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1063": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1064": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1065": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1066": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1067": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1068": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1069": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1070": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(7)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1071": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1072": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1073": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1074": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1075": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1076": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r1077": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r1078": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r1079": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, "r1080": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3" }, "r1081": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r1082": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r1083": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r1084": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r1085": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r1086": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r1087": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r1088": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r1089": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r1090": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r1091": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r1092": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r1093": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r1094": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r1095": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r1096": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r1097": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r1098": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r1099": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r1100": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r1101": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r1102": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r1103": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r1104": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "12", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-12" }, "r1105": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "19", "Subparagraph": "(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-19" }, "r1106": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r1107": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r1108": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r1109": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r1110": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r1111": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5" }, "r1112": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5" }, "r1113": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5" }, "r1114": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5A", "Subparagraph": "(SX 210.12-13A(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5A" }, "r1115": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B" }, "r1116": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B" }, "r1117": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C" }, "r1118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C" }, "r1119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C" }, "r1120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r1121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r1122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1" }, "r1123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r1124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r1125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r1126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r1127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-3" }, "r1128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1" }, "r1129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478785/954-310-50-2" }, "r1130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r1131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r1132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r1133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r1134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r1135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r1136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r1137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r1138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r1139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1" }, "r1140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1" }, "r1141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" }, "r1142": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r1143": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)(1)", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r1144": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r1145": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(b)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r1146": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r1147": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r1148": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r1149": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1150": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1151": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-20" }, "r1152": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22" }, "r1153": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482739/220-10-55-15" }, "r1154": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r1155": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r1156": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r1157": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1158": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r1159": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r1160": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r1161": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r1162": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r1163": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r1164": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r1165": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r1166": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "48", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, "r1167": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, "r1168": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r1169": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r1170": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r1171": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r1172": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A" }, "r1173": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8" }, "r1174": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24" }, "r1175": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40" }, "r1176": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "405", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477128/405-50-55-5" }, "r1177": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482395/460-10-55-27" }, "r1178": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r1179": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B" }, "r1180": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C" }, "r1181": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E" }, "r1182": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F" }, "r1183": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r1184": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r1185": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r1186": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r1187": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1188": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1189": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17" }, "r1190": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-18" }, "r1191": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11" }, "r1192": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11" }, "r1193": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11" }, "r1194": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6" }, "r1195": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6" }, "r1196": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6" }, "r1197": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8" }, "r1198": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1199": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1200": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1201": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "720", "SubTopic": "35", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483385/720-35-55-1" }, "r1202": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "217", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-217" }, "r1203": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "231", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231" }, "r1204": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479908/805-50-55-1" }, "r1205": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r1206": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r1207": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r1208": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "101", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101" }, "r1209": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "102", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102" }, "r1210": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "103", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103" }, "r1211": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r1212": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r1213": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r1214": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r1215": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r1216": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r1217": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8" }, "r1218": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53" }, "r1219": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r1220": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4" }, "r1221": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17" }, "r1222": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21" }, "r1223": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29" }, "r1224": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3" }, "r1225": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2" }, "r1226": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4" }, "r1227": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5" }, "r1228": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6" }, "r1229": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2" }, "r1230": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r1231": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, "r1232": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r1233": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r1234": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r1235": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r1236": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E" }, "r1237": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-14" }, "r1238": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-17" }, "r1239": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18" }, "r1240": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-9" }, "r1241": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r1242": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r1243": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1" }, "r1244": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r1245": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r1246": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r1247": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r1248": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column A)(Footnote 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C" }, "r1249": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column B)(Footnote 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C" }, "r1250": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r1251": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7" }, "r1252": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7" }, "r1253": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7" }, "r1254": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r1255": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11" }, "r1256": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r1257": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-13" }, "r1258": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-14" }, "r1259": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-15" }, "r1260": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-16" }, "r1261": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1262": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r1263": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r1264": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r1265": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r1266": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r1267": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r1268": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K" }, "r1269": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "b", "Paragraph": "1" }, "r1270": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "b", "Paragraph": "1", "Subparagraph": "i" }, "r1271": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "b", "Paragraph": "1", "Subparagraph": "ii" }, "r1272": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "b", "Paragraph": "1", "Subparagraph": "iii" }, "r1273": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "b", "Paragraph": "2" }, "r1274": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "c", "Paragraph": "1" }, "r1275": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "c", "Paragraph": "2" }, "r1276": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "c", "Paragraph": "2", "Subparagraph": "i" }, "r1277": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "c", "Paragraph": "2", "Subparagraph": "ii" }, "r1278": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "c", "Paragraph": "2", "Subparagraph": "iii" }, "r1279": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r1280": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r1281": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r1282": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r1283": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r1284": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r1285": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r1286": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r1287": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r1288": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r1289": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r1290": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r1291": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r1292": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r1293": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r1294": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r1295": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r1296": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r1297": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r1298": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r1299": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r1300": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r1301": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r1302": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r1303": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r1304": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r1305": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r1306": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r1307": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r1308": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r1309": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r1310": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r1311": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r1312": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r1313": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r1314": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r1315": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "ii" }, "r1316": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "i" }, "r1317": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "ii" }, "r1318": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iii" }, "r1319": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iv" }, "r1320": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "v" }, "r1321": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "vi" }, "r1322": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r1323": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r1324": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r1325": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r1326": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r1327": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r1328": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r1329": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r1330": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r1331": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r1332": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w" }, "r1333": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r1334": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r1335": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r1336": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r1337": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r1338": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r1339": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r1340": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r1341": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r1342": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r1343": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r1344": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r1345": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r1346": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r1347": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r1348": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r1349": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r1350": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r1351": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r1352": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r1353": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r1354": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r1355": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r1356": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r1357": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106" }, "r1358": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "b", "Paragraph": "1" }, "r1359": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "b", "Paragraph": "1", "Subparagraph": "i" }, "r1360": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "b", "Paragraph": "1", "Subparagraph": "ii" }, "r1361": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "b", "Paragraph": "1", "Subparagraph": "iii" }, "r1362": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "b", "Paragraph": "2" }, "r1363": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "c", "Paragraph": "1" }, "r1364": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "c", "Paragraph": "2" }, "r1365": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "c", "Paragraph": "2", "Subparagraph": "i" }, "r1366": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "c", "Paragraph": "2", "Subparagraph": "ii" }, "r1367": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "c", "Paragraph": "2", "Subparagraph": "iii" }, "r1368": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Number": "229", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1" }, "r1369": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "A", "Number": "229" }, "r1370": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Number": "229" }, "r1371": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "i", "Number": "229" }, "r1372": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r1373": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r1374": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3" }, "r1375": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10" }, "r1376": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2" }, "r1377": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2" }, "r1378": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2" }, "r1379": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481926/830-20-50-3" }, "r1380": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-3" }, "r1381": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r1382": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r1383": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r1384": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "SubTopic": "825", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B" }, "r1385": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4CC", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4CC" }, "r1386": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r1387": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(6))", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r1388": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r1389": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(1)", "Publisher": "SEC" }, "r1390": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(2)", "Publisher": "SEC" }, "r1391": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(3)", "Publisher": "SEC" }, "r1392": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(i)", "Publisher": "SEC" }, "r1393": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(ii)", "Publisher": "SEC" }, "r1394": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(iii)", "Publisher": "SEC" }, "r1395": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "11", "Subsection": "03", "Publisher": "SEC" }, "r1396": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12", "Paragraph": "Column A", "Subparagraph": "(ii)", "Footnote": "2", "Publisher": "SEC" }, "r1397": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12A", "Paragraph": "Column A", "Footnote": "2", "Publisher": "SEC" }, "r1398": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12B", "Paragraph": "Column A", "Subparagraph": "(b)", "Footnote": "1", "Publisher": "SEC" }, "r1399": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "14", "Paragraph": "Column A", "Footnote": "2", "Publisher": "SEC" }, "r1400": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "01", "Paragraph": "a", "Subparagraph": "(4)(ii)", "Publisher": "SEC" }, "r1401": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "01", "Paragraph": "a", "Subparagraph": "(4)(iii)", "Publisher": "SEC" }, "r1402": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Staff Accounting Bulletin (SAB)", "Number": "Topic 5", "Section": "Y", "Paragraph": "Question 2", "Publisher": "SEC" }, "r1403": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1404": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1405": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1406": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r1407": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r1408": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r1409": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r1410": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r1411": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(9)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r1412": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r1413": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r1414": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r1415": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r1416": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2" }, "r1417": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A" }, "r1418": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1419": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1420": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1421": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1422": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1423": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r1424": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r1425": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r1426": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r1427": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r1428": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r1429": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "55", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55" }, "r1430": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r1431": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r1432": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18" }, "r1433": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r1434": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r1435": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r1436": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r1437": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r1438": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2" }, "r1439": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/320/tableOfContent" }, "r1440": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-1" }, "r1441": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r1442": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r1443": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r1444": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r1445": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r1446": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r1447": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r1448": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r1449": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r1450": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r1451": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r1452": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9" }, "r1453": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r1454": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r1455": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r1456": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-4" }, "r1457": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r1458": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479344/326-20-45-1" }, "r1459": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4" }, "r1460": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/350-20/tableOfContent" }, "r1461": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1462": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1463": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1464": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1465": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1466": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1467": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1468": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1469": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1470": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1A" }, "r1471": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-2" }, "r1472": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/350-30/tableOfContent" }, "r1473": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1" }, "r1474": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1475": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1476": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1477": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1478": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1479": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1480": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1481": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1482": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1483": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r1484": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r1485": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r1486": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479468/405-50-50-3" }, "r1487": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r1488": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482047/420-10-45-3" }, "r1489": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1" }, "r1490": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r1491": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r1492": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r1493": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r1494": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r1495": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-3" }, "r1496": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r1497": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r1498": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r1499": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r1500": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4" }, "r1501": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r1502": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r1503": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "712", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481179/712-10-25-4" }, "r1504": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "712", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481179/712-10-25-5" }, "r1505": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480535/715-20-45-3A" }, "r1506": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1507": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1508": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1509": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1510": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1511": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-3" }, "r1512": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r1513": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480266/715-60-50-4" }, "r1514": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480606/715-80-35-1" }, "r1515": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11" }, "r1516": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-9" }, "r1517": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1518": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1519": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1520": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1521": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1522": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1523": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1524": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1525": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1526": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1527": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1528": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1529": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1530": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1531": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1532": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1533": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1534": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1535": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1536": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1537": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1538": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1539": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1540": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1541": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1542": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1543": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1" }, "r1544": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r1545": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r1546": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r1547": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15" }, "r1548": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A" }, "r1549": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2" }, "r1550": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2" }, "r1551": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22" }, "r1552": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23" }, "r1553": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3" }, "r1554": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6" }, "r1555": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r1556": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r1557": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r1558": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A" }, "r1559": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A" }, "r1560": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A" }, "r1561": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A" }, "r1562": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "15", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480123/805-50-15-3" }, "r1563": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480060/805-50-25-1" }, "r1564": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480027/805-50-30-1" }, "r1565": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480027/805-50-30-2" }, "r1566": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1A" }, "r1567": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1B" }, "r1568": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r1569": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r1570": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r1571": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r1572": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r1573": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1574": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1575": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1576": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1577": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1578": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1579": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1580": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1581": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1582": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1583": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1584": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r1585": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r1586": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r1587": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r1588": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r1589": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r1590": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r1591": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r1592": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r1593": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r1594": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r1595": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1596": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1597": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1598": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1599": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1600": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1601": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1" }, "r1602": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "932", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-10(c)(7)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479664/932-10-S99-1" }, "r1603": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "932", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477385/932-360-S50-1" }, "r1604": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "940", "SubTopic": "820", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1" }, "r1605": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2" }, "r1606": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3" }, "r1607": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3A" }, "r1608": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1609": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1610": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1611": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r1612": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r1613": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B" }, "r1614": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r1615": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r1616": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r1617": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r1618": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r1619": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C" }, "r1620": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D" }, "r1621": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4G", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G" }, "r1622": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1623": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1624": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1625": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1626": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1627": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1628": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1629": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1630": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1631": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1632": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1633": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1634": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1635": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1636": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1637": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1638": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1639": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1640": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1641": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1642": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1643": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-1" }, "r1644": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r1645": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r1646": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r1647": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r1648": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r1649": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r1650": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r1651": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r1652": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r1653": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" } } } ZIP 170 0000200406-25-000038-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000200406-25-000038-xbrl.zip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

  •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�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end GRAPHIC 18 jnj-20241229_g12.jpg begin 644 jnj-20241229_g12.jpg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Ý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end GRAPHIC 19 jnj-20241229_g13.jpg begin 644 jnj-20241229_g13.jpg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end GRAPHIC 20 jnj-20241229_g14.jpg begin 644 jnj-20241229_g14.jpg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end GRAPHIC 21 jnj-20241229_g15.jpg begin 644 jnj-20241229_g15.jpg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end GRAPHIC 22 jnj-20241229_g16.jpg begin 644 jnj-20241229_g16.jpg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end GRAPHIC 23 jnj-20241229_g17.jpg begin 644 jnj-20241229_g17.jpg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end GRAPHIC 24 jnj-20241229_g18.jpg begin 644 jnj-20241229_g18.jpg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end GRAPHIC 25 jnj-20241229_g19.jpg begin 644 jnj-20241229_g19.jpg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end GRAPHIC 26 jnj-20241229_g2.jpg begin 644 jnj-20241229_g2.jpg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end GRAPHIC 27 jnj-20241229_g20.jpg begin 644 jnj-20241229_g20.jpg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